PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mulloy, R; Salinas, S; Philips, A; Hipskind, RA				Mulloy, R; Salinas, S; Philips, A; Hipskind, RA			Activation of cyclin D1 expression by the ERK5 cascade	ONCOGENE			English	Article						MEK5; ERK1/2; NF kappa B; CRE; CCL-39 cells; breast cancer	NF-KAPPA-B; HUMAN BREAST-CANCER; CAMP-RESPONSIVE ELEMENT; C-JUN PROMOTER; GROWTH-FACTOR; BINDING PROTEIN; TRANSCRIPTION FACTOR-2; KINASE; GENE; CELLS	Transcriptional activation of the cyclin D1 gene is a key step in cell proliferation. Accordingly, cyclin D1 overexpression is frequently an early step in neoplastic transformation, particularly in mammary epithelium. Numerous studies have linked elevated cyclin D1 promoter activity to a sustained activation of the ERK1/2 cascade. Here we show that the ERK5 cascade, a distinct mitogen-induced MAPK pathway, can also drive cyclin D1 expression. In CCL39 cells, serum induces a strong, prolonged peak of ERK1/2 and ERK5 phosphorylation, and subsequently elevates cyctin D1 mRNA and protein levels. Overexpression of constitutively active MEK5 and wt ERK5 induces a cyclin D1 reporter gene (D1-973-luciferase) at least as well as constitutively active MEK1. Activation is blocked by kinase-dead mutants of ERK5 and ERK2, respectively. Mutation of the CRE at -50 in the cyclin D1 promoter decreases activation by the ERK5 but not the ERK1/2 cascade. Importantly, expression of kinase-dead ERK5 diminishes endogenous cyclin D1 protein induction by serum in CCL39 cells and the breast cancer cell lines MCF-7 and HS579. These data identify the cyclin D1 gene as a novel target of the ERK5 cascade, an observation with important implications in cancers involving cyclin D1 deregulation.	Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Hipskind, RA (corresponding author), Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.	hipskind@soleil.igm.cnrs-mop.fr	Salinas, Sara/O-1150-2019; PHILIPS, Alexandre/AAB-6047-2020; Salinas, Sara/O-1856-2013	Salinas, Sara/0000-0003-4492-2093; Salinas, Sara/0000-0003-4492-2093				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BRUNET A, 1994, ONCOGENE, V9, P3379; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; HERBER, 1994, ONCOGENE, V9, P2105; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kato Y, 2000, IMMUNOL RES, V21, P233, DOI 10.1385/IR:21:2-3:233; LAVOIE J, J BIOL CHEM, V271, P20608; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	46	75	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5387	5398		10.1038/sj.onc.1206839	http://dx.doi.org/10.1038/sj.onc.1206839			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934098				2022-12-17	WOS:000184735000003
J	Dazard, JE; Gal, H; Amariglio, N; Rechavi, G; Domany, E; Givol, D				Dazard, JE; Gal, H; Amariglio, N; Rechavi, G; Domany, E; Givol, D			Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer	ONCOGENE			English	Article						microarray; clustering; epidermis; apoptosis; chemokines	B-INDUCED APOPTOSIS; HISTONE H2AX; P53; EXPRESSION; INDUCTION; REPAIR; P63; SUPPRESSION; ONSET; CARCINOGENESIS	To gain insight into the transformation of epidermal cells into squamous carcinoma cells (SCC), we compared the response to ultraviolet B radiation (UVB) of normal human epidermal keratinocytes (NHEK) versus their transformed counterpart, SCC, using biological and molecular profiling. DNA microarray analyses (Affymetrix(R), similar to12 000 genes) indicated that the major group of upregulated genes in keratinocytes fall into three categories: (i) antiapoptotic and cell survival factors, including chemokines of the CXC/CC subfamilies (e.g. IL-8, GRO-1, -2, -3, SCYA20), growth factors (e.g. HB-EGF, CTGF, INSL-4), and proinflammatory mediators (e.g. COX-2, S100A9), (ii) DNA repair-related genes (e.g. GADD45, ERCC, BTG-1, Histones), and (iii) ECM proteases (MMP-1, -10). The major downregulated genes are DeltaNp63 and PUMILIO, two potential markers for the maintenance of keratinocyte stem cells. NHEK were found to be more resistant than SCC to UVB-induced apoptosis and this resistance was mainly because of the protection from cell death by secreted survival factors, since it can be transferred from NHEK to SCC cultures by the conditioned medium. Whereas the response of keratinocytes to UVB involved regulation of key checkpoint genes (p53, MDM2, p21(Cip1), DeltaNp63), as well as antiapoptotic and DNA repair-related genes - no or little regulation of these genes was observed in SCC. The effect of UVB on NHEK and SCC resulted in upregulation of 251 and 127 genes, respectively, and downregulation of 322 genes in NHEK and 117 genes in SCC. To further analyse these changes, we used a novel unsupervised coupled two-way clustering method that allowed the identification of groups of genes that clearly partitioned keratinocytes from SCC, including a group of genes whose constitutive expression levels were similar before UVB. This allowed the identification of discriminating genes not otherwise revealed by simple static comparison in the absence of UVB irradiation. The implication of the changes in gene profile in keratinocytes for epithelial cancer is discussed.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		DOMANY, EYTAN/K-1560-2012					Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; Brune Bernhard, 2002, J Environ Pathol Toxicol Oncol, V21, P103; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chazal M, 2002, ONCOGENE, V21, P2652, DOI 10.1038/sj.onc.1205349; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Decraene D, 2002, J BIOL CHEM, V277, P32587, DOI 10.1074/jbc.M111106200; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Garssen J, 2001, CRIT REV IMMUNOL, V21, P359; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Gloster HM, 1996, DERMATOL SURG, V22, P217, DOI 10.1111/j.1524-4725.1996.tb00312.x; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greinert R, 2000, PHOTOCHEM PHOTOBIOL, V72, P701, DOI 10.1562/0031-8655(2000)072<0701:TDDOCD>2.0.CO;2; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hanson KM, 2002, PHOTOCHEM PHOTOBIOL, V76, P57, DOI 10.1562/0031-8655(2002)076<0057:OAQOUI>2.0.CO;2; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Liefer KM, 2000, CANCER RES, V60, P4016; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; Loukinova E, 2001, INT J CANCER, V94, P637, DOI 10.1002/ijc.1514; Martini EMD, 2002, GENETICS, V160, P1375; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Notterman DA, 2001, CANCER RES, V61, P3124; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; Selgrade MK, 2001, PHOTOCHEM PHOTOBIOL, V74, P88, DOI 10.1562/0031-8655(2001)074<0088:DRFUII>2.0.CO;2; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Singh RK, 1999, MELANOMA RES, V9, P383, DOI 10.1097/00008390-199908000-00007; Soehnge Holly, 1997, Frontiers in Bioscience, V2, pD538; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xing PX, 2001, FRONT BIOSCI-LANDMRK, V6, pD1284, DOI 10.2741/Xing; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhao RB, 2000, GENE DEV, V14, P981; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	56	75	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2993	3006		10.1038/sj.onc.1206537	http://dx.doi.org/10.1038/sj.onc.1206537			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771951				2022-12-17	WOS:000182824800015
J	Wang, K; Liu, N; Radulovich, N; Wigle, DA; Johnston, MR; Shepherd, FA; Minden, MD; Tsao, MS				Wang, K; Liu, N; Radulovich, N; Wigle, DA; Johnston, MR; Shepherd, FA; Minden, MD; Tsao, MS			Novel candidate tumor marker genes for lung adenocarcinoma	ONCOGENE			English	Article						lung cancer; biomarker; subtractive hybridization; microarray; differential expression	REPRESENTATIONAL DIFFERENCE ANALYSIS; MESSENGER-RNA EXPRESSION; BINDING PROTEIN PHBP; CHROMOSOMAL LOCALIZATION; CANCER; IDENTIFICATION; COLLAGEN; INTEGRIN; CLONING; DIAGNOSIS	Using the representational difference analysis (RDA) technique on pooled mRNA of five primary lung adenocarcinomas and their corresponding non-neoplastic lung tissues, we identified six genes that were putatively overexpressed in this type of lung cancer. Five corresponded to previously isolated genes, while one (Lc19) matched with the sequence of an unannotated EST. Real-time RT-PCR analyses of expression levels in a panel of 34 paired primary non-small cell lung cancer (NSCLC) and corresponding grossly normal appearing lung tissues confirmed the common overexpression of these genes in non-small cell lung cancer. Among these genes, overexpression of Lc19, hyaluronan binding protein 2 (HABP2) and crystalline-mu appeared more specific to adenocarcinoma, whereas ceruloplasmin, integrin alpha-11 and collagen type XI alpha 1 were overexpressed at high frequency among both adenocarcinoma and squamous cell carcinoma. These genes represent novel candidate tumor biomarker genes for NSCLC and its histological subtypes.	Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Tsao, MS (corresponding author), 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Ming.Tsao@uhn.on.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; 				Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CHEN HM, 1992, GENOMICS, V14, P1115, DOI 10.1016/S0888-7543(05)80143-0; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith AJ, 1998, AM J HUM GENET, V62, P816, DOI 10.1086/301789; Hibi K, 1998, CANCER RES, V58, P5690; HIROTA M, 1985, CANCER RES, V45, P6453; Hsu NY, 2001, CANCER RES, V61, P2727; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Iwao K, 2001, INT J CANCER, V91, P433, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1059>3.0.CO;2-B; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Lehnert K, 1999, GENOMICS, V60, P179, DOI 10.1006/geno.1999.5909; Liloglou T, 2001, CANCER RES, V61, P1624; LINDER MC, 1981, JNCI-J NATL CANCER I, V67, P263; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LUBIN R, 1995, NAT MED, V1, P701, DOI 10.1038/nm0795-701; Manda R, 1999, GENOMICS, V61, P5, DOI 10.1006/geno.1999.5939; MAO L, 1994, CANCER RES, V54, P1634; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAH HD, 1992, J BIOL CHEM, V267, P22581; Palmisano WA, 2000, CANCER RES, V60, P5954; Pastorian K, 2000, ANAL BIOCHEM, V283, P89, DOI 10.1006/abio.2000.4622; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Rom WN, 2000, AM J RESP CRIT CARE, V161, P1355, DOI 10.1164/ajrccm.161.4.9908012; SCHRAML P, 1994, CANCER RES, V54, P5236; Sozzi G, 1999, CLIN CANCER RES, V5, P2689; Sumiya J, 1997, J BIOCHEM-TOKYO, V122, P983; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; Wigle DA, 2002, CANCER RES, V62, P3005; WYNDER EL, 1994, CANCER RES, V54, P5284	38	75	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7598	7604		10.1038/sj.onc.1205953	http://dx.doi.org/10.1038/sj.onc.1205953			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386823				2022-12-17	WOS:000178618200016
J	Wagner, KJ; Cooper, WN; Grundy, RG; Caldwell, G; Jones, C; Wadey, RB; Morton, D; Schofield, PN; Reik, W; Latif, F; Maher, ER				Wagner, KJ; Cooper, WN; Grundy, RG; Caldwell, G; Jones, C; Wadey, RB; Morton, D; Schofield, PN; Reik, W; Latif, F; Maher, ER			Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer	ONCOGENE			English	Article						methylation; RASSF1A; colorectal cancer; Wilms' tumour	DNA METHYLATION; EPIGENETIC INACTIVATION; H19 LOCUS; EXPRESSION; 3P21.3; LUNG; RAS; CARCINOMA; REGION; WT1	The 3p21.3 tumour suppressor gene (TSG) RASSF1A is inactivated predominantly by promoter methylation and rarely by somatic mutations. Recently we demonstrated that epigenetic inactivation of RASSF1A is frequent in both clear cell and papillary adult renal cell carcinomas (even though 3p21.3 allele loss is rare in papillary tumours). Wilms' tumour is the most common childhood kidney tumour, but relatively little is known about its molecular pathogenesis. Thus TSGs such as WT1, p16(CDKN2a) and p53 are inactivated in only a minority of cases. In view of the involvement of RASSF1A in adult renal cancers we investigated RASSF1A as a candidate Wilms' TSG. We detected RASSF1A hypermethylation in 21 of 39 (54%) primary Wilms' tumours. 3p21.3 allele loss was not detected in nine informative Wilms' tumours (five with RASSF1A methylation). In contrast to RASSF1A, only a minority (10.3%) of Wilms' tumours demonstrated p16 promoter methylation. As chromosome 3p allele loss is frequent in colorectal cancer, we proceeded to investigate RASSF1A promoter methylation in colorectal cancer and detected RASSF1A methylation in 80% (4/5) colorectal cancer cell lines and 45% (13/29) primary colorectal cancers. There was no correlation between RASSF1A and p16 methylation in colorectal cancer. We have demonstrated that RASSF1A inactivation is the most frequent genetic or epigenetic event yet reported in Wilms' tumourigenesis and that allelotyping studies may fail to identify regions containing important TSGs.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet,Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England; Birmingham Childrens Hosp, Dept Paediat Oncol, Birmingham, W Midlands, England; Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England; Univ Cambridge, Dept Anat, Cambridge CB1, England; Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet,Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England.		Reik, Wolf/I-6794-2012; MAHER, EAMONN R/A-9507-2008; Schofield, Paul/AAA-9414-2020	MAHER, EAMONN R/0000-0002-6226-6918; Schofield, Paul/0000-0002-5111-7263; Reik, Wolf/0000-0003-0216-9881				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Ahuja N, 1998, CANCER RES, V58, P5489; Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies R, 1999, CANCER RES, V59, p1747S; DAVIES R, 1999, CANCER RES, V59, pS1751; Hao XP, 2000, CANCER RES, V60, P18; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kane MF, 1997, CANCER RES, V57, P808; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lerman MI, 2000, CANCER RES, V60, P6116; LUO XN, 1995, ONCOGENE, V11, P743; Morrissey C, 2001, CANCER RES, V61, P7277; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; Richards FM, 1996, HUM MOL GENET, V5, P639, DOI 10.1093/hmg/5.5.639; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Stirzaker C, 1997, CANCER RES, V57, P2229; Thiagalingam S, 1996, CANCER RES, V56, P2936; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U	35	75	83	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7277	7282		10.1038/sj.onc.1205922	http://dx.doi.org/10.1038/sj.onc.1205922			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370819				2022-12-17	WOS:000178504600017
J	Magnard, C; Bachelier, R; Vincent, A; Jaquinod, M; Kieffer, S; Lenoir, GM; Venezia, ND				Magnard, C; Bachelier, R; Vincent, A; Jaquinod, M; Kieffer, S; Lenoir, GM; Venezia, ND			BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains	ONCOGENE			English	Article						BRCA; acetyl-CoA carboxylase; BRCT; GST pull-down	COENZYME-A CARBOXYLASE; BREAST-CANCER CELLS; NUCLEAR-LOCALIZATION SIGNAL; POLYMERASE-II HOLOENZYME; DNA-DAMAGE RESPONSE; FATTY-ACID SYNTHASE; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; OVARIAN-CANCER; MURINE BRCA1	Germ-line alterations in BRCA1 are associated with an increased susceptibility to breast and ovarian cancer. BRCA1 is a 220-kDa protein that contains a tandem of two BRCA1 C-Terminal (BRCT) domains. Among missense and nonsense BRCA1 mutations responsible for family breast cancer, some are located into the BRCT tandem of BRCA1 coding sequence. In an attempt to understand how BRCT is critical for BRCA1 function, we search for partners of this BRCT tandem of BRCA1. Using a glutathione-S-transferase (GST) pull-down assay with murine cells, we isolated only one major BRCA1-interacting protein, further identified as Acetyl Coenzyme A (CoA) Carboxylase a (ACCA). We showed that this interaction is conserved through murine and human species. We also delineated the minimum interacting region as being the whole tandem of BRCT domains. We demonstrated that BRCA1 interacts in vitro and in vivo with ACCA. This interaction is completely abolished by five distinct germline BRCA1 deleterious mutations affecting the BRCT tandem of BRCA1. Interestingly, ACCA originally known as a rate-limiting enzyme for fatty acids biosynthesis, has been recently shown to be over-expressed in breast cancers and considered as a potential target for anti-neoplastic therapy. Furthermore, our observation is making a bridge between the genetic factors involved in susceptibility to breast and ovarian cancers, and environmental factors such as nutrition considered as key elements in the etiology of those cancers.	Univ Lyon 1, CNRS, Genet Lab, Fac Med Rockefeller,UMR 5641, F-69373 Lyon 08, France; CEN Grenoble, DBMS, Lab Chim Prot, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CEA	Venezia, ND (corresponding author), Univ Lyon 1, CNRS, Genet Lab, Fac Med Rockefeller,UMR 5641, 8 Ave Rockefeller, F-69373 Lyon 08, France.	dalla@rockefeller.univ-lyon1.fr	VENEZIA, Nicole DALLA/C-6542-2017	VENEZIA, Nicole DALLA/0000-0002-4553-3535				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; BACHELIER R, 2001, VIRCHOWS ARCH, V40, P261; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brownsey RW, 1997, BIOCHEM SOC T, V25, P1232, DOI 10.1042/bst0251232; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Carroll KK, 1998, LIPIDS, V33, P1055, DOI 10.1007/s11745-998-0305-8; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Deng CX, 2000, BIOESSAYS, V22, P728; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hohenstein P, 2001, ONCOGENE, V20, P2544, DOI 10.1038/sj.onc.1204363; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Moncur JT, 1998, P NATL ACAD SCI USA, V95, P6989, DOI 10.1073/pnas.95.12.6989; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MONTESANO R, 1997, IN VIVO CELL DEV BIO, V34, P468; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patterson RE, 1999, J AM DIET ASSOC, V99, P1412, DOI 10.1016/S0002-8223(99)00341-7; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1996, CANCER RES, V56, P2745; Riboli E, 2001, J NUTR, V131, p170S, DOI 10.1093/jn/131.1.170S; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Ruderman N, 2001, SCIENCE, V291, P2558, DOI 10.1126/science.1060277; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Saitoh S, 1996, J CELL BIOL, V134, P949, DOI 10.1083/jcb.134.4.949; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; STOLL BA, 1995, ANN ONCOL, V6, P245, DOI 10.1093/oxfordjournals.annonc.a059153; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Tomlinson GE, 1998, CANCER RES, V58, P3237; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Y, 2000, GENE DEV, V14, P927; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; WITTERS LA, 1994, INT J BIOCHEM, V26, P589, DOI 10.1016/0020-711X(94)90018-3; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	80	75	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6729	6739		10.1038/sj.onc.1205915	http://dx.doi.org/10.1038/sj.onc.1205915			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360400				2022-12-17	WOS:000178315800003
J	Darbinyan, A; Darbinian, N; Safak, M; Radhakrishnan, S; Giordano, A; Khalili, K				Darbinyan, A; Darbinian, N; Safak, M; Radhakrishnan, S; Giordano, A; Khalili, K			Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein	ONCOGENE			English	Article						JCU; leader protein; agnoprotein; PML	HUMAN NEUROTROPIC POLYOMAVIRUS; T-ANTIGEN; NUCLEAR-LOCALIZATION; TUMOR-ANTIGEN; VIRUS; SIMIAN-VIRUS-40; AGNOPROTEIN; EXPRESSION; REPLICATION; ATTENUATION	The late region of the human neurotropic JC virus encodes a 71 amino acid protein, named Agnoprotein, whose biological function remains elusive. Here we demonstrate that in the absence of other viral proteins, expression of Agnoprotein can inhibit cell growth by deregulating cell progression through the cell cycle stages. Cells with constitutive expression of Agnoprotein were largely accumulated at the G2/M stage and that decline in the activity of cyclins A and B is observed in these cells. Agnoprotein showed the ability to augment p21 promoter activity in transient transfection assay and a noticeable increase in the level of p21 is detected in cells continuously expressing Agnoprotein. Results from binding studies revealed the interaction of Agnoprotein with p53 through the N-terminal of the Agnoprotein spanning residues 1 - 36. Co-expression of p53 and Agnoprotein further stimulated transcription of the p21 promoter. Thus, the interaction of p53 and Agnoprotein can lead to a higher level of p21 expression and suppression of cell cycle progression during the cell cycle.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St 015-96, Philadelphia, PA 19122 USA.	kkhalili@astro.temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				ALWINE JC, 1982, J VIROL, V42, P798, DOI 10.1128/JVI.42.3.798-803.1982; Berger JR, 1998, J NEUROVIROL, V4, P59, DOI 10.3109/13550289809113482; Caldarelli-Stefano R, 2000, HUM PATHOL, V31, P394, DOI 10.1016/S0046-8177(00)80256-7; CARSWELL S, 1986, J VIROL, V60, P1055, DOI 10.1128/JVI.60.3.1055-1061.1986; Del Valle L, 2000, ANN NEUROL, V48, P932, DOI 10.1002/1531-8249(200012)48:6<932::AID-ANA15>3.0.CO;2-E; Del Valle L, 2001, CANCER RES, V61, P4287; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY N, 1982, CELL, V29, P183, DOI 10.1016/0092-8674(82)90102-7; HAY N, 1985, MOL CELL BIOL, V5, P1327, DOI 10.1128/MCB.5.6.1327; Ishii N, 1996, J VIROL, V70, P1317, DOI 10.1128/JVI.70.2.1317-1322.1996; KHALILI K, 1988, P NATL ACAD SCI USA, V85, P354, DOI 10.1073/pnas.85.2.354; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOMURA S, 1983, J VIROL, V45, P428, DOI 10.1128/JVI.45.1.428-433.1983; Okada Y, 2001, J NEUROVIROL, V7, P302; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; RESNICK J, 1986, J VIROL, V60, P1098, DOI 10.1128/JVI.60.3.1098-1106.1986; Rinaldo CH, 1998, J VIROL, V72, P6233, DOI 10.1128/JVI.72.7.6233-6236.1998; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; STACY T, 1989, J VIROL, V63, P5208, DOI 10.1128/JVI.63.12.5208-5215.1989	27	75	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5574	5581		10.1038/sj.onc.1205744	http://dx.doi.org/10.1038/sj.onc.1205744			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165856				2022-12-17	WOS:000177442000007
J	Daly, RJ; Gu, HH; Parmar, J; Malaney, S; Lyons, RJ; Kairouz, R; Head, DR; Henshall, SM; Neel, BG; Sutherland, RL				Daly, RJ; Gu, HH; Parmar, J; Malaney, S; Lyons, RJ; Kairouz, R; Head, DR; Henshall, SM; Neel, BG; Sutherland, RL			The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer	ONCOGENE			English	Article						tyrosine kinase; growth factors; steroid hormones; signal transduction; breast cancer	INSULIN-RECEPTOR SUBSTRATE-1; CYCLIN E-CDK2 ACTIVATION; GROWTH-FACTOR; PHOSPHATASE CORKSCREW; SIGNALING PATHWAY; TYROSINE KINASE; MCF-7 CELLS; EXPRESSION; PROGRESSION; ALPHA	Grb2-associated binder 2 (Gab2) is a recently identified member of the Gab/Daughter of sevenless family of docking proteins, which localize, amplify and integrate signaling pathways activated by various receptors including receptor tyrosine kinases (RTKs). To date, Gab2 signaling has been primarily investigated in hematopoietic cells. Here we report marked overexpression of Gab2 in a subset of breast cancer cell lines relative to normal breast epithelial strains and a trend for increased Gab2 expression in estrogen receptor (ER)positive lines. Overexpression relative to normal ductal epithelium was also observed in some primary breast cancers. In MCF-7 breast cancer cells Gab2 was markedly tyrosine phosphorylated in response to heregulin and also following EGF, insulin or bFGF administration, indicating that a variety of RTKs implicated in breast cancer development or progression couple to this docking protein. In hormone-responsive breast cancer cells, GAB2 mRNA and protein expression were induced by estradiol in a manner sensitive to the pure anti-estrogen ICI 182780, indicating that this regulation is mediated via the ER. Gab2 therefore represents a novel link between steroid and growth factor signaling in breast cancer, and when overexpressed, may modulate the sensitivity of breast cancer cells to these important growth regulators.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Canc Biol Program,Div Hematol & Oncol, Boston, MA 02215 USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Daly, Roger J/C-8179-2009; Sutherland, Robert L/A-8378-2008	Daly, Roger/0000-0002-5739-8027	NCI NIH HHS [CA66600, CA49152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA049152, R01CA049152, R01CA066600] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Allard JD, 1996, DEVELOPMENT, V122, P1137; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Clarke R, 2000, J MAMMARY GLAND BIOL, V5, P245, DOI 10.1023/A:1009527609611; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; JANES PW, 1994, ONCOGENE, V9, P3601; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kurokawa H, 2000, CANCER RES, V60, P5887; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lai A, 2001, J BIOL CHEM, V276, P25823, DOI 10.1074/jbc.M100925200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MUSGROVE EA, 1993, EUR J CANCER, V29A, P2273, DOI 10.1016/0959-8049(93)90221-Z; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Rocha RL, 1997, CLIN CANCER RES, V3, P103; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	38	75	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5175	5181		10.1038/sj.onc.1205522	http://dx.doi.org/10.1038/sj.onc.1205522			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140767				2022-12-17	WOS:000176975900015
J	Bettuzzi, S; Scorcioni, F; Astancolle, S; Davalli, P; Scaltriti, M; Corti, A				Bettuzzi, S; Scorcioni, F; Astancolle, S; Davalli, P; Scaltriti, M; Corti, A			Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression	ONCOGENE			English	Article						cell cycle; clusterin; ODC; PNT2; prostate cancer; SV40	HUMAN DERMAL FIBROBLASTS; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; VENTRAL PROSTATE; SULFATED GLYCOPROTEIN-2; POLYAMINE METABOLISM; GENE-EXPRESSION; ANDROGEN RECEPTOR; HUMAN HOMOLOG; CANCER	Clusterin is a highly conserved, widely distributed glycoprotein whose biological significance is still debated. Involved in many biological processes and disease states, clusterin is induced by cell injury and tissue regression, but is repressed during cell proliferation. We have previously reported that clusterin mRNA induction is associated with epithelial cell atrophy in the rat prostate and both clusterin transcript and protein accumulated in quiescent normal human skin fibroblasts. Here we show that transient clusterin overexpression, in SV40-immortalized human prostate epithelial cells (PNT2), resulted in increased accumulation of cells in the G(0)/G(1) phases of the cell cycle, accompanied by slowdown of cell cycle progression and decrease of DNA synthesis. The activities of ornithine decarboxylase (ODC) and S-andenosylmethionine decarboxylase (AdoMetDC), and the level of histone H3 mRNA (markers of cell proliferation) concomitantly decreased, while Gas1 mRNA (a marker of cell quiescence) accumulated. Thus it appears that clusterin, by opposing the effect of SV40 on the proliferation rate of PNT2 cells, acts as an antioncogene in the prostate, suggesting a role for this gene in controlling proliferation of normal and transformed prostate epithelial cells.	Univ Parma, Dipartimento Med Sperimentale, I-43100 Parma, Italy; Univ Modena, Dipartimento Sci Biomed, I-41100 Modena, Italy	University of Parma; Universita di Modena e Reggio Emilia	Bettuzzi, S (corresponding author), Univ Parma, Dipartimento Med Sperimentale, Via Volturno 39, I-43100 Parma, Italy.	saverio.bettuzzi@unipr.it	Bettuzzi, Saverio/B-2609-2009	Bettuzzi, Saverio/0000-0003-2080-6979				Astancolle S, 2000, J ENDOCRINOL, V167, P197, DOI 10.1677/joe.0.1670197; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bettuzzi S, 2000, CANCER RES, V60, P1472; Bettuzzi S, 1995, FEBS LETT, V377, P321, DOI 10.1016/0014-5793(95)01359-8; BETTUZZI S, 1992, J ENDOCRINOL, V132, P361, DOI 10.1677/joe.0.1320361; Bettuzzi S, 1999, FEBS LETT, V448, P297, DOI 10.1016/S0014-5793(99)00375-0; Bettuzzi S, 1999, FEBS LETT, V446, P18, DOI 10.1016/S0014-5793(99)00182-9; BETTUZZI S, 1994, FEBS LETT, V348, P255, DOI 10.1016/0014-5793(94)00609-1; BETTUZZI S, 1989, BIOCHEM J, V257, P293, DOI 10.1042/bj2570293; Blanchere M, 1998, J STEROID BIOCHEM, V66, P319, DOI 10.1016/S0960-0760(98)00056-9; BUCK MRE, 1995, CANCER RES, V55, P2959; BURKEY BF, 1991, J LIPID RES, V32, P1039; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CANELLAKIS ZN, 1989, YALE J BIOL MED, V62, P481; CUSSENOT O, 1991, J UROLOGY, V146, P881, DOI 10.1016/S0022-5347(17)37953-3; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; FINK TM, 1993, GENOMICS, V16, P526, DOI 10.1006/geno.1993.1222; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948; GRASSILLI E, 1991, BIOCHEM BIOPH RES CO, V180, P59, DOI 10.1016/S0006-291X(05)81254-9; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; Huang HFS, 1997, J ANDROL, V18, P250; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; Koch-Brandt C, 1996, Prog Mol Subcell Biol, V16, P130; Konishi H, 1996, CANCER RES, V56, P434; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Latil A, 1996, J UROLOGY, V156, P2079, DOI 10.1016/S0022-5347(01)65439-9; LOWE NJ, 1980, ARCH DERMATOL, V116, P822, DOI 10.1001/archderm.116.7.822; LUK GD, 1987, ADV ENZYME REGUL, V26, P91, DOI 10.1016/0065-2571(87)90007-0; MARINELLI M, 1994, BIOCHEM CELL BIOL, V72, P515, DOI 10.1139/o94-069; Miyake H, 2000, CANCER RES, V60, P170; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; PEARSE MJ, 1992, INT IMMUNOL, V4, P1225, DOI 10.1093/intimm/4.11.1225; PEGG AE, 1988, CANCER RES, V48, P759; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; PURRELLO M, 1991, GENOMICS, V10, P151, DOI 10.1016/0888-7543(91)90495-Z; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Scorcioni F, 2001, BIOCHEM J, V354, P217, DOI 10.1042/0264-6021:3540217; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x	45	75	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4328	4334		10.1038/sj.onc.1205594	http://dx.doi.org/10.1038/sj.onc.1205594			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082621				2022-12-17	WOS:000176174200016
J	Shinagawa, T; Nomura, T; Colmenares, C; Ohira, M; Nakagawara, A; Ishii, S				Shinagawa, T; Nomura, T; Colmenares, C; Ohira, M; Nakagawara, A; Ishii, S			Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice	ONCOGENE			English	Article						co-repressor; Ski/Sno; tumor suppressor; Mad; Rb	TRANSCRIPTIONAL CO-REPRESSOR; HISTONE DEACETYLASE COMPLEX; TRANSFORMING-GROWTH-FACTOR; THYROID-HORMONE RECEPTOR; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; TGF-BETA; V-SKI; HEMATOPOIETIC-CELLS; SKELETAL-MUSCLE	The c-ski proto-oncogene product (c-Ski) acts as a corepressor and binds to other co-repressors N-CoR/ SMRT and mSin3A which form a complex with histone deacetylase (HDAC). c-Ski mediates the transcriptional repression by a number of repressors, including nuclear hormone receptors and Mad. c-Ski also directly binds to, and recruits the HDAC complex to Smads, leading to inhibition of tumor growth factor-beta (TGF-beta) signaling. This is consistent with the function of ski as an oncogene. Here we show that loss of one copy of c-ski increases susceptibility to tumorigenesis in mice. When challenged with a chemical carcinogen, c-ski heterozygous mice showed an increased level of tumor formation relative to wild-type mice. In addition, c-ski-deficient mouse embryonic fibroblasts (MEFs) had increased proliferative capacity, whereas overexpression of c-Ski suppressed the proliferation. Furthermore, the introduction of activated Ki-ras into c-ski-deficient MEFs resulted in neoplastic transformation. These findings demonstrate that c-ski acts as a tumor suppressor in some types of cells. The level of cdc25A mRNA, which is down regulated by two tumor suppressor gene products, Rb and Mad, was upregulated in e-ski-deficient MEFs, whereas it decreased by overexpressing c-Ski in MEFs. This is consistent with the fact that c-Ski acts as a co-repressor of Mad and Rb. These results support the view that the decreased activities of Mad and Rb in ski-deficient cells at least partly contribute to enhanced proliferation and susceptibility to tumorigenesis. Human c-ski gene was mapped to a region close to the p73 tumor suppressor gene at the 1p36.3 locus, which is already known to contain multiple uncharacterized tumor suppressor genes.	RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Corp, Core Res Evolutionary Sci & Technol, Res Project, Tsukuba, Ibaraki 3050074, Japan; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan	RIKEN; Japan Science & Technology Agency (JST); Cleveland Clinic Foundation; Chiba Cancer Center	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD030728, R29HD030728] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30728] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; BOYER PL, 1993, ONCOGENE, V8, P457; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHENG NC, 1995, ONCOGENE, V10, P291; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Imyanitov EN, 1999, ONCOGENE, V18, P4640, DOI 10.1038/sj.onc.1202863; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Knudson AG, 1997, ANN NY ACAD SCI, V833, P58, DOI 10.1111/j.1749-6632.1997.tb48593.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Kruzelock RP, 1997, CANCER RES, V57, P106; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MARTINSSON T, 1995, CANCER RES, V55, P5681; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NEVINS JR, 1992, SCIENCE, V258, P424; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEARSONWHITE S, 1995, BLOOD, V86, P2146, DOI 10.1182/blood.V86.6.2146.bloodjournal8662146; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; SLEEMAN JP, 1993, ONCOGENE, V8, P67; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Wang ZG, 1998, SCIENCE, V279, P1547; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	69	75	84	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8100	8108		10.1038/sj.onc.1204987	http://dx.doi.org/10.1038/sj.onc.1204987			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781823				2022-12-17	WOS:000172396800007
J	Bergoglio, V; Canitrot, Y; Hogarth, L; Minto, L; Howell, SB; Cazaux, C; Hoffmann, JS				Bergoglio, V; Canitrot, Y; Hogarth, L; Minto, L; Howell, SB; Cazaux, C; Hoffmann, JS			Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents	ONCOGENE			English	Article						DNA polymerase beta; cisplatin resistance; translesion synthesis; 6-thioguanine	ACQUIRED-RESISTANCE; REVERSE-TRANSCRIPTASE; BYPASS REPLICATION; MUTATOR PHENOTYPE; MISMATCH REPAIR; EXCISION-REPAIR; CANCER-CELLS; IN-VITRO; CISPLATIN; LINES	DNA polymerase beta, one of the most inaccurate DNA synthesizing enzymes, has been shown to confer genetic instability when up-regulated in cells, a situation found in several human cancers. Here, we demonstrated that enhanced activity and expression of this enzyme occur in the human ovarian tumor 2008/CI3*5.25 cells, which are resistant to the antitumor agent cisplatin and hypersensitive to 6-thioguanine. We found that translesion synthesis across platinated DNA crosslinks as well as increased incorporation into DNA of 6-thioguanine took place in the 2008/CI3*5.25 cells compared to the parental 2008 cells. Such features being molecular signatures of DNA polymerase beta, these findings suggest that deregulation of its expression in cancer cells may contribute to the modulation of the response to antitumor treatments and therefore to tumor progression.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France; CRU, Sch Med, LRF Mol Pharmacol Grp, Newcastle Upon Tyne, Tyne & Wear, England; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Newcastle University - UK; University of California System; University of California San Diego; University of California System; University of California San Diego	Cazaux, C (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.		Bergoglio, Valérie VB/P-1624-2014; Hoffmann, Jean-Sebastien/O-9183-2014	Bergoglio, Valérie VB/0000-0003-2773-3178; Hoffmann, Jean-Sebastien/0000-0003-2222-354X	NCI NIH HHS [CA 78648] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1996, CANCER RES, V56, P3087; ANDREWS PA, 1985, CANCER RES, V45, P6250; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; Bouayadi K, 1997, CANCER RES, V57, P110; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DIWAN BA, 1995, TOXICOL APPL PHARM, V132, P115, DOI 10.1006/taap.1995.1092; Gomi A, 1996, BIOCHEM BIOPH RES CO, V227, P558, DOI 10.1006/bbrc.1996.1545; GRINDEY GB, 1979, CANCER TREAT REV, V6, P19, DOI 10.1016/S0305-7372(79)80006-7; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; Johnson SW, 1997, CANCER RES, V57, P850; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kornberg A., 1992, DNA REPLICATION; MAMENTA EL, 1994, CANCER RES, V54, P3500; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; NELSON J, 1975, CANCER RES, P2872; OHNO Y, 1988, CANCER RES, V48, P1494; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PIL P, 1997, ENCY CANC, V1, P392; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Vaisman A, 1999, BIOCHEMISTRY-US, V38, P11026, DOI 10.1021/bi9909187; WARREN DJ, 1995, CANCER RES, V55, P1670; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	37	75	81	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6181	6187		10.1038/sj.onc.1204743	http://dx.doi.org/10.1038/sj.onc.1204743			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593426	Bronze			2022-12-17	WOS:000171206300009
J	Peace, BE; Hughes, MJ; Degen, SJF; Waltz, SE				Peace, BE; Hughes, MJ; Degen, SJF; Waltz, SE			Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis	ONCOGENE			English	Article						Ron; Stk; hepatocyte growth factor-like protein; tumorigenesis; metastasis	MACROPHAGE-STIMULATING PROTEIN; RECEPTOR TYROSINE KINASE; HEPATOCYTE GROWTH-FACTOR; MET PROTOONCOGENE; C-KIT; PHOSPHATIDYLINOSITOL-3 KINASE; ACTIVATING MUTATIONS; RET PROTOONCOGENE; SOMATIC MUTATIONS; CATALYTIC DOMAIN	The receptor tyrosine kinase Ron is a member of the receptor family that includes the proto-oncogene Met and the avian oncogene Sea. The interaction of Ron with its ligand, known as hepatocyte growth factor-like protein (HGFL) or macrophage stimulating protein (MSP), induces crucial cellular responses including invasive growth, proliferation, cell scattering, and branching morphogenesis. Based on the homology and functional similarities between Met and Ron it was hypothesized that Ron may be important in tumor formation and metastasis. To test this hypothesis, wildtype mouse Ron and three mutant forms of Ron containing mutations similar to those found in the Met gene in human hereditary papillary renal carcinoma (HPRC), were expressed in NIH3T3 cells. A transformed phenotype was produced in cell lines expressing either wild-type Ron or the mutated Ron proteins. Further, these cell lines displayed oncogenic potential by exhibiting increased proliferation and constitutive phosphorylation of Ron. These cell lines were also tested for the ability to form solid tumors. Cells expressing wild-type Ron and the three proteins with single amino acid substitutions were highly tumorigenic in vivo. In a model of experimental metastasis, two of the cell lines with altered Ron protein formed highly aggressive tumors in the lungs. These results suggest that Ron may be an aggressive oncogene when either overexpressed or when activated by mutation.	Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Waltz, SE (corresponding author), Childrens Hosp Res Fdn, Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Waltz, Susan/0000-0003-3572-4642	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036888] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058182] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07752] Funding Source: Medline; NICHD NIH HHS [HD-36888] Funding Source: Medline; NIDDK NIH HHS [DK-58182, DK-47003] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Chen QY, 1997, HEPATOLOGY, V26, P59; Chen YQ, 1998, J IMMUNOL, V161, P4950; Cirafici AM, 1997, ENDOCRINOLOGY, V138, P1450, DOI 10.1210/en.138.4.1450; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LONGATI P, 1994, ONCOGENE, V9, P49; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mera A, 1999, J BIOL CHEM, V274, P15766, DOI 10.1074/jbc.274.22.15766; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Okino T, 1999, INT J ONCOL, V15, P709; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; QUANTIN B, 1995, DEV DYNAM, V204, P383, DOI 10.1002/aja.1002040405; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Waltz SE, 1997, J BIOL CHEM, V272, P30526, DOI 10.1074/jbc.272.48.30526; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	45	75	83	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6142	6151		10.1038/sj.onc.1204836	http://dx.doi.org/10.1038/sj.onc.1204836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593422				2022-12-17	WOS:000171206300005
J	Turenne, GA; Paul, P; Laflair, L; Price, BD				Turenne, GA; Paul, P; Laflair, L; Price, BD			Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53	ONCOGENE			English	Article						ATM; p53; chk2; phosphorylation; bleomycin	DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; PROTEIN-KINASE; DEPENDENT PHOSPHORYLATION; CHECKPOINT PATHWAY; CELLULAR-RESPONSE; IN-VITRO; CDS1	The ATM protein kinase regulates the cell's response to DNA damage by regulating cell cycle checkpoints and DNA repair. ATM phosphorylates several proteins involved in the DNA-damage response, including p53. We have examined the mechanism by which ATM regulates p53's transcriptional activity. Here, we demonstrate that reintroduction of ATM into AT cells restores the activation of p53 by the radio-mimetic agent bleomycin. Further, p53 activation is lost when a kinase inactive ATM is used. or if the N-terminal of ATM is deleted. In addition, AT cells stably expressing ATM showed decreased sensitivity to Ionizing Radiation-induced cell killing, whereas cells expressing kinase inactive ATM or N-terminally deleted ATM were indistinguishable from AT cells. Finally, single point-mutations of serines 15, 20, 33 or 37 did not individually block the ATM-dependent activation of p53 transcriptional activity by bleomycin. However, double mutations of either serines 15 and 20 or serines 33 and 37 blocked the ability of ATM to activate p53. Our results indicate that the N-terminal of ATM and ATM's kinase activity are required for activation of p53's transcriptionl activity and restoration of normal sensitivity to DNA damage. In addition, activation of p53 by ATM requires multiple serine residues in p53's transactivation domain.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St,D810A, Boston, MA 02115 USA.	brendan_price@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEBAB NH, 1999, P NATL ACAD SCI USA, V96, P13777; CHEBAB NH, 2000, GENE DEV, V14, P278; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jung M, 1997, INT J RADIAT ONCOL, V37, P417, DOI 10.1016/S0360-3016(96)00500-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo CM, 1996, J BIOL CHEM, V271, P4497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; NAGASAWA H, 1994, INT J RADIAT BIOL, V66, P373, DOI 10.1080/09553009414551311; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; ONeill FJ, 1997, ONCOGENE, V14, P955, DOI 10.1038/sj.onc.1200913; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sheppard HM, 1999, ANTICANCER RES, V19, P2079; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TISHLER RB, 1993, CANCER RES, V53, P2212; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WEICHSELBAUM RR, 1978, NATURE, V271, P261, DOI 10.1038/271261a0; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	62	75	79	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5100	5110		10.1038/sj.onc.1204665	http://dx.doi.org/10.1038/sj.onc.1204665			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526498				2022-12-17	WOS:000170464000003
J	Wu, CG; Salvay, DM; Forgues, M; Valerie, K; Farnsworth, J; Markin, RS; Wang, XW				Wu, CG; Salvay, DM; Forgues, M; Valerie, K; Farnsworth, J; Markin, RS; Wang, XW			Distinctive gene expression profiles associated with Hepatitis B virus x protein	ONCOGENE			English	Article						hepatitis B virus; cDNA microarray; liver cancer; chronic active hepatitis	HEPATOCELLULAR-CARCINOMA; HBX GENE; CDNA MICROARRAY; LIVER-CANCER; P53 GENE; CELL; APOPTOSIS; ETIOLOGY; TRANSFORMATION; ACCUMULATION	Hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC), HBV encodes the potentially oncogenic HBx protein, which mainly functions as a transcriptional co-activator involving in multiple gene deregulations. However, mechanisms underlying HBx-mediated oncogenicity remain unclear, To determine the role(s) of HBx in the early genesis of HCC, we utilized the NCI Oncochip microarray that contains 2208 human cDNA clones to examine the gene expression profiles in either freshly isolated normal primary adult human hepatocytes (Hhep) or an HCC cell line (SK-Hep-l) ecotopically expressing HBx via an adenoviral system. The gene expression profiles also were determined in liver samples from HBV-infected chronic active hepatitis patients when compared with normal liver samples. The microarray results were validated through Northern blot analysis of the expression of selected genes. Using reciprocally labeling hybridizations, scatterplot analysis of gene expression ratios in human primary hepatocytes expressing HBx demonstrates that microarrays are highly reproducible. The comparison of gene expression profiles between HBx-expressing primary hepatocytes and HBV-infected liver samples shows a consistent alteration of many cellular genes including a subset of oncogenes (such as c-myc and c-myb) and tumor suppressor genes (such as APC, p53, WAF1 and WT1), Furthermore, clustering algorithm analysis showed distinctive gene expression profiles in Hhep and SK-Hep-l cells. Our findings are consistent with the hypothesis that the deregulation of cellular genes by oncogenic HBx may be an early event that favors hepatocyte proliferation during liver carcinogenesis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Virginia Commonwealth University; University of Nebraska System; University of Nebraska Medical Center	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, NIH, MSC 4255,Bldg 37,Room 2C25, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009; Valerie, Kristoffer/AAL-8299-2021	Wang, Xin Wei/0000-0001-9735-606X; 				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Andrisani OM, 1999, INT J ONCOL, V15, P373; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOVA R, 1991, INT J CLIN LAB RES, V21, P190; Bradley DW, 1999, P ASSOC AM PHYSICIAN, V111, P588, DOI 10.1046/j.1525-1381.1999.t01-1-99240.x; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; CASELMANN WH, 1995, J HEPATOL, V22, P34; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; DeRisi J, 1996, NAT GENET, V14, P457; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Han JS, 2000, BIOCHEM BIOPH RES CO, V272, P525, DOI 10.1006/bbrc.2000.2801; HARRIS CC, 1984, CARCINOGENESIS, V5, P697, DOI 10.1093/carcin/5.6.697; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kew MC, 1997, HEPATOLOGY, V25, P1037, DOI 10.1002/hep.510250442; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Kobayashi S, 1997, J SURG RES, V73, P97, DOI 10.1006/jsre.1997.5182; Koike K, 1995, INTERVIROLOGY, V38, P134, DOI 10.1159/000150424; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Ono K, 2000, CANCER RES, V60, P5007; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Robinson WS, 1999, MICROBES AND MALIGNANCY, P232; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; TAO X, 2000, CHUNG HUA KAN TSANG, V8, P161; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Valerie K, 2000, CANCER GENE THER, V7, P879, DOI 10.1038/sj.cgt.7700185; VALERIE K, 1995, MUTAT RES-DNA REPAIR, V336, P91, DOI 10.1016/0921-8777(94)00046-9; Valerie K, 1999, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, P69; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wu CG, 1997, CARCINOGENESIS, V18, P47, DOI 10.1093/carcin/18.1.47; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	56	75	84	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3674	3682		10.1038/sj.onc.1204481	http://dx.doi.org/10.1038/sj.onc.1204481			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439330				2022-12-17	WOS:000169400200008
J	Gudi, T; Casteel, DE; Vinson, C; Boss, GR; Pilz, RB				Gudi, T; Casteel, DE; Vinson, C; Boss, GR; Pilz, RB			NO activation of fos promoter elements requires nuclear translocation of G-kinase I and CREB phosphorylation but is independent of MAP kinase activation	ONCOGENE			English	Article						nitric oxide; cGMP-dependent protein kinase; c-fos; CREB	DEPENDENT PROTEIN-KINASE; MULTIPLE SEQUENCE ELEMENTS; SOLUBLE GUANYLATE-CYCLASE; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; CYCLIC-GMP; C-FOS; GENE-EXPRESSION; BINDING PROTEIN; DNA-BINDING	We have shown that nitric oxide (NO) regulates c-fos gene expression via cGMP-dependent protein kinase (G-kinase), but NO's precise mechanism of action is unclear, We now demonstrate that: (1) NO targets two transcriptional elements in the fos promoter, i,e., the fos AP-1 binding site and the cAMP-response element (CRE); (2) NO activation of these two enhancer elements requires the CRE binding protein CREB because a dominant negative CREB fully inhibits NO transactivation of reporter genes whereas dominant negative Fos or CCAAT enhancer binding proteins have no effect; (3) CREB is phosphorylated by G-kinase in vitro and its phosphorylation increases in vivo when G-kinase is activated either directly by cGMP or indirectly by NO via soluble guanylate cyclase; (4) NO activation of fos promoter elements requires nuclear translocation of G-kinase but not activation of mitogen-activated protein kinases.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; NCI, Met Lab, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07233-24] Funding Source: Medline; NIGMS NIH HHS [R01GM055586] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOSCOFELLEY E, 1994, AM J RESP CELL MOL B, V11, P159; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Callsen D, 1998, J IMMUNOL, V161, P4852; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P174; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GAUTHIERROUVIERE C, 1992, ONCOGENE, V7, P363; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; HABY C, 1994, J NEUROCHEM, V62, P496; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LevRam V, 1997, NEURON, V18, P1025, DOI 10.1016/S0896-6273(00)80340-2; Lu YF, 1999, J NEUROSCI, V19, P10250; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Moon C, 1999, P NATL ACAD SCI USA, V96, P14605, DOI 10.1073/pnas.96.25.14605; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; NAKANE M, 1990, J BIOL CHEM, V265, P16841; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; Qiang M, 1999, BEHAV PHARMACOL, V10, P215, DOI 10.1097/00008877-199903000-00010; Roberson ED, 1999, J NEUROSCI, V19, P4337; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WYATT TA, 1991, J BIOL CHEM, V266, P21274; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	61	75	80	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6324	6333		10.1038/sj.onc.1204007	http://dx.doi.org/10.1038/sj.onc.1204007			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175347				2022-12-17	WOS:000166210500016
J	Sein, TT; Thant, AA; Hiraiwa, Y; Amin, ARMR; Sohara, Y; Liu, YZ; Matsuda, S; Yamamoto, T; Hamaguchi, M				Sein, TT; Thant, AA; Hiraiwa, Y; Amin, ARMR; Sohara, Y; Liu, YZ; Matsuda, S; Yamamoto, T; Hamaguchi, M			A role for FAK in the concanavalin A-dependent secretion of matrix metalloproteinase-2 and-9	ONCOGENE			English	Article						matrix metalloproteinase; MMP-2; MMP-9; FAK; concanavalin A; signal transduction	FOCAL ADHESION KINASE; CELL-ADHESION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; C-RAS; COLLAGENASE; ACTIVATION; CANCER; INVASION; FIBROBLASTS	To study the signaling pathway critical for the secretion of matrix metalloproteinases (MMPs), we examined the role of focal adhesion kinase (FAK) in Concanavalin A (Con A)-stimulated cells, We established a cell line in which FAK gene was conditionally inducible by use of EAR-nub fibroblasts and the tetracycline repression system. In this cell line, FAK expression was undetectable in the presence of tetracycline but induced within 1 day by the removal of the drug. We found that FAK expression augmented the Con A-dependent secretion of MMP-9 and MMP-2, In contrast, proteolytic activation of MMP-2 by Con A-treatment did not require FAK expression. In addition, activation of MMP-secretion and tyrosine phosphorylation of FAK by Con A, but not the proteolytic activation of MMP-2, required attachment of the cells to the extracellular matrix. Taken together, our results suggest that the FAK signaling pathway play a pivotal role in the secretion of MMPs.	Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan	Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.			AMIN, ARM/0000-0001-9144-2960				BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3053; HURUM S, 1982, BIOCHEM BIOPH RES CO, V107, P357, DOI 10.1016/0006-291X(82)91712-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kataoka M, 1996, INT J ONCOL, V8, P773; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIOTTA LA, 1986, CANCER RES, V46, P1; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Shibata K, 1997, CANCER RES, V57, P5416; Shibata K, 1998, CANCER RES, V58, P900; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S	17	75	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5539	5542		10.1038/sj.onc.1203932	http://dx.doi.org/10.1038/sj.onc.1203932			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114732				2022-12-17	WOS:000165396100015
J	Bagnoli, M; Tomassetti, A; Figini, M; Flati, S; Dolo, V; Canevari, S; Miotti, S				Bagnoli, M; Tomassetti, A; Figini, M; Flati, S; Dolo, V; Canevari, S; Miotti, S			Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression	ONCOGENE			English	Article						ovarian cancer; caveolin; alpha-folate receptor; transcriptional regulation	HUMAN BREAST-CANCER; ONCOGENICALLY TRANSFORMED-CELLS; BINDING PROTEIN EXPRESSION; D7S522 LOCUS 7Q31.1; IN-VIVO; PROMOTER ACTIVITY; TYROSINE KINASE; GENE-EXPRESSION; MEMBRANE; LINES	Caveolin (cav-1) and the GPI-anchored alpha-folate receptor (alpha FR) are membrane proteins both found associated to caveolar structures, Several studies in tumor cells independently reported cav-l downregulation and alpha FR overexpression, Here we analysed the expression of the two molecules in normal and tumor ovarian samples derived from fresh specimens and from cultured cell lines. Whereas normal ovary surface epithelial cells displayed only cav-l expression, ovarian tumor surgical samples and cell lines (COR, IGROV1, OVCAR3 and OVCA432) displayed high alpha FR and low-level or no cav-l expression, except those cell lines (SKOV3 and SW626) with the lower alpha FR expression, SKOV3, but not two alpha FR-negative non-ovarian cell lines, exhibited down-regulation of cav-l expression following stable alpha FR cDNA transfection, Conversely, cav-l transfection in IGROV1 cells led to downregulated alpha FR expression, together with formation of caveolar structures and reduction of growth capability, Moreover, cav-l expression was induced in IGROV1 cells by transfection with intracellular anti-alpha FR antibodies to downmodulate alpha FR expression, In cav-l transfected cells, transcriptional activity of the alpha FR-specific promoter P1 was reduced by 70% and an additional specific DNA-protein complex was identified by gel-shift assay, indicating that cav-l expression influences alpha FR gene transcription. Together these results support the notion that alpha FR and cav-l protein expression is reciprocally regulated in ovary cancer cells.	Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of L'Aquila	Miotti, S (corresponding author), Ist Nazl Tumori, Unit Mol Therapies, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.		Bagnoli, Marina/K-4773-2018; Dolo, Vincenza/AAB-2885-2021; Figini, Mariangela/K-8753-2016; Tomassetti, Antonella/G-7906-2015	Bagnoli, Marina/0000-0001-7655-4630; Dolo, Vincenza/0000-0003-0424-6676; Figini, Mariangela/0000-0001-9001-8754; Tomassetti, Antonella/0000-0001-6772-9937				ALBERTI S, 1990, BIOCHEM BIOPH RES CO, V171, P1051, DOI 10.1016/0006-291X(90)90790-T; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BOTTERO F, 1993, CANCER RES, V53, P5791; CONEY LR, 1991, CANCER RES, V51, P6125; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Elwood PC, 1997, BIOCHEMISTRY-US, V36, P1467, DOI 10.1021/bi962070h; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Figini M, 1998, CANCER RES, V58, P991; Hulit J, 2000, J BIOL CHEM, V275, P21203, DOI 10.1074/jbc.M000321200; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KRUK PA, 1990, LAB INVEST, V63, P132; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; MIOTTI S, 1995, INT J CANCER, V63, P395, DOI 10.1002/ijc.2910630316; Miotti S, 1997, J CELL BIOCHEM, V65, P479; MIOTTI S, 1987, INT J CANCER, V39, P297, DOI 10.1002/ijc.2910390306; Miotti S, 2000, J CELL SCI, V113, P349; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ottone F, 1997, BRIT J CANCER, V76, P77, DOI 10.1038/bjc.1997.339; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAIKAWA Y, 1995, BIOCHEMISTRY-US, V34, P9951, DOI 10.1021/bi00031a018; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toffoli G, 1997, INT J CANCER, V74, P193, DOI 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F	38	75	76	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4754	4763		10.1038/sj.onc.1203839	http://dx.doi.org/10.1038/sj.onc.1203839			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032026				2022-12-17	WOS:000089528800010
J	Mizuno, T; Iwamoto, KS; Kyoizumi, S; Nagamura, H; Shinohara, T; Koyama, K; Seyama, T; Hamatani, K				Mizuno, T; Iwamoto, KS; Kyoizumi, S; Nagamura, H; Shinohara, T; Koyama, K; Seyama, T; Hamatani, K			Preferential induction of RET/PTC1 rearrangement by X-ray irradiation	ONCOGENE			English	Article						thyroid; radiation; RET/PTC; scid mice	PAPILLARY THYROID CARCINOMAS; RET TYROSINE KINASE; EXTERNAL RADIATION; MOLECULAR CHARACTERIZATION; ONCOGENE REARRANGEMENTS; HIGH PREVALENCE; CHERNOBYL; PROTOONCOGENE; CHILDREN; EXPRESSION	Ionizing radiation is a well known risk factor of thyroid cancer development, but the mechanism of radiation induced carcinogenesis is not clear. The RET/PTC oncogene, an activated form of the RET proto-oncogene, is frequently observed in papillary thyroid carcinoma (PTC); RET/PTC1, -2 and -3 are known to be the three major forms, High frequencies of RET/PTC rearrangements have been observed in radiation-associated PTC, such as those appearing post-Chernobyl or post-radiotherapy, but the rearrangement types differ between these two populations. We investigated whether a specific type of RET/PTC rearrangement was induced by X-rays in vivo and in vitro. ln human normal thyroid tissues transplanted in scid mice, the RET/PTC1 rearrangement was predominantly detected throughout the observation period (up to 60 days) after X-ray exposure of 50 Gy, On the other hand, RET/PTC3 was detected only 7 days after X-irradiation, and no transcript of RET/PTC2 was detected. These results are supported by the results of an in vitro study, The RET/PTC1 rearrangement was preferentially induced in a dose-dependent manner by X-rays within a high dose range (10, 50 and 100 Gy) in four cell lines. On the other hand, RET/PTC3 was induced at a much lower frequency, and no induction of RET/PTC2 was observed. These results suggest that the preferential induction of the RET/PTC1 rearrangement may play an important role in the early steps of thyroid carcinogenesis induced by acute X-irradiation.	Radiat Effects Res Fdn, Dept Radiobiol, Hiroshima 7320815, Japan	Radiation Effects Research Foundation - Japan	Mizuno, T (corresponding author), Radiat Effects Res Fdn, Dept Radiobiol, Hiroshima 7320815, Japan.							BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANCOCK SL, 1995, INT J RADIAT ONCOL, V31, P1165, DOI 10.1016/0360-3016(95)00019-U; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ITO T, 1993, JPN J CANCER RES, V84, P105, DOI 10.1111/j.1349-7006.1993.tb02840.x; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; Kitamura Y, 1999, J HUM GENET, V44, P96, DOI 10.1007/s100380050117; Klugbauer S, 1995, ONCOGENE, V11, P2459; Learoyd DL, 1998, J CLIN ENDOCR METAB, V83, P3631, DOI 10.1210/jc.83.10.3631; Mayr B, 1998, BRIT J CANCER, V77, P903, DOI 10.1038/bjc.1998.149; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; MORRIS CM, 1991, BLOOD, V78, P1078; Motomura T, 1998, THYROID, V8, P485, DOI 10.1089/thy.1998.8.485; Murnane JP, 1996, MUTAT RES-GENET TOX, V367, P11, DOI 10.1016/S0165-1218(96)90017-8; Nikiforov YE, 1997, CANCER RES, V57, P1690; Pisarchik AV, 1998, THYROID, V8, P1003, DOI 10.1089/thy.1998.8.1003; Preston DL, 1994, RADIAT RES, V137, P68; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SANTORO M, 1994, ONCOGENE, V9, P509; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.0.CO;2-L; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; THOMPSON DE, 1994, RAD RES S, V137, P17; TUCKER MA, 1991, CANCER RES, V51, P2885; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0	34	75	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					438	443		10.1038/sj.onc.1203343	http://dx.doi.org/10.1038/sj.onc.1203343			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656692				2022-12-17	WOS:000084873700015
J	Attwooll, C; Tariq, M; Harris, M; Coyne, JD; Telford, N; Varley, JM				Attwooll, C; Tariq, M; Harris, M; Coyne, JD; Telford, N; Varley, JM			Identification of a novel fusion gene involving hTAF(II)68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma	ONCOGENE			English	Article						t(9;17)(q22;q11.2); RBP56/hTAF(II)68; CHN; extraskeletal myxoid chrondrosarcoma	RNA-BINDING PROTEIN; ORPHAN NUCLEAR RECEPTOR; POLYMERASE-II; EWS; LIPOSARCOMA; CHOP; TLS/FUS; FUS/TLS; FAMILY; MEMBER	A proportion of extraskeletal myxoid chondrosarcomas (EMC) have been shown to have a characteristic translocation t(9;22)(q22;q12) involving the EWS gene at 22q12 and the CHN orphan nuclear receptor gene at 9q22, This translocation appears to be largely specific for EMC, but has not been detected in all such tumours. We report here a case of EMC with a t(9;17)(q22;q11.2) as the sole chromosome abnormality. We have determined that the translocation results in the fusion of the entire coding region of CHN to the N-terminal transactivation domain of RBP56/hTAF(II)68. This is the first report of a translocation involving RBP56/hTAF(II) 68, a protein with sequence homology to both EWS and TLS/FUS, The involvement of RBP56/hTAF(II)68 may explain some unusual features of the tumour.	Withington Hosp, Dept Histopathol, Manchester M20 8LR, Lancs, England; Paterson Inst Canc Res, CRC, Dept Canc Genet, Manchester M20 9BX, Lancs, England; Christie Hosp, Dept Oncol Cytogenet, Manchester, Lancs, England; Christie Hosp, Dept Histopathol, Manchester, Lancs, England	Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital	Varley, JM (corresponding author), Withington Hosp, Dept Histopathol, Manchester M20 8LR, Lancs, England.							Antonescu CR, 1998, CANCER, V83, P1504, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brody RI, 1997, AM J PATHOL, V150, P1049; Chhieng DC, 1998, MODERN PATHOL, V11, p8A; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; MARKVENDEL E, 1991, CANCER GENET CYTOGEN, V52, P267; Morohoshi F, 1996, GENOMICS, V38, P51, DOI 10.1006/geno.1996.0591; Morohoshi F, 1998, GENE, V221, P191, DOI 10.1016/S0378-1119(98)00463-6; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; Panagopoulos I, 1996, ONCOGENE, V12, P489; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SCOTT JE, 1965, HISTOCHEMISTRY, V5, P221, DOI 10.1007/BF00306130	17	75	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7599	7601		10.1038/sj.onc.1203156	http://dx.doi.org/10.1038/sj.onc.1203156			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602520				2022-12-17	WOS:000084119600022
J	Schwarte-Waldhoff, I; Klein, S; Blass-Kampmann, S; Hintelmann, A; Eilert, C; Dreschers, S; Kalthoff, H; Hahn, SA; Schmiegel, W				Schwarte-Waldhoff, I; Klein, S; Blass-Kampmann, S; Hintelmann, A; Eilert, C; Dreschers, S; Kalthoff, H; Hahn, SA; Schmiegel, W			DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression	ONCOGENE			English	Article						DPC4/Smad4; tumor suppressor gene; TGF-beta; urokinase; colon carcinoma; SW480	GROWTH-FACTOR-BETA; COLORECTAL-CANCER; GENE; LINES; MUTATIONS; TGF-BETA-1; INHIBITION; MICE; DPC4; APC	We recently identified DPC4/Smad4 as a candidate tumor suppressor gene mutated or lost in one half of pancreatic carcinomas and in a subset of colon and biliary tract carcinomas. DPC4 plays a key role in signal transduction of the TGF-beta superfamily of molecules and inactivation of TGF-beta mediated growth inhibition is supposed to be the driving force for DPC4 inactivation in human tumors. However, DPC4 mediated tumor suppression by reconstitution of defective cells has not yet been reported. Here we show suppression of tumorigenicity in nude mice by stable reexpression of DPC4 in SW480 colon carcinoma cells. In vitro growth of DPC4-transfected cells was not affected and resistance towards TGF-beta mediated growth inhibition was retained. Instead, cells exhibited morphological alterations and adhesion and spreading were accelerated. These phenotypic changes were associated with reduced expression levels of the endogenous urokinase-type plasminogen activator (uPA) and plasminogen-activator-inhibitor-1 (PAI-I) genes, the products of which are implicated in the control of cell adhesion and invasion. Ln patients, high expression levels of uPA and PAI-1 correlate with poor prognosis. Thus, reduced expression of uPA and PAL-I is consistent with suppression of tumorigenicity in DPC4 reconstituted cells. These results demonstrate DPC4's tumor suppressive function and suggest a potential role for DPC4 as a modulator of cell adhesion and invasion.	Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, D-44892 Bochum, Germany; Univ Essen Gesamthsch Klin, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; CAU Kiel, Klin Allgemeine & Thoraxchirurg, D-24105 Kiel, Germany	Ruhr University Bochum; University of Duisburg Essen; University of Kiel	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, Schornau 23-25, D-44892 Bochum, Germany.		Kalthoff, Holger/B-1618-2010; Hahn, Stephan/E-3880-2010; Hahn, Stephan A./AAV-6062-2021	Hahn, Stephan/0000-0003-0855-9741; Hahn, Stephan A./0000-0003-0855-9741				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLAYDES JP, 1995, ONCOGENE, V10, P307; Candia AF, 1997, DEVELOPMENT, V124, P4467; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COFFEY RJ, 1987, CANCER RES, V47, P4590; COFFEY RJ, 1986, CANCER RES, V46, P1164; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FILMUS J, 1992, ONCOGENE, V7, P521; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1995, CANCER RES, V55, P1531; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hahn SA, 1996, CANCER RES, V56, P490; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KUROKAWA M, 1989, BIOCHEM BIOPH RES CO, V142, P775; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; REISS M, 1993, CANCER RES, V53, P899; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1996, CANCER RES, V56, P2527; SCHWARTEWALDHOFF I, 1994, ONCOGENE, V9, P899; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; THIAGALINGAM S, 1996, NAT GENET, V13, P342; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019	40	75	81	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3152	3158		10.1038/sj.onc.1202641	http://dx.doi.org/10.1038/sj.onc.1202641			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340387				2022-12-17	WOS:000080388000011
J	Harhaj, EW; Good, LF; Xiao, GT; Sun, SC				Harhaj, EW; Good, LF; Xiao, GT; Sun, SC			Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation	ONCOGENE			English	Article						HTLV-I; adult T-cell leukemia; T-cell immortalization; gene array; gene expression profile	VIRUS TYPE-I; TRANSCRIPTION FACTOR YB-1; NF-KAPPA-B; LEUKEMIA-VIRUS; TAX-PROTEIN; MOLECULAR-CLONING; SIGNALING COMPLEX; BINDING PROTEIN; INFECTED-CELLS; FAS-LIGAND	Human T-cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T-cell leukemia, an acute and often fatal T-cell malignancy. A key step in HTLV-I-induced leukemigenesis is induction of abnormal T-cell growth and survival. Unlike antigen-stimulated T cells, which cease proliferation after a finite number of cell division, HTLV-I-infected T cells proliferate indefinitely (immortalized), thus facilitating occurrence of secondary genetic changes leading to malignant transformation. To explore the molecular basis of HTLV-I-induced abnormal T-cell survival, we compared the gene expression profiles of normal and HTLV-I-immortalized T cells using 'gene array'. These studies revealed a strikingly altered expression pattern of a large number of genes along with HTLV-I-mediated T-cell immortalization. Interestingly, many of these deregulated genes are involved in the control of programmed cell death or apoptosis. These findings indicate that disruption of the cellular apoptosis-regulatory network may play a role in the HTLV-I-mediated oncogenesis.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NCI NIH HHS [R01 CA68471-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi Tsuyoshi, 1997, Leukemia (Basingstoke), V11, P25; ALEXANDRE C, 1991, ONCOGENE, V6, P543; Arai M, 1998, AIDS RES HUM RETROV, V14, P261, DOI 10.1089/aid.1998.14.261; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BROWNING JL, 1995, J IMMUNOL, V154, P33; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Chenchik A, 1998, CLONTECHNIQUES, V13, P16; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dick T, 1996, MOL CELL BIOL, V16, P1966; DORMAN DM, 1992, J BIOL CHEM, V267, P1279; Eischen CM, 1997, J IMMUNOL, V159, P1135; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Fujii J, 1996, NEPHROL DIAL TRANSPL, V11, P34; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; HINTZEN RQ, 1994, IMMUNOL TODAY, V15, P307, DOI 10.1016/0167-5699(94)90077-9; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kishi S, 1997, J EXP MED, V186, P57, DOI 10.1084/jem.186.1.57; KOEFFLER HP, 1984, BLOOD, V64, P482; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mena MA, 1997, J NEUROCHEM, V69, P21; MERL S, 1984, BLOOD, V64, P967; MIGITA K, 1995, IMMUNOLOGY, V85, P550; MIURA K, 1992, BIOCHEM BIOPH RES CO, V187, P375, DOI 10.1016/S0006-291X(05)81503-7; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYOSHI I, 1981, GANN, V72, P978; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Ohga T, 1996, CANCER RES, V56, P4224; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SAGGIORO D, 1991, AIDS RES HUM RETROV, V7, P571, DOI 10.1089/aid.1991.7.571; SAURI H, 1995, BIOCHEM BIOPH RES CO, V208, P964, DOI 10.1006/bbrc.1995.1428; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SUGIMOTO A, 1995, EMBO J, V14, P4434, DOI 10.1002/j.1460-2075.1995.tb00122.x; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; Tsushima H, 1997, CELL GROWTH DIFFER, V8, P1317; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanSnick J, 1996, J IMMUNOL, V157, P2570; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Weiss Arthur, 1993, P467; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	84	75	76	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1341	1349		10.1038/sj.onc.1202405	http://dx.doi.org/10.1038/sj.onc.1202405			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022816				2022-12-17	WOS:000078510900010
J	Perletti, GP; Marras, E; Concari, P; Piccinini, F; Tashjian, AH				Perletti, GP; Marras, E; Concari, P; Piccinini, F; Tashjian, AH			PKC delta acts as a growth and tumor suppressor in rat colonic epithelial cells	ONCOGENE			English	Article						PKC isoforms; colon cancer; src oncogene	PROTEIN-KINASE-C; PHORBOL ESTER; EPSILON; OVEREXPRESSION; FIBROBLASTS; ACTIVATION; ONCOGENE	We have analysed the expression of three calcium-independent isoforms of protein kinase C (PKC), PKC delta, PKC epsilon and PKC zeta, in an in vitro model of colon carcinogenesis consisting of the nontumorigenic rat colonic epithelial cell line D/WT, and a derivative src-transformed line D/src. While PKC zeta and PKC epsilon showed similar protein levels, PKC delta was markedly decreased in D/src cells when compared to the D/WT line. To assess whether down-regulation of PKC delta was causally involved in the neoplastic phenotype in D/src cells, we prepared a kinase-defective mutant of PKC delta, Stable transfection of this sequence caused morphological and growth changes characteristic of partial transformation in D/WT cells. Moreover, to test whether PKC delta was involved in growth control and transformation in this model, we over-expressed PKC delta in D/src cells. Transfected cells underwent marked growth and morphological modifications toward the D/WT phenotype, In a late stage in culture, transfected cells ceased to proliferate, rounded up and degenerated into multinucleated, giant-like cells, We conclude that PKC delta can reverse the transformed phenotype and act as a suppressor of cell growth in D/src cells, Moreover, our data show that downregulation of this isoenzyme of PKC may cooperate in the neoplastic transformation induced by the src oncogene in D/WT cells.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Univ Milan, Ist Farmacol, I-20129 Milan, Italy; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Milan; Harvard University; Harvard Medical School	Tashjian, AH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.				NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Blobe GC, 1996, CANCER SURV, V27, P213; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; JIANG YH, 1997, CARCINOGENESIS, V18, P31; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Perletti GP, 1996, INT J ONCOL, V9, P171; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Perletti GP, 1996, ONCOGENE, V12, P847; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B; Sambrook J, 1989, MOL CLONING LAB MANU; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Wang QJ, 1998, ONCOGENE, V16, P53, DOI 10.1038/sj.onc.1201507; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	20	75	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1251	1256		10.1038/sj.onc.1202408	http://dx.doi.org/10.1038/sj.onc.1202408			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022132				2022-12-17	WOS:000078510700015
J	Salgia, R; Li, JL; Ewaniuk, DS; Wang, YB; Sattler, M; Chen, WC; Richards, W; Pisick, E; Shapiro, GI; Rollins, BJ; Chen, LB; Griffin, JD; Sugarbaker, DJ				Salgia, R; Li, JL; Ewaniuk, DS; Wang, YB; Sattler, M; Chen, WC; Richards, W; Pisick, E; Shapiro, GI; Rollins, BJ; Chen, LB; Griffin, JD; Sugarbaker, DJ			Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility	ONCOGENE			English	Article						paxillin; lung cancer; cell motility	ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; KINASE; P210(BCR/ABL); CYTOSKELETON; FIBROBLASTS; BINDING; FORMS	Lung cancer can lead to abnormalities of the actin cytoskeleton structure which may be important in transformation. In this study, we have investigated the expression of the cytoskeletal associated protein paxillin in lung cancer, Paxillin is a 68 kDa focal adhesion protein, with four tandem LIM domains at the C-terminus, involved in growth factor receptor, integrin and oncogenic signaling such as v-src, BCR/ABL, and E6 of the papilloma virus. In non-small cell lung cancer (NSCLC) cell lines, paxillin localized to the focal adhesions. The possible role of paxillin in lung cancer cells was assessed by overexpressing green fluorescence protein (GFP)-paxillin construct in two separate NSCLC cell lines (Calu-1 and H661), Over the course of 48 h, GFP-paxillin consistently caused the cells to become round and to decrease cell motility as compared to normal controls, GFP-N-terminus paxillin, or GFP-LIM transfected cells. Because some lung cancers may be quite aggressive and metastasize quickly, which may be related to the cytoskeleton, we determined the expression of paxillin in NSCLC and small cell lung cancer (SCLC) cell lines and patient tumor tissues. Expression of paxillin in NSCLC and SCLC cell lines were determined by Northern blot and Western blot analysis. The expression of paxillin was consistently low in SCLC cell lines, whereas there was paxillin expression in NSCLC cell lines. There was a variability of expression of paxillin in NSCLC tumor tissue as compared to normal lung tissue. In contrast, by immunohistochemistry, we show that there was no detectable expression of paxillin in 5/5 SCLC patients. This data suggests that absence or low level of paxillin protein expression may cause certain lung cancers, such as SCLC, to be more motile and possibly more aggressive.	Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Cellular & Mol Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Neoplast Dis Mechanisms, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Thorac Oncol & Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Salgia, R (corresponding author), Dana Farber Canc Inst, Div Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.		Li, Jian-Liang/AAE-9315-2019; Li, J L/E-6100-2018	Li, Jian-Liang/0000-0002-6487-081X; Li, J L/0000-0002-6487-081X	NCI NIH HHS [CA75348] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA075348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BERNAL SD, 1983, CANCER RES, V43, P1798; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARBONE D, 1996, LUNG CANC PRINCIPLES, P107; Charlesworth A, 1996, ONCOGENE, V12, P1337; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; KERN JA, 1993, CLIN CHEST MED, V14, P31; Lauffenburger DA, 1996, NATURE, V383, P390, DOI 10.1038/383390a0; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; PRINS J, 1993, ANTICANCER RES, V13, P1373; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sidransky D, 1996, ANNU REV MED, V47, P285; SLEBOS RJC, 1992, J NATL CANCER I MONO, V13, P23; Strauss GM, 1997, HEMATOL ONCOL CLIN N, V11, P409, DOI 10.1016/S0889-8588(05)70441-X; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Weisberg E, 1997, CRIT REV ONCOGENESIS, V8, P343, DOI 10.1615/CritRevOncog.v8.i4.40; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	39	75	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					67	77		10.1038/sj.onc.1202273	http://dx.doi.org/10.1038/sj.onc.1202273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926921				2022-12-17	WOS:000078166000008
J	Arvand, A; Bastians, H; Welford, SM; Thompson, AD; Ruderman, JV; Denny, CT				Arvand, A; Bastians, H; Welford, SM; Thompson, AD; Ruderman, JV; Denny, CT			EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction	ONCOGENE			English	Article						Ewing's sarcoma; EWS/FLI1; RDA; cell cycle; transformation; E2-C	EWINGS-SARCOMA; DNA-BINDING; FUSION GENE; TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; SISTER CHROMATIDS; PROTEIN; TRANSLOCATION; PROTEOLYSIS; SEPARATION	The EWS/FLI1 fusion gene found in Ewing's sarcoma and primitive neuroectodermal tumor, is able to transform certain cell lines by acting as an aberrant transcription factor, The ability of EWS/FLI1 to modulate gene expression in cells transformed and resistant to transformation by EWS/FLI1, was assessed by Representational Difference Analysis (RDA), We found that the cyclin selective ubiquitin conjugase murine E2-C, was up regulated in NIH3T3 cells transformed by EWS/FLI1 but not in a nontransformed NIH3T3 clone expressing EWS/FLI1, We also found that mn-C is upregulated in NIH3T3 cells transformed by other genes including activated cdc42, v-ABL and c-myc, We demonstrated that expression of mn-C in both the EWS/FLI1 transformed and parent NIH3T3 lines varies with the cell cycle. Finally, dominant-negative mE2-C, created by changing a catalytic cysteine to serine, inhibits the in vitro ubiquitination and degradation of cyclin B in human HeLa cell extracts. These data suggest that part of the biologic effect of EWS/FLI1 could be, to transcriptionally modulate genes involved in cell cycle regulation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif Los Angeles, Dept Expt Pathol Lab Med, Los Angeles, CA USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Hematol Oncol,Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Denny, CT (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.				NCI NIH HHS [CA09056, CA32737] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BRAUN BS, 1997, THESIS; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; LESSNICK SL, 1995, ONCOGENE, V10, P423; LESSNICK SL, 1994, THESIS; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; OHNO T, 1993, CANCER RES, V53, P5859; ORMEROD MG, 1996, FLOW CYTOMETRY PRACT, P75; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RON D, 1995, P NATL ACAD SCI USA, V92, P2016; Segade F, 1995, LIFE SCI, V58, P277, DOI 10.1016/0024-3205(95)02288-0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; Thompson AD, 1996, ONCOGENE, V13, P2649; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	31	75	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2039	2045		10.1038/sj.onc.1202129	http://dx.doi.org/10.1038/sj.onc.1202129			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798675				2022-12-17	WOS:000076540900003
J	Mai, M; Qian, CP; Yokomizo, A; Tindall, DJ; Bostwick, D; Polychronakos, C; Smith, DI; Liu, WG				Mai, M; Qian, CP; Yokomizo, A; Tindall, DJ; Bostwick, D; Polychronakos, C; Smith, DI; Liu, WG			Loss of imprinting and allele switching of p73 in renal cell carcinoma	ONCOGENE			English	Article						p73; imprinting; allelic expression; renal cell carcinoma	TUMOR-SUPPRESSOR; WILMS-TUMOR; CANCER; GENE; EXPRESSION; P53; NEUROBLASTOMA; METHYLATION; H19	p73, a protein that has substantial structural and functional similarity to p53, has recently been identified. It was found to be monoallelically expressed in all cell lines and normal individuals tested, To elucidate its role in cancer development and as a potential imprinted tumor suppressor, we investigated the allele-specific expression of the human p73 gene in 28 cases of renal cell carcinoma and its imprinting status in fetal pancreatic and thymic tissues. Of 12 informative pairs of renal cell carcinoma and matched normal tissues identified by StyI restriction fragment length polymorphism (RFLP) in exon 2, p73 showed monoallelic expression in 11 out of 12 normal tissues but biallelic expression in 8/12 and switched allele expression in 2/12 of the matched corresponding cancers. An imprinting study of the p73 gene in two families using a newly identified exonic BanI RFLP indicated that expression of p73 was limited to the maternal allele in RNA from fetal pancreas and thymus, demonstrating that p73 is imprinted in at least these two tissues. These findings strongly suggest that loss of imprinting or switching of allelic expression of the p73 gene is associated with the development of renal cell carcinoma.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Urol Res, Rochester, MN 55905 USA; McGill Univ, Dept Pediat, Div Endocrinol, Montreal, PQ H3H 1P3, Canada	Mayo Clinic; Mayo Clinic; McGill University	Liu, WG (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA.		Polychronakos, Constantin/B-8151-2008	Polychronakos, Constantin/0000-0002-7624-6635	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; Hibi K, 1996, CANCER RES, V56, P480; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; McBride G, 1997, J NATL CANCER I, V89, P1256; Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.0.CO;2-2; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Rachmilewitz J, 1996, ONCOGENE, V13, P1687; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Svensson K, 1998, DEVELOPMENT, V125, P61; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson JS, 1996, CANCER RES, V56, P5723; Tycko B, 1997, MUTAT RES-REV MUTAT, V386, P131, DOI 10.1016/S1383-5742(96)00049-X; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; Watanabe D, 1996, GENES CELLS, V1, P795, DOI 10.1046/j.1365-2443.1996.d01-276.x; ZHANG YH, 1993, AM J HUM GENET, V53, P113	18	75	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1739	1741		10.1038/sj.onc.1202099	http://dx.doi.org/10.1038/sj.onc.1202099			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796703				2022-12-17	WOS:000076200100012
J	Alberti, L; Borrello, MG; Ghizzoni, S; Torriti, F; Rizzetti, MG; Pierotti, M				Alberti, L; Borrello, MG; Ghizzoni, S; Torriti, F; Rizzetti, MG; Pierotti, M			Grb2 binding to the different isoforms of Ret tyrosine kinase	ONCOGENE			English	Article						Ret; Grb2; receptor tyrosine kinase; oncogene	PAPILLARY THYROID CARCINOMAS; GROWTH-FACTOR RECEPTOR; CELL-LINE; NEUROTROPHIC FACTOR; PHOSPHOTYROSINE PHOSPHATASE; DOCKING SITE; GDNFR-ALPHA; RI-ALPHA; PROTOONCOGENE; SHC	The RET proto-oncogene encodes two isoforms of a receptor tyrosine kinase which plays a role in neural crest and kidney development. Ret ligands have been recently identified as the neuron survival factor GDNF (Glial-Derived Neurotrophic Factor) and Neurturin. Somatic rearrangements of RET, designated RET/PTCs, have been frequently detected in papillary thyroid carcinomas. In addition, distinct germ-line mutations of RET gene have been associated with the inherited cancer syndromes MEN (Multiple Endocrine Neoplasia) 2A, 2B and FMTC (Familial Medullar Thyroid Carcinomas) as well as with the congenital megacolon or Hirschsprung's disease, thus enlightening a significant role of this receptor gene in diverse human pathologic conditions. In this study, by performing classical inhibition experiments using synthetic phosphopeptides and by site-directed mutagenesis of the putative docking site, we have determined that for Grb2 the latter is provided by the tyrosine 620 of Ret/ptc2 long isoform (corresponding to Tyr 1096 on proto-Ret). However, in intact cells, the interaction of Grb2 with the two short and long Ret isoforms expressed separately is of similar strength, thus suggesting that Ret short isoform interaction with Grb2 could be mediated not only by Shc but also by a molecule that binds preferentially to this isoform. This possibility is supported by the evidence that the mutant Ret/ptc2Y620F long isoform displays a weak coimmunoprecipitation with Grb2 and that this mutant, lacking the docking site for Grb2 but owing all the others phosphotyrosines, surprisingly displays a reduced transforming activity compared to that of the two WTs oncogenes. We thus conclude that in intact cells both Ret isoforms bind to Grb2, although with different modalities, In addition, the present results are in agreement with the possibility that different signal transduction pathways are associated with the two isoforms of Ret.	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Borrello, MG (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LANZI C, 1992, ONCOGENE, V7, P2189; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MYERS SM, 1995, ONCOGENE, V11, P2039; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Suvanto P, 1997, HUM MOL GENET, V6, P1267, DOI 10.1093/hmg/6.8.1267; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	75	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1079	1087		10.1038/sj.onc.1202046	http://dx.doi.org/10.1038/sj.onc.1202046			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764818				2022-12-17	WOS:000075598400003
J	Hui, R; Ball, JR; Macmillan, RD; Kenny, FS; Prall, OWJ; Campbell, DH; Cornish, AL; McClelland, RA; Daly, RJ; Forbes, JF; Blamey, RW; Musgrove, EA; Robertson, JFR; Nicholson, RI; Sutherland, RL				Hui, R; Ball, JR; Macmillan, RD; Kenny, FS; Prall, OWJ; Campbell, DH; Cornish, AL; McClelland, RA; Daly, RJ; Forbes, JF; Blamey, RW; Musgrove, EA; Robertson, JFR; Nicholson, RI; Sutherland, RL			EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival	ONCOGENE			English	Article						EMS1; cyclin D1; breast cancer; prognosis	CHROMOSOME 11Q13 REGION; ONCOGENE AMPLIFICATION; PROGNOSTIC VALUE; HUMAN CARCINOMAS; POOR PROGNOSIS; CONTACT SITES; CELL-LINES; OVEREXPRESSION; PHOSPHORYLATION; IDENTIFICATION	The EMS1 and CCND1 genes at chromosome 11q13 are amplified in about 15% of primary breast cancers but appear to confer different phenotypes in ER positive and ER negative tumours, Since there are no published data on EMS1 expression in large series of breast cancers we examined the relationship of EMS1 expression with EMSI gene copy number and expression of mRNAs for cyclin D1 and ER, In a subset of 129 patients, where matched tumour RNA and DNA was available, EMS1 mRNA overexpression was associated predominantly with gene amplification (P=0.0061), whereas cyclin DT mRNA overexpression was not (P=0.3142). In a more extensive series;of 351 breast cancers, there was no correlation between cyclin D1 and EMS1 expression in the EMS1 and cyclin D1 overexpressors (P=0.3503). Although an association between EMS1 mRNA expression and ER positivity was evident (P=0.0232), when the samples were divided into quartiles of EMSI or cyclin D1 mRNA expression, the increase in the proportion of ER positive tumours in the ascending EMS1 mRNA quartiles was not statistically significant (P=0.0951), In marked contrast there was a significant stepwise increase in ER positivity in ascending quartiles of cyclin D1 mRNA (P=0.030), A potential explanation for this difference was provided by the observation that in ER positive breast cancer cells oestradiol treatment resulted in increased cyclin D1 gene expression but was without effect on EMS1, The relationship between EMSI expression and clinical outcome was examined in a subset of 234 patients with median follow-up of 74 months, High EMSI expression was associated with age >50 years (P=0.0001), postmenopausal status (P=0.0008), lymph node negativity (P=0.019) and an apparent trend for worse prognosis in the ER negative subgroup, These data demonstrate that overexpression of EMS1 mRNA is largely due to EMSI gene amplification, is independent of cyclin DI and ER expression and, in contrast to cyclin D1, is not regulated by oestrogen, Independent overexpression of these genes may confer different phenotypes and disease outcomes in breast cancer as has been inferred from recent studies of EMSI and CCND1 gene amplification.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Mater Misericordiae Hosp, Dept Surg Oncol, Waratah, NSW 2298, Australia; City Hosp Nottingham, Dept Surg, Nottingham NG5 1PB, England; Univ Wales Coll Med, Breast Canc Unit, Tenovus Canc Res Ctr, Cardiff CF4 4XX, S Glam, Wales	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Cardiff University	Sutherland, RL (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.		Ball, Jonathon/K-1076-2015; Sutherland, Robert L/A-8378-2008; Daly, Roger J/C-8179-2009	Ball, Jonathon/0000-0003-0594-8063; Daly, Roger/0000-0002-5739-8027; Campbell, Douglas/0000-0001-9699-1854				ADNANE J, 1989, ONCOGENE, V4, P1389; Altucci L, 1996, ONCOGENE, V12, P2315; BARTKOVA J, 1995, ONCOGENE, V10, P775; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BERNS EMJJ, 1992, EUR J CANCER, V28A, P697, DOI 10.1016/S0959-8049(05)80129-7; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; Bringuier PP, 1996, ONCOGENE, V12, P1747; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FANTL V, 1993, CANCER SURV, V18, P77; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; GAFFEY MJ, 1993, MODERN PATHOL, V6, P654; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Hui R, 1996, CLIN CANCER RES, V2, P923; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Patel AM, 1996, ONCOGENE, V12, P31; Pelosio P, 1996, ANN ONCOL, V7, P695; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; vanDiest PJ, 1997, AM J PATHOL, V150, P705; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	36	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1053	1059		10.1038/sj.onc.1202023	http://dx.doi.org/10.1038/sj.onc.1202023			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747885				2022-12-17	WOS:000075560900014
J	Matsuo, T; Thiele, CJ				Matsuo, T; Thiele, CJ			p27(Kip1): a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line	ONCOGENE			English	Article						neuroblastoma; retinoids; cell cycle; p27(Kip1); N-myc; G1 cyclin; cdk	DEPENDENT KINASE INHIBITOR; HUMAN NEURO-BLASTOMA; POTENTIAL MEDIATOR; CDK2 ACTIVITY; CYCLIN-E; DIFFERENTIATION; EXPRESSION; INDUCTION; G(1); ACTIVATION	Retinoic acid (RA) treatment of SMS-KCNR neuroblastoma (NB) cells leads to G1 growth arrest and neuronal differentiation. To investigate the molecular mechanisms by which RA alters cell growth, we analysed the expression and activity of components of the cell cycle machinery after culture in RA. Within 2 days of RA treatment and prior to the arrest of NE cells in the G1 phase of the cell cycle, there is a complete downregulation of G1 cyclin/Cdk activities. Protein levels for the G1 cyclin/Cdks were essentially unchanged during this time although there was a decrease in the steady-state levels of p67(N-Myc) and hyperphosphorylated Rb proteins. The Cdk inhibitors, p21(Cipl) and p27(Kip1) were constitutively expressed in KCNR while p15(INK4B) and p16(INK4A) were not detected. RA induced an increase in the expression of p27(Kip1) but not p21(Cip1). Furthermore, coincident with the decrease in kinase activity there was an increase in G1 cyclin/Cdk bound p27(Kip1). These results indicate that changes in the level of p27(Kip1) and its binding to G1 cyclin/Cdks may play a key role in RA induced growth arrest of NB cells.	NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thiele, CJ (corresponding author), NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, 10 Ctr Dr,MSC-1928, Bethesda, MD 20892 USA.							COHEN PS, 1995, CANCER RES, V55, P2380; Cushing H, 1927, AM J PATHOL, V3, P203; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; GAETANO C, 1992, CANCER RES, V52, P4402; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIDELL N, 1982, J NATL CANCER I, V68, P589; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang QM, 1996, CANCER RES, V56, P264; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	44	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3337	3343		10.1038/sj.onc.1201830	http://dx.doi.org/10.1038/sj.onc.1201830			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681834				2022-12-17	WOS:000074343600016
J	Liu, NS; Lucibello, FC; Engeland, K; Muller, R				Liu, NS; Lucibello, FC; Engeland, K; Muller, R			A new model of cell cycle-regulated transcription: Repression of the cyclin A promoter by CDF-1 and anti-repression by E2F	ONCOGENE			English	Article						cyclin A; CDF; E2F; transcriptional repression	B-MYB TRANSCRIPTION; CDC25C TRANSCRIPTION; IN-VIVO; A GENE; SITE; EXPRESSION; INITIATION; ELEMENT; COMPLEX	Cell cycle regulation of the cyclin A gene is determined by a bipartite repressor binding site in the region of the basal promoter, termed CDE-CHR, which also controls the expression of cell cycle genes upregulated in S or G(2) (such as cdc25C). The CDE-CHR in the cyclin A promoter is recognized by both E2F complexes and CDF-1, but the contribution of each of these factors in cell cycle regulation is unknown. In the present study, we have introduced mutations into the cyclin A promoter which lead to either a loss or enhancement of E2F binding, while having only marginal effects on the interaction with CDF-1. Unlike mutants deficient for CDF-1 binding, promoter variants lacking E2F binding showed an unchanged repression in G(0), thus identifying CDF-1 as the principal repressor of the cyclin A gene. The same mutants did show, however, a delayed derepression while a mutation leading to increased E2F binding resulted in premature up-regulation. These findings clearly suggest that E2F contributes to the correct timing of cyclin A transcription, presumably by acting as an anti-repressor. In agreement with this conclusion, we find that the cyclin A promoter only poorly interacts with E2F-4, which is the major E2F family member in G, cells, while a clear binding is seen with E2F-1 and -3, which are up-regulated in late G(1).	Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Molekularbiol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016; Engeland, Kurt/AAW-9965-2020	Müller, Rolf/0000-0003-3339-4248; Engeland, Kurt/0000-0003-3525-0440				DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huet X, 1996, MOL CELL BIOL, V16, P3789; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Muller H, 1997, MOL CELL BIOL, V17, P5508; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Oswald F, 1996, MOL CELL BIOL, V16, P1889; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	31	75	75	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2957	2963		10.1038/sj.onc.1201838	http://dx.doi.org/10.1038/sj.onc.1201838			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662327				2022-12-17	WOS:000074125300001
J	Schwachtgen, JL; Janel, N; Barek, L; Duterque-Coquillaud, M; Ghysdael, J; Meyer, D; Kerbiriou-Nabias, D				Schwachtgen, JL; Janel, N; Barek, L; Duterque-Coquillaud, M; Ghysdael, J; Meyer, D; Kerbiriou-Nabias, D			Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene	ONCOGENE			English	Article						Ets family of proteins; gene regulation; von Willebrand factor; endothelial cells	HUMAN-ENDOTHELIAL-CELLS; HUMAN VONWILLEBRAND-FACTOR; DNA-BINDING; ACTIVATION PROPERTIES; VASCULAR ENDOTHELIUM; 5'-FLANKING REGION; INITIATION SITE; IIB GENE; EXPRESSION; PROTEIN	von Willebrand factor (VWF) gene expression is restricted to endothelial cells and megakaryocytes. Previous results demonstrated that basal transcription of the human vWF gene is mediated through a promoter located between base pairs -89 and +19 (cap site: +1) which is functional in endothelial and non endothelial cells, Two DNA repeats TTTCCTTT correlating,vith inverted consensus binding sites for the Ets family of transcription factors are present in the -56/-36 sequence, In order to analyse whether these DNA elements are involved in transcription, human umbilical vein endothelial cells (HUVEC), bovine calf pulmonary endothelial cell line (CPAE), HeLa and COS cells mere transfected with constructs containing deletions of the -89/+19 fragment, linked to the chloramphenicol acetyl transferase (CAT) reporter gene, The -60/+19 region exhibits significant promoter activity in HUVEC and CPAE cells only, The -42/+19 fragment is not active, Mutations of the -60/+19 promoter fragment in the 5' (-56/-49) Ets binding site abolish transcription in endothelial cells whereas mutations in the 3' (-43/ -36) site does not, The -60/-33 fragment forms three complexes with proteins from HUVEC nuclear extracts in electrophoretic mobility shift assay which are dependent on the presence of the 5' Ets binding site, Binding of recombinant Ets-1 protein to the -60/-33 fragment gives a complex which also depends on the 5' site, The -60/+19 VWF gene core promoter is transactivated in HeLa cells by cotransfecting with Ets-1 or Erg (Ets-related gene) expression plasmids, In contrast to the wild type construct, transcription of the 5' site mutants is not increased by these expressed proteins, The results indicate that the promoter activity of the -60/+19 region of the vWF gene depends on transcription factors of the Ets family of which several members like Ets-1, Ets-2 and Erg are expressed in endothelium. Cotransfection of Ets-1 and Erg expression plasmids is sufficient to induce the -60/+19 vWF promoter activity in HeLa cells.	Hop Bicetre, Unite Rech Hemostase & Thrombose, INSERM U 143, F-94275 Le Kremlin Bicetre, France; Inst Biol Lille, CNRS, UMR 319, F-59021 Lille, France; Inst Curie, Ctr Univ, CNRS, UMR 146, F-91405 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Kerbiriou-Nabias, D (corresponding author), Hop Bicetre, Unite Rech Hemostase & Thrombose, INSERM U 143, F-94275 Le Kremlin Bicetre, France.		GHYSDAEL, Jacques/F-3377-2013	Janel, Nathalie/0000-0002-4746-8941; Duterque-Coquillaud, Martine/0000-0003-3943-5629				AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; ASSOULINE Z, 1988, BIOCHEM BIOPH RES CO, V153, P1159, DOI 10.1016/S0006-291X(88)81349-4; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAHNAK BR, 1989, J CELL PHYSIOL, V138, P305, DOI 10.1002/jcp.1041380212; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BONTHRON D, 1988, EUR J BIOCHEM, V171, P51, DOI 10.1111/j.1432-1033.1988.tb13757.x; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Buttice G, 1996, ONCOGENE, V13, P2297; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; COLLINS CJ, 1987, P NATL ACAD SCI USA, V84, P4393, DOI 10.1073/pnas.84.13.4393; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGROOT PG, 1987, ARTERIOSCLEROSIS, V7, P605, DOI 10.1161/01.ATV.7.6.605; DEGUINE V, 1995, BLOOD COAGUL FIBRIN, V6, P42, DOI 10.1097/00001721-199502000-00007; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; FERREIRA V, 1993, BIOCHEM J, V293, P641, DOI 10.1042/bj2930641; FISHER RJ, 1992, J BIOL CHEM, V269, P17957; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GEBRANEYOUNES J, 1991, AM J PATHOL, V139, P1471; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HOSHI H, 1984, P NATL ACAD SCI-BIOL, V81, P6413, DOI 10.1073/pnas.81.20.6413; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JAFFE EA, 1974, P NATL ACAD SCI USA, V71, P1906, DOI 10.1073/pnas.71.5.1906; Jahroudi N, 1996, J BIOL CHEM, V271, P21413, DOI 10.1074/jbc.271.35.21413; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Janel N, 1995, GENE, V167, P291, DOI 10.1016/0378-1119(95)00696-6; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; LEMARCHANDEL V, 1993, MOL CELL BIOL, P668; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MARTIN F, 1993, J BIOL CHEM, V268, P21606; NACHMAN RL, 1975, J EXP MED, V141, P101; PAGE C, 1992, AM J PATHOL, V141, P673; PRASAD DDK, 1994, ONCOGENE, V9, P669; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROUET P, 1992, BIOTECHNIQUES, V13, P700; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SADLER JE, 1994, THROMB HAEMOSTASIS, V71, P520; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCHWACHTGEN JL, 1994, BIOTECHNIQUES, V17, P882; SCHWACHTGEN JL, 1996, J VASC RES S1, V33, P90; Shore P, 1996, MOL CELL BIOL, V16, P3338; SPORN LA, 1985, J CLIN INVEST, V76, P1102, DOI 10.1172/JCI112064; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WERNERT N, 1992, AM J PATHOL, V140, P119; WERNERT N, 1994, CANCER RES, P5683	63	75	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3091	3102		10.1038/sj.onc.1201502	http://dx.doi.org/10.1038/sj.onc.1201502			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444957				2022-12-17	WOS:000070968000009
J	TakahashiTezuka, M; Hibi, M; Fujitani, Y; Fukada, T; Yamaguchi, T; Hirano, T				TakahashiTezuka, M; Hibi, M; Fujitani, Y; Fukada, T; Yamaguchi, T; Hirano, T			Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK	ONCOGENE			English	Article						JAK; Btk; Tec; PI-3 kinase; cytokine receptor	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCER; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; BRUTON TYROSINE; SRC-FAMILY; ERYTHROPOIETIN RECEPTOR; REGULATORY SUBUNIT	Tec/Btk tyrosine kinases are members of a subgroup of Src tyrosine kinase family. They are reported to be activated in response to cytokines, such as IL-3 and IL-6. Janus kinases (JAKs) are known to associate with certain cytokine receptors, e.g. gp130, the signal transducing subunit of IL-6 receptor, and the common beta chain of IL-3 receptor, which can be activated upon receptor dimerization in response to cytokines. Here we show the association between Jak1/Jak2 and Tec or Jak1 and Btk. Furthermore, Jak1 but not Jak2 induces tyrosine phosphorylation of Btk, but not Tee. These observations suggest that upon cytokine stimulation JAKs activate Tec/Btk or induce their dimerization resulting in endogenous tyrosine phosphorylation. Furthermore using a yeast two-hybrid system we have identified the target molecules for Tee, the p85 and p55PIK subunits of PI-3 kinase, and Vav. Tec associated with Vav through its SH2 domain independently of its kinase activity. In contrast the p85 and p55PIK subunits of PI-3 kinase associated with the SH2-kinase domain of Tee, dependent on Tec kinase activity. Consistent with these, IL-6 or IL-3 induced the association between Tec and the p85 subunit of PI-3 kinase in mammalian cells. These findings suggest that Tec tyrosine kinase links cytokine receptors to PI-3 kinase probably through JAKs.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT MOL ONCOL, SUITA, OSAKA 565, JAPAN	Osaka University			Hirano, Toshio/C-8194-2009; Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARGUMEDO LS, 1995, INT IMMUNOL, V7, P163; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CANTLEY LC, 1994, J CELL SCI, P121; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKADA T, 1996, IN PRESS IMMUNITY; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARPER JW, 1993, CELL, V75, P805; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HE TC, 1993, BLOOD, V82, P3530; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HIRANO T, 1994, CYTOKINE HDB, P145; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JUCKER M, 1995, J BIOL CHEM, V270, P27817; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACHIDE M, 1995, ONCOGENE, V11, P619; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MANO H, 1995, BLOOD, V85, P343; MANO H, 1994, ONCOGENE, V9, P3205; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MIURA O, 1994, J BIOL CHEM, V269, P614; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OKADA T, 1994, J BIOL CHEM, V269, P3568; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PONS S, 1995, MOL CELL BIOL, V15, P4453; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAITO M, 1992, J IMMUNOL, V148, P4066; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TOKER A, 1994, J BIOL CHEM, V269, P32358; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITMAN M, 1989, BIOCHIM BIOPHYS ACTA, V948, P327, DOI 10.1016/0304-419X(89)90005-X; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YIN TG, 1993, J IMMUNOL, V151, P2555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x	92	75	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2273	2282		10.1038/sj.onc.1201071	http://dx.doi.org/10.1038/sj.onc.1201071			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178903				2022-12-17	WOS:A1997WY88300004
J	Akagi, T; Ono, H; Nyunoya, H; Shimotohno, K				Akagi, T; Ono, H; Nyunoya, H; Shimotohno, K			Characterization of peripheral blood T-lymphocytes transduced with HTLV-I Tax mutants with different trans-activating phenotypes	ONCOGENE			English	Article						HTLV-I; Tax; CD4; CD8; NF-kappa B; CREB/ATF	VIRUS TYPE-I; HUMAN INTERLEUKIN-6 GENE; CELL LEUKEMIA; RETROVIRAL VECTORS; EXPRESSION; TRANSCRIPTION; INFECTION; PROTEIN; GROWTH; MECHANISMS	Tax1, a transcriptional trans-activator of the Human T-cell leukemia virus type I (HTLV-I), induces the expression of many cellular genes through interaction with at least three distinct cellular transcription factors; CREB/ATF, NF-kappa B, and SRF. This Tax1-induced activation of cellular genes is considered to be a critical event in T-cell transformation by HTLV-I. To elucidate the role of each Taxi-inducible transcriptional pathway in T-cell transformation, we introduced Tax1 mutants with different trans-activating phenotypes into peripheral blood lymphocytes (PBL) by retroviral vectors. Analysis of these PBLs revealed that activation of the NF-kappa B pathway is sufficient to promote the growth response to IL-2. However, for the clonal expansion of CD4+ T-cells, which is a characteristic result of HTLV-I infection, activation of the CREB/ATF and SRF pathways is also required.	NATL CANC CTR,RES INST,DIV VIROL,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan			Nyunoya, Hiroshi/C-9705-2013	Nyunoya, Hiroshi/0000-0002-3237-9639				ABE Y, 1993, LYMPHOKINE CYTOK RES, V12, P279; AKAGI T, 1991, GENE, V106, P255, DOI 10.1016/0378-1119(91)90207-R; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; AKAGI T, 1995, FEBS LETT, V358, P34, DOI 10.1016/0014-5793(94)01390-M; ASANO M, 1994, J IMMUNOL, V153, P5373; Bailly S, 1996, EUR CYTOKINE NETW, V7, P125; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; DEROSSI A, 1985, VIROLOGY, V143, P640, DOI 10.1016/0042-6822(85)90405-2; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GULLBERG M, 1986, J EXP MED, V163, P270, DOI 10.1084/jem.163.2.270; Hahn B, 1984, Mol Biol Med, V2, P29; HARPER ME, 1986, NEW ENGL J MED, V315, P1073, DOI 10.1056/NEJM198610233151707; Higashimura N, 1996, JPN J CANCER RES, V87, P227, DOI 10.1111/j.1349-7006.1996.tb00210.x; HIMES SR, 1993, ONCOGENE, V8, P3189; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; LEE HM, 1993, J IMMUNOL, V151, P668; MARKHAM PD, 1984, INT J CANCER, V33, P13, DOI 10.1002/ijc.2910330104; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; MORI N, 1994, BLOOD, V84, P350; MORI N, 1994, BLOOD, V84, P2904; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OHBO K, 1995, J BIOL CHEM, V270, P7479, DOI 10.1074/jbc.270.13.7479; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1995, GENE DEV, V9, P2324; SOLDAINI E, 1992, EUR J IMMUNOL, V22, P1707, DOI 10.1002/eji.1830220707; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAM SW, 1994, CANCER RES, V54, P5816; TANAKA Y, 1991, INT J CANCER, V48, P623, DOI 10.1002/ijc.2910480423; TATEWAKI M, 1995, BLOOD, V86, P3109; vanBergen CAM, 1996, ANN HEMATOL, V72, P245, DOI 10.1007/s002770050167; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAMASHITA I, 1994, BLOOD, V84, P1573; YANG SC, 1990, CANCER RES, V50, P3526; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D	47	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2071	2078		10.1038/sj.onc.1201045	http://dx.doi.org/10.1038/sj.onc.1201045			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160887				2022-12-17	WOS:A1997WW80900009
J	Sun, Y; Bian, JH; Wang, YL; Jacobs, C				Sun, Y; Bian, JH; Wang, YL; Jacobs, C			Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound	ONCOGENE			English	Article						phenanthroline; p53; transcriptional activation; apoptosis; redox regulation	WILD-TYPE P53; CELL-CYCLE CHECKPOINT; DNA-BINDING; ANTICANCER AGENTS; APOPTOSIS; SEQUENCE; CONFORMATION; INDUCTION; PROTEIN; GENE	p53, a tumor suppressor gene, functioning as transcription factor, has been recently shown in a cell free system to be subject to redox (reduction/oxidation) regulation. Oxidants or metal chelating reagents disrupt wildtype p53 conformation and decrease or abolish its DNA binding activity, while reductants restore wildtype conformation and increase DNA binding. We have extended these observations to intact cell systems by using luciferase transactivation assay in two murine tumor cell lines, both harboring endogenous wildtype p53. The results showed that none of these in vitro active reagents, except 1,10-phenanthroline (OF) has a significant effect on p53 transactivation activity. OF, a metal chelator and p53 inactivator in cell free systems, however, induces p53 transactivation activity as well as sequence-specific DNA binding in a dose dependent manner. OP also differentially induces endogenous expression of several known p53 target genes such as Waf-1 and Mdm-2, but not Bar, Gadd45, and PCNA. Increased p53 activity induced by OP is not due to elevated p53 mRNA nor to protein levels. Furthermore, the OP-induced p53 transcriptional activation is not due to its potential DNA intercalating activity, but mainly due to its metal chelating activity. OF was also found to induce dramatically apoptotic cell death in these tumor cells harboring wildtype p53, to a less extent in MEF cells from p53 knockout mice and not at all in Saos-2 cells without p53 or Rb. We concluded from this study that (a) unlike what has been seen in vitro, OP induces p53 activity in intact cells (b) OP activates p53 transcriptional activity without increasing p53 protein; and (c) activation of p53 may contribute to apoptosis, but is not required.			Sun, Y (corresponding author), WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT MOL BIOL, 2800 PLYMOUTH RD, ANN ARBOR, MI 48105 USA.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ADEBODUN F, 1995, J CELL PHYSIOL, V163, P80, DOI 10.1002/jcp.1041630109; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRY DW, 1985, BIOCHEM PHARMACOL, V34, P3499, DOI 10.1016/0006-2952(85)90724-5; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUGHES FM, 1994, J STEROID BIOCHEM, V49, P303, DOI 10.1016/0960-0760(94)90272-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; SEBOLT JS, 1987, CANCER RES, V47, P4299; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SRINIVASAN R, 1993, CANCER RES, V53, P5361; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; SUN Y, 1995, INT J ONCOL, V6, P465; TISHLER RB, 1993, CANCER RES, V53, P2212; TISHLER RB, 1995, CANCER RES, V55, P6021; WHITACRE CM, 1995, CANCER RES, V55, P3697; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YI S, 1993, INT J CANCER, V55, P952, DOI 10.1002/ijc.2910550613; ZALEWSKI PD, 1991, BIOCHEM INT, V24, P1093; ZHAN QM, 1994, ONCOGENE, V9, P3743	55	75	79	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					385	393		10.1038/sj.onc.1200834	http://dx.doi.org/10.1038/sj.onc.1200834			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053835				2022-12-17	WOS:A1997WE36400001
J	deMedina, SGD; Chopin, D; ElMarjou, A; Delouvee, A; LaRochelle, WJ; Hoznek, A; Abbou, C; Aaronson, SA; Thiery, JP; Radvanyi, F				deMedina, SGD; Chopin, D; ElMarjou, A; Delouvee, A; LaRochelle, WJ; Hoznek, A; Abbou, C; Aaronson, SA; Thiery, JP; Radvanyi, F			Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; human; transitional cell carcinoma; tumor progression	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; LIGAND-BINDING SPECIFICITY; FGF RECEPTOR; K-SAM; TARGETED EXPRESSION; HUMAN KERATIN-18; CANCER; MOUSE; CLONING; FAMILY	Growth factors and growth factor receptors are involved in tumor progression, The fibroblast growth factor receptor 2 gene encodes distinct isoforms, The isoforms which bind KGF (keratinocyte growth factor or FGF-7) are called KGF-R or FGFR2b. KGF-R is expressed in different epithelia and is involved in the control of epithelial-mesenchymal interactions. Expression of KGF-R mRNA was examined in normal human bladder and transitional cell carcinoma of the bladder (TCC) by semi-quantitative RT-PCR using TFIID and GAPDH as internal standards, In normal bladder, the KGF-R mRNA was detected in the urothelium but not in the underlying stroma, In TCCs, the level of KGF-R mRNA was generally either normal or low, Eighteen out of 54 TCCs had a KGF-R mRNA level below 30% of that found in normal urothelium, This decrease in KGF-R mRNA was not accompanied by an increase in BEK (FGFR2c) mRNA, the other major splice variant of the fibroblast growth factor receptor 2 gene, Expression of the KGF-R was also monitored by immunohistochemistry using a functional KGF-immunoglobulin chimera, The receptor was uniformly expressed throughout the normal urothelium except for the umbrella cells, Immunoreactivity for KGF-R was found to be negative in tumors with low levels of KGF-R mRNA, while the peritumoral normal urothelium was positive, Among patients with muscle invasive tumors, those exhibiting a low level of HGF-R mRNA had a significantly higher proportion of cancer deaths, Our results suggest that decreased expression of KGF-R can be considered as a marker of tumor progression in muscle invasive TCCs.	INST CURIE, CNRS, UMR 144, F-75248 PARIS 05, FRANCE; CHU HENRI MONDOR, GRP ETUD TUMEURS UROL, CRCHM, F-94010 CRETEIL, FRANCE; CHU HENRI MONDOR, UROL SERV, F-94010 CRETEIL, FRANCE; NCI, NIH, BETHESDA, MD 20892 USA; MT SINAI SCH MED, RUTTENBERG CANC CTR, NEW YORK, NY USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai			Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Radvanyi, Francois/0000-0002-5696-6424; Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DIONNE CA, 1992, CYTOGENET CELL GENET, V60, P34, DOI 10.1159/000133290; EISEMANN A, 1991, ONCOGENE, V6, P1195; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISHII H, 1995, MOL CELL BIOL, V15, P3664; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNOWLES MA, 1994, CANCER RES, V54, P531; KULESH DA, 1989, GENOMICS, V4, P339, DOI 10.1016/0888-7543(89)90340-6; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LEUBE RE, 1986, DIFFERENTIATION, V33, P69, DOI 10.1111/j.1432-0436.1986.tb00412.x; LI ZL, 1989, GENE, V78, P243; LORENZI MV, 1995, ONCOGENE, V10, P2051; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; MELLON K, 1995, J UROLOGY, V153, P919, DOI 10.1016/S0022-5347(01)67604-3; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Mostofi FK, 1973, INT HISTOLOGICAL CLA; Nakagawara A, 1994, Prog Clin Biol Res, V385, P155; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; OSHIMA RG, 1986, DIFFERENTIATION, V33, P61, DOI 10.1111/j.1432-0436.1986.tb00411.x; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SPIESSL B, 1992, ILLUSTRATED GUIDE TN, P214; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	55	75	76	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	1997	14	3					323	330		10.1038/sj.onc.1200830	http://dx.doi.org/10.1038/sj.onc.1200830			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018118				2022-12-17	WOS:A1997WD51600008
J	Foster, SA; Galloway, DA				Foster, SA; Galloway, DA			Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells	ONCOGENE			English	Article						HPV; E7; epithelial cells; cell cycle	RETINOBLASTOMA GENE-PRODUCT; MAMMALIAN FIBROBLASTS; CELLULAR-RESPONSE; P53 PROTEIN; DNA DAMAGE; CYCLIN-A; PHOSPHORYLATION; EXPRESSION; E6; IMMORTALIZATION	Human mammary epithelial cells (HMEC) isolated from reduction mammoplasty tissue are proliferative for several passages but then enter a period termed 'selection' or M0 during which the majority of the cells become larger, flattened, and less proliferative. Early passage HMEC (prior to M0) were transduced with human papillomavirus type-16 E6, E7, or E6/E7 by using recombinant retroviral vectors. E7 alone or E6/E7, but not E6 alone, alleviated the M0 proliferation block, suggesting a possible role for Rb or Rb-related proteins, but not p53, in M0. In addition, cells in M0 did not have increased levels of p53 or p21 proteins, further indicating that induction of these proteins is not required for the M0 proliferation block. Early passage cells contained Rb which was primarily hyperphosphorylated while cells in M0 contained Rb protein which was predominantly underphosphorylated. Cells in M0 accumulated in G(1) or G(0) and expressed reduced levels of cyclin A and CDKZ proteins.			Foster, SA (corresponding author), FRED HUTCHINSON CANC RES CTR, CANC BIOL PROGRAM, 1124 COLUMBIA ST, C1-015, SEATTLE, WA 98104 USA.				NATIONAL CANCER INSTITUTE [R01CA064795, F32CA062584] Funding Source: NIH RePORTER; NCI NIH HHS [CA64795, CA62584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1993, ONCOGENE, V8, P1407; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Werness B A, 1991, Important Adv Oncol, P3; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	75	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1773	1779						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622898				2022-12-17	WOS:A1996UG45800020
J	Livneh, E; Shimon, T; Bechor, E; Doki, Y; Schieren, I; Weinstein, IB				Livneh, E; Shimon, T; Bechor, E; Doki, Y; Schieren, I; Weinstein, IB			Linking protein kinase C to the cell cycle: Ectopic expression of PKC eta in NIH3T3 cells alters the expression of cyclins and Cdk inhibitors and induces adipogenesis	ONCOGENE			English	Article						protein kinase C; cell cycle; cyclins; Cdk inhibitors; adipogenesis	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT REGULATION; RAT FIBROBLASTS; PHORBOL ESTER; 3T3 CELLS; NPKC-ETA; DIFFERENTIATION; PHOSPHORYLATION; ACTIVATION; EPSILON	Protein kinase C encodes a family of enzymes implicated in cellular differentiation, growth control and tumor promotion. However, very little is known with respect to the molecular mechanisms that link protein kinase C to cell cycle control. Here we report that ectopic expression of PKC eta in NIH3T3 fibroblasts blocks the normal phosphorylation of the Rb protein in quiescent cultures restimulated to enter the cell cycle; PKC eta activates a cellular program that includes increased expression of cyclins E (but not cyclin D), as well as the induced expression of the cyclin-dependent kinase inhibitors p21(WAF1) and p27(KIP1). The increased expression of the latter inhibitors and their association with the cyclin E-Cdk2 complex results in decreased cyclin E associated kinase activity. Furthermore, in contrast to the control NIH3T3 cells, the cells that express PKC eta can be induced to undergo adipocyte differentiation in response to adipogenic hormones. Thus, PKC eta induces altered expression of several cell cycle related functions, which may contribute to its ability to promote cellular differentiation.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032	Columbia University	Livneh, E (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.				NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BELL RM, 1991, J BIOL CHEM, V266, P4661; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CACACE AM, 1993, ONCOGENE, V8, P2095; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1992, TIBS, V17, P310; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DOI S, 1994, MOL CARCINOGEN, V11, P197, DOI 10.1002/mc.2940110405; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIVNEH E, 1994, SIGNAL ACTIVATED PHO, P165; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOKER A, 1994, J BIOL CHEM, V269, P32358; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WIMMEL A, 1994, ONCOGENE, V9, P995; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641	63	75	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1545	1555						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622871				2022-12-17	WOS:A1996UF07600019
J	SONODA, Y; YOSHIMOTO, T; SEKIYA, T				SONODA, Y; YOSHIMOTO, T; SEKIYA, T			HOMOZYGOUS DELETION OF THE MTS1/P16 AND MTS2/P15 GENES AND AMPLIFICATION OF THE CDK4 GENE IN GLIOMA	ONCOGENE			English	Article						GLIOMA; HOMOZYGOUS DELETION; MTS1/P16 GENE; MTS2/P15 GENE; CDK4 GENE	POLYMERASE CHAIN-REACTION; DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN BRAIN-TUMORS; MUTATIONS; DNA	Loci on chromosome 9p are frequently deleted in several malignant tumors, suggesting the presence of putative tumor suppressor genes. The MTS1/p16 and MTS2/p15 genes on 9p are considered to be candidates. Binding of p15 and p16 cell cycle-regulatory proteins to the cyclin dependent protein kinase CDK4 inhibits CDK4/cyclin D dependent phosphorylation of retinoblastoma protein. We analysed the DNAs from 37 gliomas of several grades of malignancy for allelic loss of chromosome 9p and abberations of the MTS1/p16 and MTS2/p15 genes. We detected losses of one allele and homozygous deletions at loci, including those of the MTS1/p16 and MTS2/p15 genes, in 10 and 3 tumors, respectively. However, we did not detect any tumor-specific mutation in the two genes. The CDK4 gene was amplified in two malignant gliomas without homozygous deletion of the MTS1/p16 and MTS2/p15 genes and one malignant glioma with an allelic loss of the genes. These data suggest that aberrations of the genes coding for components of the cell cycle-regulatory system occured in at least 15 of 37 gliomas.	NATL CANC CTR,RES INST,DIV ONCOGENE,CHUO KU,TOKYO 104,JAPAN; TOHOKU UNIV,SCH MED,DEPT NEUROSURG,AOBA KU,SENDAI,MIYAGI 980,JAPAN	National Cancer Center - Japan; Tohoku University				Sonoda, Yukihiko/0000-0001-7651-1374				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; COOLEMAN A, 1994, CANCER RES, V54, P344; FOUNTAIN JW, 1993, HUM MOL GENET, V2, P823, DOI 10.1093/hmg/2.6.823-a; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FULTS D, 1990, CANCER RES, V50, P5784; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; KWIATKOWSKI DJ, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658-a; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; RUBIO MP, 1994, CANCER RES, V54, P4760; SCHMIDT EE, 1994, CANCER RES, V554, P6321; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; ZULCH KJ, 1979, WHO GENEVA	29	75	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2145	2149						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478535				2022-12-17	WOS:A1995TF29700026
J	NISHINO, H; KNOLL, A; BUETTNER, VL; FRISK, CS; MARUTA, Y; HAAVIK, J; SOMMER, SS				NISHINO, H; KNOLL, A; BUETTNER, VL; FRISK, CS; MARUTA, Y; HAAVIK, J; SOMMER, SS			P53 WILD-TYPE AND P53 NULLIZYGOUS BIG-BLUE TRANSGENIC MICE HAVE SIMILAR FREQUENCIES AND PATTERNS OF OBSERVED MUTATION IN LIVER, SPLEEN AND BRAIN	ONCOGENE			English	Article						P53; LACI TRANSGENIC MICE; MUTATION FREQUENCY	P53-DEFICIENT MICE; IONIZING-RADIATION; GENE AMPLIFICATION; SOMATIC MUTATION; MAMMALIAN-CELLS; SHUTTLE VECTOR; SKIN TUMORS; MOUSE MODEL; LACI GENE; HA-RAS	Transgenic mouse mutation detection systems offer a powerful tool for analysis of spontaneous and induced mutations in vivo. Mice doubly transgenic for a null mutation of the p53 tumor suppressor gene and a lambda shuttle vector harboring the lacI gene were utilized to examine the rate and pattern of spontaneous somatic mutation of the lad transgene in vivo. Three somatic tissues were examined: liver, spleen and brain, At 6 weeks of age, three p53 wild type (+/+) and three p53 nullizygous (-/-), lad (+/-) male mice were analysed, The mutation frequencies in the two genotypes were similar. The mutant frequencies for wild type (+/+) and nullizygous (-/-) p53 genotypes were, respectively, 4.2x10(-5) and 3.6x10(-5) in the liver, 4.3x10(-5) and 3.4 x 10(-5) in the spleen and 2.8 x 10(-5) and 3.0 x 10(-5) in the brain. When the data from the three tissues were combined, the mutant frequency was 3.7x10(-5) for the (+/+) genotype and 3.3 x 10(5) for the (-/-) genotype. By sequencing both strands in the DNA-binding region of the lad gene, 91 mutations were found. When recurrent mutations in the same mouse were excluded, a total of 67 definitely independent mutations were found. No statistically significant differences were found in the mutational spectra between the two genotypes when the three tissues were analysed individually or combined (P = 0.58). These findings suggest a need to reconsider the general form of hypothesis that the p53 gene serves as the 'guardian of the genome'.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT VET MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic				Haavik, Jan/0000-0001-7865-2808; Knoll, Antje/0000-0002-1294-6923				BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; CALLAHAN JD, 1995, MUTAT RES-FUND MOL M, V327, P201, DOI 10.1016/0027-5107(94)00191-7; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cooper D. N., 1993, HUMAN GENE MUTATION; DAMARUN KM, 1994, SCIENCE, V265, P1582; DIX D, 1989, J GERONTOL, V4, P10; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower Lawrence A., 1994, Cancer Bulletin (Houston), V46, P161; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULDS L, 1958, J Chronic Dis, V8, P2, DOI 10.1016/0021-9681(58)90039-0; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GOSSEN J, 1993, TRENDS GENET, V9, P27, DOI 10.1016/0168-9525(93)90069-T; GOSSEN JA, 1991, MUTAT RES, V250, P423, DOI 10.1016/0027-5107(91)90198-W; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HENDERSON BE, 1988, CANCER RES, V48, P246; HUTCHINSON F, 1993, SEMIN CANCER BIOL, V4, P85; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425; KNOLL A, 1994, MUTAT RES-FUND MOL M, V311, P57, DOI 10.1016/0027-5107(94)90073-6; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, NUCLEIC ACIDS RES, V18, P3007, DOI 10.1093/nar/18.10.3007; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE AT, 1994, FASEB J, V8, P545, DOI 10.1096/fasebj.8.8.8181674; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1989, CANCER RES, V49, P5489; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, ANNU REV GENET, V28, P433; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEHTA CR, 1993, J AM STAT ASSOC, V78, P427; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONROE TJ, 1993, CANCER RES, V53, P5690; MYHR BC, 1991, ENVIRON MOL MUTAGEN, V18, P308, DOI 10.1002/em.2850180420; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; PIEGORSCH WW, 1994, ENVIRON MOL MUTAGEN, V23, P17, DOI 10.1002/em.2850230105; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; PROVOST GS, 1994, P NATL ACAD SCI USA, V91, P6564, DOI 10.1073/pnas.91.14.6564; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAAPER RM, 1991, GENETICS, V129, P317; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SISK SC, 1994, CARCINOGENESIS, V15, P471, DOI 10.1093/carcin/15.3.471; SOMMER SS, 1994, MUTAT RES, V307, P517; SOMMER SS, 1992, FASEB J, V6, P2767, DOI 10.1096/fasebj.6.10.1634040; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAO KS, 1993, P NATL ACAD SCI USA, V90, P10681, DOI 10.1073/pnas.90.22.10681; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	65	75	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					263	270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624143				2022-12-17	WOS:A1995RK95700007
J	JAMAL, S; ZIFF, EB				JAMAL, S; ZIFF, EB			RAF PHOSPHORYLATES P53 IN-VITRO AND POTENTIATES P53-DEPENDENT TRANSCRIPTIONAL TRANSACTIVATION IN-VIVO	ONCOGENE			English	Article						RAF; P53; TRANSCRIPTION; PHOSPHORYLATION; KINASE; BACULOVIRUS	CASEIN KINASE-II; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SERUM RESPONSE ELEMENT; MAP-KINASE; V-RAF; GENE-EXPRESSION; MOUSE P53; C-FOS; ACTIVATION	Using recombinant baculovirus expressed p53 and Raf proteins, we show that activated Raf-1 kinase can phosphorylate mouse p53 in vitro. We also show that co-expression of vRaf and p53 in NIH3T3 fibroblasts, potentiates the ability of p53 to transactivate a minimal promoter with a p53 cognate DNA binding site. A dominant negative mutant of Raf inhibits the transactivation function of p53 in NIH3T3 fibroblasts. Incubation of Raf-1 kinase with a series of p53 derived synthetic peptides maps the Raf-1 phosphorylation sites to the 27 amino terminal residue region of p53 which coincides with the transactivation domain. Phosphorylation occurs on serines which are phosphorylated in vivo. Our results suggest that the transactivation function of p53 can be regulated by a signaling cascade involving Raf.	NYU,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	Howard Hughes Medical Institute; New York University; New York University				Ziff, Edward/0000-0001-7389-8649				BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUSCHER D, 1993, ONCOGENE, V8, P3323; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRAISS S, 1990, ONCOGENE, V5, P845; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; LOWE PN, 1991, J BIOL CHEM, V266, P1672; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; METZ R, 1991, ONCOGENE, V6, P2165; MIHALY A, 1991, BRAIN RES, V547, P309, DOI 10.1016/0006-8993(91)90976-3; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; OLAH Z, 1991, EXP BRAIN RES, V84, P403; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEGAWA K, 1993, FEBS LETT, V329, P283, DOI 10.1016/0014-5793(93)80238-P; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	75	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2095	2101						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784054				2022-12-17	WOS:A1995RB70300004
J	WHITEHEAD, I; KIRK, H; KAY, R				WHITEHEAD, I; KIRK, H; KAY, R			RETROVIRAL TRANSDUCTION AND ONCOGENIC SELECTION OF A CDNA-ENCODING DBS, A HOMOLOG OF THE DBL GUANINE-NUCLEOTIDE EXCHANGE FACTOR	ONCOGENE			English	Article						GUANINE NUCLEOTIDE EXCHANGE FACTOR; DBL ONCOGENE; RETROVIRAL VECTOR	VAV PROTOONCOGENE; MOLECULAR-CLONING; SH3 DOMAINS; PROTEIN; RAS; GENE; EXPRESSION; PRODUCT; REGION; CELLS	A retroviral vector was used to transfer a large library of cDNAs from the 32D murine hemopoietic cell line to NIH3T3 fibroblasts, for the purpose of Selecting cDNAs that induce oncogenic transformation. One highly transformed colony arising in the infected NIH3T3 cell culture contained a provirus with a 1900 bp cDNA insert. After recovery and reincorporation into a retroviral vector, this cDNA induced rapid morphological transformation add proliferation when expressed in NIH3T3 or C3H10T1/2 fibroblast cell lines. The transforming cDNA encoded a protein, designated Dbs, which had a region of high sequence similarity to the Dbl proto-oncogene. This region included motifs characteristic of the CDC24 family of guanine nucleotide exchange factors, and an adjacent pleckstrin homology domain. Dbs was distinguished from Dbl by an N-terminal extension and the presence of an SH3 domain at its C terminus. Deletions of the Dbs-encoding; cDNA demonstrated that transformation of NIH3T3 cells required intact exchange factor and pleckstrin homology domains, but dial not require the SH3 domain. In contrast to Dbl, the N-terminal sequences of Dbs did hot suppress its transforming activity. The Dbs gene was expressed at low levels in several murine hemopoietic cell lines and in thymus and spleen, and at higher levels in other tissues, particularly in brain. Dbs may be one of a large family of exchange factors which provide cell-type specific pathways for regulating proliferation via the activation of Ras-like proteins.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V5Z 4E6,CANADA; BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 4E6,CANADA	University of British Columbia; British Columbia Cancer Agency								ADAMS JM, 1992, ONCOGENE, V7, P611; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAN AML, 1994, ONCOGENE, V9, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GOLDSCHMIDTCLER.PJ, 1992, CURR BIOL, V2, P669; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HESITERKAMP N, 1993, J BIOL CHEM, V268, P16903; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1989, ONCOGENE, V4, P1067; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1993, NUCLEIC ACIDS RES, V11, P2427; SELF AJ, 1993, ONCOGENE, V8, P655; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TAN EC, 1993, J BIOL CHEM, V268, P27291; TOKSOZ D, 1994, ONCOGENE, V9, P621; TRAHEY M, 1968, SCIENCE, V242, P1697; VOGELI G, 1985, ANAL BIOCHEM, V151, P442, DOI 10.1016/0003-2697(85)90202-7; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116	57	75	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					713	721						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862449				2022-12-17	WOS:A1995QH61200011
J	PATEL, U; GRUNDFESTBRONIATOWSKI, S; GUPTA, M; BANERJEE, S				PATEL, U; GRUNDFESTBRONIATOWSKI, S; GUPTA, M; BANERJEE, S			MICROSATELLITE INSTABILITIES AT 5 CHROMOSOMES IN PRIMARY BREAST-TUMORS	ONCOGENE			English	Note							DNA-POLYMERASE-BETA; DENYS-DRASH SYNDROME; COLORECTAL-CANCER; WILMS-TUMOR; LENGTH-POLYMORPHISMS; REPEAT POLYMORPHISM; SUPPRESSOR GENES; POINT MUTATIONS; LINKAGE MAP; WT1 GENE	The microsatellite instabilities at nine loci of chromosomes 2p, 8p, 10p and lip and the nm23-H1 locus on 17q21.3 were studied in primary breast tumors. Alterations in the short interspersed tandem repeats in tumor DNA in the form of either larger allele, smaller allele or LOH were observed. Significantly, a high occurrence of alterations in microsatellite polymorphisms at the ANK1, D8S135 and LPL loci of chromosome 8p (46-54%), the D2S119 locus of chromosome 2p (56%), the D10S197 locus at chromosome 10p (88%), and the nm23-H1 locus of chromosome 17q21.3 (46%) were observed in breast tumors. These results provide the first evidence for genomic instabilities at 2p, 8p and 10p in primary ductal and lobular breast carcinomas. No correlation has been found between the stage of the tumor and microsatellite instability, suggesting that microsatellite instability is an early genetic event in breast carcinogenesis.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT GEN SURG,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT CLIN PATHOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation								AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; BACKER JM, 1993, ONCOGENE, V8, P497; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1992, CANCER RES, V52, P5368; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FERRELL RE, 1983, AM J HUM GENET, V35, P78; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUTREAL PA, 1992, CANCER RES, V52, P2624; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; HAN HJ, 1993, CANCER RES, V53, P5087; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KING MC, 1992, NAT GENET, V2, P125; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1991, CANCER RES, V51, P2490; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MCBRIDE OW, 1987, P NATL ACAD SCI USA, V84, P503, DOI 10.1073/pnas.84.2.503; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Patel U., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P184; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; RHYU MG, 1994, ONCOGENE, V9, P29; SADAKANE Y, 1994, BIOCHEM BIOPH RES CO, V200, P219, DOI 10.1006/bbrc.1994.1437; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VARLEY JM, 1989, ONCOGENE, V4, P725; WADEY RB, 1990, ONCOGENE, V5, P901; WANG LM, 1992, CANCER RES, V52, P4824; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YEE CJ, 1994, CANCER RES, V54, P1641; ZULIANI G, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958-a; 1993, LOCUS MAPS COMPLEX G; 1993, CELL, V72, P971	53	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3695	3700						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970728				2022-12-17	WOS:A1994PT39200034
J	CARILLO, S; PARIAT, M; STEFF, AM; ROUX, P; ETIENNEJULAN, M; LORCA, T; PIECHACZYK, M				CARILLO, S; PARIAT, M; STEFF, AM; ROUX, P; ETIENNEJULAN, M; LORCA, T; PIECHACZYK, M			DIFFERENTIAL SENSITIVITY OF FOS AND JUN FAMILY MEMBERS TO CALPAINS	ONCOGENE			English	Article							NEUTRAL PROTEASE CALPAIN; C-FOS; V-FOS; DEPENDENT PROTEASES; MESSENGER-RNAS; PROTEINS; DEGRADATION; PROTEOLYSIS; INVITRO; SYSTEM	Degradation of c-fos protein (c-FOS) in the cytoplasm is very rapid in vivo and constitutes a crucial regulation of the nuclear steady-state level through the control of the amount of full-length molecules available for nuclear transport. Using cytoplasmic extracts from various origins, we report herein that c-FOS degradation can be initiated in a calcium-dependent manner which involves cysteine proteases called milli- and micro-calpain. Interestingly, FOS-B, a member of the fos multigene family, as well as all members of the jun family (JUN-B, c-JUN and JUN-D) are also sensitive to calpains albeit to different extents. FRA-2, which is a c-FOS-related protein, is resistant to micro- but not to milli-calpain whereas FRA-1, another member of the fos family, is resistant to both proteases. Given the fact that a work by others (Hirai et al., 1991b) suggests that calpains can be involved in c-FOS and c-JUN degradation in vivo, our observations raises the possibility of a novel contribution to the regulation of AP-1 transcription complex activity through a differential control of the steady-state level of some of its components that involves calpains.	INST GENET MOLEC MONTPELLIER,UMR 9942,F-34033 MONTPELLIER 01,FRANCE; CTR RECH BIOCHIM MACROMOLEC,CNRS,F-34033 MONTPELLIER 01,FRANCE	Centre National de la Recherche Scientifique (CNRS)			PIECHACZYK, Marc/E-7896-2013; Roux, Pierre/D-8833-2017	PIECHACZYK, Marc/0000-0003-1367-2597; ETIENNE-JULAN, Maryse/0000-0003-1339-6545; Lorca, Thierry/0000-0003-2007-8924; Steff, Ann-Muriel/0000-0002-9817-6164				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Abate C, 1990, Semin Cancer Biol, V1, P19; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BLANCHARD JM, 1992, MED SCI, V5, P455; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Curran T, 1988, ONCOGENE HDB, P307; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DOHERTY FJ, 1992, INTRACELLULAR DEGRAD; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HIRAI SI, 1990, ONCOGENE, V5, P39; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI M, 1989, J BIOL CHEM, V264, P18866; MATSUI M, 1990, ONCOGENE, V5, P249; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PARNAIK VK, 1990, MOL CELL BIOL, V10, P1287, DOI 10.1128/MCB.10.3.1287; PIECHACZYK M, 1994, IN PRESS CRIT REV ON; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1991, ONCOGENE, V6, P2155; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, IN PRESS FOS ONCOGEN; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VINCENT S, 1990, NUCLEIC ACIDS RES, V18, P3054, DOI 10.1093/nar/18.10.3054; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	45	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1679	1689						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183563				2022-12-17	WOS:A1994NL81500020
J	JANKOWSKI, SA; MITCHELL, DS; SMITH, SH; TRENT, JM; MELTZER, PS				JANKOWSKI, SA; MITCHELL, DS; SMITH, SH; TRENT, JM; MELTZER, PS			SAS, A GENE AMPLIFIED IN HUMAN SARCOMAS, ENCODES A NEW MEMBER OF THE TRANSMEMBRANE-4-SUPERFAMILY OF PROTEINS	ONCOGENE			English	Article							TUMOR-ASSOCIATED ANTIGEN; CELL-SURFACE PROTEINS; MOLECULAR-CLONING; CD9 ANTIGEN; MRC OX-44; N-MYC; C-MYC; AMPLIFICATION; FAMILY; IDENTIFICATION	Amplification of 12q13-14 occurs in a subset of human sarcomas including malignant fibrous histiocytoma and liposarcoma. This chromosomal region has previously been found to include a number of growth-related genes including the GLI proto-oncogene and the p53-associated protein, MDM2. We now report the characterization of SAS (sarcoma amplified sequence), a novel transcript found in this region. Sequence analysis demonstrates that SAS is a novel member of a transmembrane protein family (transmembrane 4 superfamily or TM4SF) thought to be involved in growth-related cellular processes. This observation adds a TM4SF protein to the cluster of genes at 12q13-14 frequently amplified in human sarcomas.	UNIV MICHIGAN, DEPT PEDIAT,MED SCI RES BLDG 2,RM C560B, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT RADIAT ONCOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA-09676, CA-56725, CA-09205] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676, R01CA056725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; AMIOT M, 1990, J IMMUNOL, V145, P4322; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; ANGELISOVA P, 1990, IMMUNOGENETICS, V32, P281, DOI 10.1007/BF00187099; AZORSA DO, 1991, BLOOD, V78, P280; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BENOIT P, 1991, HUM GENET, V86, P268, DOI 10.1007/BF00202407; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEMETRICK DJ, 1992, J NATL CANCER I, V84, P422, DOI 10.1093/jnci/84.6.422; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMI N, 1993, IMMUNOGENETICS, V37, P193; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1988, CANCER RES, V48, P2955; KHATIB ZA, 1993, CANCER RES, V53, P5535; LEACH FS, 1993, CANCER RES, V53, P2231; LEVY S, 1991, J BIOL CHEM, V266, P14597; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P503; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; ROBERTS WM, 1989, CANCER RES, V49, P5407; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEHAFER JG, 1991, BIOCHEM BIOPH RES CO, V179, P401, DOI 10.1016/0006-291X(91)91384-O; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH SH, 1992, CANCER RES, V52, P3746; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; TRENT JM, 1984, CANCER RES, V44, P233; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; WRIGHT MD, 1990, J IMMUNOL, V144, P3195	44	75	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1205	1211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134123				2022-12-17	WOS:A1994NC04800024
J	LANOIX, J; LACOSTE, J; PEPIN, N; RICE, N; HISCOTT, J				LANOIX, J; LACOSTE, J; PEPIN, N; RICE, N; HISCOTT, J			OVERPRODUCTION OF NFKB2(LYT-1O) AND C-REL - A MECHANISM FOR HTLV-I TAX-MEDIATED TRANSACTIVATION VIA THE NF-KAPPA-B SIGNALING PATHWAY	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; CANDIDATE PROTOONCOGENE BCL-3; ENHANCER-BINDING PROTEINS; LONG TERMINAL REPEAT; HUMAN T-CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; PROTO-ONCOGENE	Molecular, biochemical and epidemiological evidence implicate HTLV-I as an etiologic agent of adult T cell leukemia (ATL). The Tax protein of HTLV-I, a positive transcriptional activator of HTLV-I gene expression, is a viral oncogene that also increases transcription of cellular genes including GM-CSF, IL-2R alpha and IL-2. One of the cellular targets of the trans-activating effects of Tax is the NF-kappa B/Rel family of transcription factors, pleiotropic regulators of immunoregulatory, cytokine and viral gene expression. In this report, we demonstrate that NFKB2, (lyt-10) and c-Rel are overexpressed in HTLV-I infected and Tax-expressing cells and, together, account for the majority of the constitutive NF-kappa-B binding activity in these cells before and after PMA stimulation. Most importantly, we show a Tax-dependent correlation between expression of NFKB2(p100) and processing to the DNA binding NFKB2(p52) form, induction of c-Rel, and trans-activation of NF-kappa B-mediated gene expression. Furthermore, the NFKB2 precursor is physically associated with c-Rel and with Tax in HTLV-I infected cells. We propose that NFKB2 synthesis and processing allows continuous nuclear expression of an otherwise cytoplasmic protein and, in conjunction with overexpression of c-Rel, NFKB2 alters the NF-kappa B signalling pathway and contributes to leukemic transformation of T cells by HTLV-I.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,ABE STERN CANC RES LAB,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ,CANADA; FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD	Lady Davis Institute; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; COHEN L, 1992, J CELL PHYSIOL, V152, P10, DOI 10.1002/jcp.1041520103; CRENON L, 1993, ONCOGENE, V8, P867; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAERTLE T, 1988, J BIOL CHEM, V263, P5870; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HANNINK M, 1990, ONCOGENE, V5, P1843; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LACOSTE J, 1990, J VIROL, V64, P4726, DOI 10.1128/JVI.64.10.4726-4734.1990; LACOSTE J, 1991, VIROLOGY, V184, P553, DOI 10.1016/0042-6822(91)90425-B; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIWA M, 1984, GANN, V75, P752; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEUCHI K, 1985, J GEN VIROL, V66, P1825, DOI 10.1099/0022-1317-66-8-1825; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	73	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					841	852						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108127				2022-12-17	WOS:A1994MW55100020
J	ANDRE, C; MARTIN, E; CORNU, F; HU, WX; WANG, XP; GALIBERT, F				ANDRE, C; MARTIN, E; CORNU, F; HU, WX; WANG, XP; GALIBERT, F			GENOMIC ORGANIZATION OF THE HUMAN C-KIT GENE - EVOLUTION OF THE RECEPTOR TYROSINE KINASE SUBCLASS-III	ONCOGENE			English	Article							W-MUTANT MICE; PROTO-ONCOGENE; GROWTH-FACTOR; MOUSE; LOCUS; SEQUENCE; REGION; FAMILY; CHROMOSOME-4; CONSERVATION	The c-kit proto-oncogene encodes a transmembrane tyrosine kinase receptor. It belongs to receptor tyrosine kinase subclass III, which also includes the colony-stimulating factor I receptor (c-fms), platelet-derived growth factor receptors A and B (PDGFRA and PDGFRB), as well as FLT1 and FLT3/FLK2. c-kit and PDGFRA, c-fms and PDGFRB, FLT1 and FLT3/FLK2 are grouped by pair in three clusters in man on chromosome 4 band q11-q13. chromosome 5 band q31-q33 and chromosome 13 band q12 respectively. Here, we report the genomic organization of the human c-kit gene, which is composed of 21 small coding exons, distributed over 80 kb. Comparison of the c-kit and c-fms oncogenes shows that they share identical exon/intron boundaries in their two kinase domains, as well as a similar exon/intron organization in the extracytoplasmic domain. Comparison with the kinase domains of tyrosine kinase genes not belonging to subclass III suggests that the exon/intron organization of c-kit and c-fms is a characteristic feature of subclass III. The genomic similarities between c-kit and c-fms, in conjunction with the location in pairs on different chromosomes of the subclass III genes, has led us to hypothesize that cis and trans duplications gave rise to this group of genes.			ANDRE, C (corresponding author), HOP ST LOUIS,CTR HAYEM,HEMATOL EXPTL LAB,CNRS,UPR 41,F-75475 PARIS 10,FRANCE.							ANDRE C, 1989, ONCOGENE, V4, P1047; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COMINGS DE, 1972, NATURE, V238, P455, DOI 10.1038/238455a0; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; ELADARI ME, 1986, BIOCHEM BIOPH RES CO, V140, P313, DOI 10.1016/0006-291X(86)91092-2; ESTBROOK CA, 1991, GENOMICS, V10, P1105; FROLOVA EI, 1991, P NATL ACAD SCI USA, V88, P4821, DOI 10.1073/pnas.88.11.4821; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HALEY J, 1987, ONCOGENE RES, V1, P375; HAMPE A, 1989, ONCOGENE RES, V7, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; LALLEY PA, 1989, CYTOGENET CELL GENET, V51, P503, DOI 10.1159/000132806; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRAY JC, 1990, CYTOGENET CELL GENET, V55, P97, DOI 10.1159/000133000; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RACKWITZ HR, 1984, GENE, V30, P195, DOI 10.1016/0378-1119(84)90120-3; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Silvers W.K., 1979, COAT COLORS MICE, P206; SMITH AE, 1991, P NATL ACAD SCI USA, V88, P4811; SORRENTINO V, 1991, ONCOGENE, V6, P149; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; SUNDARESAN S, 1989, SOMAT CELL MOLEC GEN, V15, P367, DOI 10.1007/BF01534975; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	51	75	75	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					685	691						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1373482				2022-12-17	WOS:A1992HQ68200010
J	MELLSTROM, B; ACHAVAL, M; MONTERO, D; NARANJO, JR; SASSONECORSI, P				MELLSTROM, B; ACHAVAL, M; MONTERO, D; NARANJO, JR; SASSONECORSI, P			DIFFERENTIAL EXPRESSION OF THE JUN FAMILY MEMBERS IN RAT-BRAIN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; IMMEDIATE EARLY GENES; DNA-BINDING DOMAINS; NERVE GROWTH-FACTOR; C-JUN; PROTO-ONCOGENE; LEUCINE ZIPPERS; V-JUN; FOS; INDUCTION	The transcription factor AP-1 is phorbol ester-regulated and, as such, is considered to be a nuclear target of the signal transduction pathway involving protein kinase C. AP-1 is constituted by the various products of the jun and fos gene family members. These genes belong to the early response class and are inducible in different ways by growth factors, phorbol esters and depolarization. We studied the transcript distribution of c-jun,junB and junD in the rat brain. Our results show that the transcripts for these three genes are differentially distributed in various neuronal tissues. We also provide evidence for developmentally regulated expression of jun genes in post-natal brain. The spatiotemporal pattern of expression of c-jun, junB and junD offers clues to the understanding of the links between gene regulation and neuronal processes.	CSIC,INST CAJAL NEUROCIENCIA,DOCTOR ARCE 37,E-28002 MADRID,SPAIN; FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Consejo Superior de Investigaciones Cientificas (CSIC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			NARANJO, Jose R/K-1950-2014; Sassone-Corsi, Paolo/H-6182-2011	NARANJO, Jose R/0000-0002-0270-3469; 				AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BERRIDGE M, 1986, NATURE, V323, P294, DOI 10.1038/323294a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FREMEAU RT, 1986, SCIENCE, V234, P1265, DOI 10.1126/science.3775385; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; HERDEGEN T, 1990, 6TH P WORLD C PAIN; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NARANJO JR, 1991, ONCOGENE, V6, P223; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; WU BY, 1989, J BIOL CHEM, V264, P9000	42	75	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1959	1964						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719462				2022-12-17	WOS:A1991GX11900003
J	ASHTONRICKARDT, PG; WYLLIE, AH; BIRD, CC; DUNLOP, MG; STEEL, CM; MORRIS, RG; PIRIS, J; ROMANOWSKI, P; WOOD, R; WHITE, R; NAKAMURA, Y				ASHTONRICKARDT, PG; WYLLIE, AH; BIRD, CC; DUNLOP, MG; STEEL, CM; MORRIS, RG; PIRIS, J; ROMANOWSKI, P; WOOD, R; WHITE, R; NAKAMURA, Y			MCC, A CANDIDATE FAMILIAL POLYPOSIS GENE IN 5Q.21, SHOWS FREQUENT ALLELE LOSS IN COLORECTAL AND LUNG-CANCER	ONCOGENE			English	Article							ADENOMATOUS POLYPOSIS; CHROMOSOME-5; CARCINOMAS; MUTATIONS; TUMORIGENESIS; DELETIONS; TUMORS; RFLP; COLI	MCC is a gene located within human chromosome band 5q.21 that shows somatically acquired mutations in colorectal cancer, and may be identical to the gene responsible for inheritance of familial adenomatous polyposis. Here we demonstrate that alleles contiguous with or within MCC are deleted in a high proportion of sporadic colorectal carcinomas. Of 106 carcinomas that were informative concurrently at close-flanking sites both centromeric and telomeric to MCC, 41.5% showed acquired allele loss contiguous with MCC. Evidence is presented to show that the true frequency of loss of MCC alleles is higher still. In contrast, allele losses in chromosome 5 that were incompatible with involvement of MCC were very rare (2% of a total series of 201 informative tumours). Interstitial deletion was the commonest mechanism of allele loss, and L5.71-3, a probe known to include coding sequences of MCC, marks the most consistently deleted site. Moreover mapping of chromosome break-points with six probes within 5q.21 sited the common critical deletion in a 2.5 Mb region which included L5.71-3. However use of L5.71-3 itself suggested that critical deleted regions may lie on either side of the probed sequence. The simplest explanation for this unexpected finding is that MCC itself is the essential deleted gene, the lost exons lying sometimes centromeric to, sometimes telomeric to and occasionally within the region detected by L5.71-3. Tumours in which MCC-related alleles were lost by interstitial deletion were in general larger than those with other mechanisms of acquired homozygosity (e.g. mitotic recombination), but there were no other obvious associations with clinicopathological features. Between 20% and 25% of lung cancers also showed acquired allele losses contiguous with MCC. The significance of this observation is still to be determined, as lung tumours show allele losses at many other sites, but the specificity of the probes used in this study does establish that the 5q.21 losses in these tumours are compatible with involvement of MCC.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; MED RES COUNCIL HUMAN GENET UNIT,EDINBURGH,SCOTLAND; UNIV UTAH,MED CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN	University of Edinburgh; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Japanese Foundation for Cancer Research			Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851; Wood, Rachael/0000-0003-4453-623X				ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; CAREY FA, 1990, CANCER, V65, P2266, DOI 10.1002/1097-0142(19900515)65:10<2266::AID-CNCR2820651018>3.0.CO;2-R; CASTAGNOLI A, 1987, NUCLEIC ACIDS RES, V15, P866, DOI 10.1093/nar/15.2.866; DEVILEE P, 1991, ONCOGENE, V6, P1705; DOZIER C, 1986, NUCLEIC ACIDS RES, V14, P1928, DOI 10.1093/nar/14.4.1928; DUNLOP MG, 1990, AM J HUM GENET, V47, P982; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAMILTON SR, 1990, HEREDITARY COLORECTA, P315; HOSHINO Y, 1991, BIOCHEM BIOPH RES CO, V174, P298, DOI 10.1016/0006-291X(91)90520-H; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYAKI M, 1990, CANCER RES, V50, P7166; OKAMOTO M, 1990, HUM GENET, V85, P595; PURDIE CA, 1991, AM J PATHOL, V138, P807; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TOPS CM, 1989, LANCET, V2, P12361; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; XIANG K, 1987, NUCLEIC ACIDS RES, V15, P7654, DOI 10.1093/nar/15.18.7654	26	75	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1881	1886						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656365				2022-12-17	WOS:A1991GX11800022
J	WRIGHT, PA; WILLIAMS, ED; LEMOINE, NR; WYNFORDTHOMAS, D				WRIGHT, PA; WILLIAMS, ED; LEMOINE, NR; WYNFORDTHOMAS, D			RADIATION-ASSOCIATED AND SPONTANEOUS HUMAN THYROID CARCINOMAS SHOW A DIFFERENT PATTERN OF RAS ONCOGENE MUTATION	ONCOGENE			English	Note							ENZYMATIC AMPLIFICATION; ACTIVATION; TUMORS	Activated ras oncogenes in experimentally induced rodent tumours have been demonstrated to show specific patterns of oncogene activation which depend on the inducing agent, with H-ras activation in nitrosomethylurea (NMU) induced tumours, and K-ras activation in tumours induced by ionising radiation. We report a study of 12 radiation-associated human thyroid tumours, using polymerase chain reaction (PCR) amplification of paraffin-embedded material and allele-specific hybridisation with mutant-specific probes for the 3 ras oncogenes. Compared to 68 'spontaneous' human thyroid tumours, the radiation-associated cases show the same overall prevalence of ras mutation. However there is a significantly higher rate of K-ras mutation in radiation-associated follicular carcinomas than in 'spontaneous' follicular carcinomas (60% compared to 6%, P < 0.05), suggesting that radiation may preferentially activate k-ras in human as well as rodent tumours.			WRIGHT, PA (corresponding author), UNIV COLL CARDIFF,DEPT PATHOL,THYROID TUMOUR BIOL RES GRP,CANC RES CAMPAIGN,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							DONIACH I, 1958, BRIT MED BULL, V14, P181, DOI 10.1093/oxfordjournals.bmb.a069666; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; LEMOINE NR, 1988, ONCOGENE, V3, P541; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAWEY MJ, 1987, MOL CELL BIOL, V7, P932, DOI 10.1128/MCB.7.2.932	8	75	76	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					471	473						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011403				2022-12-17	WOS:A1991FT34400019
J	GUBITS, RM; FAIRHURST, JL				GUBITS, RM; FAIRHURST, JL			C-FOS MESSENGER-RNA LEVELS ARE INCREASED BY THE CELLULAR STRESSORS, HEAT-SHOCK AND SODIUM ARSENITE	ONCOGENE			English	Article									NATHAN S KLINE INST,DIV MOLEC BIOL,ORANGEBURG,NY 10962	Nathan Kline Institute for Psychiatric Research					NIGMS NIH HHS [GM38202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; BARKA T, 1986, MOL CELL BIOL, V6, P2984, DOI 10.1128/MCB.6.8.2984; BARKA T, 1987, ONCOGENE, V1, P297; BESTERMAN JM, 1985, J BIOL CHEM, V260, P1155; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; DAVIS RJ, 1985, J BIOL CHEM, V260, P2543; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUBITS RM, 1986, ENDOCRINOLOGY, V119, P1382, DOI 10.1210/endo-119-3-1382; GUBITS RM, 1984, J BIOL CHEM, V259, P2803; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIGHTOWER LE, 1981, J CELL PHYSIOL, V108, P261, DOI 10.1002/jcp.1041080216; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; HUNT SP, 1987, NATURE, V328, P631; INGOLIA TD, 1980, CELL, V21, P669, DOI 10.1016/0092-8674(80)90430-4; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LI GC, 1985, CHANGES EUKARYOTIC G, P227; LIN CY, 1984, PLANT PHYSIOL, V74, P152, DOI 10.1104/pp.74.1.152; LOWE DG, 1986, J BIOL CHEM, V261, P2102; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; PELHAM H, 1985, TRENDS GENET, V1, P31, DOI 10.1016/0168-9525(85)90012-5; RENAN MJ, 1986, BIOSCIENCE REP, V6, P819, DOI 10.1007/BF01117105; RENAN MJ, 1985, BIOSCIENCE REP, V5, P739, DOI 10.1007/BF01119872; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; SCHLESINGER MJ, 1985, CHANGES EUKARYOTIC G, P183; SIMCOX AA, 1985, MOL CELL BIOL, V5, P3397, DOI 10.1128/MCB.5.12.3397; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	52	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					163	168						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412774				2022-12-17	WOS:A1988Q053400006
J	RONAI, ZA; OKIN, E; WEINSTEIN, IB				RONAI, ZA; OKIN, E; WEINSTEIN, IB			ULTRAVIOLET-LIGHT INDUCES THE EXPRESSION OF ONCOGENES IN RAT FIBROBLAST AND HUMAN KERATINOCYTE CELLS	ONCOGENE			English	Article									COLUMBIA UNIV, INST CANC RES, NEW YORK, NY 10032 USA	Columbia University	RONAI, ZA (corresponding author), COLUMBIA UNIV, CTR COMPREHENS CANC, NEW YORK, NY 10032 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLER P, 1986, J CELL PHYSIOL, V128, P362, DOI 10.1002/jcp.1041280303; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOWDEN GT, 1986, CHEM-BIOL INTERACT, V58, P333, DOI 10.1016/S0009-2797(86)80107-7; CHANG SE, 1985, BIOCHIM BIOPHYS ACTA, V823, P161; CHASS GL, 1982, J CELL PHYSL, V111, P309; CURRAN T, 1985, CANCER SURV, V4, P655; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DRAGANI TA, 1986, CANCER RES, V46, P1915; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FITZPATRICK TB, 1985, NEW ENGL J MED, V313, P818, DOI 10.1056/NEJM198509263131310; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GINZBURG I, 1980, NUCLEIC ACIDS RES, V8, P3553, DOI 10.1093/nar/8.16.3553; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GONDA MA, 1982, J VIROL, V44, P520, DOI 10.1128/JVI.44.2.520-529.1982; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HSIEH LL, 1987, CANCER RES, V47, P3421; KACZMAREK L, 1986, CELL BIOL INT REP, V10, P455, DOI 10.1016/0309-1651(86)90041-X; KARIN M, 1983, DNA CELL BIOL, V2, P329; KELLAND LR, 1983, PHOTOCHEM PHOTOBIOL, V37, P301, DOI 10.1111/j.1751-1097.1983.tb04477.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; LAMBERT ME, 1983, CARCINOGENESIS, V4, P587, DOI 10.1093/carcin/4.5.587; LAMBERT ME, 1986, CARCINOGENESIS, V7, P1011, DOI 10.1093/carcin/7.6.1011; LAMBERT ME, 1986, ANTIMUTAGENESIS ANTI, P291; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NOMURA S, 1984, MOL CELL BIOL, V4, P1159, DOI 10.1128/MCB.4.6.1159; OLSON EN, 1986, MOL CELL BIOL, V6, P2792, DOI 10.1128/MCB.6.8.2792; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PEAK JG, 1985, PHOTOCHEM PHOTOBIOL, V41, P295, DOI 10.1111/j.1751-1097.1985.tb03488.x; RESENSTEIN BS, 1986, ENV MUT, V8, P335; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; ROBERTS JJ, 1986, MUTAT RES, V165, P207, DOI 10.1016/0167-8817(86)90056-8; RONAI ZA, 1987, IN PRESS CANCER RES; ROTEM N, 1987, MOL CELL BIOL, V7, P622, DOI 10.1128/MCB.7.2.622; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SHUIN T, 1986, CANCER RES, V46, P5302; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STIMAC E, 1984, MOL CELL BIOL, V4, P2082, DOI 10.1128/MCB.4.10.2082; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; VANDERLUBBE JLM, 1986, MUTAT RES, V165, P47, DOI 10.1016/0167-8817(86)90059-3; VLEMINCKX C, 1986, CARCINOGENESIS, V7, P229, DOI 10.1093/carcin/7.2.229; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; [No title captured]	49	75	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1988	2	2					201	204						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285298				2022-12-17	WOS:A1988M086000015
J	He, F; Song, Z; Chen, HC; Chen, ZP; Yang, P; Li, WL; Yang, Z; Zhang, T; Wang, F; Wei, JC; Wei, F; Wang, Q; Cao, J				He, Feng; Song, Zhi; Chen, Huacui; Chen, Zhuanpeng; Yang, Ping; Li, Wanglin; Yang, Zhi; Zhang, Tong; Wang, Fei; Wei, Jianchang; Wei, Fang; Wang, Qiang; Cao, Jie			Long noncoding RNA PVT1-214 promotes proliferation and invasion of colorectal cancer by stabilizing Lin28 and interacting with miR-128	ONCOGENE			English	Article							CELL-PROLIFERATION; POOR-PROGNOSIS; GASTRIC-CANCER; UP-REGULATION; PROGRESSION; MECHANISMS; APOPTOSIS; GROWTH; LOOP	Long noncoding RNAs (lncRNAs) are implicated in human cancer, but their mechanisms of action are largely unknown. In this study, we investigated lncRNA alterations that contribute to colorectal cancer (CRC) through microarray expression profiling in CRC patient samples. Here, we report that the CRC-associated lncRNA PVT1-214 is a key regulator of CRC development and progression; patients with high PVT1-214 expression had a shorter survival and poorer prognosis. In vitro and in vivo investigation of the role of PVT1-214 revealed a complex integrated phenotype affecting cell growth, stem-like properties, migration, and invasion. Furthermore, using RNA pull-down and mass spectrometry, we found that Lin28 (also known as Lin28A), a highly conserved RNA-binding protein, is associated with PVT1-214. Strikingly, we found that PVT1-214 not only upregulated Lin28 protein expression in CRC cells by stabilizing Lin28, but also participated in crosstalk with Lin28 mRNA through competition for miR-128 binding, imposing an additional level of post-transcriptional regulation. In addition, we further show that PVT1-214 repressed expression of let-7 family miRNAs, which was abrogated by Lin28 knockdown. Taken together, our findings support a model in which the PVT1-214/Lin28/let-7 axis serves as a critical regulator of CRC pathogenesis, which may simulate a new direction for CRC therapeutic development.	[He, Feng; Chen, Huacui; Chen, Zhuanpeng; Yang, Ping; Li, Wanglin; Yang, Zhi; Zhang, Tong; Wang, Fei; Wei, Jianchang; Wei, Fang; Wang, Qiang; Cao, Jie] South China Univ Technol, Affiliated Hosp 2, Dept Gen Surg, Guangzhou Digest Dis Ct,Guangzhou Peoples Hosp 1, Guangzhou 510180, Guangdong, Peoples R China; [He, Feng] South China Univ Technol, Affiliated Hosp 2, Guangzhou Peoples Hosp 1, Dept Nephrol, Guangzhou 510180, Guangdong, Peoples R China; [He, Feng; Song, Zhi; Chen, Huacui] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Song, Zhi] Sun Yat Sen Univ, Dept Operat Dent & Endodont, Guanghua Sch Stomatol, Hosp Stomatol, Guangzhou 510055, Guangdong, Peoples R China; [Song, Zhi] Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China; [Chen, Huacui; Cao, Jie] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Gen Surg, Guangzhou 510180, Guangdong, Peoples R China	South China University of Technology; South China University of Technology; Yale University; Sun Yat Sen University; Guangzhou Medical University	Cao, J (corresponding author), South China Univ Technol, Affiliated Hosp 2, Dept Gen Surg, Guangzhou Digest Dis Ct,Guangzhou Peoples Hosp 1, Guangzhou 510180, Guangdong, Peoples R China.; Cao, J (corresponding author), Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Gen Surg, Guangzhou 510180, Guangdong, Peoples R China.	czhongt@126.com			National Natural Science Foundation of China [8187101464, 81600654, 81600862]; Guangdong Natural Science Foundation [2017A030311035, 2016A030313490, 2016A030310227]; Fundamental Research Funds for the Central Universities [XZYXD2175080]; Guangdong Provincial Department of Science and Technology [2017A020215146]; Guangzhou Science Technology and Innovation Commission [201805010003]; US National Institutes of Health (NIH) [R01 HL136507]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL136507] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Provincial Department of Science and Technology; Guangzhou Science Technology and Innovation Commission; US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the National Natural Science Foundation of China (Grant no. 8187101464, 81600654 and 81600862); the Guangdong Natural Science Foundation (Grant no. 2017A030311035, 2016A030313490 and 2016A030310227); the Fundamental Research Funds for the Central Universities (Grant no. XZYXD2175080); and the Guangdong Provincial Department of Science and Technology (Grant no. 2017A020215146); Guangzhou Science Technology and Innovation Commission (Grant no. 201805010003); and US National Institutes of Health (NIH) grant R01 HL136507.	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Cao C, 2017, ONCOGENE, V36, P1112, DOI 10.1038/onc.2016.278; Cao DF, 2011, HUM PATHOL, V42, P710, DOI 10.1016/j.humpath.2010.09.007; Chen FC, 2014, EVOL BIOINFORM, V10, P219, DOI 10.4137/EBO.S20772; Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068; Dhamija S, 2016, INT J CANCER, V139, P269, DOI 10.1002/ijc.30039; Di Cecilia S, 2016, CANCER RES, V76, P5615, DOI 10.1158/0008-5472.CAN-15-1824; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gokbuget D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9584; Guo K, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699122; He F, 2016, ONCOTARGET, V7, P81156, DOI 10.18632/oncotarget.13215; He F, 2014, DIABETOLOGIA, V57, P1726, DOI 10.1007/s00125-014-3282-0; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Izaurralde E, 2012, EMBO REP, V13, P662, DOI 10.1038/embor.2012.91; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li PD, 2017, ONCOTARGET, V8, P34164, DOI 10.18632/oncotarget.15878; Lu WQ, 2017, ONCOTARGET, V8, P15242, DOI 10.18632/oncotarget.14839; Ma MZ, 2016, CANCER RES, V76, P5361, DOI 10.1158/0008-5472.CAN-15-3047; Malone CD, 2009, CELL, V136, P656, DOI 10.1016/j.cell.2009.01.045; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Powers JT, 2016, NATURE, V535, P246, DOI 10.1038/nature18632; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Takahashi Y, 2014, BRIT J CANCER, V110, P164, DOI 10.1038/bjc.2013.698; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Volders PJ, 2013, NUCLEIC ACIDS RES, V41, pD246, DOI 10.1093/nar/gks915; Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang Y, 2017, BIOCHEM BIOPH RES CO, V493, P429, DOI 10.1016/j.bbrc.2017.09.005; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Zang WQ, 2016, ONCOTARGET, V7, P19960, DOI 10.18632/oncotarget.6963; Zheng JJ, 2016, ONCOTARGET, V7, P62886, DOI 10.18632/oncotarget.11709; Zhou Q, 2016, ONCOTARGET, V7, P82620, DOI 10.18632/oncotarget.13012	38	74	76	0	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					164	179		10.1038/s41388-018-0432-8	http://dx.doi.org/10.1038/s41388-018-0432-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30076414	Green Accepted			2022-12-17	WOS:000455366700002
J	Polycarpou-Schwarz, M; Gross, M; Mestdagh, P; Schott, J; Grund, SE; Hildenbrand, C; Rom, J; Aulmann, S; Sinn, HP; Vandesompele, J; Diederichs, S				Polycarpou-Schwarz, Maria; Gross, Matthias; Mestdagh, Pieter; Schott, Johanna; Grund, Stefanie E.; Hildenbrand, Catherina; Rom, Joachim; Aulmann, Sebastian; Sinn, Hans-Peter; Vandesompele, Jo; Diederichs, Sven			The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation	ONCOGENE			English	Article							RIBOSOME PROFILING REVEALS; MEVALONATE PATHWAY; CHOLESTEROL-SYNTHESIS; MOLECULAR PORTRAITS; RNA; ACTIN; PEPTIDES; TRANSLATION; EXPRESSION; DISCOVERY	Breast cancer is a leading cause of cancer-related death in women. Small open reading frame (sORF)-encoded proteins or microproteins constitute a new class of molecules often transcribed from presumed long non-coding RNA transcripts (lncRNAs). The translation of some of these sORFs has been confirmed, but their cellular function and importance remains largely unknown. Here, we report the identification and characterization of a novel microprotein of 10 kDa, which we named Cancer-Associated Small Integral Membrane Open reading frame 1 (CASIMO1). CASIMO1 RNA is overexpressed predominantly in hormone receptor-positive breast tumors. Its knockdown leads to decreased proliferation in multiple breast cancer cell lines. Its loss disturbs the organization of the actin cytoskeleton, leads to inhibition of cell motility, and causes a G(0)/G(1) cell cycle arrest. The proliferation phenotype upon overexpression is observed only with CASIMO1 protein expression, but not with a non-translatable mutant attributing the effects to the sORF-derived protein rather than a lncRNA function. CASIMO1 microprotein interacts with squalene epoxidase (SQLE), a key enzyme in cholesterol synthesis and a known oncogene in breast cancer. Overexpression of CASIMO1 leads to SQLE protein accumulation without affecting its RNA levels and increased lipid droplet clustering, while knockdown of CASIMO1 decreased SQLE protein abundance and ERK phosphorylation downstream of SQLE. Importantly, SQLE knockdown mimicked the CASIMO1 knockdown phenotype and in turn SQLE overexpression fully rescued the effect of CASIMO1 knockdown. These findings establish CASIMO1 as the first functional microprotein that plays a role in carcinogenesis and is implicated in the cell lipid homeostasis.z	[Polycarpou-Schwarz, Maria; Gross, Matthias; Grund, Stefanie E.; Hildenbrand, Catherina; Diederichs, Sven] German Canc Res Ctr, Div RNA Biol & Canc, Heidelberg, Germany; [Polycarpou-Schwarz, Maria; Gross, Matthias; Aulmann, Sebastian; Sinn, Hans-Peter; Diederichs, Sven] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Mestdagh, Pieter; Vandesompele, Jo] Ghent Univ Belgium, Ctr Med Genet, Ghent, Belgium; [Mestdagh, Pieter; Vandesompele, Jo] Ghent Univ Belgium, CRIG, Ghent, Belgium; [Schott, Johanna] Heidelberg Univ, Div Biochem 1, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, Mannheim, Germany; [Schott, Johanna] Heidelberg Univ ZMBH, Ctr Mol Biol, DKFZ ZMBH Alliance, Mannheim, Germany; [Rom, Joachim] Univ Hosp Heidelberg, Dept Obstet & Gynecol, Heidelberg, Germany; [Diederichs, Sven] Univ Freiburg, Div Canc Res, Dept Thorac Surg, Med Ctr, Freiburg, Germany; [Diederichs, Sven] Univ Freiburg, Fac Med, Freiburg, Germany; [Diederichs, Sven] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ghent University; Ghent University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Diederichs, S (corresponding author), German Canc Res Ctr, Div RNA Biol & Canc, Heidelberg, Germany.; Diederichs, S (corresponding author), Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.; Diederichs, S (corresponding author), Univ Freiburg, Div Canc Res, Dept Thorac Surg, Med Ctr, Freiburg, Germany.; Diederichs, S (corresponding author), Univ Freiburg, Fac Med, Freiburg, Germany.; Diederichs, S (corresponding author), German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany.	s.diederichs@dkfz.de	Sinn, Hans-Peter/C-5661-2008; Vandesompele, Jo/W-3411-2018; Diederichs, Sven/J-6237-2012	Sinn, Hans-Peter/0000-0003-2836-6699; Vandesompele, Jo/0000-0001-6274-0184; Gross, Matthias/0000-0003-0449-1591; Diederichs, Sven/0000-0001-7901-4752; Polycarpou-Schwarz, Maria/0000-0002-9125-6460; Mestdagh, Pieter/0000-0001-7821-9684	German Research Foundation [DFG Di 1421/7-1]; RNA@DKFZ Cross Program Topic	German Research Foundation(German Research Foundation (DFG)); RNA@DKFZ Cross Program Topic	We thank Drs. K. Boulay and A. Roth for helpful discussions and suggestions and for critical reading of the manuscript, S. Wiemann for helpful discussions, L. Chatel-Chaix (University of Heidelberg) and R. Pepperkok (EMBL Heidelberg) for antibodies and suggestions, V. Benes, T. Ivacevic, and S. Schmidt (EMBL Heidelberg, Genome Core Facility) for support with microarray performance and the DKFZ Light Microscopy and Flow Cytometry Core Facilities and the ZMBH Flow Cytometry & FACS Core Facility (University of Heidelberg) for technical support. Research in the Diederichs lab is supported by the German Research Foundation (DFG Di 1421/7-1) and the RNA@DKFZ Cross Program Topic. This work is part of the Ph.D. thesis of M.P.-S.	Anderson DM, 2015, CELL, V160, P595, DOI 10.1016/j.cell.2015.01.009; Andrews SJ, 2014, NAT REV GENET, V15, P193, DOI 10.1038/nrg3520; Aspden JL, 2014, ELIFE, V3, DOI 10.7554/eLife.03528; Basrai MA, 1997, GENOME RES, V7, P768, DOI 10.1101/gr.7.8.768; Bazzini AA, 2014, EMBO J, V33, P981, DOI 10.1002/embj.201488411; Bhattacharyya S, 2009, CLIN EXP METASTAS, V26, P535, DOI 10.1007/s10585-009-9253-z; Bi P, 2017, SCIENCE, V356, P323, DOI 10.1126/science.aam9361; Brar GA, 2015, NAT REV MOL CELL BIO, V16, P651, DOI 10.1038/nrm4069; Brown DN, 2016, SCI REP-UK, V6, DOI 10.1038/srep19435; Cabrera-Quio LE, 2016, RNA BIOL, V13, P1051, DOI 10.1080/15476286.2016.1218589; Campellone KG, 2010, NAT REV MOL CELL BIO, V11, P237, DOI 10.1038/nrm2867; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; Chu Q, 2017, BIOCHEMISTRY-US, V56, P3299, DOI 10.1021/acs.biochem.7b00265; Couso JP, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0765-3; Couso JP, 2017, NAT REV MOL CELL BIO, V18, P575, DOI 10.1038/nrm.2017.58; D'Lima NG, 2017, NAT CHEM BIOL, V13, P174, DOI [10.1038/NCHEMBIO.2249, 10.1038/nchembio.2249]; Dinger ME, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000176; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Gill S, 2011, CELL METAB, V13, P260, DOI 10.1016/j.cmet.2011.01.015; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Gutschner T, 2011, GENOME RES, V21, P1944, DOI 10.1101/gr.122358.111; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hannus M, 2014, NUCLEIC ACIDS RES, V42, P8049, DOI 10.1093/nar/gku480; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Helms MW, 2008, BRIT J CANCER, V99, P774, DOI 10.1038/sj.bjc.6604556; Housman G, 2016, BBA-GENE REGUL MECH, V1859, P31, DOI 10.1016/j.bbagrm.2015.07.017; Inder KL, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012245; Ingolia NT, 2014, CELL REP, V8, P1365, DOI 10.1016/j.celrep.2014.07.045; Ingolia NT, 2011, CELL, V147, P789, DOI 10.1016/j.cell.2011.10.002; Ji Z, 2015, ELIFE, V4, DOI 10.7554/eLife.08890; Kastenmayer JP, 2006, GENOME RES, V16, P365, DOI 10.1101/gr.4355406; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kondo T, 2010, SCIENCE, V329, P336, DOI 10.1126/science.1188158; Lambrechts A, 2004, INT J BIOCHEM CELL B, V36, P1890, DOI 10.1016/j.biocel.2004.01.024; Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009; Lee KG, 2007, CELL CYCLE, V6, P1487; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li J, 2015, CANCER RES, V75, P3728, DOI 10.1158/0008-5472.CAN-15-0273; Lluch-Senar M, 2015, MOL SYST BIOL, V11; Ma J, 2014, J PROTEOME RES, V13, P1757, DOI 10.1021/pr401280w; Mackowiak SD, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0742-x; Magny EG, 2013, SCIENCE, V341, P1116, DOI 10.1126/science.1238802; Mestdagh P, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr646; Miettinen TP, 2015, CELL REP, V13, P2610, DOI 10.1016/j.celrep.2015.11.045; Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76; Nelson BR, 2016, SCIENCE, V351, P271, DOI 10.1126/science.aad4076; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; RYDER NS, 1992, BRIT J DERMATOL, V126, P2, DOI 10.1111/j.1365-2133.1992.tb00001.x; RYDER NS, 1985, BIOCHEM J, V230, P765, DOI 10.1042/bj2300765; Saghatelianr A, 2015, NAT CHEM BIOL, V11, P909, DOI 10.1038/nchembio.1964; Schmid I., 2001, CURR PROTOC CYTOM; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Sharova LV, 2009, DNA RES, V16, P45, DOI 10.1093/dnares/dsn030; Simigdala N, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0713-5; Skibinski A, 2015, ONCOGENE, V34, P5309, DOI 10.1038/onc.2014.475; Slavoff SA, 2014, J BIOL CHEM, V289, P10950, DOI 10.1074/jbc.C113.533968; Slavoff SA, 2013, NAT CHEM BIOL, V9, P59, DOI [10.1038/NCHEMBIO.1120, 10.1038/nchembio.1120]; Sleator RD, 2010, GENE, V461, P1, DOI 10.1016/j.gene.2010.04.008; Staudt AC, 2011, EMBO REP, V12, P35, DOI 10.1038/embor.2010.196; Stevenson J, 2014, BIOCHEM J, V461, P435, DOI 10.1042/BJ20131404; Sui ZH, 2015, TUMOR BIOL, V36, P6173, DOI 10.1007/s13277-015-3301-x; Ta MT, 2012, FEBS J, V279, P4231, DOI 10.1111/febs.12015; Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078-0432.CCR-12-0489; Wadler CS, 2007, P NATL ACAD SCI USA, V104, P20454, DOI 10.1073/pnas.0708102104; Zhang HY, 2014, THORAC CANCER, V5, P275, DOI 10.1111/1759-7714.12087; Zhang Q, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15664	69	74	78	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4750	4768		10.1038/s41388-018-0281-5	http://dx.doi.org/10.1038/s41388-018-0281-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29765154				2022-12-17	WOS:000442514400009
J	Saini, U; Naidu, S; ElNaggar, AC; Bid, HK; Wallbillich, JJ; Bixel, K; Bolyard, C; Suarez, AA; Kaur, B; Kuppusamy, P; Hays, J; Goodfellow, PJ; Cohn, DE; Selvendiran, K				Saini, U.; Naidu, S.; ElNaggar, A. C.; Bid, H. K.; Wallbillich, J. J.; Bixel, K.; Bolyard, C.; Suarez, A. A.; Kaur, B.; Kuppusamy, P.; Hays, J.; Goodfellow, P. J.; Cohn, D. E.; Selvendiran, K.			Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target	ONCOGENE			English	Article							SIGNAL TRANSDUCER; CURCUMIN ANALOG; ANTITUMOR; CELLS; HO-3867; INHIBITOR; ACTIVATION; APOPTOSIS; MODEL; PHOSPHORYLATION	Although activation of the STAT3 pathway has been associated with tumor progression in a wide variety of cancer types (including ovarian cancer), the precise mechanism of invasion and metastasis due to STAT3 are not fully delineated in ovarian cancer. We found that pSTAT3 Tyr705 is constitutively activated in patient ascites and ascites-derived ovarian cancer cells (ADOCCs), and the range of STAT3 expression could be very high to low. In vivo transplantation of ADOCCs with high pSTAT3 expression into the ovarian bursa of mice resulted in a large primary tumor and widespread peritoneal metastases. In contrast, ADOCCs with low STAT3 expression or ADOCCs with STAT3 expression knockdown, led to reduced tumor growth and an absence of metastases in vivo. Cytokines derived from the ADOCC culture medium activate the interleukin (IL)-6/STAT pathway in the STAT3 knockout (KO) cells, compensating for the absence of inherent STAT3 in the cells. Treatment with HO-3867 (a novel STAT3 inhibitor at 100 p.p.m. in an orthotopic murine model) significantly suppressed ovarian tumor growth, angiogenesis and metastasis by targeting STAT3 and its downstream proteins. HO-3867 was found to have cytotoxic effects in ex vivo cultures of freshly collected human ovarian cancers, including those resistant to platinum-based chemotherapy. Our results show that STAT3 is necessary for ovarian tumor progression/metastasis and highlight the potential for targeting STAT3 by HO-3867 as a therapeutic strategy for ovarian cancer.	[Saini, U.; Naidu, S.; ElNaggar, A. C.; Bid, H. K.; Wallbillich, J. J.; Bixel, K.; Suarez, A. A.; Hays, J.; Goodfellow, P. J.; Cohn, D. E.; Selvendiran, K.] Ohio State Univ, Wexner Med Ctr, Ctr Comprehens Canc, Div Gynecol Oncol, Columbus, OH 43210 USA; [Bolyard, C.; Kaur, B.] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Kuppusamy, P.] Dartmouth Med Sch, Dept Radiol, Hanover, NH USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Dartmouth College	Cohn, DE; Selvendiran, K (corresponding author), Ohio State Univ, Wexner Med Ctr, Ctr Comprehens Canc, Div Gynecol Oncol, Columbus, OH 43210 USA.	david.cohn@osumc.edu; selvendiran.karuppaiyah@osumc.edu	ElNaggar, Adam/V-6999-2019; Hays, John/H-3968-2012	ElNaggar, Adam/0000-0003-3409-583X; Cohn, David/0000-0002-3036-6172; Wallbillich, John/0000-0001-5913-8088	Ovarian Cancer Research Fund (OCRF); NCI [RO1-CA176078]; Drug Development Institute pilot grant; OSU CCC Internal grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD085817] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA150153, P01CA163205, P30CA016058, R01CA176078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064607] Funding Source: NIH RePORTER	Ovarian Cancer Research Fund (OCRF); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Drug Development Institute pilot grant; OSU CCC Internal grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr John Hays for his willingness to pre-review this manuscript and provide valuable comments and suggestions. We also thank Dr Vinay Puduvalli and his lab members (including Jihong Xu) for providing access to their vibrating microtome. We extend additional thanks to Dr Mitch Phelps and Dr Yonghua Ling of the Pharmacoanalytical Shared Resource (PhASR), for LC MS analysis of drug bioabsorption and metabolism. The authors are also thankful to the undergraduate students Ross Wanner, Riley Maria, Roman Zingarelli and Jack Fowler for the cell culture and basic assay help. This work was funded by Ovarian Cancer Research Fund (OCRF), NCI RO1-CA176078 grant and Drug Development Institute pilot grant (KS and DEC), and OSU CCC Internal grant to DEC.	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Bill MA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-165; Bolyard C, 2014, CLIN CANCER RES, V20, P6479, DOI 10.1158/1078-0432.CCR-14-0463; Cheng XL, 2010, BIOORGAN MED CHEM, V18, P4509, DOI 10.1016/j.bmc.2010.04.066; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Dayton A, 2010, CANCER BIOL THER, V10, P1027, DOI 10.4161/cbt.10.10.13250; Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944; Goff BA, 2015, GYNECOL ONCOL, V136, P1, DOI 10.1016/j.ygyno.2014.12.008; Greten FR, 2010, NAT MED, V16, P1085, DOI 10.1038/nm1010-1085; Gritsina G, 2015, MOL CANCER THER, V14, P1035, DOI 10.1158/1535-7163.MCT-14-0800; Hsu HS, 2011, CANCER-AM CANCER SOC, V117, P2970, DOI 10.1002/cncr.25869; Huang F, 2008, ACTA BIOCH BIOPH SIN, V40, P519, DOI 10.1111/j.1745-7270.2008.00424.x; Kalai T, 2011, J MED CHEM, V54, P5414, DOI 10.1021/jm200353f; Kim D, 2014, CANCER RES, V74, P2144, DOI 10.1158/0008-5472.CAN-13-2187; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kroon P, 2013, CANCER RES, V73, P5288, DOI 10.1158/0008-5472.CAN-13-0874; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Lee MY, 2006, BREAST, V15, P187, DOI 10.1016/j.breast.2005.05.005; Mace TA, 2013, CANCER RES, V73, P3007, DOI 10.1158/0008-5472.CAN-12-4601; Matte I, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-288; McCann Georgia A, 2014, Oncoscience, V1, P216; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Pedranzini L, 2004, J CLIN INVEST, V114, P619, DOI 10.1172/JCI200422800; Pirnia F, 2006, ANTICANCER RES, V26, P1765; Pradeep S, 2015, CANCER CELL, V28, P610, DOI 10.1016/j.ccell.2015.09.008; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Putoczki T, 2010, J LEUKOCYTE BIOL, V88, P1109, DOI 10.1189/jlb.0410226; Rath KS, 2014, CANCER RES, V74, P2316, DOI 10.1158/0008-5472.CAN-13-2433; Selvendiran K, 2006, CANCER RES, V66, P4826, DOI 10.1158/0008-5472.CAN-05-4062; Selvendiran K, 2010, MOL CANCER RES, V8, P1188, DOI 10.1158/1541-7786.MCR-10-0201; Selvendiran K, 2010, MOL CANCER THER, V9, P1169, DOI 10.1158/1535-7163.MCT-09-1207; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Seo JM, 2012, J BIOL CHEM, V287, P13840, DOI 10.1074/jbc.M111.317131; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tierney BJ, 2014, GYNECOL ONCOL, V135, P133, DOI 10.1016/j.ygyno.2014.07.087; Tierney BJ, 2012, CANCER BIOL THER, V13, P766, DOI 10.4161/cbt.20559; Vaira V, 2010, P NATL ACAD SCI USA, V107, P8352, DOI 10.1073/pnas.0907676107; Venkatesh S, 2000, J PHARM SCI-US, V89, P145, DOI 10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6; Wen W, 2014, MOL CANCER THER, V13, P3037, DOI 10.1158/1535-7163.MCT-14-0077; Yoo JY, 2014, CLIN CANCER RES, V20, P3787, DOI 10.1158/1078-0432.CCR-14-0553; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109	49	74	78	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					168	181		10.1038/onc.2016.197	http://dx.doi.org/10.1038/onc.2016.197			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27292260	Green Accepted			2022-12-17	WOS:000393938100003
J	Treps, L; Edmond, S; Harford-Wright, E; Galan-Moya, EM; Schmitt, A; Azzi, S; Citerne, A; Bidere, N; Ricard, D; Gavard, J				Treps, L.; Edmond, S.; Harford-Wright, E.; Galan-Moya, E. M.; Schmitt, A.; Azzi, S.; Citerne, A.; Bidere, N.; Ricard, D.; Gavard, J.			Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma	ONCOGENE			English	Article							NEWLY-DIAGNOSED GLIOBLASTOMA; ENDOTHELIAL-CELL PERMEABILITY; BEVACIZUMAB PLUS IRINOTECAN; STEM-CELLS; RECURRENT GLIOBLASTOMA; TUMOR-GROWTH; VE-CADHERIN; ANTI-VEGF; PHASE-II; THERAPY	Glioblastoma are malignant highly vascularized brain tumours, which feature large oedema resulting from tumour-promoted vascular leakage. The pro-permeability factor Semaphorin3A (Sema3A) produced within glioblastoma has been linked to the loss of endothelial barrier integrity. Here, we report that extracellular vesicles (EVs) released by patient-derived glioblastoma cells disrupt the endothelial barrier. EVs expressed Sema3A at their surface, which accounted for in vitro elevation of brain endothelial permeability and in vivo vascular permeability, in both skin and brain vasculature. Blocking Sema3A or its receptor Neuropilin1 (NRP1) hampered EV-mediated permeability. In vivo models using ectopically and orthotopically xenografted mice revealed that Sema3A-containing EVs were efficiently detected in the blood stream. In keeping with this idea, sera from glioblastoma multiforme (GBM) patients also contain high levels of Sema3A carried in the EV fraction that enhanced vascular permeability, in a Sema3A/NRP1-dependent manner. Our results suggest that EV-delivered Sema3A orchestrates loss of barrier integrity in glioblastoma and may be of interest for prognostic purposes.	[Treps, L.; Harford-Wright, E.; Galan-Moya, E. M.; Schmitt, A.; Azzi, S.; Citerne, A.; Bidere, N.; Gavard, J.] CNRS, UMR8104, Paris, France; [Treps, L.; Harford-Wright, E.; Galan-Moya, E. M.; Schmitt, A.; Azzi, S.; Citerne, A.; Bidere, N.; Gavard, J.] INSERM, U1016, Paris, France; [Treps, L.; Harford-Wright, E.; Galan-Moya, E. M.; Schmitt, A.; Azzi, S.; Citerne, A.; Bidere, N.; Gavard, J.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Edmond, S.; Ricard, D.] Hop Instruct Armees Val de Grace, Serv Neurol, Paris, France; [Harford-Wright, E.; Bidere, N.; Gavard, J.] INSERM, U892, Nantes, France; [Harford-Wright, E.; Bidere, N.; Gavard, J.] CNRS, UMR6299, Nantes, France; [Harford-Wright, E.; Bidere, N.; Gavard, J.] Univ Nantes, Nantes, France; [Ricard, D.] CNRS, COGNAC G UMR8257, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Val-de-Grace Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Nantes Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Gavard, J (corresponding author), CRCNA, INSERM U892, CNRS UMR6299, 8 Quai Moncousu, F-44000 Nantes, France.	julie.gavard@inserm.fr	Treps, Lucas/AAF-2499-2020; Bidère, Nicolas/K-8887-2015; Galan-Moya, Eva M/I-2912-2015; Gavard, Julie/I-5487-2012; Gavard, Julie/I-5487-2012	Treps, Lucas/0000-0003-0735-9000; Bidère, Nicolas/0000-0001-9177-0008; Galan-Moya, Eva M/0000-0001-5758-7592; Gavard, Julie/0000-0002-7985-9007; Gavard, Julie/0000-0003-3107-2026; Citerne, Antoine/0000-0002-9746-931X	Universite Paris Descartes; Ligue nationale contre le cancer, Canceropole Ile-de-France; Fondation ARC Association pour la Recherche sur le Cancer; Fondation pour la Recherche Medicale; Institut National du Cancer [INCA_6508]; Ligue nationale contre le cancer comite de Paris; Region Pays-de-la-Loire; Nantes Metropole	Universite Paris Descartes; Ligue nationale contre le cancer, Canceropole Ile-de-France; Fondation ARC Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue nationale contre le cancer comite de Paris; Region Pays-de-la-Loire(Region Pays de la Loire); Nantes Metropole(Region Pays de la Loire)	We are thankful to present and past members of the team, especially to Heloise Leclair and Armelle Le Guelte. We are grateful to Robin Lombard (Myltenyi Biotech, Paris, France) for technical assistance with the MacsQuant cytometer. We are also grateful to PO Couraud and F Niedergang's team (Institut Cochin, Paris, France) for helpful discussion and reagents. This research was funded by: Fondation pour la Recherche Medicale, Institut National du Cancer INCA_6508, Ligue nationale contre le cancer comite de Paris, Region Pays-de-la-Loire, Nantes Metropole. LT is supported by doctoral fellowship from Universite Paris Descartes. EMGM, EHW and SA are supported by post-doctoral fellowships from Ligue nationale contre le cancer, Canceropole Ile-de-France and Fondation ARC Association pour la Recherche sur le Cancer, respectively.	Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Casazza A, 2011, ARTERIOSCL THROM VAS, V31, P741, DOI 10.1161/ATVBAHA.110.211920; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Dwyer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045562; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Galan-Moya EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093505; Galan-Moya EM, 2011, EMBO REP, V12, P470, DOI 10.1038/embor.2011.39; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lai A, 2011, J CLIN ONCOL, V29, P142, DOI 10.1200/JCO.2010.30.2729; Le Guelte A, 2012, J CELL SCI, V125, P4137, DOI 10.1242/jcs.108282; Le Guelte A, 2011, BIOL CELL, V103, P593, DOI 10.1042/BC20110069; Maione F, 2012, J CLIN INVEST, V122, P1832, DOI 10.1172/JCI58976; Maione F, 2009, J CLIN INVEST, V119, P3356, DOI 10.1172/JCI36308; Narayana A, 2012, J NEUROSURG, V116, P341, DOI 10.3171/2011.9.JNS11656; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Piao YJ, 2012, NEURO-ONCOLOGY, V14, P1379, DOI 10.1093/neuonc/nos158; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Thirant C, 2012, STEM CELLS, V30, P845, DOI 10.1002/stem.1062; Vader P, 2014, TRENDS MOL MED, V20, P385, DOI 10.1016/j.molmed.2014.03.002; Vredenburgh JJ, 2007, J CLIN ONCOL, V25, P4722, DOI 10.1200/JCO.2007.12.2440; Yan K, 2013, CURR OPIN NEUROL, V26, P701, DOI 10.1097/WCO.0000000000000032; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311	34	74	75	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2615	2623		10.1038/onc.2015.317	http://dx.doi.org/10.1038/onc.2015.317			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364614				2022-12-17	WOS:000376165700008
J	Mahajan, K; Mahajan, NP				Mahajan, K.; Mahajan, N. P.			ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers	ONCOGENE			English	Review							SURGICAL ADJUVANT BREAST; ANDROGEN RECEPTOR; PROSTATE-CANCER; ACK1; ACTIVATION; AKT; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; MUTATIONS	Deregulated tyrosine kinase signaling alters cellular homeostasis to drive cancer progression. The emergence of a non-receptor tyrosine kinase (non-RTK), ACK1 (also known as activated Cdc42-associated kinase 1 or TNK2) as an oncogenic kinase, has uncovered novel mechanisms by which tyrosine kinase signaling promotes cancer progression. Although early studies focused on ACK1 as a cytosolic effector of activated transmembrane RTKs, wherein it shuttles between the cytosol and the nucleus to rapidly transduce extracellular signals from the RTKs to the intracellular effectors, recent data unfold a new aspect of its functionality as an epigenetic regulator. ACK1 interacts with the estrogen receptor (ER)/histone demethylase KDM3A (JHDM2a) complex, which modifies KDM3A by tyrosine phosphorylation to regulate the transcriptional outcome at HOXA1 locus to promote the growth of tamoxifen-resistant breast cancer. It is also well established that ACK1 regulates the activity of androgen receptor (AR) by tyrosine phosphorylation to fuel the growth of hormone-refractory prostate cancers. Further, recent explosion in genomic sequencing has revealed recurrent ACK1 gene amplification and somatic mutations in a variety of human malignancies, providing a molecular basis for its role in neoplastic transformation. In this review, we will discuss the various facets of ACK1 signaling, including its newly uncovered epigenetic regulator function, which enables cells to bypass the blockade to major survival pathways to promote resistance to standard cancer treatments. Not surprisingly, cancer cells appear to acquire an 'addiction' to ACK1-mediated survival, particularly under stress conditions, such as growth factor deprivation or genotoxic insults or hormone deprivation. With the accelerated development of potent and selective ACK1 inhibitors, targeted treatment for cancers harboring aberrant ACK1 activity may soon become a clinical reality.	[Mahajan, K.; Mahajan, N. P.] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, Tampa, FL 33612 USA; [Mahajan, K.; Mahajan, N. P.] Univ S Florida, Dept Oncol Sci, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Mahajan, K (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.	kiran.mahajan@moffitt.org; nupam.mahajan@moffitt.org	Mahajan, Kiran/ABA-3013-2020	Mahajan, Kiran/0000-0001-7192-396X	Department of Defense [W81XWH-12-1-0248, W81XWH-14-1-0251, W81XWH-14-1-0002, W81XWH-14-1-0003]; National Cancer Institute, NIH [1R01CA135328]; Moffitt Lung Cancer SPORE; NATIONAL CANCER INSTITUTE [R01CA135328] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Moffitt Lung Cancer SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Department of Defense (W81XWH-12-1-0248 and W81XWH-14-1-0251) to KM and by the National Cancer Institute, NIH (1R01CA135328), Department of Defense (W81XWH-14-1-0002 and W81XWH-14-1-0003) and Career Development Award by Moffitt Lung Cancer SPORE to NPM.	Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Buchwald M, 2013, ONCOGENE, V32, P4913, DOI 10.1038/onc.2012.515; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Chan W, 2009, J BIOL CHEM, V284, P8185, DOI 10.1074/jbc.M806877200; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Clarke R, 2001, PHARMACOL REV, V53, P25; DiMauro EF, 2007, BIOORG MED CHEM LETT, V17, P2305, DOI 10.1016/j.bmcl.2007.01.057; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gajiwala KS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053994; Galisteo ML, 2006, P NATL ACAD SCI USA, V103, P9796, DOI 10.1073/pnas.0603714103; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hitomi Y, 2013, ANN NEUROL, V74, P496, DOI 10.1002/ana.23934; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Jones S, 2014, J CELL SCI, V127, P994, DOI 10.1242/jcs.136895; Kramer OH, 2013, LEUKEMIA, V27, P792, DOI 10.1038/leu.2012.284; La Torre A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.99; La Torre A, 2006, GENE EXPR PATTERNS, V6, P886, DOI 10.1016/j.modgep.2006.02.009; Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708; Lin Q, 2012, BIOCHEM J, V445, P255, DOI 10.1042/BJ20111575; Liu Y, 2010, ONCOGENE, V29, P3208, DOI 10.1038/onc.2010.103; Lupien M, 2009, ENDOCR-RELAT CANCER, V16, P381, DOI 10.1677/ERC-09-0038; Mahajan K, 2014, AACR ED BOOK, V2014, P6; Mahajan K, 2014, J BIOL CHEM, V289, P28179, DOI 10.1074/jbc.M114.584425; Mahajan K, 2013, CANCER LETT, V338, P185, DOI 10.1016/j.canlet.2013.04.004; Mahajan K, 2012, J BIOL CHEM, V287, P22112, DOI 10.1074/jbc.M112.357384; Mahajan K, 2012, J CELL PHYSIOL, V227, P3178, DOI 10.1002/jcp.24065; Mahajan K, 2012, AM J PATHOL, V180, P1386, DOI 10.1016/j.ajpath.2011.12.028; Mahajan K, 2010, PROSTATE, V70, P1274, DOI 10.1002/pros.21163; Mahajan K, 2010, J CELL PHYSIOL, V224, P327, DOI 10.1002/jcp.22162; Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Matsumoto J, 2002, JPN J CANCER RES, V93, P1317, DOI 10.1111/j.1349-7006.2002.tb01240.x; Maxson JE, 2013, NEW ENGL J MED, V368, P1781, DOI 10.1056/NEJMoa1214514; Prieto-Echagile V., 2011, J SIGNAL TRANSDUCT, V2011; Prieto-Echague V, 2010, BMC BIOCHEM, V11, DOI 10.1186/1471-2091-11-42; Prieto-Echague V, 2010, J BIOL CHEM, V285, P10605, DOI 10.1074/jbc.M109.060459; Sakurada A, 1997, JPN J CANCER RES, V88, P1025, DOI 10.1111/j.1349-7006.1997.tb00324.x; Schlieman MG, 2003, BRIT J CANCER, V89, P2110, DOI 10.1038/sj.bjc.6601396; Schoenherr JA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002725; Shen F, 2007, MOL BIOL CELL, V18, P732, DOI 10.1091/mbc.E06-02-0142; Shinmura K, 2014, J SURG ONCOL, V109, P189, DOI 10.1002/jso.23482; Tan DSW, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-13; Urena JM, 2005, J COMP NEUROL, V490, P119, DOI 10.1002/cne.20656; van der Horst EH, 2005, P NATL ACAD SCI USA, V102, P15901, DOI 10.1073/pnas.0508014102; Yokoyama N, 2003, J BIOL CHEM, V278, P47713, DOI 10.1074/jbc.M306716200	53	74	76	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4162	4167		10.1038/onc.2014.350	http://dx.doi.org/10.1038/onc.2014.350			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347744	Green Accepted			2022-12-17	WOS:000359199800002
J	Sarkar, TR; Battula, VL; Werden, SJ; Vijay, GV; Ramirez-Pena, EQ; Taube, JH; Chang, JT; Miura, N; Porter, W; Sphyris, N; Andreeff, M; Mani, SA				Sarkar, T. R.; Battula, V. L.; Werden, S. J.; Vijay, G. V.; Ramirez-Pena, E. Q.; Taube, J. H.; Chang, J. T.; Miura, N.; Porter, W.; Sphyris, N.; Andreeff, M.; Mani, S. A.			GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; STEM-CELLS; TUMOR PROGRESSION; FACTOR RECEPTOR; MET; EXPRESSION; MORPHOGENESIS; GENE; PLASTICITY; PATHWAYS	The epithelial-mesenchymal transition (EMT) bestows cancer cells with increased stem cell properties and metastatic potential. To date, multiple extracellular stimuli and transcription factors have been shown to regulate EMT. Many of them are not druggable and therefore it is necessary to identify targets, which can be inhibited using small molecules to prevent metastasis. Recently, we identified the ganglioside GD2 as a novel breast cancer stem cell marker. Moreover, we found that GD3 synthase (GD3S)-an enzyme involved in GD2 biosynthesis-is critical for GD2 production and could serve as a potential druggable target for inhibiting tumor initiation and metastasis. Indeed, there is a small molecule known as triptolide that has been shown to inhibit GD3S function. Accordingly, in this manuscript, we demonstrate that the inhibition of GD3S using small hairpin RNA or triptolide compromises the initiation and maintenance of EMT instigated by various signaling pathways, including Snail, Twist and transforming growth factor-beta 1 as well as the mesenchymal characteristics of claudin-low breast cancer cell lines (SUM159 and MDA-MB-231). Moreover, GD3S is necessary for wound healing, migration, invasion and stem cell properties in vitro. Most importantly, inhibition of GD3S in vivo prevents metastasis in experimental as well as in spontaneous syngeneic wild-type mouse models. We also demonstrate that the transcription factor FOXC2, a central downstream effector of several EMT pathways, directly regulates GD3S expression by binding to its promoter. In clinical specimens, the expression of GD3S correlates with poor prognosis in triple-negative human breast tumors. Moreover, GD3S expression correlates with activation of the c-Met signaling pathway leading to increased stem cell properties and metastatic competence. Collectively, these findings suggest that the GD3S-c-Met axis could serve as an effective target for the treatment of metastatic breast cancers.	[Sarkar, T. R.; Werden, S. J.; Vijay, G. V.; Ramirez-Pena, E. Q.; Taube, J. H.; Sphyris, N.; Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Battula, V. L.; Andreeff, M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Miura, N.] Hamamatsu Univ, Sch Med, Dept Biochem, Hamamatsu, Shizuoka 4312102, Japan; [Porter, W.] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX USA; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Houston, TX 77030 USA; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cells & Dev Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Hamamatsu University School of Medicine; Texas A&M University System; Texas A&M University College Station; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Andreeff, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.	mandreef@mdanderson.org; smani@mdanderson.org	Mani, Sendurai A./A-7244-2009; SPHYRIS, NATHALIE/GQY-6349-2022	Mani, Sendurai A./0000-0002-5918-4276; Ramirez-Pena, Esmeralda/0000-0002-5200-7488; Raja, Geraldine Vidhya/0000-0002-4644-3080; Sphyris, Nathalie/0000-0003-1860-1958; Taube, Joseph/0000-0002-3636-5189	MD Anderson Research Trust Fellow Award; George and Barbara Bush Endowment for Innovative Cancer Research; Cancer Center Support Grant from the National Cancer Institute [CA16672]; Breast Cancer Research Foundation; Rolanette and Berdon Lawrence Research award from Bone Disease Program of Texas; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	MD Anderson Research Trust Fellow Award; George and Barbara Bush Endowment for Innovative Cancer Research; Cancer Center Support Grant from the National Cancer Institute; Breast Cancer Research Foundation; Rolanette and Berdon Lawrence Research award from Bone Disease Program of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the entire Mani Lab for invaluable suggestions and discussions, and Thiru Arumugam for his valuable help in animal imaging. This work was supported by an MD Anderson Research Trust Fellow Award, funded by the George and Barbara Bush Endowment for Innovative Cancer Research (SAM). Flow cytometry, confocal microscopy and animal imaging were in part funded by the Cancer Center Support Grant from the National Cancer Institute (CA16672). We also acknowledge support from the Breast Cancer Research Foundation (MA) and the Rolanette and Berdon Lawrence Research award from Bone Disease Program of Texas (VLB).	Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Battula VL, 2012, J CLIN INVEST, V122, P2066, DOI 10.1172/JCI59735; Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cazet A, 2010, MOL CANCER RES, V8, P1526, DOI 10.1158/1541-7786.MCR-10-0302; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DIRENZO MF, 1995, CANCER RES, V55, P1129; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hao L, 2000, ACTA PHARMACOL SIN, V21, P782; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hay ED, 1995, ACTA ANAT, V154, P8; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872; Kiviharju TM, 2002, CLIN CANCER RES, V8, P2666; Kwon HY, 2010, EXP MOL MED, V42, P849, DOI 10.3858/emm.2010.42.12.088; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Tuck AB, 1996, AM J PATHOL, V148, P225; van Leenders GJLH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026753; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Xue CS, 2003, CANCER RES, V63, P3386; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	43	74	79	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2958	2967		10.1038/onc.2014.245	http://dx.doi.org/10.1038/onc.2014.245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25109336	Green Accepted			2022-12-17	WOS:000356100500002
J	De Mei, C; Ercolani, L; Parodi, C; Veronesi, M; Lo Vecchio, C; Bottegoni, G; Torrente, E; Scarpelli, R; Marotta, R; Ruffili, R; Mattioli, M; Reggiani, A; Wade, M; Grimaldi, B				De Mei, C.; Ercolani, L.; Parodi, C.; Veronesi, M.; Lo Vecchio, C.; Bottegoni, G.; Torrente, E.; Scarpelli, R.; Marotta, R.; Ruffili, R.; Mattioli, M.; Reggiani, A.; Wade, M.; Grimaldi, B.			Dual inhibition of REV-ERB beta and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells	ONCOGENE			English	Article							CIRCADIAN CLOCK; ALPHA; METABOLISM; TIME; IDENTIFICATION; SIGNATURE; BEHAVIOR; DESIGN; LIGAND	REV-ERB alpha and REV-ERB beta nuclear receptors regulate several physiological processes, including circadian rhythm and metabolism. A previous study reported the REV-ERB alpha gene to be co-overexpressed with ERBB2 in breast cancer cell lines. Surprisingly, we found that several tumor types, including a number of breast cancer cell lines, predominantly express the REV-ERB beta variant. This pattern was independent of ERBB2 and ER status, and opposite to that of non-cancer mammary epithelial HMEC cells, in which REV-ERB alpha was the major variant. Consistent with this molecular profile, REV-ERB target genes in both circadian and metabolic pathways were derepressed upon silencing of REV-ERB beta, but not REV-ERB alpha. Strikingly, we found that REV-ERB beta is a determinant of sensitivity to chloroquine, a clinically relevant lysosomotropic agent that suppresses autophagy. The cytoprotective function of REV-ERB beta appears to operate downstream of autophagy blockade. Through compound screening, we identified ARN5187, a novel lysosomotropic REV-ERB beta ligand with a dual inhibitory activity toward REV-ERB-mediated transcriptional regulation and autophagy. Remarkably, although ARN5187 and chloroquine share similar lysosomotropic potency and have a similar effect on autophagy inhibition, ARN5187 is significantly more cytotoxic. Collectively, our results reveal that dual inhibition of REV-ERB beta and autophagy is an effective strategy for eliciting cytotoxicity in cancer cells. Furthermore, our discovery of a novel inhibitor compound of both REV-ERB and autophagy may provide a scaffold for the discovery of new multifunctional anticancer agents.	[De Mei, C.; Ercolani, L.; Parodi, C.; Veronesi, M.; Lo Vecchio, C.; Bottegoni, G.; Torrente, E.; Scarpelli, R.; Reggiani, A.; Grimaldi, B.] Ist Italiano Tecnol, Dept Drug Discovery & Dev, I-16136 Genoa, Italy; [Marotta, R.; Ruffili, R.] Ist Italiano Tecnol, EM Lab, Dept Nanochem, I-16136 Genoa, Italy; [Mattioli, M.; Wade, M.] Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, Milan, Italy	Istituto Italiano di Tecnologia - IIT; Istituto Italiano di Tecnologia - IIT; Istituto Italiano di Tecnologia - IIT	Grimaldi, B (corresponding author), Ist Italiano Tecnol, Dept Drug Discovery & Dev, Via Morego 30, I-16136 Genoa, Italy.	benedetto.grimaldi@iit.it	Scarpelli, Rita/O-9422-2015; Wade, Mark/B-6719-2009; Marotta, Roberto/HGV-1599-2022; Marotta, Roberto/B-5382-2014; Mattioli, Michela/K-3951-2013; VERONESI, MARINA/A-2749-2012	Wade, Mark/0000-0002-2688-5965; Mattioli, Michela/0000-0002-1692-9178; Ercolani, Luisa/0000-0002-0418-3460; VERONESI, MARINA/0000-0001-8491-8844; Grimaldi, Benedetto/0000-0002-2589-9302; Bottegoni, Giovanni/0000-0003-1251-583X	Istituto Italiano di Tecnologia (IIT)	Istituto Italiano di Tecnologia (IIT)	We thank Professor Daniele Piomelli for helpful discussions and for revising the manuscript. We thank Dr Gennaro Colella for MCF-7, HEP-G2 and HCT-116 cell lines, and Dr Natalia Realini for providing cDNA from H-1299, HEP-G2, A-375, A-431 and HCT-116 cells. We also thank Professor Mariapia Abbracchio, Dr Ana Guijarro, Dr Andrea Contestabile and Dr Francesco Niola for discussions. Dr L Ercolani is supported by an interdepartmental post-doctoral fellowship from the Istituto Italiano di Tecnologia (IIT).	Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Bugge A, 2012, GENE DEV, V26, P657, DOI 10.1101/gad.186858.112; Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133; Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324; Checinska A, 2011, PIGM CELL MELANOMA R, V24, P1116, DOI 10.1111/j.1755-148X.2011.00927.x; Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048; Dalvit C, 2002, COMB CHEM HIGH T SCR, V5, P605, DOI 10.2174/1386207023329923; Duez H, 2009, J APPL PHYSIOL, V107, P1972, DOI 10.1152/japplphysiol.00570.2009; Engelen E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056623; Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072; Grimaldi B, 2010, CELL METAB, V12, P509, DOI 10.1016/j.cmet.2010.10.005; Grimaldi B, 2009, INT J BIOCHEM CELL B, V41, P81, DOI 10.1016/j.biocel.2008.08.035; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; Hastak K, 2010, CANCER RES, V70, P7970, DOI 10.1158/0008-5472.CAN-09-4521; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Hu C, 2008, BIOORGAN MED CHEM, V16, P7888, DOI 10.1016/j.bmc.2008.07.076; Kelleher FC, 2014, CANCER LETT, V342, P9, DOI 10.1016/j.canlet.2013.09.040; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kojetin D, 2011, ACS CHEM BIOL, V6, P131, DOI 10.1021/cb1002575; Konigshoff M, 2003, CLIN CHEM, V49, P219, DOI 10.1373/49.2.219; Kourtidis A, 2010, CANCER RES, V70, P1783, DOI 10.1158/0008-5472.CAN-09-1550; Kumar N, 2010, ENDOCRINOLOGY, V151, P3015, DOI 10.1210/en.2009-0800; Marotta R, 2013, METHODS MOL BIOL, V1025, P179, DOI 10.1007/978-1-62703-462-3_14; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010; Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708; Nishimura Masuhiro, 2004, Drug Metab Pharmacokinet, V19, P135, DOI 10.2133/dmpk.19.135; Ozturk N, 2009, P NATL ACAD SCI USA, V106, P2841, DOI 10.1073/pnas.0813028106; Raghuram S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344; Rossetti S, 2012, CELL CYCLE, V11, P350, DOI 10.4161/cc.11.2.18792; Sahar S, 2009, NAT REV CANCER, V9, P886, DOI 10.1038/nrc2747; Savvidis C, 2012, MOL MED, V18, P1249, DOI 10.2119/molmed.2012.00077; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Tagad HD, 2011, BIOORGAN MED CHEM, V19, P5238, DOI 10.1016/j.bmc.2011.07.002; Teboul M, 2009, J APPL PHYSIOL, V107, P1965, DOI 10.1152/japplphysiol.00515.2009; Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004; Totrov M, 2008, CHEM BIOL DRUG DES, V71, P15, DOI 10.1111/j.1747-0285.2007.00605.x; Trump RP, 2013, J MED CHEM, V56, P4729, DOI 10.1021/jm400458q; Vulpetti A, 2012, DRUG DISCOV TODAY, V17, P890, DOI 10.1016/j.drudis.2012.03.014; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Woldt E, 2013, NAT MED, V19, P1039, DOI 10.1038/nm.3213; Zhou CH, 2012, AUTOPHAGY, V8, P1215, DOI 10.4161/auto.20284	44	74	79	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2597	2608		10.1038/onc.2014.203	http://dx.doi.org/10.1038/onc.2014.203			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023698	hybrid, Green Published			2022-12-17	WOS:000354541300006
J	Li, Y; Luo, H; Liu, T; Zacksenhaus, E; Ben-David, Y				Li, Y.; Luo, H.; Liu, T.; Zacksenhaus, E.; Ben-David, Y.			The ets transcription factor Fli-1 in development, cancer and disease	ONCOGENE			English	Review							GENOME-WIDE ANALYSIS; PROTEIN-KINASE-C; PRIMITIVE NEUROECTODERMAL TUMOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PARIS-TROUSSEAU-SYNDROME; ACUTE MYELOID-LEUKEMIA; STEM-CELL ENHANCER; ENDOTHELIAL-CELLS; EWING SARCOMA; DNA-BINDING	Friend leukemia virus-induced erythroleukemia-1 (Fli-1), an E26 transformation specific (ETS) transcription factor, was isolated a quarter century ago through a retrovirus mutagenesis screen. Fli-1 has since been recognized to play critical roles in normal development and homeostasis. For example, it transcriptionally regulates genes that drive normal hematopoiesis and vasculogenesis. Indeed, Fli-1 is one of 10 key regulators of hematopoietic stem/progenitor cell maintenance and differentiation. Aberrant expression of Fli-1 also underlies a number of virally induced leukemias, including Friend virus-induced erythroleukemia and various types of human cancers, and it is the target of chromosomal translocations in childhood Ewing's sarcoma. Abnormal expression of Fli-1 is important in the etiology of autoimmune diseases such as systemic lupus erythematosus and systemic sclerosis. These studies establish Fli-1 as a strong candidate for drug development. Despite difficulties in targeting transcription factors, recent studies identified small-molecule inhibitors for Fli-1. Here we review past and ongoing research on Fli-1 with emphasis on its mechanistic function in autoimmune disease and malignant transformation. The significance of identifying Fli-1 inhibitors and their clinical applications for treatment of disease and cancer with deregulated Fli-1 expression are discussed.	[Li, Y.] Jilin Univ, Norman Bethune Coll Med, Dept Anat, Changchun 130023, Peoples R China; [Luo, H.; Liu, T.; Ben-David, Y.] Div Biol, Key Lab Chem Nat Prod Guizhou Prov, Guiyang 550002, Peoples R China; [Luo, H.; Liu, T.; Ben-David, Y.] Chinese Acad Sci, Guiyang 550002, Peoples R China; [Zacksenhaus, E.; Ben-David, Y.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Zacksenhaus, E.] Univ Hlth Network, Toronto Gen Res Inst, Div Adv Diagnost, Toronto, ON, Canada	Jilin University; Chinese Academy of Sciences; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Ben-David, Y (corresponding author), Div Biol, Key Lab Chem Nat Prod Guizhou Prov, Guiyang 550002, Peoples R China.	ybd1955@gmail.com	Zacksenhaus, Eldad/AAD-3584-2020		Canadian Institute of Health Research [MOP-110952]; Canadian Breast Cancer Foundation; Science and Technology Department of Guizhou Province [6012, 4001]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Science and Technology Department of Guizhou Province	This work was supported by Canadian Institute of Health Research to YB-D (MOP-110952), Canadian Breast Cancer Foundation to EZ, the Science and Technology Department of Guizhou Province innovation and project grants (6012, 4001) to YB-D.	Anderson MK, 1999, DEVELOPMENT, V126, P3131; Ano S, 2004, J BIOL CHEM, V279, P2993, DOI 10.1074/jbc.M303816200; Asano Y, 2007, J BIOL CHEM, V282, P34672, DOI 10.1074/jbc.M703907200; Asano Y, 2010, J DERMATOL SCI, V59, P153, DOI 10.1016/j.jdermsci.2010.06.008; Asano Y, 2010, AM J PATHOL, V176, P1983, DOI 10.2353/ajpath.2010.090593; Asano Y, 2009, MOL CELL BIOL, V29, P1882, DOI 10.1128/MCB.01320-08; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Ban J, 2011, ONCOGENE, V30, P2173, DOI 10.1038/onc.2010.581; Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; Bhatia S, 2007, BLOOD, V109, P46, DOI 10.1182/blood-2006-01-023101; Boro A, 2012, INT J CANCER, V131, P2153, DOI 10.1002/ijc.27472; Bradshaw S, 2008, CLIN IMMUNOL, V129, P19, DOI 10.1016/j.clim.2008.05.010; Brown JG, 2010, AM J SURG PATHOL, V34, P942, DOI 10.1097/PAS.0b013e3181e4f32a; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Bujor AM, 2012, INT J MOL MED, V30, P1473, DOI 10.3892/ijmm.2012.1150; Bujor AM, 2011, ARTHRITIS RHEUM-US, V63, P1729, DOI 10.1002/art.30284; Camoes MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049819; Carmichael CL, 2012, P NATL ACAD SCI USA, V109, P15437, DOI 10.1073/pnas.1213454109; Cuda J, 2013, AM J DERMATOPATH, V35, P316, DOI 10.1097/DAD.0b013e318266b197; Cui JW, 2009, LEUKEMIA, V23, P1311, DOI 10.1038/leu.2009.20; De Val S, 2009, DEV CELL, V16, P180, DOI 10.1016/j.devcel.2009.01.014; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Elkareh J, 2009, AM J PHYSIOL-RENAL, V296, pF1219, DOI 10.1152/ajprenal.90710.2008; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Favier R, 2003, THROMB HAEMOSTASIS, V90, P893, DOI 10.1160/TH03-02-0120; Georgiou P, 1996, INT J ONCOL, V9, P9; Gill R, 2009, ARCH PATHOL LAB MED, V133, P967, DOI 10.1043/1543-2165-133.6.967; Ginsberg M, 2012, CELL, V151, P559, DOI 10.1016/j.cell.2012.09.032; Gosiengfiao Y, 2007, DNA CELL BIOL, V26, P577, DOI 10.1089/dna.2007.0575; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Gottgens B, 2004, MOL CELL BIOL, V24, P1870, DOI 10.1128/MCB.24.5.1870-1883.2004; Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156; Grohar PJ, 2011, NEOPLASIA, V13, P145, DOI 10.1593/neo.101202; Haller ST, 2012, AM J HYPERTENS, V25, P690, DOI 10.1038/ajh.2012.17; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Heo SH, 2010, J CELL PHYSIOL, V224, P734, DOI 10.1002/jcp.22175; Hewett PW, 2001, INT J BIOCHEM CELL B, V33, P347, DOI 10.1016/S1357-2725(01)00022-X; Johnson AD, 2010, INT J SURG PATHOL, V18, P388, DOI 10.1177/1066896908316903; Juban G, 2009, MOL CELL BIOL, V29, P2852, DOI 10.1128/MCB.01435-08; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; Kornblau SM, 2011, BLOOD, V118, P5604, DOI 10.1182/blood-2011-04-348052; Krishnamurti L, 2001, AM J HEMATOL, V66, P295, DOI 10.1002/ajh.1061; Kruse EA, 2009, P NATL ACAD SCI USA, V106, P13814, DOI 10.1073/pnas.0906556106; Kwiatkowski BA, 2000, BLOOD CELL MOL DIS, V26, P84, DOI 10.1006/bcmd.2000.0282; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Lakhanpal GK, 2010, BLOOD, V116, P428, DOI 10.1182/blood-2009-10-250217; Landry JR, 2005, BLOOD, V106, P2680, DOI 10.1182/blood-2004-12-4755; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Le Bras A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012156; Leavey PJ, 2008, EXPERT REV ANTICANC, V8, P617, DOI 10.1586/14737140.8.4.617; Lee CR, 2003, ANTICANCER RES, V23, P2159; Lelievre E, 2002, J BIOL CHEM, V277, P25143, DOI 10.1074/jbc.M201628200; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; Li L, 2014, BLOOD, V123, P501, DOI 10.1182/blood-2013-07-514612; Li YJ, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2011.52; Li Y, 2010, CANCER LETT, V294, P57, DOI 10.1016/j.canlet.2010.01.022; Liu F, 2008, CIRC RES, V103, P1147, DOI 10.1161/CIRCRESAHA.108.179713; Liu F, 2008, CURR BIOL, V18, P1234, DOI 10.1016/j.cub.2008.07.048; Ordonez JL, 2009, CANCER RES, V69, P7140, DOI 10.1158/0008-5472.CAN-08-4041; Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050; Masuya M, 2005, BLOOD, V105, P95, DOI 10.1182/blood-2003-12-4345; Mathenia J, 2010, CLIN EXP IMMUNOL, V162, P362, DOI 10.1111/j.1365-2249.2010.04245.x; McLaughlin F, 2001, BLOOD, V98, P3332, DOI 10.1182/blood.V98.12.3332; Melet F, 1996, MOL CELL BIOL, V16, P2708; MEYER D, 1993, MECH DEVELOP, V44, P109, DOI 10.1016/0925-4773(93)90061-2; Mhawech-Fauceglia P, 2007, J CLIN PATHOL, V60, P694, DOI 10.1136/jcp.2006.039230; Miser JS, 2004, J CLIN ONCOL, V22, P2873, DOI 10.1200/JCO.2004.01.041; Molano I, 2010, CLIN EXP IMMUNOL, V160, P275, DOI 10.1111/j.1365-2249.2009.04080.x; Morris EE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3189; Moussa O, 2010, MOL CELL BIOL, V30, P5194, DOI 10.1128/MCB.01112-09; Nagano A, 2010, INT J CANCER, V126, P2790, DOI 10.1002/ijc.24781; Nikitina ER, 2011, J HYPERTENS, V29, P769, DOI 10.1097/HJH.0b013e32834436a7; Noda S, 2012, BRIT J DERMATOL, V167, P1098, DOI 10.1111/j.1365-2133.2012.11055.x; Nowling TK, 2008, MOL IMMUNOL, V45, P1, DOI 10.1016/j.molimm.2007.05.018; Okada Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024837; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; Owen LA, 2006, CELL CYCLE, V5, P2049, DOI 10.4161/cc.5.18.3213; Paulo P, 2012, GENE CHROMOSOME CANC, V51, P240, DOI 10.1002/gcc.20948; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Pham VN, 2007, DEV BIOL, V303, P772, DOI 10.1016/j.ydbio.2006.10.030; Pimanda JE, 2006, BLOOD, V107, P4737, DOI 10.1182/blood-2005-12-4929; PRASAD DDK, 1992, CANCER RES, V52, P5833; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Remy P, 1996, INT J DEV BIOL, V40, P577; Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009; Sakthianandeswaren A, 2010, INFECT IMMUN, V78, P2734, DOI 10.1128/IAI.00126-10; Sakurai T, 2007, CANCER SCI, V98, P1775, DOI 10.1111/j.1349-7006.2007.00598.x; Schutte J, 2012, WIRES SYST BIOL MED, V4, P285, DOI 10.1002/wsbm.1163; Shaked Y, 2005, BLOOD, V105, P4500, DOI 10.1182/blood-2004-08-3210; Smeets MFMA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062346; Soncin F, 2003, EMBO J, V22, P5700, DOI 10.1093/emboj/cdg549; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 2010, BLOOD, V116, P4795, DOI 10.1182/blood-2010-02-270405; Stockley J, 2013, BLOOD, V122, P4090, DOI 10.1182/blood-2013-06-506873; Suzuki E, 2013, IMMUNOLOGY, V139, P318, DOI 10.1111/imm.12070; Suzuki E, 2012, CLIN IMMUNOL, V145, P201, DOI 10.1016/j.clim.2012.09.006; Svenson JL, 2010, GENES IMMUN, V11, P161, DOI 10.1038/gene.2009.73; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Tani C, 2013, CLIN EXP RHEUMATOL, V31, pS172; Torchia EC, 2007, MOL CELL BIOL, V27, P7918, DOI 10.1128/MCB.00099-07; Torlakovic EE, 2008, HISTOL HISTOPATHOL, V23, P1309, DOI 10.14670/HH-23.1309; Truong AHL, 2005, ONCOGENE, V24, P962, DOI 10.1038/sj.onc.1208323; Tyybakinoja A, 2006, GENE CHROMOSOME CANC, V45, P257, DOI 10.1002/gcc.20288; Wang YQ, 2006, ARTHRITIS RHEUM-US, V54, P2271, DOI 10.1002/art.21948; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Wenger SL, 2006, AM J MED GENET A, V140A, P704, DOI 10.1002/ajmg.a.31146; Wilson NK, 2010, CELL STEM CELL, V7, P532, DOI 10.1016/j.stem.2010.07.016; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhang XK, 2008, J IMMUNOL, V181, P1644, DOI 10.4049/jimmunol.181.3.1644; Zhang XK, 2004, J IMMUNOL, V173, P6481, DOI 10.4049/jimmunol.173.10.6481; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	119	74	77	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2022	2031		10.1038/onc.2014.162	http://dx.doi.org/10.1038/onc.2014.162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909161	Green Accepted			2022-12-17	WOS:000353173400002
J	Rupp, C; Scherzer, M; Rudisch, A; Unger, C; Haslinger, C; Schweifer, N; Artaker, M; Nivarthi, H; Moriggl, R; Hengstschlager, M; Kerjaschki, D; Sommergruber, W; Dolznig, H; Garin-Chesa, P				Rupp, C.; Scherzer, M.; Rudisch, A.; Unger, C.; Haslinger, C.; Schweifer, N.; Artaker, M.; Nivarthi, H.; Moriggl, R.; Hengstschlaeger, M.; Kerjaschki, D.; Sommergruber, W.; Dolznig, H.; Garin-Chesa, P.			IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction	ONCOGENE			English	Article							LASER CAPTURE MICRODISSECTION; GENE-EXPRESSION SIGNATURE; PROSTATE-CANCER; BREAST-CANCER; ADHESION FACTOR/MAC25; EPITHELIAL CANCERS; COLORECTAL-CANCER; POOR-PROGNOSIS; LUNG-CANCER; CELL-GROWTH	The activated tumor stroma participates in many processes that control tumorigenesis, including tumor cell growth, invasion and metastasis. Cancer-associated fibroblasts (CAFs) represent the major cellular component of the stroma and are the main source for connective tissue components of the extracellular matrix and various classes of proteolytic enzymes. The signaling pathways involved in the interactions between tumor and stromal cells and the molecular characteristics that distinguish normal 'resting' fibroblasts from cancer-associated or '-activated' fibroblasts remain poorly defined. Recent studies emphasized the prognostic and therapeutic significance of CAF-related molecular signatures and a number of those genes have been shown to serve as putative therapeutic targets. We have used immuno-laser capture microdissection and whole-genome Affymetrix GeneChip analysis to obtain transcriptional signatures from the activated tumor stroma of colon carcinomas that were compared with normal resting colonic fibroblasts. Several members of the Wnt-signaling pathway and gene sets related to hypoxia, epithelial-to-mesenchymal transition (EMT) and transforming growth factor-beta (TGF beta) pathway activation were induced in CAFs. The putative TGF beta-target IGFBP7 was identified as a tumor stroma marker of epithelial cancers and as a tumor antigen in mesenchyme-derived sarcomas. We show here that in contrast to its tumor-suppressor function in epithelial cells, IGFPB7 can promote anchorage-independent growth in malignant mesenchymal cells and in epithelial cells with an EMT phenotype when IGFBP7 is expressed by the tumor cells themselves and can induce colony formation in colon cancer cells co-cultured with IGFBP7-expressing CAFs by a paracrine tumor-stroma interaction.	[Rupp, C.; Kerjaschki, D.; Garin-Chesa, P.] Med Univ Vienna, Clin Inst Pathol, A-1090 Vienna, Austria; [Scherzer, M.; Unger, C.; Hengstschlaeger, M.; Dolznig, H.] Med Univ Vienna, Ctr Pathobiol & Genet, Inst Med Genet, A-1090 Vienna, Austria; [Rudisch, A.; Haslinger, C.; Schweifer, N.; Sommergruber, W.; Garin-Chesa, P.] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; [Artaker, M.] Med Univ Vienna, Max F Perutz Labs, A-1090 Vienna, Austria; [Nivarthi, H.; Moriggl, R.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Boehringer Ingelheim; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Ludwig Boltzmann Institute	Garin-Chesa, P (corresponding author), Med Univ Vienna, Inst Med Genet, Wahringer Str 10, A-1090 Vienna, Austria.	helmut.dolznig@meduniwien.ac.at; pilar.garin-chesa@boehringer-ingelheim.com	Dolznig, Helmut/L-7005-2015; Moriggl, Richard/H-8118-2019	Dolznig, Helmut/0000-0002-6063-3585; Moriggl, Richard/0000-0003-0918-9463	Boehringer Ingelheim Austria	Boehringer Ingelheim Austria(Boehringer Ingelheim)	This work was supported by Boehringer Ingelheim Austria. We are grateful to Christina Puri, Daniela Milovanovic, Oliver Bergner and Jakob Schnabl for help with immunohistochemistry, cell culture and in vitro assays.	Adachi Y, 2001, INT J CANCER, V95, P216, DOI 10.1002/1097-0215(20010720)95:4<216::AID-IJC1037>3.0.CO;2-O; Ahmed S, 2006, FEBS J, V273, P615, DOI 10.1111/j.1742-4658.2005.05094.x; Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bieche I, 2004, CLIN CANCER RES, V10, P6789, DOI 10.1158/1078-0432.CCR-04-0306; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen Y, 2011, LUNG CANCER, V73, P38, DOI 10.1016/j.lungcan.2010.10.015; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Christian S, 2001, J BIOL CHEM, V276, P48588, DOI 10.1074/jbc.M106152200; Degeorges A, 1999, CANCER RES, V59, P2787; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; Dolznig H, 2011, AM J PATHOL, V179, P487, DOI 10.1016/j.ajpath.2011.03.015; Evdokimova V, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003184; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregg JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-165; Grum-Schwensen B, 2005, CANCER RES, V65, P3772, DOI 10.1158/0008-5472.CAN-04-4510; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jiang W, 2008, NEOPLASIA, V10, P1335, DOI 10.1593/neo.08694; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kunz-Schughart LA, 2002, HISTOL HISTOPATHOL, V17, P599, DOI 10.14670/HH-17.599; Lin J, 2008, CANCER BIOL THER, V7, P1896, DOI 10.4161/cbt.7.12.6937; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massoner P, 2008, PROSTATE, V68, P1165, DOI 10.1002/pros.20785; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Orimo A, 2007, CANCER BIOL THER, V6, P618, DOI 10.4161/cbt.6.4.4255; Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211; Ostman A, 2007, ADV CANCER RES, V97, P247, DOI 10.1016/S0065-230X(06)97011-0; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pen A, 2008, ONCOGENE, V27, P6834, DOI 10.1038/onc.2008.287; Pilewski JM, 2005, AM J PATHOL, V166, P399, DOI 10.1016/S0002-9440(10)62263-8; Pure E, 2009, EXPERT OPIN THER TAR, V13, P967, DOI 10.1517/14728220903103841; Rasanen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ruan WJ, 2007, CANCER BIOL THER, V6, P354, DOI 10.4161/cbt.6.3.3702; Rupp C, 2006, DIAGN MOL PATHOL, V15, P35, DOI 10.1097/00019606-200603000-00006; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677; Sato Y, 2007, CANCER SCI, V98, P1055, DOI 10.1111/j.1349-7006.2007.00502.x; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan L, 2012, J UROLOGY, V188, P1354, DOI 10.1016/j.juro.2012.06.002; Tomimaru Y, 2012, INT J CANCER, V130, P319, DOI 10.1002/ijc.25994; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Vizioli MG, 2010, ONCOGENE, V29, P3835, DOI 10.1038/onc.2010.136	57	74	78	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					815	825		10.1038/onc.2014.18	http://dx.doi.org/10.1038/onc.2014.18			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24632618				2022-12-17	WOS:000349472000002
J	Raina, D; Uchida, Y; Kharbanda, A; Rajabi, H; Panchamoorthy, G; Jin, C; Kharbanda, S; Scaltriti, M; Baselga, J; Kufe, D				Raina, D.; Uchida, Y.; Kharbanda, A.; Rajabi, H.; Panchamoorthy, G.; Jin, C.; Kharbanda, S.; Scaltriti, M.; Baselga, J.; Kufe, D.			Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells	ONCOGENE			English	Article						MUC1; HER2; HER3; trastuzumab; resistance; breast cancer	GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR P27(KIP1); FACTOR-I RECEPTOR; CYCLIN-E; PHOSPHORYLATION; CONTRIBUTES; LAPATINIB; ERBB3; CHEMOTHERAPY; MECHANISM	Patients with HER2-positive breast cancer often exhibit intrinsic or acquired resistance to trastuzumab treatment. The transmembrane mucin 1 (MUC1) oncoprotein is aberrantly overexpressed in breast cancer cells and associates with HER2. The present studies demonstrate that silencing MUC1 C-terminal subunit (MUC1-C) in HER2-overexpressing SKBR3 and BT474 breast cancer cells results in the downregulation of constitutive HER2 activation. Moreover, treatment with the MUC1-C inhibitor, GO-203, was associated with disruption of MUC1-C/HER2 complexes and decreases in tyrosine-phosphorylated HER2 (p-HER2) levels. In studies of trastuzumab-resistant SKBR3R and BT474R cells, we found that the association between MUC1-C and HER2 is markedly increased (B20-fold) as compared with that in sensitive cells. In addition, silencing MUC1-C in the trastuzumab-resistant cells or treatment with GO-203 decreased p-HER2 and AKT activation. Moreover, targeting MUC1-C was associated with the downregulation of phospho-p27 and cyclin E, which confer trastuzumab resistance. Consistent with these results, targeting MUC1-C inhibited the growth and clonogenic survival of both trastuzumab-resistant cells. Our results further demonstrate that silencing MUC1-C reverses resistance to trastuzumab and that the combination of GO-203 and trastuzumab is highly synergistic. These findings indicate that MUC1-C contributes to constitutive activation of the HER2 pathway and that targeting MUC1-C represents a potential approach to abrogate trastuzumab resistance.	[Raina, D.; Panchamoorthy, G.; Kharbanda, S.] Genus Oncol, Boston, MA USA; [Uchida, Y.; Kharbanda, A.; Rajabi, H.; Jin, C.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA; [Scaltriti, M.; Baselga, J.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Memorial Sloan Kettering Cancer Center	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098, CA166480]; Susan G Komen for the Cure Grant [SAC110046]; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA166480] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for the Cure Grant(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA97098 and CA166480 awarded by the National Cancer Institute, and by the Susan G Komen for the Cure Grant SAC110046 (MS and JB).	Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Duraisamy S, 2007, INT J ONCOL, V31, P671; Fessler SP, 2009, BREAST CANCER RES TR, V118, P113, DOI 10.1007/s10549-009-0412-3; Guertin AD, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-45; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang XP, 2010, CANCER RES, V70, P1204, DOI 10.1158/0008-5472.CAN-09-3321; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Klapper LN, 2000, CANCER RES, V60, P3384; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lee-Hoeflich ST, 2011, CANCER DISCOV, V1, P326, DOI 10.1158/2159-8290.CD-11-0062; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Li PF, 2004, J BIOL CHEM, V279, P25260, DOI 10.1074/jbc.M311052200; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Mittendorf EA, 2010, ONCOGENE, V29, P3896, DOI 10.1038/onc.2010.151; Mittendorf EA, 2009, CLIN CANCER RES, V15, P7381, DOI 10.1158/1078-0432.CCR-09-1735; Motti ML, 2004, CELL CYCLE, V3, P1074; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nahta R, 2007, MOL CANCER THER, V6, P667, DOI 10.1158/1535-7163.MCT-06-0423; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, MOL CANCER THER, V10, P817, DOI 10.1158/1535-7163.MCT-10-0966; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309	47	74	81	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3422	3431		10.1038/onc.2013.308	http://dx.doi.org/10.1038/onc.2013.308			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912457	Green Accepted, Green Submitted			2022-12-17	WOS:000338779300009
J	Kumari, U; Jun, WY; Bay, BH; Lyakhovich, A				Kumari, U.; Jun, W. Ya; Bay, B. Huat; Lyakhovich, A.			Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi Anemia cells	ONCOGENE			English	Article						Fanconi Anemia; reactive oxygen species; mitochondria	INTERSTRAND CROSS-LINK; OXIDATIVE STRESS; REACTIVE OXYGEN; SUPEROXIDE-DISMUTASE; SKELETAL-MUSCLE; DNA-REPAIR; PATHWAY; MUTATION; DAMAGE; FANCD2	Fanconi Anemia (FA) is a rare genetic disorder associated with a bone-marrow failure, cancer predisposition and hypersensitivity to DNA crosslinking agents. Majority of the 15 FA genes and encoded proteins characterized so far are integrated into DNA repair pathways, however, other important functions cannot be excluded. FA cells are sensitive to oxidants, and accumulation of oxidized proteins has been characterized for several FA subgroups. Clinical phenotypes of both FA and other closely related diseases suggest altered functions of mitochondria, organelles responsible for cellular energetic metabolism, and also serving as an important producer and the most susceptible target from reactive oxidative species (ROS). In this study, we have shown that elevated level of mitochondrial ROS in FA cells is in parallel with the decrease of mitochondrial membrane potential, the decrease of ATP production, impaired oxygen uptake and pathological changes in the morphology of mitochondria. This is accompanied by inactivation of enzymes that are essential for the energy production (F1F0ATPase and cytochrome C oxidase) and detoxification of ROS (superoxide dismutase, SOD1). In turn, overexpression of SOD1 could rescue oxygen consumption rate in FA-deficient cells. Importantly, the depletion of mitochondria improved survival rate of mitomycin C treated FA cells suggesting that hypersensitivity of FA cells to chemotherapeutic drugs could be in part due to the mitochondria-mediated oxidative stress. On the basis of our results, we propose that deficiency in FA genes lead to disabling mitochondrial ROS-scavenging machinery further affecting mitochondrial functions and suppressing cell respiration.	[Kumari, U.; Lyakhovich, A.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Jun, W. Ya; Bay, B. Huat] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117595, Singapore	National University of Singapore; National University of Singapore	Lyakhovich, A (corresponding author), Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Coll Rd,Level 6, Singapore 169857, Singapore.	lyakhovich@gmail.com	Lyakhovich, Alex/B-4410-2008	Lyakhovich, Alex/0000-0002-8279-4697				Ali SS, 2010, J BIOL CHEM, V285, P32522, DOI 10.1074/jbc.M110.155432; Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559; AMANO F, 1995, FEBS LETT, V368, P425, DOI 10.1016/0014-5793(95)00700-J; Bogliolo M, 2002, MUTAGENESIS, V17, P25, DOI 10.1093/mutage/17.1.25; Bogliolo M, 2007, EMBO J, V26, P1340, DOI 10.1038/sj.emboj.7601574; Chacinska A, 2009, CELL, V138, P628, DOI 10.1016/j.cell.2009.08.005; Cossarizza A., 2001, CURR PROTOC CYTOM, DOI [10.1002/0471142956.cy0914s13, DOI 10.1002/0471142956.CY0914S13]; Cuccarolo P, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-63; DALLAPICCOLA B, 1985, HUM GENET, V69, P62, DOI 10.1007/BF00295530; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; DEGAN P, 1995, CARCINOGENESIS, V16, P735, DOI 10.1093/carcin/16.4.735; Dirmeier R, 2002, J BIOL CHEM, V277, P34773, DOI 10.1074/jbc.M203902200; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Du W, 2012, BLOOD, V119, P4142, DOI 10.1182/blood-2011-09-381970; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Fridlyand LE, 2005, ANN NY ACAD SCI, V1066, P136, DOI 10.1196/annals.1363.019; Hadjur S, 2001, BLOOD, V98, P1003, DOI 10.1182/blood.V98.4.1003; Hutter E, 2007, AGING CELL, V6, P245, DOI 10.1111/j.1474-9726.2007.00282.x; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kim Y, 2011, NAT GENET, V43, P142, DOI 10.1038/ng.750; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Li RC, 2008, BRAIN RES, V1190, P159, DOI 10.1016/j.brainres.2007.11.022; Lyakhovich A, 2010, MOL CANCER RES, V8, P46, DOI 10.1158/1541-7786.MCR-09-0373; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Miller SW, 1996, J NEUROCHEM, V67, P1897; Moldovan GL, 2009, CELL, V139, P1222, DOI 10.1016/j.cell.2009.12.006; Mukhopadhyay SS, 2006, J CELL BIOL, V175, P225, DOI 10.1083/jcb.200607061; NORDENSON I, 1977, HEREDITAS, V86, P147; O'Neill HC, 2011, AM J RESP CELL MOL, V45, P323, DOI 10.1165/rcmb.2010-0214OC; Pagano G, 2004, CARCINOGENESIS, V25, P1899, DOI 10.1093/carcin/bgh194; Pagano G, 1997, BLOOD, V89, P1111, DOI 10.1182/blood.V89.3.1111; Pagano G, 2012, BIOL CHEM, V393, P11, DOI 10.1515/BC-2011-227; Pallardo FV, 2010, BIOGERONTOLOGY, V11, P401, DOI 10.1007/s10522-010-9269-4; Petrovic S, 2011, BIOL CHEM, V392, P625, DOI 10.1515/BC.2011.064; Ponte F, 2011, TOXICOLOGY, V289, P52, DOI 10.1016/j.tox.2011.07.009; Rachek LI, 2007, ENDOCRINOLOGY, V148, P293, DOI 10.1210/en.2006-0998; Rani R, 2008, CANCER RES, V68, P9693, DOI 10.1158/0008-5472.CAN-08-1790; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; Rousset S, 2002, PHOTOCHEM PHOTOBIOL, V75, P159, DOI 10.1562/0031-8655(2002)075<0159:MAIFAF>2.0.CO;2; ROUSSET S, 1990, CANCER RES, V50, P2443; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Saadatzadeh MR, 2004, J BIOL CHEM, V279, P16805, DOI 10.1074/jbc.M313721200; SCHINDLER D, 1988, AM J HUM GENET, V43, P429; TAKEUCHI T, 1993, CARCINOGENESIS, V14, P1115, DOI 10.1093/carcin/14.6.1115; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Tobaben S, 2011, CELL DEATH DIFFER, V18, P282, DOI 10.1038/cdd.2010.92; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Wu YL, 2010, BLOOD, V116, P3780, DOI 10.1182/blood-2009-11-256016; Xue YT, 2008, HUM MOL GENET, V17, P1641, DOI 10.1093/hmg/ddn054; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103	53	74	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					165	172		10.1038/onc.2012.583	http://dx.doi.org/10.1038/onc.2012.583			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318445				2022-12-17	WOS:000329440700004
J	Xie, Y; Tobin, LA; Camps, J; Wangsa, D; Yang, J; Rao, M; Witasp, E; Awad, KS; Yoo, N; Ried, T; Kwong, KF				Xie, Y.; Tobin, L. A.; Camps, J.; Wangsa, D.; Yang, J.; Rao, M.; Witasp, E.; Awad, K. S.; Yoo, N.; Ried, T.; Kwong, K. F.			MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells	ONCOGENE			English	Article						microRNA; cancer; XIAP	MODULATES MULTIDRUG-RESISTANCE; X-LINKED INHIBITOR; TARGETING BCL2; SUPPRESSES TUMORIGENICITY; STRUCTURAL BASIS; DOWN-REGULATION; UP-REGULATION; LUNG-CANCER; MIR-24; GENE	MicroRNAs have been implicated as important mediators of cancer cell homeostasis, and accumulating data suggest compelling roles for them in the apoptosis pathway. X-linked inhibitor of apoptosis protein (XIAP) is a potent caspase inhibitor and an important barrier to apoptotic cell death, but the mechanisms that determine the diverse range of XIAP expression seen in cancer remains unclear. In this study, we present evidence that miR-24 directly targets the 3'UTR of the XIAP messenger RNA (mRNA) to exert translational repression. Using a heuristic algorithm of bioinformatics analysis and in vitro screening, we identified miR-24 as a candidate regulator of XIAP expression. Array comparative genomic hybridization and spectral karyotype analysis reveal that genomic copy number loss at the miR-24 locus is concordant with the loss of endogenous miR-24 in cancer cells. Using a luciferase construct of the XIAP 3'UTR, we showed that miR-24 specifically coordinates to the XIAP mRNA. Interference with miR-24's binding of the critical seed region, resulting from site-directed mutagenesis of the 3'UTR, significantly abrogated miR-24's effects on XIAP expression. Moreover, miR-24 overexpression can overcome apoptosis resistance in cancer cells via downregulation of XIAP expression, and the resulting cancer cell death induced by tumor necrosis factor-related apoptosis-inducing ligand is executed by the canonical caspase-mediated apoptosis pathway. In summary, our data suggest a novel mechanism by which miR-24 directly modulates XIAP expression level and consequently the apoptosis threshold in cancer cells.	[Xie, Y.; Tobin, L. A.; Yang, J.; Rao, M.; Witasp, E.; Yoo, N.; Kwong, K. F.] NCI, Sect Thorac Oncol, Surg Branch, NIH, Bethesda, MD 20892 USA; [Camps, J.; Wangsa, D.; Ried, T.] NCI, Clin Genet Branch, NIH, Bethesda, MD 20892 USA; [Witasp, E.] Swedish Chem Agcy, Sundbyberg, Sweden; [Awad, K. S.] NCI, Dept Crit Care Med, NIH Clin Ctr, NIH, Bethesda, MD 20892 USA; [Kwong, K. F.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kwong, KF (corresponding author), NCI, Sect Thorac Oncol, Surg Branch, NIH, 10 Ctr Dr,MSC 1201, Bethesda, MD 20892 USA.	kwongk2@mail.nih.gov	Yang, Jianhui/GQO-8030-2022; Camps, Jordi/AAG-3080-2020	Camps, Jordi/0000-0002-3165-3640	National Institutes of Health; NIH; NATIONAL CANCER INSTITUTE [ZIABC010833, ZIABC011046] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Steven A Rosenberg for reviewing the manuscript. This work was supported by the National Institutes of Health, Intramural Research Program (TR and KFK) and NIH Postdoctoral Cancer Research Training Awards (YX, JC, EW and KSA).	Adair SJ, 2009, CANCER IMMUNOL IMMUN, V58, P589, DOI 10.1007/s00262-008-0582-6; Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bao L, 2011, CANCER IMMUNOL IMMUN, V60, P1299, DOI 10.1007/s00262-011-1037-z; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chhabra R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005848; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Dean EJ, 2007, CANCER TREAT REV, V33, P203, DOI 10.1016/j.ctrv.2006.11.002; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Diakos C, 2010, BLOOD, V116, P4885, DOI 10.1182/blood-2009-02-206706; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Geering B, 2011, BLOOD, V117, P5953, DOI 10.1182/blood-2010-11-322206; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Holcik M, 2003, ANN NY ACAD SCI, V1010, P249, DOI 10.1196/annals.1299.043; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kang HG, 2008, CANCER GENET CYTOGEN, V180, P6, DOI 10.1016/j.cancergencyto.2007.07.021; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Ku G, 2008, HUM GENE THER, V19, P17, DOI 10.1089/hum.2007.1226; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lal A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001864; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046; Macville M, 1999, CANCER RES, V59, P141; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Mashima T, 2005, DRUG RESIST UPDATE, V8, P339, DOI 10.1016/j.drup.2005.11.001; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Niederer F, 2012, ARTHRITIS RHEUM-US, V64, P1771, DOI 10.1002/art.34334; Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Riley A, 2010, NUCLEIC ACIDS RES, V38, P4665, DOI 10.1093/nar/gkq241; Saini S, 2011, CANCER RES, V71, P6208, DOI 10.1158/0008-5472.CAN-11-0073; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Tonon G, 2004, CANCER GENET CYTOGEN, V152, P15, DOI 10.1016/j.cancergencyto.2003.10.007; Ulybina YM, 2011, TUMORI, V97, P248, DOI 10.1700/667.7794; Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709; Wang BB, 2006, MOL CELL, V22, P553, DOI 10.1016/j.molcel.2006.03.034; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang Q, 2008, BLOOD, V111, P588, DOI 10.1182/blood-2007-05-092718; Wang XY, 2009, BRAIN RES BULL, V80, P268, DOI 10.1016/j.brainresbull.2009.08.006; Yoon S, 2010, FEBS LETT, V584, P4048, DOI 10.1016/j.febslet.2010.08.025; Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3; Zhu W, 2010, INT J CANCER, V127, P2520, DOI 10.1002/ijc.25260	59	74	77	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2442	2451		10.1038/onc.2012.258	http://dx.doi.org/10.1038/onc.2012.258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22733138	Green Accepted			2022-12-17	WOS:000318694900008
J	Coppola, V; Musumeci, M; Patrizii, M; Cannistraci, A; Addario, A; Maugeri-Sacca, M; Biffoni, M; Francescangeli, F; Cordenonsi, M; Piccolo, S; Memeo, L; Pagliuca, A; Muto, G; Zeuner, A; De Maria, R; Bonci, D				Coppola, V.; Musumeci, M.; Patrizii, M.; Cannistraci, A.; Addario, A.; Maugeri-Sacca, M.; Biffoni, M.; Francescangeli, F.; Cordenonsi, M.; Piccolo, S.; Memeo, L.; Pagliuca, A.; Muto, G.; Zeuner, A.; De Maria, R.; Bonci, D.			BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition	ONCOGENE			English	Article						prostate cancer; BTG2; microRNA; basal and luminal phenotype; EMT	TRANSLOCATION GENE-2 PROTEIN; STEM-CELLS; INDUCED DIFFERENTIATION; CYCLE REGULATOR; CANCER CELLS; IN-VIVO; CARCINOMA; MICRORNAS; P63; INVASION	Prostate cancer is one of the leading causes of cancer-related death in men. Despite significant advances in prostate cancer diagnosis and management, the molecular events involved in the transformation of normal prostate cells into cancer cells have not been fully understood. It is generally accepted that prostate cancer derives from the basal compartment while expressing luminal markers. We investigated whether downregulation of the basal protein B-cell translocation gene 2 (BTG2) is implicated in prostate cancer transformation and progression. Here we show that BTG2 loss can shift normal prostate basal cells towards luminal markers expression, a phenotype also accompanied by the appearance of epithelial-mesenchymal transition (EMT) traits. We also show that the overexpression of microRNA (miR)-21 suppresses BTG2 levels and promotes the acquisition of luminal markers and EMT in prostate cells. Furthermore, by using an innovative lentiviral vector able to compete with endogenous mRNA through the overexpression of the 3'-untranslated region of BTG2, we demonstrate that in prostate tumor cells, the levels of luminal and EMT markers can be reduced by derepression of BTG2 from microRNA-mediated control. Finally, we show that the loss of BTG2 expression confers to non-tumorigenic prostate cells ability to grow in an orthotopic murine model, thus demonstrating the central role of BTG2 downregulaton in prostate cancer biology. Oncogene (2013) 32, 1843-1853; doi: 10.1038/onc.2012.194; published online 21 May 2012	[Coppola, V.; Musumeci, M.; Patrizii, M.; Cannistraci, A.; Addario, A.; Biffoni, M.; Francescangeli, F.; Pagliuca, A.; Zeuner, A.; Bonci, D.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Maugeri-Sacca, M.; De Maria, R.] Regina Elena Inst Canc Res, Rome, Italy; [Cordenonsi, M.; Piccolo, S.] Univ Padua, Sch Med, Dept Histol Microbiol & Med Biotechnol, Padua, Italy; [Memeo, L.] Mediterranean Inst Oncol, Dept Expt Oncol, Catania, Italy; [Muto, G.] S Giovanni Bosco Hosp, Dept Urol, Turin, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Padua; Mediterranean Institute of Oncology	De Maria, R (corresponding author), Regina Elena Inst Canc Res, Rome, Italy.	demaria@ifo.it; desiree.bonci@iss.it	Coppola, Valeria/K-5120-2016; Pagliuca, Alfredo/AAI-3689-2020; Zeuner, Ann/K-8607-2016; Francescangeli, Federica/K-6500-2016; Cordenonsi, Michelangelo/K-7692-2016; Bonci, Desiree/K-6488-2016; De Maria, Ruggero/S-6385-2019; Maugeri-Saccà, Marcello/K-2350-2014; Addario, Antonio/AAC-4707-2022; Biffoni, Mauro/J-8318-2016; Zeuner, Ann/A-8529-2010	Coppola, Valeria/0000-0002-5745-2572; Francescangeli, Federica/0000-0002-1086-5265; Cordenonsi, Michelangelo/0000-0002-8253-5724; Bonci, Desiree/0000-0002-2472-5140; De Maria, Ruggero/0000-0003-2255-0583; Maugeri-Saccà, Marcello/0000-0003-2287-9581; Addario, Antonio/0000-0001-8527-8738; Biffoni, Mauro/0000-0002-1304-9060; Zeuner, Ann/0000-0002-8295-3715; PICCOLO, STEFANO/0000-0002-2037-0004; Musumeci, Maria/0000-0001-6680-8158; Muto, Giovanni/0000-0003-3593-6450; Memeo, Lorenzo/0000-0003-4251-7203; pagliuca, alfredo/0000-0002-8703-2077	Italian Health Ministry; Italy-USA microRNA program; Italian Association for Cancer Research (AIRC); Fondazione Roma	Italian Health Ministry(Ministry of Health, Italy); Italy-USA microRNA program; Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma(Fondazione RomaEuropean Commission)	We thank F. Tirone and L. Leonardi for providing non-commercial His-tagged anti-BTG2 antibody, S. Soddu for kindly providing pSUPER-p53plasmid for p53 interference, T. Merlino for manuscript editing, and G. Loreto for graphical assistance. This work was supported by the Italian Health Ministry with 'Under forty researchers 2007' and Italy-USA microRNA program to DB, and by the Italian Association for Cancer Research (AIRC) and 'Fondazione Roma' support to RDM.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bonkhoff H, 1996, PROSTATE, V28, P98; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Buganim Y, 2010, CANCER RES, V70, P2274, DOI 10.1158/0008-5472.CAN-09-2661; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hao YB, 2011, CANCER INVEST, V29, P318, DOI 10.3109/07357907.2011.554477; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hu XD, 2011, BIOCHEM BIOPH RES CO, V404, P903, DOI 10.1016/j.bbrc.2010.12.064; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kawamura-Tsuzuku J, 2004, ONCOGENE, V23, P6630, DOI 10.1038/sj.onc.1207890; Lam JS, 2006, UROL ONCOL-SEMIN ORI, V24, P131, DOI 10.1016/j.urolonc.2005.11.038; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Lim IK, 2006, J CANCER RES CLIN, V132, P417, DOI 10.1007/s00432-006-0080-1; Liu M, 2009, CELL RES, V19, P828, DOI 10.1038/cr.2009.72; Maitland Norman J., 2011, Hormones & Cancer, V2, P47, DOI 10.1007/s12672-010-0058-y; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; NAGLE RB, 1987, CANCER RES, V47, P281; Passeri D, 2006, MOL CELL BIOL, V26, P5023, DOI 10.1128/MCB.01360-05; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; SHERWOOD ER, 1990, J UROLOGY, V143, P167, DOI 10.1016/S0022-5347(17)39903-2; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Signoretti S, 2005, P NATL ACAD SCI USA, V102, P11355, DOI 10.1073/pnas.0500165102; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tokar EJ, 2005, DIFFERENTIATION, V73, P463, DOI 10.1111/j.1432-0436.2005.00047.x; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Webber MM, 1997, PROSTATE, V30, P58; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246	52	74	76	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1843	1853		10.1038/onc.2012.194	http://dx.doi.org/10.1038/onc.2012.194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614007				2022-12-17	WOS:000317043900010
J	Zhou, C; Licciulli, S; Avila, JL; Cho, M; Troutman, S; Jiang, P; Kossenkov, AV; Showe, LC; Liu, Q; Vachani, A; Albelda, SM; Kissil, JL				Zhou, C.; Licciulli, S.; Avila, J. L.; Cho, M.; Troutman, S.; Jiang, P.; Kossenkov, A. V.; Showe, L. C.; Liu, Q.; Vachani, A.; Albelda, S. M.; Kissil, J. L.			The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis	ONCOGENE			English	Article						Ras; Rac1; Rac1b; lung cancer; mouse model	CELL-SURVIVAL; CANCER; EXPRESSION; GTPASES; VARIANT; RHO; PROGRESSION; ACTIVATION; ADHESION; ISOFORM	Rac1b, an alternative splice form of Rac1, has been previously shown to be upregulated in colon and breast cancer cells, suggesting an oncogenic role for Rac1b in these cancers. Our analysis of NSCLC tumor and matched normal tissue samples indicates Rac1b is upregulated in a significant fraction of lung tumors in correlation with mutational status of K-ras. To directly assess the oncogenic potential of Rac1b in vivo, we employed a mouse model of lung adenocarcinoma, in which the expression of Rac1b can be conditionally activated specifically in the lung. Although expression of Rac1b alone is insufficient to drive tumor initiation, the expression of Rac1b synergizes with an oncogenic allele of K-ras resulting in increased cellular proliferation and accelerated tumor growth. Finally, we show that in contrast to our previous findings demonstrating a requirement for Rac1 in K-ras-driven cell proliferation, Rac1b is not required in this context. Given the partially overlapping spectrum of downstream effectors regulated by Rac1 and Rac1b, our findings further delineate the signaling pathways downstream of Rac1 that are required for K-ras driven tunnorigenesis. Oncogene (2013) 32, 903-909; doi:10.1038/onc.2012.99; published online 19 March 2012	[Zhou, C.; Licciulli, S.; Avila, J. L.; Cho, M.; Troutman, S.; Kossenkov, A. V.; Showe, L. C.; Liu, Q.; Kissil, J. L.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; [Avila, J. L.; Kissil, J. L.] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; [Jiang, P.] Wistar Inst Anat & Biol, Anim Transgen Core Facil, Philadelphia, PA 19104 USA; [Vachani, A.; Albelda, S. M.] Univ Penn, Sch Med, Thorac Oncol Res Lab, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; The Wistar Institute; University of Pennsylvania	Kissil, JL (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	jkissil@wistar.org			 [CA124495]; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA124495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024693] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Derek Radisky for sharing the pEYFP-C1-mRac1b vector and members of the Kissil and Albelda labs for technical assistance. We thank the Wistar Transgenics and Animal core facilities. This work was supported by Grant CA124495 (JLK).	Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Esufali S, 2007, CANCER RES, V67, P2469, DOI 10.1158/0008-5472.CAN-06-2843; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Lozano E, 2008, J CELL SCI, V121, P933, DOI 10.1242/jcs.016121; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Orlichenko L, 2010, J BIOL CHEM, V285, P19153, DOI 10.1074/jbc.M109.099382; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118	20	74	75	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					903	909		10.1038/onc.2012.99	http://dx.doi.org/10.1038/onc.2012.99			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22430205	Green Accepted			2022-12-17	WOS:000316581100010
J	Wang, J; Ray, PS; Sim, MS; Zhou, XZ; Lu, KP; Lee, AV; Lin, X; Bagaria, SP; Giuliano, AE; Cui, X				Wang, J.; Ray, P. S.; Sim, M-S; Zhou, X. Z.; Lu, K. P.; Lee, A. V.; Lin, X.; Bagaria, S. P.; Giuliano, A. E.; Cui, X.			FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kappa B signaling	ONCOGENE			English	Article						basal-like breast cancer; FOXC1; NF-kappa B; p65/RelA; Pin1; protein stability	FORKHEAD/WINGED-HELIX GENE; CONSTITUTIVE ACTIVATION; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; EXPRESSION; TUMORS; SUBTYPES; PROGRESSION; CARCINOMAS; PHENOTYPE	Human basal-like breast cancer (BLBC) is an enigmatic and aggressive malignancy with a poor prognosis. There is an urgent need to identify therapeutic targets for BLBC, because current treatment modalities are limited and not effective. The forkhead box transcription factor FOXC1 has recently been identified as a critical functional biomarker for BLBC. However, how it orchestrates BLBC cells was not clear. Here we show that FOXC1 activates the transcription factor nuclear factor-kappa B (NF-kappa B) in BLBC cells by increasing p65/RelA protein stability. High NF-kappa B activity has been associated with estrogen receptor-negative breast cancer, particularly BLBC. The effect of FOXC1 on p65/RelA protein stability is mediated by increased expression of Pin1, a peptidyl-prolyl isomerase. FOXC1 requires NF-kappa B for its regulation of cell proliferation, migration and invasion. Notably, FOXC1 overexpression renders breast cancer cells more susceptible to pharmacological inhibition of NF-kappa B. These results suggest that BLBC cells may rely on FOXC1-driven NF-kappa B signaling. Interventions of this pathway may provide modalities for the treatment of BLBC.	[Cui, X.] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Womens Canc Program, Samuel Oschin Comprehens Canc Inst,Dept Surg, Los Angeles, CA 90048 USA; [Wang, J.; Cui, X.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA USA; [Ray, P. S.; Bagaria, S. P.; Giuliano, A. E.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Surg Oncol, Santa Monica, CA USA; [Sim, M-S] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Biostat, Santa Monica, CA USA; [Zhou, X. Z.; Lu, K. P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Canc Biol Program,Dept Med, Boston, MA 02215 USA; [Lee, A. V.] Univ Pittsburgh, Inst Canc, Womens Canc Res Ctr, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Lin, X.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	Cedars Sinai Medical Center; John Wayne Cancer Institute; John Wayne Cancer Institute; John Wayne Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center	Cui, X (corresponding author), Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Womens Canc Program, Samuel Oschin Comprehens Canc Inst,Dept Surg, 8635 W 3rd St,Suite 290W, Los Angeles, CA 90048 USA.	Xiaojiang.cui@cshs.org		Lee, Adrian/0000-0001-9917-514X	National Institutes of Health [CA151610]; QVC and the Fashion Footwear Association of New York Charitable Foundation; Associates for Breast & Prostate Cancer Studies; Avon Foundation [02-2010-068]; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); QVC and the Fashion Footwear Association of New York Charitable Foundation; Associates for Breast & Prostate Cancer Studies; Avon Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Yixian Zheng for the HA-ubiquitin plasmid, Fred Miller for 4T1 breast cancer cells, Inder M Verma for IKK double-knockout MEFs, Amer A Beg for p65-null MEFs, and Dave Hoon and Myles Cabot for technical support. This work was supported by National Institutes of Health (CA151610), QVC and the Fashion Footwear Association of New York Charitable Foundation, Associates for Breast & Prostate Cancer Studies, and the Avon Foundation (02-2010-068) to XC.	Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Collett K, 2005, CANCER EPIDEM BIOMAR, V14, P1108, DOI 10.1158/1055-9965.EPI-04-0394; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68; Gershtein ES, 2010, B EXP BIOL MED+, V150, P71, DOI 10.1007/s10517-010-1072-3; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Kidson SH, 1999, DEV BIOL, V211, P306, DOI 10.1006/dbio.1999.9314; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Lee CW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2200; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Moulder SL, 2010, CLIN BREAST CANCER, V10, pS66, DOI 10.3816/CBC.2010.s.014; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Peng SL, 2005, CELL DEATH DIFFER, V12, P699, DOI 10.1038/sj.cdd.4401640; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Rexer BN, 2009, CLIN CANCER RES, V15, P4518, DOI 10.1158/1078-0432.CCR-09-0872; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Seewaldt VL, 2007, NEW ENGL J MED, V356, pE12, DOI 10.1056/NEJMicm063760; Smith RS, 2000, HUM MOL GENET, V9, P1021, DOI 10.1093/hmg/9.7.1021; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; WETZELS RHW, 1989, AM J PATHOL, V134, P571; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x	32	74	80	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4798	4802		10.1038/onc.2011.635	http://dx.doi.org/10.1038/onc.2011.635			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22249250	Green Accepted			2022-12-17	WOS:000311033000008
J	Buache, E; Etique, N; Alpy, F; Stoll, I; Muckensturm, M; Reina-San-Martin, B; Chenard, MP; Tomasetto, C; Rio, MC				Buache, E.; Etique, N.; Alpy, F.; Stoll, I.; Muckensturm, M.; Reina-San-Martin, B.; Chenard, M. P.; Tomasetto, C.; Rio, M. C.			Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice	ONCOGENE			English	Article						TFF1/pS2; breast cancer; gain- and loss-of-function; human mammary cell lines; tumorigenicity; TFF1-KO mice	ESTROGEN-RECEPTOR; TRANSGENIC MICE; CATHEPSIN-D; IN-VIVO; EXPRESSION; PS2; INDUCTION; PEPTIDES; PROTEIN; DIFFERENTIATION	Although trefoil factor 1 (TFF1; previously named pS2) is abnormally expressed in about 50% of human breast tumors, its physiopathological role in this disease has been poorly studied. Moreover, controversial data have been reported. TFF1 function in the mammary gland therefore needs to be clarified. In this study, using retroviral vectors, we performed TFF1 gain-or loss-of-function experiments in four human mammary epithelial cell lines: normal immortalized TFF1-negative MCF10A, malignant TFF1-negative MDA-MB-231 and malignant TFF1-positive MCF7 and ZR75.1. The expression of TFF1 stimulated the migration and invasion in the four cell lines. Forced TFF1 expression in MCF10A, MDA-MB-231 and MCF7 cells did not modify anchorage-dependent or -independent cell proliferation. By contrast, TFF1 knockdown in MCF7 enhanced soft-agar colony formation. This increased oncogenic potential of MCF7 cells in the absence of TFF1 was confirmed in vivo in nude mice. Moreover, chemically induced tumorigenesis in TFF1-deficient (TFF1-KO) mice led to higher tumor incidence in the mammary gland and larger tumor size compared with wild-type mice. Similarly, tumor development was increased in the TFF1-KO ovary and lung. Collectively, our results clearly show that TFF1 does not exhibit oncogenic properties, but rather reduces tumor development. This beneficial function of TFF1 is in agreement with many clinical studies reporting a better outcome for patients with TFF1-positive breast primary tumors. Oncogene (2011) 30, 3261-3273; doi:10.1038/onc.2011.41; published online 28 February 2011	[Buache, E.; Etique, N.; Alpy, F.; Stoll, I.; Reina-San-Martin, B.; Tomasetto, C.; Rio, M. C.] Univ Strasbourg, INSERM, U964, IGBMC,CNRS,UMR 7104, Illkirch Graffenstaden, France; [Muckensturm, M.; Chenard, M. P.] CHU Hautepierre, Serv Anat Pathol Gen, F-67098 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg	Rio, MC (corresponding author), Univ Strasbourg, INSERM, U964, IGBMC,CNRS,UMR 7104, Illkirch Graffenstaden, France.	rio@igbmc.fr	Alpy, Fabien/ABD-5893-2020; Tomasetto, Catherine Laure/J-2783-2014; Reina-San-Martin, Bernardo/I-9484-2016; Chenard, Marie-Pierre/O-2373-2016; Alpy, Fabien/H-8941-2016; etique, nicolas/J-4159-2017	Alpy, Fabien/0000-0002-0526-0720; Tomasetto, Catherine Laure/0000-0002-1811-5848; Reina-San-Martin, Bernardo/0000-0003-2083-6166; Alpy, Fabien/0000-0002-0526-0720; etique, nicolas/0000-0001-6613-9257	Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer; Ligue Nationale Francaise contre le Cancer (LNCC; Comites du Haut-Rhin et du Bas-Rhin; Fondation pour la Recherche Medicale; LNCC	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Francaise contre le Cancer (LNCC; Comites du Haut-Rhin et du Bas-Rhin; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); LNCC	We would like to thank Corinne Wendling for technical help, and Emmanuelle Liaudet and Susan Chan for helpful discussion. This work was supported by funds from the Institut National de la Sante et de la Recherche Medicale, the Centre National de la Recherche Scientifique, the Hopital Universitaire de Strasbourg, the Association pour la Recherche sur le Cancer, and the Ligue Nationale Francaise contre le Cancer (LNCC; Equipe labellisee 2010) and the Comites du Haut-Rhin et du Bas-Rhin. Etique N and Buache E were recipient of Fondation pour la Recherche Medicale and LNCC fellowship, respectively.	Amiry N, 2009, ENDOCRINOLOGY, V150, P4473, DOI 10.1210/en.2009-0066; Andrew DJ, 2010, DEV BIOL, V341, P34, DOI 10.1016/j.ydbio.2009.09.024; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Buron N, 2008, INVEST OPHTH VIS SCI, V49, P3790, DOI 10.1167/iovs.07-1270; CAPONY F, 1989, CANCER RES, V49, P3904; Chenard MP, 2004, PEPTIDES, V25, P737, DOI 10.1016/j.peptides.2003.11.018; Choi EJ, 2009, DIFFERENTIATION, V77, P412, DOI 10.1016/j.diff.2008.12.004; Corte MD, 2006, BREAST CANCER RES TR, V96, P63, DOI 10.1007/s10549-005-9041-7; Crosier M, 2001, AM J PATHOL, V159, P215, DOI 10.1016/S0002-9440(10)61687-2; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Doll F, 2005, BBA-MOL CELL BIOL L, V1738, P72, DOI 10.1016/j.bbalip.2005.12.001; Dunnwald LK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1639; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; FOEKENS JA, 1990, CANCER RES, V50, P3832; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Hoffmann W, 2005, CELL MOL LIFE SCI, V62, P2932, DOI 10.1007/s00018-005-5481-9; Hoffmann W, 2007, CURR MED CHEM, V14, P2716, DOI 10.2174/092986707782023226; Karam SM, 2008, CELL PROLIFERAT, V41, P923, DOI 10.1111/j.1365-2184.2008.00562.x; Katoh M, 2003, INT J MOL MED, V12, P3; Khan ZE, 2003, GASTROENTEROLOGY, V125, P510, DOI 10.1016/S0016-5085(03)00908-9; KIDA N, 1993, EUR J BIOCHEM, V215, P671, DOI 10.1111/j.1432-1033.1993.tb18078.x; Kjellev S, 2009, CELL MOL LIFE SCI, V66, P1350, DOI 10.1007/s00018-008-8646-5; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P1033, DOI 10.1677/ERC-06-0001; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7; Madsen J, 2007, J HISTOCHEM CYTOCHEM, V55, P505, DOI 10.1369/jhc.6A7100.2007; Markicevic M, 2008, ADV EXP MED BIOL, V617, P341; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Mikhitarian K, 2005, CLIN CANCER RES, V11, P3697, DOI 10.1158/1078-0432.CCR-04-2164; Mira E, 2004, J CELL SCI, V117, P1847, DOI 10.1242/jcs.01035; Perry JK, 2008, TRENDS ENDOCRIN MET, V19, P74, DOI 10.1016/j.tem.2007.10.003; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; Poulsom R, 1997, J PATHOL, V183, P30, DOI 10.1002/(SICI)1096-9896(199709)183:1<30::AID-PATH1085>3.0.CO;2-K; Press DJ, 2010, EPIDEMIOLOGY, V21, P566, DOI 10.1097/EDE.0b013e3181e08eb3; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; Regalo G, 2005, CELL MOL LIFE SCI, V62, P2910, DOI 10.1007/s00018-005-5478-4; Ribieras S, 1998, BBA-REV CANCER, V1378, pF61, DOI 10.1016/S0304-419X(98)00016-X; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Rodrigues S, 2006, ONCOGENE, V25, P6628, DOI 10.1038/sj.onc.1209665; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Scott DJ, 2007, INT J ONCOL, V31, P557; Shi SQ, 2006, WORLD J GASTROENTERO, V12, P3119, DOI 10.3748/wjg.v12.i19.3119; Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802; Stotter A, 2010, CRIT REV ONCOL HEMAT, V75, P249, DOI 10.1016/j.critrevonc.2009.10.008; Surowiak P, 2006, BRIT J CANCER, V95, P339, DOI 10.1038/sj.bjc.6603254; Thim L, 1997, CELL MOL LIFE SCI, V53, P888, DOI 10.1007/s000180050108; Thullberg M, 2008, CELL CYCLE, V7, P984, DOI 10.4161/cc.7.8.5674; Thuwajit P, 2007, HEPATOL RES, V37, P295, DOI 10.1111/j.1872-034X.2007.00045.x; Tjensvoll K, 2009, BREAST CANCER RES TR, V116, P329, DOI 10.1007/s10549-008-0204-1; TOMASETTO C, 1989, MOL ENDOCRINOL, V3, P1579, DOI 10.1210/mend-3-10-1579; Tomasetto C, 2005, CELL MOL LIFE SCI, V62, P2916, DOI 10.1007/s00018-005-5479-3; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Tosco A, 2010, CELL MOL LIFE SCI, V67, P1943, DOI 10.1007/s00018-010-0309-7; Vestergaard EM, 2008, EARLY HUM DEV, V84, P631, DOI 10.1016/j.earlhumdev.2008.04.001; Wilson CL, 2006, ENDOCR-RELAT CANCER, V13, P617, DOI 10.1677/erc.1.01165	58	74	76	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	29					3261	3273		10.1038/onc.2011.41	http://dx.doi.org/10.1038/onc.2011.41			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21358676	hybrid, Green Published			2022-12-17	WOS:000293006800005
J	Ahmad, I; Morton, JP; Singh, LB; Radulescu, SM; Ridgway, RA; Patel, S; Woodgett, J; Winton, DJ; Taketo, MM; Wu, XR; Leung, HY; Sansom, OJ				Ahmad, I.; Morton, J. P.; Singh, L. B.; Radulescu, S. M.; Ridgway, R. A.; Patel, S.; Woodgett, J.; Winton, D. J.; Taketo, M. M.; Wu, X-R; Leung, H. Y.; Sansom, O. J.			beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation	ONCOGENE			English	Article						beta-catenin; PTEN; urothelial cell carcinoma; bladder cancer	PROGNOSTIC VALUE; EPIGENETIC INACTIVATION; ADENOMATOUS POLYPOSIS; GAMMA-CATENIN; E-CADHERIN; CYCLIN D1; C-MYC; APC; EXPRESSION; GENE	Although deregulation of the Wnt signalling pathway has been implicated in urothelial cell carcinoma (UCC), the functional significance is unknown. To test its importance, we have targeted expression of an activated form of beta-catenin to the urothelium of transgenic mice using Cre-Lox technology (UroIICRE(+) beta-catenin(exon3/+)). Expression of this activated form of beta-catenin led to the formation of localized hyperproliferative lesions by 3 months, which did not progress to malignancy. These lesions were characterized by a marked increase of the phosphatase and tensin homologue (PTEN) tumour suppressor protein. This appears to be a direct consequence of activating Wnt signalling in the bladder as conditional deletion of the adenomatous polyposis coli (Apc) gene within the adult bladder led rapidly to coincident beta-catenin and PTEN expression. This PTEN expression blocked proliferation. Next, we combined PTEN deficiency with beta-catenin activation and found that this caused papillary UCC. These tumours had increased pAKT signalling and were dependent on mammalian target of rapamycin (mTOR). Importantly, in human UCC, there was a significant correlation between high levels of beta-catenin and pAKT (and low levels of PTEN). Taken together these data show that deregulated Wnt signalling has a critical role in promoting UCC, and suggests that human UCC that have high levels of Wnt and PI3 kinase signalling may be responsive to mTOR inhibition. Oncogene (2011) 30, 178-189; doi:10.1038/onc.2010.399; published online 6 September 2010	[Ahmad, I.; Morton, J. P.; Singh, L. B.; Radulescu, S. M.; Ridgway, R. A.; Leung, H. Y.; Sansom, O. J.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Morton, J. P.] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Glasgow, Lanark, Scotland; [Patel, S.; Woodgett, J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Winton, D. J.] Addenbrookes Hosp, Cambridge Inst Med Res, Dept Oncol, Cambridge, England; [Taketo, M. M.] Kyoto Univ, Dept Pharmacol, Grad Sch Med, Kyoto, Japan; [Wu, X-R] NYU, Sch Med, Dept Urol, New York, NY 10003 USA; [Wu, X-R] NYU, Sch Med, Dept Pathol, New York, NY 10003 USA	Beatson Institute; University of Glasgow; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Kyoto University; New York University; New York University	Sansom, OJ (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Morton, Jennifer/AAJ-5113-2021; Woodgett, Jim/F-1087-2010; Morton, Jennifer P/E-1633-2011	Morton, Jennifer/0000-0001-5766-9141; Woodgett, Jim/0000-0003-3731-5797; Morton, Jennifer P/0000-0001-5766-9141; Sansom, Owen J./0000-0001-9540-3010; Ahmad, Imran/0000-0002-4404-1926; Wu, Xue-Ru/0000-0001-6058-6291; Leung, Hing Y./0000-0002-3933-3975	Cancer Research UK; MRC; AICR; Cancer Research UK [12481] Funding Source: researchfish; Medical Research Council [G0802141, G0900871] Funding Source: researchfish; MRC [G0900871, G0802141] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AICR; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Cancer Research UK and a MRC fellowship to Imran Ahmad and AICR grant to Sorina Radulescu. We thank BICR services, biological services unit, and Colin Nixon and his histology department. We also thank the 'Think Pink' charity for the purchase of the Aperio slide scanner and the Slidepath software.	Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bohm M, 1997, INT J CANCER, V74, P291; Burger M, 2008, EUR UROL, V54, P835, DOI 10.1016/j.eururo.2007.12.026; Cordon-Cardo C, 2008, SCAND J UROL NEPHROL, V42, P154, DOI 10.1080/03008880802291915; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; DIAZ DS, 2008, MINERVA UROL NEFROL, V60, P205; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; GARCIA DX, 2000, EUR J CANCER, V36, P357; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He F, 2009, CANCER RES, V69, P9413, DOI 10.1158/0008-5472.CAN-09-2158; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Kashibuchi K, 2006, EUR UROL, V49, P839, DOI 10.1016/j.eururo.2005.12.023; Kastritis E, 2009, INT J CANCER, V124, P103, DOI 10.1002/ijc.23917; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kirkegaard T, 2006, HISTOPATHOLOGY, V48, P787, DOI 10.1111/j.1365-2559.2006.02412.x; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Luis NM, 2007, CLIN TRANSL ONCOL, V9, P5, DOI 10.1007/s12094-007-0003-x; MacAulay K, 2007, CELL METAB, V6, P329, DOI 10.1016/j.cmet.2007.08.013; Marsh V, 2008, NAT GENET, V40, P1436, DOI 10.1038/ng.256; Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Miyamoto H, 1996, J UROLOGY, V155, P1444, DOI 10.1016/S0022-5347(01)66304-3; Mo L, 2005, AM J PHYSIOL-RENAL, V289, pF562, DOI 10.1152/ajprenal.00368.2004; Mo L, 2007, J CLIN INVEST, V117, P314, DOI 10.1172/JCI30062; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Nakopoulou L, 2000, ANTICANCER RES, V20, P4571; Namba R, 2006, CLIN CANCER RES, V12, P2613, DOI 10.1158/1078-0432.CCR-05-2170; Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08; Polakis P, 2000, GENE DEV, V14, P1837; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Schulz WA, 2006, INT J CANCER, V119, P1513, DOI 10.1002/ijc.21852; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shiina H, 2002, J UROLOGY, V168, P2220, DOI 10.1016/S0022-5347(05)64359-5; Shiina H, 2001, CANCER RES, V61, P7101; Shimazui T, 1996, CANCER RES, V56, P4154; Stoehr R, 2002, INT J ONCOL, V20, P905; Teng DHF, 1997, CANCER RES, V57, P5221; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuruta H, 2006, CANCER RES, V66, P8389, DOI 10.1158/0008-5472.CAN-05-4627; Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315; Zhu XD, 2000, PATHOL INT, V50, P945, DOI 10.1046/j.1440-1827.2000.01139.x	58	74	74	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					178	189		10.1038/onc.2010.399	http://dx.doi.org/10.1038/onc.2010.399			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20818428	Green Accepted			2022-12-17	WOS:000286438900006
J	Hadfield, KD; Smith, MJ; Urquhart, JE; Wallace, AJ; Bowers, NL; King, AT; Rutherford, SA; Trump, D; Newman, WG; Evans, DG				Hadfield, K. D.; Smith, M. J.; Urquhart, J. E.; Wallace, A. J.; Bowers, N. L.; King, A. T.; Rutherford, S. A.; Trump, D.; Newman, W. G.; Evans, D. G.			Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas	ONCOGENE			English	Article						mitotic recombination; schwannomatosis; SMARCB1; NF2; vestibular schwannoma	COMPARATIVE GENOMIC HYBRIDIZATION; FAMILIAL SCHWANNOMATOSIS; SMARCB1; IDENTIFICATION; NEUROFIBROMAS; METHYLATION; MUTATION; GENE; DNA	Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. Oncogene (2010) 29, 6216-6221; doi:10.1038/onc.2010.363; published online 23 August 2010	[Hadfield, K. D.; Smith, M. J.; Urquhart, J. E.; Wallace, A. J.; Bowers, N. L.; Trump, D.; Newman, W. G.; Evans, D. G.] Univ Manchester, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Dept Med Genet, Manchester M13 9WL, Lancs, England; [King, A. T.; Rutherford, S. A.] Hope Hosp, Dept Neurosurg, Manchester, Lancs, England	University of Manchester	Evans, DG (corresponding author), Univ Manchester, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Dept Med Genet, Manchester M13 9WL, Lancs, England.	gareth.evans@cmft.nhs.uk	Urquhart, Jill/G-2282-2015; Evans, D Gareth/AAB-4308-2022; Rutherford, Scott/GMX-2404-2022; King, Andrew/AAR-1656-2020; Smith, Miriam/J-4001-2015	Urquhart, Jill/0000-0002-5788-5511; Evans, D Gareth/0000-0002-8482-5784; Smith, Miriam/0000-0002-3184-0817; Newman, William/0000-0002-6382-4678; Rutherford, Scott/0000-0002-6749-2295; King, Andrew/0000-0002-6546-7248	Children's Tumor Foundation; NIHR Manchester Biomedical Research Centre	Children's Tumor Foundation; NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR))	This work was supported by a grant from the Children's Tumor Foundation. The Department of Genetic Medicine is supported by the NIHR Manchester Biomedical Research Centre. We also thank all the patients who provided samples for the study.	Boyd C, 2008, CLIN GENET, V74, P358, DOI 10.1111/j.1399-0004.2008.01060.x; Carbone L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000538; De Raedt T, 2006, GENE CHROMOSOME CANC, V45, P893, DOI 10.1002/gcc.20353; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Edelmann L, 1999, AM J HUM GENET, V64, P1076, DOI 10.1086/302343; EVANS DGR, 1992, Q J MED, V84, P603; Gonzalez-Gomez P, 2003, CLIN CANCER RES, V9, P5601; Hadfield KD, 2008, J MED GENET, V45, P332, DOI 10.1136/jmg.2007.056499; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; James L, 1996, CHROMOSOME RES, V4, P163, DOI 10.1007/BF02259711; James LA, 1999, BRIT J CANCER, V81, P300, DOI 10.1038/sj.bjc.6990691; KAPLAN JC, 1987, J MED GENET, V24, P65, DOI 10.1136/jmg.24.2.65; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; MacCollin M, 2003, NEUROLOGY, V60, P1968, DOI 10.1212/01.WNL.0000070184.08740.E0; Serra E, 2001, NAT GENET, V28, P294, DOI 10.1038/90148; Sestini R, 2008, HUM MUTAT, V29, P227, DOI 10.1002/humu.20679; Warren C, 2003, J MED GENET, V40, P802, DOI 10.1136/jmg.40.11.802	17	74	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6216	6221		10.1038/onc.2010.363	http://dx.doi.org/10.1038/onc.2010.363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20729918	Bronze			2022-12-17	WOS:000284601700003
J	Gkika, D; Flourakis, M; Lemonnier, L; Prevarskaya, N				Gkika, D.; Flourakis, M.; Lemonnier, L.; Prevarskaya, N.			PSA reduces prostate cancer cell motility by stimulating TRPM8 activity and plasma membrane expression	ONCOGENE			English	Article						prostate cancer; ion channel regulation; kallikrein; cell migration	BRADYKININ B-2 RECEPTOR; BINDING PROTEIN-3; EPITHELIAL-CELLS; SEMINAL PLASMA; CHANNEL; ANTIGEN; GROWTH; IDENTIFICATION; KALLIKREINS; ACTIVATION	Although the transient receptor potential melastatin 8 (TRPM8) cold receptor is highly expressed in prostate cancer (PCa) and constitutes a promising diagnostic and prognostic indicator, the natural agonists of this channel in the prostate, as well as its physiological and pathological functions, remain unknown. In this study, we identified the well-known PCa marker, prostate-specific antigen (PSA), as a physiological TRPM8 agonist. Electrophysiological and Ca(2+) imaging studies demonstrated that PSA activated TRPM8-mediated current by the bradykinin 2 receptor signaling pathway. Further investigation of this mechanism by cell-surface biotinylation revealed that the increase in TRPM8 current induced by PSA was due to an increase in the number of functional TRPM8 channels on the plasma membrane. Importantly, wound-healing and migration assays revealed that TRPM8 activation by PSA reduced motility of the PC3 PCa cell line, suggesting that plasma membrane TRPM8 has a protective role in PCa progression. Consequently, PSA was identified as a natural TRPM8 agonist in the prostate and we propose a putative physiological role for both of these proteins in carcinogenesis, making this pathway a potentially important target for anticancer agent development. Oncogene (2010) 29, 4611-4616; doi: 10.1038/onc.2010.210; published online 7 June 2010	[Prevarskaya, N.] USTL, INSERM, Lab Physiol Cellulaire, Equipe Labellisee Ligue Natl Canc,U1003, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Prevarskaya, N (corresponding author), USTL, INSERM, Lab Physiol Cellulaire, Equipe Labellisee Ligue Natl Canc,U1003, Batiment SN3, F-59655 Villeneuve Dascq, France.	natacha.prevarskaya@univ-lille1.fr	Gkika, Dimitra/S-3054-2019; Lemonnier, Loic/L-7289-2018	Gkika, Dimitra/0000-0001-8612-0836; Lemonnier, Loic/0000-0001-6200-5382; Prevarskaya, natacha/0000-0003-0316-197X; Flourakis, Matthieu/0000-0002-5366-9125	Institut national de la Sante et de la Recherche Medicale (INSERM); Ministere de l'education nationale and the Ligue Nationale contre le cancer; Institut National du Cancer (INCa) [07/3d1616/pdoc-110-18/ng-nc]	Institut national de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ministere de l'education nationale and the Ligue Nationale contre le cancer; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France)	This study was supported by grants from the Institut national de la Sante et de la Recherche Medicale (INSERM), Ministere de l'education nationale and the Ligue Nationale contre le cancer. Dr D Gkika was supported by a grant from the Institut National du Cancer (INCa) (Grant No: 07/3d1616/pdoc-110-18/ng-nc).	BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; Bidaux G, 2007, J CLIN INVEST, V117, P1647, DOI 10.1172/JCI30168; Bindukumar B, 2005, NEOPLASIA, V7, P241, DOI 10.1593/neo.04529; Blaukat A, 2003, ANDROLOGIA, V35, P17, DOI 10.1046/j.1439-0272.2003.00533.x; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Chuang HH, 2004, NEURON, V43, P859, DOI 10.1016/j.neuron.2004.08.038; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gkika D, 2006, EMBO J, V25, P4707, DOI 10.1038/sj.emboj.7601357; Gkika D, 2009, BBA-MOL CELL RES, V1793, P953, DOI 10.1016/j.bbamcr.2008.11.010; Hecquet C, 2000, MOL PHARMACOL, V58, P828, DOI 10.1124/mol.58.4.828; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; Henshall SM, 2003, CANCER RES, V63, P4196; Kramarenko II, 2009, BIOCHEM PHARMACOL, V77, P269, DOI 10.1016/j.bcp.2008.09.027; Lilja H, 2003, UROLOGY, V62, P27, DOI 10.1016/S0090-4295(03)00775-1; LILJA H, 1988, PROSTATE, V12, P29, DOI 10.1002/pros.2990120105; Monet M, 2009, BBA-MOL CELL RES, V1793, P528, DOI 10.1016/j.bbamcr.2009.01.003; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Platz EA, 2005, CANCER CAUSE CONTROL, V16, P255, DOI 10.1007/s10552-004-3484-8; Premkumar LS, 2005, J NEUROSCI, V25, P11322, DOI 10.1523/JNEUROSCI.3006-05.2005; Robertson SA, 2005, CELL TISSUE RES, V322, P43, DOI 10.1007/s00441-005-1127-3; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Srinivasan D, 2004, EUR J PHARMACOL, V504, P155, DOI 10.1016/j.ejphar.2004.10.004; Thebault S, 2005, J BIOL CHEM, V280, P39423, DOI 10.1074/jbc.M503544200; Tsavaler L, 2001, CANCER RES, V61, P3760; Yang ZH, 2009, ASIAN J ANDROL, V11, P157, DOI 10.1038/aja.2009.1; Zhang L, 2006, ENDOCR-RELAT CANCER, V13, P27, DOI 10.1677/erc.1.01093	28	74	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2010	29	32					4611	4616		10.1038/onc.2010.210	http://dx.doi.org/10.1038/onc.2010.210			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531306				2022-12-17	WOS:000280862300011
J	Lochhead, PA; Wickman, G; Mezna, M; Olson, MF				Lochhead, P. A.; Wickman, G.; Mezna, M.; Olson, M. F.			Activating ROCK1 somatic mutations in human cancer	ONCOGENE			English	Article						ROCK; kinase; Rho; actin; cytoskeleton; cancer	RHO-ASSOCIATED KINASE; CASPASE-MEDIATED ACTIVATION; PROGRESSION; INHIBITOR; TUMOR; METASTASIS; INVASION; PATHWAY; GTPASES; DOWNSTREAM	Cancer cells acquire characteristics of deregulated growth, survival and increased metastatic potential. Genetic mutations that provide a selective advantage by promoting these characteristics have been termed 'drivers,' whereas mutations that do not contribute to disease initiation/progression are termed 'passengers.' The advent of high-throughput methodologies has facilitated large-scale screening of cancer genomes and the subsequent identification of novel somatic mutations. Although this approach has generated valuable results, the data remain incomplete until the functional consequences of these mutations are determined to differentiate potential drivers from passengers. ROCK1 is an essential effector kinase downstream of Rho GTPases, an important pathway involved in cell migration. The Cancer Genome Project identified three nonsynonymous mutations in the ROCK1 gene. We now show that these somatic ROCK1 mutations lead to elevated kinase activity and drive actin cytoskeleton rearrangements that promote increased motility and decreased adhesion, characteristics of cancer progression. Mapping of the kinase-interacting regions of the carboxy terminus combined with structural modeling provides an insight into how these mutations likely affect the regulation of ROCK1. Consistent with the frequency of ROCK1 mutations in human cancer, these results support the conclusion that there is selective pressure for the ROCK1 gene to acquire 'driver' mutations that result in kinase activation. Oncogene (2010) 29, 2591-2598; doi:10.1038/onc.2010.3; published online 8 February 2010	[Lochhead, P. A.; Wickman, G.; Mezna, M.; Olson, M. F.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Olson, MF (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	m.olson@beatson.gla.ac.uk	Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; 	Cancer Research UK; NIH [CA030721]; NATIONAL CANCER INSTITUTE [R01CA030721] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Cancer Research UK and by a grant to MFO from the NIH (CA030721). Assistance with protein modeling was provided by Felix Krueger (Babraham Institute).	Abe H, 2008, BIOMED RES-TOKYO, V29, P155, DOI 10.2220/biomedres.29.155; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; DOKI Y, 1993, CANCER RES, V53, P3421; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jacobs M, 2006, J BIOL CHEM, V281, P260, DOI 10.1074/jbc.M508847200; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kamai T, 2002, BJU INT, V89, P449, DOI 10.1046/j.1464-4096.2001.01920.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakajima M, 2003, CANCER CHEMOTH PHARM, V52, P319, DOI 10.1007/s00280-003-0641-9; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Ogawa T, 2007, AM J TRANSPLANT, V7, P347, DOI 10.1111/j.1600-6143.2006.01647.x; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Wen WY, 2008, J BIOL CHEM, V283, P26263, DOI 10.1074/jbc.M803417200; Xue F, 2008, HEPATOL RES, V38, P810, DOI 10.1111/j.1872-034X.2008.00333.x; Ying H, 2006, MOL CANCER THER, V5, P2158, DOI 10.1158/1535-7163.MCT-05-0440	24	74	78	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2591	2598		10.1038/onc.2010.3	http://dx.doi.org/10.1038/onc.2010.3			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140017				2022-12-17	WOS:000277169400014
J	Ramakrishnan, V; Timm, M; Haug, JL; Kimlinger, TK; Wellik, LE; Witzig, TE; Rajkumar, SV; Adjei, AA; Kumar, S				Ramakrishnan, V.; Timm, M.; Haug, J. L.; Kimlinger, T. K.; Wellik, L. E.; Witzig, T. E.; Rajkumar, S. V.; Adjei, A. A.; Kumar, S.			Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs	ONCOGENE			English	Article						vascular endothelial growth factor; myeloma; angiogenesis; proliferation; apoptosis; microenvironment	BONE-MARROW ANGIOGENESIS; MULTIPLE-MYELOMA; K-RAS; ACTIVATING MUTATIONS; DISEASE PROGRESSION; DOWN-REGULATION; PLASMA-CELLS; TUMOR-CELLS; N-RAS; KINASE	Multiple myeloma is characterized by increased bone marrow neovascularization driven in part by vascular endothelial growth factor (VEGF). In addition, the Ras/Raf/MEK/ERK pathway is critical for the proliferation of myeloma cells and is often upregulated. Sorafenib (Nexavar) is a novel multi-kinase inhibitor that acts predominantly through inhibition of Raf-kinase and VEGF receptor 2, offering the potential for targeting two important aspects of disease biology. In in vitro studies, sorafenib-induced cytotoxicity in MM cell lines as well as freshly isolated patient myeloma cells. It retained its activity against MM cells in co-culture with stromal cells or with interleukin-6, VEGF or IGF; conditions mimicking tumor microenvironment. Examination of cellular signaling pathways showed downregulation of Mcl1 as well as decreased phosphorylation of the STAT3 and MEK/ERK, as potential mechanisms of its anti-tumor effect. Sorafenib induces reciprocal upregulation of Akt phosphorylation; and simultaneous inhibition of downstream mTOR with rapamycin leads to synergistic effects. Sorafenib also synergizes with drugs such as proteasome inhibitors and steroids. In a human in vitro angiogenesis assay, sorafenib showed potent anti-angiogenic activity. Sorafenib, through multiple mechanisms exerts potent anti-myeloma activity and these results favor further clinical evaluation and development of novel sorafenib combinations. Oncogene (2010) 29, 1190-1202; doi: 10.1038/onc.2009.403; published online 23 November 2009	[Ramakrishnan, V.; Timm, M.; Haug, J. L.; Kimlinger, T. K.; Wellik, L. E.; Witzig, T. E.; Rajkumar, S. V.; Kumar, S.] Mayo Clin, Div Hematol, Rochester, MN USA; [Adjei, A. A.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA	Mayo Clinic; Roswell Park Cancer Institute	Kumar, S (corresponding author), Mayo Clin & Mayo Fdn, Div Hematol, 200 1st St SW, Rochester, MN 55905 USA.	kumar.shaji@mayo.edu	Rajkumar, S. Vincent/AAV-1834-2021; Kumar, Shaji K/A-9853-2008	Rajkumar, S. Vincent/0000-0002-5862-1833; Kumar, Shaji K/0000-0001-5392-9284	Mayo Foundation; Lymphoma SPORE; Bayer Pharmaceuticals; NATIONAL CANCER INSTITUTE [P50CA097274, R01CA127433] Funding Source: NIH RePORTER	Mayo Foundation; Lymphoma SPORE; Bayer Pharmaceuticals(Bayer AG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Roberta DeGoey and Christy Finke for their assistance with processing of tumor cells and all of the patients who provided us with the tumor samples. This work was supported by Mayo Clinic Hematologic Malignancies Program, CR20 Award from Mayo Foundation and Career Development Award from Lymphoma SPORE. Sorafenib was provided through CTEP drug evaluation program by Bayer Pharmaceuticals.	Bezieau S, 2001, HUM MUTAT, V18, P212, DOI 10.1002/humu.1177; BROWN RD, 1994, LEUKEMIA LYMPHOMA, V16, P147, DOI 10.3109/10428199409114152; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; Chatterjee M, 2002, BLOOD, V100, P3311, DOI 10.1182/blood-2002-01-0102; CORRADINI P, 1993, BRIT J HAEMATOL, V83, P672, DOI 10.1111/j.1365-2141.1993.tb04711.x; Dai Y, 2002, BLOOD, V100, P3333, DOI 10.1182/blood-2002-03-0940; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Frassanito MA, 2002, BRIT J HAEMATOL, V118, P157, DOI 10.1046/j.1365-2141.2002.03559.x; Giuliani N, 2004, LEUKEMIA, V18, P628, DOI 10.1038/sj.leu.2403269; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood-2005-08-3434; Hsu JH, 2004, ONCOGENE, V23, P3368, DOI 10.1038/sj.onc.1207459; Kimlinger T, 2006, HAEMATOLOGICA, V91, P1033; Kumar S, 2005, LEUKEMIA, V19, P1466, DOI 10.1038/sj.leu.2403823; Kumar S, 2005, LEUKEMIA, V19, P1253, DOI 10.1038/sj.leu.2403776; Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood-2003-11-3811; Kumar S, 2004, BONE MARROW TRANSPL, V34, P235, DOI 10.1038/sj.bmt.1704555; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood-2002-08-2383; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Pope B, 1997, LEUKEMIA LYMPHOMA, V25, P545, DOI 10.3109/10428199709039043; PORTIER M, 1992, ONCOGENE, V7, P2539; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Raje N, 2004, BLOOD, V104, P4188, DOI 10.1182/blood-2004-06-2281; Rajkumar SV, 2002, CLIN CANCER RES, V8, P2210; Rowley M, 2002, ONCOGENE, V21, P8769, DOI 10.1038/sj.onc.1205387; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Strumberg D, 2005, ONKOLOGIE, V28, P101, DOI 10.1159/000083373; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; UCHIYAMA H, 1993, BLOOD, V82, P3712; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zhang B, 2002, J CELL PHYSIOL, V193, P42, DOI 10.1002/jcp.10148	43	74	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1190	1202		10.1038/onc.2009.403	http://dx.doi.org/10.1038/onc.2009.403			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935717	Green Accepted			2022-12-17	WOS:000274912100010
J	Zhang, J; Li, Y; Liu, Q; Lu, W; Bu, G				Zhang, J.; Li, Y.; Liu, Q.; Lu, W.; Bu, G.			Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis	ONCOGENE			English	Article						LRP6; Wnt signaling; mammary gland; breast cancer	BETA-CATENIN; C-MYC; MATRIX METALLOPROTEINASES; FIBROBLASTIC CELLS; TUMOR VIRUS; HUMAN COLON; EXPRESSION; PROTEIN; GENE; PATHWAY	Although Wnt signaling activation is frequently observed in human breast cancer, mutations in genes encoding intracellular components of the Wnt signaling pathway are rare. We found that the expression of Wnt signaling co-receptor, LRP6, is upregulated in a subset of human breast cancer tissues and cell lines. To examine whether the overexpression of LRP6 in mammary epithelial cells is sufficient to activate Wnt signaling and promote cell proliferation, we generated transgenic mice overexpressing LRP6 in mammary epithelial cells driven by the mouse mammary tumor virus (MMTV) promoter. We found that mammary glands from MMTV-LRP6 mice exhibit significant Wnt activation evidenced by the translocation of beta-catenin from membrane to cytoplasmic/nuclear fractions. The expression of several Wnt target genes including Axin2, Cyclin D1 and c-Myc was also increased in MMTV-LRP6 mice. More importantly, mammary glands from virgin MMTV-LRP6 mice exhibit significant hyperplasia, a precursor to breast cancer, when compared with wild-type littermate controls. Several matrix metalloproteinases are upregulated in MMTV-LRP6 mice that could contribute to the hyperplasia phenotype. Our results suggest that Wnt signaling activation at the cell-surface receptor level can contribute to breast cancer tumorigenesis. Oncogene (2010) 29, 539-549; doi: 10.1038/onc.2009.339; published online 2 November 2009	[Zhang, J.; Li, Y.; Liu, Q.; Lu, W.; Bu, G.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Bu, G.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Li, Y.; Lu, W.] So Res Inst, Dept Biochem & Mol Biol, Drug Discovery Div, Birmingham, AL 35255 USA	Washington University (WUSTL); Washington University (WUSTL)	Bu, G (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave, St Louis, MO 63110 USA.	bu@wustl.edu	Liu, Qiang/E-9245-2011		National Institutes of Health [R01CA100520, RO1CA124531]; NATIONAL CANCER INSTITUTE [R01CA100520, R01CA124531] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Christof Niehrs (German Cancer Research Center) for providing LRP6 cDNA, Dr Philip Leder (Harvard Medical School) for providing the MMTV-SV40-Bssk vector, Dr Gail VW Johnson (University of Rochester) for providing the GST-E-cadherin construct, and Dr Jin-Moo Lee for providing rat brain sections subjected to hypoxia-ischemia as positive controls for apoptosis. We also thank Dr Taj King for critical reading of the manuscript. This work was supported by grants from the National Institutes of Health R01CA100520 (to GB) and RO1CA124531 (to YL).	Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Blavier L, 2006, CANCER RES, V66, P2691, DOI 10.1158/0008-5472.CAN-05-2919; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chenard MP, 1999, INT J CANCER, V82, P208; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GILLETT C, 1994, CANCER RES, V54, P1812; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heppner KJ, 1996, AM J PATHOL, V149, P273; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Klopocki E, 2004, INT J ONCOL, V25, P641; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Li YH, 2004, ONCOGENE, V23, P9129, DOI 10.1038/sj.onc.1208123; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200; Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813; Lu WY, 2008, FEBS LETT, V582, P643, DOI 10.1016/j.febslet.2008.01.035; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; Nielsen BS, 1997, LAB INVEST, V77, P345; Nielsen BS, 2001, CANCER RES, V61, P7091; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498	52	74	76	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					539	549		10.1038/onc.2009.339	http://dx.doi.org/10.1038/onc.2009.339			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881541	Green Accepted			2022-12-17	WOS:000274084600007
J	Zen, K; Yasui, K; Gen, Y; Dohi, O; Wakabayashi, N; Mitsufuji, S; Itoh, Y; Zen, Y; Nakanuma, Y; Taniwaki, M; Okanoue, T; Yoshikawa, T				Zen, K.; Yasui, K.; Gen, Y.; Dohi, O.; Wakabayashi, N.; Mitsufuji, S.; Itoh, Y.; Zen, Y.; Nakanuma, Y.; Taniwaki, M.; Okanoue, T.; Yoshikawa, T.			Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma	ONCOGENE			English	Article						PAR-3; PARD3; esophageal squamous cell carcinoma; homozygous deletion; tight junction; metastasis	TIGHT JUNCTION; CANCER GENOME; COPY NUMBER; IDENTIFICATION; ARRAYS; DNA; AMPLICON; HOMOLOG; ASIP	The partition-defective 3 (PAR-3) protein is implicated in the formation of tight junctions at epithelial cell-cell contacts. We investigated DNA copy number aberrations in human esophageal squamous cell carcinoma (ESCC) cell lines using a high-density oligonucleotide microarray and found a homozygous deletion of PARD3 (the gene encoding PAR-3). Exogenous expression of PARD3 in ESCC cells lacking this gene enhanced the recruitment of zonula occludens 1 (ZO-1), a marker of tight junctions, to sites of cell-cell contact. Conversely, knockdown of PARD3 in ESCC cells expressing this gene caused a disruption of ZO-1 localization at cell-cell borders. A copy number loss of PARD3 was observed in 15% of primary ESCC cells. Expression of PARD3 was significantly reduced in primary ESCC tumors compared with their nontumorous counterparts, and this reduced expression was associated with positive lymph node metastasis and poor differentiation. Our results suggest that deletion and reduced expression of PARD3 may be a novel mechanism that drives the progression of ESCC. Oncogene (2009) 28, 2910-2918; doi:10.1038/onc.2009.148; published online 8 June 2009	[Yasui, K.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kamigyo Ku, Kyoto 6028566, Japan; [Zen, Y.; Nakanuma, Y.] Kanazawa Univ, Grad Sch Med, Dept Human Pathol, Kanazawa, Ishikawa, Japan; [Taniwaki, M.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Hematol & Oncol, Kyoto 6028566, Japan; [Okanoue, T.] Saiseikai Suita Hosp, Dept Hepatol, Suita, Osaka, Japan	Kyoto Prefectural University of Medicine; Kanazawa University; Kyoto Prefectural University of Medicine	Yasui, K (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	yasuik@koto.kpu-m.ac.jp	Dohi, Osamu/AAA-1634-2020	Dohi, Osamu/0000-0002-0498-0144	Japan Society for the Program of Science [18390223, 20590408]	Japan Society for the Program of Science	This study was supported by Grants-in-Aid for Scientific Research (18390223 and 20590408) from the Japan Society for the Program of Science (KY).	AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; BERGGREN P, 2003, CLIN CANCER RES, V14, P242; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Fang CM, 2001, CELL RES, V11, P223, DOI 10.1038/sj.cr.7290090; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gao L, 2002, GENE, V294, P99, DOI 10.1016/S0378-1119(02)00681-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hirose T, 2006, DEVELOPMENT, V133, P1389, DOI 10.1242/dev.02294; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Inagaki Y, 2008, CANCER GENET CYTOGEN, V180, P30, DOI 10.1016/j.cancergencyto.2007.09.013; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KAMB A, 1994, SCIENCE, V264, P440; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Nagayama K, 2007, GENE CHROMOSOME CANC, V46, P1000, DOI 10.1002/gcc.20485; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Vizcaino AP, 2002, INT J CANCER, V99, P860, DOI 10.1002/ijc.10427; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Yasui K, 2001, GENE CHROMOSOME CANC, V32, P112, DOI 10.1002/gcc.1172; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zitzelsberger H, 2004, GENE CHROMOSOME CANC, V40, P55, DOI 10.1002/gcc.20024	31	74	80	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2910	2918		10.1038/onc.2009.148	http://dx.doi.org/10.1038/onc.2009.148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19503097				2022-12-17	WOS:000268917100007
J	Abubaker, J; Bavi, P; Al-Harbi, S; Ibrahim, M; Siraj, AK; Al-Sanea, N; Abduljabbar, A; Ashari, LH; Alhomoud, S; Al-Dayel, F; Uddin, S; Al-Kuraya, KS				Abubaker, J.; Bavi, P.; Al-Harbi, S.; Ibrahim, M.; Siraj, A. K.; Al-Sanea, N.; Abduljabbar, A.; Ashari, L. H.; Alhomoud, S.; Al-Dayel, F.; Uddin, S.; Al-Kuraya, K. S.			Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population	ONCOGENE			English	Article						PIK3CA; MSI; PTEN; colorectal cancer	B-CELL LYMPHOMA; BREAST-CANCER; PHOSPHOINOSITIDE 3-KINASE; PTEN MUTATIONS; SAUDI-ARABIA; PATHWAY; GENE; EXPRESSION; PREVALENCE; CARCINOMAS	Activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway results in an increase in cell proliferation and survival. Somatic mutations within the PI3K catalytic subunit, PIK3CA are common cause of increasing PI3K activity and are believed to be oncogenic in many cancer types. Few reports addressed the association between PIK3CA mutations and tumor progression specifically in microsatellite instable (MSI) colorectal cancer (CRC). In the present study, we have evaluated PIK3CA mutational status in a series of 410 Middle Eastern CRC and 13 colon cell lines to study the prevalence of PIK3CA mutations in MSI cases, PTEN expression in CRC and possibility of therapeutic targeting of this set of patients. PIK3CA mutations were found in four of the cell lines tested and 51 colorectal carcinomas (12.2%). Three of these four mutated cell lines were MSI. PTEN was inactivated in 66.1% of the CRC. Furthermore, we observed a strong association between PIK3CA mutations and MSI status (P = 0.0046) while PTEN loss was more frequent in microsatellite stable (MSS) CRC (P = 0.043). A high prevalence of genetic alterations in PI3K/AKT pathway in Saudi cohort of CRC, predominance of PIK3CA mutations in the MSI subgroup and their possible involvement in development/progression of this subset of CRC are some of the significant findings of our study.	[Abubaker, J.; Bavi, P.; Al-Harbi, S.; Ibrahim, M.; Siraj, A. K.; Uddin, S.; Al-Kuraya, K. S.] King Faisal Specialist Hosp & Res Ctr, Dept Human Canc Genom Res, King Fahad Natl Ctr Childrens Canc & Res, Riyadh 11211, Saudi Arabia; [Al-Sanea, N.; Abduljabbar, A.; Ashari, L. H.; Alhomoud, S.] King Faisal Specialist Hosp & Res Ctr, Dept Colorectal Surg, Riyadh 11211, Saudi Arabia; [Al-Dayel, F.] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Al-Kuraya, KS (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Human Canc Genom Res, King Fahad Natl Ctr Childrens Canc & Res, MBC 98-16,POB 3354, Riyadh 11211, Saudi Arabia.	kkuraya@kfshrc.edu.sa	Bavi, Prashant/B-2123-2009; Al-Sanea, Nasser AN/J-1565-2016	Bavi, Prashant/0000-0002-7711-2911; Al-Sanea, Nasser AN/0000-0002-6336-5942; Uddin, Shahab/0000-0003-1886-6710; Abubaker, Jehad/0000-0003-0681-7305				Abbott RT, 2003, MODERN PATHOL, V16, P607, DOI 10.1097/01.MP.0000067423.83712.74; Abubaker J, 2007, LEUKEMIA, V21, P2368, DOI 10.1038/sj.leu.2404873; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bavi P, 2006, CANCER EPIDEM BIOMAR, V15, P1708, DOI 10.1158/1055-9965.EPI-05-0972; Boland CR, 1998, CANCER RES, V58, P5248; Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; ELHAZMI MAF, 1995, J MED GENET, V32, P623, DOI 10.1136/jmg.32.8.623; Frattini M, 2005, CANCER RES, V65, P11227, DOI 10.1158/0008-5472.CAN-05-2780; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Isbister WH, 2000, AUST NZ J SURG, V70, P269, DOI 10.1046/j.1440-1622.2000.01805.x; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; Maruyama N, 2007, CLIN CANCER RES, V13, P408, DOI 10.1158/1078-0432.CCR-06-0267; Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059; Ollikainen M, 2007, INT J CANCER, V121, P915, DOI 10.1002/ijc.22768; Philp A J, 2000, Int J Surg Investig, V2, P267; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Toyota M, 2000, J GASTROENTEROL, V35, P727, DOI 10.1007/s005350070030; Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011	32	74	77	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3539	3545		10.1038/sj.onc.1211013	http://dx.doi.org/10.1038/sj.onc.1211013			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18193083				2022-12-17	WOS:000256468500005
J	Caspi, M; Zilberberg, A; Eldar-Finkelman, H; Rosin-Arbesfeld, R				Caspi, M.; Zilberberg, A.; Eldar-Finkelman, H.; Rosin-Arbesfeld, R.			Nuclear GSK-3 beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner	ONCOGENE			English	Article						Wnt signalling; beta-catenin; GSK-3 beta; colorectal cancer; nucleus	GLYCOGEN-SYNTHASE KINASE-3; SUBCELLULAR-LOCALIZATION; NEGATIVE REGULATOR; EXPORT; INSULIN; AXIN; TRANSCRIPTION; PROTEOLYSIS; ACTIVATION; CELLS	beta-Catenin is the central signalling molecule of the canonical Wnt pathway, where it activates target genes in a complex with lymphoid enhancer factor/T-cell factor transcription factors in the nucleus. The regulation of beta-catenin activity is thought to occur via a cytoplasmatic multiprotein complex that includes the serine/threonine kinase glycogen synthase kinase-3 beta (GSK-3 beta) that phosphorylates beta-catenin, marking it for degradation by the proteasome. Here, we provide evidence showing that GSK-3 beta has a nuclear function in downregulating the activity of beta-catenin. Using colorectal cell lines that express a mutant form of beta-catenin, which cannot be phosphorylated by GSK-3 beta and ectopically expressed mutant beta-catenin protein, we show that nuclear GSK-3 beta functions in a mechanism that does not involve beta-catenin phosphorylation to reduce the levels of Wnt signalling. We show that GSK-3 beta enters the nucleus, forms a complex with beta-catenin and lowers the levels of beta-catenin/TCFdependent transcription in a mechanism that involves GSK-3 beta-Axin binding.	[Caspi, M.; Zilberberg, A.; Rosin-Arbesfeld, R.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Eldar-Finkelman, H.] Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	arina@tau.ac.il	Eldar-Finkelman, Hagit/AAF-8329-2019	Eldar-Finkelman, Hagit/0000-0002-8460-9686				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Liberman Z, 2005, J BIOL CHEM, V280, P4422, DOI 10.1074/jbc.M410610200; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Patel S, 2004, BIOCHEM SOC T, V32, P803, DOI 10.1042/BST0320803; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zilberberg A, 2004, J BIOL CHEM, V279, P17535, DOI 10.1074/jbc.M311292200	43	74	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3546	3555		10.1038/sj.onc.1211026	http://dx.doi.org/10.1038/sj.onc.1211026			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223684				2022-12-17	WOS:000256468500006
J	Kim, JM; Kakusho, N; Yamada, M; Kanoh, Y; Takemoto, N; Masai, H				Kim, J. M.; Kakusho, N.; Yamada, M.; Kanoh, Y.; Takemoto, N.; Masai, H.			Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint	ONCOGENE			English	Article						Cdc7; DNA replication checkpoint; hydroxyurea; Chk1	HUMAN CDC7-RELATED KINASE; FORK PROTECTION COMPLEX; S-PHASE ARREST; FISSION YEAST; CELL-CYCLE; GENOTOXIC STRESS; SCHIZOSACCHAROMYCES-POMBE; EFFICIENT PROGRESSION; DAMAGE RESPONSE; PROTEIN-KINASE	Cdc7 kinase is evolutionarily conserved and is involved in initiation and progression of DNA replication. However, roles of Cdc7 in checkpoint responses remain largely unknown. In this study, we show that deletion of the Cdc7 genes in mouse embryonic stem (ES) cells abrogates hydroxyurea (HU)- or UV-induced activation of Chk1. HU-induced Chk1 activation is also impaired in human cancer cell lines in which Cdc7 is depleted by siRNA, and Cdc7-depleted cells are more sensitive to HU treatment. In contrast, ATR and Rad17 are relocated to chromatin in these cells following HU treatment, indicating that stalled DNA replication forks are detected normally. Cdc7-depleted cells exhibit defects in chromatin association and phosphorylation of Claspin, suggesting that Cdc7 exerts its effect at least partially through Claspin. Consistent with this prediction, Cdc7 interacts with and phosphorylates Claspin. We propose that Cdc7 is required for activation of the ATR-Chk1 checkpoint pathway through regulation of Cl aspin.	[Kim, J. M.; Kakusho, N.; Yamada, M.; Kanoh, Y.; Masai, H.] Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, Tokyo 1138613, Japan; [Takemoto, N.] Tokyo Metropolitan Inst Med Sci, Cytokine Project, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, J BIOL CHEM, V280, P35337, DOI 10.1074/jbc.M506460200; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H, 2006, J BIOL CHEM, V281, P39249, DOI 10.1074/jbc.M608935200; Matsumoto S, 2005, J BIOL CHEM, V280, P42536, DOI 10.1074/jbc.M510575200; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; Nedelcheva MN, 2005, J MOL BIOL, V347, P509, DOI 10.1016/j.jmb.2005.01.041; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Sclafani RA, 2000, J CELL SCI, V113, P2111; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Sommariva E, 2005, MOL CELL BIOL, V25, P2770, DOI 10.1128/MCB.25.7.2770-2784.2005; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tenca P, 2007, J BIOL CHEM, V282, P208, DOI 10.1074/jbc.M604457200; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; Yoshizawa-Sugata N, 2007, J BIOL CHEM, V282, P2729, DOI 10.1074/jbc.M605596200; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	51	74	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3475	3482		10.1038/sj.onc.1210994	http://dx.doi.org/10.1038/sj.onc.1210994			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18084324				2022-12-17	WOS:000256309900012
J	Wiencke, JK; Zheng, S; Morrison, Z; Yeh, RF				Wiencke, J. K.; Zheng, S.; Morrison, Z.; Yeh, R-F			Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells	ONCOGENE			English	Article						chromatin immunoprecipitation; histone methylation; histone acetylation; tiling array; homeobox; histone code	MAMMALIAN CHROMATIN; METHYLATION PATTERNS; DNA METHYLATION; STEM-CELLS; OTX2; H3; TRANSCRIPTION; LEUKEMIA; BRAIN; MEDULLOBLASTOMAS	Histone H3 lysine 9 trimethylation ( H3K9Me3) has been associated with transcriptional repression, but recent findings implicate this chromatin modi. cation in transcriptional activation and mRNA elongation by RNA polymerase II. Here, we applied immunoprecipitation ( IP) with a custom DNA tiling microarray containing many transcription factors important in development and cancer ( for example homeotic genes; N 683 total genes) to explore the relationship between H3K9Me3 and other histone modi. cations with the differential expression of genes. Cancer cell lines derived from different tissues ( 2 leukemia, 2 medulloblastoma) were characterized with IP antibodies to H3K9Me3, H3K4 dimethylation ( H3K4Me2) and H3K9 acetylation ( H3K9Ac). MV4- 11 is known to over-express the HOXA9 and MEIS1 genes, whereas D283 overexpresses the OTX2 homeobox gene. Gene expression was assessed by Affymetrix U133 array. Mapping the number and size of histone markings demonstrated significant colocalization of H3K9Ac and H3K4Me2 with H3K9Me3, indicating a pattern of putative 'activating' and 'repressive' markings. The median site size was 600 - 821 bp and 72 - 95% or 53 - 80% of chromatin signal sites were located within 1 kb or 500 bp of transcription start sites ( TSS), respectively. A relatively small number of genes displayed additional H3K9Me3 sites in the 50- region distant from the TSS. Comparing genes with modi. cation sites to those without sites in their promoters confirmed the positive associations of H3K9Ac and H3K4Me2 with gene expression and revealed that H3K9Me3 is associated with active genes rather than being a repressive marking as previously thought. The positive regulatory effect of all three types of modi. cations were quantitatively correlated with site size, and applied to absolute gene expression within a single cell line as well as relative expression among pairs of cell lines. Extended patterns of H3K9Me3 upstream of some genes ( for example HOXA9 and OTX2) may result from the action of multiple promoter elements. We found an inverse relationship between promoter DNA hypermethylation and H3K9Me3 in three studied genes ( HOXA9, TMS1, RASSF1A). The localization of H3K9Me3 downstream of the TSSs of expressed genes and not within promoter regions of hypermethylated and silenced genes is consistent with the proposed coupling of H3K9Me3 with RNA polymerase II. Our results indicate a need for revising aspects of the histone code involving H3 lysine methylation. Awareness of H3K9Me3 as a mark of gene activity, not repression, is especially important for the classification of human cancer using chromatin and histone profiles.	[Wiencke, J. K.; Zheng, S.; Morrison, Z.] Univ Calif San Francisco, Dept Neurol Surg, Lab Neuro & Mol Epidemiol Ambulatory Care, San Francisco, CA 94143 USA; [Yeh, R-F] Univ Calif San Francisco, Dept Epidemiol & Biostat, Ctr Bioinformat & Mol Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wiencke, JK (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Lab Neuro & Mol Epidemiol Ambulatory Care, AC-34,1 Irving St,Box 441, San Francisco, CA 94143 USA.	john.wiencke@ucsf.edu		Morrison, Zachary/0000-0001-9282-7248	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006717, P30ES000002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES000002, ES06717] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acampora D, 2005, BRAIN RES BULL, V66, P410, DOI 10.1016/j.brainresbull.2005.02.005; Annabi B, 2005, J NEUROCHEM, V94, P906, DOI 10.1111/j.1471-4159.2005.03256.x; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Arslan MA, 2006, CURR CANCER DRUG TAR, V6, P623, DOI 10.2174/156800906778742479; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Boon K, 2005, CANCER RES, V65, P703; Boon K, 2003, ONCOGENE, V22, P7687, DOI 10.1038/sj.onc.1207043; Canaani E, 2004, BRIT J CANCER, V90, P756, DOI 10.1038/sj.bjc.6601639; Chomez P, 2001, CANCER RES, V61, P5544; de Haas T, 2006, J NEUROPATH EXP NEUR, V65, P176, DOI 10.1097/01.jnen.0000199576.70923.8a; Eissenberg JC, 2006, CURR OPIN GENET DEV, V16, P184, DOI 10.1016/j.gde.2006.02.004; Fossat N, 2005, DEV DYNAM, V233, P154, DOI 10.1002/dvdy.20287; Gregory RI, 2004, TRENDS CELL BIOL, V14, P695, DOI 10.1016/j.tcb.2004.10.002; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Kimura J, 2005, J NEUROSCI, V25, P5097, DOI 10.1523/JNEUROSCI.0239-05.2005; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Nguyen CT, 2002, CANCER RES, V62, P6456; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Rath MF, 2006, J NEUROCHEM, V97, P556, DOI 10.1111/j.1471-4159.2006.03773.x; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tijink BM, 2006, CLIN CANCER RES, V12, P6064, DOI 10.1158/1078-0432.CCR-06-0910; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Vernay B, 2005, J NEUROSCI, V25, P4856, DOI 10.1523/JNEUROSCI.5158-04.2005; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zhao W, 2005, J BIOCHEM, V137, P431, DOI 10.1093/jb/mvi048	42	74	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2412	2421		10.1038/sj.onc.1210895	http://dx.doi.org/10.1038/sj.onc.1210895			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968314				2022-12-17	WOS:000254844900006
J	Perez, CA; Ott, J; Mays, DJ; Pietenpol, JA				Perez, C. A.; Ott, J.; Mays, D. J.; Pietenpol, J. A.			p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm	ONCOGENE			English	Article						SELEX; consensus DNA-binding site; p63MH; ING1; PTPN14	P53 FAMILY; BIOLOGICAL FUNCTIONS; HUMAN GENOME; GENES; PROTEIN; DELTA-NP63-ALPHA; TRANSCRIPTION; EXPRESSION; SEQUENCE; DISTINCT	p53 and p63 belong to a family of sequence-specific transcription factors regulating key cellular processes. Differential composition of the p53 and p63 DNA-binding sites may contribute to distinct functions of these protein homologues. We used SELEX (systematic evolution of ligands by exponential enrichment) methodology to identify nucleic acid ligands for p63. We found that p63 bound preferentially to DNA fragments conforming to the 20 bp sequence 5'- RRRC(A/G)(A/T)GYYYRRRC(A/T) (C/T)GYYY-3'. Relative to the p53 consensus, the p63 consensus DNA-binding site (DBS) was more degenerate, particularly at positions 10 and 11, and was enriched for A/G at position 5 and C/T at position 16 of the consensus. The differences in DNA-binding site preferences between p63 and p53 influenced their ability to activate transcription from select response elements (REs) in cells. A computer algorithm, p63MH, was developed to find candidate p63-binding motifs on input sequences. We identified genes responsive to p63 regulation that contain functional p63 REs. Our results suggest that the sequence composition of REs could be one contributing factor to target gene discrimination between p63 and p53.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37203 USA; Rockefeller Univ, Lab Stat Gen, New York, NY 10021 USA	Vanderbilt University; Rockefeller University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37203 USA.	j.pietenpol@vanderbilt.edu			NCI NIH HHS [CA105436, CA68485, CA70856] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIMH NIH HHS [MH44292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070856, R01CA105436, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044292, R37MH044292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; BLACKWELL TK, 1995, METHOD ENZYMOL, V254, P604; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; Caserta TM, 2006, MOL CANCER RES, V4, P759, DOI 10.1158/1541-7786.MCR-05-0149; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hearnes JM, 2005, MOL CELL BIOL, V25, P10148, DOI 10.1128/MCB.25.22.10148-10158.2005; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; MCKAY R, 1981, NATURE, V289, P810, DOI 10.1038/289810a0; Moll UM, 2004, MOL CANCER RES, V2, P371; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Perez CA, 2007, CELL CYCLE, V6, P246, DOI 10.4161/cc.6.3.3801; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; Ponassi R, 2006, BIOCHEM PHARMACOL, V72, P1417, DOI 10.1016/j.bcp.2006.07.031; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Shimada A, 1999, CANCER RES, V59, P2781; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Thijs G, 2002, J COMPUT BIOL, V9, P447, DOI 10.1089/10665270252935566; Tomso DJ, 2005, P NATL ACAD SCI USA, V102, P6431, DOI 10.1073/pnas.0501721102; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005	35	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7363	7370		10.1038/sj.onc.1210561	http://dx.doi.org/10.1038/sj.onc.1210561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17563751				2022-12-17	WOS:000250955700008
J	Zheng, S; Ei-Naggar, AK; Kim, ES; Kurie, JM; Lozano, G				Zheng, S.; Ei-Naggar, A. K.; Kim, E. S.; Kurie, J. M.; Lozano, G.			A genetic mouse model for metastatic lung cancer with gender differences in survival	ONCOGENE			English	Article						p53; K-ras; mesotheliomas	RAS ONCOGENE ACTIVATION; CLINICAL-SIGNIFICANCE; P53 GENE; MESOTHELIOMA; MUTATIONS; ADENOCARCINOMA; ABNORMALITIES; PATHOGENESIS; PROGRESSION; XENOGRAFTS	Lung cancer is a devastating disease with poor prognosis. The design of better therapies for lung cancer patients would be greatly aided by good mouse models that closely resemble the human disease. Unfortunately, current models for lung adenocarcinoma are inadequate due to the absence of metastases. In this study, we incorporated both K-ras and p53 missense mutations into the mouse genome and established a more faithful genetic model for human lung adenocarcinoma, the most common type of lung cancer. Mice with both mutations developed advanced lung adenocarcinomas that were highly aggressive and metastasized to multiple intrathoracic and extrathoracic sites in a pattern similar to that of human lung cancer. These mice also showed a gender difference in cancer-related death. Additionally, the presence of both mutations induced pleural mesotheliomas in 23% of these mice. This mouse model recapitulates the metastatic nature of human lung cancer and will be invaluable to further probe the molecular basis of metastatic lung cancer and for translational studies.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Unit 1010, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Unit 1010, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org			NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abutaily AS, 2002, J CLIN PATHOL, V55, P662, DOI 10.1136/jcp.55.9.662; Bach PB, 2003, JNCI-J NATL CANCER I, V95, P470, DOI 10.1093/jnci/95.6.470; Bain C, 2004, JNCI-J NATL CANCER I, V96, P826, DOI 10.1093/jnci/djh143; Becher O. J., 2006, CANCER RES, V66, P3358; Becher OJ, 2006, CANCER RES, V66, P3355, DOI 10.1158/0008-5472.CAN-05-3827; Belinsky SA, 2003, CANCER RES, V63, P7089; BELINSKY SA, 1993, CANCER RES, V53, P410; CASTONGUAY A, 1991, EXP LUNG RES, V17, P485, DOI 10.3109/01902149109064434; CHIBA I, 1990, ONCOGENE, V5, P1603; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HECHT SS, 1991, EXP LUNG RES, V17, P501, DOI 10.3109/01902149109064435; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jaurand MC, 2005, PATHOL BIOL, V53, P41, DOI 10.1016/j.patbio.2003.10.005; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KERR KM, 1992, THORAX, V47, P337, DOI 10.1136/thx.47.5.337; Kitamura H, 1999, AM J CLIN PATHOL, V111, P610; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Olak J, 2004, J THORAC CARDIOV SUR, V128, P346, DOI 10.1016/j.jtcvs.2004.05.025; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ordonez NG, 2003, AM J SURG PATHOL, V27, P1031, DOI 10.1097/00000478-200308000-00001; Payne S, 2001, SOC SCI MED, V53, P1067, DOI 10.1016/S0277-9536(00)00402-0; Quint LE, 1996, ANN THORAC SURG, V62, P246, DOI 10.1016/0003-4975(96)00220-2; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; Sadikot RT, 1997, SOUTH MED J, V90, P1063, DOI 10.1097/00007611-199710000-00021; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sausville E.A., 2006, CANCER RES, V66; Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAMURA A, 1992, CANCER, V70, P437, DOI 10.1002/1097-0142(19920715)70:2<437::AID-CNCR2820700211>3.0.CO;2-L; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; Vahakangas KH, 2001, CANCER RES, V61, P4350; Wang Y, 2006, ONCOGENE, V25, P1277, DOI 10.1038/sj.onc.1209182; Wang Y, 2006, ONCOGENE, V25, P1320, DOI 10.1038/sj.onc.1209180; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183	42	74	74	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6896	6904		10.1038/sj.onc.1210493	http://dx.doi.org/10.1038/sj.onc.1210493			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486075	Bronze			2022-12-17	WOS:000250188400005
J	Migliaccio, A; Varricchio, L; De Falco, A; Castoria, G; Arra, C; Yamaguchi, H; Ciociola, A; Lombardi, M; Di Stasio, R; Barbieri, A; Baldi, A; Barone, MV; Appella, E; Auricchio, F				Migliaccio, A.; Varricchio, L.; De Falco, A.; Castoria, G.; Arra, C.; Yamaguchi, H.; Ciociola, A.; Lombardi, M.; Di Stasio, R.; Barbieri, A.; Baldi, A.; Barone, M. V.; Appella, E.; Auricchio, F.			Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth	ONCOGENE			English	Article						androgen receptor; estrogen receptor; receptor antagonist; Src; xenografts	PROSTATE-CANCER CELLS; ESTRADIOL-RECEPTOR; ESTROGEN-RECEPTOR; FACTOR-I; ACTIVATION; PATHWAY; PROTEIN; BREAST; PHOSPHORYLATION; COMPLEX	In human mammary and prostate cancer cells, steroid hormones or epidermal growth factor ( EGF) trigger association of the androgen receptor ( AR)- estradiol receptor ( ER) (alpha or beta) complex with Src. This interaction activates Src and affects the G1 to S cell cycle progression. In this report, we identify the sequence responsible for the AR/ Src interaction and describe a 10 amino- acid peptide that inhibits this interaction. Treatment of the human prostate or mammary cancer cells ( LNCaP or MCF- 7, respectively) with nanomolar concentrations of this peptide inhibits the androgen- or estradiol- induced association between the AR or the ER and Src the Src/ Erk pathway activation, cyclin D1 expression and DNA synthesis, without interfering in the receptor- dependent transcriptional activity. Similarly, the peptide prevents the S phase entry of LNCaP and MCF- 7 cells treated with EGF as well as mouse embryo fibroblasts stimulated with androgen or EGF. Interestingly, the peptide does not inhibit the S phase entry and cytoskeletal changes induced by EGF or serum treatment of AR- negative prostate cancer cell lines. The peptide is the first example of a specific inhibitor of steroid receptor-dependent signal transducing activity. The importance of these results is highlighted by the finding that the peptide strongly inhibits the growth of LNCaP xenografts established in nude mice.	Univ Naples 2, Fac Med & Chirurg, Dipartimento Patol Gen, I-80138 Naples, Italy; NCI, NIH, Cell Biol Lab, Bethesda, MD 20892 USA; Inst Cura Tumori Fdn, Naples, Italy; Univ Naples 2, Sez Anat Patol, Dipartimento Biochim & Biofis, Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Pediat, Naples, Italy	Universita della Campania Vanvitelli; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universita della Campania Vanvitelli; University of Naples Federico II	Auricchio, F (corresponding author), Univ Naples 2, Fac Med & Chirurg, Dipartimento Patol Gen, Via L Crecchio 7, I-80138 Naples, Italy.	ferdinando.auricchio@unina2.it	Migliaccio, Antimo/AAB-3376-2019; Baldi, Alfonso/ABG-2397-2021; Barbieri, Antonio/AAG-8961-2019; Castoria, Gabriella/I-3349-2019	Barbieri, Antonio/0000-0002-7788-6167; Castoria, Gabriella/0000-0002-0576-4494; Baldi, Alfonso/0000-0002-8693-3842; BARONE, Maria Vittoria/0000-0001-6190-4917; Migliaccio, Antimo/0000-0002-4197-2055; Arra, Claudio/0000-0003-3162-2091	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bonaccorsi L, 2000, ENDOCRINOLOGY, V141, P3172, DOI 10.1210/en.141.9.3172; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Castoria G, 2004, MOL CELL BIOL, V24, P7643, DOI 10.1128/MCB.24.17.7643-7653.2004; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CULIG Z, 1994, CANCER RES, V54, P5474; Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x; Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Marquez DC, 2001, ENDOCRINE, V16, P73, DOI 10.1385/ENDO:16:2:073; Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Singer CA, 1999, J NEUROSCI, V19, P2455; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	30	74	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6619	6629		10.1038/sj.onc.1210487	http://dx.doi.org/10.1038/sj.onc.1210487			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486077				2022-12-17	WOS:000250081500004
J	Vendrell, JA; Ghayad, S; Ben-Larbi, S; Dumontet, C; Mechti, N; Cohen, PA				Vendrell, J. A.; Ghayad, S.; Ben-Larbi, S.; Dumontet, C.; Mechti, N.; Cohen, P. A.			A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article						A20/TNFAIP3; breast cancer; tamoxifen; resistance; estrogen receptor status; endocrine treatment	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; ZINC-FINGER PROTEIN; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; ENDOTHELIAL-CELLS; UP-REGULATION; A20; EXPRESSION; RECEPTOR	The zinc-finger protein A20/TNFAIP3, an inhibitor of nuclear factor-kappa B (NF-kappa B) activation, has been shown to protect MCF-7 breast carcinoma cells from TNF alpha-induced apoptosis. As estrogen receptor (ER) status is an important parameter in the development and progression of breast cancer, we analysed the effect of 17 beta-estradiol (E-2) treatment on the expression of A20. We found that A20 is a new E-2-regulated gene, whose expression correlates with ER expression in both cell lines and tumor samples. With the aim of investigating the impact of A20 expression on MCF-7 cells in response to ER ligands, we established stably transfected-MCF-7 cells overexpressing A20 (MCF-7-A20). These cells exhibited a phenotype of resistance to the 4-hydroxytamoxifen cytostatic and pro-apoptotic actions and of hyper-response to E-2. Dysregulations in bax, bcl2, bak, phospho-bad, cyclin D1, cyclin E2, cyclin D2 and cyclin A2 proteins expression were shown to be related to the resistant phenotype developed by the MCF-7-A20 cells. Interestingly, we found that A20 was also overexpressed in MVLN and VP tamoxifen-resistant cell lines. Furthermore, high A20 expression levels were observed in more aggressive breast tumors (ER-negative, progesterone receptor-negative and high histological grade). These overall findings strongly suggest that A20 is a key protein involved in tamoxifen resistance, and thus represents both a new breast cancer marker and a promising target for developing new strategies to prevent the emergence of acquired mechanisms of drug resistance in breast cancer.	Univ Lyon 1, Fac Pharm Lyon, ISPB, F-69008 Lyon, France; Fac Pharm Montpellier, CNRS, UMR 5160, Ctr Pharmacol & Biotechnol Sante Fac Pharm, Montpellier, France; INSERM, UMR 590, F-69008 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cohen, PA (corresponding author), Univ Lyon 1, Fac Pharm Lyon, ISPB, 8 Av Rockefeller, F-69008 Lyon, France.	pascale.cohen@recherche.univ-lyon1.fr	Vendrell, Julie A/I-5867-2012; Cohen, Pascale/I-5875-2012	Cohen, Pascale/0000-0001-7016-9598; Dumontet, Charles/0000-0003-1875-134X				Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Badia E, 2000, CANCER RES, V60, P4130; Berstein LM, 2004, CLIN CANCER RES, V10, P1530, DOI 10.1158/1078-0432.CCR-0433-03; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bredel M, 2006, J CLIN ONCOL, V24, P274, DOI 10.1200/JCO.2005.02.9405; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Clarke M, 1998, LANCET, V351, P1451; Codd JD, 1999, J PATHOL, V187, P549; DEGOEIJ AFPM, 1988, J STEROID BIOCHEM, V29, P465, DOI 10.1016/0022-4731(88)90180-X; DEMIRPENCE E, 1993, J STEROID BIOCHEM, V46, P355, DOI 10.1016/0960-0760(93)90225-L; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; Faridi J, 2003, CLIN CANCER RES, V9, P2933; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Heyninck K, 1999, ANTICANCER RES, V19, P2863; HONIG SF, 1996, DIS BREAST, P669; Jaattela M, 1996, J IMMUNOL, V156, P1166; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Kim R, 2005, CANCER-AM CANCER SOC, V103, P2199, DOI 10.1002/cncr.21029; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kurokawa H, 2000, CANCER RES, V60, P5887; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li HL, 2006, J CELL PHYSIOL, V208, P307, DOI 10.1002/jcp.20665; Longo CR, 2005, HEPATOLOGY, V42, P156, DOI 10.1002/hep.20741; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Lu M, 2003, CANCER RES, V63, P3425; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; McCallum HM, 1996, BREAST CANCER RES TR, V39, P247, DOI 10.1007/BF01806153; Murphy LC, 2005, J MOL ENDOCRINOL, V34, P553, DOI 10.1677/jme.1.01688; Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502; Nguyen H, 2006, VIROLOGY, V354, P58, DOI 10.1016/j.virol.2006.04.028; Onose A, 2006, EUR J PHARMACOL, V541, P198, DOI 10.1016/j.ejphar.2006.03.073; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Patel VI, 2006, FASEB J, V20, P1418, DOI 10.1096/fj.05-4981com; Pichon MF, 1996, BRIT J CANCER, V73, P1545, DOI 10.1038/bjc.1996.291; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Santen RJ, 2004, CLIN CANCER RES, V10, p337S, DOI 10.1158/1078-0432.CCR-031207; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Storz P, 2005, BIOCHEM J, V387, P47, DOI 10.1042/BJ20041443; TEWARI M, 1995, J IMMUNOL, V154, P1699; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Vendrell JA, 2005, ENDOCR-RELAT CANCER, V12, P75, DOI 10.1677/erc.1.00899; Vendrell JA, 2004, J MOL ENDOCRINOL, V32, P397, DOI 10.1677/jme.0.0320397; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186; Zetoune FS, 2001, CYTOKINE, V15, P282, DOI 10.1006/cyto.2001.0921; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971	58	74	81	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4656	4667		10.1038/sj.onc.1210269	http://dx.doi.org/10.1038/sj.onc.1210269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297453				2022-12-17	WOS:000248037900006
J	Honrado, E; Osorio, A; Palacios, J; Benitez, J				Honrado, E.; Osorio, A.; Palacios, J.; Benitez, J.			Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations	ONCOGENE			English	Review						immunohistochemistry; profile; microarrays	BASAL EPITHELIAL PHENOTYPE; GERMLINE BRCA1; ESTROGEN-RECEPTOR; CANCER SUSCEPTIBILITY; CHEK2-ASTERISK-1100DELC VARIANT; IMMUNOHISTOCHEMICAL MARKERS; HISTOPATHOLOGICAL FEATURES; TRANSCRIPTIONAL ACTIVITY; TISSUE MICROARRAY; OVARIAN-CANCER	Tumors arising in BRCA1 and BRCA2 mutation carriers appear to have specific pathological and gene expression profiles, which show a high level of concordance. BRCA1 tumors are high-grade, negative for hormone receptors, have a high proliferation rate, and are positive for some cell cycle promoter genes. BRCA2 tumors present a phenotype opposite to BRCA1 tumors but very similar to sporadic tumors, except that BRCA2 overexpress some DNA repair markers such as CHEK2, show high cytoplasmic expression of RAD51, and are negative for HER-2 amplification and expression. Some of these characteristics have also been found in cDNA expression studies, although more analysis are necessary in order to obtain new markers that can be associated with a germ line mutation in BRCA1 or BRCA2. In this way, some studies in normal tissues of BRCA1/2 carriers suggest that differences exist in the level of expression of some genes when compared with noncarriers. Finally, IHC studies in tumors carrying a mutation in CHEK2 are rare and show contradictory results, probably due to the low number of these cases. However, they represent an example showing how different mutations of the same gene may be associated with specific histological subtypes of cancer.	CNIO, Spanish Natl Canc Ctr, Human Genet Grp, E-28029 Madrid, Spain; CNIO, Spanish Natl Canc Ctr, Breast & Gynecol Canc Grp, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Benitez, J (corresponding author), CNIO, Spanish Natl Canc Ctr, Human Genet Grp, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	jbenitez@cnio.es	Osorio, Ana/I-4324-2014; Palacios, Jose/AAV-3765-2020	Osorio, Ana/0000-0001-8124-3984; Honrado Franco, Emiliano/0000-0001-5668-4083				Adem C, 2004, GENE CHROMOSOME CANC, V41, P1, DOI 10.1002/gcc.20057; Agnarsson BA, 1998, BREAST CANCER RES TR, V47, P121, DOI 10.1023/A:1005853022804; Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N; Armes JE, 1999, CANCER RES, V59, P2011; Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064; ARNOLD K, 2006, CANC LETT, V28, P1; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Caligo MA, 2004, HUM MUTAT, V24, P100, DOI 10.1002/humu.20051; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cavalli LR, 2004, CANCER GENET CYTOGEN, V149, P38, DOI 10.1016/S0165-4608(03)00282-6; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Chappuis PO, 2005, ANN ONCOL, V16, P735, DOI 10.1093/annonc/mdi149; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; de Bock GH, 2004, J MED GENET, V41, P731, DOI 10.1136/jmg.2004.019737; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Eerola H, 2005, BREAST CANCER RES, V7, pR465, DOI 10.1186/bcr1025; Eerola H, 2005, BREAST CANCER RES, V7, pR93, DOI 10.1186/bcr953; Eisinger F, 1999, INT J CANCER, V84, P263, DOI 10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G; Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Foulkes WD, 2003, CANCER, V98, P1569, DOI 10.1002/cncr.11688; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Gillett CE, 1998, J PATHOL, V184, P396; Goffin JR, 2003, CANCER-AM CANCER SOC, V97, P527, DOI 10.1002/cncr.11080; Greenblatt MS, 2001, CANCER RES, V61, P4092; Gretarsdottir S, 1998, CANCER RES, V58, P859; Grushko TA, 2002, CANCER RES, V62, P1481; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100; Honrado E, 2005, J CLIN ONCOL, V23, P7503, DOI 10.1200/JCO.2005.01.3698; Hoogerbrugge N, 2003, J CLIN ONCOL, V21, P41, DOI 10.1200/JCO.2003.02.137; Huzarski T, 2005, BREAST CANCER RES TR, V90, P187, DOI 10.1007/s10549-004-3778-2; Isaacs C, 2004, BREAST CANCER RES TR, V84, P99, DOI 10.1023/B:BREA.0000018406.03679.2e; Jacquemier J, 2005, J PATHOL, V207, P260, DOI 10.1002/path.1845; Jekimovs CR, 2005, BRIT J CANCER, V92, P784, DOI 10.1038/sj.bjc.6602381; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kauff ND, 2003, CANCER-AM CANCER SOC, V97, P1601, DOI 10.1002/cncr.11225; Kilpivaara O, 2005, INT J CANCER, V113, P575, DOI 10.1002/ijc.20638; Kleibl Z, 2005, BREAST CANCER RES TR, V90, P165, DOI 10.1007/s10549-004-4023-8; Kote-Jarai Z, 2004, CLIN CANCER RES, V10, P958, DOI 10.1158/1078-0432.CCR-1067-3; Lakhani S R, 1999, Breast Cancer Res, V1, P31, DOI 10.1186/bcr10; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Lakhani SR, 1997, LANCET, V349, P1505; Lakhani SR, 1999, J PATHOL, V189, P496, DOI 10.1002/(SICI)1096-9896(199912)189:4&lt;496::AID-PATH485&gt;3.0.CO;2-D; Larson PS, 2005, J CLIN ONCOL, V23, P8613, DOI 10.1200/JCO.2005.02.1451; Linke SP, 2006, CLIN CANCER RES, V12, P1175, DOI 10.1158/1078-0432.CCR-05-1562; Lynch BJ, 1998, HUM PATHOL, V29, P1140, DOI 10.1016/S0046-8177(98)90427-0; Marcus JN, 1997, BREAST CANCER RES TR, V44, P275, DOI 10.1023/A:1005830230664; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mitchell G, 2005, BREAST CANCER RES, V7, pR1122, DOI 10.1186/bcr1348; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen TO, 2004, CANCER RES, V64, P286, DOI 10.1158/0008-5472.CAN-03-1242; Noguchi S, 1999, CANCER-AM CANCER SOC, V85, P2200, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S; Offit Kenneth, 2003, BMC Med Genet, V4, P1, DOI 10.1186/1471-2350-4-1; Oldenburg RA, 2006, CLIN CANCER RES, V12, P1693, DOI 10.1158/1078-0432.CCR-05-2230; Oldenburg RA, 2003, CANCER RES, V63, P8153; Ongusaha PP, 2003, ONCOGENE, V22, P3749, DOI 10.1038/sj.onc.1206439; Osin P, 1998, EUR J CANCER, V34, P1683, DOI 10.1016/S0959-8049(98)00248-2; Osin P P, 1999, Breast Cancer Res, V1, P36, DOI 10.1186/bcr11; Osorio A, 2004, INT J CANCER, V108, P54, DOI 10.1002/ijc.11414; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0; Palacios J, 2004, JNCI-J NATL CANCER I, V96, P712, DOI 10.1093/jnci/djh115; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phillips KA, 1999, J NATL CANCER I, V91, P469, DOI 10.1093/jnci/91.5.469; PINILLA SM, 2006, BREAST CANC RES 0316; Quenneville LA, 2002, CANCER-AM CANCER SOC, V95, P2068, DOI 10.1002/cncr.10949; Rashid MU, 2005, EUR J CANCER, V41, P2896, DOI 10.1016/j.ejca.2005.04.049; Reis JS, 2006, MODERN PATHOL, V19, P307, DOI 10.1038/modpathol.3800542; Reis JS, 2006, MODERN PATHOL, V19, P999, DOI 10.1038/modpathol.3800621; Robson M, 1998, CANCER RES, V58, P1839; Robson ME, 2004, BREAST CANCER RES, V6, pR8, DOI 10.1186/bcr658; Rodriguez-Pinilla SM, 2006, CLIN CANCER RES, V12, P1533, DOI 10.1158/1078-0432.CCR-05-2281; Ruiz C, 2006, INT J CANCER, V118, P2190, DOI 10.1002/ijc.21581; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van der Groep P, 2004, JNCI-J NATL CANCER I, V96, P712, DOI 10.1093/jnci/djh114; van Slooten HJ, 1998, BRIT J CANCER, V77, P789, DOI 10.1038/bjc.1998.128; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Vaziri SAJ, 2001, CLIN CANCER RES, V7, P1937; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Warren M, 2003, HUM MOL GENET, V12, P2645, DOI 10.1093/hmg/ddg277; Weber F, 2005, BRIT J CANCER, V92, P1922, DOI 10.1038/sj.bjc.6602557; Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	104	74	75	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5837	5845		10.1038/sj.onc.1209875	http://dx.doi.org/10.1038/sj.onc.1209875			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998498				2022-12-17	WOS:000240765900004
J	Karagiannis, TC; El-Osta, A				Karagiannis, T. C.; El-Osta, A.			Modulation of cellular radiation responses by histone deacetylase inhibitors	ONCOGENE			English	Review						chromatin remodeling; histone acetylation; histone deacetylase; HDAC inhibitor; radiosensitivity; radiation response	DOUBLE-STRAND BREAKS; SUBEROYLANILIDE HYDROXAMIC ACID; DEPENDENT PROTEIN-KINASE; SODIUM-BUTYRATE; DNA-DAMAGE; TRICHOSTATIN-A; VALPROIC ACID; IN-VIVO; H2AX PHOSPHORYLATION; CANCER-THERAPY	Histone deacetylase ( HDAC) inhibitors are emerging as a new class of targeted cancer chemotherapeutics. Several HDAC inhibitors are currently in clinical trials and promising anticancer effects at well-tolerated doses have been observed for both hematologic and solid cancers. HDAC inhibitors have been shown to induce cell-cycle and growth arrest, differentiation and in certain cases apoptosis in cell cultures and in vivo. However, it is known that these compounds induce varying responses in different cells and biological settings, and identifying their precise mechanisms of action is an area of great interest. Important findings are continually expanding our understanding of the cellular effects of HDAC inhibitors and recent studies will be briefly outlined in this review. In addition to their intrinsic anticancer properties, numerous studies have demonstrated that HDAC inhibitors can modulate cellular responses to other cytotoxic modalities including ionizing radiation, ultraviolet radiation and chemotherapeutic drugs. Hence, there is a growing interest in potential clinical use of HDAC inhibitors in combination with conventional cancer therapies. In this review, the interaction of HDAC inhibitors with other anticancer agents is discussed. The focus of the article is on the different mechanisms by which HDAC inhibitors enhance the sensitivity of cells to the effects of ionizing radiation.	Alfred Med Res & Educ Precinct, Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, Melbourne, Vic 3181, Australia; Peter MacCallum Canc Ctr, Trescowthick Res Labs, Melbourne, Vic, Australia	Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center	El-Osta, A (corresponding author), Alfred Med Res & Educ Precinct, Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, 2nd Floor,Commercial Rd, Melbourne, Vic 3181, Australia.	assam.el-osta@baker.edu.au		El-Osta, Assam/0000-0003-2969-9137; Karagiannis, Tom/0000-0002-9967-1546				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARUNDEL CM, 1987, INT J RADIAT ONCOL, V13, P593, DOI 10.1016/0360-3016(87)90077-0; ARUNDEL CM, 1985, RADIAT RES, V104, P443, DOI 10.2307/3576603; Biade S, 2001, INT J RADIAT BIOL, V77, P1033, DOI 10.1080/09553000110066068; Blaheta RA, 2005, MED RES REV, V25, P383, DOI 10.1002/med.20027; Boivin AJ, 2002, ANTI-CANCER DRUG, V13, P869, DOI 10.1097/00001813-200209000-00013; Bowden CL, 2005, ACTA PSYCHIAT SCAND, V111, P13, DOI 10.1111/j.1600-0447.2005.00522.x; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Camphausen K, 2005, INT J CANCER, V114, P380, DOI 10.1002/ijc.20774; Camphausen K, 2004, CLIN CANCER RES, V10, P6066, DOI 10.1158/1078-0432.CCR-04-0537; Camphausen K, 2004, CANCER RES, V64, P316, DOI 10.1158/0008-5472.CAN-03-2630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chang SM, 1999, J CLIN ONCOL, V17, P984, DOI 10.1200/JCO.1999.17.3.984; Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Chung YL, 2000, CLIN CANCER RES, V6, P1452; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Di Gennaro E, 2004, AMINO ACIDS, V26, P435, DOI 10.1007/s00726-004-0087-3; Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; FALZON M, 1993, J BIOL CHEM, V268, P10546; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Frey RR, 2002, BIOORG MED CHEM LETT, V12, P3443, DOI 10.1016/S0960-894X(02)00754-0; Furumai R, 2002, CANCER RES, V62, P4916; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Hess-Stumpp H, 2005, EUR J CELL BIOL, V84, P109, DOI 10.1016/j.ejcb.2004.12.010; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Jeggo P, 2002, DNA REPAIR, V1, P771, DOI 10.1016/S1568-7864(02)00096-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Ju R, 2003, CANCER RES, V63, P2891; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Jung M, 2005, RADIAT RES, V163, P488, DOI 10.1667/RR3345; Jung M, 2001, CURR MED CHEM, V8, P1505, DOI 10.2174/0929867013372058; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Karagiannis TC, 2005, CANCER BIOL THER, V4, P787, DOI 10.4161/cbt.4.7.1922; Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kim JH, 2004, INT J RADIAT ONCOL, V59, P1174, DOI 10.1016/j.ijrobp.2004.03.001; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim MS, 2005, EXP CELL RES, V306, P94, DOI 10.1016/j.yexcr.2005.02.013; Kim MS, 2003, CANCER RES, V63, P7291; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; LEITH JT, 1988, RADIAT RES, V114, P186, DOI 10.2307/3577154; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Loscher W, 1999, PROG NEUROBIOL, V58, P31, DOI 10.1016/S0301-0082(98)00075-6; Louis M, 2005, INT J ONCOL, V26, P1569; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; MIMORI T, 1986, J BIOL CHEM, V261, P375; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nome RV, 2005, MOL CANCER THER, V4, P1231, DOI 10.1158/1535-7163.MCT-04-0304; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068; Prakash S, 2001, INVEST NEW DRUG, V19, P1, DOI 10.1023/A:1006489328324; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Singh SB, 2002, J ORG CHEM, V67, P815, DOI 10.1021/jo016088w; SNEAD OC, 1985, J PEDIATR-US, V106, P323; Spotswood HT, 2002, J CLIN INVEST, V110, P577, DOI 10.1172/JCI200216547; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yoshida M, 2003, CURR MED CHEM, V10, P2351, DOI 10.2174/0929867033456602; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zgheib O, 2005, RADIOTHER ONCOL, V76, P119, DOI 10.1016/j.radonc.2005.06.026; Zhang Y, 2004, RADIAT RES, V161, P667, DOI 10.1667/RR3192; Zhang Y, 2004, INT J CANCER, V110, P301, DOI 10.1002/ijc.20117; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	120	74	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3885	3893		10.1038/sj.onc.1209417	http://dx.doi.org/10.1038/sj.onc.1209417			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16462761				2022-12-17	WOS:000238668800001
J	Cavard, C; Terris, B; Grimber, G; Christa, L; Audard, V; Bussiere, BR; Simon, MT; Renard, CA; Buendia, MA; Perret, C				Cavard, C; Terris, B; Grimber, G; Christa, L; Audard, V; Bussiere, BR; Simon, MT; Renard, CA; Buendia, MA; Perret, C			Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primaryliver tumors with beta-catenin mutations	ONCOGENE			English	Article						beta-catenin; REG1A; REG3A; hepatocellular; carcinoma; hepatoblastoma; Wnt signaling	PANCREATITIS-ASSOCIATED PROTEIN; HUMAN HEPATOCELLULAR CARCINOMAS; REG-I; CHILDHOOD HEPATOBLASTOMA; LIVER-REGENERATION; CANCER-CELLS; EXPRESSION; ADENOMAS; GROWTH; CHOLANGIOCARCINOMA	The Wnt/beta-catenin signaling pathways activated in many human hepatocellular carcinomas (HCC). We tried to identify the genes involved in carcinogenesis and progression of HCC with beta-catenin mutations. We used PCR-based subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for beta-catenin. Two of the genes identified belong to the Regenerating gene (REG) family. They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/ REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation. Using siRNA directed against beta-catenin, we demonstrated that REG3A is a target of beta-catenin signaling in Huh7 hepatoma cells. The upregulation of REG3A and REG1A expression is significantly correlated to the beta-catenin status in 42 HCC and 28 hepatoblastomas characterized for their b-catenin status. Thus, we report strong evidence that both genes are downstream targets of the Wnt pathway during liver tumorigenesis.	Univ Paris 05, INSERM, U567, CNRS,UMR 8104,Inst Cochin,Dept GDPM, F-75014 Paris, France; Univ Paris 05, Hop Cochin, Serv Anat Pathol, F-75014 Paris, France; Univ Paris 05, Inst Necker Pasteur, INSERM, U370, F-75014 Paris, France; Inst Pasteur, INSERM, U579, Unite Oncogenese & Virol Mol, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cavard, C (corresponding author), Univ Paris 05, INSERM, U567, CNRS,UMR 8104,Inst Cochin,Dept GDPM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	cavard@cochin.inserm.fr	Terris, Benoit/P-1497-2017; Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051				Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Bernard-Perrone FR, 1999, J HISTOCHEM CYTOCHEM, V47, P863, DOI 10.1177/002215549904700703; Bioulac-Sage P, 2003, HEPATOLOGY, V37, P480, DOI 10.1053/jhep.2003.50058; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Buckhaults P, 2001, CANCER RES, V61, P6996; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Chen YW, 2002, HEPATOLOGY, V36, P927, DOI 10.1053/jhep.2002.36126; Christa L, 1999, AM J PATHOL, V155, P1525, DOI 10.1016/S0002-9440(10)65468-5; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dhar DK, 2004, CANCER-AM CANCER SOC, V100, P1130, DOI 10.1002/cncr.20097; DUSETTI NJ, 1994, GENOMICS, V19, P108, DOI 10.1006/geno.1994.1019; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Fukui H, 2004, DIGESTION, V69, P177, DOI 10.1159/000078762; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Harada K, 2001, HEPATOLOGY, V33, P1036, DOI 10.1053/jhep.2001.24168; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; LASSERRE C, 1992, CANCER RES, V52, P5089; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Macadam RCA, 2000, BRIT J CANCER, V83, P188; Malka D, 2000, GASTROENTEROLOGY, V119, P816, DOI 10.1053/gast.2000.16491; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Perilongo G, 2004, EUR J CANCER, V40, P411, DOI 10.1016/j.ejca.2003.06.003; Polakis P, 2000, GENE DEV, V14, P1837; Rechreche H, 1999, INT J CANCER, V81, P688, DOI 10.1002/(SICI)1097-0215(19990531)81:5<688::AID-IJC3>3.0.CO;2-R; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Simon MT, 2003, FASEB J, V17, P1441, DOI 10.1096/fj.02-1013com; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Takayasu H, 2002, HUM PATHOL, V33, P852, DOI 10.1053/hupa.2002.125771; Takayasu H, 2001, CLIN CANCER RES, V7, P901; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Verma UN, 2003, CLIN CANCER RES, V9, P1291; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; White P, 2005, J BIOL CHEM, V280, P3715, DOI 10.1074/jbc.M410844200; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Yamaoka T, 2000, BIOCHEM BIOPH RES CO, V278, P368, DOI 10.1006/bbrc.2000.3813; Yuan RH, 2005, CLIN CANCER RES, V11, P2568, DOI 10.1158/1078-0432.CCR-04-2039; Zhang YW, 2003, WORLD J GASTROENTERO, V9, P2635; ZUCMANROSSI J, UNPUB COMP EVALUATIO	47	74	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					599	608		10.1038/sj.onc.1208860	http://dx.doi.org/10.1038/sj.onc.1208860			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16314847				2022-12-17	WOS:000234897400011
J	Ogishima, T; Shiina, H; Breault, JE; Terashima, M; Honda, S; Enokida, H; Urakami, S; Tokizane, T; Kawakami, T; Ribeiro, LA; Fujime, M; Kane, CJ; Carroll, PR; Igawa, M; Dahiya, R				Ogishima, T; Shiina, H; Breault, JE; Terashima, M; Honda, S; Enokida, H; Urakami, S; Tokizane, T; Kawakami, T; Ribeiro, LA; Fujime, M; Kane, CJ; Carroll, PR; Igawa, M; Dahiya, R			Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer	ONCOGENE			English	Article						heparanase; methylation; epigenetics; bladder cancer	HUMAN BREAST-CANCER; MAMMALIAN HEPARANASE; PANCREATIC-CANCER; DNA METHYLATION; PROSTATE-CANCER; TUMOR INVASION; GENE; CELLS; HYPERMETHYLATION; METASTASIS	Heparanase plays a critical role in the degradation of extracellular matrix and cell membrane and is frequently upregulated in malignant tumors. Transcription factor, early growth response 1 (EGR1), is closely associated with inducible transcription of the heparanase gene. We hypothesized that promoter CpG hypomethylation with increased EGR1 expression could determine heparanase expression during the pathogenesis of bladder cancer. Bladder cancer cell lines (J82, T24 and transitional cell carcinoma) significantly restored heparanase expression after 5-Aza-dC treatment. Transfection of EGR1 siRNA with T24 bladder cancer cell line significantly downregulated heparanase expression compared to the control siRNA transfection. In 54 bladder cancer and paired normal bladder samples, heparanase expression was significantly higher in bladder cancer than in normal bladder (P < 0.01). We performed methylation-specific PCR targeting the CpG sites within the core-binding consensus motifs of EGR1 (GGCG) and Sp1 (GGGCGG). Methylation prevalence was significantly higher in normal bladder than in bladder cancer (P < 0.05) and inversely correlated with heparanase expression (P = 0.055). In the total series of bladder cancer and normal bladder samples, the combination of promoter CpG methylation and EGR1 expression regulated heparanase expression in a stepwise manner, where heparanase expression was the lowest in methylation-positive and EGR1-negative samples and the highest in methylation-negative and EGR1-positive samples. To our knowledge, this is the first study demonstrating that increased heparanase expression during the pathogenesis of bladder cancer is due to promoter hypomethylation and transcription factor EGR1.	Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA; Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane 6930085, Japan; Univ Sao Paulo, Sch Med, Dept Urol, Sao Paulo, Brazil; Juntendo Univ, Sch Med, Dept Urol, Tokyo 1130082, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Shimane University; Universidade de Sao Paulo; Juntendo University	Dahiya, R (corresponding author), Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.	rdahiya@urol.ucsf.edu			FOGARTY INTERNATIONAL CENTER [R01TW006215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021418] Funding Source: NIH RePORTER; FIC NIH HHS [R01TW006215] Funding Source: Medline; NCI NIH HHS [R01CA1018447] Funding Source: Medline; NIA NIH HHS [R01AG21418] Funding Source: Medline; NIDDK NIH HHS [T32DK07790] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson E, 2003, CANCER BIOL THER, V2, P617; Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; Dahiya R, 1997, INT J CANCER, V72, P762, DOI 10.1002/(SICI)1097-0215(19970904)72:5<762::AID-IJC10>3.0.CO;2-B; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Kanaya T, 2003, ONCOGENE, V22, P2352, DOI 10.1038/sj.onc.1206365; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Koliopanos A, 2001, CANCER RES, V61, P4655; Kosir MA, 1997, J SURG RES, V67, P98, DOI 10.1006/jsre.1996.4976; Marchetti D, 1996, CANCER RES, V56, P2856; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Sasaki M, 2003, BIOCHEM BIOPH RES CO, V309, P305, DOI 10.1016/j.bbrc.2003.08.005; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Simon R, 1998, J PATHOL, V185, P345; Sobin, 2009, UICC TNM CLASSIFICAT; Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662	27	74	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6765	6772		10.1038/sj.onc.1208811	http://dx.doi.org/10.1038/sj.onc.1208811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007175				2022-12-17	WOS:000232527800004
J	Lucas, B; Grigo, K; Erdmann, S; Lausen, J; Klein-Hitpass, L; Ryffel, GU				Lucas, B; Grigo, K; Erdmann, S; Lausen, J; Klein-Hitpass, L; Ryffel, GU			HNF4 alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma	ONCOGENE			English	Article						HNF4 alpha; proliferation; microarray; renal cell carcinoma	TRANSCRIPTION FACTORS; C/EBP-ALPHA; EXPRESSION; LIVER; DIFFERENTIATION; CLASSIFICATION; HNF-4-ALPHA; INHIBITION; MUTATIONS; DISCOVERY	Hepatocyte nuclear factor 4 alpha (HNF4 alpha) is a tissue-specific transcription factor known to regulate a large number of genes in hepatocytes and pancreatic beta cells. Although HNF4 alpha is highly expressed in some sections of the kidney, little is known about its role in this organ and about HNF4 alpha-regulated genes in the kidney cells. The abundance and activity of HNF4 alpha are frequently reduced in renal cell carcinoma (RCC) indicating some tumor suppressing function of HNF4 alpha in renal cells. To determine the potential role of HNF4 alpha in RCC, we used Flp recombinase-mediated gene integration to generate human embryonic kidney cells (HEK293) that conditionally express wild-type or mutated HNF4a. Expression of wild-type HNF4 alpha but not of the mutants led to reduction of proliferation and alterations of cell morphology. These effects were reversible and induced at physiological concentrations of HNF4 alpha. Using gene expression pro. ling by microarrays, we determined genes regulated by HNF4 alpha. Interestingly, many of the genes regulated by HNF4 alpha have been shown to be deregulated in RCC microarray studies. These genes (ACY1, WT1, SELENBP1, COBL, EFHD1, AGXT2L1, ALDH5A1, THEM2, ABCB1, FLJ14146, CSPG2, TRIM9 and HEY1) are good candidates for genes whose activity is changed upon the decrease of HNF4 alpha in RCC.	Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany	University of Duisburg Essen	Ryffel, GU (corresponding author), Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany.	gerhart.ryffel@uni-essen.de						[Anonymous], 2001, NUCL RECEPTORS GENET; Berasain C, 2003, HEPATOLOGY, V38, P148, DOI 10.1053/jhep.2003.50269; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; Chabardes-Garonne D, 2003, P NATL ACAD SCI USA, V100, P13710, DOI 10.1073/pnas.2234604100; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Chiba H, 2005, EXP CELL RES, V302, P11, DOI 10.1016/j.yexcr.2004.08.014; Choi JK, 2004, FEBS LETT, V565, P93, DOI 10.1016/j.febslet.2004.03.081; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; Drewes T, 1996, MOL CELL BIOL, V16, P925; Gieseg MA, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-26; Grewal JS, 2005, BIOCHEM J, V387, P609, DOI 10.1042/BJ20041465; Gupta RK, 2004, TRENDS MOL MED, V10, P521, DOI 10.1016/j.molmed.2004.09.004; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; Ishiyama T, 2003, CANCER SCI, V94, P757, DOI 10.1111/j.1349-7006.2003.tb01515.x; Jiang Shuying, 2003, Nucl Recept, V1, P5, DOI 10.1186/1478-1336-1-5; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Laine B, 2000, FEBS LETT, V479, P41, DOI 10.1016/S0014-5793(00)01864-0; Lausen J, 2000, NUCLEIC ACIDS RES, V28, P430, DOI 10.1093/nar/28.2.430; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31; Li JX, 2000, GENE DEV, V14, P464; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linehan WM, 2004, CANCER CELL, V6, P223, DOI 10.1016/j.ccr.2004.09.006; Naiki T, 2002, J BIOL CHEM, V277, P14011, DOI 10.1074/jbc.M105403200; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Ryffel GU, 2000, MECH DEVELOP, V90, P65, DOI 10.1016/S0925-4773(99)00230-0; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Sel S, 1996, CANCER LETT, V101, P205, DOI 10.1016/0304-3835(96)04136-5; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; STUMPF H, 1995, CARCINOGENESIS, V16, P143, DOI 10.1093/carcin/16.1.143; Takahashi M, 2003, ONCOGENE, V22, P6810, DOI 10.1038/sj.onc.1206869; Taylor DG, 1996, NUCLEIC ACIDS RES, V24, P2930, DOI 10.1093/nar/24.15.2930; Thomas H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh144; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; Wagner KD, 2003, J CELL SCI, V116, P1653, DOI 10.1242/jcs.00405; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Werdien D, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e53; Xu L, 2001, CANCER RES, V61, P3176; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	45	74	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6418	6431		10.1038/sj.onc.1208794	http://dx.doi.org/10.1038/sj.onc.1208794			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007190				2022-12-17	WOS:000232038200009
J	Felty, Q; Singh, KP; Roy, D				Felty, Q; Singh, KP; Roy, D			Estrogen-induced G(1)/S transition of G(0)-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling	ONCOGENE			English	Article						cell cycle; estradiol; ROS; mitochondria	POLYMERASE CHAIN-REACTION; SUPEROXIDE FORMATION; RECEPTOR-BETA; LEYDIG-CELLS; ER-ALPHA; GROWTH; PROLIFERATION; EXPRESSION; INDUCTION; PROTEIN	We previously reported that 17-beta-estradiol (E2)-induced mitochondrial reactive oxygen species (mtROS) act as signaling molecules. The purpose of this study was to investigate the effects of E2-induced mtROS on cell cycle progression. E2-induced cell growth was reduced by antioxidants N-acetyl-L-cysteine (NAC), catalase, and the glutathione peroxidase mimic ebselen. Flow cytometry showed that mitochondrial blockers of protein synthesis (chloramphenicol), transcription and replication (ethidium bromide), and function (rotenone, rhodamine 6G) blocked E2-induced G(1) to S transition. Reduction of E2-induced DNA synthesis in the presence of mitochondrial blockers occurred without influencing the level of ATP. Additionally, the mitochondrial blockers inhibited the E2-induced expression of early cell cycle genes such as cyclins D1, D3, E1, E2, and B2. NAC or rotenone reduced E2-induced cyclin D1 expression. Furthermore, E2-induced binding of AP-1 and CREB to the TRE and CRE response sequences, respectively, in the promoter of cyclin D1 was inhibited by NAC or rotenone. In addition, E2-induced expression of PCNA, PRC1, and bcl-2 were inhibited by mitochondrial blockers. These data indicate that E2-induced mtROS are involved in the regulation of early G(1)-phase progression. Since neither antioxidants nor mitochondrial blockers used in this study are reported to bind the estrogen receptor (ER), our findings suggest that E2-induced mtROS modulates G(1) to S transition and some of the early G(1) genes through a nongenomic, ER-independent signaling pathway. Thus, our results suggest (1) a new paradigm that estrogen-induced mitochondrial oxidants control the early stage of cell cycle progression and (2) provide the basis for the discovery of novel antioxidant-based drugs or antioxidant gene therapies for the prevention and treatment of estrogen-dependent breast cancer.	Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA; Florida Int Univ, Robert Stempel Sch Publ Hlth, Miami, FL 33199 USA	University of Alabama System; University of Alabama Birmingham; State University System of Florida; Florida International University	Roy, D (corresponding author), Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA.	Droy@fiu.edu	Singh, Kamaleshwar Prasad/AAE-9166-2020	Felty, Quentin/0000-0002-7151-0441	NCI NIH HHS [CA 4788] Funding Source: Medline; NIEHS NIH HHS [ES10851] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arteaga E, 2003, MENOPAUSE, V10, P142, DOI 10.1097/00042192-200310020-00005; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Chen JQ, 2004, ANN NY ACAD SCI, V1028, P258, DOI 10.1196/annals.1322.030; Chen JQ, 2004, J CELL BIOCHEM, V93, P358, DOI 10.1002/jcb.20178; Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Du Mond JW, 2001, INT J ONCOL, V18, P623; DuMond JW, 2001, ONCOL REP, V8, P899; Felty Q, 2005, MED HYPOTHESES, V64, P133, DOI 10.1016/j.mehy.2003.12.056; Felty Quentin, 2005, J Carcinog, V4, P1, DOI 10.1186/1477-3163-4-1; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Galli S, 2003, CANCER RES, V63, P6370; Harris RE, 2003, CANCER RES, V63, P6096; HERBER B, 1994, ONCOGENE, V9, P1295; Honore S, 2003, EXP CELL RES, V285, P59, DOI 10.1016/S0014-4827(02)00038-1; *IARC WORK GROUP, 1999, MON EV HORM CONTR PO, P399; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Kim MR, 2003, BIOCHEM BIOPH RES CO, V304, P119, DOI 10.1016/S0006-291X(03)00547-3; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MADDAIAH VT, 1973, J BIOL CHEM, V248, P4263; Maruyama T, 1999, ENDOCRINOLOGY, V140, P365, DOI 10.1210/en.140.1.365; Menon SG, 2003, CANCER RES, V63, P2109; *NAT TOX PROGR, 2002, FED REP CARC, P77283; Pan-Zhou XR, 2000, ANTIMICROB AGENTS CH, V44, P496, DOI 10.1128/AAC.44.3.496-503.2000; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Planas-Silva MD, 1999, CANCER RES, V59, P4788; Ramachandran C, 2000, ANTICANCER RES, V20, P3759; Roy D, 2004, CURR GENOMICS, V5, P245, DOI 10.2174/1389202043349471; ROY D, 1988, J BIOL CHEM, V263, P3646; Roy D., 2002, RECENT RES DEV STERO, V3, P1; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Uchimaru K, 1997, BLOOD, V89, P965, DOI 10.1182/blood.V89.3.965; VANDENBOGERT C, 1986, CANCER LETT, V32, P41, DOI 10.1016/0304-3835(86)90037-6; WANG TTY, 1995, CANCER RES, V55, P2487; Wei QY, 1997, CANCER RES, V57, P1673; Williams AJ, 1999, HUM MOL GENET, V8, P1691, DOI 10.1093/hmg/8.9.1691	49	74	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4883	4893		10.1038/sj.onc.1208667	http://dx.doi.org/10.1038/sj.onc.1208667			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897899				2022-12-17	WOS:000230646500002
J	Radke, S; Pirkmaier, A; Germain, D				Radke, S; Pirkmaier, A; Germain, D			Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer	ONCOGENE			English	Article						ubiquitin; F-box protein; breast cancer; Skp2; p27	UBIQUITIN LIGASE SUBUNIT; S-PHASE; DEGRADATION; PROTEOLYSIS; P27(KIP1); P27; P45(SKP2); CARCINOMA	Skp2 is an F-box protein involved in the ubiquitination and subsequent degradation of the cyclin-dependent kinase (Cdk) inhibitor p27. Skp2 has been reported to be overexpressed in a variety of cancer types and to correlate with poor prognosis. We have identified a novel isoform of Skp2 we named Skp2B, which differs from Skp2 only in the C-terminal domain and unlike Skp2 localizes to the cytoplasm. Here, we describe the relative expression of both Skp2 and Skp2B in breast cancer cell lines and in primary breast cancers using quantitative real time RT-PCR. We show that Skp2B mRNA is expressed 10-fold less than Skp2 mRNA in the immortalized but non-transformed breast cell line, 184B5. However, Skp2B is overexpressed as frequently as Skp2, and to higher levels than Skp2 in breast cancer cell lines and primary cancers. Further, we show that cytoplasmic staining is frequent in primary breast cancers. In addition, we found that xenografts expressing Skp2B grow faster than xenografts expressing low levels of Skp2B, and that this effect is independent of p27 degradation. These findings therefore suggest that Skp2B overexpression is also observed in breast cancers and identify Skp2B as a putative oncogene.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA; Peter MacCallum Canc Ctr, Trescowthick Res Labs, Melbourne, Vic 3002, Australia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Peter Maccallum Cancer Center	Germain, D (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	doris.germain@mssm.edu						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dowen SE, 2003, INT J CANCER, V105, P326, DOI 10.1002/ijc.11066; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Masuda T, 2003, CLIN CANCER RES, V9, P5693; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Penin RM, 2002, MODERN PATHOL, V15, P1227, DOI 10.1097/01.MP.0000036589.99516.D6; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	24	74	79	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3448	3458		10.1038/sj.onc.1208328	http://dx.doi.org/10.1038/sj.onc.1208328			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15782142				2022-12-17	WOS:000229038800007
J	Spender, LC; Whiteman, HJ; Karstegl, CE; Farrell, PJ				Spender, LC; Whiteman, HJ; Karstegl, CE; Farrell, PJ			Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells	ONCOGENE			English	Article						RUNX3/ RUNX1/EBNA-2; Epstein-Barr virus; B cells	EPSTEIN-BARR-VIRUS; ACUTE MYELOID-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; VIRAL NUCLEAR ANTIGEN-2; ACTIVATED NOTCH1; GENE-EXPRESSION; FAMILY-MEMBERS; GASTRIC-CANCER; AML1; REPRESSION	RUNX transcription factors are important in development and in numerous types of human cancer. They act as either transcriptional activators or repressors and can be proto-oncogenes or tumour suppressors. Understanding their regulation and interaction may explain how RUNX factors contribute to such different and often opposing biological processes. We show that RUNX3 regulates RUNX1 expression, contributing to the mutually exclusive expression of RUNX3 and RUNX1 in human B lymphoid cell lines. RUNX3 repressed the RUNX1 P1 promoter by binding specifically to conserved RUNX sites near the transcription start of the promoter. siRNA inhibition of RUNX3 in lymphoblastoid cells resulted in increased RUNX1 expression, indicating that continuous expression of physiological levels of RUNX3 is required to maintain repression. Furthermore, expression of RUNX3 was required for efficient proliferation of B cells immortalized by Epstein-Barr virus. Cross-regulation between different RUNX family members is therefore a means of controlling RUNX protein expression and must now be considered in the interpretation of pathological changes due to loss of RUNX3 tumour suppressor function or following gene duplication or translocation events.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Farrell, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.	p.farrell@imperial.ac.uk		Farrell, Paul/0000-0002-6754-9351; Whiteman, Hannah/0000-0001-6275-6135				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Bernardin F, 2002, CANCER BIOL THER, V1, P492, DOI 10.4161/cbt.1.5.163; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hofelmayr H, 1999, J VIROL, V73, P2770; Hofelmayr H, 2001, J VIROL, V75, P2033, DOI 10.1128/JVI.75.5.2033-2040.2001; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Javed A, 2000, J CELL SCI, V113, P2221; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lebestky T, 2003, GENE DEV, V17, P348, DOI 10.1101/gad.1052803; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; Martensson A, 2001, EUR J IMMUNOL, V31, P3165, DOI 10.1002/1521-4141(200111)31:11<3165::AID-IMMU3165>3.0.CO;2-N; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; Shi MJ, 1998, J IMMUNOL, V161, P6751; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spender LC, 2002, J VIROL, V76, P4919, DOI 10.1128/JVI.76.10.4919-4927.2002; Strobl LJ, 2000, J VIROL, V74, P1727, DOI 10.1128/JVI.74.4.1727-1735.2000; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wotton S, 2002, CANCER RES, V62, P7181; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200	49	74	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1873	1881		10.1038/sj.onc.1208404	http://dx.doi.org/10.1038/sj.onc.1208404			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688019				2022-12-17	WOS:000227542000006
J	Scherberich, A; Tucker, RP; Degen, M; Brown- Luedi, M; Andres, AC; Chiquet- Ehrismann, R				Scherberich, A; Tucker, RP; Degen, M; Brown- Luedi, M; Andres, AC; Chiquet- Ehrismann, R			Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38(MAPK) activity for BMP-2 and TNF-alpha induced expression in vitro	ONCOGENE			English	Article						tumor stroma; extracellular matrix; breast cancer; p38(MAPK); alpha 8 integrin	ACTIVATED PROTEIN-KINASE; C SPLICE VARIANTS; BREAST-CANCER; NECROSIS-FACTOR; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; GROWTH-FACTOR; CELL-LINES; HA-RAS; P38	Tenascins represent a family of extracellular matrix glycoproteins with distinctive expression patterns. Here we have analyzed the most recently described member, tenascin-W, in breast cancer. Mammary tumors isolated from transgenic mice expressing hormone-induced oncogenes reveal tenascin-W in the stroma around lesions with a high likelihood of metastasis. The presence of tenascin-W was correlated with the expression of its putative receptor, alpha8 integrin. HC11 cells derived from normal mammary epithelium do not express alpha8 integrin and fail to cross tenascin-W-coated filters. However, 4T1 mammary carcinoma cells do express alpha8 integrin and their migration is stimulated by tenascin-W. The expression of tenascin-W is induced by BMP-2 but not by TGF-beta1, though the latter is a potent inducer of tenascin-C. The expression of tenascin-W is dependent on p38(MAPK) and JNK signaling pathways. Since preinflammatory cytokines also act through p38MAPK and JNK signaling pathways, the possible role of TNF-alpha in tenascin-W expression was also examined. TNF-alpha induced the expression of both tenascin-W and tenascin-C, and this induction was p38(MAPK)- and cyclooxygenase-dependent. Our results show that tenascin-W may be a useful diagnostic marker for breast malignancies, and that the induction of tenascin-W in the tumor stroma may contribute to the invasive behavior of tumor cells.	Friedrich Miescher Inst, Novartis Res Fdn, CH-4058 Basel, Switzerland; Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; Univ Bern, Dept Clin Res, Fac Med, CH-3004 Bern, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis; University of California System; University of California Davis; University of Bern; University of Geneva	Chiquet- Ehrismann, R (corresponding author), Friedrich Miescher Inst, Novartis Res Fdn, Maulbeerstr 66, CH-4058 Basel, Switzerland.	ruth.chiquet@fmi.ch	Scherberich, Arnaud/H-9554-2019; Degen, Martin/H-5791-2013	Scherberich, Arnaud/0000-0003-3468-6955; Degen, Martin/0000-0002-4356-3714				Adams M, 2002, CANCER RES, V62, P3289; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P1085, DOI 10.1016/j.biocel.2004.01.007; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P986, DOI 10.1016/j.biocel.2003.12.002; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Fischer D, 1997, MOL BIOL CELL, V8, P2055, DOI 10.1091/mbc.8.10.2055; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Geffrotin C, 2000, BBA-GEN SUBJECTS, V1524, P196, DOI 10.1016/S0304-4165(00)00158-6; Goepel C, 2000, GYNECOL ONCOL, V79, P372, DOI 10.1006/gyno.2000.5978; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Hasegawa K, 1997, ACTA NEUROPATHOL, V93, P431, DOI 10.1007/s004010050636; Huang WT, 2001, CANCER RES, V61, P8586; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.0.CO;2-G; Kaya H, 2002, EUR J GYNAECOL ONCOL, V23, P261; Latijnhouwers MAHE, 1998, MATRIX BIOL, V17, P305, DOI 10.1016/S0945-053X(98)90083-X; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; LI F, 1994, INT J CANCER, V59, P560, DOI 10.1002/ijc.2910590421; Liu LX, 2002, WORLD J GASTROENTERO, V8, P631, DOI 10.3748/wjg.v8.i4.631; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; MALIK STA, 1990, EUR J CANCER, V26, P1031, DOI 10.1016/0277-5379(90)90044-T; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; Munarini N, 2002, J CELL SCI, V115, P25; Neidhardt J, 2003, MOL CELL NEUROSCI, V23, P193, DOI 10.1016/S1044-7431(03)00012-5; Nikolova Z, 1998, J CELL SCI, V111, P2741; Ocvirk J, 2000, MELANOMA RES, V10, P253, DOI 10.1097/00008390-200010030-00007; Pouliot F, 2003, CANCER RES, V63, P277; QIN ZH, 1993, J EXP MED, V178, P355, DOI 10.1084/jem.178.1.355; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Scherberich A, 2004, J CELL SCI, V117, P571, DOI 10.1242/jcs.00867; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Schultz RM, 2003, PROG DRUG RES, V60, P59; Schwalbe M, 2003, INT J ONCOL, V23, P89; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Vinals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014-5793(01)03236-7; Weber P, 1998, J NEUROBIOL, V35, P1; Xiong SB, 2001, CANCER RES, V61, P1727; Zweers MC, 2004, J INVEST DERMATOL, V122, P885, DOI 10.1111/j.0022-202X.2004.22401.x	43	74	81	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1525	1532		10.1038/sj.onc.1208342	http://dx.doi.org/10.1038/sj.onc.1208342			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15592496				2022-12-17	WOS:000227218200005
J	Yau, TO; Chan, CY; Chan, KL; Lee, MF; Wong, CM; Fan, ST; Ng, IOL				Yau, TO; Chan, CY; Chan, KL; Lee, MF; Wong, CM; Fan, ST; Ng, IOL			HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing	ONCOGENE			English	Article						HDPR1; Dapper; beta-catenin; WNT/beta-catenin signaling; JNK signaling	BETA-CATENIN; CYCLIN D1; C-JUN; DISHEVELLED OVEREXPRESSION; MATRIX METALLOPROTEINASE-1; TRANSCRIPTIONAL ACTIVITY; WNT PATHWAY; E-CADHERIN; EXPRESSION; CANCER	Oncogenic activation of the WNT/beta-catenin signaling pathway is common in hepatocellular carcinoma (HCC). Dishevelled (Dvl), a key activator of the pathway, inhibits the adenomatous polyposis coli complex, and this leads to the accumulation of beta-catenin and promotes tumorigenesis. Recently, a novel inhibitor of Dishevelled, namely Dapper (Dpr), was isolated in Xenopus. To explore whether HDPR1, the human homologue of Dpr, has an anti-oncogenic role in hepatocarcinogenesis, we studied the expression of this gene in HCCs. We found that there were two alternatively spliced transcripts of HDPR1, designated as alpha and beta forms, in human liver. Downregulation of the gene expression was observed in 31 (43%) of the 72 human HCC samples using the primer pair that amplified both transcripts. Furthermore, the HDPR1alpha was downregulated in 42 (58%) of 72 human HCCs and the downregulation significantly correlated with accumulation of beta-catenin. Also, downregulation of HDPR1 by RNA interference in HLE cells led to cytoplasmic accumulation of beta-catenin. Furthermore, a CpG island located at the promoter region and exon 1 of the HDPR1 gene was methylated in 22 (51%) of human HCCs. We showed that downregulation of HDPR1, in hepatoma cell lines, was associated with methylation of this CpG island using bisulfite sequencing and 5-aza-2'-deoxycytidine demethylation experiment. In addition to methylation-mediated downregulation of HDPR1, allelic loss (13-28% of informative cases) was detected using microsatellite markers flanking the HDPR1 locus. To conclude, downregulation of HDPR1 is common in HCCs, frequently involves hypermethylation of the promoter region, and allelic loss of the HDPR1 locus may also play a role.	Univ Hong Kong, Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Ctr Study Liver Dis, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Ng, IOL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Room 127B,Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.	iolng@hku.hk	WONG, Chun-Ming/A-6739-2009; Fan, Sheung Tat/C-4138-2009	WONG, Chun-Ming/0000-0002-2497-7858; Ng, Irene Oi-lin/0000-0001-7532-2029				Chan CF, 2004, CLIN CANCER RES, V10, P4140, DOI 10.1158/1078-0432.CCR-03-0574; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Katoh M, 2003, INT J ONCOL, V22, P907; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Miyoshi Y, 1998, CANCER RES, V58, P2524; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Okazaki I, 1997, HEPATOLOGY, V25, P580, DOI 10.1002/hep.510250315; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Polakis P, 2000, GENE DEV, V14, P1837; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Sugioka Y, 2004, INT J CANCER, V109, P867, DOI 10.1002/ijc.20095; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Theise Neil D, 2002, Clin Liver Dis, V6, P497, DOI 10.1016/S1089-3261(02)00006-5; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459	31	74	91	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1607	1614		10.1038/sj.onc.1208340	http://dx.doi.org/10.1038/sj.onc.1208340			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15580286				2022-12-17	WOS:000227218200014
J	Kang, HJ; Nam, SW; Kim, HK; Rhee, H; Kim, NG; Kim, HY; Hyung, WJ; Noh, SH; Kim, JH; Yun, CO; Liu, ET; Kim, HG				Kang, HJ; Nam, SW; Kim, HK; Rhee, H; Kim, NG; Kim, HY; Hyung, WJ; Noh, SH; Kim, JH; Yun, CO; Liu, ET; Kim, HG			Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors	ONCOGENE			English	Article						gastrointestinal stromal tumors; KIT; PDGFRA; molecular classification; oligonucleotide microarray	OF-FUNCTION MUTATIONS; C-KIT; TYROSINE KINASES; PHOSPHORYLATION; PROTEIN; CELLS; PROLIFERATION; INHIBITION; STATS; OCCUR	Activating mutations of KIT and platelet-derived growth factor receptor alpha (PDGFRA) are known to be alternative and mutually exclusive genetic events in the development of gastrointestinal stromal tumors (GISTs). We examined the effect of the mutations of these two genes on the gene expression pro. le of 22 GISTs using the oligonucleotide microarray. Mutations of KIT and PDGFRA were found in 17 cases and three cases, respectively. The remaining two cases had no detectable mutations in either gene. The mutation status of KIT and PDGFRA was directly related to the expression levels of activated KIT and PDGFRA, and was also related to the different expression levels of activated proteins that play key roles in the downstream of the receptor tyrosine kinase III family. To evaluate the impact of mutation status and the importance of the type of mutation in gene expression and clinical features, microarray-derived data from 22 GISTs were interpreted using a principal component analysis (PCA). Three relevant principal component representing mutation of KIT, PDGFRA and chromosome 14q deletion were identified from the interpretation of the oligonucleotide microarray data with PCA. After supervised analysis, there was at least a two fold difference in expression between GISTs with KIT and PDGFRA mutation in 70 genes. Our findings demonstrate that mutations of KIT and PDGFRA affect differential activation and expression of some genes, and can be used for the molecular classification of GISTs.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Seoul 120752, South Korea; Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137710, South Korea; Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul 120752, South Korea; Genome Inst Singapore, Singapore 138672, Singapore	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Catholic University of Korea; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Kim, HG (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, 134 Sichon Dong,CPO Box 8044, Seoul 120752, South Korea.	hkyonsei@yumc.yonsei.ac.kr	Liu, Edison/C-4141-2008; Yun, Chae-Ok/P-3698-2015	Yun, Chae-Ok/0000-0002-9466-4531; Kim, Haeryoung/0000-0002-4205-9081; Noh, Sung Hoon/0000-0003-4386-6886; Hyung, Woo Jin/0000-0002-8593-9214; Kim, Hyunki/0000-0003-2292-5584				Allander SV, 2001, CANCER RES, V61, P8624; Antonescu CR, 2004, CLIN CANCER RES, V10, P3282, DOI 10.1158/1078-0432.CCR-03-0715; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Choi YR, 2003, CANCER RES, V63, P2188; El-Rifai W, 1998, ANN CHIR GYNAECOL FE, V87, P287; El-Rifai W, 2000, GENE CHROMOSOME CANC, V27, P387, DOI 10.1002/(SICI)1098-2264(200004)27:4<387::AID-GCC8>3.0.CO;2-C; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hirota Seiichi, 2000, Journal of Gastroenterology, V35, P75; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOSEPH LD, 1997, SCIENCE, V278, P680; Kim NG, 2000, INT J CANCER, V85, P633, DOI 10.1002/(SICI)1097-0215(20000301)85:5<633::AID-IJC6>3.3.CO;2-X; Kindblom LG, 1998, AM J PATHOL, V152, P1259; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; LEWIN KJ, 1992, GASTROINTESTINAL PAT, P284; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Miettinen M, 2002, EUR J CANCER, V38, pS39, DOI 10.1016/S0959-8049(02)80602-5; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Rubin BP, 2001, CANCER RES, V61, P8118; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SUBRAMANIAN S, 2004, ONCOGENE; Taniguchi M, 1999, CANCER RES, V59, P4297; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Zhang CY, 1996, MOL PHARMACOL, V50, P864	41	74	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1066	1074		10.1038/sj.onc.1208358	http://dx.doi.org/10.1038/sj.onc.1208358			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690055				2022-12-17	WOS:000226749200012
J	Lodygin, D; Diebold, J; Hermeking, H				Lodygin, D; Diebold, J; Hermeking, H			Prostate cancer is characterized by epigenetic silencing of 14-3-3 sigma expression	ONCOGENE			English	Article						epigenetic silencing; CpG methylation; tumor suppressor; p53; 14-3-3 sigma; prostate cancer	HISTONE DEACETYLASE INHIBITION; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; CELL CARCINOMA; EXPRESSION; ADENOCARCINOMA; TUMORIGENESIS; DEMETHYLATION; INACTIVATION; RECEPTOR	In order to identify tumor suppressive genes silenced by CpG methylation in prostate carcinoma (PCa), we determined genome-wide expression changes after pharmacological reversal of CpG methylation-mediated transcriptional repression in three PCa cell lines using microarray analysis. Thereby, epigenetic silencing of the 14-3-3sigma gene was detected in the cell line LNCaP. 14-3-3sigma encodes a p53-regulated inhibitor of cell cycle progression. Laser microdissection was used to isolate different cell types present in diseased prostatic tissue. Subsequent methylation-specific PCR analysis showed CpG methylation of 14-3-3sigma in all 41 primary PCa samples analysed, which was accompanied by a decrease or loss of 14-3-3sigma protein expression. In contrast, normal prostate epithelial and benign prostate hyperplasia cells showed high levels of 14-3-3sigma expression. PCa-precursor lesions (prostatic intraepithelial neoplasia) also displayed decreased levels of 14-3-3sigma expression in luminal cells, which are known to contain shortened telomeres. RNA interference-mediated inactivation of 14-3-3sigma compromised a DNA damage-induced G(2)/M arrest in the PCa cell line PC3. The generality of CpG methylation and downregulation of 14-3-3sigma expression in PCa suggests that it significantly contributes to the formation of PCa, potentially by allowing the escape from a DNA damage-induced arrest elicited by telomere shortening.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Munich, Inst Pathol, D-80337 Munich, Germany	Max Planck Society; University of Munich	Hermeking, H (corresponding author), Max Planck Inst Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	herme@biochem.mpg.de						Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kuzmin I, 2002, CANCER RES, V62, P3498; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854; Lodygin D, 2002, J CLIN INVEST, V110, P1717, DOI 10.1172/JCI200216588; Meeker AK, 2002, CANCER RES, V62, P6405; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; SAKR WA, 1994, IN VIVO, V8, P439; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Singal R, 2001, CANCER RES, V61, P4820; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	29	74	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9034	9041		10.1038/sj.onc.1208004	http://dx.doi.org/10.1038/sj.onc.1208004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489902				2022-12-17	WOS:000225492800004
J	Wei, L; Yang, Y; Zhang, X; Yu, Q				Wei, L; Yang, Y; Zhang, X; Yu, Q			Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis	ONCOGENE			English	Article						Src; anoikis; lung; cancer; tyrosine phosphorylation	TYROSINE KINASE-ACTIVITY; FOCAL ADHESION KINASE; HUMAN-COLON CARCINOMA; C-SRC; EPITHELIAL-CELLS; V-SRC; PREMALIGNANT EPITHELIA; PP60C-SRC ACTIVITY; GENE-PRODUCT; CANCER CELLS	Src plays an important role in cell proliferation, differentiation, adhesion, and migration. Altered Src activity has been strongly implicated in the development, growth, progression, and metastasis of human cancers. We have analysed the change and regulation of Src upon cell detachment in anoikis-resistant human lung adenocarcinoma cells and compared with that of relatively normal and anoikis-sensitive epithelial cells. We found that Src activity was increased in the anoikis-resistant lung tumor cells when they were detached and cultured in suspension. The detachment-induced Src activation in the tumor cells compensates for the loss of cell survival signals caused by disruption of cell-matrix interactions and contributes to anoikis resistance of the tumor cells. Pyk2, rather than PI 3K/Akt or Erk, appears to be the key downstream effecter of Src in mediating the cell survival signals. The increased Src activity is mainly due to the phosphorylation of Tyr-419, rather than the dephosphorylation of Tyr-530 of Src protein. PDGFR, not FAK or EGFR, appears to be the upstream protein tyrosine kinase responsible for the detachment-induced Src activation in the lung tumor cells. The increased Src activity upon cell detachment may contribute to the metastasis potential of malignant tumors.	Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Biochem, Boston, MA 02118 USA	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Boston University; Boston University	Yu, Q (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.	qyu@sibs.ac.cn			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059678] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59678] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; BJELFMAN C, 1990, CANCER RES, V50, P6908; Bjorge JD, 1996, BIOCHEM CELL BIOL, V74, P477, DOI 10.1139/o96-052; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; COLLETT MS, 1979, P NATL ACAD SCI USA, V76, P3159, DOI 10.1073/pnas.76.7.3159; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hisano C, 2003, CELL BIOL INT, V27, P415, DOI 10.1016/S1065-6995(03)00032-5; JACOBS C, 1983, CANCER RES, V43, P1696; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Ogata Y, 2003, HYPERTENSION, V41, P1156, DOI 10.1161/01.HYP.0000064342.30653.24; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; TAKESHIMA E, 1991, JPN J CANCER RES, V82, P1428, DOI 10.1111/j.1349-7006.1991.tb01816.x; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; Wei L, 2001, CANCER RES, V61, P2439; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1	53	74	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9052	9061		10.1038/sj.onc.1208091	http://dx.doi.org/10.1038/sj.onc.1208091			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489898				2022-12-17	WOS:000225492800006
J	Dai, JL; Wang, L; Sahin, AA; Broemeling, LD; Schutte, M; Pan, Y				Dai, JL; Wang, L; Sahin, AA; Broemeling, LD; Schutte, M; Pan, Y			NHERF (Na+/H+ Exchanger Regulatory Factor) gene mutations in human breast cancer	ONCOGENE			English	Article						spleen tyrosine kinase; NHERF; breast cancer; mutation; merlin; haploinsufficiency	TYROSINE KINASE; ALLELIC IMBALANCE; TUMOR; HAPLOINSUFFICIENCY; EZRIN; SYK; CARCINOGENESIS; SUPPRESSES; DELETION; REGIONS	Yeast two-hybrid screening was used to explore novel proteins that interact with a breast tumor or metastasis suppressor, SYK (spleen tyrosine kinase). The screening yielded NHERF (Na+/H+ exchanger regulatory factor, also known as NHERF1 or EBP-50) that binds to the interdomain B of SYK. NHERF is an estrogen-responsive gene that encodes an inhibitory factor for epithelial Na+/H+ exchanger isoform 3 (NHE3). We found intragenic mutation of the NHERF gene accompanied by loss of heterzygosity (LOH) in similar to3% (3/85) of breast cancer cell lines and primary breast tumors. Mutations occurred at the conserved PDZ domains at NHERF NH2-terminus that bound to SYK, or at its COOH-terminus motif that binds to MERLIN, the product of Neurofibromatosis 2 (NF2) tumor suppressor gene. NHERF tumorigenic mutations decreased or abolished its interaction with SYK or MERLIN, suggesting a pathway link among these three molecules that may play a critical role in mammary neoplastic progression. Primary breast tumors with LOH at the NHERF locus had clinical presentations of higher aggressiveness, indicating that deregulated NHERF signaling may be associated with disease progression. Moreover, the LOH was inversely correlated with SYK promoter methylation, suggesting that NHERF and SYK may transduce a common suppressive signal. Taken together, the results indicated NHERF to be a candidate tumor suppressor gene in human breast carcinoma that may be interconnected to the SYK and MERLIN suppressors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Erasmus MC, Josephine Nefkens Inst, Dept Med Oncol, Rotterdam, Netherlands	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Erasmus University Rotterdam; Erasmus MC	Dai, JL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 089,1515 Holcombe Blvd, Houston, TX 77030 USA.	jldai@mdanderson.org			NCI NIH HHS [R01 CA100278] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bartkova J, 1996, CANCER RES, V56, P5475; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; COUCH FJ, 2002, GENETIC BASIS HUMAN, P549; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Harkes IC, 2003, BRIT J CANCER, V89, P2289, DOI 10.1038/sj.bjc.6601448; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LUPULESCU A, 1993, EXP CLIN ENDOCRINOL, V101, P204, DOI 10.1055/s-0029-1211234; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Orsetti B, 1999, ONCOGENE, V18, P6262, DOI 10.1038/sj.onc.1203006; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; RADFORD DM, 1995, CANCER RES, V55, P3399; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; REIFENBERGER G, 1993, CANCER RES, V53, P2736; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Srivastava M, 2003, P NATL ACAD SCI USA, V100, P14287, DOI 10.1073/pnas.2235927100; Staff S, 2003, CANCER RES, V63, P4978; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Wang L, 2003, CANCER RES, V63, P4724; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; YAEGASHI S, 1995, JPN J CANCER RES, V86, P929, DOI 10.1111/j.1349-7006.1995.tb03003.x; Yuan YF, 2001, CANCER RES, V61, P5558	38	74	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8681	8687		10.1038/sj.onc.1207962	http://dx.doi.org/10.1038/sj.onc.1207962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467753				2022-12-17	WOS:000224988800014
J	Slavin, DA; Koritschoner, NP; Prieto, CC; Lopez-Diaz, FJ; Chatton, B; Bocco, JL				Slavin, DA; Koritschoner, NP; Prieto, CC; Lopez-Diaz, FJ; Chatton, B; Bocco, JL			A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function	ONCOGENE			English	Article						Kruppel-like; c-Jun; proliferation; TPA/ionomycin	TUMOR-SUPPRESSOR GENE; PROMOTER-BINDING PROTEIN; ZINC-FINGER PROTEIN; CELL-GROWTH; HA-RAS; ACTIVATION; EXPRESSION; KINASE; SP1; PROGRESSION	Kruppel-like transcription factors (KLFs) represent one of the most diverse set of regulators in vertebrate organisms. KLF family members are involved in cell proliferation and differentiation control in normal as well as in pathological situations. Here, we demonstrate that KLF6 behaves as a functional antagonist of the c-Jun proto-oncoprotein. Thus, KLF6 overexpression downregulated c-Jun-dependent transcription and a physical interaction between c-Jun and KLF6 was detected. Moreover, cell proliferation induced by c-Jun was significantly decreased by KLF6. The inhibition of c-Jun functions correlates directly with c-Jun protein degradation induced by KLF6. We also show that all KLF6 effects on c-Jun were largely dependent on phorbol ester (TPA/ionomycin) extracellular stimulation, which enhanced KLF6 nuclear translocation and transcriptional activity and modified its phosphorylation status. Our data are consistent with a novel mechanism of KLF6's role as an inhibitor of cell proliferation by counteracting the function of the c-Jun proto-oncoprotein involving enhanced c-Jun degradation by the proteasome-dependent pathway, and further reinforces KLF6 as a potential tumor suppressor gene product.	Natl Univ Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, CONICET,CIBICI, RA-5016 Cordoba, Argentina; Univ Strasbourg, Ecole Super Biotechnol Strasbourg, Strasbourg, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bocco, JL (corresponding author), Natl Univ Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, CONICET,CIBICI, Haya Torre & Medina Allende,Ciudad Univ, RA-5016 Cordoba, Argentina.	jbocco@fcq.unc.edu.ar	CHATTON, Bruno/R-3813-2019	Bocco, Jose Luis/0000-0002-9682-1270; CHATTON, Bruno/0000-0003-4515-7119				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; BISHOP JM, 1996, MOL ONCOLOGY; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blanchon L, 2001, MECH DEVELOP, V105, P185, DOI 10.1016/S0925-4773(01)00391-4; Bocco JL, 1996, ONCOGENE, V12, P1971; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Cook T, 2000, AM J PHYSIOL-GASTR L, V278, pG513, DOI 10.1152/ajpgi.2000.278.4.G513; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kojima S, 2000, BLOOD, V95, P1309; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laub F, 2001, MECH DEVELOP, V106, P167, DOI 10.1016/S0925-4773(01)00419-1; Lei L, 2001, DEVELOPMENT, V128, P1147; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; Muhlbauer KR, 2003, BRIT J CANCER, V89, P687, DOI 10.1038/sj.bjc.6601164; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Slavin D, 1999, BIOL REPROD, V61, P1586, DOI 10.1095/biolreprod61.6.1586; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	44	74	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8196	8205		10.1038/sj.onc.1208020	http://dx.doi.org/10.1038/sj.onc.1208020			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378003				2022-12-17	WOS:000224749500002
J	Brabek, J; Constancio, BS; Shin, NY; Pozzi, A; Weaver, AM; Hanks, SK				Brabek, J; Constancio, BS; Shin, NY; Pozzi, A; Weaver, AM; Hanks, SK			CAS promotes invasiveness of Src-transformed cells	ONCOGENE			English	Article						p130CAS; Src; cortactin; MMP-2; invasion; podosome	SPECIALIZED SURFACE PROTRUSIONS; CRK-ASSOCIATED SUBSTRATE; TYROSINE PHOSPHORYLATION; V-SRC; KINASE-ACTIVITY; DIFFERENTIAL REGULATION; EXTRACELLULAR-MATRIX; PODOSOME FORMATION; FAMILY KINASES; P130(CAS)	CAS ('Crk-associated substrate') is an Src substrate found at sites of integrin-mediated cell adhesion and linked to cell motility and survival. In this study, the involvement of CAS in oncogenic transformation was evaluated through analysis of mouse embryo fibroblast populations expressing an activated Src mutant, either in the presence or absence of CAS expression. CAS was not found to be a critical determinant of either Src-mediated morphologic transformation or anchorage-independent growth. However, CAS had a profound effect on other aspects of oncogenic Src function. CAS expression led to a substantial increase in the phosphotyrosine content of FAK and paxillin, supporting a role for CAS as a positive regulator of Src activity at integrin adhesion sites. Importantly, CAS expression resulted in a striking enhancement of the capacity of Src-transformed cells to invade through Matrigel. The increased invasiveness was associated with increased activation of matrix metalloproteinase MMP-2 and formation of large actin-rich podosomal aggregates appearing as ring and belt structures. Thus, elevated CAS-associated tyrosine phosphorylation signaling events occurring at sites of integrin-mediated cell adhesion can have a major role in the development of an invasive cell phenotype.	Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med Nephrol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Hanks, SK (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA.	steve.hanks@vanderbilt.edu	Brábek, Jan/J-9836-2017	Brábek, Jan/0000-0001-7754-7299; Lund, Sabata/0000-0002-6092-5131	NATIONAL CANCER INSTITUTE [R01CA094849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056018, P50DK039261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049882] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA94849-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK56018, P50 DK39261-16] Funding Source: Medline; NIGMS NIH HHS [R01 GM49882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Brabek J, 2002, BIOCHEM BIOPH RES CO, V296, P664, DOI 10.1016/S0006-291X(02)00884-7; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Chen Wen-Tien, 1994, Journal of Tissue Culture Methods, V16, P177, DOI 10.1007/BF01540646; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kaverina I, 2003, J CELL SCI, V116, P4915, DOI 10.1242/jcs.00818; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mizutani K, 2002, CANCER RES, V62, P669; Moissoglu K, 2003, J BIOL CHEM, V278, P47946, DOI 10.1074/jbc.M302720200; MONSKY WL, 1993, CANCER RES, V53, P3159; MUELLER SC, 1991, J CELL SCI, V99, P213; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Vincenti MP, 1998, MOL CARCINOGEN, V21, P194, DOI 10.1002/(SICI)1098-2744(199803)21:3<194::AID-MC7>3.0.CO;2-M; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200	44	74	75	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7406	7415		10.1038/sj.onc.1207965	http://dx.doi.org/10.1038/sj.onc.1207965			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15273716				2022-12-17	WOS:000224021400011
J	Scott, KA; Arnott, CH; Robinson, SC; Moore, RJ; Thompson, RG; Marshall, JF; Balkwill, FR				Scott, KA; Arnott, CH; Robinson, SC; Moore, RJ; Thompson, RG; Marshall, JF; Balkwill, FR			TNF-alpha regulates epithelial expression of MMP-9 and integrin alpha v beta 6 during tumour promotion. A role for TNF-alpha in keratinocyte migration?	ONCOGENE			English	Article						skin carcinogenesis; wound healing; epidermis; matrix metalloproteinase; TPA	NECROSIS-FACTOR-ALPHA; MOUSE SKIN CARCINOGENESIS; SQUAMOUS CARCINOMA-CELLS; GELATINASE-B; GENE-EXPRESSION; FACTOR RECEPTOR; HAIR-FOLLICLES; MESSENGER-RNA; MATRIX-METALLOPROTEINASE-9; GROWTH	Mice deficient in TNF-alpha (TNF-alpha(-/-) mice) are resistant to skin carcinogenesis and expression of MMP-9 is inhibited in TNF-alpha(-/-) mice during skin tumour development. In the early stages of tumour promotion, MMP-9 protein initially localized to the follicular epidermis but subsequently began to accumulate in the interfollicular epidermis of wild-type but not TNF-alpha(-/-) mice. Inhibition of TNF-alpha or MMP-9 function reduced keratinocyte migration in vitro. In addition, a deficiency of TNF-alpha delayed re-epithelialization in vivo and this correlated with reduced MMP-9 expression. Collectively, these data suggest that MMP-9 regulates keratinocyte migration in a TNF-alpha-dependent manner. Expression pro. ling of genes that control cell adhesion and migration revealed markedly lower levels of the integrin subunits alphav and beta6 in TNF-alpha(-/-) compared with wild-type keratinocytes in vitro. alphavbeta6 expression was upregulated by keratinocytes in vitro and during tumour promotion in vivo in a TNF-alpha-dependent manner. Furthermore, alphavbeta6 blockade significantly inhibited keratinocyte migration and TNF-alpha-stimulated MMP-9 expression in vitro. These data illustrate a novel TNF-alpha-dependent mechanism for the control of alphavbeta6 expression and suggest one pathway for TNF-alpha regulation of MMP-9. Increased MMP-9 and alphavbeta6 expression may stimulate epithelial cell migration during tumour formation and may be one mechanism whereby TNF-alpha acts as an endogenous tumour promoter.	Canc Res UK Canc Ctr, John Vane Sci Ctr, Dept Tumor Biol, London EC1M 6BQ, England; Canc Res UK Canc Ctr, John Vane Sci Ctr, Translat Oncol Lab, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London	Scott, KA (corresponding author), Canc Res UK Canc Ctr, John Vane Sci Ctr, Dept Tumor Biol, Charterhouse Sq, London EC1M 6BQ, England.	kate.scott@cancer.org.uk		Balkwill, Frances/0000-0002-5587-9759; Marshall, John/0000-0002-0494-2295				Arnott CH, 2002, ONCOGENE, V21, P4728, DOI 10.1038/sj.onc.1205588; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Binder RL, 1997, MOL CARCINOGEN, V20, P151, DOI 10.1002/(SICI)1098-2744(199709)20:1<151::AID-MC17>3.0.CO;2-0; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; Buck M, 1996, AM J PATHOL, V149, P195; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Frame S, 1998, PHILOS T ROY SOC B, V353, P839, DOI 10.1098/rstb.1998.0248; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; Hanemaaijer R, 2000, INT J CANCER, V86, P204, DOI 10.1002/(SICI)1097-0215(20000415)86:2<204::AID-IJC9>3.0.CO;2-6; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Kobayashi T, 2001, EMBO REP, V2, P604, DOI 10.1093/embo-reports/kve129; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Lee RH, 2000, WOUND REPAIR REGEN, V8, P547, DOI 10.1046/j.1524-475x.2000.00547.x; Liabakk NB, 1996, CANCER RES, V56, P190; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Mori R, 2002, FASEB J, V16, P963, DOI 10.1096/fj.01-0776com; Morris RJ, 2000, CANCER RES, V60, P226; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Murphy JE, 2003, J IMMUNOL, V170, P5697, DOI 10.4049/jimmunol.170.11.5697; Nakao S, 2003, J IMMUNOL, V170, P5704, DOI 10.4049/jimmunol.170.11.5704; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; Nielsen BS, 1996, INT J CANCER, V65, P57, DOI 10.1002/(SICI)1097-0215(19960103)65:1<57::AID-IJC10>3.0.CO;2-F; Papathoma AS, 2001, MOL CARCINOGEN, V31, P74, DOI 10.1002/mc.1042; Scott KA, 2000, BRIT J CANCER, V83, P1538, DOI 10.1054/bjoc.2000.1487; Scott KA, 2003, MOL CANCER THER, V2, P445; Steel JH, 1998, EUR J HISTOCHEM, V42, P143; Suganuma M, 1999, CANCER RES, V59, P4516; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V116, P898, DOI 10.1046/j.1523-1747.2001.01352.x; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Weeks BH, 2001, CANCER RES, V61, P7435; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	44	74	77	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2004	23	41					6954	6966		10.1038/sj.onc.1207915	http://dx.doi.org/10.1038/sj.onc.1207915			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15273742				2022-12-17	WOS:000223750700012
J	Sin, WC; Zhang, YP; Zhong, W; Adhikarakunnathu, S; Powers, S; Hoey, T; An, SZ; Yang, JX				Sin, WC; Zhang, YP; Zhong, W; Adhikarakunnathu, S; Powers, S; Hoey, T; An, SZ; Yang, JX			G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers	ONCOGENE			English	Article						human cancers; G protein-coupled receptors; GPR4; TDAG8; overexpression; tumorigenesis	CELL-PROLIFERATION; IDENTIFICATION; CLONING; TARGET; TRANSFORMATION; EXPRESSION; ACTIVATION; MECHANISMS; PATHWAYS; LIGANDS	The GPR4 subfamily consists of four G protein-coupled receptors that share significant sequence homology. In addition to GPR4, this subfamily includes OGR1, TDAG8 and G2A. G2A has previously been shown to be a potent transforming oncogene for murine 3T3 cells. Here we show that GPR4 also malignantly transforms NIH3T3 cells and that TDAG8 malignantly transforms the normal mammary epithelial cell line NMuMG. Overexpression of GPR4 or TDAG8 in HEK293 cells led to transcriptional activation from SRE- and CRE-driven promoters, independent of exogenously added ligand. TDAG8 and GPR4 are also overexpressed in a range of human cancer tissues. Our results suggest that GPR4 and TDAG8 overexpression in human tumors plays a role in driving or maintaining tumor formation.	Tularik Inc, Genom Div, Greenlawn, NY 11740 USA; Tularik Inc, Dept Biol, San Francisco, CA 94080 USA		Yang, JX (corresponding author), Tularik Inc, Genom Div, 266 E Pulaski Rd, Greenlawn, NY 11740 USA.	jyang@tularik.com		Powers, Scott/0000-0003-2769-1932				ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; AN SZ, 1995, FEBS LETT, V375, P121, DOI 10.1016/0014-5793(95)01196-L; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kyaw H, 1998, DNA CELL BIOL, V17, P493, DOI 10.1089/dna.1998.17.493; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; MAHADEVAN MS, 1995, GENOMICS, V30, P84, DOI 10.1006/geno.1995.0013; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nathanson NM, 2000, P NATL ACAD SCI USA, V97, P6245, DOI 10.1073/pnas.97.12.6245; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; RUSSO D, 1995, ONCOGENE, V11, P1907; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Torigoe T, 2002, ANTI-CANCER DRUG, V13, P237, DOI 10.1097/00001813-200203000-00005; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	32	74	82	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6299	6303		10.1038/sj.onc.1207838	http://dx.doi.org/10.1038/sj.onc.1207838			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221007				2022-12-17	WOS:000223399000014
J	Yin, F; Bruemmer, D; Blaschke, F; Hsueh, WA; Law, RE; Van Herle, AJ				Yin, F; Bruemmer, D; Blaschke, F; Hsueh, WA; Law, RE; Van Herle, AJ			Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells	ONCOGENE			English	Article						troglitazone; breast cancer cell; GADD45; JNK; p38; ERK1/2	ACTIVATED RECEPTOR-GAMMA; PROTEIN-KINASE ACTIVATION; PPAR-GAMMA; POSTTRANSCRIPTIONAL REGULATION; LIGAND TROGLITAZONE; GROWTH-INHIBITION; CYCLE ARREST; COLON-CANCER; IN-VITRO; STRESS	We previously reported that the PPARgamma agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells. To understand the mechanisms of antiproliferative and pro-apoptotic effects of TRO, we screened a limited DNA array containing 23 genes involved in regulating either the cell cycle and/or apoptosis. Four of the 23 genes screened exhibited regulation by TRO, with growth arrest and DNA damage-inducible gene 45 (GADD45) being the most strongly upregulated. TRO induced GADD45 mRNA expression in a time- and dose-dependent manner. Depletion of GADD45 by siRNA abrogated TRO-induced apoptosis in MCF-7 cells demonstrating the physiological relevance of GADD45 upregulation. Signaling pathways mediating TRO-induced GADD45 were also investigated. Several mitogen-activated protein kinase (MAPK) pathways were involved in the induction of GADD45 by TRO. Inhibition of the c-jun N-terminal kinase MAPK pathway by SP600125 partially abolished TRO-induced GADD45 mRNA, and protein expression and apoptosis. In contrast, inhibition of the p38 MAPK pathway by SB203580, or through overexpression of a dominant-negative mutant of p38 MAPK, augmented GADD45 mRNA induction and GADD45 promoter activation as well as cell apoptosis by TRO. Blockade of the extracellular signal-regulated kinase MAPK pathway by PD98059 also enhanced TRO's effects on GADD45 and apoptosis. Two other PPARgamma agonists pioglitazone and rosiglitazone did not induce GADD45 expression. Our finding of GADD45 induction by TRO may provide a new insight concerning the mechanisms for TRO's antiproliferative and pro-apoptotic effects in breast cancer cells.	Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, F (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, 900 Vet Ave,24-130 Warren Hall, Los Angeles, CA 90024 USA.	fyin@mednet.ucla.edu						Asou H, 1999, INT J ONCOL, V15, P1027; Bae MA, 2003, MOL PHARMACOL, V63, P401, DOI 10.1124/mol.63.2.401; Begum NM, 2002, INT J ONCOL, V20, P599; Bruemmer D, 2003, CIRC RES, V93, pE38, DOI 10.1161/01.RES.0000088344.15288.E6; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chang TH, 2000, CANCER RES, V60, P1129; Chen C, 1998, AM J HEALTH-SYST PH, V55, P905, DOI 10.1093/ajhp/55.9.905; Chen F, 2001, ONCOGENE, V20, P3585, DOI 10.1038/sj.onc.1204442; CHEN IT, 1995, ONCOGENE, V11, P1931; Chitturi S, 2002, SEMIN LIVER DIS, V22, P169, DOI 10.1055/s-2002-30102; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; Hisatake J, 2000, CANCER RES, V60, P5494; Huin C, 2002, BIOL CELL, V94, P15, DOI 10.1016/S0248-4900(01)01178-9; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kostrubsky VE, 2000, DRUG METAB DISPOS, V28, P1192; Kubota T, 1998, CANCER RES, V58, P3344; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Mossner R, 2002, J INVEST DERMATOL, V119, P576, DOI 10.1046/j.1523-1747.2002.01861.x; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Otto C, 2002, PHARMACOGENOMICS, V3, P99, DOI 10.1517/14622416.3.1.99; Palakurthi SS, 2001, CANCER RES, V61, P6213; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rumi MAK, 2001, BRIT J CANCER, V84, P1640, DOI 10.1054/bjoc.2001.1821; Sakaue M, 1999, MOL PHARMACOL, V55, P668; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Sugimura A, 1999, BIOCHEM BIOPH RES CO, V261, P833, DOI 10.1006/bbrc.1999.1049; Takahashi S, 2001, CANCER RES, V61, P1187; Takashima T, 2001, INT J ONCOL, V19, P465; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906	47	74	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4614	4623		10.1038/sj.onc.1207598	http://dx.doi.org/10.1038/sj.onc.1207598			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064713				2022-12-17	WOS:000221799000011
J	Mettus, RV; Rane, SG				Mettus, RV; Rane, SG			Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice	ONCOGENE			English	Article						cyclin-dependent kinase 4; pancreas; fertility	CELL; DEFICIENT; DYSFUNCTION	Cyclin-dependent kinase 4 (Cdk4) and Cdk6, and later Cdk2, in association with their specific cyclin partners, regulate the G1 to S phase cell cycle transition of mammalian cells by phosphorylation of retinoblastoma (Rb) family proteins. Phosphorylation of Rb results in the release of S-phase specific transcription factors; cell cycle-promoting gene expression, and advancement of the cell cycle. Loss of Cdk4 by homologous-targeted disruption leads to a delay in S-phase entry in serum-stimulated mouse embryo fibroblast (MEF) cultures. Homozygous Cdk4-deficient mice display defects in weight gain, fertility and hypoproliferation of specific endocrine cells of the pituitary and pancreas, the latter of which results in a diabetes-like phenotype. In contrast, inheritance of the p16(Ink4a)-insensitive Cdk4(R24C) mutation leads to spontaneous transformation of MEF cultures in vitro and, in vivo, hyperproliferative disorders that progress to cancer. In this manuscript, we report characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice. We observe that, whereas Cdk4 is dispensable for early pancreatic development, normal Cdk4 expression is critical for optimal growth of the organism. Also, we observe that loss of Cdk4 may result in insulin insensitivity, implicating an additional role of Cdk4 in beta-cell function, in addition to its role in beta-cell proliferation. Further, we demonstrate that loss of Cdk4 leads to an age-dependent defect in spermatogenesis and disruption in the timing of the estrus cycle. Taken together, our results indicate that the overall defects in growth, fertility and pancreatic development in Cdk4-deficient mice may be a combination of cell-type specific defects and altered glucose metabolism, as a result of defects in postnatal pancreatic development.	NCI, Cell Cycle & Human Dis Grp, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Rane, SG (corresponding author), NCI, Cell Cycle & Human Dis Grp, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.	sushil_rane@nih.gov			NCI NIH HHS [K22CA90790-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANN RP, 1976, BIOL REPROD, V15, P586, DOI 10.1095/biolreprod15.5.586; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; BENTON L, 1995, J STEROID BIOCHEM, V53, P61, DOI 10.1016/0960-0760(95)00022-R; Bouwens L, 1996, VIRCHOWS ARCH, V427, P553; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Mauvais-Jarvis F, 2002, CLIN ENDOCRINOL, V57, P1, DOI 10.1046/j.1365-2265.2002.01563.x; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; MURRAY FT, 1985, HORM METAB RES, V17, P495, DOI 10.1055/s-2007-1013588; Murray J, 2001, COMB CHEM HIGH T SCR, V4, P265; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Rane SG, 2000, FRONT BIOSCI, V5, pD1, DOI 10.2741/Rane; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sherr CJ, 2000, CANCER RES, V60, P3689; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	24	74	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8413	8421		10.1038/sj.onc.1206888	http://dx.doi.org/10.1038/sj.onc.1206888			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627982				2022-12-17	WOS:000186650300005
J	Ciechomska, I; Pyrzynska, B; Kazmierczak, P; Kaminska, B				Ciechomska, I; Pyrzynska, B; Kazmierczak, P; Kaminska, B			Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells	ONCOGENE			English	Article						Akt signalling; Forkhead transcription factor; Fas/FasL; apoptosis; cyclosporin A; glioma cells	NF-KAPPA-B; AP-1 TRANSCRIPTION FACTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; LIGAND EXPRESSION; TUMOR-SUPPRESSOR; CYCLOSPORINE-A; T-CELLS; CAENORHABDITIS-ELEGANS	Activation of Akt signalling pathway is frequently found in glioma cells and may contribute to their resistance to undergo apoptosis in response to conventional therapies. We found that cyclosporin A (CsA) induces apoptosis of C6 glioma cells, which is associated with transcriptional activation of fasL. In the present paper, we investigated an involvement of Akt signalling in the regulation of FasL expression in CsA-induced apoptosis. We demonstrated that the level of active Akt decreases significantly after CsA treatment, which results in the decrease of Forkhead phosphorylation and its translocation to the nucleus. It correlated with an increase of binding to the Forkhead-responsive element FHRE from the FasL promoter, as demonstrated by gel-shift assays. Although treatment with LY294002, a specific inhibitor of PI3 K, decreased the phosphorylation of Akt and increased Fkhr translocation to the nucleus, these events were not sufficient to induce FasL expression and apoptosis of C6 glioma cells. Interference with Akt/Forkhead signalling by membrane-targeted Akt or removal of the FKHR-binding sites from the FasL promoter significantly abolished its activation. These results indicate that downregulation of Akt signalling and activation of Forkhead is a prerequisite for the induction of FasL promoter. It may be clinically important for pharmacological intervention in gliomas.	M Nencki Inst Expt Biol, Dept Cellular Biochem, Lab Transcript Regulat, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kaminska, B (corresponding author), M Nencki Inst Expt Biol, Dept Cellular Biochem, Lab Transcript Regulat, 3 Pasteur Str, PL-02093 Warsaw, Poland.		Kaminska, Bozena/H-4592-2011; Pyrzyńska, Beata/T-2187-2018; Kaminska, Bozena/B-2915-2014; Kaźmierczak, Piotr/AAD-7059-2021; Ciechomksa, Iwona/R-4706-2016	Kaminska, Bozena/0000-0002-2642-4616; Pyrzyńska, Beata/0000-0002-0490-618X; Kaźmierczak, Piotr/0000-0002-4060-3055; Ciechomksa, Iwona/0000-0002-8068-0020				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Galanis E, 2000, BRIT J CANCER, V82, P1371, DOI 10.1054/bjoc.1999.1075; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERMANSON M, 1992, CANCER RES, V52, P3213; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hosli P, 1998, ANN ONCOL, V9, P589; KAMINSKA B, 1994, EUR J NEUROSCI, V6, P1558, DOI 10.1111/j.1460-9568.1994.tb00546.x; Kaminska B, 1996, J NEUROSCI, V16, P3968; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawaguchi S, 2000, NEUROSURGERY, V46, P431, DOI 10.1097/00006123-200002000-00030; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mosieniak G, 1998, J NEUROCHEM, V71, P134; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ozes ON, 1999, NATURE, V401, P82; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SAXENA A, 1992, ONCOGENE, V7, P243; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Shinoura N, 1998, HUM GENE THER, V9, P1983, DOI 10.1089/hum.1998.9.14-1983; Sonoda Y, 2001, CANCER RES, V61, P6674; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; TACHIBANA O, 1995, CANCER RES, V55, P5528; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200	75	74	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7617	7627		10.1038/sj.onc.1207137	http://dx.doi.org/10.1038/sj.onc.1207137			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576824				2022-12-17	WOS:000186113000009
J	Ruivenkamp, C; Hermsen, M; Postma, C; Klous, A; Baak, J; Meijer, G; Demant, P				Ruivenkamp, C; Hermsen, M; Postma, C; Klous, A; Baak, J; Meijer, G; Demant, P			LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21	ONCOGENE			English	Article						PTPRJ; colorectal cancer; LOH; CGH; 18q12-21	MOUSE	Recently, the gene PTPRJ (protein tyrosine phosphatase receptor type J) was identified as the candidate gene for the mouse colon cancer susceptibility locus Scc1. Its human homologue PTPRJ is frequently deleted in several cancer types, including colorectal cancer. To elucidate the role of PTPRJ loss in different stages of colorectal cancer and in its pathways of progression, we expanded the previously published comparative genomic hybridization results with novel data on loss of heterozygosity (LOH) at the PTPRJ locus. We identified a strong association between the LOH of PTPRJ and the loss of chromosomal region 18q12-21 (P=0.009). This observation is specific for progressed colorectal adenomas, suggesting that an interaction between LOH of PTPRJ and loss of 18q12-21 may be involved in the development of a more progressed form of adenomas.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands	Netherlands Cancer Institute; Vrije Universiteit Amsterdam	Demant, P (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	P.demant@nki.nl						Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen MAJA, 1996, HUM PATHOL, V27, P342, DOI 10.1016/S0046-8177(96)90106-9; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MOEN CJA, 1992, ONCOGENE, V7, P563; Moustakas A, 2001, J CELL SCI, V114, P4359; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243	9	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3472	3474		10.1038/sj.onc.1206246	http://dx.doi.org/10.1038/sj.onc.1206246			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776199				2022-12-17	WOS:000183128500014
J	Wessendorf, S; Schwaenen, C; Kohlhammer, H; Kienle, D; Wrobel, G; Barth, TFE; Nessling, M; Moller, P; Dohner, H; Lichter, P; Bentz, M				Wessendorf, S; Schwaenen, C; Kohlhammer, H; Kienle, D; Wrobel, G; Barth, TFE; Nessling, M; Moller, P; Dohner, H; Lichter, P; Bentz, M			Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization	ONCOGENE			English	Article						CGH; microarray; gene amplification; lymphoma	DNA COPY-NUMBER; ABERRATIONS; IMBALANCES; DELETIONS; NEOPLASMS; SURVIVAL; STAGE; GAINS	DNA amplifications are important mechanisms for protooncogene activation. Comparative genomic hybridization (CGH) to metaphase chromosome preparations has revealed amplifications in 10-20% of B-cell lymphomas (B-NHL). We analysed a series of 16 aggressive non-Hodgkin lymphomas by the new approach termed Matrix-CGH (M-CGH) using genomic DNA microarrays as hybridization target. For M-CGH, a dedicated B-cell lymphoma chip was constructed containing 496 genomic targets covering oncogenes, tumor suppressor genes as well as chromosome regions frequently altered in B-NHL. In 10 of 16 samples a total of 15 DNA amplifications were identified. The amplicons included BCL2, REL, CCND1, CCND2, JAK2, FGF4 and MDM2. Four of the 15 amplifications remained undetected by chromosomal CGH. The respective amplicons mapped to bands 2p13, 9p13-p21 and 12q24 and, were confirmed by fluorescence in situ hybridization. Furthermore, for four genomically amplified genes real-time quantitative reverse transcription polymerase chain reaction revealed elevated mRNA expression levels. These data show the superior diagnostic sensitivity of the newly developed diagnostic tool. As only a small portion of the genome (approximately 1.5%) has been analysed by the present DNA array, it is likely that gene amplifications are much more common in aggressive lymphomas than previously assumed.	Univ Ulm, Med Klin, Abt Innere Med 3, D-89081 Ulm, Germany; Deutsch Krebsforschungszentrum, Abt Mol Genet, D-69120 Heidelberg, Germany; Univ Ulm, Abt Pathol, D-89081 Ulm, Germany	Ulm University; Helmholtz Association; German Cancer Research Center (DKFZ); Ulm University	Bentz, M (corresponding author), Univ Ulm, Med Klin, Abt Innere Med 3, Robert Koch Str 8, D-89081 Ulm, Germany.		Döhner, Hartmut/C-8933-2016	Döhner, Hartmut/0000-0003-2116-5536				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.0.CO;2-T; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; GRIBBEN JG, 1991, BLOOD, V78, P3275; Houldsworth J, 1996, BLOOD, V87, P25; Jaffe ES, 2001, WORLD HLTH ORG CLASS; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V25, P410, DOI 10.1002/(SICI)1098-2264(199908)25:4<410::AID-GCC17>3.0.CO;2-J; Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494; Knuutila S, 1998, AM J PATHOL, V152, P1107; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Werner CA, 1997, AM J PATHOL, V151, P335; Wessendorf S, 2002, LAB INVEST, V82, P47, DOI 10.1038/labinvest.3780394	24	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1425	1429		10.1038/sj.onc.1206297	http://dx.doi.org/10.1038/sj.onc.1206297			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618769				2022-12-17	WOS:000181360900018
J	Ishikawa, T; Chen, J; Wang, JX; Okada, F; Sugiyama, T; Kobayashi, T; Shindo, M; Higashino, F; Katoh, H; Asaka, M; Kondo, T; Hosokawa, M; Kobayashi, M				Ishikawa, T; Chen, J; Wang, JX; Okada, F; Sugiyama, T; Kobayashi, T; Shindo, M; Higashino, F; Katoh, H; Asaka, M; Kondo, T; Hosokawa, M; Kobayashi, M			Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis	ONCOGENE			English	Article						pancreatic cancer; hypoxia; adrenomedullin; angiogenesis; adrenomedullin antagonist	POSSIBLE PROMOTION MECHANISM; AUTOCRINE GROWTH; EXPRESSION; HYPOXIA; APOPTOSIS; PEPTIDE; LINES; RECEPTORS	Since it is reported that adrenomedullin (AM) upregulated by hypoxia inhibits hypoxic cell death, we examined the effects of AM antagonist (AM C-terminal fragment; AM(22-52)) on the growth of pancreatic cancer cells. We, for the first time, demonstrated that AM antagonist significantly reduced the in vivo growth of the pancreatic cancer cell line. Immunohistochemical. analysis demonstrated that the mean diameter of blood vessels was significantly smaller in the tumor tissues treated with AM antagonist than in those treated with AM N-terminal fragment (AM(1-25)), and that the PCNA-labeling index was lower in the former than in the latter. Then we demonstrated that AM antagonist showed no effect on the in vitro growth of the pancreatic cancer cell line. These results showed that AM played an important role in the growth of pancreatic cancer cells in vivo, suggesting that AM antagonist might be a useful tool for treating pancreatic cancers.	Hokkaido Univ, Inst Med Genet, Div Canc Pathobiol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido, Japan; Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido, Japan; Hokkaido Univ, Grad Dent Sch, Dept Oral Pathobiol Sci, Sapporo, Hokkaido, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University	Kobayashi, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Canc Pathobiol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mkobaya@med.hokudai.ac.jp	Higashino, Fumihiro/F-8510-2012; Kondo, Takeshi/G-2103-2012; Shindoh, Masanobu/A-4799-2012; Asaka, Masahiro/A-5948-2012	Kondo, Takeshi/0000-0001-7455-5824; Shindoh, Masanobu/0000-0002-7782-5823; Kobayashi, Masanobu/0000-0002-7445-9741; Okada, Futoshi/0000-0003-4733-1037				Akakura N, 2001, CANCER RES, V61, P6548; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Choi S, 2000, CLIN EXP METASTAS, V18, P45, DOI 10.1023/A:1026507713080; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; EGUCHI S, 1994, ENDOCRINOLOGY, V135, P2454, DOI 10.1210/en.135.6.2454; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Hayakawa H, 1999, HYPERTENSION, V33, P689, DOI 10.1161/01.HYP.33.2.689; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Muff R, 2001, PEPTIDES, V22, P1765, DOI 10.1016/S0196-9781(01)00515-0; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Rocchi P, 2001, CANCER RES, V61, P1196; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Watanabe TX, 1996, BIOCHEM BIOPH RES CO, V219, P59, DOI 10.1006/bbrc.1996.0181; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; ZHAO L, 1996, AM J PHYSIOL, V271, P622	26	74	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1238	1242		10.1038/sj.onc.1206207	http://dx.doi.org/10.1038/sj.onc.1206207			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606950	Green Submitted			2022-12-17	WOS:000181249700012
J	Horton, LE; Bushell, M; Barth-Baus, D; Tilleray, VJ; Clemens, MJ; Hensold, J				Horton, LE; Bushell, M; Barth-Baus, D; Tilleray, VJ; Clemens, MJ; Hensold, J			p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation	ONCOGENE			English	Article						growth inhibition; mTOR; p53; polypeptide chain initiation; protein synthesis	CAP-DEPENDENT INITIATION; MESSENGER-RNA; MAMMALIAN TARGET; FACTOR 4E; PHAS-I; DIFFERENTIAL REQUIREMENTS; SIGNALING PATHWAYS; BINDING PROTEIN; PHOSPHORYLATION; RAPAMYCIN	p53 is an important regulator of cell cycle progression and apoptosis, and inactivation of p53 is associated with tumorigenesis. Although p53 exerts many of its effects through regulation of transcription, this protein is also found in association with ribosomes and several mRNAs have been identified that are translationally controlled in a p53-dependent manner. We have utilized murine erythroleukemic cells that express a temperature-sensitive p53 protein to determine whether p53 also functions at the level of translation. The data presented here demonstrate that p53 causes a rapid decrease in translation initiation. Analysis of several potential mechanisms for regulating protein synthesis shows that p53 has selective effects on the phosphorylation of the eIF4E-binding protein, 4E-BP1, and the activity of the p70 ribosomal protein S6 kinase. These data provide evidence that modulation of translational activity constitutes a further mechanism by which the growth inhibitory effects of p53 may be mediated.	St George Hosp, Sch Med, Dept Biochem & Immunol, London SW17 0RE, England; Case Western Reserve Univ, Sch Med, Dept Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA	St Georges University London; Case Western Reserve University	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Biochem & Immunol, Cranmer Terrace, London SW17 0RE, England.	M.Clemens@sghms.ac.uk			NIDDK NIH HHS [DK43414] Funding Source: Medline; PHITPO CDC HHS [HK07147-21A1] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHITPO CDC HHS		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Anthony JC, 2001, J NUTR, V131, p856S, DOI 10.1093/jn/131.3.856S; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hensold JO, 1996, J BIOL CHEM, V271, P23246, DOI 10.1074/jbc.271.38.23246; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jeffrey IW, 2002, CANCER RES, V62, P2272; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Loreni F, 2000, EUR J BIOCHEM, V267, P6594, DOI 10.1046/j.1432-1327.2000.01753.x; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; MERRICK W, 2000, CURR PROTOCALS CELL, V11; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Morley SJ, 2000, FEBS LETT, V477, P229, DOI 10.1016/S0014-5793(00)01805-6; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Pham PTT, 2000, J CELL BIOCHEM, V79, P427, DOI 10.1002/1097-4644(20001201)79:3<427::AID-JCB80>3.0.CO;2-0; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SMITH M R, 1990, New Biologist, V2, P648; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1995, J IMMUNOL, V155, P3418; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WANG Y, 2000, P NATL ACAD SCI USA, V97, P5486; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	82	74	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5325	5334		10.1038/sj.onc.1205662	http://dx.doi.org/10.1038/sj.onc.1205662			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149653				2022-12-17	WOS:000177193900013
J	Berlingieri, MT; Pierantoni, GM; Giancotti, V; Santoro, M; Fusco, A				Berlingieri, MT; Pierantoni, GM; Giancotti, V; Santoro, M; Fusco, A			Thyroid cell transformation requires the expression of the HMGA1 proteins	ONCOGENE			English	Article						thyroid cell; transformation; HMGA1; AP-1 complex; differentiation	TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; HMGI(Y) PROTEINS; C GENE; NEOPLASTIC TRANSFORMATION; NUCLEAR PROTEINS; ONCOGENE; GROWTH; I(Y); PHENOTYPE	Elevated expression of HMGA1 and HMGA2 proteins is correlated with a highly malignant phenotype in several human tumors. We previously demonstrated that the block of HMGA2 protein synthesis prevented rat thyroid cell transformation by murine retroviruses. Suppression of HMGA2 synthesis was associated with lack of induction of HMGA1 proteins suggesting that both HMGA1 and HMGA2 play a role in the process of neoplastic transformation. To determine the role of the HMGA1 gene in thyroid cell transformation, we blocked HMGA1 protein synthesis by an antisense methodology. Here we report that transfection of an HMGA1 cDNA antisense construct into a normal rat thyroid cell line (FRTL-5 C12), followed by infection with Kirsten murine sarcoma virus (KiMSV), generated a transformed cell line that expresses high levels of the v-ras-Ki oncogene and that does not require thyroid-stimulating hormones for growth. However, this cell line does not show the malignant phenotype, i.e., it neither grows in soft agar nor induces tumors after injection in athymic mice. Moreover, the lack of the neoplastic phenotype in the virus-infected thyroid cells carrying the HMGA1 antisense construct correlates with the absence of induction of AP-1 transcriptional activity.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale,CNR, I-80131 Naples, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Trieste	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale,CNR, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Pierantoni, Giovanna Maria/O-7527-2015	Pierantoni, Giovanna Maria/0000-0003-4078-8528; Fusco, Alfredo/0000-0003-3332-5197				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Bandiera A, 1998, CANCER RES, V58, P426; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; Fedele M, 2001, CANCER RES, V61, P4583; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; FEDELE M, 2002, IN PRESS ONCOGENE, V21; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GACK S, 1994, J BIOL CHEM, V269, P10363; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Scala S, 2001, CARCINOGENESIS, V22, P251, DOI 10.1093/carcin/22.2.251; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; TAMIMI Y, 1993, CANCER RES, V53, P5512; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood LJ, 2000, CANCER RES, V60, P4256; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	43	74	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2971	2980		10.1038/sj.onc.1205368	http://dx.doi.org/10.1038/sj.onc.1205368			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082527				2022-12-17	WOS:000175262700004
J	Simpson, DJ; Clayton, RN; Farrell, WE				Simpson, DJ; Clayton, RN; Farrell, WE			Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion	ONCOGENE			English	Article						DAP kinase; methylation; homozygous deletion; pituitary tumours	PROGRAMMED CELL-DEATH; DAP-KINASE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; CANCER PATIENTS; LUNG-CANCER; APOPTOSIS; GENES; ADENOMAS; TUMORS	Death Associated Protein kinase (DAP kinase) a novel calmodulin-dependent serine/threonine kinase was first identified as a positive mediator of programmed cell death. Loss of DAP kinase expression was first demonstrated in highly metastatic cells, whilst reexpression of the protein resulted in delayed local tumour growth and a decreased incidence of metastasis. Although loss of DAP kinase expression has been reported in several cell lines derived from human malignancies the mechanisms responsible have not been defined. In this study we have examined 32 sporadic pituitary tumours for expression of the DAP kinase protein and transcript. In addition, we examined the methylation and deletion status of the DAP kinase CpG island as possible mechanisms for the inactivation of the DAP kinase gene. Eleven of 32 (34%) tumours had undetectable DAP kinase expression, by Western blot and/or RT-PCR analysis. Loss of DAP kinase expression was significantly (P=0.004) associated with invasive tumours (10 of 17; 59%) compared to their noninvasive (1 of 15; 7%) counterparts. Of 11 tumours that failed to express DAP kinase, five (45%) showed de novo methylation of the CpG island contained within the promoter region, while four (36%) had evidence of homozygous deletion of this region. Statistical analysis showed that loss of DAP kinase expression was significantly (P= <0.001) associated with methylation or deletion of the DAP kinase CpG island. With two exceptions, none of the remaining tumours or five histologically normal post-mortem pituitaries examined had evidence of methylation or deletion within this region. To our knowledge this is the first report that describes two mutually exclusive mechanisms associated with loss of DAP kinase gene expression. In addition, we also show that loss of the DAP kinase protein and associated genetic aberrations preferentially segregates with tumours that show an invasive phenotype.	Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Ctr Cell & Mol Med, Stoke On Trent ST4 7QB, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Farrell, WE (corresponding author), Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Ctr Cell & Mol Med, Stoke On Trent ST4 7QB, Staffs, England.	w.e.farrell@keele.ac.uk						Bates AS, 1997, J CLIN ENDOCR METAB, V82, P818, DOI 10.1210/jc.82.3.818; Baylin SB, 1998, ADV CANCER RES, V72, P141; BOGGILD MD, 1994, J CLIN ENDOCR METAB, V78, P387, DOI 10.1210/jc.78.2.387; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Costello JF, 1996, CANCER RES, V56, P2405; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Esteller M, 1999, CANCER RES, V59, P67; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrell WE, 1997, CANCER RES, V57, P2703; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; FEINSTEIN E, 1995, TIBS, P342; Grigg GW, 1996, DNA SEQUENCE, V6, P189, DOI 10.3109/10425179609008443; Hardy J., 1979, RECENT ADV DIAGNOSIS, P375; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jones PA, 1996, CANCER RES, V56, P2463; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; LASTER SM, 1988, J IMMUNOL, V141, P2629; LIN JK, 1992, CANCER RES, V52, P385; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; Nakatsuka S, 2000, LAB INVEST, V80, P1651, DOI 10.1038/labinvest.3780175; NOVELLI F, 1994, J IMMUNOL, V152, P496; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Simpson DJ, 1999, CANCER RES, V59, P1562; Simpson DJ, 1999, GENE CHROMOSOME CANC, V24, P328; Simpson DJ, 2001, CARCINOGENESIS, V22, P1801, DOI 10.1093/carcin/22.11.1801; Simpson DJ, 2000, CANCER RES, V60, P1211; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Ueki T, 2000, CANCER RES, V60, P1835; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	36	74	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1217	1224		10.1038/sj.onc.1205195	http://dx.doi.org/10.1038/sj.onc.1205195			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850841				2022-12-17	WOS:000173729400009
J	Wu, GS; Ding, ZH				Wu, GS; Ding, ZH			Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line	ONCOGENE			English	Article						p53; chemosensitivity; apoptosis; caspases; DN-caspase 9; ovarian cancer cells	IN-VIVO; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; CYTOCHROME-C; P53; GENE; DEATH; BCL-2; EXPRESSION	The p53 gene suppresses tumor cell growth by inducing cell cycle arrest or apoptosis. Loss of its apoptosis activity has been implicated not only in tumor development but also in chemoresistance. We previously reported that targeting p53 for degradation by the human HPV E6 gene in the ovarian cancer cell line PA1 leads to an increase in the chemoresistant phenotype. Here we investigate the relationship between loss of p53-dependent caspase activation and chemosensitivity. In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation. Importantly, we showed that loss of caspase activation in PA1-E6 cells correlates with increased cell survival. Moreover, PA1 cells overexpressing a dominant negative caspase 9 were found to have decreased caspase-dependent apoptosis, as compared with vector control cells. Furthermore, these dominant negative caspase 9 expressing cells were resistant to chemotherapeutic agent-induced killing. Our results suggest that caspase 9 may be an important target for anticancer drug development. Thus, identifying novel compounds that can activate caspase 9 may be a strategy for overcoming a defect in the p53 apoptosis pathway.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Wu, GS (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dev Therapeut Program, Room E216,Prentis Bldg,110 E Warren, Detroit, MI 48201 USA.	wug@karmanos.org						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Attardi LD, 2000, GENE DEV, V14, P704; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; FAN SJ, 1995, CANCER RES, V55, P1649; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Perkins CL, 2000, CANCER RES, V60, P1645; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Velculescu VE, 1996, CLIN CHEM, V42, P858; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	49	74	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					1	8		10.1038/sj.onc.1205020	http://dx.doi.org/10.1038/sj.onc.1205020			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791171				2022-12-17	WOS:000172887800001
J	Murata-Hori, M; Fukuta, Y; Ueda, K; Iwasaki, T; Hosoya, H				Murata-Hori, M; Fukuta, Y; Ueda, K; Iwasaki, T; Hosoya, H			HeLa ZIP kinase induces diphosphorylation of myosin II regulatory light chain and reorganization of actin filaments in nonmuscle cells	ONCOGENE			English	Article						myosin II regulatory light chain; diphosphorylation; actin filament reorganization; nonmuscle cells; apoptosis	SMOOTH-MUSCLE MYOSIN; PROTEIN-KINASE; RHO-KINASE; SERINE/THREONINE KINASE; DLK/ZIP KINASE; DAP-KINASE; 2ND SITE; IN-VIVO; PHOSPHORYLATION; APOPTOSIS	Dlk/ZIP kinase is a serine/threonine kinase highly homologous to DAP kinase. We have reported that HeLa ZIP kinase (hZIPK) phosphorylated the regulatory light chain of myosin II (MRLC) at both Ser19 and Thr18 in vitro. In this study, we demonstrate that hZIPK also induces the diphosphorylation of MRLC in nonmuscle cells. Peptide mapping revealed that transient transfection of hZIPK into HeLa cells caused diphosphorylation of MRLC. In contrast, transfection of the kinase inactive mutant of hZIPK did not induce any phosphorylation of MRLC. Using antibodies specific for mono- or diphosphorylated MRLC, we showed that diphosphorylated MRLC induced by the overexpression of hZIPK was concentrated in striking aggregates or bundles of actin filaments in HeLa cells, while monophosphorylated MRLC showed no prominent localization to these aggregates. Overexpression of hZIPK also induced dramatic changes in cell shape and disruption of nuclear morphology reminiscent of changes during apoptosis. These effects of hZIPK were suppressed by the coexpression of a mutant MRLC where both phosphorylation sites were replaced with alanine, indicating that the changes in actin organization were a consequence of MRLC diphosphorylation. These results suggested that hZIPK plays a role in regulating actin organization and cell morphology in non-muscles and at least part of its effects are mediated through the diphosphorylation of MRLC.	Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Higashihiroshima, Hiroshima 7398526, Japan	Hiroshima University	Hosoya, H (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Higashihiroshima, Hiroshima 7398526, Japan.	hhosoya@sci.hiroshima-u.ac.jp		Hamao, Kozue/0000-0002-9594-1940				Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; FISHKIND DJ, 1991, J CELL BIOL, V114, P967, DOI 10.1083/jcb.114.5.967; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; IKEBE M, 1988, J BIOL CHEM, V263, P6432; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Murata-Hori M, 1998, BIOMED RES-TOKYO, V19, P111, DOI 10.2220/biomedres.19.111; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; SELLERS JR, 1985, J CELL BIOL, V101, P1897, DOI 10.1083/jcb.101.5.1897; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797	30	74	75	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2001	20	57					8175	8183		10.1038/sj.onc.1205055	http://dx.doi.org/10.1038/sj.onc.1205055			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781833				2022-12-17	WOS:000172507800002
J	Wang, J; Sampath, A; Raychaudhuri, P; Bagchi, S				Wang, J; Sampath, A; Raychaudhuri, P; Bagchi, S			Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells	ONCOGENE			English	Article						ubiquitination; proteasome; E7; human papilloma virus (HPV); retinoblastoma protein (Rb); E2F	HUMAN-PAPILLOMAVIRUS TYPE-16; E2F TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; E6 ONCOPROTEIN; CYCLE; DEGRADATION; LIGASE; PHOSPHORYLATION; ASSOCIATION; CARCINOMA	High-risk human papillomaviruses (HPVs) are etiologically linked to human cervical and oral cancers. The E6 and E7 oncoproteins encoded by HPV target host cell tumor suppressor proteins. E6 induces proteolysis of p53 through the ubiquitin-proteasome pathway. Recent studies showed that overexpression of E7 caused proteolytic degradation of the tumor suppressor Rb. However, unlike p53, Rb is not regulated by proteolysis in normal cells. In addition, it was unclear whether in its natural context E7 regulates Rb through the ubiquitin-proteasome pathway. Therefore, we sought to determine whether Rb is regulated by the ubiquitin-proteasome pathway in HPV-containing tumor cells. We carried out a detailed analysis in Caski cells, that are derived from HPV-containing cervical cancer tissues. Studies with various protease inhibitors revealed that Rb is regulated specifically by the ubiquitin-proteasome pathway in HPV-containing cervical tumor cells. Several inhibitors of the 26S proteasome significantly increased the level of Rb in the Caski cells. Rb controls cell growth by forming complexes with the E2F-family transcription factors. Surprisingly, in spite of a significant accumulation of the hypophosphorylated form of Rb, no Rb/E2F complex was detectable in the proteasome inhibitor treated cells. Further analysis revealed that there was an increased accumulation of the E7 oncoprotein. We showed that the proteasome inhibitors simultaneously blocked the proteolysis of E7 and Rb, suggesting that E7 is also regulated by the ubiquitin-dependent proteolysis in cervical cancer cells. Taken together, this study suggests that targeted inhibition of Rb proteolysis will be required for restoring Rb function in HPV-containing cervical cancer cells.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bagchi, S (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, MC 860,801 S Paulina St, Chicago, IL 60612 USA.	sbagchi@uic.edu			NCI NIH HHS [CA76276] Funding Source: Medline; NIDCR NIH HHS [DE12506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BEREZUTSKAYA E, 1997, CELL GROWTH DEATH, V8, P1; Boyer SN, 1996, CANCER RES, V56, P4620; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Galloway DA, 1996, SEMIN CANCER BIOL, V7, P309, DOI 10.1006/scbi.1996.0040; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Howley Peter M., 1996, P947; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Maki CG, 1996, CANCER RES, V56, P2649; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Niv A, 2000, J LARYNGOL OTOL, V114, P41, DOI 10.1258/0022215001903870; PAGANO M, 1992, ONCOGENE, V7, P1681; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Ruesch MN, 1998, VIROLOGY, V250, P19, DOI 10.1006/viro.1998.9359; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	39	74	79	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4740	4749		10.1038/sj.onc.1204655	http://dx.doi.org/10.1038/sj.onc.1204655			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498796				2022-12-17	WOS:000170208600014
J	Wang, JY; Del Valle, L; Gordon, J; Rubini, M; Romano, G; Croul, S; Peruzzi, F; Khalili, K; Reiss, K				Wang, JY; Del Valle, L; Gordon, J; Rubini, M; Romano, G; Croul, S; Peruzzi, F; Khalili, K; Reiss, K			Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas	ONCOGENE			English	Article						IGF-IR; medulloblastoma; IRS-1; cell proliferation; tyrosine phosphorylation	INSULIN-RECEPTOR SUBSTRATE-1; DOMINANT-NEGATIVE MUTANT; NEUROTROPIC JC VIRUS; CELL-LINE; IN-VIVO; EMBRYO FIBROBLASTS; INDUCED APOPTOSIS; TUMOR-GROWTH; C-MYC; TRANSFORMATION	Insulin-like growth factor I receptor (IGF-IR) has been implicated in the normal and malignant growth of many cell types including cells from the central nervous system. In the cerebellar cortex ICF-IR mRNA is found in granular cells and IGF-I stimulation is mitogenic and protects cells from low-potassium-induced apoptosis, Since primitive neuroectodermal tumers/medulloblastomas (PNETs/medulloblastomas) are suspected to originate from the external cerebellar granular layer, it is reasonable to postulate that IGF-IR and/or its signaling molecules may contribute to the transformation of these poorly differentiated cells. To study activation of the IGF-IR system in medulloblastomas, we have utilized an antibody (anti-pY1316) that specifically recognizes the phosphorylated (active) form of the IGF-IR, Medulloblastoma biopsy specimens were positive when examined immunohistochemically with anti-Y1316 antibody. Further analysis of the IGF-IR system was performed in three human (Daoy, TE-671, D283 Med) and four mouse (BsB8, BsB13, Bs-lb, Bs-lc) medulloblastoma cell lines. All the murine cell lines examined express IGF-IR and PI3-kinase at relatively normal levels, and grossly overexpress IRS-I, when compared with normal mouse cerebellum. Within 15 min following IGF-I stimulation both mouse and human cell lines phosphorylate the P subunit of the IGF-IR, IRS-1, Akt, and MAP kinases, They respond with cell proliferation when stimulated solely with IGF-I and are strongly inhibited when challenged with a dominant negative mutant of the IGF-IR (486/STOP), or with antisense oligonucleotides against the IGF-IR mRNA.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Ferrara; Jefferson University	Reiss, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,Biol Life Sci Bldg,Room 238, Philadelphia, PA 19122 USA.		Rubini, Michele/AFF-8477-2022; Del Valle, Luis/J-4085-2015; Peruzzi, Francesca/M-9804-2014	Rubini, Michele/0000-0003-1448-9516; Del Valle, Luis/0000-0003-3894-9206; Croul, Sidney/0000-0002-2224-5485	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NINDS NIH HHS [P0-1 NS 36466] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BASERGA R, 1995, CANCER RES, V55, P240; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAmbrosio C, 1996, CANCER RES, V56, P4013; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; Dunn SE, 1998, CANCER RES, V58, P3353; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; FULTS D, 1989, BRAIN RES, V503, P281, DOI 10.1016/0006-8993(89)91675-2; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; KALEBIC T, 1994, CANCER RES, V54, P5531; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; MIURA M, 1995, CANCER RES, V55, P663; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Morrione A, 2000, CANCER RES, V60, P2263; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Pappas IS, 1996, CELL GROWTH DIFFER, V7, P797; Patti R, 2000, INT J ONCOL, V16, P577; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PORCU P, 1994, ONCOGENE, V9, P2125; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; REISS K, 1995, AM J PHYSIOL-HEART C, V269, pH943, DOI 10.1152/ajpheart.1995.269.3.H943; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; RESNICOFF M, 1994, CANCER RES, V54, P2218; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Steller MA, 1996, CANCER RES, V56, P5087; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; WATERS SB, 1993, J BIOL CHEM, V268, P22231	51	74	76	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3857	3868		10.1038/sj.onc.1204532	http://dx.doi.org/10.1038/sj.onc.1204532			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439349				2022-12-17	WOS:000169494700011
J	Jang, SJ; Chiba, I; Hirai, A; Hong, WK; Mao, L				Jang, SJ; Chiba, I; Hirai, A; Hong, WK; Mao, L			Multiple oral squamous epithelial lesions: are they genetically related?	ONCOGENE			English	Article						multiple oral lesion; microsatellite alteration; clonality	COMMON CLONAL ORIGIN; ANDROGEN-RECEPTOR GENE; CELL LUNG-CANCER; NECK-CANCER; MICROSATELLITE ALTERATIONS; FIELD CANCERIZATION; PRIMARY TUMORS; CHROMOSOME 3P; PRIMARY HEAD; CARCINOMA	The development of second primary tumors (SPTs) in patients with head and neck squamous cell carcinoma (HNSCC) has become an increasingly important factor in clinical treatment decison, Currently, clinical and histologic parameters are used to determine whether or not SPT is present. Recent studies suggest that many SPTs in the upper aerodigestive tract have a common clonal origin, challenging the longstanding multiclonal origin concept, To determine genetic relationships among multiple oral cancerous and precancerous lesions (MOCP), we analysed 100 lesions from 26 Japanese patients, Lesion development was synchronous and metachronous. We looked for patterns of microsatellite alterations (MA) using seven markers at chromosomes 3p14, 9p21, and 17p13, where MA occurs early in oral carcinogenesis. Loss of heterozygosity (LOH) was found in 52.6% (41/78), 62.5% (60/96), and 59.3% (32/54) of informative MOCP at 3p14, 9p21, and 17p13, respectively, Microsatellite instability (MI) was observed in II, 26 and 13% of the samples at 3p14, 9p21, and 17p13 markers, respectively. Patterns of MA were concordant in only nine (14%) of 63 lesions from four (18%) of 22 patients who initially presented with noninvasive lesions. However, two of four patients with invasive cancer as indexed lesion showed 16 (43%) clonally related MOCP among 37 lesions (P=0.003). The results suggest that the majority of MOCP arise from clonally independent cells affected by field cancerization. However, the probability of mucosal spread of clonal malignant or premalignant cells may increase along with malignant progression.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, Houston, TX 77030 USA; Hokkaido Univ, Sch Dent, Sapporo, Hokkaido 060, Japan	University of Texas System; UTMD Anderson Cancer Center; Hokkaido University	Mao, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA52051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Bedi GC, 1996, CANCER RES, V56, P2484; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOYLE J, 1998, CANCER RES, V58, P4477; Buller RE, 1998, AM J OBSTET GYNECOL, V178, P641, DOI 10.1016/S0002-9378(98)70473-9; Califano J, 1996, CANCER RES, V56, P2488; CHUNG KY, 1993, CANCER RES, V53, P1676; Cianfriglia F, 1999, ORAL ONCOL, V35, P157, DOI 10.1016/S1368-8375(98)00105-5; EINHORN J, 1967, CANCER, V20, P2184, DOI DOI 10.1038/NRC1477; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; Field JK, 1996, ANTICANCER RES, V16, P2421; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jang SJ, 2000, CANCER RES, V60, P864; JONES AS, 1995, CANCER, V75, P1343, DOI 10.1002/1097-0142(19950315)75:6<1343::AID-CNCR2820750617>3.0.CO;2-T; Kim SK, 1997, CANCER RES, V57, P400; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Lydiatt WM, 1998, CANCER, V82, P1376, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1376::AID-CNCR22>3.0.CO;2-2; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1998, J NATL CANCER I, V90, P1545, DOI 10.1093/jnci/90.20.1545; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; NAWROZ H, 1994, CANCER RES, V54, P1152; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Prevo LJ, 1999, CANCER RES, V59, P4784; Roz L, 1996, CANCER RES, V56, P1228; Scholes AGM, 1998, CANCER RES, V58, P2003; SCHWARTZ LH, 1994, CANCER, V74, P1933, DOI 10.1002/1097-0142(19941001)74:7<1933::AID-CNCR2820740718>3.0.CO;2-X; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SILVERMAN S, 1984, CANCER, V53, P563; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SOZZI G, 1995, CANCER RES, V55, P135; Tseng JE, 1999, CANCER RES, V59, P4798; VANDERRIET P, 1994, CANCER RES, V54, P1156; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WORSHAM MJ, 1995, HUM PATHOL, V26, P251, DOI 10.1016/0046-8177(95)90054-3	34	74	80	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2235	2242		10.1038/sj.onc.1204311	http://dx.doi.org/10.1038/sj.onc.1204311			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402318				2022-12-17	WOS:000168404500005
J	Lindstrom, MS; Klangby, U; Wiman, KG				Lindstrom, MS; Klangby, U; Wiman, KG			p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53	ONCOGENE			English	Article						pl4ARF; MDM2; p53; nucleolus; Bmi-1; burkitt lymphoma	TUMOR-SUPPRESSOR GENE; B-CELL; INK4A/ARF LOCUS; C-MYC; MUTATIONS; ONCOGENE; P19(ARF); ASSOCIATION; METHYLATION; P16(INK4A)	The hallmark of Burkitt lymphoma (BL) is a constitutively activated c-myc gene that drives tumor cell growth. A majority of BL-derived cell lines also carry mutant p53, In addition, the p16INK4a promoter is hypermethylated in most BL biopsies and BL cell lines, leading to silencing of this gene, Activation of c-myc and/or cell cycle dysregulation can induce ARF expression and p53-dependent apoptosis, We therefore investigated the p14ARF-MDM2-p53 pathway in BL cell lines. p14ARF was expressed and localized to nucleoli in all BL carrying mutant p53, Three out of seven BL carrying wt p53 had a homozygous deletion of the CDKN2A locus that encodes both p14ARF and p16INK4a. Three BL carrying wild type p53 retained the CDKN2A locus and overexpressed MDM2, DNA sequencing revealed a point mutation in CDKN2A exon 2 in one of these BL, Seraphine, However, this point mutation did not affect p14ARF's nucleolar localization or ability to induce p53, The Bmi-1 protein that negatively regulates the p14ARF promoter and co-operates with c-myc in tumorigenesis was expressed at low to moderate levels in all BL analysed. Our results indicate that inactivation of the ARF-MDM2-p53 pathway is an essential step during the development of Burkitt lymphoma, presumably as a mechanism to escape c-myc induced apoptosis.	Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, SE-17176 Stockholm, Sweden; AB Sangtec Med, SE-16102 Bromma, Sweden	Karolinska Institutet; Karolinska University Hospital	Wiman, KG (corresponding author), Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, SE-17176 Stockholm, Sweden.		Lindström, Mikael S/AAA-1451-2019; Wiman, Klas/AAB-8399-2021	Lindström, Mikael S/0000-0003-1148-8497; Wiman, Klas/0000-0002-7113-524X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; BHATIA KG, 1992, CANCER RES, V52, P4273; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Cherney BW, 1997, CANCER RES, V57, P2508; CORDONCARDO C, 1994, CANCER RES, V54, P794; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ESTELLER M, 2000, CANCER RES, V60, P29; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gao CF, 1999, BIOCHEM BIOPH RES CO, V264, P860, DOI 10.1006/bbrc.1999.1611; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Gutierrez MI, 1997, ANN ONCOL, V8, P987, DOI 10.1023/A:1008265304712; Gutierrez MI, 1999, CANCER RES, V59, P696; HAUPT Y, 1993, ONCOGENE, V8, P3161; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; KLEIN G, 1993, GENE, V135, P189, DOI 10.1016/0378-1119(93)90065-B; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRANKS G, 1995, BLOOD, V85, P893, DOI 10.1182/blood.V85.4.893.bloodjournal854893; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Voncken JW, 1999, J CELL SCI, V112, P4627; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; WATANABE T, 1994, BLOOD, V84, P3158; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WIMAN KG, 1991, ONCOGENE, V6, P1633; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	48	74	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2171	2177		10.1038/sj.onc.1204303	http://dx.doi.org/10.1038/sj.onc.1204303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360201				2022-12-17	WOS:000168116700012
J	Zubilewicz, A; Hecquet, C; Jeanny, JC; Soubrane, G; Courtois, Y; Mascarelli, F				Zubilewicz, A; Hecquet, C; Jeanny, JC; Soubrane, G; Courtois, Y; Mascarelli, F			Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: A comparative study with VEGF	ONCOGENE			English	Article						FGF2; proliferation; endothelial cells; angiogenesis; VEGF	ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; NITRIC-OXIDE; EXPRESSION; MECHANISM; RAS; DIFFERENTIATION; APOPTOSIS	In the retina, angiogenesis is an important component of normal physiological events such as embryonic vascular development. It is also involved in pathological processes including diabetic retinopathies and age-related macular degeneration, and tumour growth such as choroidal melanoma, Fibroblast growth factor (FGF) 2 and vascular endothelial cell growth factor (VEGF) are the two major angiogenic factors in the retina. We investigated the mechanism of proliferation and regulation of the mitogenic properties of FGF2 VEGF in cultures of chorocapillary endothelial cells (CEC), FGF2 is a strong mitogen for CEC and induced a 2.5-fold increase in cell proliferation after 4 days in culture in the absence of serum. In contrast, VEGF is a poor mitogen for CEC, FGF2, but not VEGF induces a large activation of MEK1, ERK1/2 and P90(RSK) during CEC proliferation. Pharmacological inhibition of Ras processing, and of MEK1 and ERK1/2 activation reduced only by 50% FGF2-induced cell proliferation, suggesting that there is another signalling pathway for CEC proliferation. Pharmacological inhibition of the PI 3-Kinase also inhibits by half FGF2-induced CEC proliferation, FGF2 stimulates the activation of the PI 3-K, P70(S6K) and Akt, Inhibition of both ERK1/2 and PI 3-K activities suppressed FGF2-induced CEC proliferation, demonstrating that CEC proliferation requires both ERKs and PI 3-K pathways. These data on the molecular mechanism and signalling may have important implications for providing more selective methods for anti-angiogenic and anti-tumoural therapy.	Assoc Claude Bernard, CNRS, INSERM, U450, F-75016 Paris, France; Med Sch Lublin, Dept Ophthalmol, PL-20079 Lublin, Poland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Medical University of Lublin	Mascarelli, F (corresponding author), Assoc Claude Bernard, CNRS, INSERM, U450, 29 Rue Wilhem, F-75016 Paris, France.		Mascarelli, Frederic/L-8916-2018					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; BRIAN C, 1997, J BIOL CHEM, V272, P27665; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Bullard LE, 2000, INVEST OPHTH VIS SCI, V41, pS140; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; ENAIDA H, 1998, MED SCI, V44, P43; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; Guillonneau X, 1996, J CELL PHYSIOL, V166, P170, DOI 10.1002/(SICI)1097-4652(199601)166:1<170::AID-JCP19>3.0.CO;2-J; Guillonneau X, 1998, GROWTH FACTORS, V15, P95, DOI 10.3109/08977199809117186; GUYER DR, 1994, RETINA, V1, P1831; Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145; Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Marumo T, 1999, J VASC RES, V36, P510, DOI 10.1159/000025694; Mounho BJ, 1999, TOXICOL APPL PHARM, V159, P125, DOI 10.1006/taap.1999.8740; O'Gorman DM, 2000, LEUKEMIA, V14, P602, DOI 10.1038/sj.leu.2401726; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; RYAN SJ, 1994, RETINA, V2, P1027; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063; SPAKS SH, 1973, BR J OPHTHALMOL, V57, P951; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TAZAKE K, 2000, JPN J CANCER RES, V90, P647; Tudan C, 1998, BIOCHEM J, V331, P531, DOI 10.1042/bj3310531; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	55	74	83	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2001	20	12					1403	1413		10.1038/sj.onc.1204231	http://dx.doi.org/10.1038/sj.onc.1204231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313884				2022-12-17	WOS:000167595200001
J	Goldstone, S; Pavey, S; Forrest, A; Sinnamon, J; Gabrielli, B				Goldstone, S; Pavey, S; Forrest, A; Sinnamon, J; Gabrielli, B			Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR	ONCOGENE			English	Article						cell cycle checkpoint; DNA damage; ATM/ATR	DNA-DAMAGE CHECKPOINT; CDC25B PHOSPHATASE; G(2) CHECKPOINT; TYROSINE DEPHOSPHORYLATION; DEPENDENT KINASE-2; HUMAN FIBROBLASTS; PROTEIN-KINASE; HELA-CELLS; S-PHASE; PHOSPHORYLATION	Cyclin A/cdk2 is active during S and G2 phases of the cell cycle, but its regulation and function during G2 phase is poorly understood. In this study we have examined the regulation of cyclin A/cdk2 activity during normal G2 phase progression and in genotoxin-induced G2 arrest. We show that cyclin A/cdk2 is activated in early G2 phase by a cdc25 activity. In the G2 phase checkpoint arrest initiated in response to various forms of DNA damage, the cdc25-dependent activation of both cyclin A/cdk2 and cyclin B1/cdc2 is blocked. Ectopic expression of cdc25B, but not cdc25C, in G2 phase arrested cells efficiently activated both cyclin A/cdk2 and cyclin B1/cdc2. Finally, we demonstrate that the block in cyclin A/cdk2 activation in the G2 checkpoint arrest is independent of ATM/ATR. We speculate that the ATM/ ATR-independent block in G2 phase cyclin A/cdk2 activation may act as a further layer of checkpoint control, and that blocking G2 phase cyclin A/cdk2 activation contributes to the G2 phase checkpoint arrest.	Univ Queensland, Queensland Inst Med Res, Queensland Canc Fund Res Unit, Brisbane, Qld, Australia; Univ Queensland, Dept Pathol, Joint Expt Oncol Program, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Queensland Inst Med Res, Queensland Canc Fund Res Unit, Brisbane, Qld, Australia.		Pavey, Sandra/B-3662-2011; Forrest, Alistair/A-6597-2008; Gabrielli, Brian G/B-3655-2011	Pavey, Sandra/0000-0003-4519-5932; Forrest, Alistair/0000-0003-4543-1675; Gabrielli, Brian G/0000-0003-3933-1651				Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HERZINGER T, 1995, ONCOGENE, V11, P2151; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lammer C, 1998, J CELL SCI, V111, P2445; LOCK RB, 1994, CANCER RES, V54, P4933; LOCK RB, 1992, CANCER RES, V52, P1817; Maity A, 1996, ONCOGENE, V13, P1647; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; Ramsay J, 1998, BRIT J CANCER, V77, P11, DOI 10.1038/bjc.1998.2; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Tamura K, 2000, CANCER RES, V60, P1317; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; Wang XQ, 1996, CANCER RES, V56, P2510	45	74	78	2	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					921	932		10.1038/sj.onc.1204177	http://dx.doi.org/10.1038/sj.onc.1204177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314027				2022-12-17	WOS:000167097000003
J	Poon, R; Smits, R; Li, C; Jagmohan-Changur, S; Kong, M; Cheon, S; Yu, CY; Fodde, R; Alman, BA				Poon, R; Smits, R; Li, C; Jagmohan-Changur, S; Kong, M; Cheon, S; Yu, CY; Fodde, R; Alman, BA			Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor)	ONCOGENE			English	Article						aggressive fibromatosis; adenomatous polyposis coli; cyclooxygenase; beta-catenin; non-steroidal anti-inflammatory drugs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; ANTI-INFLAMMATORY DRUGS; COLON-CANCER CELLS; BETA-CATENIN; COLORECTAL-CANCER; CARCINOMA CELLS; GENE MUTATION; GROWTH-FACTOR; MOUSE MODEL	Aggressive fibromatosis is a locally invasive soft tissue lesion. Seventy-five per cent of cases harbor a somatic mutation in either the APC or beta -catenin genes, resulting in beta -catenin protein stabilization, Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin synthesis that modulates the formation of colonic neoplasia, especially in cases due to mutations resulting in beta -catenin stabilization, Human aggressive fibromatoses and lesions from the Apc+/Apc1638N mouse (a murine model for Ape-driven fibromatosis) demonstrated elevated COX-2 levels. COX-2 blockade either by the selective agent DFU or by non-selective COX blocking agents results in reduced proliferation in human tumor cell cultures. Breeding mice with Cox-2-/- mice resulted in no difference in number of aggressive fibromatoses formed, but in a smaller tumor size, while there was a decrease in number of GI lesions by 50%. Mice fed various COX blocking agents also showed a decline in tumor size. COX-2 expression was regulated by tcf-dependent transcription in this lesion, COX-2 partially regulates proliferation due to beta -catenin stabilization in aggressive fibromatosis, Although COX blockade alone does not cause tumor regression, this data suggests that it may have a role as an adjuvant therapy to slow tumor growth in this lesion.	Hosp Sick Children, Program Dev Biol, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Alman, BA (corresponding author), Hosp Sick Children, Program Dev Biol, Div Orthopaed Surg, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324				ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Alman BA, 1996, J ORTHOP RES, V14, P722, DOI 10.1002/jor.1100140507; ALMAN BA, 1992, J PEDIATR ORTHOPED, V12, P1; ALMAN BA, 1995, J ORTHOP RES, V13, P67, DOI 10.1002/jor.1100130111; BELIVEAU P, 1984, COLON RECTUM, V27, P53; Black SC, 1998, J CARDIOVASC PHARM, V32, P686, DOI 10.1097/00005344-199811000-00002; Castano E, 2000, J PHARMACOL EXP THER, V293, P509; Chan CC, 1997, EUR J PHARMACOL, V327, P221, DOI 10.1016/S0014-2999(97)89664-1; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, CANCER RES, V56, P733; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Giardiello FM, 1997, GUT, V40, P521, DOI 10.1136/gut.40.4.521; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GustafsonSvard C, 1996, GUT, V38, P79, DOI 10.1136/gut.38.1.79; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HIAL V, 1977, J PHARMACOL EXP THER, V202, P446; Hsi LC, 1999, CARCINOGENESIS, V20, P2045, DOI 10.1093/carcin/20.11.2045; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KIRSCH WM, 1991, AM J SURG, V161, P416; Lackner H, 1997, CANCER, V80, P334, DOI 10.1002/(SICI)1097-0142(19970715)80:2<334::AID-CNCR22>3.0.CO;2-U; LATTES R, 1980, TUMORS SOFT TISSUES, P1; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Mei JM, 1999, CARCINOGENESIS, V20, P737, DOI 10.1093/carcin/20.4.737; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NGUYEN KD, 1993, EXP EYE RES, V57, P97, DOI 10.1006/exer.1993.1103; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; POSNER MC, 1989, ARCH SURG-CHICAGO, V124, P191; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Sparks AB, 1998, CANCER RES, V58, P1130; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; WADDELL WR, 1983, J SURG ONCOL, V22, P197, DOI 10.1002/jso.2930220314; Watson AJM, 1998, HISTOL HISTOPATHOL, V13, P591, DOI 10.14670/HH-13.591; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wolf Leslie A., 1999, Cell Biochemistry and Biophysics, V30, P353, DOI 10.1007/BF02738119; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	51	74	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					451	460		10.1038/sj.onc.1204107	http://dx.doi.org/10.1038/sj.onc.1204107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313976				2022-12-17	WOS:000166562500005
J	Ababou, M; Dutertre, S; Lecluse, Y; Onclercq, R; Chatton, B; Amor-Gueret, M				Ababou, M; Dutertre, S; Lecluse, Y; Onclercq, R; Chatton, B; Amor-Gueret, M			ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation	ONCOGENE			English	Article						Bloom's syndrome; ATM; phosphorylation; ionizing radiation; cell cycle checkpoints	SYNDROME GENE-PRODUCT; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; CHROMATID EXCHANGES; BLOOM-SYNDROME; INSTABILITY; CANCER; BRCA1; P53; LYMPHOCYTES	Bloom's syndrome (BS), a rare genetic disease, arises through mutations in both alleles of the BLM gene which encodes a 3'-5' DNA helicase identified as a member of the RecQ family, BS patients exhibit a high predisposition to development of all types of cancer affecting the general population and BLM-deficient cells display a strong genetic instability. We recently showed that ELM protein expression is regulated during the cell cycle, accumulating to high levels in S phase, persisting in G2/M and sharply declining in G1, suggesting a possible implication of BLM in a replication (S phase) and/or post-replication (G2 phase) process, Here we show that, in response to ionizing radiation, BLM-deficient cells exhibit a normal p53 response as well as an intact G1/S cell cycle checkpoint, which indicates that ATM and p53 pathways are functional in BS cells. We also show that the BLM defect is associated with a partial escape of cells from the gamma -irradiation-induced G2/M cell cycle checkpoint. Finally, we present data demonstrating that, in response to ionizing radiation, BLM protein is phosphorylated and accumulates through an ATM-dependent pathway. Altogether, our data indicate that BLM participates in the cellular response to ionizing radiation by acting as an ATM kinase downstream effector.	Inst Gustave Roussy, Unite Mixte Rech 1598, CNRS, F-94805 Villejuif, France; Inst Gustave Roussy, IFR 54, Serv Cytomet Flux, F-94805 Villejuif, France; CU Strasbourg, Inst Genet & Biol Mol & Cellulaire, CNRS, ULP,INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, Unite Mixte Rech 1598, CNRS, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; ababou, mouna/0000-0003-4276-3754				AURIAS A, 1985, CANCER GENET CYTOGEN, V16, P131, DOI 10.1016/0165-4608(85)90006-8; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barakat A, 2000, Hum Mutat, V15, P584, DOI 10.1002/1098-1004(200006)15:6<584::AID-HUMU28>3.0.CO;2-I; BARTRAM CR, 1976, ANN HUM GENET, V40, P79, DOI 10.1111/j.1469-1809.1976.tb00166.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GALLOWAY SM, 1977, MUTAT RES, V45, P343, DOI 10.1016/0027-5107(77)90144-0; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIM ST, 2000, J BIOL CHEM, V274, P613; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEYN MS, 1995, CANCER RES, V55, P5991; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; ZHOU S, 1993, J BIOL CHEM, V268, P17754	33	74	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					5955	5963		10.1038/sj.onc.1204003	http://dx.doi.org/10.1038/sj.onc.1204003			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146546				2022-12-17	WOS:000165827900001
J	Erdmann, KS; Kuhlmann, J; Lessmann, V; Herrmann, L; Eulenburg, V; Muller, O; Heumann, R				Erdmann, KS; Kuhlmann, J; Lessmann, V; Herrmann, L; Eulenburg, V; Muller, O; Heumann, R			The Adenomatous Polyposis Coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain	ONCOGENE			English	Article						tumor suppressor; PDZ; protein tyrosine phosphatase	TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; BETA-CATENIN; GENE-PRODUCT; FUNCTIONAL INTERACTION; GUANYLATE KINASES; MOLECULAR-CLONING; CELL-MIGRATION; IN-VITRO; PHOSPHORYLATION	Mutations of the tumor suppressor protein APC (Adenomatous Polyposis Coli) are linked to familiar and sporadic human colon cancer. Here we describe a novel interaction between the APC protein and the protein tyrosine phosphatase PTP-BL carrying five PDZ protein-protein interaction domains. Exclusively, the second PDZ domain (PDZ2) of PTP-BL is binding to the extreme C-terminus of the APC protein, as determined by yeast two-hybrid studies. Using surface plasmon resonance analysis we established a dissociation constant (K-D) of 8.1 x 10(-9) M. We find that a naturally occurring splice insertion of five amino acids (PDZ2b) abolishes its binding affinity to the APC protein. The in vivo interaction between PTP-BL and the APC protein was shown by coprecipitation experiments in transfected COS cells. Furthermore, in cultured epithelial Madine Carnine Kidney cells the subcellular colocalization was demonstrated for the nucleus and also for the tips of cellular extensions, The interaction of the APC protein with a protein tyrosine phosphatase may indirectly modulate the steady state levels of tyrosine phosphorylations of associated proteins, such as beta-catenin playing a major role in the regulation of cell division, migration and cell adhesion.	Ruhr Univ Bochum, Dept Mol Neurobiochem, D-44780 Bochum, Germany; Max Planck Inst Mol Physiol, Arbeitsgrp Biophys Analyt, D-44227 Dortmund, Germany; Max Planck Inst Mol Physiol, Arbeitsgrp Tumorgenet, D-44227 Dortmund, Germany	Ruhr University Bochum; Max Planck Society; Max Planck Society	Erdmann, KS (corresponding author), Ruhr Univ Bochum, Dept Mol Neurobiochem, D-44780 Bochum, Germany.		Leßmann, Volkmar/E-8125-2013; Heumann, Rolf/ABB-9675-2021; Eulenburg, Volker/B-7263-2013; Heumann, Rolf/AAK-4390-2020; Eulenburg, Volker/B-7263-2013	Leßmann, Volkmar/0000-0002-6863-323X; Heumann, Rolf/0000-0003-4364-2655; Eulenburg, Volker/0000-0002-4878-5746; Eulenburg, Volker/0000-0001-6314-566X				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Cuppen E, 1999, FEBS LETT, V459, P291, DOI 10.1016/S0014-5793(99)01191-6; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Goold RG, 1999, J CELL SCI, V112, P3373; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Midgley CA, 1997, J PATHOL, V181, P426; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Niethammer M, 1996, J NEUROSCI, V16, P2157; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; Tseng HC, 1999, P NATL ACAD SCI USA, V96, P9503, DOI 10.1073/pnas.96.17.9503	57	74	74	1	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3894	3901		10.1038/sj.onc.1203725	http://dx.doi.org/10.1038/sj.onc.1203725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951583	Green Submitted			2022-12-17	WOS:000088614300008
J	Lee, YI; Lee, S; Das, GC; Park, US; Park, SM; Lee, YI				Lee, YI; Lee, S; Das, GC; Park, US; Park, SM; Lee, YI			Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma	ONCOGENE			English	Article						insulin-like growth factor II; p53 mutant; transcriptional activation; hepatocellular carcinoma	X GENE-PRODUCT; FUNCTION MUTATIONS; P4 PROMOTER; TREE SHREWS; VIRUS; EXPRESSION; CELLS; HEPATOCYTES; APOPTOSIS; SITE	Aflatoxin B1 (AFB1) induced mutation of the p53 gene at codon 249 (p53mt249) is critical during the formation of hepatocellular carcinoma (HCC) following hepatitis B virus (HBV) infection. p53mt249 markedly increases insulin-like growth factor II (IGF-II) transcription largely from promoter 4, accumulating the fetal form of IGF-II, Modulation of the transcription factor binding to IGF-II P4 by wild-type p53 and p53mt249 was identified. Wild-type p53 inhibited binding of transcription factors Sp1 and TBP on the P4 promoter, while p53mt249 enhanced the formation of transcriptional complexes through enhanced DNA-protein (Spl or TBP) and protein-protein (Sp1 and TBP) interactions. p53mt249 stimulates transcription factor Spl phosphorylation which might be a cause of increased transcription factor binding on the P4 promoter while wild-type p53 does not. Transfection of hepatocytes with p53mt249 impaired induction of apoptosis by the HBV-X protein and TNF-alpha. Therefore, the blocking of apoptosis through enhanced production of IGF-II should provide a favorable opportunity for the selection of transformed hepatocytes. These results explain the molecular basis for the genesis of HCC by p53mt249 which was found to be induced by a potent mutagen, AFB1.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, Taejon 305600, South Korea; Univ Texas, Ctr Hlth, Dept Mol Biol, Tyler, TX 75710 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Lee, YI (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, POB 115, Taejon 305600, South Korea.							AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CARIANI E, 1988, CANCER RES, V48, P6844; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FU XX, 1998, J VIROL, V62, P4322; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HSIAO M, 1994, AM J PATHOL, V145, P702; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HULLA JE, 1993, CANCER RES, V53, P9; HYUN SW, 1993, FEBS LETT, V332, P153, DOI 10.1016/0014-5793(93)80503-M; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kim SO, 1996, CANCER RES, V56, P3831; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; LAMAS E, 1989, FALK S OCT 15 17 BAS, V55, P45; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LUIS P, 1997, SCIENCE, V278, P687; LUSE DS, 1980, CELL, V20, P691, DOI 10.1016/0092-8674(80)90315-3; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, V1; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PERREM K, 1995, ONCOGENE, V11, P1299; SANDEEP RD, 1997, CELL, V91, P231; Shivakumar CV, 1996, ONCOGENE, V13, P323; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su JJ, 1997, EXP MOL MED, V29, P177, DOI 10.1038/emm.1997.27; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Yan RQ, 1996, J CANCER RES CLIN, V122, P289, DOI 10.1007/BF01261405; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YEH FS, 1989, CANCER RES, V49, P2506; Zhang LJ, 1998, DNA CELL BIOL, V17, P125, DOI 10.1089/dna.1998.17.125	35	74	77	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3717	3726		10.1038/sj.onc.1203694	http://dx.doi.org/10.1038/sj.onc.1203694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949925				2022-12-17	WOS:000088568400003
J	Hadsell, DL; Murphy, KL; Bonnette, SG; Reece, N; Laucirica, R; Rosen, JM				Hadsell, DL; Murphy, KL; Bonnette, SG; Reece, N; Laucirica, R; Rosen, JM			Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis	ONCOGENE			English	Article						transgenic mouse model; IGF-I; apoptosis; mutant p53; tumorigenesis	GROWTH-FACTOR-I; HUMAN-BREAST CANCER; MESSENGER-RNA EXPRESSION; TRANSGENIC MOUSE MODEL; IGF-BINDING PROTEIN-3; PROGRAMMED CELL-DEATH; RECEPTOR OVEREXPRESSION; GENE-EXPRESSION; WILD-TYPE; INSULIN	Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53(172R-H)). Nonlactating, multiparous WAP-DES mice exhibited hyperplastic lesions termed mammary interepithelial neoplasia (MIN) which constitutively expressed WAP-DES, By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas. A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice, Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2-3-fold greater than that of nontransgenic and p53(172R-H) females, Tumor latency, however, was reduced by 8 months in bitransgenic mice as compared to mice of the other three genotypes. Aneuploidy was frequently observed in tumors from bitransgenic and p53(172R-H) mice, but not from mice expressing only the WAP-DES transgene, Expression of IGFBP3 was elevated in tumors from WAP-DES, but not bitransgenic mice, indicating an alteration in the p53/IGF-I axis. These studies indicate that overexpression of des(1-3)hIGF-I increases the frequency of MIN and stochastic mammary tumors and that the appearance of tumors displaying genomic instability is accelerated by mutant p53(172R-H).	Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine; Baylor College of Medicine	Hadsell, DL (corresponding author), Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, 1 Baylor Pl, Houston, TX 77030 USA.		Hadsell, Darryl/GPF-9037-2022		NATIONAL CANCER INSTITUTE [R37CA016303, R01CA016303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052197] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline; NIDDK NIH HHS [DK52197-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Amundadottir LT, 1996, ONCOGENE, V13, P757; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CARDIFF RD, 2000, IN PRESS ONCOGENE; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; CULLEN KJ, 1990, CANCER RES, V50, P48; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dunn T, 1959, PHYSIOPATHOLOGY CANC, P38; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gai X X, 1988, Oncogene Res, V3, P377; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kleinberg DL, 1997, J MAMMARY GLAND BIOL, V2, P49, DOI 10.1023/A:1026373513521; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; MURPHY KL, 2000, IN PRESS ONCOGENE; NEIMAN PE, 1994, MOL BIOL CELL, V5, P763, DOI 10.1091/mbc.5.7.763; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Quarrie LH, 1996, J CELL PHYSIOL, V168, P559, DOI 10.1002/(SICI)1097-4652(199609)168:3<559::AID-JCP8>3.0.CO;2-O; SCHULLER AGP, 1994, MOL CELL ENDOCRINOL, V104, P57, DOI 10.1016/0303-7207(94)90051-5; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Starborg M, 1996, J CELL SCI, V109, P143; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Turner BC, 1997, CANCER RES, V57, P3079; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Villafuerte BC, 1996, MOL ENDOCRINOL, V10, P622, DOI 10.1210/me.10.6.622; WADA J, 1993, P NATL ACAD SCI USA, V90, P10360, DOI 10.1073/pnas.90.21.10360; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; Webster NJG, 1996, CANCER RES, V56, P2781; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; YEE D, 1988, CANCER RES, V48, P6691; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	48	74	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					889	898		10.1038/sj.onc.1203386	http://dx.doi.org/10.1038/sj.onc.1203386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702797				2022-12-17	WOS:000085567700006
J	Blalock, WL; Pearce, M; Steelman, LS; Franklin, RA; McCarthy, SA; Cherwinski, H; McMahon, M; McCubrey, JA				Blalock, WL; Pearce, M; Steelman, LS; Franklin, RA; McCarthy, SA; Cherwinski, H; McMahon, M; McCubrey, JA			A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells	ONCOGENE			English	Article						MEK1; signal transduction; oncogenes; cytokines	MAP KINASE KINASE; NIH 3T3 CELLS; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MALIGNANT TRANSFORMATION; INTERLEUKIN-3 RECEPTOR; CYTOKINE RECEPTORS; INTERFERON-GAMMA; DEPENDENT CELLS; GENE-EXPRESSION	The Raf/MEK/MAP kinase cascade plays a critical role in transducing growth signals from activated cell surface receptors, Using Delta MEK1:ER, a conditionally-active form of MEK1, we demonstrate the ability of this dual specificity protein kinase to abrogate the cytokine-dependency of the human rand murine hematopoietic cells lines TF-1, FDC-P1 and FL5.12. Cytokine-independent cells were obtained from TF-1, FDC-P1 and FL5.12 cells at frequencies of 2.5 x 10(-3), 5 x 10(-5) and 10(-7) respectively, indicating that not all cells expressing Delta MEK1:ER were factor-independent. In general, cells that were converted to a cytokine-independent phenotype displayed a higher level of MAP kinase activity in response to Delta MEK1:ER activation than those that remained cytokine-dependent, Delta ME K1:ER-responsive cells could be maintained long-term in the presence of beta-estradiol as well as the estrogen-receptor antagonist 4-Hydroxy-Tamoxifen and the antiestrogen ICI 164383, Removal of hormone led to the rapid cessation of cell growth in a manner similar to that observed when cytokine is withdrawn from the parental cells. Treatment of Delta MEK1:ER-responsive cells with a specific and selective inhibitor, PD98059, prevented growth in response to beta-estradiol. GM-CSF mRNA transcripts were detected in the MEK1-responsive cells indicating that the activated Delta MEK1:ER may induce a pathway leading to autocrine proliferation. Treatment of MEK1-responsive cells with an anti-GM-CSF antibody, but not a control antibody, suppressed cell growth. The cell. lines described here will be useful for elaborating the ability of the MAP kinase pathway to regulate cell proliferation in hematopoietic cells.	E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	McCubrey, JA (corresponding author), E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Brody Bldg 5N98C, Greenville, NC 27858 USA.		McCarthy, Sarah/HCI-8963-2022; McMahon, Martin/L-3303-2013; Blalock, William L/C-6959-2019	McMahon, Martin/0000-0003-2812-1042; Blalock, William L/0000-0002-8045-4840; Franklin, Richard A./0000-0003-0299-9578; McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01CA15025] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGATE PA, 1994, BLOOD, V83, P2459; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRUNET A, 1994, ONCOGENE, V9, P3379; Cleveland JL, 1994, ONCOGENE, V9, P2227; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; delPeso L, 1997, SCIENCE, V278, P687; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; DENT P, 1995, MOL CELL BIOL, V15, P4125; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Hanazono Y, 1996, ACTA HAEMATOL-BASEL, V95, P236; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; HUANG W, 1994, MOL CELL BIOL, V6, P237; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KINOSHITA T, 1995, EMBO J, V14, P265; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MAY WS, 1994, J BIOL CHEM, V269, P26865; MAYO MW, 1995, BLOOD, V86, P3139; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; MCCUBREY JA, 1995, INT J ONCOL, V7, P573; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mufson RA, 1997, FASEB J, V11, P37, DOI 10.1096/fasebj.11.1.9034164; OADI H, 1997, BLOOD, V89, P2745; OADI H, 1995, J BIOL CHEM, V270, P10800; OADI H, 1997, LEUKEMIA S3, V11, P405; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P9430; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Shelly C, 1998, LEUKEMIA, V12, P1951, DOI 10.1038/sj.leu.2401221; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Steelman LS, 1996, LEUKEMIA, V10, P528; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XY, 1997, LEUKEMIA, V11, P1711, DOI 10.1038/sj.leu.2400793; Wang XY, 1997, CYTOKINES CELL MOL T, V3, P3; Wang XY, 1996, CELL GROWTH DIFFER, V7, P487; Wang XY, 1997, INT J ONCOL, V10, P989; Wang XY, 1998, LEUKEMIA, V12, P520, DOI 10.1038/sj.leu.2400975; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	67	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					526	536		10.1038/sj.onc.1203337	http://dx.doi.org/10.1038/sj.onc.1203337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698522	Bronze			2022-12-17	WOS:000085104200006
J	Inagaki, K; Noguchi, T; Matozaki, T; Horikawa, T; Fukunaga, K; Tsuda, M; Ichihashi, M; Kasuga, M				Inagaki, K; Noguchi, T; Matozaki, T; Horikawa, T; Fukunaga, K; Tsuda, M; Ichihashi, M; Kasuga, M			Roles for the protein tyrosine phosphatase SHP-2 in cytoskeletal organization, cell adhesion and cell migration revealed by overexpression of a dominant negative mutant	ONCOGENE			English	Article						cytoskeletal organization; cell migration; integrin signaling; SHP-2	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; GROWTH-FACTOR; FOCAL ADHESION; SIGNAL-TRANSDUCTION; SYP PHOSPHATASE; RAS ACTIVATION; MAP KINASE; PHOSPHORYLATION; INSULIN	SHP-2, a SRC homology 2 domain-containing protein tyrosine phosphatase, mediates activation of Ras and mitogen-activated protein kinase by various mitogens and cell adhesion, Inhibition of endogenous SHP-2 by overexpression of a catalytically inactive (dominant negative) mutant in Chinese hamster ovary cells or Rat-1 fibroblasts has now been shown to induce a marked change in cell morphology (from elongated to less polarized) that is accompanied by substantial increases in the numbers of actin stress fibers and focal adhesion contacts. Overexpression of the SHP-2 mutant also increased the strength of cell-substratum adhesion and resulted in hyperphosphorylation of SHPS-1, a substrate of SHP-2 that contributes to cell adhesion-induced signaling, Inhibition of SHP-2 also markedly increased the rate of cell attachment to and cell spreading on extracellular matrix proteins such as fibronectin and vitronectin, effects that were accompanied by enhancement of adhesion-induced tyrosine phosphorylation of paxillin and p130Cas. In addition, cell migration mediated by fibronectin or vitronectin, but not that induced by insulin, was impaired by over-expression of the SHP-2 mutant, These results suggest that SHP-2 plays an important role in the control of cell shape by contributing to cytoskeletal organization, and that it is an important regulator of integrin-mediated cell adhesion, spreading, and migration as well as of tyrosine phosphorylation of focal adhesion contact-associated proteins.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Dept Dermatol, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University	Noguchi, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Adachi M, 1996, CELL, V85, P15; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORIKAWA T, 1995, J INVEST DERMATOL, V104, P256, DOI 10.1111/1523-1747.ep12612795; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; ILLC D, 1995, NATURE, V377, P539; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Manes S, 1999, MOL CELL BIOL, V19, P3125; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; Menzel D, 1996, CURR OPIN CELL BIOL, V8, P38, DOI 10.1016/S0955-0674(96)80046-9; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOBES CD, 1995, J CELL SCI, V108, P225; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwarzbauer JE, 1997, CURR BIOL, V7, pR292, DOI 10.1016/S0960-9822(06)00140-0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	58	74	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					75	84		10.1038/sj.onc.1203204	http://dx.doi.org/10.1038/sj.onc.1203204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644982				2022-12-17	WOS:000084844300009
J	DeCristofaro, MF; Betz, BL; Wang, WD; Weissman, BE				DeCristofaro, MF; Betz, BL; Wang, WD; Weissman, BE			Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors	ONCOGENE			English	Article						BAF47; SWI/SNF; rhabdomyosarcomas; rhabdoid; tumor suppressor genes	TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; SWI/SNF COMPLEX; HUMAN HOMOLOG; YEAST; BINDING; SNF5; STIMULATION; SWI2/SNF2; COOPERATE	The organization of genomic DNA into chromatin aids in the regulation of gene expression by limiting the access of transcriptional binding domains. The SWI/SNF family of chromatin-remodeling complexes, which are conserved from yeast to humans, open the chromatin to facilitate the transcriptional machinery to access their targets. The gene encoding the BAF47/hSNF5 subunit of the complex has been found mutated in both rhabdoid cell lines and in primary rhabdoid tumors. Since the pediatric tumors rhabdomyosarcoma (RMS) and Wilms' tumor (WT) share a similar genetic link with rhabdoid tumors, it was hypothesized that they may also show alterations of the BAF47 gene. Using primary tumors, the BAF47 protein was detected in all WT but less than 75% of the RMS tested, In cell lines, the BAF47 protein was missing in all rhabdoid cell lines and one RMS cell Line. Analysis of sample DNA displayed either a mutation or deletion of the BAF47 gene in all samples negative for the protein. Several other subunits of the human SWI/SNF complex, including BRG1 which is the subunit directly interacting with the Rb tumor suppressor gene, were detected in all tumor samples. Alteration of BAF47 may be a genetic marker associated with the poor prognosis seen in all rhabdoid tumors but only some RMS.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; NIA, Gerontol Res Ctr, Genet Lab, NIH, Baltimore, MD 21224 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Weissman, BE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295,Rm 32-062, Chapel Hill, NC 27599 USA.		Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928	NATIONAL CANCER INSTITUTE [R01CA063176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008581] Funding Source: NIH RePORTER; NCI NIH HHS [CA63176] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM08581] Funding Source: Medline; PHS HHS [5-T32-WS07017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIEGEL JA, 1990, CANCER RES, V59, P74; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Charles AK, 1998, AM J PATHOL, V153, P991, DOI 10.1016/S0002-9440(10)65641-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Green Daniel M., 1997, P733; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pappo Alberto S., 1996, Current Opinion in Oncology, V8, P311; Parham D, 1996, PEDIAT NEOPLASIA MOR, P87; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Pogacnik A, 1997, ACTA CYTOL, V41, P539, DOI 10.1159/000332553; Rosty C, 1998, GENE CHROMOSOME CANC, V21, P82, DOI 10.1002/(SICI)1098-2264(199802)21:2<82::AID-GCC2>3.0.CO;2-3; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	29	74	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7559	7565		10.1038/sj.onc.1203168	http://dx.doi.org/10.1038/sj.onc.1203168			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602515				2022-12-17	WOS:000084119600017
J	Sullivan, MJ; Taniguchi, T; Jhee, A; Kerr, N; Reeve, AE				Sullivan, MJ; Taniguchi, T; Jhee, A; Kerr, N; Reeve, AE			Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation	ONCOGENE			English	Article						IGF2; insulin-like growth factor 2; genomic imprinting; Wilms tumour; methylation	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; BIALLELIC EXPRESSION; ALLELIC METHYLATION; HUMAN EMBRYOGENESIS; EPIGENETIC CHANGES; DNA METHYLATION; MOUSE IGF2; H19 LOCUS; GENE	Relaxation of IGF2 imprinting occurs in Wilms tumours and many other cancers, but the mechanism of loss of imprinting (LOI) remains unknown. To investigate the role of altered DNA methylation in LOI, we examined the pattern of methylation of the human insulin-IGF2 region in Wilms tumours and the normal kidney. The analysis included regions homologous to three 'differentially methylated regions' of the mouse Igf2 gene (dmrs 0, 1 and 2), In tumours displaying normal IGF2 imprinting, and in the normal kidney, maternal allele-specific DNA methylation was identified spanning exons 2 and 3, This region is homologous to dmr 0, a site of maternal-specific differential methylation in the mouse. In Wilms tumours with relaxed imprinting or 11p15.5 LOH this region was unmethylated. No other differential methylation was identified, In particular, two sites of paternal methylation in the mouse (dmrs 1 and 2), and all three imprinted IGF2 promoters were not methylated in the kidney or in Wilms tumours, We postulate that LOI in Wilms tumours is associated with loss of maternal allele-specific methylation from a region located upstream of the imprinted IGF2 promoters, This region may contain cis acting sequences that coordinately influence imprinting.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand	University of Otago	Sullivan, MJ (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, New Zealand.		Sullivan, Michael/B-5459-2012	Sullivan, Michael/0000-0002-8606-5889				CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; DoucRasy S, 1996, ONCOGENE, V12, P423; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; FEIL R, 1994, DEVELOPMENT, V120, P2933; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; Hashimoto K, 1997, HUM PATHOL, V28, P862, DOI 10.1016/S0046-8177(97)90162-3; Hibi K, 1996, CANCER RES, V56, P480; Hu JF, 1997, MOL ENDOCRINOL, V11, P1891, DOI 10.1210/me.11.13.1891; Hu JF, 1997, J BIOL CHEM, V272, P20715, DOI 10.1074/jbc.272.33.20715; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Joyce JA, 1997, HUM MOL GENET, V6, P1543, DOI 10.1093/hmg/6.9.1543; Kim KS, 1997, CANCER LETT, V119, P143, DOI 10.1016/S0304-3835(97)00264-4; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Nonomura N, 1997, J UROLOGY, V157, P1977, DOI 10.1016/S0022-5347(01)64913-9; Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.0.CO;2-2; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TANIGUCHI T, 1995, ONCOGENE, V11, P751; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; WEKSBERG R, 1993, HUM MOL GENET, V2, P549, DOI 10.1093/hmg/2.5.549; Wu HK, 1997, BIOCHEM BIOPH RES CO, V231, P466, DOI 10.1006/bbrc.1997.6127; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1993, AM J HUM GENET, V53, P113	50	74	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7527	7534		10.1038/sj.onc.1203096	http://dx.doi.org/10.1038/sj.onc.1203096			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602511				2022-12-17	WOS:000084119600013
J	Liu, JL; Huang, C; Zhan, X				Liu, JL; Huang, C; Zhan, X			Src is required for cell migration and shape changes induced by fibroblast growth factor 1	ONCOGENE			English	Article						Src; FGF-1; cortactin	TYROSINE KINASE; ACTIN CYTOSKELETON; FACTOR RECEPTOR; POINT MUTATION; EGF-RECEPTOR; FACTOR-I; C-SRC; PROTEIN; CORTACTIN; ASSOCIATION	Fibroblast growth factor 1 (FGF-1) is a potent chemotactic factor and induces tyrosine phosphorylation of a cortical actin-associated protein (cortactin). The tyrosine phosphorylation of cortactin induced by FGF-1 requires the tyrosine residues 421, 482 and 466, which are targeted by the protein tyrosine kinase Src irt vitro. Furthermore, FGF-1 is unable to induce tyrosine phosphorylation of cortactin within the cells derived from Src knockout mice (Src(-/-)), indicating that Src is required for the tyrosine phosphorylation of cortactin induced by FGF-1. Although Src-/- cells are able to undergo rapid proliferation, they are impaired to respond to FGF-1 for the shape change and cell migration. Morphological analysis further reveals that FGF-1 fails to induce the formation of polarized lamellipodia and the translocation of cortactin into the leading edge of Src(-/-) cells. Consistent with the mitogenic response to FGF-1, the lack of Src does not affect the tyrosine phosphorylation of Snt (or Frs2), a FGF-1 early signaling protein that links to Ras, Therefore, our data support the notion that Src and cortactin participate in a FGF signal pathway for cell migration and shape change rather than mitogenesis.	Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Zhan, X (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [R29 HL52753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Cramer Louise P., 1997, Frontiers in Bioscience (online), V2, pD260; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HUANG SS, 1986, J BIOL CHEM, V261, P9568; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; MACIAG T, 1982, J BIOL CHEM, V257, P5333; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Weed SA, 1998, J CELL SCI, V111, P2433; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	38	74	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6700	6706		10.1038/sj.onc.1203050	http://dx.doi.org/10.1038/sj.onc.1203050			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597276				2022-12-17	WOS:000083792000010
J	Yamane, K; Tsuruo, T				Yamane, K; Tsuruo, T			Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA	ONCOGENE			English	Article						checkpoint; Cut5; DNA damage sensor; DNA repair; Nijmegen breakage syndrome	REPLICATION CHECKPOINT CONTROL; FISSION YEAST; PROTEIN; REPAIR; DAMAGE; REGULATOR; RESIDUES; CHK1; CUT5; P53	The BRCT region, the carboxyl-terminus of BRCA1 (the breast cancer susceptibility gene 1 product), is ubiquitous region homologous to regions in DNA repair enzymes and cell cycle regulators. We showed that the BRCT regions bound DNA fragments, using the TopBP1 protein (topoisomerase II binding protein 1), with eight BRCTs as a model protein. The bindings mere independent of DNA sequences, forms of DNA termini and energy. The BRCT-DNA complex showed resistance to an exonuclease, indicating that BRCT bound BNA breaks. The BRCTs also bound DNA nicks, suggesting that BRCTs play an important role in detection of both single- and double-strand DNA breaks or ends. On the other hand, BRCTs did not bind circular intact DNA, BRCTs of BRCA1 also bound DNA termini, Since some BRCTs are unique general elements in some tumor suppressions, these findings will reveal novel aspects of the tumor suppression mechanism.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YAMANE K, 1988, J BIOL CHEM, V263, P19690; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x	26	74	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5194	5203		10.1038/sj.onc.1202922	http://dx.doi.org/10.1038/sj.onc.1202922			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498869				2022-12-17	WOS:000082555700008
J	Fujii, GH; Morimoto, AM; Berson, AE; Bolen, JB				Fujii, GH; Morimoto, AM; Berson, AE; Bolen, JB			Transcriptional analysis of the PTEN/MMAC1 pseudogene, Psi PTEN	ONCOGENE			English	Article						MMAC; PTEN; tumor suppressor; pseudogene	TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; HOMOZYGOUS DELETION; PHOSPHATASE; PROTEIN; BREAST; BETA; CHROMOSOME-9; MUTATIONS; LOCUS	PTEN/MMAC1 is a recently characterized tumor suppressor. A pseudogene derived from the human PTEN/MMAC1 phosphatase, Psi PTEN, has been reported. Recent analysis of the pseudogene revealed conflicting results about the expression of Psi PTEN. In this study, we show that the PTEN/MMAC1 pseudogene is actively transcribed in all cells and tissues examined. In some cases, pseudogene transcripts were found to represent as much as 70% of the total PTEN/MMAC1 RNA. As Psi PTEN is transcribed, there is a potential for misinterpretation of PTEN/MMAC1 mutations when RT - PCR techniques are used, as well as potential for a Psi PTEN-encoded translation product, Although we were unable to detect a pseudogene protein product in the cell lines examined, a baculovirus produced GST pseudogene fusion protein exhibited phosphatase activity comparable to wild type. The results of this study, taken together, indicate the potential complication of PTEN/MMAC1 molecular analysis caused by the expression of Psi PTEN.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cellular Signaling, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Fujii, GH (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cellular Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cheney IW, 1998, CANCER RES, V58, P2331; CHENG JQ, 1994, CANCER RES, V54, P5547; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MORIMOTO AM, 1998, UNPUB; MORIMOTO AM, 1999, IN PRESS ONCOGENE; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rhei E, 1997, CANCER RES, V57, P3657; ROBINSON MA, 1993, P NATL ACAD SCI USA, V90, P2433, DOI 10.1073/pnas.90.6.2433; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SOLOVYEV V, 1997, ISMB, V5, P294; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; Whang YE, 1998, J NATL CANCER I, V90, P859, DOI 10.1093/jnci/90.11.859; WILDE CD, 1986, CRIT REV BIOCHEM MOL, V19, P323	27	74	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1765	1769		10.1038/sj.onc.1202492	http://dx.doi.org/10.1038/sj.onc.1202492			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208437				2022-12-17	WOS:000079025000011
J	Chew, YP; Ellis, M; Wilkie, S; Mittnacht, S				Chew, YP; Ellis, M; Wilkie, S; Mittnacht, S			pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F	ONCOGENE			English	Article						retinoblastoma protein; pRB; E2F; phosphorylation; checkpoint control; cell cycle	RETINOBLASTOMA-SUSCEPTIBILITY GENE; CELL-CYCLE CONTROL; RESTRICTION POINT; PROTEIN; PRODUCT; BINDING; EXPRESSION; TRANSCRIPTION; APOPTOSIS; RB	Progression of cells into S phase is controlled by the retinoblastoma protein (pRB) and relies on the functional inactivation of this tumour suppressor in late G1 via protein phosphorylation. We provide evidence here that, besides controlling entry of cells into S phase, pRB can operate to inhibit S phase completion. Differential arrays of phosphorylation appear to regulate these different events, suggesting that cycle progression at these two stages of the cell cycle may be achieved via activation of distinct downstream pRB effector pathways. In agreement with this hypothesis, pRB's ability to prevent S phase entry, but not its ability to inhibit S phase completion, correlates with repression of E2F-regulated promoters. Furthermore, ectopic expression of E2F or the E2F-regulated cyclin E gene promote S phase entry in cells expressing phosphorylation-defective pRB but neither is sufficient to trigger completion of S phase. Our findings raise the possibility that pRB, in addition to its web-established role in controlling a checkpoint in late G1, could be involved in the control of a further checkpoint operating during S phase and that implementation of this checkpoint relies on an as yet unidentified PRE effector distinct from E2F.	Inst Canc Res, Chester Beatty Labs, CRC Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Mittnacht, S (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; GAUTSCHI JR, 1973, J MOL BIOL, V80, P393, DOI 10.1016/0022-2836(73)90411-7; Geng Y, 1996, ONCOGENE, V12, P1173; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iliakis G, 1997, SEMIN ONCOL, V24, P602; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YAVUZER U, 1995, ONCOGENE, V10, P123; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	74	74	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2177	2186		10.1038/sj.onc.1202443	http://dx.doi.org/10.1038/sj.onc.1202443			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811449				2022-12-17	WOS:000076698200004
J	Sun, GQ; Sharma, AK; Budde, RJA				Sun, GQ; Sharma, AK; Budde, RJA			Autophosphorylation of Src and Yes blocks their inactivation by Csk phosphorylation	ONCOGENE			English	Article						Src and Yes regulation; Csk; protein tyrosine phosphatase 1B; autophosphorylation	PROTEIN-TYROSINE KINASE; HUMAN COLORECTAL-CANCER; C-SRC; EXPRESSION SYSTEM; PP60(C-SRC) ACTIVITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HUMAN-PLACENTA; PP60C-SRC; PURIFICATION	Csk phosphorylates Src family protein tyrosine kinases on a tyrosine residue near their C-terminus and down-regulates their activity. We previously observed that this regulation requires a stoichiometric ratio of Csk:Src in a time-independent manner. In this report we examined this unusual kinetic behavior and found it to be caused by Src autophosphorylation, First, pre-incubation of Src with ATP-Mg led to time-dependent autophosphorylation of Src, activation of its kinase activity and loss of its ability to be inactivated by Csk, However, the autophosphorylated Src can still be phosphorylated by Csk. The SH2 binding site for phospho-Tyr of this hyperactive and doubly phosphorylated form of Src is not accessible. Second, dephosphorylation of autophosphorylated Src by protein tyrosine phosphatase 1B allowed Src to be inactivated by Csk, Third, protein tyrosine phosphatase 1B preferentially dephosphorylates the Src autophosphorylation site and allows for Src regulation by Csk, Finally, Yes, another member of the Src family, was also only partially inactivated when a sub-stoichiometric amount of Csk was used. Mutation of the tyrosine autophosphorylation site of Yes to a phenylalanine resulted in a mutant Yes enzyme that can be fully inactivated by a sub-stoichiometric amount of Csk in a time-dependent manner. These results demonstrate that Csk phosphorylation inactivates Src and Yes only when they are not previously autophosphorylated and Src autophosphorylation can block the inactivation by Csk phosphorylation, This conclusion suggests a dynamic model for the regulation of the Src family protein tyrosine kinases, which is discussed in the context of previously reported observations on the regulation of Src family protein tyrosine kinases.	Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Budde, RJA (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Box 316, Houston, TX 77030 USA.				NCI NIH HHS [CA16672, CA53617] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA053617, P30CA016672, U19CA053617] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BOLEN JB, 1987, ONCOGENE RES, V1, P149; Bougeret C, 1996, J BIOL CHEM, V271, P7465, DOI 10.1074/jbc.271.13.7465; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BUDDE RJA, 1993, PREP BIOCHEM, V23, P493, DOI 10.1080/10826069308544572; Chappel J, 1997, J CELL BIOCHEM, V67, P432, DOI 10.1002/(SICI)1097-4644(19971215)67:4<432::AID-JCB2>3.0.CO;2-T; Chedin M, 1997, CARCINOGENESIS, V18, P1463, DOI 10.1093/carcin/18.8.1463; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1989, ONCOGENE RES, V5, P49; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; Levitzki A, 1996, ANTI-CANCER DRUG DES, V11, P175; Li SL, 1996, CELL BIOL INT, V20, P723; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OETKEN C, 1994, ONCOGENE, V9, P1625; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sambrook J., 1989, MOL CLONING; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STOVER DR, 1994, J BIOL CHEM, V269, P26885; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V345, P135, DOI 10.1006/abbi.1997.0236; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P194, DOI 10.1006/abbi.1997.0156; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WATANABE N, 1995, JPN J CLIN ONCOL, V25, P5; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	48	74	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1587	1595		10.1038/sj.onc.1202076	http://dx.doi.org/10.1038/sj.onc.1202076			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794236				2022-12-17	WOS:000076089900011
J	McGarvey, TW; Maruta, Y; Tomaszewski, JE; Linnenbach, AJ; Malkowicz, SB				McGarvey, TW; Maruta, Y; Tomaszewski, JE; Linnenbach, AJ; Malkowicz, SB			PTCH gene mutations in invasive transitional cell carcinoma of the bladder	ONCOGENE			English	Article						PTCH; transitional cell carcinoma of the bladder; mutations	DROSOPHILA PATCHED GENE; TUMOR-SUPPRESSOR LOCI; SONIC HEDGEHOG; HUMAN HOMOLOG; MICROSATELLITE ALTERATIONS; REGULATES EXPRESSION; MEMBRANE-PROTEIN; ALLELIC LOSSES; CANCER; CHROMOSOME-9	LOH analysis suggests that multiple tumor suppressor genes play a role in the development of human TCC. The human homolog of the Drosophila PTCH was recently cloned and mapped to the BCNS locus on 9q22.3, a chromosomal region commonly deleted in TCCs. We first examined the steady state mRNA transcription of the PTCH, SMOH and GL13 genes of the HH signal transduction pathway in TCC cell lines and normal urothelium. Normal urothelium and TCC cell lines express these three genes within the PTCH signal transduction pathway. We then screened for PTCH mutations in 'hot spot' exons 6, 8, 13 and 16 by PCR/SSCP analysis of genomic DNAs from 54 TCC tumor samples and control autologous peripheral blood lymphocytes. DNA sequence analysis confirmed TCC-specific mutations in two of 54 patients (3.7%). These mutations resulted a single amino acid substitution and two frame shifts. One tumor had PTCH mutations in exon 16 as well as exon 13 and one tumor had a mutation in exon 13 alone. Both TCC tumors that contained PTCH mutations had a loss of heterozygosity at 9q. Although the PTCH protein has an unknown function in urothelial cells, the detection of the PTCH, SMOH and GL13 transcripts in normal urothelium and TCC cell lines and rare PTCH mutations in tumor samples suggest that the HH pathway may have a role in controlling the proliferation of urothelial cells and that PTCH mutations may contribute to the development of a subset of TCCs.	Univ Penn, Med Ctr, Dept Surg, Div Urol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); The Wistar Institute	Malkowicz, SB (corresponding author), Univ Penn, Med Ctr, Dept Surg, Div Urol, 1 Rhoads,3400 Spruce St, Philadelphia, PA 19104 USA.							Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; CATALONA WJ, 1988, CAMPBELLS UROLOGY, P1094; CHANG WYH, 1995, CANCER RES, V55, P3246; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chidambaram A, 1996, CANCER RES, V56, P4599; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DOMINGUEZ M, 1996, NATURE, V372, P1621; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hepker J, 1997, DEVELOPMENT, V124, P549; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kallassy M, 1997, CANCER RES, V57, P4731; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KNOWLES MA, 1994, CANCER RES, V54, P531; Li MM, 1996, AM J PATHOL, V149, P229; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; MALKOWICZ SB, 1994, CLIN MANUAL UROLOGY, P419; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; ORLOW I, 1994, CANCER RES, V54, P2848; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1993, CANCER RES, V53, P5093; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Simoneau AR, 1996, CANCER RES, V56, P5039; SPRUCK CH, 1994, CANCER RES, V54, P784; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; Unden AB, 1997, CANCER RES, V57, P2336; WALDMAN FM, 1991, CANCER RES, V51, P3807; WINGO PA, 1997, CA CANC J CLIN, V45, P8; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	45	74	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1167	1172		10.1038/sj.onc.1202045	http://dx.doi.org/10.1038/sj.onc.1202045			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764827				2022-12-17	WOS:000075598400012
J	Maier, D; Zhang, ZW; Taylor, E; Hamou, MF; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A				Maier, D; Zhang, ZW; Taylor, E; Hamou, MF; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A			Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas	ONCOGENE			English	Article						deletion mapping; chromosome 10q23.3 and 10q25-26; PTEN/MMAC1	GLIOBLASTOMA-MULTIFORME; LONG ARM; HETEROZYGOSITY; CANCER; LOCI; PROGRESSION; METHYLATION; CARCINOMA; 10Q23-25	The l0q25-26 region between the dinucleotide markers D10S587 and D10S216 is deleted in glioblastomas and, as we have recently shown, in low-grade oligodendrogliomas. We further refined somatic mapping on 10q23-tel and simultaneously assessed the role of the candidate tumor suppressor gene PTEN/MMAC1 in glial neoplasms by sequence analysis of eight low-grade and 24 high-grade gliomas. These tumors were selected for partial or complete loss of chromosome 10 based on deletion mapping with increased microsatellite marker density at 10q23-tel. Three out of eight (38%) low-grade and 3/24 (13%) high-grade gliomas exclusively target 10q25-26.We did not find a tumor only targeting 10q23.3, and most tumors (23/32, 72%) showed large deletions on 10q including both regions. The sequence analysis of PTEN/MMAC1 revealed nucleotide alterations in 1/8 (12.5%) low-grade gliomas in a tumor with LOH at l0q21-qtel and in 5/21 (24%) high-grade gliomas displaying LOH that always included 10q23-26. Our refined mapping data point to the 10q25-26 region as the primary target on 10q, an area that also harbors the DMBT1 candidate tumor suppressor gene. The fact that we find hemizygous deletions at 10q25-qtel in low-grade astrocytomas and oligodendrogliomas - two histologically distinct entities of gliomas - suggests the existence of a putative suppressor gene involved early in glial tumorigenesis.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland	University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Merlo, A (corresponding author), Univ Basel Hosp, Dept Res, Schanzenstr 46, CH-4031 Basel, Switzerland.		Scott, Rodney J/B-2827-2013	Scott, Rodney J/0000-0001-7724-3404; Van Meir, Erwin G./0000-0003-2444-7707				Albarosa R, 1996, AM J HUM GENET, V58, P1260; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GRAY IC, 1995, CANCER RES, V55, P4800; HERBST RA, 1994, CANCER RES, V54, P3111; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JAMES CD, 1988, CANCER RES, V48, P5546; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P640; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORITA R, 1991, CANCER RES, V51, P5817; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; Nagase S, 1997, CANCER RES, V57, P1630; PEIFFER SL, 1995, CANCER RES, V55, P1922; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wang SI, 1997, CANCER RES, V57, P4183	31	74	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3331	3335		10.1038/sj.onc.1201832	http://dx.doi.org/10.1038/sj.onc.1201832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681833				2022-12-17	WOS:000074343600015
J	Lanyi, A; Deb, D; Seymour, RC; Ludes-Meyers, JH; Subler, MA; Deb, S				Lanyi, A; Deb, D; Seymour, RC; Ludes-Meyers, JH; Subler, MA; Deb, S			'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain	ONCOGENE			English	Article						mutant p53; transcriptional activation, domain	FACTOR RECEPTOR PROMOTER; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; TRANSFORMING MUTANTS; FUNCTION MUTATIONS; SUPPRESSOR GENE; MDR1 GENE; PROTEIN; CELLS	Tumor-derived p53 mutants can transcriptionally activate a number of promoters of genes involved in cellular proliferation. For this transactivation, mutant p53 does not use the wild-type p53 DNA-binding site, suggesting a mechanism of transactivation that is independent of direct DNA binding. Here me describe our analysis of the domain requirements for mutant p53 to transactivate promoters of the human epidermal growth factor receptor (EGFR), human multiple drug resistance 1 (MDR-1) and human proliferating cell nuclear antigen (PCNA) genes. We also report the identification of a structural domain required for the 'Gain of function' property of mutant p53-281G, 'Gain of function' is measured as the tumorigenicity (in nude mice) of 10(3) murine cells expressing mutant p53 constitutively. We have generated internal deletion mutants of p53-281G deleting conserved domains I, II, III, IV and V, individually. We have also generated one deletion mutant eliminating amino acids 100 through 300 that removes four of the five conserved domains (II-V); another mutant, p53-281G del 393-327, deletes the oligomerization and nonsequence-specific nucleic acid-binding domains of p53, For the EGFR and MDR-1 promoters, all these mutants have significantly lower transactivation ability than intact p53-281G, These deletion mutants, however, significantly activated the pCNA promoter, suggesting that the mechanism of transactivation of the PCNA promoter is different from that of the EGFR and MDR-I promoters, When expressed constitutively in 10(3) cells, p53-281G del 393-327 was found to be defective in inducing tumor formation in nude mice although intact p53-281G was very efficient. Thus, our results suggest that structural domains near the C-terminus are needed for 'gain of function'.	Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Deb, S (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL CANCER INSTITUTE [R01CA070712] Funding Source: NIH RePORTER; NCI NIH HHS [CA70712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE W, 1994, STRUCT BIOL, V1, P877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1995, ONCOGENE, V10, P2387; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Muller BF, 1996, ONCOGENE, V12, P1941; OROURKE RW, 1990, ONCOGENE, V5, P1829; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHALUSKI G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	47	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3169	3176		10.1038/sj.onc.1201857	http://dx.doi.org/10.1038/sj.onc.1201857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671396				2022-12-17	WOS:000074261300010
J	Pinkas-Kramarski, R; Lenferink, AEG; Bacus, SS; Lyass, L; van de Poll, MLM; Klapper, LN; Tzahar, E; Sela, M; van Zoelen, EJJ; Yarden, Y				Pinkas-Kramarski, R; Lenferink, AEG; Bacus, SS; Lyass, L; van de Poll, MLM; Klapper, LN; Tzahar, E; Sela, M; van Zoelen, EJJ; Yarden, Y			The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin	ONCOGENE			English	Article						epidermal growth factor; ErbB/HER family; signal transduction; tyrosine kinase; oncogene	NEU DIFFERENTIATION FACTOR; FACTOR-RELATED PEPTIDES; HIGH-AFFINITY; FACTOR-ALPHA; HEREGULIN ISOFORMS; CELLULAR-RESPONSE; MAMMARY-TUMORS; ERBB RECEPTORS; NDF HEREGULIN; EGF RECEPTOR	The ErbB-1 receptor tyrosine kinase binds to six different growth factors, whose prototype is the epidermal growth factor (EGF). Two homologous epithelial receptors, ErbB-3 and ErbB-4, bind all isoforms of another family of growth factors, the Neu differentiation factors (NDFs/neuregulins). The fourth member of the ErbB family, ErbB-2, acts as the preferred heterodimeric partner of ligand-occupied complexes of the three other ErbB proteins. Here we report that at high concentrations, EGF can induce cell growth and differentiation in the absence of ErbB-1. This function is shared by betacellulin, but not by three other ligands, including the transforming growth factor alpha (TGF alpha). The functional receptor was identified as a heterodimer between ErbB-3 and ErbB-2, a previously identified oncogenic complex, When singly expressed, neither ErbB-3 nor ErbB-2 can mediate signaling by EGF. In addition, when co-expressed, blocking either receptor by using site-specific antibodies inhibited EGF and betacellulin activities, indicating strict cooperativity between ErbB-3 and ErbB-2, Through analysis of chimeras between EGF and TGF alpha, we identified the middle portion of EGF (loop B) as the site that enables activation of ErbB-2/ErbB-3. In conclusion, cooperative and promiscuous binding of stroma-derived growth factors by the epithelium-expressed ErbB-2/ErbB-3 heterodimer may be significant to cancer development. The mechanistic implications of our results for a model that attributes receptor dimerization to ligand bivalency, as well as to a recently proposed mechanism of secondary dimerization, are discussed.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Catholic Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; Adv Cellular Diagnost Inc, Elmhurst, IL 60126 USA	Weizmann Institute of Science; Weizmann Institute of Science; Radboud University Nijmegen	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012; van Zoelen, Everardus J./D-9192-2012	Pinkas-Kramarski, Ronit/0000-0002-1000-369X	NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA51712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BACUS SS, 1993, CANCER RES, V53, P5251; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CAMPION SR, 1993, J BIOL CHEM, V268, P1742; CARPENTER G, 1991, EPIDERMAL GROWTH FAC, P69; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELDIN CH, 1996, CYTOKINE GROWTH F R, V7, P33; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KATSUURA M, 1989, J BIOCHEM-TOKYO, V106, P87, DOI 10.1093/oxfordjournals.jbchem.a122826; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMOINE NR, 1992, J PATHOL, V168, P269, DOI 10.1002/path.1711680305; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOY FJ, 1993, BIOCHEMISTRY-US, V32, P7334, DOI 10.1021/bi00080a003; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Stancovski I, 1994, Cancer Treat Res, V71, P161; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	74	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1249	1258		10.1038/sj.onc.1201642	http://dx.doi.org/10.1038/sj.onc.1201642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546426				2022-12-17	WOS:000072422000003
J	Rodriguez-Villanueva, J; Greenhalgh, D; Wang, XJ; Bundman, D; Cho, S; Delehedde, M; Roop, D; McDonnell, TJ				Rodriguez-Villanueva, J; Greenhalgh, D; Wang, XJ; Bundman, D; Cho, S; Delehedde, M; Roop, D; McDonnell, TJ			Human keratin-1,bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation	ONCOGENE			English	Article						bcl-2; apoptosis; keratinocyte; skin cancer	IN-VIVO PATTERNS; WILD-TYPE P53; IMMUNOHISTOCHEMICAL ANALYSIS; EPIDERMAL DIFFERENTIATION; BCL-2 PROTEIN; HAIR FOLLICLE; APOPTOSIS; GENE; CARCINOGENESIS; LYMPHOMA	Nonmelanoma skin cancers (NMSC) are among the most common malignancies in the world. Typically, these neoplasms grow slowly and are comparatively indolent in their clinical behavior. The most frequent molecular alterations implicated in the pathogenesis of these neoplasms involve genes known to be regulators of cell death including p53, Ha-ras and bcl-2. In order to evaluate the significance cell death deregulation during skin carcinogenesis, we generated a transgenic mouse model (HK1.bcl-2) using the human keratin 1 promoter to target the expression of a human bcl-2 minigene to the epidermis. Transgenic HK1.bcl-2 protein was expressed at high levels specifically in the epidermis extending from the stratum basale through the stratum granulosum. The epidermis of HK1.bcl-2 mice exhibited multifocal hyperplasia without associated hyperkeratosis and aberrant expression of keratin 6. The rate of proliferation was similar in HK1.bcl-2 and control epidermis although suprabasal BrdUrd incorporating cells were present only in HK1.bcl-2 skin, Keratinocytes from the HK1.bcl-2 mice mere significantly more resistant to cell death induction by U.V.-B, DMBA, and TPA, compared to central keratinocytes. Furthermore, papillomas developed at a significantly greater frequency and shorter latency in the HK1.bcl-2 mice compared to control littermates following initiation with DMBA and promotion with TPA. Together these results support a role for bcl-2 in the pathogenesis of NMSC.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77077 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77077 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77077 USA.			DELEHEDDE, Maryse/0000-0003-2724-143X	NCI NIH HHS [CA68233, CA52607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052607, P01CA068233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARBEIT JM, 1996, SKIN CANC, P7; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; BURNS PA, 1991, ONCOGENE, V6, P2363; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENHALG DA, 1995, SKIN CANC MECHANISMS, P317; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KANJILAL S, 1993, CANCER RES, V53, P2961; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MARIN MC, 1994, ONCOGENE, V9, P3107; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P239; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V9, P701; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; QUILAN RA, 1985, ANN NY ACAD, V455, P282; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RADY P, 1992, CANCER RES, V52, P3804; RODRIGUEZVILLANUEVA J, 1995, PATHOL RES PRACT, V191, P391, DOI 10.1016/S0344-0338(11)80724-7; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V94, P573; ROTHNAGEL JA, 1991, CELL GROWTH DIFFER, V2, P107; SCHWEIZER J, 1982, CANCER RES, V42, P1517; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STARK HJ, 1987, DIFFERENTIATION, V35, P236, DOI 10.1111/j.1432-0436.1987.tb00174.x; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WANG YS, 1993, ONCOGENE, V8, P3427; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; ZINKEL S, 1994, SEMIN CANCER BIOL, V5, P77	49	74	75	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					853	863		10.1038/sj.onc.1201610	http://dx.doi.org/10.1038/sj.onc.1201610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484776				2022-12-17	WOS:000072053200004
J	Zhan, QM; Bieszczad, CK; Bae, I; Fornace, AJ; Craig, RW				Zhan, QM; Bieszczad, CK; Bae, I; Fornace, AJ; Craig, RW			Induction of BCL2 family member MCL1 as an early response to DNA damage	ONCOGENE			English	Article						MCL1; BCL2; radiation; DNA damage	CYCLE CHECKPOINT PATHWAY; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; LEUKEMIA ML-1 CELLS; ATAXIA-TELANGIECTASIA; GENOTOXIC STRESS; MDM-2 ONCOGENE; HOMOLOG BAK; GENE FAMILY; IN-VIVO	When ML-1 human myeloid leukemia cells are exposed to DNA damaging agents, they exhibit dramatic changes in the expression of a variety of gene products, This includes an increase in p53 (wild-type), a decrease in BCL2, a p53-dependent increase in the BCL2 family member BAX, and increases in Growth Arrest and DNA Damage-inducible (GADD) genes such as GADD45; these changes occur as early events in a sequence that culminates in DNA damage-induced apoptosis, DNA damaging agents have now been tested for effects on expression of another BCL2 family member, MCL1, a gene expressed during ML-1 cell differentiation, Expression of MCL1 was found to increase upon exposure of ML-1 cells to various types of DNA damaging agents, including ionizing radiation, ultraviolet radiation, and alkylating drugs. The increase in MCL1 occurred rapidly and was transient, levels of the MCL1 mRNA being elevated within 4 h and having returned to near baseline within 24 h. An increase in the Mcl1 protein was also seen, with the maximal increase occurring at an intermediate dose of IR (5 Gray) and lesser increases occurring at either lower or higher doses, The increase in expression of MCL1 was further studied using a panel of human cell lines that includes cells containing or not containing alterations in p53 as well as cells sensitive or insensitive to the apoptosis-inducing effects of DNA damage, The DNA damage-induced increase in MCL1 mRNA did not depend upon p53 as it was seen in cells lacking functional p53, However, the increase did depend upon susceptibility to apoptosis as it was not seen in cells insensitive to apoptosis-induction by DNA damaging agents. These findings demonstrate that cytotoxic DNA damage causes an increase in the expression of MCL1 along with increases in GADD45 and BAX and a decrease in BCL2, Furthermore, while the increase in GADD45 is seen both in cells that undergo growth arrest and in cells that undergo apoptosis in response to DNA damage, alterations in the profile of expression of BCL2 family members occur exclusively in cells that undergo the apoptotic response, with some family members increasing through p53-dependent (BAX) and others through p53-independent (MCL1) pathways, Overall, expression MCL1 can increase during the induction of cell death as well as during the induction of differentiation.	DARTMOUTH COLL SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOL PHARMACOL LAB,BETHESDA,MD 20892	Dartmouth College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL CANCER INSTITUTE [R29CA054385] Funding Source: NIH RePORTER; NCI NIH HHS [CA54385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE IS, 1995, CANCER RES, V55, P2387; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; CRAIG RW, 1984, CANCER RES, V44, P442; CRAIG RW, 1984, CANCER RES, V44, P2421; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FORNACE AJ, 1980, BIOCHIM BIOPHYS ACTA, V607, P432, DOI 10.1016/0005-2787(80)90153-7; FUKUNAGAJOHNSON N, 1995, CARCINOGENESIS, V16, P1671; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kitada S, 1996, ONCOGENE, V12, P187; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; Middleton G, 1996, DEVELOPMENT, V122, P695; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1995, ONCOGENE, V10, P1053; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STROUD R, 1995, CURR OPIN STRUC BIOL, V5, P514, DOI 10.1016/0959-440X(95)80037-9; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN Q, 1996, IN PRESS ONCOGENE; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHOU P, 1997, IN PRESS BLOOD	59	74	77	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1031	1039		10.1038/sj.onc.1200927	http://dx.doi.org/10.1038/sj.onc.1200927			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070651				2022-12-17	WOS:A1997WM07000004
J	Griffiths, SD; Clarke, AR; Healy, LE; Ross, G; Ford, AM; Hooper, ML; Wyllie, AH; Greaves, M				Griffiths, SD; Clarke, AR; Healy, LE; Ross, G; Ford, AM; Hooper, ML; Wyllie, AH; Greaves, M			Absence of p53 permits propagation of mutant cells following genotoxic damage	ONCOGENE			English	Article						ionizing radiation; mutation; p53; apoptosis	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR GENE; IONIZING-RADIATION; P53-DEFICIENT MICE; HEMATOPOIETIC-CELLS; ANTICANCER AGENTS; GAMMA-IRRADIATION; HUMAN-LYMPHOCYTES; MAMMALIAN-CELLS	Much evidence has been gathered in support of a critical role for p53 in the cellular response to DNA damage. p53 dysfunction is associated with progression and poor prognosis of many human cancers and with a high incidence of tumours in p53 knockout mice. The absence of a p53-dependent G(1) arrest that facilitates DNA repair or apoptosis might impact critically on clinical cancer in two ways. First, by abrogating the impact on therapy that operates via genotoxic damage and apoptosis; and second, by encouraging progression either by inducing genomic instability and DNA mis-repair or by permitting survival of mutants. However, experiments examining the relationship between p53 deficiency and mutation frequency have so far failed to confirm these predictions. The precise role played by p53 is therefore unclear. We now report use of a short term in vitro approach to assess the influence of p53 on radiation-induced mutations at the hprt locus in murine B cell precursors that are normally radiation ultrasensitive, We find a high number of hprt mutants among X-irradiated p53 null cells, which results from preferential survival as clonogenic mutants rather than from a p53-dependent increase in mutation rate. This result has important implications for genotoxic cancer therapy.	INST CANC RES, LEUKAEMIA RES FUND CTR, LONDON SW3 6JB, ENGLAND; ROYAL MARSDEN HOSP, LONDON SW3 6JB, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, SECT RADIOTHERAPY, LONDON SW3 6JB, ENGLAND; UNIV EDINBURGH, SCH MED, DEPT PATHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Edinburgh			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Healy, Lyn/0000-0002-7044-8789				BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BLANDINO G, 1995, ONCOGENE, V10, P731; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BREIMER LH, 1988, BRIT J CANCER, V57, P6, DOI 10.1038/bjc.1988.2; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX R, 1977, NATURE, V267, P425, DOI 10.1038/267425a0; DERUIJTER YCEM, 1980, MUTAT RES, V69, P325, DOI 10.1016/0027-5107(80)90097-4; DIVE C, 1993, FRONTIERS PHARM CANC, P21; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FAN SJ, 1994, CANCER RES, V54, P5824; FURUNOFUKUSHI I, 1993, RADIAT RES, V136, P97, DOI 10.2307/3578645; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; GRIFFITHS SD, 1994, INT J RADIAT BIOL, V66, P197, DOI 10.1080/09553009414551101; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KENT, 1994, INT J RADIAT BIOL, V65, P125; KODAMA H, 1984, J CELL PHYSIOL, V118, P233, DOI 10.1002/jcp.1041180303; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE G, 1989, J IMMUNOL, V142, P3875; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOCK LF, 1986, MOL CELL BIOL, V6, P914, DOI 10.1128/MCB.6.3.914; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARUYAMA Y, 1987, ADV RADIAT BIOL, V12, P1; MERRITT AJ, 1994, CANCER RES, V54, P614; MORLEY AA, 1983, NATURE, V302, P155, DOI 10.1038/302155a0; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; NICKLAS JA, 1989, MUTAT RES, V215, P147, DOI 10.1016/0027-5107(89)90178-4; NISHINO H, 1995, ONCOGENE, V11, P263; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; PURDIE CA, 1994, ONCOGENE, V9, P603; ROSS GM, 1995, CANCER RES, V55, P1235; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SELLINS KS, 1987, J IMMUNOL, V139, P3199; THACKER J, 1992, ADV RADIAT BIOL, V16, P77; THACKER J, 1979, RAD RES; VIJAYALAXMI, 1984, MUTAT RES, V125, P87, DOI 10.1016/0027-5107(84)90035-6; WALTON MI, 1993, CANCER RES, V53, P1853; WINKLER TH, 1995, BLOOD, V85, P2045, DOI 10.1182/blood.V85.8.2045.bloodjournal8582045; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	58	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					523	531		10.1038/sj.onc.1200871	http://dx.doi.org/10.1038/sj.onc.1200871			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053850				2022-12-17	WOS:A1997WF52400003
J	Cavrois, M; Gessain, A; WainHobson, S; Wattel, E				Cavrois, M; Gessain, A; WainHobson, S; Wattel, E			Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM	ONCOGENE			English	Article						HTLV-1; adult T-cell leukemia; leukemogenesis	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; POLYMERASE CHAIN-REACTION; BLOOD MONONUCLEAR-CELLS; CYTOTOXIC LYMPHOCYTES-T; PROVIRAL DNA; PERIPHERAL-BLOOD; LEUKEMIA LYMPHOMA; MYELOPATHY; P53	Assuming that the clonal expansion of T cells harbouring the human T-cell leukemia virus type 1 (HTLV-1) provirus is a central feature of HTLV-1 infection, the identification of such cells was sought among a series of 19 asymptomatic carriers and 19 cases of tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) devoid of malignancy, Two PCR based protocols designed to amplify the host cell-HTLV-1 proviral integration sites were used, In all cases large numbers of proliferating clones could be identified, The proportion of some clones was >1/1500 peripheral blood mononuclear cells (PBMCs) with the suggestion that their number increased as a function of age among asymptomatic carriers.	INST RECH CANC LILLE,U124 INSERM,LILLE,FRANCE; INST PASTEUR,UNITE EPIDEMIOL VIRUS ONCOGENES,PARIS,FRANCE; INST PASTEUR,UNITE RETROVIROL MOL,PARIS,FRANCE; CHU,SERV MALAD SANG,LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Lille - ISITE; CHU Lille								BLATTNER WA, 1989, ANN INTERN MED, V111, P4, DOI 10.7326/0003-4819-111-1-4; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; CESARMAN E, 1992, BLOOD, V80, P3205; CHEN YX, 1995, INT J CANCER, V60, P798; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; DINCAN M, 1994, LEUKEMIA, V8, P682; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GESSAIN A, 1992, ANN INTERN MED, V117, P933, DOI 10.7326/0003-4819-117-11-933; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; IKEDA S, 1990, CANCER DETECT PREV, V14, P431; IKEDA S, 1993, BLOOD, V82, P2017; JACOBSON S, 1992, ANN NEUROL, V32, P651, DOI 10.1002/ana.410320508; KIRA J, 1991, ANN NEUROL, V29, P194, DOI 10.1002/ana.410290214; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; KUBOTA R, 1993, J NEUROIMMUNOL, V42, P147, DOI 10.1016/0165-5728(93)90004-I; MANNS A, 1991, TRANSFUSION, V31, P67, DOI 10.1046/j.1537-2995.1991.31191096189.x; MATSUMURA M, 1993, INT J CANCER, V55, P220, DOI 10.1002/ijc.2910550209; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; SAKASHITA A, 1992, BLOOD, V79, P477; SHINZATO O, 1991, BLOOD, V78, P2082; SUMMERS BA, 1978, LANCET, V1, P187; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; WILEY CA, 1988, AM J PATHOL, V133, P355; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x	33	74	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2419	2423						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649783				2022-12-17	WOS:A1996UQ22000020
J	Massimi, P; Pim, D; Storey, A; Banks, L				Massimi, P; Pim, D; Storey, A; Banks, L			HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation	ONCOGENE			English	Article						CKII; HPV; E7; TBP	HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; HUMAN KERATINOCYTES; ACTIVATION DOMAIN; MOUSE CELLS; CYCLIN-A; EJ-RAS; TRANSFORMATION; TRANSACTIVATION	The major transforming protein of HPV-16 is encoded by the E7 gene. This has been shown to cooperate with EJ-ras in the immortalisation of primary rodent cells and with the viral E6 gene in the immortalisation of primary human keratinocytes. HPV-16 E7 protein has been shown to bind to a number of cellular proteins involved in the control of cell growth; including pRB, p107 and cyclin A, Loss of pRb or p107 binding results in the loss of transforming activity. In this paper we demonstrate that HPV-16 E7 can also complex with the core component of TFIID, the TATA Box Binding Protein (TBP). This interaction is partly dependent upon phosphorylation of the E7 protein by cellular casein kinase II (CKII), since phosphorylation of E7 by CKII increases the affinity with which E7 binds TBP. Similar results are also obtained with the Adenovirus Ela protein, indicating a conservation of function between these two viral oncoproteins. Mutation of the CKII site to two acidic amino acids significantly increases the affinity of E7 for TBP, indicating that the incorporation of two negative charges at this region of E7 is important in regulating the interaction with TBP.	INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY; ROYAL LONDON HOSP, DEPT EXPTL DERMATOL, LONDON, ENGLAND	International Center for Genetic Engineering & Biotechnology (ICGEB); Barts Health NHS Trust; Royal London Hospital				Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KERR LD, 1993, NATURE, V336, P646; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1990, J GEN VIROL, V71, P965, DOI 10.1099/0022-1317-71-4-965; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TOMMASINO M, 1993, ONCOGENE, V8, P195; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	41	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2325	2330						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649772				2022-12-17	WOS:A1996UQ22000009
J	Gollahon, LS; Shay, JW				Gollahon, LS; Shay, JW			Immortalization of human mammary epithelial cells transfected with mutant p53 (273(his))	ONCOGENE			English	Article						telomerase; telomeres; senescence; life span	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN-DIPLOID FIBROBLASTS; LARGE TUMOR-ANTIGEN; LARGE T-ANTIGEN; BREAST-CANCER; CELLULAR SENESCENCE; PROTEIN; TRANSFORMATION; GENE; DNA	Normal human breast epithelial cells were transfected with expression vectors containing the p53 gene mutated at either codon 143, 175, 248 or 273, or by infection with a recombinant retroviral vector containing the p53 gene mutated at codons 143, 175, 248, or 273. The breast epithelial cells were monitored for extension of in vitro lifespan and immortalization. Expression of some, but not all, p53 mutants resulted in an extension of in vitro lifespan. Experiments with the p53 temperature sensitive mutant 143(ala) revealed that at 32 degrees C, the nonpermissive temperature, the growth of breast epithelial cells was inhibited. At 37 degrees C, the mutant conformation, there was increased proliferation of cells, resulting in extension of in vitro lifespan. Breast epithelial cells expressing p53 mutant 273(his) maintained DNA binding and transcriptional activities and one clone immortalized after a period of growth arrest (crisis). The progression of this immortalization event was characterized by the reactivation of telomerase using the telomeric repeat amplification protocol (TRAP), and terminal restriction fragment analysis (TRF). This is the first reported immortalization of human mammary epithelial cells transfected with a mutant 53.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011					ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BOND JA, 1994, ONCOGENE, V9, P1885; CALLAHAN R, 1989, J NATL CANCER I, V81, P780; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EYFJORD JE, 1995, CANCER RES, V55, P646; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORRESTER K, 1995, ONCOGENE, V10, P2103; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GILLESPIE P, 1991, P NATL ACAD SCI USA, V88, P2593; GOTZ C, 1995, INT J ONCOL, V6, P1129; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HIYAMA K, 1995, ONCOGENE, V10, P937; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANGE HJS, 1988, SCIENCE, V292, P1563; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSLER LG, 1992, CANCER-AM CANCER SOC, V69, P1896, DOI 10.1002/1097-0142(19920401)69:7+<1896::AID-CNCR2820691704>3.0.CO;2-1; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI FP, 1988, CANCER RES, V48, P5358; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU ZJ, 1995, VIROLOGY, V207, P260, DOI 10.1006/viro.1995.1075; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREIRASMITH OM, 1987, MOL CELL BIOL, V7, P1541, DOI 10.1128/MCB.7.4.1541; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Pollock Raphael E., 1992, Cancer Bulletin (Houston), V44, P268; REW DA, 1994, BRIT J SURG, V81, P1416, DOI 10.1002/bjs.1800811005; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, INT J ONCOL, V3, P559; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; SMITH ML, 1995, ONCOGENE, V10, P1053; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; VANDERHAEGEN BA, 1993, IN VITRO CELL DEV-AN, V29A, P180, DOI 10.1007/BF02634177; WATANABE S, 1989, SCIENCE, V248, P76; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119; ZHANG W, 1992, ONCOGENE, V7, P1644	78	74	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					715	725						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632893				2022-12-17	WOS:A1996TW68600002
J	THOMAS, M; MASSIMI, P; JENKINS, J; BANKS, L				THOMAS, M; MASSIMI, P; JENKINS, J; BANKS, L			HPV-18 E6 MEDIATED INHIBITION OF P53 DNA-BINDING ACTIVITY IS INDEPENDENT OF E6 INDUCED DEGRADATION	ONCOGENE			English	Article						P53; HPV18 E6; OLIGOMERIZATION; DNA BINDING	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; MUTANT P53; GENE-EXPRESSION; CELLULAR P53; PROTEIN; TRANSACTIVATION; CELLS; WILD-TYPE-P53	A key activity of the p53 protein during suppression of cell growth is its ability to stimulate transcription from promoters of cellular genes which contain a p53 responsive element. The E6 proteins from the oncogenic associated Human Papillomaviruses (HPVs) have been shown to inhibit specifically the p53 transcriptional activation and this has been proposed as a mechanism whereby the virus prevents the suppression of cell cycle progression and the induction of apoptosis. However, the mechanism by which E6 exercises this function is unknown, as is the ability of E6 to associate with different oligomeric forms of p53. In this study we demonstrate that E6 induces changes within the p53 protein which result both in inhibition of DNA binding and in dissociation of p53 protein previously bound to the DNA. These activities correlate exactly with the ability of E6 to inhibit p53 transcriptional activation and are independent of the ability of E6 to direct the degradation of the p53 protein. Further, we show that E6 labels wild type tetrameric and dimeric forms of p53 proteins for ubiquitin mediated degradation more readily than monomeric forms of the protein. However, in vivo analyses indicate that E6 is capable of inhibiting the transcriptional activation induced by the tetrameric, dimeric and monomeric forms of p53.	MARIE CURIE RES INST,OXTED RH8 0TL,SURREY,ENGLAND		THOMAS, M (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.							BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAINAUT P, 1993, CANCER RES, V53, P4469; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, ONCOGENE HDB, P403; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V362, P857; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROVINSKI B, 1988, ONCOGENE, V2, P445; SANG BC, 1994, ONCOGENE, V9, P853; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STOREY A, 1993, ONCOGENE, V8, P919; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	52	74	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					261	268						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838526				2022-12-17	WOS:A1995QC62400005
J	KIESS, M; SCHARM, B; AGUZZI, A; HAJNAL, A; KLEMENZ, R; SCHWARTEWALDHOFF, I; SCHAFER, R				KIESS, M; SCHARM, B; AGUZZI, A; HAJNAL, A; KLEMENZ, R; SCHWARTEWALDHOFF, I; SCHAFER, R			EXPRESSION OF RIL, A NOVEL LIM DOMAIN GENE, IS DOWN-REGULATED IN HRAS-TRANSFORMED CELLS AND RESTORED IN PHENOTYPIC REVERTANTS	ONCOGENE			English	Article						GENETIC SUPPRESSION; CELLULAR TRANSFORMATION; ZINC FINGER PROTEIN; IN SITU HYBRIDIZATION	CYSTEINE-RICH PROTEIN; RAT EMBRYONIC FIBROBLASTS; MESSENGER-RNA; INTESTINAL PROTEIN; TRANSGENIC MICE; LYSYL OXIDASE; DNA-BINDING; SUPPRESSION; ELEGANS; MOTIF	Several candidate genes involved in the maintenance of normal growth control (H-rev) were identified by differential expression cloning on the assumption that they are expressed in phenotypically normal rat cells and repressed in closely related H-ras transformed cells. Previously the genes coding for lysyl oxidase (H-rev142) and for an 18K-protein of unknown function (H-rev107) were recovered as cDNAs by subtraction cloning. Here we describe the identification and expression pattern of ril, a novel member of the heterogeneous group of genes encoding proteins with LIM/double zinc finger domains. The ril gene is expressed in normal fibroblasts and downregulated in H-uas-transformed derivatives. Expression is restored in several independent phenotypic revertants derived from H-ras transformed cells. The predicted protein product of ril harbors a single LIM domain but lacks a homeodomain. The ril gene is highly conserved during evolution and is transcribed in various normal cell lines. Northern blot analysis and in situ hybridization studies showed that ril is expressed in meiotic spermatocytes, in somites of developing mice, and in a side variety of tissues of adult mice.	UNIV ZURICH,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich				Aguzzi, Adriano/0000-0002-0344-6708; Schafer, Reinhold/0000-0001-7952-2124				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BALTZ R, 1992, PLANT CELL, V4, P1465, DOI 10.1105/tpc.4.12.1465; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4371; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; HENDERSON C, 1990, J HISTOTECHNOL, V12, P123; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEVENSON CW, 1993, P NATL ACAD SCI USA, V90, P712, DOI 10.1073/pnas.90.2.712; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MARTIN W, 1992, EXP CELL RES, V200, P41, DOI 10.1016/S0014-4827(05)80069-2; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLAUER L, 1993, ONCOGENE, V8, P2531; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; SCHWARTEWALDHOF.I, 1994, ONCOGENE, V9, P899; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TURNER CE, 1994, J CELL SCI, V107, P1583; WANG XK, 1992, J BIOL CHEM, V267, P9176; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	56	74	79	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					61	68						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824279				2022-12-17	WOS:A1995QA98000008
J	CHEN, SY; HUFF, SY; LAI, CC; DER, CJ; POWERS, S				CHEN, SY; HUFF, SY; LAI, CC; DER, CJ; POWERS, S			RAS-15A PROTEIN SHARES HIGHLY SIMILAR DOMINANT-NEGATIVE BIOLOGICAL PROPERTIES WITH RAS-17N AND FORMS A STABLE, GUANINE-NUCLEOTIDE RESISTANT COMPLEX WITH CDC25 EXCHANGE FACTOR	ONCOGENE			English	Article							HA-RAS MUTATION; SACCHAROMYCES-CEREVISIAE; ACTIVATION; MUTANTS; BINDING; P21RAS; SIGNAL; KINASES; INHIBITION; CYTOSOL	We show that expression of Ras-15A, previously shown to be a dominant-negative mutant in yeast, is a potent inhibitor of endogenous Ras protein function in mammalian cells. Expression of Ras-15A did not inhibit the growth of cells containing an oncogenic ras gene nor did it interfere with the ability of transiently expressed oncogenic ras or raf genes to activate transcription from a Ras-responsive ets1/AP-1 promoter. In contrast, expression of Ras-15A completely blocked growth of normal cells and activation of the ets1/AP-1 promoter by transiently overexpressed SOS1 and normal Ras proteins. These results suggest that Ras-15A, like Ras-17N, blocks endogenous Ras function by interfering with upstream activation of Ras proteins rather than downstream effects. To test whether Ras-15A and Ras-17N interfere with Ras function by blocking GDP-GTP exchange proteins, we examined their physical interaction with the CDC25 exchange protein. All three proteins formed stable complexes with CDC25 in the absence of guanine-nucleotides, but only Ras-15A was not released from CDC25 by physiological concentrations of GDP or GTP. These results establish that Ras-15A blocks the activation of normal Ras proteins by sequestering GDP-GTP exchange factors into nonproductive complexes. In contrast, it would appear that the similar biological properties of Ras-17N are mediated by a reversible, competitive sequestration of exchange factors.	ONYX PHARMACEUT,RICHMOND,CA 94806; RUTGERS STATE UNIV,GRAD PROGRAM BIOCHEM & MOLEC BIOL,PISCATAWAY,NJ 08854; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Rutgers State University New Brunswick; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Powers, Scott/0000-0003-2769-1932; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041258] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NIGMS NIH HHS [GM41258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DER CJ, 1988, ONCOGENE, V3, P105; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JOHN J, 1993, J BIOL CHEM, V268, P923; JUNG V, 1994, IN PRESS MOL CELL BI; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; POWERS S, 1991, CELL, V65, P1255; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	28	74	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2691	2698						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058333				2022-12-17	WOS:A1994PC05400030
J	KOHNO, T; MORISHITA, K; TAKANO, H; SHAPIRO, DN; YOKOTA, J				KOHNO, T; MORISHITA, K; TAKANO, H; SHAPIRO, DN; YOKOTA, J			HOMOZYGOUS DELETION AT CHROMOSOME 2Q33 IN HUMAN SMALL-CELL LUNG-CARCINOMA IDENTIFIED BY ARBITRARILY PRIMED PCR GENOMIC FINGERPRINTING	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; HUMAN DNA; CANCER; HETEROZYGOSITY; LINES; ADENOCARCINOMA; LOCALIZATION; EXPRESSION; SEQUENCES	We have searched for novel genetic alterations in human cancer cell lines by using the arbitrarily primed polymerase chain reaction (AP-PCR), which is a PCR-based genomic fingerprinting. A homozygous deletion was detected in a small-cell lung carcinoma (SCLC) cell line, NCI-H82. Since homozygous deletion is a critical genetic alteration for the inactivation of tumor suppressor gene, we defined the locus of homozygous deletion. Fluorescence in situ hybridization analysis revealed that the deletion was localized at chromosome 2q33. Allelic loss on chromosome 2q was detected in 29.4% (5/17) of SCLC and 37.5% (12/32) one non-SCLC by restriction fragment length polymorphism analysis. Considerably high incidence of allelic loss on chromosome 2q was also detected in colorectal carcinoma and neuroblastoma. These results suggest the presence of a novel tumor suppressor gene at 2q33, which is involved in the development of several human cancers. The size of the homozygous deletion in the NCI-H82 cell line was more than 20 kilobase pairs. Seven loci mapped to 2q32-qter were all retained in this cell line, suggesting the presence of submicroscopic interstitial deletion in this cell line. Homozygous deletion detected in this study should be an invaluable tool for positional cloning of the target tumor suppressor gene at 2q33.	NATL CANC CTR, RES INST, CHUO KU, TOKYO 104, JAPAN; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	National Cancer Center - Japan; St Jude Children's Research Hospital				takano, hirokuni/0000-0002-6465-7883	NCI NIH HHS [CA-21765, CA-23099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARNEY DN, 1985, CANCER RES, V45, P2913; DARIAVACH P, 1988, EUR J IMMUNOL, V18, P1901, DOI 10.1002/eji.1830181206; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; EHRENBORG E, 1991, BIOCHEM BIOPH RES CO, V176, P1250, DOI 10.1016/0006-291X(91)90420-C; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KOHLER A, 1993, GENOMICS, V15, P233, DOI 10.1006/geno.1993.1045; KOHNO T, 1993, ONCOGENE, V8, P1825; KUBOTA Y, 1987, FEBS LETT, V212, P159, DOI 10.1016/0014-5793(87)81577-6; LEE KP, 1990, J IMMUNOL, V145, P344; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Maniatis T., 1982, MOL CLONING; MATSUMOTO T, 1991, JPN J CANCER RES, V82, P820, DOI 10.1111/j.1349-7006.1991.tb02708.x; MATSUMURA Y, 1992, CANCER RES, V52, P2174; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MORI N, 1989, CANCER RES, V49, P5130; MORISS SW, 1991, BLOOD, V78, P2013; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELSH J, 1991, NUCLEIC ACIDS RES, V19, P5275, DOI 10.1093/nar/19.19.5275; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YAMADA T, 1985, JPN J CANCER RES, V76, P967; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; 1991, CYTOGENET CELL GENET, V58, P1	44	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					103	108						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905618				2022-12-17	WOS:A1994MW24700013
J	EELES, RA; WARREN, W; KNEE, G; BARTEK, J; AVERILL, D; STRATTON, MR; BLAKE, PR; TAIT, DM; LANE, DP; EASTON, DF; YARNOLD, JR; COOPER, CS; SLOANE, JP				EELES, RA; WARREN, W; KNEE, G; BARTEK, J; AVERILL, D; STRATTON, MR; BLAKE, PR; TAIT, DM; LANE, DP; EASTON, DF; YARNOLD, JR; COOPER, CS; SLOANE, JP			CONSTITUTIONAL MUTATION IN EXON-8 OF THE P53 GENE IN A PATIENT WITH MULTIPLE PRIMARY TUMORS - MOLECULAR AND IMMUNOHISTOCHEMICAL FINDINGS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; CANCER FAMILY SYNDROME; LI-FRAUMENI SYNDROME; POINT MUTATIONS; DNA; SUPPRESSOR; CARCINOMAS; ONCOGENE; SARCOMAS; TUMORS	We report a constitutional mutation of codon 273 in exon 8 of the p53 gene. The affected individual has developed multiple independent benign and malignant tumours (tricholemmoma of the scalp, multiple trichoepitheliomata of the face, osteosarcoma of the ovary, bilateral breast cancer, maligant fibrous histiocytoma of the thigh and endometrial adenocarcinoma) and belongs to a family with some, but not all, features of the Li-Fraumeni syndrome. The mutation, found in both blood lymphocyte and tumour specimens, is a cytosine to thymine transition at codon 273, resulting in an amino acid change from arginine to cysteine. The mother and sister of the index case both died of tumours at an early age. We have demonstrated that formalin-preserved material from these tumours contains the same C-->T mutation at codon 273, indicating that this mutation has probably been transmitted through the germline. All tumours from the index case, both benign and malignant, showed immunohistochemical positivity with four antibodies to the p53 protein. Positive staining was also seen in scattered nuclei of morphologically normal epidermal keratinocytes and pilosebaceous cells, but not in lymphocytes or other morphologically normal cells from the index case. However, a similar staining pattern in apparently normal tissue was also observed in 13/48 sections from other individuals with various skin conditions (melanocytic naevi, psoriasis and normal skin adjacent to malignant melanoma and fibrous histiocytomas), suggesting that this pattern of p53 staining may not be unique to individuals with constitutional p53 mutations.	ROYAL MARSDEN HOSP, DEPT HISTOPATHOL, SUTTON SM2 5PT, SURREY, ENGLAND; INST HEMATOL & BLOOD TRANSFUS, DEPT TUMOUR BIOL, CS-10103 PRAGUE, CZECHOSLOVAKIA; UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; INST CANC RES, MOLEC CARCINOGENESIS SECT, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, EPIDEMIOL SECT, SUTTON SM2 5NG, SURREY, ENGLAND; ROYAL MARSDEN HOSP, DEPT GYNAECOL ONCOL, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust; Institute of Hematology Prague; University of Dundee; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	EELES, RA (corresponding author), ROYAL MARSDEN HOSP, CRC, ACAD UNIT RADIOTHERAPY & ONCOL, DOWNS RD, SUTTON SM2 5PT, SURREY, ENGLAND.		Bartek, Jiri/G-5870-2014; Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545; Eeles, Rosalind/0000-0002-3698-6241				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; CASEY G, 1991, ONCOGENE, V6, P1791; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LAW JC, 1991, CANCER RES, V51, P6385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PROSSER J, 1990, ONCOGENE, V5, P1573; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, CANCER RES, V49, P6324; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; VARLEY JM, 1991, ONCOGENE, V6, P413; VOJETSEK B, 1992, IN PRESS J IMMUNOL M	33	74	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1269	1276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479749				2022-12-17	WOS:A1993KY32800019
J	URANO, T; FURUKAWA, K; SHIKU, H				URANO, T; FURUKAWA, K; SHIKU, H			EXPRESSION OF NM23 NDP KINASE PROTEINS ON THE CELL-SURFACE	ONCOGENE			English	Note							NUCLEOSIDE DIPHOSPHATE-KINASE; BINDING-PROTEINS; GENE; ASSOCIATION; DROSOPHILA; METASTASIS; CLONING	We determined whether proteins encoded by the nm23/nucleoside diphosphate (NDP) kinase gene, a potential metastasis-suppressor gene, are expressed on the cell surface. Monoclonal antibodies (mAb) specific for nm23-H1 or H2 proteins were prepared using the corresponding fusion proteins with glutathione S-transferase (GST) as immunogens. mAb H1-229 was specifically reactive with nm23-H1 protein, whereas mAb H2-439 was specific for nm23-H2 protein in immunoprecipitation and immunoblotting. mAb H1-229 was reactive with most human hematopoietic and some non-hematopoietic cell lines in flow cytometry. On the other hand, mAb H2-439 was reactive with only a limited number of cell lines. Based upon the surface expression of nm23/NDP kinase, cells were classified as nm23-H1+H2-, nm23-H1+H2+ or nm23-H1-H2-. No cell lines with nm23-H1-H2+ were found among those examined. The specificity of flow cytometry analysis was confirmed in the murine myeloma line NS-1 transfected with either the nm23-H1 or H2 genes. Both mAbs were reactive only to NS-1 transfected with the corresponding nm23 genes. Immunoprecipitation and SDS-PAGE analysis identified 20.5- and 18-kDa proteins with mAb H1-229 or H2-439, respectively, in cellular extracts of I-125-surface labeled NS-1 transfected with the corresponding genes. The presence of nm23/NDP kinase on the cell surface indicates an extracellular role for these proteins in addition to their reported intracellular functions.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,1-12-4 SAKAMOTO,NAGASAKI 852,JAPAN	Nagasaki University				Urano, Takeshi/0000-0003-3383-3554				BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Coligan JKA, 1991, CURRENT PROTOCOLS IM; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; URANO T, 1992, INT J ONCOL, V1, P425; WALSER A, 1989, J VIROL, V63, P3926, DOI 10.1128/JVI.63.9.3926-3933.1989	22	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1371	1376						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386830				2022-12-17	WOS:A1993KY32800031
J	BORZILLO, GV; ENDO, K; TSUJIMOTO, Y				BORZILLO, GV; ENDO, K; TSUJIMOTO, Y			BCL-2 CONFERS GROWTH AND SURVIVAL ADVANTAGE TO INTERLEUKIN-7-DEPENDENT EARLY PRE-B CELLS WHICH BECOME FACTOR INDEPENDENT BY A MULTISTEP PROCESS IN CULTURE	ONCOGENE			English	Article							HUMAN FOLLICULAR LYMPHOMA; BONE-MARROW; CHROMOSOMAL BREAKPOINT; GENE; EXPRESSION; PROTEIN; T(14-18); ONCOGENE; DEATH; TRANSLOCATION	Early pre-B cells derived from mouse lymphoid bone marrow cultures were expanded on a surrogate stromal cell line composed of NIH3T3 fibroblasts engineered to secrete interleukin 7 (IL-7). Three immortal, IL-7-dependent cell lines were generated and infected with recombinant retroviruses to determine the effects of the human follicular B-cell lymphoma gene, bcl-2, on immature stages of B-cell development. Cells expressing bcl-2 grew at rates similar to those of control (vector only) cells when plated on bone marrow stromal lines, but exhibited a c. two-fold net proliferative advantage when grown in liquid medium supplemented with IL-7 alone. Bcl-2 prevented apoptosis when the infected early pre-B-cell lines were deprived of IL-7 and other growth factors provided by stromal cells. Following factor deprivation, a subset of cells expressing bcl-2 survived indefinitely. Two such cultures spontaneously gave rise to factor-independent variants which grew slowly in unsupplemented liquid culture and formed agar colonies, yet still responded positively to IL-7 and kit ligand, and negatively to gamma-interferon. Bcl-2 thus provides a survival capacity and modest growth advantage to early pre-B cells, which may recapitulate its effects in human B cells bearing t(14;18) translocations and ultimately contribute to transformation.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	St Jude Children's Research Hospital; The Wistar Institute					NCI NIH HHS [CA-51864, CA-50551, CA-09346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009346, R01CA051864, R01CA050551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BERTOLI LF, 1988, BLOOD, V72, P94; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DORSHKIND K, 1989, J IMMUNOL METHODS, V123, P93, DOI 10.1016/0022-1759(89)90033-1; FUKUHARA S, 1979, CANCER RES, V39, P3119; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; RICHARDSON ME, 1987, BLOOD, V70, P444; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITLOCK CA, 1987, METHOD ENZYMOL, V150, P275; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0	39	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					869	876						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373874				2022-12-17	WOS:A1992HP64200005
J	FUTREAL, PA; BARRETT, JC				FUTREAL, PA; BARRETT, JC			FAILURE OF SENESCENT CELLS TO PHOSPHORYLATE THE RB PROTEIN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN-DIPLOID FIBROBLASTS; SYRIAN-HAMSTER TUMORS; CELLULAR SENESCENCE; PRODUCT; EXPRESSION; CYCLE; IDENTIFICATION; SUPPRESSION; CARCINOMA	The product of the RB susceptibility gene has been shown to be differentially phosphorylated during the cell cycle, suggesting a role in the regulation of cell cycle progression. We examined the expression and phosphorylation status of the RB protein in senescent Syrian hamster embryo cells. Both phosphorylated and unphosphorylated forms of the RB protein were observed in cells at early passages; however, only unphosphorylated RB protein was found in senescent cells. When nonsenescent cells at low population doubling levels were made quiescent by reducing the serum concentration of the media, the RB protein in these cells was mostly in the unphosphorylated protein in these cells was mostly in the unphosphorylated form. When stimulated with serum, phosphorylation of the RB protein occurred between 10-20 h after stimulation, which corresponded with the induction of DNA synthesis. Senescent cells, in contrast, did not show any phosphorylation of the RB protein in response to serum. In addition, cell lines that had escaped cellular senescence at various stages of neoplastic progression were examined; all 25 cell lines examined expressed RB protein, which was phosphorylated normally. These results suggest that the RB protein plays a role in cellular senescence with phosphorylation status determining this role. Factors controlling this phosphorylation are potential key factors in controlling cellular life span in culture.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill	FUTREAL, PA (corresponding author), NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709, USA.							BARRETT JC, 1987, MECHANISMS ENV CARCI, P73; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6464; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRISTOFALO VJ, 1985, TESTING THEORIES AGI, P201; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIORDANO T, 1989, EXP CELL RES, V185, P399, DOI 10.1016/0014-4827(89)90310-8; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1980, ANN REV GERONTOLOGY, V1, P26; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OSHIMURA M, 1988, CANCER RES, V48, P1623; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; Smith J R, 1990, Adv Cancer Res, V54, P63, DOI 10.1016/S0065-230X(08)60808-8; SMITH JR, 1989, GENOME, V31, P386, DOI 10.1139/g89-058; SMITH JR, 1989, EXP GERONTOL, V24, P377, DOI 10.1016/0531-5565(89)90045-4; STEIN GH, 1986, P NATL ACAD SCI USA, V83, P9030, DOI 10.1073/pnas.83.23.9030; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XU HJ, 1989, ONCOGENE, V4, P807; [No title captured]	45	74	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1109	1113						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861860				2022-12-17	WOS:A1991GV26000003
J	YAN, DH; CHANG, LS; HUNG, MC				YAN, DH; CHANG, LS; HUNG, MC			REPRESSED EXPRESSION OF THE HER-2/C-ERBB-2 PROTOONCOGENE BY THE ADENOVIRUS E1A GENE-PRODUCTS	ONCOGENE			English	Note							GROWTH-FACTOR-RECEPTOR; ERBB-RELATED GENE; MESSENGER-RNAS; NEU ONCOGENE; HUMAN-BREAST; TRANSCRIPTION; AMPLIFICATION; CANCER; C-ERBB-2; PROTEINS	The E3 region of adenovirus induces down-regulation of epidermal growth factor receptor (EGFR) through endocytosis. Here we report that an EGFR-related protein, the HER-2/c-erbB-2 gene product, p185, is also down-regulated by adenovirus, but via a different mechanism. We found that the adenovirus E1a gene is responsible for the repression of HER-2/c-erbB-2 at the RNA level.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT BIOL,PRINCETON,NJ 08544	University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; Princeton University			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA-45265] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045265] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GAYNOR RB, 1982, J VIROL, V44, P276, DOI 10.1128/JVI.44.1.276-285.1982; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; NEVINS JR, 1987, MICROBIOL REV, V51, P419, DOI 10.1128/MMBR.51.4.419-430.1987; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; ROSENTHAL A, 1985, NATURE, V315, P579, DOI 10.1038/315579a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; ZHANG X, 1989, ONCOGENE, V4, P985	27	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					343	345						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1672040				2022-12-17	WOS:A1991FZ13400023
J	VEILLETTE, A; FOURNEL, M				VEILLETTE, A; FOURNEL, M			THE CD4 ASSOCIATED TYROSINE PROTEIN-KINASE P56LCK IS POSITIVELY REGULATED THROUGH ITS SITE OF AUTOPHOSPHORYLATION	ONCOGENE			English	Article									MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University	VEILLETTE, A (corresponding author), MCGILL UNIV,MCGILL CANC CTR,ROOM 701,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.							ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JUNE CH, 1990, J IMMUNOL, V144, P1591; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIMPSON SC, 1989, ONCOGENE, V4, P1141; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VEILLETTE A, 1989, NATURE, V338, P357; VEILLETTE A, 1990, IN PRESS EUR J IMMUN; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WILDE DB, 1983, J IMMUNOL, V131, P2178; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	39	74	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1455	1462						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250907				2022-12-17	WOS:A1990EK50200003
J	GOMPERTS, M; PASCALL, JC; BROWN, KD				GOMPERTS, M; PASCALL, JC; BROWN, KD			THE NUCLEOTIDE-SEQUENCE OF A CDNA-ENCODING AN EGF-INDUCIBLE GENE INDICATES THE EXISTENCE OF A NEW FAMILY OF MITOGEN-INDUCED GENES	ONCOGENE			English	Note									AFRC,INST ANIM PHYSIOL & GENET RES,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BLAY J, 1985, BIOCHEM J, V225, P85, DOI 10.1042/bj2250085; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; GOMPERTS M, 1990, IN PRESS BIOCH SOC T; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; VARNUM BC, 1989, ONCOGENE, V4, P119	13	74	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1081	1083						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695727				2022-12-17	WOS:A1990DP41500021
J	DELAPEYRIERE, O; ROSNET, O; BENHARROCH, D; RAYBAUD, F; MARCHETTO, S; PLANCHE, J; GALLAND, F; MATTEI, MG; COPELAND, NG; JENKINS, NA; COULIER, F; BIRNBAUM, D				DELAPEYRIERE, O; ROSNET, O; BENHARROCH, D; RAYBAUD, F; MARCHETTO, S; PLANCHE, J; GALLAND, F; MATTEI, MG; COPELAND, NG; JENKINS, NA; COULIER, F; BIRNBAUM, D			STRUCTURE, CHROMOSOME MAPPING AND EXPRESSION OF THE MURINE FGF-6-GENE	ONCOGENE			English	Article									INSERM, U119, 27 BDS LEI ROURE, F-13009 MARSEILLE, FRANCE; NCI, FREDERICK CANC RES FACIL, BRI BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21701 USA; HOP LA TIMONE, INSERM, U242, F-13385 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Rosnet, Olivier/G-3536-2013; Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773; Birnbaum, Daniel/0000-0001-7920-9883; Rosnet, Olivier/0000-0002-3020-910X	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADELAIDE J, 1988, ONCOGENE, V2, P413; ALTABA AR, 1989, NATURE, V341, P33; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BENHARROCH D, 1990, IN PRESS ISR J MED S; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROOKES S, 1989, ONCOGENE, V4, P429; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; BUCHBERG AM, 1989, GENETICS, V122, P153; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; CECI JD, 1990, GENOMICS, V6, P72, DOI 10.1016/0888-7543(90)90449-5; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARCIA M, 1986, EMBO J, V5, P127, DOI 10.1002/j.1460-2075.1986.tb04186.x; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; GREEN EL, 1981, GENETICS PROBABILITY, P1; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KARDAMI E, 1985, P NATL ACAD SCI USA, V82, P8044, DOI 10.1073/pnas.82.23.8044; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KINGSLEY DM, 1989, GENETICS, V123, P165; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LISCIA DS, 1989, ONCOGENE, V4, P1219; LOBB RR, 1988, EUR J CLIN INVEST, V18, P321, DOI 10.1111/j.1365-2362.1988.tb01020.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARICS I, 1989, ONCOGENE, V4, P335; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; NOGUCHI T, 1988, CANCER DETECT PREV, V12, P383; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; Rugh R., 1968, MOUSE ITS REPRODUCTI, P1; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; Theiler K., 1972, P1; THEILLET C, 1989, ONCOGENE, V4, P915; VELCICH A, 1989, ONCOGENE RES, V5, P31; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	52	74	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1990	5	6					823	831						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2193291				2022-12-17	WOS:A1990DP55300007
J	WATERS, CM; HANCOCK, DC; EVAN, GI				WATERS, CM; HANCOCK, DC; EVAN, GI			IDENTIFICATION AND CHARACTERIZATION OF THE EGR-1 GENE-PRODUCT AS AN INDUCIBLE, SHORT-LIVED, NUCLEAR PHOSPHOPROTEIN	ONCOGENE			English	Article											WATERS, CM (corresponding author), IMPERIAL CANC RES FUND, DOMIN HOUSE, 59 BARTHOLOMEW CLOSE, LONDON EC1A 7BE, ENGLAND.							BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GARCHON HJ, 1989, J CELL BIOL, V108, P779, DOI 10.1083/jcb.108.3.779; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE JP, 1988, BIOCHIM BIOPHYS ACTA, V965, P60, DOI 10.1016/0304-4165(88)90151-1; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VANSTRAATEN JP, 1987, ONCOGENE RES, V1, P221; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	33	74	77	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1990	5	5					669	674						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189103				2022-12-17	WOS:A1990DG37400006
J	KRAUSS, RS; HOUSEY, GM; JOHNSON, MD; WEINSTEIN, IB				KRAUSS, RS; HOUSEY, GM; JOHNSON, MD; WEINSTEIN, IB			DISTURBANCES IN GROWTH-CONTROL AND GENE-EXPRESSION IN A C3H/10T 1/2 CELL-LINE THAT STABLY OVERPRODUCES PROTEIN KINASE-C	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NCI NIH HHS [CA08346, CA02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHENDEL CL, 1983, CANCER RES, V43, P4333; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Berenblum I, 1941, CANCER RES, V1, P44; BLUMBERG PM, 1980, CRC CR REV TOXICOL, V8, P153, DOI 10.3109/10408448009037493; BOREIKO C, 1980, CANCER RES, V40, P4709; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DIAMOND L, 1984, PHARMACOL THERAPEUT, V26, P89, DOI 10.1016/0163-7258(84)90052-4; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DORMAN BH, 1983, CARCINOGENESIS, V4, P1109, DOI 10.1093/carcin/4.9.1109; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FRAZELLE JH, 1983, CARCINOGENESIS, V4, P709, DOI 10.1093/carcin/4.6.709; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LANKAS GR, 1977, MUTAT RES, V45, P153, DOI 10.1016/0027-5107(77)90053-7; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LOWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MILOSZEWSKA J, 1986, FEBS LETT, V206, P283, DOI 10.1016/0014-5793(86)80997-8; MONDAL S, 1976, CANCER RES, V36, P2254; MORDAN LJ, 1988, CARCINOGENESIS, V9, P1129, DOI 10.1093/carcin/9.7.1129; Mottram JC, 1944, J PATHOL BACTERIOL, V56, P181, DOI 10.1002/path.1700560207; MURPHY G, 1985, J BIOL CHEM, V260, P3079; NEIDEL JE, 1983, P NATL ACAD SCI USA, V80, P36; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PARKER PJ, 1984, EMBO J, V3, P953, DOI 10.1002/j.1460-2075.1984.tb01913.x; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Rous P, 1941, J EXP MED, V73, P365, DOI 10.1084/jem.73.3.365; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, V2, P189; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, V2, P1; SOPER CJ, 1977, CANCER RES, V37, P2487; TROSKO JE, 1977, CANCER RES, V37, P188; TROSKO JE, 1984, MECHANISMS TUMOR PRO, V4, P119; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994	57	74	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					991	998						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2761987				2022-12-17	WOS:A1989AJ29700007
J	SEMSEI, I; MA, S; CUTLER, RG				SEMSEI, I; MA, S; CUTLER, RG			TISSUE AND AGE SPECIFIC EXPRESSION OF THE MYC PROTO-ONCOGENE FAMILY THROUGHOUT THE LIFE-SPAN OF THE C57BL/6J MOUSE STRAIN	ONCOGENE			English	Article									NIA,GERONTOL RES CTR,CELLULAR & MOLEC BIOL LAB,MOLEC PHYSIOL & GENET SECT,4940 EASTERN AVE,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								ADAMSON ED, 1987, DEVELOPMENT, V99, P449; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; CLEVELAND DW, 1980, CELL, V20, P96; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CUTLER RG, 1986, GERONTOLOGIST, V26, pA71; CUTLER RG, 1985, MOL BIOL AGING GENE, P307; DEAN R, 1986, BIOCHEM BIOPH RES CO, V135, P105, DOI 10.1016/0006-291X(86)90948-4; DEAN RG, 1985, ARCH GERONTOL GERIAT, V4, P43, DOI 10.1016/0167-4943(85)90017-2; FAHRLANDER PD, 1986, ONCOGENES GROWTH CON, P264; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORINE DL, 1980, CANCER RES, V40, P519; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GUERRERO I, 1987, TRENDS GENET, V3, P269, DOI 10.1016/0168-9525(87)90263-0; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HUBER BE, 1987, CANCER RES, V47, P3414; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; MATOCHA MF, 1987, BIOCHEM BIOPH RES CO, V147, P1, DOI 10.1016/S0006-291X(87)80078-5; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; OHLSSON RI, 1987, EXP CELL RES, V173, P1, DOI 10.1016/0014-4827(87)90327-2; ONO T, 1985, GERONTOLOGY, V31, P362, DOI 10.1159/000212725; ONO T, 1978, P NATL ACAD SCI USA, V75, P4431, DOI 10.1073/pnas.75.9.4431; ONO T, 1986, BIOCHEM BIOPH RES CO, V139, P1299, DOI 10.1016/S0006-291X(86)80319-9; RICHARDSON A, 1987, J BIOL CHEM, V262, P12821; RICHARDSON A, 1987, BIOL RES AGING, V3, P443; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; RUBIN H, 1985, CANCER RES, V45, P2935; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; TSONIS PA, 1985, ANTICANCER RES, V7, P617; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WILSON VL, 1987, J BIOL CHEM, V262, P9948; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	74	74	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					465	471						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2470008				2022-12-17	WOS:A1989U567700011
J	TANG, A; WU, KJ; HASHIMOTO, T; LIU, WY; TAKAHASHI, R; SHI, XH; MIHARA, K; ZHANG, FH; CHEN, YY; DU, C; QIAN, J; LIN, YG; MURPHREE, AL; QIU, WR; THOMPSON, T; BENEDICT, WF; FUNG, YKT				TANG, A; WU, KJ; HASHIMOTO, T; LIU, WY; TAKAHASHI, R; SHI, XH; MIHARA, K; ZHANG, FH; CHEN, YY; DU, C; QIAN, J; LIN, YG; MURPHREE, AL; QIU, WR; THOMPSON, T; BENEDICT, WF; FUNG, YKT			GENOMIC ORGANIZATION OF THE HUMAN RETINOBLASTOMA GENE	ONCOGENE			English	Article									UNIV SO CALIF,CHILDRENS HOSP,SCH MED,DEPT PEDIAT MICROBIOL & OPHTHALMOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California					NATIONAL CANCER INSTITUTE [R29CA044754, R01CA044754] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007846] Funding Source: NIH RePORTER; NCI NIH HHS [CA44754] Funding Source: Medline; NEI NIH HHS [EY06195, EY07846] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YOKOTA J, 1988, ONCOGENE, V3, P471	20	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					401	407						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2717184				2022-12-17	WOS:A1989U567700002
J	HATADA, I; TOKINO, T; OCHIYA, T; MATSUBARA, K				HATADA, I; TOKINO, T; OCHIYA, T; MATSUBARA, K			CO-AMPLIFICATION OF INTEGRATED HEPATITIS-B VIRUS-DNA AND TRANSFORMING GENE HST-1 IN A HEPATOCELLULAR-CARCINOMA	ONCOGENE			English	Article									OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN	Osaka University			Ochiya, Takahiro/AAH-7585-2019; Tokino, Takashi/AAI-9887-2021					ADELAIDE J, 1988, IN PRESS ONCOGENE; BRESLOW JL, 1982, P NATL ACAD SCI-BIOL, V79, P6861, DOI 10.1073/pnas.79.22.6861; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; IMAZEKI F, 1988, J VIROL, V62, P861, DOI 10.1128/JVI.62.3.861-865.1988; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; MIZUSAWA H, 1985, P NATL ACAD SCI USA, V82, P208, DOI 10.1073/pnas.82.1.208; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NALBANTOGLU J, 1986, NUCLEIC ACIDS RES, V14, P8361, DOI 10.1093/nar/14.21.8361; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PASSANANTI C, 1987, EMBO J, V6, P1697, DOI 10.1002/j.1460-2075.1987.tb02420.x; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; SAITO I, 1986, P NATL ACAD SCI USA, V83, P8664, DOI 10.1073/pnas.83.22.8664; SAKAMOTO H, 1988, BIOCHEM BIOPH RES CO, V151, P965, DOI 10.1016/S0006-291X(88)80460-1; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAWADA R, 1988, MOL CELL BIOL, V8, P588; SEKI T, 1985, P NATL ACAD SCI USA, V82, P6657, DOI 10.1073/pnas.82.19.6657; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TOKINO T, 1987, J VIROL, V61, P3848, DOI 10.1128/JVI.61.12.3848-3854.1987; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; YOSHIDA MC, 1985, JPN J CANCER RES, V76, P559; YOSHIDA MC, 1988, IN PRESS P NATL ACAD; YUASA Y, 1987, JPN J CANCER RES, V78, P1036	29	74	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					537	540						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2856253				2022-12-17	WOS:A1988R516300008
J	SHEN, WPV; ALDRICH, TH; VENTAPEREZ, G; FRANZA, BR; FURTH, ME				SHEN, WPV; ALDRICH, TH; VENTAPEREZ, G; FRANZA, BR; FURTH, ME			EXPRESSION OF NORMAL AND MUTANT RAS PROTEINS IN HUMAN ACUTE-LEUKEMIA	ONCOGENE			English	Article									MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOLEC BIOL, DE WITT WALLACE RES LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA040620, P01CA016599, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40620, CA-08748, CA-16599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENEDICT WF, 1977, CANCER RES, V37, P2209; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BLICK M, 1984, BLOOD, V64, P1234; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CLARKSON B, 1984, T AM CLIN CLIMAT ASS, V96, P41; COOPER GM, 1983, BIOCHIM BIOPHYS ACTA, V738, P9; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; FEUERSTEIN N, 1985, J CELL BIOCHEM, V29, P253, DOI 10.1002/jcb.240290309; FIALKOW PJ, 1979, NEW ENGL J MED, V301, P1, DOI 10.1056/NEJM197907053010101; FIALKOW PJ, 1984, GENES CANCER, P215; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FUHRER JP, 1986, BIOCHIM BIOPHYS ACTA, V866, P204, DOI 10.1016/0167-4781(86)90045-X; FUJITA J, 1984, NATURE, V309, P464, DOI 10.1038/309464a0; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GAMBKE C, 1985, P NATL ACAD SCI USA, V82, P879, DOI 10.1073/pnas.82.3.879; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GOLDSTEIN LS, 1984, MUTAT RES, V140, P193, DOI 10.1016/0165-7992(84)90076-9; GUERRERO I, 1984, SCIENCE, V225, P1159, DOI 10.1126/science.6474169; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HIRAI H, 1985, BLOOD, V66, P1371; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; JANSSEN JWG, 1985, CANCER RES, V45, P3262; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KURZROCK R, 1986, CANCER RES, V46, P1530; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSON RA, 1983, CANCER GENET CYTOGEN, V10, P219, DOI 10.1016/0165-4608(83)90050-X; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4394, DOI 10.1073/pnas.83.12.4394; MCCOY MS, 1983, NATURE, V302, P79, DOI 10.1038/302079a0; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NEEDLEMAN SW, 1986, BLOOD, V67, P753; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHUCHI N, 1986, CANCER RES, V46, P2511; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PEDERSENBJERGAARD J, 1982, NEW ENGL J MED, V307, P965, DOI 10.1056/NEJM198210143071601; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RICHMAN CM, 1983, AM J HEMATOL, V14, P37, DOI 10.1002/ajh.2830140105; RODENHUIS S, 1986, BLOOD, V67, P1698; ROSSON D, 1983, CANCER RES, V43, P3912; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SCHER CD, 1975, NATURE, V256, P225, DOI 10.1038/256225a0; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SKLAR MD, 1985, INT J RADIAT ONCOL, V11, P49, DOI 10.1016/0360-3016(85)90361-X; SMADJA N, 1982, PATHOL BIOL, V30, P775; SOUYRI M, 1983, P NATL ACAD SCI-BIOL, V80, P6676, DOI 10.1073/pnas.80.21.6676; SOUYRI M, 1984, GENES CANCER, P399; SOUYRI M, 1987, IN PRESS VIROLOGY; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANAKA T, 1986, CANCER RES, V46, P1465; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; VIOLA MV, 1985, J EXP MED, V161, P1213, DOI 10.1084/jem.161.5.1213; VIOLA MV, 1986, NEW ENGL J MED, V314, P133, DOI 10.1056/NEJM198601163140301; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; WEINBERG RA, 1982, ADV CANCER RES, V36, P149, DOI 10.1016/S0065-230X(08)60424-8; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YAHALOM J, 1983, AM J CLIN PATHOL, V80, P231, DOI 10.1093/ajcp/80.2.231; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	90	74	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1987	1	2					157	165						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3325880				2022-12-17	WOS:A1987J635200008
J	Jiang, SH; Hu, LP; Wang, X; Li, J; Zhang, ZG				Jiang, Shu-Heng; Hu, Li-Peng; Wang, Xu; Li, Jun; Zhang, Zhi-Gang			Neurotransmitters: emerging targets in cancer	ONCOGENE			English	Review							GAMMA-AMINOBUTYRIC-ACID; BETA-BLOCKER USE; PROMOTES TUMOR-GROWTH; NEUROPEPTIDE-Y; GASTROINTESTINAL CANCER; ACETYLCHOLINE-RECEPTOR; CELL PROLIFERATION; GASTRIC-CANCER; NK-1 RECEPTOR; MOUSE MODEL	Neurotransmitters are conventionally viewed as nerve-secreted substances that mediate the stimulatory or inhibitory neuronal functions through binding to their respective receptors. In the past decades, many novel discoveries come to light elucidating the regulatory roles of neurotransmitters in the physiological and pathological functions of tissues and organs. Notably, emerging data suggest that cancer cells take advantage of the neurotransmitters-initiated signaling pathway to activate uncontrolled proliferation and dissemination. In addition, neurotransmitters can affect immune cells and endothelial cells in the tumor microenvironment to promote tumor progression. Therefore, a better understanding of the mechanisms underlying neurotransmitter function in tumorigenesis, angiogenesis, and inflammation is expected to enable the development of the next generation of antitumor therapies. Here, we summarize the recent important studies on the different neurotransmitters, their respective receptors, target cells, as well as pro/antitumor activity of specific neurotransmitter/receptor axis in cancers and provide perspectives and insights regarding the rationales and strategies of targeting neurotransmitter system to cancer treatment.	[Jiang, Shu-Heng; Hu, Li-Peng; Wang, Xu; Li, Jun; Zhang, Zhi-Gang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200240, Peoples R China	Shanghai Jiao Tong University	Zhang, ZG (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200240, Peoples R China.	zzhang@shsci.org		Zhang, Zhi-gang/0000-0001-8965-223X; Hu, Lipeng/0000-0002-5941-3825; Wang, Xu/0000-0002-3768-777X	National Natural Science Foundation of China [81701945, 81672358, 81871923, 81802890, 81872242]; Natural Science Foundation of Shanghai [18ZR1436900]; Shanghai Sailing Program [19YF1445700]; China Postdoctoral Science Foundation [2018M640403]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20181708]; Program of Shanghai Academic/Technology Research Leader [19XD1403400]; Science and Technology Commission of Shanghai Municipality [18410721000]; Shanghai Municipal Health Bureau [2018BR32]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Shanghai Sailing Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Program of Shanghai Academic/Technology Research Leader; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Health Bureau	This work was supported by grants from the National Natural Science Foundation of China (81701945, 81672358, 81871923, 81802890, and 81872242), the Natural Science Foundation of Shanghai (18ZR1436900), Shanghai Sailing Program (19YF1445700), China Postdoctoral Science Foundation (2018M640403), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20181708), Program of Shanghai Academic/Technology Research Leader (19XD1403400), Science and Technology Commission of Shanghai Municipality (18410721000), and Shanghai Municipal Health Bureau (2018BR32).	Abdul M, 2008, ACTA ONCOL, V47, P1546, DOI 10.1080/02841860801961265; Anastas JN, 2019, MOL CELL, V74, P418, DOI 10.1016/j.molcel.2019.04.017; Arreola R, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/354957; Asada M, 2009, NEOPLASIA, V11, P408, DOI 10.1593/neo.81630; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Berger M, 2009, ANNU REV MED, V60, P355, DOI 10.1146/annurev.med.60.042307.110802; Bergeret M, 1998, BIOMED PHARMACOTHER, V52, P214, DOI 10.1016/S0753-3322(98)80019-X; Blanchart A, 2017, ONCOGENE, V36, P777, DOI 10.1038/onc.2016.245; Boilly B, 2017, CANCER CELL, V31, P342, DOI 10.1016/j.ccell.2017.02.005; Briggs KJ, 2016, CELL, V166, P126, DOI 10.1016/j.cell.2016.05.042; Chabbi-Achengli Y, 2012, P NATL ACAD SCI USA, V109, P2567, DOI 10.1073/pnas.1117792109; Chakroborty D, 2004, CLIN CANCER RES, V10, P4349, DOI 10.1158/1078-0432.CCR-04-0059; Chakroborty D, 2008, J CLIN INVEST, V118, P1380, DOI 10.1172/JCI33125; Coelho M, 2017, J CANCER RES CLIN, V143, P275, DOI 10.1007/s00432-016-2278-1; Cosentino M, 2007, BLOOD, V109, P632, DOI 10.1182/blood-2006-01-028423; Covenas R, 2014, HISTOL HISTOPATHOL, V29, P881, DOI 10.14670/HH-29.881; Czarnecka M, 2015, ONCOGENE, V34, P3131, DOI 10.1038/onc.2014.253; De Giorgi V, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.2908; Del Bello F, 2019, EUR J MED CHEM, V168, P461, DOI 10.1016/j.ejmech.2019.02.056; Dimitrov S, 2019, J EXP MED, V216, P517, DOI 10.1084/jem.20181169; Dolma S, 2016, CANCER CELL, V29, P859, DOI 10.1016/j.ccell.2016.05.002; Elisia I, 2019, CARCINOGENESIS, V40, P448, DOI 10.1093/carcin/bgz060; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; Entschladen F, 2008, SEMIN CANCER BIOL, V18, P171, DOI 10.1016/j.semcancer.2007.12.004; Farrelly LA, 2019, NATURE, V567, P535, DOI 10.1038/s41586-019-1024-7; Fujii T, 2017, J PHARMACOL SCI, V134, P1, DOI 10.1016/j.jphs.2017.05.002; Fujii T, 2014, J NEUROIMMUNOL, V267, P43, DOI 10.1016/j.jneuroim.2013.12.003; Galli S, 2016, AM J PATHOL, V186, P3040, DOI 10.1016/j.ajpath.2016.07.019; Gautam J, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0559-6; Gelb T, 2015, ONCOGENE, V34, P2711, DOI 10.1038/onc.2014.231; Grando SA, 2014, NAT REV CANCER, V14, P419, DOI 10.1038/nrc3725; Griffin N, 2018, PHARMACOL RES, V135, P12, DOI 10.1016/j.phrs.2018.07.019; Grygier B, 2013, PHARMACOL REP, V65, P672, DOI 10.1016/S1734-1140(13)71045-4; Grytli HH, 2014, EUR UROL, V65, P635, DOI 10.1016/j.eururo.2013.01.007; Gumireddy K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10715; Hanoun M, 2015, NEURON, V86, P360, DOI 10.1016/j.neuron.2015.01.026; Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005; Hondermarck H, 2018, TRENDS CANCER, V4, P93, DOI 10.1016/j.trecan.2017.11.008; Hsieh HY, 2016, CANCER LETT, V370, P56, DOI 10.1016/j.canlet.2015.09.018; Hujber Z, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0946-5; Inbar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019246; Jandaghi P, 2016, GASTROENTEROLOGY, V151, P1218, DOI 10.1053/j.gastro.2016.08.040; Jansen L, 2012, CANCER-AM CANCER SOC, V118, P3911, DOI 10.1002/cncr.26727; Jiang SH, 2019, GUT, V68, P1994, DOI 10.1136/gutjnl-2018-317479; Jiang SH, 2017, GASTROENTEROLOGY, V153, P277, DOI 10.1053/j.gastro.2017.03.008; Kaczynska K, 2018, PULM PHARMACOL THER, V48, P217, DOI 10.1016/j.pupt.2017.12.001; Kanbara K, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4149-4; Kast RE, 2010, BRIT J PHARMACOL, V161, P481, DOI 10.1111/j.1476-5381.2010.00923.x; Kim H, 2010, NAT MED, V16, P804, DOI 10.1038/nm.2173; Kim HB, 2017, INT J CANCER, V140, P513, DOI 10.1002/ijc.30443; Kim TH, 2019, FASEB J, V33, P3997, DOI 10.1096/fj.201801429RR; Krizanova O, 2016, STRESS, V19, P419, DOI 10.1080/10253890.2016.1203415; Lang K, 2003, IMMUNOL LETT, V90, P165, DOI 10.1016/j.imlet.2003.09.004; Lang K, 2007, PROG EXP TUMOR RES, V39, P99, DOI 10.1159/000100070; Le CP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10634; Levite M, 2017, J NEURAL TRANSM, V124, P775, DOI 10.1007/s00702-016-1661-z; Li JA, 2015, REGEN BIOMATER, V2, P215, DOI 10.1093/rb/rbv013; Li J, 2014, J HEPATOL, V60, P1225, DOI 10.1016/j.jhep.2014.02.025; Li ZJ, 2011, EUR J PHARMACOL, V667, P17, DOI 10.1016/j.ejphar.2011.05.077; Liu X, 2008, J CELL BIOCHEM, V105, P53, DOI 10.1002/jcb.21802; Liu Y, 2019, EUR J CANCER, V114, P8, DOI 10.1016/j.ejca.2019.03.017; Maemura K, 2009, J GASTROEN HEPATOL, V24, P688, DOI 10.1111/j.1440-1746.2008.05687.x; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Mammadova-Bach E, 2018, PLATELETS, V29, P541, DOI 10.1080/09537104.2018.1478072; Melhem-Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441; Minami K, 2017, SCI REP-UK, V7, DOI 10.1038/srep45686; Moody TW, 2016, CURR OPIN ENDOCRINOL, V23, P38, DOI 10.1097/MED.0000000000000218; Moody TW, 2015, PEPTIDES, V72, P106, DOI 10.1016/j.peptides.2015.03.018; Muma NA, 2015, ACS CHEM NEUROSCI, V6, P961, DOI 10.1021/cn500329r; Munoz M, 2017, PHARMACOL REP, V69, P696, DOI 10.1016/j.pharep.2017.02.002; Munoz M, 2016, SAUDI J GASTROENTERO, V22, P260, DOI 10.4103/1319-3767.187601; Munoz M, 2011, CURR DRUG TARGETS, V12, P909, DOI 10.2174/138945011795528796; Na ZJ, 2018, ONCOTARGETS THER, V11, P4913, DOI 10.2147/OTT.S167422; Nasi G, 2019, J NEUROIMMUNOL, V332, P233, DOI 10.1016/j.jneuroim.2019.02.007; Nilsson MB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4307; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Nocito A, 2008, CANCER RES, V68, P5152, DOI 10.1158/0008-5472.CAN-08-0202; Ondrovics M, 2017, ONCOTARGET, V8, P25783, DOI 10.18632/oncotarget.15419; Ouyang Q, 2017, CLIN EXP PHARMACOL P, V44, P841, DOI 10.1111/1440-1681.12787; Palamiuc L, 2018, J EXP MED, V215, P17, DOI 10.1084/jem.20172050; Patane S, 2014, INT J CARDIOL, V177, P646, DOI 10.1016/j.ijcard.2014.09.178; Pinoli M, 2017, J NEUROIMMUNE PHARM, V12, P602, DOI 10.1007/s11481-017-9749-2; Powe DG, 2011, NAT REV CLIN ONCOL, V8, P511, DOI 10.1038/nrclinonc.2011.123; Reijmen E, 2018, IMMUNOL LETT, V202, P38, DOI 10.1016/j.imlet.2018.07.006; Renz BW, 2018, CANCER DISCOV, V8, P1458, DOI 10.1158/2159-8290.CD-18-0046; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Ribeiro MPC, 2017, CANCER CHEMOTH PHARM, V79, P219, DOI 10.1007/s00280-016-3129-0; Rolland B, 2015, EUR NEUROPSYCHOPHARM, V25, P1631, DOI 10.1016/j.euroneuro.2015.05.008; Roney MSI, 2018, ARCH PHARM RES, V41, P384, DOI 10.1007/s12272-018-1017-3; Russo P, 2014, CURR MOL MED, V14, P1126, DOI 10.2174/1566524014666141015152601; Santala EEE, 2019, INT J CANCER, V144, P440, DOI 10.1002/ijc.31802; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Sarkar C, 2013, J NEUROIMMUNE PHARM, V8, P7, DOI 10.1007/s11481-012-9395-7; Sarrouilhe D, 2015, CURR MOL MED, V15, P62, DOI 10.2174/1566524015666150114113411; Sarrouilhe D, 2019, BIOCHIMIE, V161, P46, DOI 10.1016/j.biochi.2018.06.016; Schaal CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0901-2; Schuller HM, 2008, ANTI-CANCER DRUG, V19, P655, DOI 10.1097/CAD.0b013e3283025b58; Schuller HM, 2018, CURR MED CHEM, V25, P2566, DOI 10.2174/0929867324666170303121708; Shahzad MMK, 2010, J BIOL CHEM, V285, P35462, DOI 10.1074/jbc.M110.109579; Shapovalov Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-598; Shimizu R, 2019, INT J ONCOL, V54, P283, DOI 10.3892/ijo.2018.4631; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Soll C, 2010, HEPATOLOGY, V51, P1244, DOI 10.1002/hep.23441; Song YF, 2017, CANCER RES, V77, P1611, DOI 10.1158/0008-5472.CAN-16-2143; Sood AK, 2010, J CLIN INVEST, V120, P1515, DOI 10.1172/JCI40802; Sorensen GV, 2013, J CLIN ONCOL, V31, P2265, DOI 10.1200/JCO.2012.43.9190; Spera G, 2017, ANN ONCOL, V28, P1836, DOI 10.1093/annonc/mdx264; Sung HY, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.62; Takehara A, 2007, CANCER RES, V67, P9704, DOI 10.1158/0008-5472.CAN-07-2099; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Tilan J, 2016, NEUROPEPTIDES, V55, P55, DOI 10.1016/j.npep.2015.10.005; Wang QH, 2019, J CELL PHYSIOL, V234, P14432, DOI 10.1002/jcp.28214; Wang T, 2008, LIFE SCI, V82, P536, DOI 10.1016/j.lfs.2007.12.014; Wessler IK, 2017, J NEUROCHEM, V142, P144, DOI 10.1111/jnc.13953; Wu J, 2015, J LEUKOCYTE BIOL, V97, P191, DOI 10.1189/jlb.5A1113-626RR; Wu XY, 2018, CELL PHYSIOL BIOCHEM, V48, P2258, DOI 10.1159/000492644; Xia S, 2017, MOL PHARMACOL, V92, P265, DOI 10.1124/mol.116.107854; Yu HF, 2017, SCI REP-UK, V7, DOI 10.1038/srep40802; Yu LMJ, 2017, NEUROPHARMACOLOGY, V115, P193, DOI 10.1016/j.neuropharm.2016.02.011; Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072; Zhang DP, 2014, CANCER LETT, V348, P100, DOI 10.1016/j.canlet.2014.03.006; Zhang XX, 2014, J RECEPT SIG TRANSD, V34, P431, DOI 10.3109/10799893.2013.856918; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569; Zila I, 2017, PHYSIOL RES, V66, pS139, DOI 10.33549/physiolres.933671	124	73	75	8	39	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					503	515		10.1038/s41388-019-1006-0	http://dx.doi.org/10.1038/s41388-019-1006-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31527667				2022-12-17	WOS:000509718300002
J	Sun, J; Cai, X; Yung, MMH; Zhou, W; Li, J; Zhang, Y; Li, ZQ; Liu, SS; Cheung, ANY; Ngan, HYS; Li, YL; Dai, ZJ; Kai, Y; Tzatsos, A; Peng, WQ; Chan, DW; Zhu, WG				Sun, Jing; Cai, Xin; Yung, Mingo M. H.; Zhou, Wei; Li, Jing; Zhang, Yi; Li, Zhuqing; Liu, Stephanie S.; Cheung, Annie N. Y.; Ngan, Hextan Y. S.; Li, Yiliang; Dai, Zhijun; Kai, Yan; Tzatsos, Alexandros; Peng, Weiqun; Chan, David W.; Zhu, Wenge			miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer	ONCOGENE			English	Article							MOLECULAR-MECHANISMS; IN-VITRO; ANTISENSE OLIGODEOXYNUCLEOTIDES; INHIBITS PROLIFERATION; CELL CARCINOMA; BREAST-CANCER; TUMOR-CELLS; SENSITIVITY; EXPRESSION; MICRORNA-137	Platinum drugs are used in first-line to treat ovarian cancer, but most of the patients eventually generate resistance after treatment with these drugs. Although both c-Myc and EZH2 have been implicated in regulating cisplatin resistance in ovarian cancer, the interplay between these two regulators is poorly understood. Using RNA sequence analysis (RNA-seq), for the first time we find that miR-137 level is extremely low in cisplatin resistant ovarian cancer cells, correlating with higher levels of c-Myc and EZH2 expression. Further analyses indicate that in resistant cells c-Myc enhances the expression of EZH2 by directly suppressing miR-137 that targets EZH2 mRNA, and increased expression of EZH2 activates cellular survival pathways, resulting in the resistance to cisplatin. Inhibition of c-Myc-miR-137-EZH2 pathway re-sensitizes resistant cells to cisplatin. Both in vivo and in vitro analyses indicate that cisplatin treatment activates c-Myc-miR-137-EZH2 pathway. Importantly, elevated c-Myc-miR-137-EZH2 pathway in resistant cells is sustained by dual oxidase maturation factor 1 (DUOXA1)-mediated production of reactive oxygen species (ROS). Significantly, clinical studies further confirm the activated c-Myc-miR-137-EZH2 pathway in platinum drug-resistant or recurrent ovarian cancer patients. Thus, our studies elucidate a novel role of miR-137 in regulating c-Myc-EZH2 axis that is crucial to the regulation of cisplatin resistance in ovarian cancer.	[Sun, Jing; Cai, Xin; Zhou, Wei; Li, Jing; Zhang, Yi; Li, Zhuqing; Zhu, Wenge] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Sun, Jing; Cai, Xin; Zhou, Wei; Li, Jing; Zhang, Yi; Li, Zhuqing; Kai, Yan; Tzatsos, Alexandros; Zhu, Wenge] George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA; [Yung, Mingo M. H.; Liu, Stephanie S.; Ngan, Hextan Y. S.; Chan, David W.] Univ Hong Kong, LKS Fac Med, Dept Obstet & Gynaecol, Hong Kong, Peoples R China; [Zhou, Wei] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Hangzhou 310016, Zhejiang, Peoples R China; [Cheung, Annie N. Y.] Univ Hong Kong, LKS Fac Med, Dept Pathol, Hong Kong, Peoples R China; [Li, Yiliang] Peking Union Med Coll, Inst Radiat Med, Tianjin Key Lab Radiat Med & Mol Nucl Med, Tianjin 300192, Peoples R China; [Li, Yiliang] Chinese Acad Med Sci, Tianjin 300192, Peoples R China; [Dai, Zhijun] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Oncol, Xian 710004, Shaanxi, Peoples R China; [Kai, Yan; Peng, Weiqun] George Washington Univ, Dept Phys, Columbian Coll Arts & Sci, Washington, DC 20052 USA; [Tzatsos, Alexandros] George Washington Univ, Sch Med & Hlth Sci, Dept Anat & Regenerat Biol, Washington, DC 20037 USA	George Washington University; George Washington University; University of Hong Kong; Zhejiang University; University of Hong Kong; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Radiation Medicine - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Xi'an Jiaotong University; George Washington University; George Washington University	Zhu, WG (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA.; Zhu, WG (corresponding author), George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA.; Chan, DW (corresponding author), Univ Hong Kong, LKS Fac Med, Dept Obstet & Gynaecol, Hong Kong, Peoples R China.	dwchan@hku.hk; wz6812@gwu.edu	/AAI-2516-2019; YUNG, Mingo Ming Ho/AHB-5775-2022; Chan, David/O-9896-2018; Kai, Yan/ABH-8469-2020; Li, Zhuqing/AEW-9886-2022; Dai, Zhi-Jun/O-6826-2014; Cheung, Annie Nga Yin/C-4231-2009	YUNG, Mingo Ming Ho/0000-0003-0903-1164; Chan, David/0000-0002-6951-3467; Kai, Yan/0000-0003-3262-4160; Li, Jing/0000-0002-0079-693X; Peng, Weiqun/0000-0001-5521-9091; Dai, Zhi-Jun/0000-0001-5209-8626; Ngan, Hextan Y S/0000-0003-3945-159X; Cheung, Annie Nga Yin/0000-0002-1584-7568	National Institutes of Health [CA177898, CA184717]; McCormick Genomic and Proteomic Center [RSG-13-214-01-DMC]; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA184717, R01CA177898] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McCormick Genomic and Proteomic Center; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by funding from the National Institutes of Health (CA177898 and CA184717 to WZ), the McCormick Genomic and Proteomic Center. W. Zhu was supported by a Research Scholar Grant, RSG-13-214-01-DMC from the American Cancer Society.	Adelaiye-Ogala R, 2017, CANCER RES, V77, P6651, DOI 10.1158/0008-5472.CAN-17-0899; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Banno K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/232817; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912; Blower PE, 2008, MOL CANCER THER, V7, P1, DOI 10.1158/1535-7163.MCT-07-0573; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Brennecke J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-228; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Citro G, 1998, CANCER RES, V58, P283; Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3; Cui SC, 2017, MOL MED REP, V16, P9494, DOI 10.3892/mmr.2017.7828; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Dong S, 2016, ONCOL REP, V35, P2151, DOI 10.3892/or.2016.4604; Fabbri M, 2011, CURR OPIN HEMATOL, V18, P266, DOI 10.1097/MOH.0b013e3283476012; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Grasberger H, 2006, J BIOL CHEM, V281, P18269, DOI 10.1074/jbc.C600095200; Haenisch S, 2012, EPIGENOMICS-UK, V4, P369, DOI [10.2217/EPI.12.39, 10.2217/epi.12.39]; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hodzic J, 2011, NUCLEOS NUCLEOT NUCL, V30, P1214, DOI 10.1080/15257770.2011.629271; Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913; Jazaeri AA, 2013, MOL CANCER THER, V12, P1958, DOI 10.1158/1535-7163.MCT-12-1028; Knapp DC, 2003, ANTI-CANCER DRUG, V14, P39, DOI 10.1097/00001813-200301000-00006; LANGDON SP, 1988, CANCER RES, V48, P6166; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Lin CP, 2007, ANTI-CANCER DRUG, V18, P161, DOI 10.1097/CAD.0b013e3280109424; Liu X, 2017, EUR REV MED PHARMACO, V21, P511; Luo YW, 2016, TUMOR BIOL, V37, P7749, DOI 10.1007/s13277-015-4611-8; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; Meng YX, 2018, CANCER LETT, V428, P104, DOI 10.1016/j.canlet.2018.04.029; MIZUTANI Y, 1994, CANCER, V74, P2546, DOI 10.1002/1097-0142(19941101)74:9<2546::AID-CNCR2820740924>3.0.CO;2-Y; Moitra K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045268; Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Norouzi-Barough L, 2018, J CELL PHYSIOL, V233, P4546, DOI 10.1002/jcp.26289; Passetti F, 2009, PHARMACOGENOMICS J, V9, P1, DOI 10.1038/tpj.2008.14; Prathapam T, 2010, J BIOL CHEM, V285, P32529, DOI 10.1074/jbc.M110.151902; Pyndiah S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001556; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Reyes-Gonzalez JM, 2015, MOL CANCER THER, V14, P2260, DOI 10.1158/1535-7163.MCT-14-0801; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Sandiford SDE, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-5; Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544; SKLAR MD, 1991, CANCER RES, V51, P2118; Smonskey Matthew, 2016, Oncoscience, V3, P21; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Stronach EA, 2015, ONCOTARGET, V6, P31593, DOI 10.18632/oncotarget.3415; Sun J, 2016, AM J TRANSL RES, V8, P3077; Sun J, 2016, ONCOTARGETS THER, V9, P21, DOI 10.2147/OTT.S93305; Sun J, 2015, DRUG DES DEV THER, V9, P6327, DOI 10.2147/DDDT.S92777; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; van Jaarsveld MTM, 2013, ONCOGENE, V32, P4284, DOI 10.1038/onc.2012.433; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Walker TL, 1996, BRIT J CANCER, V73, P610, DOI 10.1038/bjc.1996.105; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Warburton A, 2015, SCHIZOPHRENIA BULL, V41, P698, DOI 10.1093/schbul/sbu117; Wu YM, 2018, CANCER RES, V78, P671, DOI 10.1158/0008-5472.CAN-17-1327; Xie XK, 2006, CANCER INVEST, V24, P1, DOI 10.1080/07357900500449520; Zhao X, 2013, LEUKEMIA, V27, P2341, DOI 10.1038/leu.2013.94; Zhou W, 2018, ONCOGENE, V37, P3981, DOI 10.1038/s41388-018-0238-8; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	64	73	77	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					564	580		10.1038/s41388-018-0459-x	http://dx.doi.org/10.1038/s41388-018-0459-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30166592	Green Accepted			2022-12-17	WOS:000456589800008
J	Begum, S; Yiu, A; Stebbing, J; Castellano, L				Begum, S.; Yiu, A.; Stebbing, J.; Castellano, L.			Novel tumour suppressive protein encoded by circular RNA, circ-SHPRH, in glioblastomas	ONCOGENE			English	Article								The previously unchartered gene expression territory governed by circular RNAs is becoming clearer with the onset of deeper sequencing technologies. The translation of circular RNAs remained a controversial theory until earlier this year, when two studies [1, 2] showed endogenous circular RNA translation in vitro and in vivo, and have further provided mechanistical evidence. In this edition of Oncogene, Zhang et al., provide evidence for the first circular RNA translated with relevance to cancer; a novel tumour suppressor protein, SHPRH-146aa, produced by circ-SHPRH driven by IRES elements. The novel tumour suppressor protein produced by the circular RNA was found to work in synergy with the full-length protein, behaving as a protective decoy molecule to decrease degradation, and thus increasing the tumour suppressive functionality of the gene. An extended patient survival time was seen in glioblastoma patients with elevated levels of SHPRH-146aa. This study also marks the discovery of the first circular RNA with an overlapping initiation and termination codon, resulting in the translation of the full circRNA, exploring a mechanism not previously found or seen.	[Begum, S.] Imperial Coll London, Dept Surg & Canc, Fac Med, Div Computat & Syst Med, South Kensington Campus,Exhibit Rd, London SW7 2AZ, England; [Yiu, A.; Stebbing, J.; Castellano, L.] Imperial Coll London, Fac Med, Div Canc, Dept Surg & Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England; [Castellano, L.] Univ Sussex, Sch Life Sci, John Maynard Smith Bldg, Brighton BN1 9QG, E Sussex, England	Imperial College London; Imperial College London; University of Sussex	Castellano, L (corresponding author), Imperial Coll London, Fac Med, Div Canc, Dept Surg & Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.; Castellano, L (corresponding author), Univ Sussex, Sch Life Sci, John Maynard Smith Bldg, Brighton BN1 9QG, E Sussex, England.	l.castellano@imperial.ac.uk	Castellano, Leandro/AAE-1366-2021	Begum, Sofina/0000-0001-7689-0087; Stebbing, Justin/0000-0002-1117-6947; Castellano, Leandro/0000-0002-3059-4829	Department of Health [NIHR-RP-011-053] Funding Source: Medline	Department of Health		CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007; Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hou LD, 2017, INT J IMMUNOPATH PH, V30, P1, DOI 10.1177/0394632016686985; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Kumar S, 2017, NATURE, V547, P40, DOI 10.1038/nature23085; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Qin ML, 2016, CANCER BIOMARK, V16, P161, DOI 10.3233/CBM-150552; Rasool Mahmood, 2016, Noncoding RNA Res, V1, P69, DOI 10.1016/j.ncrna.2016.11.001; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122	14	73	75	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4055	4057		10.1038/s41388-018-0230-3	http://dx.doi.org/10.1038/s41388-018-0230-3			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706655				2022-12-17	WOS:000439847000001
J	Xu, Z; Yang, F; Wei, D; Liu, B; Chen, C; Bao, Y; Wu, Z; Wu, D; Tan, H; Li, J; Wang, J; Liu, J; Sun, S; Qu, L; Wang, L				Xu, Z.; Yang, F.; Wei, D.; Liu, B.; Chen, C.; Bao, Y.; Wu, Z.; Wu, D.; Tan, H.; Li, J.; Wang, J.; Liu, J.; Sun, S.; Qu, L.; Wang, L.			Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma	ONCOGENE			English	Article							NF-KAPPA-B; ANTITUMOR-ACTIVITY; CANCER; PROSTATE; INHIBITION; STAT3	Although the use of sorafenib appears to increase the survival rate of renal cell carcinoma (RCC) patients, there is also a proportion of patients who exhibit a poor primary response to sorafenib therapy. It is therefore critical to elucidate the mechanisms underlying sorafenib resistance and find representative biomarkers for sorafenib treatment in RCC patients. Herein, we identified a long non-coding RNA referred to as lncRNA-SRLR (sorafenib resistance-associated lncRNA in RCC) that is upregulated in intrinsically sorafenib-resistant RCCs. lncRNA-SRLR knockdown sensitized nonresponsive RCC cells to sorafenib treatment, whereas the overexpression of lncRNA-SRLR conferred sorafenib resistance to responsive RCC cells. Mechanistically, lncRNA-SRLR directly binds to NF-kappa B and promotes IL-6 transcription, leading to the activation of STAT3 and the development of sorafenib tolerance. A STAT3 inhibitor and IL-6-receptor antagonist both restored the response to sorafenib treatment. Moreover, a clinical investigation demonstrated that high levels of lncRNA-SRLR correlated with poor responses to sorafenib therapy in RCC patients. Collectively, lncRNA-SRLR may serve as not only a predictive biomarker for inherent sorafenib resistance but also as a therapeutic target to enhance responses to sorafenib in RCC patients.	[Xu, Z.; Liu, B.; Bao, Y.; Wu, Z.; Wu, D.; Tan, H.; Li, J.; Wang, J.; Liu, J.; Qu, L.; Wang, L.] Second Mil Med Univ, Changzheng Hosp, Dept Urol, 415 Fengyang Rd, Shanghai 200003, Peoples R China; [Yang, F.; Sun, S.] Second Mil Med Univ, Dept Med Genet, 800 Xiangyin Rd, Shanghai 200433, Peoples R China; [Wei, D.] Shandong Univ, Shandong Prov Qianfoshan Hosp, Div Endocrinol, Dept Internal Med, Jinan, Peoples R China; [Chen, C.] Nanjing Univ, Jinling Hosp, Dept Med Oncol, Clin Sch Med, Nanjing, Jiangsu, Peoples R China; [Qu, L.] Nanjing Univ, Jinling Hosp, Dept Urol, Clin Sch Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China	Naval Medical University; Naval Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Nanjing University; Nanjing University	Wang, L (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Urol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.; Sun, S (corresponding author), Second Mil Med Univ, Dept Med Genet, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.; Qu, L (corresponding author), Nanjing Univ, Jinling Hosp, Dept Urol, Clin Sch Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	shsun@vip.sina.com; septsoul@hotmail.com; wanglinhuicz@163.com	Yang, Fu/C-3786-2008; Yang, Fu/L-8441-2019	Yang, Fu/0000-0003-2459-3923; Qu, Le/0000-0001-9499-4277	National Natural Science Foundation of China [81272817, 81472691, 81572521]; Leading Talent Project of Shanghai [2013046]; Youth Talent Sailing Program of Shanghai Science and Technology Committee [16YF1403600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Leading Talent Project of Shanghai; Youth Talent Sailing Program of Shanghai Science and Technology Committee	We thank Dr Feng Liu and Qifei Tao for editing this manuscript. This study was supported by grants from the National Natural Science Foundation of China (81272817, 81472691 and 81572521), the Leading Talent Project of Shanghai (2013046) and Youth Talent Sailing Program of Shanghai Science and Technology Committee (16YF1403600).	Abe H, 2013, INT J UROL, V20, P944, DOI 10.1111/iju.12187; Banfai B, 2012, GENOME RES, V22, P1646, DOI 10.1101/gr.134767.111; Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Heng DY, 2012, ANN ONCOL, V23, P1549, DOI 10.1093/annonc/mdr533; Hirata H, 2015, CANCER RES, V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kharaziha P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.1; Kong J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-7; Liang YJ, 2013, HEPATOLOGY, V57, P1847, DOI 10.1002/hep.26224; Lin MF, 2011, BIOINFORMATICS, V27, pI275, DOI 10.1093/bioinformatics/btr209; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114586; Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005; Ljungberg B, 2011, EUR UROL, V60, P615, DOI 10.1016/j.eururo.2011.06.049; Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Ozturk G, 2012, EUR REV MED PHARMACO, V16, P2064; Pang KC, 2006, TRENDS GENET, V22, P1, DOI 10.1016/j.tig.2005.10.003; Patil S, 2012, J UROLOGY, V188, P2095, DOI 10.1016/j.juro.2012.08.026; Powles T, 2016, EUR UROL, V69, P4, DOI 10.1016/j.eururo.2015.10.017; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457; Sotillo E, 2011, NAT GENET, V43, P616, DOI 10.1038/ng.870; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Ye DW, 2014, ONCOTARGETS THER, V7, P925, DOI 10.2147/OTT.S41828; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	37	73	78	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1965	1977		10.1038/onc.2016.356	http://dx.doi.org/10.1038/onc.2016.356			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27841868				2022-12-17	WOS:000398898500007
J	Chiu, LY; Hsin, IL; Yang, TY; Sung, WW; Chi, JY; Chang, JT; Ko, JL; Sheu, GT				Chiu, L-Y; Hsin, I-L; Yang, T-Y; Sung, W-W; Chi, J-Y; Chang, J. T.; Ko, J-L; Sheu, G-T			The ERK-ZEB1 pathway mediates epithelial mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SNAIL; TGF-BETA; E-CADHERIN; THYMIDYLATE SYNTHASE; SIGNALING PATHWAYS; MULTITARGETED ANTIFOLATE; MULTIDRUG-RESISTANCE; CARCINOMA-CELLS; SMAD PROTEINS; TUMOR-CELLS	High thymidylate synthase (TS) level in cancer tissue is considered to result in resistance to pemetrexed therapy for advanced stages of nonsquamous non-small cell lung cancers. To further investigate the mechanism of pemetrexed resistance and potential prognostic outcomes in lung cancer, we established pemetrexed-resistant lung adenocarcinoma cell sublines from CL1 harboring a mutated TP53 gene (R248W) and A549 harboring wild-type TP53. We found the TS expression is upregulated in both pemetrexed-resistant sublines and the reduced TS level achieved through shRNA inhibition resulted in higher pemetrexed sensitivity. We also demonstrated that the acquisitions of pemetrexed resistance enhances epithelial mesenchymal transition (EMT) in vivo with a mice animal model and in vitro with CL1 and A549 sublines, which was associated with upregulation of ZEB1 which, in turn, downregulates E-cadherin and upregulates fibronectin. When ERK1/2 phosphorylation was reduced by an inhibitor (U0126) or siRNA inhibition, both pemetrexed-resistant sublines reduced their migration and invasion abilities. Therefore, the ERK-mediated pathways induce apoptosis with pemetrexed treatment, and may in turn mediate EMT when cancer cells are resistant to pemetrexed. We further demonstrated that the growth of pemetrexed-resistant tumors could be inhibited by vinblastine in vivo and vincristine in vitro. Our data indicate that pemetrexed resistance could be relieved by non-cross-resistant chemotherapeutic drugs such as vinca alkaloids and might be independent to TP53 status. Furthermore, the phosphorylation of ERK was reduced by vincristine. This finding provides a new insight for overcoming pemetrexed resistance and metastasis by application of vinca alkaloids.	[Chiu, L-Y; Chi, J-Y; Chang, J. T.; Ko, J-L; Sheu, G-T] Chung Shan Med Univ, Inst Med, Res Bldg Room 702,110 Sec 1,Jianguo N Rd, Taichung 402, Taiwan; [Hsin, I-L] Changhua Christian Hosp, Inflammat Res & Drug Dev Ctr, Changhua, Taiwan; [Yang, T-Y] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan; [Sung, W-W] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Sung, W-W] Chung Shan Med Univ Hosp, Dept Med Educ, Taichung, Taiwan; [Sung, W-W] Jen Teh Jr Coll Med Nursing & Management, Dept Med Technol, Miaoli, Taiwan; [Ko, J-L; Sheu, G-T] Chung Shan Med Univ Hosp, Dept Med Oncol & Chest Med, Taichung, Taiwan	Chung Shan Medical University; Changhua Christian Hospital; Taichung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital	Sheu, GT (corresponding author), Chung Shan Med Univ, Inst Med, Res Bldg Room 702,110 Sec 1,Jianguo N Rd, Taichung 402, Taiwan.	gtsheu@csmu.edu.tw	Sung, Wen-Wei/P-5053-2019; Sheu, Gwo-Tarng/H-8855-2019; Chang, Jinghua/AAV-5620-2021	Sung, Wen-Wei/0000-0002-2375-0029; Sheu, Gwo-Tarng/0000-0002-1299-3375; Ko, Jiunn-Liang/0000-0001-6855-9239	Ministry of Science and Technology, Taiwan [MOST-103-2320-6-040-015, MOST-104-2320-B-040-003]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the Ministry of Science and Technology, Taiwan (MOST-103-2320-6-040-015, MOST-104-2320-B-040-003).	Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bakin AV, 2002, J CELL SCI, V115, P3193; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Buque A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063338; Calvert H, 2002, SEMIN ONCOL, V29, P54, DOI 10.1053/sonc.2002.30761; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen CY, 2011, LUNG CANCER, V74, P132, DOI 10.1016/j.lungcan.2011.01.024; Chiu LY, 2010, TOXICOL LETT, V192, P408, DOI 10.1016/j.toxlet.2009.11.018; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Kajiyama H, 2007, INT J ONCOL, V31, P277; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; Liu Y, 2013, CANCER CHEMOTH PHARM, V72, P1125, DOI 10.1007/s00280-013-2299-2; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Massague J, 2000, GENE DEV, V14, P627; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Moudi M, 2013, INT J PREVENTIVE MED, V4, P1231; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Ozasa H, 2010, CANCER SCI, V101, P161, DOI 10.1111/j.1349-7006.2009.01358.x; Piek E, 1999, J CELL SCI, V112, P4557; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; Rollins KD, 2005, CLIN THER, V27, P1343, DOI 10.1016/j.clinthera.2005.09.010; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Schultz RM, 1999, ANTICANCER RES, V19, P437; Shah AN, 2007, ANN SURG ONCOL, V14, P3629, DOI 10.1245/s10434-007-9583-5; Shih C, 1997, CANCER RES, V57, P1116; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Takkunen M, 2006, J HISTOCHEM CYTOCHEM, V54, P1263, DOI 10.1369/jhc.6A6958.2006; Tavares ALP, 2006, DEV DYNAM, V235, P1589, DOI 10.1002/dvdy.20771; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang T, 2011, TRANSPORT DYNAMICS, P663; Yang TY, 2013, MOL CARCINOGEN, V52, P183, DOI 10.1002/mc.21842; Yee DS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-162; Zhang D, 2011, CANCER LETT, V309, P228, DOI 10.1016/j.canlet.2011.06.006; Zucali PA, 2014, LUNG CANCER, V84, P265, DOI 10.1016/j.lungcan.2013.11.011	47	73	75	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					242	253		10.1038/onc.2016.195	http://dx.doi.org/10.1038/onc.2016.195			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270426	Green Published, hybrid			2022-12-17	WOS:000393938100009
J	Gopalakrishnan, R; Matta, H; Tolani, B; Triche, T; Chaudhary, PM				Gopalakrishnan, R.; Matta, H.; Tolani, B.; Triche, T., Jr.; Chaudhary, P. M.			Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors	ONCOGENE			English	Article							KAPOSIS-SARCOMA; KAPPA-B; GENE-EXPRESSION; HSP90 INHIBITOR; IN-VITRO; LENALIDOMIDE; THALIDOMIDE; VFLIP; POMALIDOMIDE; ACTIVATION	Primary effusion lymphoma (PEL) is an aggressive type of non-Hodgkin lymphoma localized predominantly in body cavities. Kaposi's sarcoma-associated herpes virus (KSHV) is the causative agent of PEL. PEL is an incurable malignancy and has extremely poor prognosis when treated with conventional chemotherapy. Immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are Food and Drug Administration-approved drugs for the treatment of various ailments. IMiDs display pronounced antiproliferative effect against majority of PEL cell lines within their clinically achievable concentrations, by arresting cells at G(0)/G(1) phase of cell cycle and without any induction of KSHV lytic cycle reactivation. Although microarray examination of PEL cells treated with lenalidomide revealed activation of interferon (IFN) signaling, blocking the IFN pathway did not block the anti-PEL activity of IMiDs. The anti-PEL effects of IMiDs involved cereblon-dependent suppression of IRF4 and rapid degradation of IKZF1, but not IKZF3. Small hairpin RNA-mediated knockdown of MYC enhanced the cytotoxicity of IMiDs. Bromodomain (BRD) and extra-terminal domain (BET) proteins are epigenetic readers, which perform a vital role in chromatin remodeling and transcriptional regulation. BRD4, a widely expressed transcriptional coactivator, belongs to the BET family of proteins, which has been shown to co-occupy the super enhancers associated with MYC. Specific BRD4 inhibitors were developed, which suppress MYC transcriptionally. Lenalidomide displayed synergistic cytotoxicity with several structurally distinct BRD4 inhibitors (JQ-1, IBET151 and PFI-1). Furthermore, combined administration of lenalidomide and BRD4 inhibitor JQ-1 significantly increased the survival of PEL bearing NOD-SCID mice in an orthotopic xenograft model as compared with either agent alone. These results provide compelling evidence for clinical testing of IMiDs alone and in combination with BRD4 inhibitors for PEL.	[Gopalakrishnan, R.; Matta, H.; Tolani, B.; Triche, T., Jr.; Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90033 USA; [Gopalakrishnan, R.; Matta, H.; Tolani, B.; Triche, T., Jr.; Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Ctr Study Blood Dis, Los Angeles, CA 90033 USA; [Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Med, 1441 Eastlake Ave,NOR 3468, Los Angeles, CA 90033 USA; [Tolani, B.] Univ Calif San Francisco, Sch Med, Dept Surg, San Francisco, CA 94143 USA	University of Southern California; University of Southern California; University of Southern California; University of California System; University of California San Francisco	Chaudhary, PM (corresponding author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Med, 1441 Eastlake Ave,NOR 3468, Los Angeles, CA 90033 USA.	preet.chaudhary@med.usc.edu	Chaudhary, Preet/E-1970-2018; Gopalakrishnan, Ramakrishnan/N-3454-2015	Gopalakrishnan, Ramakrishnan/0000-0002-5068-6886; Triche, Tim/0000-0001-5665-946X; Tolani, Bhairavi/0000-0001-9076-866X	National Institutes of Health [CA139119, DE019811, SC CTSI UL1TR000130, P30CA014089]; Stop Cancer Foundation; National Cancer Institute Cancer Center Shared Grant [P30CA014089]; USC Provost Office Dean's Development Funds; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019811] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stop Cancer Foundation; National Cancer Institute Cancer Center Shared Grant; USC Provost Office Dean's Development Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank the following investigators for their generous gift of cell lines: Dr Jae Jung (BC-3, BCBL-1, JSC-1, BC-1, BCP-1, VG-1 and APK-1); Drs Izidore Lossos and Juan Ramos (UMPEL-1 and UMPEL-3); Dr Art Shaffer (TMD8, U-2932, HBL-1, OCI-Ly7, OCI-Ly8 and OCI-Ly19); Dr Alan Epstein (DG-75); Randall Rossi (SUDHL-4, SUDHL-6, Granta, Toledo, KG-1 and MV-4-11); Dr Markus Mapara (L428, L540, L1236 and KM-H2); Dr Irene Ghobrial (BCWM.1 and WMCL-1); and Dr Alan Lichenstein (MM.1S and RPMI8226). We are grateful to Dr William Kaelin Jr for providing the shRNA constructs (CRBN, IKZF1-1 and IKZF1-2), Dr James Bradner for his generous contribution of (+) and (-) JQ-1, Dr Peter Howley for BRD4 antibody and Dr Gary Hayward for KSHV replication and transcription activator antibody. This work was supported by grants from the National Institutes of Health (CA139119, DE019811, SC CTSI UL1TR000130 and P30CA014089) and Stop Cancer Foundation. Flow Cytometry was analyzed in the USC Flow Cytometry Core Facility that is supported in part by the National Cancer Institute Cancer Center Shared Grant award P30CA014089 and the USC Provost Office Dean's Development Funds.	Antar A, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.6; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Bhatt S, 2013, BLOOD, V122, P1233, DOI 10.1182/blood-2013-01-481713; Cannon JS, 2000, J VIROL, V74, P10187, DOI 10.1128/JVI.74.21.10187-10193.2000; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chen N, 2007, J CLIN PHARMACOL, V47, P1466, DOI 10.1177/0091270007309563; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dimopoulos MA, 2013, CRIT REV ONCOL HEMAT, V88, pS23, DOI 10.1016/j.critrevonc.2013.05.013; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gopalakrishnan R, 2013, CLIN CANCER RES, V19, P5016, DOI 10.1158/1078-0432.CCR-12-3510; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; John LB, 2011, MOL IMMUNOL, V48, P1272, DOI 10.1016/j.molimm.2011.03.006; Jones D, 1998, NEW ENGL J MED, V339, P444, DOI 10.1056/NEJM199808133390705; Kasserra C, 2015, J CLIN PHARMACOL, V55, P168, DOI 10.1002/jcph.384; Keller SA, 2000, BLOOD, V96, P2537; Klein U, 2003, BLOOD, V101, P4115, DOI 10.1182/blood-2002-10-3090; Kobayashi Y, 2007, ACTA HAEMATOL-BASEL, V117, P132, DOI 10.1159/000097460; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Lee BS, 2003, J VIROL, V77, P8072, DOI 10.1128/JVI.77.14.8072-8086.2003; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Li XD, 2010, J VIROL, V84, P8945, DOI 10.1128/JVI.00244-10; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Lopez-Girona A, 2011, BRIT J HAEMATOL, V154, P325, DOI 10.1111/j.1365-2141.2011.08689.x; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036601; Matta H, 2011, J BIOL CHEM, V286, P21555, DOI 10.1074/jbc.M111.224048; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Patel S, 2013, ARCH PATHOL LAB MED, V137, P1152, DOI 10.5858/arpa.2012-0294-RS; Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292; Qin ZQ, 2014, MOL CANCER THER, V13, P154, DOI 10.1158/1535-7163.MCT-13-0466; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Richardson PG, 2013, CRIT REV ONCOL HEMAT, V88, pS36, DOI 10.1016/j.critrevonc.2013.02.001; Sarosiek KA, 2010, P NATL ACAD SCI USA, V107, P13069, DOI 10.1073/pnas.1002985107; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shaffer AL, 2009, CLIN CANCER RES, V15, P2954, DOI 10.1158/1078-0432.CCR-08-1845; Shortt J, 2013, ONCOGENE, V32, P4191, DOI 10.1038/onc.2012.599; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Tolani B, 2014, ONCOGENE, V33, P2928, DOI 10.1038/onc.2013.242; Tolani B, 2014, J VIROL, V88, P6345, DOI 10.1128/JVI.00028-14; Yang YQ, 2011, J BIOL CHEM, V286, P27988, DOI 10.1074/jbc.M110.213363; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Zhang H, 2010, INT J CANCER, V126, P1226, DOI 10.1002/ijc.24825; Zhang LH, 2013, BRIT J HAEMATOL, V160, P487, DOI 10.1111/bjh.12172; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067; Zhu YX, 2013, LEUKEMIA LYMPHOMA, V54, P683, DOI 10.3109/10428194.2012.728597; Zhu YX, 2011, BLOOD, V118, P4771, DOI 10.1182/blood-2011-05-356063	60	73	75	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1797	1810		10.1038/onc.2015.245	http://dx.doi.org/10.1038/onc.2015.245			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119939	Green Accepted			2022-12-17	WOS:000373610400006
J	Carvalho, S; Catarino, TA; Dias, AM; Kato, M; Almeida, A; Hessling, B; Figueiredo, J; Gartner, F; Sanches, JM; Ruppert, T; Miyoshi, E; Pierce, M; Carneiro, F; Kolarich, D; Seruca, R; Yamaguchi, Y; Taniguchi, N; Reis, CA; Pinho, SS				Carvalho, S.; Catarino, T. A.; Dias, A. M.; Kato, M.; Almeida, A.; Hessling, B.; Figueiredo, J.; Gaertner, F.; Sanches, J. M.; Ruppert, T.; Miyoshi, E.; Pierce, M.; Carneiro, F.; Kolarich, D.; Seruca, R.; Yamaguchi, Y.; Taniguchi, N.; Reis, C. A.; Pinho, S. S.			Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer	ONCOGENE			English	Article							CELL-CELL ADHESION; GLYCOMICS EXPERIMENT; ORAL-CANCER; IN-SITU; TOOL; GLYCOPROTEINS; ORGANIZATION; ANNOTATION; PROTEINS; FEATURES	E-cadherin is a central molecule in the process of gastric carcinogenesis and its posttranslational modifications by N-glycosylation have been described to induce a deleterious effect on cell adhesion associated with tumor cell invasion. However, the role that site-specific glycosylation of E-cadherin has in its defective function in gastric cancer cells needs to be determined. Using transgenic mice models and human clinical samples, we demonstrated that N-acetylglucosaminyltransferase V (GnT-V)-mediated glycosylation causes an abnormal pattern of E-cadherin expression in the gastric mucosa. In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with beta 1,6 GlcNAc-branched N-glycans catalyzed by GnT-V. This aberrant glycan modification on this specific asparagine site of E-cadherin was demonstrated to affect its critical functions in gastric cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular assembly and stability of the adherens junctions and cell-cell aggregation, which was further observed in human gastric carcinomas. Interestingly, manipulating this site-specific glycosylation, by preventing Asn-554 from receiving the deleterious branched structures, either by a mutation or by silencing GnT-V, resulted in a protective effect on E-cadherin, precluding its functional dysregulation and contributing to tumor suppression.	[Carvalho, S.; Catarino, T. A.; Dias, A. M.; Figueiredo, J.; Gaertner, F.; Carneiro, F.; Seruca, R.; Reis, C. A.; Pinho, S. S.] Univ Porto, Inst Res & Innovat Hlth, Rua Campo Alegre 823, P-4100 Oporto, Portugal; [Carvalho, S.; Catarino, T. A.; Dias, A. M.; Figueiredo, J.; Gaertner, F.; Carneiro, F.; Seruca, R.; Reis, C. A.; Pinho, S. S.] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Oporto, Portugal; [Carvalho, S.; Dias, A. M.; Gaertner, F.; Reis, C. A.; Pinho, S. S.] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Rua Campo Alegre 823, P-4100 Oporto, Portugal; [Kato, M.; Yamaguchi, Y.; Taniguchi, N.] RIKEN Global Res Cluster, Syst Glycobiol Res Grp, RIKEN Max Planck Joint Res Ctr, Wako, Saitama, Japan; [Almeida, A.; Kolarich, D.] Max Planck Inst Colloids & Interfaces, Dept Biomol Syst, Potsdam, Germany; [Almeida, A.] Free Univ Berlin, Inst Chem & Biochem, Berlin, Germany; [Hessling, B.; Ruppert, T.] Heidelberg Univ, Ctr Mol Biol, Heidelberg, Germany; [Sanches, J. M.] Univ Lisbon, Inst Super Tecn, LARSyS, Inst Syst & Robot ISR IST, P-1699 Lisbon, Portugal; [Miyoshi, E.] Osaka Univ, Mol Biochem & Clin Invest, Grad Sch Med, Osaka, Japan; [Pierce, M.] Univ Georgia, Complex Carbohydrate Res Ctr, Dept Biochem & Mol Biol, 220 Riverbend Rd, Athens, GA 30602 USA; [Carneiro, F.; Seruca, R.; Reis, C. A.] Univ Porto, Med Fac, Rua Campo Alegre 823, P-4100 Oporto, Portugal; [Carneiro, F.] Hosp Sao Joao, Dept Pathol, Oporto, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; RIKEN; Max Planck Society; Free University of Berlin; Ruprecht Karls University Heidelberg; Universidade de Lisboa; Instituto Superior Tecnico; Osaka University; University System of Georgia; University of Georgia; Universidade do Porto; Sao Joao Hospital	Pinho, SS (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, Glycobiol Canc Grp, Rua Doutor Roberto Frias, P-4200465 Oporto, Portugal.	salomep@ipatimup.pt	Sanches, Joao/ABG-2684-2021; Carvalho, Sandra S/K-1724-2016; Carneiro, Fatima/AAV-8677-2021; Kolarich, Daniel/B-6893-2012; Dias, Ana/AAE-8828-2020; Kolarich, Daniel/AAJ-3550-2020; Sanches, Joao Miguel/C-1947-2013; Taniguchi, Naoyuki/I-4182-2014; Carneiro, Fatima/J-6432-2013; REIS, Celso A/B-9969-2008; Yamaguchi, Yoshiki/N-5246-2015; Taniguchi, Naoyuki/A-7086-2016; Ruppert, Thomas/AAC-2467-2021; Figueiredo, Joana/J-7305-2013; Carvalho, Sandra/ABA-8715-2020; Araujo Catarino, Telmo/L-2012-2013; Gartner, Maria de Fatima/A-3530-2010; Pinho, Salome/F-1764-2011	Sanches, Joao/0000-0001-9089-2740; Carvalho, Sandra S/0000-0003-3647-3582; Carneiro, Fatima/0000-0002-1964-1006; Kolarich, Daniel/0000-0002-8452-1350; Kolarich, Daniel/0000-0002-8452-1350; Sanches, Joao Miguel/0000-0001-9089-2740; Taniguchi, Naoyuki/0000-0001-5889-5968; Carneiro, Fatima/0000-0002-1964-1006; REIS, Celso A/0000-0002-0286-6639; Yamaguchi, Yoshiki/0000-0003-0100-5439; Ruppert, Thomas/0000-0001-9152-2266; Figueiredo, Joana/0000-0002-1590-1974; Carvalho, Sandra/0000-0003-3647-3582; Araujo Catarino, Telmo/0000-0002-2498-9648; Gartner, Maria de Fatima/0000-0002-5302-0086; Pinho, Salome/0000-0002-3484-5162; Dias, Ana/0000-0003-0060-2872; Seruca, Raquel/0000-0002-8851-4166	FCT, the Portuguese Foundation for Science and Technology; FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE-; National Funds through the FCT-Foundation for Science and Technology [PTDC/CVT/111358/2009, EXPL/BIM-MEC/0149/2012, PTDC/BBB-EBI/0786/2012]; FCT [SFRH/BD/77386/2011, SFRH/BI/52380/2013, SFRH/BPD/63094/2009]; Luso-American Foundation (FLAD) [SFRH/BD/77386/2011, SFRH/BI/52380/2013, SFRH/BPD/63094/2009]; Max Planck Society; European Union [PCIG09-GA-2011-293847, 316929]; NATIONAL CANCER INSTITUTE [U01CA128454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103490] Funding Source: NIH RePORTER; Fundação para a Ciência e a Tecnologia [EXPL/BIM-MEC/0149/2012, PTDC/CVT/111358/2009, UID/EEA/50009/2013, PTDC/BBB-EBI/0786/2012] Funding Source: FCT	FCT, the Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE-; National Funds through the FCT-Foundation for Science and Technology; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Luso-American Foundation (FLAD); Max Planck Society(Max Planck SocietyFoundation CELLEX); European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Fundação para a Ciência e a Tecnologia	IPATIMUP integrates the I3S Research Unit, which is partially supported by FCT, the Portuguese Foundation for Science and Technology. This work is funded by FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE- and National Funds through the FCT-Foundation for Science and Technology, under the projects: PTDC/CVT/111358/2009; EXPL/BIM-MEC/0149/2012; and PTDC/BBB-EBI/0786/2012. SC (SFRH/BD/77386/2011), AMD (SFRH/BI/52380/2013) BiotechHealth Doctoral Programme, and SSP (SFRH/BPD/63094/2009) thank FCT and the Luso-American Foundation (FLAD) for funding. JMS acknowledges FCT (UID/EEA/50009/2013). DK acknowledges support by the Max Planck Society and European Union (Seventh Framework Programme 'Glycoproteomics', grant number PCIG09-GA-2011-293847. CAR and DK acknowledge GastricGlycoExplorer project, grant number 316929). We thank Ola Soderberg and Gaelle Cane (Department of Genetics and Pathology, University of Uppsala, Uppsala, Sweden) for providing the Streptavidin PLA probe and to Marcia Pereira and Sara Campos for the support in PLA technique and statistical analyses.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Ceroni A, 2008, J PROTEOME RES, V7, P1650, DOI 10.1021/pr7008252; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; Cooper CA, 2001, PROTEOMICS, V1, P340, DOI 10.1002/1615-9861(200102)1:2<340::AID-PROT340>3.0.CO;2-B; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Deshpande N, 2010, J PROTEOME RES, V9, P1063, DOI 10.1021/pr900956x; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gu JG, 2012, GLYCOCONJUGATE J, V29, P599, DOI 10.1007/s10719-012-9386-1; Gu J, 2009, J PROTEOME RES, V8, P431, DOI 10.1021/pr800674g; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Guo HB, 2009, J BIOL CHEM, V284, P34986, DOI 10.1074/jbc.M109.060806; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Jensen PH, 2012, NAT PROTOC, V7, P1299, DOI 10.1038/nprot.2012.063; Jones J, 2005, BIOCHIM BIOPHYS ACTA, V1726, P121; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kitada T, 2001, J BIOL CHEM, V276, P475, DOI 10.1074/jbc.M006689200; Kolarich D, 2013, MOL CELL PROTEOMICS, V12, P991, DOI 10.1074/mcp.O112.026492; Langer MD, 2012, J CELL SCI, V125, P2478, DOI 10.1242/jcs.101147; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; LEWIS JE, 1994, J CELL SCI, V107, P3615; Liwosz A, 2006, J BIOL CHEM, V281, P23138, DOI 10.1074/jbc.M512621200; Lommel M, 2013, P NATL ACAD SCI USA, V110, P21024, DOI 10.1073/pnas.1316753110; de-Freitas JCM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081579; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nita-Lazar M, 2009, CANCER RES, V69, P5673, DOI 10.1158/0008-5472.CAN-08-4512; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Paredes J, 2012, BBA-REV CANCER, V1826, P297, DOI 10.1016/j.bbcan.2012.05.002; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Pinho SS, 2013, TRENDS MOL MED, V19, P664, DOI [10.1016/j.molmed.2013, 10.1016/j.molmed.2013.07.003]; Pinho SS, 2013, BBA-GEN SUBJECTS, V1830, P2690, DOI 10.1016/j.bbagen.2012.10.021; Pinho SS, 2011, CELL MOL LIFE SCI, V68, P1011, DOI 10.1007/s00018-010-0595-0; Pinho SS, 2009, HUM MOL GENET, V18, P2599, DOI 10.1093/hmg/ddp194; Pinho SS, 2009, BIOCHEM BIOPH RES CO, V379, P1091, DOI 10.1016/j.bbrc.2009.01.024; Pruitt KD, 2012, NUCLEIC ACIDS RES, V40, pD130, DOI 10.1093/nar/gkr1079; Przybylo Malgorzata, 2002, Cancer Cell Int, V2, P6, DOI 10.1186/1475-2867-2-6; Rose PW, 2013, NUCLEIC ACIDS RES, V41, pD475, DOI 10.1093/nar/gks1200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanches JM, 2015, EUR J HUM GENET, V23, P1072, DOI 10.1038/ejhg.2014.240; Sato Y, 2009, J BIOL CHEM, V284, P11873, DOI 10.1074/jbc.M807660200; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Thaysen-Andersen M, 2012, GLYCOBIOLOGY, V22, P1440, DOI 10.1093/glycob/cws110; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; Varelas X, 2014, GLYCOBIOLOGY, V24, P579, DOI 10.1093/glycob/cwu031; Vester-Christensen MB, 2013, P NATL ACAD SCI USA, V110, P21018, DOI 10.1073/pnas.1313446110; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; York WS, 2014, GLYCOBIOLOGY, V24, P402, DOI 10.1093/glycob/cwu018; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; Zhou F, 2008, GLYCOCONJUGATE J, V25, P727, DOI 10.1007/s10719-008-9133-9	51	73	73	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1619	1631		10.1038/onc.2015.225	http://dx.doi.org/10.1038/onc.2015.225			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26189796	Green Accepted, Green Submitted, Bronze			2022-12-17	WOS:000373064200002
J	Mura, M; Hopkins, TG; Michael, T; Abd-Latip, N; Weir, J; Aboagye, E; Mauri, F; Jameson, C; Sturge, J; Gabra, H; Bushell, M; Willis, AE; Curry, E; Blagden, SP				Mura, M.; Hopkins, T. G.; Michael, T.; Abd-Latip, N.; Weir, J.; Aboagye, E.; Mauri, F.; Jameson, C.; Sturge, J.; Gabra, H.; Bushell, M.; Willis, A. E.; Curry, E.; Blagden, S. P.			LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression	ONCOGENE			English	Article							MESSENGER-RNA STABILITY; GENE-EXPRESSION; EARLY-STAGE; TARGET; TRANSLATION; SPECIMENS; PROTEINS; SURVIVAL; REVEALS; PATHWAY	RNA-binding proteins (RBPs) bind to and post-transcriptionally regulate the stability of mRNAs. La-related protein 1 (LARP1) is a conserved RBP that interacts with poly-A-binding protein and is known to regulate 5'-terminal oligopyrimidine tract (TOP) mRNA translation. Here, we show that LARP1 is complexed to 3000 mRNAs enriched for cancer pathways. A prominent member of the LARP1 interactome is mTOR whose mRNA transcript is stabilized by LARP1. At a functional level, we show that LARP1 promotes cell migration, invasion, anchorage-independent growth and in vivo tumorigenesis. Furthermore, we show that LARP1 expression is elevated in epithelial cancers such as cervical and non-small cell lung cancers, where its expression correlates with disease progression and adverse prognosis, respectively. We therefore conclude that, through the post-transcriptional regulation of genes such as mTOR within cancer pathways, LARP1 contributes to cancer progression.	[Mura, M.; Hopkins, T. G.; Michael, T.; Abd-Latip, N.; Gabra, H.; Curry, E.; Blagden, S. P.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Ovarian Canc Act Res Ctr, Div Canc, London W12 0NN, England; [Weir, J.] Charing Cross Hosp, Imperial Coll Healthcare NHS Trust, Dept Cellular Pathol, London, England; [Aboagye, E.; Sturge, J.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Canc Res UK Labs, Div Canc, London W12 0NN, England; [Mauri, F.] Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, Ctr Pathol, London W12 0NN, England; [Jameson, C.] Univ Coll London Hosp, Dept Histopathol, London, England; [Sturge, J.] Univ Hull, Sch Biol Biomed & Environm Sci, Kingston Upon Hull HU6 7RX, N Humberside, England; [Bushell, M.; Willis, A. E.] Univ Leicester, MRC Toxicol Unit, Leicester, Leics, England	Imperial College London; Imperial College London; Cancer Research UK; Imperial College London; Imperial College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Hull; University of Leicester	Blagden, SP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Ovarian Canc Act Res Ctr, Div Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	s.blagden@imperial.ac.uk	Latip, Normala Abd/O-1425-2017; Blagden, Sarah Patricia/I-2096-2019	Latip, Normala Abd/0000-0003-4957-5369; Mauri, Francesco/0000-0003-4818-8500; Sturge, Justin/0000-0002-2657-1106; Curry, Edward/0000-0002-5603-6956; Willis, Anne/0000-0002-1470-8531; ABOAGYE, Eric/0000-0003-2276-6771; Gabra, Hani/0000-0002-3322-4399	Wellbeing of Women [RG1319]; Wellcome Trust-GSK Imperial College TMT Fellowship Scheme [PS1903]; Cancer Research UK; Department of Health [C37/A7283]; Ovarian Cancer Action; Biotechnology and Biological Sciences Research Council [BB/H024980/1] Funding Source: researchfish; Medical Research Council [MC_UP_A600_1023, MC_UP_A600_1024] Funding Source: researchfish; Ovarian Cancer Action [OCA10] Funding Source: researchfish; BBSRC [BB/H024980/1] Funding Source: UKRI; MRC [MC_UP_A600_1023, MC_UP_A600_1024] Funding Source: UKRI	Wellbeing of Women(Wellbeing of Women (WoW)); Wellcome Trust-GSK Imperial College TMT Fellowship Scheme; Cancer Research UK(Cancer Research UK); Department of Health; Ovarian Cancer Action(Ovarian Cancer Action); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Ovarian Cancer Action(Ovarian Cancer Action); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	MM was funded by The Wellbeing of Women (RG1319). TGH was funded by the Wellcome Trust-GSK Imperial College TMT Fellowship Scheme (PS1903). The Division of Cancer at Imperial College London, Imperial College Healthcare NHS Trust is an Experimental Cancer Medicine Centre (ECMC) supported by funds from Cancer Research UK and the Department of Health (C37/A7283) and forms part of Imperial Cancer Research UK Centre (C42671/A12196). SB was supported by Ovarian Cancer Action. We would like to thank Professor Nahum Sonenberg, Dr Bruno Fonseca and Professor Michael Seckl for their contributions and advice in the preparation of this manuscript. We would also like to thank Jenny Steel, Naina Patel and Joel Abrahams for their technical support.	Aoki K, 2013, FEBS LETT, V587, P2173, DOI 10.1016/j.febslet.2013.05.035; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Biewenga P, 2008, GYNECOL ONCOL, V108, P520, DOI 10.1016/j.ygyno.2007.11.024; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Blagden SP, 2009, DEV BIOL, V334, P186, DOI 10.1016/j.ydbio.2009.07.016; Burrows C, 2010, NUCLEIC ACIDS RES, V38, P5542, DOI 10.1093/nar/gkq294; Castello A, 2012, CELL, V149, P1393, DOI 10.1016/j.cell.2012.04.031; Chang N, 2010, MOL CELL BIOL, V30, P3875, DOI 10.1128/MCB.00169-10; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Cheng YL, 2012, LAB INVEST, V92, P1013, DOI 10.1038/labinvest.2012.59; Dhillon T, 2010, J THORAC ONCOL, V5, P314, DOI 10.1097/JTO.0b013e3181ce6604; Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689; Graham JR, 2010, MOL CELL BIOL, V30, P5295, DOI 10.1128/MCB.00303-10; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Iwakawa M, 2007, CANCER BIOL THER, V6, P905, DOI 10.4161/cbt.6.6.4098; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Keene JD, 2005, CHROMOSOME RES, V13, P327, DOI 10.1007/s10577-005-0848-1; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Liu D, 2011, CANCER-AM CANCER SOC, V117, P3763, DOI 10.1002/cncr.25959; Lukong KE, 2008, TRENDS GENET, V24, P416, DOI 10.1016/j.tig.2008.05.004; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Matoulkova E, 2012, RNA BIOL, V9, P563, DOI 10.4161/rna.20231; Merret R, 2013, CELL REP, V5, P1279, DOI 10.1016/j.celrep.2013.11.019; Molinolo AA, 2012, CLIN CANCER RES, V18, P2558, DOI 10.1158/1078-0432.CCR-11-2824; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Sommer G, 2011, ONCOGENE, V30, P434, DOI 10.1038/onc.2010.425; Staudacher AH, 2014, EJNMMI RES, V4, DOI 10.1186/2191-219X-4-2; Sugiura R, 2011, J SIGNAL TRANSDUCT, V2011; Tcherkezian J, 2014, GENE DEV, V28, P357, DOI 10.1101/gad.231407.113; Thapar R, 2013, CELL SIGNAL, V25, P1699, DOI 10.1016/j.cellsig.2013.03.026; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; Wang MJ, 2011, TUMOR BIOL, V32, P905, DOI 10.1007/s13277-011-0191-4; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Wu XY, 2012, GENE, V500, P10, DOI 10.1016/j.gene.2012.03.021; Wurth L, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/178525; Xie C, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-272; Xu CL, 2013, MOL CANCER THER, V12, P207, DOI 10.1158/1535-7163.MCT-12-0273; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zaytseva YY, 2012, CANCER LETT, V319, P1, DOI 10.1016/j.canlet.2012.01.005	46	73	73	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5025	5036		10.1038/onc.2014.428	http://dx.doi.org/10.1038/onc.2014.428			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25531318	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000361693300003
J	Kreis, NN; Louwen, F; Yuan, J				Kreis, N-N; Louwen, F.; Yuan, J.			Less understood issues: p21(Cip1) in mitosis and its therapeutic potential	ONCOGENE			English	Review							CELL-CYCLE INHIBITORS; DNA-REPLICATION; UBIQUITIN LIGASE; CDK INHIBITOR; CYTOPLASMIC LOCALIZATION; PROTEASOMAL DEGRADATION; DEPENDENT KINASES; NUCLEAR ANTIGEN; BREAST-CANCER; S-PHASE	p21(Cip1) is a multifunctional protein and a key player in regulating different cellular processes. The transcription of p21 is regulated by p53-dependent and -independent pathways. The expression of p21 is increased in response to various cellular stresses to arrest the cell cycle and ensure genomic stability. p21 has been shown to be a tumor suppressor and an oncogene as well. The function of p21 in mitosis has been proposed but not systematically studied. We have recently shown that p21 binds to and inhibits the activity of Cdk1/cyclin B1, and is important for a fine-tuned mitotic progression. Loss of p21 prolongs the duration of mitosis and results in severe mitotic defects like chromosome segregation and cytokinesis failures promoting consequently genomic instability. Moreover, p21 is dramatically stabilized in mitotic tumor cells upon treatment with mitotic agents like paclitaxel or mitotic kinase inhibitors. Increased p21 is mainly localized in the cytoplasm and associates with cell survival indicating a crucial role of p21 in susceptibility to mitotic agents in tumor cells. In this review we will briefly summarize the structure and general physiological functions as well as regulation of p21, discuss in detail its role in mitosis and its potential to serve as a therapeutic target.	[Kreis, N-N; Louwen, F.; Yuan, J.] Goethe Univ Frankfurt, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Kreis, NN (corresponding author), Goethe Univ Frankfurt, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Nina-Naomi.Kreis@kgu.de; yuan@em.uni-frankfurt.de	Kreis, Nina-Naomi/AAF-5407-2019	Kreis, Nina-Naomi/0000-0003-4304-0160; Yuan, Juping/0000-0003-0694-0565	Deutsche Krebshilfe [108553, 109672]; Deutsche Forschungsgemeinschaft [Yu 156/2-1]	Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We apologize to the authors whose work could not be cited due to space limitations. We thank our colleagues for the critical reading of this manuscript. The work in the lab has been supported by Deutsche Krebshilfe (#108553 and #109672) and Deutsche Forschungsgemeinschaft (#Yu 156/2-1).	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Agell N, 2006, CELL CYCLE, V5, P3, DOI 10.4161/cc.5.1.2270; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chan KS, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.148; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cornils H, 2011, MOL CELL BIOL, V31, P1382, DOI 10.1128/MCB.01216-10; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Denicourt C, 2004, GENE DEV, V18, P851, DOI 10.1101/gad.1205304; Densham RM, 2009, MOL CELL BIOL, V29, P6380, DOI 10.1128/MCB.00116-09; Duensing A, 2006, CELL CYCLE, V5, P2899, DOI 10.4161/cc.5.24.3567; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Ferrandiz N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037759; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Follis AV, 2012, ADV EXP MED BIOL, V725, P27, DOI 10.1007/978-1-4614-0659-4_3; Galea CA, 2008, BIOCHEMISTRY-US, V47, P7598, DOI 10.1021/bi8006803; Garcia-Fernandez RA, 2011, LAB INVEST, V91, P1634, DOI 10.1038/labinvest.2011.133; Garrett MA, 2001, CURR SCI INDIA, V81, P515; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gartel AL, 2007, CANCER BIOL THER, V6, P1171; Gillis LD, 2009, CELL CYCLE, V8, P253, DOI 10.4161/cc.8.2.7550; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gordon RR, 2012, DRUG RESIST UPDATE, V15, P123, DOI 10.1016/j.drup.2012.01.002; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Hwang CY, 2007, BIOCHEM BIOPH RES CO, V358, P219, DOI 10.1016/j.bbrc.2007.04.120; Hwang CY, 2009, MOL CELL BIOL, V29, P3379, DOI 10.1128/MCB.01758-08; Inoue H, 2011, CANCER BIOL THER, V12, P827, DOI 10.4161/cbt.12.9.17680; Jackson JG, 2013, ONCOGENE, V32, P4325, DOI 10.1038/onc.2012.610; Jackson RJ, 2003, CANCER RES, V63, P3021; Jarviluoma A, 2006, MOL CELL BIOL, V26, P2430, DOI 10.1128/MCB.26.6.2430-2440.2006; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; JIANG HP, 1995, ONCOGENE, V10, P1855; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474-9726.2012.00870.x; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Khanna AK, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-66; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kim Y, 2008, GENE DEV, V22, P2507, DOI 10.1101/gad.1703708; Koster R, 2010, J CLIN INVEST, V120, P3594, DOI 10.1172/JCI41939; Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518; Kreis NN, 2009, CELL CYCLE, V8, P460, DOI 10.4161/cc.8.3.7651; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lacy ER, 2004, NAT STRUCT MOL BIOL, V11, P358, DOI 10.1038/nsmb746; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lee JY, 2007, MOL CELL BIOL, V27, P3187, DOI 10.1128/MCB.01461-06; Lee J, 2009, MOL BIOL CELL, V20, P1891, DOI 10.1091/mbc.E08-08-0818; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; LI Y, 1994, ONCOGENE, V9, P2261; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Liu RW, 2013, FUTURE MED CHEM, V5, P991, DOI 10.4155/fmc.13.56; Louwen F, 2013, ONCOTARGET, V4, P958, DOI 10.18632/oncotarget.1096; Lu ZM, 2010, CELL CYCLE, V9, P2342, DOI 10.4161/cc.9.12.11988; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mercer SE, 2005, J BIOL CHEM, V280, P25788, DOI 10.1074/jbc.M413594200; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Oh YT, 2007, APOPTOSIS, V12, P1339, DOI 10.1007/s10495-007-0066-8; Otieno S, 2011, BIOPHYS J, V100, P2486, DOI 10.1016/j.bpj.2011.04.014; Park SH, 2008, CANCER BIOL THER, V7, P2015, DOI 10.4161/cbt.7.12.7069; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Perez-Tenorio G, 2006, INT J ONCOL, V28, P1031; Ping B, 2006, INT J ONCOL, V29, P1103; Pomerening JR, 2008, MOL BIOL CELL, V19, P3426, DOI 10.1091/mbc.E08-02-0172; Potapova TA, 2006, NATURE, V440, P954, DOI 10.1038/nature04652; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodriguez-Vilarrupla A, 2005, MOL CELL BIOL, V25, P7364, DOI 10.1128/MCB.25.16.7364-7374.2005; Rodriguez-Vilarrupla A, 2002, FEBS LETT, V531, P319, DOI 10.1016/S0014-5793(02)03549-4; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sax JK, 2002, CELL CYCLE, V1, P90, DOI 10.4161/cc.1.1.105; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Scott MT, 2002, EMBO J, V21, P6771, DOI 10.1093/emboj/cdf684; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Solomon H, 2011, J PATHOL, V225, P475, DOI 10.1002/path.2988; Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Starostina NG, 2010, DEV CELL, V19, P753, DOI 10.1016/j.devcel.2010.10.013; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Stivala LA, 2012, CURR CANCER DRUG TAR, V12, P85; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Suzuki H, 2013, J CELL SCI, V126, P4358, DOI 10.1242/jcs.125815; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Tian H, 2000, CANCER RES, V60, P679; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Trakala M, 2013, CELL CYCLE, V12, P1030, DOI 10.4161/cc.24004; Ullah Z, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-10; Van Nguyen T, 2007, J EXP MED, V204, P1453, DOI 10.1084/jem.20062453; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vincent AJ, 2012, FEBS LETT, V586, P3429, DOI 10.1016/j.febslet.2012.07.063; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang W, 2005, BIOCHEMISTRY-US, V44, P14553, DOI 10.1021/bi051071j; Wang YF, 2011, NAT CHEM BIOL, V7, P214, DOI 10.1038/NCHEMBIO.536; Wang ZP, 2010, INT J BIOCHEM CELL B, V42, P1030, DOI 10.1016/j.biocel.2010.03.012; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wettersten HI, 2013, CANCER BIOL THER, V14, P278, DOI 10.4161/cbt.23374; Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654; Winters ZE, 2001, EUR J CANCER, V37, P2405, DOI 10.1016/S0959-8049(01)00327-6; Wolf F, 2007, CELL CYCLE, V6, P1408; Wolf F, 2006, EMBO J, V25, P2802, DOI 10.1038/sj.emboj.7601163; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xia X, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-399; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xiong Y, 2010, DEV CELL, V19, P641, DOI 10.1016/j.devcel.2010.10.020; Yamada K, 2011, J BIOL CHEM, V286, P44057, DOI 10.1074/jbc.M111.236711; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yu XG, 2011, CELL CYCLE, V10, P3213, DOI 10.4161/cc.10.19.17051; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhan J, 2007, MOL CELL BIOL, V27, P3530, DOI 10.1128/MCB.00086-06; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	179	73	77	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1758	1767		10.1038/onc.2014.133	http://dx.doi.org/10.1038/onc.2014.133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858045				2022-12-17	WOS:000352158000003
J	Yin, M; Ren, X; Zhang, X; Luo, Y; Wang, G; Huang, K; Feng, S; Bao, X; Huang, K; He, X; Liang, P; Wang, Z; Tang, H; He, J; Zhang, B				Yin, M.; Ren, X.; Zhang, X.; Luo, Y.; Wang, G.; Huang, K.; Feng, S.; Bao, X.; Huang, K.; He, X.; Liang, P.; Wang, Z.; Tang, H.; He, J.; Zhang, B.			Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-kappa B p65 to evoke reactive oxygen species generation and p53 activation	ONCOGENE			English	Article						miR-506; NF-kappa B p65; ROS; p53; lung cancer; selective killing	OXIDATIVE STRESS; APOPTOSIS; INDUCTION; PATHWAY; MODULATION; CARCINOMA; MICRORNAS; MECHANISM; DAMAGE; REQUIREMENT	The tumor suppressor p53, nuclear factor-kappa B (NF-kappa B) and reactive oxygen species (ROS) have crucial roles in tumorigenesis, although the mechanisms of cross talk between these factors remain largely unknown. Here we report that miR-506 upregulation occurs in 83% of lung cancer patients (156 cases), and its expression highly correlates with ROS. Ectopic expression of miR-506 inhibits NF-kappa B p65 expression, induces ROS accumulation and then activates p53 to suppress lung cancer cell viability, but not in normal cells. Interestingly, p53 promotes miR-506 expression level, indicating that miR-506 mediates cross talk between p53, NF-kappa B p65 and ROS. Furthermore, we demonstrated that miR-506 mimics inhibited tumorigenesis in vivo, implicating that miR-506 might be a potential therapeutic molecule for selective killing of lung cancer cells.	[Yin, M.; Ren, X.; Wang, G.; Bao, X.; Wang, Z.; Zhang, B.] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, Guangzhou 510530, Guangdong, Peoples R China; [Yin, M.; Ren, X.; He, X.; Zhang, B.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China; [Zhang, X.; Tang, H.; He, J.] Guangzhou Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Guangzhou, Guangdong, Peoples R China; [Luo, Y.; Huang, K.; Feng, S.] Guangzhou RiboBio Co Ltd, Guangzhou, Guangdong, Peoples R China; [Huang, K.; Liang, P.] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; State Key Laboratory of Respiratory Disease; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Guangzhou Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhang, B (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, 190 Kai Yuan Ave,Sci Pk, Guangzhou 510530, Guangdong, Peoples R China.	drjianxing.he@gmail.com; Zhang_biliang@gibh.org			Introduced Innovative R&D Team Program of Guangdong Province [201001Y0104789252]; 863 Program of China [2012AA022501]; Strategic Emerging Industry Key Technology Project of Guangdong Province [2012A080800006]; National Natural Science Foundation of China [30870535, 90913017]; "Hundred Talents Plan" of Guangzhou Municipality; Combination Project of Guangdong Province; "Hundred Talents Plan" of Guangzhou Municipality and Combination Project of Guangdong Province and the Ministry of Education [2011B090400478]	Introduced Innovative R&D Team Program of Guangdong Province; 863 Program of China(National High Technology Research and Development Program of China); Strategic Emerging Industry Key Technology Project of Guangdong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Hundred Talents Plan" of Guangzhou Municipality; Combination Project of Guangdong Province; "Hundred Talents Plan" of Guangzhou Municipality and Combination Project of Guangdong Province and the Ministry of Education	We would like to thank Professor Craig Mello for valuable advice throughout this research, Professor Miguel Esteban for manuscripts revision and renal cell line RCC4, Professor Duanqing Pei for the lung cancer cell line 95D. This research was supported by Introduced Innovative R&D Team Program of Guangdong Province (no. 201001Y0104789252), 863 Program of China (no. 2012AA022501), Strategic Emerging Industry Key Technology Project of Guangdong Province (no. 2012A080800006), the National Natural Science Foundation of China (nos. 30870535 and 90913017), the "Hundred Talents Plan" of Guangzhou Municipality and Combination Project of Guangdong Province and the Ministry of Education (no. 2011B090400478).	Adhikary A, 2010, FEBS LETT, V584, P7, DOI 10.1016/j.febslet.2009.10.081; Amin ARMR, 2009, CANCER PREV RES, V2, P538, DOI 10.1158/1940-6207.CAPR-09-0063; Arora H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064273; Banales JM, 2012, J HEPATOL, V56, pS15, DOI 10.1016/S0168-8278(12)60048-8; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Cheng YH, 2009, J MOL CELL CARDIOL, V47, P5, DOI 10.1016/j.yjmcc.2009.01.008; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Dey A, 2008, BRIT J CANCER, V98, P4, DOI 10.1038/sj.bjc.6604098; Dey A, 2007, CELL CYCLE, V6, P2178, DOI 10.4161/cc.6.17.4643; Dijsselbloem N, 2007, J IMMUNOL, V178, P5048, DOI 10.4049/jimmunol.178.8.5048; Ebi H, 2009, ONCOGENE, V28, P3371, DOI 10.1038/onc.2009.201; Feng SP, 2011, NUCLEIC ACIDS RES, V39, P6669, DOI 10.1093/nar/gkr232; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hileman EO, 2004, CANCER CHEMOTH PHARM, V53, P209, DOI 10.1007/s00280-003-0726-5; Hsu YL, 2004, LIFE SCI, V75, P2303, DOI 10.1016/j.lfs.2004.04.027; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu G, 2009, J IMMUNOL, V182, P5063, DOI 10.4049/jimmunol.0803526; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Montero AJ, 2011, DRUGS, V71, P1385, DOI 10.2165/11592590-000000000-00000; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102; Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Vidya Priyadarsini R, 2010, Eur J Pharmacol, V649, P84, DOI 10.1016/j.ejphar.2010.09.020; Visconti R, 2009, IDRUGS, V12, P240; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yang D, 2013, CANCER CELL, V23, P705, DOI 10.1016/j.ccr.2013.04.029; Zhang R, 2007, GENOME RES, V17, P612, DOI 10.1101/gr.6146507	58	73	79	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					691	703		10.1038/onc.2013.597	http://dx.doi.org/10.1038/onc.2013.597			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469051				2022-12-17	WOS:000348853800003
J	Tolani, B; Gopalakrishnan, R; Punj, V; Matta, H; Chaudhary, PM				Tolani, B.; Gopalakrishnan, R.; Punj, V.; Matta, H.; Chaudhary, P. M.			Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors	ONCOGENE			English	Article						Myc; PEL; BET; bromodomain; KSHV	SARCOMA-ASSOCIATED HERPESVIRUS; C-MYC; NUCLEAR ANTIGEN; SELECTIVE-INHIBITION; RNA INTERFERENCE; TERMINAL REPEAT; LATENCY; EXPRESSION; CANCER; BRD4	Primary effusion lymphoma (PEL) is an aggressive form of non-Hodgkin's B-cell lymphoma associated with infection by Kaposi's sarcoma-associated herpes virus (KSHV). (+)-JQ1 and I-BET151 are two recently described novel small-molecule inhibitors of BET bromodomain chromatin-associated proteins that have shown impressive preclinical activity in cancers in which MYC is overexpressed at the transcriptional level due to chromosomal translocations that bring the MYC gene under the control of a super-enhancer. PEL cells, in contrast, lack structural alterations in the MYC gene, but have deregulated Myc protein due to the activity of KSHV-encoded latent proteins. We report that PEL cell lines are highly sensitive to bromodomain and extra-terminal (BET) bromodomain inhibitors-induced growth inhibition and undergo G(0)/G(1) cell-cycle arrest, apoptosis and cellular senescence, but without the induction of lytic reactivation, upon treatment with these drugs. Treatment of PEL cell lines with BET inhibitors suppressed the expression of MYC and resulted in a genome-wide perturbation of MYC-dependent genes. Silencing of BRD4 and MYC expression blocked cell proliferation and cell-cycle progression, while ectopic expression of MYC from a retroviral promoter rescued cells from (+)-JQ1-induced growth arrest. In a xenograft model of PEL, (+)-JQ1 significantly reduced tumor growth and improved survival. Taken collectively, our results demonstrate that the utility of BET inhibitors may not be limited to cancers in which genomic alterations result in extremely high expression of MYC and they may have equal or perhaps greater activity against cancers in which the MYC genomic locus is structurally intact and c-Myc protein is deregulated at the post-translational level and is only modestly overexpressed.	[Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90033 USA; [Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Ctr Study Blood Dis, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Chaudhary, PM (corresponding author), Univ So Calif, Keck Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90033 USA.	preet.chaudhary@med.usc.edu	Gopalakrishnan, Ramakrishnan/N-3454-2015; Chaudhary, Preet/E-1970-2018	Gopalakrishnan, Ramakrishnan/0000-0002-5068-6886; Tolani, Bhairavi/0000-0001-9076-866X	National Institutes of Health [CA139119, DE019811, P30CA014089]; STOP Cancer Foundations; National Cancer Institute Cancer Center Shared Grant [P30CA014089]; USC Provost Office Dean's Development Funds; NATIONAL CANCER INSTITUTE [R01CA139119, P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019811] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); STOP Cancer Foundations; National Cancer Institute Cancer Center Shared Grant; USC Provost Office Dean's Development Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank Dr James Bradner (Dana-Farber Cancer Institute, Boston, MA, USA) for his generous contribution of (+)-JQ1 and (-)-JQ1, Dr Peter Howley (Harvard University) for BRD4 antibody, Gary Hayward (Johns Hopkins University) for RTA antibody, and Drs Lossos and Ramos from the University of Miami for UM-PEL-1 and UM-PEL-3 cells, respectively. This work was supported by grants from the National Institutes of Health (CA139119, DE019811 and P30CA014089) and STOP Cancer Foundations. Flow cytometry was performed in the USC Flow Cytometry Core Facility that is supported in part by the National Cancer Institute Cancer Center Shared Grant award P30CA014089 and the USC Provost Office Dean's Development Funds.	Ballestas ME, 2001, J VIROL, V75, P3250, DOI 10.1128/JVI.75.7.3250-3258.2001; Bartholomeeusen K, 2012, J BIOL CHEM, V287, P36609, DOI 10.1074/jbc.M112.410746; Bhatt S, 2011, 53 ASH ANN M EXP; Boulanger E, 2004, AM J HEMATOL, V76, P88, DOI 10.1002/ajh.20048; Boulanger E, 2003, AM J HEMATOL, V73, P143, DOI 10.1002/ajh.10341; Bubman D, 2007, ONCOGENE, V26, P4979, DOI 10.1038/sj.onc.1210299; Chung CW, 2011, J BIOMOL SCREEN, V16, P1170, DOI 10.1177/1087057111421372; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Garber AC, 2002, J BIOL CHEM, V277, P27401, DOI 10.1074/jbc.M203489200; Li XD, 2010, J VIROL, V84, P8945, DOI 10.1128/JVI.00244-10; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liu JY, 2007, J VIROL, V81, P10451, DOI 10.1128/JVI.00804-07; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lubyova B, 2007, J BIOL CHEM, V282, P31944, DOI 10.1074/jbc.M706430200; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; Nicholas J, 2007, FRONT BIOSCI-LANDMRK, V12, P265, DOI 10.2741/2063; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Ottinger M, 2006, J VIROL, V80, P10772, DOI 10.1128/JVI.00804-06; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Sarosiek KA, 2010, P NATL ACAD SCI USA, V107, P13069, DOI 10.1073/pnas.1002985107; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; You JX, 2006, J VIROL, V80, P8909, DOI 10.1128/JVI.00502-06; Zhao Hong, 2013, Methods Mol Biol, V965, P83, DOI 10.1007/978-1-62703-239-1_5; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067; Zhu XC, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-98; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	38	73	77	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2928	2937		10.1038/onc.2013.242	http://dx.doi.org/10.1038/onc.2013.242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23792448	Green Accepted			2022-12-17	WOS:000337231800012
J	Zhang, J; Chen, QM				Zhang, J.; Chen, Q. M.			Far upstream element binding protein 1: a commander of transcription, translation and beyond	ONCOGENE			English	Review						FBP1; FUSE; cancer	FBP-INTERACTING REPRESSOR; P27(KIP1) MESSENGER-RNA; DNA HELICASE-V; C-MYC GENE; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGET; KH DOMAINS; FUSE; IDENTIFICATION; CANCER	The far upstream binding protein 1 (FBP1) was first identified as a DNA-binding protein that regulates c-Myc gene transcription through binding to the far upstream element (FUSE) in the promoter region 1.5 kb upstream of the transcription start site. FBP1 collaborates with TFIIH and additional transcription factors for optimal transcription of the c-Myc gene. In recent years, mounting evidence suggests that FBP1 acts as an RNA-binding protein and regulates mRNA translation or stability of genes, such as GAP43, p27(Kip) and nucleophosmin. During retroviral infection, FBP1 binds to and mediates replication of RNA from Hepatitis C and Enterovirus 71. As a nuclear protein, FBP1 may translocate to the cytoplasm in apoptotic cells. The interaction of FBP1 with p38/JTV-1 results in FBP1 ubiquitination and degradation by the proteasomes. Transcriptional and post-transcriptional regulations by FBP1 contribute to cell proliferation, migration or cell death. FBP1 association with carcinogenesis has been reported in c-Myc dependent or independent manner. This review summarizes biochemical features of FBP1, its mechanism of action, FBP family members and the involvement of FBP1 in carcinogenesis.	[Zhang, J.; Chen, Q. M.] Univ Arizona, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona	Chen, QM (corresponding author), Univ Arizona, Dept Pharmacol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	qchen@email.arizona.edu			Arizona Biomedical Research Commission;  [NIH R01 HL 076530];  [R01 HL089958];  [R21ES017473];  [T32 ES007091]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076530, R01HL089958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES017473, T32ES007091] Funding Source: NIH RePORTER	Arizona Biomedical Research Commission; ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We acknowledge the support of NIH R01 HL 076530, R01 HL089958, R21ES017473, T32 ES007091 and Arizona Biomedical Research Commission (QMC). We thank Dr Joseph Alpert and Joshua Strom for proof reading the manuscript.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Atanassov BS, 2011, EMBO REP, V12, P924, DOI 10.1038/embor.2011.140; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Balvay L, 2009, BBA-GENE REGUL MECH, V1789, P542, DOI 10.1016/j.bbagrm.2009.07.005; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; BAZAR L, 1995, ONCOGENE, V10, P2229; Benjamin LR, 2008, P NATL ACAD SCI USA, V105, P18296, DOI 10.1073/pnas.0803279105; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; Bouchireb N, 1999, CHROMOSOME RES, V7, P577, DOI 10.1023/A:1009201914881; Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Buchan JR, 2009, MOL CELL, V36, P932, DOI 10.1016/j.molcel.2009.11.020; Chien HL, 2011, J VIROL, V85, P4698, DOI 10.1128/JVI.01950-10; Chung HJ, 2006, MOL CELL BIOL, V26, P6584, DOI 10.1128/MCB.00754-06; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Corsini L, 2009, J BIOL CHEM, V284, P630, DOI 10.1074/jbc.M805395200; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; Danckwardt S, 2011, MOL CELL, V41, P298, DOI 10.1016/j.molcel.2010.12.032; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; de Nigris F, 2003, CELL CYCLE, V2, P325, DOI 10.4161/cc.2.4.414; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Engidawork E, 2006, INT J ONCOL, V29, P721; Felty Q, 2011, CELL BIOL TOXICOL, V27, P49, DOI 10.1007/s10565-010-9170-6; Fukumoto M, 2011, CELL STRUCT FUNCT, V36, P57, DOI 10.1247/csf.10026; Gherzi R, 2010, WIRES RNA, V1, P230, DOI 10.1002/wrna.2; Giglia-Mari G, 2004, NAT GENET, V36, P714, DOI 10.1038/ng1387; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He LS, 2000, NUCLEIC ACIDS RES, V28, P4558, DOI 10.1093/nar/28.22.4558; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hsiao HH, 2010, BIOCHEMISTRY-US, V49, P4620, DOI 10.1021/bi9021445; Huang PN, 2011, NUCLEIC ACIDS RES, V39, P9633, DOI 10.1093/nar/gkr682; Huth JR, 2004, J MED CHEM, V47, P4851, DOI 10.1021/jm0497803; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Jang M, 2009, ONCOGENE, V28, P1529, DOI 10.1038/onc.2009.11; Karst AM, 2011, GYNECOL ONCOL, V123, P5, DOI 10.1016/j.ygyno.2011.05.021; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; Ko HS, 2006, J BIOL CHEM, V281, P16193, DOI 10.1074/jbc.C600041200; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Kusik BW, 2010, DEV DYNAM, V239, P482, DOI 10.1002/dvdy.22190; Lasserre JP, 2009, J PROTEOME RES, V8, P5485, DOI 10.1021/pr900480f; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; Levens David, 2008, J Natl Cancer Inst Monogr, P41, DOI 10.1093/jncimonographs/lgn004; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; Liu JH, 2001, CELL, V104, P353, DOI 10.1016/S0092-8674(01)00223-9; Liu JH, 2006, EMBO J, V25, P2119, DOI 10.1038/sj.emboj.7601101; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Malz M, 2009, HEPATOLOGY, V50, P1130, DOI 10.1002/hep.23051; Man TK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-45; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Matsushita K, 2006, CANCER RES, V66, P1409, DOI 10.1158/0008-5472.CAN-04-4459; Matsushita K, 2009, FRONT BIOSCI-LANDMRK, V14, P3401, DOI 10.2741/3461; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Milosevic J, 2009, PROTEOMICS, V9, P1230, DOI 10.1002/pmic.200700604; Morrish F, 2009, ONCOGENE, V28, P2485, DOI 10.1038/onc.2009.112; NICOLAIDES NC, 1995, GENOMICS, V29, P329, DOI 10.1006/geno.1995.9997; Niforou Katerina N., 2008, Cancer Genomics & Proteomics, V5, P63; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V205, P1380, DOI 10.1006/bbrc.1994.2818; Olanich ME, 2011, ONCOGENE, V30, P77, DOI 10.1038/onc.2010.404; Page-McCaw PS, 1999, RNA, V5, P1548, DOI 10.1017/S1355838299991938; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rabenhorst U, 2009, HEPATOLOGY, V50, P1121, DOI 10.1002/hep.23098; Rana S, 2008, EXPERT REV ANTICANC, V8, P1461, DOI 10.1586/14737140.8.9.1461; Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; Sportoletti P, 2008, BLOOD, V111, P3859, DOI 10.1182/blood-2007-06-098251; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Sully G, 2004, BIOCHEM J, V377, P629, DOI 10.1042/BJ20031484; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; TUTEJA N, 1993, NUCLEIC ACIDS RES, V21, P2323, DOI 10.1093/nar/21.10.2323; Valverde R, 2008, FEBS J, V275, P2712, DOI 10.1111/j.1742-4658.2008.06411.x; Vindigni A, 2001, NUCLEIC ACIDS RES, V29, P1061, DOI 10.1093/nar/29.5.1061; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Weber A, 2005, MOL CELL BIOL, V25, P147, DOI 10.1128/mcb.25.1.147-161.2005; Weber A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-369; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; Williams BY, 2000, FEBS LETT, V470, P207, DOI 10.1016/S0014-5793(00)01320-X; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; Xu SG, 2010, J CANCER RES CLIN, V136, P1545, DOI 10.1007/s00432-010-0812-0; Yan S, 2009, CANCER RES, V69, P3283, DOI 10.1158/0008-5472.CAN-08-0367; Zhang L, 2011, CURR DRUG METAB, V12, P455, DOI 10.2174/138920011795495303; Zhang ZB, 2008, J VIROL, V82, P5761, DOI 10.1128/JVI.00064-08; Zheng YH, 2011, INT J BIOCHEM CELL B, V43, P1641, DOI 10.1016/j.biocel.2011.08.001; Zubaidah RM, 2008, PROTEOMICS, V8, P5086, DOI 10.1002/pmic.200800322	99	73	77	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2907	2916		10.1038/onc.2012.350	http://dx.doi.org/10.1038/onc.2012.350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22926519	Green Accepted			2022-12-17	WOS:000320369700001
J	De Marco, P; Bartella, V; Vivacqua, A; Lappano, R; Santolla, MF; Morcavallo, A; Pezzi, V; Belfiore, A; Maggiolini, M				De Marco, P.; Bartella, V.; Vivacqua, A.; Lappano, R.; Santolla, M. F.; Morcavallo, A.; Pezzi, V.; Belfiore, A.; Maggiolini, M.			Insulin-like growth factor-I regulates GPER expression and function in cancer cells	ONCOGENE			English	Article						cancer cells; ER alpha; GPER; IGF-I; signal transduction	PROTEIN-COUPLED RECEPTOR; BREAST-CANCER; ESTROGEN-RECEPTOR; GENE-EXPRESSION; FACTOR SYSTEM; SIGNALING SYSTEMS; CCN FAMILY; IGF-I; GPR30; 17-BETA-ESTRADIOL	Functional cross talk between insulin-like growth factor-I (IGF-I) system and estrogen signaling has been largely reported, although the underlying molecular mechanisms remain to be fully elucidated. As GPR30/GPER mediates rapid cell responses to estrogens, we evaluated the potential of IGF-I to regulate GPER expression and function in estrogen receptor (ER)alpha-positive breast (MCF-7) and endometrial (Ishikawa) cancer cells. We found that IGF-I transactivates the GPER promoter sequence and upregulates GPER mRNA and protein levels in both cells types. Similar data were found, at least in part, in carcinoma-associated fibroblasts. The upregulation of GPER expression by IGF-I involved the IGF-IR/PKC delta/ERK/c-fos/AP1 transduction pathway and required ER alpha, as ascertained by specific pharmacological inhibitors and gene-silencing. In both MCF-7 and Ishikawa cancer cells, the IGF-I-dependent cell migration required GPER and its main target gene CTGF, whereas the IGF-I-induced proliferation required both GPER and cyclin D1. Our data demonstrate that the IGF-I system regulates GPER expression and function, triggering the activation of a signaling network that leads to the migration and proliferation of cancer cells. Oncogene (2013) 32, 678-688; doi:10.1038/onc.2012.97; published online 19 March 2012	[De Marco, P.; Bartella, V.; Vivacqua, A.; Lappano, R.; Santolla, M. F.; Pezzi, V.; Maggiolini, M.] Univ Calabria, Dept Pharmacobiol, I-87030 Arcavacata Di Rende, CS, Italy; [Morcavallo, A.; Belfiore, A.] Magna Graecia Univ Catanzaro, Dept Hlth, Catanzaro, Italy	University of Calabria; Magna Graecia University of Catanzaro	Maggiolini, M (corresponding author), Univ Calabria, Dept Pharmacobiol, Via P Bucci, I-87030 Arcavacata Di Rende, CS, Italy.	marcellomaggiolini@yahoo.it	Belfiore, Antonino/B-4652-2011; Santolla, Maria Francesca/AAH-5481-2020; Lappano, Rosamaria/Z-4857-2019; Maggiolini, Marcello/Z-4729-2019; Pezzi, Vincenzo/AAL-4017-2020; vivacqua, adele/I-2771-2015	Belfiore, Antonino/0000-0002-6181-4193; vivacqua, adele/0000-0001-5333-8396; Maggiolini, Marcello/0000-0002-7485-854X; Lappano, Rosamaria/0000-0002-9374-9701; pezzi, Vincenzo/0000-0003-2311-2286; Santolla, Maria Francesca/0000-0002-4838-5953	Associazione Italiana per la Ricerca sul Cancro (AIRC) [8925/2009, 10625/2009]; Fondazione Cassa di Risparmio di Calabria e Lucania; Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) [PRIN 2008PK2WCW/2008, PRIN 2008BKRFBH_005]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Calabria e Lucania; Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, project no. 8925/2009 to MM and project no. 10625/2009 to AB; project Calabria 2011 to AB and MM) (http://www.airc.it/), Fondazione Cassa di Risparmio di Calabria e Lucania and Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) (project PRIN 2008PK2WCW/2008 to MM and project PRIN 2008BKRFBH_005 to AB) (http://www.istruzione.it/).	Akekawatchai C, 2005, J BIOL CHEM, V280, P39701, DOI 10.1074/jbc.M509829200; Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Bai ZL, 2009, ARCH PHARM, V342, P133, DOI 10.1002/ardp.200800174; Baron S, 2007, J BIOL CHEM, V282, P11732, DOI 10.1074/jbc.M610079200; Belfiore A, 2007, CURR PHARM DESIGN, V13, P671, DOI 10.2174/138161207780249173; Belfiore A, 2008, J MAMMARY GLAND BIOL, V13, P381, DOI 10.1007/s10911-008-9099-z; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bradley LM, 2008, J STEROID BIOCHEM, V109, P185, DOI 10.1016/j.jsbmb.2007.10.006; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; Chaqour B, 2006, J BIOL CHEM, V281, P20608, DOI 10.1074/jbc.M600214200; Cortez V, 2010, Minerva Ginecol, V62, P573; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Gerdes MJ, 2006, CANCER RES, V66, P7578, DOI 10.1158/0008-5472.CAN-06-1247; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Holbourn KP, 2008, TRENDS BIOCHEM SCI, V33, P461, DOI 10.1016/j.tibs.2008.07.006; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kisfalvi K, 2009, CANCER RES, V69, P6539, DOI 10.1158/0008-5472.CAN-09-0418; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lann D, 2008, J MAMMARY GLAND BIOL, V13, P371, DOI 10.1007/s10911-008-9100-x; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Madeo A, 2010, CANCER RES, V70, P6036, DOI 10.1158/0008-5472.CAN-10-0408; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Mawson A, 2005, MOL CELL ENDOCRINOL, V229, P161, DOI 10.1016/j.mce.2004.08.002; Mendoza RA, 2011, J ENDOCRINOL, V208, P1, DOI 10.1677/JOE-10-0235; Pandey DP, 2009, EMBO J, V28, P523, DOI 10.1038/emboj.2008.304; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pike MC, 2004, ONCOGENE, V23, P6379, DOI 10.1038/sj.onc.1207899; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Recchia AG, 2011, J BIOL CHEM, V286, P10773, DOI 10.1074/jbc.M110.172247; Rosenzweig SA, 2010, BIOCHEM PHARMACOL, V80, P1115, DOI 10.1016/j.bcp.2010.06.013; Rozengurt E, 2010, CLIN CANCER RES, V16, P2505, DOI 10.1158/1078-0432.CCR-09-2229; Sirianni R, 2008, ENDOCRINOLOGY, V149, P5043, DOI 10.1210/en.2007-1593; Smith HO, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2007.01.004; Song RXD, 2007, ENDOCRINOLOGY, V148, P4091, DOI 10.1210/en.2007-0240; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Vivacqua A, 2009, MOL ENDOCRINOL, V23, P1815, DOI 10.1210/me.2009-0120; Young SH, 2010, BIOCHEM BIOPH RES CO, V401, P154, DOI 10.1016/j.bbrc.2010.09.036; Zhang G, 2010, CANCER GENET CYTOGEN, V200, P140, DOI 10.1016/j.cancergencyto.2010.04.007	54	73	76	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2013	32	6					678	688		10.1038/onc.2012.97	http://dx.doi.org/10.1038/onc.2012.97			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430216				2022-12-17	WOS:000315746700002
J	Wang, Z; Yuan, H; Roth, M; Stark, JM; Bhatia, R; Chen, WY				Wang, Z.; Yuan, H.; Roth, M.; Stark, J. M.; Bhatia, R.; Chen, W. Y.			SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells	ONCOGENE			English	Article						chronic myelogenous leukemia; BCR-ABL; SIRT1; DNA damage repair; mutation; acquired resistance	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; DOUBLE-STRAND BREAKS; DNA-DAMAGE; CLINICAL RESISTANCE; STRESS-RESPONSE; ERROR-PRONE; C-ABL; IMATINIB; REPAIR	BCR-ABL transforms bone marrow progenitor cells and promotes genome instability, leading to development of chronic myelogenous leukemia (CML). The tyrosine kinase inhibitor imatinib effectively treats CML, but acquired resistance can develop because of BCR-ABL mutations. Mechanisms for acquisition of BCR-ABL mutations are not fully understood. Using a novel culture model of CML acquired resistance, we show that inhibition of SIRT1 deacetylase by small molecule inhibitors or gene knockdown blocks acquisition of BCR-ABL mutations and relapse of CML cells on tyrosine kinase inhibitors. SIRT1 knockdown also suppresses de novo genetic mutations of hypoxanthine phosphoribosyl transferase gene in CML and non-CML cells upon treatment with DNA damaging agent cannptothecin. Although SIRT1 can enhance cellular DNA damage response, it alters functions of DNA repair machineries in CML cells and stimulates activity of error-prone DNA damage repair, in association with acquisition of genetic mutations. These results reveal a previously unrecognized role of SIRT1 for promoting mutation acquisition in cancer, and have implication for targeting SIRT1 to overcome CML drug resistance. Oncogene (2013) 32, 589-598; doi:10.1038/onc.2012.83; published online 12 March 2012	[Wang, Z.; Yuan, H.; Roth, M.; Stark, J. M.; Chen, W. Y.] City Hope Natl Med Ctr, Dept Canc Biol, Beckman Res Inst, Duarte, CA 91010 USA; [Bhatia, R.] City Hope Natl Med Ctr, Div Hematopoiet Stem Cell & Leukemia Res, Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Chen, WY (corresponding author), City Hope Natl Med Ctr, Dept Canc Biol, Beckman Res Inst, Duarte, CA 91010 USA.	wechen@coh.org	Chen, WenYong/D-6748-2012	Chen, WenYong/0000-0001-6913-5729; Bhatia, Ravi/0000-0001-5740-2316	US Department of Defense [W81XWH-06-1-0268]; STOPCANCER Foundation; V-Foundation; National Cancer Institute, NIH [R01 CA143421];  [R01 CA95684];  [R01 CA120954]; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA095684, R01CA120954, R01CA143421] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); STOPCANCER Foundation; V-Foundation; National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the following Grants: W81XWH-06-1-0268 from the US Department of Defense, a career development award from the STOPCANCER Foundation, a translational research grant from the V-Foundation and R01 CA143421 from the National Cancer Institute, NIH to WYC. RB was supported by R01 CA95684, and JMS was supported by R01 CA120954. The core facilities used in this study were supported by NCI P30 CA033572.	Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; Brady N, 2003, CANCER RES, V63, P1798; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Dinkelmann M, 2009, NAT STRUCT MOL BIOL, V16, P808, DOI 10.1038/nsmb.1639; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Fiskus W, 2006, CLIN CANCER RES, V12, P5869, DOI 10.1158/1078-0432.CCR-06-0980; Gaymes TJ, 2006, MOL CANCER RES, V4, P563, DOI 10.1158/1541-7786.MCR-06-0111; Gaymes TJ, 2002, CANCER RES, V62, P2791; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guarente L, 2007, COLD SPRING HARB SYM, V72, P483, DOI 10.1101/sqb.2007.72.024; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Issa JPJ, 1997, CANCER RES, V57, P1678; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Koschmieder S, 2011, MYELOID LEUKEMIA BAS, P69; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Perrotti D, 2010, J CLIN INVEST, V120, P2254, DOI 10.1172/JCI41246; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Quintas-Cardama A, 2011, LEUKEMIA, V25, P226, DOI 10.1038/leu.2010.276; Rass E, 2009, NAT STRUCT MOL BIOL, V16, P819, DOI 10.1038/nsmb.1641; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2006, DNA REPAIR, V5, P243, DOI 10.1016/j.dnarep.2005.10.005; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; von Bubnoff N, 2006, BLOOD, V108, P1328, DOI 10.1182/blood-2005-12-010132; Wang B, 2011, ONCOGENE, V30, P907, DOI 10.1038/onc.2010.468; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Xie AY, 2009, NAT STRUCT MOL BIOL, V16, P814, DOI 10.1038/nsmb.1640; Yu CR, 2003, CANCER RES, V63, P2118; Yuan HF, 2012, BLOOD, V119, P1904, DOI 10.1182/blood-2011-06-361691; Yuan HF, 2010, J BIOL CHEM, V285, P5085, DOI 10.1074/jbc.M109.039206; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011	58	73	76	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					589	598		10.1038/onc.2012.83	http://dx.doi.org/10.1038/onc.2012.83			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22410779	Green Accepted			2022-12-17	WOS:000316164700006
J	Sabatino, L; Fucci, A; Pancione, M; Carafa, V; Nebbioso, A; Pistore, C; Babbio, F; Votino, C; Laudanna, C; Ceccarelli, M; Altucci, L; Bonapace, IM; Colantuoni, V				Sabatino, L.; Fucci, A.; Pancione, M.; Carafa, V.; Nebbioso, A.; Pistore, C.; Babbio, F.; Votino, C.; Laudanna, C.; Ceccarelli, M.; Altucci, L.; Bonapace, I. M.; Colantuoni, V.			UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression	ONCOGENE			English	Article						UHRF1; PPARG; epigenetics; colorectal cancer prognosis	ISLAND METHYLATOR PHENOTYPE; PERIPHERAL-BLOOD; DNA METHYLATION; EXPRESSION; DNMT3B; NP95; CPG; PROMOTER	Peroxisome proliferator-activated receptor gamma (PPARG) inactivation has been identified as an important step in colorectal cancer (CRC) progression, although the events involved have been partially clarified. UHRF1 is emerging as a cofactor that coordinates the epigenetic silencing of tumor suppressor genes, but its role in CRC remains elusive. Here, we report that UHRF1 negatively regulates PPARG and is associated with a higher proliferative, clonogenic and migration potential. Consistently, UHRF1 ectopic expression induces PPARG repression through its recruitment on the PPARG promoter fostering DNA methylation and histone repressive modifications. In agreement, UHRF1 knockdown elicits PPARG re-activation, accompanied by positive histone marks and DNA demethylation, corroborating its role in PPARG silencing. UHRF1 overexpression, as well as PPARG-silencing, imparts higher growth rate and phenotypic features resembling those occurring in the epithelial-mesenchymal transition. In our series of 110 sporadic CRCs, high UHRF1-expressing tumors are characterized by an undifferentiated phenotype, higher proliferation rate and poor clinical outcome only in advanced stages III-IV. In addition, the inverse relationship with PPARG found in vitro is detected in vivo and UHRF1 prognostic significance appears closely related to PPARG low expression, as remarkably validated in an independent dataset. The results demonstrate that UHRF1 regulates PPARG silencing and both genes appear to be part of a complex regulatory network. These findings suggest that the relationship between UHRF1 and PPARG may have a relevant role in CRC progression. Oncogene (2012) 31, 5061-5072; doi:10.1038/onc.2012.3; published online 30 January 2012	[Sabatino, L.; Fucci, A.; Pancione, M.; Votino, C.; Laudanna, C.; Ceccarelli, M.; Colantuoni, V.] Univ Sannio, Dept Biol Geol & Environm Sci, I-82100 Benevento, Italy; [Carafa, V.; Nebbioso, A.; Altucci, L.] Univ Naples 2, Dept Gen Pathol, Naples, Italy; [Pistore, C.; Babbio, F.; Bonapace, I. M.] Univ Insubria, Dept Struct & Funct Biol, Busto Arsizio, Va, Italy	University of Sannio; Universita della Campania Vanvitelli; University of Insubria	Colantuoni, V (corresponding author), Univ Sannio, Dept Biol Geol & Environm Sci, Via PortArsa 11, I-82100 Benevento, Italy.	colantuoni@unisannio.it	Pancione, Massimo/AAF-2109-2019; Altucci, Lucia/S-8031-2019; NEBBIOSO, ANGELA/GVS-1294-2022; Ceccarelli, Michele/AGP-1739-2022; NEBBIOSO, Angela/C-3566-2016	BONAPACE, IAN MARC/0000-0001-6580-8893; PANCIONE, Massimo/0000-0003-1728-8816; altucci, lucia/0000-0002-7312-5387; LAUDANNA, Carmelo/0000-0002-0397-6020; carafa, vincenzo/0000-0002-8025-3758; Sabatino, Lina/0000-0001-5341-7430; NEBBIOSO, Angela/0000-0001-5374-3527; Ceccarelli, Michele/0000-0002-4702-6617	Associazione Italiana per la Ricerca sul Cancro (AIRC); Fondazione Cariplo 'Progetto Nobel'; European Union: CancerDip [200620]; European Union: Aposys [200767]; Associazione Italiana per la lotta ai linfomi e leucemie (AIL)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo 'Progetto Nobel'(Fondazione Cariplo); European Union: CancerDip(European Commission); European Union: Aposys(European CommissionEuropean Commission Joint Research Centre); Associazione Italiana per la lotta ai linfomi e leucemie (AIL)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) to LA and IMB; Fondazione Cariplo 'Progetto Nobel' to IMB; European Union: CancerDip contract no 200620, Aposys contract no 200767 to LA; Associazione Italiana per la lotta ai linfomi e leucemie (AIL) to VC. We wish to thank Prof N Zambrano for kindly providing the shRNA vectors employed.	Alhosin M, 2011, J EXP CLIN CANC RES, V15, P30; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; BURCHILL SA, 1995, BRIT J CANCER, V71, P278, DOI 10.1038/bjc.1995.56; Capaccio D, 2010, BBA-MOL BASIS DIS, V1802, P572, DOI 10.1016/j.bbadis.2010.01.012; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470-2045(04)01509-8; Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x; Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kumar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013390; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Lorenzato M, 2005, HUM PATHOL, V36, P1101, DOI 10.1016/j.humpath.2005.07.016; McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784; Meilinger D, 2009, EMBO REP, V10, P1259, DOI 10.1038/embor.2009.201; Nakazawa T, 2011, HUM PATHOL; Nosho K, 2009, CLIN CANCER RES, V15, P3663, DOI 10.1158/1078-0432.CCR-08-2383; Ogino S, 2009, GASTROENTEROLOGY, V136, P1242, DOI 10.1053/j.gastro.2008.12.048; Pancione M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014229; Pancione M, 2010, HUM PATHOL, V41, P867, DOI 10.1016/j.humpath.2009.09.019; Papait R, 2007, MOL BIOL CELL, V18, P1098, DOI 10.1091/mbc.E06-09-0874; Phe V, 2010, BJU INT, V105, P1364, DOI 10.1111/j.1464-410X.2009.09167.x; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Sabatino L, 2005, J BIOL CHEM, V280, P26517, DOI 10.1074/jbc.M502716200; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Shen CX, 2008, JPN J CLIN ONCOL, V38, P770, DOI 10.1093/jjco/hyn105; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Tien AL, 2011, BIOCHEM J, V435, P175, DOI 10.1042/BJ20100840; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002; Wang DZ, 2008, PPAR RES, V2008, DOI 10.1155/2008/931074	40	73	82	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5061	5072		10.1038/onc.2012.3	http://dx.doi.org/10.1038/onc.2012.3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286757				2022-12-17	WOS:000312000900002
J	Eng, CH; Abraham, RT				Eng, C. H.; Abraham, R. T.			The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming	ONCOGENE			English	Review						autophagy; cancer metabolism; glutaminolysis; glycolysis	TUMOR-CELL SURVIVAL; FATTY-ACID SYNTHASE; KAPPA-B ACTIVATION; SIGNALING PATHWAYS; ENERGY-METABOLISM; NEURODEGENERATIVE DISEASES; REGULATING AUTOPHAGY; GLUTAMINE-METABOLISM; HUNTINGTONS-DISEASE; AEROBIC GLYCOLYSIS	Tumorigenesis is often accompanied by metabolic changes that favor rapid energy production and increased biosynthetic capabilities. These metabolic adaptations promote the survival and proliferation of tumor cells, and in conjunction with the hypoxic and metabolically challenged tumor microenvironment, influence autophagic activity. Autophagy is a catabolic process that allows cellular macromolecules to be broken down and re-utilized as metabolic precursors. Stimulation of autophagy promotes the survival of tumor cells under stressful metabolic and environmental conditions, and counters the potentially deleterious effects of mitochondrial dysfunction and the ROS that these organelles generate. However, inhibition of autophagy has also been reported to fuel tumorigenesis. In spite of the advances in our understanding of the relationship between autophagy and tumorigenesis, it remains unclear whether the therapeutic approaches targeting autophagy should aim to increase or decrease autophagic flux in tumor tissues in human patients. Here, we review how metabolic reprogramming influences autophagic activity in tumors, and discuss how inhibition of autophagy might be exploited to target tumor cells that show altered metabolism. Oncogene (2011) 30, 4687-4696; doi: 10.1038/onc. 2011.220; published online 13 June 2011	[Eng, C. H.; Abraham, R. T.] Pfizer Oncol Res Unit, Pearl River, NY 10965 USA	Pfizer	Eng, CH (corresponding author), Pfizer Oncol Res Unit, 401 N Middletown Rd,Bldg 200,Room 4603, Pearl River, NY 10965 USA.	christina.eng@pfizer.com						Abraham RT, 2008, EXPERT OPIN THER TAR, V12, P209, DOI [10.1517/14728222.12.2.209, 10.1517/14728222.12.2.209 ]; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Brest P, 2010, CURR MOL MED, V10, P486, DOI 10.2174/156652410791608252; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Denton D, 2009, CURR BIOL, V19, P1741, DOI 10.1016/j.cub.2009.08.042; Deretic V, 2010, CURR OPIN CELL BIOL, V22, P252, DOI 10.1016/j.ceb.2009.12.009; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Eng CH, 2010, AUTOPHAGY, V6, P968, DOI 10.4161/auto.6.7.13082; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; Filimonenko M, 2010, MOL CELL, V38, P265, DOI 10.1016/j.molcel.2010.04.007; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Huang Q, 2009, CELL DEATH DIFFER, V16, P264, DOI 10.1038/cdd.2008.151; Hubbard VM, 2010, J IMMUNOL, V185, P7349, DOI 10.4049/jimmunol.1000576; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020; Kondoh H, 2005, CANCER RES, V65, P177; Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kundu M, 2008, BLOOD, V112, P1493, DOI 10.1182/blood-2008-02-137398; Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394; Lee MN, 2009, MOL CELL BIOL, V29, P3991, DOI 10.1128/MCB.00165-09; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lupu R, 2006, CURR PHARM BIOTECHNO, V7, P483, DOI 10.2174/138920106779116928; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Marino G, 2011, MOL CELL, V42, P1, DOI 10.1016/j.molcel.2011.03.003; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Meng M, 2010, CELL CYCLE, V9, P3921, DOI 10.4161/cc.9.19.13139; Mordier S, 2000, J BIOL CHEM, V275, P29900, DOI 10.1074/jbc.M003633200; Morselli E, 2011, ANTIOXID REDOX SIGN, V14, P2251, DOI 10.1089/ars.2010.3478; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; Ravitz MJ, 2007, CANCER RES, V67, P11209, DOI 10.1158/0008-5472.CAN-06-4351; Renna M, 2010, J BIOL CHEM, V285, P11061, DOI 10.1074/jbc.R109.072181; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029; Sakiyama T, 2009, GASTROENTEROLOGY, V136, P924, DOI 10.1053/j.gastro.2008.12.002; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104	107	73	74	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4687	4696		10.1038/onc.2011.220	http://dx.doi.org/10.1038/onc.2011.220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21666712				2022-12-17	WOS:000298033700001
J	Plante, I; Stewart, MKG; Barr, K; Allan, AL; Laird, DW				Plante, I.; Stewart, M. K. G.; Barr, K.; Allan, A. L.; Laird, D. W.			Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease	ONCOGENE			English	Article						gap junctions; mammary gland tumor; metastasis; connexin43; ErbB2	GAP-JUNCTIONS; MYOEPITHELIAL CELLS; HUMAN BREAST; GLAND DEVELOPMENT; DOWN-REGULATION; EXPRESSION; CONNEXIN-43; DIFFERENTIATION; CX26; PHOSPHORYLATION	Gap junctions, the channels formed by the connexin (Cx) family of proteins, are responsible for direct intercellular communication. Although connexins are considered as tumor suppressors, their overall role in cancer onset, progression and metastasis is somewhat controversial. This study uses a novel Cx43 mutant mouse model (G60S mice) and cross-breeding strategies to determine the role of Cx43 in all stages of breast tumorigenesis. G60S mice were cross-bred with ErbB2 overexpressing mice, and spontaneous and 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced tumor development was evaluated. Mice were killed when tumors reached similar to 1 cm(3) or when mice showed signs of critical illness. In both spontaneous and DMBA studies, onset of palpable tumors was delayed in G60S mice compared with mice in control groups. Moreover, while tumors from control mice reached the size threshold, most DMBA-exposed Cx43 mutant mice were killed prematurely because of labored breathing, independent of the presence of a palpable tumor. Reduced Cx43 levels in Cx43 mutant mice were accompanied by extensive mammary gland hyperplasia. Lung histology revealed that all Cx43 mutant mice exhibited mammaglobin-positive mammary gland metastases to the lung, and the number of metastases was increased by threefold in Cx43 mutant mice on treatment with DMBA. Thus, while reduced levels of Cx43 delayed the onset of palpable tumors, normal Cx43 levels inhibited mammary gland tumor metastasis to the lungs. Understanding the mechanisms of how Cx43, which is expressed primarily in myoepithelial cells, inhibits mammary gland tumor metastasis is critical as Cx43 is assessed as a candidate for therapeutic intervention. Oncogene (2011) 30, 1681-1692; doi:10.1038/onc.2010.551; published online 13 December 2010	[Plante, I.; Allan, A. L.; Laird, D. W.] Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; [Stewart, M. K. G.; Barr, K.; Laird, D. W.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; [Allan, A. L.] Univ Western Ontario, Dept Oncol, London, ON N6A 5C1, Canada; [Allan, A. L.] London Reg Canc Program, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Dent Sci Bldg,Room 00077, London, ON N6A 5C1, Canada.	Dale.laird@schulich.uwo.ca	Laird, Dale W/AAL-2407-2020; Plante, Isabelle/AAK-5997-2021	Laird, Dale W/0000-0002-4568-3285; Plante, Isabelle/0000-0003-2080-6450	Canadian Breast Cancer Research Alliance; Canadian Institutes of Health Research; Fonds de la Recherche en Sante du Quebec	Canadian Breast Cancer Research Alliance; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec)	We thank David Goodale for his technical assistance. We are grateful to Dr Janet Rossant and team at the Centre for Modeling Human Disease (Toronto, ON, Canada) for providing the mouse model. This research was funded by the Canadian Breast Cancer Research Alliance to DWL, and by Fellowships from the Canadian Institutes of Health Research, the Canadian Institutes of Health Research Strategic Training Program and the Fonds de la Recherche en Sante du Quebec to IP. ALA is supported by a Canadian Institutes of Health Research New Investigator Award.	Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; Allred DC, 2008, J MAMMARY GLAND BIOL, V13, P279, DOI 10.1007/s10911-008-9093-5; Barsky SH, 2005, J MAMMARY GLAND BIOL, V10, P249, DOI 10.1007/s10911-005-9585-5; Bodenstine TM, 2008, CANCER MICROENVIRON, V1, P1, DOI 10.1007/s12307-008-0001-8; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; De Flora S, 2006, INT J ONCOL, V29, P521; El-Sabban ME, 2003, J MAMMARY GLAND BIOL, V8, P463, DOI 10.1023/B:JOMG.0000017432.04930.76; Engel J, 2003, EUR J CANCER, V39, P1794, DOI 10.1016/S0959-8049(03)00422-2; Flenniken AM, 2005, DEVELOPMENT, V132, P4375, DOI 10.1242/dev.02011; Foschini MP, 1998, VIRCHOWS ARCH, V432, P303, DOI 10.1007/s004280050170; Gudjonsson T, 2005, J MAMMARY GLAND BIOL, V10, P261, DOI 10.1007/s10911-005-9586-4; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Herve JC, 2007, PROG BIOPHYS MOL BIO, V94, P29, DOI 10.1016/j.pbiomolbio.2007.03.010; Hewitt SC, 2002, CANCER RES, V62, P2798; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Jacquemart IC, 2009, INT J ONCOL, V34, P517, DOI 10.3892/ijo_00000177; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; Kalra J, 2006, CARCINOGENESIS, V27, P2528, DOI 10.1093/carcin/bgl110; Kanczuga-Koda L, 2006, J CLIN PATHOL, V59, P429, DOI 10.1136/jcp.2005.029272; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; Manias JL, 2008, CARDIOVASC RES, V80, P385, DOI 10.1093/cvr/cvn203; McLachlan E, 2005, CELL COMMUN ADHES, V12, P279, DOI 10.1080/15419060500514143; McLachlan E, 2007, J MEMBRANE BIOL, V218, P107, DOI 10.1007/s00232-007-9052-x; Medina Daniel, 2007, Breast Dis, V28, P63; Mese G, 2007, J INVEST DERMATOL, V127, P2516, DOI 10.1038/sj.jid.5700770; Monaghan P, 1996, EXP CELL RES, V223, P29, DOI 10.1006/excr.1996.0055; Nagata K, 2009, J PEDIATR SURG, V44, P2296, DOI 10.1016/j.jpedsurg.2009.07.070; Naoi Y, 2007, BREAST CANCER RES TR, V106, P11, DOI 10.1007/s10549-006-9465-8; Naus CC, 2010, NAT REV CANCER, V10, P435, DOI 10.1038/nrc2841; Paznekas WA, 2009, HUM MUTAT, V30, P724, DOI 10.1002/humu.20958; PITELKA DR, 1973, J CELL BIOL, V56, P797, DOI 10.1083/jcb.56.3.797; Plante I, 2008, DEV BIOL, V318, P312, DOI 10.1016/j.ydbio.2008.03.033; Plante I, 2010, BIOL REPROD, V82, P837, DOI 10.1095/biolreprod.109.081406; Rowse GJ, 1998, CANCER RES, V58, P2675; Saunders MM, 2001, CANCER RES, V61, P1765; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; Solan JL, 2005, BBA-BIOMEMBRANES, V1711, P154, DOI 10.1016/j.bbamem.2004.09.013; Solan JL, 2007, J MEMBRANE BIOL, V217, P35, DOI 10.1007/s00232-007-9035-y; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Sternlicht MD, 1997, MED HYPOTHESES, V48, P37, DOI 10.1016/S0306-9877(97)90022-0; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Talhouk RS, 2008, EXP CELL RES, V314, P3275, DOI 10.1016/j.yexcr.2008.07.030; Thomas T, 2005, J CELL SCI, V118, P4451, DOI 10.1242/jcs.02569; Tsubura A, 2007, MED MOL MORPHOL, V40, P9, DOI 10.1007/s00795-006-0351-6; van de Wouw AJ, 2003, ANN ONCOL, V14, P191, DOI 10.1093/annonc/mdg068; Yang M, 2010, MODERN PATHOL, V23, P654, DOI 10.1038/modpathol.2010.38	51	73	78	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1681	1692		10.1038/onc.2010.551	http://dx.doi.org/10.1038/onc.2010.551			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21151177				2022-12-17	WOS:000289239400006
J	Krishnan, M; Singh, AB; Smith, JJ; Sharma, A; Chen, X; Eschrich, S; Yeatman, TJ; Beauchamp, RD; Dhawan, P				Krishnan, M.; Singh, A. B.; Smith, J. J.; Sharma, A.; Chen, X.; Eschrich, S.; Yeatman, T. J.; Beauchamp, R. D.; Dhawan, P.			HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability	ONCOGENE			English	Article						tight junction; claudin-1; invasion; TSA; HDAC	HISTONE DEACETYLASE INHIBITORS; BREAST-CARCINOMA CELLS; TRICHOSTATIN-A; GENE; TUMORIGENESIS; GROWTH	Expression and cellular distribution of claudin-1, a tight junction protein, is dysregulated in colon cancer and its overexpression in colon cancer cells induced dedifferentiation and increased invasion. However, the molecular mechanism(s) underlying dysregulated claudin-1 expression in colon cancer remains poorly understood. Histone deacetylase (HDAC)-dependent histone acetylation is an important mechanism of the regulation of cancer-related genes and inhibition of HDACs induces epithelial differentiation and decreased invasion. Therefore, in this study, we examined the role of HDAC-dependent epigenetic regulation of claudin-1 in colon cancer. In this study, we show that sodium butyrate and Trichostatin A (TSA), two structurally different and widely used HDAC inhibitors, inhibited claudin-1 expression in multiple colon cancer cell lines. Further studies revealed modulation of claudin-1 mRNA stability by its 3'-UTR as the major mechanism underlying HDAC-dependent claudin-1 expression. In addition, overexpression of claudin-1 abrogated the TSA-induced inhibition of invasion in colon cancer cells suggesting functional crosstalk. Analysis of mRNA expression in colon cancer patients, showed a similar pattern of increase in claudin-1 and HDAC-2 mRNA expression throughout all stages of colon cancer. Inhibition of claudin-1 expression by HDAC-2-specific small interfering RNA further supported the role of HDAC-2 in this regulation. Taken together, we report a novel post-transcriptional regulation of claudin-1 expression in colon cancer cells and further show a functional correlation between claudin-1 expression and TSA-mediated regulation of invasion. As HDAC inhibitors are considered to be promising anticancer drugs, these new findings will have implications in both laboratory and clinical settings. Oncogene (2010) 29, 305-312; doi:10.1038/onc.2009.324; published online 2 November 2009	[Dhawan, P.] Vanderbilt Univ, Dept Surg, Med Ctr, MCN,Div Surg Oncol, Nashville, TN 37240 USA; [Smith, J. J.; Beauchamp, R. D.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37240 USA; [Chen, X.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37240 USA; [Eschrich, S.; Yeatman, T. J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Beauchamp, R. D.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37240 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; H Lee Moffitt Cancer Center & Research Institute; Vanderbilt University	Dhawan, P (corresponding author), Vanderbilt Univ, Dept Surg, Med Ctr, MCN,Div Surg Oncol, B-2211, Nashville, TN 37240 USA.	punita.dhawan@vanderbilt.edu	Sharma, Ashok/AAE-5439-2019; Smith, Jesse Joshua/AAN-5440-2020; Eschrich, Steven/K-6848-2013	Sharma, Ashok/0000-0001-7505-6023; Smith, Jesse Joshua/0000-0003-2538-5456; Eschrich, Steven/0000-0002-9833-2788; Beauchamp, Robert Daniel/0000-0002-8446-4114	NIH [CA119005, CA124977, DK58404]; AHA [0435471N, 5P50DK044757, P30DK058406]; Society of University Surgeons-Ethicon Scholarship Award [CA112215, DK052334, CA 069457]; GI Cancer SPORE [CA95103]; Vanderbilt-Ingram Cancer Center [P30CA68485]; NATIONAL CANCER INSTITUTE [R01CA069457, R21CA119005, R01CA124977, R01CA112215, P30CA068485, P50CA095103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK044757, R01DK052334, P30DK058404] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AHA(American Heart Association); Society of University Surgeons-Ethicon Scholarship Award; GI Cancer SPORE; Vanderbilt-Ingram Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant CA119005, CA124977 (P Dhawan), and AHA Grant 0435471N, 5P50DK044757 and P30DK058406 Pilot project (AB Singh), the Society of University Surgeons-Ethicon Scholarship Award (JJS) CA112215 (TJ Yeatman), DK052334, CA 069457, the GI Cancer SPORE grant CA95103 (RD Beauchamp), the Vanderbilt-Ingram Cancer Center P30CA68485 and the NIH grant supporting the Digestive Diseases Center DK58404. We thank Christian Kis for the help in real-time quantitative reverse transcription-PCR analysis.	Abuazza G, 2006, AM J PHYSIOL-RENAL, V291, pF1132, DOI 10.1152/ajprenal.00063.2006; Chavey C, 2008, MOL PHARMACOL, V74, P1359, DOI 10.1124/mol.108.047332; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532; Godman CA, 2008, CANCER BIOL THER, V7, P1570, DOI 10.4161/cbt.7.10.6561; Honda H, 2007, CANCER BIOL THER, V6, P1733, DOI 10.4161/cbt.6.11.4832; Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200; Liu PY, 2008, MOL CANCER RES, V6, P1204, DOI 10.1158/1541-7786.MCR-08-0123; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nishikiori N, 2008, JPN J OPHTHALMOL, V52, P195, DOI 10.1007/s10384-008-0524-z; Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x; Osanai M, 2007, CANCER SCI, V98, P1027, DOI 10.1111/j.1349-7006.2007.00494.x; Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6; Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0; Schefe JH, 2006, J MOL MED, V84, P901, DOI 10.1007/s00109-006-0097-6; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Wu Y, 2007, REPROD SCI, V14, P374, DOI 10.1177/1933719107302913; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	20	73	74	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					305	312		10.1038/onc.2009.324	http://dx.doi.org/10.1038/onc.2009.324			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19881542	Green Accepted			2022-12-17	WOS:000273650000013
J	Song, H; Zhang, B; Watson, MA; Humphrey, PA; Lim, H; Milbrandt, J				Song, H.; Zhang, B.; Watson, M. A.; Humphrey, P. A.; Lim, H.; Milbrandt, J.			Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis	ONCOGENE			English	Article						prostate cancer; Nkx3.1; pten; Akt; clusterin	PROLIFERATIVE INFLAMMATORY ATROPHY; LASER CAPTURE MICRODISSECTION; TRANSGENIC MOUSE MODEL; INTRAEPITHELIAL NEOPLASIA; SUPPRESSOR GENE; EXPRESSION PROFILES; MOLECULAR-FEATURES; OXIDATIVE DAMAGE; AKT ACTIVATION; PROTEIN NKX3.1	The expression of NKX3.1, a transcriptional regulator and tumor suppressor gene in prostate cancer, is downregulated during early stages of prostate tumorigenesis. However, little is known of the alterations in gene expression that occur as a result of this event. We combined laser capture microdissection and gene expression pro. ling to analyse the molecular consequences of Nkx3.1 loss during prostate cancer initiation using Nkx3.1-deficient mice. This analysis identified a cohort of genes (loss-of-Nkx3.1 signature) that are aberrantly overexpressed during loss-of-Nkx3.1-driven tumor initiation. We studied the expression of these genes in independent loss-of-Pten and c-myc overexpression prostate adenocarcinoma mouse models. Nkx3.1 expression is lost in prostate epithelial proliferation in both of these mouse models. However, Nkx3.1 loss is an early event of tumor development in the loss-of-Pten model, whereas it occurs at later stages in c-myc transgenic mice. A number of genes of the loss-of-Nkx3.1 signature, such as clusterin and quiescin Q6, are highly expressed in prostatic hyperplasia and intraepithelial neoplasia (PIN) lesions that also lack Nkx3.1 in the Pten-deficient prostate, but not in similar lesions in the c-myc transgenic model. Meta-analysis of multiple prostate cancer gene expression data sets, including those from loss-of-Nkx3.1, loss-of-Pten, c-myc overexpression and constitutively active Akt prostate cancer models, further confirmed that genes associated with the loss-of-Nkx3.1 signature integrate with PTEN-AKT signaling pathways, but do not overlap with molecular changes associated with the c-myc signaling pathway. In human prostate tissue samples, loss of NKX3.1 expression and corresponding clusterin overexpression are co-localized at sites of prostatic in. ammatory atrophy, a possible very early stage of human prostate tumorigenesis. Collectively, these results suggest that the molecular consequences of NKX3.1 loss depend on the epithelial proliferative stage at which its expression is lost, and that alterations in the PTEN-AKT-NKX3.1 axis are important for prostate cancer initiation. Oncogene (2009) 28, 3307-3319; doi:10.1038/onc.2009.181; published oline 13 July 2009	[Song, H.; Zhang, B.; Watson, M. A.; Humphrey, P. A.; Milbrandt, J.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA; [Lim, H.] Washington Univ, Dept Obstet & Gynecol, Sch Med, St Louis, MO 63110 USA; [Song, H.] Kwandong Univ, Coll Med, Mol Oncol Lab, Cheil Gen Hosp, Seoul, South Korea; [Song, H.] Kwandong Univ, Coll Med, Womens Healthcare Ctr, Seoul, South Korea	Washington University (WUSTL); Washington University (WUSTL); Catholic Kwandong University; Catholic Kwandong University	Milbrandt, J (corresponding author), Washington Univ, Dept Pathol & Immunol, Sch Med, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	jmilbrandt@wustl.edu	Lim, Hyunjung J/D-5343-2011	Lim, Hyunjung J/0000-0003-2191-666X; Milbrandt, Jeffrey/0000-0002-5477-7689; Song, Haengseok/0000-0002-5027-7310	NIH [CA111966]; Washington University; Department of Defense [PC030380]; NATIONAL CANCER INSTITUTE [R01CA111966] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Washington University; Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are deeply indebted to Rakesh Nagarajan for help with bioinformatic analysis and Robert Heuckeroth for careful review of the manuscript and helpful discussions of the data. We thank Amy Strickland, Tatiana Gorodinsky and Nina Panchenko for technical assistance. We are grateful to Hong Wu and Charles Sawyers (UCLA) for Pten conditional and cmyc transgenic mice, respectively. This work was supported by NIH grants CA111966 (to JM) and Washington University Cancer Biology Pathway Fellowship (to BZ). HS was supported by a postdoctoral fellowship from the Department of Defense (PC030380).	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Asatiani E, 2005, CANCER RES, V65, P1164, DOI 10.1158/0008-5472.CAN-04-2688; Ashida S, 2004, CANCER RES, V64, P5963, DOI 10.1158/0008-5472.CAN-04-0020; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Bethel CR, 2007, PROSTATE, V67, P1740, DOI 10.1002/pros.20579; Bethel CR, 2006, CANCER RES, V66, P10683, DOI 10.1158/0008-5472.CAN-06-0963; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; BOVA GS, 1993, CANCER RES, V53, P3869; Bowen C, 2000, CANCER RES, V60, P6111; Chan JM, 2005, J CLIN ONCOL, V23, P8152, DOI 10.1200/JCO.2005.03.1492; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; DAS SK, 1994, DEVELOPMENT, V120, P1071; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Ehrig T, 2001, J MOL DIAGN, V3, P22, DOI 10.1016/S1525-1578(10)60645-9; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Eshel R, 2002, SEMIN CANCER BIOL, V12, P139, DOI 10.1006/scbi.2001.0422; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Gleave M, 2005, WORLD J UROL, V23, P38, DOI 10.1007/s00345-004-0474-0; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Kim MJ, 2002, CANCER RES, V62, P2999; Lei QY, 2006, CANCER CELL, V9, P367, DOI 10.1016/j.ccr.2006.03.031; Luzzi V, 2003, J MOL DIAGN, V5, P9, DOI 10.1016/S1525-1578(10)60445-X; MACOSKA JA, 1995, CANCER RES, V55, P5390; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Markowski MC, 2008, CANCER RES, V68, P6896, DOI 10.1158/0008-5472.CAN-08-0578; Nelson WG, 2001, ANN NY ACAD SCI, V952, P135, DOI 10.1111/j.1749-6632.2001.tb02734.x; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oberley TD, 2002, AM J PATHOL, V160, P403, DOI 10.1016/S0002-9440(10)64857-2; Ouyang X, 2005, CANCER RES, V65, P6773, DOI 10.1158/0008-5472.CAN-05-1948; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Simard J, 2003, ENDOCR-RELAT CANCER, V10, P225, DOI 10.1677/erc.0.0100225; Simmons SO, 2006, BIOCHEM J, V393, P397, DOI 10.1042/BJ20051030; Song H, 2002, DEVELOPMENT, V129, P2879; Steadman DJ, 2000, NUCLEIC ACIDS RES, V28, P2389, DOI 10.1093/nar/28.12.2389; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tricoli JV, 2004, CLIN CANCER RES, V10, P3943, DOI 10.1158/1078-0432.CCR-03-0200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Leenders GJLH, 2003, AM J PATHOL, V162, P1529, DOI 10.1016/S0002-9440(10)64286-1; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Zheng SL, 2006, CANCER RES, V66, P69, DOI 10.1158/0008-5472.CAN-05-1550	50	73	84	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3307	3319		10.1038/onc.2009.181	http://dx.doi.org/10.1038/onc.2009.181			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19597465	Green Accepted			2022-12-17	WOS:000269893700005
J	De Santis, G; Miotti, S; Mazzi, M; Canevari, S; Tomassetti, A				De Santis, G.; Miotti, S.; Mazzi, M.; Canevari, S.; Tomassetti, A.			E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells	ONCOGENE			English	Article						E-cadherin; PI3K; cell/cell adhesion; ovarian carcinoma	BETA-CATENIN; PHOSPHOINOSITIDE 3-KINASE; PIK3CA GENE; PHOSPHATIDYLINOSITOL 3-KINASE; SURFACE EPITHELIUM; PROTEIN-KINASE; ALPHA-CATENIN; ADHESION; CANCER; EXPRESSION	E-cadherin (cadh), a member of a family of integral membrane glycoproteins that represent the major component of adherens junctions (AJs), mediates cell-cell adhesion through the calcium-dependent homophilic interaction of its extracellular domain. Metastatic human carcinomas frequently lose E-cadh expression, whereas epithelial ovarian cancer (EOCs) maintain properties characteristic of Mullerian epithelium during tumor progression, including E-cadh expression. Here, we examined the potential role of cell-cell contacts in EOCs through E-cadh homophilic interactions in PI3K/AKT activation whose altered signaling has been implicated in EOC pathogenesis. We show that E-cadh is predominantly expressed at cell-cell contacts and its functionality is necessary and sufficient for the activation of the PI3K/AKT pathway. E-cadh knockdown and phosphoinositide-3-kinase (PI3K) inhibition complement each other in impairing cell-cycle progression and proliferation of ovarian carcinoma cells. E-cadh is stably bound to the PI3K complex, and the de novo formation of E-cadh/beta-catenin complexes following calcium deprivation and subsequent calcium restoration recruits the PI3K p85 subunit to the site of the cell-cell contacts. The finding that E-cadh-mediated AJ formation contributes to PI3K/AKT activation in EOC cells by a mechanism that appears to be restricted to these cells provides the underpinning for therapeutic strategies that exploit PI3K inhibition to halt EOCs.	[De Santis, G.; Miotti, S.; Mazzi, M.; Canevari, S.; Tomassetti, A.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Unit Mol Therapies, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Tomassetti, A (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Unit Mol Therapies, Via Venezian 1, I-20133 Milan, Italy.	antonella.tomassetti@istitutotumori.mi.it	Tomassetti, Antonella/G-7906-2015	Tomassetti, Antonella/0000-0001-6772-9937	Associazione Italiana Ricerca Cancro (AIRC); Cariplo Foundation [2003-1740]	Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Cariplo Foundation(Fondazione Cariplo)	We thank Gloria Bosco for her secretarial assistance. This work was supported by grants to SC from Associazione Italiana Ricerca Cancro (AIRC) and the Cariplo Foundation (grant number 2003-1740).	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Amzel LM, 2008, NAT REV CANCER, V8, P665, DOI 10.1038/nrc2443; Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Andl CD, 2005, CANCER BIOL THER, V4, P28, DOI 10.4161/cbt.4.1.1431; Aunoble B, 2000, INT J ONCOL, V16, P567; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Carneiro F, 2008, J CLIN PATHOL, V61, P25, DOI 10.1136/jcp.2006.043679; Castellano G, 2006, CANCER RES, V66, P10709, DOI 10.1158/0008-5472.CAN-06-1327; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; Herzig M, 2007, ONCOGENE, V26, P2290, DOI 10.1038/sj.onc.1210029; Himanen JP, 2007, CURR OPIN CELL BIOL, V19, P534, DOI 10.1016/j.ceb.2007.08.004; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Marques FR, 2004, GYNECOL ONCOL, V94, P16, DOI 10.1016/j.ygyno.2004.03.037; McLachlan RW, 2007, MOL BIOL CELL, V18, P3214, DOI 10.1091/mbc.E06-12-1154; McLachlan RW, 2007, J MOL MED-JMM, V85, P545, DOI 10.1007/s00109-007-0198-x; Miotti S, 2005, AM J PATHOL, V167, P1411, DOI 10.1016/S0002-9440(10)61228-X; Niessen CM, 2008, BBA-BIOMEMBRANES, V1778, P562, DOI 10.1016/j.bbamem.2007.12.015; Pang JH, 2005, J BIOL CHEM, V280, P3043, DOI 10.1074/jbc.M412148200; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Reddy P, 2005, MOL ENDOCRINOL, V19, P2564, DOI 10.1210/me.2004-0342; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanna E, 2007, EXP CELL RES, V313, P1307, DOI 10.1016/j.yexcr.2007.02.005; Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Tomassetti A, 2008, NEOPLASIA, V10, P1481, DOI 10.1593/neo.81004; van Hengel J, 2007, BBA-MOL CELL RES, V1773, P78, DOI 10.1016/j.bbamcr.2006.08.033; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Wang Y, 2005, HUM MUTAT, V25, DOI 10.1002/humu.9316; Woenckhaus J, 2007, VIRCHOWS ARCH, V450, P387, DOI 10.1007/s00428-006-0358-3; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Xie ZJ, 2007, J BIOL CHEM, V282, P8695, DOI 10.1074/jbc.M609135200; Yap AS, 2007, CURR OPIN CELL BIOL, V19, P508, DOI 10.1016/j.ceb.2007.09.008; Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660	43	73	75	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1206	1217		10.1038/onc.2008.470	http://dx.doi.org/10.1038/onc.2008.470			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151754				2022-12-17	WOS:000263906200005
J	Samadi, N; Gaetano, C; Goping, IS; Brindley, DN				Samadi, N.; Gaetano, C.; Goping, I. S.; Brindley, D. N.			Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis	ONCOGENE			English	Article						ceramides; chemotherapy; chemoresistance; lysophosphatidate; lysophosphatidylcholine; phosphatidylinositol 3-kinase	LYSOPHOSPHATIDIC ACID RECEPTOR; RETRACTED ARTICLE. SEE; COUPLED RECEPTOR; PREVENTS APOPTOSIS; SURVIVAL FACTOR; OVARIAN; TUMOR; GROWTH; ACTIVATION; PACLITAXEL	Autotaxin (ATX) promotes cancer cell survival, growth, migration, invasion and metastasis. ATX converts extracellular lysophosphatidylcholine (LPC) into lysophosphatidate (LPA). As these lipids have been reported to affect cell signaling through their own G-protein-coupled receptors, ATX could modify the balance of this signaling. Also, ATX affects cell adhesion independently of its catalytic activity. We investigated the interactions of ATX, LPC and LPA on the apoptotic effects of Taxol, which is commonly used in breast cancer treatment. LPC had no significant effect on Taxol-induced apoptosis in MCF-7 breast cancer cells, which do not secrete significant ATX. Addition of incubation medium from MDA-MB-435 melanoma cells, which secrete ATX, or recombinat ATX enabled LPC to inhibit Taxol-induced apoptosis of MCF-7 cells. Inhibiting ATX activity blocked this protection against apoptosis. We conclude that LPC has no significant effect in protecting MCF-7 cells against Taxol treatment unless it is converted to LPA by ATX. LPA strongly antagonized Taxol-induced apoptosis through stimulating phosphatidylinositol 3-kinase and inhibiting ceramide formation. LPA also partially reversed the Taxol-induced arrest in the G2/M phase of the cell cycle. Our results support the hypothesis that therapeutic inhibition of ATX activity could improve the efficacy of Taxol as a chemotherapeutic agent for cancer treatment.	[Gaetano, C.; Goping, I. S.; Brindley, D. N.] Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada; [Samadi, N.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Brindley, DN (corresponding author), Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada.	david.brindley@ualberta.ca	Gaetano, Carlo/P-9997-2019	Gaetano, Carlo/0000-0002-5238-1832; samadi, nasser/0000-0001-7960-6432				Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Asakuma J, 2003, CANCER RES, V63, P1365; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; Bergstralh DT, 2006, CANCER TREAT REV, V32, P166, DOI 10.1016/j.ctrv.2006.01.004; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; BRINDLEY DN, 1993, J NUTR BIOCHEM, V4, P442, DOI 10.1016/0955-2863(93)90061-Z; Chappell J, 2001, J BIOL CHEM, V276, P38023; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1927, DOI 10.1152/ajpcell.00400.2006; Clair T, 2003, CANCER RES, V63, P5446; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; Cui P, 2007, BIOORG MED CHEM LETT, V17, P1634, DOI 10.1016/j.bmcl.2006.12.114; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Dennis J, 2005, J NEUROSCI RES, V82, P737, DOI 10.1002/jnr.20686; Dufour G, 2004, J BIOL CHEM, V279, P44113, DOI 10.1074/jbc.M405323200; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Ferry G, 2008, J PHARMACOL EXP THER, V327, P809, DOI 10.1124/jpet.108.141911; Fox MA, 2004, MOL CELL NEUROSCI, V27, P140, DOI 10.1016/j.mcn.2004.06.002; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Furui T, 1999, CLIN CANCER RES, V5, P4308; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; Goetzl EJ, 1999, CANCER RES, V59, P5370; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Harnois C, 2004, J CELL PHYSIOL, V198, P209, DOI 10.1002/jcp.10399; Hu XJ, 2005, J BIOL CHEM, V280, P9498, DOI 10.1074/jbc.M410455200; Inoue CN, 2001, CLIN SCI, V101, P11, DOI 10.1042/CS20000293; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kim K, 2005, FASEB J, V19, P819, DOI 10.1096/fj.04-2988fje; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Levine JS, 1997, AM J PHYSIOL-RENAL, V273, pF575, DOI 10.1152/ajprenal.1997.273.4.F575; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Marchetti P, 2002, CRIT REV ONCOL HEMAT, V44, pS3; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Melet A, 2008, ADV EXP MED BIOL, V615, P47, DOI 10.1007/978-1-4020-6554-5_4; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Murph MM, 2007, MOL CANCER RES, V5, P1201, DOI 10.1158/1541-7786.MCR-06-0338; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Pilquil C, 2006, J BIOL CHEM, V281, P38418, DOI 10.1074/jbc.M601670200; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P2049, DOI 10.1161/01.ATV.0000040598.18570.54; Rusovici R, 2007, BBA-GEN SUBJECTS, V1770, P1194, DOI 10.1016/j.bbagen.2007.04.008; Sakashita F, 2008, CANCER CHEMOTH PHARM, V62, P379, DOI 10.1007/s00280-007-0614-5; Saunders DE, 1997, INT J CANCER, V70, P214, DOI 10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I; Sietsma H, 2002, NEUROCHEM RES, V27, P665, DOI 10.1023/A:1020228117739; Snyder JP, 2001, P NATL ACAD SCI USA, V98, P5312, DOI 10.1073/pnas.051309398; So J, 2005, GYNECOL ONCOL, V97, P870, DOI 10.1016/j.ygyno.2005.03.004; Spankuch B, 2007, ONCOGENE, V26, P5793, DOI 10.1038/sj.onc.1210355; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Sun BL, 2003, INT J MOL MED, V12, P633; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; Yue JM, 2004, CELL SIGNAL, V16, P385, DOI 10.1016/j.cellsig.2003.08.012; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	72	73	79	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					1028	1039		10.1038/onc.2008.442	http://dx.doi.org/10.1038/onc.2008.442			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079345				2022-12-17	WOS:000263457400009
J	Lahsnig, C; Mikula, M; Petz, M; Zulehner, G; Schneller, D; van Zijl, F; Huber, H; Csiszar, A; Beug, H; Mikulits, W				Lahsnig, C.; Mikula, M.; Petz, M.; Zulehner, G.; Schneller, D.; van Zijl, F.; Huber, H.; Csiszar, A.; Beug, H.; Mikulits, W.			ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression	ONCOGENE			English	Article						hepatocyte; ILEI; epithelial to mesenchymal transition; HCC; tumor progression	HUMAN HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR-BETA; TGF-BETA; SIGNAL TRANSDUCERS; TUMOR-SUPPRESSOR; CANCER; CELLS; HEPATOCARCINOGENESIS; METASTASIS; ACTIVATION	In human hepatocellular carcinoma (HCC), epithelial to mesenchymal transition (EMT) correlates with aggressiveness of tumors and poor survival. We employed a model of EMT based on immortalized p19(ARF) null hepatocytes (MIM), which display tumor growth upon expression of oncogenic Ras and undergo EMT through the synergism of Ras and transforming growth factor (TGF)-beta. Here, we show that the interleukin-related protein interleukin-like EMT inducer (ILEI), a novel EMT-, tumor-and metastasis-inducing protein, cooperates with oncogenic Ras to cause TGF-beta-independent EMT. Ras-transformed MIM hepatocytes overexpressing ILEI showed cytoplasmic E-cadherin, loss of ZO-1 and induction of a-smooth muscle actin as well as platelet-derived growth factor (PDGF)/PDGF-R isoforms. As shown by dominant-negative PDGF-R expression in these cells, ILEI-induced PDGF signaling was required for enhanced cell migration, nuclear accumulation of beta-catenin, nuclear pY-Stat3 and accelerated growth of lung metastases. In MIM hepatocytes expressing the Ras mutant V12-C40, ILEI collaborated with PI3K signaling resulting in tumor formation without EMT. Clinically, human HCC samples showed granular or cytoplasmic localization of ILEI correlating with well and poorly differentiated tumors, respectively. In conclusion, these data indicate that ILEI requires cooperation with oncogenic Ras to govern hepatocellular EMT through mechanisms involving PDGF-R/beta-catenin and PDGF-R/Stat3 signaling.	[Lahsnig, C.; Zulehner, G.; Schneller, D.; van Zijl, F.; Huber, H.; Mikulits, W.] Med Univ Vienna, Dept Med 1, Div Inst Canc Res, A-1090 Vienna, Austria; [Mikula, M.; Petz, M.; Csiszar, A.; Beug, H.] Res Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mikulits, W (corresponding author), Med Univ Vienna, Dept Med 1, Div Inst Canc Res, Borschke Gasse 8A, A-1090 Vienna, Austria.	wolfgang.mikulits@meduniwien.ac.at	Csiszar, Agnes/I-2747-2019; Mikulits, Wolfgang/AAH-4043-2021	Csiszar, Agnes/0000-0001-7911-3427; Mikulits, Wolfgang/0000-0003-4612-7106; Petz, Michaela/0000-0002-6854-9919; Mikula, Mario/0000-0001-5782-0681	Austrian Science Fund, FWF [SFBF28, P19598-B13]	Austrian Science Fund, FWF(Austrian Science Fund (FWF))	We thank ORIDIS Biomed for providing HCC tissue arrays and immunohistochemical staining. This work was supported by grants from the Austrian Science Fund, FWF, Grant number SFBF28 and P19598-B13.	Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006; Campbell JS, 2007, DIFFERENTIATION, V75, P843, DOI 10.1111/j.1432-0436.2007.00235.x; Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fischer ANM, 2007, ONCOGENE, V26, P3395, DOI 10.1038/sj.onc.1210121; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Giebel B, 2006, CURR BIOL, V16, pR91, DOI 10.1016/j.cub.2006.01.022; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Kensler TW, 2003, NAT REV CANCER, V3, P321, DOI 10.1038/nrc1076; Kondoh N, 2001, INT J ONCOL, V18, P1271; Lacher MD, 2006, CANCER RES, V66, P1648, DOI 10.1158/0008-5472.CAN-05-2328; Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Macheiner D, 2006, J HEPATOL, V45, P81, DOI 10.1016/j.jhep.2005.12.017; Mikula M, 2004, HEPATOLOGY, V39, P628, DOI 10.1002/hep.20084; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Tannapfel A, 2001, ONCOGENE, V20, P7104, DOI 10.1038/sj.onc.1204902; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Waerner T, 2006, CANCER CELL, V10, P227, DOI 10.1016/j.ccr.2006.07.020; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang SF, 2007, J CLIN PATHOL, V60, P642, DOI 10.1136/jcp.2006.036970; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhou L, 2007, WORLD J SURG, V31, P1782, DOI 10.1007/s00268-007-9029-z	41	73	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					638	650		10.1038/onc.2008.418	http://dx.doi.org/10.1038/onc.2008.418			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015638	Green Accepted, Bronze			2022-12-17	WOS:000263076400002
J	Thorner, AR; Hoadley, KA; Parker, JS; Winkel, S; Millikan, RC; Perou, CM				Thorner, A. R.; Hoadley, K. A.; Parker, J. S.; Winkel, S.; Millikan, R. C.; Perou, C. M.			In vitro and in vivo analysis of B-Myb in basal-like breast cancer	ONCOGENE			English	Article						B-Myb; MYBL2; breast cancer; basal-like	RETINOBLASTOMA TUMOR-SUPPRESSOR; CENTRAL-NERVOUS-SYSTEM; C-MYB; CELL-CYCLE; A-MYB; EXPRESSION SIGNATURE; MOLECULAR PORTRAITS; GENE; TRANSCRIPTION; SUBTYPES	A defining feature of basal-like breast cancer, a breast cancer subtype with poor clinical prognosis, is the high expression of 'proliferation signature' genes. We identified B-Myb, a MYB family transcription factor that is often amplified and overexpressed in many tumor types, as being highly expressed in the proliferation signature. However, the roles of B-Myb in disease progression, and its mammary-specific transcriptional targets, are poorly understood. Here, we showed that B-Myb expression is a significant predictor of survival and pathological complete response to neoadjuvant chemotherapy in breast cancer patients. We also identified a significant association between the G/G genotype of a nonsynonymous B-Myb germline variant (rs2070235, S427G) and an increased risk of basal-like breast cancer [OR 2.0, 95% CI (1.1-3.8)]. In immortalized, human mammary epithelial cell lines, but not in basal-like tumor lines, cells ectopically expressing wild-type B-Myb or the S427G variant showed increased sensitivity to two DNA topoisomerase II alpha inhibitors, but not to other chemotherapeutics. In addition, microarray analyses identified many G2/M genes as being induced in B-Myb overexpressing cells. These results confirm that B-Myb is involved in cell cycle control, and that its dysregulation may contribute to increased sensitivity to a specific class of chemotherapeutic agents. These data provide insight into the influence of B-Myb in human breast cancer, which is of potential clinical importance for determining disease risk and for guiding treatment.	[Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; [Thorner, A. R.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Winkel, S.; Millikan, R. C.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Perou, C. M.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Perou, CM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, 450 West Dr, Chapel Hill, NC 27599 USA.	cperou@med.unc.edu	Perou, Charles M/H-9934-2014; Parker, Joel/AAG-1108-2019	Perou, Charles M/0000-0001-9827-2247; Hoadley, Katherine/0000-0002-1216-477X	NCI Breast SPORE [P50-CA5822309A1, RO1-CA-101227-01]; Breast Cancer Research Foundation; V Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA101227, P50CA058223] Funding Source: NIH RePORTER	NCI Breast SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; V Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Melissa A Troester and William K Kaufmann for comments and discussion. This work was supported by funds from the NCI Breast SPORE program (P50-CA5822309A1), by RO1-CA-101227-01, by the Breast Cancer Research Foundation and the V Foundation for Cancer Research.	Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Davidson CJ, 2005, GENETICS, V169, P215, DOI 10.1534/genetics.104.034132; Derenzini M, 2008, CLIN CANCER RES, V14, P2199, DOI 10.1158/1078-0432.CCR-07-2065; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Hu ZY, 2005, BIOTECHNIQUES, V38, P121, DOI 10.2144/05381MT02; Ito M, 2001, PLANT CELL, V13, P1891, DOI 10.1105/tpc.13.8.1891; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Malaterre J, 2007, P NATL ACAD SCI USA, V104, P3829, DOI 10.1073/pnas.0610055104; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Millikan R, 2003, BREAST CANCER RES TR, V79, P355, DOI 10.1023/A:1024068525763; Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rosinski JA, 1998, J MOL EVOL, V46, P74, DOI 10.1007/PL00006285; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sala A, 2005, EUR J CANCER, V41, P2479, DOI 10.1016/j.ejca.2005.08.004; Schwab R, 2008, ONCOGENE, V27, P2929, DOI 10.1038/sj.onc.1210947; SMITH PJ, 1994, BRIT J CANCER, V70, P914, DOI 10.1038/bjc.1994.420; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; VANEWIJK PH, 1993, ECOTOX ENVIRON SAFE, V25, P25, DOI 10.1006/eesa.1993.1003; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	44	73	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					742	751		10.1038/onc.2008.430	http://dx.doi.org/10.1038/onc.2008.430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19043454	Green Submitted, Green Accepted			2022-12-17	WOS:000263076400011
J	Guigon, CJ; Zhao, L; Willingham, MC; Cheng, SY				Guigon, C. J.; Zhao, L.; Willingham, M. C.; Cheng, S-Y			PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer	ONCOGENE			English	Article						thyroid cancer; Pten; carcinogenesis; mouse model; mutations	PROTEIN-KINASE-B; COWDEN-DISEASE; GERMLINE MUTATIONS; PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION FACTORS; SUPPRESSOR GENE; LIGAND-BINDING; BETA-RECEPTOR; HORMONE; RESISTANCE	Inactivation and silencing of PTEN have been observed in multiple cancers, including follicular thyroid carcinoma. PTEN (phosphatase and tensin homologue deleted from chromosome 10) functions as a tumour suppressor by opposing the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signalling pathway. Despite correlative data, how deregulated PTEN signalling leads to thyroid carcinogenesis is not known. Mice harbouring a dominant-negative mutant thyroid hormone receptor beta (TR beta(PV/PV) mice) spontaneously develop follicular thyroid carcinoma and distant metastases similar to human cancer. To elucidate the role of PTEN in thyroid carcinogenesis, we generated TR beta(PV/PV) mice haploinsufficient for Pten (TR beta(PV/PV)Pten(+/-) mouse). PTEN deficiency accelerated the progression of thyroid tumour and increased the occurrence of metastasis spread to the lung in TR beta(PV/PV)Pten(+/-) mice, thereby significantly reducing their survival as compared with TR beta(PV/PV)Pten(+/+) mice. AKT activation was further increased by two-fold in TR beta(PV/PV)Pten(+/-) mice thyroids, leading to increased activity of the downstream mammalian target of rapamycin (mTOR)-p70S6K signalling and decreased activity of the forkhead family member FOXO3a. Consistently, cyclin D1 expression was increased. Apoptosis was decreased as indicated by increased expression of nuclear factor-kappa B (NF-kappa B) and decreased caspase-3 activity in the thyroids of TR beta(PV/PV)Pten(+/-) mice. Our results indicate that PTEN deficiency resulted in increased cell proliferation and survival in the thyroids of TR beta(PV/PV)Pten(+/-) mice. Altogether, our study provides direct evidence to indicate that in vivo, PTEN is a critical regulator in the follicular thyroid cancer progression and invasiveness.	[Cheng, S-Y] NCI, Gene Regulat Sect, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Gene Regulat Sect, Mol Biol Lab, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov	guigon, celine/L-3518-2017	guigon, celine/0000-0002-4489-4304	Center for Cancer Research; National Cancer Institute; National Institutes of Health; NATIONAL CANCER INSTITUTE [ZIABC011191, ZIABC008752] Funding Source: NIH RePORTER	Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	;We thank Dr Hao Ying for assistance in the determination of thyroid function tests. This research was supported by the Intramural Research Program of Center for Cancer Research, National Cancer Institute, National Institutes of Health.	ABDELLATIF MM, 2008, J SURG RES IN PRESS; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eng C, 2002, ANN NY ACAD SCI, V968, P213, DOI 10.1111/j.1749-6632.2002.tb04337.x; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Furuya F, 2007, CARCINOGENESIS, V28, P2451, DOI 10.1093/carcin/bgm174; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kim CS, 2005, ENDOCRINOLOGY, V146, P4456, DOI 10.1210/en.2005-0172; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001237; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rivas M, 2003, MOL CELL ENDOCRINOL, V213, P31, DOI 10.1016/j.mce.2003.10.029; Schlumberger M, 1998, PRESSE MED, V27, P1479; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shepherd PR, 1997, DIABETOLOGIA, V40, P1172, DOI 10.1007/s001250050803; Sherman SI, 1998, CANCER-AM CANCER SOC, V83, P1012; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Uppal S, 2007, INT J CLIN PRACT, V61, P645, DOI 10.1111/j.1742-1241.2006.00896.x; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111	37	73	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					509	517		10.1038/onc.2008.407	http://dx.doi.org/10.1038/onc.2008.407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997818	Green Accepted			2022-12-17	WOS:000262866500005
J	Aranda, V; Nolan, ME; Muthuswamy, SK				Aranda, V.; Nolan, M. E.; Muthuswamy, S. K.			Par complex in cancer: a regulator of normal cell polarity joins the dark side	ONCOGENE			English	Review						polarity; cancer; ErbB2; Par6; aPKC	PROTEIN-KINASE-C; VON-HIPPEL-LINDAU; TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL TIGHT JUNCTION; HUMAN-BREAST-CANCER; MESENCHYMAL TRANSITION; APICAL LOCALIZATION; DOWN-REGULATION; CDC42 CONTROLS; ACTS UPSTREAM	In the past 20 years, the discovery and characterization of the molecular machinery that controls cellular polarization have enabled us to achieve a better understanding of many biological processes. Spatial asymmetry or establishment of cell polarity during embryogenesis, epithelial morphogenesis, neuronal differentiation, and migration of fibroblasts and T cells are thought to rely on a small number of evolutionarily conserved proteins and pathways. Correct polarization is crucial for normal cell physiology and tissue homeostasis, and is lost in cancer. Thus, cell polarity signaling is likely to have an important function in tumor progression. Recent findings have identified a regulator of cell polarity, the Par complex, as an important signaling node in tumorigenesis. In normal cell types, the Par complex is part of the molecular machinery that regulates cell polarity and maintains normal cell homeostasis. As such, the polarity regulators are proposed to have a tumor suppressor function, consistent with the loss of polarity genes associated with hyperproliferation in Drosophila melanogaster. However, recent studies showing that some members of this complex also display pro-oncogenic activities suggest a more complex regulation of the polarity machinery during cellular transformation. Here, we examine the existing data about the different functions of the Par complex. We discuss how spatial restriction, binding partners and substrate specificity determine the signaling properties of Par complex proteins. A better understanding of these processes will very likely shed some light on how the Par complex can switch from a normal polarity regulation function to promotion of transformation downstream of oncogenes.	[Aranda, V.; Nolan, M. E.; Muthuswamy, S. K.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Muthuswamy, SK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	muthuswa@cshl.edu	Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634	NCI NIH HHS [R01 CA098830-05A2, R56 CA098830, R01 CA098830] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA098830, R01CA098830] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson DC, 2008, SCIENCE, V320, P1771, DOI 10.1126/science.1156063; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bialucha CU, 2007, J CELL BIOL, V178, P575, DOI 10.1083/jcb.200612022; Bilder D, 2003, CURR BIOL, V13, pR661, DOI 10.1016/S0960-9822(03)00599-2; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bose R, 2006, CURR OPIN CELL BIOL, V18, P206, DOI 10.1016/j.ceb.2006.02.005; Cai Y, 2005, ONCOGENE, V24, P4293, DOI 10.1038/sj.onc.1208593; Calzada MJ, 2006, CANCER RES, V66, P1553, DOI 10.1158/0008-5472.CAN-05-3236; Cau JL, 2005, J CELL SCI, V118, P2579, DOI 10.1242/jcs.02385; Chabu C, 2008, DEVELOPMENT, V135, P2739, DOI 10.1242/dev.024059; Chen XY, 2006, J CELL BIOL, V172, P671, DOI 10.1083/jcb.200510061; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Donson AM, 2000, J NEURO-ONCOL, V47, P109, DOI 10.1023/A:1006406208376; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2008, FRONT BIOSCI-LANDMRK, V13, P6520, DOI 10.2741/3172; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Farooqui R, 2006, EXP CELL RES, V312, P1514, DOI 10.1016/j.yexcr.2006.01.018; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; Fields Alan P, 2003, Methods Mol Biol, V233, P539; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Fleming TP, 2000, SEMIN CELL DEV BIOL, V11, P291, DOI 10.1006/scdb.2000.0179; Gao L, 2004, J BIOL CHEM, V279, P41557, DOI 10.1074/jbc.M403723200; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; Gerard A, 2007, J CELL BIOL, V176, P863, DOI 10.1083/jcb.200608161; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Grifoni D, 2007, ONCOGENE, V26, P5960, DOI 10.1038/sj.onc.1210389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Hirose T, 2002, J CELL SCI, V115, P2485; Horne-Badovinac S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040008; Hoshino M, 2005, J BIOL CHEM, V280, P22868, DOI 10.1074/jbc.M411592200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007; Hurov J, 2007, CELL CYCLE, V6, P1966, DOI 10.4161/cc.6.16.4576; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Ji QZ, 2008, BIOCHEM CELL BIOL, V86, P227, DOI [10.1139/O08-035, 10.1139/o08-035]; Jin YT, 2008, ONCOL RES, V17, P59, DOI 10.3727/096504008784523630; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kay AJ, 2001, CURR BIOL, V11, P474, DOI 10.1016/S0960-9822(01)00141-5; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kim M, 2007, J CELL SCI, V120, P2309, DOI 10.1242/jcs.007443; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Kuehn EW, 2007, CANCER RES, V67, P4537, DOI 10.1158/0008-5472.CAN-07-0391; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Kuribayashi K, 2007, J CELL BIOL, V176, P1049, DOI 10.1083/jcb.200607019; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Li ZH, 2008, J CELL BIOL, V180, P31, DOI 10.1083/jcb.200707007; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Martin-Belmonte F, 2007, CELL CYCLE, V6, P1957, DOI 10.4161/cc.6.16.4583; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscat J, 2006, CELL DEATH DIFFER, V13, P702, DOI 10.1038/sj.cdd.4401823; Munro EM, 2006, CURR OPIN CELL BIOL, V18, P86, DOI 10.1016/j.ceb.2005.12.007; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagai-Tamai Y, 2002, GENES CELLS, V7, P1161, DOI 10.1046/j.1365-2443.2002.00590.x; Nakayama M, 2008, DEV CELL, V14, P205, DOI 10.1016/j.devcel.2007.11.021; Nance J, 2003, DEVELOPMENT, V130, P5339, DOI 10.1242/dev.00735; Nishimura T, 2005, NAT CELL BIOL, V7, P270, DOI 10.1038/ncb1227; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; NOLAN ME, 2008, CANCER RES, V68, P1; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Peterson FC, 2004, MOL CELL, V13, P665, DOI 10.1016/S1097-2765(04)00086-3; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Regala RP, 2008, CANCER RES, V68, P5888, DOI 10.1158/0008-5472.CAN-08-0438; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, NEW ENGL J MED, V317, P955, DOI 10.1056/NEJM198710083171509; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sotillos S, 2004, J CELL BIOL, V166, P549, DOI 10.1083/jcb.200311031; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Townsend TA, 2008, J BIOL CHEM, V283, P13834, DOI 10.1074/jbc.M710607200; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Tsuruga T, 2007, ONCOL RES, V16, P431, DOI 10.3727/000000007783980855; Underwood JM, 2006, J CELL PHYSIOL, V208, P141, DOI 10.1002/jcp.20639; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wang Q, 2004, J BIOL CHEM, V279, P30715, DOI 10.1074/jbc.M401930200; Wang XY, 2008, BBA-MOL BASIS DIS, V1782, P51, DOI 10.1016/j.bbadis.2007.11.002; Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089; Weyrich P, 2007, MOL CELL ENDOCRINOL, V268, P30, DOI 10.1016/j.mce.2007.01.011; Weyrich P, 2004, MOL ENDOCRINOL, V18, P1287, DOI 10.1210/me.2003-0253; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Xiang B, 2006, METHOD ENZYMOL, V406, P692, DOI 10.1016/S0076-6879(06)06054-X; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Yamanaka T, 2008, FRONT BIOSCI-LANDMRK, V13, P6693, DOI 10.2741/3182; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yi P, 2008, MOL CELL, V29, P465, DOI 10.1016/j.molcel.2007.12.030; Zhang HY, 2008, DEV CELL, V14, P216, DOI 10.1016/j.devcel.2007.11.020; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	138	73	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6878	6887		10.1038/onc.2008.340	http://dx.doi.org/10.1038/onc.2008.340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029931	Green Accepted			2022-12-17	WOS:000261108200002
J	Kitagawa, M; Aonuma, M; Lee, SH; Fukutake, S; McCormick, F				Kitagawa, M.; Aonuma, M.; Lee, S. H.; Fukutake, S.; McCormick, F.			E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines	ONCOGENE			English	Article						E2F-1; p53; Mdm2 antagonist; apoptosis; Nutlin-3	S-PHASE ENTRY; P53 PATHWAY; P53-DEPENDENT APOPTOSIS; P73; ACTIVATION; EXPRESSION; INDUCTION; P14(ARF); NUTLIN-3; LEADS	Nutlin-3 is a selective inhibitor of the p53-Mdm2 interaction, and inhibits growth in most tumor cells with wild-type p53. However, it only induces apoptosis in subsets of tumor cells. We report that the apoptotic response induced by Nutlin-3 correlates with its antitumor effects in xenograft models in athymic mice. We have investigated signals that sensitize cells to undergo apoptosis induced by Nutlin-3. We demonstrate that adenovirus E1A increases Nutlin-3-induced apoptosis through pRb inhibition in mouse embryonic fibroblast cells in a p53-dependent manner. Consistent with this, pRb depletion by siRNA transfection with Nutlin-3 synergistically increases apoptosis in HCT116 human colon cancer cells, which are insensitive to induction of apoptosis by Nutlin-3 alone. As pRb is a key negative regulator of E2F, we asked whether E2F transcriptional activity determines the apoptotic response of cancer cells to Nutlin-3. We demonstrate that transcriptional activity of E2F correlates with the apoptotic response to Nutlin-3 in various tumor cells and depletion of E2F-1 suppresses Nutlin-3-induced apoptosis in cells possessing high transcriptional activity of E2F, including retinoblastoma cells harboring mutated Rb with wild-type p53. Furthermore, we report that expression of the p53 homologue p73, a target of E2F-1, is markedly increased by Nutlin-3 in Rb-mutated tumor cells harboring wild-type p53. Depletion of p73 by siRNA transfection suppresses Nutlin-3-induced apoptosis in these cells. Taken together, our results demonstrate that E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis and p73 is important for E2F-1-mediated apoptosis induced by Nutlin-3, especially in tumor cells with mutated Rb. Furthermore, our results suggest that tumor cells, including Rb mutated cells, which harbor wildtype p53 and high E2F transcriptional activity, could be a good target for Mdm2 antagonist therapy.	[Kitagawa, M.; Lee, S. H.; McCormick, F.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA; [Kitagawa, M.; Lee, S. H.; McCormick, F.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; [Kitagawa, M.; Aonuma, M.; Fukutake, S.] Daiichi Sankyo Co Ltd, Kasai R&D Ctr, Tokyo, Japan	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; Daiichi Sankyo Company Limited	McCormick, F (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 2340 Sutter St N315,UCSF Box 0128, San Francisco, CA 94115 USA.	mccormick@cc.ucsf.edu						Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nicholson SA, 2001, CANCER RES, V61, P5636; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Putzer BM, 2000, CELL DEATH DIFFER, V7, P177, DOI 10.1038/sj.cdd.4400618; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Secchiero P, 2006, BLOOD, V107, P4122, DOI 10.1182/blood-2005-11-4465; Semizarov D, 2004, NUCLEIC ACIDS RES, V32, P3836, DOI 10.1093/nar/gkh714; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	31	73	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5303	5314		10.1038/onc.2008.164	http://dx.doi.org/10.1038/onc.2008.164			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18521084				2022-12-17	WOS:000259096100003
J	Omerovic, J; Hammond, DE; Clague, MJ; Prior, IA				Omerovic, J.; Hammond, D. E.; Clague, M. J.; Prior, I. A.			Ras isoform abundance and signalling in human cancer cell lines	ONCOGENE			English	Article						Ras; siRNA; Akt; HGF; EGF	K-RAS; GROWTH-FACTOR; H-RAS; N-RAS; CARCINOMA-CELLS; ERK ACTIVITY; PROLIFERATION; ACTIVATION; PROTEINS; PATHWAY	The ubiquitously expressed major Ras isoforms: H-, K- and N-Ras, are highly conserved, yet exhibit different biological outputs. We have compared the relative efficiencies with which epidermal or hepatocyte growth factor activates Ras isoforms and the requirement for specific isoforms in the activation of downstream pathways. We find that the relative coupling efficiencies to each Ras isoform are conserved between stimuli. Furthermore, in both cases, inhibition of receptor endocytosis led to reduced N- and H- Ras activation, but K- Ras was unaffected. Acute knockdown of each isoform with siRNA allows endogenous Ras isoform function and abundance to be probed. This revealed that there is significant variation in the contribution of individual isoforms to total Ras across a panel of cancer cell lines although typically K >= N >= H. Intriguingly, cancer cell lines where a significant fraction of endogenous Ras is oncogenically mutated showed attenuated activation of canonical Ras effector pathways. We pro. led the contribution of each Ras isoform to the total Ras pool allowing interpretation of the effect of isoform-specific knockdown on signalling outcomes. In contrast to previous studies indicating preferential coupling of isoforms to Raf and PtdIns-3-kinase pathways, we find that endogenous Ras isoforms show no specific coupling to these major Ras pathways.	[Omerovic, J.; Hammond, D. E.; Clague, M. J.; Prior, I. A.] Univ Liverpool, Dept Physiol, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Prior, IA (corresponding author), Univ Liverpool, Dept Physiol, Crown St,POB 147, Liverpool L69 3BX, Merseyside, England.	iprior@liverpool.ac.uk	Omerovic, Jasminka/D-4998-2017; Clague, Michael J/A-7199-2008	Clague, Michael J/0000-0003-3355-9479; Prior, Ian/0000-0002-4055-5161; Hammond, Dean/0000-0002-6326-8739	Cancer Research UK [A6672] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BOS JL, 1989, CANCER RES, V49, P4682; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; ELHASHIR SM, 2001, NATURE, V411, P494; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Iida M, 1999, LEUKEMIA, V13, P585, DOI 10.1038/sj.leu.2401369; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Mitin NY, 2004, J BIOL CHEM, V279, P22353, DOI 10.1074/jbc.M312867200; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; *SANG, DAT WAS OBT WELLC TR; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3; Sharpe CC, 2000, J AM SOC NEPHROL, V11, P1600, DOI 10.1681/ASN.V1191600; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VIERA AV, 1996, SCIENCE, V274, P2086; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243	34	73	75	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2754	2762		10.1038/sj.onc.1210925	http://dx.doi.org/10.1038/sj.onc.1210925			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998936	Green Accepted			2022-12-17	WOS:000255259500010
J	Zantl, N; Weirich, G; Zall, H; Seiffert, BM; Fischer, SF; Kirschnek, S; Hartmann, C; Fritsch, RM; Gillissen, B; Daniel, PT; Hacker, G				Zantl, N.; Weirich, G.; Zall, H.; Seiffert, B. M.; Fischer, S. F.; Kirschnek, S.; Hartmann, C.; Fritsch, R. M.; Gillissen, B.; Daniel, P. T.; Haecker, G.			Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance	ONCOGENE			English	Article						renal cell carcinoma; apoptosis; Bim; Bcl-2; expression	BCL-2 FAMILY-MEMBER; BH3-ONLY PROTEINS; MITOCHONDRIAL-MEMBRANE; MALIGNANT-DISEASE; BH3 DOMAINS; DEATH; BAX; PATHWAY; PUMA; GENE	Renal cell carcinoma (RCC) is resistant to chemotherapy, and this resistance is mirrored by a high apoptosis resistance of many RCC lines in vitro. Here, we report the loss of the pro-apoptotic BH3-only protein Bim in a large part of clinical RCC cases and provide evidence for a functional relevance of this loss. Immunohistochemistry of clear cell renal cell carcinoma cases and corresponding normal kidney showed strong Bim reactivity in renal tubules of all cases but loss of Bim in 35 of 45 RCC samples. Out of nine RCC cell lines investigated, six showed strongly diminished or undetectable levels of Bim protein by western blotting. Four RCC lines of varying apoptosis sensitivity were analysed further. Bcl-2, Bcl-x(L), Mcl-1, Bax and Bak expression did not correlate with apoptosis sensitivity. All cell lines underwent apoptosis upon forced expression of Bax and Bim, suggesting an upstream difference. In all four lines, adriamycin induced p53 but not its targets Puma or Noxa. However, apoptosis sensitivity correlated with levels of Bim protein. Bim siRNA reduced apoptosis sensitivity in a susceptible cell line. Furthermore, inhibition of histone deacetylation restored Bim expression in cell lines. These data suggest that Bim has a function as a tumor suppressor in RCC.	Tech Univ Munich, Inst Med Microbiol, D-81675 Munich, Germany; Tech Univ Munich, Dept Urol, D-81675 Munich, Germany; Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany; Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hacker, G (corresponding author), Tech Univ Munich, Inst Med Microbiol, Trogerstr 9, D-81675 Munich, Germany.	hacker@lrz.tum.de		Fritsch, Ralph/0000-0001-9639-3213; Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Coultas L, 2005, EMBO J, V24, P3963, DOI 10.1038/sj.emboj.7600857; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Fischer SF, 2001, INFECT IMMUN, V69, P7121, DOI 10.1128/IAI.69.11.7121-7129.2001; Gerhard MC, 2003, BRIT J CANCER, V89, P2147, DOI 10.1038/sj.bjc.6601436; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gurova KV, 2004, CANCER RES, V64, P1951, DOI 10.1158/0008-5472.CAN-03-1541; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang A, 1999, J UROLOGY, V162, P610, DOI 10.1016/S0022-5347(05)68635-1; Janzen NK, 2003, UROL CLIN N AM, V30, P843, DOI 10.1016/S0094-0143(03)00056-9; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kallio JP, 2004, J UROLOGY, V172, P2158, DOI 10.1097/01.ju.0000144334.97639.bf; Kane RC, 2006, CLIN CANCER RES, V12, P7271, DOI 10.1158/1078-0432.CCR-06-1249; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kolenko V, 1999, CANCER RES, V59, P2838; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Mickisch GHJ, 2002, BJU INT, V89, P488, DOI 10.1046/j.1464-410X.2002.02654.x; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Phillips JL, 2001, GENE CHROMOSOME CANC, V31, P1, DOI 10.1002/gcc.1111; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	53	73	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7038	7048		10.1038/sj.onc.1210510	http://dx.doi.org/10.1038/sj.onc.1210510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486061				2022-12-17	WOS:000250412200009
J	Liu, H; Zhou, Y; Boggs, SE; Belinsky, SA; Liu, J				Liu, H.; Zhou, Y.; Boggs, S. E.; Belinsky, S. A.; Liu, J.			Cigarette smoke induces demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by downregulation of DNMT3B	ONCOGENE			English	Article						synuclein-gamma; DNA methylation; DNMT3B; cigarette smoke extract; lung cancer; cell invasion	ABERRANT PROMOTER METHYLATION; HUMAN BREAST-CANCER; DNA METHYLTRANSFERASES; NOVO METHYLATION; PROTEIN-KINASE; GENE; EXPRESSION; HYPERMETHYLATION; HYPOMETHYLATION; IDENTIFICATION	The prometastatic oncogene synuclein-gamma ( SNCG) is not expressed in normal lung tissues, but it is highly expressed in lung tumors. Here, we show that cigarette smoke extract ( CSE) has strong inducing effects on SNCG gene expression in A549 lung cancer cells through demethylation of SNCG CpG island. CSE treatment also augments the invasive capacity of A549 cells in an SNCG-dependent manner. To elucidate the mechanisms underlying the demethylating effects of CSE, we examined expression levels of DNA methyltransferases ( DNMTs), 1, 3A and 3B in CSE-treated cells. We show that the mRNA expression of DNMT3B is specifically downregulated by CSE with a kinetics concurrent to SNCG reexpression. Utilizing siRNA to knockdown DNMT3B expression, we show that inhibition of DNMT3B directly increases SNCG mRNA expression. We further show that exogenous overexpression of DNMT3B in an SNCG-positive lung cancer cell line H292 suppresses SNCG mRNA and protein expression and induces de novo methylation of SNCG CpG island, whereas overexpression of DNMT1 or DNMT3A has no effects. Taken together, these new. findings demonstrate that tobacco exposure induces the abnormal expression of SNCG in lung cancer cells through downregulation of DNMT3B. This work sheds light on the molecular understanding of demethylation of this oncogene during cancer progression.	Palo Alto Hlth Care Syst, Dept Vet Affairs, Palo Alto, CA 94304 USA; Lovelace Respriatory Res Inst, Albuquerque, NM USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Lovelace Respiratory Research Institute	Liu, J (corresponding author), Palo Alto Hlth Care Syst, Dept Vet Affairs, 154P,3801 Miranda Ave, Palo Alto, CA 94304 USA.	Jingwen.Liu@med.va.gov						Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BELINSKY SA, 2004, NAT REV CANCER, V4, P11; Brueckner B, 2004, TRENDS PHARMACOL SCI, V25, P551, DOI 10.1016/j.tips.2004.09.004; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CAO D, 2005, MODERN PATHOL, V1, P1; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; Fujiwara K, 2005, CLIN CANCER RES, V11, P1219; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Ji HJ, 1997, CANCER RES, V57, P759; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Li ZK, 2004, CANCER-AM CANCER SOC, V101, P58, DOI 10.1002/cncr.20321; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Loriot A, 2006, J BIOL CHEM, V281, P10118, DOI 10.1074/jbc.M510469200; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Mercer BA, 2004, J BIOL CHEM, V279, P17690, DOI 10.1074/jbc.M313842200; Oka M, 2006, J BIOL CHEM, V281, P9901, DOI 10.1074/jbc.M511100200; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Palmisano WA, 2000, CANCER RES, V60, P5954; Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033; PFEIFER GP, 1986, FEBS LETT, V207, P75, DOI 10.1016/0014-5793(86)80015-1; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Russo AL, 2005, CLIN CANCER RES, V11, P2466, DOI 10.1158/1078-0432.CCR-04-1962; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; THOMPSON E, 1940, DRUG NEWS PERSPECT, V18, P405; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107; Zhao W, 2006, INT J ONCOL, V28, P1081; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	44	73	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5900	5910		10.1038/sj.onc.1210400	http://dx.doi.org/10.1038/sj.onc.1210400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369845				2022-12-17	WOS:000249123100007
J	Kurbanov, BM; Fecker, LF; Geilen, CC; Sterry, W; Eberle, J				Kurbanov, B. M.; Fecker, L. F.; Geilen, C. C.; Sterry, W.; Eberle, J.			Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappa B but is related to downregulation of initiator caspases and DR4	ONCOGENE			English	Article						melanoma; apoptosis; TRAIL; TRAIL-R1/DR4; initiator caspases	APOPTOSIS-INDUCING LIGAND; CANCER-CELLS; (TRAIL)-INDUCED APOPTOSIS; DEATH RECEPTORS; MALIGNANT-MELANOMA; CARCINOMA CELLS; IN-VIVO; PROTEASOME; EXPRESSION; OVERCOMES	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention as a novel anticancer agent. However, its efficiency may be diminished by occurring resistance in cancer cells. The mechanisms of TRAIL resistance in melanoma are still unsolved. Here we show for the first time that TRAIL-induced activation of NF-kappa B occurs in apoptosis-sensitive melanoma cell lines through TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4), whereas TRAIL failed to activate nuclear factor kappa B (NF-kappa B) in melanoma cells positive only for TRAIL receptor 2/death receptor 5 (TRAIL-R2/DR5). However, activation of NF-kappa B by TRAIL was not associated with enhanced expression of antiapoptotic factors: cellular FLICE-inhibitory protein (c-FLIP), Bcl-X-L, X-linked inhibitor of apoptosis protein (XIAP), Survivin, Livin. Rather in one of the cell lines, TRAIL induced the downregulation of DR4. In an established cell culture model for TRAIL resistance and regained TRAIL sensitivity, resistance was neither associated with increased NF-kappa B activity by TRAIL nor by an increased expression of antiapoptotic proteins. However, significant downregulation of caspase-8, caspase-10 and of DR4 was characteristic for TRAIL-resistant, DR4-positive melanoma cells, and regained TRAIL sensitivity coincided with re-expression of these factors. Sensitivity was also largely retained after their exogenous overexpression. Thus, initiator caspases and DR4 rather than NF-kappa B may control melanoma cell sensitivity to TRAIL, and strategies, which result in their upregulation, may be useful for enhancement of TRAIL sensitivity.	Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, D-12203 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eberle, J (corresponding author), Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, Hindenburgdamm 30, D-12203 Berlin, Germany.	juergen.eberle@charite.de		Eberle, Jurgen/0000-0001-8533-1519				Bai JR, 2005, CANCER RES, V65, P2344, DOI 10.1158/0008-5472.CAN-04-3502; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chen XF, 2003, CANCER RES, V63, P1059; Di Pietro R, 2004, J CELL PHYSIOL, V201, P331, DOI 10.1002/jcp.20099; Eberle J, 1999, J INVEST DERMATOL, V112, P925, DOI 10.1046/j.1523-1747.1999.00598.x; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Eggert A, 2001, CANCER RES, V61, P1314; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Fecker LF, 2006, J INVEST DERMATOL, V126, P1366, DOI 10.1038/sj.jid.5700192; Fischer U, 2005, CELL DEATH DIFFER, V12, P942, DOI 10.1038/sj.cdd.4401556; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Fulda S, 2006, ONCOGENE, V25, P5125, DOI 10.1038/sj.onc.1209518; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kurbanov BM, 2005, J INVEST DERMATOL, V125, P1010, DOI 10.1111/j.0022-202X.2005.23900.x; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Li-Weber M, 2003, SEMIN IMMUNOL, V15, P145, DOI 10.1016/S1044-5323(03)00030-7; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Ravi R, 2004, DRUG RESIST UPDATE, V7, P53, DOI 10.1016/j.drup.2004.01.003; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Secchiero P, 2003, J LEUKOCYTE BIOL, V74, P223, DOI 10.1189/jlb.0103004; Singh TR, 2003, CANCER RES, V63, P5390; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SH, 2004, ONCOGENE, V23, P928, DOI 10.1038/sj.onc.1207213; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Zauli G, 2005, J CELL PHYSIOL, V202, P900, DOI 10.1002/jcp.20202; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zhang XD, 2006, CLIN CANCER RES, V12, P1355, DOI 10.1158/1078-0432.CCR-05-2084; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897	52	73	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3364	3377		10.1038/sj.onc.1210134	http://dx.doi.org/10.1038/sj.onc.1210134			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17160022				2022-12-17	WOS:000246579600006
J	Timofeeva, OA; Plisov, S; Evseev, AA; Peng, S; Jose-Kampfner, M; Lovvorn, HN; Dome, JS; Perantoni, AO				Timofeeva, O. A.; Plisov, S.; Evseev, A. A.; Peng, S.; Jose-Kampfner, M.; Lovvorn, H. N.; Dome, J. S.; Perantoni, A. O.			Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis	ONCOGENE			English	Article						serine 727; STAT1; protein kinase CK2; MCL-1; HSP27; Wilms' tumor	PROTEIN-KINASE CK2; CHRONIC LYMPHOCYTIC-LEUKEMIA; TARGET GENE-EXPRESSION; SIGNAL TRANSDUCER; IFN-GAMMA; INTERFERON-GAMMA; INDUCED APOPTOSIS; CASEIN KINASE-2; CANCER-THERAPY; CELL LYMPHOMA	Wilms' tumor (WT), one of the most common pediatric solid cancers, arises in the developing kidney as a result of genetic and epigenetic changes that lead to the abnormal proliferation and differentiation of the metanephric blastema. As activation of signal transducers and activators of transcription (STATs) plays an important role in the maintenance/growth and differentiation of the metanephric blastema, and constitutively activated STATs facilitate neoplastic behaviors of a variety of cancers, we hypothesized that dysregulation of STAT signaling may also contribute to WT pathogenesis. Accordingly, we evaluated STAT phosphorylation patterns in tumors and found that STAT1 was constitutively phosphorylated on serine 727 (S727) in 19 of 21 primary WT samples and two WT cell lines. An inactivating mutation of S727 to alanine reduced colony formation of WT cells in soft agar by more than 80% and induced apoptosis under conditions of growth stress. S727-phosphorylated STAT1 provided apoptotic resistance for WT cells via upregulation of expression of the heat-shock protein (HSP) 27 and antiapoptotic protein myeloid cell leukemia (MCL)-1. The kinase responsible for STAT1 S727 phosphorylation in WT cells was identified based upon the use of selective inhibitors as protein kinase CK2, not p38, MAP-kinase kinase (MEK)1/2, phosphatidylinositol 3'-kinase, protein kinase C or Ca/calmodulin-dependent protein kinase II (CaMKII). The inhibition of CK2 blocked the anchorage-independent growth of WT cells and induced apoptosis under conditions of growth stress. Our findings suggest that serine-phosphorylated STAT1, as a downstream target of protein kinase CK2, plays a critical role in the pathogenesis of WT and possibly other neoplasms with similar STAT1 phosphorylation patterns.	NCI, Lab Comparat Carcinogenesis, Canc Res Ctr, Frederick, MD 21702 USA; Vanderbilt Univ, Dept Pediat Surg, Nashville, TN USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; St Jude Children's Research Hospital	Perantoni, AO (corresponding author), NCI, Lab Comparat Carcinogenesis, Canc Res Ctr, 1050 Boyless St,Bldg 538,R 205E, Frederick, MD 21702 USA.	peranton@ncifcrf.gov	Dome, Jeffrey/AAH-7825-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005093, ZIABC005093] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Friedberg JW, 2004, LEUKEMIA RES, V28, P139, DOI 10.1016/S0145-2126(03)00213-3; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj.onc.1205341; Hudelist G, 2005, CANCER GENET CYTOGEN, V158, P35, DOI 10.1016/j.cancergencyto.2004.08.007; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kabakov AE, 2003, CELL STRESS CHAPERON, V8, P335, DOI 10.1379/1466-1268(2003)008<0335:HSPOHS>2.0.CO;2; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100; Koesters R, 1999, CANCER RES, V59, P3880; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Koshikawa N, 2006, ONCOGENE, V25, P917, DOI 10.1038/sj.onc.1209128; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin WS, 2004, J NEUROSCI, V24, P10074, DOI 10.1523/JNEUROSCI.2604-04.2004; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; Maiti S, 2000, CANCER RES, V60, P6288; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nishiu M, 2002, JPN J CANCER RES, V93, P894, DOI 10.1111/j.1349-7006.2002.tb01335.x; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Packham G, 2005, IMMUNOLOGY, V114, P441, DOI 10.1111/j.1365-2567.2005.02117.x; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Plisov SY, 2001, DEVELOPMENT, V128, P1045; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Rigolet M, 2001, PEDIATR NEPHROL, V16, P1113, DOI 10.1007/s004670100040; Roberts D, 2005, BRIT J CANCER, V92, P1149, DOI 10.1038/sj.bjc.6602447; Ruteshouser EC, 2004, AM J MED GENET C, V129C, P29, DOI 10.1002/ajmg.c.30025; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Sarto C, 2004, PROTEOMICS, V4, P2252, DOI 10.1002/pmic.200300797; Seldin DC, 2005, MOL CELL BIOCHEM, V274, P63, DOI 10.1007/s11010-005-3078-0; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Spiekermann K, 2001, EUR J HAEMATOL, V67, P63, DOI 10.1034/j.1600-0609.2001.t01-1-00385.x; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Terui K, 2004, BIOCHEM J, V380, P203, DOI 10.1042/BJ20031891; Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wang GX, 2005, MOL CELL BIOCHEM, V274, P77, DOI 10.1007/s11010-005-3077-1; Widschwendter A, 2002, CLIN CANCER RES, V8, P3065; Xu WF, 2005, J INTERF CYTOK RES, V25, P113, DOI 10.1089/jir.2005.25.113; Yu J, 2004, CURR OPIN GENET DEV, V14, P550, DOI 10.1016/j.gde.2004.07.009; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zien P, 2005, BBA-PROTEINS PROTEOM, V1754, P271, DOI 10.1016/j.bbapap.2005.07.039; Zykova TA, 2005, CARCINOGENESIS, V26, P331, DOI 10.1093/carcin/bgh334	70	73	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7555	7564		10.1038/sj.onc.1209742	http://dx.doi.org/10.1038/sj.onc.1209742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16799645				2022-12-17	WOS:000242655500001
J	Deniaud, E; Baguet, J; Mathieu, AL; Pages, G; Marvel, J; Leverrier, Y				Deniaud, E.; Baguet, J.; Mathieu, A-L; Pages, G.; Marvel, J.; Leverrier, Y.			Overexpression of Sp1 transcription factor induces apoptosis	ONCOGENE			English	Article						apoptosis; Sp1; transcription factor	ENDOTHELIAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; CELL-GROWTH; BCL-X; HEMATOPOIETIC-CELLS; GASTRIC-CANCER; S-PHASE; EXPRESSION; INDUCTION; GENE	Transcription factor Sp1 has recently been shown to be overexpressed in a number of human cancers and its overexpression contributes to malignant transformation. Sp1 regulates the expression of a number of genes participating in multiple aspects of tumorigenesis such as angiogenesis, cell growth and apoptosis resistance. To better understand the role of increased Sp1 levels on apoptosis regulation we have used retroviruses to overexpress this protein in haematopoietic Baf-3 cells and in 3T3 fibroblasts. We have also used inducible expression systems to control ectopic Sp1 levels in different cell types. Surprisingly, Sp1 overexpression on its own induces apoptosis in all the cellular models tested. The apoptotic pathways induced by Sp1 overexpression are cell type specific. Finally, using a truncated form of Sp1, we show that Sp1-induced apoptosis requires its DNA-binding domain. Our results highlight that Sp1 levels in untransformed cells must be tightly regulated as Sp1 overexpression leads to the induction of apoptosis. Our results also suggest that cancer cells overexpressing Sp1 can avoid Sp1-induced apoptosis.	Inserm U503, F-69007 Lyon, France; BioSci Lyon Gerland, IFR 128, Lyon, France; Univ Lyon 1, F-69365 Lyon, France; Univ Nice Sophia Antipolis, CNRS, UMR 6543, Ctr Antoine Lacassagne, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Marvel, J (corresponding author), Inserm U503, 21 Ave Tony Garnier, F-69007 Lyon, France.	marvel@cervi-lyon.inserm.fr; leverrier@cervi-lyon.inserm.fr	LEVERRIER, Yann/M-3767-2014; marvel, jacqueline/H-8638-2014; Deniaud, Emmanuelle/B-9518-2008; Pages, Gilles/N-7135-2017	LEVERRIER, Yann/0000-0002-4227-5446; marvel, jacqueline/0000-0001-6241-459X; Mathieu, Anne-Laure/0000-0002-2893-7001				Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Chae YM, 2004, BIOCHEM BIOPH RES CO, V319, P550, DOI 10.1016/j.bbrc.2004.05.025; Chen F, 2000, ANTICANCER RES, V20, P661; Chiefari E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-35; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Demeret C, 2003, ONCOGENE, V22, P168, DOI 10.1038/sj.onc.1206108; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; French SW, 2003, J BIOL CHEM, V278, P948, DOI 10.1074/jbc.M207166200; Gala S, 2001, BLOOD, V97, P227, DOI 10.1182/blood.V97.1.227; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Heinrich J, 2000, J MOL MED-JMM, V78, P380, DOI 10.1007/s001090000116; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Ishibashi H, 2000, CANCER RES, V60, P6531; Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200; Kavurma MM, 2003, J BIOL CHEM, V278, P32537, DOI 10.1074/jbc.M305650200; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kumar A, 2003, MOL CELL BIOL, V23, P6631, DOI 10.1128/MCB.23.18.6631-6645.2003; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Lietard J, 1997, AM J PATHOL, V151, P1663; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Lomberk G, 2005, BIOCHEM J, V392, P1, DOI 10.1042/BJ20051234; Lou Z, 2005, CANCER RES, V65, P1007; Low W, 2001, ONCOGENE, V20, P4476, DOI 10.1038/sj.onc.1204580; Mangeney M, 1996, ONCOGENE, V13, P1441; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Mathieu AL, 2001, J BIOL CHEM, V276, P10935, DOI 10.1074/jbc.M007147200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Munoz-Pinedo C, 2001, BIOCHEM J, V353, P101, DOI 10.1042/bj3530101; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Preston GA, 1996, MOL CELL BIOL, V16, P211; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Ryu H, 2003, J NEUROSCI, V23, P3597; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Shi Q, 2001, CANCER RES, V61, P4143; SHORT ML, 1994, BIOCHEM J, V304, P391, DOI 10.1042/bj3040391; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahara T, 2000, J BIOL CHEM, V275, P38067, DOI 10.1074/jbc.M002010200; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zannetti A, 2000, CANCER RES, V60, P1546	54	73	77	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2006	25	53					7096	7105		10.1038/sj.onc.1209696	http://dx.doi.org/10.1038/sj.onc.1209696			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715126				2022-12-17	WOS:000241910500009
J	Tan, M; Li, P; Sun, M; Yin, G; Yu, D				Tan, M.; Li, P.; Sun, M.; Yin, G.; Yu, D.			Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCa and Src inhibitors	ONCOGENE			English	Article						breast cancer; invasion; metastasis; Src; PKC alpha; ErbB2	PROTEIN-KINASE-C; TUMOR PROGRESSION; FAMILY KINASES; EXPRESSION; OVEREXPRESSION; METASTASIS; THERAPY; PHOSPHORYLATION; TRANSFORMATION; INVASIVENESS	Although ErbB2 is known to enhance breast cancer metastasis, the signaling events responsible for this remain elusive. alpha-Isozyme of protein kinase C (PKC alpha), which is involved in cancer development and progression, has been suggested to be activated by ErbB2 without direct evidence. In addition, the roles of PKC alpha in ErbB2-mediated cancer cell malignancy have not been clearly identifed. In this study, we investigated whether ErbB2 can activate PKC alpha and determined what role PKCa plays in ErbB2-mediated breast cancer cell invasion. We expressed wild-type and mutant ErbB2 with altered signaling capacities in MDA-MB-435 breast cancer cells and revealed that overexpression or activation of ErbB2 in MDA-MB-435 cells upregulated and activated PKC alpha and that downregulation of ErbB2by small-interfering RNA decreased the expression and activity of PKC alpha in BT474 breast cancer cells. These in vitro results were supported by data from breast cancer patient samples. In 150 breast cancer tumor samples, ErbB2-overexpressing tumors showed significantly higher positive rates of PKCa membrane immunohistochemistry staining than that of ErbB2-low-expressing tumors. Mechanistically, we found that PKC alpha is co-immunoprecipitated with Src and PKC alpha expression and activity can be decreased by Src inhibitor PP2 and by the expression of a dominantnegative mutant of Src. Moreover, ErbB2-mediated upregulation of urokinase-type plasminogen activator receptor (uPAR) is reduced by either the PKC alpha inhibitor Go6976 or the Src inhibitor PP2, and the combination of Go6976 with PP2 is superior to either agent alone in suppressing uPAR expression and cell invasion. These results demonstrate that PKC alpha is critical for ErbB2-mediated cancer cell invasion and provide valuable insights for current and future PKC alpha and Src inhibitor clinical trials.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, D (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dyu@mdanderson.org	Tan, Ming/ABD-5847-2021; Yin, Guosheng/D-3214-2009	Tan, Ming/0000-0003-2007-9898; Yu, Dihua/0000-0001-6231-9381; Yin, Guosheng/0000-0003-3276-1392	NATIONAL CANCER INSTITUTE [R01CA109570, P01CA099031, R01CA112567, R01CA060488, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [2R01-CA60488, R01-CA112567, 1R01-CA109570, P01-CA099031, P30-CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078-0432.CCR-1565-02; de Bono JS, 2003, BREAST CANCER RES, V5, P154, DOI 10.1186/bcr597; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; GUM R, 1995, ANTICANCER RES, V15, P1167; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279; Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masur K, 2001, MOL BIOL CELL, V12, P1973, DOI 10.1091/mbc.12.7.1973; Michie AM, 2005, IMMUNOL LETT, V96, P155, DOI 10.1016/j.imlet.2004.08.013; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Morse-Gaudio M, 1998, INT J ONCOL, V12, P1349; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Palka HL, 1997, J CELL SCI, V110, P2359; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tan M, 1997, CANCER RES, V57, P1199; VADERGREER P, 1994, ANN REV CELL BIOL, V10, P251; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	39	73	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3286	3295		10.1038/sj.onc.1209361	http://dx.doi.org/10.1038/sj.onc.1209361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407820				2022-12-17	WOS:000237951200007
J	Wen, XZ; Akiyama, Y; Baylin, SB; Yuasa, Y				Wen, XZ; Akiyama, Y; Baylin, SB; Yuasa, Y			Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas	ONCOGENE			English	Article						bone morphogenetic protein 2 (BMP-2); DNA methylation; BMP-2 expression; gastrointestinal carcinoma	HISTONE DEACETYLASE INHIBITION; CPG-ISLAND METHYLATION; ABERRANT METHYLATION; CANCER; PROLIFERATION; BMP-2; DIFFERENTIATION; MUTATIONS; GROWTH; CELLS	Recently, it was reported that exogenous bone morphogenetic protein ( BMP)-2 acted as an antiproliferative agent in a variety of cell lines, including normal and cancerous gastric cell lines, indicating that BMP-2 plays an important role during cell growth. However, despite the loss of BMP-2 expression in several cancers, the underlying mechanism remains unknown. Epigenetic silencing through DNA methylation is one of the key steps during carcinogenesis. In this study, we found, through analysis by the methylation- specific polymerase chain reaction technique, CpG island methylation of the BMP-2 promoter region in gastric and colon cancer cell lines. BMP-2 mRNA was found to be activated after 5-aza-2'-deoxycytidine treatment of the methylation- positive cells. Moreover, 24 of the 56 ( 42.9%) gastric cancer tissues exhibited promoter methylation. Immunohistochemical staining revealed that 18 of the 24 ( 75%) gastric cancer tissues without methylation signals exhibited BMP-2 expression, whereas among 20 cancer tissues with strong methylation signals only four ( 20%) expressed BMP-2 ( P = 0.0003). These findings indicate that BMP-2 methylation is strongly associated with the loss of BMP-2 protein expression in the primary gastric carcinomas. BMP-2 methylation was more often observed in diffuse type ( 60.7%) than in intestinal type ( 25%) gastric carcinomas ( P = 0.007). Thus, aberrant BMP-2 methylation and the resultant loss of BMP-2 expression may be related to gastric carcinogenesis, particularly in the diffuse type.	Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan; Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA	Tokyo Medical & Dental University (TMDU); Johns Hopkins University; Johns Hopkins Medicine	Yuasa, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yuasa.monc@tmd.ac.jp						Abrams KL, 2004, J BIOL CHEM, V279, P15916, DOI 10.1074/jbc.M313531200; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Baylin SB, 1998, ADV CANCER RES, V72, P141; BECKER KF, 1994, CANCER RES, V54, P3845; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dai ZY, 2004, ONCOGENE, V23, P3521, DOI 10.1038/sj.onc.1207441; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067; Hay E, 2000, J CELL PHYSIOL, V183, P117, DOI 10.1002/(SICI)1097-4652(200004)183:1<117::AID-JCP14>3.3.CO;2-R; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Horvath LG, 2004, PROSTATE, V59, P234, DOI 10.1002/pros.10361; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Ide H, 1997, CANCER RES, V57, P5022; Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10; Jeffery TK, 2005, AM J PHYSIOL-LUNG C, V288, pL370, DOI 10.1152/ajplung.00242.2004; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294; Miyazaki H, 2004, ONCOGENE, V23, P9326, DOI 10.1038/sj.onc.1208127; Narita T, 2000, DEVELOPMENT, V127, P981; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Pouliot F, 2002, J ENDOCRINOL, V172, P187, DOI 10.1677/joe.0.1720187; Pu H, 1999, IN VITRO CELL DEV-AN, V35, P488; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Toyota M, 1999, CANCER RES, V59, P5438; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wen XZ, 2004, BIOCHEM BIOPH RES CO, V316, P100, DOI 10.1016/j.bbrc.2004.02.016; Wong GA, 2003, AM J PHYSIOL-ENDOC M, V284, pE972, DOI 10.1152/ajpendo.00385.2002; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	40	73	78	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2666	2673		10.1038/sj.onc.1209297	http://dx.doi.org/10.1038/sj.onc.1209297			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16314833				2022-12-17	WOS:000237099400010
J	Fischer, U; Stroh, C; Schulze-Osthoff, K				Fischer, U; Stroh, C; Schulze-Osthoff, K			Unique and overlapping substrate specificities of caspase-8 and caspase-10	ONCOGENE			English	Article						apoptosis; caspase-10; caspase-8; Bid; RIP	FACTOR-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; DEATH DOMAIN PROTEIN; SIGNALING COMPLEXES; MEDIATED APOPTOSIS; ACTIVATION; CLEAVAGE; RECEPTORS; LYMPHOCYTE; RIP	Although caspase-8 has an established role as an initiator of death receptor-mediated apoptosis, the function of its closest homolog, caspase-10, is almost completely unknown. To gain a closer insight into the physiological function of caspase-10, we compared the cleavage of known caspase-8 substrates by both initiator caspases. We demonstrate that caspase-10 and -8 have overlapping cleavage preferences for several substrates such as the kinases RIP and PAK2. Interestingly, in other substrates, such as the Bcl-2 protein Bid, we found additional and distinct cleavage sites for both caspases, which might have important consequences for mitochondrial targeting and propagation of the death signal. Caspase-8 and -10 also caused different interchain cleavage patterns of their enzyme precursors. Together, these results suggest that caspase-8 and -10, despite having overlapping functions, also have selective substrate cleavage specificities and might thereby exert nonredundant roles in apoptosis signaling.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Fischer, U (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	ute.fischer@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; DEGLIESPOSTI M, 2003, J BIOL CHEM, V278, P15479; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Engels IH, 2005, MOL CELL BIOL, V25, P2808, DOI 10.1128/MCB.25.7.2808-2818.2005; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Koeplinger KA, 2000, PROTEIN EXPRES PURIF, V18, P378, DOI 10.1006/prep.2000.1205; Kruidering M, 2001, J BIOL CHEM, V276, P38417, DOI 10.1074/jbc.M103471200; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Milhas D, 2005, J BIOL CHEM, V280, P19836, DOI 10.1074/jbc.M414358200; Murphy BM, 2004, J BIOL CHEM, V279, P36916, DOI 10.1074/jbc.M402039200; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	45	73	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					152	159		10.1038/sj.onc.1209015	http://dx.doi.org/10.1038/sj.onc.1209015			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16186808				2022-12-17	WOS:000234406400017
J	Krystyniak, A; Garcia-Echeverria, C; Prigent, C; Ferrari, S				Krystyniak, A; Garcia-Echeverria, C; Prigent, C; Ferrari, S			Inhibition of Aurora A in response to DNA damage	ONCOGENE			English	Article						AurA; CDK1; DNA damage; mitosis; phosphorylation	ANAPHASE-PROMOTING COMPLEX; TUMOR AMPLIFIED KINASE; PROTEIN-KINASE; CENTROSOME AMPLIFICATION; MAMMALIAN-CELLS; PHOSPHORYLATION; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; CHECKPOINT	Mitotic kinases are the ultimate target of pathways sensing genotoxic damage and impinging on the cell cycle machinery. Here, we provide evidence that Aurora A (AurA) was inhibited upon generation of double-strand breaks in DNA. We demonstrate that AurA was not downstream of CDK1 and that inhibition of AurA and CDK1 by DNA damage occurred independently. Using a cell line functionally deficient in Chk2, a selective Chk1 inhibitor and siRNA to Chk1, we show that DNA-damage signals were delivered to AurA through a Chk1-dependent pathway. With regard to the molecular mechanism of AurA inhibition, we found that the point mutation Ser342 > Ala rendered AurA resistant to inhibition by DNA damage. By means of two distinct approaches we examined the impact of reconstitution of AurA activity in DNA-damaged cells: (i) transient expression of wild-type and Ser342 > Ala mutant, but not kinase-dead, AurA led to bypass of the DNA damage block; (ii) direct transduction of highly active wt-AurA into G2 arrested cells precisely after induction of DNA damage resulted in mitotic entry. We show that the mechanism through which AurA allowed entry into mitosis was reactivation of CDK1, thus indicating that AurA plays a key role upstream of CDK1. A model depicting the possible role of AurA at the onset of mitosis and upon DNA damage is presented.	Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; Novartis Pharmaceut, Dept Oncol, Basel, Switzerland; Univ Rennes 1, CNRS, UMR6061, Cell Cycle Grp, Rennes, France	University of Zurich; Novartis; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1	Ferrari, S (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	sferrari@imcr.unizh.ch	Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Giet R, 1999, J CELL SCI, V112, P3591; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Maton G, 2003, J BIOL CHEM, V278, P21439, DOI 10.1074/jbc.M300811200; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	42	73	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					338	348		10.1038/sj.onc.1209056	http://dx.doi.org/10.1038/sj.onc.1209056			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158051				2022-12-17	WOS:000234714100002
J	Thornburg, NJ; Kulwichit, W; Edwards, RH; Shair, KHY; Bendt, KM; Raab-Traub, N				Thornburg, NJ; Kulwichit, W; Edwards, RH; Shair, KHY; Bendt, KM; Raab-Traub, N			LMP1 signaling and activation of NF-kappa B in LMP1 transgenic mice	ONCOGENE			English	Article						NF-kappa B; Epstein-Barr virus; LMP1	EPSTEIN-BARR-VIRUS; LATENT INFECTION MEMBRANE-PROTEIN-1; RECEPTOR-ASSOCIATED FACTOR-1; GROWTH-FACTOR RECEPTOR; REED-STERNBERG CELLS; PROTEIN 1 ENGAGES; HODGKINS-DISEASE; NASOPHARYNGEAL CARCINOMA; P53 GENE; EXPRESSION	Transgenic mice expressing Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) under the control of an immunoglobulin heavy-chain promoter and enhancer develop lymphoma at a threefold higher incidence than LMP1-negative mice. In vitro, LMP1 activates numerous signaling pathways including p38, c-Jun N terminal kinase (JNK), phosphatidylinositol 3 kinase (PI3K)/Akt, and NF-kappa B through interactions with tumor necrosis receptor-associated factors (TRAFs). These pathways are frequently activated in EBV-associated malignancies, although their activation cannot be definitively linked to LMP1 expression in vivo. In this study, interactions between LMP1 and TRAFs and the activation of PI3K/Akt, JNK, p38, and NF-kappa B were examined in LMP1 transgenic mice. LMP1 co-immunoprecipitated with TRAFs 1, 2, and 3. Akt, JNK, and p38 were activated in LMP1-positive and -negative splenocytes as well as LMP1-positive and -negative lymphomas. Multiple forms of NF-kappa B were activated in healthy splenocytes from LMP1 transgenic mice, in contrast to healthy splenocytes from LMP1-negative mice. However, in both LMP1-positive and -negative lymphomas, only the oncogenic NF-kappa B c-Rel, was specifically activated. Similarly to EBV-associated malignancies, p53 protein was detected at high levels in the transgenic lymphomas, although mutations were not detected in the p53 gene. These data indicate that NF-kappa B is activated in LMP1-positive healthy splenocytes; however, NF-kappa B c-Rel is specifically activated in both the transgenic lymphomas and in the rare lymphomas that develop in negative mice. The LMP1-mediated activation of NF-kappa B may contribute to the specific activation of c-Rel and lead to the increased development of lymphoma in the LMP1 transgenic mice.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Immunol Microbiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Raab-Traub, N (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Immunol Microbiol, CB 7295,Room 102,Mason Farm Rd, Chapel Hill, NC 27599 USA.	nrt@med.unc.edu		Shair, Kathy Ho Yen/0000-0002-9556-1745; Thornburg, Natalie/0000-0003-3523-3616	NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NCI NIH HHS [CA 19014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Ardila-Osorio H, 1999, INT J CANCER, V81, P645, DOI 10.1002/(SICI)1097-0215(19990517)81:4<645::AID-IJC22>3.0.CO;2-0; ARRAND JR, 1981, NUCLEIC ACIDS RES, V9, P2999, DOI 10.1093/nar/9.13.2999; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BALLERINI P, 1993, BLOOD, V81, P166; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Durkop H, 1999, BLOOD, V93, P617, DOI 10.1182/blood.V93.2.617.402k14_617_623; EDWARDS RH, 1994, J VIROL, V68, P1309, DOI 10.1128/JVI.68.3.1309-1315.1994; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liebowitz D, 1998, NEW ENGL J MED, V338, P1413, DOI 10.1056/NEJM199805143382003; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Murray PG, 2001, J PATHOL, V194, P158, DOI 10.1002/path.873; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Pai S, 2002, J VIROL, V76, P1914, DOI 10.1128/JVI.76.4.1914-1921.2002; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Panagopoulos D, 2004, J VIROL, V78, P13253, DOI 10.1128/JVI.78.23.13253-13261.2004; Stunz LL, 2004, IMMUNITY, V21, P255, DOI 10.1016/j.immuni.2004.07.008; Thornburg NJ, 2003, CANCER RES, V63, P8293; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9	47	73	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					288	297		10.1038/sj.onc.1209023	http://dx.doi.org/10.1038/sj.onc.1209023			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16247482				2022-12-17	WOS:000234583600013
J	Chen, J; Lee, BH; Williams, IR; Kutok, JL; Mitsiades, CS; Duclos, N; Cohen, S; Adelsperger, J; Okabe, R; Coburn, A; Moore, S; Huntly, BJP; Fabbro, D; Anderson, KC; Griffin, JD; Gilliland, DG				Chen, J; Lee, BH; Williams, IR; Kutok, JL; Mitsiades, CS; Duclos, N; Cohen, S; Adelsperger, J; Okabe, R; Coburn, A; Moore, S; Huntly, BJP; Fabbro, D; Anderson, KC; Griffin, JD; Gilliland, DG			FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies	ONCOGENE			English	Article						fibroblast growth factor receptor 3 (FGFR3); multiple myeloma; small molecule tyrosine inhibitor; murine bone marrow transplant (BMT) assay	GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; KINASE INHIBITOR; TYROSINE KINASE; ACTIVATING MUTATIONS; SIGNAL-TRANSDUCTION; IMATINIB MESYLATE; CELL-LINES; TRANSLOCATION; EXPRESSION	Reccurent chromosomal translocation t(4;14) (p16.3;q32.3) occurs in patients with multiple myeloma (MM) and is associated with ectopic overexpression of fibroblast growth factor receptor 3 (FGFR3) that sometimes may contain the activation mutations such as K650E thanatophoric dysplasia type II (TDII). Although there have been significant advances in therapy for MM including the use of proteasome inhibitors, t(4;14) MM has a particularly poor prognosis and most patients still die from complications related to their disease or therapy. One potential therapeutic strategy is to inhibit FGFR3 in those myeloma patients that overexpress the receptor tyrosine kinase due to chromosomal translocation. Here we evaluated PKC412, a small molecule tyrosine kinase inhibitor, for treatment of FGFR3-induced hematopoietic malignancies. PKC412 inhibited kinase activation and proliferation of hematopoietic Ba/F3 cells transformed by FGFR3 TDII or a TEL-FGFR3 fusion. Similar results were obtained in PKC412 inhibition of several different t(4;14)-positive human MM cell lines. Further more, treatment with PKC412 resulted in a statistically significant prolongation of survival in murine bone marrow transplant models of FGFR3 TDII-induced pre-B cell lymphoma, or a peripheral T-cell lymphoma associated TEL-FGFR3 fusion-induced myeloproliferative disease. These data indicate that PKC412 may be a useful molecularly targeted therapy for MM associated with overexpression of FGFR3, and perhaps other diseases associated with dysregulation of FGFR3 or related mutants.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Novartis Pharma AG, Basel, Switzerland	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Emory University; Harvard University; Dana-Farber Cancer Institute; Novartis	Gilliland, DG (corresponding author), Brigham & Womens Hosp, Div Hematol, Childrens Hosp Res Bldg,1 Blackfan Circle,5th Flo, Boston, MA 02115 USA.	ggilliland@rics.bwh.harvard.edu	huntly, brian JP/E-6725-2014; Williams, Ifor R/D-3648-2011	huntly, brian JP/0000-0003-0312-161X; Williams, Ifor R/0000-0002-8810-2911	NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; PHS HHS [P0-1 78378, R01 50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREJAUSKASBUCHDUNGER E, 1992, CANCER RES, V52, P5353; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Bastuji-Garin S, 2002, J INVEST DERMATOL, V119, P1020, DOI 10.1046/j.1523-1747.2002.19502.x; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cavo M, 2000, BLOOD, V96, P355, DOI 10.1182/blood.V96.1.355.013k02_355_357; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chen J, 2005, BLOOD, V106, P328, DOI 10.1182/blood-2004-09-3686; Chen J, 2004, BLOOD, V104, P535, DOI 10.1182/blood-2004-01-0169; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; De Angelo DJ, 2003, BLOOD, V102, p65A; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Estey EH, 2003, BLOOD, V102, p614A; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Golla A, 1997, J MED GENET, V34, P683, DOI 10.1136/jmg.34.8.683; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347; Heffner LT, 2003, DRUGS, V63, P1621, DOI 10.2165/00003495-200363160-00001; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kelly LM, 2002, CANCER CELL, V1, P421, DOI 10.1016/S1535-6108(02)00070-3; Lemoli RM, 2000, BLOOD, V95, P2234, DOI 10.1182/blood.V95.7.2234.007k25_2234_2239; Li ZH, 2001, BLOOD, V97, P2413, DOI 10.1182/blood.V97.8.2413; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Martinelli G, 2000, J CLIN ONCOL, V18, P2273, DOI 10.1200/JCO.2000.18.11.2273; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Paterson JL, 2004, BRIT J HAEMATOL, V124, P595, DOI 10.1111/j.1365-2141.2004.04814.x; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richardson P, 2002, BIOMED PHARMACOTHER, V56, P115, DOI 10.1016/S0753-3322(02)00168-3; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; San Miguel JF, 1999, HAEMATOLOGICA, V84, P36; Santra M, 2003, BLOOD, V101, P2374, DOI 10.1182/blood-2002-09-2801; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yagasaki F, 2001, CANCER RES, V61, P8371	47	73	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8259	8267		10.1038/sj.onc.1208989	http://dx.doi.org/10.1038/sj.onc.1208989			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091734				2022-12-17	WOS:000233956500005
J	Homer, C; Knight, DA; Hananeia, L; Sheard, P; Risk, J; Lasham, A; Royds, JA; Braithwaite, AW				Homer, C; Knight, DA; Hananeia, L; Sheard, P; Risk, J; Lasham, A; Royds, JA; Braithwaite, AW			Y-box factor YB1 controls p53 apoptotic function	ONCOGENE			English	Article						YB1; nuclear localization; p53 functions; apoptosis	BINDING-PROTEIN YB-1; MAMMARY EPITHELIAL-CELLS; MDR1 GENE-EXPRESSION; NUCLEAR EXPRESSION; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; P16(INK4) EXPRESSION; P-GLYCOPROTEIN; LOCALIZATION; DOMAIN	Nuclear localization and high levels of the Y-box-binding protein YB1 appear to be important indicators of drug resistance and tumor prognosis. YB1 also interacts with the p53 tumor suppressor protein. In this paper, we have continued to explore YB1/p53 interactions. We report that transcriptionally active p53 is required for nuclear localization of YB1. We go on to show that nuclear YB1 regulates p53 function. Our data demonstrate that YB1 inhibits the ability of p53 to cause cell death and to transactivate cell death genes, but does not interfere with the ability of p53 to transactivate the CDKN1A gene, encoding the kinase p21(WAF1/CIP1) required for cell cycle arrest, nor the MDM2 gene. We also show that nuclear YB1 is associated with a failure to increase the level of the Bax protein in normal mammary epithelial cells after stress activation of p53. Together these data suggest that (nuclear) YB1 selectively alters p53 activity, which may in part provide an explanation for the correlation of nuclear YB1 with drug resistance and poor tumor prognosis.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin 9001, Otago, New Zealand; Univ Otago, Sch Med Sci, Dept Physiol, Dunedin, New Zealand; Genesis Res & Dev Corp Ltd, Auckland, New Zealand	University of Otago; University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, POB 913, Dunedin 9001, Otago, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz	Risk, Joanna/A-1998-2010					ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Chen CY, 2000, GENE DEV, V14, P1236; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Huschtscha LI, 1998, CANCER RES, V58, P3508; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Levenson VV, 2000, CANCER RES, V60, P5027; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Prives C, 1999, J PATHOL, V187, P112; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SAKURA H, 1988, GENE, V73, P499; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; SUTHERLAND BW, 2005, ADV ONLINE PUBLICATI; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	47	73	74	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8314	8325		10.1038/sj.onc.1208998	http://dx.doi.org/10.1038/sj.onc.1208998			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16158057				2022-12-17	WOS:000233956500010
J	Scott, M; Hyland, PL; McGregor, G; Hillan, KJ; Russell, SEH; Hall, PA				Scott, M; Hyland, PL; McGregor, G; Hillan, KJ; Russell, SEH; Hall, PA			Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours	ONCOGENE			English	Article						septin; SEPT9; microarray; expression profile; neoplasia; RT-PCR; antibody	PUTATIVE PROTOONCOGENE; CELL-PROLIFERATION; OVARIAN-TUMORS; GENE; CANCER; MSF; GTPASES; REGION; FUSION; BREAST	Septins are an evolutionarily conserved family of GTPases with diverse functions including roles in cytokinesis that have been implicated in neoplasia. To address the potential role of SEPT9 in tumorigenesis, we assessed the expression of SEPT9 in 7287 fresh frozen human tissue samples and 292 human cell lines by microarray analysis. In addition, we used a sensitive RT-PCR strategy to de. ne the expression of SEPT9 isoforms in archival formalin-fixed and paraffin-embedded normal human tissues. The mRNA data were further concerned by immunohistological analyses of SEPT9 protein expression in normal human tissues using antisera that detect SEPT9 isoforms. Using these complementary approaches, we demonstrate that SEPT9 mRNA and protein are expressed ubiquitously, with the isoforms showing tissue-specific expression. The microarray analysis indicates that there is consistent overexpression of SEPT9 in diverse human tumours including breast, CNS, endometrium, kidney, liver, lung, lymphoid, oesophagus, ovary, pancreas, skin, soft tissue and thyroid. Since tumours are commonly associated with enhanced cell proliferation, we examined the possible correlation of Ki67 and SEPT9 express ion in normal tissues and tumours. Our data indicate that the overexpression of SEPT9 in neoplasia is not simply a proliferation-associated phenomenon, despite its role in cytokinesis.	Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BT9 7AB, Antrim, North Ireland; Genentech Inc, San Francisco, CA 94080 USA	Belfast City Hospital; Queens University Belfast; Roche Holding; Genentech	Hall, PA (corresponding author), Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Univ Floor,Tower Block, Belfast BT9 7AB, Antrim, North Ireland.	peter.hall@qub.ac.uk						Burrows JF, 2003, J PATHOL, V201, P581, DOI 10.1002/path.1484; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; HALL PA, 1990, J CLIN PATHOL, V43, P184, DOI 10.1136/jcp.43.3.184; HALL PA, 2004, J PATHOL, V204, P189; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kartmann B, 2001, J CELL SCI, V114, P839; KREMER BE, 2003, MOL BIOL CELL, V14, pA447; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Martinez C, 2004, BIOCHEM J, V382, P783, DOI 10.1042/BJ20040372; MCCORMICK D, 1993, HISTOPATHOLOGY, V22, P543, DOI 10.1111/j.1365-2559.1993.tb00174.x; McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752; Montagna C, 2003, CANCER RES, V63, P2179; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Peng XR, 2002, MOL CELL BIOL, V22, P378, DOI 10.1128/MCB.22.1.378-387.2002; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Robertson C, 2004, J PATHOL, V203, P519, DOI 10.1002/path.1551; Russell SEH, 2000, CANCER RES, V60, P4729; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sorensen AB, 2000, J VIROL, V74, P2161, DOI 10.1128/JVI.74.5.2161-2168.2000; Sorensen AB, 2002, GENE, V285, P79, DOI 10.1016/S0378-1119(02)00406-7; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030	22	73	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4688	4700		10.1038/sj.onc.1208574	http://dx.doi.org/10.1038/sj.onc.1208574			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15782116				2022-12-17	WOS:000230304500007
J	Michaelson, JS; Cho, S; Browning, B; Zheng, TS; Lincecum, JM; Wang, MZ; Hsu, YM; Burkly, LC				Michaelson, JS; Cho, S; Browning, B; Zheng, TS; Lincecum, JM; Wang, MZ; Hsu, YM; Burkly, LC			Tweak induces mammary epithelial branching morphogenesis	ONCOGENE			English	Article						Tweak; Fn14; breast cancer; TNF; MMP-9	TUMOR-NECROSIS-FACTOR; FACTOR SCATTER FACTOR; KAPPA-B ACTIVATION; MONOCLONAL-ANTIBODIES; ENDOTHELIAL-CELLS; CDNA MICROARRAY; CANCER-THERAPY; FACTOR FAMILY; IN-VITRO; RECEPTOR	Members of the tumor necrosis factor (TNF) superfamily regulate cell survival and proliferation and have been implicated in cancer. Tweak (TNF-related weak inducer of apoptosis) has pleiotropic biological functions including proapoptotic, proangiogenic and proinflammatory activities. We explored a role for Tweak in mammary gland transformation using a three-dimensional model culture system. Tweak stimulates a branching morphogenic phenotype, similar to that induced by pro-oncogenic factors, in Eph4 mammary epithelial cells cultured in matrigel. Increased proliferation and invasiveness are observed, with a concomitant inhibition of functional differentiation. Levels of matrix metalloproteinase-9 (MMP- 9) are significantly increased following Tweak treatment. Notably, MMP inhibitors are sufficient to block the branching phenotype induced by Tweak. The capacity to promote proliferation, inhibit differentiation and induce invasion suggests a role for Tweak in mammary gland tumorigenesis. Consistent with this, we have observed elevated protein levels of the Tweak receptor, Fn14, in human breast tumor cell lines and xenograft models as well as in primary human breast tumors. Together, our results suggest that the Tweak/Fn14 pathway may be protumorigenic in human breast cancer.	Biogen Idec, Dept Transcript Profiling, Cambridge, MA USA; Biogen Idec, Dept Prot Chem, Cambridge, MA USA	Biogen; Biogen	Michaelson, JS (corresponding author), BiogenIdec, Dept Exploratory Sci, 12 Cambridge Ctr,Bio6-320, Cambridge, MA USA.	Jennifer.Michaelson@BiogenIdec.com						BARSKY SH, 1983, LANCET, V1, P296; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chicheportiche Y, 2002, ARTHRITIS RES, V4, P126, DOI 10.1186/ar388; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Gaide O, 2003, NAT MED, V9, P614, DOI 10.1038/nm861; Han HY, 2002, CANCER RES, V62, P2890; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; IP MM, 1992, ENDOCRINOLOGY, V130, P2833, DOI 10.1210/en.130.5.2833; Jakubowski A, 2002, J CELL SCI, V115, P267; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kaptein A, 2000, FEBS LETT, V485, P135, DOI 10.1016/S0014-5793(00)02219-5; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Lee PPH, 2001, J CELL PHYSIOL, V188, P75, DOI 10.1002/jcp.1090; Lee PPH, 2000, ENDOCRINOLOGY, V141, P3764, DOI 10.1210/en.141.10.3764; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Mariani L, 2001, J NEURO-ONCOL, V53, P161, DOI 10.1023/A:1012253317934; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Nakayama M, 2003, BIOCHEM BIOPH RES CO, V306, P819, DOI 10.1016/S0006-291X(03)01051-9; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Pinkas J, 2002, CANCER RES, V62, P4781; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Shea-Eaton WK, 2001, ENDOCRINOLOGY, V142, P2558, DOI 10.1210/en.142.6.2558; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tran NL, 2003, AM J PATHOL, V162, P1313, DOI 10.1016/S0002-9440(10)63927-2; Varela LM, 2001, J CELL PHYSIOL, V188, P120, DOI 10.1002/jcp.1103; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Younes A, 2003, J CLIN ONCOL, V21, P3526, DOI 10.1200/JCO.2003.09.037	41	73	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 14	2005	24	16					2613	2624		10.1038/sj.onc.1208208	http://dx.doi.org/10.1038/sj.onc.1208208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735761				2022-12-17	WOS:000228356700003
J	Kim, TH; Xiong, H; Zhang, ZH; Ren, B				Kim, TH; Xiong, H; Zhang, ZH; Ren, B			beta-Catenin activates the growth factor endothelin-1 in colon cancer cells	ONCOGENE			English	Article						beta-catenin; endothelin-1; colon cancer; ChIP; promoter arrays	C-MYC; COLORECTAL-CANCER; CARCINOMA-CELLS; EMERGING ROLE; A RECEPTOR; APC; IDENTIFICATION; INHIBITION; APOPTOSIS; LITHIUM	Endothelin-1 (EDN1) is a growth factor that is frequently produced by cancer cells and plays a critical role in tumorigenesis. However, the molecular mechanism controlling the expression of EDN1 in cancers is unknown. Constitutive activation of beta-catenin pathway is responsible for the initiation of the vast majority of colon cancers. Here we show that the EDN1 gene is directly regulated by beta-catenin in colon cancer cells. A specific DNA element within the EDN1 promoter is required for activation, and is associated with beta-catenin's cognate DNA binding partner, TCF4, in vivo. Inhibition of beta-catenin signaling results in lowered expression of EDN1, while enhancement of beta-catenin signaling leads to further activation of the gene. Significantly elevated EDN1 expression occurs in 80% of primary human colon cancers, consistent with it being a direct target of beta-catenin. Furthermore, EDN1 is able to rescue colon cancer cells from growth arrest and apoptosis resulting from inhibition of beta-catenin signaling, implicating a key role of EDN1 in promoting the oncogenic function of beta-catenin. These results indicate EDN1 overexpression as a major cause in colon cancers and reveal further details of the genetic programs responsible for tumorigenesis of colon cancers.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Lab Gene Regulat, La Jolla, CA 92093 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Zhang, ZH (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Lab Gene Regulat, 9500 Gilman Dr, La Jolla, CA 92093 USA.	benzz@burnham.org; biren@ucsd.edu		Kim, Tae Hoon/0000-0003-3950-7557	NATIONAL CANCER INSTITUTE [F32CA108313] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA108313, 1F32CA108313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagnato A, 2003, TRENDS ENDOCRIN MET, V14, P44, DOI 10.1016/S1043-2760(02)00010-3; Bagnato A, 2002, CANCER RES, V62, P6381; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Cohen MM, 2003, AM J MED GENET A, V122A, P303, DOI 10.1002/ajmg.a.20473; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Eberl LP, 2003, BRIT J CANCER, V88, P788, DOI 10.1038/sj.bjc.6600810; Egidy G, 2000, AM J PATHOL, V157, P1863, DOI 10.1016/S0002-9440(10)64825-0; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KUSUHARA M, 1990, CANCER RES, V50, P3257; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson JB, 2003, J UROLOGY, V170, pS65, DOI 10.1097/01.ju.0000096372.07687.86; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosano L, 2003, CANCER RES, V63, P2447; Sellers WR, 2003, J UROLOGY, V170, pS67; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100	36	73	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					597	604		10.1038/sj.onc.1208237	http://dx.doi.org/10.1038/sj.onc.1208237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15558022				2022-12-17	WOS:000226420400007
J	Glover, DM				Glover, DM			Polo kinase and progression through M phase in Drosophila: a perspective from the spindle poles	ONCOGENE			English	Article						Polo kinase; centrosome; spindle; microtubule-organizing centre	ANAPHASE-PROMOTING COMPLEX; XENOPUS EGG EXTRACTS; KINESIN-LIKE PROTEIN; TUBULIN RING COMPLEX; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; MITOTIC COMMITMENT; REGULATORY SUBUNIT; GIANT-NUCLEI; PHOSPHORYLATION	Genes for the mitotic kinases Polo and Aurora A were first identified in Drosophila through screens of maternal effect lethal mutations for defects in spindle pole behaviour. These enzymes have been shown to be highly conserved and required for multiple functions in mitosis. Polo is stabilized at the centrosome by association with Hsp90. It is required for centrosome maturation on M-phase entry in order to recruit the gamma-tubulin ring complex and activate the abnormal spindle protein, Asp. These events facilitate the nucleation of minus ends of microtubules at the centrosome. The localization of Polo at the kinetochore and the mid-zone of the central spindle together with the phenotypes of polo mutants point to functions at the metaphase to anaphase transition and in cytokinesis. The latter are mediated, at least in part, through the Pavarotti kinesin-like motor protein and its conserved counterparts in other metazoans.	Univ Cambridge, Dept Genet, Cell Cycle Genet Res Grp, Canc Res UK, Cambridge CB2 3EH, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Glover, DM (corresponding author), Univ Cambridge, Dept Genet, Cell Cycle Genet Res Grp, Canc Res UK, Downing St, Cambridge CB2 3EH, England.	dmg25@mole.bio.cam.ac.uk		Glover, David/0000-0003-0956-0103				Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Avides MD, 1999, SCIENCE, V283, P1733, DOI 10.1126/science.283.5408.1733; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Barbosa V, 2003, J CELL SCI, V116, P929, DOI 10.1242/jcs.00295; Barbosa V, 2000, GENE DEV, V14, P3126, DOI 10.1101/gad.182800; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; BETTENCOURTDIAS M, 2004, IN PRESS NATURE; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Cambiazo V, 2000, FEBS LETT, V483, P37, DOI 10.1016/S0014-5793(00)02077-9; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Deak P, 2003, J CELL SCI, V116, P4147, DOI 10.1242/jcs.00722; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GLOVER DM, 1989, J CELL SCI, P277; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; Grallert A, 2002, EMBO J, V21, P3096, DOI 10.1093/emboj/cdf294; Herrmann S, 1998, CHROMOSOMA, V107, P440, DOI 10.1007/PL00013778; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee LA, 2003, GENE DEV, V17, P2979, DOI 10.1101/gad.1132603; LEIBOWITZ MH, 1990, THESIS U LONDON UK; Leismann O, 2003, J CELL SCI, V116, P2453, DOI 10.1242/jcs.00411; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Logarinho E, 1998, J CELL SCI, V111, P2897; MacIver FH, 2003, GENE DEV, V17, P1507, DOI 10.1101/gad.256003; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; Moutinho-Santos T, 1999, BIOL CELL, V91, P585, DOI 10.1016/S0248-4900(00)88523-8; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Renault AD, 2003, DEVELOPMENT, V130, P2997, DOI 10.1242/dev.00501; Reynolds N, 2003, J CELL SCI, V116, P1377, DOI 10.1242/jcs.00314; Riparbelli MG, 2002, J CELL SCI, V115, P913; Riparbelli MG, 2000, J CELL SCI, V113, P3341; Sampaio P, 2001, CURR BIOL, V11, P1788, DOI 10.1016/S0960-9822(01)00561-9; Saunders RDC, 1997, J CELL BIOL, V137, P881, DOI 10.1083/jcb.137.4.881; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Wakefield JG, 2001, J CELL BIOL, V153, P637, DOI 10.1083/jcb.153.4.637; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002	66	73	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					230	237		10.1038/sj.onc.1208279	http://dx.doi.org/10.1038/sj.onc.1208279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640838				2022-12-17	WOS:000226183100003
J	Nagata, KI; Inagaki, M				Nagata, KI; Inagaki, M			Cytoskeletal modification of Rho guanine nucleotide exchange factor activity: identification of a Rho guanine nucleotide exchange factor as a binding partner for Sept9b, a mammalian septin	ONCOGENE			English	Article						septin; sept9; RhoGEF; actin	ACUTE MYELOID-LEUKEMIA; CHROMOSOME 17Q; ALLELIC LOSS; FAMILY; GENE; OVARIAN; BREAST; EXPRESSION; REGION; MSF	Small GTPase Rho and septin family proteins are thought to be related to tumorigenesis. We have identified a Rho-guanine nucleotide exchange factor (GEF) as a binding partner for a mammalian septin Sept9b using yeast two-hybrid screening. We termed this molecule septin-associated RhoGEF (SA-RhoGEF). Molecular dissection analyses indicated that the C-terminal area of SA-RhoGEF exhibited binding to the N-terminal variable region of Sept9b. SA-RhoGEF was found by immunoprecipitation analysis to associate with septin complexes in REF52 fibroblast cells, maybe through direct interaction with Sept9b. Immunofluorescence analyses revealed the colocalization of SA-RhoGEF and Sept9b along with actin stress fibers in REF52 cells, and their colocalization along stress fibers was most likely to depend on their mutual interaction. In transient expression analyses, Sept9b inhibited SA-RhoGEF-dependent Rho activation in COS7 and HeLa cells. SA-RhoGEF and its fragments expressed in REF52 cells altered endogenous septin. lament structures. To our knowledge, SA-RhoGEF is the first molecule providing a link between septins and Rho signaling.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Inagaki, M (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, 713-8 Kamiya Cho, Kasugai, Aichi 4800392, Japan.	knagata@inst-hsc.jp; minagaki@aichi-cc.jp	Inagaki, Masaki/B-9920-2016					Burrows JF, 2003, J PATHOL, V201, P581, DOI 10.1002/path.1484; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; Hanai N, 2004, FEBS LETT, V568, P83, DOI 10.1016/j.febslet.2004.05.030; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NAGATA KI, 1992, J BIOL CHEM, V267, P19600; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Phelan CM, 1998, CANCER RES, V58, P1004; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Russell SEH, 2000, CANCER RES, V60, P4729; SAITO H, 1993, CANCER RES, V53, P3382; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, CANCER RES, V59, P4261; THEILE M, 1995, ONCOGENE, V10, P439; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; TOKSOZ D, 1994, ONCOGENE, V9, P621; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5	38	73	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					65	76		10.1038/sj.onc.1208101	http://dx.doi.org/10.1038/sj.onc.1208101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558029				2022-12-17	WOS:000226125800009
J	Caraglia, M; D'Alessandro, AM; Marra, M; Giuberti, G; Vitale, G; Viscomi, C; Colao, A; Del Prete, S; Tagliaferri, P; Tassone, P; Budillon, A; Venuta, S; Abbruzzese, A				Caraglia, M; D'Alessandro, AM; Marra, M; Giuberti, G; Vitale, G; Viscomi, C; Colao, A; Del Prete, S; Tagliaferri, P; Tassone, P; Budillon, A; Venuta, S; Abbruzzese, A			The farnesyl transferase inhibitor R115777 (Zarnestra (R)) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa (R)) and Pamidronate	ONCOGENE			English	Article						farnesyl transferase inhibitor; bisphosphonates; epidermoid cancer; apoptosis; ras; Akt	NITROGEN-CONTAINING BISPHOSPHONATES; GERANYLGERANYLTRANSFERASE-I INHIBITORS; ACTIVATED PROTEIN-KINASE; BONE METASTASES; PYROPHOSPHATE SYNTHASE; BREAST-CANCER; NITRIC-OXIDE; VITRO; FARNESYLTRANSFERASE; PRENYLATION	Pamidronate (PAM) and zoledronic acid (ZOL) are aminobisphosphonates (BPs) able to affect the isoprenylation of intracellular small G proteins. We have investigated the antitumor activity of BPs and R115777 farnesyl transferase inhibitor (FTI) against epidermoid cancer cells. In human epidermoid head and neck KB and lung H1355 cancer cells, 48 h exposure to PAM and ZOL induced growth inhibition (IC50 25 and 10 muM, respectively) and apoptosis and abolished the proliferative and antiapoptotic stimuli induced by epidermal growth factor (EGF). In these experimental conditions, ZOL induced apoptosis through the activation of caspase 3 and a clear fragmentation of PARP was also demonstrated. A strong decrease of basal ras activity and an antagonism on its stimulation by EGF was recorded in the tumor cells exposed to BPs. These effects were paralleled by impaired activation of the survival enzymes extracellular signal regulated kinase 1 and 2 (Erk-1/2) and Akt that were not restored by EGF. Conversely, farnesol induced a recovery of ras activity and antagonized the proapoptotic effects induced by BPs. The combined treatment with BPs and R115777 resulted in a strong synergism both in growth inhibition and apoptosis in KB and H1355 cells. The synergistic activity between the drugs allowed BPs to produce tumor cell growth inhibition and apoptosis at in vivo achievable concentrations (0.1 mumolar for both drugs). Moreover, the combination was highly effective in the inhibition of ras, Erk and Akt activity, while farnesol again antagonized these effects. In conclusion, the combination of BPs and FTI leads to enhanced antitumor activity at clinically achievable drug concentrations that resides in the inhibition of farnesylation-dependent survival pathways and warrants further studies for clinical translation.	Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy; Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy; Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, Catanzaro, Italy; Dept Oncol, Turin, Italy; Natl Canc Inst Naples Fdn G Pascale, Naples, Italy	Universita della Campania Vanvitelli; University of Naples Federico II; Magna Graecia University of Catanzaro	Abbruzzese, A (corresponding author), Univ Naples 2, Dept Biochem & Biophys, Via Costantinopoli 16, I-80138 Naples, Italy.	Michele.Caraglia@unina2.it; Alberto.Abbruzzese@unina2.it	Tassone, Pierfrancesco/AIA-5373-2022; Caraglia, Michele/N-5670-2015; Caraglia, Michele/AFY-9729-2022; Vitale, Giovanni/B-6548-2008; Tagliaferri, Pierosandro/K-9546-2016; Budillon, Alfredo/K-4763-2016; Caraglia, Michele/AAK-4569-2020	Tassone, Pierfrancesco/0000-0002-8298-6787; Caraglia, Michele/0000-0003-2408-6091; Caraglia, Michele/0000-0003-2408-6091; Vitale, Giovanni/0000-0003-2478-683X; Budillon, Alfredo/0000-0002-6330-6053; Caraglia, Michele/0000-0003-2408-6091				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Ali SM, 2001, J CLIN ONCOL, V19, P3434, DOI 10.1200/JCO.2001.19.14.3434; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; AVERBUCH SD, 1993, CANCER-AM CANCER SOC, V72, P3443, DOI 10.1002/1097-0142(19931201)72:11+<3443::AID-CNCR2820721611>3.0.CO;2-3; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131; Boissier S, 2000, CANCER RES, V60, P2949; Cascinu S, 1998, SUPPORT CARE CANCER, V6, P139, DOI 10.1007/s005200050148; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; COLEMAN RE, 1988, BRIT J CANCER, V58, P621, DOI 10.1038/bjc.1988.272; DeSolms SJ, 2003, J MED CHEM, V46, P2973, DOI 10.1021/jm020587n; End DW, 1999, INVEST NEW DRUG, V17, P241, DOI 10.1023/A:1006380320290; Fiordalisi JJ, 2003, J BIOL CHEM, V278, P41718, DOI 10.1074/jbc.M305733200; FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495-199142060-00003; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Haluska P, 2002, EUR J CANCER, V38, P1685, DOI 10.1016/S0959-8049(02)00166-1; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; Johnson DH, 2002, ARTHROSCOPY, V18, P26, DOI 10.1053/jars.2002.36506; Kelland LR, 2001, CLIN CANCER RES, V7, P3544; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lee MV, 2001, CANCER RES, V61, P2602; LIPTON A, 1994, ANN ONCOL S7, V5, P31; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Mitsui H, 2001, INT J CANCER, V92, P55, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1143>3.0.CO;2-O; MORTON AR, 1988, BRIT MED J, V297, P772, DOI 10.1136/bmj.297.6651.772; Peng H, 1998, J CEREBR BLOOD F MET, V18, P349, DOI 10.1097/00004647-199804000-00002; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rogers MJ, 1996, J BONE MINER RES, V11, P1482; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; Selleri C, 2003, BLOOD, V102, P1490, DOI 10.1182/blood-2003-01-0178; Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131; Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365-2141.1997.2713086.x; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Smalley KSM, 2002, INT J CANCER, V98, P514, DOI 10.1002/ijc.10213; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Tamanoi F, 2001, J CELL BIOCHEM, V84, P64, DOI 10.1002/jcb.10067; Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770; Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; Vitale G, 2001, BRIT J CANCER, V84, P1586, DOI 10.1054/bjoc.2001.1832; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295; Yan CYI, 1998, J NEUROSCI, V18, P4042; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	56	73	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6900	6913		10.1038/sj.onc.1207814	http://dx.doi.org/10.1038/sj.onc.1207814			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286715				2022-12-17	WOS:000223750700007
J	Miyoshi, K; Wakioka, T; Nishinakamura, H; Kamio, M; Yang, L; Inoue, M; Hasegawa, M; Yonemitsu, Y; Komiya, S; Yoshimura, A				Miyoshi, K; Wakioka, T; Nishinakamura, H; Kamio, M; Yang, L; Inoue, M; Hasegawa, M; Yonemitsu, Y; Komiya, S; Yoshimura, A			The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization	ONCOGENE			English	Article						migration; ERK; Sprouty; metastasis; Rho; signal transduction	SERUM RESPONSE FACTOR; ERK ACTIVATION; SENDAI-VIRUS; DROSOPHILA-SPROUTY; FOCAL ADHESIONS; STRESS FIBERS; ONCOGENIC RAS; KINASE; BINDING; EXPRESSION	Sprouty and the Sprouty-related protein, Spred (Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology-1 (EVH1) domain-containing protein), inhibit Ras-dependent extracellular signal-regulated kinase (ERK) signaling induced by a variety of growth factors. Since Sprouty proteins have been shown to inhibit not only ERK activation but also cell migration, we postulated that Spreds also inhibit cellular migration. Using stably highly metastatic LM8 cells infected with the Spred1-Sendai virus vector, we demonstrated that Spred1 inhibits the metastasis of LM8 cells in nude mice. Spred1 overexpression also inhibited migration of cells in vitro in response to chemokines, CCL19 and CCL21. We also found that Spred1 overexpression dissolved actin-stress fibers. Both EVH1 domain and C-terminal Sprouty-related domain were required for actin reassembly. Spred1 and Spred2 suppressed constitutively activated RhoA (V14RhoA)-induced stress fiber formation and serum response factor activation. Spred1 bound to activated RhoA, but not cdc42 and Rac. Spred1 also inhibited chemokine-induced RhoA activation and active RhoA-induced Rho-kinase activation. These data suggest that Spreds are key regulators of RhoA-mediated cell motility and signal transduction. Furthermore, our study suggests that the induction of Spreds could be a novel strategy for preventing cancer cell metastasis.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kagoshima Univ, Fac Med, Dept Orthoped Surg, Kagoshima 8908520, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kagoshima University; DNAVEC Corporation; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Inoue, Makoto/0000-0003-0804-7439				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Bonacchi A, 2001, J BIOL CHEM, V276, P9945, DOI 10.1074/jbc.M010303200; Cabrita MA, 2003, THROMB HAEMOSTASIS, V90, P586, DOI 10.1160/TH03-04-0217; Callebaut I, 1998, FEBS LETT, V441, P181, DOI 10.1016/S0014-5793(98)01541-5; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hashimoto S, 2002, MECH DEVELOP, V119, pS303, DOI 10.1016/S0925-4773(03)00132-1; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Joo A, 2004, ONCOGENE, V23, P726, DOI 10.1038/sj.onc.1207174; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Kramer S, 1999, DEVELOPMENT, V126, P2515; Kranenburg O, 1997, J CELL SCI, V110, P2417; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Minowada G, 1999, DEVELOPMENT, V126, P4465; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Reich A, 1999, DEVELOPMENT, V126, P4139; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakai Y, 1999, FEBS LETT, V456, P221, DOI 10.1016/S0014-5793(99)00960-6; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970, DOI 10.1038/79463; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	43	73	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5567	5576		10.1038/sj.onc.1207759	http://dx.doi.org/10.1038/sj.onc.1207759			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184877				2022-12-17	WOS:000222629500001
J	Yokota, T; Matsuzaki, Y; Miyazawa, K; Zindy, F; Roussel, MF; Sakai, T				Yokota, T; Matsuzaki, Y; Miyazawa, K; Zindy, F; Roussel, MF; Sakai, T			Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter	ONCOGENE			English	Article						histone deacetylase inhibitors; p19(INK4d); Sp1; Sp3; HDAC2; promoter activation	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; TRICHOSTATIN-A; TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN; P21/WAF1/CIP1 GENE; N-COR; BUTYRATE; P19(INK4D); REGULATORS	Histone deacetylase (HDAC) inhibitors are known to arrest human tumor cells at the G1 phase of the cell cycle and activate the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1). However, several studies have suggested the existence of a p21(WAF1/Cip1)-independent molecular pathway. We report here that HDAC inhibitors activate a member of the INK4 family, the INK4d gene, causing G1 phase arrest, in the human T cell leukemia cell line, Jurkat. One of the major Trichostatin A (TSA)-responsive elements is a specific Sp1 binding site in the INK4d promoter. Electrophoretic mobility-shift assay revealed that Sp1 and Sp3 can specifically interact with this Sp1 binding site. Furthermore, using chromatin immunoprecipitation assay, we demonstrated that HDAC2 was present in the INK4d proximal promoter region in the absence, but not the presence, of TSA. Taken together, these results suggest that treatment with TSA transcriptionally activates INK4d by releasing HDAC2 from the histone-DNA complex at the INK4d promoter. Using a p21(WAF1/Cip1)-deleted human colorectal carcinoma cell line, HCT116 p21 (-/-), we show that upregulation of p19(INK4d) by TSA is associated with inhibition of cell proliferation. Moreover, mouse embryo fibroblasts lacking Ink4d were resistant to the growth inhibitory effects of TSA as compared to their wild-type counterpart. Our findings suggest that p19(INK4d) in addition to p21(WAF1/Cip1) is an important molecular target of HDAC inhibitors inducing growth arrest.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Dept Digest Surg, Kamigyo Ku, Kyoto 6028566, Japan; St Jude Childrens Res Hosp, Dept Tumor Cell Biol & Genet, Memphis, TN 38105 USA	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; St Jude Children's Research Hospital	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp	Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; BORGONOVO BL, 1996, EUR J HAEMATOL, V56, P313; Chang ST, 1996, BIOCHEM BIOPH RES CO, V221, P594, DOI 10.1006/bbrc.1996.0641; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Kim YB, 2000, J ANTIBIOT, V53, P1191, DOI 10.7164/antibiotics.53.1191; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Matsuzaki Y, 2002, FEBS LETT, V517, P272, DOI 10.1016/S0014-5793(02)02647-9; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; SAKAI T, 1996, JPN J HYG, V50, P1036; SAMBROOK J, 2001, CLONING LAB MANUAL; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Wharton W, 2000, J BIOL CHEM, V275, P33981, DOI 10.1074/jbc.M005600200; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zariwala M, 1996, ONCOGENE, V13, P2033; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	40	73	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5340	5349		10.1038/sj.onc.1207689	http://dx.doi.org/10.1038/sj.onc.1207689			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107822				2022-12-17	WOS:000222491600009
J	Aoyama, Y; Avruch, J; Zhang, XF				Aoyama, Y; Avruch, J; Zhang, XF			Norel inhibits tumor cell growth independent of Ras or the MST1/2 kinases	ONCOGENE			English	Article						Nore1; RASSF1A; growth suppression; Ras; MST	EPIGENETIC INACTIVATION; SUPPRESSOR GENE; FAMILY PROTEIN; RASSF1A; IDENTIFICATION; BINDING; LUNG; PROLIFERATION; HIPPO	Nore1, a noncatalytic protein identified by its ability to bind selectively to active Ras, is most closely related in amino-acid sequence to the tumor suppressor RASSF1. Both are expressed predominantly as a longer (Nore1A/RASSF1A) and/or shorter (Nore1B/RASSF1C) polypeptide; all four polypeptides contain a Ras-association domain and bind, through their conserved carboxytermini, the proapoptotic protein kinases MST1 and MST2. Moreover, the expression of the longer polypeptide is downregulated in human tumor cell lines through promoter methylation (frequently for RASSF1A, less regularly for Nore1A). Forced expression of RASSF1A in several such lines (including the NSCLC line A549) has been shown to suppress tumorigenicity; herein we inquire whether Nore has growth inhibitory activity. Four tumor cell lines were tested, selected for their low expression of both Nore1A and Nore1B; the two NSCLC lines, A549 and NCI-H460, each have a mutant active Ras oncogene, whereas the two melanoma lines G361 and M14 each contain the constitutively active BRaf(V599E) oncogene and wild-type Ras. The expression of Nore1A or Nore1B suppresses colony formation by the A549 and G361 lines, as effectively in A549 as does RASSF1A; colony formation in the NCI-H460 and M14 lines is unaffected. Nore1A inhibits anchorage-independent growth by A549 cells and delays A549 progression through G1 without evidence of increased apoptosis. The growth suppressive action of Nore1A is largely unaffected by deletion of both the MST- and Ras-binding domains, as well as by mutation of the Nore1A zinc finger. Thus, Nore1 suppresses the growth of some tumor cell lines through as yet unidentified effectors, independent of Ras-like proteins or MST1/2.	Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu; zhang@mmolbio.mgh.harvard.edu			NCI NIH HHS [CA073818] Funding Source: Medline; NIDDK NIH HHS [DK17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cifone M A, 1982, Cancer Metastasis Rev, V1, P335, DOI 10.1007/BF00124216; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Steiner G, 1996, CANCER RES, V56, P5044; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	27	73	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3426	3433		10.1038/sj.onc.1207486	http://dx.doi.org/10.1038/sj.onc.1207486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15007383				2022-12-17	WOS:000220975000017
J	Rajasekhar, VK; Holland, EC				Rajasekhar, VK; Holland, EC			Postgenomic global analysis of translational control induced by oncogenic signaling	ONCOGENE			English	Review						AKT; cancer; eiF-4E; oncogenic signal; Ras; translation	INITIATION-FACTOR 4E; MESSENGER-RNA TRANSLATION; CAP-BINDING PROTEIN; GENE-EXPRESSION PATTERNS; INTERNAL RIBOSOME ENTRY; 5' UNTRANSLATED REGION; GROWTH-FACTOR; MAMMALIAN TARGET; BREAST-CANCER; ORNITHINE-DECARBOXYLASE	It is commonly assumed that developmental and oncogenic signaling achieve their phenotypic effects primarily by directly regulating the transcriptional profile of cells. However, there is growing evidence that the direct effect on transcription may be overshadowed by differential effects on the translational efficiency of specific existing mRNA species. Global analysis of this effect using microarrays indicates that this mechanism of controlling protein production provides a highly specific, robust, and rapid response to oncogenic and developmental stimuli. The mRNAs so affected encode proteins involved in cell cell interaction, signal transduction, and growth control. Furthermore, a large number of transcription factors capable of secondarily rearranging the transcriptional pro. le of the cell are controlled at this level as well. To what degree this translational control is either necessary or sufficient for tumor formation or maintenance remains to be determined.	Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Rajasekhar, VK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, 1275 York Ave, New York, NY 10021 USA.	vinagolr@mskcc.org; hollande@mskcc.org		Vinagolu, Rajasekhar/0000-0002-7364-2675	NCI NIH HHS [R01CA94842, U01CA894314, R01CA099489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA099489, R01CA094842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe A, 2002, TOHOKU J EXP MED, V198, P181, DOI 10.1620/tjem.198.181; Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Amara FM, 1996, J BIOL CHEM, V271, P15279, DOI 10.1074/jbc.271.25.15279; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Anant S, 2002, BBA-GENE STRUCT EXPR, V1575, P54, DOI 10.1016/S0167-4781(02)00250-6; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aronov S, 1999, J MOL NEUROSCI, V12, P131, DOI 10.1007/BF02736927; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; Aster JC, 2001, CURR OPIN HEMATOL, V8, P237, DOI 10.1097/00062752-200107000-00010; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; Baehrecke EH, 2003, CURR BIOL, V13, pR473, DOI 10.1016/S0960-9822(03)00405-6; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BARNARD GF, 1993, CANCER RES, V53, P4048; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Begemann M, 2002, BRAIN PATHOL, V12, P117; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOHM H, 1991, BIOMED BIOCHIM ACTA, V50, P1193; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calkhoven CF, 2002, TRENDS MOL MED, V8, P577, DOI 10.1016/S1471-4914(02)02424-3; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Cheok MH, 2003, NAT GENET, V34, P85, DOI 10.1038/ng1151; CHESTER KA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P297, DOI 10.1016/0167-4781(89)90119-X; Child SJ, 1999, INT J BIOCHEM CELL B, V31, P201, DOI 10.1016/S1357-2725(98)00068-5; Choe G, 2003, CANCER RES, V63, P2742; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Dahlman T, 2002, INT J CANCER, V98, P186, DOI 10.1002/ijc.10181; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; de la Vega CM, 2001, BIOCHEM J, V357, P819; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; DeFatta RJ, 2000, LARYNGOSCOPE, V110, P928, DOI 10.1097/00005537-200006000-00007; Del Valle L, 2000, ANN NEUROL, V48, P932, DOI 10.1002/1531-8249(200012)48:6<932::AID-ANA15>3.0.CO;2-E; Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Doherty JK, 1999, GYNECOL ONCOL, V74, P408, DOI 10.1006/gyno.1999.5467; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Dyer JR, 2003, NAT NEUROSCI, V6, P219, DOI 10.1038/nn1018; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Edmonds BT, 1996, J CELL SCI, V109, P2705; ELBADRY OM, 1991, PROG CLIN BIOL RES, V366, P257; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; ENDER B, 1993, MOL CARCINOGEN, V7, P18, DOI 10.1002/mc.2940070104; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; Flynn A, 1996, CANCER SURV, V27, P293; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gopalkrishnan RV, 1999, INT J BIOCHEM CELL B, V31, P151, DOI 10.1016/S1357-2725(98)00138-1; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; GRENS A, 1990, J BIOL CHEM, V265, P11810; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Guan XY, 2001, CANCER RES, V61, P3806; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Ha PK, 2003, CLIN CANCER RES, V9, P3058; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Han XS, 2001, ONCOGENE, V20, P7976, DOI 10.1038/sj.onc.1204996; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henics T, 2000, BIOCHEM BIOPH RES CO, V279, P40, DOI 10.1006/bbrc.2000.3900; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Hernandez-Munoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586; Hernandez-Munoz I, 2003, CANCER RES, V63, P4188; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hoover DS, 1997, CELL GROWTH DIFFER, V8, P1371; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Kolettas E, 1998, ANTICANCER RES, V18, P385; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Kuhn KM, 2001, MOL CELL BIOL, V21, P916, DOI 10.1128/MCB.21.3.916-927.2001; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Kurz EU, 2001, BIOCHEM BIOPH RES CO, V285, P981, DOI 10.1006/bbrc.2001.5262; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; Lai EC, 2003, CURR BIOL, V13, pR285, DOI 10.1016/S0960-9822(03)00203-3; Lasko P, 2003, DEV CELL, V5, P671, DOI 10.1016/S1534-5807(03)00333-2; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LECAM A, 1995, EUR J BIOCHEM, V231, P620; Leonardi P, 2002, ONCOGENE, V21, P5108, DOI 10.1038/sj.onc.1205694; Lin L, 2001, J CELL BIOCHEM, V80, P483, DOI 10.1002/1097-4644(20010315)80:4<483::AID-JCB1002>3.0.CO;2-B; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Linnemann T, 2002, J BIOL CHEM, V277, P7831, DOI 10.1074/jbc.M110800200; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lyubimova A, 2000, J CELL BIOCHEM, V76, P1, DOI 10.1002/(SICI)1097-4644(20000101)76:1<1::AID-JCB1>3.0.CO;2-R; Manjeshwar S, 2003, CANCER RES, V63, P5251; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Marchetti A, 2001, INT J ONCOL, V18, P175; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Mathur S, 1998, CANCER, V82, P816, DOI 10.1002/(SICI)1097-0142(19980301)82:5<816::AID-CNCR3>3.0.CO;2-H; McGonigle S, 2002, BIOCHEMISTRY-US, V41, P579, DOI 10.1021/bi011407z; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Meric F, 2002, MOL CANCER THER, V1, P971; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MIMORI K, 1995, CANCER, V75, P1446, DOI 10.1002/1097-0142(19950315)75:6+<1446::AID-CNCR2820751509>3.0.CO;2-P; Mimori K, 1996, GUT, V38, P66, DOI 10.1136/gut.38.1.66; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; Mousses S, 2002, CANCER RES, V62, P1256; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nathan CAO, 2000, CANCER RES, V60, P3599; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; O'Donnell WT, 2002, ANNU REV NEUROSCI, V25, P315, DOI 10.1146/annurev.neuro.25.112701.142909; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Pedersen N, 2003, CANCER RES, V63, P1943; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Pollack JR, 2002, SEMIN ONCOL, V29, P280, DOI 10.1053/sonc.2002.32903; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Prendergast GC, 2003, CANCER CELL, V4, P244, DOI 10.1016/S1535-6108(03)00247-2; Proud CG, 1997, BIOCHEM J, V328, P329; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Ptashne M, 2003, SCIENCE, V299, P1025, DOI 10.1126/science.1081519; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rajagopal S, 2001, CELL COMMUN ADHES, V8, P87, DOI 10.3109/15419060109080709; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; RAO LVM, 1983, PLANT SCI LETT, V29, P207; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 2003, CANCER-AM CANCER SOC, V98, P1080, DOI 10.1002/cncr.11619; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rothe M, 2000, AM J PATHOL, V157, P1597, DOI 10.1016/S0002-9440(10)64797-9; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Savitsky K, 1997, NUCLEIC ACIDS RES, V25, P1678, DOI 10.1093/nar/25.9.1678; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Saxena A, 2002, CANCER LETT, V187, P199, DOI 10.1016/S0304-3835(02)00378-6; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Senga T, 2001, J BIOL CHEM, V276, P32678, DOI 10.1074/jbc.M105749200; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Shantz LM, 1996, CANCER RES, V56, P3265; Shibao K, 1999, INT J CANCER, V83, P732; Shuda M, 2000, ANTICANCER RES, V20, P2489; Signori E, 2001, ONCOGENE, V20, P4596, DOI 10.1038/sj.onc.1204620; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sorrells DL, 1999, HEAD NECK-J SCI SPEC, V21, P60, DOI 10.1002/(SICI)1097-0347(199901)21:1<60::AID-HED8>3.0.CO;2-J; Sorrells DL, 1998, ANN SURG ONCOL, V5, P232, DOI 10.1007/BF02303778; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Spurdle AB, 2003, GYNECOL ONCOL, V90, P145, DOI 10.1016/S0090-8258(03)00193-8; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Struyk L, 2000, MOL CARCINOGEN, V28, P42, DOI 10.1002/(SICI)1098-2744(200005)28:1<42::AID-MC6>3.3.CO;2-#; Tanaka M, 2001, MOL BRAIN RES, V91, P81, DOI 10.1016/S0169-328X(01)00125-5; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Van der Velden AW, 2000, INT J DEV BIOL, V44, P843; VARESIO L, 1980, J IMMUNOL, V124, P2288; Verma A, 2003, CANCER METAST REV, V22, P423, DOI 10.1023/A:1023805715476; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WANG CY, 1993, CELL GROWTH DIFFER, V4, P871; Wang LJ, 2002, CIRC RES, V91, P821, DOI 10.1161/01.RES.0000041029.97988.E9; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Witteck A, 2003, EXP CELL RES, V287, P106, DOI 10.1016/S0014-4827(03)00129-0; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; WOLTHUIS RMF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P160, DOI 10.1016/0167-4889(93)90035-N; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Yu JJ, 2001, ONCOGENE, V20, P7694, DOI 10.1038/sj.onc.1204977; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	253	73	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3248	3264		10.1038/sj.onc.1207546	http://dx.doi.org/10.1038/sj.onc.1207546			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094774				2022-12-17	WOS:000220879700013
J	Bahar, A; Bicknell, JE; Simpson, DJ; Clayton, RN; Farrell, WE				Bahar, A; Bicknell, JE; Simpson, DJ; Clayton, RN; Farrell, WE			Loss of expression of the growth inhibitory gene GADD45 gamma, in human pituitary adenomas, is associated with CpG island methylation	ONCOGENE			English	Article						GADD45 gamma; CpG island methylation; pituitary adenomas	DNA METHYLATION; MAMMALIAN-CELLS; BREAST-CANCER; P16 GENE; TUMORS; HYPERMETHYLATION; INACTIVATION; TUMORIGENESIS; PATHOGENESIS; DELETION	Inappropriate expression of cell-cycle regulatory genes and/or their protein products are a frequent finding in pituitary tumours; however, genetic changes associated with or responsible for their dysregulation are in general uncommon. In a search for novel genes, and employing eDNA-representational difference analysis, the gene encoding GADD45gamma was recently isolated and identified as being under-represented in pituitary adenomas. GADD45gamma is a member of a family of genes that are induced by DNA damage and function in the negative regulation of cell growth. In this study, we further confirm this initial report that the majority of pituitary adenomas (22 of 33; 67%) do not express GADD45gamma as determined by RT-PCR analysis. Loss of expression was not associated with either loss of heterozygosity or mutations within the coding region of this gene. In marked contrast, epigenetic change, namely methylation of the GADD45gamma genes CpG island, was a frequent finding (19 of 33 adenoma; 58%) and was significantly associated with tumours in which GADD45gamma transcript was not expressed (18 of 22; 82%; P = 0.002). In common with the primary tumours, methylation-associated gene silencing of the GADD45gamma gene was also found in the pituitary tumour cell line AtT20. The treatment of AtT20 cells with the demethylating agent, 5-Aza-2'-deoxycytidine, induced the re-expression of this gene. These findings show that silencing of the GADD45gamma gene in pituitary tumours is primarily associated with methylation of the genes CpG island. Methylation has functional importance since reversal of this epigenetic change in a pituitary-derived cell line is associated with reexpression. Silencing of GADD45gamma, a negative regulator of cell growth, is most likely responsible for conferring a selective growth advantage during tumour evolution and outgrowth.	Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent ST4 7QB, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Farrell, WE (corresponding author), Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent ST4 7QB, Staffs, England.	w.e.farrell@keele.ac.uk						Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Bates AS, 1997, J CLIN ENDOCR METAB, V82, P818, DOI 10.1210/jc.82.3.818; Baylin SB, 1998, ADV CANCER RES, V72, P141; BOGGILD MD, 1994, J CLIN ENDOCR METAB, V78, P387, DOI 10.1210/jc.78.2.387; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Davis JRE, 2001, REPRODUCTION, V121, P363, DOI 10.1530/rep.0.1210363; Esteller M, 2001, CANCER RES, V61, P3225; Farrell WE, 2000, FRONT NEUROENDOCRIN, V21, P174, DOI 10.1006/frne.1999.0195; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Frost SJ, 1999, MOL ENDOCRINOL, V13, P1801, DOI 10.1210/me.13.11.1801; Grigg GW, 1996, DNA SEQUENCE, V6, P189, DOI 10.3109/10425179609008443; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hibberts NA, 1999, CLIN CANCER RES, V5, P2133; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Jaffrain-Rea ML, 1999, CLIN ENDOCRINOL, V51, P317; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Korabiowska M, 1999, IN VIVO, V13, P483; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Ruebel KH, 2001, ENDOCR PATHOL, V12, P281, DOI 10.1385/EP:12:3:281; Seemann N, 2001, J PATHOL, V193, P491, DOI 10.1002/path.833; Simpson DJ, 1999, GENE CHROMOSOME CANC, V24, P328; Simpson DJ, 2002, ONCOGENE, V21, P1217, DOI 10.1038/sj.onc.1205195; Simpson DJ, 2001, CARCINOGENESIS, V22, P1149, DOI 10.1093/carcin/22.8.1149; Simpson DJ, 2000, CANCER RES, V60, P1211; SIMPSON DJ, 1999, CANCER RES, V59, P2703; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; TERADA T, 1995, ENDOCR PATHOL, V6, P301, DOI 10.1007/BF02738730; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Wan YS, 2000, INT J MOL MED, V6, P683; Woloschak M, 1997, MOL CARCINOGEN, V19, P221, DOI 10.1002/(SICI)1098-2744(199708)19:4<221::AID-MC1>3.0.CO;2-F; Yan PS, 2000, CLIN CANCER RES, V6, P1432; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761	38	73	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					936	944		10.1038/sj.onc.1207193	http://dx.doi.org/10.1038/sj.onc.1207193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647444				2022-12-17	WOS:000188486600009
J	Vargiu, P; De Abajo, R; Garcia-Ranea, JA; Valencia, A; Santisteban, P; Crespo, P; Bernal, J				Vargiu, P; De Abajo, R; Garcia-Ranea, JA; Valencia, A; Santisteban, P; Crespo, P; Bernal, J			The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors	ONCOGENE			English	Article						Ras; thyroid hormone; striatum; adrenergic receptor; PC12 cells	RAS SUPERFAMILY MEMBER; BETA(2)-ADRENERGIC RECEPTOR; ACTIVATION; IDENTIFICATION; DEXRAS1; BLOCKS; CELLS; GENE; DISRUPTION; DEFICIENCY	The Ras homolog enriched in striatum, Rhes, is the product of a thyroid hormone-regulated gene during brain development. Rhes and the dexamethasone-induced Dexras1 define a novel distinct subfamily of proteins within the Ras family, characterized by an extended variable domain in the carboxyl terminal region. We have carried this study because there is a complete lack of knowledge on Rhes signaling. We show that in PC12 cells, Rhes is targeted to the plasma membrane by farnesylation. We demonstrate that about 30% of the native Rhes protein is bound to GTP and this proportion is unaltered by typical Ras family nucleotide exchange factors. However, Rhes is not transforming in murine fibroblasts. We have also examined the role of Rhes in cell signaling. Rhes does not stimulate the ERK pathway. By contrast, it binds to and activates PI3K. On the other hand, we demonstrate that Rhes impairs the activation of the cAMP/PKA pathway by thyroid-stimulating hormone, and by an activated beta2 adrenergic receptor by a mechanism that suggests uncoupling of the receptor to its cognate heterotrimeric complex. Overall, our results provide the initial insights into the role in signal transduction of this novel Ras family member.	CSIC, Inst Invest Biomed Alverto Sols, E-28029 Madrid, Spain; Univ Autonoma Madrid, Madrid 28029, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bernal, J (corresponding author), CSIC, Inst Invest Biomed Alverto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	jbernal@iib.uam.es	Santisteban, Pilar/E-7829-2016; Bernal, Juan/J-6086-2014; Valencia, Alfonso/I-3127-2015; Crespo, Piero/M-3273-2014	Santisteban, Pilar/0000-0002-2758-796X; Bernal, Juan/0000-0002-5867-4951; Valencia, Alfonso/0000-0002-8937-6789; Garcia Ranea, Juan Antonio/0000-0003-0327-1837; Crespo, Piero/0000-0003-2825-7783				Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chan SLF, 2002, BRIT J PHARMACOL, V136, P31, DOI 10.1038/sj.bjp.0704680; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DELONG GR, 1985, DEV MED CHILD NEUROL, V27, P317; Falk JD, 1999, J NEUROSCI RES, V57, P782, DOI 10.1002/(SICI)1097-4547(19990915)57:6<782::AID-JNR3>3.0.CO;2-9; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; FARRELL FX, 1993, BIOCHEM J, V289, P349, DOI 10.1042/bj2890349; Foster R, 1996, MOL CELL BIOL, V16, P2689; Graham TE, 2001, ENDOCRINOLOGY, V142, P2631, DOI 10.1210/en.142.6.2631; Graham TE, 2002, J BIOL CHEM, V277, P10876, DOI 10.1074/jbc.M110397200; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Jaffrey SR, 2002, CHEM BIOL, V9, P1329, DOI 10.1016/S1074-5521(02)00293-4; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Mott HR, 1997, BIOCHEMISTRY-US, V36, P3640, DOI 10.1021/bi962790o; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; Park J, 1997, J MOL BIOL, V273, P349, DOI 10.1006/jmbi.1997.1288; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; St Croix B, 2000, SCIENCE, V289, P1197; Takesono A, 2002, J BIOL CHEM, V277, P13827, DOI 10.1074/jbc.M201064200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vargiu P, 2001, MOL BRAIN RES, V94, P1, DOI 10.1016/S0169-328X(01)00140-1; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WITTINGHOFER A, 1995, GUIDEBOOK SMALL GTPA, P20	36	73	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					559	568		10.1038/sj.onc.1207161	http://dx.doi.org/10.1038/sj.onc.1207161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724584				2022-12-17	WOS:000188098300027
J	Trauzold, A; Schmiedel, S; Sipos, B; Wermann, H; Westphal, S; Roder, C; Klapper, W; Arlt, A; Lehnert, L; Ungefroren, H; Johannes, FJ; Kalthoff, H				Trauzold, A; Schmiedel, S; Sipos, B; Wermann, H; Westphal, S; Roder, C; Klapper, W; Arlt, A; Lehnert, L; Ungefroren, H; Johannes, FJ; Kalthoff, H			PKC mu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells	ONCOGENE			English	Article						pancreatic cancer; apoptosis resistance; protein kinase C; death receptor	PROTEIN-KINASE-C; TELOMERASE ACTIVITY; CANCER-CELLS; ADENOCARCINOMA CELLS; PROTEOLYTIC CLEAVAGE; MEDIATED APOPTOSIS; MOLECULAR-CLONING; PHORBOL ESTERS; DNA-SYNTHESIS; ACTIVATION	Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumour progression. Protein kinases C (PKC) have been shown to be important in the regulation of proliferation and apoptosis. In this report, we investigated the role of the PKC-like kinase PKCmu in the control of these processes in pancreatic adenocarcinoma cells. We demonstrate that in these cells, PKCmu expression strongly correlates with resistance to CD95-induced apoptosis. Inhibition of PKCmu with Goe6983 sensitized resistant cells to CD95-induced apoptosis. In CD95-sensitive Colo357 cells, forced overexpression of PKCmu strongly reduced CD95-mediated apoptosis, an effect that could be reversed by pretreatment with Goe6983. In addition, PKCmu overexpression led to a strongly enhanced cell growth and to a significant increase of telomerase activity. In an attempt to identify the signalling pathways affected by PKCmu, we identified the antiapoptotic proteins c-FLIPL and survivin to be strongly upregulated in PKCmu over-expressing cells. Immunohistochemical analysis of pancreatic tumour tissue of 48 patients and 10 normal pancreatic tissues revealed marked overexpression of PKCmu in tumours. In conclusion, we showed that PKCmu controls proliferative, as well as anti-apoptotic, signalling pathways and therefore plays an important role in acquiring the malignant phenotype of pancreatic tumours.	Univ Kiel, Clin Gen Surg & Thorac Surg, D-24105 Kiel, Germany; Univ Kiel, Inst Pathol, D-24105 Kiel, Germany; Univ Kiel, Inst Hematopathol, D-24105 Kiel, Germany; Univ Kiel, Lymph Node Registry, D-24105 Kiel, Germany; Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Fraunhofer Inst Interfacial Engn, D-70569 Stuttgart, Germany	University of Kiel; University of Kiel; University of Kiel; University of Kiel; University of Kiel; Fraunhofer Gesellschaft	Kalthoff, H (corresponding author), Univ Kiel, Clin Gen Surg & Thorac Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Trauzold, Anna/P-4398-2014; Kalthoff, Holger/B-1618-2010; Roeder, Christian/F-1068-2010; Arlt, Alexander/G-7308-2019; Klapper, Wolfram/S-6314-2016; Klapper, Wolfram/D-2516-2010	Roeder, Christian/0000-0001-7881-9110; Arlt, Alexander/0000-0002-6160-1059; 				Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Elnemr A, 2001, INT J ONCOL, V18, P311; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Guha S, 2002, CANCER RES, V62, P1632; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; Hamilton HB, 1996, J NEUROSURG, V85, P329, DOI 10.3171/jns.1996.85.2.0329; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; Hayano RS, 1999, EUR PHYS J A, V6, P99, DOI 10.1007/s100500050322; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hiyama E, 1997, CANCER RES, V57, P326; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kim YW, 2001, EXP MOL MED, V33, P156, DOI 10.1038/emm.2001.27; KLAPPER W, 1998, BIOCHIM BIOPHYS ACTA, V8, P2; Krammer P H, 1999, Adv Immunol, V71, P163; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Palmantier R, 2001, CANCER RES, V61, P2445; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.0.CO;2-D; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ryder NM, 2001, J CELL PHYSIOL, V186, P53, DOI 10.1002/1097-4652(200101)186:1<53::AID-JCP1004>3.0.CO;2-Q; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Satoh K, 2001, CANCER, V92, P271, DOI 10.1002/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Ungefroren H, 1998, CANCER RES, V58, P1741; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Yu CC, 2001, BIOCHEM J, V355, P459, DOI 10.1042/0264-6021:3550459; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200	48	73	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8939	8947		10.1038/sj.onc.1207001	http://dx.doi.org/10.1038/sj.onc.1207001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654790				2022-12-17	WOS:000186982200015
J	Young, AP; Nagarajan, R; Longmore, GD				Young, AP; Nagarajan, R; Longmore, GD			Mechanisms of transcriptional regulation by Rb-E2F segregate by biological pathway	ONCOGENE			English	Article						E2F; Rb; biological pathways	CELL-CYCLE PROGRESSION; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; DNA-REPLICATION; REPRESS TRANSCRIPTION; MICROARRAY ANALYSIS; COMPLEX-FORMATION; GROWTH-REGULATION; FACTOR E2F1; EXPRESSION	The E2F family of transcription factors are critical regulators of the cell cycle and have also been implicated in apoptosis, development, DNA damage checkpoints, and differentiation. Retinoblastoma (Rb) proteins interact with E2F to regulate transcription, and several mechanisms have been proposed for Rb-E2F transcriptional regulation. We designed microarray-based experiments to characterize the relative contributions of each mechanism, and unexpectedly, we found that distinct functional gene groups show preference for one mechanism over the others. We propose that such a distribution may provide signaling specificity to enable regulatory proteins to turn on or off entire pathways that determine cell fate.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, 4940 Parkview Pl, St Louis, MO 63110 USA.				NCI NIH HHS [CA 85839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Geng Y, 1996, ONCOGENE, V12, P1173; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Koziczak M, 2001, EUR J BIOCHEM, V268, P4969, DOI 10.1046/j.0014-2956.2001.02428.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NEUMAN E, 1994, MOL CELL BIOL, V14, P6017; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Reed SI, 1997, CANCER SURV, V29, P7; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	42	73	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7209	7217		10.1038/sj.onc.1206804	http://dx.doi.org/10.1038/sj.onc.1206804			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562049				2022-12-17	WOS:000185955000012
J	Macaluso, M; Paggi, MG; Giordano, A				Macaluso, M; Paggi, MG; Giordano, A			Genetic and epigenetic alterations as hallmarks of the intricate road to cancer	ONCOGENE			English	Review						cell transformation; cancer development and progression	METASTASIS SUPPRESSOR GENE; CELL-CYCLE CONTROL; DNA METHYLATION; HISTONE DEACETYLASE; HUMAN-BREAST; TRANSCRIPTIONAL REPRESSION; P53; EXPRESSION; PROTEIN; FAMILY	Despite the clonal origin of most tumors, their tremendous heterogeneity suggests that cancer progression springs from the combined forces of both genetic and epigenetic events, which produce variant clonal populations, together with the selective pressures of the microenvironment, which promote growth and, perhaps, dissemination of variants with a specific set of characteristics. Although the importance of genetic mutations in cancer has long been recognized, the role of epigenetic events has been suggested more recently. This review focuses on the genetic and epigenetic molecular mechanisms involved in cancer onset and progression, and discusses the possibility of new strategies in the development of anticancer treatments.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Palermo, Dept Oncol, Sect Mol Oncol, Reg Reference Ctr Biomol Characterizat Neoplasm &, Palermo, Italy; Regina Elena Inst Canc Res, Ctr Expt Res, Rome, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Palermo; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010; Paggi, Marco G./K-3494-2018	Giordano, Antonio/0000-0002-5959-016X; 				Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Aplin AE, 1998, PHARMACOL REV, V50, P197; Bartkova J, 1996, CANCER RES, V56, P5475; Beasley MB, 2003, HUM PATHOL, V34, P136, DOI 10.1053/hupa.2003.8; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brat DJ, 1998, AM J SURG PATHOL, V22, P163, DOI 10.1097/00000478-199802000-00003; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CINTI C, 2000, EMERGING THER TARGET, V4, P765; Cornelius LA, 1998, J IMMUNOL, V161, P6845; De Luca A, 2003, CANCER RES, V63, P1430; Ding HF, 2002, ANN MED, V34, P451, DOI 10.1080/078538902321012405; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Duensing S, 2001, CANCER RES, V61, P2356; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Frank SA, 2003, CURR BIOL, V13, pR261, DOI 10.1016/S0960-9822(03)00195-7; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; GAN DD, 2003, IN PRESS J EXP CLIN; Gatenby RA, 2003, NATURE, V421, P321, DOI 10.1038/421321a; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; HAJES JJ, 2001, CURR OPIN GENE DEV, V11, P124; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; JEN J, 1994, CANCER RES, V54, P6353; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KALEBIC T, 2003, ANN ACAD SCI, V293, P278; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Konopka G, 2003, CURR MOL MED, V3, P73, DOI 10.2174/1566524033361609; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Lee JH, 1997, CANCER RES, V57, P2384; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Meijer L, 1995, Prog Cell Cycle Res, V1, P351; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Muegge K, 2003, ANN NY ACAD SCI, V983, P55, DOI 10.1111/j.1749-6632.2003.tb05962.x; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Newcomb EW, 2000, HUM PATHOL, V31, P115, DOI 10.1016/S0046-8177(00)80207-5; OHTA M, 1994, CANCER RES, V54, P5269; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Paggi MG, 2001, CANCER RES, V61, P4651; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Russo A, 2001, CANCER, V92, P294, DOI 10.1002/1097-0142(20010715)92:2<294::AID-CNCR1322>3.0.CO;2-9; RUSSO A, 2003, IN PRESS ENCY HUM GE; Saikawa Y, 2001, JPN J CANCER RES, V92, P1102, DOI 10.1111/j.1349-7006.2001.tb01065.x; Sandal T, 2002, ONCOLOGIST, V7, P73, DOI 10.1634/theoncologist.7-1-73; Sarkar S, 2000, CANCER RES, V60, P3862; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297; Skubitz Amy P N, 2002, Cancer Treat Res, V107, P305; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; Stewart CL, 2001, J NEURO-ONCOL, V51, P183, DOI 10.1023/A:1010615822317; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sutherland JE, 2003, ANN NY ACAD SCI, V983, P151, DOI 10.1111/j.1749-6632.2003.tb05970.x; TEMPIACALIERA AA, 2002, J SURG ONCOL, V9, P668; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Toyota M, 2002, J GASTROENTEROL, V37, P97, DOI 10.1007/BF03326425; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; von Willebrand M, 2003, CANCER RES, V63, P1420; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yasui W, 2003, ANN NY ACAD SCI, V983, P220, DOI 10.1111/j.1749-6632.2003.tb05977.x; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057; Zini N, 2001, J CELL PHYSIOL, V189, P34, DOI 10.1002/jcp.1135; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451	98	73	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6472	6478		10.1038/sj.onc.1206955	http://dx.doi.org/10.1038/sj.onc.1206955			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528270				2022-12-17	WOS:000185700700002
J	Totzke, G; Schulze-Osthoff, K; Janicke, RU				Totzke, G; Schulze-Osthoff, K; Janicke, RU			Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition	ONCOGENE			English	Article						NS-398; nimesulide; COX-2; death receptor; apoptosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANCER CELLS; ANTICANCER AGENTS; HUMAN COLON; KAPPA-B; EXPRESSION; CELECOXIB; GROWTH; SUPPRESSION; INDUCTION	Cyclooxygenase-2 (COX-2) is involved in diverse processes such as inflammation, carcinogenesis and apoptosis. As COX-2 inhibitors interfere with these processes, inhibition of COX-2 has been suggested as a promising anticancer treatment. However, the role of COX-2 in modulation of apoptosis as well as the death pathways affected by COX-2 inhibitors are poorly characterized. Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E-2 (PGE(2)) production, only in H21 cells. TNF did also not induce PGE(2) production in MCF-7/casp-3 cells stably expressing COX-2; however, nimesulide strongly enhanced TNF-induced apoptosis in these cells. Furthermore, COX-2 activity in HeLa H21 cells could be inhibited by NS-398 concentrations that were 10000-fold lower compared to those required for the induction of cell death. Most intriguingly, sensibilization to apoptosis was specifically observed in response to activation of death receptors. Not only TNF-induced cell death but also apoptosis triggered by the CD95 and TRAIL receptors was enhanced by nimesulide. In contrast, apoptosis induced by the anticancer drugs doxorubicine and etoposide that target the mitochondrial death pathway remained unaffected. Together, our data suggest that COX-2 inhibitors overcome apoptosis resistance and selectively sensitize tumor cells to the extrinsic death receptor-induced apoptotic pathway independently of COX-2.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Callejas NA, 2002, HEPATOLOGY, V35, P341, DOI 10.1053/jhep.2002.31163; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Elder DJE, 2002, INT J CANCER, V99, P323, DOI 10.1002/ijc.10330; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; GUPTA RA, 2000, ANN NY ACAD SCI, V10, P196; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 2000, CLIN CANCER RES, V6, P2006; Hsi LC, 2000, EXP CELL RES, V256, P563, DOI 10.1006/excr.2000.4863; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang Y, 2001, CANCER RES, V61, P6918; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; JENDROSSEK V, 2003, IN PRESS FASSEB J; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KO Y, 1995, MOL CELL PROBE, V9, P215, DOI 10.1016/S0890-8508(95)90070-5; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Liu XH, 1998, CANCER RES, V58, P4245; Masferrer JL, 2000, CANCER RES, V60, P1306; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Nzeako UC, 2002, HEPATOLOGY, V35, P552, DOI 10.1053/jhep.2002.31774; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Ravi R, 2002, CANCER RES, V62, P4180; Ricchi P, 2002, BRIT J CANCER, V86, P1501, DOI 10.1038/sj.bjc.6600289; Ristimaki A, 1997, CANCER RES, V57, P1276; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shureiqi I, 2000, CANCER RES, V60, P6846; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Song XQ, 2002, J NATL CANCER I, V94, P585; Souza RF, 2000, CANCER RES, V60, P5767; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stier S, 2000, FEBS LETT, V467, P299, DOI 10.1016/S0014-5793(00)01177-7; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Tang XM, 2002, CANCER RES, V62, P4903; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tucker ON, 1999, CANCER RES, V59, P987; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Waskewich C, 2002, CANCER RES, V62, P2029; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wong BCY, 2003, ONCOGENE, V22, P1189, DOI 10.1038/sj.onc.1206234; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zimmermann KC, 1999, CANCER RES, V59, P198	58	73	77	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8021	8030		10.1038/sj.onc.1206837	http://dx.doi.org/10.1038/sj.onc.1206837			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970750				2022-12-17	WOS:000185388200017
J	Haga, N; Fujita, N; Tsuruo, T				Haga, N; Fujita, N; Tsuruo, T			Mitochondrial aggregation precedes cytochrome c 1release from mitochondria during apoptosis	ONCOGENE			English	Article						apoptosis; mitochondria; aggregation; cytochrome c; laser scanning cytometer	CELL-DEATH; ROCK-I; RELEASE; ACTIVATION; CASPASE-2; CLEAVAGE; PROTEIN; BCL-2; BAX; REQUIREMENT	Mitochondria play a central role in apoptotic signaling pathways. Upon exposure to apoptotic stimuli, mitochondria release cytochrome c to the cytoplasm and activate caspase cascade leading to cell death. However, the events upstream of cytochrome c release are not fully understood. Here, we quantitate mitochondrial aggregation in situ using a novel laser scanning cytometry technique and reveal that mitochondria aggregate during apoptosis in a budding-like shape. The quantitative analysis reveals that mitochondrial aggregation is not inhibited by caspase-3 inhibitor ZEVD. Furthermore, bcl-x(L) transfection cannot suppress mitochondrial aggregation. However, overexpression of bcl-x(L) inhibits cytochrome c release from mitochondria. Therefore, mitochondrial aggregation is an event upstream of cytochrome c release during apoptosis. This mitochondrial aggregation was not observed in human leukemia H9 cells where apoptosis occurs in a mitochondria-independent fashion. Our studies imply that changes in the localization of mitochondria participate in the regulation of apoptosis through cytochrome c release.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferreira CG, 2000, CANCER RES, V60, P7133; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Haga N, 1998, INT J CANCER, V76, P86, DOI 10.1002/(SICI)1097-0215(19980330)76:1<86::AID-IJC14>3.0.CO;2-E; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	36	73	76	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5579	5585		10.1038/sj.onc.1206576	http://dx.doi.org/10.1038/sj.onc.1206576			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944905				2022-12-17	WOS:000184865900006
J	Shin, HJ; Baek, KH; Jeon, AH; Kim, SJ; Jang, KL; Sung, YC; Kim, CM; Lee, CW				Shin, HJ; Baek, KH; Jeon, AH; Kim, SJ; Jang, KL; Sung, YC; Kim, CM; Lee, CW			Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation	ONCOGENE			English	Article							CYCLIN-A; KINETOCHORE LOCALIZATION; APOPTOSIS; KINASE; BUBR1; MITOSIS	Histone modification through acetylation and deacetylation is a key process in transcription, DNA replication, and chromosome segregation. During mitosis, histones are highly acetylated and chromatin is condensed. Here, we investigate the mechanistic involvement of histone deacetylase (HDAC) activity in the regulation of mitotic checkpoint activation. Inhibition of HDAC activity was found to cause the improper kinetochore localization of the mitotic checkpoint proteins, and to prolong mitotic arrest, and thus to lead to chromosomal instability due to aberrant exit from the mitotic cell cycle arrest. In addition, treatment with HDAC inhibitor attenuated the activations of p38 and ERK kinases, and increased the expression levels of cIAP-1, suggesting that the observed increased adaptation and chromosomal instability induced by inhibiting HDAC activity might be directly connected with the activations of cell survival and/or antiapoptotic signals. Moreover, the treatment of cells with mitotic defects with HDAC inhibitor increased their susceptibility to chromosomal instability. These results support the notion that HDAC activity plays an important role in the regulation of mitotic checkpoint activation, and thus the aberrant control of HDAC activity contributes to chromosomal instability.	Natl Canc Ctr, Res Inst, Goyang 411764, Gyeonggi Do, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang, South Korea; Pusan Natl Univ, Dept Microbiol, Pusan 609735, South Korea	National Cancer Center - Korea (NCC); Pohang University of Science & Technology (POSTECH); Pusan National University	Lee, CW (corresponding author), Natl Canc Ctr, Res Inst, Goyang 411764, Gyeonggi Do, South Korea.	cwlee@ncc.re.kr		Lee, Chang-Woo/0000-0002-0943-1646				Amato SF, 1998, CANCER RES, V58, P241; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Lieu CH, 1998, CELL GROWTH DIFFER, V9, P767; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1	26	73	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3853	3858		10.1038/sj.onc.1206502	http://dx.doi.org/10.1038/sj.onc.1206502			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813458				2022-12-17	WOS:000183612000004
J	Medrano, EE				Medrano, EE			Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis	ONCOGENE			English	Article						melanocytes; melanoma; Ski; c-ski; Smad2; Smad3; RB; p21(Waf-1); SnoN	TRANSFORMING-GROWTH-FACTOR; HISTONE DEACETYLASE COMPLEX; TUMOR SUPPRESSIVE FUNCTIONS; ANAPHASE-PROMOTING COMPLEX; DEATH-ASSOCIATED PROTEINS; PROTOONCOGENE C-SKI; TRANSCRIPTIONAL REPRESSION; SMAD PROTEINS; V-SKI; MALIGNANT-MELANOMA	Transforming growth factor-beta (TGF-beta) has dual and paradoxical functions as a tumor suppressor and promoter of tumor progression and metastasis. TGF-beta-mediated growth inhibition is gradually lost during melanoma tumor progression, but there are no measurable defects at the receptor level. Furthermore, melanoma cells release high levels of TGF-beta to the microenvironment, which upon activation induces matrix deposition, angiogenesis, survival, and transition to more aggressive phenotypes. The SKI and SnoN protein family associate with and repress the activity of Smad2, Smad3, and Smad4, three members of the TGF-beta signaling pathway. SKI also facilitates cell-cycle progression by targeting the RB pathway by at least two ways: it directly associates with RB and represses its activity when expressed at high levels, and indirectly, it represses Smad-mediated induction of p21(Waf-1). This results in increased CDK2 activity, RB phosphorylation, and inactivation. Therefore, high levels of SKI result in lesions to the RB pathway in a manner similar to p16(INK4a) loss. SKI mRNA and protein levels dramatically increase during human melanoma tumor progression. In addition, the SKI protein shifts from nuclear localization in intraepidermal melanoma cells to nuclear and cytoplasmic in invasive and metastatic melanomas. Here, I discuss the basis for repression of intracellular TGF-beta signaling by SKI, some additional activities of this protein, and propose that by disrupting multiple tumor suppressor pathways, SKI functions as a melanoma oncogene.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Medrano, EE (corresponding author), Baylor Coll Med, Huffington Ctr Aging, 1 Baylor Plaza M320, Houston, TX 77030 USA.							Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Amaravadi LS, 1997, DEV BIOL, V192, P392, DOI 10.1006/dbio.1997.8780; [Anonymous], GENOME BIOL; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; BARKAS A, 1986, THESIS NEW YORK U NE; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Berking C, 2001, CANCER RES, V61, P8306; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Cohen SB, 1999, NUCLEIC ACIDS RES, V27, P1006, DOI 10.1093/nar/27.4.1006; Colmenares C, 2002, NAT GENET, V30, P106, DOI 10.1038/ng770; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Ichikawa K, 1997, BIOCHEM J, V328, P607, DOI 10.1042/bj3280607; JANG CW, 2001, NAT CELL BIOL; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaufman CD, 2000, MECH DEVELOP, V95, P147, DOI 10.1016/S0925-4773(00)00351-8; Kelder B, 1997, GENE, V202, P15, DOI 10.1016/S0378-1119(97)00439-3; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kissil JL, 1998, MOL MED TODAY, V4, P268, DOI 10.1016/S1357-4310(98)01263-5; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Krasagakis K, 1999, J CELL PHYSIOL, V178, P179, DOI 10.1002/(SICI)1097-4652(199902)178:2<179::AID-JCP7>3.0.CO;2-5; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; LYONS GE, 1994, DEV DYNAM, V201, P354, DOI 10.1002/aja.1002010407; Massague J, 2000, GENE DEV, V14, P627; Moustakas A, 2001, J CELL SCI, V114, P4359; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; NAMCIU S, 1994, ONCOGENE, V9, P1407; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; REED JA, 1994, AM J PATHOL, V145, P97; Reed JA, 2001, CANCER RES, V61, P8074; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RODECK U, 1994, CANCER RES, V54, P575; Rooke HM, 2001, PATHOLOGY, V33, P73; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Shinagawa T, 2001, ONCOGENE, V20, P8100, DOI 10.1038/sj.onc.1204987; SOBBALLE PW, 1994, MELANOMA RES, V4, P213; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stone JG, 1997, J CELL SCI, V110, P1673; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Tietze MK, 2000, MOL MED TODAY, V6, P408, DOI 10.1016/S1357-4310(00)01781-0; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wong SF, 2001, PATHOLOGY, V33, P85; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yang FC, 2001, SEMIN CANCER BIOL, V11, P261, DOI 10.1006/scbi.2000.0376; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	82	73	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3123	3129		10.1038/sj.onc.1206452	http://dx.doi.org/10.1038/sj.onc.1206452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12793438				2022-12-17	WOS:000183096600014
J	Ramirez, RD; Herbert, BS; Vaughan, MB; Zou, Y; Gandia, K; Morales, CP; Wright, WE; Shay, JW				Ramirez, RD; Herbert, BS; Vaughan, MB; Zou, Y; Gandia, K; Morales, CP; Wright, WE; Shay, JW			Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells	ONCOGENE			English	Article						replicative senescence; epithelial cells; cell cycle; ageing; Cdk inhibitors	HUMAN-DIPLOID FIBROBLASTS; CELLULAR SENESCENCE; DNA-REPLICATION; G(1) ARREST; LIFE-SPAN; GROWTH; P16; P53; RB; IMMORTALIZATION	Many stimuli causing 'stress' or DNA damage in cells can produce phenotypes that overlap with telomere-based replicative senescence. In epithelial systems, the p16/RB pathway may function as a stress senescence-signaling pathway independent of telomere shortening. Overexpressing cyclin-dependent kinase 4 (Cdk4) in human epidermal keratinocytes and human mammary epithelial cells not only prevents the p16(INK4a)-associated premature growth arrest due to telomere-independent stress (e.g., inadequate culture conditions), but also bypasses the ensuing telomere-dependent senescence (M1). Overexpressed Cdk4 in epithelial cells induces a dramatic upregulation of p16(INK4a) and milder upregulation of p53 and p21(WAF1), which become unresponsive to UV irradiation. Despite the high levels of these checkpoint factors, Cdk4-overexpressing cells divide in an apparently normal regulated fashion, are able to respond to changes in calcium levels, retain the stem cell phenotype, and fully differentiate and stratify. These results suggest that the differentiation pathways in Cdk4-overexpressing cells remain intact.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Dallas Vet Affairs Med Ctr, Dept Internal Med, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ramirez, RD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	ruben.ramirez@utsouthwestern.edu	Vaughan, Melville B/J-6637-2016; Shay, Jerry W/F-7878-2011	Vaughan, Melville B/0000-0003-4648-6141; Zou, Ying/0000-0003-2787-1917	NATIONAL INSTITUTE ON AGING [R37AG001228, R01AG001228] Funding Source: NIH RePORTER; NIA NIH HHS [AG01228] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jarrard DF, 1999, CANCER RES, V59, P2957; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; PARENTEAU N, 1994, KERATINOCYTE METHODS, P45; Pavey S, 1999, CANCER RES, V59, P4185; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reddel RR, 2001, J CLIN INVEST, V108, P665, DOI 10.1172/JCI200113818; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shay Jerry W., 1994, Molecular and Cellular Differentiation, V2, P1; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; Stein GH, 1999, MOL CELL BIOL, V19, P2109; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	52	73	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					433	444		10.1038/sj.onc.1206046	http://dx.doi.org/10.1038/sj.onc.1206046			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545164				2022-12-17	WOS:000180379100012
J	Hawighorst, T; Oura, H; Streit, M; Janes, L; Nguyen, L; Brown, LF; Oliver, G; Jackson, DG; Detmar, M				Hawighorst, T; Oura, H; Streit, M; Janes, L; Nguyen, L; Brown, LF; Oliver, G; Jackson, DG; Detmar, M			Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice	ONCOGENE			English	Article						TSP-1; VEGF; Prox1; LYVE-1; chemoprevention	ENDOTHELIAL GROWTH-FACTOR; CARCINOMA CELL-LINE; MULTISTAGE CARCINOGENESIS; SKIN CARCINOGENESIS; VESSEL MATURATION; MOUSE SKIN; CANCER; PROMOTES; PROGRESSION; EXPRESSION	The roles played by the endogenous angiogenesis inhibitor thrombospondin-1 (TSP-1) in the early stages of multi-step carcinogenesis and in the control of hematogenous versus lymphatic metastasis are unknown. To investigate these issues we compared tumor development in normal mice and in transgenic mice with targeted overexpression of TSP-1 in the epidermis following a standard two-step chemical skin carcinogenesis regimen. Overexpression of TSP-1 resulted in delayed and reduced development of premalignant epithelial. hyperplasias, but did not inhibit the malignant conversion to squamous cell carcinomas. TSP-1 overexpression also suppressed tumor angiogenesis and distant organ metastasis, but failed to inhibit tumor-associated lymphangiogenesis or lymphatic tumor spread to regional lymph nodes. Concomitant with these results, we found that the endothelial TSP-1 receptor CD36 was mostly absent from cutaneous lymphatic vessels. Our findings indicate the potential use of TSP-1 for the prevention of premalignant stages of tumorigenesis and are likely to have implications for the further development of anti-angiogenic cancer therapies.	Massachusetts Gen Hosp, Dept Dermatol, CBRC, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; John Radcliffe Hosp, Inst Mol Med, IMCR Human Immunol Unit, Oxford OX3 9DS, England	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; St Jude Children's Research Hospital; University of Oxford	Detmar, M (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, CBRC, Bldg 149,13st St, Charlestown, MA 02129 USA.	michael.detmar@cbrc2.mgh.harvard.edu		, david/0000-0002-4133-9364	NATIONAL CANCER INSTITUTE [R01CA069184, R01CA086410, R01CA091861] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058462] Funding Source: NIH RePORTER; NCI NIH HHS [CA69184, CA86410, CA91861] Funding Source: Medline; NEI NIH HHS [EY12162] Funding Source: Medline; NIGMS NIH HHS [GM58462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez AA, 2001, GYNECOL ONCOL, V82, P273, DOI 10.1006/gyno.2001.6287; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Beasley NJP, 2002, CANCER RES, V62, P1315; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Brekken RA, 1998, CANCER RES, V58, P1952; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Eberhard A, 2000, CANCER RES, V60, P1388; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; Hawighorst T, 2002, AM J PATHOL, V160, P1381, DOI 10.1016/S0002-9440(10)62565-5; Hawighorst T, 2001, EMBO J, V20, P2631, DOI 10.1093/emboj/20.11.2631; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Ito N, 1995, CRIT REV ONCOL HEMAT, V21, P105, DOI 10.1016/1040-8428(94)00169-3; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Karpanen T, 2001, CANCER RES, V61, P1786; Kodama J, 2001, CLIN CANCER RES, V7, P2826; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LEONE A, 1993, ONCOGENE, V8, P2325; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Marks F, 2000, EUR J CANCER, V36, P314, DOI 10.1016/S0959-8049(99)00318-4; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; YUSPA SH, 1994, CANCER RES, V54, P1178; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	42	73	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7945	7956		10.1038/sj.onc.1205956	http://dx.doi.org/10.1038/sj.onc.1205956			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439745				2022-12-17	WOS:000179097200004
J	Pamment, J; Ramsay, E; Kelleher, M; Dornan, D; Ball, KL				Pamment, J; Ramsay, E; Kelleher, M; Dornan, D; Ball, KL			Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway	ONCOGENE			English	Article						IRF-1; protein turnover; ATM; p53; DNA damage	TRANSCRIPTION FACTOR IRF-1; ATAXIA-TELANGIECTASIA; P53-DEPENDENT TRANSCRIPTION; IONIZING-RADIATION; MESSENGER-RNA; DNA-DAMAGE; LONG ARM; FACTOR-I; C-JUN; P53	The mechanism by which genotoxic stress induces IRF-1 and the signalling components upstream of this anti-oncogenic transcription factor during the response to DNA damage are not known. We demonstrate that IRF-1 and the tumour suppressor protein p53 are coordinately up-regulated during the response to DNA damage in an ATM-dependent manner. Induction of IRF-1 protein by either ionizing radiation (IR) or etoposide occurs through a concerted mechanism involving increased IRF-1 expression/synthesis and an increase in the half-life of the IRF-1 protein. A striking defect in the induction of both IRF-1 mRNA and IRF-1 protein was observed in ATM deficient cells. Although ATM deficient cells failed to increase IRF-1 in response to genotoxic stress, the induction of IRF-1 in response to viral mimetics remained intact. Re-expression of the ATM kinase in AT cells restored the DNA damage inducibility of IRF-1, whilst the PI-3 kinase inhibitor wortmannin inhibited IRF-1 induction by DNA damage in ATM-positive cells. The data highlight a role for the ATM kinase in orchestrating the coordinated induction and transcriptional cooperation of IRF-1 and p53 to regulate p21 expression. Thus, IRF-1 is controlled by two distinct signalling pathways; a JAK/STAT-signalling pathway in viral infected cells and an ATM-signalling pathway in DNA damaged cells.	Univ Dundee, Sch Med, Canc Res UK Labs, Dundee DD1 9SY, Scotland	University of Dundee	Ball, KL (corresponding author), Univ Dundee, Sch Med, Canc Res UK Labs, Dundee DD1 9SY, Scotland.	k.l.ball@dundee.ac.uk		Kelleher, Michael/0000-0002-0005-3079				BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Beretta L, 1996, ONCOGENE, V12, P1593; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; BOULTWOOD J, 1993, BLOOD, V82, P2611; CANMAN CE, 1994, CANCER RES, V54, P5054; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Eason DE, 1999, BBA-GENE STRUCT EXPR, V1446, P140, DOI 10.1016/S0167-4781(99)00078-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Fukao T, 1999, BLOOD, V94, P1998; Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111; Green WB, 1999, LEUKEMIA, V13, P1960, DOI 10.1038/sj.leu.2401596; HARADA H, 1994, ONCOGENE, V9, P3313; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; LEE WH, 1991, COLD SH Q B, V56, P211; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lin RT, 1999, MOL CELL BIOCHEM, V191, P169, DOI 10.1023/A:1006850009017; Lin WC, 2001, GENE DEV, V15, P1833; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; PAULES RS, 1995, CANCER RES, V55, P1763; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Prost S, 1998, FASEB J, V12, P181, DOI 10.1096/fasebj.12.2.181; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sharf R, 1997, J BIOL CHEM, V272, P9785; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; SiddooAtwal C, 1996, CANCER RES, V56, P443; Sikpi MO, 1999, INT J RADIAT BIOL, V75, P893, DOI 10.1080/095530099139953; STEVENS AM, 1994, MOL ENDOCRINOL, V8, P345, DOI 10.1210/me.8.3.345; STEVENS AM, 1992, MOL ENDOCRINOL, V6, P2236, DOI 10.1210/me.6.12.2236; Tamura G, 1996, CANCER RES, V56, P612; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TAMURANISHIMURA M, 1990, FEBS LETT, V261, P343, DOI 10.1016/0014-5793(90)80587-9; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; TANIGUCHI T, 1989, J INTERFERON RES, V9, P633, DOI 10.1089/jir.1989.9.633; Taniguchi T, 1998, EUR CYTOKINE NETW, V9, P43; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Wang Q, 1998, GENE, V222, P83, DOI 10.1016/S0378-1119(98)00476-4; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	67	73	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7776	7785		10.1038/sj.onc.1205981	http://dx.doi.org/10.1038/sj.onc.1205981			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420214				2022-12-17	WOS:000178946000002
J	Malek, RL; Irby, RB; Guo, QBM; Lee, K; Wong, S; He, M; Tsai, J; Frank, B; Liu, ET; Quackenbush, J; Jove, R; Yeatman, TJ; Lee, NH				Malek, RL; Irby, RB; Guo, QBM; Lee, K; Wong, S; He, M; Tsai, J; Frank, B; Liu, ET; Quackenbush, J; Jove, R; Yeatman, TJ; Lee, NH			Identification of Src transformation fingerprint in human colon cancer	ONCOGENE			English	Article						Src; colon cancer; expression profiling; microarray	BETA-PROTEIN-PRECURSOR; C-SRC; GENE-EXPRESSION; V-SRC; BINDING PROTEIN; MESSENGER-RNA; SARCOMA VIRUS; ACTIVATION; OVEREXPRESSION; GROWTH	We used a classical rodent model of transformation to understand the transcriptional processes, and hence the molecular and cellular events a given cell undergoes when progressing from a normal to a transformed phenotype. Src activation is evident in 80% of human colon cancer, yet the myriad of cellular processes effected at the level of gene expression has yet to be fully documented. We identified a Src 'transformation fingerprint' within the gene expression profiles of Src-transformed rat 3Y1 fibroblasts demonstrating a progression in transformation characteristics. To evaluate the role of this gene set in human cancer development and progression, we extracted the orthologous genes present on the Affymetrix Hu95A GeneChip(TM) (12k named genes) and compared expression profiles between the Src-induced rodent cell line model of transformation and staged colon tumors where Src is known to be activated. A similar gene expression pattern between the cell line model and staged colon tumors for components of the cell cycle, cytoskeletal associated proteins, transcription factors and lysosomal proteins suggests the need for co-regulation of several cellular processes in the progression of cancer. Genes not previously implicated in tumorigenesis were detected, as well as a set of 14 novel, highly conserved genes with here-to-fore unknown function. These studies define a set of transformation associated genes whose up-regulation has implications for understanding Src mediated transformation and strengthens the role of Src in the development and progression of human colon cancer. Supportive Supplemental Data can be viewed at http:// pga.tigr.org/PGApubs.shtml.	Univ S Florida, Coll Med, Dept Surg, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Johns Hopkins Canc Ctr, Div Canc Biol, Baltimore, MD 21231 USA; Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; NCI, Div Clin Sci, Med Branch,Mol Signaling & Oncogenesis Sect, Dept Canc & Cell Biol, Bethesda, MD 20892 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yeatman, TJ (corresponding author), Univ S Florida, Coll Med, Dept Surg, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA.	yeatman@moffitt.usf.edu; nhlee@tigr.org	Liu, Edison/C-4141-2008	Quackenbush, John/0000-0002-2702-5879	NATIONAL CANCER INSTITUTE [K24CA085429, R01CA077049, U01CA085052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059781] Funding Source: NIH RePORTER; NCI NIH HHS [CA77049-02, CA85429-01, CA85052-A1] Funding Source: Medline; NHLBI NIH HHS [HL59781] Funding Source: Medline; PHS HHS [6120-119-L0-A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akamatsu H, 1996, CANCER RES, V56, P4541; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Ben-Dor A, 1999, J COMPUT BIOL, V6, P281, DOI 10.1089/106652799318274; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BYRNE JA, 1995, CANCER RES, V55, P2896; Chew CS, 2000, J CELL SCI, V113, P2035; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Freier S, 1999, GUT, V44, P704, DOI 10.1136/gut.44.5.704; Guo QM, 2000, CANCER RES, V60, P5922; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; Iravani S, 1998, LAB INVEST, V78, P365; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Manenti S, 1998, CANCER RES, V58, P1429; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; Niinaka Y, 1998, CANCER RES, V58, P2667; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OKAMOTOINOUE M, 1990, J CELL SCI, V96, P631; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SKOTZKO M, 1995, CANCER RES, V55, P5493; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; TAKEKURA N, 1990, INT J CANCER, V45, P847, DOI 10.1002/ijc.2910450510; TAKEYA T, 1982, J VIROL, V44, P12, DOI 10.1128/JVI.44.1.12-18.1982; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WICKUS G, 1975, P NATL ACAD SCI USA, V72, P746, DOI 10.1073/pnas.72.2.746; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852; YANO M, 1999, CANC LETT, V22, P45; Yeung KY, 2001, BIOINFORMATICS, V17, P309, DOI 10.1093/bioinformatics/17.4.309; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	54	73	79	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7256	7265		10.1038/sj.onc.1205900	http://dx.doi.org/10.1038/sj.onc.1205900			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370817				2022-12-17	WOS:000178504600015
J	Gad, S; Caux-Moncoutier, V; Pages-Berhouet, S; Gauthier-Villars, M; Coupier, I; Pujol, P; Frenay, M; Gilbert, B; Maugard, C; Bignon, YJ; Chevrier, A; Rossi, A; Fricker, JP; Nguyen, TD; Demange, L; Aurias, A; Bensimon, A; Stoppa-Lyonnet, D				Gad, S; Caux-Moncoutier, V; Pages-Berhouet, S; Gauthier-Villars, M; Coupier, I; Pujol, P; Frenay, M; Gilbert, B; Maugard, C; Bignon, YJ; Chevrier, A; Rossi, A; Fricker, JP; Nguyen, TD; Demange, L; Aurias, A; Bensimon, A; Stoppa-Lyonnet, D			Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families	ONCOGENE			English	Article						BRCA1 mutations; rearrangements; breast-ovarian cancer	KB DELETION; COMBED DNA; IDENTIFICATION; MUTATIONS; REGION; INDIVIDUALS; DUPLICATION; SEQUENCE; LIES	Genetic linkage data have shown that alterations of the BRCA1 gene are responsible for the majority of hereditary breast-ovarian cancers. However, BRCA1 germline mutations are found much less frequently than expected, especially as standard PCR-based mutation detection approaches focus on point and small gene alterations. In order to estimate the contribution of large gene rearrangements to the BRCA1 mutation spectrum, we have extensively analysed a series of 120 French breast-ovarian cancer cases. Thirty-eight were previously found carrier of a BRCA1 point mutation, 14 of a BRCA2 point mutation and one case has previously been reported as carrier of a large BRCA1 deletion. The remaining 67 cases were studied using the BRCA1 bar code approach on combed DNA which allows a panoramic view of the BRCA1 region. Three additional rearrangements were detected: a recurrent 23.8 kb deletion of exons 8-13, a 17.2 kb duplication of exons 3-8 and a 8.6 kb duplication of exons 18-20. Thus, in our series, BRCA1 large rearrangements accounted for 3.3% (4/120) of breast-ovarian cancer cases and 9.5% (4/42) of the BRCA1 gene mutation spectrum, suggesting that their screening is an important step that should be now systematically included in genetic testing surveys.	Inst Curie, Serv Genet Oncol, Med Sect, F-75248 Paris 05, France; CHU Arnaud Villeneuve, Montpellier, France; Ctr Antoine Lacassagne, F-06054 Nice, France; CHU Dupuytren, Limoges, France; Ctr Rene Gauducheau, F-44035 Nantes, France; Ctr Jean Perrin, Clermont Ferrand, France; Hop Charles Nicolle, Rouen, France; Ctr Paul Strauss, Strasbourg, France; Inst Jean Godinot, Reims, France; Inst Curie, INSERM, U509 Pathol Mol Canc, F-75248 Paris 05, France; Inst Pasteur, ADN, Biophys Lab, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Montpellier; CHU de Montpellier; UNICANCER; Centre Antoine Lacassagne; CHU Limoges; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Centre Jean Perrin; CHU de Rouen; UNICANCER; Centre Paul Strauss; UNICANCER; Institut Jean Godinot; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Stoppa-Lyonnet, D (corresponding author), Inst Curie, Serv Genet Oncol, Med Sect, 26 Rue Ulm, F-75248 Paris 05, France.	dominique.stoppa-lyonnet@curie.net	, bignon/Y-3243-2019	GAD (LAPITEAU), Sophie/0000-0002-3158-6791				Armour JAL, 2000, NUCLEIC ACIDS RES, V28, P605, DOI 10.1093/nar/28.2.605; Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; Brown MA, 1996, ONCOGENE, V12, P2507; Bruder CEG, 2001, HUM MOL GENET, V10, P271, DOI 10.1093/hmg/10.3.271; Carson N, 1999, AM J HUM GENET, V65, pA287; Charbonnier F, 2000, CANCER RES, V60, P2760; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Gad S, 2001, J MED GENET, V38, P388, DOI 10.1136/jmg.38.6.388; Gad S, 2001, GENE CHROMOSOME CANC, V31, P75, DOI 10.1002/gcc.1120; Laurendeau I, 1999, CLIN CHEM, V45, P982; Mazoyer S, 2000, AM J HUM GENET, V67, P207, DOI 10.1086/302974; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Montagna M, 1999, ONCOGENE, V18, P4160, DOI 10.1038/sj.onc.1202754; Nordling M, 1998, CANCER RES, V58, P1372; Pages S, 2001, BRIT J CANCER, V84, P482, DOI 10.1054/bjoc.2000.1627; Payne SR, 2000, GENE CHROMOSOME CANC, V29, P58, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1008>3.0.CO;2-F; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Puget N, 1999, AM J HUM GENET, V64, P300, DOI 10.1086/302211; Puget N, 1997, CANCER RES, V57, P828; Puget N, 1999, CANCER RES, V59, P455; Rohlfs EM, 2000, HUM GENET, V107, P385, DOI 10.1007/s004390000372; Rohlfs EM, 2000, GENE CHROMOSOME CANC, V28, P300, DOI 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1; Serova O, 1996, AM J HUM GENET, V58, P42; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Swensen J, 1997, HUM MOL GENET, V6, P1513, DOI 10.1093/hmg/6.9.1513; Unger MA, 2000, AM J HUM GENET, V67, P841, DOI 10.1086/303076; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; Wang T, 2001, GENE CHROMOSOME CANC, V31, P91, DOI 10.1002/gcc.1110; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057	34	73	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6841	6847		10.1038/sj.onc.1205685	http://dx.doi.org/10.1038/sj.onc.1205685			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360411				2022-12-17	WOS:000178315800015
J	Godthelp, BC; Artwert, F; Joenje, H; Zdzienicka, MZ				Godthelp, BC; Artwert, F; Joenje, H; Zdzienicka, MZ			Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1	ONCOGENE			English	Article						Fanconi anemia; MMC; Rad51 foci; nuclear accumulation; homologous recombination	PROTEIN; GENE; RECOMBINATION; REPAIR; COMPLEX; CLONING; BRCA2; CDNA	Fanconi anemia is a hereditary cancer susceptibility disorder characterized at the cellular level by spontaneous chromosomal instability and specific hypersensitivity to DNA cross-linking agents such as mitomycin C. This phenotype suggests a possible role for the Fanconi anemia proteins in the repair of DNA lesions induced by these agents, but the molecular mechanism underlying the defect in this disorder has not yet been identified. Here, we show that amongst eight so far identified complementation groups of Fanconi anemia, only fibroblasts derived from group D1 are defective in the formation of nuclear Rad51 foci after X-ray irradiation or mitomycin C treatment. This indicates that the FANCD1 gene product is uniquely involved in the assembly and/or stabilization of the Rad51 complex. Since DNA damage-induced Rad51 nuclear foci are thought to reflect repair of DNA double-strand breaks by homologous recombination, our results suggest that FANCD1 is likely to be involved in homologous recombination-dependent repair.	Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, NL-2333 AL Leiden, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; Ludwik Rydygier Univ Med Sci, Dept Mol Cell Genet, Bydgoszcz, Poland	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Nicolaus Copernicus University	Zdzienicka, MZ (corresponding author), Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	M.Z.Zdzienicka@LUMC.nl						Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; MURNANE JP, 1985, EXP CELL RES, V158, P119, DOI 10.1016/0014-4827(85)90437-9; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Smith J, 1998, J MOL BIOL, V281, P815, DOI 10.1006/jmbi.1998.1971; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Yuan SSF, 1999, CANCER RES, V59, P3547	29	73	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					5002	5005		10.1038/sj.onc.1205656	http://dx.doi.org/10.1038/sj.onc.1205656			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118380				2022-12-17	WOS:000176874800016
J	Li, L; Cleary, S; Mandarano, MA; Long, WW; Birchmeier, C; Jones, FE				Li, L; Cleary, S; Mandarano, MA; Long, WW; Birchmeier, C; Jones, FE			The breast proto-oncogene, HRG alpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland	ONCOGENE			English	Article						heregulin; neuregulin; mammary gland development; lactogenesis; epithelial proliferation; lobuloalveoli	GROWTH-FACTOR; DIFFERENTIATION FACTOR; RNA SURVEILLANCE; TRANSGENIC MICE; HEREGULIN; EXPRESSION; REVEALS; CELLS; MORPHOGENESIS; AMPHIREGULIN	Members of the EGF family of growth factors play critical roles during normal and neoplastic breast development. EGF family member HRGalpha is the only HRG1 isoform expressed in the mouse mammary gland and our previous experiments suggest that HRG1 has a unique role in mammary development. To determine the function of HRGalpha activity during mouse mammary gland development, we generated a HRGalpha-deficient mouse strain. Unlike mice with HRG1 or isoform specific HRGbeta gene deletions, HRGalpha-null mice survive to adulthood. HRGalpha-deficient mice display pronounced defects in mammary gland lobuloalveolar development at 17 days of pregnancy and 3 days post-partum. Terminal and lateral ductal alveoli were condensed and alveolar outgrowth during pregnancy was severely impaired. A dramatic reduction in beta-casein expression accompanied defective alveolar development in the HRGalpha-null mice, as determined by in situ hybridization and Northern blot analysis of HRGalpha-deficient mammary glands at 3 days post-partum. Expression of the milk-protein genes WAP and alpha-lactalbumin was not adversely affected. In situ incorporation of BrdU demonstrated that epithelial proliferation was significantly curtailed in mammary glands of HRGalpha-deficient mice at 17 days post-coitus and 3 days postpartum. These results demonstrate that HRGalpha is an important mammary gland mitogen regulating alveolar development and lactogenesis.	Tulane Univ, Sch Med, Hlth Sci Ctr, Dept Struct & Cellular Biol, New Orleans, LA 70112 USA; Max Delbruck Ctr Mol Med, Dept Med Genet, D-13122 Berlin, Germany; Univ Scranton, Inst Mol Biol & Med, Scranton, PA 18510 USA; Univ Scranton, Dept Biol, Scranton, PA 18510 USA	Tulane University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Scranton; University of Scranton	Jones, FE (corresponding author), Tulane Univ, Sch Med, Hlth Sci Ctr, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.				NCI NIH HHS [1R01CA95783-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095783] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Krane IM, 1996, ONCOGENE, V12, P1781; Le XF, 2000, CANCER RES, V60, P3522; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SAKAKURA T, 1991, INT REV CYTOL, V125, P165, DOI 10.1016/S0074-7696(08)61219-X; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Torres RM, 1997, LAB PROTOCOLS CONDIT; TRAURIG HH, 1967, ANAT REC, V159, P239, DOI 10.1002/ar.1091590213; TRAURIG HH, 1967, ANAT REC, V157, P489, DOI 10.1002/ar.1091570309; Visscher DW, 1997, BREAST CANCER RES TR, V45, P75, DOI 10.1023/A:1005845512804; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	27	73	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4900	4907		10.1038/sj.onc.1205634	http://dx.doi.org/10.1038/sj.onc.1205634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118369				2022-12-17	WOS:000176874800005
J	Park, WS; Lee, JH; Shin, MS; Park, JY; Kim, HS; Lee, JH; Kim, YS; Lee, SN; Xiao, WH; Park, CH; Lee, SH; Yoo, NJ; Lee, JY				Park, WS; Lee, JH; Shin, MS; Park, JY; Kim, HS; Lee, JH; Kim, YS; Lee, SN; Xiao, WH; Park, CH; Lee, SH; Yoo, NJ; Lee, JY			Inactivating mutations of the caspase-10 gene in gastric cancer	ONCOGENE			English	Article						caspase-10; mutation; LOH; gastric cancer; apoptosis	FAS APO-1/CD95 GENE; DEATH DOMAIN; APOPTOSIS; LUNG; AMPLIFICATION; CARCINOMA; DELETION; LIGAND	We have analysed the genetic alteration of the entire coding region and all splice sites of caspase-8 and -10 genes in 99 gastric cancers by polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and sequencing. We found LOH of the caspase-8 and -10 in nine (28%) of 32 and in four (15%) of 26 informative cases, respectively. Overall, three of 99 gastric cancers (3%) were found to have the caspase-10 mutations, which were identified in the coding regions of the death effector domain (codon 147) and the p17 large protease domain (codons 257 and 410), whereas no mutation was detected in caspase-8. In vitro expression studies, the M147T and Q257stop mutants severely impaired caspase-10-mediated apoptosis, whereas the V410I which was the same mutation detected in ALPS patient had a significant, albeit less severe, effect on apoptosis. The data presented here suggest that somatic alterations of the caspase-10 gene might contribute to the pathogenesis in a subset of gastric cancers through the loss of their apoptotic function.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea	Lee, JY (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.	stingray@cmc.cuk.ac.kr	Yoo, Nam Jin/GNM-9060-2022; kim, Hong Sug/G-2731-2014					FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gronbaek K, 2000, BLOOD, V95, P2184; Gronbaek K, 1998, BLOOD, V92, P3018; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; KOHNO T, 1994, ONCOGENE, V9, P103; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1998, LAB INVEST, V78, P453; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Park WS, 2001, J PATHOL, V193, P162; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wyllie AH, 1999, BRIT J CANCER, V80, P34	25	73	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2919	2925		10.1038/sj.onc.1205394	http://dx.doi.org/10.1038/sj.onc.1205394			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973654				2022-12-17	WOS:000175063700019
J	Okutani, Y; Kitanaka, A; Tanaka, T; Kamano, H; Ohnishi, H; Kubota, Y; Ishida, T; Takahara, J				Okutani, Y; Kitanaka, A; Tanaka, T; Kamano, H; Ohnishi, H; Kubota, Y; Ishida, T; Takahara, J			Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway	ONCOGENE			English	Article						Src; STAT5; erythropoietin; tyrosine phosphorylation; antisense	COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; ERYTHROID-DIFFERENTIATION; RECEPTOR; EXPRESSION; KINASES; INTERLEUKIN-3; TRANSDUCTION; PROLACTIN; LEUKEMIA	Signal transducers and activators of transcription (STAT) proteins are transcription factors activated by phosphorylation on tyrosine residues after cytokine stimulation. In erythropoietin receptor (EPOR)-mediated signaling, STAT5 is tyrosine-phosphorylated by EPO stimulation. Although Janus Kinase 2 (JAK2) is reported to play a crucial role in EPO-induced activation of STAT5, it is unclear whether JAK2 alone can tyrosine-phosphorylate STAT5 after EPO stimulation. Several studies indicate that STAT activation is caused by members of other families of protein tyrosine kinases such as the Src family. We previously reported that reduction of Src by induction of antisense src RNA expression suppressed EPO-promoted erythroid differentiation in K562 cells. In the present study, we explored the function of Src downstream of the EPOR-initiated signaling. Reduction of Src diminished tyrosine phosphorylation of STAT5 in K562 cells regardless of EPO treatment. The tyrosine phosphorylation level of STAT5 induced by EPO in F-36P cells was reduced in the presence of PPI or PP2 selective Src inhibitor. In addition, the expression of dominant negative Src in F-36P cells reduced the tyrosine phosphorylation of STAT5. When Src and STAT5 were co-expressed in COS7 cells, tyrosine phosphorylation of STAT5 was observed, and tyrosine residue 694 (Tyr 694) of STAT5A was identified as the major phosphorylation site by Src. In vitro kinase assay revealed that GST-STAT5 fusion protein with the conserved C-terminal, but not the C-terminal-truncated mutant which lacks Tyr 694, was tyrosine-phosphorylated by Src. Src can thus directly tyrosine-phosphorylate the activation site of STAT5 (Tyr 694 in STAT5A), and Src may contribute to EPO-induced signal transduction via STAT5.	Kagawa Med Univ, Dept Internal Med 1, Kagawa 7610793, Japan; Kagawa Med Univ, Lab Med, Kagawa 7610793, Japan; Kagawa Univ, Hlth Sci Ctr, Kagawa 7608521, Japan	Kagawa University; Kagawa University; Kagawa University	Tanaka, T (corresponding author), Kagawa Med Univ, Dept Internal Med 1, Kagawa 7610793, Japan.	tanaka@kms.ac.jp						Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHIBA S, 1991, BLOOD, V78, P2261; Chin H, 1998, BLOOD, V91, P3734; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kitanaka A, 1999, J IMMUNOL, V162, P1952; KITANAKA A, 1994, BIOCHEM BIOPH RES CO, V201, P1534, DOI 10.1006/bbrc.1994.1878; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	34	73	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6643	6650		10.1038/sj.onc.1204807	http://dx.doi.org/10.1038/sj.onc.1204807			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641791				2022-12-17	WOS:000171404200019
J	Tanaka, S; Sugimachi, K; Saeki, H; Kinoshita, J; Ohga, T; Shimada, M; Maehara, Y; Sugimachi, K				Tanaka, S; Sugimachi, K; Saeki, H; Kinoshita, J; Ohga, T; Shimada, M; Maehara, Y; Sugimachi, K			A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma	ONCOGENE			English	Article						gastric carcinoma; scirrhous; stroma; WISP1; CCN	TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; TUMOR-GROWTH; IN-VIVO; FAMILY; CYR61; ANGIOGENESIS; ADHESION; CELLS; IDENTIFICATION	Scirrhous carcinoma of the stomach is characterized by rapid growth with a vast fibrous stroma, high invasiveness, and substantially a poor prognosis. Little is known of the molecular pathogenesis of this disease. Members of the emerging family of the CCN gene (for connective tissue growth factor, cysteine-rich 61, nephroblastoma overexpressed) encode cysteine-rich secreted proteins with roles in human fibrotic disorders and cancer progression. Using targeted differential displays, we identified a novel variant of the CCN family member WISP1 (Wnt-induced secreted protein 1), named WISP1v, as overexpressed in scirrhous. gastric carcinomas. Predicted protein of the WISP1v completely lacks a module of Von Willebrand type C that is thought to participate in protein complex formation. Ectopic expression revealed WISP1v to be a secreted oncoprotein inducing a striking cellular transformation and rapid piling-up growth. It is noteworthy that WISP1v transfectants enhanced the invasive phenotype of cocultured gastric carcinoma cells, while wild-type WISP1 had no such potential. These findings suggest that CCN protein WISP1v is involved in the aggressive progression of scirrhous gastric carcinoma.	Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan; Kyushu Univ, Stn Collaborat Res, Fukuoka, Japan	Kyushu University; Kyushu University	Tanaka, S (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Maehara, Yoshihiko/A-4867-2010					Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CHUNG LWK, 1995, CANCER SURV, V23, P33; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; KITAMURA K, 1995, J SURG ONCOL, V58, P112, DOI 10.1002/jso.2930580208; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Scholz G, 1996, MOL CELL BIOL, V16, P481; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; SUGIMACHI K, 1993, CURR OPIN GEN SURG, V1, P216; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Tanaka S, 1998, P NATL ACAD SCI USA, V95, P10164, DOI 10.1073/pnas.95.17.10164; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Xu LF, 2000, GENE DEV, V14, P585; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	25	73	76	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5525	5532		10.1038/sj.onc.1204723	http://dx.doi.org/10.1038/sj.onc.1204723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571650				2022-12-17	WOS:000170781100013
J	Boulanger, CA; Smith, GH				Boulanger, CA; Smith, GH			Reducing mammary cancer risk through premature stem cell senescence	ONCOGENE			English	Article						mammary; stem cell; cancer risk; cellular senescence; MMTV	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 TRANSGENE; TUMOR VIRUS; EXPRESSION; MICE; GLAND; DIFFERENTIATION; TISSUES	The reproductive capacity of the mammary epithelial stem cell is reduced coincident with the number of symmetric divisions it must perform. In a study of FVB/ N mice with the transgene, WAP-TGF beta1, we discovered that mammary epithelial stem tells were prematurely aged due to ectopic expression of TGF-beta1. To test whether premature aging of mammary epithelial stem cells would have an impart on susceptibility or resistance to mammary cancer, female littermates from FVB/ N x WAP-TGF-beta1 mating were injected with mouse mammary tumor virus (MMTV) at 8-10 weeks of age. A total of 44 females were inoculated, maintained as breeders and observed for tumor development for up to 18 months. Only one mammary tumor appeared in 17 TGF-beta1 females while 15 were collected from 29 wild type sisters. Premalignant mammary epithelial cells in infected glands were identified by transplantation of single cell(1 x 10(5)) suspensions into nulliparous hosts and testing for hyperplastic outgrowth. Although the number of positive takes was significantly reduced with TGF-beta1 cells, both MMTV-infected TGF-beta1 and wild type cells produced hyperplastic outgrowths suggesting that premalignant transformation was achieved in each group. The results suggest a positive correlation between the procreative life-span of mammary epithelial stem cells and mammary cancer risk.	NCI, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, GH (corresponding author), NIH, Bldg 10,Room 8H07,9000 Rockville Pike, Bethesda, MD 20892 USA.							ARTHUR LO, 1978, INT J CANCER, V22, P433, DOI 10.1002/ijc.2910220411; BUGGIANO V, 2001, IN PRESS INT J CANC; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; DANIEL CW, 1971, EXP GERONTOL, V6, P95, DOI 10.1016/0531-5565(71)90053-2; DANIEL CW, 1971, EXP CELL RES, V65, P27, DOI 10.1016/S0014-4827(71)80046-0; DEOME KB, 1959, CANCER RES, V19, P515; DEOME KB, 1978, CANCER RES, V38, P2103; DEOME KB, 1978, CANCER RES, V38, P4050; FELLUGA B, 1969, J NATL CANCER I, V43, P319; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HELD W, 1994, IMMUNOL TODAY, V15, P184, DOI 10.1016/0167-5699(94)90317-4; Hook LM, 2000, J VIROL, V74, P8876, DOI 10.1128/JVI.74.19.8876-8883.2000; IMAI S, 1994, J VIROL, V68, P3437, DOI 10.1128/JVI.68.5.3437-3442.1994; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Kamiya K, 1999, J RADIAT RES, V40, P128, DOI 10.1269/jrr.40.S128; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Kordon EC, 1998, DEVELOPMENT, V125, P1921; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEDINA D, 1973, METHOD CANCER RES, V7, P3; NICOLL CHARLES S., 1965, LIFE SCI, V4, P993, DOI 10.1016/0024-3205(65)90203-1; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Rasmussen S. B., 2000, METHODS MAMMARY GLAN, P75; Ross SR, 1998, IMMUNOL RES, V17, P209, DOI 10.1007/BF02786445; ROUBINIAN JR, 1980, J NATL CANCER I, V65, P795, DOI 10.1093/jnci/65.4.795; SELL S, 1994, LAB INVEST, V70, P6; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; SMITH GH, 1984, CANCER RES, V44, P3426; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SQUARTINI F, 1983, CANCER RES, V43, P5879; VANNIE R, 1977, INT J CANCER, V19, P383, DOI 10.1002/ijc.2910190316; YANG HAS, 2000, P AM ASSOC CANC RES, V41, P225; YOUNG LJT, 1971, EXP GERONTOL, V6, P49, DOI 10.1016/0531-5565(71)90048-9	35	73	73	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2264	2272		10.1038/sj.onc.1204312	http://dx.doi.org/10.1038/sj.onc.1204312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402321				2022-12-17	WOS:000168404500008
J	Germani, A; Bruzzoni-Giovanelli, H; Fellous, A; Gisselbrecht, S; Varin-Blank, N; Calvo, F				Germani, A; Bruzzoni-Giovanelli, H; Fellous, A; Gisselbrecht, S; Varin-Blank, N; Calvo, F			SIAH-1 interacts with alpha-tubulin and degrades the kinesin Kid by the proteasome pathway during mitosis	ONCOGENE			English	Article						SIAH-1; kid; mitosis; ubiquitin degradation; kinesin	ELONGATION-FACTOR 1-ALPHA; TUMOR SUPPRESSION; MURINE HOMOLOGS; BINDING-PROTEIN; SINA GENE; DROSOPHILA; APOPTOSIS; ABSENTIA; CHROMOSOMES; ACTIVATION	SIAH-1, a human homologue of the Drosophila seven in absentia (Sina), has been implicated in ubiquitin-mediated proteolysis of different target proteins through its N-terminal RING finger domain, SIAH-1 is also induced during p53-mediated apoptosis, Furthermore, SIAH-1-transfected breast cancer cell line MCF-7 exhibits an altered mitotic process resulting in multi-nucleated giant cells, Now, using the two-hybrid system, we identified two new SIAH interacting proteins: Kid (kinesin like DNA binding protein) and a-tubulin. We demonstrate that SIAH is involved in the degradation of Kid via the ubiquitin-proteasome pathway. Our results suggest that SIAH-1 but not its N-terminal deletion mutant, affects the mitosis by an enhanced reduction of kinesin levels, Our results imply, for the first time, SIAH-1 in regulating the degradation of proteins directly implicated in the mitotic process.	Hop Cochin, Unite 363 INSERM, Inst Cochin Genet Mol, F-75014 Paris, France; Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM EP9932, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Germani, A (corresponding author), Hop Cochin, Unite 363 INSERM, Inst Cochin Genet Mol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Varin-Blank, Nadine/G-4396-2013	VARIN-BLANK, Nadine/0000-0003-2769-018X; calvo, fabien/0000-0002-0298-7633				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Germani A, 1999, MOL CELL BIOL, V19, P3798; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Holloway AJ, 1997, GENOMICS, V41, P160, DOI 10.1006/geno.1997.4642; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Moore RC, 1998, CELL MOTIL CYTOSKEL, V41, P168, DOI 10.1002/(SICI)1097-0169(1998)41:2<168::AID-CM7>3.0.CO;2-A; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Pfleger CM, 2000, GENE DEV, V14, P655; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	32	73	78	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5997	6006		10.1038/sj.onc.1204002	http://dx.doi.org/10.1038/sj.onc.1204002			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146551				2022-12-17	WOS:000165827900006
J	Sweeney, C; Carraway, KL				Sweeney, C; Carraway, KL			Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage	ONCOGENE			English	Review						ErbB receptor; tyrosine kinase; EGF-like ligands; ligand discrimination	EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE-PHOSPHATASE; ERYTHROPOIETIN RECEPTOR; BREAST-CANCER; KINASE; DIMERIZATION; ACTIVATION; NETWORK; TRANSDUCTION; DOMAIN	The four members of the ErbB family of receptor tyrosine kinases (RTKs) mediate a variety of cellular responses to epidermal growth factor (EGF)-like growth factors, and serve as a model for the generation of both diversity and specificity in RTK signaling. Previous studies indicate that receptor-receptor interactions figure prominently in signaling through ErbB receptors, In addition to a role in receptor kinase activation, ligand-induced ErbB receptor homo- and heterodimerization is thought to account for the diversity of biological responses stimulated by EGF-like growth factors. Since each receptor has the potential to couple to different complements of signaling pathways, EGF-like ligands specify cellular response by dictating which pairs of receptors become activated. More recently evidence has been uncovered for ligand discrimination by individual ErbB receptor dimers; receptors appear to realize which ligand is binding and differentially respond through autophosphorylation site usage. These observations indicate that ligand stimulation of RTKs is not generic, and point to another layer in the ErbB signal diversification mechanism. The mechanistic implications of ligand discrimination are discussed.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Sweeney, C (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Room 1018,330 Brookline Ave, Boston, MA 02215 USA.		Mieszkowska, Magdalena/O-6753-2017		NATIONAL CANCER INSTITUTE [R01CA071702] Funding Source: NIH RePORTER; NCI NIH HHS [CA71702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LONARDO F, 1990, New Biologist, V2, P992; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Otsuka T, 2000, MOL CELL BIOL, V20, P2055, DOI 10.1128/MCB.20.6.2055-2065.2000; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Shak S, 1999, SEMIN ONCOL, V26, P71; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wilson IA, 1999, CURR OPIN STRUC BIOL, V9, P696, DOI 10.1016/S0959-440X(99)00032-9	50	73	75	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5568	5573		10.1038/sj.onc.1203913	http://dx.doi.org/10.1038/sj.onc.1203913			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114736				2022-12-17	WOS:000165659300003
J	Jackson, JG; Kreisberg, JI; Koterba, AP; Yee, D; Brattain, M				Jackson, JG; Kreisberg, JI; Koterba, AP; Yee, D; Brattain, M			Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells	ONCOGENE			English	Article						forkhead; FKHR; EGF; breast cancer	PROTEIN-KINASE-B; CAENORHABDITIS-ELEGANS; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; FACTOR RECEPTORS; BINDING-SITE; INSULIN; AKT; TRANSLOCATION; LONGEVITY	Akt, when activated by IGF/insulin, can phosphorylate forkhead transcription factors. We undertook this study to determine whether epidermal growth factor (EGF) treatment could produce a signaling cascade resulting in phosphorylation of the forkhead transcription factor FKHR in a breast cancer cell line, MDA-MB-231, After establishing ErbB1, cbl, PI3 kinase and Akt were activated in EGF treated MDA-MB-231, we determined by immunoblot with FKHR antiserum that the electrophoretic mobility of FKHR was retarded after EGF treatment. This mobility retardation was reversible by treatment with alkaline phosphatase, and immunoblot with phospho-Ser(256) FKHR antibody further confirmed phosphorylation on an Akt consensus site after EGF treatment. EGF stimulated FKHR phosphorylation was blocked by the PI3 kinase inhibitor LY294002, and the ErbB1 inhibitor AG1478, FKHR immunoblotting after purification of nuclear and cytoplasmic proteins showed that EGF induced a simultaneous increase of FKHR in the cytoplasm and decrease in the nucleus. This finding was confirmed by immunofluorescence staining. Treatment of cells with pharmacological inhibitors of PI3 kinase or ErbB1 blocked this effect. Thus, these results demonstrate the phosphorylation and nuclear exclusion of FKHR after EGF treatment by a PI3 kinase dependent mechanism, and represent the first report of growth factor regulation of endogenous FKHR localization.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Hosp, Div Res & Dev, San Antonio, TX 78229 USA; Univ Minnesota, Ctr Canc, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Minnesota System; University of Minnesota Twin Cities	Brattain, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Yee, Douglas/0000-0002-3387-4009; Jackson, James Griffith/0000-0002-2640-6442	NATIONAL CANCER INSTITUTE [R01CA054807, R01CA034432, R01CA074285] Funding Source: NIH RePORTER; NCI NIH HHS [CA74285, CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLASS WF, 1993, J CELL PHYSIOL, V157, P296; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lewis GD, 1996, CANCER RES, V56, P1457; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	39	73	73	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4574	4581		10.1038/sj.onc.1203825	http://dx.doi.org/10.1038/sj.onc.1203825			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030146				2022-12-17	WOS:000089438200003
J	Nguyen, M; Lee, MC; Wang, JL; Tomlinson, JS; Shao, ZM; Alpaugh, ML; Barsky, SH				Nguyen, M; Lee, MC; Wang, JL; Tomlinson, JS; Shao, ZM; Alpaugh, ML; Barsky, SH			The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype	ONCOGENE			English	Article						thrombospondin-l; hypoxia inducible factor-1; angiogenic inhibitors; angiogenic factors	BREAST-CARCINOMA; TUMOR-GROWTH; ENDOTHELIAL-CELLS; INHIBITOR; METASTASIS; CANCER; SERPIN; THROMBOSPONDIN-1; PROLIFERATION; COMPLEMENTARY	Human myoepithelial cells which surround ducts and acini of certain organs such as the breast form a natural border separating epithelial cells from stromal angiogenesis. Myoepithelial cell lines (HMS-1-6), derived from diverse benign myoepithelial tumors, all constitutively express high levels of active angiogenic inhibitors which include TIMP-1, thrombospondin-1 and soluble bFGF receptors but very low levels of angiogenic factors. These myoepithelial cell lines inhibit endothelial cell chemotaxis and proliferation. These myoepithelial cell lines sense hypoxia, respond to low O-2 tension by increased HIF-1 alpha but with only a minimal increase in VEGF and iNOS steady state mRNA levels. Their corresponding xenografts (HMS-X-6X) grow very slowly compared to their non-myoepithelial carcinomatous counterparts and accumulate an abundant extracellular matrix devoid of angiogenesis but containing bound angiogenic inhibitors. These myoepithelial xenografts exhibit only minimal hypoxia but extensive necrosis in comparison to their non-myoepithelial xenograft counterparts. These former xenografts inhibit local and systemic tumor-induced angiogenesis and metastasis presumably from their matrix-bound and released circulating angiogenic inhibitors. These observations collectively support the hypothesis that the human myoepithelial cell (even when transformed) is a natural suppressor of angiogenesis.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Surg Oncol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Revlon UCLA Breast Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.			DiNome, Maggie/0000-0002-1926-292X	NCI NIH HHS [CA71195, CA83111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA071195, R21CA083111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpaugh ML, 1999, CANCER RES, V59, P5079; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; CAVENEE WK, 1993, J CLIN INVEST, V91, P3, DOI 10.1172/JCI116185; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P1; Folkman J., 1995, MOL BASIS CANC, P206; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Safarians S, 1996, INT J CANCER, V66, P151, DOI 10.1002/(SICI)1097-0215(19960410)66:2<151::AID-IJC2>3.0.CO;2-1; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sternlicht MD, 1996, IN VITRO CELL DEV-AN, V32, P550; Sternlicht MD, 1996, LAB INVEST, V74, P781; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tobacman JK, 1997, CANCER RES, V57, P2823; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	31	73	75	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3449	3459		10.1038/sj.onc.1203677	http://dx.doi.org/10.1038/sj.onc.1203677			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918603				2022-12-17	WOS:000088346500001
J	Eggert, A; Ikegaki, N; Liu, XG; Chou, TT; Lee, VM; Trojanowski, JQ; Brodeur, GM				Eggert, A; Ikegaki, N; Liu, XG; Chou, TT; Lee, VM; Trojanowski, JQ; Brodeur, GM			Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; tyrosine kinase receptors; neurotrophins; signal transduction; differentiation	NERVE GROWTH-FACTOR; NGF RECEPTOR; TYROSINE KINASES; IN-VITRO; ACTIVATION; EXPRESSION; ASSOCIATION; PROTEIN; PROTOONCOGENE; TRANSFECTION	Activation of the neurotrophin receptor TrkA by its ligand nerve growth factor (NGF) initiates a cascade of signaling events leading to neuronal differentiation in vitro and might play an important role in the differentiation of favorable neuroblastomas (NB) in vivo. To study TrkA signal transduction pathways and their effects on differentiation in NE, we stably expressed wild-type TrkA and five different TrkA mutants in the NGF unresponsive human NE cell line SH-SY5Y. Resulting clones were characterized by TrkA mRNA and protein expression, and by autophosphorylation of the receptor. Introduction of wild-type TrkA restored NGF responsiveness of SH-SY5Y cells, as demonstrated by morphological differentiation, activation of mitogen-activated protein kinases (MAPK) and induction of immediate-early genes, Expression of TrkA in the absence of NGF resulted in growth inhibition of transfectants compared to parental cells, whereas NGF-treatment increased their proliferation rate, Analysis of downstream signal transduction pathways indicated that NGF-induced differentiation was dependent on TrkA kinase activity, Our data suggest that several redundant pathways are present further downstream but activation of the RAS/MAPK signaling pathway seems to be of major importance for NGF mediated differentiation of NE cells. Our results also show that the signaling effector SH2-B is a substrate of NGF-mediated Trk signaling in NE, whereas it is not activated by NGF in rat pheochromocytoma PC12 cells, This might explain the differences we observed in TrkA signaling between neuroblastoma and PC12 cells. Further insight into TrkA signaling may suggest new options for the treatment of NB.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Brodeur, GM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC Rm 902-D 3516 Civic Ctr Blvd, Philadelphia, PA 19104 USA.		Eggert, Angelika/AAE-6907-2022	Eggert, Angelika/0000-0003-3476-8184	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 34514] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRODEUR GM, 1993, J NATL CANCER I, V85, P344, DOI 10.1093/jnci/85.5.344; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; EGGERT A, 2000, IN PRESS BIOTECHNIQU, V28; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1997, CULTURING NERVE CELL; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOGNER P, 1993, CANCER RES, V53, P2044; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOEB DM, 1993, J NEUROSCI, V13, P2919; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muragaki Y, 1997, J NEUROSCI, V17, P530; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PELLICI G, 1992, CELL, V70, P93; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; POLUHA W, 1995, ONCOGENE, V10, P185; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STEPHENS RM, 1994, NEURON, V12, P1; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	39	73	79	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2043	2051		10.1038/sj.onc.1203518	http://dx.doi.org/10.1038/sj.onc.1203518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803465				2022-12-17	WOS:000086613200008
J	Garcia-Guzman, M; Dolfi, F; Zeh, K; Vuori, K				Garcia-Guzman, M; Dolfi, F; Zeh, K; Vuori, K			Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation	ONCOGENE			English	Article						kinase; oncogenesis; signal transduction; tyrosine phosphorylation	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NECROSIS-FACTOR-ALPHA; GRB2 BINDING-SITE; INVASIVE-GROWTH; DOCKING PROTEIN; V-CRK; PROLONGED ACTIVATION; CELL-TRANSFORMATION; CARBOXY-TERMINUS	Constitutive activation of the Met tyrosine kinase results in transformation of cells of diverse origin. Recent studies have demonstrated a role for the c-Jun N-terminal kinase (JNK) in Met-induced transformation, but little is known about the molecular mechanisms that connect Met to JNK activation. Our studies show that activated Met associates with, and phosphorylates, the docking protein Gab1, which in turn binds to the src homology 2 (SH2)-domain of the adapter protein Crk and recruits Crk to the Met signaling complex. Formation of the Gab1-Crk complex correlates with Met-induced JNK activation, and mutant forms of Met that fail to induce the complex formation also fail to activate JNK. Importantly, expression of a loss-of-function mutant of Crk severely impairs activation of the JNK pathway by Met. We also show here that Met controls the transcription of the matrix metalloproteinase-l (MMP-1) gene in carcinoma cells and that this transcriptional regulation occurs in a Crk-JNK-dependent manner through an AP-1 element in the MMP-1 promoter. Taken together, our data implicate the Gab1-Crk signaling complex in Met-induced JNK activation and suggest that the Gab1-Crk complex formation may be an important event in regulating the tumorigenic phenotype of Met-transformed cells.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA076037, R01CA071560] Funding Source: NIH RePORTER; NCI NIH HHS [CA76037, CA71560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARDELLI A, 1994, J BIOTECHNOL, V37, P109, DOI 10.1016/0168-1656(94)90002-7; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FELLER SM, 1995, ONCOGENE, V10, P1465; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keegan K, 1996, ONCOGENE, V12, P1537; Khwaja A, 1996, ONCOGENE, V12, P2491; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LONGATI P, 1994, ONCOGENE, V9, P49; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; PATCH LA, 1995, J CELL SCI, V108, P1371; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	63	73	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7775	7786		10.1038/sj.onc.1203198	http://dx.doi.org/10.1038/sj.onc.1203198			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618718				2022-12-17	WOS:000084256900007
J	Yan, J; Kuroyanagi, H; Tomemori, T; Okazaki, N; Asato, K; Matsuda, Y; Suzuki, Y; Ohshima, Y; Mitani, S; Masuho, Y; Shirasawa, T; Muramatsu, M				Yan, J; Kuroyanagi, H; Tomemori, T; Okazaki, N; Asato, K; Matsuda, Y; Suzuki, Y; Ohshima, Y; Mitani, S; Masuho, Y; Shirasawa, T; Muramatsu, M			Mouse ULK2, a novel member of the UNC-51-like protein kinases: unique features of functional domains	ONCOGENE			English	Article						protein kinase; signal transduction; UNC-51-like kinases; C. elegans; autophosphorylation	CAENORHABDITIS-ELEGANS; C-ELEGANS; SERINE/THREONINE KINASE; AXONAL ELONGATION; SACCHAROMYCES-CEREVISIAE; GENE; EXPRESSION; NEURONS; MUTANTS; IDENTIFICATION	The UNC-51 serine/threonine kinase of C. elegans plays an essential role in axonal elongation, and unc-51 mutants exhibit uncoordinated movements. We have previously identified mouse and human cDNAs encoding UNC-51-like kinase (ULK1), Here we report the identification and characterization of the second murine member of this kinase family, ULK2, Mouse ULK2 cDNA encodes a putative polypeptide of 1033 aa which has an overall 52% and 33% amino acid identity to ULK1 and UNC-51, respectively. ULKs and UNC-51 share a typical domain structure of an amino-terminal kinase domain, a central proline/serine rich (PS) domain, and a carboxy-terminal (C) domain. Northern blot analysis showed that ULK2 mRNA is widely expressed in adult tissues. In situ hybridization analysis indicated that ULK2 mRNA is ubiquitously localized in premature as well as mature neurons in developing nervous system. ULK2 gene was mapped to mouse chromosome 11B1.3 and rat chromosome 10q23 by FISH. HA-tagged ULK2 expressed in COS7 cells had an apparent molecular size of similar to 150 kDa and was autophosphorylated in vitro. Truncation mutants suggested that the autophosphorylation occurs in the PS domain. Although expression of ULK2 failed to rescue unc-51 mutant of C. elegans, a series of ULK2/UNC-51 chimeric kinases revealed that function of the kinase and PS domains are conserved among species, while the C domain acts in a species-specific manner. These results suggest that ULK2 is involved in a previously uncharacterized signaling pathway in mammalian cells.	Helix Res Inst, Chiba 2920812, Japan; Tokyo Metropolitan Inst Gerontol, Dept Mol Genet, Itabashi Ku, Tokyo 1730015, Japan; Univ Tokyo, Inst Mol Biosci, Lab Cellular Biosynth, Bunkyou Ku, Tokyo 1130032, Japan; Nagoya Univ, Sch Agr Sci, Lab Anim Genet, Chikusa Ku, Nagoya, Aichi 46401, Japan; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 81281, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1628666, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Tokyo Metropolitan Institute of Gerontology; University of Tokyo; Nagoya University; Kyushu University; Tokyo Women's Medical University; Japan Science & Technology Agency (JST)	Muramatsu, M (corresponding author), Helix Res Inst, 1532-3 Yana, Chiba 2920812, Japan.							Chen WN, 1996, J BIOL CHEM, V271, P26362, DOI 10.1074/jbc.271.42.26362; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HANKS SK, 1995, FASEB J, V9, P579; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuroyanagi H, 1998, GENOMICS, V51, P76, DOI 10.1006/geno.1998.5340; LAND M, 1994, J BIOL CHEM, V269, P9234; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; Ogura K, 1997, GENE DEV, V11, P1801, DOI 10.1101/gad.11.14.1801; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; SHIRASAWA T, 1993, DEV DYNAM, V198, P1, DOI 10.1002/aja.1001980102; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; WatkinsChow D, 1996, MAMM GENOME, V6, pS201; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA J, 1994, MAMM GENOME, V5, P63, DOI 10.1007/BF00292332; Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546	29	73	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5850	5859		10.1038/sj.onc.1202988	http://dx.doi.org/10.1038/sj.onc.1202988			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557072				2022-12-17	WOS:000083270700002
J	Dudenhoffer, C; Kurth, M; Janus, F; Deppert, W; Wiesmuller, L				Dudenhoffer, C; Kurth, M; Janus, F; Deppert, W; Wiesmuller, L			Dissociation of the recombination control and the sequence-specific transactivation function of P53	ONCOGENE			English	Article						genetic stability; homologous recombination; mismatch recognition; p53; C-terminus; MDM2	WILD-TYPE P53; CARBOXY-TERMINAL DOMAIN; DNA-BINDING ACTIVITY; CELL-CYCLE CONTROL; HOMOLOGOUS RECOMBINATION; MUTANT P53; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; SINGLE STRANDS; ENDOGENOUS P53	Recently, we described a new biological function of p53 in inhibiting recombination processes when encountering mismatches in heteroduplexes (Dudenhoffer et al,, 1998). Here, we characterized protein domains of p53 participating in this process by in vitro analysis of mutated p53 proteins, and by applying our SV40-based assay system on monkey cells, which express different p53 variants. We present evidence that both binding of artificial recombination intermediates and p53-dependent recombination control require an intact p53 core and the oligomerization domain, strongly suggesting that the recognition of DNA undergoing recombination represents an essential step of this genomic surveillance mechanism, Further analyses indicated a role of the C-terminus in negatively regulating recombination control, an effect which can be neutralized by concurrent mismatch recognition. p53 lacking the oligomerization domain totally lost its ability to suppress homologous recombination. The cancer-related mutant p53(273H) was also significantly defective in this function, although we observed only twofold reductions in the corresponding transactivation activities on p53-response elements in episomal constructs. HDM2, an inhibitor of p53's transcriptional and growth regulatory activities, interfered with the inhibition of DNA exchange processes by p53 only weakly, Thus, functions of p53 in recombination control can be structurally dissociated from p53-dependent transcriptional transactivation.	Univ Hamburg, Dept Dermatol, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Hamburg, Dept Dermatol, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Albor A, 1998, CANCER RES, V58, P2091; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAIN R, 1994, ONCOGENE, V9, P1775; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CARDER P, 1993, ONCOGENE, V8, P1397; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hall AR, 1997, ONCOGENE, V14, P1371, DOI 10.1038/sj.onc.1200962; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Janus F, 1999, MOL CELL BIOL, V19, P2155; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARK DJ, 1994, ONCOGENE, V9, P1899; PELLEGATA NS, 1995, ONCOGENE, V11, P337; Prasad KAN, 1997, BIOCHEM BIOPH RES CO, V232, P14, DOI 10.1006/bbrc.1997.6212; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; SCHNEIDER E, 1998, 9 P53 WORKSH MAY 9 1, P176; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SIEGEL J, 1995, ONCOGENE, V11, P1363; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUBLER MA, 1994, ONCOGENE, V9, P1351; Tarunina M, 1996, ONCOGENE, V13, P589; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Wiesmuller L, 1996, J VIROL, V70, P737; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	82	73	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5773	5784		10.1038/sj.onc.1202964	http://dx.doi.org/10.1038/sj.onc.1202964			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523858				2022-12-17	WOS:000083095100006
J	Sourvinos, G; Tsatsanis, C; Spandidos, DA				Sourvinos, G; Tsatsanis, C; Spandidos, DA			Overexpression of the Tpl-2/Cot oncogene in human breast cancer	ONCOGENE			English	Article						Tpl-2/Cot; gene amplification; breast cancer	NF-KAPPA-B; COMPARATIVE GENOMIC HYBRIDIZATION; POLYMERASE CHAIN-REACTION; ACTIVATED PROTEIN-KINASE; CARCINOMA IN-SITU; T-CELL LINES; MAP KINASE; GENETIC ALTERATIONS; COPY NUMBER; EXPRESSION	Tpl-2/Cot proto-oncogene encodes a serine threonine kinase and was initially cloned as a provirus insertion site in MoMuLV-induced T cell lymphomas in rats. Tpl-2 locus was also shown to be affected by provirus insertion in MMTV-induced mammary carcinomas in mice, The involvement of Tpl-2 in 35 human breast paired tumour specimens versus their corresponding adjacent normal tissue was evaluated. Tpl-2 was found overexpressed in 14 of the 35 breast tumours tested using a semi-quantitative RT-PCR method. Gene amplification was detected in eight out of the 14 specimens overexpressing Tpl-2, suggesting the increased number of copies of Tpl-2 gene as a possible mechanism for Tpl-2 overexpression. Significant association was found between the overexpression of Tpl-2 and stage I of the tumours, indicating that this molecular alteration may be an early event in the development of the disease. Furthermore, overexpression of Tpl-2 was associated with positive progesterone receptor status of the samples. This is the first report on the Tpl-2 oncogene linked to human breast tumours suggesting that it may be a key molecule for the study of human breast cancer.	Univ Crete, Sch Med, Virol Lab, Iraklion 71409, Crete, Greece; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Crete; Jefferson University	Spandidos, DA (corresponding author), Univ Crete, Sch Med, Virol Lab, POB 1393, Iraklion 71409, Crete, Greece.		Tsatsanis, Christos/AAM-9362-2020	Tsatsanis, Christos/0000-0003-1214-4151; Spandidos, Demetrios/0000-0002-1146-931X				Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BLACK DM, 1994, EUR J CANCER, V30A, P1957, DOI 10.1016/0959-8049(94)00386-J; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Christeli E, 1996, ONCOL REP, V3, P1115; Coutts AS, 1998, CANCER RES, V58, P4071; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis CD, 1995, CARCINOGENESIS, V16, P3087, DOI 10.1093/carcin/16.12.3087; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; Erny KM, 1996, ONCOGENE, V13, P2015; FRYE RA, 1989, ONCOGENE, V4, P1153; ITO I, 1995, BRIT J CANCER, V71, P438, DOI 10.1038/bjc.1995.89; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Janssen JAMJL, 1998, LANCET, V352, P490, DOI 10.1016/S0140-6736(05)79230-8; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KIARIS H, 1994, INT J ONCOL, V5, P1243; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEUBAUER A, 1992, ONCOGENE, V7, P1019; OHARA R, 1995, J CELL SCI, V108, P97; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1994, J VIROL, V68, P7927, DOI 10.1128/JVI.68.12.7927-7932.1994; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RIED T, 1995, CANCER RES, V55, P5415; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sourvinos G, 1997, TUMOR BIOL, V18, P157, DOI 10.1159/000218026; SZOLLOSI J, 1995, CANCER RES, V55, P5400; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Visscher DW, 1997, GENE CHROMOSOME CANC, V18, P1	37	73	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4968	4973		10.1038/sj.onc.1202891	http://dx.doi.org/10.1038/sj.onc.1202891			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490831				2022-12-17	WOS:000082321700009
J	Huang, Y; Sheikh, MS; Fornace, AJ; Holbrook, NJ				Huang, Y; Sheikh, MS; Fornace, AJ; Holbrook, NJ			Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells	ONCOGENE			English	Article						MAP kinases; TPCK; apoptosis; c-Raf-1; Bcl-2	INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASE; DNA FRAGMENTATION; KINASE ACTIVATION; LEUKEMIA-CELLS; T-LYMPHOCYTES; CANCER CELLS; RAF-1; INVOLVEMENT	The mechanism of Taxol-induced apoptosis was investigated in MCF-7 human breast carcinoma cells, Taxol-induced apoptosis was associated with phosphorylation of both c-Raf-1 and Bcl-2 and activation of ERK and JNK MAP kinases, The serine protease inhibitor N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) effectively blocked apoptosis, but N-p-tosyl-L-lysine chloromethyl ketone (TLCK), another serine protease inhibitor, was without effect. TPCK treatment also prevented phosphorylation of c-Raf-1 and Bcl-2 in response to Taxol treatment. The serine protease inhibitor did not alter JNK activity, but it enhanced Taxol-induced activation of ERK1/2 Treatment of cells with the inhibitor of MEK activation, PD98059, prevented Taxol-induced ERK activation both in the presence and absence of TPCK, but did not influence survival of either Taxol- or Taxol plus TPCK-treated cells. In addition, PD98059 had no effect on c-Raf-1 or Bcl-2 phosphorylation, Thus, while the Taxol-induced phosphorylations of c-Raf-1 and Bcl-2 proteins appear to be coupled, these events can be disassociated from ERK1/2 activation, In summary, these findings suggest that phosphorylation of c-Raf-1 and Bcl-2, but not ERK1/2, are important signaling events in Taxol-induced apoptosis of MCF-7 breast cancer cells and that a TPCK inhibitable protease(s) is required for these processes.	NIA, Gene Express & Aging Sect, Biol Chem Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; NCI, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Holbrook, NJ (corresponding author), NIA, Gene Express & Aging Sect, Biol Chem Lab, Gerontol Res Ctr, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei PN, 1996, J CLIN INVEST, V98, P2588, DOI 10.1172/JCI119078; BAKER ME, 1977, NATURE, V269, P810, DOI 10.1038/269810a0; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dong Z, 1997, AM J PATHOL, V151, P1205; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Guyton KZ, 1996, CANCER RES, V56, P3480; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Huang Y, 1997, APOPTOSIS, V2, P199, DOI 10.1023/A:1026420616484; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAR N, 1981, J BIOL CHEM, V256, P435; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, TRENDS CELL BIOL, V7, P111; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Saunders DE, 1997, INT J CANCER, V70, P214, DOI 10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Sebestyen A, 1997, ANTICANCER RES, V17, P2609; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TUDELA J, 1986, INT J BIOCHEM, V18, P285, DOI 10.1016/0020-711X(86)90121-7; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WEIS M, 1995, EXP CELL RES, V219, P699, DOI 10.1006/excr.1995.1281; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILSON WE, 1989, J BIOL CHEM, V264, P17777; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	61	73	76	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3431	3439		10.1038/sj.onc.1202685	http://dx.doi.org/10.1038/sj.onc.1202685			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376521				2022-12-17	WOS:000080850600001
J	Fulop, V; Colitti, CV; Genest, D; Berkowitz, RS; Yiu, GK; Ng, SW; Szepesi, J; Mok, SC				Fulop, V; Colitti, CV; Genest, D; Berkowitz, RS; Yiu, GK; Ng, SW; Szepesi, J; Mok, SC			DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases	ONCOGENE			English	Article						trophoblastic diseases; DOC-2; Dab2; tumor suppressor; cancer	PROLINE-RICH PEPTIDES; SUSCEPTIBILITY GENE; OVARIAN-CANCER; SH3 DOMAINS; BINDING; SEQUENCE; CLONING; PHOSPHOTYROSINE; IDENTIFICATION; PROTEINS	Gestational trophoblastic diseases comprise a spectrum of interrelated diseases including partial mole, complete mole and gestational choriocarcinoma, Using reverse transcriptase PCR (RT-PCR) analysis, we identified higher levels of DOC-2/hDab2 expression in the normal trophoblast cells in culture than in choriocarcinoma cell lines. Subsequent study using immunohistochemistry showed high levels of DOC-2/hDab2 protein expression in normal trophoblast tissues but significantly lower levels of expression in gestational trophoblastic disease tissues, particularly in complete mole and choriocarcinoma. When DOC-2/hDab2 was transfected into the choriocarcinoma cell lines, Jar, JEG and BeWo, the stable transfectants showed significantly reduced growth rate in culture. These data suggest that down regulation of DOC-2/hDab2 may play an important role in the development of gestational trophoblastic diseases.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA; Haymal Imre Univ Hlth Sci, Dept Obstet & Gynecol, Budapest, Hungary	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mok, SC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA.		Yiu, Glenn/AAF-2858-2020		NATIONAL CANCER INSTITUTE [R01CA069291, R01CA069453, R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381, R01CA69291, R01CA69453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEUNG ANY, 1993, J CLIN PATHOL, V46, P204, DOI 10.1136/jcp.46.3.204; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FULOP V, 1998, IN PRESS J REPROD ME; Hancock BW, 1997, GESTATIONAL TROPHOBL; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOK SC, 1998, IN PRESS ONCOGENE, V15; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; XU X, 1997, AM ASS CANC RES P, V38, P157; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	19	73	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					419	424		10.1038/sj.onc.1201955	http://dx.doi.org/10.1038/sj.onc.1201955			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696034				2022-12-17	WOS:000075043000003
J	Droin, N; Dubrez, L; Eymin, B; Renvoize, C; Breard, J; Dimanche-Boitrel, MT; Solary, E				Droin, N; Dubrez, L; Eymin, B; Renvoize, C; Breard, J; Dimanche-Boitrel, MT; Solary, E			Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis	ONCOGENE			English	Article						apoptosis; caspases; etoposide; human tumor cells	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TOPOISOMERASE-II INHIBITORS; CAENORHABDITIS-ELEGANS; POLY(ADP-RIBOSE) POLYMERASE; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; CYSTEINE PROTEASES; MESSENGER-RNA; HL-60 CELLS; DEATH	Caspases are aspartate-specific cysteine proteases that play a pivotal role in drug-induced cell death. We designed RT-PCR assays to analyse the expression of CASP-3, CASP-4, CASP-6 and the long and short isoforms of CASP-2 genes in human cells. These genes heterogeneously coexpress in leukemic cell lines and bone marrow samples from patients with de nova acute myelogenous leukemia at diagnosis. Treatment of U937 and HL60 leukemic cells and HT29 colon carcinoma cells with the topoisomerase IT inhibitor etoposide upregulates CASP-2 and CASP-3 genes in these cells before inducing their apoptosis. This effect of etoposide is not observed in K562 cells and bcl-2-transfected U937 cells which are less sensitive to drug-induced apoptosis. Nuclear run-on experiments demonstrate that etoposide increases GASP gene transcription in U937 cells, an effect that is prevented by Bcl-2 overexpression. Upregulation of GASP genes is associated with an enhanced synthesis of related procaspases that precedes the appearance of apoptosis markers including caspase-3 activation, poly(ADP-ribose) polymerase cleavage and internucleosomal DNA fragmentation. These results suggest that the ability of tumor cells to upregulate CASP-2 and CASP-3 genes in response to cytotoxic drugs could be predictive of their sensitivity to drug-induced apoptosis.	UFR Med, Biol & Therapy Canc Grp, INSERM, CJF 94 08, F-21000 Dijon, France; UFR Pharm, INSERM, U461, Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Solary, E (corresponding author), UFR Med, Biol & Therapy Canc Grp, INSERM, CJF 94 08, 7 Blvd Jeanne dArc, F-21000 Dijon, France.		Eymin, Beatrice/M-1962-2013; Dubrez, Laurence/I-4971-2016; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; Laurence, Dubrez/P-9472-2019; Droin, Nathalie M/Y-5506-2018; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; Dubrez, Laurence/0000-0002-7030-2181; Laurence, Dubrez/0000-0002-7030-2181; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Solary, Eric/0000-0002-8629-1341; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; CHAPMAN RS, 1994, CANCER RES, V54, P5131; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DUBREZ J, 1996, EMBO J, V15, P504; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Eymin B, 1997, CANCER RES, V57, P686; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1996, P NATL ACAD SCI USA, V93, P7404; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; Greidinger EL, 1996, FEBS LETT, V390, P299, DOI 10.1016/0014-5793(96)00678-3; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HENTGARTNER MO, 1994, CELL, V76, P665; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAMESAKI S, 1993, CANCER RES, V53, P4251; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIMOSHITA M, 1997, J CER BLOOD FLOW MET, V17, P507; KOOS RD, 1989, BIOCHEM BIOPH RES CO, V165, P82, DOI 10.1016/0006-291X(89)91036-X; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P200; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Yves, 1997, P153; RENVOIZE C, 1997, IN PRESS J IMMUNOL; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLARY E, 1994, LEUKEMIA LYMPHOMA, V15, P21, DOI 10.3109/10428199409051674; SOLARY E, 1993, BLOOD, V81, P1359; SRIVASTAVA KK, 1993, BIOTECHNIQUES, V15, P226; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	58	73	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2885	2894		10.1038/sj.onc.1201821	http://dx.doi.org/10.1038/sj.onc.1201821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671409				2022-12-17	WOS:000073988200007
J	McCormack, SJ; Weaver, Z; Deming, S; Natarajan, G; Torri, J; Johnson, MD; Liyanage, M; Ried, T; Dickson, RB				McCormack, SJ; Weaver, Z; Deming, S; Natarajan, G; Torri, J; Johnson, MD; Liyanage, M; Ried, T; Dickson, RB			Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability	ONCOGENE			English	Article						c-myc; genomic instability; chromosome 11; mammary development	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; C-MYC; GENE AMPLIFICATION; HUMAN-BREAST; EPITHELIAL-CELLS; MICE; APOPTOSIS; CANCER	We have examined defects in mammary development and tumorigenesis in a transgenic model expressing the c-myc gene under the MMTV-LTR promoter, The stochastic tumors which arise from hyperplastic ductal and lobular lesions in this model are characterized by high rates both of apoptosis and of chromosomal instability, Since the p53 gene product is thought to be central in the maintenance of genomic integrity, in part due to its ability to induce apoptosis in cells harboring DNA damage, we examined its expression and possible mutation. Initially, we observed that unmutated p53 is strongly expressed in premalignant mammary glands and in mammary tumors derived from the MMTV-c-myc strain. We then mated the MMTV-myc strain to a p53-deficient strain as a means of examining the effect of this lesion on mammary development and tumorigenesis in the context of c-myc overexpression, A lack of both p53 alleles in the presence of c-myc overexpression resulted in a dramatic hyerplastic alteration in mammary gland development, Specifically, in female bitransgenic MMTV-c-myc/p53 null mice (MMTV-myc/p53(-/-)), lobular hyperplasias were observed at almost every ductal end bud as early as 32 days of age, In contrast, only mild ductal and lobular hyperplasias were seen in MMTV-myc mice that contained both p53 alleles (MMTV-myc/p53(+/+)); an intermediate phenotype occurred in mice with a single intact (MMTV-myc/p53(+/-)) p53 allele, Mammary carcinomas arose with a high frequency in MMTV-myc/p53(+/-) mice; the tumors were comparable in frequency, histology and apoptotic index to the tumors in MMTV-myc/p53(+/+) mice, Also, as previously observed (Elson et al,, 1995), lymphomas arose with extremely short latency in MMTV-myc/ p53(-/-) mice, precluding study of the fate of their hyperplastic mammary lesions in situ, The frequency of p53 mutations in MMTV-myc/p53(+/+) and MMTV-myc/ p53+/- mammary tumors and in cell lines derived from these tumors was examined by direct sequencing. No point mutations or deletions in p53 were observed in mammary tumors or cell lines from either genotype, Finally, a detailed chromosomal analysis using multicolor spectral karyotyping (SKY) revealed that there were multiple chromosomal alterations in the c-myc-overexpressing cells that contained either one or two unmutated p53 alleles, Variable ploidy changes, a common translocation of chromosome 11, and other chromosomal aberrations were observed. Our data thus support an interaction between c-Myc and p53 in mammary development, but suggest that loss of p53 is required neither for c-myc-dependent tumorigenesis nor for c-myc-dependent chromosomal instability.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA.				NCI NIH HHS [IP5OCA58185] Funding Source: Medline; NIA NIH HHS [R01AG1496-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLYTH K, 1995, ONCOGENE, V10, P1717; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BUCHBERG AM, 1989, GENETICS, V122, P153; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELSON A, 1995, ONCOGENE, V11, P181; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; Mai S, 1996, ONCOGENE, V12, P277; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; McCullagh P, 1989, GEN LINEAR MODELS, P151; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOJTESEK B, 1993, J CELL SCI, V105, P607; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	44	73	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2755	2766		10.1038/sj.onc.1201804	http://dx.doi.org/10.1038/sj.onc.1201804			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652742				2022-12-17	WOS:000073812200007
J	Chen, Y; Martinez, LA; LaCava, M; Coghlan, L; Conti, CJ				Chen, Y; Martinez, LA; LaCava, M; Coghlan, L; Conti, CJ			Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1	ONCOGENE			English	Article						prostate cancer cell lines; androgen; cyclin D1; gene transfection; cell proliferation; tumorigenicity	TUMOR-SUPPRESSOR PROTEIN; E2F TRANSCRIPTION FACTOR; HUMAN ESOPHAGEAL CANCER; ANDROGEN RECEPTOR; DEPENDENT KINASES; CHROMOSOME 11Q13; GENE-EXPRESSION; BREAST-CANCER; NUDE-MICE; PROGRESSION	Deregulated expression of cyclin D1 has been found in several types of human tumors. In order to investigate factors involved in human prostate cancer progression, we studied the effects of cyclin D1 overexpression on human prostate cancer cell proliferation and tumorigenicity by transfecting LNCaP cells with a retroviral vector containing human cyclin D1 cDNA. When compared to the parental and control-vector transfected LNCaP cells, these cyclin D1-transfected cells had more cells in S-phase and lower growth factor requirements. Furthermore, these cells grew more in androgen-free medium. We also detected higher levels of Rb phosphorylation and E2F-1 protein levels in LNCaP/cyclin D1 cells than that in the parental and vector control cells in medium with or without androgen. Cyclin D1 transfected clones formed tumors more rapidly than control and parental cells. These tumors mere refractory to the androgen-ablation treatment by castration, whereas tumors from parental and vector-control LNCaP cells regressed within 4 weeks after castration. These results suggest that overexpression of cyclin D1 changes the growth properties, increases tumorigenicity and decreases the requirement for androgen stimulation in LNCaP cells both in vitro and in vivo.	Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Conti, CJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.							BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BREEN B, 1987, STEROID HORMONES PRA; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen Y, 1995, Urol Oncol, V1, P101, DOI 10.1016/1078-1439(95)00027-F; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; FURUYA Y, 1995, ENDOCRINOLOGY, V136, P1898, DOI 10.1210/en.136.5.1898; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; ISRAELI RS, 1994, CANCER RES, V54, P1807; JANIK P, 1975, CANCER RES, V35, P3698; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KALLAKURY BVS, 1994, HUM PATHOL, V25, P92, DOI 10.1016/0046-8177(94)90177-5; KATO J, 1993, GENE DEV, V7, P331; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; NEVINS JR, 1992, SCIENCE, V258, P424; OSWALD F, 1994, ONCOGENE, V9, P2029; PRETLOW TG, 1991, CANCER RES, V51, P3814; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHUURING E, 1992, ONCOGENE, V7, P355; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; TAM SW, 1994, ONCOGENE, V9, P2663; TILLEY WD, 1994, CANCER RES, V54, P4096; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VOELLER HJ, 1994, J UROLOGY, V151, P492; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350; ZHOU P, 1995, ONCOGENE, V11, P571	55	73	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	1998	16	15					1913	1920		10.1038/sj.onc.1201719	http://dx.doi.org/10.1038/sj.onc.1201719			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591774	Bronze			2022-12-17	WOS:000073079400002
J	Flaman, JM; Robert, V; Lenglet, S; Moreau, V; Iggo, R; Frebourg, T				Flaman, JM; Robert, V; Lenglet, S; Moreau, V; Iggo, R; Frebourg, T			Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	ONCOGENE			English	Article						p53; transcription; cell cycle; apoptosis; functional assay	DNA-BINDING; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; PROTEIN; GENE; SUPPRESSION; DOMAIN	Recent studies have suggested that a rare class of p53 mutants found in tumours has a subtle transcriptional defect affecting bax induction but not p21 induction. We have therefore developed simple functional assays in yeast which can be used to identify these mutants. Analysis of 51 different mutations observed in human tumours showed that all mutants tested scored as mutant with the bax reporter strain but nine scored as wild-type with the p21 reporter strain. These results, which can be explained by the lower affinity of the p53 protein for the bax site, may suggest that p21 is not the key target of p53 mutations in tumours. Since p21 status has recently been shown to modulate the chemotherapeutic and radiotherapeutic sensitivities of cancerous cells, the functional assays described here may have important clinical implications.	CHU Rouen, Genet Mol Lab, F-76031 Rouen, France; IFRMP, F-76821 Mont St Aignan, France; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	CHU de Rouen; Swiss Institute Experimental Cancer Research	Frebourg, T (corresponding author), CHU Rouen, Genet Mol Lab, F-76031 Rouen, France.		LENGLET, Sébastien/N-8923-2013; Frebourg, Thierry/AAK-8390-2020; Iggo, Richard/G-3546-2014; Flaman, Jean-Michel/K-8415-2018	LENGLET, Sébastien/0000-0002-4853-8163; Flaman, Jean-Michel/0000-0003-3544-0199				Beroud C, 1996, NUCLEIC ACIDS RES, V24, P147, DOI 10.1093/nar/24.1.147; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1992, CANCER RES, V52, P6976; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MIYASHITA T, 1995, CELL, V80, P293; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SIKORSKI RS, 1989, GENETICS, V122, P19; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	29	73	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1369	1372		10.1038/sj.onc.1201889	http://dx.doi.org/10.1038/sj.onc.1201889			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546439	Bronze			2022-12-17	WOS:000072422000016
J	Li, BL; Murphy, KL; Laucirica, R; Kittrell, F; Medina, D; Rosen, JM				Li, BL; Murphy, KL; Laucirica, R; Kittrell, F; Medina, D; Rosen, JM			A transgenic mouse model for mammary carcinogenesis	ONCOGENE			English	Article						transgenic mouse model; mutant p53; carcinogenesis	MUTANT P53; FUNCTION MUTATIONS; CANCER PATIENTS; RAS ONCOGENES; BREAST-CANCER; CELL-CYCLE; MICE; TUMORS; GENE; TUMORIGENESIS	Missense mutations in the p53 tumor suppressor occur frequently in human breast cancer and influence both the prognosis and response to chemotherapy, Amino acid 175 (equivalent to murine 172) is the second most common site of missense mutations in p53 in human breast cancer, Over 95% of these mutations are arginine-to-histidine (R-H) substitutions resulting in a gain-of-function, and not merely a dominant-negative phenotype, Transgenic mice expressing a p53 172(R-H) construct targeted to the mammary gland by means of a whey acidic protein (WAP) promoter were characterized as a model system in order to determine the specific effects of this mutation on mammary tumorigenesis. Although transgene expression alone had no apparent effect on normal mammary development, transgenic mice treated with the chemical carcinogen dimethylbenz(a)anthracene developed tumors with much shorter latency than did control littermates and had a greater tumor burden, Tumors arising in transgenic mice did not exhibit either decreased apoptosis or increased cell proliferation relative to tumors arising in nontransgenic littermates, but did display increased genomic instability, Large pleiomorphic nuclei were visible in many tumors from transgenic mice, and DNA flow analysis confirmed the presence of significant aneuploid cell populations, Since these transgenic mice develop very few spontaneous tumors, while accelerating carcinogen-and oncogene-mediated tumorigenesis, this mouse model will, therefore, be useful in the investigation of early events in mammary tumorigenesis, It may also be used as a preclinical model to test newly developed chemotherapeutic strategies.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Hughes Inst, Roseville, MN 55113 USA	Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Mieszkowska, Magdalena/O-6753-2017		NATIONAL CANCER INSTITUTE [R37CA016303, R01CA016303] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline; NIGMS NIH HHS [GM08231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIMENEZCONTI IB, 1992, MOL CARCINOGEN, V5, P259, DOI 10.1002/mc.2940050405; GOH HS, 1995, CANCER RES, V55, P5217; GUZMAN RC, 1992, CANCER RES, V52, P5732; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HEDLEY DW, 1985, CYTOMETRY, V6, P327, DOI 10.1002/cyto.990060409; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUMAR R, 1990, ONCOGENE, V5, P1271; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIN JY, 1995, ONCOGENE, V10, P2387; NAKAZAWA H, 1992, ONCOGENE, V7, P2295; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PROSSER J, 1990, ONCOGENE, V5, P1573; SHANKEY TV, 1993, CYTOMETRY, V14, P472, DOI 10.1002/cyto.990140503; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; ZHANG R, 1990, CANCER RES, V50, P4286	46	73	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					997	1007		10.1038/sj.onc.1201621	http://dx.doi.org/10.1038/sj.onc.1201621			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519874				2022-12-17	WOS:000072335900006
J	Alblas, J; Slager-Davidov, R; Steenbergh, PH; Sussenbach, JS; van der Burg, B				Alblas, J; Slager-Davidov, R; Steenbergh, PH; Sussenbach, JS; van der Burg, B			The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells	ONCOGENE			English	Article						Erk; Jun kinase; AP1; MCF7; phorbol ester; cell cycle	ACTIVATED PROTEIN-KINASES; ESTROGEN-RECEPTOR ACTIVITY; C-JUN; GROWTH-FACTOR; GENE-EXPRESSION; REGULATORY ELEMENTS; CARCINOMA-CELLS; FOS PROTEINS; DIFFERENTIATION; PROLIFERATION	In MCF7 breast cancer cells, mitogen-activated protein (MAP) kinase (i.e. Erk-1/2) is activated by the mitogen insulin, but also by the growth inhibiting agent TPA, though with very different kinetics, Insulin induces a relatively transient activation of Erk2 ( < 15 min), whereas TPA is able to induce a prolonged activation of Erk2 ( > 6 h), Expression of immediate-early genes of the c-fos and c-jun families, whose transcription and activation are regulated by MAP kinases, is differentially induced by insulin and TPA, Whereas insulin stimulates prolonged induction of c-jun, but not of junB mRNA, resulting in c-jun expression during the entire G(1) period, the growth inhibitor TPA induces junB much longer than c-jun. Inhibition of the Erk2 pathway by PD98059, specific for the upstream MAP kinase kinase (MEK1), abolishes TPA-stimulated junB but not insulin-induced c-jun, In agreement with this, insulin readily stimulates Jun kinase (JNK), whereas TPA does not, Furthermore, insulin-induced pRB hyperphosphorylation at the G(1)-S transition and S-phase entry is insensitive to MAP kinase inhibition by PD98059, On the other hand, PD98059 reverts the inhibitory effect of TPA on cell cycle entry as web as on pRB hyperphosphorylation, indicating that Erk effecters function as inhibitors of proliferation in MCF7 cells.	Univ Utrecht, Physiol Chem Lab, Stratenum, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Alblas, J (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Room G03550,POB 85500, NL-3508 GA Utrecht, Netherlands.			Alblas, Jacqueline/0000-0002-2996-9697				ABE M, 1986, J CELL PHYSIOL, V126, P126, DOI 10.1002/jcp.1041260117; ALKHALAF M, 1992, MOL ENDOCRINOL, V6, P1625, DOI 10.1210/me.6.10.1625; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; CARTER R, 1991, ONCOGENE, V6, P229; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DEGROOT RP, 1991, CELL GROWTH DIFFER, V2, P631; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; HERBER B, 1994, ONCOGENE, V9, P1295; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUKAS J, 1994, ONCOGENE, V9, P707; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYO MW, 1994, ONCOGENE, V9, P1999; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NISHINA Y, 1993, EXP CELL RES, V208, P492, DOI 10.1006/excr.1993.1271; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; REDNER RL, 1992, ONCOGENE, V7, P43; RUPPRECHT HD, 1993, AM J PHY SL, V265, P351; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VALETTE A, 1987, CANCER RES, V47, P1615; VANDERBURG B, 1990, CANCER RES, V50, P7770; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VANZOELEN EJJ, 1993, GROWTH FACTORS PRACT, P13; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030	63	73	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					131	139		10.1038/sj.onc.1201485	http://dx.doi.org/10.1038/sj.onc.1201485			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467952				2022-12-17	WOS:000071236800016
J	Fang, XJ; Jin, XM; Xu, HJ; Liu, L; Peng, HQ; Hogg, D; Roth, JA; Yu, YH; Xu, FJ; Bast, RC; Mills, GB				Fang, XJ; Jin, XM; Xu, HJ; Liu, L; Peng, HQ; Hogg, D; Roth, JA; Yu, YH; Xu, FJ; Bast, RC; Mills, GB			Expression of p16 induces transcriptional downregulation of the RB gene	ONCOGENE			English	Article						p16; RB; expression; ovarian cancer	TUMOR-SUPPRESSOR GENE; CANCER CELL-LINES; KINASE-4 INHIBITOR GENE; RETINOBLASTOMA-PROTEIN; CDK4 AMPLIFICATION; SQUAMOUS-CELL; CYCLE CONTROL; MTS1 GENE; P16(INK4); INACTIVATION	The RE and p16(INK4A) tumor suppressor genes function in the same pathway of cell cycle control. Previous evidence indicates that the p16(INK4A) gene is transcriptionally repressed by the RE gene product, pRB. In this study using human ovarian cancer cell lines, we found that RE protein and mRNA were expressed at higher levels in cell lines lacking p16 than in those with normal p16. Since this suggests a potential role of p16 in regulating the cellular level of pRB, we studied the effect of wild-type p16(INK4A) on expression of the RE gene. Introduction of p16(INK4A), carried by an adenovirus vector,;into p16-negative cell lines dramatically decreased expression of RE protein and mRNA. Nuclei run-off assays demonstrated that p16 expression induced transcriptional downregulation of the RE gene. These results indicate that expression of RE is inversely regulated by p16. The findings reveal a new dimension of pRB-p16 interaction and should have implications for p16(INK4A)-mediated gene therapy.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Toronto, Dept Med, Toronto, ON M5G 1L7, Canada; Toronto Gen Hosp, Toronto, ON M5G 1L7, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Mills, GB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Div Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAST RC, 1983, CANCER RES, V43, P1395; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUICK RN, 1985, CANCER RES, V45, P3668; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DODSON MK, 1994, CANCER RES, V54, P610; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GREENBERG ME, 1992, SHORT PROTOCOLS MOL; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1992, CANCER RES, V52, P2980; JIN XM, 1995, CANCER RES, V55, P3250; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P430; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MORI T, 1994, CANCER RES, V54, P3396; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OSWALD F, 1994, ONCOGENE, V9, P2029; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PALES E, 1993, EMBO J, V12, P961; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PENG HQ, 1993, CANCER RES, V53, P3574; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Ueki K, 1996, CANCER RES, V56, P150; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; XU L, 1994, CANCER RES, V54, P5262; ZHOU XL, 1994, ONCOGENE, V9, P3737	52	73	87	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					1	8		10.1038/sj.onc.1201525	http://dx.doi.org/10.1038/sj.onc.1201525			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467937				2022-12-17	WOS:000071236800001
J	Bustelo, XR; Crespo, P; LopezBarahona, M; Gutkind, JS; Barbacid, M				Bustelo, XR; Crespo, P; LopezBarahona, M; Gutkind, JS; Barbacid, M			Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation	ONCOGENE			English	Article						Cbl family; Vav; tyrosine phosphorylation; JNK activation	PROTOONCOGENE PRODUCT; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; STEEL FACTOR; SH2 DOMAIN; T-CELLS; BINDING; RECEPTORS; P95(VAV)	We have used the yeast two-hybrid system to identify proteins that interact with Vav, a GDP/GTP exchange factor for the Rac-1 GTPase that plays an important role in cell signaling and oncogenic transformation, This experimental approach resulted in the isolation of Cbl-b, a signal transduction molecule highly related to the mammalian c-cbl proto-oncogene product and to the C. elegans Sli-1 protein, a negative regulator of the EGF-receptor-like Let23 protein, The interaction between Vav and Cbl-b requires the entire SH3-SH2-SH3 carboxy-terminal domain of Vav and a long stretch of proline-rich sequences present in the central region of Cbl-b. Stimulation of quiescent rodent fibroblasts with either epidermal or platelet-derived growth factors induces an increased affinity of Vav for Cbl-b and results in the subsequent formation of a Vav-dependent trimeric complex with the ligand-stimulated tyrosine kinase receptors. During this process, Vav, but not Cbl-b, becomes highly phosphorylated on tyrosine residues, Overexpression of Cbl-b inhibits the signal transduction pathway of Vav that leads to the stimulation of c-Jun N-terminal kinase. By contrast, expression of truncated Cbl-b proteins and of missense mutants analogous to those found in inactive Sli-1 proteins have no detectable effect on Vav activity, These results indicate that Vav and Cbl-b act coordinately in the first steps of tyrosine protein kinase receptor-mediated signaling and suggest that members of the Sli-l/Cbl family are also negative regulators of signal transduction in mammalian cells.	SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,UNIV HOSP,STONY BROOK,NY 11794; NIDR,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bustelo, XR (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL ONCOL,POB 4000,PRINCETON,NJ 08543, USA.		Gutkind, J. Silvio/J-1201-2016; Bustelo, Xose R./AAD-2081-2022; Gutkind, J. Silvio/A-1053-2009; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783				ALAI M, 1992, J BIOL CHEM, V267, P18021; Bartel PL, 1993, CELLULAR INTERACTION, P153; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BUTELO XR, 1996, CRIT REV ONCOGEN, V7, P65; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1996, ONCOGENE, V13, P355; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISHER KD, 1995, NATURE, V374, P474; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KEANE MM, 1995, ONCOGENE, V10, P2367; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; MACHIDE M, 1995, ONCOGENE, V11, P619; Marengere LEM, 1997, J IMMUNOL, V159, P70; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Romero F, 1996, MOL CELL BIOL, V16, P37; Schuebel KE, 1996, ONCOGENE, V13, P363; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	37	73	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2511	2520		10.1038/sj.onc.1201430	http://dx.doi.org/10.1038/sj.onc.1201430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399639				2022-12-17	WOS:A1997YG73200001
J	DuflotDancer, A; Mesnil, M; Yamasaki, H				DuflotDancer, A; Mesnil, M; Yamasaki, H			Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes	ONCOGENE			English	Article						gap junction; cell-cell communication; tumor suppression; Cx26	MARIE-TOOTH DISEASE; JUNCTIONAL INTERCELLULAR COMMUNICATION; TUMOR-SUPPRESSOR GENES; C6 GLIOMA-CELLS; GAP-JUNCTIONS; LIVER TUMOR; MUTATIONS; PROTEIN; CDNA; TRANSFECTION	Connexin genes exert negative growth control when transfected into various types of tumor cell lines, We previously demonstrated that connexin 26 (Cx26) suppresses in vitro and in vivo growth of HeLa cells, In this study, we have examined whether certain Cx26 mutants can abrogate cell growth control and the gap junctional intercellular communication (GJIC) capacity of such Cx26-transfected HeLa cells, For this purpose, we transfected three mutated Cx26 genes (C60F, P87L and R143W) into HeLa cells already containing the wild-type Cx26 gene, which are GJIC-competent and non-tumorigenic. Transfection of P87L and R143W mutants enhanced the tumorigenicity of the HeLa Cx26 cells in nude mice without any change in GJIC capacity, On the other hand, transfection of the C60F mutant reduced the GJIC capacity of HeLa Cx26 cells without affecting their growth in vivo. Immunostaining studies demonstrated that the Cx26 proteins were localized mainly at cell-cell contact areas in the Hel,a Cx26 cells both before and after transfection of mutated Cx26 genes, These results suggest that certain mutant Cx26 proteins exert a dominant-negative effect on Cx26-regulated growth of HeLa cells and that such effects may be independent of the effect on GJIC ability, It is proposed that wild-type and mutant Cx26 proteins produce heteromeric connexons and that such heteromeric connexons may exert different effects on growth control from those of homomeric connexons.	INT AGCY RES CANC,UNIT MULTISTAGE CARCINOGENESIS,F-69372 LYON 08,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)				Mesnil, Marc/0000-0003-4922-0365	NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-40534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRUZZONE R, 1994, NEURON, V13, P1253, DOI 10.1016/0896-6273(94)90063-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dahl E, 1996, J BIOL CHEM, V271, P17903, DOI 10.1074/jbc.271.30.17903; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; Krutovskikh V, 1996, CARCINOGENESIS, V17, P1761, DOI 10.1093/carcin/17.8.1761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; MESNIL M, 1993, MOL CARCINOGEN, V7, P14, DOI 10.1002/mc.2940070103; MESNIL M, 1993, EUR J PHARM-ENVIRON, V248, P59, DOI 10.1016/0926-6917(93)90025-L; MIRONOV NM, 1994, CANCER RES, V54, P41; NAUS CCG, 1992, CANCER RES, V52, P4208; Omori Y, 1996, CARCINOGENESIS, V17, P2077, DOI 10.1093/carcin/17.9.2077; Omori Y, 1996, MOL BIOL CELL, V7, P907, DOI 10.1091/mbc.7.6.907; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; Saito T, 1997, CANCER RES, V57, P375; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SATO K, 1997, IN PRESS NEUROPATHOL; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	33	73	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2151	2158		10.1038/sj.onc.1201393	http://dx.doi.org/10.1038/sj.onc.1201393			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393973				2022-12-17	WOS:A1997YD01900003
J	Blaydes, JP; Gire, V; Rowson, JM; WynfordThomas, D				Blaydes, JP; Gire, V; Rowson, JM; WynfordThomas, D			Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2	ONCOGENE			English	Article						p53; transcriptional activation; mdm-2; microinjection; transformed epithelial cells	DNA-DAMAGING AGENTS; TUMOR-SUPPRESSOR GENE; LARGE-T-ANTIGEN; MUTANT HA-RAS; GROWTH ARREST; BINDING-SITE; TRANSACTIVATION FUNCTION; TRANSCRIPTIONAL ACTIVITY; COLORECTAL-CARCINOMA; PROTEIN ACCUMULATION	A significant proportion of human cancers express high levels of p53 protein in the absence of an underlying mutation in the gene. Using transformed (Vh1) and non-transformed (FRTL-5) rat thyroid epithelial cell lines as a model, we have examined the mechanisms by which high levels of wild-type p53 may be tolerated. Stable transfection with p53-dependent reporter constructs demonstrated that the 'excess' wild-type p53 in Vh1 cells is not associated with a comparable increase in p53-dependent transcription (though the response to u.v. irradiation is retained). Mdm-2, which binds p53 and inhibits its transactivation activity, is overexpressed in Vh1 cells in the absence of gene amplification and in a p53-dependent manner. Furthermore disruption of p53-mdm-2 complex formation in Vh1 cells by microinjection of an antibody to the p53-binding domain of mdm-2 resulted in a dramatic increase in p53-dependent transcription. Since only a small proportion of the p53 in Vh1 cells was found to be in complex with mdm-2 (the majority of unbound protein being in a latent form), this suggests that mdm-2 selectively binds a pool of p53 that would otherwise be active as a sequence-specific activator of transcription. We suggest that, in some types of tumour, the 'sensitivity' of the p53-driven mdm-2 feedback loop may be sufficient to prevent free, active p53 reaching the level required for growth arrest or apoptosis, making them an ideal target for therapies designed to disrupt p53-mdm-2 interactions.	UNIV WALES COLL MED,DEPT PATHOL,THYROID TUMOUR BIOL RES GRP,CANC RES CAMPAIGN,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University			Blaydes, Jeremy/AAC-6939-2019; Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017	Blaydes, Jeremy/0000-0001-8525-0209; Gire, Veronique/0000-0002-9009-2185				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BLAYDES JP, 1995, ONCOGENE, V10, P307; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; Burden AD, 1996, J CUTAN PATHOL, V23, P25, DOI 10.1111/j.1600-0560.1996.tb00773.x; BURNS JS, 1992, INT J ONCOL, V1, P79; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; CARBONE DP, 1994, CHEST S, V106, P377; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORNELIS RS, 1994, CANCER RES, V54, P4200; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIX B, 1994, BRIT J CANCER, V70, P585, DOI 10.1038/bjc.1994.355; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; DOWELL SP, 1995, J PATHOL, V177, P221, DOI 10.1002/path.1711770302; DUNN JM, 1993, BRIT J SURG, V80, P1410, DOI 10.1002/bjs.1800801118; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FREBOURG T, 1992, CANCER RES, V52, P6976; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUPPI K, 1994, ONCOGENE, V9, P3017; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANG FF, 1994, ONCOGENE, V9, P949; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUTZKER SG, 1996, NAT MED, V2, P802; MACGEOCH C, 1993, DIS MARKERS, V11, P239, DOI 10.1155/1993/480686; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; RENZING J, 1995, ONCOGENE, V10, P1865; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; RUBIO MP, 1993, CANCER RES, V53, P3465; Sambrook J, 1989, MOL CLONING LAB MANU; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TISHLER RB, 1993, CANCER RES, V53, P2212; TOP B, 1995, INT J CANCER, V64, P83, DOI 10.1002/ijc.2910640203; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	74	73	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1859	1868		10.1038/sj.onc.1201018	http://dx.doi.org/10.1038/sj.onc.1201018			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150392				2022-12-17	WOS:A1997WW16600012
J	Yang, TT; Namba, H; Hara, T; Takmura, N; Nagayama, Y; Fukata, S; Ishikawa, N; Kuma, K; Ito, K; Yamashita, S				Yang, TT; Namba, H; Hara, T; Takmura, N; Nagayama, Y; Fukata, S; Ishikawa, N; Kuma, K; Ito, K; Yamashita, S			p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thyroid cells	ONCOGENE			English	Article						ionizing radiation; p53; DNA end-jointing; apoptosis; thyroid cell; thyroid carcinoma	WILD-TYPE P53; SEQUENCE SIMILARITY; ONCOGENE ACTIVATION; HIGH PREVALENCE; CYCLE CONTROL; EARLY EVENT; GENE; DEATH; BCL-2; EXPRESSION	To understand the effects of ionizing radiation on thyroid cells, we investigated the role of p53 in mediating apoptosis and in DNA repair following in vivo and in vitro irradiation of thyroid cells, In vitro exposure of human thyroid cells to ionizing radiation of up to 5-8 Gy failed to induce apoptosis in primary cells, The same results were obtained when the thyroid gland was irradiated in the intact rat, To explore the mechanism of failure of the wild-type p53 in inducing apoptosis in thyroid cells, we investigated the expression of apoptosis-related genes, bar, bcl-2 and fas/APO-1 following irradiation or induction of temperature-sensitive p53. The expression of Bar, Bcl-2 and Fas/APO-1 in human primary cultured thyroid cells did not change after irradiation, To further confirm the results, we established a clonal cell line (tsFRO) in which a temperature sensitive p53 (Val138) expression vector was stably transfected to a thyroid carcinoma cell line lacking endogenous p53, Incubation of tsFRO cells at the permissive temperature for three days, however, did not induce apoptosis although G(1) arrest was noted, Although enhanced expression of the bar mRNA level was observed, the expression of Bar, Bcl-2 and Fas/APO-1 protein did not change by shifting tsFRO cells to permissive temperature as well as irradiated primary cells, Furthermore, DNA end-jointing ability was examined by transfection of linearized luciferase plasmid into tsFRO cells, Increased luciferase activity occurred when the cells were cultured at the permissive temperature, indicating that the mild-type p53 enhances DNA end-jointing activity, Our results indicate that the wild-type p53 does not lead to apoptosis but facilitates DNA end-jointing in thyroid cells, These results may reflect specific responses in thyroid cells following irradiation.	NAGASAKI UNIV,SCH MED,INST ATOM DIS,DEPT CELL PHYSIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PHARMACOL,NAGASAKI 852,JAPAN; ITO HOSP,TOKYO 150,JAPAN; KUMA HOSP,KOBE 650,JAPAN	Nagasaki University; Nagasaki University; Kuma Hospital			Ting-Ting, YANG/E-6009-2010; Yamashita, Shunichi/GVS-9508-2022	Ting-Ting, YANG/0000-0001-5975-8359; Yamashita, Shunichi/0000-0001-6399-6261				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARRIER F, 1994, J BIOL CHEM, V269, P32672; DEGROOT LJ, 1986, CURRENT THERAPY ENDO, P92; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; Fagin JA, 1996, CANCER RES, V56, P765; FAGIN JA, 1994, ANNU REV MED, V45, P45; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GORCZYCA W, 1992, CANCER RES, V52, P3491; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1992, CANCER RES, V52, P1369; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWABE Y, 1989, J CLIN ENDOCR METAB, V68, P1174, DOI 10.1210/jcem-68-6-1174; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kitada S, 1996, ONCOGENE, V12, P187; Klugbauer S, 1995, ONCOGENE, V11, P2459; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEMOINE NR, 1989, ONCOGENE, V4, P159; LIN EY, 1993, J IMMUNOL, V151, P1979; LOWE SW, 1993, NATURE, V362, P786; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MIKIFOROV YE, 1996, ONCOGENE, V13, P687; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAGATAKI S, 1989, LANCET, V2, P385; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NAMBA H, 1993, ENDOCRINOLOGY, V132, P839, DOI 10.1210/en.132.2.839; NAMBA H, 1995, CANCER RES, V55, P2075; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Santoro M, 1996, ONCOGENE, V12, P1821; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNEIDER AB, 1985, MEDICINE, V64, P1; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMATO K, 1995, ONCOGENE, V11, P1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHAN QM, 1994, ONCOGENE, V9, P3743	69	73	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1511	1519		10.1038/sj.onc.1200979	http://dx.doi.org/10.1038/sj.onc.1200979			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129141				2022-12-17	WOS:A1997WQ54800001
J	Nikiforov, MA; Hagen, K; Ossovskaya, VS; Connor, TMF; Lowe, SW; Deichman, GI; Gudkov, AV				Nikiforov, MA; Hagen, K; Ossovskaya, VS; Connor, TMF; Lowe, SW; Deichman, GI; Gudkov, AV			p53 Modulation of anchorage independent growth and experimental metastasis	ONCOGENE			English	Article						anchorage dependence; apoptosis; metastasis; p53	TUMOR-SUPPRESSOR GENES; WILD-TYPE P53; DRUG-RESISTANCE; EXTRACELLULAR-MATRIX; ADHESION MOLECULES; BREAST-CARCINOMA; BCL-2 EXPRESSION; CANCER; APOPTOSIS; CELLS	Death in circulation is one of the natural barriers preventing dissemination of tumor cells and formation of metastases. One of the negative factors acting in circulation is the loss of cell contact with natural substrate which can be imitated in vitro by the incubation of cells in suspension or in semi-solid media. Normal mouse fibroblasts (MEFs) stay viable in suspension and undergo p53-independent G(1) growth arrest. Transformation with Ela and ras oncogenes leads to the abrogation of this arrest and to the p53-dependent apoptosis occurring in G, phase of the cell cycle. Suppression of apoptosis by p53 gene knock-out, transduction of dominant negative p53 mutant or bcl-2 prevents death in suspension and greatly induces frequency of colony formation in semi-solid media. The ability of cells to undergo apoptosis does not correlate with their tumorigenicity in nude mice but does correlate with their ability to survive in lungs of intravenously injected mice and to form experimental metastases. We suggest that abrogation of a p53-mediated apoptosis facilitates experimental metastasis by promoting survival of tumor cells in circulation.	UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60607 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; CTR CANC RES, INST CARCINOGENESIS, MOSCOW 115478, RUSSIA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cold Spring Harbor Laboratory				Gudkov, Andrei/0000-0003-2548-0154	FOGARTY INTERNATIONAL CENTER [R03TW000475] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW00475] Funding Source: Medline; NCI NIH HHS [R01-CA60730, R21CA62045] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BENZEEV A, 1980, CELL, V21, P365, DOI 10.1016/0092-8674(80)90473-0; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERTORELLE R, 1995, AM J SURG PATHOL, V19, P463, DOI 10.1097/00000478-199504000-00008; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGUE A, 1994, ONCOGENE, V9, P3367; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYES DF, 1995, SEMIN ONCOL, V22, P5; HELLMAN K, 1991, MICROCIRCULATION CAN, P67; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KERBEL RS, 1994, INVAS METAST, V14, P50; KERBEL RS, 1994, J CELL BIOCHEM, V56, P37, DOI 10.1002/jcb.240560108; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Lafrenie R M, 1993, Cell Biophys, V23, P3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MYERS RB, 1994, PROSTATE, V25, P243, DOI 10.1002/pros.2990250504; NEIMAN PE, 1994, MOL BIOL CELL, V5, P763, DOI 10.1091/mbc.5.7.763; NOONAN KD, 1977, J CELL PHYSIOL, V91, P201, DOI 10.1002/jcp.1040910206; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; POUPON MF, 1992, AIDS RES HUM RETROV, V8, P796; PROSS HF, 1993, NAT IMMUN, V12, P279; SIERRA A, 1995, INT J CANCER, V60, P54, DOI 10.1002/ijc.2910600108; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; THOMPSON TC, 1995, ONCOGENE, V10, P869; UHLMAN DL, 1994, J NATL CANCER I, V86, P1470, DOI 10.1093/jnci/86.19.1470; ULBRIGHT TM, 1994, MODERN PATHOL, V7, P64; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WEISS L, 1989, CLIN EXP METASTAS, V7, P127, DOI 10.1007/BF01787020; WEISS L, 1994, INVAS METAST, V14, P192; Weiss L., 1985, PRINCIPLES METASTASI; WHITESIDE TL, 1994, IMMUNOL SER, V61, P159; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOYAMA M, 1994, ANTICANCER RES, V14, P2477; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	57	73	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1709	1719						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895517				2022-12-17	WOS:A1996VM88700016
J	Kojima, H; Nakajima, K; Hirano, T				Kojima, H; Nakajima, K; Hirano, T			IL-6-inducible complexes on an IL-6 response element of the junB promoter contain Stat3 and 36 kDa CRE-like site binding protein(s)	ONCOGENE			English	Article						interleukin-6; junB promoter; Stat; CRE-like site	SIGNAL TRANSDUCER GP130; GROWTH-FACTOR; INTERLEUKIN-6; RECEPTOR; ACTIVATION; DNA; TRANSCRIPTION; EXPRESSION; CLONING; FAMILY	The junB gene is one of immediate-early genes whose expression are regulated by a variety of extracellular stimuli and play important roles in cellular responses to the given stimuli. Interleukin-6 (IL-6) activates the junB promoter through an IL-6 response element, JRE-IL6, that is composed of two cooperative DNA motifs, a low affinity Stat-binding site overlapping with an Ets-binding site (JEBS) and a cAMP responsive element (CRE)-like site. This element is a target for the Jak-Stat signal transduction pathway. We showed that IL-6 induced novel complexes on JRE-IL6, termed JRE-IL6-BC1 and 2, which contained Stat3 but migrated more slowly than the complexes containing homo- or heterodimer of Stat3 and Stat1 in gel shift assays, These slow-migrating JRE-IL6-BCs appeared to contain CRE-like site binding proteins besides Stat3, since the formation of JRE-IL6-BCs required both the JEBS and CRE-like site of JRE-IL6 and oligonucleotides containing the CRE-like site or somatostatin CRE efficiently competed with JRE-IL6 for making JRE-IL6-BCs. The formation of the complexes correlated well with the responsiveness of JRE-IL6 to IL-6 signals. U.v.-cross linking study revealed that JRE-IL6 bound a 90 kDa protein, corresponding to Stat3, and a 36 kDa protein, most likely a CRE-like site binding protein(s), Furthermore, we showed that the IL-6/interferon gamma (IFN gamma) response element in the IRF-1 promoter (IR/IRF-1), which contains a Stat-binding site and an adjacent CRE-like site, also makes IL-6-induced binding complexes similar to JRE-IL6-BCs.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT MOLEC ONCOL, SUITA, OSAKA 565, JAPAN	Osaka University			Hirano, Toshio/C-8194-2009					AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; COFFER P, 1995, ONCOGENE, V10, P985; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JIANG CK, 1994, MOL CELL BIOL, V14, P4759, DOI 10.1128/MCB.14.7.4759; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1993, J IMMUNOL, V151, P2555; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	42	73	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					547	554						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637711				2022-12-17	WOS:A1996TV59700011
J	Yamashiro, DJ; Nakagawara, A; Ikegaki, N; Liu, XG; Brodeur, GM				Yamashiro, DJ; Nakagawara, A; Ikegaki, N; Liu, XG; Brodeur, GM			Expression of TrkC in favorable human neuroblastomas	ONCOGENE			English	Article						neuroblastoma; TrkA; TrkB; TrkC; NT-3	NERVE GROWTH-FACTOR; N-MYC AMPLIFICATION; RAT TRKC; FACTOR RECEPTOR; CELL LINES; PROTOONCOGENE; ENCODES; NEUROTROPHIN-3; CULTURE; FAMILY	Human neuroblastomas have been found to express the neurotrophin receptors TrkA and TrkB. Expression of TrkA correlates with favorable outcome, while expression of full-length TrkB is associated with unfavorable, more aggressive, N-myc amplified tumors. In this study we have determined the expression of TrkC in neuroblastoma primary tumors and cell lines. Using probes for the extracellular domain and the tyrosine kinase domain of human TrkC, we found by Northern analysis that TrkC mRNA is expressed in 14 of 55 (25%) tumors from a representative panel of neuroblastomas, A 14 kb transcript was detected by both probes, indicating that it would encode the full-length TrkC protein. A significant association was found between TrkC mRNA expression detected by Northern analysis and lower stage tumors [stage 1, 2, 4S, 11 of 30 (37%); vs stage 3, 4, 3 of 25 (12%), chi(2) = 4.4, P< 0.04]. Only one of eight primary tumors with N-myc amplification had detectable TrkC mRNA expression and none of the eight neuroblastoma cell lines expressed TrkC by Northern analysis. Our results suggest that TrkC is involved in the biology of favorable neuroblastomas.	CHILDRENS HOSP,DIV ONCOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NCI NIH HHS [CA 09615] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009615] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1978, CANCER RES, V38, P3751; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; BRODEUR GM, 1994, SEMIN DIAGN PATHOL, V11, P118; BRODEUR GM, 1993, J NATL CANCER I, V85, P344, DOI 10.1093/jnci/85.5.344; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHN SL, 1990, ONCOGENE, V5, P1821; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KAPLAN DR, 1991, SCIENCE, V252, P158; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KOGNER P, 1993, CANCER RES, V53, P2044; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; NAKAGAWARA A, 1995, GENOMICS, V25, P538, DOI 10.1016/0888-7543(95)80055-Q; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SAMBROOK J, 1990, MOL CLONING LABORATO; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TISCHLER AS, 1984, CANCER, V54, P1344, DOI 10.1002/1097-0142(19841001)54:7<1344::AID-CNCR2820540718>3.0.CO;2-J; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WARIS T, 1973, EXPERIENTIA, V29, P1128, DOI 10.1007/BF01946760; [No title captured]	35	73	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					37	41						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552397				2022-12-17	WOS:A1996TQ01400005
J	HUANG, LW; TURCK, CW; RAO, P; PETERS, KG				HUANG, LW; TURCK, CW; RAO, P; PETERS, KG			GRB2 AND SH-PTP2 - POTENTIALLY IMPORTANT ENDOTHELIAL SIGNALING MOLECULES DOWNSTREAM OF THE TEK/TIE2 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article						ENDOTHELIUM; GRB2; SH-PTP2; RECEPTOR TYROSINE KINASE	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; EXPRESSION CLONING; VASCULAR ENDOTHELIUM; SH3 DOMAINS; RAS; IDENTIFICATION; MORPHOGENESIS	TEK is a newly cloned receptor tyrosine kinase that is expressed predominantly in the endothelium of actively growing blood vessels. Disruption of TEK function in transgenic mice results in a profound defect in vascular development leading to embryonic lethality. These studies show that TEK signaling is indispensable for the development of the embryonic vasculature and suggest that TEK, signaling may also be required for the development of the tumor vasculature. Because the ligand for TEPC has not been identified, it has been difficult to study signal transduction by this important endothelial receptor. To circumvent this problem, a soluble TEK kinase domain (GTEKH) was developed which could be easily purified, autophosphorylated, and radiolabeled, Using the autophosphorylated, radiolabeled GTEKH to probe a mouse embryo expression library only two candidate signaling molecules were isolated, SH-PTP2 and GRB2. Autophosphorylated GTEKH associated with GRB2 and SH-PTP2 from endothelial lysates and not with PI3 kinase or PLC gamma. The association of GRB2 and SH-PTP2 with TEK was highly dependent on specific tyrosine residues in the TEK c-tail. These studies identify GRB2 and SH-PTP2 as potentially important mediators of TEK signaling that may trigger crucial endothelial responses during embryonic vascular development and during pathologic vascular growth.	DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOVASC, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BANNWARTH W, 1992, HELV CHIM ACTA, V75, P707, DOI 10.1002/hlca.19920750305; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASE RD, 1994, J BIOL CHEM, V269, P10467; COFFIN JD, 1988, DEVELOPMENT, V102, P735; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG FS, 1994, TIG, V10, P54; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PETERS KG, 1992, COLD SPRING HARB SYM, V57, P63, DOI 10.1101/SQB.1992.057.01.008; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SCHWARTZ SM, 1993, J CARDIOVASC PHARM, V21, pS31, DOI 10.1097/00005344-199321001-00007; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TURCK CW, 1992, PEPTIDE RES, V5, P156; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WELLBROCK C, 1995, ONCOGENE, V10, P2135; XIAO S, 1994, J BIOL CHEM, V269, P21244; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1993, ONCOGENE, V8, P663	62	73	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2097	2103						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478529				2022-12-17	WOS:A1995TF29700020
J	MAHER, J; BAKER, DA; MANNING, M; DIBB, NJ; ROBERTS, IAG				MAHER, J; BAKER, DA; MANNING, M; DIBB, NJ; ROBERTS, IAG			EVIDENCE FOR CELL-SPECIFIC DIFFERENCES IN TRANSFORMATION BY N-RAS, H-RAS AND K-RAS	ONCOGENE			English	Article						N-RAS; H-RAS; K-RAS; TRANSFORMATION	MURINE SARCOMA-VIRUS; GENE FAMILY; PROTO-ONCOGENE; HARVEY-RAS; LINE; P21; EXPRESSION; DIFFERENTIATION; INDEPENDENCE; PROTEINS	Although Ras plays a fundamental role in cellular proliferation, differentiation and transformation, clear functional differences between the three major Ras proteins (N-, H- and K-Ras) have not as yet been demonstrated. In this study, chimeric constructs were used to compare directly transformation by N-, H- and E-vas oncogenes. In Rat-2 and MH3T3 fibroblasts, transformation assays (anchorage independence, focus-formation and growth in 1% FCS) showed that H-12-Ras was more transforming than N-12-Ras or K-12-Ras. By contrast, in the human multipotent haemopoietic cell line, TF-1, N-12-Ras exhibited greater biological activity. Northern blotting and protein analyses indicated that these findings were not the result of differences in expression or stability of p21Ras. Using further H-ras/N-ras chimeric constructs, we found that the greater transforming activity of H-12-Ras in fibroblasts was not due to the hypervariable-CAAX region, but rather to unique sequences between amino acids 84 and 143. These data demonstrate cell specific differences in the intrinsic transforming potential of N-ras, H-ras and K-ras oncogenes.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT OBSTET & GYNAECOL, LONDON W12 0NN, ENGLAND	Imperial College London; Imperial College London				Maher, John/0000-0001-8275-8488				ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BAKER DA, 1994, LEUKEMIA, V8, P1970; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CARBONE A, 1991, ONCOGENE, V6, P731; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DELGADO MD, 1992, CANCER RES, V52, P5979; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FIORUCCI G, 1988, BIOCHIM BIOPHYS ACTA, V950, P81, DOI 10.1016/0167-4781(88)90076-0; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MAHER J, 1994, EXP HEMATOL, V22, P8; MAHER J, 1994, IN PRESS LEUKEMIA, V84; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; TOKSOZ D, 1989, BRIT J HAEMATOL, V71, P1, DOI 10.1111/j.1365-2141.1989.tb06265.x; UEMURA N, 1992, BLOOD, V80, P3198; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	45	73	73	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1639	1647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478589				2022-12-17	WOS:A1995TC53500023
J	FOX, GM; HOLST, PL; CHUTE, HT; LINDBERG, RA; JANSSEN, AM; BASU, R; WELCHER, AA				FOX, GM; HOLST, PL; CHUTE, HT; LINDBERG, RA; JANSSEN, AM; BASU, R; WELCHER, AA			CDNA CLONING AND TISSUE DISTRIBUTION OF 5 HUMAN EPH-LIKE RECEPTOR PROTEIN-TYROSINE KINASES	ONCOGENE			English	Article						PROTEIN TYROSINE KINASES	MOLECULAR-CLONING; FAMILY; IDENTIFICATION; GENE; MEMBERS; EMBRYO; EXPRESSION; CHICKEN; BRAIN; HEK	We have isolated cDNA clones from a human fetal brain library that encode five members of the EPH sub-family of receptor protein tyrosine kinases (PTKs), Comparison of the DNA sequences of these receptors to the Genbank database reveals that two of our clones correspond to the previously identified HEK and ERK receptors, two are apparently human homologues of the mouse receptors Sek and Bsk and one is novel, With these additions, the number of known human EPH sub-family members is nine and the total in all vertebrate species is 13 making it the largest known sub-family of PTKs. Analysis of the expression pattern of EPH sub-family mRNAs reveals that some are expressed in a wide variety of adult tissues while others are quite restricted, Consistent with the amplification of these sequences from a fetal brain cDNA library, all five members which we have isolated are expressed in the brain. We have named these receptors HEK4, HEK5, HEK7, HEK8 and HEK11, following the nomenclature of Wicks et al. (1992) and the numbering convention set forth by Sajjadi et al. (1991), Analysis of these new EPH sub-family members will increase our understanding of the biology of this receptor family and their isolation will provide reagents for the identification of ligands for this large family of orphan receptors.			FOX, GM (corresponding author), AMGEN INC, AMGEN CTR, DEPT IMMUNOL, THOUSAND OAKS, CA 91320 USA.							ANDRES AC, 1994, ONCOGENE, V9, P1461; BARBACID M, 1993, ONCOGENE, V8, P2033; BARTLEY M, 1994, NATURE, V368, P558; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; IWASE T, 1993, BIOCHEM BIOPH RES CO, V194, P698, DOI 10.1006/bbrc.1993.1878; KIYOKAWA E, 1994, CANCER RES, V54, P3645; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; Maniatis T., 1982, MOL CLONING LAB MANU; MARCELLE C, 1992, ONCOGENE, V7, P2479; MARU Y, 1990, ONCOGENE RES, V5, P199; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	34	73	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					897	905						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898931				2022-12-17	WOS:A1995QL03800011
J	SHAULIAN, E; HAVIV, I; SHAUL, Y; OREN, M				SHAULIAN, E; HAVIV, I; SHAUL, Y; OREN, M			TRANSCRIPTIONAL REPRESSION BY THE C-TERMINAL DOMAIN OF P53	ONCOGENE			English	Article						P53; TRANSCRIPTION; TRANSACTIVATION	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENES; TATA-BINDING PROTEIN; DNA-BINDING; RESPONSIVE ELEMENT; ACTIVATION DOMAIN; SEQUENCE; TRANSFORMATION; INHIBITION	We have previously shown that monomeric p53 can transactivate target genes in vivo and that C-terminal fragments of p53 are oncogenic. To further elaborate these findings a series of C-terminal truncations of p53 was generated. The transactivation capacity and the ability of the truncated p53 to suppress oncogene-mediated transformation were studied. We found that p53 truncated at amino acid 303 (p53wtdl303) can still function in both assays, though less efficiently than full length wild type (wt) p53. Transforming C-terminal fragments inhibited transactivation induced by full length wt p53. Surprisingly, they also inhibited transactivation by wtdl303, with which they do not share e any overlapping sequences. Furthermore, the C-terminal fragments repressed the transactivation domains of several viral and cellular transcriptional activators. These data raise the possibility that the C-terminal domain of p53 may compete with the p53 transactivation domain for a common basal transcription factor.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Haviv, Izhak/E-3782-2015	Haviv, Izhak/0000-0002-0837-5005	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, IN PRESS GENE DEV; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BERNS A, 1994, CURR BIOL, V4, P137, DOI 10.1016/S0960-9822(94)00031-X; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1944, SCIENCE, V265, P386; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUPP TR, 1994, IN PRESS COLD SPRING, V59; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	80	73	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					671	680						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862444				2022-12-17	WOS:A1995QH61200006
J	METTUS, RV; LITVIN, J; WALI, A; TOSCANI, A; LATHAM, K; HATTON, K; REDDY, EP				METTUS, RV; LITVIN, J; WALI, A; TOSCANI, A; LATHAM, K; HATTON, K; REDDY, EP			MURINE A-MYB - EVIDENCE FOR DIFFERENTIAL SPLICING AND TISSUE-SPECIFIC EXPRESSION	ONCOGENE			English	Article							DNA-BINDING DOMAIN; C-MYB; B-MYB; NUCLEOTIDE-SEQUENCE; ONCOGENE ACTIVATION; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION; FUNCTIONAL DOMAINS; MYELOID-LEUKEMIA	The myb gene family consists of three members, A-myb, B-myb and c-myb. The proteins encoded by these genes bind DNA in a sequence-specific manner and regulate transcription of target genes. In this communication, we report the nucleotide sequence of murine A-myb cDNA. This gene encodes a protein of 751 amino acids with an estimated molecular weight of 83 kDa. cDNA sequence analysis of multiple independent cDNA clones reveals the presence of alternatively spliced mRNAs that encode smaller proteins. Northern blot analysis of adult mouse tissue RNAs reveals A-myb expression predominantly in the testis, with very low levels of expression in the ovaries, spleen and brain. In situ hybridization analysis of adult mouse testis shows that this gene is expressed at high levels in type A spermatogonia (stem cells), and preleptotene and pachytene spermatocytes, with concomitant downregulation of expression upon terminal differentiation of these cells into mature spermatozoa. This pattern of expression suggests that A-myb is involved in the control of proliferation and differentiation of spermatogonia. This potential function of A-myb in spermatogenesis is reminiscent of the role of c-myb in hematopoiesis.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [5-P30-CA12227, CA-52009] Funding Source: Medline; NIGMS NIH HHS [GM49489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009, P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUER KH, 1987, EMBO J, V6, P2719; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIDENKAPP H, 1988, NATURE, V355, P835; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1994, ONCOGENE, V9, P2469; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; LAM EWF, 1992, ONCOGENE, V7, P1885; MCMAHON J, 1988, ONCOGENE, V3, P717; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PAULES RS, 1988, ONCOGENE, V3, P59; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; Russel D. L., 1990, HISTOLOGICAL HISTOPA; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILLIAMS DL, 1987, BIOTECHNIQUES, V5, P718; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	43	73	75	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3077	3086						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084617				2022-12-17	WOS:A1994PG82200041
J	BRAIN, R; JENKINS, JR				BRAIN, R; JENKINS, JR			HUMAN P53 DIRECTS DNA STRAND REASSOCIATION AND IS PHOTOLABELED BY 8-AZIDO ATP	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; LARGE T-ANTIGEN; NUCLEOTIDE-SEQUENCE; HELICASE ACTIVITY; PROTEIN; TRANSFORMATION; GENE; REPLICATION; ONCOGENE; INVITRO	p53 is the most frequent known target for mutation in human cancer. Evidence suggests that p53 protein may be involved variously in transcription and cell cycle control, in DNA replication and in G1 checkpoint control following the cellular response to radiation induced DNA damage. p53 blocks DNA replication of the small DNA tumour virus, simian virus 40, by inhibiting unwinding of the viral origin of replication by the DNA helicase activity of the virally encoded large T antigen protein. Here we report the novel observation that human p53 protein can bind ATP and exhibits an intrinsic ATP stimulated DNA strand reassociation activity. Both activities map to the carboxyl terminal 128 amino acids of p53. Thus, in addition to any role in transcription, our results indicate that p53 is potentially capable of inhibiting mammalian replicative DNA synthesis by blocking the DNA strand separation step during replication origin recruitment. However, the ability of p53 to modulate the topological relationship between complementary nucleotide strands is also compatible with a direct role for p53 in other aspects of DNA synthesis, recombination or repair,	MARIE CURIE RES INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND									ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COX MM, 1981, NUCLEIC ACIDS RES, V9, P389, DOI 10.1093/nar/9.2.389; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KANDA T, 1994, IN PRESS MOL CELL BI; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; ROVINSKI B, 1988, ONCOGENE, V2, P445; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	37	73	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1775	1780						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183576				2022-12-17	WOS:A1994NL81500033
J	LIANG, XH; VOLKMANN, M; KLEIN, R; HERMAN, B; LOCKETT, SJ				LIANG, XH; VOLKMANN, M; KLEIN, R; HERMAN, B; LOCKETT, SJ			COLOCALIZATION OF THE TUMOR-SUPPRESSOR PROTEIN P53 AND HUMAN PAPILLOMAVIRUS-E6 PROTEIN IN HUMAN CERVICAL-CARCINOMA CELL-LINES	ONCOGENE			English	Article								The loss of the tumor-suppressor activity of p53, either by mutation or by interaction with the human papillomavirus (HPV) E6 protein, is considered to be an important mechanism in the carcinogenesis of cervical cancer. We have studied the cytological distribution of these proteins in human cervical carcinoma cell lines using polyclonal anti-p53 and monoclonal anti-E6 antibodies. The antibody specificity was confirmed by immunoblot and immunocompetition analyses. The intracellular localization of p53 and E6 was detected using the techniques of conventional and three-dimensional confocal microscopy. In the HPV-18 or -16 integrated cell lines, HeLa, CaSki and SiHa, viral oncoprotein E6 and endogenous tumor-suppressor protein, p53, were observed by immunofluorescence in the cytoplasm; p53 also had a weak punctate staining in the nuclei of HeLa and CaSki cells. In the HPV-negative cervical carcinoma cell lines, C-33A and HT-3, which have mutated p53, p53 was localized predominantly to the nucleus, with C-33A cells having elevated levels of p53 compared with the other cell lines. High spatial resolution imaging, using confocal microscopy, was performed on the cells after double fluorescence staining for p53 (fluorescein) and E6 (rhodamine). The images showed that both p53 and E6 had similar cytoplasmic distributions, which implied that these two proteins may exist as a cytoplasmic complex. To substantiate this implication, fluorescence resonance energy transfer microscopy was performed, which provided direct evidence of a close association between p53 and E6 within individual HeLa cells. The results from this study support the theory that p53 protein binds HPV-16/18 E6 protein in the cell cytoplasm, thus preventing p53 from exerting its tumor-suppressor function in the nucleus. Hence, inactivation of wild-type p53 by p53-E6 complex formation in cervical cancer may be a critical step in malignant transformation.	GERMAN CANC RES CTR, W-6900 HEIDELBERG, GERMANY; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC RES CTR, CHAPEL HILL, NC 27599 USA	Helmholtz Association; German Cancer Research Center (DKFZ); University of North Carolina; University of North Carolina Chapel Hill	LIANG, XH (corresponding author), UNIV N CAROLINA, DEPT CELL BIOL & ANAT, CELL BIOL LABS, 22 TAYLOR HALL, CB 7090, CHAPEL HILL, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R37CA051323, R01CA051323] Funding Source: NIH RePORTER; NCI NIH HHS [CA51323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHEN TM, 1992, ONCOGENE, V7, P1541; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; DEVILLIERS EM, 1992, GENITOURIN MED, V68, P50; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GUIOT MCP, 1989, CANCER CEL, V7, P193; HAUSEN HZ, 1982, LANCET, V2, P1370; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOCKETT SJ, 1991, ANAL QUANT CYTOL, V13, P27; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MONTENARH M, 1987, J VIROL, V61, P940, DOI 10.1128/JVI.61.3.940-944.1987; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIOU G, 1990, LANCET, V335, P1171; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	41	73	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2645	2652						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397367				2022-12-17	WOS:A1993LX34300005
J	HALL, FL; WILLIAMS, RT; WU, LT; WU, F; CARBONAROHALL, DA; HARPER, JW; WARBURTON, D				HALL, FL; WILLIAMS, RT; WU, LT; WU, F; CARBONAROHALL, DA; HARPER, JW; WARBURTON, D			2 POTENTIALLY ONCOGENIC CYCLINS, CYCLIN-A AND CYCLIN-D1, SHARE COMMON PROPERTIES OF SUBUNIT CONFIGURATION, TYROSINE PHOSPHORYLATION AND PHYSICAL ASSOCIATION WITH THE RB PROTEIN	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; HISTONE-H1 KINASE-ACTIVITY; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CANDIDATE ONCOGENE; CDC2; MITOSIS; P34CDC2; TRANSFORMATION	Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene. Other recent studies have identified human cyclin D1 (PRAD1) as a putative G1 cyclin and candidate proto-oncogene. However, the specific enzymatic activities and, hence, the precise biochemical mechanisms through which cyclins function to govern cell cycle progression remain unresolved. In the present study we have investigated the coordinate interactions between these two potentially oncogenic cyclins, cyclin-dependent protein kinase subunits (cdks) and the Rb tumor-suppressor protein. The distribution of cyctin D isoforms was modulated by serum factors in primary fetal rat lung epithelial cells. Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro. In synchronized human osteosarcoma cells, cyclin D1 is induced in early G1 and becomes associated with p9Ckshs1, a Cdk-binding subunit. Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity. Immobilized, recombinant cyclins A and D1 were found to associate with cellular proteins in complexes that contain the p105Rb protein. This study identifies several common aspects of cyclin biochemistry, including tyrosine phosphorylation and the potential to interact directly or indirectly with the Rb protein, that may ultimately relate membrane-mediated signaling events to the regulation of gene expression.	UNIV SO CALIF, SCH MED, CHILDRENS HOSP, DIV NEONATAL & PEDIAT PULMUNOL, LOS ANGELES, CA 90054 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90054 USA	Children's Hospital Los Angeles; University of Southern California; Baylor College of Medicine; University of Southern California	HALL, FL (corresponding author), UNIV SO CALIF, SCH MED, CHILDRENS HOSP LOS ANGELES, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA.			Harper, Jeffrey/0000-0002-6944-7236	NHLBI NIH HHS [HL-44977, HL-44060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044977, R01HL044060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLANQUET V, 1990, GENOMICS, V8, P595, DOI 10.1016/0888-7543(90)90052-V; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARBONAROHALL D, 1993, IN PRESS ONCOGENE; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HARADA S, 1991, ONCOGENE, V6, P461; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1991, NATURE, V349, P367, DOI 10.1038/349367a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POST M, 1988, AM REV RESPIR DIS, V137, P525, DOI 10.1164/ajrccm/137.3.525; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; TAMURA T, 1990, ONCOGENE, V5, P1259; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WARBURTON D, 1989, J APPL PHYSIOL, V66, P901, DOI 10.1152/jappl.1989.66.2.901; WILLIAMS RT, 1992, ONCOGENE, V7, P423; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	60	73	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1377	1384						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479754				2022-12-17	WOS:A1993KY32800032
J	STOREY, A; BANKS, L				STOREY, A; BANKS, L			HUMAN PAPILLOMAVIRUS TYPE-16 E6-GENE COOPERATES WITH EJ-RAS TO IMMORTALIZE PRIMARY MOUSE CELLS	ONCOGENE			English	Article							HUMAN FORESKIN KERATINOCYTES; HUMAN EPITHELIAL-CELLS; CERVICAL-CARCINOMA; ACTIVATED RAS; TUMOR-ANTIGEN; GENE-PRODUCT; E7 GENE; P53; TRANSFORMATION; EXPRESSION	Human papillomaviruses (HPVs) are small DNA tumor viruses, a subset of which is closely associated with the development of cervical cancer. The viral E6 and E7 open reading frames encode multifunctional proteins that bind respectively to the p53 protein and to the product of the retinoblastoma tumor-suppressor gene. In this study we demonstrate that the HPV-16 E6 gene cooperates with EJ-ras to immortalize primary cultures of mouse kidney epithelial cells. HPV-16-immortalized cell lines expressing E6 but not E7 contained low levels of wild-type p53 protein. In contrast, those cells immortalized by EJ-ras alone contained elevated p53 protein levels, and were shown to contain a mutation in the gene, These results suggest that activating mutations in the p53 gene can functionally substitute for HPV-16 E6 in transforming primary cells.			STOREY, A (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.			Storey, Alan/0000-0003-2001-9772				BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARTEK J, 1990, ONCOGENE, V5, P893; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MUNGER K, 1989, J VIROL, V63, P4417; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989	40	73	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					919	924						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384359				2022-12-17	WOS:A1993KT22000013
J	HILBERG, F; WAGNER, EF				HILBERG, F; WAGNER, EF			EMBRYONIC STEM (ES) CELLS LACKING FUNCTIONAL C-JUN - CONSEQUENCES FOR GROWTH AND DIFFERENTIATION, AP-1 ACTIVITY AND TUMORIGENICITY	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; OSTEO-SARCOMA VIRUS; BINDING AFFINITIES; CYCLE PROGRESSION; MOUSE FIBROBLASTS; CARCINOMA-CELLS; GENE-EXPRESSION; PROTO-ONCOGENE; LEUCINE ZIPPER; FOS PROTEINS	The proto-oncogene c-jun encodes the major component of the transcription factor AP-1 and is thought to have important functions in cell proliferation and differentiation as well as in the cellular response to a variety of external stimuli. To investigate directly the role of c-jun in growth, differentiation and tumorigenicity we generated mouse embryonic stem (ES) cell lines in which both copies of the c-jun gene have been inactivated by homologous recombination. The disruption of both copies of the c-jun gene had no apparent effect on ES cell viability, growth rate and in vitro differentiation potential. Transcriptional activation of the c-jun, junB and c-fos genes following TPA/serum induction was unaffected and efficient transactivation of AP-1 reporter constructs was demonstrated in these cells. Remarkably, subcutaneous injection of ES cells lacking c-Jun into syngeneic mice led to a drastic reduction in the formation of teratocarcinomas. We propose that whereas most of the functions of c-Jun in ES cells appear to be complemented by other Jun proteins in vitro, functional c-Jun protein is essential for efficient tumor growth in vivo.	RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BURKERT U, 1991, NEW BIOL, V3, P698; CARTER R, 1991, ONCOGENE, V6, P229; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P48, DOI 10.1007/BF00376370; HASTY P, 1991, MOL CELL BIOL, V11, P5586, DOI 10.1128/MCB.11.11.5586; HILBERG F, 1987, P NATL ACAD SCI USA, V84, P5232, DOI 10.1073/pnas.84.15.5232; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REDNER RL, 1992, ONCOGENE, V7, P43; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SAWAI S, 1991, NEW BIOL, V3, P861; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	50	73	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2371	2380						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281302				2022-12-17	WOS:A1992KA85600001
J	MARTINERIE, C; VIEGASPEQUIGNOT, E; GUENARD, I; DUTRILLAUX, B; NGUYEN, VC; BERNHEIM, A; PERBAL, B				MARTINERIE, C; VIEGASPEQUIGNOT, E; GUENARD, I; DUTRILLAUX, B; NGUYEN, VC; BERNHEIM, A; PERBAL, B			PHYSICAL MAPPING OF HUMAN LOCI HOMOLOGOUS TO THE CHICKEN NOV PROTOONCOGENE	ONCOGENE			English	Note							ANTI-MULLERIAN HORMONE; IMMEDIATE-EARLY GENE; GROWTH-FACTOR; INDUCIBLE GENE; EXPRESSION; SEQUENCES; CELLS	The human locus (novH) corresponding to the nov proto-oncogene overexpressed in avian nephroblastoma has been identified and mapped on chromosome 8q24.1. Another locus sharing homology with novH and corresponding to the connective tissue growth factor (CTGF) gene has also been mapped on chromosome 6q23.1. The chromosomal assignment of nov and CTGF proximal to c-myc and c-myb respectively is of interest because chromosomal abnormalities involving these regions have been associated with different human tumors including Wilms'.	INST CURIE,ONCOL VIRALE & MOLEC LAB,F-91405 ORSAY,FRANCE; IGR,VILLEJUIF,FRANCE; UNIV PARIS 07,F-75221 PARIS 05,FRANCE; INST CURIE,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; COHENHAGUENAUER O, 1987, CYTOGENET CELL GENET, V44, P2, DOI 10.1159/000132332; DOZIER C, 1986, NUCLEIC ACIDS RES, V14, P1928, DOI 10.1093/nar/14.4.1928; DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638; HEINE U, 1962, JNCI-J NATL CANCER I, V29, P41; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; LEBEAU J, 1991, ONCOGENE, V6, P1125; MARTINERIE C, 1991, CR ACAD SCI III-VIE, V313, P345; NGUYEN VC, 1986, ANN GENET-PARIS, V29, P20; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SORET J, 1989, J VIROL, V63, P1803, DOI 10.1128/JVI.63.4.1803-1807.1989; VANSOMEREN H, 1974, HUMANGENETIK, V25, P189; VELLARD M, 1991, ONCOGENE, V6, P505; Viegas-Pequignot E, 1992, IN SITU HYBRIDIZATIO, P137; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; WANGWUU S, 1990, CANCER RES, V50, P2786; 1990, CYTOGENET CELL GENET, V55, P358; 1989, CYTOGENET CELL GENET, V51, P1	25	73	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2529	2534						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334251				2022-12-17	WOS:A1992KA85600020
J	PRITCHARDJONES, K; FLEMING, S				PRITCHARDJONES, K; FLEMING, S			CELL-TYPES EXPRESSING THE WILMS-TUMOR GENE (WT1) IN WILMS-TUMORS - IMPLICATIONS FOR TUMOR HISTOGENESIS	ONCOGENE			English	Article							TRANSLOCATION BREAKPOINTS; EPIDEMIOLOGICAL FEATURES; GENITOURINARY DYSPLASIA; HUMAN CHROMOSOME-11; BAND 11P13; ANIRIDIA; DELETION; LOCUS; HETEROZYGOSITY; MAP	Wilms' tumour (nephroblastoma), a childhood embryonal kidney tumour, is believed to arise from malignant transformation of abnormally persistent metanephric blastemal cells. At a histological level, tumours show a remarkable mimicry of the normal nephrogenic pathway. There is histological and epidemiological evidence for at least two pathogenetic groupings within Wilms' tumour which may reflect different timings of the tumorigenic insult in this pathway and/or involvement of different genes. Tumorigenesis is thought to result from loss of function of a so-called tumour-suppressor gene which has an essential role in control of normal genitourinary development. Such a candidate, Wilms' tumour gene (WT1) mapping to chromosome 11p13, has been isolated and is known to be mutated in some tumours. We have examined the cell types expressing this gene in 32 Wilms' tumours and in nephroblastomatosis by in situ mRNA hybridization. Our results show that WT1 is expressed only in neoplastic structures whose normal counterparts also express the gene and that abnormally persistent high levels of expression are common in both these lesions. Thus, WT1 expression is a good marker for tumour differentiation and reveals how the normal pattern of differentiation is disrupted in Wilms' tumours. We postulate that mutation of the WT1 gene at the 11p13 locus results in Wilms' tumours associated with intralobar nephrogenic rests, which frequently show stromal-predominant histology. We have used our results and ideas to reinterpret current theories on tumour histogenesis and propose a model which explains how patterns of epithelial differentiation are disrupted in Wilms' tumour 2nd how malignant stroma can result from mutation in WT1.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Pritchard-Jones, Kathy/F-4286-2014	Pritchard-Jones, Kathy/0000-0002-2384-9475				BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BEHESHTI M, 1984, UROLOGY, V24, P130, DOI 10.1016/0090-4295(84)90413-8; BENNINGTON JL, 1975, ATLAS TUMOR PATHOLOG; BICKMORE WA, 1989, GENOMICS, V5, P685, DOI 10.1016/0888-7543(89)90109-2; Bove K E, 1976, Perspect Pediatr Pathol, V3, P185; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS LM, 1988, SCIENCE, V241, P840, DOI 10.1126/science.2841760; DELEMARRE JFM, 1982, PEDIATRIC ONCOLOGY, P261; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; EKBLOM P, 1981, MED BIOL, V59, P139; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FLEMING S, 1985, HISTOPATHOLOGY, V9, P729, DOI 10.1111/j.1365-2559.1985.tb02859.x; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASER T, 1986, NATURE, V321, P882, DOI 10.1038/321882a0; GREENBERG F, 1988, AM J MED GENET, V29, P773, DOI 10.1002/ajmg.1320290406; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HOU LT, 1967, J PATHOL BACTERIOL, V93, P477; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JONES KL, 1988, SMITHS RECOGNIZABLE, P136; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LANGDALEBROWN B, 1990, J PATHOL, V160, pA162; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MAKIN CA, 1984, J CLIN PATHOL, V37, P975, DOI 10.1136/jcp.37.9.975; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PASTORE G, 1988, MED PEDIATR ONCOL, V16, P7, DOI 10.1002/mpo.2950160103; PENDERGRASS TW, 1976, CANCER, V37, P403, DOI 10.1002/1097-0142(197601)37:1<403::AID-CNCR2820370152>3.0.CO;2-H; PERLMAN M, 1973, J PEDIATR-US, V83, P414, DOI 10.1016/S0022-3476(73)80264-1; PING AJ, 1989, AM J HUM GENET, V44, P720; PORTEOUS DJ, 1987, P NATL ACAD SCI USA, V84, P5355, DOI 10.1073/pnas.84.15.5355; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHMIDT D, 1982, PATHOBIOL ANN, V12, P281; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SHANNON RS, 1982, ARCH DIS CHILD, V57, P685, DOI 10.1136/adc.57.9.685; TURLEAU C, 1984, CLIN GENET, V26, P356; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WADEY RB, 1990, ONCOGENE, V5, P901	57	73	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2211	2220						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722569				2022-12-17	WOS:A1991GX73500006
J	HADDOW, S; FOWLIS, DJ; PARKINSON, K; AKHURST, RJ; BALMAIN, A				HADDOW, S; FOWLIS, DJ; PARKINSON, K; AKHURST, RJ; BALMAIN, A			LOSS OF GROWTH-CONTROL BY TGF-BETA OCCURS AT A LATE STAGE OF MOUSE SKIN CARCINOGENESIS AND IS INDEPENDENT OF RAS GENE ACTIVATION	ONCOGENE			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; LIVER EPITHELIAL-CELLS; HA-RAS; TERMINAL DIFFERENTIATION; INHIBITION; PROLIFERATION; ONCOGENE; PROGRESSION; HEPATOCYTES; EXPRESSION	The relationship between the expression of a mutant ras gene in epithelial cells and loss of responsiveness to the negative effects of transforming growth factor-beta (TGF-beta) is presently unclear. We have investigated this question using a series of cell lines derived from benign and malignant mouse skin tumours which express mutant forms of the H-ras gene. Immortalised, non-tumorigenic mouse epidermal cells respond to TGF-beta by cessation of growth, whereas in a series of malignant carcinoma lines the response was substantially reduced. Introduction of a mutant H-ras gene into the immortalised cells did not lead to any appreciable change in TGF-beta responsiveness, suggesting that initiation of carcinogenesis by ras mutation does not directly alter growth control by this pathway. Of two non-tumorigenic papilloma lines tested which had mutant H-ras genes, one retained complete sensitivity to TGF-beta, whereas the other showed a similar response to carcinomas. We conclude that growth control by TGF-beta is lost at a relatively late stage of carinogenesis in this system, and is independent of ras gene activation.	BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,BEARSDEN,GLASGOW G61 1BD,SCOTLAND; YORKHILL HOSP,DUNCAN GUTHRIE INST MED GENET,GLASGOW,SCOTLAND	Beatson Institute				AKHURST, ROSEMARY/0000-0002-4474-9668				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BOYD JA, 1990, CANCER RES, V50, P3394; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; FUSENIG N E, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V19, P219; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HOUCK KA, 1989, ONCOGENE, V4, P19; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; KULESZMARTIN M, 1990, CANCER RES, V50, P686; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN P, 1987, BIOCHEM BIOPH RES CO, V143, P26, DOI 10.1016/0006-291X(87)90624-3; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MANNING A, 1991, IN PRESS ONCOGENE; MANSBRIDGE JN, 1988, J INVEST DERMATOL, V90, P336, DOI 10.1111/1523-1747.ep12456286; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCMAHON JB, 1986, CANCER RES, V46, P4665; NAGY P, 1989, MOL CARCINOGEN, V2, P345, DOI 10.1002/mc.2940020609; PARKINSON EK, 1990, CARCINOGENESIS, V11, P195; PERA MF, 1984, CARCINOGENESIS, V5, P671, DOI 10.1093/carcin/5.5.671; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Reddel R R, 1988, Oncogene Res, V3, P401; REISS M, 1987, CANCER RES, V47, P6705; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROLLINS BJ, 1989, J CELL PHYSIOL, V139, P455, DOI 10.1002/jcp.1041390302; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TERZAGHIHOWE M, 1989, CARCINOGENESIS, V10, P973, DOI 10.1093/carcin/10.6.973; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WOLLENBERG GK, 1987, CANCER RES, V47, P6595; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0	39	73	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1465	1470						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886717				2022-12-17	WOS:A1991GX27200025
J	SEFTON, BM				SEFTON, BM			THE LCK TYROSINE PROTEIN-KINASE	ONCOGENE			English	Review							T-CELL RECEPTOR; RETROVIRUS PROMOTER INSERTION; AMINO-TERMINAL DOMAIN; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAINS; LYMPHOCYTES-T; CD4 RECEPTOR; PHOSPHORYLATION; P56LCK				SEFTON, BM (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.							ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HURLEY TR, 1989, ONCOGENE, V4, P265; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; THOM RE, 1987, FEBS LETT, V222, P104, DOI 10.1016/0014-5793(87)80200-4; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	39	73	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					683	686						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1905004				2022-12-17	WOS:A1991GT82500001
J	ZHANG, XK; HUANG, DP; QIU, DK; CHIU, JF				ZHANG, XK; HUANG, DP; QIU, DK; CHIU, JF			THE EXPRESSION OF C-MYC AND C-N-RAS IN HUMAN CIRRHOTIC LIVERS, HEPATOCELLULAR CARCINOMAS AND LIVER-TISSUE SURROUNDING THE TUMORS	ONCOGENE			English	Article									UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NATIONAL CANCER INSTITUTE [R01CA042969, R01CA025098] Funding Source: NIH RePORTER; NCI NIH HHS [CA42969, CA25098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHONY PP, 1976, CANCER RES, V36, P2579; BEER DG, 1986, CANCER RES, V46, P2435; BERMAN C, 1958, ADV CANCER RES, V5, P55, DOI 10.1016/S0065-230X(08)60409-1; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOK JR, 1986, J BIOL CHEM, V261, P4463; CORCOS D, 1984, BIOCHEM BIOPH RES CO, V122, P259, DOI 10.1016/0006-291X(84)90468-6; COTE GJ, 1987, BIOCHEM BIOPH RES CO, V143, P624, DOI 10.1016/0006-291X(87)91399-4; COTE GJ, 1985, CANCER LETT, V26, P121, DOI 10.1016/0304-3835(85)90017-5; FAUSTO N, 1983, HEPATOLOGY, V3, P1016; HIRAI H, 1973, ALPHA FETOPROTEIN HE; HSIEH LL, 1988, CANCER RES, V48, P265; HSIEH LL, 1987, CANCER RES, V47, P3421; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; KLEIN G, 1986, CANCER RES, V46, P3211; KOSS B, 1982, CANCER RES, V42, P2146; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAKINO R, 1984, BIOCHEM BIOPH RES CO, V119, P1096, DOI 10.1016/0006-291X(84)90887-8; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MANIATIS T, 1982, MOL CLONING LAB MANU, P221; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NAGY P, 1988, CANCER RES, V48, P5522; NICOLSON GL, 1987, CANCER RES, V47, P1473; POPPER H, 1979, ENVIRON RES, V19, P482, DOI 10.1016/0013-9351(79)90072-0; REN GJ, 1986, J CELL PHYSIOL, V4, P13; ROGERS AE, 1965, LAB INVEST, V14, P1710; ROGERS AE, 1969, CANCER RES, V29, P1965; STRIVASTAVA A, 1985, J BIOL CHEM, V260, P6404; SU TS, 1985, BIOCHEM BIOPH RES CO, V32, P264; TANG ZY, 1985, SUBCLINICAL HEPATOCE, P54; TASHIRO F, 1986, BIOCHEM BIOPH RES CO, V138, P854; THOMPSON NL, 1986, CANCER RES, V46, P3111; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780; ZHANG XK, 1988, CANCER LETT, V41, P147, DOI 10.1016/0304-3835(88)90111-5; ZHANG XK, 1987, BIOCHEM BIOPH RES CO, V142, P923	36	73	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					909	914						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2163054				2022-12-17	WOS:A1990DP55300018
J	GROSSMAN, SR; LAIMINS, LA				GROSSMAN, SR; LAIMINS, LA			E6-PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE-18 BINDS ZINC	ONCOGENE			English	Article									UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; Howard Hughes Medical Institute; University of Chicago								ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARBOSA MS, 1988, J VIROL, V62, P1088, DOI 10.1128/JVI.62.3.1088-1092.1988; BEDELL M, 1989, IN PRESS J VIROL; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MALLON RG, 1987, J VIROL, V61, P1655, DOI 10.1128/JVI.61.5.1655-1660.1987; MAZEN A, 1988, ANAL BIOCHEM, V172, P39, DOI 10.1016/0003-2697(88)90408-3; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NEARY K, 1989, J VIROL, V63, P259, DOI 10.1128/JVI.63.1.259-266.1989; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Summers MD, 1987, TEXAS AGR EXPT STATI; VALEE BL, 1970, PROTEINS, V5, P87; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989	30	73	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1089	1093						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2550872				2022-12-17	WOS:A1989AM53100006
J	VOUSDEN, KH; JAT, PS				VOUSDEN, KH; JAT, PS			FUNCTIONAL SIMILARITY BETWEEN HPV16 E7, SV40 LARGE T AND ADENOVIRUS E1A PROTEINS	ONCOGENE			English	Article											VOUSDEN, KH (corresponding author), ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOEBERITZ MV, 1988, CANCER RES, V8, P3780; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GISSMANN L, 1987, CANCER CELL, V5, P275; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; LINZER DIH, 1988, TRENDS GENET, V4, P245, DOI 10.1016/0168-9525(88)90029-7; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RILEY TEW, 1988, THESIS CAMBRIDGE UK; ROBERTS RJ, 1987, NUCLEIC ACIDS RES, V15, pR189, DOI 10.1093/nar/15.suppl.r189; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	24	73	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					153	158						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2538790				2022-12-17	WOS:A1989U567500005
J	Yu, WW; Ding, J; He, M; Chen, Y; Wang, RH; Han, ZW; Xing, EZ; Zhang, CT; Yeh, SY				Yu, Weiwei; Ding, Jie; He, Maio; Chen, Yuan; Wang, Ronghao; Han, Zhenwei; Xing, Emily Z.; Zhang, Cuntai; Yeh, Shuyuan			Estrogen receptor beta promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer	ONCOGENE			English	Article							LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR PROGRESSION; CERVICAL-CANCER; GROWTH-FACTOR; IN-VITRO; EXPRESSION; METASTASIS; MALAT1; ADENOCARCINOMA	While estrogen receptor beta (ER beta) may impact the progression of non-small cell lung cancer (NSCLC), its linkage to alteration of the vasculogenic mimicry (VM) formation to influence the NSCLC cell invasion remains unclear. Here, we analyzed immunohistochemistry data from NSCLC tissues and found that ER beta-positive NSCLC female patients had worse survival outcomes than those of ER beta-negative NSCLC female patients. In vitro studies using multiple NSCLC cell lines also revealed that ER beta could increase the VM formation and cell invasion. Molecular mechanism dissection suggested that ER beta could increase the lncRNA-MALAT1 (MALAT1) expression via directly binding to the estrogen response elements (EREs) located on the promoter of MALAT1, which could then lead to (i) suppressing the miR145-5p and (ii) increasing the NEDD9 protein expression as miR145-5p can directly target the 3'-UTR of NEDD9-mRNA. A preclinical study using the in vivo mouse model further confirmed the in vitro cell lines data. Together, results from the above studies demonstrated that ER beta can promote NSCLC VM formation and cell invasion via altering the ER beta/MALAT1/miR145-5p/NEDD9 signaling. Targeting this newly identified signaling pathway with small molecules may help the development of novel therapies to better suppress the NSCLC metastasis.	[Yu, Weiwei; Chen, Yuan; Zhang, Cuntai] Huazhong Univ Sci & Technol, Gen Dept, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Yu, Weiwei; Ding, Jie; He, Maio; Chen, Yuan; Wang, Ronghao; Han, Zhenwei; Xing, Emily Z.; Zhang, Cuntai; Yeh, Shuyuan] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Yu, Weiwei; Ding, Jie; He, Maio; Chen, Yuan; Wang, Ronghao; Han, Zhenwei; Xing, Emily Z.; Zhang, Cuntai; Yeh, Shuyuan] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA	Huazhong University of Science & Technology; University of Rochester; University of Rochester	Zhang, CT (corresponding author), Huazhong Univ Sci & Technol, Gen Dept, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.; Zhang, CT; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Zhang, CT; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	ctzhang0425@163.com; shuyuan_yeh@URMC.Rochester.edu	Wang, Ronghao/AAV-9769-2021		George Whipple Professorship Endowment	George Whipple Professorship Endowment	This work was partially supported by George Whipple Professorship Endowment. We thank Karen Wolf for assistance in manuscript preparation.	Aiello A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38414; [Anonymous], 1996, J Cell Biochem Suppl, V24, P1; Belani CP, 2007, LUNG CANCER, V55, P15, DOI 10.1016/j.lungcan.2006.09.008; CASERO RA, 1986, BIOCHEM BIOPH RES CO, V134, P572, DOI 10.1016/S0006-291X(86)80458-2; Chen Y, 2016, CELL PHYSIOL BIOCHEM, V38, P2194, DOI 10.1159/000445575; Chiang YY, 2014, ONCOL REP, V31, P597, DOI 10.3892/or.2013.2867; Choi I, 2001, MOL CELL ENDOCRINOL, V181, P139, DOI 10.1016/S0303-7207(01)00492-0; Coelho AL, 2017, ONCOTARGET, V8, P39795, DOI 10.18632/oncotarget.7794; Cui D, 2016, TUMOR BIOL, V37, P4127, DOI 10.1007/s13277-015-4261-x; Ding Y, 2012, ONCOGENE, V31, P2899, DOI 10.1038/onc.2011.467; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Hammoud Z, 2008, ENDOCR-RELAT CANCER, V15, P475, DOI 10.1677/ERC-08-0002; Hartman J, 2012, STEROIDS, V77, P1262, DOI 10.1016/j.steroids.2012.07.002; He JB, 2016, SCI REP-UK, V6, DOI 10.1038/srep20586; Hu HB, 2016, LUNG CANCER, V97, P87, DOI 10.1016/j.lungcan.2016.04.017; Huang NS, 2016, ONCOTARGET, V7, P37957, DOI 10.18632/oncotarget.9364; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; Jiang T, 2017, CLIN LUNG CANCER, V18, P421, DOI 10.1016/j.cllc.2016.12.012; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; Kiyohara C, 2010, GENDER MED, V7, P381, DOI 10.1016/j.genm.2010.10.002; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Li YW, 2016, CANCER BIOL THER, V17, P272, DOI 10.1080/15384047.2016.1139242; Liu JH, 2017, FRONT BIOSCI-LANDMRK, V22, P66, DOI 10.2741/4472; Liu MJ, 2016, ONCOL REP, V36, P1679, DOI 10.3892/or.2016.4909; Liu RL, 2015, INT J BIOL MACROMOL, V81, P491, DOI 10.1016/j.ijbiomac.2015.08.016; Liu SK, 2016, TUMOR BIOL, V37, P633, DOI 10.1007/s13277-015-3732-4; Lother SA, 2013, HORM CANCER-US, V4, P270, DOI 10.1007/s12672-013-0149-7; Lu HZ, 2016, TUMOR BIOL, V37, P1683, DOI 10.1007/s13277-015-3946-5; Lu RJ, 2014, J CANCER RES CLIN, V140, P387, DOI 10.1007/s00432-013-1577-z; Lu Y, 2016, ONCOTARGETS THER, V9, P3077, DOI 10.2147/OTT.S102658; Luo J, 2014, TUMOR BIOL, V35, P11541, DOI 10.1007/s13277-014-2442-7; Luo Z, 2015, INT J CLIN EXP MED, V8, P8686; Ma LH, 2016, TRANSL LUNG CANCER R, V5, P202, DOI 10.21037/tlcr.2016.04.04; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marquez-Garban DC, 2009, ANN NY ACAD SCI, V1155, P194, DOI 10.1111/j.1749-6632.2009.04116.x; Monica V, 2012, CLIN LUNG CANCER, V13, P416, DOI 10.1016/j.cllc.2012.03.006; Morimoto K, 2014, PROSTATE, V74, P901, DOI 10.1002/pros.22809; Nelson AW, 2017, MOL CELL ENDOCRINOL, V440, P138, DOI 10.1016/j.mce.2016.11.016; Nie FQ, 2015, MOL CANCER THER, V14, P268, DOI 10.1158/1535-7163.MCT-14-0492; Nose N, 2011, LUNG CANCER, V71, P350, DOI 10.1016/j.lungcan.2010.06.009; Onn A, 2003, CLIN CANCER RES, V9, P5532; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Qiu MT, 2014, TUMOR BIOL, V35, P5375, DOI 10.1007/s13277-014-1700-z; Rodriguez-Lara V, 2017, ENDOCR RES, V42, P219, DOI 10.1080/07435800.2017.1292526; Rousseau B, 2015, SCI REP-UK, V5, DOI 10.1038/srep10356; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Shagisultanova E, 2015, GENE, V567, P1, DOI 10.1016/j.gene.2015.04.086; Shen LQ, 2015, J NEURO-ONCOL, V121, P101, DOI 10.1007/s11060-014-1613-0; Shi ZM, 2017, ONCOGENE, V36, P2577, DOI 10.1038/onc.2016.414; Siegfried JM, 2014, SEMIN ONCOL, V41, P5, DOI 10.1053/j.seminoncol.2013.12.009; Skjefstad K, 2016, STEROIDS, V113, P5, DOI 10.1016/j.steroids.2016.05.008; Slowikowski BK, 2017, MOL BIOL REP, V44, P35, DOI 10.1007/s11033-016-4086-8; Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707; Wang JZ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3151-6; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Wang XY, 2015, J BIOL CHEM, V290, P3925, DOI 10.1074/jbc.M114.596866; Weitsman GE, 2006, BREAST CANCER RES TR, V100, P23, DOI 10.1007/s10549-006-9229-5; Wu CT, 2005, HUM PATHOL, V36, P1108, DOI 10.1016/j.humpath.2005.08.003; Wu WJ, 2007, MOL CANCER THER, V6, P471, DOI 10.1158/1535-7163.MCT-06-0416; Wu XL, 2012, J CELL BIOCHEM, V113, P711, DOI 10.1002/jcb.23443; Wu Y, 2015, ONCOTARGET, V6, P9160, DOI 10.18632/oncotarget.3247; Xia WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16901; Yao LL, 2016, J CELL MOL MED, V20, P1673, DOI 10.1111/jcmm.12862; Zhang CG, 2017, EUR REV MED PHARMACO, V21, P115; Zhang GF, 2009, MOL ENDOCRINOL, V23, P146, DOI 10.1210/me.2008-0431; Zhao GF, 2012, MOL ENDOCRINOL, V26, P1304, DOI 10.1210/me.2012-1028; Zhu LC, 2015, PATHOL ONCOL RES, V21, P1259, DOI 10.1007/s12253-015-9960-5	67	72	73	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1225	1238		10.1038/s41388-018-0463-1	http://dx.doi.org/10.1038/s41388-018-0463-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30250297				2022-12-17	WOS:000459249800006
J	Meng, QC; Shi, S; Liang, C; Liang, DK; Hua, J; Zhang, B; Xu, J; Yu, XJ				Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun			Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3 beta/Snail signaling	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; TAMOXIFEN RESISTANCE; CELLS; SNAIL; EXPRESSION; SURVIVAL; RISK; OVEREXPRESSION; POLYMORPHISM; GEMCITABINE	The devastating prognosis of pancreatic ductal adenocarcinoma (PDAC) is partially attributed to chemotherapy resistance. Glutathione peroxidase-1 (GPx1) plays various roles in the development and progression of multiple tumors, with the exception of pancreatic cancer. Here, we tentatively explored the role of GPx1 in the malignant biological behavior and gemcitabine (GEM) resistance of PDAC. GPx1 levels were detected using tissue microarrays and were negatively correlated with the overall survival of patients with PDAC. GPx1 silencing induced a mesenchymal transition phenotype and increased GEM resistance in vitro and in vivo. Additionally, the activation of reactive oxygen species (ROS)-mediated Akt/glycogen synthase kinase 3 beta (GSK3 beta)/Snail signaling was involved in this process, as determined by RNA sequencing. Moreover, low GPx1 expression correlated with a worse survival rate in patients with PDAC who received GEM adjuvant chemotherapy, whereas this correlation was not detected in patients receiving fluoropyrimidine. Based on our results, GPx1 inhibits the epithelial-mesenchymal transition (EMT) and chemoresistance by regulating the Akt/GSK3 beta/Snail signaling axis in PDAC. Furthermore, GPx1 may be a potential predictive biomarker in GEM-treated PDAC patients.	[Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun] Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Yu, XJ (corresponding author), Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Yu, XJ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Yu, XJ (corresponding author), Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China.; Yu, XJ (corresponding author), Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China.	yuxianjun@fudanpci.org		Liang, Chen/0000-0003-0578-7589; Shi, Si/0000-0002-6652-0629; yu, xianjun/0000-0002-6697-7143	National Science Foundation for Distinguished Young Scholars of China [81625016]; Shanghai Sailing Program [17YF1402500]	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Shanghai Sailing Program	We thank Professor Daming Gao (Institutes for Biological Sciences, Chinese Academy of Sciences) and Professor Yi Qin (Cancer Research Institute, Fudan University) for providing critical comments. This study was supported by grants from the National Science Foundation for Distinguished Young Scholars of China (no. 81625016) and the Shanghai Sailing Program (no. 17YF1402500).	Arsova-Sarafinovska Z, 2009, INT UROL NEPHROL, V41, P63, DOI 10.1007/s11255-008-9407-y; Brigelius-Flohe R, 2009, BBA-GEN SUBJECTS, V1790, P1555, DOI 10.1016/j.bbagen.2009.03.006; Chao W, 2017, MOLECULES, V22, DOI 10.3390/molecules22040537; Cullen JJ, 2003, PANCREAS, V26, P23, DOI 10.1097/00006676-200301000-00005; Faucher K, 2005, MOL CELL BIOCHEM, V277, P81, DOI 10.1007/s11010-005-5075-8; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Gao X, 2017, ONCOTARGET, V8, P51888, DOI 10.18632/oncotarget.17128; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hiscox S, 2004, CLIN EXP METASTAS, V21, P201, DOI 10.1023/B:CLIN.0000037697.76011.1d; Hoos WA, 2013, J CLIN ONCOL, V31, P3432, DOI 10.1200/JCO.2013.49.4823; Ichimura Y, 2004, J UROLOGY, V172, P728, DOI 10.1097/01.ju.0000130942.40597.9d; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Kodydkova J, 2013, PANCREAS, V42, P614, DOI 10.1097/MPA.0b013e318288360a; Kourie HR, 2016, WORLD J GASTRO ONCOL, V8, P297, DOI 10.4251/wjgo.v8.i3.297; Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li SJ, 2000, CANCER RES, V60, P3927; Liang C, 2015, ONCOTARGET, V6, P14440, DOI 10.18632/oncotarget.3885; Marechal R, 2012, GASTROENTEROLOGY, V143, P664, DOI 10.1053/j.gastro.2012.06.006; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Midha S, 2016, CANCER LETT, V381, P269, DOI 10.1016/j.canlet.2016.07.022; Miething C, 2014, NATURE, V510, P402, DOI 10.1038/nature13239; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Namba T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.172; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031; Ratnasinghe D, 2000, CANCER RES, V60, P6381; Ravn-Haren G, 2006, CARCINOGENESIS, V27, P820, DOI 10.1093/carcin/bgi267; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soltysova A, 2005, NEOPLASMA, V52, P435; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Sun SB, 2017, CELL BIOL INT, V41, P842, DOI 10.1002/cbin.10792; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Xiong GB, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0739-x; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu LF, 2012, LAB INVEST, V92, P744, DOI 10.1038/labinvest.2012.8	50	72	76	1	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5843	5857		10.1038/s41388-018-0392-z	http://dx.doi.org/10.1038/s41388-018-0392-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29980787				2022-12-17	WOS:000448943100003
J	Al Habyan, S; Kalos, C; Szymborski, J; McCaffrey, L				Al Habyan, Sara; Kalos, Christina; Szymborski, Joseph; McCaffrey, Luke			Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer	ONCOGENE			English	Article							EXPRESSION; ASCITES; CADHERIN; HETEROGENEITY; BEHAVIOR; MODEL	Ovarian cancer is the most lethal gynecological cancer, where survival rates have had modest improvement over the last 30 years. Metastasis of cancer cells is a major clinical problem, and patient mortality occurs when ovarian cancer cells spread beyond the confinement of ovaries. Disseminated ovarian cancer cells typically spread within the abdomen, where ascites accumulation aids in their transit. Metastatic ascites contain multicellular spheroids, which promote chemo-resistance and recurrence. However, little is known about the origin and mechanisms through which spheroids arise. Using live-imaging of 3D culture models and animal models, we report that epithelial ovarian cancer (EOC) cells, the most common type of ovarian cancer, can spontaneously detach as either single cells or clusters. We report that clusters are more resistant to anoikis and have a potent survival advantage over single cells. Using in vivo lineage tracing, we found that multicellular spheroids arise preferentially from collective detachment, rather than aggregation in the abdomen. Finally, we report that multicellular spheroids from collective detachment are capable of seeding intra-abdominal metastases that retain intra-tumoral heterogeneity from the primary tumor.	[Al Habyan, Sara; Kalos, Christina; Szymborski, Joseph; McCaffrey, Luke] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Al Habyan, Sara; Kalos, Christina; Szymborski, Joseph; McCaffrey, Luke] McGill Univ, Div Expt Med, Montreal, PQ H4A 3J1, Canada; [McCaffrey, Luke] McGill Univ, Gerald Bronfman Dept Oncol, Montreal, PQ H4A 3T2, Canada	McGill University; McGill University; McGill University	McCaffrey, L (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; McCaffrey, L (corresponding author), McGill Univ, Div Expt Med, Montreal, PQ H4A 3J1, Canada.; McCaffrey, L (corresponding author), McGill Univ, Gerald Bronfman Dept Oncol, Montreal, PQ H4A 3T2, Canada.	luke.mccaffrey@mcgill.ca		Szymborski, Joseph/0000-0003-1559-6225	CIHR [MOP-119482]	CIHR(Canadian Institutes of Health Research (CIHR))	We thank Dr. Didier Trono (Ecole Polytechnique Federale de Lausanne, Switzerland) for lentiviral plasmids acquired through Addgene, and Dr. Patricia Tonin (McGill University) for OV90 cells. This project was supported by funds from CIHR (MOP-119482) to LM. LM is a FRQS Research Scholar - Junior 2.	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; ALLEN HJ, 1987, EXP CELL BIOL, V55, P194; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cai Q, 2015, ONCOGENE, V34, P3315, DOI 10.1038/onc.2014.264; Cody NAL, 2007, ONCOGENE, V26, P618, DOI 10.1038/sj.onc.1209821; Davidowitz RA, 2014, J CLIN INVEST, V124, P2611, DOI 10.1172/JCI69815; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; HAMILTON TC, 1983, CANCER RES, V43, P5379; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Katz E, 2009, CLIN CANCER RES, V15, P70, DOI 10.1158/1078-0432.CCR-08-1233; Kim S, 2016, CANCER SCI, V107, P1173, DOI 10.1111/cas.12987; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Klymenko Y, 2017, NEOPLASIA, V19, P549, DOI 10.1016/j.neo.2017.04.002; Kobel M, 2011, INT J GYNECOL PATHOL, V30, P366, DOI 10.1097/PGP.0b013e31820d20ba; Koensgen D, 2010, ANTICANCER RES, V30, P2525; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Narod S, 2016, NAT REV CLIN ONCOL, V13, P255, DOI 10.1038/nrclinonc.2015.224; Puiffe ML, 2007, NEOPLASIA, V9, P820, DOI 10.1593/neo.07472; Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Timmins Nicholas E., 2007, V140, P141; Vankelecom H, 2009, COLD SPRING HARB PRO, V4, P1; Wintzell M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-359; Xu S, 2014, SCI REP-UK, V4, DOI 10.1038/srep05646; Yin MZ, 2016, J CLIN INVEST, V126, P4157, DOI 10.1172/JCI87252; Zhang M, 2015, CANCER DISCOV, V5, P520, DOI 10.1158/2159-8290.CD-14-1101	32	72	72	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5127	5135		10.1038/s41388-018-0317-x	http://dx.doi.org/10.1038/s41388-018-0317-x			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29789717	Green Published, hybrid			2022-12-17	WOS:000444405300008
J	Chen, A; Sceneay, J; Godde, N; Kinwel, T; Ham, S; Thompson, EW; Humbert, PO; Moller, A				Chen, Anna; Sceneay, Jaclyn; Godde, Nathan; Kinwel, Tanja; Ham, Sunyoung; Thompson, Erik W.; Humbert, Patrick O.; Moller, Andreas			Intermittent hypoxia induces a metastatic phenotype in breast cancer	ONCOGENE			English	Article							SUPPRESSOR-CELLS; SIGNALING PATHWAYS; GENE-EXPRESSION; DOWN-REGULATION; TUMOR-CELLS; MECHANISMS; ANGIOGENESIS; PROGRESSION; AUTOPHAGY; PROMOTES	Hypoxia arises frequently in solid tumors and is a poor prognostic factor as it promotes tumor cell proliferation, invasion, angiogenesis, therapy resistance, and metastasis. Notably, there are two described forms of hypoxia present in a growing tumor: chronic hypoxia, caused by abnormal tumor vasculature, and intermittent hypoxia, caused by transient perfusion facilitated by tumor-supplying blood vessels. Here, we demonstrate that intermittent hypoxia, but not chronic hypoxia, endows breast cancer cells with greater metastatic potential. Using an immunocompetent and syngeneic murine model of breast cancer, we show that intermittent hypoxia enhances metastatic seeding and outgrowth in lungs in vivo. Furthermore, exposing mammary tumor cells to intermittent hypoxia promoted clonal diversity, upregulated metastasis-associated gene expression, induced a pro-tumorigenic secretory profile, increased stem-like cell marker expression, and gave rise to tumor-initiating cells at a relatively higher frequency. This work demonstrates that intermittent hypoxia, but not chronic hypoxia, induces a number of genetic, molecular, biochemical, and cellular changes that facilitate tumor cell survival, colonization, and the creation of a permissive microenvironment and thus enhances metastatic growth.	[Chen, Anna; Godde, Nathan; Kinwel, Tanja; Humbert, Patrick O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, St Andrews Pl, Melbourne, Vic 3002, Australia; [Chen, Anna; Kinwel, Tanja; Humbert, Patrick O.] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; [Chen, Anna; Sceneay, Jaclyn; Ham, Sunyoung; Moller, Andreas] QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Brisbane, Qld 4006, Australia; [Godde, Nathan; Kinwel, Tanja; Humbert, Patrick O.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia; [Godde, Nathan; Humbert, Patrick O.] Univ Melbourne, Sir Peter MaCallum Dept Oncol, Parkville, Vic 3010, Australia; [Godde, Nathan] CSIRO, Australian Anim Hlth Lab, Pathol & Pathogenesis Grp, Diagnost Surveillance & Response, Geelong, Vic 3220, Australia; [Thompson, Erik W.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4000, Australia; [Thompson, Erik W.] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld 4000, Australia; [Thompson, Erik W.] Univ Melbourne, St Vincents Hosp, Dept Surg, East Melbourne 3002, Australia; [Humbert, Patrick O.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; [Sceneay, Jaclyn] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Peter Maccallum Cancer Center; University of Melbourne; QIMR Berghofer Medical Research Institute; La Trobe University; University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Queensland University of Technology (QUT); Queensland University of Technology (QUT); University of Melbourne; University of Melbourne; Harvard University; Brigham & Women's Hospital	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.; Humbert, PO (corresponding author), Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia.; Moller, A (corresponding author), QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Brisbane, Qld 4006, Australia.; Humbert, PO (corresponding author), La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia.; Humbert, PO (corresponding author), Univ Melbourne, Sir Peter MaCallum Dept Oncol, Parkville, Vic 3010, Australia.; Humbert, PO (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	p.humbert@latrobe.edu.au; andreas.moller@qimrberghofer.edu.au	Möller, Andreas/O-1063-2015; Humbert, Patrick O/L-4264-2016; Thompson, Erik/GPK-2067-2022; Thompson, Erik W/A-1425-2009	Möller, Andreas/0000-0002-8618-6998; Humbert, Patrick O/0000-0002-1366-6691; Thompson, Erik/0000-0002-9723-4924; Thompson, Erik W/0000-0002-9723-4924; Godde, Nathan/0000-0002-3413-407X	National Health and Medical Research Council of Australia [APP1068510, APP1079133]; Cancer Council Queensland [APP1045620]; National Breast Cancer Foundation (Australia) [ECF-11-09, NC-13-26]; APA scholarship	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Queensland(Cancer Council Queensland); National Breast Cancer Foundation (Australia); APA scholarship	The authors thank Carmen Yong for help with flow cytometry and IV injections, and the groups of POH and AM for proof-reading the manuscript. This work was supported by funding from a project grant from the National Health and Medical Research Council of Australia (APP1068510 to AM). POH was supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia (APP1079133). AM was supported by Cancer Council Queensland (APP1045620), and National Breast Cancer Foundation (Australia) fellowship and grant (ECF-11-09, NC-13-26). AC was supported by an APA scholarship.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Alqawi O, 2007, FREE RADICAL RES, V41, P788, DOI 10.1080/10715760701361531; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bayer C, 2012, STRAHLENTHER ONKOL, V188, P616, DOI 10.1007/s00066-012-0085-4; Bhaskara VK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030905; Boidot R, 2014, ONCOTARGET, V5, P6947, DOI 10.18632/oncotarget.2285; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196; Cairns RA, 2001, CANCER RES, V61, P8903; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan N, 2008, CANCER RES, V68, P605, DOI 10.1158/0008-5472.CAN-07-5472; Chen A, 2015, ONCOTARGET, V6, P862, DOI 10.18632/oncotarget.2696; Cooper C, 2004, CLIN CANCER RES, V10, P8720, DOI 10.1158/1078-0432.CCR-04-1235; Daneau G, 2010, CLIN CANCER RES, V16, P410, DOI 10.1158/1078-0432.CCR-09-0583; Fang YY, 2015, CELL BIOL INT, V39, P891, DOI 10.1002/cbin.10463; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gupta R, 2011, INT J ONCOL, V38, P733, DOI 10.3892/ijo.2010.883; Gutsche K, 2016, FREE RADICAL BIO MED, V101, P129, DOI 10.1016/j.freeradbiomed.2016.10.002; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hsieh CH, 2012, MOL IMAGING BIOL, V14, P489, DOI 10.1007/s11307-011-0516-0; Hsieh CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023945; Hsieh CH, 2010, ONCOL REP, V24, P1629, DOI 10.3892/or_00001027; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hussein D, 2006, MOL CANCER THER, V5, P2241, DOI 10.1158/1535-7163.MCT-06-0145; Kalliomaki TM, 2009, CANCER LETT, V282, P98, DOI 10.1016/j.canlet.2009.03.009; Kamat CD, 2007, CANCER LETT, V249, P209, DOI 10.1016/j.canlet.2006.08.017; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Liu YL, 2010, J CELL BIOCHEM, V111, P554, DOI 10.1002/jcb.22739; Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinive P, 2006, CANCER RES, V66, P11736, DOI 10.1158/0008-5472.CAN-06-2056; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015; Miao ZF, 2014, TUMOR BIOL, V35, P6801, DOI 10.1007/s13277-014-1928-7; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moller A, 2009, ONCOGENE, V28, P289, DOI 10.1038/onc.2008.382; Mujcic H, 2013, CLIN CANCER RES, V19, P6126, DOI 10.1158/1078-0432.CCR-13-0526; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Rofstad EK, 2010, INT J CANCER, V127, P1535, DOI 10.1002/ijc.25176; Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029; Sceneay J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066388; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Toffoli S, 2008, FEBS J, V275, P2991, DOI 10.1111/j.1742-4658.2008.06454.x; Wong CSF, 2012, CANCER RES, V72, P1694, DOI 10.1158/0008-5472.CAN-11-3310; Zhu HT, 2014, ONCOL REP, V32, P935, DOI 10.3892/or.2014.3298; Zolzer F, 2002, INT J RADIAT ONCOL, V54, P910, DOI 10.1016/S0360-3016(02)02963-2	60	72	73	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4214	4225		10.1038/s41388-018-0259-3	http://dx.doi.org/10.1038/s41388-018-0259-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713057				2022-12-17	WOS:000440566100002
J	Liao, YN; Xia, XH; Liu, NN; Cai, JY; Guo, ZQ; Li, YL; Jiang, LL; Dou, QP; Tang, DL; Huang, HB; Liu, JB				Liao, Yuning; Xia, Xiaohong; Liu, Ningning; Cai, Jianyu; Guo, Zhiqiang; Li, Yanling; Jiang, Lili; Dou, Q. Ping; Tang, Daolin; Huang, Hongbiao; Liu, Jinbao			Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; PROSTATE-CANCER; ENZYME USP14; E3 LIGASE; ASSOCIATION; DEGRADATION; ACTIVATION; EXPRESSION; AURANOFIN	It has been well known that androgen receptor (AR) is critical to prostate cancer development and progression. It has also been documented that AR is expressed in more than 60% of breast tumors, which promotes the growth of estrogen receptor-negative (ER-)/AR-positive (AR(+)) breast cancer cells. Thus, AR might be a potential therapeutic target for AR-positive/ER-negative breast cancer patients. Previously we reported that in prostate cancer cells proteasome-associated deubiquitinase ubiquitin-specific protease 14 (USP14) stabilized AR protein level by removing its ubiquitin chain. In the current study, we studied the USP14-AR protein interaction and cell proliferation status after USP14 reduction or inhibition in breast cancer cells, and our results support the conclusion that targeting USP14 is a novel strategy for treating AR-responsive breast cancer. We found that inhibition of USP14 accelerated the K48-ubiquitination and proteasome-mediated degradation of AR protein. Additionally, both genetic and pharmacological inhibition of USP14 significantly suppressed cell proliferation in AR-responsive breast cancer cells by blocking G(0)/G(1) to S phase transition and inducing apoptosis. Moreover, AR overexpression inhibited USP14 inhibition-induced events, suggesting that AR deubiquitination by USP14 is critical for breast cancer growth and USP14 inhibition is a possible strategy to treat AR-positive breast cancer.	[Liao, Yuning; Xia, Xiaohong; Cai, Jianyu; Guo, Zhiqiang; Li, Yanling; Jiang, Lili; Dou, Q. Ping; Huang, Hongbiao; Liu, Jinbao] Guangzhou Med Univ, Affiliated Canc Hosp, Prot Modificat & Degradat Lab, SKLRD,Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China; [Liu, Ningning] Guangzhou Med Univ, Guangzhou Inst Cardiovasc Dis, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China; [Dou, Q. Ping] Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI USA; [Dou, Q. Ping] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA; [Dou, Q. Ping] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Dou, Q. Ping] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; [Tang, Daolin] Guangzhou Med Univ, Affiliated Hosp 3, Ctr DAMP Biol,Prot Modificat & Degradat Lab, Key Lab Major Obstet Dis Guangdong Prov,Key Lab R, Guangzhou, Guangdong, Peoples R China; [Tang, Daolin] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA	Guangzhou Medical University; Guangzhou Medical University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University; Guangzhou Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huang, HB; Liu, JB (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp, Prot Modificat & Degradat Lab, SKLRD,Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China.	hhb800616@126.com; jliu@gzhmu.edu.cn	Tang, Daolin/ABD-5062-2021; Tang, Daolin/B-2905-2010; li, yan/GTI-4638-2022	Tang, Daolin/0000-0002-1903-6180; Liu, Ningning/0000-0002-9587-2332; Dou, Qingping/0000-0002-6465-1473	National Natural Science Foundation of China [81472390, 81472762, 31671435]; National Funds for Developing Local Colleges and Universities [B16056001]; Science and Technology Program of Guangzhou [201604020001]; Pearl River S&T Nova Program of Guangzhou [201506010071]; Innovative Academic Team of Guangzhou Education System [1201610014]; Guangzhou Education Commission [1201610098]; Science and Technology Planning Project of Guangdong Province, China [2014A020212691, 2016A030308]; Research Award Fund for Outstanding Young Teachers in Guangdong Provincial Higher Education Institutions [YQ2015136]; Project of Department of Education of Guangdong Province [2016KTSCX118, 2016KTSCX119]; Research Scholar Grant from the American Cancer Society [RSG-16-014-01-CDD]; National Institutes of Health, USA [R01CA160417, R01GM115366]; Natural Science Foundation of Guangdong Province [2016A030308011]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; NATIONAL CANCER INSTITUTE [R01CA160417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM115366] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Funds for Developing Local Colleges and Universities; Science and Technology Program of Guangzhou; Pearl River S&T Nova Program of Guangzhou; Innovative Academic Team of Guangzhou Education System; Guangzhou Education Commission; Science and Technology Planning Project of Guangdong Province, China; Research Award Fund for Outstanding Young Teachers in Guangdong Provincial Higher Education Institutions; Project of Department of Education of Guangdong Province; Research Scholar Grant from the American Cancer Society(American Cancer Society); National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. The study was supported by the National Natural Science Foundation of China (81472390, 81472762, and 31671435), the National Funds for Developing Local Colleges and Universities (B16056001), the Science and Technology Program of Guangzhou (201604020001), Pearl River S&T Nova Program of Guangzhou (201506010071), Innovative Academic Team of Guangzhou Education System (1201610014), General Project (1201610098) from Guangzhou Education Commission, the Science and Technology Planning Project of Guangdong Province, China (2014A020212691 and 2016A030308), a Research Award Fund for Outstanding Young Teachers in Guangdong Provincial Higher Education Institutions (YQ2015136), the Project of Department of Education of Guangdong Province(2016KTSCX118, 2016KTSCX119), a Research Scholar Grant from the American Cancer Society (RSG-16-014-01-CDD), the National Institutes of Health, USA (R01CA160417 and R01GM115366), the Natural Science Foundation of Guangdong Province (2016A030308011), and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2017). We thank the Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University for flow cytometry analysis.	Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Burska UL, 2013, J BIOL CHEM, V288, P32641, DOI 10.1074/jbc.M113.485912; Chen ST, 2015, J BIOL CHEM, V290, P21713, DOI 10.1074/jbc.M114.628255; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; Collins LC, 2011, MODERN PATHOL, V24, P924, DOI 10.1038/modpathol.2011.54; D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Dirac AMG, 2010, MOL CANCER RES, V8, P844, DOI 10.1158/1541-7786.MCR-09-0424; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Draker R, 2011, NUCLEIC ACIDS RES, V39, P3529, DOI 10.1093/nar/gkq1352; Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf; Faus H, 2005, MOL CELL ENDOCRINOL, V245, P138, DOI 10.1016/j.mce.2005.11.011; Gonzalez-Angulo AM, 2009, CLIN CANCER RES, V15, P2472, DOI 10.1158/1078-0432.CCR-08-1763; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832; Huang HB, 2016, ONCOTARGET, V7, P2796, DOI 10.18632/oncotarget.6425; Huang HBA, 2014, TOXICOL LETT, V228, P170, DOI 10.1016/j.toxlet.2014.05.012; Huang HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049062; Huang HB, 2011, CANCER LETT, V301, P221, DOI 10.1016/j.canlet.2010.12.015; Huang HB, 2010, CELL RES, V20, P1372, DOI 10.1038/cr.2010.123; Hurvitz SA, 2009, FUTURE ONCOL, V5, P1015, DOI 10.2217/FON.09.68; Lee BH, 2016, NATURE, V532, P398, DOI 10.1038/nature17433; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Liao YN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.477; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu NN, 2014, ONCOTARGET, V5, P5453, DOI 10.18632/oncotarget.2113; McClurg UL, 2015, ONCOTARGET, V6, P9657, DOI 10.18632/oncotarget.3922; Mialki RK, 2013, J BIOL CHEM, V288, P15437, DOI 10.1074/jbc.C112.446682; Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Sahtoe DD, 2015, MOL CELL, V57, P887, DOI 10.1016/j.molcel.2014.12.039; Sarkar S, 2014, ONCOGENE, V33, P26, DOI 10.1038/onc.2012.561; Shi XP, 2014, CLIN CANCER RES, V20, P151, DOI 10.1158/1078-0432.CCR-13-1063; Shinji S, 2006, ONCOL REP, V15, P539; Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033; Wang YY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0379-8; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032	40	72	75	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1896	1910		10.1038/s41388-017-0069-z	http://dx.doi.org/10.1038/s41388-017-0069-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29353883	hybrid, Green Published			2022-12-17	WOS:000429303300007
J	Wang, CH; Wang, PJ; Hsieh, YC; Lo, S; Lee, YC; Chen, YC; Tsai, CH; Chiu, WC; Hu, SCS; Lu, CW; Yang, YF; Chiu, CC; Ou-Yang, F; Wang, YM; Hou, MF; Yuan, SSF				Wang, C-H; Wang, P-J; Hsieh, Y-C; Lo, S.; Lee, Y-C; Chen, Y-C; Tsai, C-H; Chiu, W-C; Hu, S. Chu-Sung; Lu, C-W; Yang, Y-F; Chiu, C-C; Ou-Yang, F.; Wang, Y-M; Hou, M-F; Yuan, S-S F.			Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties	ONCOGENE			English	Article							ESTROGEN-RECEPTOR; 3T3-L1 ADIPOCYTES; EPITHELIAL-CELLS; REGULATED KINASE; GENE-EXPRESSION; INFLAMMATION; TRANSITION; PATHWAYS; BINDING; ALLIANCE	Growing evidence indicates that resistin-an obesity-related cytokine-is upregulated in breast cancer patients, yet its impact on breast cancer behavior remains to be ascertained. Similarly, Toll-like receptor 4 (TLR4) has been implicated in breast cancer progression, however, its clinically relevant endogenous ligand remains elusive. In this study, we observed that high serum resistin levels in breast cancer patients positively correlated with tumor stage, size and lymph node metastasis. These findings were replicated in animal models of breast cancer tumorigenesis and metastasis. Resistin was found to promote epithelial-mesenchymal transition and stemness in breast cancer cells-mechanisms critical to tumorigenesis and metastasis-through a TLR4/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B)/signal transducer and activator of transcription 3 (STAT3) signaling pathway and negated by TLR4-specific antibody and antagonist. These findings provide clear evidence that resistin is a clinically relevant endogenous ligand for TLR4, which promotes tumor progression via TLR4/NF-kappa B/STAT3 signaling, providing insights into a novel therapeutic target in breast cancer.	[Wang, C-H; Wang, P-J; Lo, S.; Lee, Y-C; Chen, Y-C; Tsai, C-H; Lu, C-W; Yang, Y-F; Yuan, S-S F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung 807, Taiwan; [Wang, C-H; Chen, Y-C; Yuan, S-S F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Wang, C-H; Chen, Y-C; Yuan, S-S F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan; [Hsieh, Y-C] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Lo, S.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Lee, Y-C] Kaohsiung Med Univ, Sch Med, Dept Anat, Coll Med, Kaohsiung, Taiwan; [Tsai, C-H; Ou-Yang, F.] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Chiu, W-C] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Thorac Surg, Dept Surg, Kaohsiung, Taiwan; [Hu, S. Chu-Sung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Dermatol, Kaohsiung, Taiwan; [Hu, S. Chu-Sung] Kaohsiung Med Univ, Dept Dermatol, Coll Med, Kaohsiung, Taiwan; [Chiu, C-C] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung, Taiwan; [Ou-Yang, F.] Kaohsiung Med Univ Hosp, Dept Surg, Kaohsiung, Taiwan; [Wang, Y-M] Natl Chiao Tung Univ, Inst Mol Med & Bioengn, Dept Biol Sci & Technol, Hsinchu, Taiwan; [Wang, Y-M] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan; [Hou, M-F] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Canc Ctr, Kaohsiung, Taiwan; [Hou, M-F] Kaohsiung Municipal Shiao Kang Hosp, Dept Surg, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of Glasgow; University of Glasgow; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Yang Ming Chiao Tung University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Yuan, SSF (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung 807, Taiwan.; Yuan, SSF (corresponding author), 100,Zihyou 1st Rd, Kaohsiung 80708, Taiwan.	yuanssf@kmu.edu.tw		Hou, Ming-Feng/0000-0001-6030-9702; Hu, Stephen Chu-Sung/0000-0002-1832-4471; Wang, Chie-Hong/0000-0003-0774-5323; yuan, shyng-shiou/0000-0002-4753-788X	Kaohsiung Medical University Hospital [KMUH102-2T07, KMUH103-3R28, KMUH104-4R29]; Kaohsiung Medical University (Aim for the Top Journals Grant) [KMU-DT105008, KMU-TP104D17]; National Health Research Institutes [NHRI-EX104-10212BI]; Ministry of Health and Welfare, Health and welfare surcharge of tobacco products of Taiwan [MOHW105-TDU-B-212-134007]	Kaohsiung Medical University Hospital; Kaohsiung Medical University (Aim for the Top Journals Grant); National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Health and Welfare, Health and welfare surcharge of tobacco products of Taiwan	We thank Dr Tsung-Hsien Chuang and Dr Wen-Chun Hung from National Health Research Institutes, Taiwan, for providing plasmid. This work was supported by Kaohsiung Medical University Hospital (KMUH102-2T07, KMUH103-3R28, KMUH104-4R29); Kaohsiung Medical University (Aim for the Top Journals Grant, KMU-DT105008, KMU-TP104D17); National Health Research Institutes (NHRI-EX104-10212BI); and Ministry of Health and Welfare, Health and welfare surcharge of tobacco products (MOHW105-TDU-B-212-134007) of Taiwan.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Assiri AMA, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/253519; Bauer AK, 2005, J NATL CANCER I, V97, P1778, DOI 10.1093/jnci/dji403; Chen YH, 2006, ENDOCRINOLOGY, V147, P4496, DOI 10.1210/en.2005-1655; Chung SS, 2015, ANTICANCER RES, V35, P39; Codoner-Franch P, 2015, CLIN CHIM ACTA, V438, P46, DOI 10.1016/j.cca.2014.07.043; Conde J, 2011, BIOFACTORS, V37, P413, DOI 10.1002/biof.185; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Ehsan N, 2013, TUMOR BIOL, V34, P1053, DOI 10.1007/s13277-013-0645-y; Franco HL, 2015, MOL CELL, V58, P21, DOI 10.1016/j.molcel.2015.02.001; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gonzalez-Reyes S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-665; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hsieh YY, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-59; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Iqbal J, 2013, J CLIN PATHOL, V66, P485, DOI 10.1136/jclinpath-2012-201304; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jing YY, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-98; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Lee JO, 2016, SCI REP-UK, V6, DOI 10.1038/srep18923; Lee MJ, 2008, AM J PHYSIOL-CELL PH, V294, pC1542, DOI 10.1152/ajpcell.00403.2007; Lee YC, 2012, GYNECOL ONCOL, V125, P742, DOI 10.1016/j.ygyno.2012.02.032; Li L, 2013, OCHSNER J, V13, P109; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; McTernan CL, 2002, LANCET, V359, P46, DOI 10.1016/S0140-6736(02)07281-1; Mehmeti M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0640-x; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Oblak A, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/609579; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Pradhan M, 2010, J BIOL CHEM, V285, P31100, DOI 10.1074/jbc.M110.155309; Schwartz DR, 2011, TRENDS ENDOCRIN MET, V22, P259, DOI 10.1016/j.tem.2011.03.005; Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886; Song JM, 2007, PLOS PATHOG, V3, P541, DOI 10.1371/journal.ppat.0030060; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Tarkowski A, 2010, J CELL MOL MED, V14, P1419, DOI 10.1111/j.1582-4934.2009.00899.x; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Wang W, 2015, CURR MED CHEM, V22, P264; Wendt Michael K, 2014, JAKSTAT, V3, pe28975, DOI 10.4161/jkst.28975; Yang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109980; Yokota S, 2010, INFECT IMMUN, V78, P468, DOI 10.1128/IAI.00903-09; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang XJ, 2015, INT J ONCOL, V46, P1141, DOI 10.3892/ijo.2014.2809; Zhou CC, 2012, ORAL ONCOL, V48, P1068, DOI 10.1016/j.oraloncology.2012.06.005	50	72	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					589	600		10.1038/onc.2017.357	http://dx.doi.org/10.1038/onc.2017.357			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991224				2022-12-17	WOS:000423812200005
J	Muppala, S; Xiao, R; Krukovets, I; Verbovetsky, D; Yendamuri, R; Habib, N; Raman, P; Plow, E; Stenina-Adognravi, O				Muppala, S.; Xiao, R.; Krukovets, I.; Verbovetsky, D.; Yendamuri, R.; Habib, N.; Raman, P.; Plow, E.; Stenina-Adognravi, O.			Thrombospondin-4 mediates TGF-beta-induced angiogenesis	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; BREAST-CANCER; FIBROSIS; PATHWAY; TARGET; PROTEINS; CELLS	TGF-beta is a multifunctional cytokine affecting many cell types and implicated in tissue remodeling processes. Due to its many functions and cell-specific effects, the consequences of TGF-beta signaling are process-and stage-dependent, and it is not uncommon that TGF-beta exerts distinct and sometimes opposing effects on a disease progression depending on the stage and on the pathological changes associated with the stage. The mechanisms underlying cell-and process-specific effects of TGF-beta are poorly understood. We are describing a novel pathway that mediates induction of angiogenesis in response to TGF-beta 1. We found that in endothelial cells (EC) thrombospondin-4 (TSP-4), a secreted extracellular matrix (ECM) protein, is upregulated in response to TGF-beta 1 and mediates the effects of TGF-beta 1 on angiogenesis. Upregulation of TSP-4 does not require the synthesis of new protein, is not caused by decreased secretion of TSP-4, and is mediated by activation of SMAD3. Using Thbs4(-/-) mice and TSP-4 shRNA, we found that TSP-4 mediated pro-angiogenic functions in cultured EC and angiogenesis in vivo in response to TGF-beta 1. We observed similar to 3-fold increases in tumor mass and levels of angiogenesis markers in animals injected with TGF-beta 1, and these effects did not occur in Thbs4(-/-) animals. Injections of an inhibitor of TGF-beta 1 signaling SB-431542 also decreased the weights of tumors and cancer angiogenesis. Our results from in vivo angiogenesis models and cultured EC document that TSP-4 mediates upregulation of angiogenesis by TGF-beta 1. Upregulation of pro-angiogenic TSP-4 and selective effects of TSP-4 on EC may contribute to stimulation of tumor growth by TGF-beta despite the inhibition of cancer cell proliferation.	[Muppala, S.; Xiao, R.; Krukovets, I.; Verbovetsky, D.; Yendamuri, R.; Habib, N.; Plow, E.; Stenina-Adognravi, O.] Cleveland Clin, Dept Mol Cardiol, 9500 Euclid Ave NB50-66, Cleveland, OH 44195 USA; [Raman, P.] North Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH USA	Cleveland Clinic Foundation; Northeast Ohio Medical University (NEOMED)	Stenina-Adognravi, O (corresponding author), Cleveland Clin, Dept Mol Cardiol, 9500 Euclid Ave NB50-66, Cleveland, OH 44195 USA.	stenino@ccf.org	Xiao, Roy/AAZ-1915-2020; muppala, santoshi/AAK-2385-2020; Santoo/B-2423-2018; Muppala, Santoshi/K-6910-2019	Santoo/0000-0001-7830-9591; Muppala, Santoshi/0000-0001-7830-9591; Xiao, Roy/0000-0003-4459-0746	NIH [R01HL117216, CA177771]; National Center for Advancing Translational Sciences component of the National Institutes of Health [UL1TR000439]; National Institutes of Health Roadmap for Medical Research; NATIONAL CANCER INSTITUTE [R01CA177771] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117216] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences component of the National Institutes of Health; National Institutes of Health Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by NIH R01HL117216 (OS-A and EP) and NIH CA177771 (OS-A). Isolation of HUVECs was supported by UL1TR000439. HUVECs were provided by a grant awarded to Clinical and Translational Science Collaborative of Cleveland, a grant from the National Center for Advancing Translational Sciences (UL1TR000439) component of the National Institutes of Health, and National Institutes of Health Roadmap for Medical Research.	Araujo-Jorge TC, 2012, CLIN PHARMACOL THER, V92, P613, DOI 10.1038/clpt.2012.102; Bhattacharyya S, 2008, J BIOL CHEM, V283, P5699, DOI 10.1074/jbc.M706435200; Bhattacharyya S, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.005967; Blahna MT, 2012, FEBS LETT, V586, P1906, DOI 10.1016/j.febslet.2012.01.041; Blanco FF, 2014, MOL CELL BIOL, V34, P180, DOI 10.1128/MCB.01020-13; Cho JY, 2011, CLIN CANCER RES, V17, P1850, DOI 10.1158/1078-0432.CCR-10-2180; Chou YT, 2006, J BIOL CHEM, V281, P18451, DOI 10.1074/jbc.M601720200; Cingolani OH, 2011, CIRC RES, V109, P1410, DOI 10.1161/CIRCRESAHA.111.256743; Congote LF, 2004, BIOCHEM BIOPH RES CO, V324, P673, DOI 10.1016/j.bbrc.2004.09.107; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dietz HC, 2010, J CLIN INVEST, V120, P403, DOI 10.1172/JCI42014; Eming SA, 2011, EXP DERMATOL, V20, P605, DOI 10.1111/j.1600-0625.2011.01309.x; Fernandez Isis E, 2012, Proc Am Thorac Soc, V9, P111, DOI 10.1513/pats.201203-023AW; Frolova EG, 2012, FASEB J, V26, P2363, DOI 10.1096/fj.11-190728; Frolova EG, 2010, CIRC RES, V107, P1313, DOI 10.1161/CIRCRESAHA.110.232371; Garcia R, 2015, BBA-MOL BASIS DIS, V1852, P1520, DOI 10.1016/j.bbadis.2015.04.006; Hoover LL, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.146pe48; Hubmacher D, 2013, CURR OPIN RHEUMATOL, V25, P65, DOI 10.1097/BOR.0b013e32835b137b; James D, 2010, NAT BIOTECHNOL, V28, P161, DOI 10.1038/nbt.1605; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Joseph JV, 2013, BIOCHEM PHARMACOL, V85, P478, DOI 10.1016/j.bcp.2012.11.005; Katz LH, 2013, EXPERT OPIN THER TAR, V17, P743, DOI 10.1517/14728222.2013.782287; Kostourou V, 2014, BBA-GEN SUBJECTS, V1840, P2403, DOI 10.1016/j.bbagen.2014.02.018; Krishnan S, 2015, ONCOTARGET, V6, P22480, DOI 10.18632/oncotarget.4310; Lan HY, 2012, SEMIN NEPHROL, V32, P236, DOI 10.1016/j.semnephrol.2012.04.002; Loeys BL, 2013, PEDIATR ENDOCR REV P, V10, P417; Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6; Lynch JM, 2012, CELL, V149, P1257, DOI 10.1016/j.cell.2012.03.050; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Mahabeleshwar Ganapati H., 2006, V129, P197; Muppala S, 2015, ARTERIOSCL THROM VAS, V35, P1975, DOI 10.1161/ATVBAHA.115.305912; Mustonen E, 2012, ANN MED, V44, P793, DOI 10.3109/07853890.2011.614635; Perrot CY, 2013, PHARMACOL THERAPEUT, V137, P183, DOI 10.1016/j.pharmthera.2012.10.002; Petroll WM, 1998, INVEST OPHTH VIS SCI, V39, P2018; Prendes MA, 2013, BRIT J OPHTHALMOL, V97, P680, DOI 10.1136/bjophthalmol-2011-301132; Samarakoon R, 2013, CELL SIGNAL, V25, P264, DOI 10.1016/j.cellsig.2012.10.003; Senger DR, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005090; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Soloviev Dmitry A., 2006, V129, P267; Stenina OI, 2003, CIRCULATION, V108, P1514, DOI 10.1161/01.CIR.0000089085.76320.4E; Toma I, 2012, CELL TISSUE RES, V347, P155, DOI 10.1007/s00441-011-1189-3; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Weiss A, 2013, WIRES DEV BIOL, V2, P47, DOI 10.1002/wdev.86; Yanagita M, 2012, NEPHROL DIAL TRANSPL, V27, P3686, DOI 10.1093/ndt/gfs381; Yang SNY, 2010, J DIABETES, V2, P233, DOI 10.1111/j.1753-0407.2010.00089.x; Yang Y, 2009, J CELL BIOCHEM, V106, P1102, DOI 10.1002/jcb.22100; Yokoyama H, 1996, DIABETIC MED, V13, P313, DOI 10.1002/(SICI)1096-9136(199604)13:4<313::AID-DIA56>3.3.CO;2-Z	49	72	77	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5189	5198		10.1038/onc.2017.140	http://dx.doi.org/10.1038/onc.2017.140			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481870	Green Accepted			2022-12-17	WOS:000409371100010
J	Guo, JY; Hsu, HS; Tyan, SW; Li, FY; Shew, JY; Lee, WH; Chen, JY				Guo, J-Y; Hsu, H-S; Tyan, S-W; Li, F-Y; Shew, J-Y; Lee, W-H; Chen, J-Y			Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; CD44; FIBROBLASTS; EXPRESSION; OVEREXPRESSION; ACTIVATION; ADHESION; PROTEOGLYCAN	Tumor microenvironment (TME) plays an active role in promoting tumor progression. To further understand the communication between TME and tumor cells, this study aimed at investigating the involvement of CD44, a type I cell surface receptor, in the crosstalk between tumor cells and TME. We have previously shown that chondroitin sulfate proteoglycan serglycin (SRGN), a CD44-interacting factor, was preferentially secreted by cancer-associated fibroblasts (CAFs) for promoting tumor growth in breast cancer patients. In this study, we show that SRGN is overexpressed in primary non-small cell lung cancers (NSCLCs), by both carcinoma and stromal cells. Using gain-of-function and loss-of-function approaches, we show that SRGN promotes NSCLC cell migration and invasion as well as colonization in the lung and liver in a CD44-dependent manner. SRGN induces lung cancer cell stemness, as demonstrated by its ability to enhance NSCLC cell sphere formation via Nanog induction, accompanied with increased chemoresistance and anoikis-resistance. SRGN promotes epithelial-mesenchymal transition by enhancing vimentin expression via CD44/NF-kappa B/claudin-1(CLDN1) axis. In support, CLDN1 and SRGN expression are tightly linked together in primary NSCLC. Most importantly, increased expression of SRGN and/or CLDN1 predicts poor prognosis in primary lung adenocarcinomas. In summary, we demonstrate that SRGN secreted by tumor cells and stromal components in the TME promotes malignant phenotypes through interacting with tumor cell receptor CD44, suggesting that a combined therapy targeting both CD44 and its ligands in the TME may be an attractive approach for cancer therapy.	[Guo, J-Y; Chen, J-Y] Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan; [Hsu, H-S] Taipei Vet Gen Hosp, Dept Thorac Surg, Taipei, Taiwan; [Tyan, S-W] Chia Nan Univ Pharm & Sci, Dept Biotechnol, Tainan, Taiwan; [Li, F-Y] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan; [Shew, J-Y; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Lee, W-H] China Med Univ, Inst Clin Med, Taichung, Taiwan; [Chen, J-Y] Natl Yang Ming Univ, Dept Life Sci, Taipei, Taiwan; [Chen, J-Y] Natl Yang Ming Univ, Inst Genome Sci, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Veterans General Hospital; Chia Nan University of Pharmacy & Science; Taipei Veterans General Hospital; Academia Sinica - Taiwan; China Medical University Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chen, JY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	bmchen@ibms.sinica.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018		Academia Sinica and Ministry of Science and Technology [MOST 104-0210-01-09-02, MOST-104-2320-B-001-010]; Academia Sinica, Taiwan	Academia Sinica and Ministry of Science and Technology; Academia Sinica, Taiwan(Academia Sinica - Taiwan)	This research was supported by Academia Sinica and Ministry of Science and Technology (MOST 104-0210-01-09-02 and MOST-104-2320-B-001-010 to JYC), and a post-doctoral fellowship to JYG from Academia Sinica, Taiwan.	Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Chen Hong-Chen, 2004, V294, P15; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; dos Reis PP, 2008, CANCER-AM CANCER SOC, V113, P3169, DOI 10.1002/cncr.23934; Edlund K, 2012, INT J CANCER, V131, P2264, DOI 10.1002/ijc.27518; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hassona Y, 2013, CARCINOGENESIS, V34, P1286, DOI 10.1093/carcin/bgt035; He J, 2014, WORLD J GASTROENTERO, V20, P3025, DOI 10.3748/wjg.v20.i11.3025; He L, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0707-4; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kinugasa Y, 2014, STEM CELLS, V32, P145, DOI 10.1002/stem.1556; Korpetinou A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078157; Lee JC, 2008, NCM 2008: 4TH INTERNATIONAL CONFERENCE ON NETWORKED COMPUTING AND ADVANCED INFORMATION MANAGEMENT, VOL 2, PROCEEDINGS, P28, DOI 10.1109/NCM.2008.203; Lee J, 2007, IEEE ASIAN SOLID STA, P67, DOI 10.1109/ASSCC.2007.4425733; Leotlela PD, 2007, ONCOGENE, V26, P3846, DOI 10.1038/sj.onc.1210155; Leung ELH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014062; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Li XJ, 2011, CANCER RES, V71, P3162, DOI 10.1158/0008-5472.CAN-10-3557; LIN H, 2013, MATH PROBL ENG, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0060516; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu CA, 2004, ONCOGENE, V23, P8731, DOI 10.1038/sj.onc.1208106; Liu YJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0040003, 10.1371/journal.pone.0036949, 10.1371/journal.pone.0032127, 10.1186/1746-1596-7-49]; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Orian-Rousseau V, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00154; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Purushothaman A, 2014, J BIOL CHEM, V289, P5499, DOI 10.1074/jbc.M113.532143; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Shiozaki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038049; Singh A. K., 2012, J ENV SCI TOXICOL FO, V1, P1, DOI DOI 10.1016/J.BMC.2011.09.022; Singh AB, 2011, GASTROENTEROLOGY, V141, P2140, DOI 10.1053/j.gastro.2011.08.038; Skliris A, 2013, FEBS J, V280, P2342, DOI 10.1111/febs.12179; Sudhir PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep09633; Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Tyan SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035128; Tyan SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015313; Vered M, 2010, INT J CANCER, V127, P1356, DOI 10.1002/ijc.25358; Volz Y, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150093	53	72	75	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2457	2471		10.1038/onc.2016.404	http://dx.doi.org/10.1038/onc.2016.404			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27819672	hybrid, Green Published			2022-12-17	WOS:000400268900011
J	Saitoh, M; Endo, K; Furuya, S; Minami, M; Fukasawa, A; Imamura, T; Miyazawa, K				Saitoh, M.; Endo, K.; Furuya, S.; Minami, M.; Fukasawa, A.; Imamura, T.; Miyazawa, K.			STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SMAD TRANSCRIPTIONAL ACTIVITY; PROTEIN INHIBITOR; ACTIVATOR; PATHWAY; GROWTH; CELLS; IL-6; EMT; TRANSDUCER	The epithelial-mesenchymal transition (EMT) is a crucial morphological event that occurs during the progression of epithelial tumors. EMT can be induced by transforming growth factor beta (TGF-beta) in certain kinds of cancer cells through the induction of Snail, a key regulator of EMT. We have previously found that TGF-beta remarkably induces Snail expression in cooperation with Ras signals; however, the underlying mechanism of this synergism has not yet been determined. Here, we demonstrate that signal transducer and activator of transcription 3 (STAT3) acts as a mediator that synergizes TGF-beta and Ras signals. The overexpression of STAT3 enhanced Snail induction, whereas siRNA-mediated knockdown of STAT3 inhibited it. The STAT3-gamma F mutant, which has Tyr 705 substituted with Phe, did not enhance Snail induction. Several STAT3 mutants lacking transcriptional activity also failed to enhance it; however, the putative STAT3-binding elements in the Snail promoter regions were not required for STAT3-mediated Snail induction. Protein inhibitor of activated STAT3 (PIAS3) inhibited the enhanced Snail promoter activity induced by TGF-beta and Ras. The interaction between PIAS3 and STAT3 was reduced by TGF-beta in cells harboring oncogenic Ras, whereas TGF-beta promoted the binding of PIAS3 to Smad3, a crucial mediator of TGF-beta signaling. Therefore, these findings suggest that STAT3 enhances Snail induction when it is dissociated from PIAS3 by TGF-beta in cooperation with Ras signals.	[Saitoh, M.; Endo, K.; Furuya, S.; Minami, M.; Fukasawa, A.; Miyazawa, K.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Biochem, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan; [Furuya, S.; Minami, M.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Res Training Program Undergrad, Chuo, Yamanashi 4093898, Japan; [Imamura, T.] Ehime Univ, Grad Sch Med, Dept Mol Med Pathogenesis, Matsuyama, Ehime 790, Japan	University of Yamanashi; University of Yamanashi; Ehime University	Saitoh, M (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Biochem, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.	msaitoh-ind@umin.ac.jp			JSPS KAKENHI [24390419]; JSPS; Ministry of Education, Culture, Sports, Science and Technology of Japan; Astellas Foundation for Research on Metabolic Disorders; Fugaku Trust for Medicinal Research; Mitsubishi Foundation; Terumo Life Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Astellas Foundation for Research on Metabolic Disorders; Fugaku Trust for Medicinal Research; Mitsubishi Foundation; Terumo Life Science Foundation(Terumo Life Science Foundation)	We would like to thank M Myogahara for her excellent secretarial assistance. We also thank Dr T Shirakihara, Dr K Horiguchi, Dr D Koinuma, Dr S Ehata, Dr H Suzuki, and Dr K Miyazono for their helpful advice. This work was supported by JSPS KAKENHI Grant Number 24390419, the JSPS Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling', and a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also supported by Astellas Foundation for Research on Metabolic Disorders (to MS) and research grants from the Fugaku Trust for Medicinal Research, the Mitsubishi Foundation, and Terumo Life Science Foundation (to KM). This work was supported by JSPS KAKENHI Grant Number 24390419, the JSPS Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling', and a research program of the Project for the Development of Innovative Research on Cancer Therapeutics (P-Direct) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also supported by Astellas Foundation for Research on Metabolic Disorders (to MS) and research grants from the Fugaku Trust for Medicinal Research, the Mitsubishi Foundation and Terumo Life Science Foundation (to KM).	Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fu XT, 2015, INT J ONCOL, V46, P587, DOI 10.3892/ijo.2014.2761; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Huang C, 2011, NEOPLASMA, V58, P396, DOI 10.4149/neo_2011_05_396; Inman GJ, 2011, CURR OPIN GENET DEV, V21, P93, DOI 10.1016/j.gde.2010.12.004; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Kohsaka S, 2012, MOL CANCER THER, V11, P1289, DOI 10.1158/1535-7163.MCT-11-0801; Lee J, 2012, J BIOL CHEM, V287, P18182, DOI 10.1074/jbc.M111.328831; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Liu Y, 2013, J BIOL CHEM, V288, P30708, DOI 10.1074/jbc.M113.478685; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Ozawa Y, 2008, J BIOL CHEM, V283, P24561, DOI 10.1074/jbc.M802238200; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Saitoh M, 2012, J BIOCHEM, V151, P563, DOI 10.1093/jb/mvs040; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Subramaniam A, 2013, BBA-REV CANCER, V1835, P46, DOI 10.1016/j.bbcan.2012.10.002; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yagil Z, 2010, TRENDS IMMUNOL, V31, P199, DOI 10.1016/j.it.2010.01.005; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X; Zhang QF, 2013, J BIOL CHEM, V288, P31280, DOI 10.1074/jbc.M113.505057	35	72	73	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1049	1057		10.1038/onc.2015.161	http://dx.doi.org/10.1038/onc.2015.161			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961936				2022-12-17	WOS:000370823300010
J	Shain, KH; Dalton, WS; Tao, J				Shain, K. H.; Dalton, W. S.; Tao, J.			The tumor microenvironment shapes hallmarks of mature B-cell malignancies	ONCOGENE			English	Review							CHRONIC LYMPHOCYTIC-LEUKEMIA; BONE-MARROW MICROENVIRONMENT; MEDIATED DRUG-RESISTANCE; SPLEEN TYROSINE KINASE; MULTIPLE-MYELOMA CELLS; NF-KAPPA-B; FOLLICULAR LYMPHOMA; STROMAL CELLS; THERAPEUTIC TARGET; T-CELLS	B-cell tumorigenesis results from a host of known and unknown genetic anomalies, including non-random translocations of genes that normally function as determinants of cell proliferation or cell survival to regions juxtaposed to active immunoglobulin heavy chain enhancer elements, chromosomal aneuploidy, somatic mutations that further affect oncogenic signaling and loss of heterozygosity of tumor-suppressor genes. However, it is critical to recognize that even in the setting of a genetic disease, the B-cell/plasma cell tumor microenvironment (TME) contributes significantly to malignant transformation and pathogenesis. Over a decade ago, we proposed the concept of cell adhesion-mediated drug resistance to delineate a form of TME-mediated drug resistance that protects hematopoietic tumor cells from the initial effect of diverse therapies. In the interim, it has been increasingly appreciated that TME also contributes to tumor initiation and progression through sustained growth/proliferation, self-renewal capacity, immune evasion, migration and invasion as well as resistance to cell death in a host of B-cell malignancies, including mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenstroms macroglobulinemia, chronic lymphocytic leukemia and multiple myeloma. Within this review, we propose that TME and the tumor co-evolve as a consequence of bidirectional signaling networks. As such, TME represents an important target and should be considered integral to tumor progression and drug response.	[Shain, K. H.; Dalton, W. S.] Dept Malignant Hematol, Tampa, FL USA; [Shain, K. H.; Dalton, W. S.] Chem Biol & Mol Med Program, Tampa, FL USA; [Dalton, W. S.] DeBartolo Family Personalized Med Inst, Tampa, FL USA; [Tao, J.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematopathol & Lab Med, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Shain, KH (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, MCC LAB 2071,12902 Magnolia Dr, Tampa, FL 33612 USA.	ken.shain@moffitt.org; jianguo.tao@moffitt.org			Department of Health Bankhead-Coley Team Science Program grant [2BT03]; US Army Medical Research and Materiel Command [W81XWH-08-2-0101]; National Cancer Institute [P30-CA076292]; National Cancer Institutes [R01CA137123]; Lymphoma Research Foundation; Maher Fund; Moffitt Cancer Center Foundation; NATIONAL CANCER INSTITUTE [R01CA137123, R25CA174664, P30CA076292] Funding Source: NIH RePORTER	Department of Health Bankhead-Coley Team Science Program grant; US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institutes(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lymphoma Research Foundation; Maher Fund; Moffitt Cancer Center Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Department of Health Bankhead-Coley Team Science Program grant (2BT03), the US Army Medical Research and Materiel Command under Award W81XWH-08-2-0101 for a National Functional Genomics Center, the National Cancer Institute under Award (P30-CA076292), National Cancer Institutes (R01CA137123), Lymphoma Research Foundation, Maher Fund and the Moffitt Cancer Center Foundation.	Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Ai WZ, 2009, INT J CANCER, V124, P239, DOI 10.1002/ijc.23881; Arana E, 2008, J CELL SCI, V121, P2279, DOI 10.1242/jcs.017905; Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood-2008-10-186668; Blotta S, 2012, BLOOD, V120, P5002, DOI 10.1182/blood-2011-07-368142; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Boucher K, 2012, CLIN CANCER RES, V18, P6155, DOI 10.1158/1078-0432.CCR-12-0531; Brown JR, 2014, BLOOD, V123, P3390, DOI 10.1182/blood-2013-11-535047; Buchner M, 2009, CANCER RES, V69, P5424, DOI 10.1158/0008-5472.CAN-08-4252; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burger JA, 2012, CURR OPIN ONCOL, V24, P643, DOI 10.1097/CCO.0b013e3283589950; Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood-2009-06-225326; Byrd JC, 2014, J CLIN ONCOL, V32, P3039, DOI 10.1200/JCO.2014.55.8262; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Cacciatore M, 2012, ADV HEMATOL, V2012, DOI DOI 10.1155/2012/138079; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dasmahapatra G, 2013, BRIT J HAEMATOL, V161, P43, DOI 10.1111/bjh.12206; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; de Haart SJ, 2013, CLIN CANCER RES, V19, P5591, DOI 10.1158/1078-0432.CCR-12-3676; de Jong D, 2008, J INTERN MED, V264, P528, DOI 10.1111/j.1365-2796.2008.02032.x; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Du WL, 2004, PATHOL INT, V54, P285, DOI 10.1111/j.1440-1827.2004.01622.x; Emmons MF, 2011, MOL CANCER THER, V10, P2257, DOI 10.1158/1535-7163.MCT-11-0149; Fan F, 2012, J ONCOL, V2012, DOI 10.1155/2012/281261; Flinn IW, 2014, BLOOD, V123, P3406, DOI 10.1182/blood-2013-11-538546; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Ghobrial J, 2007, ONCOLOGY-NY, V21, P785; Gilbert LA, 2012, GENE DEV, V26, P1758, DOI 10.1101/gad.197590.112; Glas AM, 2005, BLOOD, V105, P301, DOI 10.1182/blood-2004-06-2298; Gorgun GT, 2013, BLOOD, V121, P2975, DOI 10.1182/blood-2012-08-448548; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Herman SEM, 2012, ASH ANN M, V120, P185; Herreros B, 2008, LEUKEMIA, V22, P49, DOI 10.1038/sj.leu.2404970; Hirsch E, 2014, ONCOGENE, V33, P3083, DOI 10.1038/onc.2013.265; Hodge LS, 2012, BLOOD, V120, P3774, DOI 10.1182/blood-2012-03-419440; Hoellenriegel J, 2012, LEUKEMIA, V26, P1576, DOI 10.1038/leu.2012.24; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Hu YP, 2012, LEUKEMIA LYMPHOMA, V53, P130, DOI 10.3109/10428194.2011.601698; Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood-2009-06-222943; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jones JA, 2014, BLOOD, V123, P1455, DOI 10.1182/blood-2013-09-453092; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Kahl BS, 2014, BLOOD, V123, P3398, DOI 10.1182/blood-2013-11-537555; Kiaii S, 2013, J CLIN ONCOL, V31, P2654, DOI 10.1200/JCO.2012.44.2137; Kimlinger T, 2006, HAEMATOLOGICA, V91, P1033; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Koster A, 2005, CURR OPIN ONCOL, V17, P611, DOI 10.1097/01.cco.0000181404.83084.b5; Kumar S, 2003, LEUKEMIA, V17, P2025, DOI 10.1038/sj.leu.2403084; Kuppers R, 2004, NEW ENGL J MED, V351, P2152, DOI 10.1056/NEJMp048257; Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Lin J, 2011, LEUKEMIA, V25, P145, DOI 10.1038/leu.2010.230; Lutzny G, 2013, CANCER CELL, V23, P77, DOI 10.1016/j.ccr.2012.12.003; Lwin T, 2007, LEUKEMIA, V21, P1521, DOI 10.1038/sj.leu.2404723; Lwin T, 2009, LEUKEMIA, V23, P170, DOI 10.1038/leu.2008.266; Lwin T, 2013, J CLIN INVEST, V123, P4612, DOI 10.1172/JCI64210; McMillin DW, 2013, NAT REV DRUG DISCOV, V12, P217, DOI 10.1038/nrd3870; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Medina DJ, 2012, HAEMATOL-HEMATOL J, V97, P1255, DOI 10.3324/haematol.2011.040659; Mitsiades CS, 2007, HEMATOL ONCOL CLIN N, V21, P1007, DOI 10.1016/j.hoc.2007.08.007; Moller C, 2003, LEUKEMIA, V17, P203, DOI 10.1038/sj.leu.2402717; Mourcin F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00280; Mraz M, 2011, BRIT J HAEMATOL, V155, P53, DOI 10.1111/j.1365-2141.2011.08794.x; Mueller CG, 2007, J LEUKOCYTE BIOL, V82, P567, DOI 10.1189/jlb.0706481; Neffendorf JE, 2013, NEW ENGL J MED, V369, P1277, DOI 10.1056/NEJMc1309710; Ngo HT, 2008, BLOOD, V112, P150, DOI 10.1182/blood-2007-12-129395; Noonan K, 2011, CANCER MICROENVIRON, V4, P313, DOI 10.1007/s12307-011-0086-3; Nyman JS, 2011, J BONE MINER RES, V26, P1252, DOI 10.1002/jbmr.326; O'Callaghan K, 2012, BLOOD, V119, P1717, DOI 10.1182/blood-2011-04-347518; Ostman A, 2012, NAT MED, V18, P1332, DOI 10.1038/nm.2938; Pilarski LM, 2002, CLIN CANCER RES, V8, P3198; Podar K, 2007, CELL CYCLE, V6, P538, DOI 10.4161/cc.6.5.3922; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Quiroga MP, 2009, BLOOD, V114, P1029, DOI 10.1182/blood-2009-03-212837; Rajkumar SV, 2003, LEUKEMIA, V17, P775, DOI 10.1038/sj.leu.2402866; Ramachandran IR, 2013, J IMMUNOL, V190, P3815, DOI 10.4049/jimmunol.1203373; Rappa G, 2008, EXP CELL RES, V314, P2110, DOI 10.1016/j.yexcr.2008.03.008; Richter J, 2012, NAT GENET, V44, P1316, DOI 10.1038/ng.2469; Ruan J, 2013, BLOOD, V121, P5192, DOI 10.1182/blood-2013-03-490763; Sacedon R, 2005, J IMMUNOL, V174, P1456, DOI 10.4049/jimmunol.174.3.1456; Seifert Marc, 2013, Methods Mol Biol, V971, P1, DOI 10.1007/978-1-62703-269-8_1; Shain KH, 2014, ONCOGENE, V33, P4107, DOI 10.1038/onc.2013.379; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03; Stein R, 2010, BLOOD, V115, P5180, DOI 10.1182/blood-2009-06-228288; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood-2011-12-396853; Tao JC, 2014, CELL CYCLE, V13, P191, DOI 10.4161/cc.27646; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Troeger A, 2012, BLOOD, V119, P4708, DOI 10.1182/blood-2011-12-395939; Vij R, 2012, ASH ANN M, V120, P4039; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Wobus M, 2012, EXP HEMATOL, V40, P867, DOI 10.1016/j.exphem.2012.06.004; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Xu D, 2001, BRIT J CANCER, V84, P621, DOI 10.1054/bjoc.2000.1655; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937; Yu L, 2008, BLOOD, V111, P4617, DOI 10.1182/blood-2007-10-121137; Zhang L, 2012, BLOOD, V120, P3783, DOI 10.1182/blood-2012-04-424630; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	120	72	75	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4673	4682		10.1038/onc.2014.403	http://dx.doi.org/10.1038/onc.2014.403			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25639873	Green Accepted			2022-12-17	WOS:000360931500001
J	Cui, J; Yang, Y; Li, H; Leng, Y; Qian, K; Huang, Q; Zhang, C; Lu, Z; Chen, J; Sun, T; Wu, R; Sun, Y; Song, H; Wei, X; Jing, P; Yang, X; Zhang, C				Cui, J.; Yang, Y.; Li, H.; Leng, Y.; Qian, K.; Huang, Q.; Zhang, C.; Lu, Z.; Chen, J.; Sun, T.; Wu, R.; Sun, Y.; Song, H.; Wei, X.; Jing, P.; Yang, X.; Zhang, C.			MiR-873 regulates ER alpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; CROSS-TALK; PHOSPHORYLATION; MECHANISMS; ANTAGONISM; INHIBITORS; SERINE-118; EXPRESSION; MICRORNAS; SURVIVAL	miRNAs (microRNAs) are frequently and aberrantly expressed in many cancers. MiR-873 has been revealed to be downregulated in colorectal cancer and glioblastoma. However, its function remains unclear. Here we report that miR-873 is downregulated in breast tumor compared with normal tissue. Enforced expression of miR-873 decreases the transcriptional activity of ER (estrogen receptor)-alpha but not ER beta through the modulation of ER alpha phosphorylation in ER-positive breast cancer cells. We also found that miR-873 inhibits breast cancer cell proliferation and tumor growth in nude mice. Reporter gene assays revealed cyclin-dependent kinase 3 (CDK3) as a direct target of miR-873. CDK3 was shown to be overexpressed in breast cancer and phosphorylate ERa at Ser104/116 and Ser118. Furthermore, we found that Mir-873 inhibits ER activity and cell growth via targeting CDK3. Interestingly, miR-873 was observed to be downregulated in tamoxifen-resistant MCF-7/TamR cells, while CDK3 is overexpressed in these cells. More importantly, re-expression of miR-873 reversed tamoxifen resistance in MCF-7/TamR cells. Our data demonstrate that miR-873 is a novel tumor suppressor in ER-positive breast cancer and a potential therapeutic approach for treatment of tamoxifen-resistant breast cancer.	[Cui, J.; Lu, Z.; Wu, R.; Sun, Y.; Song, H.; Zhang, C.] Acad Mil Med Sci, Inst Dis Control & Prevent, Beijing, Peoples R China; [Yang, Y.] Capital Med Univ, Beijing Inst Neurosci, Beijing, Peoples R China; [Li, H.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Leng, Y.; Qian, K.] Jiujiang Univ, Affiliated Hosp, Jiujiang, Peoples R China; [Huang, Q.] Jilin Agr Univ, Dept Anim Sci & Technol, Changchun, Peoples R China; [Zhang, C.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Chen, J.; Sun, T.] Nanchang Univ, Hosp 1, Dept Urol, Nanchang, Peoples R China; [Wei, X.] Peking Univ, Coll Chem & Mol Engn, Dept Appl Chem, Beijing 100871, Peoples R China; [Jing, P.] Purdue Univ, Indiana Univ, Coll Arts & Sci, Dept Chem, Ft Wayne, IN USA; [Yang, X.] Anhui Univ, Inst Hlth Sci, Hefei 230039, Peoples R China	Academy of Military Medical Sciences - China; Capital Medical University; Chinese Academy of Sciences; University of Kentucky; Jiujiang University; Jilin Agricultural University; Cincinnati Children's Hospital Medical Center; Nanchang University; Peking University; Purdue University System; Indiana University Purdue University Fort Wayne; Anhui University	Yang, X (corresponding author), Anhui Univ, Inst Hlth Sci, Hefei 230039, Peoples R China.	Stanleyxingyuan@hotmail.com; zhangcfu@gmail.com		Zhang, Chunni/0000-0002-7329-7162	National Natural Science Foundation of China [81102005, 31271154]; National High Technology Research and Development Program of China [2014AA020516]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China)	We are grateful to Mingjun Bi, Anne-Marie Overstreet and Alex Meredith for their advice, discussion and editor assistance. We thank Dr. Guanxuan Tan and his lab members for reagents and advice. We also thank Bill Evans for editorial support and grammar correction. This study was supported by the National Natural Science Foundation of China (Nos. 81102005, 31271154) and the National High Technology Research and Development Program of China (No. 2014AA020516).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BULLRICH F, 1995, CANCER RES, V55, P1199; Cho YY, 2009, CANCER RES, V69, P272, DOI 10.1158/0008-5472.CAN-08-3125; Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Cui JJ, 2012, CANCER RES, V72, P5625, DOI 10.1158/0008-5472.CAN-12-1305; Cui JJ, 2011, CELL MOL LIFE SCI, V68, P1091, DOI 10.1007/s00018-010-0511-7; de Leeuw R, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/232435; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Hoffman JT, 2014, ANN ONCOL         S1, V25, pi27; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Klinge CM, 2012, TRENDS ENDOCRIN MET, V23, P223, DOI 10.1016/j.tem.2012.03.002; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kok M, 2009, JNCI-J NATL CANCER I, V101, P1725, DOI 10.1093/jnci/djp412; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Manavathi B, 2013, ENDOCR REV, V34, P1, DOI 10.1210/er.2011-1057; McCartan D, 2012, CANCER RES, V72, P220, DOI 10.1158/0008-5472.CAN-11-1976; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841; Nana-Sinkam SP, 2013, CLIN PHARMACOL THER, V93, P98, DOI 10.1038/clpt.2012.192; Nilsson S, 2011, NAT REV DRUG DISCOV, V10, P778, DOI 10.1038/nrd3551; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Sarwar N, 2006, ENDOCR-RELAT CANCER, V13, P851, DOI 10.1677/erc.1.01123; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Skalsky RL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024248; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Sun X, 2014, ONCOGENE, V33, P4967, DOI [10.1038/onc.2013.492, 10.1038/onc.2014.224]; Sutherland RL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2454; Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Tian W, 2013, CLIN TRANSL ONCOL, V15, P335, DOI 10.1007/s12094-012-0929-5; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Tyson JJ, 2011, NAT REV CANCER, V11, P523, DOI 10.1038/nrc3081; Vendrell JA, 2005, ENDOCR-RELAT CANCER, V12, P75, DOI 10.1677/erc.1.00899; Wang L, 2014, MOL MED REP, V9, P2582, DOI 10.3892/mmr.2014.2095; Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128; Wardell SE, 2013, CLIN CANCER RES, V19, P2420, DOI 10.1158/1078-0432.CCR-12-3771; Wesierska-Gadek J, 2011, J CELL BIOCHEM, V112, P761, DOI 10.1002/jcb.23004; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Ye X, 2001, P NATL ACAD SCI USA, V98, P1682, DOI 10.1073/pnas.041596198; Zhang DX, 2011, J BIOL CHEM, V286, P17746, DOI 10.1074/jbc.M110.206029; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zheng D, 2008, CANCER RES, V68, P7650, DOI 10.1158/0008-5472.CAN-08-1137	55	72	73	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3895	3907		10.1038/onc.2014.430	http://dx.doi.org/10.1038/onc.2014.430			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25531331				2022-12-17	WOS:000358544200002
J	Li, A; Jiao, Y; Yong, KJ; Wang, F; Gao, C; Yan, B; Srivastava, S; Lim, GSD; Tang, P; Yang, H; Tenen, DG; Chai, L				Li, A.; Jiao, Y.; Yong, K. J.; Wang, F.; Gao, C.; Yan, B.; Srivastava, S.; Lim, G. S. D.; Tang, P.; Yang, H.; Tenen, D. G.; Chai, L.			SALL4 is a new target in endometrial cancer	ONCOGENE			English	Article						endonnetrial cancer; SALL4; metastasis; chemoresistance	GENE-EXPRESSION SIGNATURE; EMBRYONIC STEM-CELLS; C-MYC ONCOGENE; LEUKEMIC-CELLS; BREAST-CANCER; LUNG-CANCER; CARCINOMA; PROLIFERATION; PLURIPOTENCY; METASTASIS	Aggressive cancers and embryonic stem (ES) cells share a common gene expression signature. Identifying the key factors/pathway(s) within this ES signature responsible for the aggressiveness of cancers can lead to a potential cure. In this study, we find that SALL4, a gene involved in the maintenance of ES cell self-renewal, is aberrantly expressed in 47.7% of primary human endometrial cancer samples. It is not expressed in normal or hyperplastic endometrial. More importantly, SALL4 expression is positively correlated with worse patient survival and aggressive features such as metastasis in endometrial carcinoma. Further functional studies have shown that loss of SALL4 inhibits endometrial cancer cell growth in vitro and tumorigenicity in vivo, as a result of inhibition of cell proliferation and increased apoptosis. In addition, downregulation of SALL4 significantly impedes the migration and invasion properties of endometrial cancer cells in vitro and their metastatic potential in vivo. Furthermore, manipulation of SALL4 expression can affect drug sensitivity of endometrial cancer cells to carboplatin. Moreover, we show that SALL4 specifically binds to the c-Myc promoter region in endometrial cancer cells. While downregulation of SALL4 leads to a decreased expression of c-Myc at both protein and nnRNA levels, ectopic SALL4 overexpression causes increased c-Myc protein and mRNA expression, indicating that c-Myc is one of the SALL4 downstream targets in endometrial tumorigenesis. In summary, we are the first to demonstrate that SALL4 has functional role(s) in metastasis and drug resistance in aggressive endometrial cancer. As a consequence of its functional roles in cancer cell and absence in normal tissue, SALL4 is a potential novel therapeutic target for the high-risk endometrial cancer patient population.	[Li, A.; Jiao, Y.; Wang, F.; Gao, C.; Tang, P.; Chai, L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Yong, K. J.; Srivastava, S.; Yang, H.; Tenen, D. G.] Natl Univ Singapore, Ctr Translat Med, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Wang, F.] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing 100021, Peoples R China; [Wang, F.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Yan, B.; Lim, G. S. D.] Natl Univ Hlth Syst, Dept Pathol, Singapore, Singapore; [Yan, B.; Lim, G. S. D.] Natl Univ Singapore, Singapore 117548, Singapore; [Tenen, D. G.] Harvard Stem Cell Inst, Ctr Life Sci, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; National University of Singapore; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; National University of Singapore; National University of Singapore; Harvard University	Chai, L (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	lchai@partners.org	Srivastava, Supriya/HDJ-9671-2022	Chai, Li/0000-0003-1937-4750; Tenen, Daniel/0000-0002-6423-3888; Srivastava, Supriya/0000-0002-6727-3076	NIH [PO1DK080665, RO1HL092437, PO1HL095489]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092437, P01HL095489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK080665] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part through NIH grants PO1DK080665, NIH RO1HL092437, and PO1HL095489 (to LC). We also thank Nicole Tenen and Joline Lim in assisting with the preparation of the manuscript and Xi Tian in helping with mouse work.	Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BORST MP, 1990, GYNECOL ONCOL, V38, P364, DOI 10.1016/0090-8258(90)90074-U; Cao DF, 2009, CANCER-AM CANCER SOC, V115, P2640, DOI 10.1002/cncr.24308; Du YCN, 2011, P NATL ACAD SCI USA, V108, P16753, DOI 10.1073/pnas.1114022108; Elit L, 2002, CURR OPIN OBSTET GYN, V14, P67, DOI 10.1097/00001703-200202000-00011; Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Hermeking H, 2003, CURR CANCER DRUG TAR, V3, P163, DOI 10.2174/1568009033481949; Jeong HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018372; Knapp DC, 2003, ANTI-CANCER DRUG, V14, P39, DOI 10.1097/00001813-200301000-00006; Kobayashi D, 2011, ONCOL REP, V26, P965, DOI 10.3892/or.2011.1374; Kobayashi D, 2011, INT J ONCOL, V38, P933, DOI 10.3892/ijo.2011.929; Levan K, 2010, GENE EXPRESSION, V14, P361, DOI 10.3727/105221610X12735213181242; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Renaud EJ, 2005, P NATL ACAD SCI USA, V102, P111, DOI 10.1073/pnas.0407772101; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; Saso S, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3954; vanWaardenburg RCAM, 1996, ANTICANCER RES, V16, P1963; Wolfer A, 1996, P NATL ACAD SCI USA, V107, P3698; Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yang JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI 10.1073/pnas.0809321105; Yong KJ, 2013, NEW ENGL J MED, V368, P2266, DOI 10.1056/NEJMoa1300297; You JS, 2009, CANCER RES, V69, P5716, DOI 10.1158/0008-5472.CAN-08-4953; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481	31	72	77	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					63	72		10.1038/onc.2013.529	http://dx.doi.org/10.1038/onc.2013.529			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24336327	Green Accepted, Green Submitted			2022-12-17	WOS:000349740100006
J	Kamekura, R; Kolegraff, KN; Nava, P; Hilgarth, RS; Feng, M; Parkos, CA; Nusrat, A				Kamekura, R.; Kolegraff, K. N.; Nava, P.; Hilgarth, R. S.; Feng, M.; Parkos, C. A.; Nusrat, A.			Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling	ONCOGENE			English	Article						Desmosome; intestinal epithelium; EGFR; desmoglein; desmocollin; cancer	ADHESION; EXPRESSION; INHIBITION; CARCINOMAS; APOPTOSIS; RECEPTOR; DSG2	Desmosomal cadherins mediate cell-cell adhesion in epithelial tissues and have been known to be altered in cancer. We have previously shown that one of the two intestinal epithelial desmosomal cadherins, desmocollin-2 (Dsc2) loss promotes colonic epithelial carcinoma cell proliferation and tumor formation. In this study we show that loss of the other intestinal desmosomal cadherin, desmoglein-2 (Dsg2) that pairs with Dsc2, results in decreased epithelial cell proliferation and suppressed xenograft tumor growth in mice. Dsg2-deficient cells demonstrated a compensatory increase in Dsc2 expression, and small interfering RNA-mediated loss of Dsc2 restored proliferation in Dsg2-deficient cells. Dsg2 downregulation inhibited epidermal growth factor receptor (EGFR) signaling and cell proliferation through altered phosphorylation of EGFR and downstream extracellular signal-regulated kinase activation in parallel with inhibited EGFR receptor internalization. Additionally, we demonstrated a central role of Dsc2 in controlling EGFR signaling and cell proliferation in intestinal epithelial cells. Consistent with these findings, analyses of human colon cancers demonstrated increased Dsg2 protein expression. Taken together, these data demonstrate that partner desmosomal cadherins Dsg2 and Dsc2 play opposing roles in controlling colonic carcinoma cell proliferation through differential effects on EGFR signaling.	[Kamekura, R.; Kolegraff, K. N.; Hilgarth, R. S.; Feng, M.; Parkos, C. A.; Nusrat, A.] Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol & Mucosal Inflammat Res Unit, Atlanta, GA 30322 USA; [Nava, P.] Ctr Res & Adv Studies CINVESTAV, Dept Physiol Biophys & Neurosci, Mexico City, DF, Mexico	Emory University; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional	Nusrat, A (corresponding author), Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol & Mucosal Inflammat Res Unit, Whitehead Biomed Res Bldg,Room 105M, Atlanta, GA 30322 USA.	anusrat@emory.edu	Nava, Porfirio/D-8306-2012	Nava, Porfirio/0000-0002-0506-1510	Japan Society of Immunology and Allergology in Otolaryngology; American Gastroenterological Association Research Scholar Award; Crohn's and Colitis Foundation of America Career Development Award; CONACyT [175854]; National Institutes of Health [DK061379, DK072564, DK055679, DK059888]; DDRDC [DK064399]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK061379, R01DK072564, R29DK055679, R01DK079392, R01DK059888, T32DK007771, R01DK055679] Funding Source: NIH RePORTER	Japan Society of Immunology and Allergology in Otolaryngology; American Gastroenterological Association Research Scholar Award; Crohn's and Colitis Foundation of America Career Development Award; CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DDRDC; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the 12th Glaxo-SmithKline International Award from Japan Society of Immunology and Allergology in Otolaryngology (RK), an American Gastroenterological Association Research Scholar Award (PN), a Crohn's and Colitis Foundation of America Career Development Award (PN), a CONACyT grant 175854 (PN) and National Institutes of Health grants DK061379, DK072564 (CAP), DK055679, DK059888 (AN) and DDRDC DK064399.	Baron S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050024; Biedermann K, 2005, J PATHOL, V207, P199, DOI 10.1002/path.1821; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Brennan D, 2007, J CELL SCI, V120, P758, DOI 10.1242/jcs.03392; Brennan D, 2009, CELL ADHES MIGR, V3, P148, DOI 10.4161/cam.3.2.7539; Chen YJ, 2007, ONCOGENE, V26, P467, DOI 10.1038/sj.onc.1209802; Getsios S, 2004, DIFFERENTIATION, V72, P419, DOI 10.1111/j.1432-0436.2004.07208008.x; Getsios S, 2009, J CELL BIOL, V185, P1243, DOI 10.1083/jcb.200809044; Holthofer B, 2007, INT REV CYTOL, V264, P65, DOI 10.1016/S0074-7696(07)64003-0; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ishii K, 2001, J INVEST DERMATOL, V117, P26, DOI 10.1046/j.0022-202x.2001.01400.x; Kolegraff K, 2011, CELL ADHES MIGR, V5, P306, DOI 10.4161/cam.5.4.16911; Kolegraff K, 2011, MOL BIOL CELL, V22, P1121, DOI 10.1091/mbc.E10-10-0845; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; Mannan T, 2011, CELL PROLIFERAT, V44, P301, DOI 10.1111/j.1365-2184.2011.00765.x; Nava P, 2007, MOL BIOL CELL, V18, P4565, DOI 10.1091/mbc.E07-05-0426; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Resnik N, 2011, J BIOL CHEM, V286, P1499, DOI 10.1074/jbc.M110.189464; Schlegel N, 2010, AM J PHYSIOL-GASTR L, V298, pG774, DOI 10.1152/ajpgi.00239.2009; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Wex T, 2012, HUM PATHOL, V43, P1745, DOI 10.1016/j.humpath.2011.12.024	22	72	74	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4531	4536		10.1038/onc.2013.442	http://dx.doi.org/10.1038/onc.2013.442			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24166502	Green Accepted			2022-12-17	WOS:000341158800008
J	Zhou, ZN; Sharma, VP; Beaty, BT; Roh-Johnson, M; Peterson, EA; Van Rooijen, N; Kenny, PA; Wiley, HS; Condeelis, JS; Segall, JE				Zhou, Z. N.; Sharma, V. P.; Beaty, B. T.; Roh-Johnson, M.; Peterson, E. A.; Van Rooijen, N.; Kenny, P. A.; Wiley, H. S.; Condeelis, J. S.; Segall, J. E.			Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo	ONCOGENE			English	Article						HBEGF; breast cancer invasion; EGFR; metastasis	LIPOSOME-MEDIATED DEPLETION; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR; HB-EGF; RECEPTOR; PARACRINE; CORTACTIN; INVADOPODIA; MIGRATION; MOTILITY	Increased expression of HBEGF in estrogen receptor-negative breast tumors is correlated with enhanced metastasis to distant organ sites and more rapid disease recurrence upon removal of the primary tumor. Our previous work has demonstrated a paracrine loop between breast cancer cells and macrophages in which the tumor cells are capable of stimulating macrophages through the secretion of colony-stimulating factor-1 while the tumor-associated macrophages (TAMs), in turn, aid in tumor cell invasion by secreting epidermal growth factor. To determine how the autocrine expression of epidermal growth factor receptor (EGFR) ligands by carcinoma cells would affect this paracrine loop mechanism, and in particular whether tumor cell invasion depends on spatial ligand gradients generated by TAMs, we generated cell lines with increased HBEGF expression. We found that autocrine HBEGF expression enhanced in vivo intravasation and metastasis and resulted in a novel phenomenon in which macrophages were no longer required for in vivo invasion of breast cancer cells. In vitro studies revealed that expression of HBEGF enhanced invadopodium formation, thus providing a mechanism for cell autonomous invasion. The increased invadopodium formation was directly dependent on EGFR signaling, as demonstrated by a rapid decrease in invadopodia upon inhibition of autocrine HBEGF/EGFR signaling as well as inhibition of signaling downstream of EGFR activation. HBEGF expression also resulted in enhanced invadopodium function via upregulation of matrix metalloprotease 2 (MMP2) and MMP9 expression levels. We conclude that high levels of HBEGF expression can short-circuit the tumor cell/macrophage paracrine invasion loop, resulting in enhanced tumor invasion that is independent of macrophage signaling.	[Zhou, Z. N.; Sharma, V. P.; Beaty, B. T.; Roh-Johnson, M.; Condeelis, J. S.; Segall, J. E.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; [Peterson, E. A.; Kenny, P. A.] Albert Einstein Coll Med, Dev & Mol Biol, Bronx, NY 10461 USA; [Van Rooijen, N.] Free Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands; [Wiley, H. S.] Pacific NW Natl Lab, Syst Biol Program, Richland, WA 99352 USA; [Wiley, H. S.] Pacific NW Natl Lab, Environ Mol Sci Lab, Richland, WA 99352 USA; [Condeelis, J. S.; Segall, J. E.] Albert Einstein Coll Med, Gruss Lipper Ctr Biophoton, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Vrije Universiteit Amsterdam; United States Department of Energy (DOE); Pacific Northwest National Laboratory; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Yeshiva University; Albert Einstein College of Medicine	Segall, JE (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA.	jeffrey.segall@einstein.yu.edu	Van Rooijen, Nico/Z-1578-2019	Sharma, Ved P/0000-0001-9998-5070; Wiley, Steven/0000-0003-0232-6867	Susan G. Komen for the Cure [KG111405]; NIH F32 postdoctoral fellowship [F32-CA159663-01]; NIH [1K12GM102779-01];  [CA100324];  [CA77522];  [T32-GM007288]; NATIONAL CANCER INSTITUTE [R01CA077522, P30CA013330, F32CA159663, P01CA100324] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288, K12GM102779] Funding Source: NIH RePORTER	Susan G. Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NIH F32 postdoctoral fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Condeelis, Cox, Hodgson and Segall labs for their comments and suggestions. We thank Carl Manthey and Johnson and Johnson for providing the JnJ compound. JES is the Betty and Sheldon Feinberg Senior Faculty Scholar in Cancer Research. Funding was provided by CA100324 (ERS, ARB, DC, JWP, JC and JES), CA77522 (JES), T32-GM007288 (ZNZ), a postdoctoral fellowship from the Susan G. Komen for the Cure, KG111405 (VPS), an NIH F32 postdoctoral fellowship F32-CA159663-01 (MRJ) and an NIH 1K12GM102779-01 (EAP).	Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Artacho-Cordon A, 2012, CANCER BIOL THER, V13, P14, DOI 10.4161/cbt.13.1.18869; Artym VV, 2011, EUR J CELL BIOL, V90, P172, DOI 10.1016/j.ejcb.2010.06.006; Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Bonde AK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-35; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Garton KJ, 2002, BIOTECHNIQUES, V32, P830, DOI 10.2144/02324rr01; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hayes KE, 2013, ONCOGENE, V32, P4766, DOI 10.1038/onc.2012.513; Hernandez L, 2009, METHODS MOL BIOL, V571, P227, DOI 10.1007/978-1-60761-198-1_15; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Joslin EJ, 2007, J CELL SCI, V120, P3688, DOI 10.1242/jcs.010488; Joslin EJ, 2010, MOL BIOSYST, V6, P1293, DOI 10.1039/c003921g; Kedrin D, 2007, CURR PROTOC CELL BIO, P1; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; Lue HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027720; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Roussos ET, 2011, CLIN EXP METASTAS, V28, P515, DOI 10.1007/s10585-011-9388-6; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; SCOTT J, 1985, J CELL SCI, P19; Sharma VP, 2013, METHODS MOL BIOL, V1046, P343, DOI 10.1007/978-1-62703-538-5_21; Shimura T, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-205; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Smirnova T, 2012, ONCOGENE, V31, P706, DOI 10.1038/onc.2011.275; Smirnova T, 2011, AM J PATHOL, V178, P2857, DOI 10.1016/j.ajpath.2011.02.030; Tolino MA, 2011, BBA-GEN SUBJECTS, V1810, P875, DOI 10.1016/j.bbagen.2011.05.011; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Wilson KJ, 2012, GROWTH FACTORS, V30, P107, DOI 10.3109/08977194.2011.649918; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yagi H, 2008, MOL CANCER THER, V7, P3441, DOI 10.1158/1535-7163.MCT-08-0417; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yotsumoto F, 2010, INT J CANCER, V127, P2707, DOI 10.1002/ijc.25472; Zaynagetdinov R, 2011, J IMMUNOL, V187, P5703, DOI 10.4049/jimmunol.1100558; Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240	52	72	72	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3784	3793		10.1038/onc.2013.363	http://dx.doi.org/10.1038/onc.2013.363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	24013225	Green Accepted			2022-12-17	WOS:000339394100004
J	Quan, H; Zhou, F; Nie, D; Chen, Q; Cai, X; Shan, X; Zhou, Z; Chen, K; Huang, A; Li, S; Tang, N				Quan, H.; Zhou, F.; Nie, D.; Chen, Q.; Cai, X.; Shan, X.; Zhou, Z.; Chen, K.; Huang, A.; Li, S.; Tang, N.			Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition	ONCOGENE			English	Article						hepatitis C virus; epigenetic silencing; SFRP1; Wnt/beta-catenin signaling pathway; methylation	BETA-CATENIN; DNA METHYLATION; EXPRESSION; CANCER; TUMOR; DIFFERENTIATION; TARGET; GENES; CELLS; DNMT1	Hepatocellular carcinoma (HCC) is one of the most deadly cancers. Aberrant oncogenic activation of the Wnt/beta-catenin signaling pathway contributes to hepatocellular carcinogenesis. Various epigenetic modifications of the Wnt antagonist secreted frizzledrelated protein (SFRP) family have been implicated in regulating Wnt signaling. Here, we report that Hepatitis C virus (HCV) core protein downregulates SFRP1 expression when it is expressed in Huh7 and HepG2 cells. SFRP1 expression can be effectively restored by using either a DNA methylation inhibitor alone or in combination with a histone deacetylase inhibitor. DNA methylation analysis of the SFRP1 promoter revealed that cytosine-phosphate-guanine (CpG) islands close to the transcriptional start site (TSS) in the SFRP1 promoter were hypermethylated in core-expressing Huh7 cells, suggesting that HCV core protein may downregulate SFRP1 expression by inducing hypermethylation of the SFRP1 promoter. Chromatin immunoprecipitation revealed that HCV core protein markedly increased the expression level and binding of DNA methyltransferase-1 (Dnmt1) and histone deacetylase-1 (HDAC1) to the TSS of the SFRP1 promoter region, resulting in repression of acetyl-histone H3-binding capacity to SFRP1 promoter and the eventual epigenetic silencing of SFRP1 expression. Furthermore, the core protein-promoted cell proliferation, migration and invasiveness were effectively abrogated either by Dnmt1 knockdown or restoration of SFRP1 expression in hepatoma cells. Dnmt1 knockdown or SFRP1 overexpression also inhibited HCV core-induced epithelial-mesenchymal transition (EMT) and significantly decreased the expression levels of activated b-catenin and Wnt/b-catenin target genes, c-Myc and cyclin D1. We further showed that knockdown of Dnmt1 and restoration of SFRP1 inhibited core-induced in vivo tumor growth and aggressiveness in a xenograft HCC model. Taken together, our results strongly suggest that the HCV core-induced epigenetic silencing of SFRP1 may lead to the activation of the Wnt signaling pathway and thus contribute to HCC aggressiveness through induction of EMT.	[Quan, H.; Zhou, F.; Nie, D.; Chen, Q.; Cai, X.; Shan, X.; Zhou, Z.; Chen, K.; Huang, A.; Li, S.; Tang, N.] Chongqing Med Univ, Affiliated Hosp 2, Chongqing 400010, Peoples R China; [Quan, H.; Zhou, F.; Nie, D.; Chen, Q.; Cai, X.; Shan, X.; Zhou, Z.; Chen, K.; Huang, A.; Li, S.; Tang, N.] Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Chinese Minist Educ, Chongqing 400010, Peoples R China	Chongqing Medical University; Chongqing Medical University	Li, S (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Lin Jiang Rd, Chongqing 400010, Peoples R China.	cqlsw@yahoo.com.cn; nitang809@hotmail.com	Tang, Ni/Z-5133-2019	Tang, Ni/0000-0001-5830-8786	Major National S T program [2013ZX10002002, 2012ZX10002005-003-002]; China National Natural Science Foundation [30972586, 31171307, 81171563]; Natural Science Foundation Project of CQMU	Major National S T program; China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of CQMU	This study was supported by research grants from Major National S&T program (2013ZX10002002, AH; 2012ZX10002005-003-002, NT), China National Natural Science Foundation (# 30972586, # 31171307, NT; # 81171563, ZZ) and Natural Science Foundation Project of CQMU (NT). We thank Dr T-C He of University of Chicago, USA, for kind provision of adenoviruses AdGFP, AdsiDnmt1 and AdSFRP1. We are also grateful for Dr Takaji Wakita (National Institute of Infectious Diseases, Tokyo) for providing the HCV JFH-1 cDNA clone.	Akkari L, 2012, J HEPATOL, V57, P1021, DOI 10.1016/j.jhep.2012.06.027; Arora P, 2008, CANCER LETT, V261, P244, DOI 10.1016/j.canlet.2007.11.033; Austinat M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-21; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Benegiamo G, 2012, DIGEST DIS SCI, V57, P1598, DOI 10.1007/s10620-012-2160-1; Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254; Bose SK, 2012, J VIROL, V86, P13621, DOI 10.1128/JVI.02016-12; Campbell PM, 2003, CARCINOGENESIS, V24, P17, DOI 10.1093/carcin/24.1.17; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chiam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025634; Clement S, 2010, J HEPATOL, V52, P635, DOI 10.1016/j.jhep.2009.10.035; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Danam RP, 2005, MOL CANCER THER, V4, P61; Easwaran V, 2003, CANCER RES, V63, P3145; Fang S, 2013, CLIN EXP MED, V13, P127, DOI 10.1007/s10238-012-0182-9; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gauger KJ, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-25; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Gong CM, 2012, TOXICOL LETT, V209, P264, DOI 10.1016/j.toxlet.2012.01.007; Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025; Guo N, 2012, J CELL BIOCHEM, V113, P3419, DOI 10.1002/jcb.24218; Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478-3231.2009.02111.x; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Kaneda A, 2012, CANCER RES, V72, P3445, DOI 10.1158/0008-5472.CAN-11-3919; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Kaur P, 2012, TUMOR BIOL, V33, P325, DOI 10.1007/s13277-012-0331-5; Lee JY, 2012, J AM CHEM SOC, V134, P173, DOI 10.1021/ja210273w; Li KQK, 2013, ANTI-CANCER AGENT ME, V13, P242; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Liu JX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023098; Mao W, 2011, INVEST OPHTH VIS SCI, V53, P7043; Milavetz B, 2012, EPIGENETICS-US, V7, P528, DOI 10.4161/epi.20057; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750; Sturgeon SR, 2012, EPIGENETICS-US, V7, P1258, DOI 10.4161/epi.22220; Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582-4934.2008.00569.x; Vaid M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023000; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang XB, 2012, ONCOL LETT, V4, P334, DOI 10.3892/ol.2012.713; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032	44	72	76	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2826	2835		10.1038/onc.2013.225	http://dx.doi.org/10.1038/onc.2013.225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23770846				2022-12-17	WOS:000337231800002
J	Wu, DW; Lee, MC; Wang, J; Chen, CY; Cheng, YW; Lee, H				Wu, D-W; Lee, M-C; Wang, J.; Chen, C-Y; Cheng, Y-W; Lee, H.			DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer	ONCOGENE			English	Article						DDX3; p53 inactivation; survival; relapse; lung cancer	BOX RNA HELICASE; E-CADHERIN EXPRESSION; REPRESSES E-CADHERIN; 16/18 E6 ONCOPROTEIN; HUMAN-PAPILLOMAVIRUS; BETA-CATENIN; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; DOWN-REGULATION	P53 inactivation by p53 mutation and E6 oncoprotein has a crucial role in human carcinogenesis. DDX3 has been shown to be a target of p53. In this study, we hypothesized that DDX3 loss by p53 inactivation may promote tumor malignancy and poor patients' outcome. Mechanically, DDX3 loss by p53 knockdown and E6 overexpression was observed in A549 lung cancer cells. Conversely, DDX3 expression was markedly elevated by wild-type (WT) p53 ectopic expression in p53-null H1299 cells, E6-knockdown TL-1 lung cancer and SiHa cervical cancer cells. Interestingly, DDX3 loss promotes soft-agar growth and invasive capability; however, both capabilities were suppressed by DDX3 overexpression. We next expected that DDX3 loss might result in Slug-suppressed E-cadherin expression via decreased MDM2-mediated Slug degradation. As expected, MDM2 transcription is suppressed by DDX3 loss via decreased SP1 binding activity to the MDM2 promoter. Consequently, Slug expression was elevated by the reduction of MDM2 because of DDX3 loss, and E-cadherin expression was suppressed by Slug. Consistent observations in the correlation of DDX3 loss with MDM2, Slug and E-cadherin were seen in lung tumors from lung cancer patients. In addition, patients with low-DDX3 tumors had poorer survival and relapse than patients with high-DDX3 tumors. In conclusion, we suggest that DDX3 loss by p53 inactivation via MDM2/Slug/E-cadherin pathway promotes tumor malignancy and poor patient outcome.	[Wu, D-W; Cheng, Y-W; Lee, H.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei 115, Taiwan; [Lee, M-C] Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan; [Wang, J.] Taichung Vet Gen Hosp, Dept Pathol, Taichung, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan	Taipei Medical University; Taichung Veterans General Hospital; Taichung Veterans General Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Room 5,12F,3 Yuancyu St, Taipei 115, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [NSC-96-2628-B-040-002-MY3, DOH100-TD-C-111-005]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council (NSC-96-2628-B-040-002-MY3; DOH100-TD-C-111-005) of Taiwan, ROC.	Al Moustafa AE, 2008, CURR PHARM DESIGN, V14, P2159, DOI 10.2174/138161208785740216; [Anonymous], 2014, ONCOGENE, P1515; BARAK Y, 1994, COLD SPRING HARB SYM, V59, P225, DOI 10.1101/SQB.1994.059.01.027; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Boulenouar S, 2010, CARCINOGENESIS, V31, P473, DOI 10.1093/carcin/bgp281; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Cheng YW, 2008, CLIN CANCER RES, V14, P7173, DOI 10.1158/1078-0432.CCR-08-0850; Cheng YW, 2008, CLIN CANCER RES, V14, P4705, DOI 10.1158/1078-0432.CCR-07-4675; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Cheng YW, 2001, ENVIRON MOL MUTAGEN, V37, P304, DOI 10.1002/em.1037; Chien WP, 2010, ANN SURG ONCOL, V17, P1194, DOI 10.1245/s10434-009-0853-2; Coissard CJ, 2005, MODERN PATHOL, V18, P1606, DOI 10.1038/modpathol.3800472; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Hajra KM, 2002, CANCER RES, V62, P1613; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hsu NY, 2009, ONCOL REP, V21, P81, DOI 10.3892/or_00000192; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Klein F, 2009, LUNG CANCER, V65, P13, DOI 10.1016/j.lungcan.2008.10.003; Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019; Koshiol J, 2011, JNCI-J NATL CANCER I, V103, P501, DOI 10.1093/jnci/djr003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laurson J, 2010, CARCINOGENESIS, V31, P918, DOI 10.1093/carcin/bgq027; Lim SO, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-83; Lim SO, 2010, FEBS LETT, V584, P2231, DOI 10.1016/j.febslet.2010.04.006; Matthews K, 2003, J VIROL, V77, P8378, DOI 10.1128/JVI.77.15.8378-8385.2003; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ramasami S, 2000, J PATHOL, V192, P427; Retera JMAM, 1998, J CLIN PATHOL, V51, P891, DOI 10.1136/jcp.51.12.891; Sekiguchi T, 2007, BIOCHEM BIOPH RES CO, V356, P668, DOI 10.1016/j.bbrc.2007.03.038; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Simen-Kapeu A, 2010, CANCER EPIDEM BIOMAR, V19, P1879, DOI 10.1158/1055-9965.EPI-10-0356; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Sulzer MA, 1998, AM J RESP CRIT CARE, V157, P1319, DOI 10.1164/ajrccm.157.4.9703099; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu YH, 2010, CANCER RES, V70, P10422, DOI 10.1158/0008-5472.CAN-10-2615; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yoshino I, 2002, ANN THORAC SURG, V73, P933, DOI 10.1016/S0003-4975(01)03434-8; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Yuan A, 2002, J CLIN ONCOL, V20, P900, DOI 10.1200/JCO.20.4.900; Zhang KJ, 2011, LAB INVEST, V91, P426, DOI 10.1038/labinvest.2010.201; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	57	72	78	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1515	1526		10.1038/onc.2013.107	http://dx.doi.org/10.1038/onc.2013.107			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584477				2022-12-17	WOS:000333244200005
J	Li, X; Stevens, PD; Yang, H; Gulhati, P; Wang, W; Evers, BM; Gao, T				Li, X.; Stevens, P. D.; Yang, H.; Gulhati, P.; Wang, W.; Evers, B. M.; Gao, T.			The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer	ONCOGENE			English	Article						PHLPP; USP46; Akt; deubiquitination; tumor suppressor	PROTEIN-KINASE-C; E3 LIGASE; PHOSPHATASE; GLIOBLASTOMA; ACTIVATION; STABILITY; APOPTOSIS; FEEDBACK; PTEN	PH domain leucine-rich-repeats protein phosphatase (PHLPP) is a family of Ser/Thr protein phosphatases that serve as tumor suppressors by negatively regulating Akt. Our recent studies have demonstrated that the ubiquitin proteasome pathway has an important role in the downregulation of PHLPP in colorectal cancer. In this study, we show that the deubiquitinase USP46 stabilizes the expression of both PHLPP isoforms by reducing the rate of PHLPP degradation. USP46 binds to PHLPP and directly removes the polyubiquitin chains from PHLPP in vitro and in cells. Increased USP46 expression correlates with decreased ubiquitination and upregulation of PHLPP proteins in colon cancer cells, whereas knockdown of USP46 has the opposite effect. Functionally, USP46-mediated stabilization of PHLPP and the subsequent inhibition of Akt result in a decrease in cell proliferation and tumorigenesis of colon cancer cells in vivo. Moreover, reduced USP46 protein level is found associated with poor PHLPP expression in colorectal cancer patient specimens. Taken together, these results indentify a tumor suppressor role of USP46 in promoting PHLPP expression and inhibiting Akt signaling in colon cancer. Oncogene (2013) 32, 471-478; doi:10.1038/onc.2012.66; published online 5 March 2012	[Li, X.; Stevens, P. D.; Gulhati, P.; Wang, W.; Evers, B. M.; Gao, T.] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; [Yang, H.] Taizhou Hosp, Dept Oncol, Taizhou, Peoples R China; [Gulhati, P.; Evers, B. M.] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; [Gulhati, P.] Univ Texas Med Branch, MD PhD Program, Galveston, TX 77555 USA; [Gao, T.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Texas System; University of Texas Medical Branch Galveston; University of Kentucky	Gao, T (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	tianyan.gao@uky.edu			NIH [R01CA133429]; American Cancer Society [RSG0822001TBE, P20CA1530343, R01DK48498]; NATIONAL CANCER INSTITUTE [P20CA150343, R01CA133429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048498] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Wade Harper (Harvard Medical School) for providing USP46, USP7 and USP16 expression plasmids, and Dr Hui-Kuan Lin (University of Texas MD Anderson Cancer Center) for providing His-tagged ubiquitin construct. The Biostatistic Core at the Markey Cancer Center (University of Kentucky) provided assistant with the statistical analysis in our study. This work was supported by NIH R01CA133429 (TG), American Cancer Society RSG0822001TBE (TG), P20CA1530343 (UK GI SPORE) and R01DK48498 (BME).	Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kowalski JR, 2011, J NEUROSCI, V31, P1341, DOI 10.1523/JNEUROSCI.4765-10.2011; Li X, 2011, EMBO REP, V12, P818, DOI 10.1038/embor.2011.106; Li X, 2009, MOL CELL BIOL, V29, P6192, DOI 10.1128/MCB.00681-09; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Liu JY, 2011, J BIOL CHEM, V286, P6510, DOI 10.1074/jbc.M110.183087; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017; REINER A, 1990, CANCER RES, V50, P7057; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Shimizu K, 2010, MOL BIOSYST, V6, P38, DOI 10.1039/b911410f; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Warfel NA, 2011, J BIOL CHEM, V286, P19777, DOI 10.1074/jbc.M111.237081; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065	24	72	74	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					471	478		10.1038/onc.2012.66	http://dx.doi.org/10.1038/onc.2012.66			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391563	Green Accepted			2022-12-17	WOS:000315551300008
J	Hon, WC; Berndt, A; Williams, RL				Hon, W-C; Berndt, A.; Williams, R. L.			Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases	ONCOGENE			English	Article						PIK3CA mutations; p110 alpha; lipid binding; crystal structure; inhibitor; growth factor signalling	KINASE-C-ALPHA; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3'-KINASE; PIK3CA MUTATIONS; CANCER; DOMAIN; PATHWAY; PI3K; PI3K-ALPHA; P110-ALPHA	Somatic missense mutations in PIK3CA, which encodes the p110 alpha catalytic subunit of phosphoinositide 3-kinases, occur frequently in human cancers. Activating mutations spread across multiple domains, some of which are located at inhibitory contact sites formed with the regulatory subunit p85 alpha. PIK3R1, which encodes p85 alpha, also has activating somatic mutations. We find a strong correlation between lipid kinase and lipid-binding activities for both wild-type (WT) and a representative set of oncogenic mutant complexes of p110 alpha/p85 alpha. Lipid binding involves both electrostatic and hydrophobic interactions. Activation caused by a phosphorylated receptor tyrosine kinase (RTK) peptide binding to the p85 alpha N-terminal SH2 domain (nSH2) induces lipid binding. This depends on the polybasic activation loop as well as a conserved hydrophobic motif in the C-terminal region of the kinase domain. The hotspot E545K mutant largely mimics the activated WT p110 alpha. It shows the highest basal activity and lipid binding, and is not significantly activated by an RTK phosphopeptide. Both the hotspot H1047R mutant and rare mutations (C420R, M1043I, H1047L, G1049R and p85 alpha-N564D) also show increased basal kinase activities and lipid binding. However, their activities are further enhanced by an RTK phosphopeptide to levels markedly exceeding that of activated WT p110 alpha. Phosphopeptide binding to p110 beta/p85 alpha and p110 delta/p85 alpha complexes also induces their lipid binding. We present a crystal structure of WT p110 alpha complexed with the p85 alpha inter-SH2 domain and the inhibitor PIK-108. Additional to the ATP-binding pocket, an unexpected, second PIK-108 binding site is observed in the kinase C-lobe. We show a global conformational change in p110 alpha consistent with allosteric regulation of the kinase domain by nSH2. These findings broaden our understanding of the differential biological outputs exhibited by distinct types of mutations regarding growth factor dependence, and suggest a two-tier classification scheme relating p110 alpha and p85 alpha mutations with signalling potential. Oncogene (2012) 31, 3655-3666; doi:10.1038/onc.2011.532; published online 28 November 2011	[Hon, W-C; Berndt, A.; Williams, R. L.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England	MRC Laboratory Molecular Biology	Williams, RL (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 0QH, England.	rlw@mrc-lmb.cam.ac.uk		Williams, Roger/0000-0001-7754-4207	Medical Research Council, UK; Medical Research Council [MC_U105184308] Funding Source: researchfish; MRC [MC_U105184308] Funding Source: UKRI	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to Kevan Shokat and co-workers (UCSF, USA), including Beth Apsel, Benjamin Houseman, Eli Zunder, Morri Feldman and Zachary Knight, for their generous gift of PI3K inhibitors, which were crucial for crystallization screening. We thank the beamline scientists and members of the staff at the ESRF beamlines ID14-1, ID14-2, ID14-4, ID23-1, ID23-2, and ID29 (Grenoble, France) and Diamond Light Source beamlines I02 and I03 (UK). We also thank past and present members of the Williams's group, particularly Simon Miller, for assistance with remote crystal data collection, Olga Perisic for providing baculovirus of mouse p110 beta, Alexey Murzin for his structural insight of the WIF motif conformation, Andrew Leslie and Nicolas Soler for providing scripts to create Figure 4d. This work was supported by the Medical Research Council, UK.	Adams JR, 2011, CANCER RES, V71, P2706, DOI 10.1158/0008-5472.CAN-10-0738; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Berndt A, 2010, NAT CHEM BIOL, V6, P117, DOI [10.1038/nchembio.293, 10.1038/NCHEMBIO.293]; Burke JE, 2011, STRUCTURE, V19, P1127, DOI 10.1016/j.str.2011.06.003; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Carson JD, 2008, BIOCHEM J, V409, P519, DOI 10.1042/BJ20070681; Chakrabarty A, 2010, ONCOGENE, V29, P5193, DOI 10.1038/onc.2010.257; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Drees BE, 2003, COMB CHEM HIGH T SCR, V6, P321; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Gills JJ, 2009, CURR ONCOL REP, V11, P102, DOI 10.1007/s11912-009-0016-4; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Guerrero-Valero M, 2009, P NATL ACAD SCI USA, V106, P6603, DOI 10.1073/pnas.0813099106; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Mandelker D, 2009, P NATL ACAD SCI USA, V106, P16996, DOI 10.1073/pnas.0908444106; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Miller S, 2010, SCIENCE, V327, P1638, DOI 10.1126/science.1184429; Narayan K, 2006, METHODS, V39, P122, DOI 10.1016/j.ymeth.2006.05.006; Oda K, 2008, CANCER RES, V68, P8127, DOI 10.1158/0008-5472.CAN-08-0755; Pang H, 2009, CANCER RES, V69, P8868, DOI 10.1158/0008-5472.CAN-09-1968; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43; Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Wu HY, 2009, P NATL ACAD SCI USA, V106, P20258, DOI 10.1073/pnas.0902369106; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhang HJ, 2008, BREAST CANCER RES TR, V112, P217, DOI 10.1007/s10549-007-9847-6; Zhang XX, 2011, MOL CELL, V41, P567, DOI 10.1016/j.molcel.2011.01.026; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	51	72	74	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	32					3655	3666		10.1038/onc.2011.532	http://dx.doi.org/10.1038/onc.2011.532			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22120714	Green Accepted			2022-12-17	WOS:000307653800001
J	Slee, RB; Steiner, CM; Herbert, BS; Vance, GH; Hickey, RJ; Schwarz, T; Christan, S; Radovich, M; Schneider, BP; Schindelhauer, D; Grimes, BR				Slee, R. B.; Steiner, C. M.; Herbert, B-S; Vance, G. H.; Hickey, R. J.; Schwarz, T.; Christan, S.; Radovich, M.; Schneider, B. P.; Schindelhauer, D.; Grimes, B. R.			Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability	ONCOGENE			English	Article						pericentromeric heterochromatin; chromosome instability; JMJD2 demethylase	ALPHA-SATELLITE DNA; CENP-B BOX; HISTONE DEMETHYLASES; HUMAN KINETOCHORE; CHROMATIN; CENTROMERE; DISTINCT; OVEREXPRESSION; INACTIVATION; ORGANIZATION	Many tumors exhibit elevated chromosome mis-segregation termed chromosome instability (CIN), which is likely to be a potent driver of tumor progression and drug resistance. Causes of CIN are poorly understood but probably include prior genome tetraploidization, centrosome amplification and mitotic checkpoint defects. This study identifies epigenetic alteration of the centromere as a potential contributor to the CIN phenotype. The centromere controls chromosome segregation and consists of higher-order repeat (HOR) alpha-satellite DNA packaged into two chromatin domains: the kinetochore, harboring the centromere-specific H3 variant centromere protein A (CENP-A), and the pericentromeric heterochromatin, considered important for cohesion. Perturbation of centromeric chromatin in model systems causes CIN. As cancer cells exhibit widespread chromatin changes, we hypothesized that pericentromeric chromatin structure could also be affected, contributing to CIN. Cytological and chromatin immunoprecipitation and PCR (ChIP-PCR)-based analyses of HT1080 cancer cells showed that only one of the two HORs on chromosomes 5 and 7 incorporate CENP-A, an organization conserved in all normal and cancer-derived cells examined. Contrastingly, the heterochromatin marker H3K9me3 (trimethylation of H3 lysine 9) mapped to all four HORs and ChIP-PCR showed an altered pattern of H3K9me3 in cancer cell lines and breast tumors, consistent with a reduction on the kinetochore-forming HORs. The JMJD2B demethylase is overexpressed in breast tumors with a CIN phenotype, and overexpression of exogenous JMJD2B in cultured breast epithelial cells caused loss of centromere-associated H3K9me3 and increased CIN. These findings suggest that impaired maintenance of pericentromeric heterochromatin may contribute to CIN in cancer and be a novel therapeutic target. Oncogene (2012) 31, 3244-3253; doi:10.1038/onc.2011.502; published online 28 November 2011	[Slee, R. B.; Steiner, C. M.; Herbert, B-S; Vance, G. H.; Radovich, M.; Schneider, B. P.; Grimes, B. R.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Slee, R. B.; Herbert, B-S; Vance, G. H.; Hickey, R. J.; Schneider, B. P.; Grimes, B. R.] Indiana Univ Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA; [Hickey, R. J.; Schneider, B. P.] IUSM, Dept Med, Indianapolis, IN 46202 USA; [Schwarz, T.; Christan, S.; Schindelhauer, D.] Univ Munich, Dept Med Genet, Munich, Germany	Indiana University System; Indiana University Bloomington; University of Munich	Grimes, BR (corresponding author), Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.	brgrimes@iupui.edu			INGEN (Indiana Genomics Initiative); IUSM Cytogenetics Division; US DOD BCRP [W81XWH-09-1-0424]; American Cancer Society [IRG-84-002-24]; IUSM Biomedical Research Grants; NCI [N01 CN-43300]; Deutsche Forschungsgemeinschaft; Friedrich Baur Institute; Lilly Endowment; NIH [NRSA 1 T32 CA 111198]; NATIONAL CANCER INSTITUTE [T32CA111198] Funding Source: NIH RePORTER	INGEN (Indiana Genomics Initiative); IUSM Cytogenetics Division; US DOD BCRP; American Cancer Society(American Cancer Society); IUSM Biomedical Research Grants; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Friedrich Baur Institute; Lilly Endowment; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kinya Yoda for advice with ChIP assays; Simone Schuffenhauer and Jan Murken for BF cells; Hunt Willard, Mariano Rocci and Theo Hulsebos for centromere plasmid probes; Tim Yen for CENP-E antibodies; Mervin Yoder for HUVEC samples; Virginia Thurston for advice on the patient BF sample and Andrew Ross, Nikki Collins, Janak Bhavsar, Tony Brown, Waylan Bessler and Laura Mead for technical assistance. This research was supported in part by INGEN (Indiana Genomics Initiative), the IUSM Cytogenetics Division and grants from the US DOD BCRP (W81XWH-09-1-0424) and American Cancer Society (IRG-84-002-24) awarded to BRG, IUSM Biomedical Research Grants awarded to RBS and an NCI grant (N01 CN-43300) to BSH. DS was supported by Deutsche Forschungsgemeinschaft and the Friedrich Baur Institute. INGEN is supported in part by Lilly Endowment. MR was supported by an NIH pre-doctoral fellowship (NRSA 1 T32 CA 111198 Cancer Biology Training Program).	Alonso A, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-6; Amato A, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-119; ARCHIDIACONO N, 1995, GENOMICS, V25, P477, DOI 10.1016/0888-7543(95)80048-Q; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bergmann JH, 2011, EMBO J, V30, P328, DOI 10.1038/emboj.2010.329; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bourgo RJ, 2009, MOL BIOL CELL, V20, P3192, DOI 10.1091/mbc.E08-12-1224; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cardinale S, 2009, MOL BIOL CELL, V20, P4194, DOI 10.1091/mbc.E09-06-0489; David G, 2006, ONCOGENE, V25, P7354, DOI 10.1038/sj.onc.1209734; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Finelli P, 1996, GENOMICS, V38, P325, DOI 10.1006/geno.1996.0635; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Grimes BR, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r89; Grimes BR, 2009, STEM CELLS DEV, V18, P717, DOI 10.1089/scd.2008.0255; Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109; HAAF T, 1994, HUM MOL GENET, V3, P697, DOI 10.1093/hmg/3.5.697; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Hochreiter AE, 2006, CLIN CANCER RES, V12, P3184, DOI 10.1158/1078-0432.CCR-05-2760; HULSEBOS T, 1988, CYTOGENET CELL GENET, V47, P144, DOI 10.1159/000132533; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Lohse B, 2011, BIOORGAN MED CHEM, V19, P3625, DOI 10.1016/j.bmc.2011.01.046; Malorni L, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.10621; Mitelman F., 1994, CATALOG CHROMOSOME A; Mravinac B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006602; Nakano M, 2008, DEV CELL, V14, P507, DOI 10.1016/j.devcel.2008.02.001; Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Radovich M, TRANSCRIPTIONA UNPUB; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Rosandic M, 2006, CHROMOSOME RES, V14, P735, DOI 10.1007/s10577-006-1078-x; Rose NR, 2010, J MED CHEM, V53, P1810, DOI 10.1021/jm901680b; SCHINDELHAUER D, 1995, GENOMICS, V28, P605, DOI 10.1006/geno.1995.1202; Schuffenhauer S, 1996, AM J MED GENET, V65, P56, DOI 10.1002/(SICI)1096-8628(19961002)65:1<56::AID-AJMG9>3.3.CO;2-X; Shin HJ, 2003, ONCOGENE, V22, P3853, DOI 10.1038/sj.onc.1206502; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; SULLIVAN BA, 1999, PRACT APPROACH SER, V200, P81; Sullivan LL, 2011, CHROMOSOME RES, V19, P457, DOI 10.1007/s10577-011-9208-5; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801; Tomonaga T, 2003, CANCER RES, V63, P3511; Vafa O, 1997, CURR BIOL, V7, P897, DOI 10.1016/S0960-9822(06)00381-2; Verdaasdonk JS, 2011, NAT REV MOL CELL BIO, V12, P320, DOI 10.1038/nrm3107; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; Warburton PE, 1996, HUMAN GENOME EVOLUTI, P121; WAYE JS, 1987, MOL CELL BIOL, V7, P349, DOI 10.1128/MCB.7.1.349; WEVRICK R, 1991, NUCLEIC ACIDS RES, V19, P2295, DOI 10.1093/nar/19.9.2295; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wong LH, 2007, GENOME RES, V17, P1146, DOI 10.1101/gr.6022807; Yang J, 2010, CANCER RES, V70, P6456, DOI 10.1158/0008-5472.CAN-10-0413; Yoda K, 2004, METHOD ENZYMOL, V375, P253	61	72	72	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	27					3244	3253		10.1038/onc.2011.502	http://dx.doi.org/10.1038/onc.2011.502			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22081068				2022-12-17	WOS:000306113400004
J	Law, EWL; Cheung, AKL; Kashuba, VI; Pavlova, TV; Zabarovsky, ER; Lung, HL; Cheng, Y; Chua, D; Kwong, DLW; Tsao, SW; Sasaki, T; Stanbridge, EJ; Lung, ML				Law, E. W. L.; Cheung, A. K. L.; Kashuba, V. I.; Pavlova, T. V.; Zabarovsky, E. R.; Lung, H. L.; Cheng, Y.; Chua, D.; Kwong, D. Lai-wan; Tsao, S. W.; Sasaki, T.; Stanbridge, E. J.; Lung, M. L.			Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma	ONCOGENE			English	Article						anti-angiogenic; fibulin-2; nasopharyngeal carcinoma; tumor suppressor; VEGF; methylation	EXTRACELLULAR-MATRIX PROTEIN; CHROMOSOME 3P21.3; COPY NUMBER; EXPRESSION; BREAST; CANCER; IDENTIFICATION; PROGRESSION; METASTASIS; ESOPHAGEAL	Fibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. Oncogene (2012) 31, 728-738; doi:10.1038/onc.2011.272; published online 11 July 2011	[Law, E. W. L.; Cheung, A. K. L.; Lung, H. L.; Cheng, Y.; Chua, D.; Kwong, D. Lai-wan; Lung, M. L.] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Law, E. W. L.; Cheung, A. K. L.; Lung, H. L.; Cheng, Y.; Chua, D.; Kwong, D. Lai-wan; Lung, M. L.] Univ Hong Kong, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China; [Kashuba, V. I.; Pavlova, T. V.; Zabarovsky, E. R.] Karolinska Inst, Dept Clin Sci & Educ, Dept Microbiol Tumor & Cell Biol, Sodersjukhuset, Stockholm, Sweden; [Zabarovsky, E. R.] Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Struct & Funct Genom, Moscow, Russia; [Chua, D.] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Happy Valley, Hong Kong, Peoples R China; [Tsao, S. W.] Univ Hong Kong, Dept Anat, Pokfulam, Hong Kong, Peoples R China; [Sasaki, T.] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Dept Expt Med 1, D-91054 Erlangen, Germany; [Stanbridge, E. J.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA	University of Hong Kong; University of Hong Kong; Karolinska Institutet; Sodersjukhuset Hospital; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Hong Kong; University of Erlangen Nuremberg; University of California System; University of California Irvine	Lung, ML (corresponding author), Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China.	mlilung@hku.hk	Cheung, Arthur Kwok Leung/H-8940-2013; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017; Kashuba, Vladimir/AAO-7742-2020; Cheng, Yue/E-9853-2010; Lung, Maria Li/C-4495-2009	Kashuba, Vladimir I/0000-0001-9416-8282; Cheng, Yue/0000-0002-2472-1879; Cheung, Arthur Kwok Leung/0000-0001-5446-2209; Pavlova, Tatiana/0000-0002-2857-5696; Lung, Maria Li/0000-0003-2559-3626	University Grants Council [AoE/M-06/08]; Swedish Cancer Society; Swedish Research Council; Swedish Institute; Karolinska Institute	University Grants Council; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Institute; Karolinska Institute(Karolinska Institutet)	This work was supported by University Grants Council Area of Excellence grant AoE/M-06/08 to MLL and the Swedish Cancer Society, the Swedish Research Council, the Swedish Institute, and Karolinska Institute to ERZ.	Chattopadhyay I, 2010, MUTAT RES-GEN TOX EN, V696, P130, DOI 10.1016/j.mrgentox.2010.01.001; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheung AKL, 2008, CANCER RES, V68, P8137, DOI 10.1158/0008-5472.CAN-08-0904; Cheung AKL, 2009, P NATL ACAD SCI USA, V106, P14478, DOI 10.1073/pnas.0900198106; de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6; Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001; Grassel S, 1999, EUR J BIOCHEM, V263, P471, DOI 10.1046/j.1432-1327.1999.00523.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Li JF, 2002, P NATL ACAD SCI USA, V99, P10724, DOI 10.1073/pnas.132271699; Libra M, 2009, INT J ONCOL, V34, P897, DOI 10.3892/ijo_00000215; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Lung HL, 2010, INT J CANCER, V127, P304, DOI 10.1002/ijc.25047; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; Mutirangura A, 1997, BRIT J CANCER, V76, P770, DOI 10.1038/bjc.1997.460; Nakao M, 2011, ONCOL REP, V25, P1603, DOI 10.3892/or.2011.1246; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PFAFF M, 1995, EXP CELL RES, V219, P87, DOI 10.1006/excr.1995.1208; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Senchenko VN, 2004, ONCOGENE, V23, P5719, DOI 10.1038/sj.onc.1207760; Strom A, 2006, CARDIOVASC RES, V69, P755, DOI 10.1016/j.cardiores.2005.12.001; Tsuda T, 2001, DEV DYNAM, V222, P89, DOI 10.1002/dvdy.1172; Wu Y, 2010, J THROMB HAEMOST, V8, P185, DOI 10.1111/j.1538-7836.2009.03662.x; Yau WL, 2006, INT J CANCER, V119, P2821, DOI 10.1002/ijc.22232; Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478; Zhang H, 2004, CANCER GENET CYTOGEN, V150, P144, DOI 10.1016/j.cancergencyto.2003.09.007; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003	32	72	75	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					728	738		10.1038/onc.2011.272	http://dx.doi.org/10.1038/onc.2011.272			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21743496				2022-12-17	WOS:000300222100006
J	Girnita, A; Zheng, H; Gronberg, A; Girnita, L; Stahle, M				Girnita, A.; Zheng, H.; Gronberg, A.; Girnita, L.; Stahle, M.			Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor	ONCOGENE			English	Article						LL-37; breast cancer; IGF-1R; invasion; metastasis	ANTIMICROBIAL PROTEIN HCAP18/LL-37; INNATE IMMUNE-SYSTEM; BREAST-CANCER CELLS; BETA-ARRESTIN; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; IGF-1 RECEPTOR; 7-TRANSMEMBRANE RECEPTORS; UVEAL MELANOMA; PICROPODOPHYLLIN; KINASE	The human cathelicidin antimicrobial protein-18 and its C terminal peptide, LL-37, displays broad antimicrobial activity that is mediated through direct contact with the microbial cell membrane. In addition, recent studies reveal that LL-37 is involved in diverse biological processes such as immunomodulation, apoptosis, angiogenesis and wound healing. An intriguing role for LL-37 in carcinogenesis is also beginning to emerge and the aim of this paper was to explore if and how LL-37 contributes to the signaling involved in tumor development. To this end, we investigated the putative interaction between LL-37 and growth factor receptors known to be involved in tumor growth and progression. Among several receptors tested, LL-37 bound with the highest affinity to insulin-like growth factor 1 receptor (IGF-1R), a receptor that is strongly linked to malignant cellular transformation. Furthermore, this interaction resulted in a dose-dependent phosphorylation and ubiquitination of IGF-1R, with downstream signaling confined to the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK)-pathway but not affecting phosphatidylinositol 3 kinase/Akt signaling. We found that signaling induced by LL-37 was dependent on the recruitment of beta-arrestin to the fully functional IGF-1R and by using mutant receptors we demonstrated that LL-37 signaling is dependent on beta-arrestin-1 binding to the C-terminus of IGF-1R. When analyzing the biological consequences of increased ERK activation induced by LL-37, we found that it resulted in enhanced migration and invasion of malignant cells in an IGF-1R/beta-arrestin manner, but did not affect cell proliferation. These results indicate that LL-37 may act as a partial agonist for IGF-1R, with subsequent intra-cellular signaling activation driven by the binding of beta-arrestin-1 to the IGF-1R. Functional experiments show that LL-37-dependent activation of the IGF-1R signaling resulted in increased migratory and invasive potential of malignant cells. Oncogene (2012) 31, 352-365; doi:10.1038/onc.2011.239; published online 20 June 2011	[Girnita, A.; Zheng, H.; Girnita, L.] Karolinska Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, S-17176 Stockholm, Sweden; [Girnita, A.; Gronberg, A.; Stahle, M.] Karolinska Inst, Dept Med, Unit Dermatol, Stockholm, Sweden; [Girnita, A.; Gronberg, A.; Stahle, M.] Karolinska Univ Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Girnita, A (corresponding author), Karolinska Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, CCK R8 04, S-17176 Stockholm, Sweden.	Ada.Girnita@ki.se	Girnita, Ada/AAC-4518-2020; Girnita, Leonard/A-4168-2008	Girnita, Leonard/0000-0003-0280-9500; Zheng, Huiyuan/0000-0003-1431-1590	Swedish Cancer Society; Swedish Medical Council; Children Cancer Society; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Vinnova; Stockholm Cancer Society; Stockholm County; Karolinska Institute	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Council(Swedish Medical Research Council (SMRC)); Children Cancer Society; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Vinnova(Vinnova); Stockholm Cancer Society; Stockholm County(Stockholm County Council); Karolinska Institute(Karolinska Institutet)	This work was supported by grants funded by the Swedish Cancer Society, Swedish Medical Council, Children Cancer Society, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, Vinnova, Stockholm Cancer Society, the Stockholm County, and the Karolinska Institute. Dr Renato Baserga is greatly acknowledged for providing us with IGF-1R positive and negative cell lines as well as IGF-1R mutants' cells.	Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barlow PG, 2006, J LEUKOCYTE BIOL, V80, P509, DOI 10.1189/jlb.1005560; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Baserga R, 2009, EXP CELL RES, V315, P727, DOI 10.1016/j.yexcr.2008.09.017; Chamorro CI, 2009, J INVEST DERMATOL, V129, P937, DOI 10.1038/jid.2008.321; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Coffelt SB, 2008, CANCER RES, V68, P6482, DOI 10.1158/0008-5472.CAN-08-0044; Coffelt SB, 2008, INT J CANCER, V122, P1030, DOI 10.1002/ijc.23186; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 2001, CANCER RES, V61, P1367; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Heilborn JD, 2005, INT J CANCER, V114, P713, DOI 10.1002/ijc.20795; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Hubbard SR, 2007, CURR OPIN CELL BIOL, V19, P117, DOI 10.1016/j.ceb.2007.02.010; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Mader JS, 2006, EXPERT OPIN INV DRUG, V15, P933, DOI 10.1517/13543784.15.8.933; Menu E, 2006, BLOOD, V107, P655, DOI 10.1182/blood-2005-01-0293; Natalishvili N, 2009, EXP CELL RES, V315, P1458, DOI 10.1016/j.yexcr.2009.01.008; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Radek K, 2007, SEMIN IMMUNOPATHOL, V29, P27, DOI 10.1007/s00281-007-0064-5; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Razuvaev A, 2007, J VASC SURG, V46, P108, DOI 10.1016/j.jvs.2007.02.066; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shaykhiev R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001393; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; Tornkvist M, 2008, BIOCHEM BIOPH RES CO, V368, P793, DOI 10.1016/j.bbrc.2008.01.162; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Vasilcanu R, 2008, MOL PHARMACOL, V73, P930, DOI 10.1124/mol.107.040014; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; von Haussen J, 2008, LUNG CANCER, V59, P12, DOI 10.1016/j.lungcan.2007.07.014; Weber G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2221; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yin SC, 2010, NEURO-ONCOLOGY, V12, P19, DOI 10.1093/neuonc/nop008; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147	60	72	76	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					352	365		10.1038/onc.2011.239	http://dx.doi.org/10.1038/onc.2011.239			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685939	Green Published, hybrid			2022-12-17	WOS:000299542100008
J	Ip, CKM; Cheung, ANY; Ngan, HYS; Wong, AST				Ip, C. K. M.; Cheung, A. N. Y.; Ngan, H. Y. S.; Wong, A. S. T.			p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells	ONCOGENE			English	Article						p70 S6 kinase; ovarian cancer; actin; Rac1; Cdc42	GROWTH-FACTOR; MESSENGER-RNA; RHO-GTPASES; G-PROTEINS; LOCALIZATION; ACTIVATION; EXPRESSION; ONCOGENE; PHOSPHORYLATION; INHIBITION	Ovarian cancer is highly metastatic with a poor prognosis. The serine/threonine kinase, p70 S6 kinase (p70(S6K)), which is a downstream effector of phosphatidylinositol 3-kinase/Akt pathway, is frequently activated in ovarian cancer. Here, we show that p70(S6K) is a critical regulator of the actin cytoskeleton in the acquisition of the metastatic phenotype. This regulation is through two important activities: p70(S6K) acts as an actin filament cross-linking protein and as a Rho family GTPase-activating protein. Ectopic expression of constitutively active p70(S6K) in ovarian cancer cells induced a marked reorganization of the actin cytoskeleton and promoted directional cell migration. Using cosedimentation and differential sedimentation assays, p70(S6K) was found to directly bind to and cross-link actin filaments. Immunofluorescence studies showed p70(S6K) colocalized with cytochalasin D-sensitive actin at the leading edge of motile cells. The p70(S6K) did not affect the kinetics of spontaneous actin polymerization, but could stabilize actin filaments by the inhibition of cofilin-induced actin depolymerization. In addition, we showed that p70(S6K) stimulated the rapid activation of both Rac1 and Cdc42, and their downstream effector p21-activated kinase (PAK1), but not RhoA. Depletion of p70(S6K) expression or inhibition of its activity resulted in significant inhibition of actin cytoskeleton reorganization and reduced migration, with a concomitant reduction in Rac1, Cdc42 and PAK1 activation, confirming that the effect was p70(S6K) specific. Similarly, the actin cytoskeleton reorganization/migratory phenotype could be reversed by expression of dominant negative Rac1 and Cdc42, or inhibition of PAK1. These results reveal a new direction for understanding the oncogenic roles of p70(S6K) in tumor progression. Oncogene (2011) 30, 2420-2432; doi:10.1038/onc.2010.615; published online 24 January 2011	[Ip, C. K. M.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Cheung, A. N. Y.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Ngan, H. Y. S.] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022; Cheung, Annie Nga Yin/C-4231-2009	Wong, Alice/0000-0002-0676-6475; Ip, Carman K.M./0000-0002-6672-5982; Ngan, Hextan Y S/0000-0003-3945-159X; Cheung, Annie Nga Yin/0000-0002-1584-7568	Research Grant Council [HKU 7599/05M]; HKU	Research Grant Council(Hong Kong Research Grants Council); HKU(University of Hong Kong)	We thank Dr N Auersperg, G Thomas and A Hall for providing cell lines and cDNA constructs. This work was supported by the Research Grant Council grant HKU 7599/05M and the HKU Outstanding Young Research Award (AST Wong).	Ahmed N, 2006, AM J PHYSIOL-CELL PH, V290, pC1532, DOI 10.1152/ajpcell.00478.2005; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; BUICK RN, 1985, CANCER RES, V45, P3668; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Filonenko VV, 2004, EXP ONCOL, V26, P294; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanein D, 1997, J CELL BIOL, V139, P387, DOI 10.1083/jcb.139.2.387; HOLMES GR, 1976, BIOCHIM BIOPHYS ACTA, V446, P445, DOI 10.1016/0005-2795(76)90010-6; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; Liu LZ, 2006, FREE RADICAL BIO MED, V41, P1521, DOI 10.1016/j.freeradbiomed.2006.08.003; Nozawa H, 2007, CANCER LETT, V251, P105, DOI 10.1016/j.canlet.2006.11.008; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Philp AJ, 2001, CANCER RES, V61, P7426; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Siu MKY, 2010, INT J CANCER, V127, P21, DOI 10.1002/ijc.25005; Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Wong AST, 2004, EXP CELL RES, V299, P248, DOI 10.1016/j.yexcr.2004.06.002; Zhou HY, 2006, ENDOCRINOLOGY, V147, P2557, DOI 10.1210/en.2005-1404	38	72	76	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2420	2432		10.1038/onc.2010.615	http://dx.doi.org/10.1038/onc.2010.615			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21258406	Bronze, Green Submitted			2022-12-17	WOS:000291008000004
J	He, X; Arslan, AD; Pool, MD; Ho, TT; Darcy, KM; Coon, JS; Beck, WT				He, X.; Arslan, A. D.; Pool, M. D.; Ho, T-T; Darcy, K. M.; Coon, J. S.; Beck, W. T.			Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer	ONCOGENE			English	Article						splicing factors; polypyrimidine tract-binding protein; SRp20; siRNA; tissue microarray; epithelial ovarian cancer	TRACT-BINDING-PROTEIN; HUMAN BREAST-CANCER; MESSENGER-RNA; CONTINGENCY-TABLES; EXON; CD44; GENE; ABERRANT; VARIANT; PHOSPHORYLATION	Our previous study revealed that two splicing factors, polypyrimidine tract-binding protein (PTB) and SRp20, were upregulated in epithelial ovarian cancer (EOC) and knockdown of PTB expression inhibited ovarian tumor cell growth and transformation properties. In this report, we show that knockdown of SRp20 expression in ovarian cancer cells also causes substantial inhibition of tumor cell growth and colony formation in soft agar and the extent of such inhibition appeared to correlate with the extent of suppression of SRp20. Massive knockdown of SRp20 expression triggered remarkable apoptosis in these cells. These results suggest that overexpression of SRp20 is required for ovarian tumor cell growth and survival. Immunohistochemical staining for PTB and SRp20 of two specialized tissue microarrays, one containing benign ovarian tumors, borderline/low malignant potential (LMP) ovarian tumors as well as invasive EOC and the other containing invasive EOC ranging from stage I to stage IV disease, reveals that PTB and SRp20 are both expressed differentially between benign tumors and invasive EOC, and between borderline/LMP tumors and invasive EOC. There were more all-negative or mixed staining cases (at least two evaluable section cores per case) in benign tumors than in invasive EOC, whereas there were more all-positive staining cases in invasive EOC than in the other two disease classifications. Among invasive EOC, the majority of cases were stained all positive for both PTB and SRp20, and there were no significant differences in average staining or frequency of positive cancer cells between any of the tumor stages. Therefore, the expression of PTB and SRp20 is associated with malignancy of ovarian tumors but not with stage of invasive EOC. Oncogene (2011) 30, 356-365; doi:10.1038/onc.2010.426; published online 20 September 2010	[He, X.; Arslan, A. D.; Ho, T-T; Beck, W. T.] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; [He, X.; Beck, W. T.] Univ Illinois, Coll Pharm, Core Lab Mol Pharmacol, GOG, Chicago, IL 60612 USA; [He, X.; Arslan, A. D.; Ho, T-T; Beck, W. T.] Univ Illinois, Ctr Canc, Chicago, IL 60612 USA; [Pool, M. D.; Coon, J. S.] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA; [Darcy, K. M.] Roswell Pk Canc Inst, GOG Stat & Data Ctr, Buffalo, NY 14263 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; Roswell Park Cancer Institute	Beck, WT (corresponding author), Univ Illinois, Dept Biopharmaceut Sci MC 865, 833 S Wood St, Chicago, IL 60612 USA.	xiaohe@uic.edu; WTBeck@uic.edu			National Cancer Institute [CA40570, CA138762, CA27469, CA37517]; Rush University Medical Center; University of Illinois at Chicago; NCRR NIH [C06RR15482]; NATIONAL CANCER INSTITUTE [U10CA027469, U10CA037517, R01CA138762, R01CA040570] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015482] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Rush University Medical Center; University of Illinois at Chicago; NCRR NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank the Gynecologic Oncology Group (GOG) Tissue Bank for providing unstained ovarian tumor TMAs. We thank our colleague, Martina Vaskova, for her outstanding administrative assistance. We also thank Dr Richard Gemeinhart for allowing us to use his IX70 microscope and Ernest Gemeinhart for his excellent technical assistance with microscopy. This work was supported by the National Cancer Institute Grants CA40570 and CA138762 to WTB, CA27469 to the GOG, GOG Tissue Bank and GOG Molecular Pharmacology Core Lab and CA37517 to the GOG Statistical and Data Center as well as the Ovarian Cancer Research Fund (XH), Rush University Medical Center and the University of Illinois at Chicago. It was conducted in a facility constructed with support from the NCRR NIH grant C06RR15482.	Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Castelo-Branco P, 2004, MOL CELL BIOL, V24, P4174, DOI 10.1128/MCB.24.10.4174-4183.2004; Cornelis S, 2005, NUCLEIC ACIDS RES, V33, P3095, DOI 10.1093/nar/gki611; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; de la Mata M, 2006, NAT STRUCT MOL BIOL, V13, P973, DOI 10.1038/nsmb1155; De Marzo AM, 1998, PROSTATE, V34, P162; Feltes CM, 2002, CANCER RES, V62, P6688; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; Galiana-Arnoux D, 2003, J BIOL CHEM, V278, P32943, DOI 10.1074/jbc.M301090200; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hamilton BJ, 2003, MOL CELL BIOL, V23, P510, DOI 10.1128/MCB.23.2.510-525.2003; He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jin W, 2000, CANCER RES, V60, P1221; Jin W, 2003, CANCER RES, V63, P6154; Jumaa H, 2000, BBA-GENE STRUCT EXPR, V1494, P137, DOI 10.1016/S0167-4781(00)00233-5; Jumaa H, 1999, CURR BIOL, V9, P899, DOI 10.1016/S0960-9822(99)80394-7; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; Kosinski PA, 2003, J IMMUNOL, V170, P979, DOI 10.4049/jimmunol.170.2.979; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Lockhart MS, 2001, ONCOL REP, V8, P145; Loomis RJ, 2009, MOL CELL, V33, P450, DOI 10.1016/j.molcel.2009.02.003; Lou H, 1999, MOL CELL BIOL, V19, P78; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Lukas J, 2001, CANCER RES, V61, P3212; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Ries LAG, 2007, SEER CANC STAT REV 1; Schroder W, 1999, ANTICANCER RES, V19, P3901; Sen S, 2009, MOL CELL BIOL, V29, P871, DOI 10.1128/MCB.01709-08; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Stoilov P, 2002, DNA CELL BIOL, V21, P803, DOI 10.1089/104454902320908450; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang ZN, 2003, CANCER RES, V63, P655; Watermann DO, 2006, CANCER RES, V66, P4774, DOI 10.1158/0008-5472.CAN-04-3294; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; WIELENGA VJM, 1993, CANCER RES, V53, P4754; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Xie JY, 2003, P NATL ACAD SCI USA, V100, P8776, DOI 10.1073/pnas.1432696100; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu QM, 2004, J NEUROCHEM, V90, P164, DOI 10.1111/j.1471-4159.2004.02477.x; Zang WQ, 2001, J VIROL, V75, P10779, DOI 10.1128/JVI.75.22.10779-10786.2001	55	72	76	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					356	365		10.1038/onc.2010.426	http://dx.doi.org/10.1038/onc.2010.426			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20856201	Green Accepted			2022-12-17	WOS:000286418800010
J	Park, HD; Lee, Y; Oh, YK; Jung, JG; Park, YW; Myung, K; Kim, KH; Koh, SS; Lim, DS				Park, H. D.; Lee, Y.; Oh, Y. K.; Jung, J. G.; Park, Y. W.; Myung, K.; Kim, K-H; Koh, S. S.; Lim, D-S			Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation	ONCOGENE			English	Article						PAUF; TLR; CXCR4; TPL2; ERK; NF-kappa B	TOLL-LIKE RECEPTORS; TUMOR-GROWTH; CARBOHYDRATE SPECIFICITIES; STRUCTURAL BASIS; BINDING LECTINS; CANCER-CELLS; ANGIOGENESIS; LIPOPOLYSACCHARIDE; INFLAMMATION; PROGRESSION	Pancreatic adenocarcinoma upregulated factor (PAUF) is overproduced in certain types of cancer. However, little is known of the tumorigenic function of PAUF. In this study, we report the X-ray crystal structure of PAUF and reveal that PAUF is a mammalian lectin normally found in plant lectins. We also identify PAUF as an endogenous ligand of Toll-like receptor 2 (TLR2) and TLR4 by screening extracellular domain receptor pools. We further confirmed the specificity of the PAUF-TLR2 interaction. PAUF induces extracellular signal-regulated kinase (ERK) phosphorylation and activates the IKK-beta-mediated TPL2/MEK/ERK signaling pathway through TLR2. In agreement with the result of TLR2-mediated ERK activation by PAUF, PAUF induces increased expression of the protumorigenic cytokines RANTES and MIF in THP-1 cells. However, PAUF does not fully activate I kappa-B-alpha signaling pathways in THP-1 cells, and fails to translocate the p65 subunit of the nuclear factor-kappa B (NF-kappa B) complex into the nucleus, resulting in no NF-kappa B activation. Surprisingly, we found that PAUF also associated with the CXC chemokine receptor (CXCR4)-TLR2 complex and inhibited CXCR4-dependent, TLR2-mediated NF-kappa B activation. Together, these findings suggest that the new cancer-associated ligand, PAUF, may activate TLR-mediated ERK signaling to produce the protumorigenic cytokines, but inhibits TLR-mediated NF-kappa B signaling, thereby facilitating tumor growth and escape from innate immune surveillance. Oncogene (2011) 30, 201-211; doi:10.1038/onc.2010.401; published online 30 August 2010	[Lee, Y.; Jung, J. G.; Park, Y. W.; Kim, K-H; Koh, S. S.] Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon, South Korea; [Park, H. D.; Lee, Y.; Lim, D-S] Natl Creat Res Initiat Ctr Cell Div & Differentia, Dept Biol Sci, Taejon, South Korea; [Park, H. D.; Oh, Y. K.] LG Life Sci, Dept Pharmacol, Taejon, South Korea; [Myung, K.] NHGRI, NIH, Bethesda, MD 20892 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); LG Life Sciences Ltd; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Koh, SS (corresponding author), Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon, South Korea.	sskoh@kribb.re.kr; daesiklim@kaist.ac.kr	Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555	National Creative Research Initiative Center; World Class University (WCU); Ministry of Education, Science and Technology in Korea; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG012003] Funding Source: NIH RePORTER	National Creative Research Initiative Center; World Class University (WCU); Ministry of Education, Science and Technology in Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by grants from the National Creative Research Initiative Center Program, World Class University (WCU) program and the 21st Century Frontier Functional Human Genome Project of the Ministry of Education, Science and Technology in Korea. We thank Sang Yong Hong for technical support with the cloning work. We thank the staff of Beamline 4A at the Pohang Accelerator Laboratory, Korea, for assistance in data collection and Dr Hyun Kyu Song of Korea University for help with MAD data analysis.	Adachi H, 2003, ACTA CRYSTALLOGR D, V59, P194, DOI 10.1107/S0907444902019741; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Azenshtein E, 2002, CANCER RES, V62, P1093; Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Barre A, 2001, BIOCHIMIE, V83, P645, DOI 10.1016/S0300-9084(01)01315-3; Bourne Y, 1999, STRUCTURE, V7, P1473, DOI 10.1016/S0969-2126(00)88338-0; Chen R, 2008, ONCOGENE, V27, P225, DOI 10.1038/sj.onc.1210907; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hajishengallis G, 2008, P NATL ACAD SCI USA, V105, P13532, DOI 10.1073/pnas.0803852105; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jeyaprakash AA, 2004, J MOL BIOL, V338, P757, DOI 10.1016/j.jmb.2004.03.040; Jeyaprakash AA, 2003, J MOL BIOL, V332, P217, DOI 10.1016/S0022-2836(03)00901-X; Jouault T, 2006, J IMMUNOL, V177, P4679, DOI 10.4049/jimmunol.177.7.4679; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Kim SA, 2009, CANCER SCI, V100, P828, DOI 10.1111/j.1349-7006.2009.01106.x; Lee Y, 2010, ONCOGENE, V29, P56, DOI 10.1038/onc.2009.298; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Li Y, 2008, J IMMUNOL, V181, P2781, DOI 10.4049/jimmunol.181.4.2781; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Miettinen M, 2008, J LEUKOCYTE BIOL, V84, P1092, DOI 10.1189/jlb.1206737; Morse RJ, 2001, STRUCTURE, V9, P409, DOI 10.1016/S0969-2126(01)00601-3; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; SHIMIZU T, 1994, EMBO J, V13, P1003, DOI 10.1002/j.1460-2075.1994.tb06348.x; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; Triantafilou M, 2008, EUR J IMMUNOL, V38, P192, DOI 10.1002/eji.200636821	34	72	77	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	2					201	211		10.1038/onc.2010.401	http://dx.doi.org/10.1038/onc.2010.401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20802527	Green Accepted			2022-12-17	WOS:000286438900008
J	Lau, KM; Chan, QKY; Pang, JCS; Li, KKW; Yeung, WW; Chung, NYF; Lui, PC; Tam, YS; Li, HM; Zhou, L; Wang, Y; Mao, Y; Ng, HK				Lau, K-M; Chan, Q. K. Y.; Pang, J. C. S.; Li, K. K. W.; Yeung, W. W.; Chung, N. Y. F.; Lui, P. C.; Tam, Y-S; Li, H-M; Zhou, L.; Wang, Y.; Mao, Y.; Ng, H-K			Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion	ONCOGENE			English	Article						medulloblastoma; MCM2; MCM3; MCM7; migration; invasion	COMPARATIVE GENOMIC HYBRIDIZATION; PRIMITIVE NEUROECTODERMAL TUMORS; DNA-REPLICATION; MCM PROTEINS; PROLIFERATION MARKER; PEDIATRIC MEDULLOBLASTOMAS; INDEPENDENT PREDICTOR; CHECKPOINT KINASES; PROSTATE-CANCER; S-PHASE	Minichromosome maintenance (MCM) proteins 2-7 are important in DNA replication licensing. Functional roles beyond licensing are speculated. In addition, significances in medulloblastoma (MB) remain unclear. In this study, we showed the frequent deregulation of MCM2 and MCM3 expression in 7 MB cell lines and 31 clinical samples. Moreover, DAOY and ONS76 and the clinical samples expressed elevated MCM7 transcripts with genomic gain of the gene. Immunopositivity restricted to tumor cells was found in 41, 37 and 53 out of 73 MB cases for MCM2, MCM3 and MCM7, respectively. High-MCM3 expression was associated with poor prognosis. Knockdowns of these MCMs significantly inhibited anchorage-dependent and -independent MB cell growth. The inhibition of MCM3 expression by small interfering RNA knockdown was related to G1 arrest with reduced cyclin A expression, whereas the MCM2- and MCM7-knocked-down cells arrested at G2/M with increased cyclin A expression. Interestingly, we demonstrated the links of these MCMs with cell migration and invasion using wound-healing and Transwell migration/invasion assays. Exogenous overexpression of MCM2, MCM3 and MCM7 increased anchorage-independent cell growth, and also cell migration and invasion capabilities in MB cells. The knockdown reduced the number of filopodial cells and the cells with intense stress fibers by blocking cdc42 and Rho activation. Taken together, deregulation of MCM2, MCM3 and MCM7 expression might be involved in MB tumorigenesis and we revealed undefined roles of these MCMs in control of MB cell migration and invasion. Oncogene (2010) 29, 5475-5489; doi:10.1038/onc.2010.287; published online 26 July 2010	[Lau, K-M; Chan, Q. K. Y.; Pang, J. C. S.; Li, K. K. W.; Yeung, W. W.; Chung, N. Y. F.; Lui, P. C.; Tam, Y-S; Li, H-M; Ng, H-K] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; [Lau, K-M; Pang, J. C. S.; Ng, H-K] Chinese Univ Hong Kong, State Key Lab So China Oncol, Shatin, Hong Kong, Peoples R China; [Zhou, L.; Mao, Y.] Fudan Univ, Hua Shan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China; [Wang, Y.] Fudan Univ, Hua Shan Hosp, Dept Neuropathol, Shanghai 200433, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Fudan University; Fudan University	Lau, KM (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Room 38018,Clinical Sci Bldg, Shatin, Hong Kong, Peoples R China.	kmlau@cuhk.edu.hk; hkng@cuhk.edu.hk	Ng, Ho Keung/I-3952-2015	Mao, Ying/0000-0001-8055-115X; Lau, Kin-Mang/0000-0001-5888-1937	Hong Kong Research Grants Council [472307]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	This work was supported by the Hong Kong Research Grants Council General Research Fund 472307.	Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; Bailis JM, 2004, CURR OPIN GENET DEV, V14, P17, DOI 10.1016/j.gde.2003.11.002; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Blow JJ, 2008, NAT REV CANCER, V8, P799, DOI 10.1038/nrc2500; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Crevel G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000833; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; De Bortoli M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-223; Dudderidge TJ, 2007, BRIT J CANCER, V96, P1384, DOI 10.1038/sj.bjc.6603718; Dudderidge TJ, 2005, CLIN CANCER RES, V11, P2510, DOI 10.1158/1078-0432.CCR-04-1776; Eberhart CG, 2002, BRAIN PATHOL, V12, P36, DOI 10.1111/j.1750-3639.2002.tb00420.x; Endl E, 2001, J PATHOL, V195, P457, DOI 10.1002/path.978; Feng DR, 2003, CANCER RES, V63, P7356; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Freeman A, 1999, CLIN CANCER RES, V5, P2121; GIANGASPERO F, 2000, PATHOLOGY GENETICS T, P129; Gilhuis HJ, 2000, CLIN NEUROL NEUROSUR, V102, P203, DOI 10.1016/S0303-8467(00)00112-8; Giordana MT, 1998, CHILD NERV SYST, V14, P256, DOI 10.1007/s003810050221; Gonzalez MA, 2005, NAT REV CANCER, V5, P135, DOI 10.1038/nrc1548; Gonzalez MA, 2003, J CLIN ONCOL, V21, P4306, DOI 10.1200/JCO.2003.04.121; Ha SA, 2004, CLIN CANCER RES, V10, P8386, DOI 10.1158/1078-0432.CCR-04-1029; Hanna-Morris A, 2009, J CLIN PATHOL, V62, P325, DOI 10.1136/jcp.2007.054643; Haverty PM, 2002, NUCLEIC ACIDS RES, V30, P214, DOI 10.1093/nar/30.1.214; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Hui ABY, 2005, CLIN CANCER RES, V11, P4707, DOI 10.1158/1078-0432.CCR-05-0128; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; Kato H, 2003, J SURG ONCOL, V84, P24, DOI 10.1002/jso.10287; Ke N, 2004, BIOTECHNIQUES, V36, P826, DOI 10.2144/04365ST07; Korkolopoulou P, 2005, HUM PATHOL, V36, P899, DOI 10.1016/j.humpath.2005.06.008; Lei M, 2005, CURR CANCER DRUG TAR, V5, P365, DOI 10.2174/1568009054629654; Lei M, 1996, MOL CELL BIOL, V16, P5081; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Meng MV, 2001, CLIN CANCER RES, V7, P2712; Nicholson JC, 1999, BRIT J CANCER, V80, P1322, DOI 10.1038/sj.bjc.6690525; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Nishizaki T, 1999, PEDIATR NEUROSURG, V31, P27, DOI 10.1159/000028827; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Polkinghorn WR, 2007, NAT CLIN PRACT ONCOL, V4, P295, DOI 10.1038/ncponc0794; Ramnath N, 2001, J CLIN ONCOL, V19, P4259, DOI 10.1200/JCO.2001.19.22.4259; Reardon DA, 1997, CANCER RES, V57, P4042; Ren B, 2006, ONCOGENE, V25, P1090, DOI 10.1038/sj.onc.1209134; Rodins K, 2002, CLIN CANCER RES, V8, P1075; Rossi MR, 2006, GENE CHROMOSOME CANC, V45, P290, DOI 10.1002/gcc.20292; Schrader C, 2005, BRIT J CANCER, V93, P939, DOI 10.1038/sj.bjc.6602795; Scott WC, 2005, AM J DRUG ALCOHOL AB, V31, P455, DOI 10.1081/ADA-200056807; Shechter D, 2004, P NATL ACAD SCI USA, V101, P10845, DOI 10.1073/pnas.0404143101; Stoeber K, 2001, J CELL SCI, V114, P2027; Tachibana KEK, 2005, J PATHOL, V205, P123, DOI 10.1002/path.1708; Takahashi TS, 2005, TRENDS BIOCHEM SCI, V30, P437, DOI 10.1016/j.tibs.2005.06.007; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tong CYK, 2004, J NEUROSURG, V100, P187, DOI 10.3171/ped.2004.100.2.0187; Wharton SB, 2007, ACTA NEUROPATHOL, V113, P119, DOI 10.1007/s00401-006-0177-2; Wharton SB, 2001, NEUROPATH APPL NEURO, V27, P305, DOI 10.1046/j.0305-1846.2001.00333.x; Williams GH, 2007, CURR OPIN CELL BIOL, V19, P672, DOI 10.1016/j.ceb.2007.10.005; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Yu ZL, 2004, J MOL BIOL, V340, P1197, DOI 10.1016/j.jmb.2004.05.024	60	72	75	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5475	5489		10.1038/onc.2010.287	http://dx.doi.org/10.1038/onc.2010.287			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20661220				2022-12-17	WOS:000282945800005
J	Tsang, YH; Lamb, A; Romero-Gallo, J; Huang, B; Ito, K; Peek, RM; Ito, Y; Chen, LF				Tsang, Y. H.; Lamb, A.; Romero-Gallo, J.; Huang, B.; Ito, K.; Peek, R. M., Jr.; Ito, Y.; Chen, L. F.			Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation	ONCOGENE			English	Article						CagA; degradation; H. pylori; RUNX3; ubiquitination	GROWTH-FACTOR; EPITHELIAL-CELLS; BETA-CATENIN; EXPRESSION; CANCER; RISK; METHYLATION; COOPERATION; MECHANISMS; INFECTION	Chronic infection with cagA-positive Helicobacter pylori is the strongest risk factor for the development of gastric adenocarcinoma. The cagA gene product CagA is injected into gastric epithelial cells and disturbs cellular functions by physically interacting with and deregulating a variety of cellular signaling molecules. RUNX3 is a tumor suppressor in many tissues, and it is frequently inactivated in gastric cancer. In this study, we show that H. pylori infection inactivates the gastric tumor suppressor RUNX3 in a CagA-dependent manner. CagA directly associates with RUNX3 through a specific recognition of the PY motif of RUNX3 by a WW domain of CagA. Deletion of the WW domains of CagA or mutation of the PY motif in RUNX3 abolishes the ability of CagA to induce the ubiquitination and degradation of RUNX3, thereby extinguishing its ability to inhibit the transcriptional activation of RUNX3. Our studies identify RUNX3 as a novel cellular target of H. pylori CagA and also reveal a mechanism by which CagA functions as an oncoprotein by blocking the activity of gastric tumor suppressor RUNX3. Oncogene (2010) 29, 5643-5650; doi:10.1038/onc.2010.304; published online 2 August 2010	[Tsang, Y. H.; Lamb, A.; Huang, B.; Chen, L. F.] Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; [Tsang, Y. H.; Ito, Y.] Inst Mol & Cell Biol, Proteos, Singapore; [Romero-Gallo, J.; Peek, R. M., Jr.] Vanderbilt Univ, Sch Med, Dept Med & Canc Biol, Div Gastroenterol, Nashville, TN 37212 USA; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 852, Japan	University of Illinois System; University of Illinois Urbana-Champaign; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Vanderbilt University; Nagasaki University	Chen, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem, MC-714, Urbana, IL 61801 USA.	lfchen@life.illinois.edu			UIUC; NIH [DK-085158, DK-58587, CA-77955, CA-116087]; CMB-TG; NATIONAL CANCER INSTITUTE [P01CA116087, R29CA077955, R01CA077955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, R01DK085158, P30DK058404] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CMB-TG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Hatakeyama (University of Tokyo, Japan) for providing the expression vector for CagA-HA and CagA-PRHA. This work is supported in part by ICR provided by UIUC and NIH Grants DK-085158 (to LFC) and DK-58587, CA-77955 and CA-116087 (to RMP). AL is a recipient of the CMB-TG. YHT is an A*STAR-Illinois Partnership fellow.	BLASER MJ, 1995, CANCER RES, V55, P2111; Chang TL, 2010, GASTROENTEROLOGY, V138, P255, DOI 10.1053/j.gastro.2009.08.044; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hatakeyama M, 2008, CURR OPIN MICROBIOL, V11, P30, DOI 10.1016/j.mib.2007.12.003; Hatakeyama M, 2009, J GASTROENTEROL, V44, P239, DOI 10.1007/s00535-009-0014-1; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hsu PI, 2009, ANN SURG ONCOL, V16, P1686, DOI 10.1245/s10434-009-0428-2; Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/j.gastro.2003.08.033; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Katayama Y, 2009, BIOCHEM BIOPH RES CO, V388, P496, DOI 10.1016/j.bbrc.2009.08.003; Kitajima Y, 2008, ONCOL REP, V19, P197; Lamb A, 2009, EMBO REP, V10, P1242, DOI 10.1038/embor.2009.210; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek Richard M Jr, 2005, Sci STKE, V2005, ppe14; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sugiura H, 2008, ONCOL REP, V19, P713; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	32	72	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5643	5650		10.1038/onc.2010.304	http://dx.doi.org/10.1038/onc.2010.304			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676134	Green Accepted			2022-12-17	WOS:000282946900010
J	Wang, Q; Sun, ZX; Allgayer, H; Yang, HS				Wang, Q.; Sun, Z-X; Allgayer, H.; Yang, H-S			Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells	ONCOGENE			English	Article						Pdcd4; beta-catenin/Tcf-dependent transcription; E-cadherin; u-PAR; c-Myc; stably knockdown	INITIATION-FACTOR 4A; RECEPTOR U-PAR; SUPPRESSOR PDCD4; C-MYC; TRANSFORMATION SUPPRESSOR; PROGRAMMED CELL-DEATH-4; EUKARYOTIC TRANSLATION; AP-1 TRANSACTIVATION; COLORECTAL-CANCER; TUMOR PROGRESSION	We reported earlier that knockdown of tumor suppressor Pdcd4 (programed cell death 4) downregulates E-cadherin expression and activates beta-catenin/Tcf (T-cell factor)dependent transcription in colon tumor cells. However, the underlying mechanism of these observations remains unknown. In this study, we showed that knockdown of Pdcd4 downregulates E-cadherin expression through elevated protein level of Snail. Over-expression of Pdcd4 upregulates E-cadherin expression and inhibits beta-catenin/Tcf-dependent transcription. We then showed that knockdown of E-cadherin activates beta-catenin/Tcf-dependent transcription. Conversely, over-expression of E-cadherin in Pdcd4 knockdown cells inhibits beta-catenin/Tcf-dependent transcription. In addition, Pdcd4 knockdown stimulates urokinase-type plasminogen activator receptor (u-PAR) and c-Myc expression, whereas u-PAR and c-Myc expression can be reversed by over-expressing E-cadherin in Pdcd4 knockdown cells. Using chromatin immunoprecipitation, we showed that beta-catenin/Tcf4 directly binds to the promoters of u-PAR and c-myc in Pdcd4 knockdown cells. Futhermore, knockdown of u-PAR or c-Myc inhibits invasion in Pdcd4 knockdown cells, suggesting that both u-PAR and c-Myc contribute to invasion induced by Pdcd4 knockdown. Taken together, our data showed that elevated Snail expression by Pdcd4 knockdown leads to downregulation of E-cadherin resulting in activating beta-catenin/Tcf-dependent transcription and stimulating the expression of c-Myc and u-PAR, thus providing molecular explanation of how Pdcd4 suppresses tumor invasion.	[Wang, Q.; Yang, H-S] Univ Kentucky, Grad Ctr Toxicol, Coll Med, Lexington, KY 40536 USA; [Sun, Z-X] Beijing Univ Chinese Med, Dept Pharmaceut, Sch Chinese Pharm, Beijing, Peoples R China; [Allgayer, H.] Univ Heidelberg, Dept Expt Surg & Mol Oncol Solid Tumors, Med Fac Mannheim, D-6800 Mannheim, Germany; [Allgayer, H.] KDFZ Heidelberg, Mannheim, Germany; [Yang, H-S] Univ Kentucky, Lucille P Markey Canc Ctr, Coll Med, Lexington, KY 40536 USA	University of Kentucky; Beijing University of Chinese Medicine; Ruprecht Karls University Heidelberg; University of Kentucky	Yang, HS (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Coll Med, Lexington, KY 40536 USA.	hyang3@uky.edu	Yang, Hsin-Sheng/AAF-6793-2020; Yang, Hsin-Sheng/A-6419-2008	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036	NCI [R01CA129015]; ACS Institutional Research [IRG-85-001-19]; NCRR CORBE pilot [P20RR020171]; NATIONAL CANCER INSTITUTE [R01CA129015] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS Institutional Research; NCRR CORBE pilot(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Ji Hshiung Chen (Tzu Chi University, Taiwan) for kindly providing E-cadherin promoter and Dr Xiaoling Guo for technical support. This work was supported by NCI Grant R01CA129015, ACS Institutional Research Grant IRG-85-001-19, and NCRR CORBE pilot grant P20RR020171.	Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Fuchs SY, 2005, CELL CYCLE, V4, P1522; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; KARIKO K, 1993, CANCER RES, V53, P3109; Kemler R, 1992, Semin Cell Biol, V3, P149; Laufs S, 2006, CELL CYCLE, V5, P1760; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Memarzedeh S, 2002, P NATL ACAD SCI USA, V99, P10647, DOI 10.1073/pnas.152127499; MIYAKI M, 1994, CANCER RES, V54, P3011; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Nestl A, 2001, CANCER RES, V61, P1569; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Ozpolat B, 2007, MOL CANCER RES, V5, P95, DOI 10.1158/1541-7786.MCR-06-0125; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Schmid T, 2008, CANCER RES, V68, P1254, DOI 10.1158/0008-5472.CAN-07-1719; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	37	72	78	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					128	138		10.1038/onc.2009.302	http://dx.doi.org/10.1038/onc.2009.302			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19784072	Green Accepted			2022-12-17	WOS:000273373500012
J	Reis-Sobreiro, M; Gajate, C; Mollinedo, F				Reis-Sobreiro, M.; Gajate, C.; Mollinedo, F.			Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions	ONCOGENE			English	Article						lipid rafts; Fas/CD95 signaling; mitochondrial transmembrane potential; multiple myeloma; T-cell leukemia; resveratrol	DEATH-RECEPTOR; MULTIPLE-MYELOMA; SELECTIVE APOPTOSIS; CANCER; FAS; CELLS; EDELFOSINE; COMPLEX; REDISTRIBUTION; ACTIVATION	We have found that resveratrol (trans-3,4',5-trihydroxystilbene) induced apoptosis in multiple myeloma (MM) and T-cell leukemia cells through coclustering of Fas/CD95 death receptor and lipid rafts, whereas normal lymphocytes were spared. Tumor necrosis factor-related apoptosis-inducing ligand receptors, Fas-associated death domain-containing protein (FADD), procaspase-8, procaspase-10, c-Jun amino-terminal kinase and Bid were also recruited into lipid rafts on resveratrol incubation with MM and T-cell leukemia cells. Raft disruption inhibited resveratrol-induced apoptosis. Bcl-X-L overexpression prevented resveratrol-induced disruption of mitochondrial transmembrane potential (Delta Psi(m)) and apoptosis. A FADD dominant-negative mutant, that blocked Fas/CD95 downstream signaling, precluded resveratrol-induced Delta Psi(m) loss and apoptosis, indicating a sequence of Fas/CD95 signaling -> mitochondrion in the apoptotic response triggered by resveratrol. Cells deficient in Fas/CD95 did not undergo resveratrol-induced apoptosis. Pretreatment of MM cells with interferon-gamma upregulated Fas/CD95 and caspase-8, and potentiated resveratrol-induced apoptosis. Our data indicate that recruitment of Fas/CD95 death receptor and downstream signaling molecules into lipid rafts, followed by Delta Psi(m) disruption, underlies the apoptotic action of resveratrol in MM and T-cell leukemic cells. Combination of resveratrol with perifosine or bortezomib potentiated the apoptotic response induced by each single drug. These results also highlight the role of recruitment of Fas/CD95 signaling in lipid rafts in antimyeloma and antileukemia chemotherapy. Oncogene (2009) 28, 3221-3234; doi: 10.1038/onc.2009.183; published online 29 June 2009	[Reis-Sobreiro, M.; Gajate, C.; Mollinedo, F.] Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, E-37007 Salamanca, Spain; [Gajate, C.] Hosp Univ Salamanca, Unidad Invest, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Mollinedo, F (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es	2009, Secribsal/A-1266-2012	Gajate, Consuelo/0000-0003-0604-6459; Reis Sobreiro, Mariana/0000-0003-0286-0824	Ministerio de Ciencia e Innovacion [SAF2008-02251, SAF2005-04293, RD06/0020/1037]; Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III; Fondo de Investigacion Sanitaria and European Commission [FIS-FEDER 06/0813, 04/0843]; Junta de Castilla y Leon [CSI01A08, SAN673/SA32/08]; Experimental Therapeutics and Translational Oncology Program [GR15]; Fundacion de Investigacion Medica Mutua Madrilena (FMM); Fundacion 'la Caixa' [BM05-30-0]; Fundacao para a Ciencia e Tecnologia (Ministerio da Ciencia, Tecnologia e Ensino Superior of Portugal); Ministerio de Ciencia e Innovacion of Spain	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III(Instituto de Salud Carlos III); Fondo de Investigacion Sanitaria and European Commission(Instituto de Salud Carlos III); Junta de Castilla y Leon(Junta de Castilla y Leon); Experimental Therapeutics and Translational Oncology Program; Fundacion de Investigacion Medica Mutua Madrilena (FMM); Fundacion 'la Caixa'(La Caixa Foundation); Fundacao para a Ciencia e Tecnologia (Ministerio da Ciencia, Tecnologia e Ensino Superior of Portugal)(Portuguese Foundation for Science and Technology); Ministerio de Ciencia e Innovacion of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was supported by grants from Ministerio de Ciencia e Innovacion (SAF2008-02251, SAF2005-04293, RD06/0020/1037-Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III), Fondo de Investigacion Sanitaria and European Commission (FIS-FEDER 06/0813, 04/0843), Junta de Castilla y Leon (CSI01A08, SAN673/SA32/08, and GR15-Experimental Therapeutics and Translational Oncology Program), Fundacion de Investigacion Medica Mutua Madrilena (FMM) and Fundacion 'la Caixa' (BM05-30-0). MRS is recipient of a predoctoral fellowship from the Fundacao para a Ciencia e Tecnologia (Ministerio da Ciencia, Tecnologia e Ensino Superior of Portugal). CG is supported by the Ramon y Cajal Program from the Ministerio de Ciencia e Innovacion of Spain. We thank Lienhard Schmitz (University of Bern, Switzerland) for providing the stably transfected Jurkat FADD-DN cell line.	Ashkenazi A, 2008, J CLIN ONCOL, V26, P3621, DOI 10.1200/JCO.2007.15.7198; Aziz MH, 2003, INT J ONCOL, V23, P17; Barille-Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248; Barjot C, 2007, LIFE SCI, V81, P1565, DOI 10.1016/j.lfs.2007.08.047; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Christian AE, 1997, J LIPID RES, V38, P2264; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Fulda S, 2005, EUR J CANCER, V41, P786, DOI 10.1016/j.ejca.2004.12.020; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2000, INT J CANCER, V86, P208, DOI 10.1002/(SICI)1097-0215(20000415)86:2<208::AID-IJC10>3.0.CO;2-E; Gajate C, 2003, CLIN CANCER RES, V9, P1535; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Gajate C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005044; Gajate C, 2009, BIOCHEM BIOPH RES CO, V380, P780, DOI 10.1016/j.bbrc.2009.01.147; Gill C, 2007, PROSTATE, V67, P1641, DOI 10.1002/pros.20653; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hofmann TG, 2001, INT J CANCER, V93, P185, DOI 10.1002/ijc.1316; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Lonial S, 2007, CLIN LYMPHOMA MYELOM, V8, pS18, DOI 10.3816/CLM.2007.s.029; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MOLLINEDO F, 1992, J IMMUNOL, V149, P323; Mollinedo F, 2007, EXPERT OPIN THER PAT, V17, P385, DOI 10.1517/13543776.17.4.385; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Mollinedo Faustino, 2006, P13; Nieto-Miguel T, 2008, ONCOGENE, V27, P1779, DOI 10.1038/sj.onc.1210816; Nieto-Miguel T, 2006, J BIOL CHEM, V281, P14833, DOI 10.1074/jbc.M511251200; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; WESTENDORF JJ, 1995, BLOOD, V85, P3566, DOI 10.1182/blood.V85.12.3566.bloodjournal85123566	36	72	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3221	3234		10.1038/onc.2009.183	http://dx.doi.org/10.1038/onc.2009.183			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19561642				2022-12-17	WOS:000269673400005
J	Peschiaroli, A; Scialpi, F; Bernassola, F; Pagano, M; Melino, G				Peschiaroli, A.; Scialpi, F.; Bernassola, F.; Pagano, M.; Melino, G.			The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73	ONCOGENE			English	Article						ubiquitin; F-box proteins; p73; degradation; proteasome	SCF UBIQUITIN-LIGASE; TRCP-MEDIATED DEGRADATION; KINASE C-ABL; TUMOR-SUPPRESSOR; BETA-TRCP; APOPTOTIC RESPONSE; REGULATES P73; P53; FAMILY; P63	The transcription factor p73, a member of the p53 family, mediates cell-cycle arrest and apoptosis in response to DNA damage-induced cellular stress, acting thus as a proapoptotic gene. Similar to p53, p73 activity is regulated by post-translational modi. cation, including phosphorylation, acetylation and ubiquitylation. In C. elegans, the F-box protein FSN-1 controls germline apoptosis by regulating CEP-1, the single ancestral p53 family member. Here we report that FBXO45, the human ortholog of FSN-1, binds specifically to p73 triggering its proteasome-dependent degradation. Importantly, SCFFBXO45 ubiquitylates p73 both in vivo and in vitro. Moreover, siRNA-mediated depletion of FBXO45 stabilizes p73 and concomitantly induces cell death in a p53-independent manner. All together, these results show that the orphan F-box protein FBXO45 regulates the stability of p73, highlighting a conserved pathway evolved from nematode to human by which the p53 members are regulated by an SCF-dependent mechanism. Oncogene (2009) 28, 3157-3166; doi: 10.1038/onc.2009.177; published online 6 July 2009	[Peschiaroli, A.; Melino, G.] Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; [Pagano, M.] NYU, Sch Med, Dept Pathol, Inst Canc, New York, NY USA; [Pagano, M.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY USA; [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	University of Rome Tor Vergata; New York University; Howard Hughes Medical Institute; New York University; University of Leicester	Melino, G (corresponding author), Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it		PESCHIAROLI, ANGELO/0000-0001-6311-2382; pagano, michele/0000-0003-3210-2442	Medical Research Council, UK; EU [LSHB-CT-019067]; Alleanza contro il Cancro [ACC12]; MIUR/PRIN [RBIP06LCA9_0023]; AIRC [2008-20105471]; ISS [N526D5]; Italian Human ProteomeNet [RBRN07BMCT_007]; Telethon [GGPO4110]; National Institutes of Health [R01-GM57587, R37-CA76584, R21-CA125173]; Multiple Myeloma Research Fundation; Philip Morris USA Inc.; Philip Morris International; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R21CA125173, R37CA076584, R21CA161108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EU(European Commission); Alleanza contro il Cancro; MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); ISS; Italian Human ProteomeNet; Telethon(Fondazione Telethon); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multiple Myeloma Research Fundation; Philip Morris USA Inc.; Philip Morris International; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank V De Laurenzi for critically reading the manuscript. This study has been supported by the Medical Research Council, UK; grants from EU EPISTEM (LSHB-CT-019067), 'Alleanza contro il Cancro' (ACC12), MIUR/PRIN (RBIP06LCA9_0023), AIRC (2008-20105471), ISS 'Program Italia-USA' N526D5, Italian Human ProteomeNet RBRN07BMCT_007 and Telethon (GGPO4110) to GM; and grants from the National Institutes of Health (R01-GM57587, R37-CA76584 and R21-CA125173) and Multiple Myeloma Research Fundation to MP. Research described in this article was also supported in part by Philip Morris USA Inc. and Philip Morris International to GM. MP is an Investigator with the Howard Hughes Medical Institute.	Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Agami R, 1999, NATURE, V399, P809; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bloom J, 2005, METHOD ENZYMOL, V399, P249, DOI 10.1016/S0076-6879(05)99017-4; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chopin V, 2002, BRIT J PHARMACOL, V135, P79, DOI 10.1038/sj.bjp.0704456; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gao MX, 2008, CELL DEATH DIFFER, V15, P1054, DOI 10.1038/cdd.2008.30; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hershko A, 2005, ANGEW CHEM INT EDIT, V44, P5932, DOI 10.1002/anie.200501724; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koida N, 2008, J BIOL CHEM, V283, P8555, DOI 10.1074/jbc.M710608200; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, ANN NY ACAD SCI, V1010, P9, DOI 10.1196/annals.1299.002; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Ou HD, 2007, EMBO J, V26, P3463, DOI 10.1038/sj.emboj.7601764; Parry G, 2004, SEMIN CELL DEV BIOL, V15, P221, DOI 10.1016/j.semcdb.2003.12.003; Perez-Losada J, 2005, ONCOGENE, V24, P5521, DOI 10.1038/sj.onc.1208799; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Saha A, 2008, MOL CELL, V32, P21, DOI 10.1016/j.molcel.2008.08.021; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Soond SM, 2008, CELL CYCLE, V7, P1214, DOI 10.4161/cc.7.9.5777; Thomas JH, 2006, GENOME RES, V16, P1017, DOI 10.1101/gr.5089806; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Watson IR, 2006, NEOPLASIA, V8, P655, DOI 10.1593/neo.06439; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	54	72	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3157	3166		10.1038/onc.2009.177	http://dx.doi.org/10.1038/onc.2009.177			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19581926	Green Accepted			2022-12-17	WOS:000269515100007
J	Mattera, L; Escaffit, F; Pillaire, MJ; Selves, J; Tyteca, S; Hoffmann, JS; Gourraud, PA; Chevillard-Briet, M; Cazaux, C; Trouche, D				Mattera, L.; Escaffit, F.; Pillaire, M-J; Selves, J.; Tyteca, S.; Hoffmann, J-S; Gourraud, P-A; Chevillard-Briet, M.; Cazaux, C.; Trouche, D.			The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways	ONCOGENE			English	Article						colon cancer; apoptosis; chromatin; p400; Tip60	TIP60 HISTONE ACETYLTRANSFERASE; P53 PATHWAY; ACETYLATION; APOPTOSIS; COMPLEX; P400; HISTONE-DEACETYLASE-3; PROGRESSION; CHROMATIN; REPAIR	The Tip60 histone acetyltransferase belongs to a multi-molecular complex that contains many chromatin remodeling enzymes including the ATPase p400, a protein involved in nucleosomal incorporation of specific histone variants and that can directly or indirectly repress some Tip60-dependent pathways. Tip60 activity is critical for the cellular response to DNA damage and is affected during cancer progression. Here, we found that the ratio between Tip60 and p400 mRNAs is affected in most colorectal carcinoma. Strikingly, reversing the p400/Tip60 imbalance by Tip60 overexpression or the use of siRNAs resulted in increased apoptosis and decreased proliferation of colon-cancer-derived cells, suggesting that this ratio defect is important for cancer progression. Furthermore, we demonstrate that the p400/Tip60 ratio controls the oncogene-induced DNA damage response, a known anticancer barrier. Finally, we found that it is also critical for the response to 5-fluorouracil, a first-line treatment against colon cancer. Together, our data indicate that the p400/Tip60 ratio is critical for colon cancer cells proliferation and response to therapeutic drugs through the control of stress-response pathways.	[Trouche, D.] CNRS, LBCMCP, UMR 5088, F-31062 Toulouse, France; [Mattera, L.; Escaffit, F.; Pillaire, M-J; Selves, J.; Tyteca, S.; Hoffmann, J-S; Gourraud, P-A; Chevillard-Briet, M.; Cazaux, C.; Trouche, D.] Univ Toulouse, UPS, Toulouse, France; [Pillaire, M-J; Hoffmann, J-S; Cazaux, C.] CNRS, IPBS, F-31062 Toulouse, France; [Selves, J.] Fac Med Toulouse, INSERM, CPTP, F-31073 Toulouse, France; [Gourraud, P-A] Hop Toulouse, INSERM, Serv Epidemiol, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Trouche, D (corresponding author), CNRS, LBCMCP, UMR 5088, 118 Route Narbonne, F-31062 Toulouse, France.	dtrouche@cict.fr	Selves, Janick/M-7719-2014; Gourraud, Pierre-Antoine FD/O-3024-2015; Hoffmann, Jean-Sebastien/O-9183-2014; ESCAFFIT, Fabrice/AAE-4832-2021; Pillaire, Marie-Jeanne/P-1579-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Pillaire, Marie-Jeanne/0000-0001-6866-7416; Trouche, Didier/0000-0003-1398-6481; Gourraud, Pierre-Antoine/0000-0003-1131-9554	ARC; Institut National du Cancer (INCa); Canceropole Grand Sud-Ouest (ACI 2004/2007); French Ministry of Science; 'Fondation de France'	ARC(Australian Research Council); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Grand Sud-Ouest (ACI 2004/2007)(French National Research Agency (ANR)); French Ministry of Science; 'Fondation de France'(Fondation de France)	We thank Professor JF Beaulieu and K Helin for materials, Professor B Ducommun, Dr G Legube and Dr Y Canitrot for critical reading of the paper. We also acknowledge JJ Maoret, responsible person of the QPCR platform at IFR31 (INSERM), as well as S Mazeres (IPBS) and P Grosclaude (INSERM) for their help to format the data concerning tumor analysis. This work was supported by a grant to DT as a 'subvention libre' from the ARC and the Institut National du Cancer (INCa), Canceropole Grand Sud-Ouest (ACI 2004/2007, to CC). LM and ST were supported by studentships from the French Ministry of Science and the ARC, respectively, whereas FE was supported by a fellowship from the 'Fondation de France'.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869-06; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gevry N, 2007, GENE DEV, V21, P1869, DOI 10.1101/gad.1545707; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Lleonart ME, 2006, ONCOL REP, V16, P603; Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200	20	72	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1506	1517		10.1038/onc.2008.499	http://dx.doi.org/10.1038/onc.2008.499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19169279				2022-12-17	WOS:000264537400003
J	Galluzzi, L; Kepp, O; Tajeddine, N; Kroemer, G				Galluzzi, L.; Kepp, O.; Tajeddine, N.; Kroemer, G.			Disruption of the hexokinase - VDAC complex for tumor therapy	ONCOGENE			English	Editorial Material						apoptosis; mitochondria; voltage-dependent anion channel (VDAC)	PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCASE-2; CELL-DEATH; MITOCHONDRIA; CHEMOTHERAPY; APOPTOSIS; PHOSPHORYLATION; BINDING; KINASE; AKT	Unlike mitochondria from most normal tissues, cancer cell mitochondria demonstrate an association between the glycolytic enzyme hexokinase (HK) and the voltage-dependent anion channel (VDAC). This provides a therapeutic opportunity, as the association appears to protect tumor cells from mitochondrial outer membrane permeabilization (MOMP), an event that marks the point of no return in multiple pathways leading to cell death. In this issue of Oncogene, the plant hormone methyl jasmonate (MJ) is shown to disrupt the interaction between human HK and VDAC, causing the inhibition of glycolysis and the induction of MOMP. MJ has already been shown to have selective anticancer activity in preclinical studies, and this finding may stimulate the development of a novel class of small anticancer compounds that inhibit the HK-VDAC interaction.	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Galluzzi, L.; Kepp, O.; Tajeddine, N.; Kroemer, G.] Univ Paris 11, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/AAH-3286-2021; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/GPX-8627-2022; Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/AAG-6432-2019; Galluzzi, Lorenzo/K-2709-2012	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Galluzzi, Lorenzo/0000-0003-2257-8500				Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Alcala S, 2008, ONCOGENE, V27, P44, DOI 10.1038/sj.onc.1210600; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Jang JY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1857; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Le Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Sun L, 2008, MOL CELL BIOL, V28, P1007, DOI 10.1128/MCB.00224-07; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	21	72	76	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4633	4635		10.1038/onc.2008.114	http://dx.doi.org/10.1038/onc.2008.114			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18469866				2022-12-17	WOS:000258236300001
J	Menges, CW; McCance, DJ				Menges, C. W.; McCance, D. J.			Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA(2) receptor	ONCOGENE			English	Article						Raf-MEK1; Ras; PI3; AKT; kinase; EphA(2) receptor	TYROSINE KINASE; PROTEIN-KINASE; CYCLE ARREST; AKT; DIFFERENTIATION; CELLS; P21(CIP1); GROWTH; PROLIFERATION; ANGIOGENESIS	The Raf-mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)-AKT pathways are two downstream effectors of the small GTPase Ras. Although both pathways are positively regulated by Ras, the Raf-MAPK and PI3K-AKT pathways have been shown to control opposing functions within the cell, suggesting a need for cross-talk regulation. The PI3K -AKT pathway can inhibit the Raf-MAPK pathway directly during processes such as muscle differentiation. Here we describe the ability of the Raf-MAPK pathway to negatively regulate the PI3K-AKT pathway during cellular arrest. Constitutive activation of Raf or methyl ethyl ketone 1 (MEK1) leads to inhibition of AKT and cellular arrest. Furthermore, we show that activation of Raf-MEK1 signaling causes negative feedback inhibition of Ras through the ephrin receptor EphA(2). EphA(2)-mediated negative feedback inhibition is required for Raf-induced AKT inhibition and cell cycle arrest, therefore establishing the inhibition of the Ras-PI3K-AKT pathway as a necessary event for the Raf-MEK1-regulated cellular arrest.	[Menges, C. W.; McCance, D. J.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Menges, C. W.] Univ Rochester, Sch Med, Dept Biochem, Rochester, NY USA; [Menges, C. W.] Univ Rochester, Sch Med, Dept Biophys, Rochester, NY USA; [McCance, D. J.] Univ Rochester, Sch Med, Dept Microbiol, Rochester, NY USA; [McCance, D. J.] Univ Rochester, Sch Med, Dept Immunol, Rochester, NY USA; [McCance, D. J.] Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Rochester, NY USA	Queens University Belfast; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	McCance, DJ (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, MBC Bldg, Belfast BT9 7BL, Antrim, North Ireland.	d.mccance@qub.ac.uk			NIAID NIH HHS [R01 AI 30798] Funding Source: Medline; NIDCR NIH HHS [R01 DE015935] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015935] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cheng N, 2002, MOL CANCER RES, V1, P2; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cichowski K, 2003, GENE DEV, V17, P449, DOI 10.1101/gad.1054703; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Holt KH, 1996, MOL CELL BIOL, V16, P577; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Laprise P, 2004, J CELL PHYSIOL, V199, P32, DOI 10.1002/jcp.10432; Lawlor MA, 2001, J CELL SCI, V114, P2903; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	28	72	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2934	2940		10.1038/sj.onc.1210957	http://dx.doi.org/10.1038/sj.onc.1210957			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18059341				2022-12-17	WOS:000255502500015
J	Endo, Y; Sakai, R; Ouchi, M; Onimatsu, H; Hioki, M; Kagawa, S; Uno, F; Watanabe, Y; Urata, Y; Tanaka, N; Fujiwara, T				Endo, Y.; Sakai, R.; Ouchi, M.; Onimatsu, H.; Hioki, M.; Kagawa, S.; Uno, F.; Watanabe, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T.			Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation	ONCOGENE			English	Article						adenovirus; telomerase; dendritic cell; uric acid; danger signal	DENDRITIC CELLS; URIC-ACID; CANCER; PA28	Dendritic cells ( DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell- to- cell interaction and cytokine production. The optimal forms of tumor cell death for priming DCs for the release of danger signals are not fully understood. OBP- 301 ( Telomelysin) is a telomerase-specific replication- competent adenovirus that induces selective E1 expression and exclusively kills human cancer cells. Here, we show that OBP- 301 replication produced the endogenous danger signaling molecule, uric acid, in infected human tumor cells, which in turn stimulated DCs to produce interferon-gamma ( IFN-gamma) and interleukin 12 ( IL- 12). Subsequently, IFN-gamma release upregulated the endogenous expression of the proteasome activator PA28 in tumor cells and resulted in the induction of cytotoxic T- lymphocytes. Our data suggest that virus- mediated oncolysis might be the effective stimulus for immature DCs to induce specific activity against human cancer cells.	[Endo, Y.; Sakai, R.; Hioki, M.; Kagawa, S.; Uno, F.; Fujiwara, T.] Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan; [Endo, Y.; Sakai, R.; Hioki, M.; Kagawa, S.; Uno, F.; Tanaka, N.; Fujiwara, T.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, Div Surg Oncol, Okayama, Japan; [Ouchi, M.; Onimatsu, H.; Watanabe, Y.; Urata, Y.] Oncolys BioPharma Inc, Tokyo, Japan	Okayama University; Okayama University; Oncolys BioPharma	Fujiwara, T (corresponding author), Okayama Univ Hosp, Ctr Gene & Cell Therapy, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				Aliberti J, 2003, J IMMUNOL, V170, P5349, DOI 10.4049/jimmunol.170.11.5349; Bartholomae WC, 2004, J IMMUNOL, V173, P1012, DOI 10.4049/jimmunol.173.2.1012; Glantzounis GK, 2005, CURR PHARM DESIGN, V11, P4145, DOI 10.2174/138161205774913255; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Hu DE, 2004, CANCER RES, V64, P5059, DOI 10.1158/0008-5472.CAN-04-1586; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Lenaerts L, 2006, ANTIVIR RES, V71, P172, DOI 10.1016/j.antiviral.2006.04.007; LINDENMANN J, 1967, J EXP MED, V126, P93, DOI 10.1084/jem.126.1.93; Manjili MH, 2005, IMMUNOBIOLOGY, V210, P295, DOI 10.1016/j.imbio.2005.04.002; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sijts A, 2002, MOL IMMUNOL, V39, P165, DOI 10.1016/S0161-5890(02)00099-8; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Sun Y, 2002, CANCER RES, V62, P2875; Taki M, 2005, ONCOGENE, V24, P3130, DOI 10.1038/sj.onc.1208460; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Watanabe T, 2006, EXP CELL RES, V312, P256, DOI 10.1016/j.yexcr.2005.10.026	16	72	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2375	2381		10.1038/sj.onc.1210884	http://dx.doi.org/10.1038/sj.onc.1210884			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17982491	Green Submitted			2022-12-17	WOS:000254844900002
J	Partridge, L; Bruning, JC				Partridge, L.; Bruening, J. C.			Forkhead transcription factors and ageing	ONCOGENE			English	Review						forkhead transcription factor; FOXO; signaling; ageing; lifespan; ageing-related disease	EXTENDS LIFE-SPAN; NEMATODE CAENORHABDITIS-ELEGANS; ACTIVATED PROTEIN-KINASE; C-ELEGANS; INSULIN-RECEPTOR; OXIDATIVE-STRESS; DIETARY RESTRICTION; CALORIE RESTRICTION; TUMOR SUPPRESSION; FACTOR FOXO1	Mutations in single genes and environmental interventions can extend healthy lifespan in laboratory model organisms. Some of the mechanisms involved show evolutionary conservation, opening the way to using simpler invertebrates to understand human ageing. Forkhead transcription factors have been found to play a key role in lifespan extension by alterations in the insulin/IGF pathway and by dietary restriction. Interventions that extend lifespan have also been found to delay or ameliorate the impact of ageing-related pathology and disease, including cancer. Understanding the mode of action of forkheads in this context will illuminate the mechanisms by which ageing acts as a risk factor for ageing-related disease, and could lead to the development of a broad-spectrum, preventative medicine for the diseases of ageing.	[Partridge, L.] Inst Healthy Aging, London WC1E 6BT, England; [Bruening, J. C.] Univ Cologne, Inst Genet, Dept Mouse Genet & Metab, D-5000 Cologne, Germany	University of London; University College London; University of Cologne	Partridge, L (corresponding author), Inst Healthy Aging, GEE,Darwin Bldg,Gower Street, London WC1E 6BT, England.	l.partridge@ucl.ac.uk	Partridge, Linda/A-5501-2010; Partridge, Linda/E-7342-2015	Partridge, Linda/0000-0001-9615-0094	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alcedo J, 2004, NEURON, V41, P45, DOI 10.1016/S0896-6273(03)00816-X; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Baldauf SL, 1999, AM NAT, V154, pS178, DOI 10.1086/303292; Barnes AI, 2006, P ROY SOC B-BIOL SCI, V273, P939, DOI 10.1098/rspb.2005.3388; Berdichevsky A, 2006, CELL, V125, P1165, DOI 10.1016/j.cell.2006.04.036; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bonkowski MS, 2006, P NATL ACAD SCI USA, V103, P7901, DOI 10.1073/pnas.0600161103; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cargill SL, 2003, AGING CELL, V2, P185, DOI 10.1046/j.1474-9728.2003.00049.x; Carter ME, 2007, CURR BIOL, V17, pR113, DOI 10.1016/j.cub.2007.01.008; Casas-Tinto S, 2007, BBA-GENE STRUCT EXPR, V1769, P236, DOI 10.1016/j.bbaexp.2007.03.003; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Chintapalli VR, 2007, NAT GENET, V39, P715, DOI 10.1038/ng2049; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; DAVIS RJ, 1994, CANCER RES, V54, P2869; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; DORMAN JB, 1995, GENETICS, V141, P1399; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; FRIEDMAN DB, 1988, GENETICS, V118, P75; Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6; Fukuoka M, 2003, INT J MOL MED, V12, P503; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gershman B, 2007, PHYSIOL GENOMICS, V29, P24, DOI 10.1152/physiolgenomics.00061.2006; Giannakou ME, 2007, TRENDS BIOCHEM SCI, V32, P180, DOI 10.1016/j.tibs.2007.02.007; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; GIANNAKOU ME, 2007, DROSOPHILA AGING CEL, V6, P429; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Houthoofd Koen, 2007, V35, P98; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Jin GS, 2004, ACTA MED OKAYAMA, V58, P197; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein TL, 2006, AGING CELL, V5, P487, DOI 10.1111/j.1474-9726.2006.00238.x; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Kuningas M, 2007, EUR J HUM GENET, V15, P294, DOI 10.1038/sj.ejhg.5201766; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lee GD, 2006, AGING CELL, V5, P515, DOI 10.1111/j.1474-9726.2006.00241.x; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Li J, 2007, DEV BIOL, V301, P82, DOI 10.1016/j.ydbio.2006.10.013; Libert S, 2007, SCIENCE, V315, P1133, DOI 10.1126/science.1136610; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu YF, 2002, BIOCHEM J, V366, P633, DOI 10.1042/BJ20020095; Lunetta KL, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S13; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Marr MT, 2007, GENE DEV, V21, P175, DOI 10.1101/gad.1506407; Mazet F, 2003, GENE, V316, P79, DOI 10.1016/S0378-1119(03)00741-8; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; McElwee JJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r132; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Naimi M, 2007, ENDOCRINOLOGY, V148, P2424, DOI 10.1210/en.2006-1411; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Pan KZ, 2007, AGING CELL, V6, P111, DOI 10.1111/j.1474-9726.2006.00266.x; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Partridge L, 2007, NATURE, V450, P165, DOI 10.1038/450165a; Patel NV, 2005, NEUROBIOL AGING, V26, P995, DOI 10.1016/j.neurobiolaging.2004.09.014; Peng SL, 2007, AUTOIMMUNITY, V40, P462, DOI 10.1080/08916930701464913; Perrot V, 2005, MOL ENDOCRINOL, V19, P2283, DOI 10.1210/me.2004-0292; Pinkston-Gosse J, 2007, NAT GENET, V39, P1403, DOI 10.1038/ng.2007.1; PIPER MDW, IN PRESS J INTERNAL; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Puig O, 2006, CELL CYCLE, V5, P503, DOI 10.4161/cc.5.5.2501; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qin WP, 2006, J BIOL CHEM, V281, P21745, DOI 10.1074/jbc.M602909200; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; SELMAN C, 2007, FASEB J; Sloop KW, 2004, J CLIN INVEST, V113, P1571, DOI 10.1172/JCI200420911; Spindler SR, 2007, ANNU REV NUTR, V27, P193, DOI 10.1146/annurev.nutr.27.061406.093743; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Syntichaki P, 2007, NATURE, V445, P922, DOI 10.1038/nature05603; Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179; TANNENBAUM A, 1949, CANCER RES, V9, P724; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tuteja G, 2007, CELL, V130, DOI 10.1016/j.cell.2007.09.005; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Vatamaniuk MZ, 2006, DIABETES, V55, P2730, DOI 10.2337/db05-0470; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; Wang MC, 2003, DEV CELL, V5, P811, DOI 10.1016/S1534-5807(03)00323-X; Wang Y, 2006, MECH AGEING DEV, V127, P741, DOI 10.1016/j.mad.2006.05.005; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; Wessells RJ, 2004, NAT GENET, V36, P1275, DOI 10.1038/ng1476; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI200318698; Wolkow Catherine A., 2000, Science (Washington D C), V290, P147, DOI 10.1126/science.290.5489.147; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zahn JM, 2007, CURR OPIN BIOTECH, V18, P355, DOI 10.1016/j.copbio.2007.07.004	135	72	74	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2351	2363		10.1038/onc.2008.28	http://dx.doi.org/10.1038/onc.2008.28			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391977				2022-12-17	WOS:000254782700010
J	Weiss, C; Faust, D; Schreck, I; Ruff, A; Farwerck, T; Melenberg, A; Schneider, S; Oesch-Bartlomowicz, B; Zatloukalova, J; Vondracek, J; Oesch, F; Dietrich, C				Weiss, C.; Faust, D.; Schreck, I.; Ruff, A.; Farwerck, T.; Melenberg, A.; Schneider, S.; Oesch-Bartlomowicz, B.; Zatloukalova, J.; Vondracek, J.; Oesch, F.; Dietrich, C.			TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A	ONCOGENE			English	Article						aryl hydrocarbon receptor; contact inhibition; cell cycle control; JunD; cyclin A; liver oval cells	ARYL-HYDROCARBON RECEPTOR; C-JUN; EPITHELIAL-CELLS; DIOXIN RECEPTOR; TUMOR PROMOTION; GROWTH ARREST; PROLIFERATION; EXPRESSION; HEPATOCYTES; APOPTOSIS	The aryl hydrocarbon receptor (AhR) is a transcription factor involved in physiological processes, but also mediates most, if not all, toxic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Activation of the AhR by TCDD leads to its dimerization with aryl hydrocarbon nuclear translocator (ARNT) and transcriptional activation of several phase I and II metabolizing enzymes. However, this classical signalling pathway so far failed to explain the pleiotropic hazardous effects of TCDD, such as developmental toxicity and tumour promotion. Thus, there is an urgent need to de. ne genetic programmes orchestrated by AhR to unravel its role in physiology and toxicology. Here we show that TCDD treatment of rat liver oval cells leads to induction of the transcription factor JunD, resulting in transcriptional upregulation of the proto-oncogene cyclin A which finally triggers a release from contact inhibition. Ectopic expression of cyclin A in confluent cultures overcomes G(1) arrest, indicating that increased cyclin A levels are indeed sufficient to bypass contact inhibition. Functional interference with AhR-, but not with ARNT, abolished TCDD-induced increase in JunD and cyclin A and prevented loss of contact inhibition. In summary, we have discovered a novel AhR- dependent and probably ARNT-independent signalling pathway involving JunD and cyclin A, which mediates TCDD-induced deregulation of cell cycle control.	[Schreck, I.; Schneider, S.] Res Ctr Karlsruhe, Inst Genet & Toxicol, D-76344 Eggenstein Leopoldshafen, Germany; [Weiss, C.; Faust, D.; Ruff, A.; Farwerck, T.; Melenberg, A.; Oesch-Bartlomowicz, B.; Oesch, F.; Dietrich, C.] Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; [Zatloukalova, J.; Vondracek, J.] Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic	Helmholtz Association; Karlsruhe Institute of Technology; Johannes Gutenberg University of Mainz; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Dietrich, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.	carsten.weiss@itg.fzk.de; cdietric@uni-mainz.de	Vondracek, Jan/J-3037-2012; Weiss, Carsten/I-1811-2013; Prochazkova, Jirina/D-4403-2015; Oesch, Franz/AAA-8746-2020	Vondracek, Jan/0000-0003-4071-1969; Weiss, Carsten/0000-0002-5380-3208; Prochazkova, Jirina/0000-0003-2738-8546; 				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V69, P1; Bock KW, 2005, BIOCHEM PHARMACOL, V69, P1403, DOI 10.1016/j.bcp.2005.02.004; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chramostova K, 2004, TOXICOL APPL PHARM, V196, P136, DOI 10.1016/j.taap.2003.12.008; Coleman WB, 1997, AM J PATHOL, V151, P353; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Dietrich C, 2003, INT J CANCER, V103, P435, DOI 10.1002/ijc.10830; Dietrich C, 2002, TOXICOL APPL PHARM, V183, P117, DOI 10.1006/taap.2002.9475; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Dumble ML, 2002, CARCINOGENESIS, V23, P435, DOI 10.1093/carcin/23.3.435; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Faust D, 2005, ONCOGENE, V24, P7941, DOI 10.1038/sj.onc.1208948; FOX TR, 1993, CANCER RES, V53, P2265; Hailey JR, 2005, TOXICOL PATHOL, V33, P165, DOI 10.1080/01926230590888324; HEBERT CD, 1990, CARCINOGENESIS, V11, P1335, DOI 10.1093/carcin/11.8.1335; Heit I, 2001, ONCOGENE, V20, P5143, DOI 10.1038/sj.onc.1204657; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; Hushka DR, 1995, MUTAT RES-FUND MOL M, V333, P89, DOI 10.1016/0027-5107(95)00135-2; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Libbrecht L, 2000, J HEPATOL, V33, P76, DOI 10.1016/S0168-8278(00)80162-2; Ma Q, 1996, MOL CELL BIOL, V16, P8878; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; Munzel P, 1996, CARCINOGENESIS, V17, P197, DOI 10.1093/carcin/17.2.197; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; PITOT HC, 1980, CANCER RES, V40, P3616; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Shafritz DA, 2002, J HEPATOL, V36, P552, DOI 10.1016/S0168-8278(02)00013-2; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; STEINBERG P, 1994, LAB INVEST, V71, P700; STINCHCOMBE S, 1995, CARCINOGENESIS, V16, P1271, DOI 10.1093/carcin/16.6.1271; TSAO MS, 1987, AM J PATHOL, V127, P168; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; Tuomisto J., 2005, TOXICOL APPL PHARM, V207, pS2; Vondracek J, 2005, TOXICOL SCI, V83, P53, DOI 10.1093/toxsci/kfi009; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; Worner W, 1996, CANCER RES, V56, P1272	50	72	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2198	2207		10.1038/sj.onc.1210859	http://dx.doi.org/10.1038/sj.onc.1210859			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952121				2022-12-17	WOS:000254621300010
J	Safina, A; Ren, MQ; Vandette, E; Bakin, AV				Safina, A.; Ren, M-Q; Vandette, E.; Bakin, A. V.			TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis	ONCOGENE			English	Article						angiogenesis; invasion; metastasis; MMP-9; TAK1; TGF-beta	GROWTH-FACTOR-BETA; NF-KAPPA-B; BREAST-CANCER CELLS; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR SMAD4; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITION; TRANSIENT ACTIVATION; SIGNAL-TRANSDUCTION	Transforming growth factor-beta 1 (TGF-beta 1) signaling in tumor cells has been implicated in tumor angiogenesis and metastasis by regulating matrix proteolysis. Although MMP-9/gelatinase-B is an important component of these TGF-b1 responses, the mechanism of its regulation is not well understood. Here, we present evidence that TGF-beta-activated protein kinase 1 (TAK1) is critical for TGF-beta regulation of MMP-9 and the metastatic potential of breast cancer cell line MDA-MB-231. We found that suppression of TAK1 signaling by dominant-negative (dn) TAK1 or RNA interference (siRNA) reduces expression of MMP-9 and tumor cell invasion, without growth inhibition in cell culture. The orthotopic xenograft studies in SCID mice showed that suppression of TAK1 signaling by Dn-TAK1 reduces tumor growth and formation of lung metastases. QJ; Dn-TAK1 reduced the proliferation Ki-67 index and neovasculature of orthotopic xenografts. TAK1-mediated regulation of MMP-9 involves NF-kappa B signaling. Dn-TAK1 reduces NF-kappa B transcriptional response and inhibition of NF-kappa B reduces expression of MMP-9 and activity of the MMP-9 promoter reporter. Together, these findings suggest that TAK1 contributes to TGF-beta 1-mediated tumor angiogenesis and metastasis via a mechanism involving the TAK1-NF-kappa B-MMP-9 pathway.	[Safina, A.; Ren, M-Q; Vandette, E.; Bakin, A. V.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	andrei.bakin@roswellpark.org		Bakin, Andrei/0000-0002-7728-1969	NCI NIH HHS [R01 CA095263, CA 16056, R01 CA95263, P30 CA016056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA095263] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Azuma M, 1999, EXP CELL RES, V250, P213, DOI 10.1006/excr.1999.4503; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 2002, J CELL SCI, V115, P3193; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bitzer M, 2000, GENE DEV, V14, P187; Chantrain CF, 2004, CANCER RES, V64, P1675, DOI 10.1158/0008-5472.CAN-03-0160; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dunker N, 2000, EUR J BIOCHEM, V267, P6982, DOI 10.1046/j.1432-1327.2000.01825.x; Farina AR, 1998, INT J CANCER, V75, P721; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Johansson N, 2000, J CELL SCI, V113, P227; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ogata H, 2001, CANCER LETT, V172, P159, DOI 10.1016/S0304-3835(01)00648-6; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Safina A, 2007, ONCOGENE, V26, P2407, DOI 10.1038/sj.onc.1210046; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SATO H, 1993, ONCOGENE, V8, P395; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Tobe M, 2003, BIOORGAN MED CHEM, V11, P3869, DOI 10.1016/S0968-0896(03)00438-3; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Wang WS, 2005, J AM SOC NEPHROL, V16, P1371, DOI 10.1681/ASN.2004121070; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	50	72	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1198	1207		10.1038/sj.onc.1210768	http://dx.doi.org/10.1038/sj.onc.1210768			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17828308				2022-12-17	WOS:000253407000002
J	Rayter, S; Elliott, R; Travers, J; Rowlands, MG; Richardson, TB; Boxall, K; Jones, K; Linardopoulos, S; Workman, P; Aherne, W; Lord, CJ; Ashworth, A				Rayter, S.; Elliott, R.; Travers, J.; Rowlands, M. G.; Richardson, T. B.; Boxall, K.; Jones, K.; Linardopoulos, S.; Workman, P.; Aherne, W.; Lord, C. J.; Ashworth, A.			A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D	ONCOGENE			English	Article						PPM1D; chemical inhibitor; breast cancer	PHOSPHATASE PPM1D; CHK2 KINASE; WIP1; CANCER; IDENTIFICATION; AMPLIFICATION; EXPRESSION; VALIDATION; MECHANISM; TARGET	The PPM1D gene is aberrantly amplified in a range of common cancers and encodes a protein phosphatase that is a potential therapeutic target. However, the issue of whether inhibition of PPM1D in human tumour cells that overexpress this protein compromises their viability has not yet been fully addressed. We show here, using an RNA interference ( RNAi) approach, that inhibition of PPM1D can indeed reduce the viability of human tumour cells and that this effect is selective; tumour cell lines that overexpress PPM1D are sensitive to PPM1D inhibition whereas cell lines with normal levels are not. Loss of viability associated with PPM1D RNAi in human tumour cells occurs via the activation of the kinase P38. To identify chemical inhibitors of PPM1D, a high-throughput screening of a library of small molecules was performed. This strategy successfully identified a compound that selectively reduces viability of human tumour cell lines that overexpress PPM1D. As expected of a specific inhibitor, the toxicity to PPM1D overexpressing cell lines after inhibitor treatment is P38 dependent. These results further validate PPM1D as a therapeutic target and identify a proof-of-principle small molecule inhibitor.	[Rayter, S.; Elliott, R.; Richardson, T. B.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Travers, J.; Rowlands, M. G.; Boxall, K.; Jones, K.; Linardopoulos, S.; Workman, P.; Aherne, W.] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	Alan.Ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021; Jones, Keith/R-7629-2016	Lord, Christopher J/0000-0002-3226-0515; Jones, Keith/0000-0002-9440-4094; Linardopoulos, Spiros/0000-0002-6600-400X	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		ARCHER S, 1982, J MED CHEM, V25, P220, DOI 10.1021/jm00345a006; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Brody LC, 2005, NEW ENGL J MED, V353, P949, DOI 10.1056/NEJMcibr052331; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Burns S, 2006, J BIOMOL SCREEN, V11, P822, DOI 10.1177/1087057106290992; Chen LW, 2006, CRIT CARE MED, V34, P142, DOI 10.1097/01.CCM.0000190621.48720.8C; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Collins I, 2006, NAT CHEM BIOL, V2, P689, DOI 10.1038/nchembio840; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fitzgerald CE, 2003, NAT STRUCT BIOL, V10, P764, DOI 10.1038/nsb949; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Proia DA, 2006, J BIOL CHEM, V281, P7089, DOI 10.1074/jbc.M511839200; Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896; Saito-Ohara F, 2003, CANCER RES, V63, P1876; SCANLON W, 1973, Patent No. 2245518; Schmid AC, 2004, BIOCHEM SOC T, V32, P348, DOI 10.1042/BST0320348; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; von Leoprechting A, 2004, J BIOMOL SCREEN, V9, P719, DOI 10.1177/1087057104268805; Warner G, 2004, CURR MED CHEM, V11, P721, DOI 10.2174/0929867043455693; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200; Yu E, 2007, BREAST CANCER RES TR, V101, P269, DOI 10.1007/s10549-006-9304-y; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	39	72	72	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1036	1044		10.1038/sj.onc.1210729	http://dx.doi.org/10.1038/sj.onc.1210729			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700519				2022-12-17	WOS:000253136700002
J	Kim, SI; Bresnick, EH				Kim, S-I; Bresnick, E. H.			Transcriptional control of erythropoiesis: emerging mechanisms and principles	ONCOGENE			English	Review						erythropoiesis; chromatin; transcription; epigenetic mark	LOCUS-CONTROL REGION; BETA-GLOBIN GENE; CREB-BINDING-PROTEIN; KRUPPEL-LIKE FACTOR; RNA-POLYMERASE-II; CHROMATIN-REMODELING COMPLEX; HISTONE ACETYLTRANSFERASE COMPLEXES; GATA FACTOR INTERPLAY; DNA-BINDING; FACTOR NF-E2	Transcriptional networks orchestrate fundamental biological processes, including hematopoiesis, in which hematopoietic stem cells progressively differentiate into specific progenitors cells, which in turn give rise to the diverse blood cell types. Whereas transcription factors recruit coregulators to chromatin, leading to targeted chromatin modification and recruitment of the transcriptional machinery, many questions remain unanswered regarding the underlying molecular mechanisms. Furthermore, how diverse cell type- specific transcription factors function cooperatively or antagonistically in distinct cellular contexts is poorly understood, especially since genes in higher eukaryotes commonly encompass broad chromosomal regions ( 100 kb and more) and are littered with dispersed regulatory sequences. In this article, we describe an important set of transcription factors and coregulators that control erythropoiesis and highlight emerging transcriptional mechanisms and principles. It is not our intent to comprehensively survey all factors implicated in the transcriptional control of erythropoiesis, but rather to underscore specific mechanisms, which have potential to be broadly relevant to transcriptional control in diverse systems.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Med Sci Ctr 385, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Med Sci Ctr 385, 1300 Univ Ave, Madison, WI 53706 USA.	ehbresni@wisc.edu		Kim, Shin-Il/0000-0002-1742-3718; Kim, Shin-Il/0000-0002-7350-0087	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK068634, R01DK068634, R01DK050107, R01DK055700] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK68634, DK50107, DK55700] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Anderson KP, 2000, BLOOD, V95, P1652, DOI 10.1182/blood.V95.5.1652.005k23_1652_1655; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bank A, 2006, BLOOD, V107, P435, DOI 10.1182/blood-2005-05-2113; Bean TL, 1997, NUCLEIC ACIDS RES, V25, P2509, DOI 10.1093/nar/25.12.2509; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; Belakavadi M, 2006, REV PHYSIOL BIOCH P, V156, P23, DOI 10.1007/s10254-005-0002-7; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Bourquin JP, 2006, P NATL ACAD SCI USA, V103, P3339, DOI 10.1073/pnas.0511150103; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; Bresnick EH, 2005, J CELL PHYSIOL, V205, P1, DOI 10.1002/jcp.20393; Bresnick EH, 2006, PROG NUCLEIC ACID RE, V81, P435, DOI 10.1016/S0079-6603(06)81011-1; Brown RC, 2002, MOL CELL BIOL, V22, P161, DOI 10.1128/MCB.22.1.161-170.2002; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2005, GENE DEV, V19, P2849, DOI 10.1101/gad.1364105; Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Casteel D, 1998, BLOOD, V91, P3193, DOI 10.1182/blood.V91.9.3193.3193_3193_3201; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan WYI, 2007, BLOOD, V109, P1908, DOI 10.1182/blood-2006-05-023226; CHANG TC, 2007, ANN REV GENOMICS HUM; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; Chen XY, 2004, MOL CELL BIOL, V24, P10416, DOI 10.1128/MCB.24.23.10416-10424.2004; Chen XY, 2001, MOL CELL BIOL, V21, P3118, DOI 10.1128/MCB.21.9.3118-3125.2001; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Chung YS, 2002, DEVELOPMENT, V129, P5511, DOI 10.1242/dev.00149; Coghill E, 2001, BLOOD, V97, P1861, DOI 10.1182/blood.V97.6.1861; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; Crispino JD, 2005, SEMIN CELL DEV BIOL, V16, P137, DOI 10.1016/j.semcdb.2004.11.002; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; Daftari P, 1999, ONCOGENE, V18, P5482, DOI 10.1038/sj.onc.1202916; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Dean A, 2006, TRENDS GENET, V22, P38, DOI 10.1016/j.tig.2005.11.001; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; Drissen R, 2005, MOL CELL BIOL, V25, P5205, DOI 10.1128/MCB.25.12.5205-5214.2005; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; Ema M, 2003, GENE DEV, V17, P380, DOI 10.1101/gad.1049803; Emery DW, 2000, P NATL ACAD SCI USA, V97, P9150, DOI 10.1073/pnas.160159597; Emery DW, 2002, BLOOD, V100, P2012, DOI 10.1182/blood-2002-01-0219; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Forsberg EC, 1999, J BIOL CHEM, V274, P26850, DOI 10.1074/jbc.274.38.26850; Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339; Forsberg EC, 1999, MOL CELL BIOL, V19, P5565; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Fujiwara Y, 2004, BLOOD, V103, P583, DOI 10.1182/blood-2003-08-2870; Garriga-Canut M, 2004, J BIOL CHEM, V279, P23597, DOI 10.1074/jbc.M313987200; Gering M, 2003, DEVELOPMENT, V130, P6187, DOI 10.1242/dev.00875; Gillemans N, 1998, GENE DEV, V12, P2863, DOI 10.1101/gad.12.18.2863; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Grass JA, 2006, MOL CELL BIOL, V26, P7056, DOI 10.1128/MCB.01033-06; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Grewal SIS, 2007, NATURE, V447, P399, DOI 10.1038/nature05914; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hodge D, 2006, BLOOD, V107, P3359, DOI 10.1182/blood-2005-07-2888; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; HROMAS R, 1993, BLOOD, V82, P2998; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Huebert DJ, 2006, METHODS, V40, P365, DOI 10.1016/j.ymeth.2006.07.032; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Hung HL, 2001, J BIOL CHEM, V276, P10715, DOI 10.1074/jbc.M007846200; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Im Hogune, 2004, Methods Mol Biol, V284, P129; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Johnson KD, 2003, MOL CELL BIOL, V23, P6484, DOI 10.1128/MCB.23.18.6484-6493.2003; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Johnson KD, 2007, BLOOD, V109, P5230, DOI 10.1182/blood-2007-02-072983; Johnson KD, 2006, P NATL ACAD SCI USA, V103, P15939, DOI 10.1073/pnas.0604041103; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Katz SG, 2002, MOL CELL BIOL, V22, P3121, DOI 10.1128/MCB.22.9.3121-3128.2002; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; Khandekar M, 2007, DEVELOPMENT, V134, P1703, DOI 10.1242/dev.001297; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kiekhaefer CM, 2004, J BIOL CHEM, V279, P7456, DOI 10.1074/jbc.M309750200; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kim SI, 2007, MOL CELL BIOL, V27, P4551, DOI 10.1128/MCB.00235-07; Kirmizis A, 2004, EXP BIOL MED, V229, P705, DOI 10.1177/153537020422900803; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kong SM, 1997, MOL CELL BIOL, V17, P3955, DOI 10.1128/MCB.17.7.3955; Kooren J, 2007, J BIOL CHEM, V282, P16544, DOI 10.1074/jbc.M701159200; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kung AL, 2000, GENE DEV, V14, P272; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Letting DL, 2004, P NATL ACAD SCI USA, V101, P476, DOI 10.1073/pnas.0306315101; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Levings PP, 2006, FEBS J, V273, P746, DOI 10.1111/j.1742-4658.2005.05107.x; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Liew CW, 2006, J BIOL CHEM, V281, P28296, DOI 10.1074/jbc.M602830200; Liew CK, 2005, P NATL ACAD SCI USA, V102, P583, DOI 10.1073/pnas.0407511102; Lin AC, 2004, J BIOL CHEM, V279, P55017, DOI 10.1074/jbc.M411240200; Ling JH, 2004, J BIOL CHEM, V279, P51704, DOI 10.1074/jbc.M404039200; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lopez RA, 2002, P NATL ACAD SCI USA, V99, P602, DOI 10.1073/pnas.022412699; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Lugus JJ, 2007, DEVELOPMENT, V134, P393, DOI 10.1242/dev.02731; Mahajan MC, 2005, P NATL ACAD SCI USA, V102, P15012, DOI 10.1073/pnas.0507596102; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; Martin J, 1990, ORGAN SCI, V1, P339, DOI 10.1287/orsc.1.4.339; Martowicz ML, 2005, J BIOL CHEM, V280, P1724, DOI 10.1074/jbc.M406038200; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meier N, 2006, DEVELOPMENT, V133, P4913, DOI 10.1242/dev.02656; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; Mikkola HKA, 2006, DEVELOPMENT, V133, P3733, DOI 10.1242/dev.02568; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Minegishi N, 1999, BLOOD, V93, P4196, DOI 10.1182/blood.V93.12.4196.412k23_4196_4207; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOON AM, 1991, BLOOD, V77, P2272; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Munugalavadla V, 2005, MOL CELL BIOL, V25, P6747, DOI 10.1128/MCB.25.15.6747-6759.2005; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Nilson DG, 2006, EXP HEMATOL, V34, P705, DOI 10.1016/j.exphem.2006.02.018; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; O'Neill D, 1999, P NATL ACAD SCI USA, V96, P349, DOI 10.1073/pnas.96.2.349; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Oike Y, 1999, BLOOD, V93, P2771; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pal S, 2004, J BIOL CHEM, V279, P31348, DOI 10.1074/jbc.M403475200; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; Pal S, 2006, J CELL BIOL, V174, P1047, DOI 10.1083/jcb.200603152; Patterson LJ, 2007, BLOOD, V109, P2389, DOI 10.1182/blood-2006-02-003087; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Pilon AM, 2006, MOL CELL BIOL, V26, P4368, DOI 10.1128/MCB.02216-05; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; Puthenveetil G, 2004, BLOOD, V104, P3445, DOI 10.1182/blood-2004-04-1427; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rooke HM, 2006, BLOOD, V107, P3527, DOI 10.1182/blood-2005-10-4309; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shyu YC, 2005, MOL CELL BIOL, V25, P10365, DOI 10.1128/MCB.25.23.10365-10378.2005; Simon E., 1892, Histoire naturelle des araignees, V1, P1; Stopka T, 2005, EMBO J, V24, P3712, DOI 10.1038/sj.emboj.7600834; Stumpf M, 2006, P NATL ACAD SCI USA, V103, P18504, DOI 10.1073/pnas.0604494103; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Szutorisz H, 2005, TRENDS BIOCHEM SCI, V30, P593, DOI 10.1016/j.tibs.2005.08.006; Szutorisz H, 2005, MOL CELL BIOL, V25, P1804, DOI 10.1128/MCB.25.5.1804-1820.2005; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Tewari R, 1998, EMBO J, V17, P2334, DOI 10.1093/emboj/17.8.2334; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Travers A, 1999, P NATL ACAD SCI USA, V96, P13634, DOI 10.1073/pnas.96.24.13634; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Uhlmann T, 2007, J BIOL CHEM, V282, P2163, DOI 10.1074/jbc.M608451200; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Versaw WK, 1998, P NATL ACAD SCI USA, V95, P8756, DOI 10.1073/pnas.95.15.8756; Vieira KF, 2004, J BIOL CHEM, V279, P50350, DOI 10.1074/jbc.M408883200; Vyas P, 1999, DEVELOPMENT, V126, P2799; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Welch JJ, 2004, BLOOD, V104, P3136, DOI 10.1182/blood-2004-04-1603; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; Wozniak RJ, 2007, J BIOL CHEM, V282, P14665, DOI 10.1074/jbc.M700792200; XU Z, 2003, J DISTANCE ED TECHNO, V1, P1; Xu ZX, 2007, GENE DEV, V21, P942, DOI 10.1101/gad.1528507; Xu ZX, 2006, BIOCHEM J, V399, P297, DOI 10.1042/BJ20060873; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhao W, 2006, BLOOD, V107, P907, DOI 10.1182/blood-2005-06-2516; Zhou DW, 2006, J BIOL CHEM, V281, P16052, DOI 10.1074/jbc.M601182200; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200	270	72	75	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6777	6794		10.1038/sj.onc.1210761	http://dx.doi.org/10.1038/sj.onc.1210761			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934485				2022-12-17	WOS:000250147000009
J	Leonard, JP; Goldenberg, DM				Leonard, J. P.; Goldenberg, D. M.			Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies	ONCOGENE			English	Review						non-Hodgkin's lymphoma; B-cell; CD20; CD22; efficacy; epratuzumab	NON-HODGKINS-LYMPHOMA; LL2 MONOCLONAL-ANTIBODY; Y-90 IBRITUMOMAB TIUXETAN; IODINE I-131 TOSITUMOMAB; MULTICENTER PHASE-II; LOW-GRADE; FOLLICULAR LYMPHOMA; IMMUNOGLOBULIN SUPERFAMILY; RADIOLABELED ANTIBODIES; HISTORICAL-PERSPECTIVE	The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treatment of these malignancies. It is clear that antibodies targeting other B-cell-specific molecules, such as CD22, also offer potential therapeutic benefit. Epratuzumab is a humanized anti-CD22 monoclonal, which has undergone preclinical and phase I/II clinical evaluation in patients with indolent or aggressive lymphoma. Data suggest that this agent is well tolerated, and can induce tumor regressions. Trials are currently evaluating its safety and activity in combination with rituximab (chimeric anti-CD20) and standard chemotherapy are ongoing. Initial results suggest that these regimens have acceptable toxicity, and that epratuzumab warrants further evaluation as an adjunct to standard lymphoma treatment regimens.	Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Dept Med, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY 10021 USA; Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ USA; Immunomedics Inc, Morris Plains, NJ USA	Cornell University; NewYork-Presbyterian Hospital; Immunomedics Inc	Leonard, JP (corresponding author), Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Dept Med, Starr Bldg,Room 340,520 E 70th St, New York, NY 10021 USA.	jpleonar@med.cornell.edu	Leonard, John/M-4379-2014	Leonard, John/0000-0002-5083-1115				Ansell SM, 2002, J CLIN ONCOL, V20, P3885, DOI 10.1200/JCO.2002.10.143; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BAUM RP, 1994, CANCER, V73, P896, DOI 10.1002/1097-0142(19940201)73:3+<896::AID-CNCR2820731322>3.0.CO;2-H; BECKER WS, 1995, CANCER RES, V55, pS5771; Behr TM, 1999, CLIN CANCER RES, V5, p3304S; BEHR TM, 2002, TUMOR TARGET, V3, P32; BLEND MJ, 1995, CANCER RES, V55, pS5764; BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; Carnahan J, 2003, CLIN CANCER RES, V9, p3982S; Carnahan J, 2007, MOL IMMUNOL, V44, P1331, DOI 10.1016/j.molimm.2006.05.007; Cesano A, 2002, BLOOD, V100, p350A; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; CHATAL JF, 2005, P SOC NUCL MED, pP155; Cheson BD, 2005, BIODRUGS, V19, P309, DOI 10.2165/00063030-200519050-00004; Cheson BD, 2003, BLOOD, V101, P391, DOI 10.1182/blood-2002-06-1793; Chow KU, 2002, HAEMATOLOGICA, V87, P33; Coffey J, 2003, EUR J NUCL MED MOL I, V30, pS28, DOI 10.1007/s00259-003-1157-6; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 1998, BLOOD, V92, P1927; Czuczman MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Dorner T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1942; DORKEN B, 1986, J IMMUNOL, V136, P4470; Dosik AD, 2006, CANCER-AM CANCER SOC, V106, P616, DOI 10.1002/cncr.21606; EMMANOUILIDES C, 2004, P AN M AM SOC CLIN, V23, P6580; ENGEL P, 1993, J IMMUNOL, V150, P4719; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; Fisher Richard I, 2004, Hematology Am Soc Hematol Educ Program, P221; Friedberg Jonathan W, 2004, Expert Rev Anticancer Ther, V4, P18, DOI 10.1586/14737140.4.1.18; FURMAN RR, 2006, CANC TREAT RES, V131, P141; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; GASPARINI M, 1995, TUMORI, V81, P173, DOI 10.1177/030089169508100304; Ghielmini M, 2004, BLOOD, V103, P4416, DOI 10.1182/blood-2003-10-3411; Golay J, 2000, BLOOD, V95, P3900; Goldenberg DM, 2003, CANCER IMMUNOL IMMUN, V52, P281, DOI 10.1007/s00262-002-0348-5; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; Goldenberg DM, 2001, CRIT REV ONCOL HEMAT, V39, P195; Gordon LI, 2004, CLIN LYMPHOMA, V5, P98, DOI 10.3816/CLM.2004.n.015; GREINER TC, 1995, CANCER-AM CANCER SOC, V75, P370, DOI 10.1002/1097-0142(19950101)75:1+<370::AID-CNCR2820751319>3.0.CO;2-Q; Griffiths GL, 2003, J NUCL MED, V44, P77; Grillo-Lopez AJ, 2000, SEMIN ONCOL, V27, P9, DOI 10.1053/sonc.2000.20444; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Harjunpaa A, 2000, SCAND J IMMUNOL, V51, P634; Hiddemann W, 2005, J CLIN ONCOL, V23, P6394, DOI 10.1200/JCO.2005.07.019; Jazirehi AR, 2005, CANCER RES, V65, P264; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Johnson P, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50025; JUWEID M, 1995, CANCER RES, V55, pS5899; Juweid ME, 1999, CLIN CANCER RES, V5, p3292S; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; KAMINSKI MS, 1992, J CLIN ONCOL, V10, P1696, DOI 10.1200/JCO.1992.10.11.1696; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KREITMAN RJ, 1993, CANCER RES, V53, P819; Lamonica D, 2002, CANCER BIOTHER RADIO, V17, P689, DOI 10.1089/108497802320970307; LAW CL, 1993, J IMMUNOL, V151, P175; Leonard John P, 2005, Hematology Am Soc Hematol Educ Program, P335; Leonard JP, 2005, J CLIN ONCOL, V23, P5044, DOI 10.1200/JCO.2005.13.821; Leonard JP, 2003, J CLIN ONCOL, V21, P3051, DOI 10.1200/JCO.2003.01.082; Leonard JP, 2004, CLIN CANCER RES, V10, P5327, DOI 10.1158/1078-0432.CCR-04-0294; Leung SO, 1995, MOL IMMUNOL, V32, P1413, DOI 10.1016/0161-5890(95)00080-1; Linden O, 2002, ACTA ONCOL, V41, P297, DOI 10.1080/02841860260088854; Linden O, 1999, CLIN CANCER RES, V5, p3287S; Linden O, 2005, CLIN CANCER RES, V11, P5215, DOI 10.1158/1078-0432.CCR-05-0172; Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30156; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Micallef INM, 2006, CANCER-AM CANCER SOC, V107, P2826, DOI 10.1002/cncr.22342; Morschhauser F, 2005, BLOOD, V106, p683A; Morschhauser F, 2004, BLOOD, V104, p41A; MURTHY S, 1992, EUR J NUCL MED, V19, P394; Newton DL, 2001, CRIT REV ONCOL HEMAT, V39, P79, DOI 10.1016/S1040-8428(01)00116-0; Newton DL, 2001, BLOOD, V97, P528, DOI 10.1182/blood.V97.2.528; Nitschke L, 2005, CURR OPIN IMMUNOL, V17, P290, DOI 10.1016/j.coi.2005.03.005; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PAWLAKBYCZKOWSKA EJ, 1989, CANCER RES, V49, P4568; Postema EJ, 2003, CLIN CANCER RES, V9, p3995S; Press OW, 2003, SEMIN ONCOL, V30, P10, DOI 10.1053/sonc.2003.23798; PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Sharkey RM, 2005, J NUCL MED, V46, p115S; Sharkey RM, 2003, J NUCL MED, V44, P2000; Sharkey Robert M, 2005, Expert Rev Clin Immunol, V1, P47, DOI 10.1586/1744666X.1.1.47; SHIH LB, 1994, INT J CANCER, V56, P538, DOI 10.1002/ijc.2910560413; SIEGEL JA, 1991, ANTIBODY IMMUNOCONJ, V4, P649; Silverman DH, 2004, CANCER TREAT REV, V30, P165, DOI 10.1016/j.ctrv.2003.07.006; Skarin AT, 1997, CA-CANCER J CLIN, V47, P351, DOI 10.3322/canjclin.47.6.351; Skvortsova I, 2005, J RADIAT RES, V46, P241, DOI 10.1269/jrr.46.241; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Stein R, 2004, CLIN CANCER RES, V10, P2868, DOI 10.1158/1078-0432.CCR-03-0493; STEIN R, 1993, CANCER IMMUNOL IMMUN, V37, P293, DOI 10.1007/BF01518451; STEIN R, 1994, DRUGS FUTURE, V18, P997; Steinfeld SD, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2018; Steinfeld SD, 2006, EXPERT OPIN BIOL TH, V6, P943, DOI 10.1517/14712598.6.9.943; Strauss SJ, 2006, J CLIN ONCOL, V24, P3880, DOI 10.1200/JCO.2006.05.6291; Tedder TF, 2005, ADV IMMUNOL, V88, P1, DOI 10.1016/S0065-2776(05)88001-0; Teeling JL, 2004, BLOOD, V104, P1793, DOI 10.1182/blood-2004-01-0039; Theuer Charles P, 2004, Biotechnol Annu Rev, V10, P265; Tuscano JM, 1999, BLOOD, V94, P1382, DOI 10.1182/blood.V94.4.1382.416k14_1382_1392; Vose JM, 2004, ONCOLOGIST, V9, P160, DOI 10.1634/theoncologist.9-2-160; Vose JM, 2000, LEUKEMIA LYMPHOMA, V38, P91, DOI 10.3109/10428190009060322; Wagner HN, 2002, J NUCL MED, V43, P267; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WILSON GL, 1993, J IMMUNOL, V150, P5013; Winter Jane N, 2004, Hematology Am Soc Hematol Educ Program, P203; Witzig TE, 2004, DRUGS TODAY, V40, P111, DOI 10.1358/dot.2004.40.2.799423; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zelenetz AD, 2002, BLOOD, V100, p357A; Zinzani PL, 2005, SEMIN ONCOL, V32, pS4, DOI 10.1053/j.seminoncol.2005.01.008	111	72	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3704	3713		10.1038/sj.onc.1210370	http://dx.doi.org/10.1038/sj.onc.1210370			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530024				2022-12-17	WOS:000246816100013
J	He, H; Sun, Y				He, H.; Sun, Y.			Ribosomal protein S27L is a direct p53 target that regulates apoptosis	ONCOGENE			English	Article						RPS27L; p53; apoptosis; ribosomal protein; gene expression and siRNA silencing	BREAST-CANCER; TUMOR-MARKER; DNA-DAMAGE; GROWTH; CARCINOMA; ACTIVATION; METALLOPANSTIMULIN; INHIBITION; EXPRESSION; CELLS	Ribosomal proteins were recently shown to regulate p53 activity by abrogating Mdm2-induced p53 degradation (L23, L11, L5) or by enhancing p53 translation (L26). Here, we report that a novel ribosomal protein, RPS27L (S27-like protein), is a direct p53 target. RPS27L, but not its family member RPS27, was identified as a p53 inducible gene in a genome-wide chip-profiling study. Further characterization revealed a p53-dependent induction of RPS27L in multiple cancer cell models. Indeed, a consensus p53-binding site was identified in the first intron of the RPS27L gene and a direct binding of p53 to this site was demonstrated both in vitro and in vivo. Characterization of a luciferase reporter driven by the RPS27L intron fragment revealed a p53-binding site-dependent transaction by wild-type p53, but not by several transactivating-deficient p53 mutants. This transactivation was enhanced by etoposide, a DNA damaging agent that activates p53 and was completely blocked by a dominant-negative p53 mutant. Functionally, overexpression of RPS27L within the physiological inducible levels promoted, whereas siRNA silencing of RPS27L inhibited, apoptosis induced by etoposide. This is the first report, to our knowledge, that p53 directly induces the expression of a ribosomal protein, RPS27L, which in turn promotes apoptosis.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, 4304 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287	NATIONAL CANCER INSTITUTE [R01CA111554] Funding Source: NIH RePORTER; NCI NIH HHS [1R01-CA111554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atsuta Y, 2002, CANCER LETT, V182, P101, DOI 10.1016/S0304-3835(02)00068-X; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FernandezPol JA, 1997, ANTICANCER RES, V17, P1519; FERNANDEZPOL JA, 1993, J BIOL CHEM, V268, P21198; FERNANDEZPOL JA, 1994, CELL GROWTH DIFFER, V5, P811; FernandezPol JA, 1996, ANTICANCER RES, V16, P2177; Ganger DR, 1997, ANTICANCER RES, V17, P1993; Ganger DR, 2001, CANCER DETECT PREV, V25, P231; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Lee WJ, 2004, OTOLARYNG HEAD NECK, V131, P466, DOI 10.1016/j.otohns.2004.03.011; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 2005, NEOPLASIA, V7, P312, DOI 10.1593/neo.04325; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Robinson M, 2003, CANCER BIOL THER, V2, P406, DOI 10.4161/cbt.2.4.437; Stack Brendan C Jr, 2004, World J Surg Oncol, V2, P45, DOI 10.1186/1477-7819-2-45; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; Sun YJ, 2006, IEEE T CIRCUITS-II, V53, P409, DOI 10.1109/TCSII.2006.869913; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; WONG JM, 1993, CANCER RES, V53, P1916; Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005	38	72	77	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2707	2716		10.1038/sj.onc.1210073	http://dx.doi.org/10.1038/sj.onc.1210073			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057733				2022-12-17	WOS:000246210600005
J	Mahtouk, K; Cremer, FW; Reme, T; Jourdan, M; Baudard, M; Moreaux, J; Requirand, G; Fiol, G; De Vos, J; Moos, M; Quittet, P; Goldschmidt, H; Rossi, JF; Hose, D; Klein, B				Mahtouk, K.; Cremer, F. W.; Reme, T.; Jourdan, M.; Baudard, M.; Moreaux, J.; Requirand, G.; Fiol, G.; De Vos, J.; Moos, M.; Quittet, P.; Goldschmidt, H.; Rossi, J-F; Hose, D.; Klein, B.			Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma	ONCOGENE			English	Article						myeloma; EGF-family; neuregulin; syndecan-1; heparin	MALIGNANT PLASMA-CELLS; BLOOD B-CELLS; BONE-MARROW; NORMAL COUNTERPART; ERBB RECEPTORS; BINDING; SYNDECAN-1; INTERLEUKIN-6; SURVIVAL; PROLIFERATION	The epidermal growth factor (EGF)/EGF-receptor (ErbB1-4) family is involved in the biology of multiple myeloma (MM). In particular, ErbB-specific inhibitors induce strong apoptosis of myeloma cells (MMC) in vitro. To delineate the contribution of the 10 EGF-family ligands to the pathogenesis of MM, we have assessed their expression and biological activity. Comparing Affymetrix DNA-microarray-expression-profiles of CD138-purified plasma-cells from 65 MM-patients and 7 normal individuals to those of plasmablasts and B-cells, we found 5/10 EGF-family genes to be expressed in MMC. Neuregulin-2 and neuregulin-3 were expressed by MMC only, while neuregulin-1, amphiregulin and transforming growth factor-alpha were expressed by both MMC and normal plasma-cells. Using real-time polymerase chain reaction, we found HB-EGF, amphiregulin, neuregulin1 and epiregulin to be expressed by cells from the bone marrow-environment. Only the EGF-members able to bind heparan-sulphate proteoglycans (HSPGs) neuregulin-1, amphiregulin, HB-EGF -promote the growth of MMC. Those ligands strongly bind MMC through HSPGs. The binding and the MMC growth activity was abrogated by heparitinase, heparin or deletion of the HS-binding domain. The number of HS-binding EGF ligand molecules bound to MMC was higher than 10(5) molecules/cell and paralleled that of syndecan-1. Syndecan-1, the main HSPG present on MM cells, likely concentrates high levels of HS-binding-EGF-ligands at the cell membrane and facilitates ErbB-activation. Altogether, our data further identify EGF-signalling as promising target for MM-therapy.	INSERM U475, F-34197 Montpellier, France; CHU Montpellier, Inst Res Biotherapy, Montpellier, France; Univ Klinikum Heidelberg, Med Klin & Poliklin 5, INF410, Heidelberg, Germany; CHU Montpellier, Dept Clin Hematol, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Ruprecht Karls University Heidelberg; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), INSERM U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	klein@montp.inserm.fr	J, Moreaux/ABA-2974-2021; De Vos, John/A-5703-2010; moreaux, jerome/HGA-5649-2022	J, Moreaux/0000-0002-5717-3207; De Vos, John/0000-0003-1880-4130; 				Bayer-Garner IB, 2001, MODERN PATHOL, V14, P1052, DOI 10.1038/modpathol.3880435; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Borset M, 2000, BLOOD, V96, P2528; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Costes V, 1999, HUM PATHOL, V30, P1405, DOI 10.1016/S0046-8177(99)90160-0; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Dhodapkar MV, 1997, BRIT J HAEMATOL, V99, P368, DOI 10.1046/j.1365-2141.1997.3893203.x; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hendriks J, 2005, CELL DEATH DIFFER, V12, P637, DOI 10.1038/sj.cdd.4401647; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Jelinek DF, 1997, J IMMUNOL, V159, P487; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; KAREY KP, 1988, CANCER RES, V48, P4083; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; KLEIN B, 1989, BLOOD, V73, P517; Klein B, 1999, CURR TOP MICROBIOL, V246, P335; Klerk CPW, 2005, J CLIN ONCOL, V23, P2130, DOI 10.1200/JCO.2005.03.134; Kragh M, 2005, INT J ONCOL, V27, P1159; Kumar A, 2003, LANCET ONCOL, V4, P293, DOI 10.1016/S1470-2045(03)01077-5; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Mahtouk K, 2005, ONCOGENE, V24, P3512, DOI 10.1038/sj.onc.1208536; Mahtouk K, 2004, BLOOD, V103, P1829, DOI 10.1182/blood-2003-05-1510; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Mummery RS, 2000, J IMMUNOL, V165, P5671, DOI 10.4049/jimmunol.165.10.5671; Paria BC, 1999, DEVELOPMENT, V126, P1997; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Seidel C, 2000, BLOOD, V95, P388, DOI 10.1182/blood.V95.2.388; Seidel C, 2000, BLOOD, V96, P3139, DOI 10.1182/blood.V96.9.3139.h8003139_3139_3146; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sun RX, 1997, J IMMUNOL METHODS, V205, P73, DOI 10.1016/S0022-1759(97)00056-2; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; Tarte K, 2000, BLOOD, V96, p514A; Van Driel M, 2002, LEUKEMIA, V16, P135, DOI 10.1038/sj.leu.2402336; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Wijdenes J, 1996, BRIT J HAEMATOL, V94, P318, DOI 10.1046/j.1365-2141.1996.d01-1811.x; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; ZHANG XG, 1994, BLOOD, V83, P3654	51	72	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7180	7191		10.1038/sj.onc.1209699	http://dx.doi.org/10.1038/sj.onc.1209699			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732320	Green Submitted, Green Accepted			2022-12-17	WOS:000242046900007
J	Enk, CD; Jacob-Hirsch, J; Gal, H; Verbovetski, I; Amariglio, N; Mevorach, D; Ingber, A; Givol, D; Rechavi, G; Hochberg, M				Enk, CD; Jacob-Hirsch, J; Gal, H; Verbovetski, I; Amariglio, N; Mevorach, D; Ingber, A; Givol, D; Rechavi, G; Hochberg, M			The UVB-induced gene expression profile of human epidermis in vivo is different from that of cultured keratinocytes	ONCOGENE			English	Article						UVB; epidermis; p53; in vivo; in vitro; microarrays	CELL CARCINOMA ANTIGENS; MATRIX METALLOPROTEINASES; FUNCTIONAL GENOMICS; CYCLE CHECKPOINT; DNA MICROARRAYS; MESSENGER-RNA; P53 PROTEIN; ULTRAVIOLET; SKIN; APOPTOSIS	In order to obtain a comprehensive picture of the molecular events regulating cutaneous photodamage of intact human epidermis, suction blister roofs obtained after a single dose of in vivo ultraviolet ( UV) B exposure were used for microarray profiling. We found a changed expression of 619 genes. Half of the UVB-regulated genes had returned to pre-exposure baseline levels at 72 h, underscoring the transient character of the molecular cutaneous UVB response. Of special interest was our finding that several of the central p53 target genes remained unaffected following UVB exposure in spite of p53 protein accumulation. We next compared the in vivo expression profiles of epidermal sheets to that of cultured human epidermal keratinocytes exposed to UVB in vitro. We found 1931 genes that differed in their expression profiles between the two groups. The expression pro. le in intact epidemis was geared mainly towards DNA repair, whereas cultured keratinocytes responded predominantly by activating genes associated with cell-cycle arrest and apoptosis. These differences in expression profiles might reflect differences between mature differentiating keratinocytes in the suprabasal epidermal layers versus exponentially proliferating keratinocytes in cell culture. Our findings show that extreme care should be taken when extrapolating from findings based on keratinocyte cultures to changes in intact epidermis.	Hebrew Univ Jerusalem, Dept Dermatol, Hadassah Med Ctr, IL-91010 Jerusalem, Israel; Safra Childrens Hosp, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Lab Cellular Mol Immunol, Hadassah Med Ctr, Dept Med, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah University Medical Center	Enk, CD (corresponding author), Hebrew Univ Jerusalem, Dept Dermatol, Hadassah Med Ctr, POB 12000, IL-91010 Jerusalem, Israel.	enk@md.huji.ac.il						Abts HF, 1999, J MOL BIOL, V293, P29, DOI 10.1006/jmbi.1999.3159; Alowami Salem, 2003, BMC Dermatol, V3, P1, DOI 10.1186/1471-5945-3-1; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BAADSGAARD O, 1991, ARCH DERMATOL, V127, P99, DOI 10.1001/archderm.127.1.99; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Becker B, 2001, J INVEST DERMATOL, V116, P983, DOI 10.1046/j.1523-1747.2001.01347.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Boni R, 1997, J CUTAN PATHOL, V24, P76, DOI 10.1111/j.1600-0560.1997.tb01100.x; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; BROWN DW, 1993, BIOCHEMISTRY-US, V32, P10527, DOI 10.1021/bi00091a001; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; Chaturvedi V, 2004, J INVEST DERMATOL, V123, P1200, DOI 10.1111/j.0022-202X.2004.23514.x; Courtois SJ, 1997, EXP CELL RES, V233, P135, DOI 10.1006/excr.1997.3537; CROMBACH G, 1989, CANCER, V63, P1337, DOI 10.1002/1097-0142(19890401)63:7<1337::AID-CNCR2820630719>3.0.CO;2-J; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; Decraene D, 2004, J INVEST DERMATOL, V122, pA140; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DUK JM, 1989, CANCER, V64, P1652, DOI 10.1002/1097-0142(19891015)64:8<1652::AID-CNCR2820640816>3.0.CO;2-M; EL DW, 1993, CELL, V75, P817; Enk CD, 2004, PHOTODERMATOL PHOTO, V20, P129, DOI 10.1111/j.1600-0781.2004.00097.x; ENK CD, 1994, ARCH DERMATOL RES, V287, P72, DOI 10.1007/BF00370722; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Gibbs S, 1998, CELL TISSUE RES, V292, P107, DOI 10.1007/s004410051040; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Grimbaldeston MA, 2003, J INVEST DERMATOL, V121, P1168, DOI 10.1046/j.1523-1747.2003.12561.x; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HALL PA, 1993, ONCOGENE, V8, P203; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Horiuchi Yasuhiro, 1994, Journal of Dermatology (Tokyo), V21, P67; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Joos L, 2003, SWISS MED WKLY, V133, P31; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kato H, 1996, ANTICANCER RES, V16, P2149; Kosmoski JV, 2001, P NATL ACAD SCI USA, V98, P10113, DOI 10.1073/pnas.181073398; Lahmann C, 2001, PHOTOCHEM PHOTOBIOL, V73, P657, DOI 10.1562/0031-8655(2001)073<0657:IOMFMM>2.0.CO;2; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee JH, 2002, PHOTODERMATOL PHOTO, V18, P253, DOI 10.1034/j.1600-0781.2002.02755.x; Lee KM, 2005, BRIT J DERMATOL, V152, P52, DOI 10.1111/J.1365-2133.2005.06412.X; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Li G, 1998, BRIT J DERMATOL, V139, P3; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Liu XQ, 2000, BIOCHEMISTRY-US, V39, P557, DOI 10.1021/bi991771m; Maelandsmo GM, 1997, INT J CANCER, V74, P464, DOI 10.1002/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9; Marionnet C, 2003, J INVEST DERMATOL, V121, P1447, DOI 10.1111/j.1523-1747.2003.12629.x; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Murakami T, 2001, J DERMATOL SCI, V27, P121, DOI 10.1016/S0923-1811(01)00124-4; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Pfundt R, 2000, ARCH DERMATOL RES, V292, P180, DOI 10.1007/s004030050475; Pisarchik A, 2004, GENE, V341, P199, DOI 10.1016/j.gene.2004.06.046; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; Sellheyer K, 2004, J AM ACAD DERMATOL, V51, P681, DOI 10.1016/j.jaad.2004.03.038; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sudel KM, 2003, PHOTOCHEM PHOTOBIOL, V78, P355, DOI 10.1562/0031-8655(2003)078<0355:TCOMMA>2.0.CO;2; Suminami Y, 2000, BRIT J CANCER, V82, P981, DOI 10.1054/bjoc.1999.1028; Takao J, 2002, PHOTODERMATOL PHOTO, V18, P5, DOI 10.1034/j.1600-0781.2002.180102.x; Takeda A, 2002, J INVEST DERMATOL, V118, P147, DOI 10.1046/j.0022-202x.2001.01610.x; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanaka N, 2000, BRIT J DERMATOL, V143, P728, DOI 10.1046/j.1365-2133.2000.03766.x; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Tran SEF, 2004, TRENDS BIOCHEM SCI, V29, P601, DOI 10.1016/j.tibs.2004.09.009; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Welss T, 2003, BIOCHEMISTRY-US, V42, P7381, DOI 10.1021/bi027307q; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; Zhang T, 2002, J INVEST DERMATOL, V119, P1196, DOI 10.1046/j.1523-1747.2002.19520.x; Zhao RB, 2000, GENE DEV, V14, P981	81	72	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2601	2614		10.1038/sj.onc.1209292	http://dx.doi.org/10.1038/sj.onc.1209292			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16434974				2022-12-17	WOS:000237099400004
J	Josson, S; Xu, Y; Fang, F; Dhar, SK; St Clair, DK; St Clair, WH				Josson, S; Xu, Y; Fang, F; Dhar, SK; St Clair, DK; St Clair, WH			RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells	ONCOGENE			English	Article						RelB; radiation; MnSOD	NF-KAPPA-B; NF-KAPPA-B2 P100; INDUCTION; TRANSCRIPTION; SPECIFICITY; RESPONSES; ASSAY	The relationship between NF-kappa B and resistance to radiation treatment in many tumor cell types has been generally well recognized. However, which members of the NF-kappa B family contribute to radiation resistance is unclear. In the present study, we demonstrate that RelB plays an important radioprotective role in aggressive prostate cancer cells, in part by the induction of antioxidant and antiapoptotic manganese superoxide dismutase (MnSOD) gene. RelB is both constitutively present and is inducible by radiation in aggressive prostate cancer cells. Using ectopically expressed dominant negative inhibitor, p100 mutant, and the siRNA approach, we demonstrate that selective inhibition of RelB significantly decreases the levels of MnSOD resulting in a significant increase in the sensitivity of prostate cancer cells to radiation treatment. These results demonstrate that RelB plays an important role in redox regulation of the cell and protects aggressive prostate cancer cells against radiation-induced cell death. Thus, inhibition of RelB could be a novel mechanism to radiosensitize prostate cancer.	Univ Kentucky, Chandler Med Ctr, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	St Clair, WH (corresponding author), Univ Kentucky, Chandler Med Ctr, Dept Radiat Med, 800 Rose St N-10, Lexington, KY 40536 USA.	stclair@uky.edu			NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49797, R01 CA049797, R01 CA049797-14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; LESSARD L, 2005, P AM ASSOC CANC RES, V46, P3160; Murley JS, 2004, RADIAT RES, V162, P536, DOI 10.1667/RR3256; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401	19	72	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1554	1559		10.1038/sj.onc.1209186	http://dx.doi.org/10.1038/sj.onc.1209186			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261162	Green Accepted			2022-12-17	WOS:000235890400012
J	Cezar-de-Mello, PFT; Nascimento-Silva, V; Villela, CG; Fierro, IM				Cezar-de-Mello, PFT; Nascimento-Silva, V; Villela, CG; Fierro, IM			Aspirin-triggered Lipoxin A(4) inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly	ONCOGENE			English	Article						lipoxins; angiogenesis; cytoskeleton; FAK; p38	15-EPI-LIPOXIN A(4); EICOSANOID REGULATION; PHOSPHORYLATION; ACTIVATION; KINASE; ANGIOGENESIS; CYCLOOXYGENASE-2; PROLIFERATION; RECRUITMENT; LEUKOTRIENE	Angiogenesis, the growth of new capillaries from preexisting ones, occurs through dynamic functions of the endothelial cells (EC), including migration, which is essential to achieve an organized formation of the vessel sprout. We demonstrated previously that an aspirintriggered lipoxin analog, 15-epi-16-(para-fluoro)- phenoxylipoxin A4 (ATL-1), inhibits vascular endothelial growth factor (VEGF)- induced EC migration. In the present study, we investigated the effects of ATL-1 in the actin cytoskeleton reorganization of EC stimulated with VEGF. Pretreatment of EC with ATL-1 caused a reduction in VEGF-induced stress. bers and therefore reduced the intracellular content of lamentous actin. A concomitant impairment in stress-activated protein kinase (SAPK2/p38) phosphorylation suggests that ATL inhibition of VEGF- stimulated actin polymerization involves the SAPK2 p38 pathway. Moreover, ATL-1 treatment inhibited focal adhesion clustering due to inhibition of focal adhesion kinase (FAK) phosphorylation and the subsequent association of FAK with the actin cytoskeleton. This final event, which ultimately allows cell migration, was reverted by an LX receptor antagonist, but not by a cys-LT1R antagonist, indicating an effect via the Gproteinlinked LXA4 receptor. Together our results provide evidence that ATL-1 inhibits EC migration via the concerted inhibition of actin polymerization and proper assembly of focal adhesions, supporting a role for these novel lipid mediators as angiogenesis modulators.	Univ Estado Rio de Janeiro, Dept Farmacol & Psicobiol, Inst Biol Roberto Alcantara Gomes, BR-20551030 Rio De Janeiro, Brazil	Universidade do Estado do Rio de Janeiro	Fierro, IM (corresponding author), Univ Estado Rio de Janeiro, Dept Farmacol & Psicobiol, Inst Biol Roberto Alcantara Gomes, Av 28 Setembro 87 Fundos,5o Andar,Sala 2,Vila Isa, BR-20551030 Rio De Janeiro, Brazil.	iolanda@uerj.br	Fierro, Iolanda/AAJ-2705-2021	Fernandes Tavares Cezar de Mello, Paula/0000-0002-9293-9773				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ARENBERG AD, 1999, GALLIN JI SNYDERMAN, P851; Ashton AW, 2004, CIRC RES, V95, P372, DOI 10.1161/01.RES.0000138300.41642.15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Chiang N, 2004, P NATL ACAD SCI USA, V101, P15178, DOI 10.1073/pnas.0405445101; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fierro IM, 2002, J PHARMACOL EXP THER, V300, P385, DOI 10.1124/jpet.300.2.385; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; GRANESS A, 2000, BIOCHEM J, V15, P441; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Lynch KR, 1999, NATURE, V399, P789; Maderna P, 2000, AM J PHYSIOL-CELL PH, V279, pC945, DOI 10.1152/ajpcell.2000.279.4.C945; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nie DT, 2004, SEMIN THROMB HEMOST, V30, P119; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Ohira T, 2004, J IMMUNOL, V173, P2091, DOI 10.4049/jimmunol.173.3.2091; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SERHAN CN, 1999, INFLAMMATION BASIC P, P373; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Shtivelband MI, 2003, J THROMB HAEMOST, V1, P2225, DOI 10.1046/j.1538-7836.2003.00446.x; Strieter RM, 2004, SEMIN CANCER BIOL, V14, P195, DOI 10.1016/j.semcancer.2003.10.006; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Vane J, 2000, THORAX, V55, pS3, DOI 10.1136/thorax.55.suppl_2.S3; Wang DZ, 2004, SEMIN ONCOL, V31, P64, DOI 10.1053/j.seminoncol.2004.01.008; Zachary I, 2003, BIOCHEM SOC T, V31, P1171	39	72	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					122	129		10.1038/sj.onc.1209002	http://dx.doi.org/10.1038/sj.onc.1209002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16132039				2022-12-17	WOS:000234406400013
J	Dominguez, PL; Kolodney, MS				Dominguez, PL; Kolodney, MS			Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens	ONCOGENE			English	Article						polymerase chain reaction (PCR); locked nucleic acid (LNA); BRAF; melanoma	POINT MUTATIONS; DNA; PCR	Detection and sequencing of mutations from clinical specimens is often complicated by the presence of an excess of nonmutated cells. To facilitate the detection and sequencing of minority mutations from clinical specimens, we developed wild-type blocking polymerase chain reaction (WTB-PCR). This technique allows sensitive detection of minority mutations in a tissue sample containing excess wild-type DNA. In WTB-PCR, a nonextendable locked nucleic acid (LNA) oligonucleotide binds tightly to a region of wild-type DNA known to develop point mutations. This LNA sequence blocks amplification of wild-type DNA during PCR while permitting amplification of mutant exon 15. Our results show that the LNA blocking oligonucleotide inhibits amplification of wild-type DNA in a dose-dependent manner. WTB-PCR was able to detect mutant DNA in clinical samples of melanoma tissue containing an excess of nonmelanoma cells. This method was also able to detect small amounts of point mutated or tandem mutated DNA diluted with a much larger concentration of wild-type DNA. This rapid and simple assay overcomes the limitations of current methods to detect minority mutations. The potential applications of WTB-PCR include early diagnosis and prognosis of various cancers.	Harbor UCLA Med Ctr, Div Dermatol, Dept Med, Torrance, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Kolodney, MS (corresponding author), Harbor UCLA Med Ctr, Div Dermatol, Dept Med, 1000 W Carson St,Box 459, Torrance, CA 90509 USA.	mkolodney@labiomed.org		kolodney, Michael/0000-0003-1931-8644				Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Kaur M, 2002, MUTAGENESIS, V17, P365, DOI 10.1093/mutage/17.5.365; Latorra D, 2003, MOL CELL PROBE, V17, P253, DOI 10.1016/S0890-8508(03)00062-8; Liu Q, 2002, BIOTECHNIQUES, V33, P129, DOI 10.2144/02331rr04; Makrigiorgos GM, 2004, HUM MUTAT, V23, P406, DOI 10.1002/humu.20024; Miller CJ, 2004, J INVEST DERMATOL, V123, P990, DOI 10.1111/j.0022-202X.2004.23468.x; Mouritzen P, 2003, EXPERT REV MOL DIAGN, V3, P27, DOI 10.1586/14737159.3.1.27; Oliver DH, 2000, J MOL DIAGN, V2, P202, DOI 10.1016/S1525-1578(10)60638-1; Parsons BL, 1997, MUTAT RES-REV MUTAT, V387, P97, DOI 10.1016/S1383-5742(97)00026-4; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Yu D, 1997, BIOTECHNIQUES, V23, P714, DOI 10.2144/97234st06; YU D, 1997, BIOTECHNIQUES, V23, P718	12	72	106	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6830	6834		10.1038/sj.onc.1208832	http://dx.doi.org/10.1038/sj.onc.1208832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16116485				2022-12-17	WOS:000232527800010
J	Beer, HD; Bittner, M; Niklaus, G; Munding, C; Max, N; Goppelt, A; Werner, S				Beer, HD; Bittner, M; Niklaus, G; Munding, C; Max, N; Goppelt, A; Werner, S			The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair	ONCOGENE			English	Article						epidermis; heparin; KGF; skin; wound	FACTOR EXPRESSION; FACTOR RECEPTOR-2; PROLIFERATION; INDUCTION; REVEALS; BP; MORPHOGENESIS; SPECIFICITY; PROTECTION; CLONING	The fibroblast growth factor-binding protein (FGF-BP) binds and activates FGF-1 and FGF-2, thereby contributing to tumor angiogenesis. In this study, we identified novel binding partners of FGF-BP, and we provide evidence for a role of this protein in epithelial repair processes. We show that expression of FGF-BP increases after injury to murine and human skin, in particular in keratinocytes. This upregulation is most likely achieved by major keratinocyte mitogens present at the wound site. Most importantly, we demonstrate that FGF-BP interacts with FGF-7, FGF-10, and with the recently identified FGF-22, and enhances the activity of low concentrations of ligand. Due to the important functions of FGF-7 and FGF-10 for repair of injured epithelia, our findings suggest that upregulation of FGF-BP expression after injury stimulates FGF activity at the wound site, thus enhancing the process of epithelial repair.	ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; Switch Biotech AG, D-82061 Neuried, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710; Beer, Hans-Dietmar/0000-0002-8085-713X; Goppelt, Andreas/0000-0002-0780-1332				Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Aigner A, 2002, ONCOGENE, V21, P5733, DOI 10.1038/sj.onc.1205560; Aigner A, 2002, HISTOCHEM CELL BIOL, V117, P1, DOI 10.1007/s00418-001-0360-4; Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; Beyer TA, 2003, EXP CELL RES, V287, P228, DOI 10.1016/S0014-4827(03)00139-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DELL KR, 1992, J BIOL CHEM, V267, P21225; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Kurtz A, 2004, NEOPLASIA, V6, P595, DOI 10.1593/neo.04214; Liu XH, 2001, KIDNEY INT, V59, P1717, DOI 10.1046/j.1523-1755.2001.0590051717.x; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Nakatake Y, 2001, BBA-GENE STRUCT EXPR, V1517, P460, DOI 10.1016/S0167-4781(00)00302-X; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sauter ER, 2001, INT J CANCER, V92, P374, DOI 10.1002/ijc.1207; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Steiling H, 2003, CURR OPIN BIOTECH, V14, P533, DOI 10.1016/j.copbio.2003.08.003; Steiling H, 2003, ONCOGENE, V22, P4380, DOI 10.1038/sj.onc.1206499; Tagashira S, 1997, GENE, V197, P399, DOI 10.1016/S0378-1119(97)00187-X; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WU DQ, 1991, J BIOL CHEM, V266, P16778	43	72	81	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5269	5277		10.1038/sj.onc.1208560	http://dx.doi.org/10.1038/sj.onc.1208560			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15806171				2022-12-17	WOS:000231158500001
J	Sun, YP; Lowther, W; Kato, K; Bianco, C; Kenney, N; Strizzi, L; Raafat, D; Hirota, M; Khan, NI; Bargo, S; Jones, B; Salomon, D; Callahan, R				Sun, YP; Lowther, W; Kato, K; Bianco, C; Kenney, N; Strizzi, L; Raafat, D; Hirota, M; Khan, NI; Bargo, S; Jones, B; Salomon, D; Callahan, R			Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling	ONCOGENE			English	Article						Notch4ICD; Smad3; TGF-beta	GROWTH-FACTOR-BETA; MAMMARY EPITHELIAL-CELLS; TRUNCATED INT3 GENE; NEOPLASTIC TRANSFORMATION; BRANCHING MORPHOGENESIS; TUMOR-SUPPRESSOR; MAMMALIAN NOTCH; CROSS-TALK; EXPRESSION; RECEPTORS	We present evidence that Notch4ICD attenuates TGF-beta signaling. Cells expressing the activated form of the Notch4 receptor (ICD4) were resistant to the growth-inhibitory effects of TGF-beta. Notch4ICD was found to bind to Smad2, Smad3 and Smad4 but with higher affinity to Smad3. Deletion analysis showed that binding of Smad3 to ICD4 was mediated by its MH2 domain and was not dependent on the presence of the RAM23 region in ICD4. Using two TGF-beta/Activin reporter luciferase assays, RT-PCR and Western blot analysis, we demonstrate that ICD4 and ICD4 delta RAM23 inhibit Smad-binding element and 3TP luciferase reporter activity and PAI-1 gene expression. MCF-7 human breast cancer cells express Notch4ICD (ICD4) and are resistant to the growth-inhibitory effects of TGF-beta. Blockage of Notch4 processing to ICD4 by gamma-secretase inhibitor renders MCF-7 cells sensitive to growth inhibition by TGF-beta. The interplay between these two signaling pathways may be a significant determinant during mammary tumorigenesis.	NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA; NCI, Oncogenesis Sect, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Salomon, D (corresponding author), NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA.	salomond@mail.nih.gov; Callahro@mail.nih.gov		Hirota, Morihisa/0000-0001-5682-0911	NATIONAL CANCER INSTITUTE [Z01BC009003, ZIABC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Baron M, 2002, MOL MEMBR BIOL, V19, P27, DOI 10.1080/09687680110112929; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallahan D, 1996, CANCER RES, V56, P1775; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miyazono K, 2000, J CELL SCI, V113, P1101; Moustakas A, 2001, J CELL SCI, V114, P4359; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Rao P, 2003, MOL CELL BIOL, V23, P6694, DOI 10.1128/MCB.23.18.6694-6701.2003; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Sun Y, 2001, MOL CELL ENDOCRINOL, V172, P177, DOI 10.1016/S0303-7207(00)00370-1; Sun YP, 2002, J BIOL CHEM, V277, P19080, DOI 10.1074/jbc.M200936200; Takizawa T, 2003, NUCLEIC ACIDS RES, V31, P5723, DOI 10.1093/nar/gkg778; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xie W, 2002, CANCER RES, V62, P497; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhou YL, 2000, MOL ENDOCRINOL, V14, P2066, DOI 10.1210/me.14.12.2066	54	72	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5365	5374		10.1038/sj.onc.1208528	http://dx.doi.org/10.1038/sj.onc.1208528			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007227				2022-12-17	WOS:000231158500010
J	Chang, NS; Schultz, L; Hsu, LJ; Lewis, J; Su, M; Sze, CI				Chang, NS; Schultz, L; Hsu, LJ; Lewis, J; Su, M; Sze, CI			17 beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo	ONCOGENE			English	Article						WWOX; FOR2; WOX1; WOX2; estrogen; androgen	DOMAIN-CONTAINING OXIDOREDUCTASE; WILD-TYPE P53; SHORT-CHAIN DEHYDROGENASES/REDUCTASES; NECROSIS-FACTOR CYTOTOXICITY; ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR; NEUROBLASTOMA-CELLS; EPITHELIAL-CELLS; DELETED REGIONS; HYALURONIC-ACID	Human WWOX gene encodes a proapoptotic WW domain-containing oxidoreductase WOX1 ( also named WWOX, FOR2 or WWOXv1). Apoptotic and stress stimuli activate WOX1 via Tyr33 phosphorylation and nuclear translocation. WOX1 possesses a tetrad NSYK motif in the C-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain, which may bind estrogen and androgen. Here, we determined that 17beta-estradiol (E-2) activated WOX1, p53 and ERK in COS7 fibroblasts, primary lung epithelial cells, and androgen receptor (AR)-negative prostate DU145 cells, but not in estrogen receptor ( ER)positive breast MCF7 cells. Androgen also activated WOX1 in the AR-negative DU145 cells. These observations suggest that sex hormone-mediated Tyr33 phosphorylation and nuclear translocation of WOX1 is independent of ER and AR. Stress stimuli increase physical binding of p53 with WOX1 in vivo. We determined here that E2 increased the formation of p53/WOX1 complex and their nuclear translocation in COS7 cells; however, nuclear translocation of this complex could not occur in MCF7 cells. By immunohistochemistry, we determined that progression of prostate from normal to hyperplasia, cancerous and metastatic stages positively correlate with upregulation and activation of WOX1 and WOX2 (FOR1/WWOXv2). In contrast, breast cancer development to a premetastatic state is associated with upregulation and Tyr33 phosphorylation of cytosolic WOX1 and WOX2, followed by significant downregulation or absent expression during metastasis. These Tyr33-phosphorylated proteins are mostly located in the mitochondria without translocating to the nuclei, which is comparable to those findings in cultured breast cancer cells. Together, sex steroid hormone-induced activation of WOX1 and WOX2 is independent of ER and AR, and this activation positively correlates with cancerous progression of prostate and breast to a premetastatic state.	Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Chang, NS (corresponding author), Guthrie Res Inst, Lab Mol Immunol, 1 Guthrie Sq, Sayre, PA 18840 USA.	chang_nanshan@guthrie.org	Hsu, Li-Jin/G-7822-2011					Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Bednarek AK, 2000, CANCER RES, V60, P2140; BRONZERT DA, 1982, ENDOCRINOLOGY, V110, P2177, DOI 10.1210/endo-110-6-2177; Burchardt M, 2001, PROSTATE, V48, P225, DOI 10.1002/pros.1101; Caligo MA, 1998, INT J ONCOL, V13, P177; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-8; Chang NS, 2002, INT J MOL MED, V9, P19; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chen ST, 2004, NEUROSCIENCE, V124, P831, DOI 10.1016/j.neuroscience.2003.12.036; CHEN ST, 2004, IN PRESS NEUROSCIENC; COEZY E, 1982, CANCER RES, V42, P317; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Elo JP, 1999, BRIT J CANCER, V79, P156, DOI 10.1038/sj.bjc.6690025; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Filling C, 2001, MOL CELL ENDOCRINOL, V171, P99, DOI 10.1016/S0303-7207(00)00419-6; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Gangolli EA, 1997, J STEROID BIOCHEM, V61, P1, DOI 10.1016/S0960-0760(97)00003-4; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gartel AL, 2003, ONCOL RES, V13, P405; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; Green PS, 1997, J NEUROSCI, V17, P511; Gridley KE, 1998, MOL PHARMACOL, V54, P874, DOI 10.1124/mol.54.5.874; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; He XY, 2001, EUR J BIOCHEM, V268, P4899, DOI 10.1046/j.0014-2956.2001.02421.2421.x; ISAACS WB, 1991, CANCER RES, V51, P4716; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Lau KM, 2000, CANCER RES, V60, P3175; Li CD, 1999, GENE CHROMOSOME CANC, V24, P175, DOI 10.1002/(SICI)1098-2264(199903)24:3<175::AID-GCC1>3.3.CO;2-8; Linja MJ, 2003, PROSTATE, V55, P180, DOI 10.1002/pros.10242; Lokeshwar V, 1999, PROSTATE CANCER P D, V2, pS21, DOI 10.1038/sj.pcan.4500346; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Patel S, 2002, INT J CANCER, V97, P416, DOI 10.1002/ijc.1638; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Setalo G, 2002, J NEUROBIOL, V50, P1, DOI 10.1002/neu.10000; Song RXD, 2003, APOPTOSIS, V8, P55, DOI 10.1023/A:1021649019025; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452; Watanabe A, 2003, CANCER RES, V63, P8629; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wolff A, 2001, ONCOGENE, V20, P1307, DOI 10.1038/sj.onc.1204251; WOLLIN M, 1989, RADIOTHER ONCOL, V15, P285, DOI 10.1016/0167-8140(89)90097-2; Xu Y, 1996, ENDOCRINOLOGY, V137, P5634, DOI 10.1210/en.137.12.5634	50	72	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					714	723		10.1038/sj.onc.1208124	http://dx.doi.org/10.1038/sj.onc.1208124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580310				2022-12-17	WOS:000226420400019
J	Rudner, J; Jendrossek, V; Lauber, K; Daniel, PT; Wesselborg, S; Belka, C				Rudner, J; Jendrossek, V; Lauber, K; Daniel, PT; Wesselborg, S; Belka, C			Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies	ONCOGENE			English	Article						TRAIL; Bcl-2; apoptosis	TUMOR-NECROSIS-FACTOR; TYROSINE KINASE LCK; CD95 TYPE-I; CYTOCHROME-C; MEDIATED APOPTOSIS; CASPASE-8 ACTIVATION; IONIZING-RADIATION; SIGNALING COMPLEX; LIGAND TRAIL; SMAC/DIABLO RELEASE	Death receptor-induced apoptosis is paradigmatically mediated via the recruitment of FADD adapter molecule to the ligand/receptor complex and subsequent activation of caspase-8. However, several observations provided evidence that components of the mitochondrial apoptosis pathway are involved in death receptor-mediated apoptosis. In this regard, caspase-8-mediated activation of Bid induces the release of cytochrome c from the mitochondria, which, in turn, triggers the formation of the apoptosome protein complex, resulting in the activation of caspase-9. Whereas Bax or Bak were shown to be required for the proapoptotic effect of Bid, Bcl-2 was described to interfere with its action. Up to now, contradictory results regarding the role of Bcl-2 in TRAIL-induced apoptosis have been published. In order to study the influence of Bcl-2 on TRAIL-induced cell death more detailed, we utilized a tetracycline-regulated Bcl-2 expression system in Jurkat T cells. After having analysed the dose response for TRAIL-induced activation of caspase-8, -9, -3, breakdown of the mitochondrial membrane potential, and changes in the apoptotic morphology in cells expressing different Bcl-2 levels, we conclude that overexpression of Bcl-2 mediates a partial resistance towards lower doses of TRAIL that can be overcome when higher doses of TRAIL are applied. Thus, the requirement of the mitochondrial pathway for death receptor-induced apoptosis in type II cells should be reconsidered, since the protective effect of Bcl-2 is limited to lower TRAIL doses or early observation time points.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Humboldt Univ, Charite, Dept Mol Hematol & Oncol, D-13125 Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019; Rudner, Justine/ABD-1397-2021	Jendrossek, Verena/0000-0003-1058-2107; Wesselborg, Sebastian/0000-0002-5236-942X				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 2003, STRAHLENTHER ONKOL, V179, P141, DOI 10.1007/s00066-003-1047-7; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 2000, NAT MED, V6, P502, DOI 10.1038/74972; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; RUFFOLO SC, 2003, J BIOL CHEM, V29, P29; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; SUN XM, 2002, J BIOL CHEM, V18, P18; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; TECCHIO C, 2004, BLOOD, V15, P15; Velthuis JHL, 2002, J BIOL CHEM, V277, P24631, DOI 10.1074/jbc.M111572200; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zhang XD, 2001, CANCER RES, V61, P7339	78	72	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					130	140		10.1038/sj.onc.1208191	http://dx.doi.org/10.1038/sj.onc.1208191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531922				2022-12-17	WOS:000226125800015
J	Romanova, LY; Willers, H; Blagosklonny, MV; Powell, SN				Romanova, LY; Willers, H; Blagosklonny, MV; Powell, SN			The interaction of p53 with replication protein A mediates suppression of homologous recombination	ONCOGENE			English	Article						p53; RPA; homologous recombination; replication	WILD-TYPE P53; STRAND BREAK REPAIR; DNA-BINDING DOMAIN; HUMAN RAD51; MUTANT P53; CELL-CYCLE; 3'-TO-5' EXONUCLEASE; HOLLIDAY JUNCTIONS; MAMMALIAN-CELLS; RPA	The tumor suppressor protein p53 is emerging as a central regulator of homologous recombination (HR) processes and DNA replication. P53 may downregulate HR through multiple mechanisms including the reported associations with the Rad51 and Rad54 recombinases, and the BLM and WRN helicases. Here, we investigated whether the interaction of p53 with human replication protein A (RPA) is necessary for the regulation of HR. By employing a plasmid-based HR assay in p53-null H1299 lung carcinoma cells, we, studied the HR-suppressing properties of a panel of p53 mutants, which varied in their ability to interact with RPA. Both wild-type p53 and a transactivation-deficient p53 mutant (L22Q/W23S) suppressed HR and prevented RPA binding to ssDNA in vitro and in vivo. Conversely, p53 mutations that specifically disrupt the RPA-binding domain, while not compromising p53 transactivation function (D48H/D49H and W53S/F54S), did not affect HR. Suppression of HR was also not seen with missense mutations in the p53 core domain (His175 and His273), which retained the ability to interact with RPA, suggesting that the disruption of additional binding interactions of p53, for example, with Rad51 or recombination intermediates, also impacts on HR. We hypothesize that sequestration of RPA by p53 at the sites of recombination is one means by which p53 can inhibit HR processes. Our data support and extend the previously formulated 'dual model' of p53's role as guardian of the genome.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Lab Mol & Celllular Radiat Biol, Charlestown, MA 02129 USA; New York Med Coll, Brander Canc Res Inst, Hawthorne, NY 10532 USA	Harvard University; Massachusetts General Hospital; New York Medical College	Powell, SN (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Lab Mol & Celllular Radiat Biol, Charlestown, MA 02129 USA.	snpowell@partners.org			NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER; NCI NIH HHS [CA58985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Alberts B, 2003, NATURE, V421, P431, DOI 10.1038/nature01407; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Leiter LM, 1996, ONCOGENE, V12, P2661; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Linke SP, 2003, CANCER RES, V63, P2596; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MOSNER J, 1994, ONCOGENE, V9, P3321; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Treuner K, 1998, J BIOL CHEM, V273, P31744, DOI 10.1074/jbc.273.48.31744; Walther AP, 1999, NUCLEIC ACIDS RES, V27, P656, DOI 10.1093/nar/27.2.656; Wiese C, 2001, CANCER RES, V61, P1129; Wiesmuller L, 1996, J VIROL, V70, P737; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Willers H, 2000, INT J RADIAT BIOL, V76, P1055; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Willers Henning, 2002, Journal of Biomedicine & Biotechnology, V2, P86, DOI 10.1155/S1110724302204027; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zhou JM, 2003, NUCLEIC ACIDS RES, V31, P3881, DOI 10.1093/nar/gkg468; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	73	72	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9025	9033		10.1038/sj.onc.1207982	http://dx.doi.org/10.1038/sj.onc.1207982			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489903				2022-12-17	WOS:000225492800003
J	Blagosklonny, MV				Blagosklonny, MV			Prospective strategies to enforce selectively cell death in cancer cells	ONCOGENE			English	Review						apoptosis; cancer therapy; drug resistance	NF-KAPPA-B; PACLITAXEL-INDUCED APOPTOSIS; TYROSINE KINASE INHIBITOR; GROWTH-FACTOR RECEPTOR; S-PHASE CHECKPOINT; LEUKEMIA-CELLS; ACHILLES-HEEL; DEPENDENT POTENTIATION; CHEMOTHERAPEUTIC DRUGS; MOLECULAR DETERMINANTS	Although induction of apoptosis (cell death mediated by caspases) determines response to cancer therapy, this approach is limited by lack of selectivity in available apoptosis-inducing agents. Furthermore, most cancers, almost by definition, are resistant to apoptosis, growth arrest and cell senescence. Then, how can anticancer agents kill cancer cell without unacceptable toxicity to a patient? The potential therapeutic approaches range from selective inhibition of antiapoptotic pathways, antiangiogenic therapy, tissue-selective therapy (including immunotherapy) to exploitation of, for example, drug resistance, oncoprotein addiction, unrestricted cell cycles, hypermitogenic and hypoxic features of cancer cells. These overlapping and complementary approaches rely on rational drug combinations (at mechanism-based doses and sequences) aimed at matching targets. To ensure killing of cancer cells selectively, we may combine apoptosis- and senescence-inducing agents with inhibitors of apoptosis (to protect normal cells), inhibitors of signal transduction with cell cycle-dependent chemotherapy, antiangiogenic agents with hypoxia-inducible factor-1 inhibitors, tissue-selective therapy with differentiating agents and activators of death receptors with chemotherapy. In theory, consecutive use of these drug combinations may control cancer.	New York Med Coll, Brander Canc Res Inst, Valhalla, NY 10532 USA	New York Medical College	Blagosklonny, MV (corresponding author), New York Med Coll, Brander Canc Res Inst, 19 Bradhurst Ave, Valhalla, NY 10532 USA.	m_blagosklonny@nymc.edu						Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Akay C, 2003, CELL CYCLE, V2, P358, DOI 10.4161/cc.2.4.417; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berg G, 2002, J ENDOCRINOL INVEST, V25, P44, DOI 10.1007/BF03343960; Bishop PC, 2002, ONCOGENE, V21, P119, DOI 10.1038/sj.onc.1205028; Blagosklonny MV, 2002, CELL CYCLE, V1, P375, DOI 10.4161/cc.1.6.259; Blagosklonny MV, 2003, DRUG DISCOV TODAY, V8, P1104, DOI 10.1016/S1359-6446(03)02806-X; Blagosklonny MV, 2003, BRIT J CANCER, V89, P1147, DOI 10.1038/sj.bjc.6601256; Blagosklonny MV, 2003, TRENDS MOL MED, V9, P307, DOI 10.1016/S1471-4914(03)00111-4; Blagosklonny MV, 2003, EMBO REP, V4, P358, DOI 10.1038/sj.embor.embor806; Blagosklonny MV, 2002, NAT REV CANCER, V2, P221, DOI 10.1038/nrc743; Blagosklonny MV, 2002, CANCER BIOL THER, V1, P113, DOI 10.4161/cbt.53; Blagosklonny MV, 1998, INT J CANCER, V78, P511, DOI 10.1002/(SICI)1097-0215(19981109)78:4<511::AID-IJC19>3.0.CO;2-8; Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257; Blagosklonny MV, 2001, INT J ONCOL, V19, P257; Blalock WL, 2003, LEUKEMIA, V17, P1058, DOI 10.1038/sj.leu.2402925; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Broker LE, 2002, CANCER RES, V62, P4081; Brown JM, 1998, CANCER RES, V58, P1408; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Cohn DE, 2000, CURR OPIN ONCOL, V12, P492, DOI 10.1097/00001622-200009000-00017; Daley GQ, 2003, CELL CYCLE, V2, P190, DOI 10.4161/cc.2.3.401; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Dixon H, 2002, CELL CYCLE, V1, P362, DOI 10.4161/cc.1.6.257; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Ebnoether M, 2002, LANCET, V359, P1751, DOI 10.1016/S0140-6736(02)08616-6; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FREI E, 1985, CANCER RES, V45, P6523; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; FUMO G, 2003, BLOOD; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; George D, 2003, ADV EXP MED BIOL, V532, P141; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Goncalves A, 2000, BIOCHEM PHARMACOL, V60, P1579, DOI 10.1016/S0006-2952(00)00481-0; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grant S, 2002, CELL CYCLE, V1, P383, DOI 10.4161/cc.1.6.260; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Ibrado AM, 1997, CANCER RES, V57, P1109; Jia WT, 2003, BLOOD, V102, P1824, DOI 10.1182/blood-2002-12-3785; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones RH, 2003, EUR J CANCER, V39, P147, DOI 10.1016/S0959-8049(02)00612-3; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Kim CY, 1997, CANCER RES, V57, P4200; Klement G, 2002, CLIN CANCER RES, V8, P221; Krishnamachary B, 2003, CANCER RES, V63, P1138; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Mack PC, 2003, CANCER CHEMOTH PHARM, V51, P337, DOI 10.1007/s00280-003-0571-6; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; Mayer F, 2003, CLIN CANCER RES, V9, P767; McCarty MF, 2003, MED HYPOTHESES, V61, P509, DOI 10.1016/S0306-9877(03)00229-9; Merlin JL, 2000, ANTI-CANCER DRUG, V11, P295, DOI 10.1097/00001813-200004000-00011; Milner AE, 2002, CELL DEATH DIFFER, V9, P287, DOI 10.1038/sj/cdd/4400945; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Mueller T, 2003, CANCER RES, V63, P513; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Overwijk WW, 2000, CRIT REV IMMUNOL, V20, P433; Panvichian R, 1998, CANCER RES, V58, P4667; Pardee AB, 2002, CANCER BIOL THER, V1, P426, DOI 10.4161/cbt.1.4.22; Pelikan DMV, 1997, CLIN ENDOCRINOL, V47, P713, DOI 10.1046/j.1365-2265.1997.3281154.x; Pepper C, 2003, CELL CYCLE, V2, P53, DOI 10.4161/cc.2.1.249; Perkins CL, 2000, CANCER RES, V60, P1645; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Reese DM, 2000, LANCET, V355, P1474, DOI 10.1016/S0140-6736(00)02155-3; Roninson IB, 2003, CANCER RES, V63, P2705; Sane AT, 1999, CANCER RES, V59, P3565; Sattler M, 2003, SEMIN HEMATOL, V40, P4, DOI 10.1053/shem.2003.50034; Sattler M, 2003, SEMIN HEMATOL, V40, pS4; Sawyers CL, 2002, CANCER CELL, V1, P413, DOI 10.1016/S1535-6108(02)00080-6; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Shao RG, 1997, CANCER RES, V57, P4029; Simon D, 2002, EUR J NUCL MED MOL I, V29, P775, DOI 10.1007/s00259-001-0737-6; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Sohal J, 2003, BLOOD, V101, P3188, DOI 10.1182/blood-2002-06-1800; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; Solit DB, 2003, CANCER RES, V63, P2139; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Strair RK, 2002, CLIN CANCER RES, V8, P2512; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Voelkel-Johnson C, 2003, CANCER BIOL THER, V2, P283, DOI 10.4161/cbt.2.3.398; von Mehren M, 2003, CANCER INVEST, V21, P553, DOI 10.1081/CNV-120022374; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Wilkinson E, 2002, LANCET ONCOL, V3, P583, DOI 10.1016/S1470-2045(02)00883-5; Winegarden JD, 2003, LUNG CANCER-J IASLC, V39, P191, DOI 10.1016/S0169-5002(02)00447-6; Yao Q, 2003, CLIN CANCER RES, V9, P4483; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Zhivotovsky B, 2003, SEMIN CANCER BIOL, V13, P125, DOI 10.1016/S1044-579X(02)00130-X	109	72	82	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2967	2975		10.1038/sj.onc.1207520	http://dx.doi.org/10.1038/sj.onc.1207520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077157				2022-12-17	WOS:000220799600021
J	Yanamandra, N; Gumidyala, KV; Waldron, KG; Gujrati, M; Olivero, WC; Dinh, D; Rao, JS; Mohanam, S				Yanamandra, N; Gumidyala, KV; Waldron, KG; Gujrati, M; Olivero, WC; Dinh, D; Rao, JS; Mohanam, S			Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis	ONCOGENE			English	Article						cathepsin B; angiogenesis; glioblastoma; antisense	ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS CARCINOMA-CELLS; HUMAN BRAIN-TUMORS; IN-VITRO; CYSTEINE PROTEINASES; INVASIVE PROPERTIES; VEGF EXPRESSION; DOWN-REGULATION; ENZYME-ACTIVITY; IV COLLAGENASE	The cysteine proteinase cathepsin B has been implicated in tumor progression by virtue of its increased mRNA and protein levels, as well as its localization at the invading front of the tumor. In this study, we examined whether blocking cathepsin B expression in human glioblastoma SNB19 cells affects angiogenesis. Stable transfectants of human glioblastoma cells with a plasmid containing antisense cathepsin B cDNA showed decreased migration rates in wound- and spheroid- migration assays. Analysis showed a reduction in VEGF protein and MMP- 9 activity in the cathepsin B antisense cDNA- transfected cells. Regarding angiogenesis in vitro, we found that the conditioned medium of glioblastoma cells with downregulated cathepsin B expression reduced cell - cell interaction of human microvascular endothelial cells, resulting in the disruption of capillary- like network formation. Furthermore, a marked reduction in microvasculature development was seen in an in vivo dorsal air sac assay of glioblastoma cells with downregulated cathepsin B expression. Taken together, these results provide evidence that inhibition of cathepsin B expression can suppress glioblastoma- induced neovascularization.	Univ Illinois, Coll Med, Program Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Mohanam, S (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	smohanam@uic.edu			NATIONAL CANCER INSTITUTE [R01CA076350, R01CA075557, R01CA085216, R01CA092393] Funding Source: NIH RePORTER; NCI NIH HHS [CA76350, CA75557, CA92393, CA85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Chandrasekar N, 2000, CLIN EXP METASTAS, V18, P337, DOI 10.1023/A:1010833730407; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945-053X(98)90068-3; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; GARRIDO T, 1995, BRIT J CANCER, V71, P770, DOI 10.1038/bjc.1995.149; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Hizel C, 1998, ONCOL REP, V5, P31; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Kachra Z, 1999, CLIN EXP METASTAS, V17, P555, DOI 10.1023/A:1006760632766; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kruger S, 1999, CANCER RES, V59, P6010; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lopes MBS, 2003, MICROSC RES TECHNIQ, V60, P225, DOI 10.1002/jemt.10260; Lorenzo K, 2000, CANCER RES, V60, P4070; Machein MR, 2000, J NEURO-ONCOL, V50, P109, DOI 10.1023/A:1006416003964; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Miyoshi C, 2001, IN VIVO, V15, P233; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; NAKAO H, 1989, INT J BIOCHEM, V21, P739; Nirmala C, 2000, INT J CANCER, V88, P766, DOI 10.1002/1097-0215(20001201)88:5<766::AID-IJC13>3.0.CO;2-Y; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Sameni Mansoureh, 1995, Pathol Oncol Res, V1, P43; SLOANE BF, 1994, J CELL SCI, V107, P373; SPIESS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917, DOI 10.1177/42.7.8014475; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Szpaderska AM, 2001, CANCER RES, V61, P3493; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Virgintino D, 2003, HISTOCHEM CELL BIOL, V119, P227, DOI 10.1007/s00418-003-0510-y; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099	43	72	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2224	2230		10.1038/sj.onc.1207338	http://dx.doi.org/10.1038/sj.onc.1207338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14730346				2022-12-17	WOS:000220280900012
J	Guardavaccaro, D; Pagano, M				Guardavaccaro, D; Pagano, M			Oncogenic aberrations of cullin-dependent ubiquitin ligases	ONCOGENE			English	Review						ubiquitin; cancer; cullin; cell cycle	F-BOX PROTEIN; KAPPA-B-ALPHA; SIGNAL-INDUCED UBIQUITINATION; ANAPHASE-PROMOTING COMPLEX; LINDAU TUMOR-SUPPRESSOR; TARGETS CYCLIN-E; BETA-TRCP; S-PHASE; CELL-CYCLE; MEDIATED PROTEOLYSIS	Accumulating evidence points to a key role of the ubiquitin - proteasome pathway in oncogenesis. Aberrant proteolysis of substrates involved in cellular processes such as the cell division cycle, gene transcription, the DNA damage response and apoptosis has been reported to contribute significantly to neoplastic transformation. Cullin-dependent ubiquitin ligases (CDLs) form a class of structurally related multisubunit enzymes central to the ubiquitin-mediated proteolysis of many important biological substrates. In this review, we describe the role of CDLs in the ubiquitinylation of cancer-related substrates and discuss how altered ubiquitinylation by CDLs may contribute to tumor development.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Pagano, M (corresponding author), NYU, Sch Med, Dept Pathol, MSB 599,550 1st Ave, New York, NY 10016 USA.	michele.pagano@med.nyu.edu		Guardavaccaro, Daniele/0000-0002-4517-1765; pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; BASHIR T, 2004, IN PRESS NATURE; Ben-Izhak O, 2003, J UROLOGY, V170, P241, DOI 10.1097/01.ju.0000072113.34524.a7; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Chen LC, 1998, CANCER RES, V58, P3677; CHEN W, 1995, MOL CELL BIOL, V15, P3424; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Dow MR, 1998, GENETICS, V150, P119; Dowen SE, 2003, ONCOGENE, V22, P2531, DOI 10.1038/sj.onc.1206296; El-Rifai W, 2001, INT J CANCER, V92, P832, DOI 10.1002/ijc.1264; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kipreos ET, 2000, DEVELOPMENT, V127, P5071; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Ko HW, 2002, NATURE, V420, P673, DOI 10.1038/nature01272; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koike J, 2000, BIOCHEM BIOPH RES CO, V269, P103, DOI 10.1006/bbrc.2000.2241; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Kudo Y, 2001, CANCER RES, V61, P7044; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mantovani F, 2003, J BIOL CHEM, V278, P42477, DOI 10.1074/jbc.M302799200; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Maruyama S, 2001, GENOMICS, V78, P214, DOI 10.1006/geno.2001.6658; Masuda T, 2002, CANCER RES, V62, P3819; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Okabe H, 2001, CANCER RES, V61, P2129; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; Pagano M, 2003, CANCER CELL, V4, P251, DOI 10.1016/S1535-6108(03)00243-5; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters JM, 2003, MOL CELL, V11, P1420, DOI 10.1016/S1097-2765(03)00233-8; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Piva R, 2002, MOL CELL BIOL, V22, P8375, DOI 10.1128/MCB.22.23.8375-8387.2002; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Saitoh T, 2001, INT J ONCOL, V18, P959; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shim EH, 2003, CANCER RES, V63, P1583; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 2002, CANCER RES, V62, P4535; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yasui K, 2002, HEPATOLOGY, V35, P1476, DOI 10.1053/jhep.2002.33683; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	146	72	80	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2037	2049		10.1038/sj.onc.1207413	http://dx.doi.org/10.1038/sj.onc.1207413			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021891				2022-12-17	WOS:000220213400008
J	Wang, D; Shen, Q; Chen, YQ; Wang, MH				Wang, D; Shen, Q; Chen, YQ; Wang, MH			Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta 1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinases; transforming-growth factor; epithelial-mesenchymal transitions; signal transduction	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR SNAIL; FACTOR SCATTER FACTOR; E-CADHERIN; SIGNAL-TRANSDUCTION; CELL PLASTICITY; GENE; METASTASIS; RAS; EXPRESSION	Epithelial to mesenchymal transition (EMT) is a process occurring during embryonic development and cancer progression. Using recepteur d'origine nantais (RON)expressing epithelial cells as a model, we showed that RON activation causes spindle-shaped morphology with increased cell motilities. These activities resemble those observed in EMT induced by transforming growth factor (TGF)-beta1 or by Ras-Raf signaling. By immunofluorescent and Western blot analyses, we found that constitutive RON expression results in diminished expression of E-cadherin, redistribution of beta-catenin, reorganization of actin cytoskeleton, and increased expression of vimentin, a mesenchymal. lament. RON expression is also essential for TGF-beta1-induced expression of alpha-smooth muscle actin (alpha-SMA), a specialized mesenchymal marker. In the study of signaling pathways responsible for RON-mediated EMT, it was found that PD98059, a MAP kinase inhibitor, blocks the collaborative activities of RON and TGF-beta1 in induction of alpha-SMA expression and restores epithelial cells to their original morphology. Moreover, we showed that RON expression increases Smad2 gene promoter activities and protein expression, which significantly lowers TGF-beta1 threshold for EMT induction. These results suggest that persistent RON expression and activation cause the loss of epithelial phenotypes. These changes, collaborating with TGF-beta1 signaling, could play a critical role in epithelial transdifferentiation towards invasiveness and metastasis of certain cancers.	UCHSC, Dept Med, Denver Hlth Med Ctr, Denver, CO 80204 USA; Zhejiang Univ, Lab Chang Jiang Scholar Endowment Biomed Sci, Inst Infect Dis, Sch Med, Hangzhou 310027, Zhejiang, Peoples R China; Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou 310027, Zhejiang, Peoples R China; Univ Colorado, Sch Med, Dept Med, Ctr Canc, Denver, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; Zhejiang University; Zhejiang University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wang, MH (corresponding author), UCHSC, Dept Med, Denver Hlth Med Ctr, 777 Bannock St,Mail 4000, Denver, CO 80204 USA.	ming-hai.wang@uchsc.edu			NCI NIH HHS [R01 CA91890] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Ellenrieder V, 2001, CANCER RES, V61, P4222; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gherardi E, 1997, CIBA F SYMP, V212, P24; Gilles C, 2003, CANCER RES, V63, P2658; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grille SJ, 2003, CANCER RES, V63, P2172; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Masszi A, 2003, AM J PHYSIOL-RENAL, V284, pF911, DOI 10.1152/ajprenal.00183.2002; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nicolas FJ, 2003, J BIOL CHEM, V278, P3251, DOI 10.1074/jbc.M209019200; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Piek E, 1999, J CELL SCI, V112, P4557; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Ruiz P, 1996, WORLD J UROL, V14, P141; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhou YQ, 2002, J BIOL CHEM, V277, P38104, DOI 10.1074/jbc.M206167200; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	53	72	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1668	1680		10.1038/sj.onc.1207282	http://dx.doi.org/10.1038/sj.onc.1207282			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001985				2022-12-17	WOS:000220029300003
J	Ismail, IH; Martensson, S; Moshinsky, D; Rice, A; Tang, C; Howlett, A; McMahon, G; Hammarsten, O				Ismail, IH; Martensson, S; Moshinsky, D; Rice, A; Tang, C; Howlett, A; McMahon, G; Hammarsten, O			SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization	ONCOGENE			English	Article						radiotherapy; DNA-PK; radio sensitizer; ATM	SEVERE COMBINED IMMUNODEFICIENCY; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN TUMOR-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; MAMMALIAN DNA; HISTONE H2AX; PHOSPHORYLATION; WORTMANNIN	Loss of the DNA-dependent protein kinase (DNA-PK) results in increased sensitivity to ionizing radiation due to inefficient repair of DNA double-strand breaks. Overexpression of DNA-PK in tumor cells conversely results in resistance to ionizing radiation. It is therefore possible that inhibition of DNA-PK will enhance the preferential killing of tumor cells by radiotherapy. Available inhibitors of DNA-PK, like wortmannin, are cytotoxic and stop the cell cycle because they inhibit phoshatidylinositol-3-kinases at 100-fold lower concentrations required to inhibit DNA-PK. In an effort to develop a specific DNA-PK inhibitor, we have characterized SU11752, from a three-substituted indolin-2-ones library. SU11752 and wortmannin were equally potent inhibitors of DNA-PK. In contrast, inhibition of the phoshatidylinositol-3-kinase p110gamma required 500-fold higher concentration of SU11752. Thus, SU11752 was a more selective inhibitor of DNA-PK than wortmannin. Inhibition kinetics and a direct assay for ATP binding showed that SU11752 inhibited DNA-PK by competing with ATP. SU11752 inhibited DNA double-strand break repair in cells and gave rise to a five-fold sensitization to ionizing radiation. At concentrations of SU11752 that inhibited DNA repair, cell cycle progression was still normal and ATM kinase activity was not inhibited. We conclude that SU11752 defines a new class of drugs that may serve as a starting point for the development of specific DNA-PK inhibitors.	Gothenburg Univ, Sahlgrens Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden; SUGEN Inc, San Francisco, CA 94080 USA	Sahlgrenska University Hospital; University of Gothenburg; Pfizer	Hammarsten, O (corresponding author), Gothenburg Univ, Sahlgrens Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden.	ola.hammarsten@clinchem.gu.se	Hammarsten, Ola/A-2791-2012	Ismail, Ismail Hassan/0000-0002-5526-6063				Ahn JY, 2000, CANCER RES, V60, P5934; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; Christodoulopoulos G, 1998, CANCER RES, V58, P1789; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dibiase SJ, 2000, CANCER RES, V60, P1245; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Elmroth K, 2000, INT J RADIAT BIOL, V76, P1501, DOI 10.1080/09553000050176261; Elmroth K, 2003, DNA REPAIR, V2, P363, DOI 10.1016/S1568-7864(02)00235-5; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frit P, 1999, MOL PHARMACOL, V56, P141, DOI 10.1124/mol.56.1.141; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Izzard RA, 1999, CANCER RES, V59, P2581; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Martensson S, 2002, J BIOL CHEM, V277, P3020, DOI 10.1074/jbc.M106711200; Martensson S, 2003, RADIAT RES, V160, P291, DOI 10.1667/0033-7587(2003)160[0291:AOTDPK]2.0.CO;2; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; NIAS AHW, 1998, INTRO RADIOBIOLOGY, P116; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Puglianiello A, 2000, J ENDOCRINOL, V165, P123, DOI 10.1677/joe.0.1650123; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; RUBIN P, 1993, CLIN ONCOLOGY MULTID, P71; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shen HX, 1997, ONCOL RES, V9, P295; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shin EK, 1997, J IMMUNOL, V158, P3565; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Stenerlow B, 2003, RADIAT RES, V159, P502, DOI 10.1667/0033-7587(2003)159[0502:MOPDDS]2.0.CO;2; Stockley M, 2001, BIOORG MED CHEM LETT, V11, P2837, DOI 10.1016/S0960-894X(01)00537-6; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TAKE Y, 1995, BIOCHEM BIOPH RES CO, V215, P41, DOI 10.1006/bbrc.1995.2431; Take Y, 1996, BIOCHEM BIOPH RES CO, V221, P207, DOI 10.1006/bbrc.1996.0575; Tounekti O, 2001, BRIT J CANCER, V84, P1272, DOI 10.1054/bjoc.2001.1786; Vaganay-Juery S, 2000, BRIT J CANCER, V83, P514, DOI 10.1054/bjoc.2000.1258; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HC, 2001, CANCER RES, V61, P270; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Williams CJ, 2001, MOL CELL BIOL, V21, P400, DOI 10.1128/MCB.21.2.400-413.2001; XU W, 2002, NAT CELL BIOL, V2, P339; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073	67	72	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					873	882		10.1038/sj.onc.1207303	http://dx.doi.org/10.1038/sj.onc.1207303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661061				2022-12-17	WOS:000188486600002
J	Umehara, S; Higashi, H; Ohnishi, N; Asaka, M; Hatakeyama, M				Umehara, S; Higashi, H; Ohnishi, N; Asaka, M; Hatakeyama, M			Effects of Helicobacter pylori CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma	ONCOGENE			English	Article						H. pylori; CagA; MALT lymphoma; B cell; apoptosis	ATROPHIC GASTRITIS; GENE-EXPRESSION; ULCER DISEASE; LOW-GRADE; IN-VITRO; T(11-18)(Q21-Q21); PHOSPHORYLATION; TRANSLOCATION; STRAINS; KINASE	Helicobacter pylori (H. pylori) is a causative agent of gastrointestinal diseases such as atrophic gastritis and gastroduodenal ulcer. Infection of cagA-positive H. pylori is also associated with gastric carcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. The cagA gene product CagA is directly injected into the bacteria-attached host cells via the bacterial type IV secretion system. The translocated CagA deregulates intracellular signaling pathways and thereby initiates pathogenesis. In this work, we examined the biological effects of CagA on B cells, from which MALT lymphoma arises. Ectopic expression of CagA in interleukin 3-dependent B cells inhibited cell proliferation by suppressing the JAK-STAT signaling. CagA was also capable of preventing hydroxyurea-induced B-cell apoptosis through inhibiting p53 accumulation. In contrast to the effects of CagA in gastric epithelial cells, the observed CagA activities in B cells were independent of its tyrosine phosphorylation. Our results indicate that CagA possesses both phosphorylation-dependent and -independent activities in mammalian cells and that biological impacts of CagA depend on cell-type context. As a result of B-cell growth inhibition, CagA may diminish anti-H. pylori immune responses. Furthermore, CagA may play a role in the development of MALT lymphoma by impairing p53-dependent apoptosis.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Dept Gastroenterol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita-15,Nishi-7, Sapporo, Hokkaido 0600815, Japan.		Higashi, Hideaki/F-6872-2012; OHNISHI, Naomi/F-6914-2012; Asaka, Masahiro/A-5948-2012	OHNISHI, Naomi/0000-0002-2382-3152; 				Auer IA, 1997, ANN ONCOL, V8, P979, DOI 10.1023/A:1008202303666; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; BLASER MJ, 1995, CANCER RES, V55, P2111; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Du MQ, 2002, LANCET ONCOL, V3, P97, DOI 10.1016/S1470-2045(02)00651-4; Eck M, 1997, GASTROENTEROLOGY, V112, P1482, DOI 10.1016/S0016-5085(97)70028-3; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59; Kuipers EJ, 1997, ALIMENT PHARM THER, V11, P71, DOI 10.1046/j.1365-2036.11.s1.5.x; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ott G, 1997, CANCER RES, V57, P3944; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sheu BS, 1999, DIGEST DIS SCI, V44, P868, DOI 10.1023/A:1026627707103; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Tsutsumi R, 2003, J BIOL CHEM, V278, P3664, DOI 10.1074/jbc.M208155200; Wang X, 2000, APMIS, V108, P503, DOI 10.1034/j.1600-0463.2000.d01-89.x; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	29	72	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8337	8342		10.1038/sj.onc.1207028	http://dx.doi.org/10.1038/sj.onc.1207028			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614457				2022-12-17	WOS:000186541500012
J	Suzuki, A; Kusakai, G; Kishimoto, A; Lu, J; Ogura, T; Esumi, H				Suzuki, A; Kusakai, G; Kishimoto, A; Lu, J; Ogura, T; Esumi, H			ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation	ONCOGENE			English	Article						ARK5; Akt; cell survival; caspase 8; HepG2	TRAIL-INDUCED APOPTOSIS; PROTEIN-KINASE; GLUCOSE STARVATION; SIGNALING COMPLEX; TUMOR-CELLS; B-CELLS; AKT; INVOLVEMENT; TOLERANCE; SURVIVAL	AMPK is a serine/threonine protein kinase family and we recently identified a novel member, ARK5. The activation of ARK5 is triggered by Akt, and ARK5 induces tumor cell survival during nutrient starvation. In the current study, we investigated the mechanisms of induction of cell survival by ARK5. Human hepatoma HepG2 cells undergo necrotic cell death within 24 h after the start of glucose starvation, and the cell death signaling has been found to be mediated by death-receptor-independent activation of caspase 8. When HepG2 cells were transfected with ARK5 expression vector and subjected to several cell death stimuli, ARK5 was found to suppress cell death by glucose starvation, TRAIL, and TNF-alpha, but not by ultraviolet irradiation, camptothecin, or doxorubicin. Western blotting analysis revealed that both TRAIL and glucose starvation induced Bid cleavage and FLIP degradation following caspase 8 activation in a time-dependent manner, and ARK5 overexpression clearly delayed Bid cleavage, FLIP degradation, and caspase 8 activation. On the basis of the results of this study, we report that cell survival induced by ARK5 is, at least in part, due to inhibition of caspase 8 activation.	Natl Canc Ctr, Res Inst E, Invest Treatment Div, Chiba 2778577, Japan	National Cancer Center - Japan	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Invest Treatment Div, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200; Folkman J, 2001, P NATL ACAD SCI USA, V98, P398, DOI 10.1073/pnas.98.2.398; Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gupta S., 2001, Current Molecular Medicine (Hilversum), V1, P317, DOI 10.2174/1566524013363780; Hasegawa J, 1996, CANCER RES, V56, P1713; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Izuishi K, 2000, CANCER RES, V60, P6201; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, ONCOGENE, V12, P2045; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266	45	72	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6177	6182		10.1038/sj.onc.1206899	http://dx.doi.org/10.1038/sj.onc.1206899			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679856				2022-12-17	WOS:000185506200007
J	Lammering, G; Hewit, TH; Valerie, K; Contessa, JN; Amorino, GP; Dent, P; Schmidt-Ullrich, RK				Lammering, G; Hewit, TH; Valerie, K; Contessa, JN; Amorino, GP; Dent, P; Schmidt-Ullrich, RK			EGFRvIII-mediated radioresistance through a strong cytoprotective response	ONCOGENE			English	Article						radiation; EGFRvIII; EGFR; MAP kinase; PI3 kinase; AKT	GROWTH-FACTOR RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; MAMMARY-CARCINOMA CELLS; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; GLIOMA-CELLS; KINASE; GENE	The constitutively active, truncated epidermal growth factor receptor EGFRvII lacks the ability of EGF binding due to a deletion of the NH2-terminal domain. EGFRvIII confers increased tumorigenicity, is coexpressed with EGFR wild type (wt) in human carcinoma and malignant glioma cells when grown as xenografts, but is not expressed in vitro. The effects of EGFRvIII expression on cellular radiation responses were studied in Chinese hamster ovary (CHO) cells transfected with plasmids expressing EGFRvIII (CHO.EGFRvIII) or EGFRwt (CHO.EGFRwt). CHO cells expressing similar levels of either receptor were employed to define their roles in response to EGF and ionizing radiation. EGF activated EGFRwt with no effect on EGFRvIII. In contrast, a single radiation exposure of 2 Gy resulted in a 2.8- and 4.3-fold increase in Tyr phosphorylation of EGFRwt and EGFRvIII, respectively. Downstream consequences of this radiation-induced activation were examined by inhibiting EGFRwt and EGFRvIII with AG1478 (kinase inhibitor). The radiation-induced 8.5-fold activation of the pro-proliferative mitogen-activated protein kinase and the 3.2-fold stimulation of the antiapoptotic AKT/phosphatidylinositol-3-kinase pathways by EGFRvII far exceeded that in CHO.EGFR wt cells. Thus, based on colony formation and apoptosis assays, EGFRvIII expression conferred a stronger cytoprotective response to radiation than EGFRwt, resulting in relative radioresistance. Therefore, disabling EGFRvIII in addition to EGFRwt needs to be considered in any therapeutic approach aimed at targeting EGFR for tumor cell radiosensitization.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Dusseldorf, Dept Radiat Oncol, D-4000 Dusseldorf, Germany	Virginia Commonwealth University; Heinrich Heine University Dusseldorf	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, POB 980058, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA65896, P01 CA72955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Frederick L, 2000, CANCER RES, V60, P1383; Han YC, 1996, CANCER RES, V56, P3859; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; Lammering G, 2001, CLIN CANCER RES, V7, P682; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965	31	72	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5545	5553		10.1038/sj.onc.1206788	http://dx.doi.org/10.1038/sj.onc.1206788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944901				2022-12-17	WOS:000184865900002
J	Di Bacco, A; Gill, G				Di Bacco, A; Gill, G			The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptor	ONCOGENE			English	Article						cell proliferation; mannose-6-phosphate receptor; NTERA-2; tumor suppressor	EMBRYONAL CARCINOMA-CELLS; MANNOSE 6-PHOSPHATE; RETINOIC ACID; NEURONAL DIFFERENTIATION; PERINATAL LETHALITY; UROKINASE RECEPTOR; GENE-EXPRESSION; TGF-ALPHA; IGF-II; ACTIVATION	Secreted proteins and their cognate receptors are implicated in a myriad of activities that regulate cell proliferation, differentiation, and development. CREG, a cellular repressor of E1A-stimulated genes, is a secreted glycoprotein that antagonizes cellular transformation by E1A and ras. We have previously shown that CREG expression is induced very early during differentiation of pluripotent cells and, even in the absence of other inducers, CREG promotes neuronal differentiation of human teratocarcinoma NTERA-2 cells. Here we show that ectopic expression of CREG in NTERA-2 cells results in a delay of the G1/S phase transition of the cell cycle and growth inhibition. We show that CREG binds directly to the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) dependent on CREG glycosylation. The M6P/IGF2R is a tumor suppressor that functions to control cell growth through interactions with multiple ligands. By analysing CREG activity in cells lacking M6P/IGF2R expression, we show that this receptor is required for CREG-induced growth inhibition. These studies reveal that CREG inhibits cell growth dependent on the M6P/IGF2R and suggest that interactions between CREG and a well-characterized tumor suppressor may contribute to regulation of proliferation and differentiation in multiple lineages.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Gill, G (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.							ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Hankins GR, 1996, ONCOGENE, V12, P2003; Ikushima H, 2000, P NATL ACAD SCI USA, V97, P8439, DOI 10.1073/pnas.97.15.8439; Jadot M, 1999, J BIOL CHEM, V274, P21104, DOI 10.1074/jbc.274.30.21104; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Journet A, 2000, ELECTROPHORESIS, V21, P3411, DOI 10.1002/1522-2683(20001001)21:16<3411::AID-ELPS3411>3.0.CO;2-M; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; Kang JX, 1998, P NATL ACAD SCI USA, V95, P13687, DOI 10.1073/pnas.95.23.13687; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Kunita R, 2002, GENOMICS, V80, P456, DOI 10.1006/geno.2002.6857; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Lorenzo K, 2000, CANCER RES, V60, P4070; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Ma XY, 2002, BLOOD, V100, P833, DOI 10.1182/blood.V100.3.833; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; Mitsuhashi T, 2001, P NATL ACAD SCI USA, V98, P6435, DOI 10.1073/pnas.111051398; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Piquemal D, 2002, GENOMICS, V80, P361, DOI 10.1006/geno.2002.6836; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TODDERUD G, 1988, J BIOL CHEM, V263, P17893; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; Veal E, 2000, ONCOGENE, V19, P2120, DOI 10.1038/sj.onc.1203529; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942; Wang SN, 1997, CANCER RES, V57, P2543; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Xie S., 2002, MED SCI MONIT INT ME, V8, P293, DOI [10.3390/ijms21186968, DOI 10.3390/IJMS21186968]	53	72	76	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5436	5445		10.1038/sj.onc.1206670	http://dx.doi.org/10.1038/sj.onc.1206670			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934103				2022-12-17	WOS:000184735000008
J	Lodygin, D; Yazdi, AS; Sander, CA; Herzinger, T; Hermeking, H				Lodygin, D; Yazdi, AS; Sander, CA; Herzinger, T; Hermeking, H			Analysis of 14-3-3 sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma	ONCOGENE			English	Article						tumour suppressor; basal cell carcinoma; CpG-methylation; keratinocytes; cell cycle	HIGH-FREQUENCY; EARLY EVENT; HYPERMETHYLATION; GENE; INACTIVATION; LEADS	The p53-regulated 14-3-3sigma gene encodes an inhibitor of cell cycle progression essential for senescence and clonal evolution of keratinocytes in vitro. Here we analysed the in vivo expression of 14-3-3sigma protein in several skin diseases, which are characterized by hyperproliferative keratinocytes. Unexpectedly, the 14-3-3sigma protein was expressed at high levels in psoriasis (11 of 11 patients), condylomata acuminata (11/11), actinic keratoses (11/11) and squamous cell carcinomas (SCC) (11/11). However, keratinocytes that had undergone transformation to basal cell carcinoma (BCC) showed partial (10 of 41; 24.4%) or complete (19 of 41; 46.3%) loss of 14-3-3sigma protein expression. BCC (5/5), SCC (6/6) and actinic keratoses (7/7) concomitantly expressed the p53-homolog p63 and 14-3-3sigma at high levels, ruling out potential inhibitory effects of p63 isoforms on 14-3-3sigma transcription as the basis for loss of 14-3-3sigma expression. Of 41 BCC samples isolated by laser-capture microdissection, 28 (68.3%) showed CpG-hypermethylation of the 14-3-3sigma promoter combined with reduced or absent 14-3-3sigma protein levels in 22 cases (78.6%). Since it has been reported that BCC retain wild-type p16(INK4A) and here BCC with CpG-methylation of 14-3-3sigma did not show CpG-methylation of p16(INK4A) (0/17), silencing of 14-3-3sigma may contribute to evasion of senescence in BCC. As experimental removal of 14-3-3sigma sensitizes to DNA damage, silencing of 14-3-3sigma may explain the high efficacy of radiation therapy in the treatment of BCC.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Munich, Dept Dermatol, D-80539 Munich, Germany	Max Planck Society; University of Munich	Hermeking, H (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	herme@biochem.mpg.de						Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Li Z, 2002, CANCER RES, V62, P1939; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Saridaki Z, 2000, J INVEST DERMATOL, V115, P719, DOI 10.1046/j.1523-1747.2000.00098.x; Schubert J, 1997, Mund Kiefer Gesichtschir, V1, P44; Tokugawa T, 2002, CANCER RES, V62, P4938; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4	20	72	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5519	5524		10.1038/sj.onc.1206854	http://dx.doi.org/10.1038/sj.onc.1206854			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934112				2022-12-17	WOS:000184735000017
J	Do, TN; Rosal, RV; Drew, L; Raffo, AJ; Michl, J; Pincus, MR; Friedman, FK; Petrylak, DP; Cassai, N; Szmulewicz, J; Sidhu, G; Fine, RL; Brandt-Rauf, PW				Do, TN; Rosal, RV; Drew, L; Raffo, AJ; Michl, J; Pincus, MR; Friedman, FK; Petrylak, DP; Cassai, N; Szmulewicz, J; Sidhu, G; Fine, RL; Brandt-Rauf, PW			Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site	ONCOGENE			English	Article						breast cancer; p53; MDM2; necrosis	TUMOR-SUPPRESSOR GENE; C-TERMINAL PEPTIDE; IN-VIVO; INTRACELLULAR DELIVERY; MUTANT P53; ANTENNAPEDIA HOMEODOMAIN; PROTEIN TRANSDUCTION; CIRCULAR-DICHROISM; 3RD HELIX; DOMAIN	p53 is the most frequently altered gene in human cancer and therefore represents an ideal target for cancer therapy. Several amino terminal p53-derived synthetic peptides were tested for their antiproliferative effects on breast cancer cell lines MDA-MB-468 (mutant p53), MCF-7 (overexpressed wild-type p53), and MDA-MB-157 (null p53). p53(15)Ant peptide representing the majority of the mouse double minute clone 2 binding site on p53 (amino acids 12-26) fused to the Drosophila carrier protein Antennapedia was the most effective. p53(15)Ant peptide induced rapid, nonapoptotic cell death resembling necrosis in all breast cancer cells; however, minimal cytotoxicity was observed in the nonmalignant breast epithelial cells MCF-10-2A and MCF-10F. Bioinformatic/biophysical analysis utilizing hydrophobic moment and secondary structure predictions as well as circular dichroism spectroscopy revealed an alpha-helical hydrophobic peptide structure with membrane disruptive potential. Based on these findings, p53(15)Ant peptide may be a novel peptide cancer therapeutic because it induces necrotic cell death and not apoptosis, which is uncommon in traditional cancer therapy.	Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, New York, NY 10032 USA; Harbor VA Med Ctr, Dept Pathol & Lab Med, Manhasset, NY 10010 USA; Harbor VA Med Ctr, Dept Pathol & Lab Med, Brooklyn, NY 11209 USA; Suny Downstate Med Ctr, Dept Pathol, Brooklyn, NY 11203 USA; NIH, Lab Metab, Bethesda, MD 20892 USA	Columbia University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; National Institutes of Health (NIH) - USA	Brandt-Rauf, PW (corresponding author), Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA.		Friedman, Fred/O-6173-2019; Friedman, Fred K/D-4208-2016	Friedman, Fred/0000-0002-0284-7067; 	NCI NIH HHS [R01 CA 42500, CA 82528] Funding Source: Medline; NIOSH CDC HHS [OH 04192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082528, R01CA042500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH004192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIOSH CDC HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DEKROON AIP, 1993, LIPID PEPTIDE INTERA; DELACONSTANTINO.G, 1987, ANTICANCER RES, V7, P1011; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Fahraeus R, 1999, J PATHOL, V187, P138; FINE RL, 1996, ONCOLOGIST, V1, P261; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GARNIER JG, 1996, METHOD ENZYMOL, P540; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOFTS FJ, 1993, ONCOGENE, V8, P2813; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Prives C, 1999, J PATHOL, V187, P112; Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x; Rousselle C, 2000, MOL PHARMACOL, V57, P679, DOI 10.1124/mol.57.4.679; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHERBET GV, 1989, EXP CELL BIOL, V57, P198; Soussi T, 2000, Bull Cancer, V87, P689; SOUSSI T, 1990, ONCOGENE, V5, P945; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; SPECTOR AA, 1987, CANCER RES, V47, P4529; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Velculescu VE, 1996, CLIN CHEM, V42, P858; Wang JL, 2000, CANCER RES, V60, P1498; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Yeung TK, 1999, BIOCHEM BIOPH RES CO, V263, P398, DOI 10.1006/bbrc.1999.1375; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911	43	72	86	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1431	1444		10.1038/sj.onc.1206258	http://dx.doi.org/10.1038/sj.onc.1206258			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629507				2022-12-17	WOS:000181411900001
J	Bilsland, AE; Anderson, CJ; Fletcher-Monaghan, AJ; McGregor, F; Evans, TRJ; Ganly, I; Knox, RJ; Plumb, JA; Keith, WN				Bilsland, AE; Anderson, CJ; Fletcher-Monaghan, AJ; McGregor, F; Evans, TRJ; Ganly, I; Knox, RJ; Plumb, JA; Keith, WN			Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase	ONCOGENE			English	Article						telomerase; hTERT; hTR; gene therapy; nitroreductase; GDEPT; adenovirus	THYMIDYLATE SYNTHASE PROMOTER; REVERSE-TRANSCRIPTASE GENE; ENZYME PRODRUG THERAPY; TUMOR-CELLS; RNA GENE; TATA-LESS; HMLH1 EXPRESSION; IMMORTAL CELLS; HTERT; ACTIVATION	Reactivation of telomerase maintains telomere function and is considered critical to immortalization in most human cancer cells. Elevation of telomerase expression in cancer cells is highly specific: transcription of both RNA (hTR) and protein (hTERT) components is strongly upregulated in cancer cells relative to normal cells. Therefore, telomerase promoters may be useful in cancer gene therapy by selectively expressing suicide genes in cancer cells and not normal cells. One example of suicide gene therapy is the bacterial nitroreductase (NTR) gene, which bioactivates the prodrug CB1954 into an active cytotoxic alkylating agent. We describe construction of adenovirus vectors harbouring the bacterial NTR gene under control of the hTR or hTERT promoters. Western blot analysis of NTR expression in normal and cancer cells infected with adenoviral vectors showed cancer cell-specific nitroreductase expression. Infection with adenoviral telomerase-NTR constructs in a panel of seven cancer cell lines resulted in up to 18-fold sensitization to the prodrug CB1954, an effect that was retained in two drug-resistant ovarian lines. Importantly, no sensitization was observed with either promoter in any of the four normal cell strains. Finally, an efficacious effect was observed in cervical and ovarian xenograft models following single intratumoural injection with low doses of vector, followed by injection with CB1954.	Univ Glasgow, Canc Res UK, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Enact Pharma Plc, Salisbury SP4 0JQ, Wilts, England	Beatson Institute; Cancer Research UK; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, Canc Res UK, Dept Med Oncol, Beatson Labs, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.		Bilsland, Alan/G-2629-2010; Cairney, Claire/H-6989-2012; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Bilsland, Alan/0000-0003-0957-3908; Cairney, Claire/0000-0001-6531-245X				Abdul-Ghani R, 2000, MOL THER, V2, P539, DOI 10.1006/mthe.2000.0196; Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q; ANLEZARK GM, 1992, BIOCHEM PHARMACOL, V44, P2289, DOI 10.1016/0006-2952(92)90671-5; Anthoney DA, 1996, CANCER RES, V56, P1374; Boyd M, 2001, J GENE MED, V3, P165, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM158>3.0.CO;2-C; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Chung-Faye G, 2001, CLIN CANCER RES, V7, P2662; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cui W, 1999, GENE THER, V6, P764, DOI 10.1038/sj.gt.3300873; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Dong S, 2000, J CELL BIOCHEM, V77, P50, DOI 10.1002/(SICI)1097-4644(20000401)77:1<50::AID-JCB6>3.0.CO;2-C; Downey MG, 2001, J ORAL PATHOL MED, V30, P577, DOI 10.1034/j.1600-0714.2001.301001.x; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Garrett MD, 1999, EUR J CANCER, V35, P2010, DOI 10.1016/S0959-8049(99)00280-4; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gu J, 2000, CANCER RES, V60, P5359; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Horikawa I, 1999, CANCER RES, V59, P826; Karamouzis MV, 2002, CLIN CANCER RES, V8, P949; KEITH WN, 2002, EXP REV MOL MED; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Koga S, 2001, ANTICANCER RES, V21, P1937; Komata T, 2001, CANCER RES, V61, P5796; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Naasani I, 1999, CANCER RES, V59, P4004; Pascolo E, 2002, J BIOL CHEM, V277, P15566, DOI 10.1074/jbc.M201266200; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Ring CJA, 1996, GENE THER, V3, P1094; Rudge TL, 1999, J CELL BIOCHEM, V73, P90, DOI 10.1002/(SICI)1097-4644(19990401)73:1<90::AID-JCB10>3.0.CO;2-W; Sarvesvaran J, 1999, CARCINOGENESIS, V20, P1649, DOI 10.1093/carcin/20.8.1649; Scapin G, 2002, DRUG DISCOV TODAY, V7, P601, DOI 10.1016/S1359-6446(02)02290-0; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shi QW, 1997, HUM GENE THER, V8, P403, DOI 10.1089/hum.1997.8.4-403; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Soder AI, 1998, ONCOGENE, V16, P979, DOI 10.1038/sj.onc.1201620; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Takakura M, 1999, CANCER RES, V59, P551; Vassaux G, 1999, GENE THER, V6, P1192, DOI 10.1038/sj.gt.3300910; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wisman GBA, 2000, HUM PATHOL, V31, P1304, DOI 10.1053/hupa.2000.19299; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhao JQ, 1998, ONCOGENE, V16, P1345, DOI 10.1038/sj.onc.1201892; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114	51	72	79	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					370	380		10.1038/sj.onc.1206168	http://dx.doi.org/10.1038/sj.onc.1206168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545158				2022-12-17	WOS:000180379100006
J	Perry, C; Sklan, EH; Birikh, K; Shapira, M; Trejo, L; Eldor, A; Soreq, H				Perry, C; Sklan, EH; Birikh, K; Shapira, M; Trejo, L; Eldor, A; Soreq, H			Complex regulation of acetylcholinesterase gene expression in human brain tumors	ONCOGENE			English	Article						acetylcholinesterase; human brain tumors; Runx1; AML1	TISSUE-SPECIFIC EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; NEURONAL DIFFERENTIATION; SPLICE VARIANTS; CELL-GROWTH; BUTYRYLCHOLINESTERASE; PROTEIN; LEUKEMIA; FORMS	To study the regulation of acetylcholinesterase (AChE) gene expression in human brain tumors, 3' splice variants of AChE mRNA and potentially relevant transcription factor mRNAs were labeled in primary astrocytomas and melanomas. AChE-S and AChE-R mRNA, as well as Runx1/AML1 mRNA accumulated in astrocytomas in correlation with tumor aggressiveness, but neither HNF3beta nor c-fos mRNA was observed in melanoma and astrocytomas. immunohistochemistry demonstrated nuclear Runx1/AML1 and cellular AChE-S and AChE-R in melanomas, however, only AChE-S, and not the secreted AChE-R variant, was retained in astrocyte tumor cells. Runx1/AML1 revealed weak linkage with ACHE promoter sequences, yet enhanced ACHE gene expression in co-transfected COS1 cells. The p300 coactivator and the ACHE promoter's distal enhancer facilitated this effect, which was independent of much of the Runx1/AML1 trans-activation domain. Surprisingly, GASP, a fusion product of green fluorescence protein (GFP) and ASP(67), a peptide composed of the 67 C-terminal amino acid residues of AChE-S, localized to COS1 cell nuclei. However, GARP, the corresponding fusion product of GFP with a peptide having the 51 C-terminal residues of AChE-E or GFP alone, remained cytoplasmic. Runx1/AML1 exhibited improved nuclear retention in GASP-expressing COS1 cells, suggesting modulated nuclear localization processes. Together, these findings reveal brain tumor-specific regulation of both expression and cellular retention of variant ACHE gene products.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, IL-64239 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Pathol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, IL-64239 Tel Aviv, Israel; RAS, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117799, Russia	Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il	Birikh, Klara/AAO-4069-2021	Birikh, Klara/0000-0001-6124-447X; Soreq, Hermona/0000-0002-0955-526X				ACHESON AL, 1984, J NEUROSCI, V4, P1771; ALOYA RB, 1993, P NATL ACAD SCI USA, V90, P2471; Barbosa M, 2001, SURG NEUROL, V55, P106, DOI 10.1016/S0090-3019(01)00351-2; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Ben Aziz-Aloya R, 1998, CELL DEATH DIFFER, V5, P765, DOI 10.1038/sj.cdd.4400415; BERGER R, 1985, CYTOGENET CELL GENET, V40, P490, DOI 10.1159/000132181; Bigbee JW, 1999, ENVIRON HEALTH PERSP, V107, P81, DOI 10.2307/3434475; BROWN LM, 1990, CANCER RES, V50, P6585; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; Coleman BA, 1996, J BIOL CHEM, V271, P4410; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EHRLICH G, 1992, GENOMICS, V13, P1192, DOI 10.1016/0888-7543(92)90037-S; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; GETMAN DK, 1992, AM J HUM GENET, V51, P170; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Goodman RH, 2000, GENE DEV, V14, P1553; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisaru D, 1999, MOL CELL BIOL, V19, P788; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Grisaru D, 2001, MOL MED, V7, P93, DOI 10.1007/BF03401943; Haas R, 1996, BIOCHEM J, V314, P817, DOI 10.1042/bj3140817; Karpel R, 1996, J NEUROCHEM, V66, P114; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitange G, 1999, MODERN PATHOL, V12, P618; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; LAPIDOTLIFSON Y, 1989, P NATL ACAD SCI USA, V86, P4715, DOI 10.1073/pnas.86.12.4715; LeBeau MM, 1996, BLOOD, V88, P1930; LI Y, 1991, J BIOL CHEM, V266, P23083; Li YK, 2000, J NEUROSCI, V20, P149, DOI 10.1523/JNEUROSCI.20-01-00149.2000; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Neskovic-Konstantinovic Z, 1999, J EXP CLIN CANC RES, V18, P347; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Perry C, 2002, LEUKEMIA RES, V26, P221, DOI 10.1016/S0145-2126(01)00128-X; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAZON N, 1984, EXP NEUROL, V84, P681, DOI 10.1016/0014-4886(84)90215-2; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; SaezValero J, 1996, BBA-MOL BASIS DIS, V1317, P210, DOI 10.1016/S0925-4439(96)00061-0; SaezValero J, 1996, NEUROSCI LETT, V206, P173, DOI 10.1016/S0304-3940(96)12452-6; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; SOREQ H, 1984, EMBO J, V3, P1371, DOI 10.1002/j.1460-2075.1984.tb01979.x; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Valter MM, 1999, CANCER RES, V59, P5608; VELAN B, 1994, J BIOL CHEM, V269, P22719; Welker P, 2000, BRIT J CANCER, V82, P1453, DOI 10.1054/bjoc.1999.1076; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yamada M, 1996, J NEUROSCI RES, V43, P355, DOI 10.1002/(SICI)1097-4547(19960201)43:3<355::AID-JNR10>3.0.CO;2-4; ZAKUT H, 1988, CANCER, V61, P727, DOI 10.1002/1097-0142(19880215)61:4<727::AID-CNCR2820610416>3.0.CO;2-L; Zhang HT, 2000, BRIT J CANCER, V83, P63	61	72	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8428	8441		10.1038/sj.onc.1205945	http://dx.doi.org/10.1038/sj.onc.1205945			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466963				2022-12-17	WOS:000179480100006
J	Murata, H; Khattar, NH; Kang, Y; Gu, LY; Li, GM				Murata, H; Khattar, NH; Kang, Y; Gu, LY; Li, GM			Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability	ONCOGENE			English	Article						hMSH2; hMLH1; microsatellite instability; hypermethylation; breast cancer	NONPOLYPOSIS COLORECTAL-CANCER; IN-SITU; PROMOTER HYPERMETHYLATION; ENDOMETRIAL CARCINOMAS; CELL-LINES; GASTRIC CARCINOMAS; HIGH-FREQUENCY; COLON-CANCER; TUMOR-CELLS; DNA	Breast cancer is the most common cancer in women, but its pathogenesis is still unclear. Microsatellite instability (MSI) has been identified in breast cancer cells, suggesting an association with mismatch repair defects. To test this hypothesis, we investigated MSI, protein expression of hMSH2 and hMLH1, as well as genetic and epigenetic modifications of these two genes in 32 sporadic breast tumors. MSI was identified in 15 cases. Immunohistochemistry analysis revealed that all MSI cases but one had lower than normal expression of hMSH2 (nine cases), hMLH1 (12 cases), or both (seven cases). In tumors with MSI, both genetic and epigenetic modifications of these mismatch repair genes were also identified. Eight cases harbored mutations or polymorphisms in hMSH2 and hMLH1, and 10 exhibited hypermethylation in the promoter region of hMLH1. These results suggest that both genetic and epigenetic alterations of hMSH2 and especially of h-MLH1 contribute to genomic instability and tumorigenesis in sporadic breast cancer.	Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky	Li, GM (corresponding author), Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Markey Canc Ctr, Suite MS 117,800 Rose St, Lexington, KY 40536 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALDAZ CM, 1995, CANCER RES, V55, P3976; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bevilacqua RAU, 2000, INT J CANCER, V87, P200, DOI 10.1002/1097-0215(20000715)87:2<200::AID-IJC7>3.0.CO;2-I; Boland CR, 1998, CANCER RES, V58, P5248; CONTEGIACOMO A, 1995, INT J CANCER, V64, P264, DOI 10.1002/ijc.2910640409; CUI J, 1998, CHUNG HUA I HSUEH I, V15, P348; Cunningham JM, 1998, CANCER RES, V58, P3455; DeMarchis L, 1997, CLIN CANCER RES, V3, P241; Deng GR, 1999, CANCER RES, V59, P2029; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fleisher AS, 1999, CANCER RES, V59, P1090; Friedrich M, 1999, HISTOCHEM J, V31, P717, DOI 10.1023/A:1003996431044; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fujii Satoshi, 1998, Hiroshima Journal of Medical Sciences, V47, P89; Grady WM, 2001, CANCER RES, V61, P900; Gurin CC, 1999, CANCER RES, V59, P462; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hosoya N, 1998, JPN J CANCER RES, V89, P33, DOI 10.1111/j.1349-7006.1998.tb00476.x; Jonsson M, 1995, EUR J CANCER, V31A, P2330, DOI 10.1016/0959-8049(95)00447-5; Kane MF, 1997, CANCER RES, V57, P808; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Leung SY, 1999, CANCER RES, V59, P159; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lynch HT, 1999, J MED GENET, V36, P801; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Paulson TG, 1996, CANCER RES, V56, P4021; Rosenberg CL, 1997, HUM PATHOL, V28, P214, DOI 10.1016/S0046-8177(97)90109-X; Rush EB, 1997, ANN SURG ONCOL, V4, P310, DOI 10.1007/BF02303580; Salvesen HB, 2000, CLIN CANCER RES, V6, P3607; Scott RJ, 2001, AM J HUM GENET, V68, P118, DOI 10.1086/316942; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; Shen KL, 2000, J SURG ONCOL, V74, P100, DOI 10.1002/1096-9098(200006)74:2<100::AID-JSO5>3.0.CO;2-O; Siah SP, 2000, BREAST CANCER RES TR, V60, P135, DOI 10.1023/A:1006315315060; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Thibodeau SN, 1998, CANCER RES, V58, P1713; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Toyama T, 1996, CANCER LETT, V108, P205, DOI 10.1016/S0304-3835(96)04414-X; Toyama T, 1996, INT J CANCER, V68, P447, DOI 10.1002/(SICI)1097-0215(19961115)68:4<447::AID-IJC8>3.0.CO;2-0; Vasen HFA, 2001, AM J HUM GENET, V68, P1533, DOI 10.1086/320610; Walsh T, 1998, J PATHOL, V185, P18, DOI 10.1002/(SICI)1096-9896(199805)185:1<18::AID-PATH41>3.0.CO;2-G; Weber TK, 1997, CANCER RES, V57, P3798; YEE CJ, 1994, CANCER RES, V54, P1641; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155	57	72	84	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5696	5703		10.1038/sj.onc.1205683	http://dx.doi.org/10.1038/sj.onc.1205683			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173039				2022-12-17	WOS:000177463400004
J	Gurbuxani, S; Bruey, JM; Fromentin, A; Larmonier, N; Parcellier, A; Jaattela, M; Martin, F; Solary, E; Garrido, C				Gurbuxani, S; Bruey, JM; Fromentin, A; Larmonier, N; Parcellier, A; Jaattela, M; Martin, F; Solary, E; Garrido, C			Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells	ONCOGENE			English	Article						HSP70; apoptosis; immunogenicity; tumorigenicity; colon cancer cells	HEAT-SHOCK-PROTEIN; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; IMMUNE-RESPONSE; DIFFERENTIAL EXPRESSION; TUMOR IMMUNOGENICITY; NEGATIVE REGULATION; IN-VITRO; ANTIGEN; DEATH; TUMORIGENICITY	Expression of inducible heat shock protein 70 (HSP70) in tumor cells has been proposed to enhance their immunogenicity. However, HSP70 has also been demonstrated to prevent tumor cell death, a key process for the development of tumor cell immunogenicity. In the present study, we investigated the influence of the HSP70 protein level on PRO colon cancer cell growth and immunogenicity in syngeneic BDIX rats and nude mice. These cells have a basal expression of HSP70 which can be substantially increased by heat shock. When injected subcutaneously in syngeneic animals, PRO cells do not induce any detectable immune response and give rise to progressive, metastatic and lethal tumors. Stable transfection of an anti-sense hsp70 cDNA in PRO cells (PRO-70AS cells) strongly decreased HSP70 expression and sensitized cell-free extracts to cytochrome c/dATP-mediated activation of caspases. Subcutaneous injection of PRO-70AS cells induced tumors that rapidly regressed in syngeneic rats while they grew normally in nude mice. Syngeneic rats injected with PRO-70AS cells became protected against a further challenge with PRO cells. The tumor-specific immune response induced by HSP70-depleted PRO-70AS cells was associated with an increased rate of cell death in viro. These PRO-70AS cells were also more sensitive to NO-mediated, caspase-dependent, macrophage cytotoxicity in vivo. Altogether, these results indicate that reduced level of HSP70 expression in PRO- colon cancer cells results in the generation of a specific immune response by promoting cell death in vivo.	Fac Med, INSERM, U517, IFR 100, F-21033 Dijon, France; Danish Canc Soc, DK-2100 Copenhagen, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Danish Cancer Society	Garrido, C (corresponding author), Fac Med, INSERM, U517, IFR 100, 7 Blvd Jeanne Darc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Jäättelä, Marja/AAT-7932-2021; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018	Jäättelä, Marja/0000-0001-5950-7111; Garrido, carmen/0000-0003-1368-1493; Solary, Eric/0000-0002-8629-1341				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BELL DA, 1991, CLIN IMMUNOL IMMUNOP, V60, P13, DOI 10.1016/0090-1229(91)90108-M; Blachere NE, 1995, SEMIN CANCER BIOL, V6, P349, DOI 10.1016/1044-579X(95)90004-7; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; BONNOTTE B, 2001, IN PRESS J IMMUNOL; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; CAIGNARD A, 1988, INT J CANCER, V42, P883, DOI 10.1002/ijc.2910420616; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kaur J, 2000, INT J CANCER, V85, P1; Kaur J, 1995, INT J CANCER, V63, P774, DOI 10.1002/ijc.2910630604; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Melcher A, 1999, J MOL MED-JMM, V77, P824, DOI 10.1007/s001099900066; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Negulyaev YA, 1996, BBA-BIOMEMBRANES, V1282, P156, DOI 10.1016/0005-2736(96)00055-7; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Ralhan R, 1995, CLIN CANCER RES, V1, P1217; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Shrestha A, 1999, LAB INVEST, V79, P1629; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; Srivastava PK, 2000, NAT IMMUNOL, V1, P363, DOI 10.1038/80795; Todryk S, 1999, J IMMUNOL, V163, P1398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wells AD, 2000, IMMUNOL TODAY, V21, P129, DOI 10.1016/S0167-5699(99)01558-3; Wells AD, 1998, INT IMMUNOL, V10, P609, DOI 10.1093/intimm/10.5.609; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643	47	72	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7478	7485		10.1038/sj.onc.1204948	http://dx.doi.org/10.1038/sj.onc.1204948			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709719				2022-12-17	WOS:000171976900004
J	Gilmore, TD; Cormier, C; Jean-Jacques, J; Gapuzan, ME				Gilmore, TD; Cormier, C; Jean-Jacques, J; Gapuzan, ME			Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel	ONCOGENE			English	Article						Rel; c-Rel; NF-kappa B; Bcl-2; v-Rel; malignant transformation	NF-KAPPA-B; ONCOPROTEIN; ONCOGENE; LYMPHOMA; VIRUS; GENES; BCL-2; PROTOONCOGENE; AMPLIFICATION; FIBROBLASTS	Rel/NF-kappaB transcription factors control a variety of cellular processes, such as cell growth and apoptosis, that are relevant to oncogenesis, and mutations in genes encoding Rel/NF-kappaB transcription factors have been found in several human lymphoid cell cancers. In this study, we have used a sensitive cell outgrowth assay to demonstrate that wild-type human c-Rel can malignantly transform primary chicken spleen cells, and that transformation by c-Rel is accelerated by co-expression of Bcl-2. Full-length mouse c-Rel can also transform chicken spleen cells. These results are the first demonstration of a lymphoid cell malignant transforming ability for mammalian Rel/NF-kappaB transcription factors, and implicate c-Rel as a molecular target for cancer therapeutics.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; Bohlander SK, 2000, CYTOGENET CELL GENET, V91, P52, DOI 10.1159/000056818; BROWNELL E, 1989, ONCOGENE, V4, P935; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, DNA PROVIRUS, P109; GILMORE TD, 2000, DNA ALTERATIONS CANC, P121; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; HENDERSON E, 1977, VIROLOGY, V76, P152, DOI 10.1016/0042-6822(77)90292-6; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huang HHT, 2000, J MANUF SYST, V19, P73, DOI 10.1016/S0278-6125(00)80001-1; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Kaye KM, 1999, J VIROL, V73, P10525, DOI 10.1128/JVI.73.12.10525-10530.1999; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LU D, 1991, ONCOGENE, V6, P1235; Mainville CA, 2001, J VIROL, V75, P1816, DOI 10.1128/JVI.75.4.1816-1823.2001; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SIF S, 1993, ONCOGENE, V8, P2501; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1997, SCIENCE, V276, P185; White DW, 1996, ONCOGENE, V13, P891	35	72	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7098	7103		10.1038/sj.onc.1204898	http://dx.doi.org/10.1038/sj.onc.1204898			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704834				2022-12-17	WOS:000171739300013
J	Tang, QB; Chen, WX; Gonzales, MS; Finch, J; Inoue, H; Bowden, GT				Tang, QB; Chen, WX; Gonzales, MS; Finch, J; Inoue, H; Bowden, GT			Role of cyclic AMP responsive element in the UVB induction of cyclooxygenase-2 transcription in human keratinocytes	ONCOGENE			English	Article						UVB; CREB; p38; COX-2; transcription	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATOR PROTEIN-1 ACTIVATION; SYNTHASE-2 GENE-EXPRESSION; MESSENGER-RNA STABILITY; GROWTH-FACTOR-ALPHA; COLON-CANCER CELLS; P38 MAP KINASE; NUCLEAR FACTOR; PHORBOL ESTER; ENDOTHELIAL-CELLS	It has been shown that UVB irradiation induces expression of COX-2 and up-regulation of COX-2 plays a functional role in UVB tumor promotion. In this study, we examined the cis-elements in the human COX-2 promoter that may be responsible for the UVB induction of COX-2. Analyses with the COX-2 promoter region revealed that the cyclic AMP responsive element near the TATA box was essential for both basal and UVB induced COX-2 expression. This was further supported by studies using a dominant negative mutant of CREB, which strongly inhibited the activity of COX-2 promoter. Electrophoretic mobility shift assays indicated that CREB and ATF-I were the major proteins binding to the COX-2 CRE. CREB and ATF-I were phosphorylated upon UVB treatment, and SB202190, a p38 MAPK inhibitor, decreased the phosphorylation of CREB/ATF-1 and suppressed COX-2 promoter activity. In contrast, treatment with forskolin, an activator of adenylyl cyclase, led to phosphorylation of CREB and ATF-I and activation of COX-2 promoter. Finally, enhanced binding of phospho-CREB/ATF-1 to the COX-2 CRE was observed after UVB induction. Thus, one signaling pathway for UVB induction of human COX-2 involves activation of p38, subsequent phosphorylation of CREB/ATF-1, and activation of the COX-2 CRE through enhanced binding of phosphorylated CREB/ATF-1.	Univ Arizona, Coll Med, Ctr Canc, Dept Radiat Oncol, Tucson, AZ 85724 USA; Natl Cardiovasc Ctr, Dept Pharmacol, Inst Res, Suita, Osaka 5658565, Japan	University of Arizona; National Cerebral & Cardiovascular Center - Japan	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Ctr Canc, Dept Radiat Oncol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA27502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Boolbol SK, 1996, CANCER RES, V56, P2556; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; CHEN W, 2001, IN PRESS ONCOGENE; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2000, MOL CARCINOGEN, V28, P196, DOI 10.1002/1098-2744(200008)28:4<196::AID-MC2>3.0.CO;2-C; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang M, 1998, CANCER RES, V58, P1208; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Isoherranen K, 1999, BRIT J DERMATOL, V140, P1017; Kam PCA, 2000, ANAESTHESIA, V55, P442, DOI 10.1046/j.1365-2044.2000.01271.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; MOATTER T, 1992, J CELL PHYSIOL, V151, P571, DOI 10.1002/jcp.1041510317; Nusing RM, 1996, BIOCHEM J, V313, P617, DOI 10.1042/bj3130617; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA T, 1991, J BIOL CHEM, V266, P13621; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; Reddy BS, 1996, CANCER RES, V56, P4566; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Sheng HM, 1998, CANCER RES, V58, P362; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH W, 1997, ADV EXP MED BIOL, P989; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 2000, CANCER RES, V60, P2399; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	49	72	74	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5164	5172		10.1038/sj.onc.1204667	http://dx.doi.org/10.1038/sj.onc.1204667			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526505				2022-12-17	WOS:000170464000010
J	Whitehead, IP; Zohn, IE; Der, CJ				Whitehead, IP; Zohn, IE; Der, CJ			Rho GTPase-dependent transformation by G protein-coupled receptors	ONCOGENE			English	Article						gene transfer assays; Dbl family proteins	NUCLEOTIDE EXCHANGE FACTOR; CONSTITUTIVELY ACTIVATING MUTATION; HETEROTRIMERIC G-PROTEINS; SERUM RESPONSE FACTOR; MUTANT ALPHA-SUBUNIT; CELL LUNG-CANCER; SWISS 3T3 CELLS; RAS TRANSFORMATION; BINDING PROTEIN; THROMBIN RECEPTOR	G protein coupled receptors (GPCRs) constitute the largest family of cell surface receptors, with more than 1000 members, and are responsible for converting a diverse array of extracellular stimuli into intracellular signaling events. Most members of the family have defined roles in intermediary metabolism and generally perform these functions in well-differentiated cells. However, there is an increasing awareness that some GPCRs can also regulate proliferative signaling pathways and that chronic stimulation or mutational activation of receptors can lead to oncogenic transformation. Activating mutations in GPCRs are associated with several types of human tumors and some receptors exhibit potent oncogenic activity due to agonist overexpression, Additionally, expression screening analyses for novel oncogenes identified GPCRs whose expression causes the oncogenic transformation of NIH3T3 mouse fibroblasts, These include Mas, G2A, and the PAR-1 thrombin receptor. In this review we summarize the signaling and transforming properties of these GPCR oncoproteins. What has emerged from these studies is the delineation of a GTPase cascade where transforming GPCRs cause aberrant growth regulation via activation of Rho family small GTPases.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA; Rockefeller Univ, Mol Embryol Lab, New York, NY 10021 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rockefeller University; University of North Carolina; University of North Carolina Chapel Hill	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA.			Zohn, Irene/0000-0001-7688-682X; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978, CA55008, CA77493, CA63071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063071, R01CA055008, R29CA077493, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRASS LF, 1998, ANN NEW YORK ACAD SC; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHARDIN P, 1993, GTPASES BIOL, V1, pCH12; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V66, P184; CRESPO P, 1994, NATURE, V379, P557; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; del Peso L, 1997, ONCOGENE, V15, P3047; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2664; Ellis S, 2000, CURR BIOL, V10, P1387, DOI 10.1016/S0960-9822(00)00777-6; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAHMOUD S, 1991, CANCER RES, V51, P1798; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; MARTIN CB, 2001, IN PRESS ONCOGENE; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MONNOT C, 1991, MOL ENDOCRINOL, V5, P1477, DOI 10.1210/mend-5-10-1477; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; POYNER DR, 1990, BIOCHEM J, V271, P605, DOI 10.1042/bj2710605; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROSS PC, 1990, P NATL ACAD SCI USA, V87, P3052, DOI 10.1073/pnas.87.8.3052; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; SEITZ JF, 1991, J CLIN GASTROENTEROL, V13, P1541; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.biochem.63.1.101; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANOBBERGHENSCHILLING E, 1993, THROMB HAEMOSTASIS, V70, P163; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	88	72	77	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1547	1555		10.1038/sj.onc.1204188	http://dx.doi.org/10.1038/sj.onc.1204188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313901				2022-12-17	WOS:000168089800004
J	Arlt, A; Grobe, O; Sieke, A; Kruse, ML; Folsch, UR; Schmidt, WE; Schafer, H				Arlt, A; Grobe, O; Sieke, A; Kruse, ML; Folsch, UR; Schmidt, WE; Schafer, H			Expression of the NF-kappa B target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells	ONCOGENE			English	Article						programmed cell death; NF-kappa B; early response gene; cell cycle	EARLY-RESPONSE GENE; ALPHA-INDUCED APOPTOSIS; TRANSCRIPTIONAL REGULATION; CYCLIN D1; C-MYC; INHIBITOR; PROTEIN; ACTIVATION; PROMOTER; GROWTH	P22(PRG1/IEX-1) is putative NF-kappaB target gene implicated in the regulation of cellular viability. Here, we show that in HeLa cells TNF alpha induces expression of p22(PRG1/IEX-1) in an NF-kappaB dependent fashion. Blockade of NF-kappaB activation by various NF-kappaB inhibitors abolished TNF alpha -induced p22(PRG1/IEX-1) expression and increased the sensitivity to apoptosis induced by TNF alpha, an activating Fas-antibody or the anti-cancer drug etoposide, Surprisingly, ectopic expression of p22(PRG1/IEX-1) in HeLa cells transfected with an inducible p22(PRG1/IEX-1)-expression vector augments the susceptibility to apoptosis initiated by death-receptor ligands or by etoposide, In addition, p22(PRG1/IEX-1) expressing HeLa cells exhibit an accelerated progression through the cell cycle. Transfection of an antisense hammerhead ribozyme targeted to p22(PRG1/IEX-1) reduced the speed in cell cycle progression and decreased the apoptotic response to death ligands. Our data demonstrate that p22(PRG1/IEX-1) is specifically induced during NF-kappaB activation, but this seems not to be related to the anti-apoptotic actions of NF-kappaB, Instead, NF-kappaB dependent recruitment of p22(PRG1/IEX-1) might be related to a modulation in the cell cycle, and hereby, p22(PRG1/IEX-1) accelerate cell growth on the one hand, but may trigger apoptosis on the other.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Ruhr Univ Bochum, St Josef Hosp, Dept Med 1, D-4630 Bochum, Germany	University of Kiel; Ruhr University Bochum	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHARLES CH, 1993, ONCOGENE, V8, P797; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jiang MC, 1996, ONCOGENE, V13, P609; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kroll M, 1999, CHEM BIOL, V6, P689, DOI 10.1016/S1074-5521(00)80016-2; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sakamuro D, 1995, ONCOGENE, V11, P2411; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Usami I, 1998, BIOCHEM PHARMACOL, V55, P185, DOI 10.1016/S0006-2952(97)00429-2; VAN AD, 1996, SCIENCE, V274, P787; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	43	72	76	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					69	76		10.1038/sj.onc.1204061	http://dx.doi.org/10.1038/sj.onc.1204061			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244505				2022-12-17	WOS:000166361400008
J	Reddy, TR; Tang, HL; Xu, WD; Wong-Staal, F				Reddy, TR; Tang, HL; Xu, WD; Wong-Staal, F			Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA	ONCOGENE			English	Article						nuclear export; RNA helicase A; Sam68; Tap; RRE; CTE	CONSTITUTIVE TRANSPORT ELEMENT; HIV-1 REV PROTEIN; MESSENGER-RNA; NUCLEAR EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; BINDING; IDENTIFICATION; EXPRESSION; SEQUENCES; SIGNAL	Unlike cellular mRNA, retroviral mRNA bypasses the tight coupling of the splicing and nuclear export steps to allow the export of intron-containing viral RNA transcripts to the cytoplasm. Two distinct nuclear export pathways for retroviral mRNA have been described: a CRM-1 dependent pathway mediated by the HIV-1 Rev protein and the Rev Response Element (RRE), and a CRM-1 independent pathway mediated by the Constitutive Transport Element (CTE) of type D retroviruses. Two CTE-binding proteins, RNA helicase A (RHA) and Tap, have been implicated in the nuclear export of CTE-containing RNA. Recently, we reported that expression of RRE-containing RNA could also be mediated by a cellular protein, Sam68, independently of Rev. Here we report evidence that Sam68, RHA and Tap cooperate in the nuclear export of both CTE- and RRE-containing RNA. RHA binds to Sam68 and to Tap both in vivo and in vitro. Over-expression of Sam68 activates both RRE-and CTE-regulated reporter gene expression in human cells and in quail cells in the presence of human lap. This activation was competitively inhibited by the nuclear transport domain (NTD) of RHA and a transdominant negative mutant of Tap. Conversely, the activation of CTE by Tap in quail cells was inhibited by a transdominant mutant of Sam68 and NTD. We propose that both HIV and type D retroviruses may access the same constitutive RNA nuclear export path tray involving RHA, Tap and Sam68, even though HIV also utilizes the Rev protein for more efficient nuclear export, it is likely that this constitutive export pathway is also used by cellular mRNA, but at a different interface with the splicing process.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Tang, Hengli/F-2085-2014		NIGMS NIH HHS [GM56089] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bear J, 1999, MOL CELL BIOL, V19, P6306; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; EMST RK, 1997, MOL CELL BIOL, V17, P135; Fornerod M, 1997, CELL, V90, P1051; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; SOLOMIN L, 1990, J VIROL, V64, P6010, DOI 10.1128/JVI.64.12.6010-6017.1990; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yoon DW, 1997, IMMUNITY, V6, P571, DOI 10.1016/S1074-7613(00)80345-3; Zhang SS, 1999, J CELL SCI, V112, P1055; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994	34	72	72	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3570	3575		10.1038/sj.onc.1203676	http://dx.doi.org/10.1038/sj.onc.1203676			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951562				2022-12-17	WOS:000088568300002
J	Alimov, A; Kost-Alimova, M; Liu, J; Li, CD; Bergerheim, U; Imreh, S; Klein, G; Zabarovsky, ER				Alimov, A; Kost-Alimova, M; Liu, J; Li, CD; Bergerheim, U; Imreh, S; Klein, G; Zabarovsky, ER			Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma	ONCOGENE			English	Article						tumor suppressor genes; allele titration assay; deletion mapping; human chromosome 3	TUMOR-SUPPRESSOR GENE; COMPARATIVE GENOMIC HYBRIDIZATION; LUNG-CANCER; HOMOZYGOUS DELETION; SHORT ARM; T(3-8) BREAKPOINT; LINKING CLONES; SOLID TUMORS; REGION; CHROMOSOME-3	We have recently developed an allele titration assay (ATA) to assess the sensitivity and influence of normal cell admixture in loss of heterozygosity (LOH) studies based on CA-repeat, The assay showed that these studies are biased by the size-dependent differential sensitivity of allele detection. Based on these data, we have set up new criteria for evaluation of LOH, By combining these new rules with comparative genome hybridization (CGH) we have shown the presence of interstitial deletions in renal cell carcinoma (RCC) biopsies and cell lines, At least three out of 11 analysed RCC cell lines and three out of 37 biopsies contain interstitial deletions on chromosome 3, Our study suggests the presence of several regions on human chromosome 3 that might contribute to tumor development by their loss: (i) 3p25-p26, around the VHL gene (D3S1317); (ii) 3p21.3-p22 (between D3S1260 and D3S1611); (iii) 3p21.2 (around D3S1235 and D3S1289); (iv) 3p13-p14 (around D3S1312 and D3S1285), For the first time, AP20 region (3p21.3-p22) was carefully tested for LOH in RCC, It was found that the AP20 region is the most frequently affected area. Our data also suggest that another tumor suppressor gene is located near the VHL gene in 3p25-p26.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Russian Acad Sci, Engellhardt Inst Mol Biol, Moscow 117984, Russia; Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden; Karolinska Inst, Ctr Genom Res, S-17177 Stockholm, Sweden	Karolinska Institutet; Russian Academy of Sciences; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Zabarovsky, ER (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Alimov, Andrei/J-7358-2018; Zabarovsky, Eugene R/A-6645-2010	Li, Chunde/0000-0003-4331-079X; Alimov, Andrei/0000-0002-8495-7728				BEAR A, 1987, CANCER RES, V47, P3856; BERGERHEIM U, 1989, CANCER RES, V49, P1390; Bergerheim USR, 1996, CANCER GENET CYTOGEN, V86, P95, DOI 10.1016/0165-4608(95)00201-4; Chudek J, 1997, INT J CANCER, V73, P225, DOI 10.1002/(SICI)1097-0215(19971009)73:2<225::AID-IJC11>3.3.CO;2-N; DALY MC, 1993, ONCOGENE, V8, P1721; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; GEMMILL RM, 1995, NATURE, V377, P299; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hu LF, 1996, GENE CHROMOSOME CANC, V17, P118, DOI 10.1002/(SICI)1098-2264(199610)17:2<118::AID-GCC7>3.0.CO;2-8; IMREH S, 1994, GENE CHROMOSOME CANC, V11, P237, DOI 10.1002/gcc.2870110406; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; KHOLODNYUK I, 1996, GENE CHROMOSOME CANC, V18, P1; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; LUBINSKI J, 1994, CANCER RES, V54, P3710; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PRESTI JC, 1993, CANCER RES, V53, P5780; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Roche J, 1996, ONCOGENE, V12, P1289; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; Tomita Y, 1996, INT J CANCER, V66, P322, DOI 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; vandenBerg A, 1996, CYTOGENET CELL GENET, V72, P225, DOI 10.1159/000134196; vandenBerg A, 1996, GENE CHROMOSOME CANC, V15, P64, DOI 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2; VANDENBERG A, 1995, CYTOGENET CELL GENET, V68, P91; VANDERHOUT AH, 1991, GENOMICS, V11, P537, DOI 10.1016/0888-7543(91)90060-R; VANDERHOUT AH, 1993, INT J CANCER, V53, P353; WANG JY, 1994, GENOMICS, V20, P105, DOI 10.1006/geno.1994.1133; Wei MH, 1996, CANCER RES, V56, P1487; WILHELM M, 1995, CANCER RES, V55, P5383; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YANO H, 1988, IN VITRO CELL DEV B, V24, P9	40	72	78	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1392	1399		10.1038/sj.onc.1203449	http://dx.doi.org/10.1038/sj.onc.1203449			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723130				2022-12-17	WOS:000085942700004
J	Kapoor, M; Hamm, R; Yan, W; Taya, Y; Lozano, G				Kapoor, M; Hamm, R; Yan, W; Taya, Y; Lozano, G			Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation	ONCOGENE			English	Article						phosphorylation; DNA binding; UV radiation	TUMOR-SUPPRESSOR PROTEIN-P53; DNA-BINDING; ULTRAVIOLET-RADIATION; GAMMA-RADIATION; KINASE; DAMAGE; TERMINUS; IDENTIFICATION; ACETYLATION; SERINE-389	The activity of the tumor suppressor p53 is induced in response to DNA-damaging agents such as UV and gamma radiation. Phosphorylation is one of the key regulatory steps for activating p53 function. Recent reports have shown that p53 is phosphorylated at both serines 15 and 392 in response to UV radiation, Phosphorylation at serine 15 prevents the binding of HDM2, a negative regulator of p53. Phosphorylation at serine 392 induces the DNA-binding function of p53, We examined the requirement for phosphorylation at both serines and show that both these modifications occur on the same molecule of p53, In vitro assays demonstrate that phosphorylation at either one of these sites is not sufficient to yield an active p53. Phosphorylation by DNA-PK, that modifies serines 15 and 37, inhibits HDM2 binding to p53 but does not induce the DNA-binding activity of p53, Phosphorylation at serine 392, on the other hand, stimulates the DNA-binding ability of p53 but does not make it immune to binding and inhibition by HDM2, Thus, our results demonstrate that multiple sites need to be modified to yield a functional p53.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan	University of Texas System; UTMD Anderson Cancer Center; National Cancer Center - Japan	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	33	72	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					358	364		10.1038/sj.onc.1203300	http://dx.doi.org/10.1038/sj.onc.1203300			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656682				2022-12-17	WOS:000084873700005
J	Zhu, KC; Wang, J; Zhu, JH; Jiang, JY; Shou, J; Chen, XB				Zhu, KC; Wang, J; Zhu, JH; Jiang, JY; Shou, J; Chen, XB			p53 induces TAP1 and enhances the transport of MHC class I peptides	ONCOGENE			English	Article						p53; TAP1; MHC class I; interferon gamma; tumor surveillance	MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN CANCERS; ANTIGEN PRESENTATION; GENE-EXPRESSION; DOWN-REGULATION; BREAST-CANCER; CELLS; APOPTOSIS; PROTEIN; IDENTIFICATION	The transporter associated with antigen processing (TAP) I is required for the major histocompatibility complex (MHC) class I antigen presentation pathway, which plays a key role in host tumor surveillance. Since more than 50% of tumors have a dysfunctional p53, evasion of tumor surveillance by tumor cells may be linked to loss of p53 function. Here we found that TAP1 is strongly induced by p53 and DNA-damaging agents through a p53-responsive element. We also found that p73, which is homologous to p53, is capable of inducing TAP1 and cooperates with p53 to activate TAP1. Furthermore, me found that by inducing TAP1, p53 enhances the transport of MHC class I peptides and expression of surface MHC-peptide complexes, and cooperates with interferon gamma to activate the MHC class I pathway. These results suggest that tumor surveillance may be a mechanism by which p53 and/or p73 function as tumor suppressors.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.			Zhu, Kuichun/0000-0002-3594-5616	NCI NIH HHS [CA81237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; Alpan RS, 1996, CANCER RES, V56, P4358; Amiot L, 1998, BRIT J HAEMATOL, V100, P655, DOI 10.1046/j.1365-2141.1998.00631.x; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gobin SJP, 1997, IMMUNITY, V6, P601, DOI 10.1016/S1074-7613(00)80348-9; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Johnsen A, 1998, CANCER RES, V58, P3660; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAKLAMANIS L, 1995, CANCER RES, V55, P5191; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khanna R, 1998, CANCER RES, V58, P310; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma WL, 1997, J BIOL CHEM, V272, P16585, DOI 10.1074/jbc.272.26.16585; Martin BK, 1997, IMMUNITY, V6, P591, DOI 10.1016/S1074-7613(00)80347-7; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MUNGER K, 1989, J VIROL, V63, P4417; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; RESTIFO NP, 1993, J IMMUNOTHER, V14, P182, DOI 10.1097/00002371-199310000-00004; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Vitale M, 1998, CANCER RES, V58, P737; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang ZG, 1998, CANCER RES, V58, P2149; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061	47	72	72	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7740	7747		10.1038/sj.onc.1203235	http://dx.doi.org/10.1038/sj.onc.1203235			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618714				2022-12-17	WOS:000084256900003
J	Pim, D; Banks, L				Pim, D; Banks, L			HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6	ONCOGENE			English	Article						HPV E6; p531 E6*; apoptosis	HUMAN PAPILLOMAVIRUS TYPE-16; OPEN READING FRAME; MESSENGER-RNA; CELL-LINE; EARLY GENES; TRANSCRIPTION; ONCOPROTEIN; PATTERNS; DNA; IDENTIFICATION	We have previously demonstrated that ectopic expression of the HPV-18 E6*I protein has an antiproliferative effect in cells derived from HPV-containing cervical tumours. This effect correlated with the ability of E6*I to inhibit the E6-mediated degradation of p53 both in vitro and in vivo and with an increase in p53 transcriptional trans-activation. The observation that the E6*I protein can interact with both full-length HPV-18 E6 and E6-AP proteins in vitro indicated the mechanism by which this activity was mediated. In this study we describe a mutational strategy to attempt to differentiate between the E6-AP and full-length HPV-18 E6 interactions, with respect to the biological function of E6. We identify regions of the E6*I protein essential for its interaction with full-length E6 and important for its interaction with E6-AP. We show that a mutant of E6*I which is unable to bind to full-length HPV-18 E6 protein is unable to inhibit the E6-directed degradation of p53 and is also unable to inhibit the proliferation of a cervical tumour-derived cell line. Finally, we show that inhibition of transformed cell growth by E6*I protein correlates with its ability to induce apoptosis in a p53-dependent manner. These results raise the intriguing possibility of using E6*I as a basis for therapeutic intervention in HPV-associated tumours.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Pim, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.							BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; LOWE SW, 1993, CELL, V74, P847; Mantovani F, 1999, ONCOGENE, V18, P3309, DOI 10.1038/sj.onc.1202688; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHERMAN L, 1992, VIROLOGY, V191, P953, DOI 10.1016/0042-6822(92)90271-P; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1995, J VIROL, V69, P7023, DOI 10.1128/JVI.69.11.7023-7031.1995; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	25	72	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7403	7408		10.1038/sj.onc.1203134	http://dx.doi.org/10.1038/sj.onc.1203134			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602499				2022-12-17	WOS:000084119600001
J	Ismail, PM; Lu, T; Sawadogo, M				Ismail, PM; Lu, T; Sawadogo, M			Loss of USF transcriptional activity in breast cancer cell lines	ONCOGENE			English	Article						USF; breast cancer cell lines; c-Myc; transcription activation	DNA-BINDING; C-MYC; PROTEINS; EXPRESSION; PROMOTER; UPSTREAM; ONCOGENE; FAMILY; MOTIF; FORMS	USF is a family of transcription factors that are structurally related to the Myc oncoproteins and also share with Myc a common DNA-binding specificity. USF overexpression can prevent c-Myc-dependent cellular transformation and also inhibit the proliferation of certain transformed cells, These antiproliferative activities suggest that USF inactivation could be implicated in carcinogenesis. To explore this possibility, we compared the activities of the ubiquitous USF1 and USF2 proteins in several cell lines derived from either normal breast epithelium or breast tumors. The DNA-binding activities of USF1 and USF2 were present at similar levels in all cell lines. In the non-tumorigenic MCF-10A cells, USF in general, and USF2 in particular, exhibited strong transcriptional activities. In contrast, USF1 and USF2 were completely inactive in three out of six transformed breast cell lines investigated, while the other three transformed cell lines exhibited loss of USF2 activity. Analyses in cells cultured from healthy tissue confirmed the transcriptional activity of USF in normal human mammary epithelial cells. These results demonstrate that a partial or complete loss of USF function is a common event in breast cancer cell lines, perhaps because, like Myc overexpression, it favors rapid proliferation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Sawadogo, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NCI NIH HHS [CA09299, CA79578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079578, T32CA009299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; ESCOT C, 1993, ONCOGENE, V8, P969; FISCHER DE, 1991, GENE DEV, V5, P2342; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KREIPE H, 1993, CANCER RES, V53, P1956; KRIEF P, 1989, INT J CANCER, V43, P658, DOI 10.1002/ijc.2910430420; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; ROUXDOSSETO M, 1992, EUR J CANCER, V28A, P1600, DOI 10.1016/0959-8049(92)90050-C; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SOULE HD, 1990, CANCER RES, V50, P6075; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; VARLEY JM, 1987, ONCOGENE, V1, P423; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WOOD WM, 1989, J BIOL CHEM, V264, P14840	31	72	72	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5582	5591		10.1038/sj.onc.1202932	http://dx.doi.org/10.1038/sj.onc.1202932			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523835				2022-12-17	WOS:000082894700011
J	Labelle, Y; Bussieres, J; Courjal, F; Goldring, MB				Labelle, Y; Bussieres, J; Courjal, F; Goldring, MB			The EWS TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator	ONCOGENE			English	Article						EWS TEC; chondrosarcomas; fusion proteins; nuclear receptors; EWS; transcriptional activation	ORPHAN NUCLEAR RECEPTOR; EWINGS-SARCOMA TRANSLOCATION; NGFI-B; MALIGNANT-MELANOMA; DNA-BINDING; SOFT PARTS; MYXOID CHONDROSARCOMA; GENE FUSION; FAMILY; IDENTIFICATION	The EWS/TEC gene fusion generated by the t(9;22) chromosomal translocation found in extraskeletal myxoid chondrosarcomas encodes a fusion protein containing the amino-terminal domain of the EWS protein fused to the whole coding sequence of the orphan nuclear receptor TEC. We have compared the DNA-binding and transcriptional activation properties of various TEC isoforms and the corresponding EWS/TEC fusion proteins. Band-shift experiments show that the full-length TEC receptor can efficiently bind the NGFI-B Response Element (NBRE), whereas an isoform lacking the entire carboxyl-terminal domain of the receptor binds much less efficiently the NBRE, Addition of the aminoterminal domain of EWS to either isoforms does not alter significantly their DNA-binding properties to the NBRE, Co-transfection experiments of COS cells and human chondrocytes indicate that whereas TEC moderately activates transcription from a NBRE-containing promoter, the corresponding EWS/TEC fusion protein is a highly potent transcriptional activator of the same promoter, being approximately 270-fold more active than the native receptor. EWS/TEC may thus exert its oncogenic potential in chrondrosarcomas by activating the transcription of target genes involved in cell proliferation.	CHUQ, Unite Rech Genet Humaine & Mol, Quebec City, PQ G1L 3L5, Canada; Univ Laval, Fac Med, Ste Foy, PQ G1K 7P4, Canada; Beth Israel Deaconess Med Ctr, Harvard Inst Med, Boston, MA 02115 USA	Laval University; Laval University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Labelle, Y (corresponding author), CHUQ, Unite Rech Genet Humaine & Mol, Pavillon St Francois dAssise, Quebec City, PQ G1L 3L5, Canada.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brody RI, 1997, AM J PATHOL, V150, P1049; Buono P, 1997, BIOCHEM J, V323, P245, DOI 10.1042/bj3230245; CALVIO C, 1995, RNA, V1, P724; Castillo SO, 1997, GENOMICS, V41, P250, DOI 10.1006/geno.1997.4677; Clark J, 1996, ONCOGENE, V12, P229; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fujimura Y, 1996, ONCOGENE, V12, P159; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	72	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3303	3308		10.1038/sj.onc.1202675	http://dx.doi.org/10.1038/sj.onc.1202675			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359536				2022-12-17	WOS:000080523800013
J	Fukazawa, T; Fujiwara, T; Morimoto, Y; Shao, J; Nishizaki, M; Kadowaki, Y; Hizuta, A; Owen-Schaub, LB; Roth, JA; Tanaka, N				Fukazawa, T; Fujiwara, T; Morimoto, Y; Shao, J; Nishizaki, M; Kadowaki, Y; Hizuta, A; Owen-Schaub, LB; Roth, JA; Tanaka, N			Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells	ONCOGENE			English	Article						p53; apoptosis; CD95; CD95 ligand; adenovirus vector	FAS LIGAND; MOLECULAR-CLONING; TUMOR-REGRESSION; SURFACE ANTIGEN; LUNG-CANCER; EXPRESSION; GROWTH; ACTIVATION; INHIBITOR; PATHWAYS	The CD95 (Fas/APO-1) system regulates a number of physiological and pathological processes of cell death. The ligand for CD95 induces apoptosis in sensitive target cells by interacting with a transmembrane cell surface CD95 receptor. We previously reported that the recombinant adenovirus-mediated transfer of the wildtype p53 gene caused apoptotic cell death in a variety of human cancer cells. To better understand the mechanism responsible for this cell death signaling, we have investigated the potential involvement of the CD95 receptor/ligand system in p53-mediated apoptosis. The transient expression of the wild-type p53 gene upregulated the CD95 ligand mRNA as well as protein expression in H1299 human lung cancer cells deficient for p53 and in DLD-1 and SW620 human colon cancer cells with mutated p53, all of which constitutively expressed CD95 receptor as shown by a flow cytometric analysis, and induced rapid apoptotic cell death as early as 24 h after gene transfer. However, the sensitivity to the cytolytic effect of agonistic anti-CD95 antibody (CH11) varied among these cell lines: CN11 induced apoptosis in H1299 cells, but not in DLD-1 and SW620 cells despite their abundant CD95 receptor expression, suggesting that the CD95 receptors on DLD-1 and SW620 cells might be inactivated. In addition, an antagonistic anti-CD95 ligand antibody (4H9) that interfered with the CD95-receptor-ligand interaction partially reduced the apoptosis induced by the wild-type p53 gene transfer in H1299 cells, whereas apoptosis of DLD-1 and SW620 cells occurred in the presence of 4H9. Taken together, these findings led us to conclude that the CD95 receptor/ligand system is differentially involved in p53-mediated apoptosis, suggesting that the restoration of the wild-type p53 function may mediate apoptosis through CD95 receptor/ligand interactions as well as an alternative pathway.	Okayama Univ, Sch Med, Sect Mol Oncol, Okayama 700, Japan; Okayama Univ, Sch Med, Dept Surg 1, Okayama 700, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	Okayama University; Okayama University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fujiwara, T (corresponding author), Okayama Univ, Sch Med, Sect Mol Oncol, Okayama 700, Japan.		Fukazawa, Takuya/GLR-7099-2022		NCI NIH HHS [P50-CA70907, R01CA45187, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045187, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs EJ, 1997, CANCER RES, V57, P2550; FUJIWARA T, 1993, CANCER RES, V53, P4129; FULUDA S, 1997, CANCER RES, V57, P3823; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HARPER JW, 1993, CELL, V75, P805; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OEHM A, 1992, J BIOL CHEM, V267, P10709; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SEAMUS JM, 1995, CELL, V82, P349; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; ZHANG WW, 1994, CANCER GENE THER, V1, P1	38	72	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2189	2199		10.1038/sj.onc.1202561	http://dx.doi.org/10.1038/sj.onc.1202561			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327065				2022-12-17	WOS:000079525100003
J	Florenes, VA; Lu, C; Bhattacharya, N; Rak, J; Sheehan, C; Slingerland, JM; Kerbel, RS				Florenes, VA; Lu, C; Bhattacharya, N; Rak, J; Sheehan, C; Slingerland, JM; Kerbel, RS			Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21(WAF1/CIP1) is lost during progression of human malignant melanoma	ONCOGENE			English	Article						melanoma; IL-6; sensitivity; p21(WAF1/CIP1); p27(Kip1); STAT	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINES; TGF-BETA; MAMMALIAN-CELLS; BREAST-CANCER; POTENTIAL MEDIATOR; EPITHELIAL-CELLS; CDK INHIBITORS; IL-6 FUNCTIONS	Human melanoma cell lines derived from early stage primary tumors are particularly sensitive to growth arrest induced by interleukin-6 (IL-6), This response is lost in cell lines derived from advanced lesions, a phenomenon which may contribute to tumor aggressiveness. We sought to determine whether resistance to growth inhibition by IL-6 can be explained by oncogenic alterations in cell cycle regulators or relevant components of intracellular signaling, Our results show that IL-6 treatment of early stage melanoma cell lines caused G(1) arrest, which could not be explained by changes in levels of G1 cyclins (D1, E), cdks (cdk4, cdk2) or by loss of cyclin/cdk complex formation. Instead, IL-6 caused a marked induction of the cdk inhibitor p21(WAF1/CIP1) in three different IL-6 sensitive cell lines, two of which also showed a marked accumulation of the cdk inhibitor p27(Kip1). In contrast, IL-6 failed to induce p21(WAF1/CIP1) transcript and did not increase p21(WAF1/CIP1) Or p27(Kip1) proteins in any of the resistant lines, In fact, of five IL-6 resistant cell lines, only two expressed detectable levels of p21(WAF1/CIP1) mRNA and protein, while in three other lines, p21(WAF1/CIP1) was undetectable. IL-6 dependent upregulation of p21(WAF1/CIP1) was associated with binding of both STAT3 and STAT1 to the p21(WAF1/CIP1) promoter. Surprisingly, however, IL-6 stimulated STAT binding to this promoter in both sensitive and resistant cell lines (with one exception), suggesting that gross deregulation of this event is not the unifying cause of the defect in p21(WAF1/CIP1) induction in IL-6 resistant cells, In somatic cell hybrids of IL-6 sensitive and resistant cell lines, the resistant phenotype was dominant and IL-6 failed to induce p21(WAF1/CIP1), Thus, our results suggest that in early stage human melanoma cells, IL-6 induced growth inhibition involves induction of p21(WAF1/CIP1) which is lost in the course of tumor progression presumably as a result of a dominant oncogenic event.	Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Kerbel, RS (corresponding author), Univ Toronto, Dept Med Biophys, 2075 Bayview Ave,S-218, Toronto, ON M4N 3M5, Canada.				NCI NIH HHS [CA 41223] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARNHILL RL, 1993, AM J PATHOL, V143, P99; BORSELLINO N, 1995, CANCER RES, V55, P4633; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chiu JJ, 1996, CLIN CANCER RES, V2, P215; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Florenes VA, 1996, ONCOGENE, V13, P2447; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Flores JF, 1996, CANCER RES, V56, P5023; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAMA T, 1995, BLOOD, V86, P841; ISHIKAWA M, 1988, CANCER RES, V48, P665; ISHIKAWA M, 1988, CANCER RES, V48, P4897; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Martin-Castellanos C, 1997, TRENDS CELL BIOL, V7, P95, DOI 10.1016/S0962-8924(96)10055-6; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; MITZUTANI Y, 1995, CANCER RES, V55, P590; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; Okamoto M, 1997, CANCER RES, V57, P141; OTSUKI T, 1995, CANCER RES, V55, P1436; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; REED JA, 1995, CANCER RES, V55, P2713; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; TAM SW, 1994, ONCOGENE, V9, P2663; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; Welch DR, 1996, MOL CELL DIFFER, V4, P91; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG XG, 1989, BLOOD, V74, P11	73	72	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1023	1032		10.1038/sj.onc.1202382	http://dx.doi.org/10.1038/sj.onc.1202382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023678				2022-12-17	WOS:000078510600019
J	Tomizawa, Y; Kohno, T; Fujita, T; Kiyama, M; Saito, R; Noguchi, M; Matsuno, Y; Hirohashi, S; Yamaguchi, N; Nakajima, T; Yokota, J				Tomizawa, Y; Kohno, T; Fujita, T; Kiyama, M; Saito, R; Noguchi, M; Matsuno, Y; Hirohashi, S; Yamaguchi, N; Nakajima, T; Yokota, J			Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma	ONCOGENE			English	Article						stage I NSCLC; p53 mutation; p53 expression; prognosis	TUMOR-SUPPRESSOR GENE; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; BREAST-CANCER; MUTANT P53; MUTATIONS; HETEROZYGOSITY; EXPRESSION; 17P13.3; TP53	The association of p53 abnormalities with the prognosis of patients,vith non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial, Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC, p53 mutations were detected in 49 of 103 (48%) tumors, Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8, Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression,vas only 69%, p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P < 0.001), Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P = 0.243 in null mutations), These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Chuo Ku, Tokyo 1040045, Japan; Gunma Univ, Sch Med, Dept Pathol 2, Gunma 3718511, Japan; Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan; Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Gunma University; Hitachi Limited; Gunma University	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji, Tokyo 1040045, Japan.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; Casey G, 1996, ONCOGENE, V13, P1971; CHIBA I, 1990, ONCOGENE, V5, P1603; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; deAnta JM, 1997, ONCOGENE, V15, P2951, DOI 10.1038/sj.onc.1201475; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FONG KM, 1995, CANCER RES, V55, P4268; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE T, 1994, JPN J CANCER RES, V85, P1240, DOI 10.1111/j.1349-7006.1994.tb02936.x; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Kiyama M, 1996, BIOTECHNIQUES, V21, P710; LOHMANN D, 1993, DIAGN MOL PATHOL, V2, P36, DOI 10.1097/00019606-199300020-00006; MINNA JD, 1991, HARRISONS PRINCIPLES, P1102; Mitsudomi T, 1995, Ann Oncol, V6 Suppl 3, pS9; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; MOORE DF, 1996, LUNG CANC PRINCIPLES, P481; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohno A, 1997, INT J ONCOL, V10, P521; OKAMOTO A, 1991, CANCER RES, V51, P5632; OKAMOTO A, 1991, CANCER RES, V51, P5157; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sakamoto T, 1996, GYNECOL ONCOL, V63, P173, DOI 10.1006/gyno.1996.0302; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Schultz DC, 1996, CANCER RES, V56, P1997; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; *WHO, 1981, HIST TYP LUNG TUM, V1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	43	72	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1007	1014		10.1038/sj.onc.1202384	http://dx.doi.org/10.1038/sj.onc.1202384			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023676				2022-12-17	WOS:000078510600017
J	Qiu, GF; Ahmed, M; Sells, SF; Mohiuddin, M; Weinstein, MH; Rangnekar, VM				Qiu, GF; Ahmed, M; Sells, SF; Mohiuddin, M; Weinstein, MH; Rangnekar, VM			Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4	ONCOGENE			English	Article						Par-4; Bcl-2; apoptosis; prostate	PROTEIN-KINASE-C; CELL-DEATH; APOPTOSIS; CANCER; ISOFORMS; FAMILY	Par-4 is a widely expressed protein that sensitizes both prostatic and non-prostatic cells to apoptosis, Constitutive- or regulated- overexpression of Par-4 caused a reduction in the levels of the anti-apoptotic protein Bcl-2, Replenishment of Bcl-2 levels abrogated susceptibility to Par-4-dependent apoptosis, suggesting that Par-4-mediated apoptosis requires downmodulation of Bcl-2 levels. The inverse correlation between Par-4 and Bcl-2 expression was recapitulated in human prostate tumors, Par-4 but not Bcl-2 was detected in the secretory epithelium of benign prostatic tumors and in primary and metastatic prostate cancers that are apt to undergo apoptosis, Moreover, xenografts of human, androgen-dependent CWR22 tumors showed Par-4 but not Bcl-2 expression. By contrast, androgen-independent CWR22R tumors derived from the CWR22 xenografts showed mutually exclusive expression patterns of Par-4 and Bcl-2, These findings suggest a mechanism by which Par-4 may sensitize prostate tumor cells to apoptosis.	Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA.				NCI NIH HHS [CA60872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIHARA M, 1995, CANCER-AM CANCER SOC, V75, P522, DOI 10.1002/1097-0142(19950115)75:2<522::AID-CNCR2820750215>3.0.CO;2-W; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Berges RR, 1995, CLIN CANCER RES, V1, P473; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Bromberg Jacqueline, 1993, Current Opinion in Oncology, V5, P546, DOI 10.1097/00001622-199305000-00017; CARTER HB, 1990, PROSTATE, V16, P39; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ishibashi Y, 1998, BIOCHEM BIOPH RES CO, V243, P609, DOI 10.1006/bbrc.1998.8145; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Krajewska M, 1996, AM J PATHOL, V148, P1567; MCCOLLOUGH DL, 1988, DIAGNOSIS MANAGEMENT, P405; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; NAGABHUSHAN M, 1996, CANCER RES, V56, P6049; RAFFO A, 1990, CANCER RES, V55, P4438; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; StClair EG, 1997, J BIOL CHEM, V272, P29347; Tu HC, 1996, INT J CANCER, V69, P357, DOI 10.1002/(SICI)1097-0215(19961021)69:5<357::AID-IJC1>3.0.CO;2-4; WHEELER TM, 1994, J CELL BIOCHEM, P202; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	30	72	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					623	631		10.1038/sj.onc.1202344	http://dx.doi.org/10.1038/sj.onc.1202344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989812				2022-12-17	WOS:000078394400007
J	Iwata, S; Sato, Y; Asada, M; Takagi, M; Tsujimoto, A; Inaba, T; Yamada, T; Sakamoto, S; Yata, J; Shimogori, T; Igarashi, K; Mizutani, S				Iwata, S; Sato, Y; Asada, M; Takagi, M; Tsujimoto, A; Inaba, T; Yamada, T; Sakamoto, S; Yata, J; Shimogori, T; Igarashi, K; Mizutani, S			Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation	ONCOGENE			English	Article						polyamine; anti-tumor activity; cancer	TISSUE-CULTURE CELLS; POLYAMINE TRANSPORT; GENE; EXPRESSION; PROTEIN; INHIBITION; APOPTOSIS; HETEROZYGOSITY; DEGRADATION; LEUKEMIAS	Cell proliferation and transformation induced by growth factor stimulation or by carcinogens, viruses, or oncogenes are characterized by an associated increase in polyamine levels, which is mediated by increased polyamine biosynthesis and enhanced uptake of polyamines, Polyamine biosynthesis is catalyzed particularly, in the level of ornithine decarboxylase (ODC), The elevation of cellular polyamine levels on the other hand accelerates the induction of ornithine decarboxylase antizyme (antizyme), which is involved not only in ODC-degradation, but in the negative regulation of polyamine transport. Taking advantage of these characteristics of antizyme, the potential of antizyme as a factor having anti-cell growth and anti-tumor activity was investigated. We show that antizyme can induce cell death associated with a rapid decline of intracellular polyamine contents. The possible anti-tumor activities of ectopically expressed antizyme were tested in p21H-ras (Val 12)-transformed NIH3T3 cells and several human malignant cell lines including a line with loss of p53 expression, and they were shown to be as sensitive as nontransformed NIH3T3 cells in vitro. The in vivo antitumor activity was also tested using nude mice inoculated with H-vas transformed NIH3T3 cells that had been transfected with inducible antizyme expression vector and the results showed that antizyme expression in vivo blocks tumor formation in these mice. These results suggest that ectopic antizyme expression is of possible therapeutic benefit in the treatment of cancer, which is mediated by ODC inactivation and intracellular polyamine depletion.	Natl Childrens Med Res Ctr, Dept Virol, Setagaya Ku, Tokyo 154, Japan; Jichi Med Sch, Dept Mol Biol, Minami Kawachi, Tochigi, Japan; Kyoto Inst Technol, Dept Polymer Sci & Engn, Kyoto 606, Japan; Tokyo Med & Dent Univ, Dept Pediat, Tokyo 113, Japan; Chiba Univ, Fac Pharmaceut Sci, Chiba, Japan	National Center for Child Health & Development - Japan; Jichi Medical University; Kyoto Institute of Technology; Tokyo Medical & Dental University (TMDU); Chiba University	Mizutani, S (corresponding author), Natl Childrens Med Res Ctr, Dept Virol, Setagaya Ku, 3-35-31 Taishido, Tokyo 154, Japan.		Takagi, Masatoshi/F-3713-2011; Shimogori, Tomomi/L-2893-2013	Takagi, Masatoshi/0000-0002-7580-9184; Shimogori, Tomomi/0000-0002-6931-5401; Igarashi, Kazuei/0000-0003-3751-3187				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; EVANS BD, 1982, BRIT J CANCER, V45, P466, DOI 10.1038/bjc.1982.75; FUKUCHI J, 1992, EUR J BIOCHEM, V209, P689, DOI 10.1111/j.1432-1033.1992.tb17337.x; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HADDOX MK, 1980, CANCER RES, V40, P604; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HE Y, 1994, BIOCHEM BIOPH RES CO, V203, P608, DOI 10.1006/bbrc.1994.2226; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Ichimiya A., 1994, Surface Review and Letters, V1, P1, DOI 10.1142/S0218625X94000023; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kankare K, 1997, BIOCHEM J, V324, P807, DOI 10.1042/bj3240807; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LINDBLOM A, 1993, CANCER RES, V53, P4356; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MANDAHL N, 1989, GENE CHROMOSOME CANC, V1, P9, DOI 10.1002/gcc.2870010104; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Matsufuji S, 1996, GENOMICS, V38, P102, DOI 10.1006/geno.1996.0601; Matsufuji S, 1996, EMBO J, V15, P1360, DOI 10.1002/j.1460-2075.1996.tb00478.x; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MOSHIER JA, 1993, CANCER RES, V53, P2618; MURAKAMI Y, 1994, BIOCHEM J, V304, P183, DOI 10.1042/bj3040183; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; OCHI H, 1986, CANCER GENET CYTOGEN, V22, P295, DOI 10.1016/0165-4608(86)90022-1; Pabst T, 1996, BLOOD, V88, P1026, DOI 10.1182/blood.V88.3.1026.bloodjournal8831026; Parchment R E, 1991, In Vivo, V5, P493; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; SATO T, 1991, CANCER RES, V51, P5118; SCALABRINO G, 1982, ADV CANCER RES, V36, P1, DOI 10.1016/S0065-230X(08)60422-4; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TEWARI DS, 1994, BBA-PROTEIN STRUCT M, V1209, P293, DOI 10.1016/0167-4838(94)90199-6; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Yang D, 1997, J BIOL CHEM, V272, P3376, DOI 10.1074/jbc.272.6.3376	47	72	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					165	172		10.1038/sj.onc.1202275	http://dx.doi.org/10.1038/sj.onc.1202275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926931				2022-12-17	WOS:000078166000018
J	Wang, XJ; Ohnishi, K; Takahashi, A; Ohnishi, T				Wang, XJ; Ohnishi, K; Takahashi, A; Ohnishi, T			Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation	ONCOGENE			English	Article						p53; WAF1; signal transduction; PARP; 3AB	WILD-TYPE P53; HUMAN GLIOBLASTOMA CELLS; DNA-BINDING FUNCTION; GAMMA-IRRADIATION; ADP-RIBOSYLATION; GROWTH ARREST; PROTEIN; POLYMERASE; INDUCTION; APOPTOSIS	p53 and poly(ADP-ribose) polymerase (PARP) are both DNA damage recognition proteins and can be functionally activated by DNA strand breaks. To understand the functional interaction between these two proteins, the effects of a PARP inhibitor, 3-aminobenzamide (3AB), on the p53 pathway were investigated in human glioblastoma cells with different p53 status. Consistent with previous studies, irradiation with gamma-rays induced both p53 and WAF1 accumulation in A-172 cells (wtp53) but not in T98G cells (mp53). However, the presence of 3AB but not its analog suppressed radiation-induced accumulation of wtp53 and the expression of WAF1 and MDM2. Similar results were also obtained from U87MG, another human glioblastoma cell line with wtp53 status. Northern blotting analysis showed that 3AB inhibited the gamma-ray-induced WAF1 gene expression. Moreover, 3AB but not its analog inhibited irradiation-induced activation of sequence-specific DNA binding of wtp53 as detected using P-32-labeled or biotin-labeled p53 consensus sequence (p53CON). However, immunoblotting with an anti-poly(ADP-ribose) antibody showed that p53 proteins of the p53CON-bound fraction did not contain poly(ADP-ribose) (PAR). These findings suggested that poly(ADP-ribosyl)ation is required for rapid accumulation of p53, activation of p53 sequence-specific DNA binding and its transcriptional activity after DNA damage.	Nara Med Univ, Dept Biol, Kashihara, Nara 6348521, Japan	Nara Medical University	Ohnishi, T (corresponding author), Nara Med Univ, Dept Biol, Kashihara, Nara 6348521, Japan.			Takahashi, Akihisa/0000-0002-9960-2153				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Aoki H, 1998, MOL CARCINOGEN, V21, P171, DOI 10.1002/(SICI)1098-2744(199803)21:3<171::AID-MC4>3.0.CO;2-P; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DING RC, 1994, CANCER RES, V54, P4627; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUCHS B, 1995, ONCOGENE, V10, P789; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Hall PA, 1996, J PATHOL, V180, P1; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; McDonald E, 1996, CANCER RES, V56, P2250; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Ohnishi K, 1998, EXP CELL RES, V238, P399, DOI 10.1006/excr.1997.3842; Ohnishi T, 1998, ONCOGENE, V16, P1507, DOI 10.1038/sj.onc.1201663; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Ohtsubo T, 1997, CANCER RES, V57, P3910; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SHALL S, 1994, MOL CELL BIOCHEM, V138, P71, DOI 10.1007/BF00928445; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SIMONIN F, 1993, J BIOL CHEM, V268, P13454; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; Wang XJ, 1997, EXP CELL RES, V237, P186, DOI 10.1006/excr.1997.3780; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; WHITACRE CM, 1995, CANCER RES, V55, P3697; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	48	72	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2819	2825		10.1038/sj.onc.1202216	http://dx.doi.org/10.1038/sj.onc.1202216			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879988				2022-12-17	WOS:000077286400002
J	Kaul, SC; Duncan, EL; Englezou, A; Takano, S; Reddel, RR; Mitsui, Y; Wadhwa, R				Kaul, SC; Duncan, EL; Englezou, A; Takano, S; Reddel, RR; Mitsui, Y; Wadhwa, R			Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein	ONCOGENE			English	Article						NIH3T3; malignant transformation; mot-2 protein	3' UNTRANSLATED REGION; MOUSE EMBRYO CELLS; SPONTANEOUS IMMORTALIZATION; REPLICATIVE SENESCENCE; CELLULAR MORTALITY; TUMOR SUPPRESSION; EPITHELIAL-CELLS; HSP70 FAMILY; FIBROBLASTS; EXPRESSION	The murine mortalin genes, mot-1 and mot-2, are members of the hsp70 family of proteins and differ from each other by only two amino acid residues. Mot-1 is expressed in normal cells and has pancytosolic cellular distribution whereas mot-2 is found in the perinuclear region of immortal cells. We report here that a high level of expression of mot-2 protein resulted in malignant transformation of cells as analysed by anchorage independent growth and nude mice assays. A high level of protein expression is attributed to the 900 bp 3' untranslated region of the cDNA which does not have any transforming activity per se. Mortalin cDNA clones isolated from human transformed cells were also found to have transforming activity in similar assays and a high level of expression was apparent in some of the human immortalized cells that showed non-pancytosolic mortalin immunofluorescence, Taken together, the data suggest that nonpancytosolic mortalin may have a role in tumorigenesis.	AIST, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Childrens Med Res Inst, Sydney, NSW 2145, Australia; Chugai Res Inst Mol Med, Niihari, Ibaraki 30041, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Children's Medical Research Institute - Australia; University of Sydney	Kaul, SC (corresponding author), AIST, Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.		Takano, Shuichi/I-6512-2013; Kaul, Sunil C/L-8671-2018; Reddel, Roger R/A-6635-2014; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Reddel, Roger R/0000-0002-6302-6107; Wadhwa, Renu/0000-0001-8248-5192				BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Derventzi A, 1996, ANTICANCER RES, V16, P2901; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; Gallie DR, 1996, NUCLEIC ACIDS RES, V24, P1954, DOI 10.1093/nar/24.10.1954; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Kaul SC, 1997, EXP CELL RES, V232, P56, DOI 10.1006/excr.1997.3503; Kaul SC, 1996, ONCOGENE, V13, P1231; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RITTLING SR, 1992, ONCOGENE, V7, P935; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Sambrook J, 1989, MOL CLONING LAB MANU; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SUGHARA T, 1997, J BIOL CHEM, V273, P3033; SUGIHARA T, 1994, BBA-MOL CELL RES, V1224, P365, DOI 10.1016/0167-4889(94)90269-0; Takano S, 1997, EXP CELL RES, V237, P38, DOI 10.1006/excr.1997.3754; TOKUMITSU M, 1994, MOL CARCINOGEN, V10, P52, DOI 10.1002/mc.2940100109; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; Wadhwa R, 1996, EXP CELL RES, V226, P381, DOI 10.1006/excr.1996.0239; WADHWA R, 1993, J BIOL CHEM, V268, P22239; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1995, INT J ONCOL, V7, P69; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804	31	72	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					907	911		10.1038/sj.onc.1202017	http://dx.doi.org/10.1038/sj.onc.1202017			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780007				2022-12-17	WOS:000075448800012
J	Healy, E; Belgaid, C; Takata, M; Harrison, D; Zhu, NW; Burd, DAR; Rigby, HS; Matthews, JNS; Rees, JL				Healy, E; Belgaid, C; Takata, M; Harrison, D; Zhu, NW; Burd, DAR; Rigby, HS; Matthews, JNS; Rees, JL			Prognostic significance of allelic losses in primary melanoma	ONCOGENE			English	Article						loss of heterozygosity; fractional allelic loss; tumour suppressor gene; proliferation; p53; p21(WAF1)	HUMAN-MALIGNANT MELANOMA; PRIMARY CUTANEOUS MELANOMA; TUMOR-SUPPRESSOR GENE; P53 PROTEIN; HOMOZYGOUS DELETIONS; METASTATIC MELANOMA; SPORADIC MELANOMA; FAMILIAL MELANOMA; CELL CARCINOMA; POOR-PROGNOSIS	Loss of genetic material, including loss of loci on chromosome arms 6q, 9p, and 10q, occurs frequently in cutaneous melanoma but infrequently in benign melanocytic nevi or other melanocytic lesions, suggesting that these genetic alterations are important in the development and progression of melanoma, To examine whether allelic loss is of prognostic importance in melanoma, disease-free survival was related to loss of heterozygosity on 6q, 9p and 10q in 83 individuals with sporadic primary cutaneous melanoma, Loss of chromosome arms 6q and 10q were each significantly associated with a poorer clinical outcome (P = 0.013 and P = 0.001 respectively). In a subgroup of 41 subjects whose primary tumours mere allelotyped, the fractional allelic loss (FAL) at 39 autosomal arms also significantly correlated with disease-free survival (P = 0.013), with an increase in FAL associated with a poorer outcome; this association remained significant when controlled for tumour thickness (P = 0.035). In addition, a greater proportion of cells were immunopositive for Ki67 antigen, p53 and p21(WAF1) protein in the primary melanomas than in the benign melanocytic nevi, however, only p53 overexpression was significantly associated with improved survival (P = 0.041).	Univ Newcastle Upon Tyne, Dept Dermatol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Frenchay Hosp, Dept Plast Surg, Bristol BS16 1LE, Avon, England; Frenchay Hosp, Dept Pathol, Bristol BS16 1LE, Avon, England	Newcastle University - UK; Newcastle University - UK	Rees, JL (corresponding author), Univ Newcastle Upon Tyne, Dept Dermatol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.		Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X; Healy, Eugene/0000-0001-5591-6970				ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; Barth A, 1995, J Am Coll Surg, V181, P193; Boni R, 1996, J AM ACAD DERMATOL, V35, P416, DOI 10.1016/S0190-9622(96)90607-6; BOUZUBAR N, 1989, BRIT J CANCER, V59, P943, DOI 10.1038/bjc.1989.200; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Collett D., 2014, MODELLING SURVIVAL D; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; FLORENES VA, 1994, BRIT J CANCER, V69, P253, DOI 10.1038/bjc.1994.48; Flores JF, 1996, CANCER RES, V56, P5023; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FURIHATA M, 1993, CANCER RES, V53, P4823; Gabra H, 1996, CANCER RES, V56, P950; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, AM J PATHOL, V146, P1199; HARPER JW, 1993, CELL, V75, P805; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HEATON KM, 1993, AM J SURG, V166, P648, DOI 10.1016/S0002-9610(05)80672-5; HERBST RA, 1994, CANCER RES, V54, P3111; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISHIDA T, 1993, CANCER RES, V53, P5000; ISSHIKI K, 1994, ONCOGENE, V9, P1649; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; JACKSON DP, 1992, PCR PRACTICAL APPROA, P29; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V10, P1855; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kim SK, 1997, CANCER RES, V57, P400; LEE SM, 1995, BRIT MED BULL, V51, P609, DOI 10.1093/oxfordjournals.bmb.a072982; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; MAEDA K, 1994, CANCER, V73, P528, DOI 10.1002/1097-0142(19940201)73:3<528::AID-CNCR2820730306>3.0.CO;2-P; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLIKIN D, 1991, CANCER RES, V51, P5449; MONTANO X, 1994, ONCOGENE, V9, P1455; MORTON DL, 1993, CANCER-AM CANCER SOC, V71, P3737, DOI 10.1002/1097-0142(19930601)71:11<3737::AID-CNCR2820711143>3.0.CO;2-7; MUHONEN T, 1992, BRIT J CANCER, V66, P528, DOI 10.1038/bjc.1992.307; OHTA M, 1994, CANCER RES, V54, P5269; Prescher G, 1996, LANCET, V347, P1222; PUIG S, 1995, AM J HUM GENET, V57, P395; QUELLE DE, 1995, CELL, V83, P993; QUINLAN DC, 1992, CANCER RES, V52, P4828; RAMSAY JA, 1995, J INVEST DERMATOL, V105, P22, DOI 10.1111/1523-1747.ep12312431; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Rees JL, 1996, CLIN EXP DERMATOL, V21, P253, DOI 10.1111/j.1365-2230.1996.tb00089.x; ROSES DF, 1983, ANN SURG, V198, P65, DOI 10.1097/00000658-198307000-00013; SCHEISTROEN M, 1995, CANCER, V75, P72, DOI 10.1002/1097-0142(19950101)75:1<72::AID-CNCR2820750113>3.0.CO;2-G; *STATA CORP, 1997, STATA STAT SOFTW REL; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STRETCH JR, 1991, CANCER RES, V51, P5976; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAKAHASHI S, 1995, CANCER RES, V55, P4114; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; UMEBAYASHI Y, 1995, ARCH DERMATOL RES, V287, P718, DOI 10.1007/BF01105795; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Wang YP, 1996, ONCOGENE, V12, P1069; Weinberg RA, 1995, CANCER SURV, V25, P3; Wiest JS, 1997, CANCER RES, V57, P1	70	72	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2213	2218		10.1038/sj.onc.1200203	http://dx.doi.org/10.1038/sj.onc.1200203			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619830	Bronze			2022-12-17	WOS:000073298000006
J	Kimmelman, A; Tolkacheva, T; Lorenzi, MV; Osada, M; Chan, AML				Kimmelman, A; Tolkacheva, T; Lorenzi, MV; Osada, M; Chan, AML			Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution	ONCOGENE			English	Article						Ras; TC21; R-ras; G-protein; transformation; MAPK	NUCLEOTIDE DISSOCIATION STIMULATOR; GTPASE-ACTIVATING PROTEIN; NIH 3T3 CELLS; R-RAS; ONCOGENIC RAS; MALIGNANT TRANSFORMATION; SIGNALING PATHWAY; K-RAS; H-RAS; KINASE	Members of the Ras subfamily of GTP-binding proteins, including Ras (H-, K-, and N-), TC21, and R-ras have been shown to display transforming activity, and activating lesions have been detected in human tumors. We have identified an additional member of the Ras gene family which shows significant sequence similarity to the human TC21 gene. This novel human ras-related gene, R-rad, encodes for a protein of 209 amino acids, and shows similar to 60-75% sequence identity in the N-terminal catalytic domain with members of the Ras subfamily of GTP-binding proteins. An activating mutation corresponding to the leucine 61 oncogenic lesion of the ras oncogenes when introduced into R-ras3, activates its transforming potential. R-ras3 weakly stimulates the mitogen-activated protein kinase (MAPK) activity, but this effect is greatly potentiated by the co-expression of c-raf-l. By the yeast two-hybrid system, R-rad interacts only weakly with known Ras effecters, such as Raf and RalGDS, but not with RglII. In addition, R-ras3 displays modest stimulatory effects on trans-activation from different nuclear response elements which bind transcription factors, such as SRF, ETS/TCF, Jun/Fos, and NF-kappa B/Rel. Interestingly, Northern blot analysis of total RNA isolated from various tissues revealed that the 3.8 kilobasepair (kb) transcript of R-rad is highly restricted to the brain and heart. The close evolutionary conservation between R-rad and Ras family members, in contrast to the significant differences in its biological activities and the pattern of tissue expression, raise the possibility that R-rad may control novel cellular functions previously not described for other GTP-binding proteins.	CUNY MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464	NCI NIH HHS [CA66654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BOS JL, 1989, CANCER RES, V49, P4682; CHAN AML, 1994, P NATL ACAD SCI USA, V82, P2394; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GALANG CK, 1994, ONCOGENE, V9, P2913; GOLEMIS EA, 1997, GENE CLONING ANAL CU, V4, P11; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOTOH T, 1997, BIOL CHEM, V272, P18602; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HATTORI S, 1992, ONCOGENE, V7, P481; HUANG Y, 1995, ONCOGENE, V11, P1255; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Li WQ, 1996, ONCOGENE, V13, P731; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAEZ R, 1994, ONCOGENE, V9, P2977; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	54	72	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2675	2685		10.1038/sj.onc.1201674	http://dx.doi.org/10.1038/sj.onc.1201674			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400994				2022-12-17	WOS:A1997YH46800005
J	Bosch, E; Cherwinski, H; Peterson, D; McMahon, M				Bosch, E; Cherwinski, H; Peterson, D; McMahon, M			Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1	ONCOGENE			English	Article						A-Raf; B-Raf; c-Raf-1; protein-serine/threonine kinases; oncogenes; transformation	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; NIH 3T3 CELLS; GROWTH-FACTOR; MAP KINASE; B-RAF; IN-VITRO; 14-3-3 PROTEIN; C-RAF; PHOSPHORYLATION	The catalytic domains of the Raf family of protein kinases (Delta Raf) differ in their ability to activate MEK in vitro and in vivo and in their ability to oncogenically transform mammalian cells, The kinase domain of B-Raf is more active than the equivalent portion of Raf-1 which in turn is more active than A-Raf, In Raf-1 the phosphorylation or mutation to aspartic acid of two key tyrosine residues upstream of the ATP binding site has been demonstrated to significantly potentiate catalytic activity. In A-Raf the analogous amino acids are also tyrosine whereas in B-Raf they are aspartic acid. To determine if these differences in amino acid sequence influence the relative catalytic activity of the Raf kinase domains we constructed forms of Delta A-Raf, Delta B-Raf and Delta Raf-1 that encode either aspartic acid [DD], phenylalanine [FF] or tyrosine [YY] at these positions, These proteins were expressed both in mammalian cells as fusions with the hormone binding domain of the estrogen receptor and as epitope-tagged proteins in Sf9 insect cells to test their oncogenic and catalytic potentials. When expressed in Rat1 or 3T3 cells in the presence of hormone all of the Delta Raf-1:ER and Delta A-Raf:ER proteins were transforming with the exception of the [FF] form of Delta A-Raf. In general the [DD] forms of the Delta Raf-1:ER and Delta A-Raf:ER proteins were the most potently oncogenic which correlated with their ability to elicit activation of the MAP kinase pathway, Consistent with the transformation data, the catalytic activity of the [DD] forms of Delta A-Raf:ER and Delta Raf-1:ER was about ten times greater than the cognate [FF] and [YY] forms of the proteins, By contrast all of the Delta B-Raf:ER proteins were highly transforming and Delta B-Raf catalytic activity was largely unaffected by mutation of the aforementioned aspartic acids to either tyrosine or phenylalanine. Similar results were obtained with epitope-tagged forms of Delta A-Raf, Delta B-Raf and Delta Raf-1 expressed in Sf9 cells, These data provide support for the model that key tyrosine residues in the protein kinase domains of A-Raf and Raf-1 are important in the regulation of catalytic activity. In addition they demonstrate that the higher intrinsic activity of B-Raf cannot be explained simply by the presence of aspartic acids at the analogous positions.	DNAX RES INST MOL & CELLULAR BIOL INC, DEPT CELL SIGNALING, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042				AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ASHWORTH A, 1992, ONCOGENE, V7, P2555; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Papin C, 1996, ONCOGENE, V12, P2213; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; RAPP UR, 1991, ONCOGENE, V6, P495; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SOZERI O, 1992, ONCOGENE, V7, P2259; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	72	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1021	1033		10.1038/sj.onc.1201270	http://dx.doi.org/10.1038/sj.onc.1201270			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285556				2022-12-17	WOS:A1997XT16100003
J	Haas, K; Staller, P; Geisen, C; Bartek, J; Eilers, M; Moroy, T				Haas, K; Staller, P; Geisen, C; Bartek, J; Eilers, M; Moroy, T			Mutual requirement of CDK4 and Myc in malignant transformation: Evidence for cyclin D1/CDK4 and p16(INK4A) as upstream regulators of Myc	ONCOGENE			English	Article						oncogene cooperation; REF assay; cell cycle regulation; Myc function; CDK4	CELL-CYCLE; C-MYC; RETINOBLASTOMA-PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC ACTIVITY; RAS COTRANSFORMATION; HOMOZYGOUS DELETION; NUCLEAR-PROTEIN; KINASE-ACTIVITY	We demonstrate in this paper that CDK4 which is a G1 phase specific cell cycle regulator and catalytic subunit of D-type cyclins has oncogenic activity similar to D-type cyclins themselves and is able to provoke focus formation when cotransfected with activated Ha-ras into primary rat embryo fibroblasts. Surprisingly, using two different mutants we show that CDK4's ability to bind to p16(INK4a) and not its kinase activity is important for its transforming potential. In addition, p16(INK4a) but not a mutant form that is found in human tumours can completely abrogate focus formation by CDK4 suggesting that CDK4 can malignantly transform cells by sequestering p16(INK4a) Or other CKIs. We demonstrate that both cyclin D1 and CDK4 functionally depend on active Myc to exert their potential as oncogenes and vice versa that the transforming ability of Myc requires functional cyclin D/CDK complexes. Moreover, we find that p16(INK4a) and the Rb related protein p107 which releases Myc after phosphorylation by cyclin D1/CDK4 efficiently block Myc's activity as a transcriptional transactivator and as an oncogene. We conclude that both p16(INK4a) and cyclin D/CDK4 complexes are upstream regulators of Myc and directly govern Myc function in transcriptional transactivation and transformation via the pocket protein p107.	UNIV ESSEN GESAMTHSCH KLINIKUM,INST ZELLBIOL TUMORFORSCH,D-45122 ESSEN,GERMANY; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY; DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK	University of Duisburg Essen; Ruprecht Karls University Heidelberg; Danish Cancer Society			Moroy, Tarik/D-9923-2011; Bartek, Jiri/G-5870-2014	Eilers, Martin/0000-0002-0376-6533				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOTZ J, 1996, JOURNAL, V16, P3401; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CERNI C, 1995, ONCOGENE, V11, P587; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Geng Y, 1996, ONCOGENE, V12, P1173; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HALL M, 1995, ONCOGENE, V11, P1581; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HU J, 1992, MOL CELL BIOL, V12, P971; JIANG W, 1993, ONCOGENE, V8, P3447; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KHATIB ZA, 1993, CANCER RES, V53, P5535; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOBORI T, 1994, NATURE, V368, P53; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYMOND A, 1995, ONCOGENE, V11, P1173; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1994, J CELL SCI, V107, P581; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONODA Y, 1995, ONCOGENE, V11, P2145; Starostik P, 1996, MOL CELL BIOL, V16, P3606; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	88	72	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					179	192		10.1038/sj.onc.1201171	http://dx.doi.org/10.1038/sj.onc.1201171			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244353				2022-12-17	WOS:A1997XK37200006
J	Zeng, WR; Scherer, SW; Koutsilieris, M; Huizenga, JJ; Filteau, F; Tsui, LC; Nepveu, A				Zeng, WR; Scherer, SW; Koutsilieris, M; Huizenga, JJ; Filteau, F; Tsui, LC; Nepveu, A			Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas	ONCOGENE			English	Article						uterine leiomyoma; tumor suppressor gene; chromosome 7q22; CUTL1; human Cut homeobox gene; loss of heterozygosity	HUMAN ERYTHROPOIETIN GENE; CCAAT DISPLACEMENT PROTEIN; ACUTE MYELOGENOUS LEUKEMIA; IN-SITU HYBRIDIZATION; MOLECULAR-CLONING; ABNORMALITIES; CHROMOSOME-7; ENHANCER; HYPOXIA; 7Q22	Cytogenetic analyses has revealed deletions and/or rearrangments at several chromosomal positions in approximately half of uterine leiomyomas. The most frequent genetic alteration, deletion of 7q22, was found in approximately 35% of studied cases with cytogenetic abnormalities (128/366=35%), The same chromosomal band was also found to be deleted in a fraction of acute myeloid leukemias and myelodysplastic syndromes, The frequent deletion of 7q22 in some tumors suggest that a tumor suppressor gene may be located in this region, The human Cut-like homeobox gene, CUTL1, is one of the genes localized to 7q22 and it was shown previously to encode a transcriptional repressor that down-modulates the expression of c-Myc, Activation of the c-Myc oncogenic potential has been shown in many cancers to result from alterations in one or the other of its several mechanisms of regulation, These observations led us to hypothesize that CUTL1 could act as a tumor suppressor gene, In the present study, we have identified polymorphic markers within and directly adjacent to CUTL1 at 7q22 and demonstrated that these markers are present in a commonly deleted region in seven out of 50 uterine leiomyomas samples examined, Furthermore, Northern blot analysis revealed that CUTL1 mRNA levels were reduced in eight tumors out of 13. These results suggest that CUTL1 may act as a tumor suppressor gene whose inactivation could be of pathological importance in the etiology of uterine leiomyomas.	HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ,CANADA; UNIV LAVAL,CHU LAVAL,CTR RECH,MOL ENDOCRINOL LAB,ST FOY,PQ G1K 7P4,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; McGill University; McGill University; Laval University; University of Toronto			Koutsilieris, Michael/AAD-3648-2019; Scherer, Stephen W./B-3785-2013; Tsui, Lap-chee/A-1081-2010; /AAB-8315-2020	Scherer, Stephen W./0000-0002-8326-1999; 				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DALCIN P, 1995, GENE CHROMOSOME CANC, V13, P219; DALCIN P, 1995, CANCER RES, V55, P1565; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; FENAUX P, 1989, BRIT J HAEMATOL, V73, P61, DOI 10.1111/j.1365-2141.1989.tb00221.x; FU P, 1993, MOL CELL ENDOCRINOL, V93, P107, DOI 10.1016/0303-7207(93)90113-X; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HEIM S, 1992, LEUKEMIA RES, V16, P43, DOI 10.1016/0145-2126(92)90098-R; HONN KV, 1992, CANCER METAST REV, V11, P353, DOI 10.1007/BF01307187; HORII A, 1994, BIOCHEM BIOPH RES CO, V204, P1257, DOI 10.1006/bbrc.1994.2598; ISHWAD CS, 1995, GENE CHROMOSOME CANC, V14, P51, DOI 10.1002/gcc.2870140109; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JOHANNING GL, 1992, P NATL ACAD SCI USA, V89, P10964, DOI 10.1073/pnas.89.22.10964; LEMIEUX N, 1994, GENOMICS, V24, P191, DOI 10.1006/geno.1994.1603; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LITT M, 1993, BIOTECHNIQUES, V15, P280; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; NILBERT M, 1989, CANCER GENET CYTOGEN, V42, P51, DOI 10.1016/0165-4608(89)90007-1; NILBERT M, 1990, HUM GENET, V85, P605; NILBERT M, 1988, CYTOGENET CELL GENET, V49, P300, DOI 10.1159/000132682; OZISIK YY, 1993, CANCER GENET CYTOGEN, V71, P1, DOI 10.1016/0165-4608(93)90195-R; OZISIK YY, 1993, CANCER GENET CYTOGEN, V67, P59, DOI 10.1016/0165-4608(93)90045-N; PANDIS N, 1990, GENE CHROMOSOME CANC, V2, P311, DOI 10.1002/gcc.2870020409; PANDIS N, 1991, CANCER GENET CYTOGEN, V55, P11, DOI 10.1016/0165-4608(91)90229-N; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; REIN MS, 1991, OBSTET GYNECOL, V77, P923; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAIT SNJ, 1989, CANCER GENET CYTOGEN, V37, P157; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SCHERER S, 1991, P33; SCHERER SW, 1993, HUM MOL GENET, V2, P751, DOI 10.1093/hmg/2.6.751; SCHERER SW, 1993, GENOMICS, V15, P695, DOI 10.1006/geno.1993.1130; SCHUSTER SJ, 1989, BLOOD, V73, P13; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; SOLBERG R, 1992, GENOMICS, V14, P63, DOI 10.1016/S0888-7543(05)80284-8; Sourla A, 1996, CANCER RES, V56, P3123; SWANSBURY GJ, 1994, CANCER GENET CYTOGEN, V73, P1, DOI 10.1016/0165-4608(94)90174-0; TAGUCHI T, 1994, GENOMICS, V20, P146, DOI 10.1006/geno.1994.1148; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VANNI R, 1991, CANCER GENET CYTOGEN, V53, P247, DOI 10.1016/0165-4608(91)90101-Y; WILCOX LS, 1994, OBSTET GYNECOL, V83, P549, DOI 10.1097/00006250-199404000-00011; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YUNIS JJ, 1988, BRIT J HAEMATOL, V68, P189, DOI 10.1111/j.1365-2141.1988.tb06188.x	58	72	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2355	2365		10.1038/sj.onc.1201076	http://dx.doi.org/10.1038/sj.onc.1201076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178912				2022-12-17	WOS:A1997WY88300013
J	Harvat, BL; Seth, P; Jetten, AM				Harvat, BL; Seth, P; Jetten, AM			The role of p27(Kip1) in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells	ONCOGENE			English	Article						p27(Kip1); growth inhibition; mammary epithelial cells; cdk2; cyclin E; mammary carcinoma	CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; CDK INHIBITORS; TGF-BETA; DNA-REPLICATION; BREAST-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; POTENTIAL MEDIATOR; GENE-EXPRESSION; MAMMALIAN-CELLS	Interferon gamma (IFN gamma) induces growth arrest in normal human mammary epithelial cells by establishing a block during mid-G(1) corresponding to the time when the retinoblastoma protein (Rb) would normally be inactivated by hyperphosphorylation. IFN gamma inhibits the kinase activities of cdk2, cdk4 and cdk6 within 24 h of treatment, Protein levels of the cdks and G(1) cyclins do not change within this time period, although cdk4 levels are significantly reduced by 48 h. IFN gamma treatment induces p27(Kip1) protein levels, presumably by a posttranscriptional mechanism as no change was observed in the mRNA levels. In addition, IFN gamma-induced inhibition of cdk2 and cyclin E-associated kinase activities is accompanied by a 4.5-fold or greater increase of p27(Kip1) in cdk2 complexes, p27 may also have a role in the inhibition of cdk4/6 kinase activities, as p27 protein associated with these complexes was increase by 55-70% after IFN gamma. In mammary carcinoma cell Lines which are resistant to growth inhibition by IFN gamma, p27 levels are not induced by IFN gamma nor is cdk2 kinase activity inhibited, despite high baseline levels of p27 in cdk2 complexes, However, exogenous expression of p27 in these cells induces growth arrest, In addition, purified p27 protein added to cdk2 complexes immunoprecipitated from carcinoma cells is able to inhibit the kinase activity in a dose dependent manner, Our results suggest that p27(Kip1) has a role in mediating IFN gamma-induced terminal growth arrest. Resistance of mammary carcinomas to growth inhibition by IFN gamma does not appear to involve resistance of cdk2 complexes to the action of p27, but rather an inability to appropriately regulate the balance of cdk2, cyclin E and p27 levels.	NIEHS,CELL BIOL SECT,PULM PATHOBIOL LAB,NIH,RES TRIANGLE PK,NC 27709; NCI,MED BREAST CANC SECT,MED BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445				ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BATES S, 1994, ONCOGENE, V9, P71; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EBLEN ST, 1995, CELL GROWTH DIFFER, V6, P915; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ferrando AA, 1996, HUM GENET, V97, P91; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERZINGER T, 1995, ONCOGENE, V10, P2079; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sgambato A, 1996, CANCER RES, V56, P1389; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	81	72	74	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2111	2122		10.1038/sj.onc.1201055	http://dx.doi.org/10.1038/sj.onc.1201055			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160891				2022-12-17	WOS:A1997WW80900013
J	Meyerhardt, JA; Look, AT; Bigner, SH; Fearon, ER				Meyerhardt, JA; Look, AT; Bigner, SH; Fearon, ER			Identification and characterization of neogenin, a DCC-related gene	ONCOGENE			English	Article						tumor suppressor gene; DCC (deleted in colorectal cancer) gene; brain tumor; neuroblastoma; gene expression; chromosome 18q	COLORECTAL-CANCER; PANCREATIC ADENOCARCINOMA; ALLELOTYPE ANALYSIS; C-ELEGANS; CARCINOMA; CELL; DIFFERENTIATION; HETEROZYGOSITY; CHROMOSOME; EXPRESSION	DCC (deleted in colorectal cancer), a candidate tumor suppressor gene located in chromosome band 18q21.2, encodes a transmembrane protein of 1447 amino acids. Neogenin, a protein with nearly 50% amino acid identity to DCC, was recently identified because of its dynamic expression in the developing nervous system and gastrointestinal tract of the chicken. To explore a role for the human neogenin (NGN) gene in cancer, we have isolated cDNAs for two alternatively spliced forms of NGN, encoding proteins of 1461 and 1408 amino acids. Fluorescence in situ hybridization studies (FISH) localized NGN in chromosome band 15q22, a region infrequently affected by alterations in cancer. NGN transcripts of about 7.5 and 5.5 kb were detected in all adult tissues studied. In contrast to the frequent loss of DCC expression, no alterations in NGN expression were observed in more than 50 cancers studied, including glioblastoma, medulloblastoma, neuroblastoma, colorectal, breast, cervical and pancreatic cancer cell lines and xenografts. Based on their sequence conservation and similar expression during development, DCC and NGN may have related functions. However, the chromosomal location and ubiquitous expression of NGN in various human tumors suggest it is infrequently altered in cancer.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV MED & MOL GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; St Jude Children's Research Hospital; Duke University					NATIONAL CANCER INSTITUTE [R01CA070097, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA70097, CA23009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHAN S, 1995, WORM BREEDERS GAZETT, V13, P48; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CLIBY W, 1993, CANCER RES, V53, P2393; Cooper HM, 1995, ONCOGENE, V11, P2243; CULOTTI JG, 1994, CURR OPIN GENET DEV, V4, P587, DOI 10.1016/0959-437X(94)90077-G; Ekstrand BC, 1995, ONCOGENE, V11, P2393; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1995, CLIN ONCOLOGY, P11; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; FUJINO T, 1994, CANCER RES, V54, P4294; HAHN SA, 1995, CANCER RES, V55, P4670; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KNOWLES MA, 1994, CANCER RES, V54, P531; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; MITRA AB, 1994, CANCER RES, V54, P4481; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; REALE MA, 1994, CANCER RES, V54, P4493; Reale MA, 1996, CLIN CANCER RES, V2, P1097; SATO T, 1990, CANCER RES, V50, P7184; Schold S C Jr, 1983, J Neurooncol, V1, P5; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SEYMOUR AB, 1994, CANCER RES, V54, P2761; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; Wick W, 1996, ONCOGENE, V12, P973; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	40	72	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1129	1136		10.1038/sj.onc.1200935	http://dx.doi.org/10.1038/sj.onc.1200935			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121761				2022-12-17	WOS:A1997WM78200001
J	Burke, CL; Lemmon, MA; Coren, BA; Engelman, DM; Stern, DF				Burke, CL; Lemmon, MA; Coren, BA; Engelman, DM; Stern, DF			Dimerization of the p185(neu) transmembrane domain is necessary but not sufficient for transformation	ONCOGENE			English	Article						receptor tyrosine kinase; dimerization; transmembrane domain; neu/HERZ/erbB-2	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; NEU-ONCOGENE; POINT MUTATION; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; PROTO-ONCOGENE; CROSS-LINKING	The neu proto-oncogene encodes a receptor tyrosine kinase (RTK). The oncogenic allele neu* (p185*) bears a glutamic acid for valine substitution at position 664 within the predicted transmembrane domain. We have used this mutant to explore the role of the transmembrane domain in signal transduction by RTKs. Analysis of a panel of neu* proteins with second-site mutations in the transmembrane domain revealed a strong correlation of dimerization with transformation. Both dimerization and transformation are dependent on a domain formed by the amino acids Val663-Glu664-Gly665 (VEG). However, movement of the VEG elsewhere within the transmembrane domain promoted weak dimerization but not transformation, Epidermal growth factor receptor (EGFR)/neu chimeras were used to determine if mutations that disrupt activation by Glu664 affect hormone-regulated signal transduction as well. These mutations (of Val663 and Gly665) did not affect regulation by EGF, Introduction of the known transmembrane dimerization domain from Glycophorin A (GpA) stimulated dimerization, but was not sufficient for transformation. These results indicate that dimerization is necessary but not sufficient for transforming activity. The homologous wild-type domain, VVG, is not required for hormone-regulated signaling.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; UNIV PENN, SCH MED, DEPT BIOPHYS & BIOCHEM, PHILADELPHIA, PA 19104 USA	Yale University; Yale University; Yale University; University of Pennsylvania				Lemmon, Mark/0000-0002-3379-5319	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, IN PRESS; AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1991, ONCOGENE, V6, P705; CAO HN, 1992, J BIOL CHEM, V267, P20489; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LONGO N, 1992, J BIOL CHEM, V267, P12416; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKAHSHI M, 1987, J BIOL CHEM, V263, P3400; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	72	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					687	696		10.1038/sj.onc.1200873	http://dx.doi.org/10.1038/sj.onc.1200873			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038376				2022-12-17	WOS:A1997WG43000007
J	Amundadottir, LT; Nass, SJ; Berchem, GJ; Johnson, MD; Dickson, RB				Amundadottir, LT; Nass, SJ; Berchem, GJ; Johnson, MD; Dickson, RB			Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis	ONCOGENE			English	Article						c-Myc; TGF alpha; apoptosis; mammary tumorigenesis	HUMAN-BREAST-CANCER; PROGRAMMED CELL-DEATH; DNA STRAND BREAKS; TRANSGENIC MICE; EPITHELIAL-CELLS; FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; MEDIATED APOPTOSIS; FACTOR RECEPTOR; LEUKEMIA-CELLS	We have previously shown that TGF alpha and c-Myc interact in a strong, synergistic fashion to induce mammary gland tumors in double transgenic mice. Here we show this interaction can be explained, at least in part, by a cooperative growth stimulus by the two proteins, and by TGF alpha-mediated inhibition of c-Myc-induced apoptosis, We initially compared rapidly progressing mammary tumors from double transgenic mice to long latency tumors from single transgenic mice and observed a striking difference in the occurrence of apoptosis among the three groups, Tumors exhibiting apoptosis were derived exclusively from mice that expressed the c-myc transgene in the absence of the TGF alpha transgene, indicating that TGF alpha might protect c-Myc-overexpressing cells from programmed cell death, Cell lines were derived from single and double transgenic mammary tumors to examine further the mechanism underlying the cooperative interaction between the two gene products, In accordance with our in vivo data, apoptosis was only detected when the c-myc transgene was expressed without the TGF alpha transgene, Furthermore, exogenous addition of TGF alpha inhibited apoptosis in cells overexpressing c-Myc alone, In addition, tumor-derived cells that overexpressed both TGF alpha and c-Myc exhibited faster growth rates in vitro and in vivo and were less sensitive to the inhibitory effects of TGF beta in vitro compared to cell lines expressing only one of the transgenes, Based on our findings we propose that TGF alpha acts both as a proliferative and a survival factor for c-Myc-expressing tumor cells, Our results indicate that TGF alpha and c-Myc cooperate in tumorigenesis via a dual mechanism: TGF alpha can inhibit c-Myc-induced apoptosis and both proteins provide a growth stimulus.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT CELL BIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,DIV HEMATOL ONCOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University; Georgetown University			Berchem, Guy/C-9364-2014; Amundadottir, Laufey T/L-7656-2016	Berchem, Guy/0000-0003-0157-2257; Amundadottir, Laufey T/0000-0003-1859-8971				AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; ARTEAGA CL, 1988, CANCER RES, V48, P5023; ASKEW DS, 1991, ONCOGENE, V6, P1915; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; CATCHPOOLE DR, 1993, CANCER RES, V53, P4287; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DERYNCK R, 1987, CANCER RES, V47, P707; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GARCIA I, 1989, CANCER RES, V49, P6675; GORSCH SM, 1992, CANCER RES, V52, P6949; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAVRILESKY LJ, 1995, CANCER RES, V55, P944; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HSU B, 1995, ONCOGENE, V11, P175; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KAMESAKI S, 1993, CANCER RES, V53, P4251; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KHAZAIE K, 1991, ONCOGENE, V6, P21; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PERROTEAU I, 1986, BREAST CANCER RES TR, V7, P201, DOI 10.1007/BF01806251; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Sakamuro D, 1995, ONCOGENE, V11, P2411; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SMITH GH, 1995, AM J PATHOL, V147, P1081; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAETLE R, 1993, CANCER RES, V53, P3386; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TRAVERS MT, 1988, BRIT MED J, V296, P1621, DOI 10.1136/bmj.296.6637.1621; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WITKIEWICZ H, 1993, BIOTECHNIQUES, V14, P458; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	65	72	73	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					757	765						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761297				2022-12-17	WOS:A1996VD43300011
J	Bacus, SS; Yarden, Y; Oren, M; Chin, DM; Lyass, L; Zelnick, CR; Kazarov, A; Toyofuku, W; GrayBablin, J; Beerli, RR; Hynes, NE; Nikiforov, M; Haffner, R; Gudkov, A; Keyomarsi, K				Bacus, SS; Yarden, Y; Oren, M; Chin, DM; Lyass, L; Zelnick, CR; Kazarov, A; Toyofuku, W; GrayBablin, J; Beerli, RR; Hynes, NE; Nikiforov, M; Haffner, R; Gudkov, A; Keyomarsi, K			Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells	ONCOGENE			English	Article						heregulin; Neu; p53; p21(WAF1/CIP1); cell cycle; erbB-2	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODIES; MAMMARY-TUMORS; P53; PROTEIN; GENE; PHOSPHORYLATION; IDENTIFICATION; AMPLIFICATION	Previously we reported that neu differentiation factor (NDF)/heregulin (HRG) elevates tyrosine phosphorylation of its receptors erbB-3, erbB-4, and erbB-2 (through heterodimer formation). We also showed that both NDF/HRG and antibodies to erbB-2 can arrest growth and induce differentiation in breast cancer cells. In this study, we report on the mechanism of NDF/HRG-induced cellular effects. We show that NDF/HRG and antibodies to erbB-2 receptors up-regulate expression of p53 by stabilizing the protein. This is accompanied by upregulation of the p53 inducible gene, p21(CIP1/WAF1), in a variety of cell lines: MCF7 and their derivatives (MCF7/HER2, MN1 and MCF-7-puro), ZR75T and LnCap cells, The induction of p21 is further enhanced when cells are treated with both NDF/HRG and DNA-damaging chemotherapeutic agents (i.e. doxorubicin). The NDF/HRG mediated induction of p21 is dependent on wildtype p53, as it fails to occur in cells expressing dominant negative p53 (MDD2). Furthermore, p21 induction is capable of inactivating cdk2 complexes as measured by Histone H1 phosphorylation assays. Finally, we show that in primary cultures of breast and other cancers, p21 is significantly induced in response to NDF/HRG treatment. Collectively, these observations suggest that the mechanism of breast cancer cell growth inhibition and differentiation via erbB receptors activation is through a p53-mediated pathway.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR, ALBANY, NY 12201 USA; ADV CELLULAR DIAGNOST INC, ELMHURST, IL 60126 USA; UNIV ILLINOIS, CHICAGO, IL 60612 USA; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	State University of New York (SUNY) System; Wadsworth Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Weizmann Institute of Science; Friedrich Miescher Institute for Biomedical Research			Keyomarsi, Khandan/H-2716-2016; YARDEN, YOSEF/K-1467-2012	Keyomarsi, Khandan/0000-0002-5440-0849; Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; NCI NIH HHS [CA62045, CA60730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAGASE H, 1990, J PHARMACOBIO-DYNAM, V13, P263, DOI 10.1248/bpb1978.13.263; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CANCER RES, V52, P2580; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUDAS J, 1995, ONCOGENE, V11, P253; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KWOK TT, 1991, INT J CANCER, V49, P73, DOI 10.1002/ijc.2910490114; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu Y, 1996, CANCER RES, V56, P31; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SACHS L, 1987, CANCER RES, V47, P1981; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIEGALL CB, 1995, J BIOL CHEM, V270, P7625, DOI 10.1074/jbc.270.13.7625; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668; ZIANG H, 1993, MOL BIOL CELL DIFF, V1, P285	67	72	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2535	2547						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700512				2022-12-17	WOS:A1996UW48700007
J	Leung, HY; Dickson, C; Robson, CN; Neal, DE				Leung, HY; Dickson, C; Robson, CN; Neal, DE			Over-expression of fibroblast growth factor-8 in human prostate cancer	ONCOGENE			English	Article						fibroblast growth factor-8, FGF-8; androgen induced growth factor; prostate cancer; in situ hybridisation			IMPERIAL CANC RES FUND,VIRAL CARCINOGENESIS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Leung, HY (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				DEARNALEY DP, 1994, BRIT MED J, V308, P780, DOI 10.1136/bmj.308.6931.780; LEUNG HY, 1994, INT J ONCOL, V4, P1219; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928	8	72	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1833	1835						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622905				2022-12-17	WOS:A1996UG45800027
J	FUCHS, B; OCONNOR, D; FALLIS, L; SCHEIDTMANN, KH; LU, X				FUCHS, B; OCONNOR, D; FALLIS, L; SCHEIDTMANN, KH; LU, X			P53 PHOSPHORYLATION MUTANTS RETAIN TRANSCRIPTION ACTIVITY	ONCOGENE			English	Note						P53; PHOSPHORYLATION; TRANSCRIPTION GROWTH SUPPRESSION	CASEIN KINASE-II; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; NUCLEAR-LOCALIZATION; SEQUENCE; SITE; TRANSACTIVATION; EXPRESSION; MUTATION; P34CDC2	To investigate the effect of phosphorylation on the transcription activity of p53, ten phosphorylation mutants were constructed covering all the identified phosphorylation sites of rat p53. These included mutants of two casein kinase I sites (Ser6 and Ser9), two DNA-PK sites (Ser15 and Ser39), a p34cdc2 site(Ser313), the adjacent Ser312 and a casein kinase II site (Ser390). Two double phosphorylation mutants (Ser4, 6 and Ser15, 390) and one triple phosphorylation mutant (Ser4, 6 and 15) were also constructed. The transcription activity of all the p53 phosphorylation mutants was tested by transfection into two different types of cells, Saos-2 cells and p53(-/-) fibroblasts derived from p53 knock out mice, which both lack endogenouse p53. Surprisingly, all the p53 phosphorylation mutants retain transcription activity and the seven mutants tested can also suppress cell growth.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; UNIV BONN,INST GENET,MOLEK GENET ABT,D-53117 BONN,GERMANY	Imperial College London; Ludwig Institute for Cancer Research; University of Bonn				Lu, Xin/0000-0002-6587-1152				ADDISON C, 1990, ONCOGENE, V5, P423; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHEN JY, 1993, ONCOGENE, V8, P2159; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; FREBOURG T, 1992, CANCER RES, V52, P6976; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V289, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; Sambrook J., 1989, MOL CLONING LAB MANU; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231	32	72	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					789	793						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862459				2022-12-17	WOS:A1995QH61200022
J	PLET, A; EICK, D; BLANCHARD, JM				PLET, A; EICK, D; BLANCHARD, JM			ELONGATION AND PREMATURE TERMINATION OF TRANSCRIPTS INITIATED FROM C-FOS AND C-MYC PROMOTERS SHOW DISSIMILAR PATTERNS	ONCOGENE			English	Article						IN VIVO FOOTPRINT; C-FOS AND C-MYC; PROTOONCOGENES; INTRAGENIC BLOCK; ELONGATION	RNA POLYMERASE-II; SEQUENCE REQUIREMENTS; DROSOPHILA-MELANOGASTER; TRANS-ACTIVATION; GENE-EXPRESSION; DOWN-REGULATION; MESSENGER-RNA; INVIVO; BLOCK; CELLS	RNA polymerase II seems to be prone to stop at intrinsic pause sites, thus introducing a further potential level of regulation. It was recently shown that RNA polymerase Lf was held at the P2 promoter of c-myc gene. We confirmed the presence of engaged polymerases in the murine fibroblastic Ltk(-) and pre-B lymphoid 70Z3 cell lines. High resolution run-on analysis and in vivo permanganate-dependent footprinting showed that this holds true for the c-fos gene in unstimulated cells where a strong block to transcription elongation was evidenced. In contrast to what was observed in the c-myc gene, an even more intense signal was observed in run-on experiments downstream to the promoter, on a c-fos oligonucleotide including position +385 where an in vitro transcription arrest site was previously mapped. Genomic footprinting of DNA from intact cells and isolated nuclei confirmed the involvement of several thymidines belonging to a T-rich stretch in a melted region which was not detected upon polymerase release. In order to observe a short abortive c-fos transcript accumulating in vivo we resorted to microinjection of c-fos templates in Xenopus oocytes where transcripts were stable.	UNIV MONTPELLIER 2,MONTPELLIER 1,FRANCE; FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY	Universite de Montpellier	PLET, A (corresponding author), INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,BP 5051,1919 ROUTE MENDE,MONTPELLIER 1,FRANCE.							ASSELIN C, 1989, ONCOGENE, V4, P549; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1988, BIOCHIMIE, V70, P877, DOI 10.1016/0300-9084(88)90228-3; BONNIEU A, 1989, ONCOGENE, V4, P881; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MIDDLETON KM, 1990, MOL CELL BIOL, V10, P727, DOI 10.1128/MCB.10.2.727; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MIRKOVITCH J, 1992, MOL BIOL CELL, V3, P1085, DOI 10.1091/mbc.3.10.1085; MORGAN GT, 1984, NUCLEIC ACIDS RES, V12, P6043, DOI 10.1093/nar/12.15.6043; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PLET A, 1992, ONCOGENE, V7, P1847; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SALDITTGEORGIEF.M, 1980, CELL, V19, P69; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SZENTIRMAY MN, 1993, EMBO J, V12, P4677, DOI 10.1002/j.1460-2075.1993.tb06156.x; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	44	72	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					319	328						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838531				2022-12-17	WOS:A1995QC62400011
J	TORTORA, G; PEPE, S; BIANCO, C; BALDASSARRE, G; BUDILLON, A; CLAIR, T; CHOCHUNG, YS; BIANCO, AR; CIARDIELLO, F				TORTORA, G; PEPE, S; BIANCO, C; BALDASSARRE, G; BUDILLON, A; CLAIR, T; CHOCHUNG, YS; BIANCO, AR; CIARDIELLO, F			THE RI-ALPHA-SUBUNIT OF PROTEIN-KINASE-A CONTROLS SERUM DEPENDENCY AND ENTRY INTO CELL-CYCLE OF HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							TISSUE-SPECIFIC EXTINGUISHER; AMP BINDING-PROTEINS; I REGULATORY SUBUNIT; AMINO-ACID SEQUENCE; C-HA-RAS; GROWTH-INHIBITION; MOLECULAR-CLONING; MAMMALIAN-CELLS; DOWN-REGULATION; HL-60 LEUKEMIA	MCP-10A, a nontransformed mammary epithelial cell line, requires a mixture of hormones and growth factors for optimal cell proliferation. In this report we show that when MCF-10A cells are cultured in serum free medium they become quiescent and accumulate in G(0)/G(1) phases of the cell cycle. Following addition of complete medium to quiescent cells, MCF-10A cells enter into the S phase within 15-18h and resume the cell cycle distribution of proliferating cells within 24 h. Measurement of RI alpha subunit of the cAMP-dependent protein kinase (PKA) shows a 10- to 15-fold increase in protein levels at 6 h following complete medium addition, thus preceding cell entry into the S phase. Retroviral vector-mediated overexpression of RI alpha, but not of RII beta or C alpha subunits of PKA, enables MCF-10A cells to grow in serum-free medium. In addition, RI alpha downregulation by specific antisense oligodeoxynucleotide treatment or following infection with a retroviral vector containing the RI alpha cDNA in antisense orientation determines growth arrest of proliferating MCF-10A cells and is able to partially block S phase entry of quiescent MCF-10A cells following complete medium addition. These results suggest that RI alpha/PKAI is involved in the control of cell cycle progression of mammary epithelial cells at a G(1) to S transition border, and that its overexpression is able to overcome serum and growth factors requirement for cell proliferation.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TORTORA, G (corresponding author), UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,I-80131 NAPLES,ITALY.		Budillon, Alfredo/K-4763-2016; Baldassarre, Gustavo/K-1350-2016; Tortora, Giampaolo/AAA-1252-2019	Budillon, Alfredo/0000-0002-6330-6053; Baldassarre, Gustavo/0000-0002-9750-8825; Ciardiello, Fortunato/0000-0002-3369-4841; Tortora, Giampaolo/0000-0002-1378-4962				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BYUS CV, 1977, NATURE, V268, P63, DOI 10.1038/268063a0; CERESETO A, 1993, P AM ASSOC CANC RES, V34, P175; CHOCHUNG YS, 1991, PHARMACOL THERAPEUT, V50, P1, DOI 10.1016/0163-7258(91)90071-S; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1993, INT J CANCER, V53, P438, DOI 10.1002/ijc.2910530315; CIARDIELLO F, 1994, ONCOGENE, V9, P291; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; MILLER WR, 1990, BRIT J CANCER, V61, P263, DOI 10.1038/bjc.1990.48; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PEPE S, 1994, CYTOMETRY, V15, P73, DOI 10.1002/cyto.990150112; RIABOWOL KT, 1992, BIOCHEM CELL BIOL, V70, P1064, DOI 10.1139/o92-151; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SOULE HD, 1990, CANCER RES, V50, P6075; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; TAIT L, 1990, CANCER RES, V50, P6087; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; TORTORA G, 1993, CELL GROWTH DIFFER, V4, P359; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1990, J BIOL CHEM, V265, P18067; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	39	72	73	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3233	3240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936647				2022-12-17	WOS:A1994PM65800016
J	SUBLER, MA; MARTIN, DW; DEB, S				SUBLER, MA; MARTIN, DW; DEB, S			OVERLAPPING DOMAINS ON THE P53 PROTEIN REGULATE ITS TRANSCRIPTIONAL ACTIVATION AND REPRESSION FUNCTIONS	ONCOGENE			English	Article							WILD-TYPE P53; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; TRANSFORMED-CELLS; BINDING PROTEIN; GENE-EXPRESSION; T-ANTIGEN; MUTANT; ONCOGENE	Wild-type p53 has been shown to inhibit transcription from several viral and cellular promoters without known p53-binding sites, while transactivating promoters with p53-binding sites. Using a series of N- and C-terminal p53 deletion mutants and wild-type p53, we have defined the domains on p53 responsible for its transcriptional functions. To test transcriptional activation by p53 we have used a promoter-chloramphenicol acetyltransferase (CAT) construct containing synthetic p53-binding sites. To check transcriptional inhibition by p53 we have used a human cytomegalovirus immediate-early promoter construct, CMV-CAT. Using transient transfection-transcription assays in Saos-2 cells, we determined that the p53 transcriptional activation and repression domains overlap at the N-terminus. This suggests the possibility that the same transcriptional machinery is involved in both functions. A C-terminal deletion up to amino acid 327 (del 393-327) eliminated repression of CMV-CAT, while preserving the transactivation function to a large extent. Using gluteraldehyde cross-linking experiments, we observed that the mutant del 393-327, which is transactivation-competent, but repression-defective, could not oligomerize. Thus, oligomerization of p53 is not required for transactivation, but may be essential for repression. Interestingly, transactivation by the oligomerization-defective mutant could be inhibited by cotransfection with a plasmid expressing the transforming mutant p53-175H.	UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1993, ONCOGENE, V8, P2555	73	72	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1351	1359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152795				2022-12-17	WOS:A1994NH40100006
J	DOBBELSTEIN, M; ARTHUR, AK; DEHDE, S; VANZEE, K; DICKMANNS, A; FANNING, E				DOBBELSTEIN, M; ARTHUR, AK; DEHDE, S; VANZEE, K; DICKMANNS, A; FANNING, E			INTRACISTRONIC COMPLEMENTATION REVEALS A NEW FUNCTION OF SV40 T-ANTIGEN THAT COOPERATES WITH RB AND P53 BINDING TO STIMULATE DNA-SYNTHESIS IN QUIESCENT CELLS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE TUMOR-ANTIGEN; ADENOVIRUS E1A PROTEINS; SIMIAN VIRUS-40; CELLULAR DNA; PRODUCT; PHOSPHORYLATION; TRANSFORMATION; GROWTH; CYCLE	The ability of the oncogene products of DNA tumor viruses to induce DNA sythesis in quiescent cells is thought to depend on their capacity to bind to cellular proteins such as the retinoblastoma-suppressor protein Rb and the tumor suppressor p53, thereby abolishing the growth-arresting properties of these proteins. We have tested this hypothesis using SV40 T antigens carrying lesions that affect Rb binding, p53 binding or other functions involved in cell transformation. The results demonstrate that Rb binding is not essential for growth stimulation by T antigen. However, detailed analysis, including intracistronic complementation, suggests that at least three functions, Rb binding, a novel second activity localized to the DNA-binding domain and a function residing in the carboxy terminus, probably p53 binding, cooperate to generate the full growth induction potential of T antigen.	INST BIOCHEM, KARLSTR 23, W-8000 MUNICH 2, GERMANY					Dobbelstein, Matthias/0000-0001-5052-3967				ARTHUR AK, 1988, J VIROL, V62, P1999, DOI 10.1128/JVI.62.6.1999-2006.1988; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BAUMANN EA, 1985, J VIROL, V54, P882, DOI 10.1128/JVI.54.3.882-885.1985; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1982, EMBO J, V1, P1023, DOI 10.1002/j.1460-2075.1982.tb01290.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GLUZMAN Y, 1982, VIROLOGY, V123, P78, DOI 10.1016/0042-6822(82)90296-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTL M, 1990, J VIROL, V64, P2884, DOI 10.1128/JVI.64.6.2884-2894.1990; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KERN SE, 1991, ONCOGENE, V6, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LEVINSON A, 1984, Journal of Molecular and Applied Genetics, V2, P507; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STILLMAN B, 1985, EMBO J, V4, P2933, DOI 10.1002/j.1460-2075.1985.tb04026.x; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TJIAN R, 1978, P NATL ACAD SCI USA, V75, P1279, DOI 10.1073/pnas.75.3.1279; TORNOW J, 1983, P NATL ACAD SCI-BIOL, V80, P6312, DOI 10.1073/pnas.80.20.6312; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116	84	72	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					837	847						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570154				2022-12-17	WOS:A1992HP64200002
J	CASTELLAZZI, M; DANGY, JP; MECHTA, F; HIRAI, SI; YANIV, M; SAMARUT, J; LASSAILLY, A; BRUN, G				CASTELLAZZI, M; DANGY, JP; MECHTA, F; HIRAI, SI; YANIV, M; SAMARUT, J; LASSAILLY, A; BRUN, G			OVEREXPRESSION OF AVIAN OR MOUSE C-JUN IN PRIMARY CHICK-EMBRYO FIBROBLASTS CONFERS A PARTIALLY TRANSFORMED PHENOTYPE	ONCOGENE			English	Article									INST PASTEUR,DEPT BIOL MOLEC,UNITE VIRUS ONCOGENES,CNRS,URA 152,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	CASTELLAZZI, M (corresponding author), ECOLE NORM SUPER,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYONS 07,FRANCE.		Samarut, Jacques/AAD-2587-2019; MECHTA-GRIGORIOU, Fatima/C-5253-2017; Lassailly, Anne/K-6975-2013	MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989; 				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FEO S, 1985, NATURE, V313, P493, DOI 10.1038/313493a0; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MECHTA F, 1989, New Biologist, V1, P297; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAVATIER P, 1989, J VIROL, V63, P513, DOI 10.1128/JVI.63.2.513-522.1989; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; VOGT PK, 1990, IN PRESS ADV CANCER; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	46	72	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1541	1547						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2123532				2022-12-17	WOS:A1990EK50200014
J	BROOKES, S; SMITH, R; CASEY, G; DICKSON, C; PETERS, G				BROOKES, S; SMITH, R; CASEY, G; DICKSON, C; PETERS, G			SEQUENCE ORGANIZATION OF THE HUMAN INT-2 GENE AND ITS EXPRESSION IN TERATOCARCINOMA CELLS	ONCOGENE			English	Article									IMPERIAL CANC RES FUND LABS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BROOKES, S (corresponding author), ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DOMIN HOUSE,LONDON EC1A 7BE,ENGLAND.							ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ADELAIDE J, 1988, ONCOGENE, V2, P413; ANDREWS PW, 1980, INT J CANCER, V26, P269, DOI 10.1002/ijc.2910260304; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FANTL V, 1988, CANCER CELLS, V7; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NUSSE R, 1986, TRENDS GENET, V2, P244, DOI 10.1016/0168-9525(86)90247-7; NUSSE R, 1988, BREAST CANCER CELLUL, P283; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PERA MF, 1987, INT J CANCER, V40, P334, DOI 10.1002/ijc.2910400309; PETERS G, 1989, FRONTIERS MOL BIOL O; Peters G, 1987, CELLULAR MOL BIOL MA, P307; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P81, DOI 10.1016/0968-0004(86)90271-9; THOMPSON S, 1984, J CELL SCI, V72, P37; TSUDA T, 1988, JPN J CANCER RES, V79, P584, DOI 10.1111/j.1349-7006.1988.tb00026.x; VARLEY JM, 1988, ONCOGENE, V3, P87; WANG N, 1980, CANCER RES, V40, P792; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279	41	72	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					429	436						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2470007				2022-12-17	WOS:A1989U567700006
J	FARR, CJ; MARSHALL, CJ; EASTY, DJ; WRIGHT, NA; POWELL, SC; PARASKEVA, C				FARR, CJ; MARSHALL, CJ; EASTY, DJ; WRIGHT, NA; POWELL, SC; PARASKEVA, C			A STUDY OF RAS GENE-MUTATIONS IN COLONIC ADENOMAS FROM FAMILIAL POLYPOSIS COLI PATIENTS	ONCOGENE			English	Article									INST CANC RES,CHESTER BEATTY LABS,CELL & MOLEC BIOL SECT,FULHAM RD,LONDON SW3 6JB,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOPATHOL,LONDON W12 0HS,ENGLAND; UNIV BRISTOL,SCH MED,DEPT PATHOL,BRISTOL BS8 1TD,AVON,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; University of Bristol				Wright, Nicholas/0000-0002-5525-3457; Farr, Christine/0000-0002-5357-5962				ALEXANDER RJ, 1986, GASTRENTEROLOGY, V91, P1510; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1985, BRIT J CANCER, V51, P1, DOI 10.1038/bjc.1985.1; BERRY RD, 1988, CARCINOGENESIS, V9, P447, DOI 10.1093/carcin/9.3.447; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BOS JL, 1988, REV GENET TOXICOL, V195, P255; BRATTAIN MG, 1982, J NATL CANCER I, V69, P767; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BUSSEY HJR, 1982, RECENT RES CANCER, V83, P45; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIEBOVITZ A, 1976, CANCER RES, V36, P4562; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NAMBA M, 1983, INT J CANCER, V32, P697, DOI 10.1002/ijc.2910320608; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PARASKEVA C, 1985, BRIT J CANCER, V51, P131, DOI 10.1038/bjc.1985.19; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PELLING JC, 1988, CARCINOGENESIS, V9, P665, DOI 10.1093/carcin/9.4.665; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; YANEZ L, 1987, ONCOGENE, V1, P315; YUASA Y, 1986, JPN J CANCER RES, V77, P901; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	42	72	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					673	678						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577869				2022-12-17	WOS:A1988R646000008
J	KRAFT, AS; BAKER, VV; MAY, WS				KRAFT, AS; BAKER, VV; MAY, WS			BRYOSTATIN INDUCES CHANGES IN PROTEIN-KINASE-C LOCATION AND ACTIVITY WITHOUT ALTERING C-MYC GENE-EXPRESSION IN HUMAN PROMYELOCYTIC LEUKEMIA-CELLS (HL-60)	ONCOGENE			English	Article									UNIV ALABAMA, DIV GYNECOL ONCOL, BIRMINGHAM, AL 35294 USA; JOHNS HOPKINS UNIV HOSP, CTR ONCOL, DEPT HEMATOL, BALTIMORE, MD 21205 USA	University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine	KRAFT, AS (corresponding author), UNIV ALABAMA, DIV HEMATOL ONCOL, BIRMINGHAM, AL 35294 USA.				NCI NIH HHS [CA 37903, CA 42533] Funding Source: Medline; NIADDK NIH HHS [AM 27157] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P01AM027157] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R23CA037903, R01CA042533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; FILMUS J, 1985, CANCER RES, V45, P822; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GROSSO LE, 1985, CANCER RES, V45, P847; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; INOUE M, 1977, J BIOL CHEM, V252, P7610; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; MACFARLANE DE, 1986, J BIOL CHEM, V261, P6947; MATSUI T, 1986, CANCER RES, V46, P583; MAY WS, 1984, P NATL ACAD SCI-BIOL, V81, P2016, DOI 10.1073/pnas.81.7.2016; MAY WS, 1985, J BIOL CHEM, V260, P9419; MAY WS, 1986, P NATL ACAD SCI USA, V83, P1281, DOI 10.1073/pnas.83.5.1281; MAY WS, 1985, NATURE, V317, P549, DOI 10.1038/317549a0; MELLONI E, 1985, P NATL ACAD SCI USA, V82, P6435, DOI 10.1073/pnas.82.19.6435; MELLONI E, 1986, J BIOL CHEM, V261, P4101; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MITA S, 1984, EXP CELL RES, V154, P492, DOI 10.1016/0014-4827(84)90173-3; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NACCACHE PH, 1985, FEBS LETT, V193, P227, DOI 10.1016/0014-5793(85)80157-5; NISHIHIRA J, 1986, BIOCHEM BIOPH RES CO, V134, P587, DOI 10.1016/S0006-291X(86)80460-0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PETTIT GR, 1983, J NAT PROD, V46, P528, DOI 10.1021/np50028a017; PETTIT GR, 1983, J ORG CHEM, V48, P5354, DOI 10.1021/jo00174a037; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; PONTREMOLI S, 1986, J BIOL CHEM, V261, P8309; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDENBARK GR, 1984, J CLIN INVEST, V73, P448, DOI 10.1172/JCI111231; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366	59	72	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1987	1	2					111	118						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3325877				2022-12-17	WOS:A1987J635200003
J	Brown, TP; Bhattacharjee, P; Ramachandran, S; Sivaprakasam, S; Ristic, B; Sikder, MOF; Ganapathy, V				Brown, Timothy P.; Bhattacharjee, Pushpak; Ramachandran, Sabarish; Sivaprakasam, Sathish; Ristic, Bojana; Sikder, Mohd Omar F.; Ganapathy, Vadivel			The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment	ONCOGENE			English	Article							MURINE DENDRITIC CELLS; UP-REGULATION; LACTIC-ACID; METABOLISM; INFLAMMATION; GENERATION; EXPRESSION; GPR109A; PROTEIN; ACTIVATION	GPR81 is a G-protein-coupled receptor for lactate, which is upregulated in breast cancer and plays an autocrine role to promote tumor growth by tumor cell-derived lactate. Here we asked whether lactate has any paracrine role via activation of GPR81 in cells present in tumor microenvironment to help tumor growth. First, we showed that deletion of Gpr81 suppresses breast cancer growth in a constitutive breast cancer mouse model (MMTV-PyMT-Tg). We then used a syngeneic transplant model by monitoring tumor growth from a mouse breast cancer cell line (AT-3, Gpr81-negative) implanted in mammary fat pad of wild-type mice and Gpr81-null mice. Tumor growth was suppressed in Gpr81-null mice compared with wild-type mice. There were more tumor-infiltrating T cells and MHCIIhi-immune cells in tumors from Gpr81-null mice compared with tumors from wild-type mice. RNA-seq analysis of tumors indicated involvement of immune cells and antigen presentation in Gpr81-dependent tumor growth. Antigen-presenting dendritic cells expressed Gpr81 and activation of this receptor by lactate suppressed cell-surface presentation of MHCII. Activation of Gpr81 in dendritic cells was associated with decreased cAMP, IL-6 and IL-12. These findings suggest that tumor cell-derived lactate activates GPR81 in dendritic cells and prevents presentation of tumor-specific antigens to other immune cells. This paracrine mechanism is complementary to the recently discovered autocrine mechanism in which lactate induces PD-L1 in tumor cells via activation of GPR81 in tumor cells, thus providing an effective means for tumor cells to evade immune system. As such, blockade of GPR81 signaling could boost cancer immunotherapy.	[Brown, Timothy P.; Bhattacharjee, Pushpak; Ramachandran, Sabarish; Sivaprakasam, Sathish; Ristic, Bojana; Sikder, Mohd Omar F.; Ganapathy, Vadivel] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Ganapathy, V (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.	vadivel.ganapathy@ttuhsc.edu	Sivaprakasam, Sathish/E-9367-2018; Bhattacharjee, Pushpak/AFV-4590-2022	Sivaprakasam, Sathish/0000-0002-9230-0144; 	Welch Endowed Chair in Biochemistry at Texas Tech University Health Sciences Center [BI-0028]; South Plains Foundation	Welch Endowed Chair in Biochemistry at Texas Tech University Health Sciences Center; South Plains Foundation	This work was supported by the Welch Endowed Chair in Biochemistry, Grant no. BI-0028, at Texas Tech University Health Sciences Center (VG) and a grant from the South Plains Foundation (SR).	Ahmed K, 2010, CELL METAB, V11, P311, DOI 10.1016/j.cmet.2010.02.012; Brasel K, 2000, BLOOD, V96, P3029, DOI 10.1182/blood.V96.9.3029.h8003029_3029_3039; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Dvorak CA, 2012, ACS MED CHEM LETT, V3, P637, DOI 10.1021/ml3000676; Elangovan S, 2014, CANCER RES, V74, P1166, DOI 10.1158/0008-5472.CAN-13-1451; Feng J, 2017, ONCOGENE, V36, P5829, DOI 10.1038/onc.2017.188; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Fisel P, 2018, CTS-CLIN TRANSL SCI, V11, P352, DOI 10.1111/cts.12551; Frauwirth KA, 2004, J IMMUNOL, V172, P4661, DOI 10.4049/jimmunol.172.8.4661; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; Ge H, 2008, J LIPID RES, V49, P797, DOI 10.1194/jlr.M700513-JLR200; GOLDMAN RD, 1964, CANCER RES, V24, P389; Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hoque R, 2014, GASTROENTEROLOGY, V146, P1763, DOI 10.1053/j.gastro.2014.03.014; Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Lee YJ, 2016, ONCOTARGET, V7, P70898, DOI 10.18632/oncotarget.12286; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; Naik SH, 2005, J IMMUNOL, V174, P6592, DOI 10.4049/jimmunol.174.11.6592; Offermanns S, 2017, TRENDS ENDOCRIN MET, V28, P227, DOI [10.1016/J.tem.2016.11.007, 10.1016/j.tem.2016.11.007]; Ranganathan P, 2018, J IMMUNOL, V200, P1781, DOI 10.4049/jimmunol.1700604; Raychaudhuri D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01878; Roland CL, 2014, CANCER RES, V74, P5301, DOI 10.1158/0008-5472.CAN-14-0319; Romero-Garcia S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00052; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; STANISLAUS D, 1994, ENDOCRINOLOGY, V135, P2220, DOI 10.1210/en.135.5.2220; Stewart TJ, 2009, J IMMUNOL, V183, P117, DOI 10.4049/jimmunol.0804132; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thangaraju M, 2009, CANCER RES, V69, P2826, DOI 10.1158/0008-5472.CAN-08-4466; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Wagner W, 2017, J PHYSIOL PHARMACOL, V68, P555; Wagner W, 2017, DNA REPAIR, V52, P49, DOI 10.1016/j.dnarep.2017.02.007; Wagner W, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0114-x; Walenta S, 2000, CANCER RES, V60, P916; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Xu YK, 2007, J IMMUNOL, V179, P7577, DOI 10.4049/jimmunol.179.11.7577	47	71	74	3	30	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3292	3304		10.1038/s41388-020-1216-5	http://dx.doi.org/10.1038/s41388-020-1216-5		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32071396				2022-12-17	WOS:000514262700001
J	Tan, BS; Yang, MC; Singh, S; Chou, YC; Chen, HY; Wang, MY; Wang, YC; Chen, RH				Tan, Boon-Shing; Yang, Min-Chi; Singh, Shaifali; Chou, Yu-Chi; Chen, Hsin-Yi; Wang, Ming-Yang; Wang, Yi-Ching; Chen, Ruey-Hwa			LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P	ONCOGENE			English	Article							LONG NONCODING RNAS; HIPPO PATHWAY; CELL CONTACT; CO-REPRESSOR; YAP/TAZ; GROWTH; DISRUPTION; THERAPY; PUMILIO	Metastasis is responsible for most cancer mortality, but its molecular mechanism has not been completely understood. In addition to coding genes and miRNAs, the contribution of long noncoding RNAs (lncRNAs) to tumor metastatic dissemination and the mechanisms controlling their expression are areas of intensive investigation. Here, we show that lncRNA NORAD is downregulated in lung and breast cancers, and that NORAD low expression in these cancer types is associated with lymph node metastasis and poor prognosis. NORAD is transcriptionally repressed by the Hippo pathway transducer YAP/TAZ-TEAD complex in conjunction with the action of NuRD complex. Functionally, NORAD elicits potent inhibitory effects on migration and invasion of multiple lung and breast cancer cell lines, and repression of NORAD expression participates in the migration- and invasion-stimulatory effects of the YAP pathway. Mechanistically, NORAD exploits its multiple repeated sequences to function as a multivalent platform for binding and sequestering S100P, thereby suppressing S100P-elicited pro-metastatic signaling network. Using cell and mouse models, we show that the S100P decoy function of NORAD suppresses lung and breast cancer migration, invasion, and metastasis. Together, our study identifies NORAD as a novel metastasis suppressor, elucidates its regulatory and functional mechanisms, and highlights its prognostic value.	[Tan, Boon-Shing; Yang, Min-Chi; Singh, Shaifali; Chen, Ruey-Hwa] Acad Sinica, Inst Biol Chem, Taipei, Taiwan; [Yang, Min-Chi; Chen, Ruey-Hwa] Natl Taiwan Univ, Inst Biochem Sci, Coll Life Sci, Taipei, Taiwan; [Singh, Shaifali; Chen, Ruey-Hwa] Acad Sinica, Chem Biol & Mol Biophys Program, Taiwan Int Grad Program, Taipei, Taiwan; [Singh, Shaifali] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu, Taiwan; [Chou, Yu-Chi] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Chen, Hsin-Yi] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Wang, Ming-Yang] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Wang, Yi-Ching] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan; [Wang, Yi-Ching] Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan; National Tsing Hua University; Academia Sinica - Taiwan; Taipei Medical University; National Taiwan University; National Taiwan University Hospital; National Cheng Kung University; National Cheng Kung University	Chen, RH (corresponding author), Acad Sinica, Inst Biol Chem, Taipei, Taiwan.; Chen, RH (corresponding author), Natl Taiwan Univ, Inst Biochem Sci, Coll Life Sci, Taipei, Taiwan.; Chen, RH (corresponding author), Acad Sinica, Chem Biol & Mol Biophys Program, Taiwan Int Grad Program, Taipei, Taiwan.	rhchen@gate.sinica.edu.tw	Wang, Yi-Ching/J-8702-2019; Tan, Boon Shing/C-7715-2014	Wang, Yi-Ching/0000-0002-7694-2067; Tan, Boon Shing/0000-0002-3789-8673	National Health Research Institute [NHRI-EX107-10708BI]; Institute of Biological Chemistry, Academia Sinica	National Health Research Institute(National Health Research Institutes - Taiwan); Institute of Biological Chemistry, Academia Sinica(Academia Sinica - Taiwan)	We thank Sherry Hsueh-Chi Yen and Pan-Chyr Yang for reagents, Suh-Yuen Liang for TCGA analysis, National RNAi Core Facility for shRNA constructs and CRISPR vectors and constructs, Academia Sinica Animal Core Facility for IVIS analysis, Institute of Biological Chemistry Histopathology Core Facility for tissue processing and histology, Academia Sinica Common Mass Spectrometry Facilities for MS analysis, Human Biobank, Research Center of Clinical Medicine, and Cancer Data Bank of National Cheng Kung University Hospital for patient's specimens. This work is supported by National Health Research Institute Grant NHRI-EX107-10708BI and intramural fund from Institute of Biological Chemistry, Academia Sinica.	Arumugam T, 2011, AMINO ACIDS, V41, P893, DOI 10.1007/s00726-010-0496-4; Austermann J, 2008, J BIOL CHEM, V283, P29331, DOI 10.1074/jbc.M806145200; Brunner AL, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-8-r75; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Das A, 2016, J BIOL CHEM, V291, P6096, DOI 10.1074/jbc.M115.708313; de Andres-Pablo A, 2017, CURR GENET, V63, P29, DOI 10.1007/s00294-016-0615-1; Du M, 2012, J BIOL CHEM, V287, P15330, DOI 10.1074/jbc.M112.349787; Elster D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05370-7; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Gibadulinova A, 2016, ONCOTARGET, V7, P22508, DOI 10.18632/oncotarget.7999; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Heil A, 2011, J BIOL CHEM, V286, P7227, DOI 10.1074/jbc.M110.135095; Hu BR, 2017, INT J BIOCHEM CELL B, V92, P34, DOI 10.1016/j.biocel.2017.09.008; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kawasaki N, 2018, CANCER SCI, V109, P2211, DOI 10.1111/cas.13626; Kim JK, 2009, INT J ONCOL, V35, P1257, DOI 10.3892/ijo_00000442; Kim M, 2015, CELL REP, V11, P270, DOI 10.1016/j.celrep.2015.03.015; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; Kugel JF, 2012, TRENDS BIOCHEM SCI, V37, P144, DOI 10.1016/j.tibs.2011.12.003; Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Lee S, 2016, CELL, V164, P69, DOI 10.1016/j.cell.2015.12.017; Li HM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0576-5; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Munschauer M, 2018, NATURE, V561, P132, DOI 10.1038/s41586-018-0453-z; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Prica F, 2016, AM J CANCER RES, V6, P562; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034; Tichon A, 2018, GENE DEV, V32, P70, DOI 10.1101/gad.309138.117; Tichon A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12209; Valencia-Sama I, 2015, J BIOL CHEM, V290, P16906, DOI 10.1074/jbc.M115.642363; von Eyss B, 2015, CANCER CELL, V28, P743, DOI 10.1016/j.ccell.2015.10.013; Whiteman HJ, 2007, CANCER RES, V67, P8633, DOI 10.1158/0008-5472.CAN-07-0545; Wilusz JE, 2016, BBA-GENE REGUL MECH, V1859, P128, DOI 10.1016/j.bbagrm.2015.06.003; Wu HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4214; Wu XL, 2017, ONCOL RES TREAT, V40, P370, DOI 10.1159/000464465; Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006; Yuan WC, 2014, MOL CELL, V54, P586, DOI 10.1016/j.molcel.2014.03.035; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhou YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010138	49	71	71	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5612	5626		10.1038/s41388-019-0812-8	http://dx.doi.org/10.1038/s41388-019-0812-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967631				2022-12-17	WOS:000474845100005
J	Guha, P; Gardell, J; Darpolor, J; Cunetta, M; Lima, M; Miller, G; Espat, NJ; Junghans, RP; Katz, SC				Guha, Prajna; Gardell, Jillian; Darpolor, Josephine; Cunetta, Marissa; Lima, Matthew; Miller, George; Espat, N. Joseph; Junghans, Richard P.; Katz, Steven C.			STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; T-CELLS; IMMUNE-RESPONSE; IN-VIVO; GM-CSF; CANCER; FAS; PROMOTES; INFLAMMATION	Immunosuppressive myeloid-derived suppressor cells (MDSC) subvert antitumor immunity and limit the efficacy of chimeric antigen receptor T cells (CAR-T). Previously, we reported that the GM-CSF/JAK2/STAT3 axis drives liver-associated MDSC (L-MDSC) proliferation and blockade of this axis rescued antitumor immunity. We extended these findings in our murine liver metastasis (LM) model, by treating tumor-bearing mice with STAT3 inhibitors (STATTIC or BBI608) to further our understanding of how STAT3 drives L-MDSC suppressive function. STAT3 inhibition caused significant reduction of tumor burden as well as L-MDSC frequencies due to decrease in pSTAT3 levels. L-MDSC isolated from STATTIC or BBI608-treated mice had significantly reduced suppressive function. STAT3 inhibition of L-MDSC was associated with enhanced antitumor activity of CAR-T. Further investigation demonstrated activation of apoptotic signaling pathways in L-MDSC following STAT3 inhibition as evidenced by an upregulation of the pro-apoptotic proteins Bax, cleaved caspase-3, and downregulation of the anti-apoptotic protein Bcl-2. Accordingly, there was also a decrease of pro-survival markers, pErk and pAkt, and an increase in pro-death marker, Fas, with activation of downstream JNK and p38 MAPK. These findings represent a previously unrecognized link between STAT3 inhibition and Fas-induced apoptosis of MDSCs. Our findings suggest that inhibiting STAT3 has potential clinical application for enhancing the efficacy of CAR-T cells in LM through modulation of L-MDSC.	[Guha, Prajna; Gardell, Jillian; Darpolor, Josephine; Cunetta, Marissa; Lima, Matthew; Espat, N. Joseph; Junghans, Richard P.; Katz, Steven C.] Roger Williams Med Ctr, Dept Surg, Providence, RI 02908 USA; [Miller, George] NYU, Sch Med, New York, NY USA; [Espat, N. Joseph; Katz, Steven C.] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA	Roger Williams Medical Center; New York University; Boston University	Katz, SC (corresponding author), Roger Williams Med Ctr, Dept Surg, Providence, RI 02908 USA.; Katz, SC (corresponding author), Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA.	skatz@chartercare.org			National Institutes of Health [1K08CA160662-01A1]; NATIONAL CANCER INSTITUTE [K08CA160662] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Sorrento Therapeutics, Inc. for generously preparing the CEA-Fc for anti-CEA CAR detection and Prometheus, Inc. for providing Proleukin (IL2). We also thank Dr. John Morgan and Roger Williams Medical Center Core Facility for providing us with the flow cytometry core facility. Support for this work was provided by the National Institutes of Health (1K08CA160662-01A1).	Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Burga RA, 2015, CANCER IMMUNOL IMMUN, V64, P817, DOI 10.1007/s00262-015-1692-6; Cahill MA, 1996, ONCOGENE, V13, P2087; Chipoy C, 2007, ONCOGENE, V26, P6653, DOI 10.1038/sj.onc.1210492; Condamine T, 2015, J LEUKOCYTE BIOL, V98, P913, DOI 10.1189/jlb.4RI0515-204R; Connolly MK, 2010, J LEUKOCYTE BIOL, V87, P713, DOI 10.1189/jlb.0909607; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gotthardt D, 2014, BLOOD, V124, P2370, DOI 10.1182/blood-2014-03-564450; Guha P, 2017, CANCER GENE THER, V24, P114, DOI 10.1038/cgt.2016.54; Guha P, 2017, J LEUKOCYTE BIOL, V102, P201, DOI 10.1189/jlb.5HI0716-322RR; Hamilton JA, 2002, TRENDS IMMUNOL, V23, P403, DOI 10.1016/S1471-4906(02)02260-3; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hu XL, 2013, J BIOL CHEM, V288, P19103, DOI 10.1074/jbc.M112.434530; Ilkovitch D, 2009, CANCER RES, V69, P5514, DOI 10.1158/0008-5472.CAN-08-4625; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Ji T, 2013, CANCER LETT, V341, P231, DOI 10.1016/j.canlet.2013.08.022; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; Katz SC, 2005, HEPATOLOGY, V42, P293, DOI 10.1002/hep.20795; Katz SC, 2013, ANN SURG ONCOL, V20, P946, DOI 10.1245/s10434-012-2668-9; Katz SC, 2009, ANN SURG ONCOL, V16, P2524, DOI 10.1245/s10434-009-0585-3; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Kujawski M, 2010, CANCER RES, V70, P9599, DOI 10.1158/0008-5472.CAN-10-1293; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Lee H, 2011, CURR TOP MICROBIOL, V344, P41, DOI 10.1007/82_2010_51; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; Liu K, 2010, WORLD J GASTRO ONCOL, V2, P399, DOI 10.4251/wjgo.v2.i11.399; Low W, 1999, ONCOGENE, V18, P3737, DOI 10.1038/sj.onc.1202702; Ma C, 2012, J LEUKOCYTE BIOL, V92, P1199, DOI 10.1189/jlb.0212059; Ma QZ, 2004, CANCER GENE THER, V11, P297, DOI 10.1038/sj.cgt.7700685; Nefedova Y, 2005, CANCER RES, V65, P9525, DOI 10.1158/0008-5472.CAN-05-0529; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Obermajer N, 2012, IMMUNOL INVEST, V41, P635, DOI 10.3109/08820139.2012.695417; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ostrand-Rosenberg S, 2012, CANCER IMMUNOL IMMUN, V61, P1319, DOI 10.1007/s00262-012-1269-6; Pan PY, 2008, BLOOD, V111, P219, DOI 10.1182/blood-2007-04-086835; Parikh N, 2004, J IMMUNOL, V173, P6220, DOI 10.4049/jimmunol.173.10.6220; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Salmon RA, 1997, J IMMUNOL, V159, P5309; Scholz M, 2005, MED RES REV, V25, P331, DOI 10.1002/med.20025; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Sinha P, 2011, BLOOD, V117, P5381, DOI 10.1182/blood-2010-11-321752; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Thorn M, 2016, CANCER GENE THER, V23, P188, DOI 10.1038/cgt.2016.19; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Turcotte S, 2014, CANCER IMMUNOL RES, V2, P530, DOI 10.1158/2326-6066.CIR-13-0180; Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wittig Ilka, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P449, DOI 10.2174/156800805774912999; Wu AA, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1016700; Yang F, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.21; Ye TH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.452; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang YM, 2016, CANCER MED-US, V5, P1251, DOI 10.1002/cam4.675; Zhang YL, 2009, J IMMUNOL, V182, P3801, DOI 10.4049/jimmunol.0801548; Zhao CG, 2015, ONCOTARGET, V6, P14472, DOI 10.18632/oncotarget.3991; Zhao HF, 2015, INT J ONCOL, V47, P429, DOI 10.3892/ijo.2015.3052	76	71	76	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					533	548		10.1038/s41388-018-0449-z	http://dx.doi.org/10.1038/s41388-018-0449-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30158673				2022-12-17	WOS:000456589800006
J	Xi, JJ; Huang, Q; Wang, LD; Ma, XD; Deng, QP; Kumar, M; Zhou, ZY; Li, L; Zeng, ZY; Young, KH; Zhang, MZ; Li, Y				Xi, Jiajia; Huang, Qian; Wang, Lei; Ma, Xiaodong; Deng, Qipan; Kumar, Munish; Zhou, Zhiyuan; Li, Ling; Zeng, Zhaoyang; Young, Ken H.; Zhang, Mingzhi; Li, Yong			miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; INTERFERON-GAMMA; IFN-GAMMA; EXPRESSION; MICRORNAS; CANCER; IDENTIFICATION; CELLS; RNAS; INTERLEUKIN-4	MicroRNA-21 (miR-21) is one of the most abundant microRNAs in mammalian cells. It has been intensively studied for its role in regulating apoptosis and oncogenic transformation. However, the impact of miR-21 on host anti-tumor immunity remains unknown. Tumor-associated macrophages are a major leukocyte type that infiltrates tumors and predominantly develops into immunosuppressive, tumor-promoting M2-like macrophages. In contrast, the pro-inflammatory M1-like macrophages have tumoricidal activity. In this study, we show that genetic deficiency of miR-21 promotes the polarization of macrophages toward an M1-like phenotype in vivo and in vitro in the presence of tumor cells; thus it confers host mice with enhanced anti-tumor immunity. By downregulating JAK2 and STAT1, miR-21 inhibits the IFN-gamma-induced STAT1 signaling pathway, which is required for macrophage M1 polarization. We also show that the expression of miR-21 in macrophages is regulated upon polarization stimuli as well as upon macrophages co-culturing with tumor cells. Thus, tumor cells may stimulate miR-21 expression in tumor-associated macrophages to prevent tumoricidal M1 polarization. However, augmented STAT1 signaling mediated by miR-21 deficiency upregulates PD-L1 expression in macrophages, which is known to inhibit phagocytic anti-tumor activity. This adverse effect can be alleviated by PD-1 blockade; indeed, miR-21 depletion in macrophages and PD-1 antibody treatment offer superior anti-tumor activity than either agent alone. These studies shed lights on potential application of the combination of miR-21 inhibition and immune checkpoint blockade to target the tumor microenvironment.	[Xi, Jiajia; Huang, Qian; Ma, Xiaodong; Deng, Qipan; Kumar, Munish; Zhou, Zhiyuan; Li, Yong] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; [Wang, Lei; Ma, Xiaodong] South China Normal Univ, Inst Brain Res & Rehabil, Guangzhou 510631, Guangdong, Peoples R China; [Kumar, Munish] Univ Allahabad, Dept Biochem, UGC, Allahabad, Uttar Pradesh, India; [Zhou, Zhiyuan; Li, Ling; Zhang, Mingzhi] Zhengzhou Univ, Affiliated Hosp 1, Lymphoma Diag & Treatment Ctr Henan Prov, Dept Oncol, Zhengzhou 450000, Henan, Peoples R China; [Zeng, Zhaoyang] Cent South Univ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Young, Ken H.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Cleveland Clinic Foundation; South China Normal University; University of Allahabad; Zhengzhou University; Central South University; University of Texas System; UTMD Anderson Cancer Center	Li, Y (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.	liy2@ccf.org	LI, LI/GVS-5344-2022; Li, Li/AEM-3636-2022; MA, XIAO/HHN-5611-2022; li, li/AAT-2097-2020; li, li/GPX-3938-2022; Kumar, Munish/Z-4106-2019; LI, LI QING/GRR-8855-2022	Deng, Qipan/0000-0002-3803-1676; Li, Yong/0000-0001-8838-1714; Wang, Lei/0000-0001-5492-5613	NIH [CA138688, CA177810]; Natural Science Foundation of China [81528019]; NATIONAL CANCER INSTITUTE [R01CA138688, R01CA177810] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study is supported by NIH R01 grants (CA138688 and CA177810) and Natural Science Foundation of China (No. 81528019).	Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Anaya J., 2016, PEER J COMPUT SCI, V13, P2; Baer C, 2016, NAT CELL BIOL, V18, P790, DOI 10.1038/ncb3371; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Buscaglia Lindsey E Becker, 2011, Chin J Cancer, V30, P371; Caescu CI, 2015, BLOOD, V125, pE1, DOI 10.1182/blood-2014-10-608000; Carissimi C, 2014, BIOCHIMIE, V107, P319, DOI 10.1016/j.biochi.2014.09.021; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Duchaine TF, 2009, CURR ONCOL, V16, P265; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Haverkamp JM, 2014, IMMUNITY, V41, P947, DOI 10.1016/j.immuni.2014.10.020; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Liu Y, 2016, CANCER LETT, V370, P125, DOI 10.1016/j.canlet.2015.10.011; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Ma XD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8151; Ma XD, 2013, CARCINOGENESIS, V34, P1216, DOI 10.1093/carcin/bgt044; Ma XD, 2011, P NATL ACAD SCI USA, V108, P10144, DOI 10.1073/pnas.1103735108; Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Paludan SR, 1998, SCAND J IMMUNOL, V48, P459; Pratheeshkumar P, 2016, SCI REP-UK, V6, DOI 10.1038/srep37227; Rivera LB, 2013, CANCER CELL, V24, P687, DOI 10.1016/j.ccr.2013.11.014; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; TAUB DD, 1995, J LEUKOCYTE BIOL, V58, P80, DOI 10.1002/jlb.58.1.80; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Venturutti L, 2016, ONCOGENE, V35, P2208, DOI 10.1038/onc.2015.281; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Yang CH, 2011, J BIOL CHEM, V286, P39172, DOI 10.1074/jbc.M111.285098; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	49	71	73	2	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3151	3165		10.1038/s41388-018-0178-3	http://dx.doi.org/10.1038/s41388-018-0178-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540832	Green Accepted			2022-12-17	WOS:000434641400008
J	Kim, S; Lee, E; Jung, J; Lee, JW; Kim, HJ; Kim, J; Yoo, HJ; Lee, HJ; Chae, SY; Jeon, SM; Son, BH; Gong, G; Sharan, SK; Chang, S				Kim, Sinae; Lee, Eunji; Jung, Jaeyun; Lee, Jong Won; Kim, Hee Jung; Kim, Jisun; Yoo, Hyun ju; Lee, Hee Jin; Chae, Sun Young; Jeon, Sang Min; Son, Byung Ho; Gong, Gyungyup; Sharan, Shyam K.; Chang, Suhwan			microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer	ONCOGENE			English	Article							GENE-EXPRESSION; MIR-155; REVEALS; CELLS; TARGETS; GROWTH; FOXO3A; BRCA1; MYC	MicroRNA is an endogenous, small RNA controlling multiple target genes and playing roles in various biological processes including tumorigenesis. Here, we addressed the function of miR-155 using LC-MS/MS-based metabolic profiling of miR-155 deficient breast cancer cells. Our results revealed the loss of miR-155 hampers glucose uptake and glycolysis, via the down-regulation of glucose transporters and metabolic enzymes including HK2, PKM2, and LDHA. We showed this is due to the down-regulation of cMYC, controlled through phosphoinositide-3-kinase regulatory subunit alpha (PIK3R1)-PDK1/AKT-FOXO3a pathway. UTR analysis of the PIK3R1 and FOXO3a indicated miR-155 directly represses these genes. A stable expression of miR-155 in patient-derived cells (PDCs) showed activated glucose metabolism whereas a stable inhibition of miR-155 reduced in vivo tumor growth with retarded glucose metabolism. Furthermore, analysis of 50 triple-negative breast cancer (TNBC) specimens and specific uptake value (SUV) of PET images revealed a positive correlation between miR-155 level and glucose usage in human breast tumors via PIK3R1-PDK/AKT-FOXO3a-cMYC axis. Collectively, these data demonstrate the miR-155 is a key regulator of glucose metabolism in breast cancer.	[Kim, Sinae; Lee, Eunji; Jung, Jaeyun; Chang, Suhwan] Univ Ulsan, Coll Med, Dept Biomed Sci, Seoul 05505, South Korea; [Lee, Jong Won; Kim, Hee Jung; Kim, Jisun; Son, Byung Ho] Asan Med Ctr, Dept Surg, Seoul 05505, South Korea; [Yoo, Hyun ju] Univ Ulsan, Coll Med, Dept Convergence Med, Seoul 05505, South Korea; [Lee, Hee Jin; Gong, Gyungyup] Asan Med Ctr, Dept Pathol, Seoul 05505, South Korea; [Chae, Sun Young] Asan Med Ctr, Dept Nucl Med, Seoul 05505, South Korea; [Jeon, Sang Min] Ajou Univ, Coll Pharm, Suwon 16499, South Korea; [Jeon, Sang Min] Ajou Univ, Inst Pharmaceut Sci & Technol, Suwon 16499, South Korea; [Sharan, Shyam K.] Frederick Natl Lab, Mouse Canc Genet Program, Frederick, MD 21702 USA	University of Ulsan; University of Ulsan; Ajou University; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chang, S (corresponding author), Univ Ulsan, Coll Med, Dept Biomed Sci, Seoul 05505, South Korea.	suhwan.chang@amc.seoul.kr	Jeon, Sang-Min/I-7917-2018	Jeon, Sang-Min/0000-0002-0132-925X; Chang, Suhwan/0000-0002-0282-0120; KIM, JISUN/0000-0002-4884-6107; Lee, Hee Jin/0000-0002-4963-6603	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI13C1538]; National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea [1320140]; NATIONAL CANCER INSTITUTE [ZIABC011311] Funding Source: NIH RePORTER	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea; National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank to Dr. Ahn, Sung Gwe (Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine) for valuable suggestions. The biospecimen and data used in this study was provided by Asan Bio-Resource Center, Korea Biobank Network (2014-3(72)). This work is supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare (Grant number: HI13C1538) and by the National R&D Program for Cancer Control, Ministry of Health & Welfare (No. 1320140), Republic of Korea.	Brodersen P, 2009, NAT REV MOL CELL BIO, V10, P141, DOI 10.1038/nrm2619; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Chang SW, 2009, J CLIN INVEST, V119, P3160, DOI 10.1172/JCI39836; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Dang CV, 2011, COLD SH Q B, V76, P369, DOI 10.1101/sqb.2011.76.011296; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang CV., 2007, E SCHERING FDN S P, V4, P35; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013; Ferber EC, 2012, CELL DEATH DIFFER, V19, P968, DOI 10.1038/cdd.2011.179; Geltz NR, 1998, BLOOD, V91, P930, DOI 10.1182/blood.V91.3.930.930_930_939; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Huang X, 2012, AM J PATHOL, V181, P26, DOI 10.1016/j.ajpath.2012.03.013; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Kim S, 2016, ONCOTARGET, V7, P11094, DOI 10.18632/oncotarget.7150; Kim S, 2015, CANCER LETT, V357, P488, DOI 10.1016/j.canlet.2014.11.058; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin XL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006308; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loeb GB, 2012, MOL CELL, V48, P760, DOI 10.1016/j.molcel.2012.10.002; Lv X, 2016, MOL MED REP, V14, P1332, DOI 10.3892/mmr.2016.5394; Mattiske S, 2012, CANCER EPIDEM BIOMAR, V21, P1236, DOI 10.1158/1055-9965.EPI-12-0173; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Tili E, 2009, INT REV IMMUNOL, V28, P264, DOI 10.1080/08830180903093796; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang J, 2012, FRONT BIOSCI-LANDMRK, V17, P2350, DOI 10.2741/4056; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028	33	71	73	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2982	2991		10.1038/s41388-018-0124-4	http://dx.doi.org/10.1038/s41388-018-0124-4			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29527004	hybrid, Green Published			2022-12-17	WOS:000433936300006
J	Swayampakula, M; McDonald, PC; Vallejo, M; Coyaud, E; Chafe, SC; Westerback, A; Venkateswaran, G; Shankar, J; Gao, G; Laurent, EMN; Lou, Y; Bennewith, KL; Supuran, CT; Nabi, IR; Raught, B; Dedhar, S				Swayampakula, M.; McDonald, P. C.; Vallejo, M.; Coyaud, E.; Chafe, S. C.; Westerback, A.; Venkateswaran, G.; Shankar, J.; Gao, G.; Laurent, E. M. N.; Lou, Y.; Bennewith, K. L.; Supuran, C. T.; Nabi, I. R.; Raught, B.; Dedhar, S.			The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; BREAST-CANCER; MATRIX-METALLOPROTEINASES; FIBROBLAST COLLAGENASE; PROTEOMIC PIPELINE; THERAPEUTIC TARGET; ACTIVATION-ENERGY; MAMMALIAN-CELLS; METASTASIS	Carbonic anhydrase IX (CAIX) is a hypoxia inducible factor 1-induced, cell surface pH regulating enzyme with an established role in tumor progression and clinical outcome. However, the molecular basis of CAIX-mediated tumor progression remains unclear. Here, we have utilized proximity dependent biotinylation (BioID) to map the CAIX 'interactome' in breast cancer cells in order to identify physiologically relevant CAIX-associating proteins with potential roles in tumor progression. High confidence proteins identified include metabolic transporters, beta 1 integrins, integrin-associated protein CD98hc and matrix metalloprotease 14 (MMP14). Biochemical studies validate the association of CAIX with alpha 2 beta 1 integrin, CD98hc and MMP14, and immunofluorescence microscopy demonstrates colocalization of CAIX with alpha 2 beta 1 integrin and MMP14 in F-actin/cofilin-positive lamellipodia/pseudopodia, and with MMP14 to cortactin/Tks5-positive invadopodia. Modulation of CAIX expression and activity results in significant changes in cell migration, collagen degradation and invasion. Mechanistically, we demonstrate that CAIX associates with MMP14 through potential phosphorylation residues within its intracellular domain, and that CAIX enhances MMP14-mediated collagen degradation by directly contributing hydrogen ions required for MMP14 catalytic activity. These findings establish hypoxia-induced CAIX as a novel metabolic component of cellular migration and invasion structures, and provide new mechanistic insights into its role in tumor cell biology.	[Swayampakula, M.; McDonald, P. C.; Vallejo, M.; Chafe, S. C.; Westerback, A.; Venkateswaran, G.; Lou, Y.; Bennewith, K. L.; Dedhar, S.] BC Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC, Canada; [Vallejo, M.; Dedhar, S.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; [Coyaud, E.; Laurent, E. M. N.; Raught, B.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Shankar, J.; Gao, G.; Nabi, I. R.] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC, Canada; [Supuran, C. T.] Univ Firenze, Lab Chim Bioinorgan, Florence, Italy	British Columbia Cancer Agency; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of British Columbia; University of Florence	Dedhar, S (corresponding author), Univ British Columbia, BC Canc Res Ctr, Dept Integrat Oncol, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@bccrc.ca	Laurent, Estelle/AFV-5442-2022; Nabi, Ivan/GWZ-5144-2022; COYAUD, Etienne/ABD-9726-2020	Nabi, Ivan/0000-0002-0670-0513; COYAUD, Etienne/0000-0002-5893-4557; Dedhar, Shoukat/0000-0003-4355-1657; Chafe, Shawn/0000-0001-8802-651X	Canadian Institutes for Health Research (CIHR); Canadian Cancer Society Research Institute (CCSRI); Canadian Cancer Society; Pancreas Centre, BC	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Pancreas Centre, BC	This work was supported by research grants to B. Raught and S. Dedhar from the Canadian Institutes for Health Research (CIHR), the Canadian Cancer Society Research Institute (CCSRI) through funds raised by the Canadian Cancer Society, and Pancreas Centre, BC. KL Bennewith is a Michael Smith Foundation for Health Research Biomedical Research Scholar. We thank Jordan Gillespie and Nancy LePard for help with the in vivo and clonogenic experiments.	Amith SR, 2015, INT J DEV BIOL, V59, P367, DOI 10.1387/ijdb.140336lf; Amith SR, 2017, CELL SIGNAL, V29, P69, DOI 10.1016/j.cellsig.2016.10.005; Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Beaty BT, 2014, J CELL BIOL, V205, P737, DOI 10.1083/jcb.201312046; Busco G, 2010, FASEB J, V24, P3903, DOI 10.1096/fj.09-149518; Chafe SC, 2015, CANCER RES, V75, P996, DOI 10.1158/0008-5472.CAN-14-3000; Chafe SC, 2010, MOL BIOL CELL, V21, P2483, DOI 10.1091/mbc.E10-03-0176; Chan PK, 2014, DATA BRIEF, V1, P76, DOI 10.1016/j.dib.2014.10.001; Chen J, 2005, GUT, V54, P920, DOI 10.1136/gut.2004.047340; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Choi-Rhee E, 2004, PROTEIN SCI, V13, P3043, DOI 10.1110/ps.04911804; Counillon L, 2016, BBA-MOL CELL RES, V1863, P2465, DOI 10.1016/j.bbamcr.2016.02.018; Coyaud E, 2015, MOL CELL PROTEOMICS, V14, P1781, DOI 10.1074/mcp.M114.045658; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deutsch EW, 2010, PROTEOMICS, V10, P1150, DOI 10.1002/pmic.200900375; Diaz B, 2013, J CELL BIOL, V201, P279, DOI 10.1083/jcb.201209151; Dingar D, 2015, J PROTEOMICS, V118, P95, DOI 10.1016/j.jprot.2014.09.029; Ditte P, 2011, CANCER RES, V71, P7558, DOI 10.1158/0008-5472.CAN-11-2520; Eng JK, 2013, PROTEOMICS, V13, P22, DOI 10.1002/pmic.201200439; Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255; Gioia M, 2010, J BIOL INORG CHEM, V15, P1219, DOI 10.1007/s00775-010-0680-8; Gould CM, 2014, CELL ADHES MIGR, V8, P226, DOI 10.4161/cam.28346; Gupta GD, 2015, CELL, V163, P1484, DOI 10.1016/j.cell.2015.10.065; Hamilton MJ, 2014, J IMMUNOL, V192, P512, DOI 10.4049/jimmunol.1300096; Hanna SC, 2013, J CLIN INVEST, V123, P2078, DOI 10.1172/JCI66715; Hauff SJ, 2014, OTOLARYNG HEAD NECK, V151, P612, DOI 10.1177/0194599814545083; Innocenti A, 2009, BIOORG MED CHEM LETT, V19, P5825, DOI 10.1016/j.bmcl.2009.08.088; JEFFREY JJ, 1983, J BIOL CHEM, V258, P1123; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Kaewprag J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071611; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kessner D, 2008, BIOINFORMATICS, V24, P2534, DOI 10.1093/bioinformatics/btn323; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Liu GM, 2010, NAT BIOTECHNOL, V28, P1015, DOI 10.1038/nbt1010-1015; Lloyd MC, 2016, CANCER RES, V76, P3136, DOI 10.1158/0008-5472.CAN-15-2962; Lock FE, 2013, ONCOGENE, V32, P5210, DOI 10.1038/onc.2012.550; Lodillinsky C, 2016, ONCOGENE, V35, P344, DOI 10.1038/onc.2015.87; Lohse I, 2014, CANCERS, V6, P459, DOI 10.3390/cancers6010459; Lou YM, 2008, DEV DYNAM, V237, P2755, DOI 10.1002/dvdy.21658; Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261; Lucien F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028851; Macpherson IR, 2014, J CELL SCI, V127, P3893, DOI 10.1242/jcs.135947; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; McDonald PC, 2012, ONCOTARGET, V3, P84, DOI 10.18632/oncotarget.422; McIntyre A, 2012, CLIN CANCER RES, V18, P3100, DOI 10.1158/1078-0432.CCR-11-1877; Neri D, 2011, NAT REV DRUG DISCOV, V10, P767, DOI 10.1038/nrd3554; Ng SSW, 2000, CANCER RES, V60, P5451; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Pacchiano F, 2011, J MED CHEM, V54, P1896, DOI 10.1021/jm101541x; Parks SK, 2015, J CELL PHYSIOL, V230, P1954, DOI 10.1002/jcp.24930; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Pedrioli PGA, 2010, METHODS MOL BIOL, V604, P213, DOI 10.1007/978-1-60761-444-9_15; Peitzsch C, 2014, INT J RADIAT BIOL, V90, P636, DOI 10.3109/09553002.2014.916841; Radvak P, 2013, ONCOL REP, V29, P1147, DOI 10.3892/or.2013.2226; Robey IF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/485196; Rosse C, 2014, P NATL ACAD SCI USA, V111, pE1872, DOI 10.1073/pnas.1400749111; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Tomari T, 2009, CANCER SCI, V100, P1284, DOI 10.1111/j.1349-7006.2009.01173.x; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Ward C, 2015, ONCOTARGET, V6, P24856, DOI 10.18632/oncotarget.4498; WELGUS HG, 1981, J BIOL CHEM, V256, P9516; WILBUR KM, 1948, J BIOL CHEM, V176, P147; Yamaguchi H., 2006, ADHESIVE INTERACTION, P37; Yamaguchi H, 2012, EUR J CELL BIOL, V91, P902, DOI 10.1016/j.ejcb.2012.04.005; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278	69	71	72	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6244	6261		10.1038/onc.2017.219	http://dx.doi.org/10.1038/onc.2017.219			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692057	hybrid, Green Published			2022-12-17	WOS:000414774800004
J	Banasavadi-Siddegowda, YK; Russell, L; Frair, E; Karkhanis, VA; Relation, T; Yoo, JY; Zhang, J; Sif, S; Imitola, J; Baiocchi, R; Kaur, B				Banasavadi-Siddegowda, Y. K.; Russell, L.; Frair, E.; Karkhanis, V. A.; Relation, T.; Yoo, J. Y.; Zhang, J.; Sif, S.; Imitola, J.; Baiocchi, R.; Kaur, B.			PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells	ONCOGENE			English	Article							RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; CELLULAR SENESCENCE; HUMAN BRAIN; STEM-CELL; SURVIVAL; GENE; PHOSPHATASE; EXPRESSION; INHIBITORS	Glioblastoma (GBM) represents the most common and aggressive histologic subtype among malignant astrocytoma and is associated with poor outcomes because of heterogeneous tumour cell population including mature non-stem-like cell and immature stem-like cells within the tumour. Thus, it is critical to find new target-specific therapeutic modalities. Protein arginine methyltransferase enzyme 5 (PRMT5) regulates many cellular processes through its methylation activity and its overexpression in GBM is associated with more aggressive disease. Previously, we have shown that silencing of PRMT5 expression in differentiated GBM cell lines results in apoptosis and reduced tumour growth in mice. Here, we report the critical role of PRMT5 in GBM differentiated cells (GBMDC) grown in serum and GBM neurospheres (GBMNS) grown as neurospheres in vitro. Our results uncover a very significant role for PRMT5 in GBMNS self-renewal capacity and proliferation. PRMT5 knockdown in GBMDC led to apoptosis, knockdown in GBMNS led to G1 cell cycle arrest through upregulation of p27 and hypophoshorylation of retinoblastoma protein, leading to senescence. Comparison of impact of PRMT5 on cellular signalling by the Human Phospho-Kinase Array and chromatin immunoprecipitation-PCR revealed that unlike GBMDC, PRMT5 regulates PTEN expression and controls Akt and ERk activity in GBMNS. In vivo transient depletion of PRMT5 decreased intracranial tumour size and growth rate in mice implanted with both primary tumour-derived GBMNS and GBMDC. This is the first study to identify PTEN as a potential downstream target of PRMT5 and PRMT5 is vital to support both mature and immature GBM tumour cell populations.	[Banasavadi-Siddegowda, Y. K.; Russell, L.; Frair, E.; Relation, T.; Yoo, J. Y.; Kaur, B.] Ohio State Univ, Coll Med, Dept Neurol Surg, 410W 12th Ave,CCC Room 385D, Columbus, OH 43210 USA; [Karkhanis, V. A.; Baiocchi, R.] Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, 400W 12th Ave,CCC 453, Columbus, OH 43210 USA; [Zhang, J.] Ctr Biostat, Dept Biomed Informat, Columbus, OH USA; [Sif, S.] Qatar Univ, Coll Arts & Sci, Dept Biol & Environm Sci, Doha, Qatar; [Imitola, J.] Ohio State Univ, Coll Med, Dept Neurol, Lab Neural Stem Cells & Funct Neurogenet,Div Neur, Columbus, OH 43210 USA; [Imitola, J.] Ohio State Univ, Coll Med, Dept Neurosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Qatar University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kaur, B (corresponding author), Ohio State Univ, Coll Med, Dept Neurol Surg, 410W 12th Ave,CCC Room 385D, Columbus, OH 43210 USA.; Baiocchi, R (corresponding author), Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, 400W 12th Ave,CCC 453, Columbus, OH 43210 USA.	robert.baiocchi@osumc.edu; kaur.11@osu.edu	Sif, Said/AAE-5554-2019	Yoo, Ji Young/0000-0002-6767-1111; Sif, Said/0000-0001-6268-1145; /0000-0002-4730-6918	NIH RO1 [CA150153, NS064607]; NIH P01 [CA163205]; NIH P30 [NS045758]; NIH [R21 NS071346];  [IRG-67-003-50]; NATIONAL CANCER INSTITUTE [P01CA163205, P30CA016058, R01CA150153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064607, P30NS045758, R21NS071346] Funding Source: NIH RePORTER	NIH RO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH P01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH P30; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was financially supported by: Kaur: NIH RO1 (CA150153), NIH P01 (CA163205), NIH P30 (NS045758), NIH RO1 (NS064607); Baiocchi: NIH R21 NS071346 and Yoo: IRG-67-003-50.	ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Grossman SA, 2010, CLIN CANCER RES, V16, P2443, DOI 10.1158/1078-0432.CCR-09-3106; Gu CY, 2013, STEM CELLS, V31, P870, DOI 10.1002/stem.1322; Han XS, 2014, J NEURO-ONCOL, V118, P61, DOI 10.1007/s11060-014-1419-0; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907; Karberg S, 2009, CELL, V139, P1029, DOI 10.1016/j.cell.2009.11.038; KATO J, 1993, GENE DEV, V7, P331; Lee JJ, 2011, CELL DEATH DIFFER, V18, P666, DOI 10.1038/cdd.2010.139; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Masui K, 2012, NEUROPATH APPL NEURO, V38, P271, DOI 10.1111/j.1365-2990.2011.01238.x; McDowell KA, 2011, CURR PHARM DESIGN, V17, P2411; Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057; Otsuki A, 2008, MOL THER, V16, P1546, DOI 10.1038/mt.2008.155; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; Scoumanne A, 2009, NUCLEIC ACIDS RES, V37, P4965, DOI 10.1093/nar/gkp516; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tan W, 2015, J CELL BIOCHEM, V116, P1583, DOI 10.1002/jcb.25112; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Yen F, 2014, CANCER RES, V74, P1752; Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568	46	71	73	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					263	274		10.1038/onc.2016.199	http://dx.doi.org/10.1038/onc.2016.199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27292259	Green Accepted			2022-12-17	WOS:000393938100011
J	Lindblad, O; Cordero, E; Puissant, A; Macaulay, L; Ramos, A; Kabir, NN; Sun, J; Vallon-Christersson, J; Haraldsson, K; Hemann, MT; Borg, A; Levander, F; Stegmaier, K; Pietras, K; Ronnstrand, L; Kazi, JU				Lindblad, O.; Cordero, E.; Puissant, A.; Macaulay, L.; Ramos, A.; Kabir, N. N.; Sun, J.; Vallon-Christersson, J.; Haraldsson, K.; Hemann, M. T.; Borg, A.; Levander, F.; Stegmaier, K.; Pietras, K.; Ronnstrand, L.; Kazi, J. U.			Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; FLT3; MUTATIONS; INHIBITORS; KINASE; PKI-587; PKC412; TARGET; PI3K/AKT/MTOR; CYTOGENETICS	Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient. To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib. Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors. Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells. Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer FLT3 dependent. Gene expression analysis of sensitive and resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway in the resistant phenotype, which was further supported by next-generation sequencing and phospho-specific-antibody array analysis. Furthermore, a selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation, and induced apoptosis in resistant cell lines. Gedatolisib significantly extended survival of mice in a sorafenib-resistant AML patient-derived xenograft model. Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway in FLT3-ITD-dependent AML results in resistance to drugs targeting FLT3.	[Lindblad, O.; Cordero, E.; Macaulay, L.; Sun, J.; Pietras, K.; Ronnstrand, L.; Kazi, J. U.] Lund Univ, Dept Lab Med, Div Translat Canc Res, Medicon Village 404 C3, S-22363 Lund, Skane, Sweden; [Lindblad, O.; Macaulay, L.; Sun, J.; Ronnstrand, L.; Kazi, J. U.] Lund Univ, Dept Lab Med, Lund Stem Cell Ctr, Lund, Sweden; [Lindblad, O.] Skane Univ Hosp, Dept Hematol & Vasc Disorders, Lund, Sweden; [Puissant, A.; Stegmaier, K.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA; [Puissant, A.; Stegmaier, K.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA; [Ramos, A.; Hemann, M. T.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Kabir, N. N.; Kazi, J. U.] KN Biomed Res Inst, Lab Computat Biochem, Barisal, Bangladesh; [Vallon-Christersson, J.; Haraldsson, K.; Borg, A.] Lund Univ, Dept Oncol & Pathol, Lund, Sweden; [Levander, F.] Lund Univ, Dept Immunotechnol, BILS, Lund, Sweden	Lund University; Lund University; Lund University; Skane University Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT); Lund University; Lund University	Kazi, JU (corresponding author), Lund Univ, Dept Lab Med, Div Translat Canc Res, Medicon Village 404 C3, S-22363 Lund, Skane, Sweden.	kazi.uddin@med.lu.se	Pietras, Kristian/ABG-2097-2021; Pietras, Kristian/ABE-8727-2020; Kazi, Julhash/D-9190-2011	Pietras, Kristian/0000-0001-6738-4705; Kazi, Julhash/0000-0002-0719-5336; Ronnstrand, Lars/0000-0003-1275-5809; Levander, Fredrik/0000-0002-0710-9792; Vallon-Christersson, Johan/0000-0002-2195-0385	Kungliga Fysiografiska Sallskapet i Lund; Ollie and Elof Ericssons Stiftelse; Ake-Wiberg Stiftelse; Lars Hiertas Minne Stiftelse; Stiftelsen Olle Engkvist Byggmastare; Harald Jeanssons Stiftelse and Harald och Greta Jeanssons Stiftelse; Swedish Childhood Cancer Foundation; Crafoord foundation; Stiftelsen Clas Groschinskys Minnesfond; Swedish Cancer Foundation; Swedish Research Council; Region Skane; Research Funds at Skane University Hospital; Gunnar Nilssons Cancer Foundation; NIH [R01CA140292]; NATIONAL CANCER INSTITUTE [R01CA140292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007287] Funding Source: NIH RePORTER	Kungliga Fysiografiska Sallskapet i Lund; Ollie and Elof Ericssons Stiftelse; Ake-Wiberg Stiftelse; Lars Hiertas Minne Stiftelse; Stiftelsen Olle Engkvist Byggmastare(Swedish Research Council); Harald Jeanssons Stiftelse and Harald och Greta Jeanssons Stiftelse; Swedish Childhood Cancer Foundation(European Commission); Crafoord foundation; Stiftelsen Clas Groschinskys Minnesfond; Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Region Skane; Research Funds at Skane University Hospital; Gunnar Nilssons Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Peter J Valk at Erasmus University Medical Center for help with AML patient data and Dr David Weinstock for leading the development of a bank of patient-derived xenograft models of leukemia at the DFCI. This research was funded by Kungliga Fysiografiska Sallskapet i Lund (JUK), Ollie and Elof Ericssons Stiftelse (JUK), Ake-Wiberg Stiftelse (JUK), Lars Hiertas Minne Stiftelse (JUK), Stiftelsen Olle Engkvist Byggmastare (JUK), Harald Jeanssons Stiftelse and Harald och Greta Jeanssons Stiftelse (JUK), the Swedish Childhood Cancer Foundation (JUK), the Crafoord foundation (JUK), Stiftelsen Clas Groschinskys Minnesfond (JUK), Swedish Cancer Foundation (LR), Swedish Research Council (LR), Region Skane (LR), the Research Funds at Skane University Hospital (LR), Gunnar Nilssons Cancer Foundation (LR) and the NIH R01CA140292 (KS). JUK is a recipient of Assistant Professorship (forskarassistenttjanst) grant from the Swedish Childhood Cancer Foundation. KP is the Goran & Birgitta Grosskopf Professor of Molecular Medicine at Lund University.	Albers C, 2013, LEUKEMIA, V27, P1416, DOI 10.1038/leu.2013.14; Barrett D, 2012, PEDIATR DRUGS, V14, P299, DOI 10.2165/11594740-000000000-00000; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Breitenbuecher F, 2009, BLOOD, V113, P4063, DOI 10.1182/blood-2007-11-126664; Cui J, 2006, CLIN CHIM ACTA, V368, P155, DOI 10.1016/j.cca.2005.12.043; D'Amato V, 2014, BRIT J CANCER, V110, P2887, DOI 10.1038/bjc.2014.241; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Gedaly R, 2012, J SURG RES, V176, P542, DOI 10.1016/j.jss.2011.10.045; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Hakkinen J, 2009, J PROTEOME RES, V8, P3037, DOI 10.1021/pr900189c; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Juliusson G, 2009, BLOOD, V113, P4179, DOI 10.1182/blood-2008-07-172007; Kiyoi H, 2005, INT J HEMATOL, V82, P85, DOI 10.1532/IJH97.05066; Knapper S, 2006, BLOOD, V108, P3494, DOI 10.1182/blood-2006-04-015487; Kutok JL, 2011, J CELL MOL MED, V15, P86, DOI 10.1111/j.1582-4934.2009.00925.x; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Leung AYH, 2013, LEUKEMIA, V27, P260, DOI 10.1038/leu.2012.195; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Mallon R, 2011, CLIN CANCER RES, V17, P3193, DOI 10.1158/1078-0432.CCR-10-1694; Man CH, 2014, BLOOD, V123, P2530, DOI 10.1182/blood-2013-07-512194; Man CH, 2012, BLOOD, V119, P5133, DOI 10.1182/blood-2011-06-363960; Martelli AM, 2011, LEUKEMIA, V25, P1064, DOI 10.1038/leu.2011.46; Masson K, 2009, CELL SIGNAL, V21, P1717, DOI 10.1016/j.cellsig.2009.06.002; Meshinchi S, 2008, BLOOD, V111, P4930, DOI 10.1182/blood-2008-01-117770; Nogami A, 2015, ONCOTARGET, V6, P9189, DOI 10.18632/oncotarget.3279; Puissant A, 2014, CANCER CELL, V25, P226, DOI 10.1016/j.ccr.2014.01.022; Razumovskaya E, 2009, EXP HEMATOL, V37, P979, DOI 10.1016/j.exphem.2009.05.008; Sandhofer N, 2015, LEUKEMIA, V29, P828, DOI 10.1038/leu.2014.305; Sandin M, 2013, MOL CELL PROTEOMICS, V12, P1407, DOI 10.1074/mcp.O112.021907; Sasore T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105280; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Sheikhha Mohammad Hasan, 2003, Hematol J, V4, P41, DOI 10.1038/sj.thj.6200224; Smith CC, 2013, BLOOD, V121, P3165, DOI 10.1182/blood-2012-07-442871; Smith CC, 2012, NATURE, V485, P260, DOI 10.1038/nature11016; Stolzel F, 2010, ANN HEMATOL, V89, P653, DOI 10.1007/s00277-009-0889-1; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Stone RM, 2015, ASH ANN M, V126, P6, DOI DOI 10.1182/blood.V126.23.6.6; Sun J, 2014, ONCOGENE, V33, P5360, DOI 10.1038/onc.2013.479; Venkatesan AM, 2010, J MED CHEM, V53, P2636, DOI 10.1021/jm901830p; von Bubnoff N, 2009, CANCER RES, V69, P3032, DOI 10.1158/0008-5472.CAN-08-2923; Wang W, 2010, BLOOD, V116, P254, DOI 10.1182/blood-2009-11-254664; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299	45	71	72	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5119	5131		10.1038/onc.2016.41	http://dx.doi.org/10.1038/onc.2016.41			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26999641	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000384433000004
J	Liu, F; Gong, J; Huang, W; Wang, Z; Wang, M; Yang, J; Wu, C; Wu, Z; Han, B				Liu, F.; Gong, J.; Huang, W.; Wang, Z.; Wang, M.; Yang, J.; Wu, C.; Wu, Z.; Han, B.			MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes	ONCOGENE			English	Article						glioma; miR-106b-5p; cell proliferation; apoptosis; retinoblastoma-like (RBL1/2); caspase-8	EXPRESSION; MICRORNAS; MIR-106B; APOPTOSIS; CASPASE-8; MIR-20A; CLUSTER; RNAS	Aberrant expression of microRNAs (miRNAs) has been implicated in cancer initiation and progression. However, little is known about the potential role of miRNAs in glioma tumorigenesis. In this study, we found that miRNA-106b-5p was significantly upregulated in glioma tumor samples and cell lines compared with normal brain tissues, and its expression level correlated with the pathological grading. Overexpression of miR-106b-5p in glioma tumor cells significantly promoted cell proliferation, although inhibited cell apoptosis in vitro and in vivo. In contrast, knockdown of miR-106b-5p significantly inhibited cell proliferation, although enhanced cell apoptosis. Mechanistic study revealed that two target genes, retinoblastoma-like 1 (RBL1) and RBL2, were involved in miR-106b-5p's regulation of cell proliferation and one target gene, caspase-8 (CASP8), mediated miR-106b-5p's regulation of apoptosis. We also investigated the function of the three targets in glioma tumorigenesis by RNA interference manipulation and demonstrated that knockdown of these target genes led to cell proliferation enhancement or cell apoptosis inhibition in vitro. More interestingly, the expression levels of these targets were significantly downregulated in glioma samples and knockdown of these targets in glioma cells inhibited the xenograft tumor formation in vivo. Moreover, we verified the regulation function of miR-106b-5p and its targets on cell proliferation and apoptosis of the primary cultured astrocytes isolated from glioma tumor samples and healthy controls. Collectively, our findings show the critical roles of miR-106b-5p and its targets, RBL1, RBL2 and CASP8, in glioma tumorigenesis and provide potential candidates for malignant glioma therapy.	[Liu, F.; Gong, J.; Huang, W.; Wang, M.; Yang, J.; Wu, C.; Wu, Z.; Han, B.] Changzhou 2 Peoples Hosp, Dept Neurosurg, Changzhou 213003, Jiangsu, Peoples R China; [Wang, Z.] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China	Soochow University - China	Huang, W (corresponding author), Changzhou 2 Peoples Hosp, Dept Neurosurg, Changzhou 213003, Jiangsu, Peoples R China.	doctorliu411@163.com; w13306208761@hotmail.com			Open Project Program of Jiangsu Province's Key Discipline/Laboratory of Medicine [KF200971]; Changzhou Health Bureau [ZD201112]	Open Project Program of Jiangsu Province's Key Discipline/Laboratory of Medicine; Changzhou Health Bureau	This work was supported by the Open Project Program of Jiangsu Province's Key Discipline/Laboratory of Medicine (KF200971), Key Project of Changzhou Health Bureau (ZD201112).	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Ashley DM, 2005, CANCER-AM CANCER SOC, V104, P1487, DOI 10.1002/cncr.21323; Bogler O, 2005, J CELL BIOCHEM, V96, P16, DOI 10.1002/jcb.20475; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Cai KM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-73; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Guo CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017734; Hu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016221; Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Li BQ, 2011, PROSTATE, V71, P567, DOI 10.1002/pros.21272; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Malzkorn B, 2010, BRAIN PATHOL, V20, P539, DOI 10.1111/j.1750-3639.2009.00328.x; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Sharif A, 2012, METHODS MOL BIOL, V814, P137, DOI 10.1007/978-1-61779-452-0_11; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Takahashi K, 2006, J IMMUNOL, V176, P4520, DOI 10.4049/jimmunol.176.8.4520; Trompeter HI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016138; Wang HL, 2010, BRAIN RES, V1357, P166, DOI 10.1016/j.brainres.2010.08.023; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Wang X, 2012, ONCOL REP, V28, P1293, DOI 10.3892/or.2012.1927; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001; Zhang Y, 2012, FRONT BIOSCI-LANDMRK, V17, P700, DOI 10.2741/3952	31	71	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4813	4822		10.1038/onc.2013.428	http://dx.doi.org/10.1038/onc.2013.428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24166509	Bronze			2022-12-17	WOS:000343240100003
J	Brighenti, E; Calabrese, C; Liguori, G; Giannone, FA; Trere, D; Montanaro, L; Derenzini, M				Brighenti, E.; Calabrese, C.; Liguori, G.; Giannone, F. A.; Trere, D.; Montanaro, L.; Derenzini, M.			Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer	ONCOGENE			English	Article						IL-6; ribosome biogenesis; p53; chronic inflammation; EMT; cancer	MULTIPLE-MYELOMA CELLS; C-MYC TRANSLATION; E-CADHERIN; HEPATOCELLULAR-CARCINOMA; LIVER INFLAMMATION; STAT3; ACTIVATION; IMMUNITY; IL-6; RNA	Chronic inflammation is an established risk factor for the onset of cancer, and the inflammatory cytokine IL-6 has a role in tumorigenesis by enhancing proliferation and hindering apoptosis. As factors stimulating proliferation also downregulate p53 expression by enhancing ribosome biogenesis, we hypothesized that IL-6 may cause similar changes in inflamed tissues, thus activating a mechanism that favors neoplastic transformation. Here, we showed that IL-6 downregulated the expression and activity of p53 in transformed and untransformed human cell lines. This was the consequence of IL-6-dependent stimulation of c-MYC mRNA translation, which was responsible for the upregulation of rRNA transcription. The enhanced rRNA transcription stimulated the MDM2-mediated proteasomal degradation of p53, by reducing the availability of ribosome proteins for MDM2 binding. The p53 downregulation induced the acquisition of cellular phenotypic changes characteristic of epithelial-mesenchymal transition, such as a reduced level of E-cadherin expression, increased cell invasiveness and a decreased response to cytotoxic stresses. We found that these changes also occurred in colon epithelial cells of patients with ulcerative colitis, a very representative example of chronic inflammation at high risk for tumor development. Histochemical and immunohistochemical analysis of colon biopsy samples showed an upregulation of ribosome biogenesis, a reduced expression of p53, together with a focal reduction or absence of E-cadherin expression in chronic colitis in comparison with normal mucosa samples. These changes disappeared after treatment with anti-inflammatory drugs. Taken together, the present results highlight a new mechanism that may link chronic inflammation to cancer, based on p53 downregulation, which is activated by the enhancement of rRNA transcription upon IL-6 exposure.	[Brighenti, E.; Trere, D.; Montanaro, L.; Derenzini, M.] Univ Bologna, Dept Expt Diagnost & Specialty Med, I-40138 Bologna, Italy; [Calabrese, C.; Liguori, G.; Giannone, F. A.] Univ Bologna, Dept Med & Surg Sci, I-40138 Bologna, Italy; [Giannone, F. A.] Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Biomed & Appl Res Ctr, Bologna, Italy	University of Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Derenzini, M (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med, Via Massarenti 9, I-40138 Bologna, Italy.	massimo.derenzini@unibo.it	Montanaro, Lorenzo/I-4236-2019; Trere', Davide/AAC-4725-2021	Montanaro, Lorenzo/0000-0001-9776-9518; Trere', Davide/0000-0003-1127-1052; Calabrese, Carlo/0000-0003-3657-4463	Roberto and Cornelia Pallotti's Legacy; Vanini-Cavagnino Grant (Centro Interdipartimentale per le Ricerche sul Cancro, Bologna, Italy); Italian Ministry of Education, University and Research (MIUR); Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG13480]	Roberto and Cornelia Pallotti's Legacy; Vanini-Cavagnino Grant (Centro Interdipartimentale per le Ricerche sul Cancro, Bologna, Italy); Italian Ministry of Education, University and Research (MIUR); Associazione Italiana per la Ricerca sul Cancro (AIRC)	This work was supported by the Roberto and Cornelia Pallotti's Legacy for Cancer Research, the Vanini-Cavagnino Grant (Centro Interdipartimentale per le Ricerche sul Cancro, Bologna, Italy), the Italian Ministry of Education, University and Research (MIUR: grants for orientated fundamental research) and Associazione Italiana per la Ricerca sul Cancro (AIRC, grant no IG13480).	Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Derenzini M, 1998, AM J PATHOL, V152, P1291; Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48; Faccioli S, 1996, MODERN PATHOL, V9, P120; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Kim S, 2008, CANCER RES, V68, P323, DOI 10.1158/0008-5472.CAN-07-2924; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; LENNARDJONES JE, 1989, SCAND J GASTROENTERO, V24, P2, DOI 10.3109/00365528909091339; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Moran DM, 2008, J SURG RES, V147, P23, DOI 10.1016/j.jss.2007.04.022; Nakagawa H, 2009, INT J CANCER, V125, P2264, DOI 10.1002/ijc.24720; Niu GL, 2005, MOL CELL BIOL, V25, P7432, DOI 10.1128/MCB.25.17.7432-7440.2005; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Risques RA, 2011, CANCER RES, V71, P1669, DOI 10.1158/0008-5472.CAN-10-1966; Rocchi L, 2013, NUCLEIC ACIDS RES, V41, P8308, DOI 10.1093/nar/gkt587; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shi YJ, 2011, J BIOL CHEM, V286, P67, DOI 10.1074/jbc.M110.153221; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Trere D, 2003, HEPATOLOGY, V37, P72, DOI 10.1053/jhep.2003.50039; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	35	71	74	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4396	4406		10.1038/onc.2014.1	http://dx.doi.org/10.1038/onc.2014.1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24531714	hybrid, Green Published			2022-12-17	WOS:000341157800004
J	Myatt, SS; Kongsema, M; Man, CWY; Kelly, DJ; Gomes, AR; Khongkow, P; Karunarathna, U; Zona, S; Langer, JK; Dunsby, CW; Coombes, RC; French, PM; Brosens, JJ; Lam, EWF				Myatt, S. S.; Kongsema, M.; Man, C. W-Y; Kelly, D. J.; Gomes, A. R.; Khongkow, P.; Karunarathna, U.; Zona, S.; Langer, J. K.; Dunsby, C. W.; Coombes, R. C.; French, P. M.; Brosens, J. J.; Lam, E. W-F			SUMOylation inhibits FOXM1 activity and delays mitotic transition	ONCOGENE			English	Article						FOXM1; SUMO; chemotherapy; drug resistance; breast cancer; cell cycle	BREAST-CANCER; TRANSCRIPTION FACTOR; POSTTRANSLATIONAL MODIFICATION; UBIQUITIN LIGASE; SUMO; CELLS; RNF4; EXPRESSION; RESISTANCE; PATHWAY	The forkhead box transcription factor FOXM1 is an essential effector of G2/M-phase transition, mitosis and the DNA damage response. As such, it is frequently deregulated during tumorigenesis. Here we report that FOXM1 is dynamically modified by SUMO1 but not by SUMO2/3 at multiple sites. We show that FOXM1 SUMOylation is enhanced in MCF-7 breast cancer cells in response to treatment with epirubicin and mitotic inhibitors. Mutation of five consensus conjugation motifs yielded a SUMOylation-deficient mutant FOXM1. Conversely, fusion of the E2 ligase Ubc9 to FOXM1 generated an auto-SUMOylating mutant (FOXM1-Ubc9). Analysis of wild-type FOXM1 and mutants revealed that SUMOylation inhibits FOXM1 activity, promotes translocation to the cytoplasm and enhances APC/Cdh1-mediated ubiquitination and degradation. Further, expression of the SUMOylation-deficient mutant enhanced cell proliferation compared with wild-type FOXM1, whereas the FOXM1-Ubc9 fusion protein resulted in persistent cyclin B1 expression and slowed the time from mitotic entry to exit. In summary, our findings suggest that SUMOylation attenuates FOXM1 activity and causes mitotic delay in cytotoxic drug response.	[Myatt, S. S.; Kongsema, M.; Kelly, D. J.; Gomes, A. R.; Khongkow, P.; Karunarathna, U.; Zona, S.; Langer, J. K.; Coombes, R. C.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, London W12 0NN, England; [Man, C. W-Y] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; [Kelly, D. J.; Dunsby, C. W.; French, P. M.] Univ London Imperial Coll Sci Technol & Med, Dept Phys, Photon Grp, London W12 0NN, England; [Brosens, J. J.] Univ Hosp, Warwick Med Sch, Div Reprod Hlth, Clin Sci Res Labs, Coventry, W Midlands, England	Imperial College London; Hong Kong Polytechnic University; Imperial College London; University of Warwick	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, Room 134,1st Floor,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	French, Paul/E-8649-2011; Kongsema, Mesayamas/H-3063-2017; Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Khongkow, Pasarat/0000-0003-3068-2412; Brosens, Jan/0000-0003-0116-9329; Coombes, Raoul Charles/0000-0002-4811-1100; French, Paul/0000-0002-0478-6755; Kongsema, Mesayamas/0000-0001-7146-9349	Breast Cancer Campaign; Cancer Research UK; Royal Thai Government; BBSRC; EPSRC; Biomedical Research Unit in Reproductive Health, University Hospital Coventry and Warwickshire, UK; Biotechnology and Biological Sciences Research Council [1243234] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Breast Cancer Campaign [2012MayPR070, 2012NovPhD016] Funding Source: researchfish	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Royal Thai Government; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biomedical Research Unit in Reproductive Health, University Hospital Coventry and Warwickshire, UK; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Breast Cancer Campaign	This work was funded by grants from Breast Cancer Campaign and from Cancer Research UK. MK and PK are recipients of studentships from the Royal Thai Government, and UK is supported by BBSRC. ARG is a post-doctoral fellow supported by Cancer Research UK, and SZ is a post-doc funded by Breast Cancer Campaign. DJK is supported by a studentship from EPSRC. JJ.B was supported by the Biomedical Research Unit in Reproductive Health, University Hospital Coventry and Warwickshire, UK.	Alibhai D, 2013, J BIOPHOTONICS, V6, P398, DOI 10.1002/jbio.201200185; Alvarez-Fernandez M, 2010, EMBO REP, V11, P452, DOI 10.1038/embor.2010.46; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Behren A, 2010, ONCOGENE, V29, P1519, DOI 10.1038/onc.2009.436; Burrage PS, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2564; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Chien AJ, 2008, SEMIN ONCOL, V35, pS1, DOI 10.1053/j.seminoncol.2008.02.010; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Darieva Z, 2006, NATURE, V444, P494, DOI 10.1038/nature05339; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Down CF, 2012, BBA-GENE REGUL MECH, V1819, P855, DOI 10.1016/j.bbagrm.2012.03.008; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Hakli M, 2005, EXP CELL RES, V304, P224, DOI 10.1016/j.yexcr.2004.10.029; Hannoun Z, 2010, TOXICOLOGY, V278, P288, DOI 10.1016/j.tox.2010.07.013; Heideker J, 2009, DNA REPAIR, V8, P517, DOI 10.1016/j.dnarep.2009.01.010; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Jakobs A, 2007, NAT METHODS, V4, P245, DOI 10.1038/NMETH1006; Jones MC, 2006, P NATL ACAD SCI USA, V103, P16272, DOI 10.1073/pnas.0603002103; Kho C, 2011, NATURE, V477, P601, DOI 10.1038/nature10407; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Knipscheer P, 2007, EMBO J, V26, P2797, DOI 10.1038/sj.emboj.7601711; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Leisner C, 2008, CURR BIOL, V18, P1249, DOI 10.1016/j.cub.2008.07.091; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593; Park YY, 2012, CARCINOGENESIS, V33, P1843, DOI 10.1093/carcin/bgs167; Prudden J, 2007, EMBO J, V26, P4089, DOI 10.1038/sj.emboj.7601838; Ran Y, 2011, J MOL CELL BIOL, V3, P283, DOI 10.1093/jmcb/mjr020; Rytinki MM, 2009, J BIOL CHEM, V284, P26184, DOI 10.1074/jbc.M109.038943; Spengler ML, 2006, J BIOL CHEM, V281, P5567, DOI 10.1074/jbc.M600035200; Sun H, 2007, EMBO J, V26, P4102, DOI 10.1038/sj.emboj.7601839; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Wadosky KM, 2012, AM J PHYSIOL-HEART C, V302, pH515, DOI 10.1152/ajpheart.00703.2011; Warren SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070687; Werner A, 2012, MOL CELL, V46, P287, DOI 10.1016/j.molcel.2012.02.017; Xue Y, 2006, NUCLEIC ACIDS RES, V34, pW254, DOI 10.1093/nar/gkl207; Yin YL, 2012, GENE DEV, V26, P1196, DOI 10.1101/gad.189274.112; Zhang N, 2012, CLIN CANCER RES, V18, P5961, DOI 10.1158/1078-0432.CCR-12-0039; Zhang XD, 2008, MOL CELL, V29, P729, DOI 10.1016/j.molcel.2008.01.013; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200	54	71	72	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4316	4329		10.1038/onc.2013.546	http://dx.doi.org/10.1038/onc.2013.546			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24362530	Green Accepted, Green Published			2022-12-17	WOS:000341156900005
J	Huang, CK; Yang, CY; Jeng, YM; Chen, CL; Wu, HH; Chang, YC; Ma, C; Kuo, WH; Chang, KJ; Shew, JY; Lee, WH				Huang, C-K; Yang, C-Y; Jeng, Y-M; Chen, C-L; Wu, H-H; Chang, Y-C; Ma, C.; Kuo, W-H; Chang, K-J; Shew, J-Y; Lee, W-H			Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-kappa B-mediated antiapoptotic pathway	ONCOGENE			English	Article						antiapoptosis; autocrine; IL-17RB; NF-kappa B; tumorigenesis	CYTOKINE RECEPTOR; TUMOR-DEVELOPMENT; PROSTATE-CANCER; IL-17; EXPRESSION; IDENTIFICATION; GROWTH; TRASTUZUMAB; METASTASIS; APOPTOSIS	Gain of function of membrane receptor was a good strategy exploited by cancer cells to benefit own growth and survival. Overexpression of HER2 has been found to serve as a target for developing trastuzumab to treat 20-25% of breast cancer. However, little or none of the other membrane receptor was found to be useful as a potential target for breast cancer treatment since then. Here, we showed that amplified signaling of interleukin-17 receptor B (IL-17RB) and its ligand IL-17B promoted tumorigenicity in breast cancer cells and impeded acinus formation in immortalized normal mammary epithelial cells. External signal transmitted through IL-17RB activated nuclear factor-kappa B to upregulate antiapoptotic factor Bcl-2 and induced etoposide resistance. Elevated expression of IL-17RB had a stronger correlation with poor prognosis than HER2 in breast cancer patients. Interestingly, breast cancer patients with high expression of IL-17RB and HER2 had the shortest survival rate. Depletion of IL-17RB in trastuzumab-resistant breast cancer cells significantly reduced their tumorigenic activity, suggesting that IL-17RB and HER2 have an independent role in breast carcinogenesis. Furthermore, treatment with antibodies specifically against IL-17RB or IL-17B effectively attenuated tumorigenicity of breast cancer cells. These results suggest that the amplified IL-17RB/IL-17B signaling pathways may serve as a therapeutic target for developing treatment to manage IL-17RB-associated breast cancer.	[Huang, C-K; Shew, J-Y; Lee, W-H] Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 10764, Taiwan; [Huang, C-K; Yang, C-Y; Chen, C-L; Wu, H-H; Chang, Y-C; Ma, C.; Shew, J-Y; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Jeng, Y-M] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; [Kuo, W-H; Chang, K-J] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chang, K-J] Cheng Chin Gen Hosp, Taichung, Taiwan; [Lee, W-H] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	whlee@uci.edu	Chang, Yi-cheng/O-1334-2018; Alex, Che/AAF-3280-2019	Chang, Yi-cheng/0000-0002-8077-5011; Alex, Che/0000-0002-4741-2307; Chang, King jen/0000-0001-9811-3422; JENG, YUNG-MING/0000-0002-3878-4491; KUO, WEN-HUNG/0000-0002-9881-4605	Academia Sinica (Taiwan); NIH [CA94170]; NATIONAL CANCER INSTITUTE [R01CA094170] Funding Source: NIH RePORTER	Academia Sinica (Taiwan)(Academia Sinica - Taiwan); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hung-Wen Lai for kindly providing a Herceptin (Trastuzumab)-resistant strain of SKBR3, and Dr Wendy W Hwang-Verslues and Dr Pei-Chi Wei for reading this manuscript. This work was supported by Academia Sinica (Taiwan) and by NIH (CA94170; to WHL).	Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Furuta S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001374; He DG, 2010, J IMMUNOL, V184, P2281, DOI 10.4049/jimmunol.0902574; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Maezawa Y, 2006, J IMMUNOL, V176, P1013, DOI 10.4049/jimmunol.176.2.1013; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Rickel EA, 2008, J IMMUNOL, V181, P4299, DOI 10.4049/jimmunol.181.6.4299; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Singer CF, 2003, CLIN CANCER RES, V9, P4877; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Tian EM, 2000, ONCOGENE, V19, P2098, DOI 10.1038/sj.onc.1203577; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Wang L, 2010, CANCER RES, V70, P10112, DOI 10.1158/0008-5472.CAN-10-0775; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhu XW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2195	35	71	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2968	2977		10.1038/onc.2013.268	http://dx.doi.org/10.1038/onc.2013.268			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851503				2022-12-17	WOS:000337232200003
J	Stebbing, J; Lit, LC; Zhang, H; Darrington, RS; Melaiu, O; Rudraraju, B; Giamas, G				Stebbing, J.; Lit, L. C.; Zhang, H.; Darrington, R. S.; Melaiu, O.; Rudraraju, B.; Giamas, G.			The regulatory roles of phosphatases in cancer	ONCOGENE			English	Review						cancer; phosphatases; solid tumours	PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR GENE; RENAL-CELL CARCINOMA; HUMAN BREAST-CANCER; NF-KAPPA-B; DOXORUBICIN-INDUCED APOPTOSIS; ADENOVIRUS-MEDIATED TRANSFER; FAS-ASSOCIATED PHOSPHATASE-1; HUMAN PROSTATE-CANCER; OVARIAN-CANCER	The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3-kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies.	[Stebbing, J.; Lit, L. C.; Zhang, H.; Darrington, R. S.; Melaiu, O.; Rudraraju, B.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Div Canc, London W12 0NN, England	Imperial College London	Giamas, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	g.giamas@imperial.ac.uk	Melaiu, Ombretta/Z-3461-2019; Giamas, Georgios/AAP-3487-2021; Zhang, Hua/AAV-2344-2020; LIT, LEI CHENG/B-8875-2010; Lit, Lei Cheng/AAS-9778-2021	Melaiu, Ombretta/0000-0001-7118-5186; Zhang, Hua/0000-0001-7704-4712; LIT, LEI CHENG/0000-0002-3210-4491; Lit, Lei Cheng/0000-0002-3210-4491; Stebbing, Justin/0000-0002-1117-6947; Giamas, Georgios/0000-0002-4417-2707	National Institutes of Health Research; Imperial Biomedical Research Centre; Experimental Cancer Medicine Centre; Breast Cancer Campaign; Cancer Research UK; Action Against Cancer; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	National Institutes of Health Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Imperial Biomedical Research Centre; Experimental Cancer Medicine Centre; Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Action Against Cancer; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We thank Aleksandra Filipovic for helping in editing the manuscript. JS and GG are supported by grants from the National Institutes of Health Research, Imperial Biomedical Research Centre and Experimental Cancer Medicine Centre, Breast Cancer Campaign, Cancer Research UK and Action Against Cancer.	Abaan OD, 2005, ONCOGENE, V24, P2715, DOI 10.1038/sj.onc.1208247; Albert H, 2012, MOL ONCOL, V6, P542, DOI 10.1016/j.molonc.2012.06.003; Albert H, 2011, CLIN CHEM LAB MED, V49, P1707, DOI 10.1515/CCLM.2011.635; Ali AY, 2012, ONCOGENE, V31, P2175, DOI 10.1038/onc.2011.399; Allard JE, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00065; Amant F, 2002, GYNECOL ONCOL, V85, P165, DOI 10.1006/gyno.2002.6601; Anbalagan M, 2012, BREAST CANCER RES TR, V132, P391, DOI 10.1007/s10549-011-1513-3; Antonello D, 2002, CANCER LETT, V183, P179, DOI 10.1016/S0304-3835(01)00802-3; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bakken T, 2010, VIROLOGY, V397, P379, DOI 10.1016/j.virol.2009.11.030; Balavenkatraman KK, 2006, ONCOGENE, V25, P6319, DOI 10.1038/sj.onc.1209647; Balavenkatraman KK, 2011, MOL CANCER RES, V9, P1377, DOI 10.1158/1541-7786.MCR-11-0198; Balko JM, 2012, NAT MED, V18, P1052, DOI 10.1038/nm.2795; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Bansal N, 2012, J GYNECOL ONCOL, V23, P35, DOI 10.3802/jgo.2012.23.1.35; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Bell HS, 2008, CANCER RES, V68, P4959, DOI 10.1158/0008-5472.CAN-08-0182; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Bhardwaj A, 2011, MOL CANCER THER, V10, P720, DOI 10.1158/1535-7163.MCT-10-1096; Bockelman C, 2011, BRIT J CANCER, V105, P989, DOI 10.1038/bjc.2011.346; Boldrini L, 2007, HUM PATHOL, V38, P1563, DOI 10.1016/j.humpath.2007.03.006; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Bonin S, 2006, VIRCHOWS ARCH, V448, P539, DOI 10.1007/s00428-005-0146-5; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Boyault S, 2012, BREAST CANCER RES TR, V132, P29, DOI 10.1007/s10549-011-1518-y; Brems-Eskildsen AS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-646; Broggini M, 2000, ANTICANCER RES, V20, P4835; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Cairns P, 1997, CANCER RES, V57, P4997; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Cao X, 2012, ANN THORAC SURG, V93, P1674, DOI 10.1016/j.athoracsur.2011.12.056; Carlucci A, 2010, J BIOL CHEM, V285, P39260, DOI 10.1074/jbc.M110.174706; Castro ME, 2008, CARCINOGENESIS, V29, P491, DOI 10.1093/carcin/bgm246; Cejudo-Marin R, 2012, J MOL BIOL, V420, P128, DOI 10.1016/j.jmb.2012.04.004; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Chen SY, 2009, J BIOL CHEM, V284, P25576, DOI 10.1074/jbc.M109.043133; Chen Y, 2011, BREAST CANCER RES TR, V128, P69, DOI 10.1007/s10549-010-1024-7; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng Y, 2011, CANCER GENET-NY, V204, P375, DOI 10.1016/j.cancergen.2011.05.002; Chiappinelli KB, 2010, GYNECOL ONCOL, V119, P146, DOI 10.1016/j.ygyno.2010.06.015; Chiarugi P, 2004, ONCOGENE, V23, P3905, DOI 10.1038/sj.onc.1207508; Chitale D, 2009, ONCOGENE, V28, P2773, DOI 10.1038/onc.2009.135; Chiu YT, 2009, J MOL BIOL, V385, P446, DOI 10.1016/j.jmb.2008.10.070; Chow JYC, 2008, AM J PHYSIOL-GASTR L, V294, pG899, DOI 10.1152/ajpgi.00411.2007; Chow JYC, 2010, AM J PHYSIOL-GASTR L, V298, pG275, DOI 10.1152/ajpgi.00344.2009; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Chuang YC, 1997, J UROLOGY, V158, P1684, DOI 10.1016/S0022-5347(01)64095-3; Cohen PTW, 2002, J CELL SCI, V115, P241; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2004, J UROLOGY, V171, P907, DOI 10.1097/01.ju.0000092859.16817.8e; Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571; Da N, 2009, WORLD J GASTROENTERO, V15, P1499, DOI 10.3748/wjg.15.1499; Dellinger TH, 2009, EXPERT REV ANTICANC, V9, P905, DOI 10.1586/ERA.09.54; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong J, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-81; Dromard M, 2007, CANCER RES, V67, P6806, DOI 10.1158/0008-5472.CAN-07-0513; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Cariaga-Martinez AE, 2009, ADV UROL, V2009, DOI 10.1155/2009/723831; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Farrow B, 2003, BIOCHEM BIOPH RES CO, V301, P50, DOI 10.1016/S0006-291X(02)02983-2; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Feng XL, 2011, MOL CELL BIOL, V31, P3457, DOI 10.1128/MCB.05523-11; Fernandez-Marcos PJ, 2009, P NATL ACAD SCI USA, V106, P12962, DOI 10.1073/pnas.0813055106; Fujimoto T, 2009, GYNECOL ONCOL, V112, P342, DOI 10.1016/j.ygyno.2008.10.019; Funato K, 2011, EXP THER MED, V2, P457, DOI 10.3892/etm.2011.231; Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368; Gloria-Bottini F, 2012, AM J MED SCI, V344, P32, DOI 10.1097/MAJ.0b013e31823e5cfa; Gonzalez-Angulo AM, 2011, MOL CANCER THER, V10, P1093, DOI 10.1158/1535-7163.MCT-10-1089; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Grossmann Allie H., 2012, Sarcoma, V2012, P380896, DOI 10.1155/2012/380896; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Gu MX, 1996, P NATL ACAD SCI USA, V93, P12980, DOI 10.1073/pnas.93.23.12980; Guo K, 2008, CANCER BIOL THER, V7, P750, DOI 10.4161/cbt.7.5.5764; Hager M, 2007, PATHOLOGY, V39, P482, DOI 10.1080/00313020701570012; Hager M, 2011, CANCER INVEST, V29, P427, DOI 10.3109/07357907.2011.584782; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Harima Y, 2009, INT J RADIAT ONCOL, V75, P1232, DOI 10.1016/j.ijrobp.2009.07.002; Hatakeyama M, 2009, J GASTROENTEROL, V44, P239, DOI 10.1007/s00535-009-0014-1; He KX, 2010, J GENET GENOMICS, V37, P249, DOI 10.1016/S1673-8527(09)60043-6; Henkens R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-147; Hou GQ, 2011, DIGEST DIS SCI, V56, P1315, DOI 10.1007/s10620-010-1474-0; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Hsieh SM, 2007, ADV EXP MED BIOL, V599, P31; Huang CC, 2008, ONCOGENE, V27, P2422, DOI 10.1038/sj.onc.1210888; Imai A, 2006, J Obstet Gynaecol, V26, P37; Ito Yasuhiro, 2004, Breast Cancer, V11, P295, DOI 10.1007/BF02984552; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jiang YJ, 2011, CANCER RES, V71, P234, DOI 10.1158/0008-5472.CAN-10-1487; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Karagoz ID, 2010, TUMOR BIOL, V31, P597, DOI 10.1007/s13277-010-0075-z; Kawaguchi K, 2005, HUM PATHOL, V36, P357, DOI 10.1016/j.humpath.2005.01.017; Kim JS, 2010, DIGEST DIS SCI, V55, P1565, DOI 10.1007/s10620-009-0924-z; Kobayashi I, 2012, LIFE SCI, V90, P212, DOI 10.1016/j.lfs.2011.11.006; Kong WH, 2009, CANCER BIOL THER, V8, P555, DOI 10.4161/cbt.8.6.7742; Korff S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-329; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; Krndija D, 2010, ONCOGENE, V29, P2724, DOI 10.1038/onc.2010.25; Krueger AB, 2013, J BIOMOL SCREEN, V18, P85, DOI 10.1177/1087057112453936; Ksiaa F, 2009, CLIN CHIM ACTA, V404, P128, DOI 10.1016/j.cca.2009.03.044; Kuroda N, 1998, VIRCHOWS ARCH, V433, P331, DOI 10.1007/s004280050257; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Kurose K, 2000, GENE CHROMOSOME CANC, V29, P166, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1025>3.3.CO;2-D; Kwon HY, 2008, ARCH PHARM RES, V31, P171, DOI 10.1007/s12272-001-1137-y; Lai MW, 2012, UROL ONCOL-SEMIN ORI, V30, P871, DOI 10.1016/j.urolonc.2010.09.010; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Lavecchia A, 2010, EXPERT OPIN THER PAT, V20, P405, DOI 10.1517/13543771003623232; Lax SF, 1998, HUM PATHOL, V29, P924, DOI 10.1016/S0046-8177(98)90197-6; Lee JW, 2007, APMIS, V115, P47, DOI 10.1111/j.1600-0463.2007.apm_554.x; Lee JS, 2003, J SURG ONCOL, V84, P166, DOI 10.1002/jso.10302; Lee S, 2005, GYNECOL ONCOL, V97, P26, DOI 10.1016/j.ygyno.2004.11.051; Lessard L, 2010, BBA-PROTEINS PROTEOM, V1804, P613, DOI 10.1016/j.bbapap.2009.09.018; Li CK, 2008, LINEAR MULTILINEAR A, V56, P1, DOI 10.1080/03081080701538074; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Li W, 2011, EUR J CANCER, V47, P2654, DOI 10.1016/j.ejca.2011.08.014; Li W, 2011, CANCER LETT, V304, P117, DOI 10.1016/j.canlet.2011.02.009; Li XP, 2011, CANCER-AM CANCER SOC, V117, P4201, DOI 10.1002/cncr.26028; Li ZR, 2007, SURG TODAY, V37, P646, DOI 10.1007/s00595-006-3437-9; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Lin MS, 2011, ONCOL LETT, V2, P1219, DOI 10.3892/ol.2011.414; Lin Pei-Yin, 2007, Mol Cancer, V6, P16, DOI 10.1186/1476-4598-6-16; Lin Q, 2005, AM J PATHOL, V167, P969, DOI 10.1016/S0002-9440(10)61187-X; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu JH, 2000, MOL CARCINOGEN, V29, P143, DOI 10.1002/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A; Liu J, 2011, GYNECOL ONCOL, V122, P430, DOI 10.1016/j.ygyno.2011.04.031; Liu T, 2010, ONCOL RES, V19, P125, DOI 10.3727/096504011X12935427587768; Loda M, 1996, AM J PATHOL, V149, P1553; Ma J, 2012, J HUM GENET, V57, P261, DOI 10.1038/jhg.2012.15; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Malentacchi F, 2005, BIOCHEM BIOPH RES CO, V334, P875, DOI 10.1016/j.bbrc.2005.06.176; Manzano RG, 2002, ONCOGENE, V21, P4435, DOI 10.1038/sj.onc.1205542; Marsit CJ, 2005, HUM PATHOL, V36, P768, DOI 10.1016/j.humpath.2005.05.006; Martin-Granados C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040769; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349-7006.2009.01257.x; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; McConechy MK, 2011, J PATHOL, V223, P567, DOI 10.1002/path.2848; Mehdipour P, 2009, CELL BIOL INT, V33, P1050, DOI 10.1016/j.cellbi.2009.06.016; Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9; Meng F, 2013, J OBSTET GYNAECOL RE, V39, P272, DOI 10.1111/j.1447-0756.2012.01952.x; Miller TW, 2009, CANCER RES, V69, P4192, DOI 10.1158/0008-5472.CAN-09-0042; Minaguchi T, 1999, CANCER RES, V59, P6063; Miskad UA, 2007, VIRCHOWS ARCH, V450, P303, DOI 10.1007/s00428-006-0361-8; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Miyazaki T, 2006, J GASTROEN HEPATOL, V21, P84, DOI 10.1111/j.1440-1746.2005.04155.x; Mizuno R, 2005, ONCOL REP, V14, P639; Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; Mollevi DG, 2008, BRIT J CANCER, V99, P1718, DOI 10.1038/sj.bjc.6604747; Moncho-Amor V, 2011, ONCOGENE, V30, P668, DOI 10.1038/onc.2010.449; Montagut C, 2010, BRIT J CANCER, V102, P1137, DOI 10.1038/sj.bjc.6605612; Mori Y, 2004, CANCER RES, V64, P2434, DOI 10.1158/0008-5472.CAN-03-3508; Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Muller P, 1999, CLIN CANCER RES, V5, P3569; Mundhenk J, 2011, ONCOL LETT, V2, P1089, DOI 10.3892/ol.2011.374; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Ngan ESW, 2003, ONCOGENE, V22, P734, DOI 10.1038/sj.onc.1206121; Nishioka K, 2001, BRIT J CANCER, V85, P412, DOI 10.1054/bjoc.2001.1934; Nitsche C, 2012, GASTROENTEROLOGY, V142, P377, DOI 10.1053/j.gastro.2011.10.026; Nunes-Xavier CE, 2010, J BIOL CHEM, V285, P26417, DOI 10.1074/jbc.M110.121830; Okami K, 1998, CANCER RES, V58, P509; Olivero M, 2006, MOL CANCER THER, V5, P1126, DOI 10.1158/1535-7163.MCT-06-0013; Omerovic J, 2010, BIOCHEM J, V426, P65, DOI 10.1042/BJ20091413; Ooki A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-122; Ozen M, 2005, CLIN CANCER RES, V11, P4701, DOI 10.1158/1078-0432.CCR-04-2551; Padma S, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-7; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Pandey RN, 2010, ONCOGENE, V29, P3715, DOI 10.1038/onc.2010.122; Peng LR, 2006, BIOCHEM BIOPH RES CO, V342, P179, DOI 10.1016/j.bbrc.2006.01.102; Pham NA, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-43; Philpott N, 2011, J VIROL, V85, P1140, DOI 10.1128/JVI.01362-10; Planas-Silva MD, 2006, BIOCHEM BIOPH RES CO, V341, P73, DOI 10.1016/j.bbrc.2005.12.164; Polato F, 2005, CLIN CANCER RES, V11, P6835, DOI 10.1158/1078-0432.CCR-04-2357; Prasad S, 2007, LIFE SCI, V81, P1323, DOI 10.1016/j.lfs.2007.07.033; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Rahmouni S, 2006, NAT CELL BIOL, V8, P524, DOI 10.1038/ncb1398; Rajarubendra N, 2010, UROLOGY, V76, P782, DOI 10.1016/j.urology.2009.12.050; Ren TT, 2009, PATHOL ONCOL RES, V15, P555, DOI 10.1007/s12253-009-9153-1; Revillion F, 2009, INT J CANCER, V124, P638, DOI 10.1002/ijc.23989; Rodriguez-Ubreva FJ, 2010, ONCOGENE, V29, P345, DOI 10.1038/onc.2009.329; Roy D, 2011, AM J PATHOL, V179, P2108, DOI 10.1016/j.ajpath.2011.06.017; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Sadakata H, 2009, GENES CELLS, V14, P295, DOI 10.1111/j.1365-2443.2008.01270.x; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sangai T, 2012, CLIN CANCER RES, V18, P5816, DOI 10.1158/1078-0432.CCR-12-1141; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schild C, 2009, MOL CARCINOGEN, V48, P1149, DOI 10.1002/mc.20569; Schneider E, 2011, INT J ONCOL, V38, P823, DOI 10.3892/ijo.2010.893; Scrima M, 2012, AM J PATHOL, V180, P1202, DOI 10.1016/j.ajpath.2011.11.038; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; Shamay M, 2012, J VIROL, V86, P5179, DOI 10.1128/JVI.00169-12; Shin CM, 2012, J PATHOL, V226, P654, DOI 10.1002/path.2990; Shor Audrey C, 2008, Cancer Control, V15, P47; Shorning BY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016209; Siligan C, 2005, ONCOGENE, V24, P2512, DOI 10.1038/sj.onc.1208455; Singh AP, 2008, CANCER LETT, V259, P28, DOI 10.1016/j.canlet.2007.09.018; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Small GW, 2007, CANCER RES, V67, P4459, DOI 10.1158/0008-5472.CAN-06-2644; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Su FQ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3134; Su WP, 2007, BIOCHEM BIOPH RES CO, V356, P181, DOI 10.1016/j.bbrc.2007.02.099; Sugiyama M, 2005, ONCOL REP, V13, P813; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Takei Y, 2008, MOL CANCER THER, V7, P704, DOI 10.1158/1535-7163.MCT-06-0724; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Tang JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-128; Tanyi JL, 2003, CLIN CANCER RES, V9, P3534; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Tassidis H, 2012, TUMOR BIOL; Tassidis H, 2010, INT J CANCER, V126, P2296, DOI 10.1002/ijc.24917; Teng DHF, 1997, CANCER RES, V57, P5221; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Valencia AM, 1997, FEBS LETT, V406, P42, DOI 10.1016/S0014-5793(97)00235-4; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang Bin, 2004, Ai Zheng, V23, P885; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wang JG, 2010, MAGNETIC FRINGE FIELDS AND INTERFERENCE IN HIGH INTENSITY ACCELERATORS, P1; Wang JG, 2012, MED ONCOL, V29, P948, DOI 10.1007/s12032-011-9911-2; Wang LF, 2007, WORLD J GASTROENTERO, V13, P5692, DOI 10.3748/wjg.v13.i43.5692; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wang Z, 2009, ANN SURG ONCOL, V16, P208, DOI 10.1245/s10434-008-0214-6; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Wong LL, 2010, EXP CELL RES, V316, P3387, DOI 10.1016/j.yexcr.2010.06.007; Wong LL, 2009, INT J ONCOL, V34, P1291, DOI 10.3892/ijo_00000256; Wu CW, 2006, CANCER LETT, V242, P95, DOI 10.1016/j.canlet.2005.10.046; Wu CW, 2006, ANTICANCER RES, V26, P1643; Wu Hui-juan, 2011, Zhonghua Zhong Liu Za Zhi, V33, P165; Wu HJ, 2008, CANCER LETT, V271, P205, DOI 10.1016/j.canlet.2008.06.018; Wu SD, 2009, J MED CHEM, V52, P6716, DOI 10.1021/jm901016k; Wu S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-413; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yamazaki S, 2003, J INFECT DIS, V187, P334, DOI 10.1086/367807; Yang SH, 2005, CLIN CANCER RES, V11, P612; Yao H, 2004, BRIT J CANCER, V91, P1718, DOI 10.1038/sj.bjc.6602136; Yeh LS, 2007, INT J GYNECOL CANCER, V17, P868, DOI 10.1111/j.1525-1438.2007.00880.x; You YJ, 2012, CANCER LETT, V315, P138, DOI 10.1016/j.canlet.2011.08.032; Yu NW, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.03.061; Yu XY, 2012, ASIAN PAC J CANCER P, V13, P931, DOI 10.7314/APJCP.2012.13.3.931; Yuan TC, 2010, J BIOL CHEM, V285, P14861, DOI 10.1074/jbc.M109.099879; Zapata PD, 2002, J CLIN ENDOCR METAB, V87, P915, DOI 10.1210/jc.87.2.915; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zeng QY, 2012, CANCER GENET-NY, V205, P442, DOI 10.1016/j.cancergen.2012.06.002; ZHAI YF, 1993, CANCER RES, V53, P2272; Zhang Qingxiu, 2012, Enzyme Res, V2012, P659649, DOI 10.1155/2012/659649; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; Zhao YQ, 2010, P NATL ACAD SCI USA, V107, P2592, DOI 10.1073/pnas.0914884107; Zheng X, 2008, INT J CANCER, V122, P1999, DOI 10.1002/ijc.23321; Zheng YH, 2011, MOL CELL BIOL, V31, P4258, DOI 10.1128/MCB.05547-11; Zhong H, 2000, CANCER RES, V60, P1541; Zhou YA, 2010, BIOSCI BIOTECH BIOCH, V74, P736, DOI 10.1271/bbb.90787; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	271	71	71	2	42	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					939	953		10.1038/onc.2013.80	http://dx.doi.org/10.1038/onc.2013.80			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23503460	Bronze, Green Submitted			2022-12-17	WOS:000331933200001
J	Hulf, T; Sibbritt, T; Wiklund, ED; Patterson, K; Song, JZ; Stirzaker, C; Qu, W; Nair, S; Horvath, LG; Armstrong, NJ; Kench, JG; Sutherland, RL; Clark, SJ				Hulf, T.; Sibbritt, T.; Wiklund, E. D.; Patterson, K.; Song, J. Z.; Stirzaker, C.; Qu, W.; Nair, S.; Horvath, L. G.; Armstrong, N. J.; Kench, J. G.; Sutherland, R. L.; Clark, S. J.			Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer	ONCOGENE			English	Article						microRNA; miR-205; MED1; epigenetics; prostate cancer	ANDROGEN RECEPTOR; EXPRESSION PROFILES; COREGULATORY ROLE; MEDIATOR COMPLEX; LUNG-CANCER; GENE; MIR-205; OVEREXPRESSION; PROLIFERATION; DEREGULATION	Deregulation of microRNA (miRNA) expression can have a critical role in carcinogenesis. Here we show in prostate cancer that miRNA-205 (miR-205) transcription is commonly repressed and the MIR-205 locus is hypermethylated. LOC642587, the MIR-205 host gene of unknown function, is also concordantly inactivated. We show that miR-205 targets mediator 1 (MED1, also called TRAP220 and PPARBP) for transcriptional silencing in normal prostate cells, leading to reduction in MED1 mRNA levels, and in total and active phospho-MED1 protein. Overexpression of miR-205 in prostate cancer cells negatively affects cell viability, consistent with a tumor suppressor function. We found that hypermethylation of the MIR-205 locus was strongly related with a decrease in miR-205 expression and an increase in MED1 expression in primary tumor samples (n = 14), when compared with matched normal prostate (n = 7). An expanded patient cohort (tumor n = 149, matched normal n = 30) also showed significant MIR-205 DNA methylation in tumors compared with normal, and MIR-205 hypermethylation is significantly associated with biochemical recurrence (hazard ratio = 2.005, 95% confidence interval (1.109, 3.625), P = 0.02), in patients with low preoperative prostate specific antigen. In summary, these results suggest that miR-205 is an epigenetically regulated tumor suppressor that targets MED1 and may provide a potential biomarker in prostate cancer management.	[Hulf, T.; Sibbritt, T.; Wiklund, E. D.; Patterson, K.; Song, J. Z.; Stirzaker, C.; Qu, W.; Nair, S.; Horvath, L. G.; Armstrong, N. J.; Kench, J. G.; Sutherland, R. L.; Clark, S. J.] St Vincents Hosp, Garvan Inst Med Res, Epigenet Grp, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Wiklund, E. D.] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; [Horvath, L. G.] Royal Prince Alfred Hosp, Dept Med Oncol, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; [Armstrong, N. J.] Univ New S Wales, Sch Math & Stat, Sydney, NSW, Australia; [Kench, J. G.] Royal Prince Alfred Hosp, Dept Tissue Pathol, Camperdown, NSW 2050, Australia; [Clark, S. J.] Univ NSW, St Vincents Clin Sch, St Vincents Hosp, Darlinghurst, NSW, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Aarhus University; University of Sydney; University of New South Wales Sydney; University of Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Clark, SJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Epigenet Grp, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	s.clark@garvan.org.au	Clark, Susan J/U-7365-2019; Armstrong, Nicola J./AAF-3045-2021; Clark, Susan J/B-2272-2008	Clark, Susan J/0000-0001-5925-5030; Armstrong, Nicola J./0000-0002-4477-293X; Clark, Susan J/0000-0001-5925-5030; Kench, James Geoffrey/0000-0001-8687-4988; Horvath, Lisa/0000-0001-6842-9223; Patterson, Kate/0000-0003-3919-7261; Stirzaker, Clare/0000-0001-5601-3140	Cancer Institute NSW (CINSW); Cure Cancer Australia fellowships; National Health and Medical Research Council; CINSW project grants	Cancer Institute NSW (CINSW); Cure Cancer Australia fellowships; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); CINSW project grants	We would like to thank Gillian Lehrbach, Ann-Maree Haynes, Ruth Pe Benito and Clarisse Puno for technical assistance. This work is supported by Cancer Institute NSW (CINSW), Cure Cancer Australia fellowships (TH), and National Health and Medical Research Council and CINSW project grants (SJC).	Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Belakavadi M, 2008, MOL CELL BIOL, V28, P3932, DOI 10.1128/MCB.02191-07; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Childs G, 2009, AM J PATHOL, V174, P736, DOI 10.2353/ajpath.2009.080731; Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60; Chung TKH, 2009, INT J CANCER, V124, P1358, DOI 10.1002/ijc.24071; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Cooper CS, 2009, BRIT J CANCER, V100, P240, DOI 10.1038/sj.bjc.6604771; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; Devaney J, 2011, CANCER EPIDEM BIOMAR, V20, P148, DOI 10.1158/1055-9965.EPI-10-0719; Dijckmeester WA, 2009, J GASTROINTEST SURG, V13, P846, DOI 10.1007/s11605-009-0799-5; Feber A, 2008, J THORACIC CARDIOVAS, V135, P60; Feber A, 2008, J THORAC CARDIOV SUR, V135, P255, DOI 10.1016/j.jtcvs.2007.08.055; Fletcher AM, 2008, TRANSL ONCOL, V1, P202, DOI 10.1593/tlo.08163; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Horvath LG, 2004, CLIN CANCER RES, V10, P615, DOI 10.1158/1078-0432.CCR-0707-03; Hulf T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-54; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Karginov FV, 2010, MOL CELL, V38, P781, DOI 10.1016/j.molcel.2010.06.001; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Koschubs T, 2010, NUCLEIC ACIDS RES, V38, P3186, DOI 10.1093/nar/gkq029; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majid S, 2010, CANCER-AM CANCER SOC, V116, P5637, DOI 10.1002/cncr.25488; Markou A, 2008, CLIN CHEM, V54, P1696, DOI 10.1373/clinchem.2007.101741; Mouillet JF, 2010, FASEB J, V24, P2030, DOI 10.1096/fj.09-149724; Neely LA, 2010, UROL ONCOL-SEMIN ORI, V28, P39, DOI 10.1016/j.urolonc.2008.06.006; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Paoletti AC, 2006, P NATL ACAD SCI USA, V103, P18928, DOI 10.1073/pnas.0606379103; Platica Micsunica, 1997, In Vitro Cellular and Developmental Biology Animal, V33, P147; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Ryan D, 2006, MOL VIS, V12, P1175; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Tran N, 2007, BIOCHEM BIOPH RES CO, V358, P12, DOI 10.1016/j.bbrc.2007.03.201; Vijayvargia R, 2007, CANCER RES, V67, P4034, DOI 10.1158/0008-5472.CAN-06-3039; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yu J, 2008, P NATL ACAD SCI USA, V105, P19300, DOI 10.1073/pnas.0803992105; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	55	71	76	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2891	2899		10.1038/onc.2012.300	http://dx.doi.org/10.1038/onc.2012.300			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22869146				2022-12-17	WOS:000320369100009
J	Wu, S; Lin, Y; Xu, D; Chen, J; Shu, M; Zhou, Y; Zhu, W; Su, X; Zhou, Y; Qiu, P; Yan, G				Wu, S.; Lin, Y.; Xu, D.; Chen, J.; Shu, M.; Zhou, Y.; Zhu, W.; Su, X.; Zhou, Y.; Qiu, P.; Yan, G.			MiR-135a functions as a selective killer of malignant glioma	ONCOGENE			English	Article						malignant glioma; microRNA; apoptosis; nucleic-acid drug	PROSTATE-CANCER CELLS; GENE-EXPRESSION; SELF-RENEWAL; APOPTOSIS; MICRORNAS; MOUSE; IDENTIFICATION; PROLIFERATION; DISRUPTION; ACTIVATION	Glioma is the most common and fatal primary brain tumor. Thus far, therapeutic strategies to efficiently and specifically antagonize glioma are limited and poorly developed. Here we report that glia-enriched miR-135a, a microRNA that is dramatically downregulated in malignant glioma and correlated with the pathological grading, is capable of inducing mitochondria-dependent apoptosis of malignant glioma by regulating various genes including STAT6, SMAD5 and BMPR2, as well as affecting the signaling pathway downstream. Moreover, this lethal effect is selectively towards malignant glioma cells, but not neurons and glial cells, through a novel mechanism. Our findings suggest an important role of miR-135a in glioma etiology and provide a potential candidate for malignant glioma therapy. Oncogene (2012) 31, 3866-3874; doi:10.1038/onc.2011.551; published online 5 December 2011	[Wu, S.; Lin, Y.; Xu, D.; Chen, J.; Shu, M.; Zhou, Y.; Zhu, W.; Su, X.; Zhou, Y.; Qiu, P.; Yan, G.] Sun Yat Sen Univ, Dept Pharmacol, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University	Yan, G (corresponding author), Sun Yat Sen Univ, Dept Pharmacol, Zhongshan Sch Med, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	ygm@mail.sysu.edu.cn		Lin, Yuan/0000-0002-7152-0965; Wu, Sihan/0000-0001-8329-7492	Key program, National Natural Science Foundation of China [30830111]; Guangzhou Scientific and Technological program [2008Z1-E561]; Guangdong Natural Science Foundation [S2011040004371]	Key program, National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Scientific and Technological program; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province)	This work was supported by Key program, National Natural Science Foundation of China (No. 30830111), Guangzhou Scientific and Technological program (No. 2008Z1-E561) and Guangdong Natural Science Foundation (No. S2011040004371).	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011; Bomben VC, 2010, GLIA, V58, P1145, DOI 10.1002/glia.20994; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Girard M, 2008, J HEPATOL, V48, P648, DOI 10.1016/j.jhep.2008.01.019; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Hsu SD, 2008, NUCLEIC ACIDS RES, V36, pD165, DOI 10.1093/nar/gkm1012; Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714; Kim H, 2009, MOL CELL, V36, P487, DOI 10.1016/j.molcel.2009.09.030; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kumar B, 2001, IN VITRO CELL DEV-AN, V37, P259; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li KKW, 2009, HUM PATHOL, V40, P1234, DOI 10.1016/j.humpath.2009.02.003; Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105; Lim M, 2010, LAB INVEST, V90, P222, DOI 10.1038/labinvest.2009.128; Liu ZP, 2009, BBA-MOL CELL RES, V1793, P1819, DOI 10.1016/j.bbamcr.2009.09.012; Malzkorn B, 2010, BRAIN PATHOL, V20, P539, DOI 10.1111/j.1750-3639.2009.00328.x; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Masuda A, 2001, J BIOL CHEM, V276, P26107, DOI 10.1074/jbc.M011475200; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Nahreini P, 2003, CELL MOL NEUROBIOL, V23, P27, DOI 10.1023/A:1022541017085; Navarro A, 2009, BLOOD, V114, P2945, DOI 10.1182/blood-2009-02-204842; Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011; Rebholz-Schuhmann D, 2007, BIOINFORMATICS, V23, pE237, DOI 10.1093/bioinformatics/btl302; Ritchie W, 2010, BIOINFORMATICS, V26, P223, DOI 10.1093/bioinformatics/btp649; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Sun YX, 2005, EXP CELL RES, V306, P85, DOI 10.1016/j.yexcr.2005.02.012; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wurster AL, 2002, J BIOL CHEM, V277, P27169, DOI 10.1074/jbc.M201207200; Yang SX, 2006, CANCER RES, V66, P4285, DOI 10.1158/0008-5472.CAN-05-4456; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zhang WJ, 2008, CYTOKINE, V42, P39, DOI 10.1016/j.cyto.2008.01.016; Zhang Y, 2009, J MOL MED, V87, P43, DOI 10.1007/s00109-008-0403-6	38	71	75	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	34					3866	3874		10.1038/onc.2011.551	http://dx.doi.org/10.1038/onc.2011.551			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139076				2022-12-17	WOS:000307925000004
J	Jean, C; Gravelle, P; Fournie, JJ; Laurent, G				Jean, C.; Gravelle, P.; Fournie, J-J; Laurent, G.			Influence of stress on extracellular matrix and integrin biology	ONCOGENE			English	Review						stress; ECM; integrin biology; remodeling; cellular response	MEDIATED DRUG-RESISTANCE; FOCAL ADHESION KINASE; ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; CARCINOMA CELL INVASION; HUMAN-ENDOTHELIAL-CELLS; HAIRLESS MOUSE SKIN; GENE-EXPRESSION; IN-VITRO; TUMOR-CELLS	Dynamic interactions between cells and extracellular matrix (ECM) through integrins influence most cellular functions. Normal cells, but even more, tumor cells are subjected to different forms of stress, including ischemia, radical oxygen species production, starvation, mechanical stress or genotoxic insults due to anti-cancer drugs or irradiation. In these situations, an adaptative cellular response occurs, integrating a complex network of intracellular signaling modules, which, depending on stress intensity, may result to either damage repair followed by complete restitution of cellular functions, or programmed cell death. Because of its implication in oncogenesis and anti-cancer therapy, cellular stress response has been thoroughly investigated. However, most of these studies have been performed in the context of isolated cells without taking into consideration that most cells are part of the tissue within which they interact with ECM through integrin. Few studies have described the influence of stress on cell-to-ECM interaction. However, one can speculate that, in these conditions, cells could functionally interact with protein microenvironment either to create positive interactions to survive (for example by facilitating protective pathways) or negative interaction to die (for example by facilitating detachment). In this review, we summarize the knowledge relative to the influence of different stress modalities on ECM remodeling, integrin expression and/or function modifications, and possible functional consequences, independently from the cellular model as these findings came from a large variety of cells (mesenchymal, endothelial, muscular, epithelial and glandular) and fields of application (cancer, vascular biology and tissue engineering). Most studies support the general notion that non-lethal stress favors ECM stiffness, integrin activation and enhanced survival. This field opens large perspectives not only in tumor biology but also in anti-cancer therapy by targeting one or several steps of the integrin-mediated signaling pathway, including integrin ligation, or activation of integrin-linked enzymes or integrin adaptors. Oncogene (2011) 30, 2697-2706; doi: 10.1038/onc.2011.27; published online 21 February 2011	[Jean, C.] CHU Purpan, INSERM, CPTP, UMR1037,Canc Res Ctr Toulouse, F-31024 Toulouse, France; [Jean, C.; Gravelle, P.; Fournie, J-J; Laurent, G.] Univ Toulouse, Toulouse, France; [Laurent, G.] CHU Purpan, Serv Hematol, F-31024 Toulouse, France; [Jean, C.; Gravelle, P.; Fournie, J-J; Laurent, G.] CNRS ERL, Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; CHU de Toulouse; Centre National de la Recherche Scientifique (CNRS)	Jean, C (corresponding author), CHU Purpan, INSERM, CPTP, UMR1037,Canc Res Ctr Toulouse, Pavillon Lefebvre Bat B,Pl Dr Baylac,BP 3028, F-31024 Toulouse, France.	christine.jean@inserm.fr	jean, christine/P-2920-2014; Fournie, Jean-Jacques/J-7805-2013; GRAVELLE, PAULINE/D-1405-2015	jean, christine/0000-0002-6936-289X; Fournie, Jean-Jacques/0000-0001-6542-6908; GRAVELLE, PAULINE/0000-0002-0462-5652				Beinke C, 2003, INT J RADIAT BIOL, V79, P721, DOI 10.1080/09553000310001610231; Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Blaschke F, 2002, BIOCHEM BIOPH RES CO, V296, P890, DOI 10.1016/S0006-291X(02)02033-8; BOYER B, 1992, J PHOTOCH PHOTOBIO B, V14, P247, DOI 10.1016/1011-1344(92)85102-Z; Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Casanova I, 2008, INT J CANCER, V123, P217, DOI 10.1002/ijc.23516; Case D, 2007, AM J PHYSIOL-LUNG C, V292, pL154, DOI 10.1152/ajplung.00192.2006; Cha MC, 2010, CELL BIOL INT, V34, P587, DOI 10.1042/CBI20090096; Cheng JCH, 2006, ONCOGENE, V25, P7009, DOI 10.1038/sj.onc.1209706; Chiarugi P, 2008, IUBMB LIFE, V60, P301, DOI 10.1002/iub.45; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Dahl KDC, 2005, MOL BIOL CELL, V16, P1901; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; De Croos JNA, 2010, J ORTHOP RES, V28, P921, DOI 10.1002/jor.21064; De Toni F, 2006, ONCOGENE, V25, P3113, DOI 10.1038/sj.onc.1209346; De Toni-Costes F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009807; Demou ZN, 2010, ANN BIOMED ENG, V38, P3509, DOI 10.1007/s10439-010-0097-0; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; DiDonato A, 1997, NEPHRON, V76, P192, DOI 10.1159/000190168; Duensing S, 1996, INVAS METAST, V16, P65; Eckes B, 2006, J INVEST DERM SYMP P, V11, P66, DOI 10.1038/sj.jidsymp.5650003; Estrugo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000269; Fouquet S, 2004, J BIOL CHEM, V279, P43061, DOI 10.1074/jbc.M405095200; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Ghosh S, 2005, J CELL PHYSIOL, V204, P522, DOI 10.1002/jcp.20320; Gong LM, 2004, LIFE SCI, V74, P1225, DOI 10.1016/j.lfs.2003.07.046; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hannafin JA, 2006, J ORTHOP RES, V24, P149, DOI 10.1002/jor.20018; Hazane F, 2005, J PHOTOCH PHOTOBIO B, V79, P171, DOI 10.1016/j.jphotobiol.2005.02.001; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hernandez-Pigeon H, 2006, J BIOL CHEM, V281, P13525, DOI 10.1074/jbc.M512694200; Hernandez-Pigeon H, 2007, J BIOL CHEM, V282, P8157, DOI 10.1074/jbc.M607436200; Hofmann C, 2007, GASTROENTEROLOGY, V132, P587, DOI 10.1053/j.gastro.2006.11.017; Horino Y, 2002, LIFE SCI, V71, P3031, DOI 10.1016/S0024-3205(02)02142-2; Horning JL, 2008, MOL PHARMACEUT, V5, P849, DOI 10.1021/mp800047v; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hoyt DG, 1996, CANCER RES, V56, P4146; Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; Iovine B, 2009, BIOCHIMIE, V91, P364, DOI 10.1016/j.biochi.2008.10.017; Ise K, 2004, TRANSPL P, V36, P1183, DOI 10.1016/j.transproceed.2004.04.029; Ishikawa J, 2005, HYPERTENS RES, V28, P995, DOI 10.1291/hypres.28.995; Janig E, 2007, AM J PATHOL, V171, P1474, DOI 10.2353/ajpath.2007.061064; Jean C, 2009, CANCER RES, V69, P3291, DOI 10.1158/0008-5472.CAN-08-1909; Jikko A, 1996, RADIAT RES, V146, P93, DOI 10.2307/3579401; Katsumi A, 2005, J BIOL CHEM, V280, P16546, DOI 10.1074/jbc.C400455200; Keely S, 2009, FASEB J, V23, P1338, DOI 10.1096/fj.08-125344; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Kim SH, 2010, CANCER RES, V70, P4054, DOI 10.1158/0008-5472.CAN-09-2110; Kizaki K, 2006, PHARMACOL RES, V53, P341, DOI 10.1016/j.phrs.2006.01.001; Kligman LH, 1999, PHOTODERMATOL PHOTO, V15, P198, DOI 10.1111/j.1600-0781.1999.tb00085.x; KLIGMAN LH, 1989, J INVEST DERMATOL, V93, P210, DOI 10.1111/1523-1747.ep12277573; Kock LM, 2009, J BIOMECH, V42, P2177, DOI 10.1016/j.jbiomech.2009.05.039; Koike T, 2004, P NATL ACAD SCI USA, V101, P8132, DOI 10.1073/pnas.0402088101; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Kozlova NI, 2004, BIOCHEM BIOPH RES CO, V316, P1173, DOI 10.1016/j.bbrc.2004.03.004; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lahiji K, 2004, IN VITRO CELL DEV-AN, V40, P138, DOI 10.1290/1543-706X(2004)40<138:CSSPCA>2.0.CO;2; LAMBERT CA, 1992, LAB INVEST, V66, P444; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Lee SH, 2011, J CELL PHYSIOL, V226, P484, DOI 10.1002/jcp.22358; Lee SH, 2009, CARCINOGENESIS, V30, P1997, DOI 10.1093/carcin/bgp233; Liang Y, 2001, EUR J CANCER, V37, P1041, DOI 10.1016/S0959-8049(01)00086-7; Lugo-Martinez VH, 2009, AM J PHYSIOL-GASTR L, V296, pG235, DOI 10.1152/ajpgi.90313.2008; Matsunaga T, 2008, LEUKEMIA, V22, P353, DOI 10.1038/sj.leu.2405017; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Milner R, 2008, MOL CELL NEUROSCI, V38, P43, DOI 10.1016/j.mcn.2008.01.013; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Miyazaki Y, 2008, INT J ONCOL, V32, P145; Miyoshi A, 2006, INT J ONCOL, V29, P1533; Monferran S, 2008, INT J CANCER, V123, P357, DOI 10.1002/ijc.23498; Moore SW, 2010, DEV CELL, V19, P194, DOI 10.1016/j.devcel.2010.07.018; Munoz J, 2010, J CELL PHYSIOL, V222, P111, DOI 10.1002/jcp.21927; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Muszynska A, 2001, EUR J PHARMACOL, V411, P17, DOI 10.1016/S0014-2999(00)00847-5; Myllyharju J, 2010, CELL TISSUE RES, V339, P19, DOI 10.1007/s00441-009-0841-7; Neitmann M, 1999, BRIT J DERMATOL, V141, P794, DOI 10.1046/j.1365-2133.1999.03151.x; Netti PA, 2000, CANCER RES, V60, P2497; Noborio-Hatano K, 2009, ONCOGENE, V28, P231, DOI 10.1038/onc.2008.385; Orr AW, 2006, MOL BIOL CELL, V17, P4686, DOI 10.1091/mbc.E06-04-0289; Oswald J, 2006, STEM CELLS, V24, P494, DOI 10.1634/stemcells.2005-0276; Provenzano PP, 2009, ONCOGENE, V28, P4326, DOI 10.1038/onc.2009.299; Quan TH, 2004, AM J PATHOL, V165, P741, DOI 10.1016/S0002-9440(10)63337-8; REPESH LA, 1993, CLIN EXP METASTAS, V11, P91, DOI 10.1007/BF00880070; Rohwer N, 2008, CANCER RES, V68, P10113, DOI 10.1158/0008-5472.CAN-08-1839; Salo S, 2009, INT J CANCER, V125, P1814, DOI 10.1002/ijc.24532; SASAKI T, 1987, J CLIN INVEST, V80, P1735, DOI 10.1172/JCI113265; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood-2003-12-4218; SCHUETZ JD, 1993, CELL GROWTH DIFFER, V4, P31; Schwartz MA, 2008, CURR OPIN CELL BIOL, V20, P551, DOI 10.1016/j.ceb.2008.05.005; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Skuli N, 2009, CANCER RES, V69, P3308, DOI 10.1158/0008-5472.CAN-08-2158; Song JH, 2009, INT J CANCER, V125, P1074, DOI 10.1002/ijc.24386; Sood AK, 2010, J CLIN INVEST, V120, P1515, DOI 10.1172/JCI40802; StCroix B, 1996, NAT MED, V2, P1204; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Ta HQ, 2008, CANCER RES, V68, P8796, DOI 10.1158/0008-5472.CAN-08-2426; Takahashi I, 2003, EUR J CELL BIOL, V82, P182, DOI 10.1078/0171-9335-00307; Tanjoni I, 2010, CANCER BIOL THER, V9, P764, DOI 10.4161/cbt.9.10.11434; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Thao LB, 2009, CANCER BIOL THER, V8, P683, DOI 10.4161/cbt.8.8.7779; Ulrich TA, 2009, CANCER RES, V69, P4167, DOI 10.1158/0008-5472.CAN-08-4859; van Nimwegen MJ, 2006, MOL PHARMACOL, V70, P1330, DOI 10.1124/mol.106.026195; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Verhaar R, 2008, BLOOD, V112, P4935, DOI 10.1182/blood-2008-04-151043; Walsh C, 2010, CANCER BIOL THER, V9, P778, DOI 10.4161/cbt.9.10.11433; Walton HL, 2000, J CELL BIOCHEM, V78, P674, DOI 10.1002/1097-4644(20000915)78:4<674::AID-JCB16>3.0.CO;2-G; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Weber LM, 2008, TISSUE ENG PT A, V14, P1959, DOI 10.1089/ten.tea.2007.0238; Wen HA, 2009, INT WOUND J, V6, P149, DOI 10.1111/j.1742-481X.2009.00591.x; Westhoff MA, 2008, ONCOGENE, V27, P5169, DOI 10.1038/onc.2008.148; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Yao J, 2009, INT J MOL MED, V24, P153, DOI 10.3892/ijmm_00000218; Zamir E, 2001, J CELL SCI, V114, P3583	123	71	78	3	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2697	2706		10.1038/onc.2011.27	http://dx.doi.org/10.1038/onc.2011.27			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21339741				2022-12-17	WOS:000291678500001
J	Vinnedge, LMP; McClaine, R; Wagh, PK; Wikenheiser-Brokamp, KA; Waltz, SE; Wells, SI				Vinnedge, L. M. Privette; McClaine, R.; Wagh, P. K.; Wikenheiser-Brokamp, K. A.; Waltz, S. E.; Wells, S. I.			The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer	ONCOGENE			English	Article						DEK; breast cancer; metastasis; beta-catenin; cancer stem cells	PROTOONCOGENE PROTEIN DEK; HUMAN-PAPILLOMAVIRUS E7; STEM-CELLS; EXPRESSION SIGNATURE; IDENTIFICATION; CHROMATIN; BINDING; DNA; CARCINOGENESIS; RETINOBLASTOMA	Breast cancer is a major cause of cancer-related deaths in American women; therefore, the identification of novel breast cancer-related molecules for the discovery of new markers and drug targets remains essential. The human DEK gene, which encodes a chromatin-binding protein and DNA topology regulator, is upregulated in many types of cancer. DEK has been implicated as an oncogene in breast cancer based on mRNA expression studies, but its functional significance in breast cancer growth and progression has not yet been tested directly. We demonstrate that DEK is highly expressed in breast cancer cells compared with normal tissue, and functionally important for cellular growth, invasion and mammosphere formation. DEK overexpression in non-tumorigenic MCF10A cells resulted in increased growth and motility, with a concomitant downregulation of E-cadherin. Conversely, DEK knockdown in MCF7 and MDA-MB-468 breast cancer cells resulted in decreased growth and motility with upregulation of E-cadherin. The use of DEK-proficient and -deficient breast cancer cells in orthotopic xenografts provided further in vivo evidence that DEK contributes to tumor growth. Activation of the beta-catenin signaling pathway is important for normal and cancer stem cell character, growth and metastasis. We show that DEK expression stimulated, and DEK knockdown repressed beta-catenin nuclear translocation and activity. Importantly, the expression of constitutively active beta-catenin rescued breast cancer invasion defects of DEK knockdown cells. Together, our data indicate that DEK expression stimulates the growth, stem cell character and motility of breast cancer cells, and that DEK-dependent cellular invasion occurs at least in part via beta-catenin activation. Oncogene (2011) 30, 2741-2752; doi: 10.1038/onc.2011.2; published online 14 February 2011	[Vinnedge, L. M. Privette; Wells, S. I.] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Dept Hematol, Cincinnati, OH 45229 USA; [Vinnedge, L. M. Privette; Wells, S. I.] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Dept Oncol, Cincinnati, OH 45229 USA; [McClaine, R.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; [Wagh, P. K.; Waltz, S. E.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH USA; [Wikenheiser-Brokamp, K. A.] Cincinnati Childrens Hosp Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Wells, SI (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Dept Hematol, TCHRF Room S7-206,MLC 7013,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Susanne.Wells@cchmc.org	Vinnedge, Lisa Privette/H-5869-2019	Vinnedge, Lisa Privette/0000-0003-2087-4920	NIH [AR-47363]; National Cancer Institute [F32CA139931, T32HL091805]; Public Health Service [CA116316, CA100002, HL079193]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	We thank Yi Zheng for critical evaluation of this manuscript. We also thank James Lessard, Aaron Zorn, Jose Cancelas, James Mulloy and James Wells for reagents and discussion, Gerard Grosveld for Dek knockout mice, Gina Kavanaugh for the immortalized Dek wild-type and knockout mouse embryonic fibroblasts and the Viral Vector Core at CCHMC. We would like to acknowledge the assistance of the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center, supported in part by NIH AR-47363. This research was supported by Kirschstein National Research Service Awards (NRSA) F32CA139931 and T32HL091805 from the National Cancer Institute (L.M.P.V.), and Public Health Service grants CA116316 (S.I.W.), CA100002 (S.E.W.), and HL079193 (K. W-B.)	Abba MC, 2007, MOL CANCER RES, V5, P881, DOI 10.1158/1541-7786.MCR-07-0055; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alexiadis V, 2000, GENE DEV, V14, P1308; Allan AL, 2006, AM J PATHOL, V169, P233, DOI 10.2353/ajpath.2006.051152; American Cancer Society [ACS], 2009, BREAST CANC FACTS FI; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988; Bowles E, 2007, GENE CHROMOSOME CANC, V46, P118, DOI 10.1002/gcc.20383; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Carro MS, 2006, CELL CYCLE, V5, P1202, DOI 10.4161/cc.5.11.2801; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dontu G, 2005, STEM CELL REV, V1, P207, DOI 10.1385/SCR:1:3:207; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Kappes F, 2008, MOL CELL BIOL, V28, P3245, DOI 10.1128/MCB.01921-07; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Kondoh N, 1999, CANCER RES, V59, P4990; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lu ZL, 2005, WORLD J GASTROENTERO, V11, P3850; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Soares LMM, 2006, SCIENCE, V312, P1961, DOI 10.1126/science.1128659; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Prahalad P, 2004, AM J PHYSIOL-CELL PH, V286, pC693, DOI 10.1152/ajpcell.00124.2003; Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ribeiro-Silva A, 2003, ARCH PATHOL LAB MED, V127, P336; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Sammons M, 2006, J BIOL CHEM, V281, P26802, DOI 10.1074/jbc.M600915200; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shibata T, 2010, ONCOGENE, V29, P4671, DOI 10.1038/onc.2010.217; SOULE HD, 1990, CANCER RES, V50, P6075; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tubiana M, 1999, ACTA ONCOL, V38, P295; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Waldmann T, 2004, GENE, V343, P1, DOI 10.1016/j.gene.2004.08.029; Waldmann T, 2003, NUCLEIC ACIDS RES, V31, P7003, DOI 10.1093/nar/gkg864; Waldmann T, 2002, J BIOL CHEM, V277, P24988, DOI 10.1074/jbc.M204045200; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	52	71	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2741	2752		10.1038/onc.2011.2	http://dx.doi.org/10.1038/onc.2011.2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21317931	Green Accepted			2022-12-17	WOS:000291678500005
J	Deng, R; Tang, J; Ma, JG; Chen, SP; Xia, LP; Zhou, WJ; Li, DD; Feng, GK; Zeng, YX; Zhu, XF				Deng, R.; Tang, J.; Ma, J-G; Chen, S-P; Xia, L-P; Zhou, W-J; Li, D-D; Feng, G-K; Zeng, Y-X; Zhu, X-F			PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation	ONCOGENE			English	Article						Akt; Mre11; DSB repair; ionizing radiation	STRAND-BREAK REPAIR; DNA-REPAIR; HISTONE H2AX; SIGNALING PATHWAY; CERVICAL-CANCER; COLON-CANCER; TUMOR-CELLS; KINASE-B; INHIBITION; COMPLEX	An elevated DNA-repair capacity in cancer cells leads to radiation resistance and severely limits the efficacy of radiation therapy. Activation of Akt is tightly associated with resistance to radiotherapy, and Mre11 protein has important role during the repair of DNA double-strand breaks (DSBs). In this report, our results showed that inhibition of Akt activity impaired the repair of DSBs in CNE2 cells, whereas activated Akt promoted the repair of DSBs in HeLa cells. Knockdown of Mre11 also impaired the process of DSB repair in both these two cell lines. More importantly, we found that Akt could regulate Mre11 expression. Inhibition of Akt activity by small interfering RNA or LY294002 efficiently downregulated the Mre11 expression in CNE2 cells, and transfection with myr-Akt plasmid in HeLa cells upregulated the Mre11 expression. In addition, luciferase reporter analysis revealed that Mre11 reporter activity increased after transfection with myr-Akt1 plasmids, and this myr-Akt1-induced transcriptional activity was blocked in the presence of LY294002. Further study showed GSK3 beta/beta-catenin/LEF-1 pathway was involved in this regulation. Knockdown of beta-catenin or LEF-1 led to the downregulation of Mre11, whereas overexpression of beta-catenin led to upregulation of Mre11. The chromatin immuno-precipitation assay assay showed beta-catenin/LEF-1 heterodimer could directly bind to the promoter of Mre11 in vivo. And the luciferase activity of the pGL3-Mre11 and pGL3-Lef increased in HeLa cells following beta-catenin plasmid co-transfected, but was abolished when the LEF-1- binding conserved sequences of Mre11 promoter were mutated. These results together support Akt can upregulate the expression of Mre11 through GSK3 beta/ beta-catenin/LEF pathway to elevate DSB-repair capacity in cancer cells. Oncogene (2011) 30, 944-955; doi:10.1038/onc.2010.467; published online 18 October 2010	[Deng, R.; Tang, J.; Ma, J-G; Chen, S-P; Xia, L-P; Zhou, W-J; Li, D-D; Feng, G-K; Zeng, Y-X; Zhu, X-F] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	zhuxfeng@mail.sysu.edu.cn			National Significant New Drug Creation [2008ZX09312-002]; 863 program [2006AA02A404]; National Nature Science Foundation of China [81001446]; Medical Scientific Research Foundation of Guangdong province [B2008059]	National Significant New Drug Creation; 863 program(National High Technology Research and Development Program of China); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Scientific Research Foundation of Guangdong province	We thank Professor Bert Vogelstein from the Howard Hughes Medical Institute Research Laboratory Sidney Kimmel Comprehensive Cancer Center for providing us with the beta-catenin plasmid (wild type). This work was supported by grants from Major science and technology project of 'National Significant New Drug Creation' (2008ZX09312-002), 863 program (2006AA02A404), the National Nature Science Foundation of China (81001446), and Medical Scientific Research Foundation of Guangdong province (B2008059).	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Banath JP, 2003, CANCER RES, V63, P4347; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Borde V, 2009, INT J BIOCHEM CELL B, V41, P1249, DOI 10.1016/j.biocel.2008.12.013; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Brognard J, 2001, CANCER RES, V61, P3986; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deng R, 2006, ONCOGENE, V25, P7070, DOI 10.1038/sj.onc.1209686; Deng R, 2009, MOL CANCER THER, V8, P873, DOI 10.1158/1535-7163.MCT-08-1080; Deng YB, 2009, NATURE, V460, P914, DOI 10.1038/nature08196; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding J, 2006, TRENDS PHARMACOL SCI, V27, P338, DOI 10.1016/j.tips.2006.04.007; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; HE X, 2007, LETT BIOTECHNOL, V18, P978; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim IA, 2005, CANCER RES, V65, P7902, DOI 10.1158/0008-5472.CAN-05-0513; Kim TJ, 2006, BRIT J CANCER, V94, P1678, DOI 10.1038/sj.bjc.6603180; Lee CM, 2006, CLIN CANCER RES, V12, P250, DOI 10.1158/1078-0432.CCR-05-1084; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Pitts SA, 2001, HUM MOL GENET, V10, P1155, DOI 10.1093/hmg/10.11.1155; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Takahashi-Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Williams RS, 2008, CELL, V135, P97, DOI 10.1016/j.cell.2008.08.017; Williams RS, 2007, BIOCHEM CELL BIOL, V85, P509, DOI 10.1139/O07-069; Wu Y, 2007, NAT STRUCT MOL BIOL, V14, P832, DOI 10.1038/nsmb1286	42	71	73	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					944	955		10.1038/onc.2010.467	http://dx.doi.org/10.1038/onc.2010.467			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20956948				2022-12-17	WOS:000287695900006
J	Sheridan, C; Brumatti, G; Elgendy, M; Brunet, M; Martin, SJ				Sheridan, C.; Brumatti, G.; Elgendy, M.; Brunet, M.; Martin, S. J.			An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs	ONCOGENE			English	Article						apoptosis; cisplatin; Noxa; BH3-only; ERK; Ras	CISPLATIN-INDUCED APOPTOSIS; BH3-ONLY PROTEINS; MITOCHONDRIAL APOPTOSIS; PROTEASOME INHIBITION; SIGNALING PATHWAY; BCL-2 FAMILY; HL-60 CELLS; CANCER; ACTIVATION; BIM	Cisplatin is a widely used cancer chemotherapeutic that promotes DNA damage-associated apoptosis. Although platinum compounds are known to form DNA adducts and provoke DNA damage, the molecular mechanism of cisplatin-induced cell death remains unclear. In this article, we show that the BH3-only protein Noxa is strongly transcriptionally upregulated in response to cisplatin and related platinum compounds. Cisplatin-induced Noxa expression was ERK dependent, but p53 independent, and inhibition of ERK activation markedly attenuated cisplatin-induced cell death, as well as Noxa expression. Furthermore, siRNA-mediated ablation of Noxa expression also inhibited cisplatin-induced cell death and permitted clonogenic survival. These observations reveal a novel ERK-regulated route to Noxa expression that is important for the cell killing activity of platinum-based chemotherapeutic drugs. Oncogene (2010) 29, 6428-6441; doi:10.1038/onc.2010.380; published online 30 August 2010	[Sheridan, C.; Brumatti, G.; Elgendy, M.; Brunet, M.; Martin, S. J.] Trinity Coll Dublin, Mol Cell Biol Lab, Dept Genet, Smurfit Inst, Dublin D2, Ireland	Trinity College Dublin	Martin, SJ (corresponding author), Trinity Coll Dublin, Mol Cell Biol Lab, Dept Genet, Smurfit Inst, Dublin D2, Ireland.	martinsj@tcd.ie		Martin, Seamus/0000-0002-8539-3143	Science Foundation Ireland [08/IN.1/B203]; Irish Cancer Society [CRP08MAR]; IRCSET	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Irish Cancer Society; IRCSET(Irish Research Council for Science, Engineering and Technology)	We thank Dr Julian Downward, Dr Richard Marais and Dr Maria Soengas for provision of Ras, B-Raf and Bax/Bak shRNA expression plasmids, respectively; Dr Eric Eldering for provision of shRNA constructs against Noxa and Mcl-1; Dr Dean Fennell for provision of H460 cells and for very useful discussions; Dr Yihong Ye for provision of shRNA constructs against ATF4 and Dr Hans van Dam for provision of shRNA constructs against Fra1 and ATF3. We thank Science Foundation Ireland (08/IN.1/B203) and The Irish Cancer Society (CRP08MAR) for support of this work. GB was supported, in part, by an IRCSET post-doctoral fellowship. CS was supported, in part, by an IRCSET PhD studentship. SJM is a Science Foundation Ireland Principal Investigator.	Adrain C, 2006, SCIENCE, V311, P785, DOI 10.1126/science.1124154; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Amran D, 2005, BBA-MOL CELL RES, V1743, P269, DOI 10.1016/j.bbamcr.2004.10.009; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOI SS, 1995, ONCOGENE, V11, P1693; Cosaert J, 2002, BRIT J CANCER, V87, P825, DOI 10.1038/sj.bjc.6600540; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gong JG, 1999, NATURE, V399, P806; Hao D, 2006, SEMIN RADIAT ONCOL, V16, P10, DOI 10.1016/j.semradonc.2005.08.002; Kim GP, 2007, EXPERT OPIN DRUG MET, V3, P281, DOI 10.1517/17425255.3.2.281; Kim H, 2009, MOL CELL, V36, P487, DOI 10.1016/j.molcel.2009.09.030; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kollmannsberger C, 2006, CANCER-AM CANCER SOC, V106, P1217, DOI 10.1002/cncr.21742; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; MARTIN SJ, 1990, CELL TISSUE KINET, V23, P545, DOI 10.1111/j.1365-2184.1990.tb01345.x; Muggia F, 2009, GYNECOL ONCOL, V112, P275, DOI 10.1016/j.ygyno.2008.09.034; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; O'Reilly LA, 2009, J IMMUNOL, V183, P261, DOI 10.4049/jimmunol.0803853; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pectasides D, 2008, CANCER TREAT REV, V34, P603, DOI 10.1016/j.ctrv.2008.05.006; Petit T, 2003, MOL CANCER THER, V2, P165; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Schimmer AD, 2008, CLIN CANCER RES, V14, P8295, DOI 10.1158/1078-0432.CCR-08-0999; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schweyer S, 2004, BRIT J CANCER, V91, P589, DOI 10.1038/sj.bjc.6601919; Sheridan C, 2008, J BIOL CHEM, V283, P22128, DOI 10.1074/jbc.M800271200; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; von Kriegsheim A, 2009, NAT CELL BIOL, V11, P1458, DOI 10.1038/ncb1994; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937	49	71	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6428	6441		10.1038/onc.2010.380	http://dx.doi.org/10.1038/onc.2010.380			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20802529				2022-12-17	WOS:000285138900003
J	Nogueira, C; Kim, KH; Sung, H; Paraiso, KHT; Dannenberg, JH; Bosenberg, M; Chin, L; Kim, M				Nogueira, C.; Kim, K-H; Sung, H.; Paraiso, K. H. T.; Dannenberg, J-H; Bosenberg, M.; Chin, L.; Kim, M.			Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis	ONCOGENE			English	Article						melanoma; PTEN; RAS; E-cadherin; AKT2; mouse model	TUMOR-SUPPRESSOR GENE; PTEN/MMAC1 ALTERATIONS; MALIGNANT-MELANOMA; BRAF MUTATIONS; UP-REGULATION; KINASE-B; BREAST; LEADS; INACTIVATION; NEOPLASIA	Mitogen-activated protein kinase (MAPK) and AKT pathways are frequently co-activated in melanoma through overexpression of receptor tyrosine kinases, mutations in their signaling surrogates, such as RAS and BRAF, or loss of negative regulators such as PTEN. As RAS can be a positive upstream regulator of PI3-K, it has been proposed that the loss of PTEN and the activation of RAS are redundant events in melanoma pathogenesis. Here, in genetically engineered mouse models of cutaneous melanomas, we sought to better understand the genetic interactions between HRAS activation and PTEN inactivation in melanoma genesis and progression in vivo. We showed that HRAS activation cooperates with Pten+/- and Ink4a/Arf-/- to increase melanoma penetrance and promote metastasis. Correspondingly, gain-and loss-of-function studies established that Pten loss increases invasion and migration of melanoma cells and non-transformed melanocytes, and such biological activity correlates with a shift to phosphorylation of AKT2 isoform and E-cadherin down-regulation. Thus, Pten inactivation can drive the genesis and promote the metastatic progression of RAS activated Ink4a/Arf deficient melanomas. Oncogene (2010) 29, 6222-6232; doi:10.1038/onc.2010.349; published online 16 August 2010	[Chin, L.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA; [Chin, L.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Nogueira, C.; Dannenberg, J-H; Chin, L.; Kim, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Nogueira, C.] Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP Med Fac, P-4100 Oporto, Portugal; [Kim, K-H; Sung, H.; Paraiso, K. H. T.; Kim, M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr,Mol Oncol Dept, Tampa, FL 33612 USA; [Bosenberg, M.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Universidade do Porto; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Vermont	Chin, L (corresponding author), Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, 44 Binney St, Boston, MA 02115 USA.	Lynda_Chin@dfci.harvard.edu; Minjung.Kim@moffitt.org	Nogueira, Cristina/N-4574-2015	Nogueira, Cristina/0000-0002-0853-5304; Kim, Minjung/0000-0002-5682-6640; KIM, KWAN HYUN/0000-0003-4975-2839	FCT [PRAXIS/BD/21794/99]; Claudia Adams Barr Program; Dermatology Foundation; Melanoma Research Foundation; Damon-Runyon Cancer Research Foundation; Dutch Cancer Society; NIH [UO1 CA84313, RO1 CA93947]; Bankhead Coley Pilot Research Award; American Cancer Society [93-032-13]; NATIONAL CANCER INSTITUTE [U01CA084313, R01CA093947] Funding Source: NIH RePORTER	FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Claudia Adams Barr Program; Dermatology Foundation; Melanoma Research Foundation; Damon-Runyon Cancer Research Foundation; Dutch Cancer Society(KWF Kankerbestrijding); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bankhead Coley Pilot Research Award; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	C Nogueira was supported by a fellowship from FCT (PRAXIS/BD/21794/99). M Kim was supported by the Claudia Adams Barr Program, the Dermatology Foundation, and Melanoma Research Foundation. JH Dannenberg was supported by Damon-Runyon Cancer Research Foundation and the Dutch Cancer Society. This work was supported by grants from the NIH (UO1 CA84313; RO1 CA93947) to L Chin and from the Bankhead Coley Pilot Research Award and American Cancer Society Institutional Research Grant (#93-032-13) to M Kim. We thank Dr Jin Q Cheng (Moffitt Cancer Center) for helpful discussion and adenoviruses for PTEN and DN-AKT2 expression, and Dr Ronald A DePinho for critical reading of this paper.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Arboleda MJ, 2003, CANCER RES, V63, P196; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Dhawan P, 2002, CANCER RES, V62, P7335; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Forbes SA, 2008, CURR PROTOC HUM GENE, V57, DOI DOI 10.11.1-10.11.26; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Guldberg P, 1997, CANCER RES, V57, P3660; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Ikeda T, 2000, ONCOL REP, V7, P567; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; JAFARI M, 1995, J CANCER RES CLIN, V121, P23, DOI 10.1007/BF01202725; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Lahtz C, 2010, J INVEST DERMATOL, V130, P620, DOI 10.1038/jid.2009.226; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stahl JM, 2003, CANCER RES, V63, P2881; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Sviderskaya EV, 1997, J INVEST DERMATOL, V108, P30, DOI 10.1111/1523-1747.ep12285621; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2000, CANCER RES, V60, P1800; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200	58	71	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6222	6232		10.1038/onc.2010.349	http://dx.doi.org/10.1038/onc.2010.349			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	21686270	Green Accepted			2022-12-17	WOS:000284601700004
J	Khodarev, N; Ahmad, R; Rajabi, H; Pitroda, S; Kufe, T; McClary, C; Joshi, MD; MacDermed, D; Weichselbaum, R; Kufe, D				Khodarev, N.; Ahmad, R.; Rajabi, H.; Pitroda, S.; Kufe, T.; McClary, C.; Joshi, M. D.; MacDermed, D.; Weichselbaum, R.; Kufe, D.			Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer	ONCOGENE			English	Article						MUC1; STAT1; breast cancer; IFN gamma; auto-inductive loop; inflammation	CARCINOMA-ASSOCIATED ANTIGEN; BETA-CATENIN; TRANSCRIPTION FACTOR; C-SRC; APOPTOTIC RESPONSE; GENE-TRANSCRIPTION; DNA-DAMAGE; CELLS; ACTIVATION; EXPRESSION	Signal transducer and activator of transcription 1 (STAT1) is activated in the inflammatory response to interferons. The MUC1 oncoprotein is overexpressed in human breast cancers. Analysis of genes differentially expressed in MUC1-transformed cells has identified a network linking MUC1 and STAT1 that is associated with cellular growth and inflammation. The results further show that the MUC1-C subunit associates with STAT1 in cells and the MUC1-C cytoplasmic domain binds directly to the STAT1 DNA-binding domain. The interaction between MUC1-C and STAT1 is inducible by IFN gamma in non-malignant epithelial cells and constitutive in breast cancer cells. Moreover, the MUC1-STAT1 interaction contributes to the activation of STAT1 target genes, including MUC1 itself. Analysis of two independent databases showed that MUC1 and STAT1 are coexpressed in about 15% of primary human breast tumors. Coexpression of MUC1 and the STAT1 pathway was found to be significantly associated with decreased recurrence-free and overall survival. These findings indicate that (i) MUC1 and STAT1 function in an auto-inductive loop, and (ii) activation of both MUC1 and the STAT1 pathway in breast tumors confers a poor prognosis for patients. Oncogene (2010) 29, 920 -929; doi:10.1038/onc.2009.391; published online 16 November 2009	[Ahmad, R.; Rajabi, H.; Kufe, T.; McClary, C.; Joshi, M. D.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Khodarev, N.; Pitroda, S.; MacDermed, D.; Weichselbaum, R.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098, CA111423]; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA111423] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA97098 and CA111423 awarded by the National Cancer Institute.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang L, 2003, CANCER BIOL THER, V2, P702; Khodarev NN, 2007, CANCER RES, V67, P9214, DOI 10.1158/0008-5472.CAN-07-1019; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Khodarev NN, 2003, GENOMICS, V81, P202, DOI 10.1016/S0888-7543(02)00042-3; Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100; Kimchi ET, 2005, CANCER RES, V65, P3146, DOI 10.1158/0008-5472.CAN-04-2490; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P10515; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	46	71	81	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					920	929		10.1038/onc.2009.391	http://dx.doi.org/10.1038/onc.2009.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915608	Green Accepted			2022-12-17	WOS:000274397800014
J	Blackburn, JS; Liu, I; Coon, CI; Brinckerhoff, CE				Blackburn, J. S.; Liu, I.; Coon, C. I.; Brinckerhoff, C. E.			A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis	ONCOGENE			English	Article						MMP-1; PAR-1; angiogenesis; superarray; xenograft	THROMBIN RECEPTOR; CELLS; EXPRESSION; PAR-1; GROWTH; PROGRESSION; INHIBITION; MECHANISMS; PROGNOSIS; SYSTEM	Hallmarks of malignant melanoma are its propensity to metastasize and its resistance to treatment, giving patients with advanced disease a poor prognosis. The transition of melanoma from non-invasive radial growth phase (RGP) to invasive and metastatically competent vertical growth phase (VGP) is a major step in tumor progression, yet the mechanisms governing this transformation are unknown. Matrix metalloproteinase-1 (MMP-1) is highly expressed by VGP melanomas, and is thought to contribute to melanoma progression by degrading type I collagen within the skin to facilitate melanoma invasion. Protease activated receptor-1 (PAR-1) is activated by MMP-1, and is also expressed by VGP melanomas. However, the effects of MMP-1 signaling through PAR-1 have not been examined in melanoma. Here, we demonstrate that an MMP-1/PAR-1 signaling axis exists in VGP melanoma, and is necessary for melanoma invasion. Introduction of MMP-1 into RGP melanoma cells induced gene expression associated with tumor progression and promoted invasion in vitro, and enhanced tumor growth and conferred metastatic capability in vivo. This study demonstrates that both the type I collagenase and PAR-1 activating functions of MMP-1 are required for melanoma progression, and suggests that MMP-1 may be a major contributor to the transformation of melanoma from non-invasive to malignant disease. Oncogene (2009) 28, 4237-4248; doi: 10.1038/onc.2009.272; published online 7 September 2009	[Blackburn, J. S.; Coon, C. I.; Brinckerhoff, C. E.] Dartmouth Med Sch, Dept Biochem, Lebanon, NH 03756 USA; [Liu, I.; Brinckerhoff, C. E.] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Dept Med, Lebanon, NH 03766 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Brinckerhoff, CE (corresponding author), Dartmouth Med Sch, Dept Med, 1 Med Ctr Dr,Rubin Bldg,HB 7936, Lebanon, NH 03756 USA.	brinckerhoff@dartmouth.edu		Blackburn, Jessica/0000-0001-9464-3784	NIH [CA-77267, AR-26599, T32-AI07363]; Friends of the Norris Cotton Cancer Center; NATIONAL CANCER INSTITUTE [P30CA023108, R01CA077267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R37AR026599] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Friends of the Norris Cotton Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Shaun Coughlin (University of California, San Francisco, CA, USA) for his generous gift of the AP-PAR-1 construct. This work was supported by NIH grants CA-77267 and AR-26599 (to CEB), NIH grant T32-AI07363 (to JSB) and the Prouty Pilot Grant by the Friends of the Norris Cotton Cancer Center (to CEB).	Agarwal A, 2008, MOL CANCER THER, V7, P2746, DOI 10.1158/1535-7163.MCT-08-0177; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Balch CM, 2004, CA-CANCER J CLIN, V54, P131, DOI 10.3322/canjclin.54.3.131; Berwick M, 2009, DERMATOL CLIN, V27, P205, DOI 10.1016/j.det.2008.12.002; Blackburn JS, 2007, CANCER RES, V67, P10849, DOI 10.1158/0008-5472.CAN-07-1791; Blackburn JS, 2008, AM J PATHOL, V173, P1736, DOI 10.2353/ajpath.2008.080512; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Clark W H Jr, 1975, Semin Oncol, V2, P83; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Depasquale I, 2008, HISTOPATHOLOGY, V52, P500, DOI 10.1111/j.1365-2559.2008.02978.x; DURKO M, 1998, BIOCHIM BIOPHYS ACTA, V1356, P271; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Fingleton B, 2006, FRONT BIOSCI-LANDMRK, V11, P479, DOI 10.2741/1811; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Haluska Frank G, 2006, Curr Oncol Rep, V8, P400, DOI 10.1007/s11912-006-0065-x; Hofmann UB, 2005, BIOCHIMIE, V87, P307, DOI 10.1016/j.biochi.2005.01.013; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Iida J, 2004, J INVEST DERMATOL, V122, P167, DOI 10.1046/j.0022-202X.2003.22114.x; Ishii Y, 2003, INT J CANCER, V103, P161, DOI 10.1002/ijc.10808; Leiter U, 2004, J SURG ONCOL, V86, P172, DOI 10.1002/jso.20079; Loffek S, 2005, J INVEST DERMATOL, V124, P638, DOI 10.1111/j.0022-202X.2005.23629.x; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Massi D, 2005, HUM PATHOL, V36, P676, DOI 10.1016/j.humpath.2005.04.008; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; Nikkola J, 2005, CLIN CANCER RES, V11, P5158, DOI 10.1158/1078-0432.CCR-04-2478; Ntayi C, 2001, EXP CELL RES, V270, P110, DOI 10.1006/excr.2001.5306; Ornstein DL, 2001, INT J HEMATOL, V73, P157, DOI 10.1007/BF02981932; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Salah Z, 2007, MOL CANCER RES, V5, P229, DOI 10.1158/1541-7786.MCR-06-0261; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Tellez CS, 2007, J INVEST DERMATOL, V127, P387, DOI 10.1038/sj.jid.5700539; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Villares GJ, 2008, CANCER RES, V68, P9078, DOI 10.1158/0008-5472.CAN-08-2397; Wyatt CA, 2005, CANCER RES, V65, P11101, DOI 10.1158/0008-5472.CAN-05-2446	41	71	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4237	4248		10.1038/onc.2009.272	http://dx.doi.org/10.1038/onc.2009.272			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19734937	Green Accepted			2022-12-17	WOS:000272876300002
J	Chen, CH; Chien, CY; Huang, CC; Hwang, CF; Chuang, HC; Fang, FM; Huang, HY; Chen, CM; Liu, HL; Huang, CYF				Chen, C-H; Chien, C-Y; Huang, C-C; Hwang, C-F; Chuang, H-C; Fang, F-M; Huang, H-Y; Chen, C-M; Liu, H-L; Huang, C-Y F.			Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity	ONCOGENE			English	Article						FLJ10540; migration; invasion; FOXM1; MMP-2	MATRIX METALLOPROTEINASE-2 TRANSCRIPTION; GENE-EXPRESSION; CANCER PROGRESSION; IV COLLAGENASE; TUMOR-GROWTH; LUNG-CANCER; ACTIVATION; PROTEIN; HEAD; NECK	Matrix metalloproteinase (MMP)-2 plays critical roles in tumor development and in the metastasis of multiple cancers, including human oral cavity squamous cell carcinoma (OCSCC). One of the upstream regulators of MMP-2 is FOXM1, which is overexpressed in a microarray dataset of OCSCC. It is interesting that FLJ10540 exhibits similar gene expression profiles with MMP-2 and FOXM1, raising the possibility that these molecules might participate in MMP-2-elicited cancer progression and metastasis of OCSCC. To examine this connection, we first showed that FLJ10540 was significantly overexpressed in OCSCC. A strong FLJ10540 expression was significantly correlated with an advanced tumor node metastasis stage and the cumulative 5-year survival rate. Thus, an elevated FLJ10540 expression is an indicator of poor survival. Functionally, FLJ10540 had the abilities to stimulate cell migration and invasion in oral cancer cells through increased FOXM1 and MMP-2 expressions. Conversely, the depletion of the FLJ10540 expression by small interefering RNAs suppressed the FOXM1 and MMP-2 protein expressions. The suppression of either FLJ10540 or FOXM1 could cause significant inhibition on cell migratory and invasive ability in oral cancer cells. Finally, the immunohistochemical and western blotting analyses of human aggressive OCSCC specimens showed a significant positive correlation among FLJ10540, FOXM1 and MMP-2 expressions. These findings suggest that FLJ10540 is not only an important prognostic factor but also a new therapeutic target in the FLJ10540/FOXM1/MMP-2 pathway for OCSCC treatment. Oncogene (2009) 28, 2723-2737; doi:10.1038/onc.2009.128; published online 15 June 2009	[Chen, C-H; Chien, C-Y; Hwang, C-F; Chuang, H-C; Liu, H-L] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Otolaryngol, Kaohsiung 833, Taiwan; [Chen, C-H; Chien, C-Y; Huang, C-C; Hwang, C-F; Chuang, H-C; Fang, F-M; Huang, H-Y; Chen, C-M; Liu, H-L] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Kaohsiung Chang Gung Head & Neck Oncol Grp, Kaohsiung, Taiwan; [Huang, C-C; Huang, H-Y; Chen, C-M] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Pathol, Kaohsiung 833, Taiwan; [Fang, F-M] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Radiat Oncol, Kaohsiung 833, Taiwan; [Huang, C-Y F.] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University	Chien, CY (corresponding author), Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Otolaryngol, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.	cychien3965@adm.cgmh.org.tw; cyhuang5@ym.edu.tw	Hwang, Chung-Feng/ABC-1138-2021; Huang, Chi-Ying/AAG-7672-2022; Huang, Chi-Ying/AFL-7729-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937; Chien, Chih-Yen/0000-0002-6690-6038	Chang Gung Memorial Hospital, Taiwan [CMRPG860512, CMRPG870281, CMRPG870282]; National Science Council [NSC97-2314-B182A-065, NSC97-2627-B-010-011, NSC97-3112-B-010-025-CC1]	Chang Gung Memorial Hospital, Taiwan(Chang Gung Memorial Hospital); National Science Council(Ministry of Science and Technology, Taiwan)	This work was supported by the grants from the Chang Gung Memorial Hospital, Taiwan ( grant numbers CMRPG860512, CMRPG870281, and CMRPG870282), and NSC97-2314-B182A-065 and in part by grants from NSC97-2627-B-010-011, NSC97-3112-B-010-025-CC1 ( National Science Council) and the Program for Promoting Academic Excellence of Universities ( National Yang Ming University) to Chi-Ying F Huang. We thank Dr Wen-Chun Hung, for providing the MMP-2 luciferase plasmids.	BEENKEN SW, 2003, CURRENT SURG DIAGNOS, P282; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Chandu A, 2006, J ORAL MAXIL SURG, V64, P495, DOI 10.1016/j.joms.2005.11.028; Chen CH, 2007, ONCOGENE, V26, P4272, DOI 10.1038/sj.onc.1210207; Chen CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005052; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Gao ZB, 2005, INT J MOL MED, V16, P599; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Hardisson D, 2003, EUR ARCH OTO-RHINO-L, V260, P502, DOI 10.1007/s00405-003-0581-3; Hong SD, 2000, ORAL ONCOL, V36, P207, DOI 10.1016/S1368-8375(99)00088-3; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jezierska A, 2009, MED SCI MONITOR, V15, pRA32; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kamat AA, 2006, CLIN CANCER RES, V12, P1707, DOI 10.1158/1078-0432.CCR-05-2338; Kato Y, 2006, ONCOL REP, V16, P1009; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lev DC, 2004, J CLIN ONCOL, V22, P2092, DOI 10.1200/JCO.2004.11.070; Lo WL, 2003, J ORAL MAXIL SURG, V61, P751, DOI 10.1016/S0278-2391(03)00149-6; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Martinez-Garay I, 2006, GENOMICS, V87, P243, DOI 10.1016/j.ygeno.2005.11.006; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Park MJ, 2002, CANCER RES, V62, P6318; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel BP, 2007, HEAD NECK-J SCI SPEC, V29, P564, DOI 10.1002/hed.20561; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Ruokolainen H, 2006, MODERN PATHOL, V19, P208, DOI 10.1038/modpathol.3800506; Ruokolainen H, 2004, CLIN CANCER RES, V10, P3110, DOI 10.1158/1078-0432.CCR-03-0530; Sakai M, 2006, ONCOGENE, V25, P480, DOI 10.1038/sj.onc.1209051; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sudbo J, 2005, INT J CANCER, V115, P339, DOI 10.1002/ijc.20896; Werner JA, 2002, CLIN EXP METASTAS, V19, P275, DOI 10.1023/A:1015531319087; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015	44	71	73	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2723	2737		10.1038/onc.2009.128	http://dx.doi.org/10.1038/onc.2009.128			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19525975				2022-12-17	WOS:000268452900003
J	Nakamura, H; Tanimoto, K; Hiyama, K; Yunokawa, M; Kawamoto, T; Kato, Y; Yoshiga, K; Poellinger, L; Hiyama, E; Nishiyama, M				Nakamura, H.; Tanimoto, K.; Hiyama, K.; Yunokawa, M.; Kawamoto, T.; Kato, Y.; Yoshiga, K.; Poellinger, L.; Hiyama, E.; Nishiyama, M.			Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2	ONCOGENE			English	Article						MLH1; DEC1; DEC2; hypoxia; HIF-1	TUMOR-SUPPRESSOR PROTEIN; MAMMALIAN-CELLS; DOWN-REGULATION; CANCER-THERAPY; EXPRESSION; LOOP; MICROENVIRONMENT; DEC1/STRA13; INSTABILITY; MECHANISMS	Tumor hypoxia has been reported to cause a functional loss in DNA mismatch repair (MMR) system as a result of downregulation of MMR genes, although the precise molecular mechanisms remain unclear. In this study, we focused on the downregulation of a key MMR gene, MLH1, and demonstrated that hypoxia-inducible transcription repressors, differentiated embryo chondrocytes (DEC1 and 2), participated in its transcriptional regulation via their bindings to E-box-like motif(s) in MLH1 promoter region. In all cancer cell lines examined, hypoxia increased expression of DEC1 and 2, known as hypoxia-inducible genes, but decreased MLH1 expression in an exposure time-dependent manner at both the mRNA and protein levels. Co-transfection reporter assay revealed that DEC1 and, to greater extent, DEC2 as well as hypoxia-repressed MLH1 promoter activity. We further found that the action was remarkably inhibited by trichostatin A, and identified a possible DEC-response element in the MLH1 promoter. In vitro electrophoretic gel mobility shift and chromatin immunoprecipitation assays demonstrated that DEC1 or 2 directly bounds to the suggested element, and transient transfection assay revealed that overexpression of DEC2 repressed endogenous MLH1 expression in the cells. Hypoxia-induced DEC may impair MMR function through repression of MLH1 expression, possibly via the histone deacethylase-mediated mechanism in cancer cells.	[Nakamura, H.; Tanimoto, K.; Hiyama, K.; Yunokawa, M.; Nishiyama, M.] Hiroshima Univ, Dept Translat Canc Res, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348551, Japan; [Kawamoto, T.; Kato, Y.] Hiroshima Univ, Dept Dent & Med Biochem, Hiroshima 7348551, Japan; [Yoshiga, K.] Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Oral Med & Maxillofacial Surg, Hiroshima 7348551, Japan; [Poellinger, L.] Karolinska Inst, Med Noble Inst, Stockholm, Sweden; [Nakamura, H.; Hiyama, E.] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima 7348551, Japan; [Nishiyama, M.] Saitama Med Univ, Int Med Ctr, Saitama, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Karolinska Institutet; Hiroshima University; Saitama Medical University	Tanimoto, K (corresponding author), Hiroshima Univ, Dept Translat Canc Res, Res Inst Radiat Biol & Med, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	ktanimo@hiroshima-u.ac.jp	, 河本健/D-7938-2015; Hiyama, Eiso/A-2013-2019; Keiji, Tanimoto/U-1839-2019	, 河本健/0000-0003-3337-1775; Hiyama, Eiso/0000-0001-9179-5037; Keiji, Tanimoto/0000-0003-4912-4197				Bindra RS, 2007, CANCER LETT, V252, P93, DOI 10.1016/j.canlet.2006.12.011; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; BINDRA RS, 2006, ONCOGENE, V26, P1; Brown JM, 1998, CANCER RES, V58, P1408; Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Ivanov SV, 2007, ONCOGENE, V26, P802, DOI 10.1038/sj.onc.1209842; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Kawamoto T, 2004, BIOCHEM BIOPH RES CO, V313, P117, DOI 10.1016/j.bbrc.2003.11.099; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Reynolds TY, 1996, CANCER RES, V56, P5754; Sato F, 2004, EUR J BIOCHEM, V271, P4409, DOI 10.1111/j.1432-1033.2004.04379.x; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tanimoto K, 2003, CARCINOGENESIS, V24, P1779, DOI 10.1093/carcin/bgg132; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Yuan JL, 2000, CANCER RES, V60, P4372; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4	30	71	73	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4200	4209		10.1038/onc.2008.58	http://dx.doi.org/10.1038/onc.2008.58			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345027	Green Submitted			2022-12-17	WOS:000257496800007
J	Stevens, FE; Beamish, H; Warrener, R; Gabrielli, B				Stevens, F. E.; Beamish, H.; Warrener, R.; Gabrielli, B.			Histone deacetylase inhibitors induce mitotic slippage	ONCOGENE			English	Article						HDACi; centromere; mitosis; aurora B	CHROMOSOMAL PASSENGER COMPLEX; CENTROMERE PROTEIN INCENP; AURORA-B; SPINDLE CHECKPOINT; CENP-E; MICROTUBULE-ATTACHMENT; TUMOR-CELLS; SURVIVIN; MITOSIS; PHOSPHORYLATION	Chromosomal passenger proteins have emerged as key players in the regulation of mitosis and cytokinesis. Histone deacetylase inhibitors (HDACi) are a class of anticancer drugs that induce aberrant mitosis and can overcome the spindle assembly checkpoint. Here, we investigate the mechanism by which HDACi disrupt normal mitotic progression and checkpoint function. We demonstrate that HDACi treatment temporarily delays mitotic progression through prometaphase due to activation of the spindle assembly checkpoint. Despite failing to congress chromosomes to the metaphase plate, cells aberrantly segregate their chromosomes and exit mitosis to undergo a failed cytokinesis. We show that this premature exit from mitosis is a form of mitotic slippage. Chromosomal passenger proteins fail to accumulate at the centromere following HDACi treatment. This results in inadequate concentrations of chromosomal passenger proteins at the centromere, which are insufficient to regulate the phosphorylation of the kinetochore checkpoint component BubR1, and an inability to maintain the mitotic arrest. Thus, the centromeric accumulation of chromosomal passenger complex components is critical for regulating kinetochore but not centromeric processes, and failure of this accumulation underlies the HDACi-induced mitotic slippage.	[Stevens, F. E.; Beamish, H.; Warrener, R.; Gabrielli, B.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Res Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Res Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia.	brianG@uq.edu.au	Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651; Stevens, Frankie/0000-0002-2556-473X				Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Aoyagi S, 2005, TRENDS CELL BIOL, V15, P565, DOI 10.1016/j.tcb.2005.09.003; Beardmore VA, 2004, J CELL SCI, V117, P4033, DOI 10.1242/jcs.01242; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Delacour-Larose M, 2004, CELL CYCLE, V3, P1418, DOI 10.4161/cc.3.11.1203; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dowling M, 2005, CANCER BIOL THER, V4, P197, DOI 10.4161/cbt.4.2.1441; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kelly AE, 2007, DEV CELL, V12, P31, DOI 10.1016/j.devcel.2006.11.001; Klein UR, 2006, MOL BIOL CELL, V17, P2547, DOI 10.1091/mbc.E05-12-1133; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Mao YH, 2005, J CELL BIOL, V170, P873, DOI 10.1083/jcb.200505040; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Morrow CJ, 2005, J CELL SCI, V118, P3639, DOI 10.1242/jcs.02487; Murata-Hori M, 2002, J CELL BIOL, V159, P45, DOI 10.1083/jcb.200207014; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Robbins AR, 2005, CELL CYCLE, V4, P717, DOI 10.4161/cc.4.5.1690; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	38	71	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1345	1354		10.1038/sj.onc.1210779	http://dx.doi.org/10.1038/sj.onc.1210779			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828304				2022-12-17	WOS:000253548200001
J	Cascio, S; Bartella, V; Auriemma, A; Johannes, GJ; Russo, A; Giordano, A; Surmacz, E				Cascio, S.; Bartella, V.; Auriemma, A.; Johannes, G. J.; Russo, A.; Giordano, A.; Surmacz, E.			Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1 alpha	ONCOGENE			English	Article						breast cancer; HIF; hyperinsulinemia; leptin	TRANSCRIPTION FACTOR; GENE-EXPRESSION; FACTOR-I; RECEPTOR; OBESITY; PROMOTER; ACTIVATION; INSULIN; HIF-1-ALPHA; PATHWAYS	We reported previously that the obesity hormone leptin is overexpressed in breast cancer biopsies. Here, we investigated molecular mechanisms involved in this process, focusing on conditions that are associated with obesity, that is, hyperinsulinemia and induction of hypoxia. By using quantitative real-time PCR, immunofluorescent detection of proteins and enzyme-linked immunosorbent assays, we found that treatment of MCF-7 breast cancer cells with high doses of insulin or the hypoxia-mimetic agent CoCl2, or culturing the cells under hypoxic conditions significantly increased the expression of leptin mRNA and protein. Notably, the greatest leptin mRNA and protein expression were observed under combined hyperinsulinemia and hypoxia or hypoxia-mimetic treatments. Luciferase reporter assays suggested that increased leptin synthesis could be related to the activation of the leptin gene promoter. DNA affinity precipitation and chromatin immunoprecipitation experiments revealed that insulin, CoCl2 and/or hypoxia treatments augmented nuclear accumulation of hypoxia-inducible factor-1 alpha ( HIF-1 alpha) and increased its interaction with several upstream leptin regulatory sequences, especially with the proximal promoter containing four hypoxia-response elements and three GC-rich regions. By using reverse chromatin precipitation, we determined that loading of HIF-1 alpha on the proximal leptin promoter concurred with the recruitment of p300, the major HIF coactivator, suggesting that the HIF/p300 complex is involved in leptin transcription. The importance of HIF-1 alpha in insulin- and CoCl2-activated leptin mRNA and protein expression was confirmed using RNA interference.	[Cascio, S.; Bartella, V.; Giordano, A.; Surmacz, E.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Cascio, S.; Russo, A.] Univ Palermo, Sect Med Oncol, Dept Surg & Oncol Sci, Palermo, Italy; [Bartella, V.] Univ Calabria, Dept PharmacoBiol, I-87036 Cosenza, Italy; [Auriemma, A.] Univ Verona, Dept Oncol, I-37100 Verona, Italy; [Johannes, G. J.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Palermo; University of Calabria; University of Verona; Drexel University	Surmacz, E (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, 1900 N,12th St,Room 446, Philadelphia, PA 19122 USA.	surmacz@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cascio, Sandra/0000-0003-4234-0508				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Calle EE, 2004, ONCOGENE, V23, P6365, DOI 10.1038/sj.onc.1207751; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; De Vos P, 1998, EUR J BIOCHEM, V253, P619, DOI 10.1046/j.1432-1327.1998.2530619.x; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eisenberg A, 2004, FEBS LETT, V565, P139, DOI 10.1016/j.febslet.2004.03.089; Garofalo C, 2006, CLIN CANCER RES, V12, P1447, DOI 10.1158/1078-0432.CCR-05-1913; Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472; Garofalo C, 2004, CLIN CANCER RES, V10, P6466, DOI 10.1158/1078-0432.CCR-04-0203; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Gonzalez RR, 2006, J BIOL CHEM, V281, P26320, DOI 10.1074/jbc.M601991200; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Grosfeld A, 2002, J BIOL CHEM, V277, P42953, DOI 10.1074/jbc.M206775200; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Klein S, 2002, GASTROENTEROLOGY, V123, P882, DOI 10.1053/gast.2002.35514; Losso JN, 2005, J AGR FOOD CHEM, V53, P3751, DOI 10.1021/jf0479719; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; Meissner U, 2003, BIOCHEM BIOPH RES CO, V303, P707, DOI 10.1016/S0006-291X(03)00401-7; Melzner I, 2002, J BIOL CHEM, V277, P45420, DOI 10.1074/jbc.M208511200; Miki N, 2004, J BIOL CHEM, V279, P15025, DOI 10.1074/jbc.M313186200; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Morelli C, 2004, ONCOGENE, V23, P7517, DOI 10.1038/sj.onc.1208014; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Porter GA, 2006, ANN SURG ONCOL, V13, P327, DOI 10.1245/ASO.2006.03.049; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Revillion F, 2006, CLIN CANCER RES, V12, P2088, DOI 10.1158/1078-0432.CCR-05-1904; Snoussi K, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-38; Surmacz E, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1638; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Wauters M, 2000, EUR J ENDOCRINOL, V143, P293, DOI 10.1530/eje.0.1430293; Zhong H, 1999, CANCER RES, V59, P5830	34	71	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					540	547		10.1038/sj.onc.1210660	http://dx.doi.org/10.1038/sj.onc.1210660			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653093				2022-12-17	WOS:000252426100014
J	Roses, RE; Xu, M; Koski, GK; Czerniecki, BJ				Roses, R. E.; Xu, M.; Koski, G. K.; Czerniecki, B. J.			Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer	ONCOGENE			English	Review						cancer; immunotherapy; Toll-like receptor; radiation	HUMAN DENDRITIC CELLS; ENHANCES TUMOR RESPONSE; TOTAL-BODY IRRADIATION; HEAT-SHOCK PROTEINS; CD8(+) T-CELLS; NF-KAPPA-B; IMMUNE-RESPONSE; GAMMA-IRRADIATION; MOUSE MODEL; MEDIATED REGRESSION	The identification of pathogen-associated molecular patterns, conserved microbial structures that act on Toll-like receptors, has led to a novel avenue of investigation aimed at developing a new generation of cancer immunotherapies. Ligation of Toll-like receptors results in the induction of robust immune responses that may be directed against tumor-associated antigens. Recent data suggest that such strategies may result in enhanced antitumor immunity. Nonetheless, as clinically effective immunotherapy for cancer remains a somewhat distant goal, attention has shifted toward multimodality approaches to cancer therapy, sometimes combining novel immune interventions and conventional treatments. The traditional view of radiation therapy as immunosuppressive has now been challenged, prompting a re-evaluation of its potential as an adjunct to immunotherapy. Radiation therapy can enhance the expression of tumor-associated antigens, induce immune-mediated targeting of tumor stroma, and diminish regulatory T cell activity. Recent evidence suggests that radiation therapy may also activate effectors of innate immunity through TLR-dependent mechanisms, thereby augmenting the adaptive immune response to cancer. In this paper, we will review evidence for enhanced tumor-directed immunity resulting from radiation exposure and early promising data suggesting synergistic effects of radiation and TLR-targeted immunotherapies.	[Roses, R. E.; Xu, M.; Czerniecki, B. J.] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Koski, G. K.] Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA	University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic Foundation	Czerniecki, BJ (corresponding author), Hosp Univ Penn, Dept Surg, 4 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	brian.czerniecki@uphs.upenn.edu			NCI NIH HHS [R01-CA096997-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acker JC, 1998, RADIAT RES, V149, P350, DOI 10.2307/3579697; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Ambach A, 2004, MOL IMMUNOL, V40, P1307, DOI 10.1016/j.molimm.2004.01.002; Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Bourquin C, 2006, INT J CANCER, V118, P2790, DOI 10.1002/ijc.21681; Cao MD, 2004, CELL BIOL INT, V28, P223, DOI 10.1016/j.cellbi.2003.12.006; Cao ZA, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-11; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; Chakravarty PK, 1999, CANCER RES, V59, P6028; Chakravarty PK, 2006, ONCOLOGY-BASEL, V70, P245, DOI 10.1159/000096288; Chiang CS, 2000, CANCER GENE THER, V7, P1172, DOI 10.1038/sj.cgt.7700217; COLE S, 1986, J INVEST DERMATOL, V87, P608, DOI 10.1111/1523-1747.ep12455853; Czerniecki BJ, 2007, CANCER RES, V67, P1842, DOI 10.1158/0008-5472.CAN-06-4038; Demaria S, 2005, CLIN CANCER RES, V11, P728; Demaria S, 2005, INT J RADIAT ONCOL, V63, P655, DOI 10.1016/j.ijrobp.2005.06.032; Demaria S, 2004, INT J RADIAT ONCOL, V58, P862, DOI 10.1016/j.ijrobp.2003.09.012; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; DUNN PL, 1991, J LEUKOCYTE BIOL, V49, P388, DOI 10.1002/jlb.49.4.388; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Hallahan DE, 1999, RADIAT RES, V152, P6, DOI 10.2307/3580044; Hallahan DE, 1998, CANCER RES, V58, P5216; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HAREYAMA M, 1991, CANCER, V67, P2269, DOI 10.1002/1097-0142(19910501)67:9<2269::AID-CNCR2820670910>3.0.CO;2-Z; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hashimoto S, 1999, RADIAT RES, V151, P717, DOI 10.2307/3580211; HAUSER SH, 1993, CANCER RES, V53, P1952; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hong JH, 1999, INT J RADIAT BIOL, V75, P1421, DOI 10.1080/095530099139287; Ina Y, 2005, INT J RADIAT BIOL, V81, P721, DOI 10.1080/09553000500519808; ISHIHARA H, 1995, J RADIAT RES, V36, P112, DOI 10.1269/jrr.36.112; JAMES RFL, 1989, TRANSPLANTATION, V47, P929, DOI 10.1097/00007890-198906000-00001; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kim KW, 2004, INT J CANCER, V109, P685, DOI 10.1002/ijc.20036; Kochling J, 2003, CLIN CANCER RES, V9, P3142; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Liao YP, 2004, J IMMUNOL, V173, P2462, DOI 10.4049/jimmunol.173.4.2462; Liu HM, 1998, BLOOD, V92, P3730, DOI 10.1182/blood.V92.10.3730.422k20_3730_3736; Lohr F, 2000, MOL THER, V2, P195, DOI 10.1006/mthe.2000.0114; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; Mason KA, 2005, CLIN CANCER RES, V11, P361; McBride WH, 2004, RADIAT RES, V162, P1, DOI 10.1667/RR3196; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Merrick A, 2005, BRIT J CANCER, V92, P1450, DOI 10.1038/sj.bjc.6602518; Milas L, 2004, CANCER RES, V64, P5074, DOI 10.1158/0008-5472.CAN-04-0926; Miller GM, 2003, ONCOLOGY-BASEL, V65, P229, DOI 10.1159/000074476; NEMOTO K, 1995, J RADIAT RES, V36, P125, DOI 10.1269/jrr.36.125; Nikitina EY, 2001, INT J CANCER, V94, P825, DOI 10.1002/1097-0215(20011215)94:6<825::AID-IJC1545>3.0.CO;2-5; NORTH RJ, 1986, J EXP MED, V164, P1652, DOI 10.1084/jem.164.5.1652; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Scheffer SR, 2003, INT J CANCER, V103, P205, DOI 10.1002/ijc.10777; SCHREIBER RD, 2004, CANC IMMUN S1, V5, P1; Seetharam S, 1999, INT J ONCOL, V15, P769; Shi YH, 2007, CANCER RES, V67, P1823, DOI 10.1158/0008-5472.CAN-06-2381; Shigematsu A, 2007, J RADIAT RES, V48, P51, DOI 10.1269/jrr.06048; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; WASSERMAN J, 1989, B NEW YORK ACAD MED, V65, P36; WEICHSELBAUM RR, 1994, CANCER RES, V54, P4266; Wesa A, 2007, J IMMUNOTHER, V30, P75, DOI 10.1097/01.cji.0000211316.15278.6e; Wrzesinski C, 2007, J CLIN INVEST, V117, P492, DOI 10.1172/JCI30414; Xu SW, 2006, SURGERY, V140, P170, DOI 10.1016/j.surg.2006.03.006; Xu SW, 2003, J IMMUNOL, V171, P2251, DOI 10.4049/jimmunol.171.5.2251; Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1084/jem.20062056	75	71	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					200	207		10.1038/sj.onc.1210909	http://dx.doi.org/10.1038/sj.onc.1210909			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176601				2022-12-17	WOS:000252163600006
J	Chen, CH; Lu, PJ; Chen, YC; Fu, SL; Wu, KJ; Tsou, AP; Lee, YCG; Lin, TCE; Hsu, SL; Lin, WJ; Huang, CYF; Chou, CK				Chen, C-H; Lu, P-J; Chen, Y-C; Fu, S-L; Wu, K-J; Tsou, A-P; Lee, Y-C G.; Lin, T-C E.; Hsu, S-L; Lin, W-J; Huang, C-Y F.; Chou, C-K			FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway	ONCOGENE			English	Article						HCC; PI3K interaction protein; PI3K/AKT	HUMAN HEPATOCELLULAR-CARCINOMA; 3-KINASE PATHWAY; BETA-CATENIN; AURORA-A; C-MYC; EXPRESSION; PROTEIN; GENE; CANCER; PHOSPHORYLATION	A significant challenge in the post-genomic era is how to prioritize differentially expressed and uncharacterized novel genes found in hepatocellular carcinoma (HCC) microarray profiling. One such category is cell cycle regulated genes that have only evolved in higher organisms but not in lower eukaryotic cells. Characterization of these genes may reveal some novel human cancer-specific abnormalities. A novel transcript, FLJ10540 was identified. FLJ10540 is overexpressed in HCC as examined by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. The patients with higher FLJ10540 expression had a poor survival than those with lower FLJ10540 expression. Functional characterization indicates that FLJ10540 displays a number of characteristics associated with an oncogene, including anchorage-independent growth, enhanced cell growth at low serum levels and induction of tumorigenesis in nude mice. FLJ10540-elicited cell transformation is mediated by activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway. Moreover, FLJ10540 forms a complex with PI3K and can activate PI3K activity, which provides a mechanistic basis for FLJ10540-mediated oncogenesis. Together, using a combination of bioinformatics searches and empirical data, we have identified a novel oncogene, FLJ10540, which is conserved only in higher organisms. The finding raises the possibility that FLJ10540 is a potential new therapeutic target for HCC treatment. These findings may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT pathway in cancer cells.	Natl Hlth Res Inst, Canc Res Inst, Taipei 114, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Miaoli County, Taiwan; Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan; Kaohsiung Vet Gen Hosp, Dept Surg, Div Gen Surg, Kaohsiung, Taiwan; Natl Yang Ming Univ, Inst Tradit Med, Sch Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Taipei Med Univ, Grad Inst Med Informat, Taipei, Taiwan; Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan; Natl Yang Ming Univ, Inst Bio Pharmaceut Sci, Taipei 112, Taiwan; Chang Gung Univ, Dept Life Sci, Tao Yuan, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Kaohsiung Veterans General Hospital; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Medical University; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; Chang Gung University	Huang, CYF (corresponding author), Natl Hlth Res Inst, Canc Res Inst, Room 9321,No 161,Sect 6,Min Chuan E Rd, Taipei 114, Taiwan.	chiying@nhri.org.tw; ckchou@mail.cgu.edu.tw	Huang, Chi-Ying/AFL-7729-2022; Wu, Kou-Juey/P-4654-2015; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chen YL, 2004, CANCER RES, V64, P8723, DOI 10.1158/0008-5472.CAN-03-3091; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Fu SL, 2005, BIOCHEM BIOPH RES CO, V338, P830, DOI 10.1016/j.bbrc.2005.10.045; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu JM, 2004, J BIOL CHEM, V279, P32592, DOI 10.1074/jbc.M404950200; Kim SA, 2006, CANCER LETT, V235, P53, DOI 10.1016/j.canlet.2005.04.003; Kobayashi N, 2003, BLOOD, V102, P3186, DOI 10.1182/blood-2003-02-0567; Kolligs FT, 2000, GENE DEV, V14, P1319; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Nakanishi K, 2005, CANCER-AM CANCER SOC, V103, P307, DOI 10.1002/cncr.20774; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Okano J, 2003, BIOCHEM BIOPH RES CO, V309, P298, DOI 10.1016/j.bbrc.2003.04.002; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sakai M, 2006, ONCOGENE, V25, P480, DOI 10.1038/sj.onc.1209051; Su LJ, 2006, GENE EXPRESSION, V13, P107, DOI 10.3727/000000006783991872; Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Xu XD, 2004, ONCOL REP, V11, P25; Yang CW, 2005, BIOCHEM BIOPH RES CO, V330, P489, DOI 10.1016/j.bbrc.2005.03.005; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015	29	71	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4272	4283		10.1038/sj.onc.1210207	http://dx.doi.org/10.1038/sj.onc.1210207			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237822				2022-12-17	WOS:000247619900010
J	Shinmura, K; Bennett, RA; Tarapore, P; Fukasawa, K				Shinmura, K.; Bennett, R. A.; Tarapore, P.; Fukasawa, K.			Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication	ONCOGENE			English	Article						p53; centrosome; centrosome duplication	CYCLIN-E OVEREXPRESSION; NUCLEAR EXPORT SIGNAL; CHROMOSOME INSTABILITY; AMPLIFICATION; CELLS; P21; SUPPRESSION; INHIBITOR; INDUCTION; MUTANTS	Abnormal amplification of centrosomes is the major cause of mitotic defects and chromosome instability in cancer cells. Centrosomes duplicate once in each cell cycle, and abrogation of the regulatory mechanism underlying centrosome duplication leads to centrosome amplification. p53 tumor suppressor protein is involved in the regulation of centrosome duplication: loss of p53 as well as expression of certain p53 mutants result in deregulated centrosome duplication and centrosome amplification. p53 at least in part depends on its transactivation function to control centrosome duplication, primarily via upregulation of p21 cyclin-dependent kinase (CDK) inhibitor, which prevents untimely activation of CDK2/cyclin E, a key initiator of centrosome duplication. However, numerous studies have shown the presence of p53 at centrosomes, yet the role of the centrosomally localized p53 in the regulation of centrosome duplication had been enigmatic. Here, we comparatively examined wild-type p53 and p53 mutants that are transactivation(+)/centrosome-binding(-), transactivation(-)/centrosome-binding(+) and transactivation(-)/centrosome-binding(+) for their abilities to control centrosome duplication. We found that the transactivation(+)/centrosome-binding(-) and transactivation(-)/centrosome-binding(+) mutants suppress centrosome duplication only partially compared with wild-type p53. Moreover, the transactivation(-)/centrosome-binding(-) mutant almost completely lost the ability to suppress centrosome duplication. These observations provide direct evidence for the centrosomally localized p53 to participate in the regulation of centrosome duplication in a manner independent of its transactivation function in addition to its transactivation-dependent regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	Kenji.Fukasawa@uc.edu	Tarapore, Pheruza/A-8876-2013; Shinmura, Kazuya/K-8940-2012	Tarapore, Pheruza/0000-0003-0911-3661; Shinmura, Kazuya/0000-0003-4963-746X	NATIONAL CANCER INSTITUTE [R01CA090522, R01CA095925] Funding Source: NIH RePORTER; NCI NIH HHS [CA90522, CA95925] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Kaul SC, 2001, NEOPLASIA, V3, P110, DOI 10.1038/sj.neo.7900139; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Ma Z, 2006, ONCOGENE, V25, P5377, DOI 10.1038/sj.onc.1209543; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Oakley BR, 2000, CURR TOP DEV BIOL, V49, P27; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shinmura K, 2005, FEBS LETT, V579, P6621, DOI 10.1016/j.febslet.2005.10.057; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	35	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2939	2944		10.1038/sj.onc.1210085	http://dx.doi.org/10.1038/sj.onc.1210085			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072342				2022-12-17	WOS:000246210800013
J	Pole, JCM; Courtay-Cahen, C; Garcia, MJ; Blood, KA; Cooke, SL; Alsop, AE; Tse, DML; Caldas, C; Edwards, PAW				Pole, J. C. M.; Courtay-Cahen, C.; Garcia, M. J.; Blood, K. A.; Cooke, S. L.; Alsop, A. E.; Tse, D. M. L.; Caldas, C.; Edwards, P. A. W.			High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation	ONCOGENE			English	Article						8p12; breast cancer; array CGH; chromosome translocation; chromosome inversion; deletion	COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; IN-SITU HYBRIDIZATION; CARCINOMA CELL-LINES; GAMMA-HEREGULIN; CYTOGENETIC ANALYSIS; COLORECTAL-CANCER; BLADDER-CANCER; POOR-PROGNOSIS; GROWTH-FACTOR	The short arm of chromosome 8, 8p, is often rearranged in carcinomas, typically showing distal loss by unbalanced translocation. We analysed 8p rearrangements in 48 breast, pancreatic and colon cancer cell lines by fluorescence in situ hybridization (FISH) and array comparative genomic hybridization, with a tiling path of 0.2 Mb resolution over 8p12 and 1 Mb resolution over chromosome 8. Selected breast lines (MDA-MB-134, MDA-MB-175, MDA-MB-361, T-47D and ZR-75-1) were analysed further. Most cell lines showed loss of 8p distal to a break that was between 31 Mb (5' to NRG1) and the centromere, but the translocations were accompanied by variable amplifications, deletions and inversions proximal to this break. The 8p12 translocation in T-47D was flanked by an inversion of 4 Mb, with a 100 kb deletion at the proximal end. The dicentric t(8; 11) in ZR-75-1 carries multiple rearrangements including interstitial deletions, a triplicated translocation junction between NRG1 and a fragment of 11q (unconnected to CCND1), and two separate amplifications, of FGFR1 and CCND1. We conclude that if there is a tumour suppressor gene on 8p it may be near 31 Mb, for example WRN; but the complexity of 8p rearrangements suggests that they target various genes proximal to 31 Mb including NRG1 and the amplicon centred around ZNF703/FLJ14299.	Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Canc Genom Program, Cambridge CB2 2XZ, England; Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Cambridge CB2 2XZ, England	University of Cambridge; University of Cambridge	Edwards, PAW (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Canc Genom Program, Cambridge CB2 2XZ, England.	pawe1@cam.ac.uk	Edwards, Paul A/M-8291-2014; Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008; García, María J/G-1361-2016	Edwards, Paul A/0000-0002-4789-3374; Caldas, Carlos/0000-0003-3547-1489; García, María J/0000-0002-2236-9912	Breast Cancer Now [2005NOV68] Funding Source: Medline	Breast Cancer Now		Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Adams J, 2005, CANCER RES, V65, P66; Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Alsop AE, 2006, CANCER GENET CYTOGEN, V164, P97, DOI 10.1016/j.cancergencyto.2005.09.011; Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Asatiani E, 2005, CANCER RES, V65, P1164, DOI 10.1158/0008-5472.CAN-04-2688; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bernardino L, 1998, GENE CHROMOSOME CANC, V23, P100, DOI 10.1002/(SICI)1098-2264(199810)23:2<100::AID-GCC2>3.0.CO;2-6; Birnbaum D, 2003, LANCET ONCOL, V4, P639, DOI 10.1016/S1470-2045(03)01225-7; Courtay-Cahen C, 2000, GENOMICS, V66, P15, DOI 10.1006/geno.2000.6178; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; DIB A, 1995, ONCOGENE, V10, P995; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gribble SM, 2005, J MED GENET, V42, P8, DOI 10.1136/jmg.2004.024141; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hinck L, 2004, DEV CELL, V7, P783, DOI 10.1016/j.devcel.2004.11.002; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Hwang ES, 2004, CLIN CANCER RES, V10, P5160, DOI 10.1158/1078-0432.CCR-04-0165; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Klaus M, 2003, CANCER GENET CYTOGEN, V144, P36, DOI 10.1016/S0165-4608(02)00876-2; Krane IM, 1996, ONCOGENE, V12, P1781; Lemieux N, 1996, CANCER GENET CYTOGEN, V90, P75, DOI 10.1016/0165-4608(96)00061-1; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; Mann SM, 1997, CHROMOSOME RES, V5, P145, DOI 10.1023/A:1018426426477; Margolin AA, 2005, BIOINFORMATICS, V21, P3308, DOI 10.1093/bioinformatics/bti500; Morris JS, 1997, GENE CHROMOSOME CANC, V20, P120, DOI 10.1002/(SICI)1098-2264(199710)20:2<120::AID-GCC3>3.0.CO;2-5; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Rousseau-Merck MF, 1999, CANCER RES, V59, P3152; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Toomes C, 2003, GENE CHROMOSOME CANC, V37, P132, DOI 10.1002/gcc.10191; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Veltman JA, 2003, CANCER RES, V63, P2872; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950	48	71	76	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5693	5706		10.1038/sj.onc.1209570	http://dx.doi.org/10.1038/sj.onc.1209570			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636668				2022-12-17	WOS:000240599100011
J	Leung, N; Turbide, C; Olson, M; Marcus, V; Jothy, S; Beauchemin, N				Leung, N.; Turbide, C.; Olson, M.; Marcus, V.; Jothy, S.; Beauchemin, N.			Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis	ONCOGENE			English	Article						CEACAM1; colon cancer; azoxymethane; knockout; CEA	INDEPENDENT PROGNOSTIC-SIGNIFICANCE; ABERRANT CRYPT FOCI; BILIARY GLYCOPROTEIN; COLORECTAL-CANCER; EPITHELIAL-CELLS; C-CAM; BETA-CATENIN; HEPATOCELLULAR CARCINOMAS; EXPRESSION PROFILES; SIGNAL-TRANSDUCTION	Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a glycoprotein that is part of the carcinoembryonic antigen and the immunoglobulin superfamilies. We have shown that it functions as a tumor suppressor and that this function depends upon the presence of the longer CEACAM1 cytoplasmic domain. In this report, we describe the generation of a Ceacam1-/- mouse. The Ceacam1-/- colon exhibits increased in vivo proliferation relative to the wild-type counterpart with a corresponding decreased expression of the p21(Cip1) and p27(Kip1) Cyclin D kinase inhibitors. The colonic villi undergo decreased apoptosis. Out of 35 litters of mice, no spontaneous tumors in any tissues normally expressing CEACAM1 were found over the lifespan of the animals, suggesting that CEACAM1 may not be involved in initiation of tumor development. However, when mice are treated with azoxymethane to induce colonic tumors, we find that Ceacam1-/- mice developed a significantly greater number of tumors than their littermate controls. Moreover, the tumor size was greater in the knockout mice relative to that in the wild-type mice. These results indicate that deletion of CEACAM1 favors progression of colon tumorigenesis.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pathol, Montreal, PQ H3G 1Y6, Canada; St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto, ON, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, McIntyre Bldg,Room 711,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	Nicole.Beauchemin@mcgill.ca						Bamberger AM, 1998, AM J PATHOL, V152, P1401; Beauchemin N, 1999, EXP CELL RES, V252, P243; Blau DM, 2001, J VIROL, V75, P8173, DOI 10.1128/JVI.75.17.8173-8186.2001; Brabletz T, 2002, VIRCHOWS ARCH, V441, P1, DOI 10.1007/s00428-002-0642-9; Buckhaults P, 2001, CANCER RES, V61, P6996; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chan CHF, 2004, MOL THER, V9, P775, DOI 10.1016/j.ymthe.2004.03.009; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; COURNOYER D, 1988, CANCER RES, V48, P3153; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Eberhard A, 2000, CANCER RES, V60, P1388; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; Frangsmyr L, 1999, TUMOR BIOL, V20, P277, DOI 10.1159/000030075; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; Hemmila E, 2004, J VIROL, V78, P10156, DOI 10.1128/JVI.78.18.10156-10165.2004; HIXSON DC, 1985, CANCER RES, V45, P3742; HORST AK, 2006, IN PRESS J CLIN INVE; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ilantzis C, 1997, LAB INVEST, V76, P703; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Jantscheff P, 2003, J CLIN ONCOL, V21, P3638, DOI 10.1200/JCO.2003.55.135; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; Laack E, 2002, J CLIN ONCOL, V20, P4279, DOI 10.1200/JCO.2002.08.067; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Maltzman T, 1997, CARCINOGENESIS, V18, P2435, DOI 10.1093/carcin/18.12.2435; Muenzner P, 2000, INFECT IMMUN, V68, P3601, DOI 10.1128/IAI.68.6.3601-3607.2000; Muller MM, 2005, BLOOD, V105, P3925, DOI 10.1182/blood-2004-09-3618; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Notterman DA, 2001, CANCER RES, V61, P3124; OKAMOTO M, 1995, CARCINOGENESIS, V16, P2659, DOI 10.1093/carcin/16.11.2659; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; Papanikolaou A, 1998, CANCER LETT, V130, P29, DOI 10.1016/S0304-3835(98)00101-3; Phan D, 2004, CANCER RES, V64, P3072, DOI 10.1158/0008-5472.CAN-03-3730; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Robitaille J, 1999, EUR J BIOCHEM, V264, P534, DOI 10.1046/j.1432-1327.1999.00660.x; ROSENBERG M, 1993, CANCER RES, V53, P4938; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; Singer BB, 2000, CANCER RES, V60, P1236; Singh J, 1997, INT J ONCOL, V10, P449; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Thies A, 2002, J CLIN ONCOL, V20, P2530, DOI 10.1200/JCO.2002.05.033; Turbide C, 1997, CANCER RES, V57, P2781; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777; Volpert O, 2002, J BIOL CHEM, V277, P35696, DOI 10.1074/jbc.M205319200; Wang QS, 2000, MOL CARCINOGEN, V28, P139, DOI 10.1002/1098-2744(200007)28:3<139::AID-MC2>3.0.CO;2-V; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Wong SCC, 2004, CLIN CANCER RES, V10, P1401, DOI 10.1158/1078-0432.CCR-0157-03; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	69	71	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5527	5536		10.1038/sj.onc.1209541	http://dx.doi.org/10.1038/sj.onc.1209541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619040				2022-12-17	WOS:000240370400006
J	Angelastro, JM; Canoll, PD; Kuo, J; Weicker, M; Costa, A; Bruce, JN; Greene, LA				Angelastro, JM; Canoll, PD; Kuo, J; Weicker, M; Costa, A; Bruce, JN; Greene, LA			Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5	ONCOGENE			English	Article						ATF5; astrocytes; glioma; apoptosis; brain tumor	NEURAL PROGENITOR CELLS; MALIGNANT GLIOMA; DIFFERENTIATION; TRANSCRIPTION; CHECKPOINT; FAMILY; GROWTH; LINE; P53	Glioblastoma multifome is the most common and most aggressive primary brain tumor with no current curative therapy. We found expression of the bZip transcription factor ATF5 in all 29 human glioblastomas and eight human and rat glioma cell lines assessed. ATF5 is not detectably expressed by mature brain neurons and astrocytes, but is expressed by reactive astrocytes. Interference with ATF5 function or expression in all glioma cell lines tested causes marked apoptotic cell death. In contrast, such manipulations do not affect survival of ATF5-expressing cultured astrocytes or of several other cell types that express this protein. In a proof-of-principle experiment, retroviral delivery of a function-blocking mutant form of ATF5 into a rat glioma model evokes death of the infected tumor cells, but not of infected brain cells outside the tumors. The widespread expression of ATF5 in glioblastomas and the selective effect of interference with ATF5 function/expression on their survival suggest that ATF5 may be an attractive target for therapeutic intervention in such tumors.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Neurosurg, New York, NY USA	Columbia University; Columbia University; Columbia University	Angelastro, JM (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 2165 Haring Hall,1 Shields Ave, Davis, CA 95616 USA.	jmangelastro@ucdavis.edu	Kuo, John S/D-3561-2013; Bruce, Jeffrey N/AAC-5307-2022	Kuo, John S/0000-0001-6809-4806; 				AIELLO L, 1979, VIROLOGY, V94, P460, DOI 10.1016/0042-6822(79)90476-8; Angelastro JM, 2003, J NEUROSCI, V23, P4590; Angelastro JM, 2005, J NEUROSCI, V25, P3889, DOI 10.1523/JNEUROSCI.3447-04.2005; Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Badie B, 1999, CANCER GENE THER, V6, P155, DOI 10.1038/sj.cgt.7700009; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Collins V P, 2004, J Neurol Neurosurg Psychiatry, V75 Suppl 2, pii2, DOI 10.1136/jnnp.2004.040337; Dai CK, 2001, BBA-REV CANCER, V1551, pM19, DOI 10.1016/S0304-419X(01)00027-0; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Hansen MB, 2002, GENOMICS, V80, P344, DOI 10.1006/geno.2002.6838; Hirose Y, 2001, CANCER RES, V61, P5843; JENSEN AM, 1991, J NEUROSCI, V11, P1674; KLEIHUES P, 1993, HISTOLOGY TYPING TUM; KO L, 1980, ACTA NEUROPATHOL, V51, P23, DOI 10.1007/BF00688846; KRUSE CA, 1992, IN VITRO CELL DEV-AN, V28A, P609; LEVISON SW, 1991, ASTROGLIA CULTURE, P309; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mason JL, 2005, MOL CELL NEUROSCI, V29, P372, DOI 10.1016/j.mcn.2005.03.004; MCLENDON RE, 1998, RUSSELL RUBINSTEINS, P307; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; Pati D, 1999, MOL CELL BIOL, V19, P5001; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; PINKERTON H, 1976, P SOC EXP BIOL MED, V151, P532; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; Qi YP, 1997, J NEUROSCI, V17, P1217; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonoda Y, 2001, CANCER RES, V61, P4956; Vogelbaum MA, 1999, J NEUROSURG, V91, P483, DOI 10.3171/jns.1999.91.3.0483; Yamagishi N, 1995, J RADIAT RES, V36, P239, DOI 10.1269/jrr.36.239	33	71	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					907	916		10.1038/sj.onc.1209116	http://dx.doi.org/10.1038/sj.onc.1209116			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170340	Bronze			2022-12-17	WOS:000235212700010
J	Wallick, CJ; Gamper, I; Thorne, M; Feith, DJ; Takasaki, KY; Wilson, SM; Seki, JA; Pegg, AE; Byus, CV; Bachmann, AS				Wallick, CJ; Gamper, I; Thorne, M; Feith, DJ; Takasaki, KY; Wilson, SM; Seki, JA; Pegg, AE; Byus, CV; Bachmann, AS			Key role for p27(Kip1), retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G(1) cell cycle arrest in MYCN-amplified human neuroblastoma cells	ONCOGENE			English	Article						DFMO; SAM486A; MYCN-amplified neuroblastoma; p27(Kip1); Rb; cell cycle	S-ADENOSYLMETHIONINE DECARBOXYLASE; ALPHA-DIFLUOROMETHYLORNITHINE; N-MYC; ORNITHINE DECARBOXYLASE; PHASE-I; BIOSYNTHESIS INHIBITOR; RETINOIC ACID; POSTRADIOTHERAPY CHEMOTHERAPY; NEURO-BLASTOMA; BREAST-CANCER	Alpha-difluoromethylornithine (DFMO) inhibits the protooncogene ornithine decarboxylase (ODC) and is known to induce cell cycle arrest. However, the effect of DFMO on human neuroblastoma (NB) cells and the exact mechanism of DFMO-induced cell death are largely unknown. Treatment with DFMO in combination with SAM486A, an S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor, has been shown to enhance polyamine pool depletion. Therefore, we analysed the mechanism of action of DFMO and/or SAM486A in two established MYCN-amplified human NB cell lines. DFMO and SAM486A caused rapid cell growth inhibition, polyamine depletion, and G(1) cell cycle arrest without apoptosis in cell lines LAN-1 and NMB-7. These effects were enhanced with combined inhibitors and largely prevented by cotreatment with exogenous polyamines. The G(1) cell cycle arrest was concomitant with an increase in cyclin-dependent kinase inhibitor p27(Kip1). In a similar fashion, DFMO and DFMO/SAM486A inhibited the phosphorylation of the G(1)/S transition-regulating retinoblastoma protein Rb at residues Ser795 and Ser807/811. Moreover, we observed a dramatic decrease in MYCN protein levels. Overexpression of MYCN induces an aggressive NB phenotype with malignant behavior. We show for the first time that DFMO and SAM486A induce G(1) cell cycle arrest in NB cells through p27(Kip1) and Rb hypophosphorylation.	Univ Hawaii, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	Cancer Research Center of Hawaii; University of Hawaii System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California Riverside	Bachmann, AS (corresponding author), Univ Hawaii, Canc Res Ctr Hawaii, 1236 Lauhala St, Honolulu, HI 96813 USA.	abachmann@crch.hawaii.edu			NCI NIH HHS [R01CA18138, R01 CA018138, R01CA79909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079909, R01CA018138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmann Andre S, 2004, Hawaii Med J, V63, P371; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Carbone PP, 2001, CANCER EPIDEM BIOMAR, V10, P657; CHAPMAN SK, 1980, LIFE SCI, V26, P1359, DOI 10.1016/0024-3205(80)90097-1; Coleman C S, 1998, Methods Mol Biol, V79, P41; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Davidson NE, 1999, ENDOCR-RELAT CANCER, V6, P69, DOI 10.1677/erc.0.0060069; DORHOUT B, 1995, INT J CANCER, V62, P738, DOI 10.1002/ijc.2910620615; Eskens FALM, 2000, CLIN CANCER RES, V6, P1736; Fabian CJ, 2002, CLIN CANCER RES, V8, P3105; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; GILBERT RS, 1991, ANAL BIOCHEM, V199, P86, DOI 10.1016/0003-2697(91)90273-V; Goldman SC, 1996, AM J PATHOL, V148, P1381; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Kramer DL, 2001, CANCER RES, V61, P7754; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Levin VA, 2000, CLIN CANCER RES, V6, P3878; Levin VA, 2003, CLIN CANCER RES, V9, P981; Lu XH, 2003, CANCER LETT, V197, P125, DOI 10.1016/S0304-3835(03)00096-X; Lutz W, 1996, ONCOGENE, V13, P803; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; McKenzie PP, 2003, CANCER RES, V63, P3840; MELINO G, 1991, PROG CLIN BIOL RES, V366, P283; MELINO G, 1988, EXP CELL RES, V179, P429, DOI 10.1016/0014-4827(88)90281-9; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Paridaens R, 2000, BRIT J CANCER, V83, P594, DOI 10.1054/bjoc.2000.1305; PEGG AE, 1988, CANCER RES, V48, P759; Pless M, 2004, CLIN CANCER RES, V10, P1299, DOI 10.1158/1078-0432.CCR-0977-03; Porter C. W., 1992, V62, P301; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; REGENASS U, 1994, CANCER RES, V54, P3210; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shantz L M, 1998, Methods Mol Biol, V79, P45; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; Singh R, 2001, CARCINOGENESIS, V22, P1863, DOI 10.1093/carcin/22.11.1863; Siu LL, 2002, CLIN CANCER RES, V8, P2157; Svensson F, 1997, BIOCHEM J, V322, P297, DOI 10.1042/bj3220297; TABIB A, 1994, BIOCHEM BIOPH RES CO, V202, P720, DOI 10.1006/bbrc.1994.1990; Takahashi Y, 2000, INT J CANCER, V85, P243, DOI 10.1002/(SICI)1097-0215(20000115)85:2<243::AID-IJC15>3.0.CO;2-2; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, CANCER RES, V61, P8; van Zuylen L, 2004, CLIN CANCER RES, V10, P1949, DOI 10.1158/1078-0432.CCR-02-0995; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327	50	71	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5606	5618		10.1038/sj.onc.1208808	http://dx.doi.org/10.1038/sj.onc.1208808			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007177				2022-12-17	WOS:000231296100007
J	Barnes, K; McIntosh, E; Whetton, AD; Daley, GQ; Bentley, J; Baldwin, SA				Barnes, K; McIntosh, E; Whetton, AD; Daley, GQ; Bentley, J; Baldwin, SA			Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation	ONCOGENE			English	Article						Glivec; GLUT1; TonB210; protein kinase B; Bcr-Abl; apoptosis	COLONY-STIMULATING FACTORS; TYROSINE KINASE; PROGENITOR CELLS; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; POSITIVE CELLS; INTERLEUKIN-3; APOPTOSIS; SURVIVAL; IMATINIB	In chronic myeloid leukaemia (CML) expression of the chimeric tyrosine kinase, Bcr-Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in the absence of IL-3. Stimulation of glucose uptake appears to play an important role in the suppression of apoptosis by this cytokine in normal haemopoietic cells. To investigate whether the cell survival mechanisms mediated by the oncoprotein and cytokine showed any similarities, we employed a haemopoietic cell line, TonB210, engineered for inducible expression of Bcr-Abl. Tyrosine kinase expression in cytokine-deprived cells was found to mimic the effect of IL-3 in maintaining a higher V-max for hexose uptake. In both IL-3-treated cells and those expressing Bcr-Abl, high rates of hexose uptake were associated with the retention at the cell surface of approximately 80% of the total cellular content of the GLUT1 glucose transporter. In contrast, treatment of Bcr-Abl-expressing cells for 6 h with the Bcr-Abl kinase inhibitor Glivec (10 &mu; M), in the absence of IL-3, led to internalization of approximately 90% of the cell-surface transporters and drastically decreased (4.4&PLUSMN; 0.9 (mean&PLUSMN; s.e.m., 4)-fold) the V-max for hexose uptake, without significant effect on the K-m for this process or on the total cellular transporter content. These effects were not the result of any significant loss in cell viability, and preceded the onset of apoptosis caused by inhibition of Bcr-Abl. Both IL-3 treatment and expression of Bcr-Abl led to enhanced phosphorylation of Akt ( protein kinase B). The stimulation of transport by IL-3 and Bcr-Abl in TonB210 cells was inhibitable by phosphatidylinositol 3-kinase inhibitors, indicating the involvement of this kinase in the signal transduction pathway. These findings suggest that inhibition of glucose transport plays an important role in the therapeutic action of Glivec, and that the signal transduction pathways involved in transport stimulation by Bcr-Abl may offer novel therapeutic targets for CML.	Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Manchester, Inst Sci & Technol, Manchester M60 1QD, Lancs, England; Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	University of Leeds; University of Manchester; Massachusetts Institute of Technology (MIT); Whitehead Institute; Cancer Research UK; Saint James's University Hospital; University of Leeds	Barnes, K (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England.	k.barnes@leeds.ac.uk		WHETTON, ANTHONY D/0000-0002-1098-3878				Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bentley J, 2003, J BIOL CHEM, V278, P39337, DOI 10.1074/jbc.M305689200; Bentley J, 2001, BRIT J HAEMATOL, V112, P212, DOI 10.1046/j.1365-2141.2001.02428.x; BERRIDGE MV, 1995, J CELL PHYSIOL, V163, P466, DOI 10.1002/jcp.1041630306; Boren J, 2001, J BIOL CHEM, V276, P37747; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CHAPMAN RS, 1996, HEMATOPOIETIC CELL G, P151; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; DAVIES A, 1990, BIOCHEM J, V266, P799; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; HEYWORTH CM, 1992, BLOOD, V80, P2230; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kansara M, 2004, EXP CELL RES, V293, P321, DOI 10.1016/j.yexcr.2003.10.027; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Marley SB, 2004, BRIT J HAEMATOL, V125, P500, DOI 10.1111/j.1365-2141.2004.04933.x; McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276; Nagar B, 2002, CANCER RES, V62, P4236; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	36	71	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 5	2005	24	20					3257	3267		10.1038/sj.onc.1208461	http://dx.doi.org/10.1038/sj.onc.1208461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735728				2022-12-17	WOS:000228881800004
J	Nabha, SM; Glaros, S; Hong, M; Lykkesfeldt, AE; Schiff, R; Osborne, K; Reddy, KB				Nabha, SM; Glaros, S; Hong, M; Lykkesfeldt, AE; Schiff, R; Osborne, K; Reddy, KB			Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells	ONCOGENE			English	Article						tamoxifen resistance; PKC-delta; MAPK; AKT; breast cancer	PROTEIN-KINASE-C; HUMAN-BREAST-CANCER; ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; FACTOR CROSS-TALK; TAMOXIFEN RESISTANCE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CARCINOMA CELLS; STEROID-HORMONE	Acquired resistance to tamoxifen (Tam) in breast cancer patients is a serious therapeutic problem. We have previously reported that protein kinase C-delta (PKC-delta) plays a major role in estrogen (E2)-mediated cell proliferation. To determine if PKC-delta is one of the major alternate signaling pathways that supports cell growth in the presence of Tam, we determined the levels of PKC isoforms in four different models of antiestrogen-resistant cells. Three out of four antiestrogen resistance cell lines (Tam/MCF-7, ICI/MCF-7 and HER-2/MCF-7) expressed significantly high levels of both total and activated PKC-delta levels compared to sensitive cells. Estrogen receptor ( ER) alpha content and function are maintained in all the antiestrogen-resistant cell lines. Overexpressing active PKC-delta in Tam-sensitive MCF-7 cells (PKC-delta/ MCF-7) led to Tam resistance both in vitro and in vivo. Inhibition of PKC-delta by rottlerin ( a relatively specific inhibitor of PKC-delta) or siRNA significantly inhibited estrogen- and Tam-induced growth in antiestrogen-resistant cells. PKC-delta levels are significantly higher in Tam-resistant tumors compared to Tam-sensitive tumors in xenograft model (P<0.05). Taken together, these data suggest that PKC-delta plays a major role in antiestrogen resistance in breast tumor cells and thus provides a new target for treatment.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Danish Canc Soc, Inst Canc Biol, Dept Tumor Endocrinol, DK-2100 Copenhagen, Denmark; Baylor Coll Med, Ctr Brest, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA	Wayne State University; Danish Cancer Society; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.	kreddy@med.wayne.edu			NCI NIH HHS [R01 CA 83964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083964] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; BALTUCH GH, 1995, J NEURO-ONCOL, V24, P241, DOI 10.1007/BF01052840; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; Berstein LM, 2003, ENDOCR-RELAT CANCER, V10, P267, DOI 10.1677/erc.0.0100267; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BRUNNER N, 1993, CANCER RES, V53, P3229; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cartee L, 2000, CANCER INVEST, V18, P731, DOI 10.3109/07357900009012205; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Chisamore MJ, 2001, CLIN CANCER RES, V7, P3156; Clarke R, 2001, PHARMACOL REV, V53, P25; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEL PL, 1997, SCIENCE, V278, P687; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204; Goekjian PG, 1999, CURR MED CHEM, V6, P877; GOUBIN F, 1995, ONCOGENE, V10, P2281; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HORWITZ KB, 1995, ENDOCRINOLOGY, V136, P821, DOI 10.1210/en.136.3.821; JARVIS WD, 1994, CANCER RES, V54, P1707; Johnston SRD, 2003, CLIN CANCER RES, V9, p524S; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kruger JS, 2003, MOL CANCER RES, V1, P801; Kurokawa H, 2000, CANCER RES, V60, P5887; LEE SA, 1992, CANCER RES, V52, P3750; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; LYKKESFELDT AE, 1986, BRIT J CANCER, V53, P29, DOI 10.1038/bjc.1986.5; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; McCracken MA, 2003, MOL CANCER THER, V2, P273; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nicholson RI, 2000, BRIT J CANCER, V82, P501; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1989, CANCER RES, V49, P3215; OSBORNE CK, 1994, BREAST CANCER RES TR, V32, P49, DOI 10.1007/BF00666205; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; OSBORNE CK, 1987, EUR J CANCER CLIN ON, V23, P1189; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; RAPP UR, 1991, ONCOGENE, V6, P495; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; REDDY KB, 1992, CANCER RES, V52, P3636; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Santen RJ, 1996, J CLIN ENDOCR METAB, V81, P2027, DOI 10.1210/jc.81.6.2027; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; SELINA G, 2004, P AACR 2004 ANN M OR; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Sun M, 2001, CANCER RES, V61, P5985; Takimoto GS, 1999, J STEROID BIOCHEM, V69, P45, DOI 10.1016/S0960-0760(98)00148-4; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tortora G, 2003, SEMIN ONCOL, V30, P26, DOI 10.1016/S0093-7754(03)00282-3; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	81	71	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3166	3176		10.1038/sj.onc.1208502	http://dx.doi.org/10.1038/sj.onc.1208502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735693				2022-12-17	WOS:000228728100010
J	Karst, AM; Dai, DL; Martinka, M; Li, G				Karst, AM; Dai, DL; Martinka, M; Li, G			PUMA expression is significantly reduced in human cutaneous melanomas	ONCOGENE			English	Article						PUMA; tissue microarray; melanoma; gene expression	COLORECTAL-CANCER CELLS; MALIGNANT-MELANOMA; APOPTOSIS; CHEMORESISTANCE; RESISTANCE; MECHANISMS; SIGNALS; DEATH; GENE; P53	Cutaneous malignant melanoma is an aggressive form of skin cancer, characterized by strong chemoresistance and poor patient prognosis. The molecular mechanisms underlying its resistance to chemotherapy remain unclear but are speculated to involve the dysregulation of apoptotic pathways. In this study, we sought to determine whether PUMA (p53 upregulated modulator of apoptosis) contributes to human melanoma formation, tumor progression, and survival. We used tissue microarray and immunohistochemistry to examine PUMA expression in 107 primary melanomas, 51 metastatic melanomas, and 64 dysplastic nevi. Here we report that PUMA expression is significantly weaker in primary melanomas compared to dysplastic nevi ( P<0.0001), and is further reduced in metastatic melanomas compared to primary tumors ( P = 0.001). We show that weak PUMA expression in melanoma correlates with poorer overall and disease-specific 5-year survival ( P<0.005 and P<0.001, respectively) of melanoma patients and that PUMA expression in tumor tissue is an independent predictor of both overall and disease-specific 5-year survival ( P = 0.05). Additionally, we show that exogenous PUMA expression in human melanoma cell lines ( both wild type and mutant p53) results in significant apoptotic cell death. Our results suggest that PUMA expression may be an important prognostic marker for human melanoma and that adenoviral delivery of PUMA sensitizes melanoma cells to apoptosis.	Univ British Columbia, Dept Med, Div Dermatol, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Coastal Hlth Res Inst, Div Anat Pathol, Vancouver, BC, Canada	University of British Columbia; Vancouver Coastal Health Research Institute	Li, G (corresponding author), Univ British Columbia, Dept Med, Div Dermatol, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011					Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Serrone L, 2000, J EXP CLIN CANC RES, V19, P21; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; STAUNTON MJ, 1995, AM J CLIN PATHOL, V103, P300, DOI 10.1093/ajcp/103.3.300; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	21	71	84	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1111	1116		10.1038/sj.onc.1208374	http://dx.doi.org/10.1038/sj.onc.1208374			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690057				2022-12-17	WOS:000226749200018
J	Teramoto, H; Castellone, MD; Malek, RL; Letwin, N; Frank, B; Gutkind, JS; Lee, NH				Teramoto, H; Castellone, MD; Malek, RL; Letwin, N; Frank, B; Gutkind, JS; Lee, NH			Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12	ONCOGENE			English	Article						Ras; NIH3T3; RNAi; siRNA; microarray; osteopontin	DOWNSTREAM-REGULATED GENE-2; FAMILY SMALL GTPASES; CELL-MIGRATION; RAS; EXPRESSION; BINDING; CD44; IDENTIFICATION; PROTEIN; RAC1	Activated forms of Ras family members are prevalent in many cancers where Ras mutants transduce signals essential for transformation, angiogenesis, invasion and metastasis. As a cancer progression model, we used NIH3T3 cells to explore the mechanism of Ras-induced tumorigenesis. Ras family mutants H-RasV12 and Rit79L strongly induced foci formation, while Rho family mutants RhoA-QL, Rac1-QL and Cdc42-QL were less effective. A comparison of downstream transcriptional targets of Ras and Rho family members using a 26 383 element cDNA microarray revealed that the osteopontin (OPN) gene exhibited the best correlation between magnitude of gene expression change and level of foci formation (r=0.96, P<0.001). In association with H-RasV12- and Rit79L-mediated transformation, foci secreted OPN protein and upregulated the OPN receptor CD44, suggesting the novel initiation of an aberrant OPN-CD44-Rac autocrine pathway. In support of this were the following observations. First, RGD-deficient OPN protein-binding activity was present in H-RasV12- transformed cells but not in control cells, and binding activity was inhibited by the CD44 blocking antibody. Second, foci formation, cell invasion and Rac activity were induced by H-RasV12 and inhibited by the CD44 blocking antibody. Third, foci formation by H-RasV12 was substantially reduced by a short interfering RNA ( siRNA) specifically targeting OPN expression for knockdown. Fourth, H-RasV12- mediated transformation was not blocked by the GRGDS peptide, suggesting that OPN effects were not mediated by the integrins. Lastly, OPN knockdown affected the downstream expression of 160 '2nd tier' genes, and at least a subset of these genes appears to be involved in transformation. Indeed, four genes were selected for knockdown, each resulting in a disruption of foci formation and/or invasion. These results underscore the role of aberrant autocrine signaling and transcriptional networking during tumorigenesis.	Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA	J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); George Washington University	Gutkind, JS (corresponding author), Inst Genom Res, Dept Funct Genom, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	sg39v@nih.gov; nhlee@tigr.org	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bachelder RE, 2003, CANCER RES, V63, P5230; Berken A, 2003, ONCOGENE, V22, P8524, DOI 10.1038/sj.onc.1207195; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Breen EC, 2003, J CELL BIOCHEM, V88, P848, DOI 10.1002/jcb.10398; Bug G, 2002, J LEUKOCYTE BIOL, V72, P837; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Choi SC, 2003, FEBS LETT, V553, P413, DOI 10.1016/S0014-5793(03)01030-5; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Crowe DL, 2004, ANTICANCER RES, V24, P593; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Feng F, 2000, BREAST CANCER RES TR, V63, P71, DOI 10.1023/A:1006466516192; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Katagiri YU, 1996, J CELL BIOCHEM, V62, P123, DOI 10.1002/(SICI)1097-4644(199607)62:1<123::AID-JCB13>3.0.CO;2-O; Katagiri YU, 1999, CANCER RES, V59, P219; Mahabeleshwar GH, 2004, J BIOL CHEM, V279, P9733, DOI 10.1074/jbc.M311400200; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Oates AJ, 1997, INVAS METAST, V17, P1; Oates AJ, 1996, ONCOGENE, V13, P97; Ownby SE, 2002, LIPIDS, V37, P185, DOI 10.1007/s11745-002-0879-1; Pavlidis P, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-10-research0042; Qu XH, 2002, J BIOL CHEM, V277, P35574, DOI 10.1074/jbc.M206451200; Rozsnyay Z, 1999, IMMUNOL LETT, V68, P101, DOI 10.1016/S0165-2478(99)00037-1; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sehgal A, 1999, ANTICANCER RES, V19, P4947; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shiraishi Y, 1999, J NEUROSCI, V19, P8389; Singh R. P., 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P75, DOI 10.1615/JEnvPathToxOncol.v22.i2.10; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Wang L, 2003, MOL THER, V8, P72, DOI 10.1016/S1525-0016(03)00128-X; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Wu Y, 2000, BRIT J CANCER, V83, P156; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; Zhang J, 2001, CANCER LETT, V171, P215, DOI 10.1016/S0304-3835(01)00607-3; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	55	71	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					489	501		10.1038/sj.onc.1208209	http://dx.doi.org/10.1038/sj.onc.1208209			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516973				2022-12-17	WOS:000226279700019
J	Missiaglia, E; Donadelli, M; Palmieri, M; Crnogorac-Jurcevic, T; Scarpa, A; Lemoine, NR				Missiaglia, E; Donadelli, M; Palmieri, M; Crnogorac-Jurcevic, T; Scarpa, A; Lemoine, NR			Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2 '-deoxycytidine treatment is associated with activation of the interferon signalling pathway	ONCOGENE			English	Article						pancreatic cancer cell lines; microarrays; 5-aza-2 '-deoxycytidine	MESSENGER-RNA EXPRESSION; DNA METHYLATION; CPG ISLANDS; RECEPTOR EXPRESSION; CHROMATIN-STRUCTURE; NUCLEAR ANTIGEN; MICROARRAY DATA; MULTIPLE GENES; METHYLTRANSFERASE; INDUCTION	Alteration of methylation status has been recognized as a possible epigenetic mechanism of selection during tumorigenesis in pancreatic cancer. This type of cancer is characterized by poor prognosis partly due to resistance to conventional drug treatments. We have used microarray technology to investigate the changes in global gene expression observed after treatment of different pancreatic cancer cell lines with the methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR). We have observed that this agent is able to inhibit to various degrees the growth of three pancreatic cancer cell lines. In particular, this inhibition was associated with induction of interferon (IFN)-related genes, as observed in other tumour types. Thus, expression of STAT1 seems to play a key role in the cellular response to treatment with the cytosine analogue. Moreover, we found increased p21(WAF1) and gadd45A expression to be associated with the efficacy of the treatment; this induction may correlate with activation of the IFN signalling pathway. Expression of the p16(INK) protein was also linked to the ability of cells to respond to 5-aza-CdR. Finally, genome-wide demethylation induced sensitization that significantly increased response to further treatment with various chemotherapy agents.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Canc Res UK, Mol Oncol Unit, London, England; Univ Verona, Sez Anat Patol, Dipartimento Patol, I-37134 Verona, Italy; Univ Verona, Sez Biochim, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy	Cancer Research UK; Imperial College London; University of Verona; University of Verona	Scarpa, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Canc Res UK, Mol Oncol Unit, Hammersmith Campus, London, England.	aldo.scarpa@univr.it; nick.lemoine@cancer.org.uk	scarpa, aldo/K-6832-2016; Donadelli, Massimo/AAC-2003-2022	scarpa, aldo/0000-0003-1678-739X; Donadelli, Massimo/0000-0001-9224-9230; missiaglia, edoardo/0000-0001-9221-0117				Adorjan P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21; Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Aparicio Ana, 2002, Curr Opin Investig Drugs, V3, P627; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Bender CM, 1998, CANCER RES, V58, P95; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1993, COLD SPRING HARB SYM, V58, P281, DOI 10.1101/SQB.1993.058.01.033; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Brysk MM, 1995, J INTERF CYTOK RES, V15, P1029, DOI 10.1089/jir.1995.15.1029; CARAGLIA M, 1994, ANN ONCOL, V5, P269, DOI 10.1093/oxfordjournals.annonc.a058806; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Chen B, 2000, CANCER RES, V60, P3290; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; DAVIDSON S, 1992, EUR J CANCER, V28A, P362, DOI 10.1016/S0959-8049(05)80054-1; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; DORE BT, 1992, ANTI-CANCER DRUG, V3, P281, DOI 10.1097/00001813-199206000-00012; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Eggert A, 2000, MED PEDIATR ONCOL, V35, P603, DOI 10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hobeika AC, 1998, INT J CANCER, V77, P138, DOI 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Kane MF, 1997, CANCER RES, V57, P808; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kominsky S, 1998, ONCOGENE, V17, P2973, DOI 10.1038/sj.onc.1202217; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Liang G, 2002, CANCER RES, V62, P961; Lu XQ, 2002, J BIOL CHEM, V277, P24340, DOI 10.1074/jbc.M200065200; Lubomierski N, 2001, CANCER RES, V61, P5905; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Nieto M, 2004, ONCOGENE, V23, P735, DOI 10.1038/sj.onc.1207175; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; REID TR, 1992, J INTERFERON RES, V12, P131, DOI 10.1089/jir.1992.12.131; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; SAKAI T, 1991, AM J HUM GENET, V48, P880; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2003, CANCER RES, V63, P3735; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Venkatasubbarao K, 2001, CANCER RES, V61, P6239; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Yamada T, 1996, ANTICANCER RES, V16, P735; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yoder JA, 1996, BIOL CHEM, V377, P605; Youssef EM, 2004, CANCER RES, V64, P2411, DOI 10.1158/0008-5472.CAN-03-0164; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	89	71	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					199	211		10.1038/sj.onc.1208018	http://dx.doi.org/10.1038/sj.onc.1208018			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637593				2022-12-17	WOS:000226125800022
J	De Cecco, L; Marchionni, L; Gariboldi, M; Reid, JF; Lagonigro, MS; Caramuta, S; Ferrario, C; Bussani, E; Mezzanzanica, D; Turatti, F; Delia, D; Daidone, MG; Oggionni, M; Bertuletti, N; Ditto, A; Raspagliesi, F; Pilotti, S; Pierotti, MA; Canevari, S; Schneider, C				De Cecco, L; Marchionni, L; Gariboldi, M; Reid, JF; Lagonigro, MS; Caramuta, S; Ferrario, C; Bussani, E; Mezzanzanica, D; Turatti, F; Delia, D; Daidone, MG; Oggionni, M; Bertuletti, N; Ditto, A; Raspagliesi, F; Pilotti, S; Pierotti, MA; Canevari, S; Schneider, C			Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2	ONCOGENE			English	Article						ovarian cancer; gene expression profiling; automated class discovery; epithelial-mesenchymal transition; epithelial-stromal interaction	FIBROBLAST-GROWTH-FACTOR; SURFACE EPITHELIAL-CELLS; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; SULFATE PROTEOGLYCAN; ADHESION MOLECULES; SIGNALING PATHWAYS; MESSENGER-RNA; RECEPTOR; CARCINOMAS	Epithelial ovarian cancer (EOC) is the gynecological disease with the highest death rate. We applied an automatic class discovery procedure based on gene expression pro. ling to stages III-IV tumors to search for molecular signatures associated with the biological properties and progression of EOC. Using a complementary DNA microarray containing 4451 cancer-related, sequence-verified features, we identified a subset of EOC characterized by the expression of numerous genes related to the extracellular matrix (ECM) and its remodeling, along with elements of the fibroblast growth factor 2 (FGF2) signaling pathway. A total of 10 genes were validated by quantitative real-time polymerase chain reaction, and coexpression of FGF2 and fibroblast growth factor receptor 4 in tumor cells was revealed by immunohistochemistry, confirming the reliability of gene expression by cDNA microarray. Since the functional relationships among these genes clearly suggested involvement of the identified molecular signature in processes related to epithelial-stromal interactions and/or epithelial-mesenchymal cellular plasticity, we applied supervised learning analysis on ovarian-derived cell lines showing distinct cellular phenotypes in culture. This procedure enabled construction of a gene classifier able to discriminate mesenchymal-like from epithelial-like cells. Genes overexpressed in mesenchymal-like cells proved to match the FGF2 signaling and ECM molecular signature, as identified by unsupervised class discovery on advanced tumor samples. In vitro functional analysis of the cell plasticity classifier was carried out using two isogenic and immortalized cell lines derived from ovarian surface epithelium and displaying mesenchymal and epithelial morphology, respectively. The results indicated the autocrine, but not intracrine stimulation of mesenchymal conversion and cohort/scatter migration of cells by FGF2, suggesting a central role for FGF2 signaling in the maintenance of cellular plasticity of ovary-derived cells throughout the carcinogenesis process. These findings raise mechanistic hypotheses on EOC pathogenesis and progression that might provide a rational underpinning for new therapeutic modalities.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Lab Nazl CIB, I-34012 Trieste, Italy; IFOM FIRC Inst Mol Oncol, I-20139 Milan, Italy; Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Surg Oncol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; schneide@sci.area.trieste.it	Pierotti, Marco Alessandro/AAC-4728-2022; De Cecco, Loris/K-7036-2016; Mezzanzanica, Delia/C-2607-2017; Ditto, Antonino/H-2219-2017; Reid, James/G-2496-2010; Raspagliesi, Francesco/K-5473-2018; Daidone, Maria Grazia/E-9232-2017; Marchionni, Luigi/S-6774-2017; Gariboldi, Manuela/K-4744-2016	Pierotti, Marco Alessandro/0000-0002-7431-8332; De Cecco, Loris/0000-0002-7066-473X; Mezzanzanica, Delia/0000-0002-9664-6871; Ditto, Antonino/0000-0002-5684-8225; Raspagliesi, Francesco/0000-0001-8953-1657; Daidone, Maria Grazia/0000-0002-4786-1321; Marchionni, Luigi/0000-0002-7336-8071; Reid, James/0000-0001-6997-2850; Gariboldi, Manuela/0000-0001-8406-165X				AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Aunoble B, 2000, INT J ONCOL, V16, P567; Balli S, 2000, EUR J CANCER, V36, P2061, DOI 10.1016/S0959-8049(00)00193-3; Bertrand V, 2003, CELL, V115, P615, DOI 10.1016/S0092-8674(03)00928-0; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; DIBLASIO AM, 1995, J STEROID BIOCHEM, V53, P375, DOI 10.1016/0960-0760(95)00082-B; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Fujimoto J, 1997, EUR J GYNAECOL ONCOL, V18, P349; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; HORI A, 1991, CANCER RES, V51, P6180; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hough CD, 2001, CANCER RES, V61, P3869; Hough CD, 2000, CANCER RES, V60, P6281; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Karavanova ID, 1996, DEVELOPMENT, V122, P4159; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kodama J, 2001, ANTICANCER RES, V21, P2983; KRUK PA, 1990, LAB INVEST, V63, P132; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Liotta LA, 2002, JNCI-J NATL CANCER I, V94, P1113; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; MainesBandiera SL, 1997, INT J GYNECOL PATHOL, V16, P250, DOI 10.1097/00004347-199707000-00010; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Matias-Guiu X, 1998, VIRCHOWS ARCH, V433, P103, DOI 10.1007/s004280050224; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Obermair A, 1998, CANCER LETT, V130, P69, DOI 10.1016/S0304-3835(98)00119-0; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Parrott JA, 2001, MOL CELL ENDOCRINOL, V175, P29, DOI 10.1016/S0303-7207(01)00436-1; PERANTONI AO, 1995, P NATL ACAD SCI USA, V92, P4696, DOI 10.1073/pnas.92.10.4696; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Radmacher MD, 2002, J COMPUT BIOL, V9, P505, DOI 10.1089/106652702760138592; Righetti SC, 1999, CELL GROWTH DIFFER, V10, P473; Santala M, 1999, CLIN CANCER RES, V5, P4091; Schafer T, 2004, J BIOL CHEM, V279, P6244, DOI 10.1074/jbc.M310500200; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schwartz DR, 2003, CANCER RES, V63, P2913; Schwartz DR, 2002, CANCER RES, V62, P4722; Sheng GJ, 2003, CELL, V115, P603, DOI 10.1016/S0092-8674(03)00927-9; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Shridhar V, 2001, CANCER RES, V61, P5895; Simojoki M, 2001, GYNECOL ONCOL, V82, P110, DOI 10.1006/gyno.2001.6212; Steele IA, 2001, ONCOGENE, V20, P5878, DOI 10.1038/sj.onc.1204755; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Sundfeldt K, 1997, INT J CANCER, V74, P275, DOI 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.3.CO;2-V; Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; VANNIEKERK CC, 1993, AM J PATHOL, V142, P157; von Heydebreck A, 2001, Bioinformatics, V17 Suppl 1, pS107; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176	64	71	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8171	8183		10.1038/sj.onc.1207979	http://dx.doi.org/10.1038/sj.onc.1207979			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377994				2022-12-17	WOS:000224692500015
J	Saidi, SA; Holland, CM; Kreil, DP; MacKay, DJC; Charnock-Jones, DS; Print, CG; Smith, SK				Saidi, SA; Holland, CM; Kreil, DP; MacKay, DJC; Charnock-Jones, DS; Print, CG; Smith, SK			Independent component analysis of microarray data in the study of endometrial cancer	ONCOGENE			English	Article						endometrial cancer; lipid metabolism; principal components analysis; independent component analysis; gene microarrays	GENE-EXPRESSION PROFILES; ENDOGENOUS HORMONES; CLASSIFICATION; HETEROZYGOSITY	Gene microarray technology is highly effective in screening for differential gene expression and has hence become a popular tool in the molecular investigation of cancer. When applied to tumours, molecular characteristics may be correlated with clinical features such as response to chemotherapy. Exploitation of the huge amount of data generated by microarrays is difficult, however, and constitutes a major challenge in the advancement of this methodology. Independent component analysis (ICA), a modern statistical method, allows us to better understand data in such complex and noisy measurement environments. The technique has the potential to significantly increase the quality of the resulting data and improve the biological validity of subsequent analysis. We performed microarray experiments on 31 postmenopausal endometrial biopsies, comprising 11 benign and 20 malignant samples. We compared ICA to the established methods of principal component analysis (PCA), Cyber-T, and SAM. We show that ICA generated patterns that clearly characterized the malignant samples studied, in contrast to PCA. Moreover, ICA improved the biological validity of the genes identified as differentially expressed in endometrial carcinoma, compared to those found by Cyber-T and SAM. In particular, several genes involved in lipid metabolism that are differentially expressed in endometrial carcinoma were only found using this method. This report highlights the potential of ICA in the analysis of microarray data.	Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 2SW, England; Univ Cambridge, Dept Pathol, Cambridge CB1 1QP, England; Univ Cambridge, Cavendish Lab, Dept Phys, Inference Grp, Cambridge CB3 0HE, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Saidi, SA (corresponding author), Rosie Hosp, Dept Obstet & Gynaecol, Box 223,Robinson Way, Cambridge CB2 2SW, England.	samsaidi@obgyn.cam.ac.uk	Smith, Stephen K/F-6938-2012; Kreil, D/O-1783-2013; Charnock-Jones, D. Stephen/B-3743-2009; Charnock-Jones, D. Stephen/AAE-3391-2020	Kreil, D/0000-0001-7538-2056; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Print, Cristin/0000-0001-8345-7812; Smith, Stephen/0000-0003-1912-3935; Saidi, Samir/0000-0001-5165-2461				Akhmedkhanov A, 2001, ANN NY ACAD SCI, V943, P296, DOI 10.1111/j.1749-6632.2001.tb03811.x; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Badawi AF, 2002, INT J ONCOL, V20, P1109; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Borthwick JM, 2003, MOL HUM REPROD, V9, P19, DOI 10.1093/molehr/gag004; Burgess JK, 2001, CLIN EXP PHARMACOL P, V28, P321, DOI 10.1046/j.1440-1681.2001.03448.x; Draghici S, 2001, Curr Opin Drug Discov Devel, V4, P332; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evans Amanda L., 2003, Angiogenesis, V6, P93, DOI 10.1023/B:AGEN.0000011732.83724.e5; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; Kreil DP, 2003, COMP FUNCT GENOM, V4, P300, DOI 10.1002/cfg.298; Liebermeister W, 2002, BIOINFORMATICS, V18, P51, DOI 10.1093/bioinformatics/18.1.51; Martoglio AM, 2002, BIOINFORMATICS, V18, P1617, DOI 10.1093/bioinformatics/18.12.1617; Miskin J. W., 2000, THESIS U CAMBRIDGE; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Niederacher D, 1998, EUR J CANCER, V34, P1770, DOI 10.1016/S0959-8049(98)00270-6; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Risinger JI, 2003, CANCER RES, V63, P6; Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14; Sirchia SM, 2000, CANCER GENET CYTOGEN, V121, P156, DOI 10.1016/S0165-4608(00)00240-5; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wernisch L, 2003, BIOINFORMATICS, V19, P53, DOI 10.1093/bioinformatics/19.1.53; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13; Wildsmith SE, 2001, BIOTECHNIQUES, V30, P202, DOI 10.2144/01301dd04	29	71	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6677	6683		10.1038/sj.onc.1207562	http://dx.doi.org/10.1038/sj.onc.1207562			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247901				2022-12-17	WOS:000223530800016
J	Apostolou, S; Klein, JO; Mitsuuchi, Y; Shetler, JN; Poulikakos, PI; Jhanwar, SC; Kruger, WD; Testa, JR				Apostolou, S; Klein, JO; Mitsuuchi, Y; Shetler, JN; Poulikakos, PI; Jhanwar, SC; Kruger, WD; Testa, JR			Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype	ONCOGENE			English	Article						mesothelioma; selenium; chemoprevention; apoptosis; SEP15 genotype	SUPPRESSION SUBTRACTIVE HYBRIDIZATION; HUMAN-MALIGNANT MESOTHELIOMA; CANCER PREVENTION; EXPRESSION; GENE; SELENOCYSTEINE; PROTEIN; REGION; RISK	Malignant mesotheliomas (MMs) are aggressive tumors derived from mesothelial cells lining the lungs, pericardium and peritoneum, and are often associated with occupational asbestos exposure. Suppression subtractive hybridization was used to identify genes differentially expressed in MM cells compared to normal mesothelial cells. A gene, SEP15, encoding a 15-kDa selenium-containing protein was isolated using this approach and was subsequently shown to be downregulated in similar to60% of MM cell lines and tumor specimens. A SEP15 polymorphic variant, 1125A, resides in the SECIS recognition element in the 3'-UTR and may influence the efficiency of Sec incorporation into the protein during translation. Since previous studies have implicated a potential role of the trace element selenium as a chemopreventive agent in animal models and in several types of human cancer, we investigated the effect of selenium on MM cells and its dependence on SEP15 genotype. Selenium was shown to inhibit cell growth and induce apoptosis in a dose-dependent manner in MM cells but had minimal effect on normal mesothelial cells. However, MM cells with downregulated SEP15 or the 1125A variant were somewhat less responsive to the growth inhibitory and apoptotic effects of selenium than MM cells expressing wild-type protein. RNAi-based knockdown studies demonstrated that SEP15 inhibition makes sensitive MM cells more resistant to selenium. These data imply that selenium may be useful as a chemopreventive agent in individuals at high risk of MM due to asbestos exposure, although those with the 1125A polymorphism may be less responsive to the protective benefits of dietary selenium supplementation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	JR_Testa@fccc.edu	Kruger, Warren/Y-2541-2018; kruger, warren/A-6407-2008	kruger, warren/0000-0002-4990-3695	NATIONAL CANCER INSTITUTE [R01CA045745, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, CA-45745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apostolou S, 1999, CELL, V97, P684, DOI 10.1016/S0092-8674(02)09765-9; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DIPLOCK AT, 1993, AM J CLIN NUTR, V57, P256, DOI 10.1093/ajcn/57.2.256S; ELBAYOUMY K, 1991, CANCER PRINCIPLES PR, P1; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Hu YJ, 2001, CANCER RES, V61, P2307; Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1; HUNTER DJ, 1990, JAMA-J AM MED ASSOC, V264, P1128, DOI 10.1001/jama.264.9.1128; Ip C, 1998, J NUTR, V128, P1845, DOI 10.1093/jn/128.11.1845; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kumaraswamy E, 2000, J BIOL CHEM, V275, P35540, DOI 10.1074/jbc.M004014200; Lee WC, 1996, CANCER RES, V56, P4297; Menter DG, 2000, CANCER EPIDEM BIOMAR, V9, P1171; Roberts D, 2002, DNA CELL BIOL, V21, P11, DOI 10.1089/10445490252810276; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Van Lieshout EMM, 1998, ONCOL REP, V5, P959; VANDENBRANDT PA, 1993, CANCER RES, V53, P4860; Zhang ZH, 1997, BIOL TRACE ELEM RES, V57, P147, DOI 10.1007/BF02778198	21	71	72	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5032	5040		10.1038/sj.onc.1207683	http://dx.doi.org/10.1038/sj.onc.1207683			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107826				2022-12-17	WOS:000222237300009
J	Kandouz, M; Bier, A; Carystinos, GD; Alaoui-Jamali, MA; Batist, G				Kandouz, M; Bier, A; Carystinos, GD; Alaoui-Jamali, MA; Batist, G			Connexin43 pseudogene is expressed in tumor cells and inhibits growth	ONCOGENE			English	Article						Connexin43; pseudogene; transcription; translation; cancer	LIVE MAMMALIAN-CELLS; GAP-JUNCTIONS; CHROMOSOMAL LOCALIZATION; PROCESSED PSEUDOGENES; PROTEOME EVOLUTION; BREAST-CANCER; GENE FAMILY; MUTATIONS; COMMUNICATION; PROMOTER	Pseudogenes are classically thought of as nonfunctional DNA sequences due to their inability to be translated, or to produce a functional protein. Gap junctions, a multiprotein complex made of proteins called connexins, are involved in intercellular communication and are deregulated in many cancers. Connexin43 (Cx43) is the only connexin for which a pseudogene has been reported so far. The Cx43 pseudogene (PsiCx43) has all of the features of an expressed gene. We identified the presence of a PsiCx43 mRNA transcript in several cancer cell lines and in none of the normal mammary epithelial cells studied. Using an in vitro translation assay, we found that the PsiCx43 coding plasmid could be translated into a 43 kDa protein. This was further confirmed by expressing a PsiCx43-green fluorescence protein fusion protein in breast cancer MCF-7 cells. We then examined the functional significance of the PsiCx43. In both MTT growth and colony formation assays, significant growth inhibition was observed, a feature common to cells overexpressing the Cx43 gene. However, using a scrape-loading assay, we could not detect any effect on gap junctional intercellular communication. Based on our findings, PsiCx43 joins and enlarges the thus far restricted group of functionally transcribed and translated pseudogenes.	McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Pharmacol & Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Expt Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Batist, G (corresponding author), McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Oncol, Montreal, PQ H3T 1E2, Canada.	gbatist@onc.jgh.mcgill.ca						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREA JE, 1995, BIOCHEM J, V310, P835, DOI 10.1042/bj3100835; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Boschan C, 2002, GENOMICS, V79, P387, DOI 10.1006/geno.2001.6715; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Cai J, 1998, INT J MOL MED, V1, P273; Carystinos GD, 2001, J MAMMARY GLAND BIOL, V6, P431, DOI 10.1023/A:1014787014851; Carystinos GD, 2003, MOL PHARMACOL, V63, P821, DOI 10.1124/mol.63.4.821; CHAKRABARTI R, 1995, GENE, V153, P163, DOI 10.1016/0378-1119(94)00751-D; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FLAGGNEWTON J, 1979, J MEMBRANE BIOL, V50, P65, DOI 10.1007/BF01868788; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Harrison P, 2002, J MOL BIOL, V316, P409, DOI 10.1006/jmbi.2001.5343; Harrison PM, 2002, J MOL BIOL, V318, P1155, DOI 10.1016/S0022-2836(02)00109-2; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kleene KC, 1999, GENOMICS, V61, P194, DOI 10.1006/geno.1999.5945; Korneev SA, 1999, J NEUROSCI, V19, P7711; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 2001, METH MOL B, V154, P135; MCCARREY JR, 1990, NUCLEIC ACIDS RES, V18, P949, DOI 10.1093/nar/18.4.949; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Puget N, 2002, AM J HUM GENET, V70, P858, DOI 10.1086/339434; RENAUDIE F, 1992, MAMM GENOME, V2, P143, DOI 10.1007/BF00302872; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; Sun D, 1998, CYTOGENET CELL GENET, V81, P79, DOI 10.1159/000014993; Tanooka H, 1998, CANCER RES, V58, P5649; Thiele H, 2000, EUR J BIOCHEM, V267, P5473, DOI 10.1046/j.1432-1327.2000.01609.x; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Uechi T, 2002, NUCLEIC ACIDS RES, V30, P5369, DOI 10.1093/nar/gkf696; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Vine AL, 2002, CANCER METAST REV, V21, P199, DOI 10.1023/A:1021250624933; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang CL, 2000, ONCOGENE, V19, P4346, DOI 10.1038/sj.onc.1203795; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003	43	71	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4763	4770		10.1038/sj.onc.1207506	http://dx.doi.org/10.1038/sj.onc.1207506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122329				2022-12-17	WOS:000221799200011
J	Kumar, AS; Naruszewicz, I; Wang, P; Leung-Hagesteijn, C; Hannigan, GE				Kumar, AS; Naruszewicz, I; Wang, P; Leung-Hagesteijn, C; Hannigan, GE			ILKAP regulates ILK signaling and inhibits anchorage-independent growth	ONCOGENE			English	Article						ILKAP; ILK signaling; GSK3 beta; oncogenesis; phosphatase	INTEGRIN-LINKED KINASE; GLYCOGEN-SYNTHASE KINASE; PROTEIN-TYROSINE PHOSPHATASE-1; PROSTATE-CANCER CELLS; TUMOR-SUPPRESSOR; CYCLIN D1; BETA-CATENIN; SERINE/THREONINE PHOSPHATASES; DEPENDENT REGULATION; PATHWAYS	ILKAP is a protein phosphatase 2C that selectively associates with integrin linked kinase, ILK, to modulate cell adhesion and growth factor signaling. We investigated the role of endogenous cellular ILKAP in antagonizing ILK signaling of two key targets, PKB and GSK3beta. Silencing of endogenous ILKAP by short interfering RNA ( siRNA) stimulated GSK3beta phosphorylation at S9, with no effect on PKB S473 phosphorylation. In LNCaP prostate carcinoma cells, transient or stable expression of ILKAP suppressed ILK immune complex kinase activity, demonstrating an interaction between ILKAP and ILK. Consistent with the silencing data, ILKAP inhibition of ILK selectively inhibited S9 phosphorylation of GSK3beta without affecting S473 phosphorylation of PKB. The ILKAP-mediated inhibition of S9 phosphorylation was rescued by overexpression of ILK, but not by a dominant-negative ILK mutant. The expression level of cyclin D1, a target of ILK-GSK3beta signaling, was inversely correlated with ILKAP protein levels, suggesting that antagonism of ILK modulates cell cycle progression. ILKAP expression increased the proportion of LNCaP cells in G1, relative to vector control cells, and siRNA suppression of ILKAP increased entry of cells into the S phase, consistent with ILK antagonism. Anchorage-independent growth of LNCaP cells was inhibited by ILKAP, suggesting a critical role in the suppression of cellular transformation. Taken together, our results indicate that endogenous ILKAP activity inhibits the ILK-GSK3beta signaling axis, and suggest that ILKAP activity plays an important role in inhibiting oncogenic transformation.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Hosp Sick Children, Res Inst, Canc Res Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Hannigan, GE (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	hannigan@sickkids.ca	Hannigan, Greg/A-5092-2009					Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Barker N, 2000, BIOESSAYS, V22, P961; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Koh CG, 2002, CURR BIOL, V12, P317, DOI 10.1016/S0960-9822(02)00652-8; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Marsolier MC, 2000, GENETICS, V154, P1523; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Noguchi T, 2001, J BIOL CHEM, V276, P15216, DOI 10.1074/jbc.M007208200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Polakis P, 2000, GENE DEV, V14, P1837; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rodriguez PL, 1998, PLANT MOL BIOL, V38, P919, DOI 10.1023/A:1006054607850; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Takada T, 2002, J BIOL CHEM, V277, P34359, DOI 10.1074/jbc.M206541200; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tan KML, 2001, J BIOL CHEM, V276, P44193, DOI 10.1074/jbc.M105880200; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Wan XS, 2003, ONCOL REP, V10, P1569; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	56	71	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3454	3461		10.1038/sj.onc.1207473	http://dx.doi.org/10.1038/sj.onc.1207473			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990992				2022-12-17	WOS:000220975000020
J	Gross, M; Yang, R; Top, I; Gasper, C; Shuai, K				Gross, M; Yang, R; Top, I; Gasper, C; Shuai, K			PIASy-mediated repression of the androgen receptor is independent of sumoylation	ONCOGENE			English	Article						protein inhibitor of activated STAT; androgen receptor; sumoylation	PROTEIN INHIBITOR; PROSTATE-CANCER; TRANSCRIPTIONAL ACTIVATION; GENE ACTIVATION; COREPRESSOR; SUMO; UBIQUITIN; LIGASES; MOTIF; COREGULATOR	PIASy, a member of the protein inhibitor of activated STAT (PIAS) family, represses the transcriptional activity of the androgen receptor (AR). In this report, we investigate the mechanism of PIASy-mediated repression of AR. We show that AR binds to the RING-finger like domain of PIASy. PIASy contains two transcriptional repression domains, RD1 and RD2. RD1, but not RD2, is required for PIASy-mediated repression of AR. We show that the RD1 domain binds HDAC1 and HDAC2 and that HDAC activity is required for PIASy-mediated AR repression. PIAS proteins possess small ubiquitin-related modifier (SUMO) E3 ligase activity. Conjugation of SUMO-1 to AR has been implicated in the regulation of AR activity. We examine if the SUMO ligase activity of PIASy is required for PIASy to repress AR. We show that a mutant PIASy, defective in promoting sumoylation, retains the ability to repress AR transcription. In addition, mutation of all the known sumoylation acceptor sites of AR does not affect the transrepression activity of PIASy on AR. Our results suggest that PIASy may repress AR by recruiting histone deacetylases, independent of its SUMO ligase activity.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Cedars Sinai Med Ctr, Louis Warschaw Prostate Canc Ctr, Los Angeles, CA 90048 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Cedars Sinai Medical Center	Shuai, K (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	kshuai@mednet.ucla.edu		Gross, Mitchell/0000-0002-1691-921X	NCI NIH HHS [CA32737] Funding Source: Medline; NIAID NIH HHS [AI39612] Funding Source: Medline; NIDDK NIH HHS [K08 DK064379, DK64379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK064379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Wu L, 2001, GENE THER, V8, P1416, DOI 10.1038/sj.gt.3301549; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang LQ, 2002, MOL THER, V5, P223, DOI 10.1006/mthe.2002.0551	31	71	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3059	3066		10.1038/sj.onc.1207443	http://dx.doi.org/10.1038/sj.onc.1207443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14981544				2022-12-17	WOS:000220845200010
J	Shridhar, R; Zhang, J; Song, J; Booth, BA; Kevil, CG; Sotiropoulou, G; Fsloane, B; Keppler, D				Shridhar, R; Zhang, J; Song, J; Booth, BA; Kevil, CG; Sotiropoulou, G; Fsloane, B; Keppler, D			Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells	ONCOGENE			English	Article						cystatins; cathepsins; lysosomal proteases; protease inhibitors; tumor progression	CYSTEINE PROTEINASE-INHIBITOR; SQUAMOUS CARCINOMA-CELLS; CATHEPSIN-B; BREAST-CANCER; MAMMALIAN LEGUMAIN; PLASMINOGEN-ACTIVATOR; PROTEASE INHIBITORS; CHICKEN CYSTATIN; M/E EXPRESSION; TUMOR-CELLS	Proteases are involved in many aspects of tumor progression, including cell survival and proliferation, escape from immune surveillance, cell adhesion and migration, remodeling and invasion of the extracellular matrix. Several lysosomal cysteine proteases have been cloned and shown to be overexpressed in cancer; yet, despite the great potential for development of novel therapeutics, we still know little about the regulation of their proteolytic activity. Cystatins such as cystatin M are potent endogenous protein inhibitors of lysosomal cysteine proteases. Cystatin M is expressed in normal and premalignant human epithelial cells, but not in many cancer cell lines. Here, we examined the effects of cystatin M expression on malignant properties of human breast carcinoma MDA-MB-435S cells. Cystatin M was found to significantly reduce in vitro: cell proliferation, migration, Matrigel invasion, and adhesion to endothelial cells. Reduction of cell proliferation and adhesion to an endothelial cell monolayer were both independent of the inhibition of lysosomal cysteine proteases. In contrast, cell migration and matrix invasion seemed to rely on lysosomal cysteine proteases, as both recombinant cystatin M and E64 were able to block these processes. This study provides the first evidence that cystatin M may play important roles in safeguarding against human breast cancer.	LSUHSC, Sch Med, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; Univ Patras, Dept Pharm, Patras 26500, Greece; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Wayne State University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Patras; Barbara Ann Karmanos Cancer Institute; Wayne State University	Keppler, D (corresponding author), LSUHSC, Sch Med, Dept Cellular Biol & Anat, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.	dkeppl@lsuhsc.edu	Zhang, Jun/AAN-4970-2021; Kevil, Christopher/G-9318-2011; Keppler, Daniel/B-4309-2012	Zhang, Jun/0000-0001-7886-6187; Kevil, Christopher/0000-0003-0863-7260	NATIONAL CANCER INSTITUTE [R21CA091785, R01CA036481] Funding Source: NIH RePORTER; NCI NIH HHS [CA91785, CA36481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BELL ET, 1989, ARCH BIOCHEM BIOPHYS, V271, P359, DOI 10.1016/0003-9861(89)90285-3; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Brunner N, 1994, Cancer Treat Res, V71, P299; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; Guo M, 2002, J BIOL CHEM, V277, P14829, DOI 10.1074/jbc.M108180200; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hulkower KI, 2000, EUR J BIOCHEM, V267, P4165, DOI 10.1046/j.1432-1327.2000.01458.x; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; Keppler D, 1997, MECH AGEING DEV, V98, P151, DOI 10.1016/S0047-6374(97)00080-8; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1442, DOI 10.1152/ajpcell.2001.281.5.C1442; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; LABER B, 1989, FEBS LETT, V248, P162, DOI 10.1016/0014-5793(89)80453-3; LEUNGTACK J, 1990, EXP CELL RES, V188, P16, DOI 10.1016/0014-4827(90)90272-C; Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243; Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Liu C, 2003, CANCER RES, V63, P2957; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; Mason RW, 2002, BIOL CHEM, V383, P1113, DOI 10.1515/BC.2002.120; Merz GS, 1997, J CELL PHYSIOL, V173, P423; Ni J, 1997, J BIOL CHEM, V272, P10853; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PRICE JE, 1990, CANCER METAST REV, V8, P285, DOI 10.1007/BF00052605; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; REDWOOD SM, 1992, CANCER, V69, P1212; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sameni M, 2000, NEOPLASIA, V2, P496, DOI 10.1038/sj.neo.7900116; Sexton PS, 1997, MELANOMA RES, V7, P97, DOI 10.1097/00008390-199704000-00002; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; SUN Q, 1989, EXP CELL RES, V180, P150, DOI 10.1016/0014-4827(89)90219-X; Taupin P, 2000, NEURON, V28, P385, DOI 10.1016/S0896-6273(00)00119-7; TAVERA C, 1992, BIOCHEM BIOPH RES CO, V182, P1082, DOI 10.1016/0006-291X(92)91842-E; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Vigneswaran N, 2003, ORAL ONCOL, V39, P559, DOI 10.1016/S1368-8375(03)00038-1; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x	63	71	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2206	2215		10.1038/sj.onc.1207340	http://dx.doi.org/10.1038/sj.onc.1207340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676833				2022-12-17	WOS:000220280900010
J	Surace, EI; Haipek, CA; Gutmann, DH				Surace, EI; Haipek, CA; Gutmann, DH			Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function	ONCOGENE			English	Article						merlin; schwannomin; ERM proteins; FERM; Protein 4.1; phosphorylation	TUMOR-SUPPRESSOR PROTEIN; CELL EXTENSION ACTIVITY; ERM PROTEINS; PLASMA-MEMBRANE; TERMINAL DOMAIN; EZRIN; MOESIN; BINDING; ASSOCIATION; GROWTH	The neurofibromatosis 2 (NF2) tumor suppressor gene product, merlin, belongs to the ezrin-radixin-moesin (ERM) subgroup of the Protein 4.1 family, which links cell surface glycoproteins to the actin cytoskeleton. Previous studies have suggested that phosphorylation of merlin, similar to other ERM proteins, may regulate its function. To determine whether merlin phosphorylation has functional consequences for merlin suppression of cell growth and motility, we generated doxycycline-regulatable RT4 schwannoma cell lines that inducibly express full-length merlin with mutations at two potential phosphorylation sites (amino-acid residues S518 and T576). Whereas a mutation at S518 that mimics constitutive phosphorylation (S518D) abrogates the ability of merlin to suppress cell growth and motility, the S518A merlin mutant, which mimics nonphosphorylated merlin, functions equivalently to wild-type merlin. Similar mutations involving T576, the analogous phosphorylation site in ERM proteins important for regulating their function, had no effect. In contrast to other functionally inactive missense merlin mutants, the regulated overexpression of S518D merlin resulted in dramatic changes in cell shape and the elaboration of filopodial extensions. These results provide the first direct demonstration that the S518D merlin mutation, which mimics merlin phosphorylation, impairs not only merlin growth and motility suppression but also leads to an acquisition of a novel phenotype previously ascribed to ERM proteins.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NINDS NIH HHS [NS35848] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gopalbhai K, 2003, J BIOL CHEM, V278, P8118, DOI 10.1074/jbc.M211870200; Gutmann DH, 1998, HUM MOL GENET, V7, P335, DOI 10.1093/hmg/7.3.335; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Jabbur JR, 2002, CANCER BIOL THER, V1, P277, DOI 10.4161/cbt.81; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497	41	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					580	587		10.1038/sj.onc.1207142	http://dx.doi.org/10.1038/sj.onc.1207142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724586				2022-12-17	WOS:000188098300029
J	Holmes, WF; Soprano, DR; Soprano, KJ				Holmes, WF; Soprano, DR; Soprano, KJ			Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway	ONCOGENE			English	Article						retinoids; apoptosis; CD437; MAP kinase; TR3; MEF-2	SYNTHETIC RETINOID CD437; ACID RECEPTOR-GAMMA; LUNG-CANCER CELLS; CYTOCHROME-C RELEASE; PROTEIN-KINASE; CASPASE ACTIVATION; TRANSCRIPTION FACTORS; INDEPENDENT PATHWAY; SELECTIVE RETINOIDS; MELANOMA-CELLS	Retinoids have great potential in the areas of cancer therapy and chemoprevention. 6-[3-(1-admantyl)]-4-hydroxyphenyl]2-naphthalene carboxylic acid (CD437) is a conformationally restricted synthetic retinoid that has been reported to induce growth arrest and apoptosis in ovarian tumor cell lines but the entire mechanism for apoptotic induction has not been fully defined. We set out to identify the early events of CD437-induced apoptosis of the CA-OV-3 cell line and determine if these occur in a CA-OV-3 cell line resistant to CD437 (CA-CD437R). Using inhibitors for the MAP kinase cascade, we determined that MEK and p38 inhibitors could block CD437-induced apoptosis of the CA-OV-3 cell line. Moreover, treatment of CA-OV-3 and CA-CD437R cells with CD437 resulted in increased phosphorylation and activity of p38 independent of caspase-3 activation. Furthermore, p38 induced the phosphorylation of MEF2 in both CA-OV-3 and CA-CD437R cells after CD437 treatment. Finally, GFP-TR3 protein translocated to the cytosol and associated with mitochondria in both cell lines in response to CD437 treatment. This leads to depolarization of mitochondria and subsequent induction of apoptosis only in CA-OV-3 cells. These results identify a number of initial molecular events in the induction of apoptosis by CD437 in CA-OV-3 cells and demonstrate that the alteration in CA-CD437R cells, which results in resistance to CD437 maps downstream of these early events after TR3 translocation but prior to mitochondrial depolarization.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline; NIAID NIH HHS [AI 07101] Funding Source: Medline; NIDCR NIH HHS [DE 13139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Bild AH, 2002, ONCOGENE, V21, P6649, DOI 10.1038/sj.onc.1205819; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Dawson MI, 2001, CANCER RES, V61, P4723; DE LUCA LM, 1991, FASEB J, V5, P2924; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gudas Lorraine J., 1994, P443; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kumar A, 2001, CANCER RES, V61, P7552; Langdon SP, 1998, CANCER CHEMOTH PHARM, V42, P429, DOI 10.1007/s002800050841; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Moon Richard C., 1994, P573; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Sakaue M, 2001, CELL DEATH DIFFER, V8, P411, DOI 10.1038/sj.cdd.4400818; Sanchez-Perez I, 2002, MOL BIOL CELL, V13, P2933, DOI 10.1091/mbc.E02-01-0022; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 2002, CANCER RES, V62, P2430; Sun SY, 1997, CANCER RES, V57, P4931; Sun SY, 2000, CANCER RES, V60, P7149; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; Widschwendter M, 1997, INT J CANCER, V71, P497; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zhang YX, 2002, BLOOD, V100, P2917, DOI 10.1182/blood.V100.8.2917; Zhao M, 2000, ACTA BIOCH BIOPH SIN, V32, P258; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	56	71	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6377	6386		10.1038/sj.onc.1206694	http://dx.doi.org/10.1038/sj.onc.1206694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508518				2022-12-17	WOS:000185535300008
J	Carbone, M; Pass, HI; Miele, L; Bocchetta, M				Carbone, M; Pass, HI; Miele, L; Bocchetta, M			New developments about the association of SV40 with human mesothelioma	ONCOGENE			English	Article						SV40; mesothelioma; human cancer	LARGE T-ANTIGEN; HUMAN PLEURAL MESOTHELIOMA; DNA-SEQUENCES; HUMAN TUMORS; MALIGNANT MESOTHELIOMA; MOLECULAR-MECHANISMS; ABERRANT METHYLATION; GENE FAMILY; SIMIAN-VIRUS-40; CELL	Simian virus 40 (SV40) has been detected in human tumors in over 40 different laboratories. Many of these reports linked SV40 to human mesotheliomas. The Vaccine Safety Committee of the Institute of Medicine (IOM), National Academy of Sciences, USA, recently reviewed the evidence associating polio vaccines and/or SV40 with human tumors. The IOM conclusions about polio vaccines and human cancer were: (1) 'the evidence is inadequate to accept or reject a causal relation between SV40-containing polio vaccines and cancer' because the 'epidemiological studies are sufficiently flawed'; (2) 'the biological evidence is of moderate strength that SV40 exposure from the polio vaccines is related to SV40 infection in humans'. The epidemiological studies were considered flawed because it was not possible to distinguish reliably among exposed and nonexposed cohorts. Concerning SV40, the IOM concluded that (1) 'the evidence is strong that SV40 is a transforming virus; (2) the evidence is of moderate strength that SV40 exposure could lead to cancer in humans under natural conditions' (IOM, 2002). Similar conclusions were reached at an International consensus meeting on SV40 and human tumors held at the University of Chicago in 2001. G Klein and C Croce, who chaired the final panel that reviewed all the published evidence linking SV40 to human tumors, stated that 'the presence of SV40 in human tumors has been convincingly demonstrated' (Klein et al, 2002). In addition, a workshop organized by the Biological Carcinogenesis Branch of the National Cancer Institute, Bethesda, MD, chaired by J Pagano, has reached similar conclusions (Wong et aL, 2002). Therefore, three independent scientific panels have all agreed that there is compelling evidence that SV40 is present in some human cancers and that SV40 could contribute to the pathogenesis of some of them. It should be noted that the presence of SV40 in mesothelioma and other human tumor types has been challenged by a research team that has consistently reported negative findings (Strickler et aL, 2001). However, a member of this research team has recently acknowledged - in sworn testimony -sensitivity problems and possible irregularities that raise concerns about these negative reports (MacLachlan, 2002). These revelations, together with the conclusions of the three independent panels mentioned above, appear to bring to an end the apparent controversy about the presence of SV40 in human mesotheliomas and brain tumors.	Loyola Univ, Dept Pathol, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Maywood, IL 60153 USA; Wayne State Univ, Sch Med, Karmanos Canc Ctr, Detroit, MI USA; Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL USA	Loyola University Chicago; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Carbone, M (corresponding author), Loyola Univ, Dept Pathol, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Room 205,2160 S 1st Ave, Maywood, IL 60153 USA.	mcarbon@orion.it.luc.edu		Miele, Lucio/0000-0002-5853-7287; Pass, Harvey/0000-0003-3222-3471				BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; CARBONE M, 2003, IN PRESS INT J CANC; Carroll-Pankhurst C, 2001, BRIT J CANCER, V85, P1295, DOI 10.1054/bjoc.2001.2065; De Rienzo A, 2002, J CELL BIOCHEM, V84, P455, DOI 10.1002/jcb.10058.abs; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Dhaene K, 1999, VIRCHOWS ARCH, V435, P1, DOI 10.1007/s004280050387; Emri S, 2000, ANTICANCER RES, V20, P891; Engels EA, 2002, INT J CANCER, V101, P348, DOI 10.1002/ijc.10621; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Fisher SG, 1999, ANTICANCER RES, V19, P2173; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; GEISSLER E, 1990, PROG MED VIROL, V37, P211; Gordon GJ, 2002, ONCOL REP, V9, P631; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; Heinsohn S, 2000, ANTICANCER RES, V20, P4539; Hirvonen A, 1999, MOL CARCINOGEN, V26, P93, DOI 10.1002/(SICI)1098-2744(199910)26:2<93::AID-MC4>3.3.CO;2-Q; Hubner R, 2002, CANCER CAUSE CONTROL, V13, P121, DOI 10.1023/A:1014321729038; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; *IOM, 2002, IMM SAF REV SV40 CON; Jasani B, 1999, THORAX, V54, P750, DOI 10.1136/thx.54.8.750b; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; JENSEN F, 1964, J NATL CANCER I, V32, P917; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; Leithner A, 2002, CANCER BIOL THER, V1, P375; MacLachlan DS, 2002, ANTICANCER RES, V22, P3495; MARK EJ, 1991, ANN NY ACAD SCI, V643, P196, DOI 10.1111/j.1749-6632.1991.tb24463.x; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; Mulatero C, 1999, THORAX, V54, P60, DOI 10.1136/thx.54.1.60; Olin P, 1998, DEV BIOL STAND, V94, P227; Pass HI, 1996, CANCER RES, V56, P4044; Ramael M, 1999, EUR RESPIR J, V14, P1381, DOI 10.1183/09031936.99.14613819; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Salewski H, 1999, CANCER RES, V59, P1980; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; Strickler HD, 2001, CANCER EPIDEM BIOMAR, V10, P523; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Testa JR, 1998, CANCER RES, V58, P4505; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; Toyooka S, 2001, CANCER RES, V61, P5727; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; Waheed I, 1999, CANCER RES, V59, P6068; Weggen S, 2000, BRAIN PATHOL, V10, P85; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	58	71	83	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5173	5180		10.1038/sj.onc.1206552	http://dx.doi.org/10.1038/sj.onc.1206552			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910254				2022-12-17	WOS:000184615100008
J	Orend, G; Huang, WT; Olayioye, MA; Hynes, NE; Chiquet-Ehrismann, R				Orend, G; Huang, WT; Olayioye, MA; Hynes, NE; Chiquet-Ehrismann, R			Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4	ONCOGENE			English	Article						fibronectin; tenascin-C; syndecan-4; cell cycle; cdk2; FAK	FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; HEPARIN-BINDING; MAMMARY-GLAND; RHO GTPASES; INTEGRIN; EXPRESSION; P27(KIP1); GROWTH	Tenascin-C is an adhesion-modulatory extracellular matrix protein that is predominantly expressed during embryonic development, wound healing and in tumor stroma. Here we report that anchorage-dependent human, rat and mouse fibroblasts adhere poorly and fail to proliferate on pure tenascin-C. This was due to a significant reduction of cyclin-dependent kinase 2 (cdk2) activity, resulting from elevated expression and association of the cdk inhibitors (CKIs) p21Cip1 and p27Kip1. To analyse the effect of tenascin-C on fibronectin-mediated adhesion, cells were plated on a mixed. bronectin/tenascin-C substratum. Compared to fibronectin alone, cell spreading and adhesion signaling were compromised, as determined by delayed phosphorylation kinetics of focal adhesion kinase (FAK). Despite the presence of growth factors, these cells remained arrested in the G1 phase of the cell cycle. In contrast to cells plated on pure tenascin-C, cdk2activity appeared to be inhibited independently of CKIs. Interestingly, overexpression of the transmembrane proteoglycan syndecan-4 restored cell spreading, adhesion signaling and DNA replication on the fibronectin/tenascin-C substratum. A similar rescue was observed using a recombinant peptide that spans the syndecan-4-binding site in fibronectin. This indicates that tenascin-C causes cell cycle arrest and cdk2 inactivation by interfering with fibronectin-syndecan-4 interactions. We therefore propose that syndecan-4 signaling plays a central role in the control of cellular proliferation of anchorage-dependent fibroblasts.	Novartis Forschungsstiftung, Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Orend, G (corresponding author), Univ Basel, Inst Biochem & Genet, Vesalgasse 1, CH-4051 Basel, Switzerland.		Orend, Gertraud/E-8446-2015	Orend, Gertraud/0000-0003-2522-1195				Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Denhez F, 2002, J BIOL CHEM, V277, P12270, DOI 10.1074/jbc.M110291200; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Garcion E, 2001, DEVELOPMENT, V128, P2485; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOULD VE, 1990, CELL DIFFER DEV, V32, P409, DOI 10.1016/0922-3371(90)90057-4; Graus-Porta D, 2001, NEURON, V31, P367, DOI 10.1016/S0896-6273(01)00374-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hauzenberger D, 1999, EUR J IMMUNOL, V29, P1435, DOI 10.1002/(SICI)1521-4141(199905)29:05<1435::AID-IMMU1435>3.0.CO;2-N; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Huang WT, 2001, CANCER RES, V61, P8586; HYNES RO, 1994, CURR OPIN GENET DEV, V4, P569, DOI 10.1016/0959-437X(94)90074-D; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kalembeyi I, 1997, INT J DEV BIOL, V41, P569; Kuzumaki T, 1997, BIOCHEM BIOPH RES CO, V238, P169, DOI 10.1006/bbrc.1997.7267; Landry R, 2001, CELL GROWTH DIFFER, V12, P497; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Mackie EJ, 1999, J CELL SCI, V112, P3847; Midwood KS, 2002, MOL BIOL CELL, V13, P3601, DOI 10.1091/mbc.E02-05-0292; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Orend G, 2000, EXP CELL RES, V261, P104, DOI 10.1006/excr.2000.5041; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VAN AL, 1997, GENE DEV, V11, P2295; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Vollmer G, 1997, CRIT REV ONCOL HEMAT, V25, P187, DOI 10.1016/S1040-8428(97)00004-8; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Wilcox-Adelman SA, 2002, J BIOL CHEM, V277, P32970, DOI 10.1074/jbc.M201283200; YOUNG SL, 1994, DEV BIOL, V161, P615, DOI 10.1006/dbio.1994.1057; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	55	71	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3917	3926		10.1038/sj.onc.1206618	http://dx.doi.org/10.1038/sj.onc.1206618			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813465				2022-12-17	WOS:000183612000011
J	Fleury-Feith, J; Lecomte, C; Renier, A; Matrat, M; Kheuang, L; Abramowski, V; Levy, F; Janin, A; Giovannini, M; Jaurand, MC				Fleury-Feith, J; Lecomte, C; Renier, A; Matrat, M; Kheuang, L; Abramowski, V; Levy, F; Janin, A; Giovannini, M; Jaurand, MC			Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours	ONCOGENE			English	Article						asbestos; NF2; mesothelioma; hemizygous mice	HUMAN-MALIGNANT MESOTHELIOMA; FACTOR SCATTER FACTOR; NEUROFIBROMATOSIS TYPE-2; SUPPRESSOR GENES; FISCHER-344 RATS; VITREOUS FIBERS; MINERAL FIBERS; INTRAPERITONEAL; GROWTH; TOXICITY	Biallelic NF2 gene inactivation is frequently found in human malignant mesothelioma. In order to assess whether NF2 hemizygosity may enhance susceptibility to asbestos fibres, we investigated the Nf2 status in mesothelioma developed in mice presenting a heterozygous mutation of the Nf2 gene (Nf2(KO3/+)), after intraperitoneal inoculation of crocidolite fibres. Asbestos-exposed Nf2(KO3/+) mice developed tumoural ascites and mesothelioma at a higher frequency than their wild-type (WT) counterparts (P<0.05). Six out of seven mesothelioma cell lines established from neoplastic ascitic fluids of Nf2(KO3/+) mice exhibited loss of the WT Nf2 allele and no neurofibromatosis type 2 protein expression was found in these cells. The res its show the importance of the NF2 gene in mesothelial oncogenesis, the potential association of asbestos exposure and tumour suppressor gene inactivation, and suggest that NF2 gene mutation may be a susceptibility factor to asbestos.	Univ Paris 12, INSERM EMI 99 09, Fac Med, F-94010 Creteil, France; Hop Tenon, Serv Histol Biol Tumorale, F-75020 Paris, France; Ctr Hosp Intercommunal, Serv Pathol Professionelles, F-94010 Creteil, France; Fdn Jean Dasset, INSERM U434, CEPH, F-75010 Paris, France; Univ Paris 07, Pathol Lab, ERM 220 INSERM, Hop St Louis, F-75010 Paris, France; Univ Paris 07, ERM 220 INSERM, Pathol Lab, Hop St Louis, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jaurand, MC (corresponding author), Univ Paris 12, INSERM EMI 99 09, Fac Med, 8 Rue Gen Sarrail, F-94010 Creteil, France.		JAURAND, MARIE-CLAUDE/S-3538-2017	JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; Boulange-Lecomte, Celine/0000-0002-2461-7473; Matrat, Mireille/0000-0001-9252-2612				Adachi S, 2001, IND HEALTH, V39, P168, DOI 10.2486/indhealth.39.168; ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230; ASPLUND T, 1994, CANCER RES, V54, P4516; Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; CRAIGHEAD JE, 1994, LUNG BIOL HEALTH DIS, V78, P79; Cullen RT, 2000, INHAL TOXICOL, V12, P959; Cullen RT, 2000, J APPL TOXICOL, V20, P49, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<49::AID-JAT627>3.0.CO;2-L; DAVIS JMG, 1991, INT J EXP PATHOL, V72, P263; Deguen B, 1998, INT J CANCER, V77, P554, DOI 10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6; Giovannini M, 2000, GENE DEV, V14, P1617; GOODGLICK LA, 1986, CANCER RES, V46, P5558; Grander D, 1998, MED ONCOL, V15, P20, DOI 10.1007/BF02787340; Gutmann DH, 2001, HUM MOL GENET, V10, P747, DOI 10.1093/hmg/10.7.747; HANSTEEN IL, 1993, CANCER GENET CYTOGEN, V70, P94, DOI 10.1016/0165-4608(93)90174-K; Harvey P, 1996, J PATHOL, V180, P389; HESTERBERG TW, 1993, FUND APPL TOXICOL, V20, P464, DOI 10.1006/faat.1993.1057; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; Kociok N, 1999, CANCER GENET CYTOGEN, V111, P71, DOI 10.1016/S0165-4608(98)00221-0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lechner JF, 1997, ENVIRON HEALTH PERSP, V105, P1061, DOI 10.2307/3433510; Lee YCG, 2002, AM J RESP CRIT CARE, V165, P88, DOI 10.1164/ajrccm.165.1.2104006; MAST RW, 1995, INHAL TOXICOL, V7, P425, DOI 10.3109/08958379509015208; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MOALLI PA, 1987, AM J PATHOL, V128, P426; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; POTT F, 1987, EXP PATHOL-JENA, V32, P129, DOI 10.1016/S0232-1513(87)80044-0; Pylkkanen L, 2002, ONCOL REP, V9, P955; Roller M, 1996, EXP TOXICOL PATHOL, V48, P3, DOI 10.1016/S0940-2993(96)80084-4; Roller M, 1997, ENVIRON HEALTH PERSP, V105, P1253, DOI 10.2307/3433542; Sandhu H, 2000, CARCINOGENESIS, V21, P1023, DOI 10.1093/carcin/21.5.1023; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shibuya M, 1999, CANCER CHEMOTH PHARM, V43, pS72, DOI 10.1007/s002800051102; SMITH DM, 1987, ANN OCCUP HYG, V31, P731, DOI 10.1093/annhyg/31.4B.731; SUZUKI Y, 1984, ENVIRON RES, V35, P277, DOI 10.1016/0013-9351(84)90136-1; Unfried K, 1997, ENVIRON HEALTH PERSP, V105, P1103, DOI 10.2307/3433516; Vaslet CA, 2002, TOXICOL SCI, V68, P331, DOI 10.1093/toxsci/68.2.331; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364; 2001, J O REPUBLIQUE  0608, P9094	41	71	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3799	3805		10.1038/sj.onc.1206593	http://dx.doi.org/10.1038/sj.onc.1206593			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802287				2022-12-17	WOS:000183551000014
J	Gabet, AS; Mortreux, F; Charneau, P; Riou, P; Duc-Dodon, M; Wu, YL; Jeang, KT; Wattel, E				Gabet, AS; Mortreux, F; Charneau, P; Riou, P; Duc-Dodon, M; Wu, YL; Jeang, KT; Wattel, E			Inactivation of hTERT transcription by Tax	ONCOGENE			English	Article						telomere; telomerase HTLV-1 hTERT oncogene; oncogenegic leukemogenesis	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; COMPARATIVE GENOMIC HYBRIDIZATION; INHIBITS TELOMERASE ACTIVITY; HTLV-1 TAX; P53 GENE; IN-VIVO; BINDING ELEMENT; CANCER CELLS; CYCLE ARREST	Telomerase expression is the hallmark of tumor cells in which this ribonucleoprotein complex preserves chromosome integrity by maintaining telomere length and thereby prevents cell death. However, recent data support a role of the combination of p53 and telomerase inactivation in initiating genetic instability that promotes malignant transformation. Through its pleiotropic effects on infected T-cell metabolism, the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax plays a central role in leukemogenesis. Here, we show that Tax inhibits human telomerase reverse transcriptase (hTERT) transcription, which is the rate-limiting factor of telomerase activity. This inhibitory effect, that occurs in competition with c-Myc through a canonical c-Myc binding site within the hTERT promoter, results in a decreased telomerase activity of Tax-expressing cells. This is the first demonstration of hTERT inhibition by an oncogene. Tax, which is only expressed in preleukemic cells, triggers infected T-cell cycle and keeps these cells cycling while inactivating p53. We propose that, in combination with these effects, h TER T repression by Tax at an early phase of carcinogenesis might contribute to the massive ploidy changes associated with the development of HTLV-1-associated malignancies.	Ctr Leon Berard, CNRS UMR 5537, Unite Oncogenese Viral, F-69373 Lyon 08, France; Inst Pasteur, Grp Virol Mol & Vector, F-75724 Paris, France; Fac Med Lyon Laennec, CNRS UMR 5537, F-69372 Lyon 8, France; NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA; Hop Edouard Herriot, Hematol Serv, F-69437 Lyon 03, France	UNICANCER; Centre Leon Berard; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); CHU Lyon	Wattel, E (corresponding author), Univ Lyon 1, UMR5578 CNRS, Ctr Leon Berard, 28 Rue Laennec, F-69373 Lyon 08, France.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; CESARMAN E, 1992, BLOOD, V80, P3205; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; FUJII M, 1991, ONCOGENE, V6, P1023; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; Gauthier LR, 2001, BRIT J CANCER, V84, P631, DOI 10.1054/bjoc.2000.1662; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Horikawa I, 1999, CANCER RES, V59, P826; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kitagawa Y, 2000, CLIN CANCER RES, V6, P2868; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; LEE M, J BIOL CHEM, V277, P27748; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NISHIMURA S, 1995, LEUKEMIA, V9, P598; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; REID RL, 1993, ONCOGENE, V8, P3029; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Royer-Leveau C, 2002, J VIROL METHODS, V105, P133, DOI 10.1016/S0166-0934(02)00097-6; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SAKASHITA A, 1992, BLOOD, V79, P477; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 2000, BLOOD, V95, P3939; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Uchida N, 1999, LEUKEMIA RES, V23, P311, DOI 10.1016/S0145-2126(98)00170-2; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	59	71	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3734	3741		10.1038/sj.onc.1206468	http://dx.doi.org/10.1038/sj.onc.1206468			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802280				2022-12-17	WOS:000183551000007
J	Wang, WS; Chen, PM; Hsiao, HL; Ju, SY; Su, Y				Wang, WS; Chen, PM; Hsiao, HL; Ju, SY; Su, Y			Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells	ONCOGENE			English	Article						thymosin beta-4; SW480; E-cadherin; beta-catenin; c-Myc; malignancy	ACTIN-SEQUESTERING PEPTIDE; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; EPITHELIAL-CELLS; PROSTATE-CANCER; CATENIN COMPLEX; BREAST-CANCER; E-CADHERIN; EXPRESSION; CYTOSKELETON	Thymosin beta-4 (Tbeta-4), a small peptide originally isolated from calf thymus, modulates the formation of F-actin microfilaments by sequestering the monomeric G-actin. Recent studies have shown that overexpression of the Tbeta-4 gene occurs not only in many human carcinomas but also in the highly metastatic melanomas and fibrosarcomas. However, little is known about the specific growth advantages acquired by different tumors from this genetic abnormality. To address the above questions, Tbeta-4-overexpressing human colon carcinoma (SW480) cells were established by stable transfection and their phenotypic changes were monitored. We found that both the morphology and the cortical actin cytoskeleton of SW480 cells were altered by Tbeta-4 overexpression. Moreover, both cellular level and that distributed over the intercellular junctions of the E-cadherin were decreased in the Tbeta-4 overexpressers, which were accompanied by a twofold increase in their saturation densities. Meanwhile, these cells also exhibited an increased ability to form colonies in soft agar. Interestingly, a dramatic increase of growth rate was detected in the Tbeta-4 overexpressers, which might be attributed to an accelerated proliferation induced by c-Myc that was activated by nuclear beta-catenin. Finally, a motility increase of these cells was demonstrated by two independent migration assays, which was accompanied by an enhanced focal contact. Taken together, our data suggest that the drastic growth property and motility changes of the SW480 cells overexpressing Tbeta-4 gene are due mainly to a deregulated cell-cell adhesion arisen from the downregulation of E-cadherin, plus uncontrolled cell proliferation owing to the upregulation of beta-catenin, both resulted from a breakdown of actin microfilaments caused by the overexpression of this G-actin sequestering peptide.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan; Natl Yang Ming Univ, Coll Life Sci, Inst Pharmacol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tv						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Barker N, 2000, BIOESSAYS, V22, P961; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Califano D, 1998, CANCER RES, V58, P823; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Chakravarti A, 2000, UROLOGY, V55, P635, DOI 10.1016/S0090-4295(00)00462-3; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gold JS, 1997, MODERN PATHOL, V10, P1106; Golla R, 1997, CELL MOTIL CYTOSKEL, V38, P187, DOI 10.1002/(SICI)1097-0169(1997)38:2<187::AID-CM7>3.0.CO;2-4; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Lee SH, 2001, ONCOGENE, V20, P6700, DOI 10.1038/sj.onc.1204683; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; LOW TLK, 1982, J BIOL CHEM, V257, P1000; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakanishi K, 2002, CANCER RES, V62, P2971; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Quigley JP, 1998, CELL, V94, P281, DOI 10.1016/S0092-8674(00)81470-1; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P307, DOI 10.1002/cm.970310407; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sardi I, 2002, INT J MOL MED, V9, P541; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sellin JH, 2001, CANCER RES, V61, P2899; Sosne G, 2002, CURR EYE RES, V24, P268, DOI 10.1076/ceyr.24.4.268.8414; Su Y, 2000, MOL CELL BIOCHEM, V203, P163, DOI 10.1023/A:1007020619788; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tang RY, 1997, J VIROL METHODS, V65, P153, DOI 10.1016/S0166-0934(97)02176-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VARNUMFINNEY B, 1994, J CELL BIOL, V127, P1071, DOI 10.1083/jcb.127.4.1071; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WETERMAN MAJ, 1993, INT J CANCER, V53, P278, DOI 10.1002/ijc.2910530218; Xie D, 2002, INT J ONCOL, V21, P499; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103	57	71	79	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3297	3306		10.1038/sj.onc.1206404	http://dx.doi.org/10.1038/sj.onc.1206404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761500				2022-12-17	WOS:000183040000012
J	Fink, SP; Mikkola, D; Willson, JKV; Markowitz, S				Fink, SP; Mikkola, D; Willson, JKV; Markowitz, S			TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines	ONCOGENE			English	Article						TGF-beta; Smad4; Smad2; Smad3; colon cancer	GROWTH-FACTOR-BETA; HUMAN PANCREATIC ADENOCARCINOMA; TUMOR-SUPPRESSOR GENE; SIGNALING PATHWAYS; RECEPTOR; DPC4; INHIBITION; COMPLEX; PHOSPHORYLATION; ACTIVATION	Smad4 is a tumor suppressor gene that is commonly lost or mutated in colorectal and pancreatic cancers. The activated transforming growth factor-beta (TGF-beta) receptor phosphorylates Smad2 and Smad3, which then complex with Smad4 and translocate to the nucleus. Smad4 mutations when detected as present in some human cancers have been considered sufficient to inactivate TGF-beta signaling. In this work, we describe a colon cancer cell line, VACO-9M, that is Smad4 null when analysed by multiple assays. To study the role of Smad4 in TGF-beta-induced translocation of the receptor-activated Smads to the nucleus, we analysed by immunofluorescence the cellular localization of endogenous Smad2 and Smad3 after TGF-beta treatment of VACO-9M, plus four additional Smad4 null cell lines of breast (MDA-MB-468), or pancreatic (BxPC3, Hs766T, CFPAC-1) origin. In each cell line, TGF-beta treatment resulted in both Smad2 and Smad3 moving to the nucleus in a Smad4-independent fashion. Nuclear translocation of Smad2 and Smad3 was, however, not sufficient to activate reporters for TGF-beta-induced transcriptional responses, which were however restored by transient transfection of wild-type Smad4. We conclude that Smad4 is not required for nuclear translocation of Smad2 and Smad3, but is needed activation of at least certain transcriptional responses.	Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA; Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA	Case Western Reserve University; Howard Hughes Medical Institute; University Hospitals of Cleveland	Markowitz, S (corresponding author), Case Western Reserve Univ, Ireland Canc Ctr, Coroners Bldg,Suite 200,11001 Cedar Rd, Cleveland, OH 44106 USA.			Fink, Stephen/0000-0003-4107-7912	NATIONAL CANCER INSTITUTE [R01CA072160, R01CA067409, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA72160, P30 CA43703, R01 CA67409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Fink SP, 2001, CANCER RES, V61, P256; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Grady WM, 1999, CANCER RES, V59, P320; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; Simeone DM, 2000, ANN SURG, V232, P73, DOI 10.1097/00000658-200007000-00011; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Venkatasubbarao K, 2000, ANTICANCER RES, V20, P43; WILLSON JKV, 1987, CANCER RES, V47, P2704; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	26	71	73	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1317	1323		10.1038/sj.onc.1206128	http://dx.doi.org/10.1038/sj.onc.1206128			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618756				2022-12-17	WOS:000181360900005
J	Frese, KK; Lee, SS; Thomas, DL; Latorre, IJ; Weiss, RS; Glaunsinger, BA; Javier, RT				Frese, KK; Lee, SS; Thomas, DL; Latorre, IJ; Weiss, RS; Glaunsinger, BA; Javier, RT			Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein	ONCOGENE			English	Article						adenovirus; E4-ORF1; PDZ; PI3K; oncoprotein	TUMOR-SUPPRESSOR PROTEIN; PAPILLOMAVIRUS E6 ONCOPROTEINS; READING FRAME-1 ENCODES; GUANYLATE KINASE; S6 KINASE; ONCOGENIC TRANSFORMATION; MAMMARY TUMORIGENESIS; SIGNALING PATHWAY; DOMAIN PROTEIN; HUMAN HOMOLOG	While PDZ domain-containing proteins represent cellular targets for several different viral oncoproteins, including human papillomavirus E6, human T-cell leukemia virus type 1 Tax, and human adenovirus E4-ORF1, the functional consequences for such interactions have not been elucidated. Here we report that, at the plasma membrane of cells, the adenovirus E4-ORF1 oncoprotein selectively and potently stimulates phosphatidylinositol 3-kinase (PI3K), triggering a downstream cascade of events that includes activation of both protein kinase B and p70S6-kinase. This activity of E4-ORF1 could be abrogated by overexpression of its PDZ-protein targets or by disruption of its PDZ domain-binding motif, which was shown to mediate complex formation between E4-ORF1 and PDZ proteins at the plasma membrane of cells. Furthermore, E4-ORF1 mutants unable to activate the PI3K pathway failed to transform cells in culture or to promote tumors in animals, and drugs that block either PI3K or p70S6-kinase inhibited E4-ORF1-induced transformation of cells. From these results, we propose that the transforming and tumorigenic potentials of the adenovirus E4-ORF1 oncoprotein depend on its capacity to activate PI3K through a novel PDZ protein-dependent mechanism of action.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Javier, RT (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.	rjavier@bcm.tmc.edu		Latorre, Isabel/0000-0003-0638-1783	NCI NIH HHS [R01 CA058541, T32 CA009197, R01 CA58541, T32 CA09197] Funding Source: Medline; NIAID NIH HHS [T32 AI07471, T32 AI007471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009197, R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; PELECH SL, 1987, J BIOL CHEM, V262, P11598; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SUSA M, 1992, J BIOL CHEM, V267, P22951; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas DL, 2001, J VIROL, V75, P557, DOI 10.1128/JVI.75.2.557-568.2001; Tsatsanis C, 2000, INT J MOL MED, V5, P583; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Uthoff SMS, 2001, MOL CARCINOGEN, V31, P56, DOI 10.1002/mc.1039; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamada KM, 2001, J CELL SCI, V114, P2375; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	51	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					710	721		10.1038/sj.onc.1206151	http://dx.doi.org/10.1038/sj.onc.1206151			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569363	Green Accepted			2022-12-17	WOS:000180642100008
J	Kanai, M; Konda, Y; Nakajaima, T; Izumi, Y; Kanda, N; Nanakin, A; Kubohara, Y; Chiba, T				Kanai, M; Konda, Y; Nakajaima, T; Izumi, Y; Kanda, N; Nanakin, A; Kubohara, Y; Chiba, T			Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway	ONCOGENE			English	Article						DIF-1; STAT3; ERK; cell growth; gastric cancer	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; SERINE PHOSPHORYLATION; DICTYOSTELIUM-DISCOIDEUM; CONSTITUTIVE ACTIVATION; PUTATIVE MORPHOGEN; SUPPRESSES GROWTH; LEUKEMIA-CELLS; DNA-BINDING; IN-VITRO	Differentiation-inducing factor-1 (DIF-1) is a chlorinated hexaphenone isolated from Dictyostelium. DIF-1 exhibits antitumor activity in several types of mammalian tumor cells, although the underlying mechanisms remain unknown. On the other hand, recent studies indicate that constitutively activated STAT3 acts as an oncogene and could be a target for antitumor drug. In the present study, we examined the effects of DIF-1 on proliferation of gastric cancer cell lines as well as on its signal transduction pathways, focusing mainly on STAT proteins. DIF-1 inhibited proliferation of gastric cancer cells. Western blot analysis and electrophoretic mobility shift assay showed that DIF-1 inhibited STAT3 activity in an MEK-ERK-dependent manner in gastric cancer cell lines, AGS and MKN28. Moreover, blockade of STAT3 activity by ectopic expression of dominant-negative STAT3 or the Janus kinase inhibitor, tyrphostin AG490, inhibited cell growth of AGS cells. These results suggest that STAT3 activity plays an important role for cell growth in AGS cells, and raises the possibility that inhibition of STAT3 activity is one of the mechanisms responsible for the antitumor effect of DIF-1 in these cells.	Kyoto Univ, Grad Sch Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Dept Mol Physiol, Maebashi, Gumma 3718512, Japan	Kyoto University; Gunma University	Konda, Y (corresponding author), Kyoto Univ, Grad Sch Med, Div Gastroenterol & Hepatol, Sakyo Ku, 54 Shogoin, Kyoto 6068507, Japan.		Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648				ASAHI KI, 1995, BIOCHEM BIOPH RES CO, V208, P1036, DOI 10.1006/bbrc.1995.1438; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gollob JA, 1999, J IMMUNOL, V162, P4472; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ishiyama M, 1997, TALANTA, V44, P1299, DOI 10.1016/S0039-9140(97)00017-9; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KUBOHARA Y, 1995, FEBS LETT, V359, P119, DOI 10.1016/0014-5793(95)00022-2; Kubohara Y, 1999, BIOCHEM BIOPH RES CO, V263, P790, DOI 10.1006/bbrc.1999.1468; Kubohara Y, 1997, BIOCHEM BIOPH RES CO, V236, P418, DOI 10.1006/bbrc.1997.6964; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neugut AI, 1996, SEMIN ONCOL, V23, P281; Ni Z, 2000, CANCER RES, V60, P1225; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Niu GL, 2001, CANCER RES, V61, P3276; Sartor CI, 1997, CANCER RES, V57, P978; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	31	71	75	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					548	554		10.1038/sj.onc.1206109	http://dx.doi.org/10.1038/sj.onc.1206109			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555068				2022-12-17	WOS:000180538200008
J	Gunnarsson, C; Ahnstrom, M; Kirschner, K; Olsson, B; Nordenskjold, B; Rutqvist, LE; Skoog, L; Stal, O				Gunnarsson, C; Ahnstrom, M; Kirschner, K; Olsson, B; Nordenskjold, B; Rutqvist, LE; Skoog, L; Stal, O			Amplification of HSD17B1 and ERBB2 in primary breast cancer	ONCOGENE			English	Article						17q; 17 beta-HSD; breast cancer; ERBB2 estrogen; HSD17B1; real-time PCR	17-BETA-HYDROXYSTEROID DEHYDROGENASE; ESTRADIOL LEVELS; EXPRESSION; REGIONS; TYPE-1; TISSUE; TUMORS; CELLS; RECURRENCE; TAMOXIFEN	Estrogens play a crucial role in the development of breast cancer. Estradiol can be produced in the breast tissue in situ, and one of the enzymes involved in this process is 17beta-hydroxysteriod dehydrogenase (17beta-HSD) type 1 that catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17beta-HSD type 1 (HSD17B1) is located at 17q12-21, close to the more studied ERBB2 and BRCA1. The aim of this study was to investigate if HSD17B1 shows an altered gene copy number in breast cancer. We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2. In all, 32 tumors (14.5%) showed amplification of HSD17B1 and 21% were amplified for ERBB2. Amplification of the two genes was correlated (P = 0.00078) and in 14 tumors (44%) with amplification of HSD17B1, ERBB2 was co amplified. The patients with amplification in at least one of the genes had a significantly worse outcome than patients without (P = 0.0059). For estrogen receptor (ER)-positive patients who received adjuvant tamoxifen, amplification of HSD17B1 was related to decreased breast cancer survival (P=0.017), whereas amplification of ERRB2 was not. Amplification of HSD17B1 might be an indicator of adverse prognosis among ER-positive patients, and possibly a mechanism for decreased benefit from tamoxifen treatment.	Linkoping Univ, Dept Biomed & Surg, Div Oncol, Fac Hlth Sci, SE-58185 Linkoping, Sweden; Huddinge Univ Hosp, Dept Oncol, SE-14186 Stockholm, Sweden; Karolinska Hosp, Div Cytol, SE-10401 Stockholm, Sweden	Linkoping University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Stal, O (corresponding author), Linkoping Univ Hosp, Dept Oncol, SE-58185 Linkoping, Sweden.		Gunnarsson, Cecilia/ABD-9170-2021	Kirschner, Kristina/0000-0001-7607-8670				Bieche I, 1998, INT J CANCER, V78, P661, DOI 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.3.CO;2-9; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bieche I, 1996, CANCER RES, V56, P3886; Dowsett M, 1997, J STEROID BIOCHEM, V61, P261; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Feigelson HS, 2001, CANCER RES, V61, P785; Gunnarsson C, 2001, CANCER RES, V61, P8448; Jarvinen TAH, 2000, AM J PATHOL, V156, P839, DOI 10.1016/S0002-9440(10)64952-8; Kauraniemi P, 2001, CANCER RES, V61, P8235; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Latham C, 2001, CANCER GENET CYTOGEN, V127, P16, DOI 10.1016/S0165-4608(00)00427-1; LuuThe V, 1995, J STEROID BIOCHEM, V55, P581, DOI 10.1016/0960-0760(95)00209-X; MANNERMAA A, 1994, HUM GENET, V93, P319, DOI 10.1007/BF00212030; Miettinen MM, 1996, BIOCHEM J, V314, P839, DOI 10.1042/bj3140839; Miyoshi Y, 2001, INT J CANCER, V94, P685, DOI 10.1002/ijc.1525; Osborne RJ, 2000, CANCER RES, V60, P3706; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; POUTANEN M, 1992, INT J CANCER, V50, P386, DOI 10.1002/ijc.2910500310; Purohit A, 2002, BREAST CANCER RES, V4, P65, DOI 10.1186/bcr425; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Sasano H, 1996, J CLIN ENDOCR METAB, V81, P4042, DOI 10.1210/jc.81.11.4042; Speirs V, 1999, BRIT J CANCER, V81, P690, DOI 10.1038/sj.bjc.6690749; Speirs V, 1998, BRIT J CANCER, V78, P1421, DOI 10.1038/bjc.1998.702; Speirs V, 1998, J STEROID BIOCHEM, V67, P267, DOI 10.1016/S0960-0760(98)00119-8; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; Stal O, 2000, ANN ONCOL, V11, P1545, DOI 10.1023/A:1008313310474; Suzuki T, 2000, BRIT J CANCER, V82, P518; Utsumi T, 1999, CANCER RES, V59, P377; Vihko P, 2001, MOL CELL ENDOCRINOL, V171, P71, DOI 10.1016/S0303-7207(00)00389-0; Yue W, 1998, CANCER RES, V58, P927	30	71	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					34	40		10.1038/sj.onc.1206078	http://dx.doi.org/10.1038/sj.onc.1206078			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527905				2022-12-17	WOS:000180166900004
J	Hobbs, SS; Coffing, SL; Le, AT; Cameron, EM; Williams, EE; Andrew, M; Blommel, EN; Hammer, RP; Chang, H; Riese, DJ				Hobbs, SS; Coffing, SL; Le, AT; Cameron, EM; Williams, EE; Andrew, M; Blommel, EN; Hammer, RP; Chang, H; Riese, DJ			Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation	ONCOGENE			English	Article						heregulins; neuregulins; ErbB3; ErbB4; HER3; HER4	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASES; SIGNALING NETWORK; CELLULAR-RESPONSE; BETA-RECEPTOR; EGF DOMAIN; HEREGULIN; PROTEIN; LIGAND	During the last decade, several novel members of the Epidermal Growth Factor family of peptide growth factors have been identified. Most prominent among these are the Neuregulins or Heregulins. To date, four different Neuregulin genes have been identified (Neuregulin1-4) and several different splicing isoforms have been identified for :at least two of these genes (Neuregulin1 and Neuregulin2). While Neuregulin1 isoforms have been extensively studied, comparatively little is known about Neuregulin3, Neuregulin4, or the Neuregulin2 isoforms. Indeed, there has been no systematic comparison of the activities of these molecules. Here we demonstrate that Neuregulin2alpha and Neuregulin2beta stimulate ErbB3 tyrosine phosphorylation and coupling to biological responses. In contrast, Neuregulin3 and Neuregulin4 fail to activate ErbB3 signaling. Furthermore, Neuregulin2beta, but not Neuregulin2alpha, stimulates ErbB4 tyrosine phosphorylation and coupling to biological responses. Finally, both Neuregulin3 and Neuregulin4 stimulate modest amounts of ErbB4 tyrosine phosphorylation. However, whereas Neuregulin3 stimulates a modest amount of ErbB4 coupling to biological responses, Neuregulin4 fails to stimulate ErbB4 coupling to biological responses. This suggests that there are qualitative as well as quantitative differences in ErbB family receptor activation by Neuregulin isoforms.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Louisiana State University System; Louisiana State University; Bristol-Myers Squibb	Riese, DJ (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, 1333 RHPH,Room 224D, W Lafayette, IN 47907 USA.		Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [F33CA085049, R21CA080770] Funding Source: Medline; NIGMS NIH HHS [T32GM008737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F33CA085049, R21CA080770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; DrummondBarbosa D, 1997, BBA-REV CANCER, V1332, pM1, DOI 10.1016/S0304-419X(96)00034-0; Feroz K, 2002, CELL SIGNAL, V14, P793, DOI 10.1016/S0898-6568(02)00019-0; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Gullick WJ, 2001, ENDOCR-RELAT CANCER, V8, P75, DOI 10.1677/erc.0.0080075; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Hijazi MM, 1998, INT J ONCOL, V13, P1061; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Kumar R, 2000, J CLIN LIGAND ASSAY, V23, P233; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; Pinkas-Kramarski R, 1999, MOL CELL BIOL, V19, P8695; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; SWEENEYCROVELLO C, 1998, J BIOL CHEM, V273, P26954; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	39	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8442	8452		10.1038/sj.onc.1205960	http://dx.doi.org/10.1038/sj.onc.1205960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466964				2022-12-17	WOS:000179480100007
J	He, J; Navarrete, S; Jasinski, M; Vulliamy, T; Dokal, I; Bessler, M; Mason, PK				He, J; Navarrete, S; Jasinski, M; Vulliamy, T; Dokal, I; Bessler, M; Mason, PK			Targeted disruption of Dkc1, the gene mutated in X-linked dyskeratosis congenita, causes embryonic lethality in mice	ONCOGENE			English	Article						dyskerin; dyskeratosis congenita; Dkc1; deficient mice; telomerase	RIBOSOMAL-RNA; IN-VIVO; SHORT TELOMERES; MUTATIONS; INACTIVATION; COMPONENT; CBF5P	Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome associated with increased cancer susceptibility. The X-linked form is due to mutations in the DKC1 gene encoding dyskerin, a nucleolar protein predicted to be involved in rRNA processing and associated with the telomerase complex. Available evidence suggests the pathology of DC is due to telomerase defects. We have used the inducible Cre/loxP system to produce deletions in the murine Dkc1 gene in early embryogenesis. A large deletion lacking exons 12-15 and a small deletion lacking only the last exon, were produced. We found both deletions showed a parent-of-origin effect with 100% embryonic lethality when the mutation occurred on the maternal Dkc1. Embryonic analysis at day E7.5 and E9.5 showed no male embryos carrying either deletion whereas females with maternally derived deletions died around day E9.5, with degeneration of the extra embryonic tissue, in which the paternal X-chromosome is inactivated. Female mice carrying the deletion in the paternally derived Dkc1 show extreme skewing of X-inactivation with the wild type X-chromosome active in all cells. Since mice with no telomerase are viable in the first generations the lethality we observe is unlikely to be due to the effects of mutated dyskerin on telomerase activity.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Hematol, Div Invest Sci, London W12 0NN, England	Washington University (WUSTL); Imperial College London	Bessler, M (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S euclid Ave,Box 8125, St Louis, MO 63110 USA.			Dokal, Inderjeet/0000-0003-4462-4782	NCI NIH HHS [CA-89091, P30CA91842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089091, P30CA091842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER BP, 1998, HEMATOLOGY INFANCY C, V1, P216; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cadwell C, 1997, MOL CELL BIOL, V17, P6175, DOI 10.1128/MCB.17.10.6175; Giordano E, 1999, J CELL BIOL, V144, P1123, DOI 10.1083/jcb.144.6.1123; HARPER MI, 1982, J EMBRYOL EXP MORPH, V67, P127; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Keller P, 1999, P NATL ACAD SCI USA, V96, P7479, DOI 10.1073/pnas.96.13.7479; Knight SW, 1999, BRIT J HAEMATOL, V107, P335, DOI 10.1046/j.1365-2141.1999.01690.x; Knight SW, 1999, AM J HUM GENET, V65, P50, DOI 10.1086/302446; Knight SW, 2001, HUM GENET, V108, P299, DOI 10.1007/s004390100494; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Marciniak RA, 2000, TRENDS GENET, V16, P193, DOI 10.1016/S0168-9525(00)01984-3; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Prescott JC, 1999, CURR OPIN GENET DEV, V9, P368, DOI 10.1016/S0959-437X(99)80055-0; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Spedaliere CJ, 2000, BIOCHEMISTRY-US, V39, P9459, DOI 10.1021/bi001079n; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2002, LANCET, V359, P2168, DOI 10.1016/S0140-6736(02)09087-6; Vulliamy TJ, 1999, BLOOD, V94, P1254, DOI 10.1182/blood.V94.4.1254.416k24_1254_1260; Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461	27	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7740	7744		10.1038/sj.onc.1205969	http://dx.doi.org/10.1038/sj.onc.1205969			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400016				2022-12-17	WOS:000178756200013
J	Krause, DS				Krause, DS			Regulation of hematopoietic stem cell fate	ONCOGENE			English	Article						hematopoiesis; microenvironment; differentiation; niche; notch	GROWTH-FACTOR; STROMAL CELLS; HUMAN HOMOLOG; ERYTHROID-DIFFERENTIATION; NOTCH LIGAND; IN-VITRO; EXPRESSION; LEUKEMIA; TRANSCRIPTION; PROGENITORS		Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA	Yale University	Krause, DS (corresponding author), Yale Univ, Sch Med, Dept Lab Med, 333 Cedar St, New Haven, CT 06520 USA.	diane.krause@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL063357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63357] Funding Source: Medline; NIDDK NIH HHS [DK 53037] Funding Source: Medline; PHITPO CDC HHS [HK 69207] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHITPO CDC HHS		Becker PS, 1999, EXP HEMATOL, V27, P533, DOI 10.1016/S0301-472X(98)00037-X; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; Billia F, 2001, BLOOD, V97, P2257, DOI 10.1182/blood.V97.8.2257; Bond HM, 1998, STEM CELLS, V16, P136, DOI 10.1002/stem.160136; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brouard N, 1998, LEUKEMIA, V12, P1128, DOI 10.1038/sj.leu.2401081; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Coulombel L, 1997, ACTA HAEMATOL-BASEL, V97, P13, DOI 10.1159/000203655; Craddock CF, 1997, BLOOD, V90, P4779, DOI 10.1182/blood.V90.12.4779.4779_4779_4788; Dao MA, 1999, LEUKEMIA, V13, P1473, DOI 10.1038/sj.leu.2401537; Detmer K, 2000, BLOOD CELL MOL DIS, V26, P360, DOI 10.1006/bcmd.2000.0318; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; EAVES CJ, 1991, BLOOD, V78, P110; Florence B, 1998, GENETICS, V150, P1497; Fortunel N, 2000, STEM CELLS, V18, P102, DOI 10.1634/stemcells.18-2-102; Goodman RH, 2000, GENE DEV, V14, P1553; Hayflick L, 1998, EXP GERONTOL, V33, P639, DOI 10.1016/S0531-5565(98)00023-0; HENSCHLER R, 1994, BLOOD, V84, P2898, DOI 10.1182/blood.V84.9.2898.bloodjournal8492898; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; JACOBSEN FW, 1995, BLOOD, V86, P2957; Jensen UB, 1999, DEVELOPMENT, V126, P2409; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Koyano-Nakagawa N, 1999, MOL CELL NEUROSCI, V14, P327, DOI 10.1006/mcne.1999.0783; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Levesque JP, 1999, EXP HEMATOL, V27, P579, DOI 10.1016/S0301-472X(98)00069-1; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; McNiece I, 2001, EXP HEMATOL, V29, P3, DOI 10.1016/S0301-472X(00)00610-X; MILNER LA, 1994, BLOOD, V83, P2057; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Montecino-Rodriguez E, 2001, J LEUKOCYTE BIOL, V70, P341; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PAPAYANNOPOULOU T, 1993, P NATL ACAD SCI USA, V90, P9374, DOI 10.1073/pnas.90.20.9374; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Rosendaal Martin, 2000, Pathology and Oncology Research, V6, P243; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sitnicka E, 1996, BLOOD, V88, P82; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Valdez P, 1999, COLD SPRING HARB SYM, V64, P27, DOI 10.1101/sqb.1999.64.27; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	68	71	74	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3262	3269		10.1038/sj.onc.1205316	http://dx.doi.org/10.1038/sj.onc.1205316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032767				2022-12-17	WOS:000175633300002
J	Wade, R; Bohl, J; Pol, SV				Wade, R; Bohl, J; Pol, SV			Paxillin null embryonic stem cells are impaired in cell spreading and tyrosine phosphorylation of focal adhesion kinase	ONCOGENE			English	Article						cytoskeleton; paxillin; FAK; integrin; kinases; actin	PHOSPHATASE-PEST; BINDING PROTEIN; C-ABL; ASSOCIATION; LOCALIZATION; MOTIF; IDENTIFICATION; FIBROBLASTS; MIGRATION; INTEGRINS	Paxillin is a focal-adhesion associated protein implicated in the regulation of integrin signaling and organization of the actin cytoskeleton. Paxillin associates with numerous signaling molecules including adaptor molecules (p130Cas, CRK), kinases (FAK, Pyk2, PAK and SRC), tyrosine phosphatases (PTP-PEST), ARF-GAP proteins (p95pkl, PAG3) and papillomavirus E6 oncoproteins. Although paxillin is tyrosine phosphorylated in cellular processes such as cell attachment and spreading, little direct evidence is available about paxillin's role in these events. Targeted gene disruption was used to generate paxillin null mouse embryonic stem (ES) cells and paxillin null differentiated cells. Paxillin null ES cells exhibit delayed spreading on integrin binding substrates fibronectin and laminin, and there is reduced tyrosine phosphorylation of Focal Adhesion Kinase (FAK). Both of these phenotypes are recovered in paxillin knockout cells upon exogenous re-expression of paxillin. The individual LD motifs of paxillin that are binding sites for FAK, vinculin and ARF-GAP proteins, as well as tyrosine residues that when phosphorylated create binding sites for CRK family members, are dispensable for FAK phosphorylation and early cell spreading. These results demonstrate that paxillin contributes to attachment-dependent tyrosine phosphorylation of FAK and early cell spreading in ES cells.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Pol, SV (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	sbv@po.cwru.edu	Pol, Scott Vande/AAO-1068-2020	Pol, Scott Vande/0000-0002-0587-4802	NATIONAL CANCER INSTITUTE [R29CA069292, R01CA069292] Funding Source: NIH RePORTER; NCI NIH HHS [CA69292, R29 CA069292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Brown MC, 2000, J CELL BIOCHEM, V76, P99; Buckley CD, 1998, MOL MEMBR BIOL, V15, P167, DOI 10.3109/09687689709044318; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HUMPHRIES M, 1998, CURR PROT CELL BIOL, V1; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Matise M A W, 2000, PRODUCTION TARGETED; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; NIKOLOPOULOS SN, 2001, J BIOL CHEM, V13, P13; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tozer EC, 1996, BIOCHEM CELL BIOL, V74, P785, DOI 10.1139/o96-085; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2000, J CELL SCI, V113, P4139; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Wheeler GN, 2001, GENE, V262, P291, DOI 10.1016/S0378-1119(00)00512-6; WILES MV, 1993, METHOD ENZYMOL, V225, P900	55	71	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					96	107		10.1038/sj.onc.1205013	http://dx.doi.org/10.1038/sj.onc.1205013			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791180	Bronze			2022-12-17	WOS:000172887800010
J	Butz, K; Denk, C; Fitscher, B; Crnkovic-Mertens, I; Ullmann, A; Schroder, CH; Hoppe-Seyler, F				Butz, K; Denk, C; Fitscher, B; Crnkovic-Mertens, I; Ullmann, A; Schroder, CH; Hoppe-Seyler, F			Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity	ONCOGENE			English	Article						liver cancer; Hepatitis B virus; peptide aptamers; therapy; virus replication	TRANSIENT EXPRESSION; DNA; INHIBITION; PARTICLES; SELECTION; MUTANTS; CANCER; IDENTIFICATION; REPLICATION; 2-HYBRID	A substantial proportion of the worldwide liver cancer incidence is associated with chronic hepatitis B virus (HBV) infection. The therapeutic management of HBV infections is still problematic and novel antiviral strategies are urgently required. Using the peptide aptamer screening system, we aimed to isolate new molecules, which can block viral replication by interfering with capsid formation. Eight peptide aptamers were isolated from a randomized expression library, which specifically bound to the HBV core protein under intracellular conditions. One of them, named C1-1, efficiently inhibited viral capsid formation and, consequently, HBV replication and virion production. Hence, C1-1 is a novel model compound for inhibiting HBV replication by blocking capsid formation and provides a new basis for the development of therapeutic molecules with specific antiviral potential against HBV infections.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz-heidelberg.de		Hoppe-Seyler, Felix/0000-0002-1864-300X				Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; Bottcher B, 1998, EMBO J, V17, P6839, DOI 10.1093/emboj/17.23.6839; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; BUTZ K, 1995, ONCOGENE, V10, P927; CALVERT J, 1994, J VIROL, V68, P2084, DOI 10.1128/JVI.68.4.2084-2090.1994; CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Colas P, 2000, CURR OPIN CHEM BIOL, V4, P54, DOI 10.1016/S1367-5931(99)00051-4; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; Cunningham BC, 1997, CURR OPIN STRUC BIOL, V7, P457, DOI 10.1016/S0959-440X(97)80107-8; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; DYSON MR, 1995, P NATL ACAD SCI USA, V92, P2194, DOI 10.1073/pnas.92.6.2194; Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; GANEM D, 1996, VIROLOGY, P2703; HARLOW E, 1999, USING ANTIBODIES LAB, P221; Hoppe-Seyler F, 2000, J MOL MED, V78, P426, DOI 10.1007/s001090000140; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Konig S, 1998, J VIROL, V72, P4997; LADNER RC, 1995, TRENDS BIOTECHNOL, V13, P426, DOI 10.1016/S0167-7799(00)88997-0; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; LAMBERTS C, 1993, J VIROL, V67, P3756, DOI 10.1128/JVI.67.7.3756-3762.1993; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROINGEARD P, 1990, HEPATOLOGY, V11, P277, DOI 10.1002/hep.1840110219; Scaglioni P, 1996, HEPATOLOGY, V24, P1010; SCAGLIONI PP, 1994, VIROLOGY, V205, P112, DOI 10.1006/viro.1994.1625; Seifer M, 1995, INTERVIROLOGY, V38, P47, DOI 10.1159/000150414; SUMMERS J, 1990, J VIROL, V64, P2819, DOI 10.1128/JVI.64.6.2819-2824.1990; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; von Weizsacker F, 1999, HEPATOLOGY, V30, P308, DOI 10.1002/hep.510300139; vonWeizsacker F, 1996, HEPATOLOGY, V24, P294; vonWeizsacker F, 1997, HEPATOLOGY, V26, P251, DOI 10.1002/hep.510260237; WRIGHT TL, 1993, LANCET, V342, P1340, DOI 10.1016/0140-6736(93)92250-W; WU TT, 1990, VIROLOGY, V175, P255, DOI 10.1016/0042-6822(90)90206-7; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046	50	71	81	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6579	6586		10.1038/sj.onc.1204805	http://dx.doi.org/10.1038/sj.onc.1204805			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641783				2022-12-17	WOS:000171404200011
J	Fruhwald, MC; O'Dorisio, MS; Dai, ZY; Tanner, SM; Balster, DA; Gao, X; Wright, FA; Plass, C				Fruhwald, MC; O'Dorisio, MS; Dai, ZY; Tanner, SM; Balster, DA; Gao, X; Wright, FA; Plass, C			Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - Implications for tumor biology and potential clinical utility	ONCOGENE			English	Article						medulloblastoma; primitive neuroectodermal tumor; DNA methylation; genome scanning	PRIMITIVE NEUROECTODERMAL TUMORS; HUMAN BRAIN-TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; CENTRAL-NERVOUS-SYSTEM; CHROMOSOME ARM 17P; CHILDHOOD MEDULLOBLASTOMA; DNA HYPERMETHYLATION; E-CADHERIN; DELETION; P16	Medulloblastomas exhibit an array of diverse cytogenetic abnormalities. To evaluate the significance of epigenetic rather than genetic lesions in medulloblastomas and other primitive neuroectodermal tumors (PNETs) of the childhood CNS we performed a systematic analysis of gene specific and global methylation. Methylation-specific PCR detected no methylation for p15(INK4B), von Hippel Lindau and TP53 and only limited methylation for E-Cadherin and p16(INK4A) in tumors. The cell lines Daoy and MHH-PNET-5 in which the p16(INK4A) promoter was methylated did not express the gene, but demonstrated abnormalities by SSCP. Immunohistochemistry for p16 was negative in all examined normal cerebella and medulloblastomas. Using the technique of Restriction Landmark Genomic Scanning we detected methylation affecting up to 1% of all CpG islands in primary MB/PNETs and 6% in MB cell lines. Methylation patterns differed between medulloblastomas and PNETs. Examination of several methylated sequences revealed homologies to known genes and expressed sequences. Analysis of survival data identified seven of 30 hypermethylated sequences significantly correlating with poor prognosis. We suggest that DNA hypermethylation has an outstanding potential for the identification of novel tumor suppressors as well as diagnostic and therapeutic targets in MBs and other PNETs of the CNS.	Univ Munster, Klin & Poliklin Kinderheilkunde, D-48149 Munster, Germany; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA	University of Munster; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Plass, C (corresponding author), Univ Munster, Klin & Poliklin Kinderheilkunde, Albert Schweitzer Str 33, D-48149 Munster, Germany.	plass-1@medctr.osu.edu	Plass, Christoph/H-7192-2014	O'Dorisio, M Sue/0000-0003-0690-1160	NCI NIH HHS [P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldosari N, 2000, ACTA NEUROPATHOL, V99, P345, DOI 10.1007/s004010051134; Barker FG, 1997, J NEURO-ONCOL, V31, P17, DOI 10.1023/A:1005768910871; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burnett ME, 1997, CANCER GENET CYTOGEN, V97, P25, DOI 10.1016/S0165-4608(96)00319-6; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; David KM, 1997, J NEUROSURG, V86, P13, DOI 10.3171/jns.1997.86.1.0013; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2000, J MED GENET, V37, P501, DOI 10.1136/jmg.37.7.501; FRUHWALD MC, 1999, NEURO-ONCOLOGY, V1, P311; GRAFF JR, 1995, CANCER RES, V55, P5195; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JEN J, 1994, CANCER RES, V54, P6353; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KLABFLEISCH JD, 1984, STAT ANAL FAILURE TI; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lescop S, 1999, J NEURO-ONCOL, V44, P119, DOI 10.1023/A:1006387518100; Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338; LITOFSKY NS, 1994, NEUROSURGERY, V34, P967, DOI 10.1227/00006123-199406000-00003; Marino S, 2000, GENE DEV, V14, P994; Mulhern RK, 1999, ANN NEUROL, V46, P834, DOI 10.1002/1531-8249(199912)46:6<834::AID-ANA5>3.0.CO;2-M; Packer RJ, 1999, BRAIN DEV-JPN, V21, P75, DOI 10.1016/S0387-7604(98)00085-0; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Reardon DA, 1997, CANCER RES, V57, P4042; Rorke LB, 1997, BRAIN PATHOL, V7, P765, DOI 10.1111/j.1750-3639.1997.tb01063.x; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Sambrook J, 1989, MOL CLONING LAB MANU; Sato K, 1996, INT J CANCER, V66, P305, DOI 10.1002/(SICI)1097-0215(19960503)66:3<305::AID-IJC6>3.0.CO;2-2; Scheurlen WG, 1998, J CLIN ONCOL, V16, P2478, DOI 10.1200/JCO.1998.16.7.2478; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Schwechheimer K, 1998, VIRCHOWS ARCH, V432, P163, DOI 10.1007/s004280050151; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Sommer A, 1999, INT J CANCER, V82, P810, DOI 10.1002/(SICI)1097-0215(19990909)82:6<810::AID-IJC7>3.0.CO;2-V; Tanner SM, 1998, HUM MUTAT, V11, P62, DOI 10.1002/(SICI)1098-1004(1998)11:1<62::AID-HUMU10>3.3.CO;2-C; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	39	71	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5033	5042		10.1038/sj.onc.1204613	http://dx.doi.org/10.1038/sj.onc.1204613			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526488				2022-12-17	WOS:000170439800013
J	Sibley, K; Stern, P; Knowles, MA				Sibley, K; Stern, P; Knowles, MA			Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours	ONCOGENE			English	Article						FGFR3; mutation; tumour	HUMAN PROSTATIC-CARCINOMA; CELL-LINE; ACTIVATING MUTATIONS; CERVICAL-CARCINOMA; MULTIPLE-MYELOMA; FGFR3; TRANSLOCATION; GENE; TRANSFORMATION; CHROMOSOME	Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma, In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours, Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FCFR3, suggesting that these mutations are important only in the development of certain types of tumour.	St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England; Paterson Inst Canc Res, CRC, Immunol Grp, Manchester M20 4BX, Lancs, England	Saint James's University Hospital; Paterson Institute for Cancer Research	Knowles, MA (corresponding author), St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657				BLOOM ET, 1972, CANCER RES, V32, P960; Brady CS, 1999, J GEN VIROL, V80, P3233, DOI 10.1099/0022-1317-80-12-3233; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; JONES PA, 1975, INT J CANCER, V16, P616, DOI 10.1002/ijc.2910160411; KAIGHN ME, 1979, INVEST UROL, V17, P16; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Wu R, 2000, ONCOGENE, V19, P5543, DOI 10.1038/sj.onc.1203934; Wuchner C, 1997, HUM GENET, V100, P215, DOI 10.1007/s004390050493; Yee CJ, 2000, JNCI-J NATL CANCER I, V92, P1848, DOI 10.1093/jnci/92.22.1848	22	71	71	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4416	4418		10.1038/sj.onc.1204543	http://dx.doi.org/10.1038/sj.onc.1204543			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466624				2022-12-17	WOS:000169912600017
J	Mohanam, S; Jasti, SL; Kondraganti, SR; Chandrasekar, N; Lakka, SS; Kin, Y; Fuller, GN; Yung, AWK; Kyritsis, AP; Dinh, DH; Olivero, WC; Gujrati, M; Ali-Osman, F; Rao, JS				Mohanam, S; Jasti, SL; Kondraganti, SR; Chandrasekar, N; Lakka, SS; Kin, Y; Fuller, GN; Yung, AWK; Kyritsis, AP; Dinh, DH; Olivero, WC; Gujrati, M; Ali-Osman, F; Rao, JS			Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells	ONCOGENE			English	Article						glioblastoma; invasion; cathepsin B	HUMAN GLIOMAS; CYSTATIN-C; PROTEASE INHIBITORS; TUMOR PROGRESSION; CANCER METASTASIS; PROGNOSTIC FACTOR; BREAST-CANCER; ANGIOGENESIS; LOCALIZATION; LINES	Increases in abundance of cathepsin B transcript and protein correlate with increases in tumor grade and alterations in subcellular localization and activity of cathepsin B, The enzyme is able to degrade the components of the extracellular matrix (ECM) and activate other proteases capable of degrading ECM, To investigate the role played by this protease in the invasion of brain tumor cells, we transfected SNB19 human glioblastoma cells with a plasmid containing cathepsin B cDNA in antisense orientation. Control cells were transfected with vector alone. Clones expressing antisense cathepsin B cDNA exhibited significant reductions in cathepsin B mRNA, enzyme activity and protein compared to controls. Matrigel Invasion assay showed that the antisense-transfected cells had markedly diminished invasiveness compared with controls. When tumor spheroids containing antisense transfected SNB19 cells expressing reduced cathepsin B were co-cultured with fetal rat brain aggregates, invasion of fetal rat brain aggregates was significantly reduced. Green Fluorescent Protein (GFP) expressing parental cells and antisense transfectants were generated for detection in mouse brain tissue without any post-chemical treatment. Intracerebral injection of SNB19 stable antisense transfectants resulted in reduced tumor formation in nude mice. These results strongly support a role for cathepsin B in the invasiveness of human glioblastoma cells and suggest cathepsin B antisense may prove useful in cancer therapy.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neuropathol, Houston, TX 77030 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA.			Fuller, Gregory/0000-0001-9447-2647	NCI NIH HHS [P30 CA-16672, CA 76350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA076350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cox JL, 1999, MELANOMA RES, V9, P369, DOI 10.1097/00008390-199908000-00005; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013; Friedrich B, 1999, EUR J CANCER, V35, P138, DOI 10.1016/S0959-8049(98)00273-1; Go Y, 1996, CANCER LETT, V110, P225, DOI 10.1016/S0304-3835(96)04515-6; Goldbrunner RH, 1998, MICROSC RES TECHNIQ, V43, P250, DOI 10.1002/(SICI)1097-0029(19981101)43:3<250::AID-JEMT7>3.0.CO;2-C; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Heidtmann HH, 1997, CLIN EXP METASTAS, V15, P368, DOI 10.1023/A:1018494020001; Hirai K, 1999, HUM PATHOL, V30, P680, DOI 10.1016/S0046-8177(99)90094-1; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; Kostoulas G, 1999, FEBS LETT, V455, P286, DOI 10.1016/S0014-5793(99)00897-2; Kruger S, 1999, CANCER RES, V59, P6010; Lah TT, 1998, BIOL CHEM, V379, P125; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maguire TM, 1998, INT J BIOL MARKER, V13, P139, DOI 10.1177/172460089801300303; MCCORMICK D, 1993, NEUROPATH APPL NEURO, V19, P146, DOI 10.1111/j.1365-2990.1993.tb00420.x; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Navab R, 1997, CLIN EXP METASTAS, V15, P121, DOI 10.1023/A:1018496625936; Nygaard SJT, 1995, INVAS METAST, V15, P179; PEDERSEN PH, 1993, CANCER RES, V53, P5158; REMPEL SA, 1994, CANCER RES, V54, P6027; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; Sinha AA, 1998, ANAT REC, V252, P281; SIVAPARVATHI M, 1995, CLIN EXP METASTAS, V13, P49, DOI 10.1007/BF00144018; Sivaparvathi M, 1996, CLIN EXP METASTAS, V14, P27, DOI 10.1007/BF00157683; SPIESS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917, DOI 10.1177/42.7.8014475; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Van Noorden CJF, 1998, CLIN EXP METASTAS, V16, P159; Werle B, 1999, BRIT J CANCER, V81, P510, DOI 10.1038/sj.bjc.6690723	39	71	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3665	3673		10.1038/sj.onc.1204480	http://dx.doi.org/10.1038/sj.onc.1204480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439329				2022-12-17	WOS:000169400200007
J	Landberg, G; Ostlund, H; Nielsen, NH; Roos, G; Emdin, S; Burger, AM; Seth, A				Landberg, G; Ostlund, H; Nielsen, NH; Roos, G; Emdin, S; Burger, AM; Seth, A			Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors	ONCOGENE			English	Article						IGFBP; breast cancer; proliferation; cell cycle; estrogen receptor	TISSUE MICROARRAY ANALYSIS; EXPRESSION; AMPLIFICATION; MAC25; D1	The complex insulin-like growth factor network of ligands, receptors and binding proteins has been shown to be disturbed in breast cancer, In addition to defects in proteins controling cell cycle checkpoints, this type of aberrations could affect tumor growth and survival thereby influencing both tumor aggressiveness and potential response to treatments, We have previously identified the T1A12/mac25 protein, which is identical to the IGFBP-rP1, as a differentially expressed gene product in breast cancer cells compared with normal cells, Here we compare the expression of IGFBP-rP1 in 106 tumor samples with known status of cell cycle aberrations and other clinicopathological data, This was done using a tumor tissue section array system that allows for simultaneous immunohistochemical staining of ail samples in parallel, Cytoplasmic staining of variable intensity was observed in most tumors, 15% Lacked IGFBP-rP1 staining completely, 20% had weak staining, 32% intermediate and 33% showed strong staining, Low IGFBP-rP1 was associated with high cyclin E protein content, retinoblastoma protein (pRb) inactivation, low bcl-2 protein, poorly differentiated tumors and higher stage, There was a significantly impaired prognosis for patients with low IGFBP-rP1 protein tumors, Interestingly, IGFBP-rP1 showed an inverse association with proliferation (Ki-67%) in estrogen receptor negative tumors as well as in cyclin E high tumors suggesting a separate cell cycle regulatory function for IGFBP-rP1 independent of interaction with the estrogen receptor or the pRb pathway.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Sunnbrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Univ Freiburg, Tumor Biol Ctr, Freiburg, Germany; Umea Univ, Dept Surg & Perioperat Sci, S-90187 Umea, Sweden; Umea Univ, Dept Med Biosci Pathol, S-90187 Umea, Sweden; Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, Malmo, Sweden	University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Freiburg; Umea University; Umea University; Lund University; Skane University Hospital	Seth, A (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 76 Greenville St, Toronto, ON, Canada.							Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; DEGEORGES A, 1998, CANCER RES, V50, P2787; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Kato MV, 1996, ONCOGENE, V12, P1361; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Landberg G, 1997, APMIS, V105, P575, DOI 10.1111/j.1699-0463.1997.tb05056.x; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; LUKAS J, 1995, CANCER RES, V55, P4818; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1999, BREAST CANCER RES TR, V56, P105; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Nielsen NH, 1998, ANAL CELL PATHOL, V17, P177, DOI 10.1155/1998/659712; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGE DL, 1995, AM J CLIN PATHOL, V103, P123; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sprenger CC, 1999, CANCER RES, V59, P2370; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301	25	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3497	3505		10.1038/sj.onc.1204471	http://dx.doi.org/10.1038/sj.onc.1204471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429696				2022-12-17	WOS:000169478300005
J	Kokontis, JM; Wagner, AJ; O'Leary, M; Liao, S; Hay, N				Kokontis, JM; Wagner, AJ; O'Leary, M; Liao, S; Hay, N			A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function	ONCOGENE			English	Article						p53; apoptosis; transactivation; transrepression; cell cycle arrest	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; MYC-MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; EXPRESSION; GROWTH; BCL-2; IDENTIFICATION; REPRESSION	The tumor suppressor p53 is an inducer of cell cycle arrest and programmed cell death (apoptosis), The ability of p53 to induce cell cycle arrest is linked to its ability to induce transcription of genes such as the cyclin-dependent kinase inhibitor p21, However, the dependence of p53-mediated apoptosis on transcriptional activation remains control versial. Ectopic expression of a temperature-sensitive (ts) p53 allele induced expression of p53 target genes and elicited both G1 and G2/M cell cycle arrest upon shift to the permissive temperature. Ectopic expression of the same ts p53 allele with two additional point mutations (Gln22, Ser23) that abolish p53-transcriptional activation did not induce p53 target genes and G1 nor G2/M cell cycle arrest. In HCT116 colon carcinoma cells ectopic expression of wild type p53 does not elicit apoptosis whereas p53 mutant deficient in trans-activation induces apoptosis, The ability of wild type p53 to induce apoptosis is restored in HCT116 cells that are null for p21, However, the trans-activation deficient mutant of p53 is still more potent mediator of apoptosis than wild type p53 in the p21 null cells. Although the ability of Gln22,Ser23 to trans-activate p53 target genes is diminished, it retains the ability to repress Bcl-2 expression. Thus, we conclude that while ectopic expression of wild type p53 can induce both G1 and G2/M;I arrest, in a p21 dependent manner, without apoptosis, a p53 mutant defective in transactivation elicits apoptosis without inducing cell cycle arrest. Further, the anti-apoptotic function of p53 is dependent on trans-activation and is linked to cell cycle arrest. The results strongly suggest that the transactivation deficient mutant is a more potent inducer of apoptosis because it lost its anti-apoptotic function and retains its ability to repress pro-apoptotic genes such as Bcl-2, Taken together, the results imply that employing a trans-activation deficient p53 in gene therapy approaches or the use of drugs that convert mutant p53 to a transactivation-independent mediator of apoptosis may be much more efficient therapeutic approaches than current approaches that employ wild type p53.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Hay, N (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.				NATIONAL CANCER INSTITUTE [R01CA058073, U24CA078174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78174, CA-58073] Funding Source: Medline; NIA NIH HHS [AG-16927] Funding Source: Medline; NIDDK NIH HHS [DK-41670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANNON JV, 1990, EMBO J, V9, P1595; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TA, 2000, GENE DEV, V14, P1584; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Harn HJ, 1996, HISTOPATHOLOGY, V28, P317, DOI 10.1046/j.1365-2559.1996.d01-431.x; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; ISAACS WB, 1991, CANCER RES, V51, P4716; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	40	71	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					659	668		10.1038/sj.onc.1204139	http://dx.doi.org/10.1038/sj.onc.1204139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11313999				2022-12-17	WOS:000166806000001
J	Li, Y; DeFatta, R; Anthony, C; Sunavala, G; De Benedetti, A				Li, Y; DeFatta, R; Anthony, C; Sunavala, G; De Benedetti, A			A translationally regulated Tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed	ONCOGENE			English	Article						eIF4E; translational regulation; histone H3 kinase; Tousled-like kinase; radioresistance	INITIATION-FACTOR 4E; PROTEIN-KINASE; MESSENGER-RNA; DNA-REPLICATION; BUDDING YEAST; CELL-CYCLE; GROWTH; GENE; FIBROBLASTS; EXPRESSION	The gene Tousled of Arabidopsis Thaliana encodes a protein kinase which, when mutated, results in abnormal flower development, From a library of mRNAs that are translationally upregulated by overexpression of the translation initiation factor 4E, we identified a mammalian Tousled Like kinase (TLK1B), The human TLK1B mRNA contains a 5'UTR 1088-nt-long with two upstream AUG codons, and was found to be very inhibitory for translation, The TLK1B protein localizes almost exclusively mammalian cells rendered them more resistant to ionizing radiation OR). Purified TLK1S phosphorylated histone H3 at S-10 with high specificity both in a mis of core histones and in isolated chromatin, suggesting that histone H3 is a physiological substrate for TLK1B, Moreover, overexpression of TLK1B in transfected cells resulted in a higher degree of H3 phosphorylation. Expression of TLK1B in a yeast strain that harbors a temperature-sensitive mutation of the major H3 kinase, IpI1, complemented the growth defect; restored normal levels of histone H3 phosphorylation; and increased their resistance to IR. Phosphorylation of H3 has been linked to the activation of the immediate-early gems upon mitogenic stimulation, and to chromatin condensation during mitotic/meiotic events, A possible role for TLK1B in radioprotection is discussed.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	De Benedetti, A (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.				NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHAN CSM, 1993, GENETICS, V135, P677; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; DEBENEDETTI A, 1991, NUCLEIC ACIDS RES, V19, P1925, DOI 10.1093/nar/19.8.1925; GEBALLE AP, 1994, TIBS, V19, P150; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; GROSS DS, 1985, J MOL BIOL, V183, P251, DOI 10.1016/0022-2836(85)90218-9; Howard EL, 1999, MOL CELL BIOL, V19, P1990; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MOORE SA, 1988, J BIOL CHEM, V263, P9674; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Newton GL, 1996, RADIAT RES, V145, P776, DOI 10.2307/3579370; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Shalom S, 1999, MOL REPROD DEV, V52, P392, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;392::AID-MRD8&gt;3.0.CO;2-Y; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yamakawa A, 1997, GENE, V202, P193, DOI 10.1016/S0378-1119(97)00495-2	36	71	72	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					726	738		10.1038/sj.onc.1204147	http://dx.doi.org/10.1038/sj.onc.1204147			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314006				2022-12-17	WOS:000166806000008
J	Ohira, M; Kageyama, H; Mihara, M; Furuta, S; Machida, T; Shishikura, T; Takayasu, H; Islam, A; Nakamura, Y; Takahashi, M; Tomioka, N; Sakiyama, S; Kaneko, Y; Toyoda, A; Hattori, M; Sakaki, Y; Ohki, M; Horii, A; Soeda, E; Inazawa, J; Seki, N; Kuma, H; Nozawa, I; Nakagawara, A				Ohira, M; Kageyama, H; Mihara, M; Furuta, S; Machida, T; Shishikura, T; Takayasu, H; Islam, A; Nakamura, Y; Takahashi, M; Tomioka, N; Sakiyama, S; Kaneko, Y; Toyoda, A; Hattori, M; Sakaki, Y; Ohki, M; Horii, A; Soeda, E; Inazawa, J; Seki, N; Kuma, H; Nozawa, I; Nakagawara, A			Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line	ONCOGENE			English	Article						neuroblastoma; homozygous deletion; 1p36; tumor suppressor gene	MESSENGER-RNA EXPRESSION; TUMOR-SUPPRESSOR GENES; CHROMOSOME 1P36.3; ALLELIC LOSS; N-MYC; DNA; APOPTOSIS; PROTEIN; CANCER; UBIQUITINATION	Loss of heterozygosity of the distal region of chromosome Ip where tumor suppressor gene(s) might harbor is frequently observed in many human cancers including neuroblastoma (NBL) with MYCN amplification and poor prognosis. We have identified for the first time a homozygously deleted region at the marker D1S244 within the smallest region of overlap at 1p36.2-p36.3 in two NBL cell lines, NB-1 and NB-C201 (MASS-NB-SCH1), although our genotyping has suggested the possibility that both lines are derived from the same origin. The 800-kb PAC contig covering the entire region of homozygous deletion was made and partially sequenced (about 60%). The estimated length of the deleted region was 500 kb. We have, thus far, identified sis genes within the region which include three known genes (DFF45, PGD, and CORT) as well as three other genes which have been reported during processing our present project for the last 31/2 years (HDNB1/UFD2, KIAA0591F/KIF1B-beta, and PEX14). They include the genes related to apoptosis, glucose metabolism, ubiquitin-proteasome pathway, a neuronal microtubule-associated motor molecule and biogenesis of peroxisome. At least three genes (HDNB1/UFD2, KIAA0591F/KIF1B-beta, and PEX14) were differentially expressed at high levels in favorable and at low levels in unfavorable subsets of primary neuroblastoma. Since the Ip distal region is reported to be imprinted, those differentially expressed genes could be the new members of the candidate NBL suppressor, although RT-PCR-SSCP analysis has demonstrated infrequent mutation of the genes so far identified. Full-sequencing and gene prediction for the region of homozygous deletion would elucidate more detailed structure of this region and might lead to discovery of additional candidate genes.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Saitama Canc Ctr Hosp, Dept Canc Chemotherapy, Ina, Saitama 3620806, Japan; RIKEN, Gen Sci Ctr, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan; Natl Canc Ctr, Res Inst, Canc Gen Div, Chuoh Ku, Tokyo 1040045, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Sendai, Miyagi 9808575, Japan; RIKEN Gene Bank, Tsukuba, Ibaraki 3050074, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Div Genet,Bunkyo Ku, Tokyo 1138519, Japan; Helix Res Inst Inc, Biol Technol Lab, Chiba 2920812, Japan; Hisamitsu Pharmaceut Co Inc, Tsukuba Res Labs, Cent Res Ctr, New Technol Dev Dept, Tsukuba, Ibaraki 3050856, Japan	Chiba Cancer Center; RIKEN; University of Tokyo; National Cancer Center - Japan; Tohoku University; RIKEN; Tokyo Medical & Dental University (TMDU); Eisai Co Ltd; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.		Hattori, Masahira/C-6958-2016; Hattori, Masahira/AAD-3785-2019; Horii, Akira/AAW-2839-2021	Hattori, Masahira/0000-0001-9467-0344; Horii, Akira/0000-0002-3967-3291				AMLER LC, 1995, ONCOGENE, V10, P1095; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Carling T, 1999, INT J CANCER, V83, P80, DOI 10.1002/(SICI)1097-0215(19990924)83:1<80::AID-IJC15>3.0.CO;2-E; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHEN FS, 1995, MICROW OPT TECHN LET, V10, P297, DOI 10.1002/mop.4650100512; deLecea L, 1997, GENOMICS, V42, P499, DOI 10.1006/geno.1997.4763; Diccianni MB, 1996, CANCER LETT, V104, P183, DOI 10.1016/0304-3835(96)04250-4; DRACOPOLI N C, 1988, Genomics, V3, P124, DOI 10.1016/0888-7543(88)90142-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENOMOTO H, 1994, ONCOGENE, V9, P2785; Fukusumi S, 1997, BIOCHEM BIOPH RES CO, V232, P157, DOI 10.1006/bbrc.1997.6252; Hattori M, 1997, NUCLEIC ACIDS RES, V25, P1802, DOI 10.1093/nar/25.9.1802; He LS, 1998, CANCER RES, V58, P4238; Hiraiwa H, 1997, CANCER, V79, P2036, DOI 10.1002/(SICI)1097-0142(19970515)79:10<2036::AID-CNCR27>3.3.CO;2-M; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; IMASHUKU S, 1973, J CLIN ENDOCR METAB, V36, P931, DOI 10.1210/jcem-36-5-931; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTINSSON T, 1995, CANCER RES, V55, P5681; Martinsson T, 1997, CANCER GENET CYTOGEN, V95, P183, DOI 10.1016/S0165-4608(96)00259-2; Nagai M, 2000, INT J ONCOL, V16, P907; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Pukatzki S, 1998, J BIOL CHEM, V273, P24131, DOI 10.1074/jbc.273.37.24131; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Sunahara M, 1998, INT J ONCOL, V13, P319; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Takemura R, 1996, J NEUROSCI, V16, P31; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; Tsui SKW, 1996, BIOCHEM GENET, V34, P367, DOI 10.1007/BF00554412; WHITE PS, 1993, GENE CHROMOSOME CANC, V7, P102, DOI 10.1002/gcc.2870070207; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Will GK, 1999, MOL CELL BIOL, V19, P2265; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10	43	71	77	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4302	4307		10.1038/sj.onc.1203786	http://dx.doi.org/10.1038/sj.onc.1203786			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980605				2022-12-17	WOS:000089032900014
J	Seidel, HM; Lamb, P; Rosen, J				Seidel, HM; Lamb, P; Rosen, J			Pharmaceutical intervention in the JAK/STAT signaling pathway	ONCOGENE			English	Article						JAK; STAT; mimics; antagonists; cytokine	RECOMBINANT HUMAN ERYTHROPOIETIN; RESONANCE ENERGY-TRANSFER; GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE; DNA-BINDING; T-CELLS; FLUORESCENCE POLARIZATION; TARGETED DISRUPTION; ASSAY TECHNOLOGIES; INTERFERON-GAMMA	Many cytokines exert their effect via the JAK/STAT signal transduction pathway, Due to the medical relevance of many of these cytokines, they are being exploited, either directly, or through antagonists, as therapeutics for a variety of serious diseases. Currently, these therapeutics consist almost entirely of protein products, with all of their attendant drawbacks, Delineation of the signaling mechanisms for the cytokines, however, has allowed the design and implementation of a variety of cell-based and biochemical screens for small molecule mimics or antagonists of these cytokines, Several successful assays will be described along with the advantages of each type of assay, Use of assays of this type should make it possible to discover numerous small molecule cytokine modulators with significant utility in the clinic.	Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Ligand Pharmaceuticals	Rosen, J (corresponding author), Ligand Pharmaceut Inc, 10275 Sci Ctr Dr, San Diego, CA 92121 USA.							Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Ahmed T, 1992, J Clin Apher, V7, P129, DOI 10.1002/jca.2920070306; Baselga J, 1998, CANCER RES, V58, P2825; Braunwalder AF, 1996, ANAL BIOCHEM, V234, P23, DOI 10.1006/abio.1996.0044; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GIRALT S, 1995, SEMIN HEMATOL, V32, P152; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HOOFNAGLE JH, 1990, J HEPATOL, V11, pS100, DOI 10.1016/0168-8278(90)90173-O; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kolb A, 1997, HIGH THROUGHPUT SCRE, P345; Lamb P, 1998, DRUG DISCOV TODAY, V3, P122, DOI 10.1016/S1359-6446(97)01157-4; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; Lindsay KL, 1999, J HEPATOL, V31, P232, DOI 10.1016/S0168-8278(99)80408-5; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Nasir MS, 1999, COMB CHEM HIGH T SCR, V2, P177; NEMUNAITIS J, 1988, BLOOD, V72, P834; Panitch H S, 1995, Mult Scler, V1 Suppl 1, pS17; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RACKER E, 1991, METHOD ENZYMOL, V200, P107; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Schneider H, 1997, BLOOD, V89, P473, DOI 10.1182/blood.V89.2.473; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Silverman L, 1998, CURR OPIN CHEM BIOL, V2, P397, DOI 10.1016/S1367-5931(98)80015-X; Sittampalam GS, 1997, CURR OPIN CHEM BIOL, V1, P384, DOI 10.1016/S1367-5931(97)80078-6; SPIELBERGER RT, 1992, LEUKEMIA, V6, P142; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; STONE WJ, 1988, AM J MED SCI, V296, P171, DOI 10.1097/00000441-198809000-00005; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Trieu VN, 2000, BIOCHEM BIOPH RES CO, V267, P22, DOI 10.1006/bbrc.1999.1905; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang LH, 1999, J IMMUNOL, V162, P3897; WeIte K, 1987, J EXP MED, V165, P941; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Whitty A, 1999, CHEM BIOL, V6, pR107, DOI 10.1016/S1074-5521(99)80034-9; Wu PG, 1997, ANAL BIOCHEM, V249, P29, DOI 10.1006/abio.1997.2158	67	71	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2645	2656		10.1038/sj.onc.1203550	http://dx.doi.org/10.1038/sj.onc.1203550			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851064				2022-12-17	WOS:000087459400021
J	Reymond, A; Volorio, S; Merla, G; Al-Maghtheh, M; Zuffardi, O; Bulfone, A; Ballabio, A; Zollo, M				Reymond, A; Volorio, S; Merla, G; Al-Maghtheh, M; Zuffardi, O; Bulfone, A; Ballabio, A; Zollo, M			Evidence for interaction between human PRUNE and nm23-H1 NDPKinase	ONCOGENE			English	Article						PRUNE; NDPK; nm 23-H1	NUCLEOSIDE-DIPHOSPHATE KINASE; DROSOPHILA MUTANT-GENES; TUMOR-METASTASIS; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; POINT MUTATION; MESSENGER-RNA; LOCUS RP18; IN-VITRO; PROTEIN	We have isolated a human and murine homologue of the Drosophila prune gene through dbEST searches. The gene is ubiquitously expressed in human adult tissues, while in mouse developing embryos a high level of expression is confined to the nervous system particularly in the dorsal root ganglia, cranial nerves, and neural retina. The gene is composed of eight exons and is located in the 1q21.3 chromosomal region. A pseudogene has been sequenced and mapped to chromosomal region 13q12, PRUNE protein retains the four characteristic domains of DHH phosphoesterases. The synergism between prune and awd(K-pn) in Drosophila has led various authors to propose an interaction between these genes. However, such an interaction has never been supported by biochemical data. By using interaction-mating and in vitro co-immunoprecipitation experiments, we show for the first time the ability of human PRUNE to interact with the human homologue of awd protein (nm23-H1). In contrast, PRUNE is impaired in its interaction with nm23-H1-S120G mutant, a gain-of-function mutation associated with advanced neuroblastoma stages. Consistently, PRUNE and nm23-H1 proteins partially colocalize in the cytoplasm, The data presented are consistent with the view that PRUNE acts as a negative regulator of the nm23-H1 protein. We discuss how PRUNE regulates nm23-H1 protein and postulate possible implications of PRUNE in neuroblastoma progression.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Univ Milan, Osped San Raffaele, Lab Citogenet, I-20127 Milan, Italy; Univ Milan, Osped San Raffaele, Serv Genet Med, I-20127 Milan, Italy; UCL, Inst Ophthalmol, Ophthalmol Dept Mol Genet, London, England	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; University College London	Zollo, M (corresponding author), Telethon Inst Genet & Med, San Raffaele Biomed Sci Pk, I-20132 Milan, Italy.		merla, giuseppe/K-4627-2012; BALLABIO, Andrea/AAL-2672-2020	merla, giuseppe/0000-0001-5078-928X; BALLABIO, Andrea/0000-0003-1381-4604; zuffardi, orsetta/0000-0002-1466-4559; Reymond, Alexandre/0000-0003-1030-8327	Telethon [TGM97000, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; Betke Herbert, 1998, Polish Journal of Pathology, V49, P93; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; Bulfone A, 1998, HUM MOL GENET, V7, P1997, DOI 10.1093/hmg/7.13.1997; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; Chiarelli I, 1998, MOL CELL PROBE, V12, P125, DOI 10.1006/mcpr.1998.0159; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FERRE J, 1986, BIOCH GENET, V7, P545; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Gazzeri S, 1996, LAB INVEST, V74, P158; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; Guo X, 1998, INT J CANCER, V79, P596, DOI 10.1002/(SICI)1097-0215(19981218)79:6<596::AID-IJC7>3.0.CO;2-Y; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hartsough MT, 1998, AM J HUM GENET, V63, P6, DOI 10.1086/301942; Inglehearn CF, 1998, J MED GENET, V35, P788, DOI 10.1136/jmg.35.9.788; Jensen SL, 1996, WORLD J UROL, V14, pS21; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1993, ONCOGENE, V8, P855; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MACDONALD NJ, 1995, EUR J CANCER, V31A, P1096, DOI 10.1016/0959-8049(95)00152-9; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; MERLO GR, 1989, CANCER RES, V49, P6966; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Mesnildrey S, 1998, J BIOL CHEM, V273, P4436, DOI 10.1074/jbc.273.8.4436; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; ODONNELL JM, 1989, DEV GENET, V10, P273, DOI 10.1002/dvg.1020100316; OREVI N, 1975, MUTAT RES, V33, P193, DOI 10.1016/0027-5107(75)90195-5; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; REYMOND A, 1995, ONCOGENE, V11, P1173; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; Sambrook J, 1989, MOL CLONING LAB MANU; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SASTREGARAU X, 1992, B CANCER, V79, P465; Shimada M, 1998, LIVER, V18, P337; STAHL JA, 1991, CANCER RES, V51, P445; STURTEVANT AH, 1956, GENETICS, V41, P118; Tagashira H, 1998, INT J MOL MED, V2, P65; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; Timmons L, 1996, GENETICS, V144, P1589; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; Volorio S, 1998, DNA SEQUENCE, V9, P307, DOI 10.3109/10425179809008469; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Xu SY, 1996, HUM MOL GENET, V5, P1193, DOI 10.1093/hmg/5.8.1193; Xu SY, 1998, HUM GENET, V102, P493, DOI 10.1007/s004390050728; Yoshida H, 1998, INT J ONCOL, V13, P1141; Zheng XY, 1998, J EXP CLIN CANC RES, V17, P337	66	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7244	7252		10.1038/sj.onc.1203140	http://dx.doi.org/10.1038/sj.onc.1203140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602478				2022-12-17	WOS:000084119400008
J	Smart, P; Lane, EB; Lane, DP; Midgley, C; Vojtesek, B; Lain, S				Smart, P; Lane, EB; Lane, DP; Midgley, C; Vojtesek, B; Lain, S			Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B	ONCOGENE			English	Article						leptomycin B; senescence; p53 response; normal fibroblasts; neuroblastoma	CYTOPLASMIC SEQUESTRATION; ANTICANCER ACTIVITY; DNA-DAMAGE; IN-VIVO; PROTEIN; CYCLE; EXPRESSION; IRRADIATION; ANTIBODIES; SENESCENCE	p53 tumour suppressor protein levels and p53-dependent transcriptional activity have been recently shown to increase in cells treated with leptomycin B (LMB), an inhibitor of nuclear export. Experiments presented here show that LMB treatment leads to growth arrest and a senescence-like phenotype in human normal fibroblast cultures. This effect is reversible after removal of the drug and further passage by trypsinization. Instead, LMB has a strong cytotoxic effect on human neuroblastoma cell lines even at nanomolar concentrations. In both these cell types the effects of LMB are attenuated when the activity of the endogenous wild type p53 protein is abrogated by overexpression of a dominant negative p53 mutant. We conclude that the induction of the p53 response by LMB plays an important role in the effects of this drug on cultured cells.	Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 5EH, Scotland; Univ Dundee, Dept Anat & Physiol, CRC, Cell Struct Res Grp, Dundee DD1 5EH, Scotland; Masaryk Mem Canc Inst, Dept Cellular & Mol Oncol, Brno 65653, Czech Republic	University of Dundee; University of Dundee; Masaryk Memorial Cancer Institute	Lain, S (corresponding author), Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, MSI-WTB Complex, Dundee DD1 5EH, Scotland.		Lain, Sonia/B-6980-2014; Lane, David P/C-4920-2008	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; deLaat A, 1996, PHOTOCHEM PHOTOBIOL, V63, P492; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; JENNEY M, 1994, LANCET, V344, P210, DOI 10.1016/S0140-6736(94)92991-2; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kuhnt M, 1998, APPL ENVIRON MICROB, V64, P714; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; LAIN S, IN PRESS EXP CELL RE; LEOPOLD WR, 1984, CANCER RES, V44, P1928; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Melino G, 1997, APOPTOSIS AND CANCER, P222; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Newlands ES, 1996, BRIT J CANCER, V74, P648, DOI 10.1038/bjc.1996.415; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Renzing J, 1996, J CELL SCI, V109, P1105; ROBERTS BJ, 1986, CANCER CHEMOTH PHARM, V16, P95; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULIAN E, 1995, ONCOGENE, V10, P671; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TUNAC JB, 1985, J ANTIBIOT, V38, P460, DOI 10.7164/antibiotics.38.460; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Wynford-Thomas D, 1999, J PATHOL, V187, P100; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	40	71	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7378	7386		10.1038/sj.onc.1203260	http://dx.doi.org/10.1038/sj.onc.1203260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602494				2022-12-17	WOS:000084119400024
J	Mollenhauer, J; Holmskov, U; Wiemann, S; Krebs, I; Herbertz, S; Madsen, J; Kioschis, P; Coy, JF; Poustka, A				Mollenhauer, J; Holmskov, U; Wiemann, S; Krebs, I; Herbertz, S; Madsen, J; Kioschis, P; Coy, JF; Poustka, A			The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability	ONCOGENE			English	Article						DMBT1; tumour suppressor; scavenger-receptor cysteine-rich; exon-intron structure; genomic instability	TUMOR-SUPPRESSOR GENES; PROSTATE-CANCER; IDENTIFICATION; CHROMOSOME-10; RECOMBINATION; PROGRESSION; GLIOMAS; MEMBER; BRAIN; LOCI	Increasing evidence has accumulated for an involvement of the inactivation of tumour suppressor genes at chromosome 10q in the carcinogenesis of brain tumours, melanomas, and carcinomas of the lung, the prostate, the pancreas, and the endometrium. The gene DMBT1 (Deleted in Malignant Brain Tumours 1) is located at chromosome 10q25.3-q26.1, within one of the putative intervals for tumour suppressor genes. DMBT1 is a member of the scavenger-receptor cysteine-rich (SRCR) superfamily and displays homozygous deletions or lack of expression in glioblastoma multiforme, medulloblastoma, and in gastrointestinal and lung cancers. Based on these properties, DMBT1 has been proposed to be a candidate tumour suppressor gene. We have determined the genomic sequence of DMBT1 to allow analyses of mutations. The gene has at least 54 exons that span a genomic region of about 80 kb, We have identified a putative exon with coding potential for a transmembrane domain. Our data further suggest that alternative splicing gives rise to isoforms of DMBT1 with a differential utilization of SRCR domains and SRCR interspersed domains. The major part of the gene harbours locus specific repeats. These repeats may point to the DMBT1 locus as a region susceptible to chromosomal instability.	Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany; Odense Univ, Univ So Denmark, Inst Med Biol, DK-5000 Odense C, Denmark	Helmholtz Association; German Cancer Research Center (DKFZ); University of Southern Denmark	Mollenhauer, J (corresponding author), Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Madsen, Jens/N-8082-2013; Mollenhauer, Jan/G-4452-2012; Wiemann, Stefan/E-4424-2013; Holmskov, Uffe/AAA-3056-2022	Madsen, Jens/0000-0003-1664-7645; Wiemann, Stefan/0000-0003-4683-3174; Holmskov, Uffe/0000-0002-2391-9445				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Cheng H, 1996, ANAT REC, V244, P327; HAHN SA, 1995, CANCER RES, V55, P4670; Healy E, 1996, CANCER RES, V56, P589; Hogger P, 1998, J IMMUNOL, V161, P1883; HOLMSKOV V, 1999, IN PRESS P NATL ACAD; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mori M, 1999, BRIT J CANCER, V79, P211, DOI 10.1038/sj.bjc.6690035; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; O'Keeffe MA, 1999, IMMUNOGENETICS, V49, P45, DOI 10.1007/s002510050462; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; Wu WG, 1999, CANCER RES, V59, P1846	24	71	75	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6233	6240		10.1038/sj.onc.1203071	http://dx.doi.org/10.1038/sj.onc.1203071			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597221				2022-12-17	WOS:000083934100006
J	Desaintes, C; Goyat, S; Garbay, S; Yaniv, M; Thierry, F				Desaintes, C; Goyat, S; Garbay, S; Yaniv, M; Thierry, F			Papillomavirus E2 induces p53-independent apoptosis in HeLa cells	ONCOGENE			English	Article						HPV18 E2 mutants; apoptosis; p53 HeLa cells	CERVICAL-CARCINOMA CELLS; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; DNA-REPLICATION; FUNCTIONAL INTERACTION; CYCLE ARREST; E6 PROMOTER; TYPE-1 E2; PROTEIN; P53	We have previously shown that expression of the papillomavirus E2 protein in HeLa cells induces p53 accumulation and causes both cell cycle arrest and apoptosis, In contrast to growth arrest, onset of apoptosis was not correlated with an increase of p53 transcriptional activity, In the present study, we conducted biochemical and genetic experiments in order to determine whether Et-induced apoptosis was independent of p53 induction. We showed that E2 did not alter the transcription of Bar, a known p53-activated cell death inducer. The time course of apoptotic cell death preceded p53 induction by several hours. Overexpression of the HPV18 E6 oncogene prevented E2-mediated p53 accumulation, but did not alter the rate of cell death. Finally, point mutants of the HPV18 E2 transactivation domain induced apoptosis, although they were unable to induce high p53 accumulation or cell cycle arrest. In addition, the results obtained with these mutants indicated that both transcriptional activation and replication functions of E2 were dispensable for the induction of cell death. These observations show that E2-induced apoptosis is an early event, independent of p53 accumulation and unrelated to downstream p53-dependent transcriptional events.	Inst Pasteur, Dept Biotechnol, CNRS,URA 1644, Unite Virus Oncogenes, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Thierry, F (corresponding author), Inst Pasteur, Dept Biotechnol, CNRS,URA 1644, Unite Virus Oncogenes, 25 Rue Dr Roux, F-75724 Paris 15, France.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; BERUMEN J, 1994, INT J CANCER, V56, P640, DOI 10.1002/ijc.2910560506; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Demeret C, 1995, NUCLEIC ACIDS RES, V23, P4777, DOI 10.1093/nar/23.23.4777; Demeret C, 1997, J VIROL, V71, P9343, DOI 10.1128/JVI.71.12.9343-9349.1997; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Hwang ES, 1996, ONCOGENE, V12, P795; LEMOAL MA, 1994, J VIROL, V68, P1085, DOI 10.1128/JVI.68.2.1085-1093.1994; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCBRIDE A, 1996, THEORETICAL BIOL BIO, V3, P15; MIYASHITA T, 1995, CELL, V80, P293; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998	48	71	74	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4538	4545		10.1038/sj.onc.1202818	http://dx.doi.org/10.1038/sj.onc.1202818			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467398				2022-12-17	WOS:000082018600003
J	Bertrand, P; Akhmedov, AT; Delacote, F; Durrbach, A; Lopez, BS				Bertrand, P; Akhmedov, AT; Delacote, F; Durrbach, A; Lopez, BS			Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation	ONCOGENE			English	Article						TLS/FUS; DNA homologous pairing; cell proliferation; recombination	STRAND-BREAK REPAIR; RNA-POLYMERASE-II; ABL TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; ESCHERICHIA-COLI; BINDING PROTEIN; RAD51 PROTEIN; RECA PROTEIN; C-ABL	We have previously developed an assay to measure DNA homologous pairing activities in crude extracts: The POM blot. In mammalian nuclear extracts, we detected two major DNA homologous pairing activities: POMp100 and POMp75. Here, we present the purification and identification of POMp75 as the pro-oncoprotein TLS/FUS. Because of the pro-oncogene status of TLS/FUS, we studied in addition, the relationships between cell proliferation and POM activities. We show that transformation of human fibroblasts by SV40 large T antigen results in a strong increase of both POMp100 and TLS/POMp75 activities. Although detectable levels of both POMp100 and TLS/POMp75 are observed in non-immortalized fibroblasts or lymphocytes, fibroblasts at mid confluence or lymphocytes stimulated by phytohaemaglutinin, show higher levels of POM activities. Moreover, induction of differentiation of mouse F9 line by retinoic acid leads to the inhibition of both POMp100 and TLS/POMp75 activities. Comparison of POM activity of TLS/FUS with the amount of TLS protein detected by Western blot, suggests that the POM activity could be regulated by post-translation modification. Taken together, these results indicate that POMp100 and TLS/POMp75 activitites are present in normal cells but are connected to cell proliferation. Possible relationship between cell proliferation, response to DNA damage and DNA homologous pairing activity of the pro-oncoprotein TLS/FUS are discussed.	CEA, DSV, DRR, CNRS,UMR 217, F-92265 Fontenay Aux Roses, France; Inst Curie, Biol Sect, F-75231 Paris 05, France; Grp Hosp Bichat Claude Bernard, F-75877 Paris 18, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Lopez, BS (corresponding author), CEA, DSV, DRR, CNRS,UMR 217, 60-68 Av Gen Leclerc,BP6, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; BERTRAND, Pascale/0000-0002-9019-742X				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; AKHMEDOV AT, 1995, P NATL ACAD SCI USA, V92, P1729, DOI 10.1073/pnas.92.5.1729; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BERTRAND P, 1993, NUCLEIC ACIDS RES, V21, P3653, DOI 10.1093/nar/21.16.3653; Bertrand P, 1995, BIOCHIMIE, V77, P840, DOI 10.1016/0300-9084(95)90001-2; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P6225, DOI 10.1073/pnas.93.13.6225; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; GOLUB EI, 1992, NUCLEIC ACIDS RES, V20, P3121, DOI 10.1093/nar/20.12.3121; Hong XK, 1996, MOL MICROBIOL, V21, P953, DOI 10.1046/j.1365-2958.1996.591419.x; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; LOPEZ B, 1987, NUCLEIC ACIDS RES, V15, P6813, DOI 10.1093/nar/15.17.6813; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; Luo CM, 1996, J BIOL CHEM, V271, P4497; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; Sambrook J, 1989, MOL CLONING LAB MANU; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Thyagarajan B, 1997, J BIOL CHEM, V272, P23328, DOI 10.1074/jbc.272.37.23328; Thyagarajan B, 1996, NUCLEIC ACIDS RES, V24, P4084, DOI 10.1093/nar/24.20.4084; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Yamamoto A, 1996, MOL GEN GENET, V251, P1; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zinszner H, 1997, J CELL SCI, V110, P1741	65	71	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4515	4521		10.1038/sj.onc.1203048	http://dx.doi.org/10.1038/sj.onc.1203048			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442642				2022-12-17	WOS:000081813500013
J	Fabbrizio, E; Le Cam, L; Polanowska, J; Kaczorek, M; Lamb, N; Brent, R; Sardet, C				Fabbrizio, E; Le Cam, L; Polanowska, J; Kaczorek, M; Lamb, N; Brent, R; Sardet, C			Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity	ONCOGENE			English	Article						E2F transcription factors; peptidic inhibitors; cell proliferation; DNA binding and dimerization domains	S-PHASE ENTRY; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; DEREGULATED EXPRESSION; RETINOBLASTOMA PROTEIN; NA+/H+ ANTIPORTER; FAMILY MEMBERS; DNA-SYNTHESIS; APOPTOSIS; LEADS	The p16-cyclin D-pRB-E2F pathway is frequently deregulated in human tumors. This critical regulatory pathway controls the G1/S transition of the mammalian cell cycle by positive and negative regulation of E2F-responsive genes required for DNA replication. To assess the value of the transcription factors E2Fs as targets for antiproliferative strategies, we have initiated a program aiming to develop inhibitors targeting specifically these proteins in vitro and in vivo. The cellular activity of E2F is the result of the heterodimeric association of two families of proteins, E2Fs and DPs, which then bind DNA. Here, we use a two hybrid approach to isolate from combinatorial libraries peptide aptamers that specifically interact with E2Fs DNA binding and dimerization domains. One of these is a potent inhibitor of E2F binding activity in vitro and in mammalian fibroblasts, blocks cells in G1, and the free variable region from this aptamer has the same effect. Our experiments argue that the variable region of this aptamer is structured, and that it functions by binding E2F with a motif that resembles a DP heterodimerization region, and blocking E2F's association with DP. Those results show that cell proliferation can be inhibited using genetically-selected synthetic peptides that specifically target protein-protein interaction motifs within cell cycle regulators. These results also emphasize the critical role of the E2F pathway for cell proliferation and might allow the design of novel antiproliferative agents targeting the cyclin/CDK-pRB-E2F pathway.	Inst Mol Genet, UMR 5535 CNRS, F-34293 Montpellier, France; Syntiem, F-30000 Nimes, France; Inst Genet Humaine, F-34094 Montpellier, France; Inst Mol Sci, Berkeley, CA 94704 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; The Molecular Sciences Institute	Sardet, C (corresponding author), Inst Mol Genet, UMR 5535 CNRS, 1919 Route Mende, F-34293 Montpellier, France.		Polanowska, Jolanta/P-9117-2016; Le Cam, Laurent/O-1408-2016	Polanowska, Jolanta/0000-0001-7666-7010; LE CAM, Laurent/0000-0003-0325-878X				Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY R, 1996, DNA CLONING EXPRESSI, V6, P169; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hayashida W, 1996, J BIOL CHEM, V271, P21985, DOI 10.1074/jbc.271.36.21985; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MANN D, 1996, CURR BIOL, V4, P474; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SARDET C, 1997, PROGR GENE EXPRESSIO, V2, P1; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; VIDAL M, 1996, P NATL ACAD SCI USA, V93, P19; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; XU W, 1997, P NATL ACAD SCI USA, V94, P12473	38	71	80	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4357	4363		10.1038/sj.onc.1202825	http://dx.doi.org/10.1038/sj.onc.1202825			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439043				2022-12-17	WOS:000081732700008
J	Zauberman, A; Zipori, D; Krupsky, M; Ben-Levy, R				Zauberman, A; Zipori, D; Krupsky, M; Ben-Levy, R			Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3	ONCOGENE			English	Article						p38; STAT; IL-6 signaling	SIGNAL-TRANSDUCTION PATHWAY; ACUTE-PHASE RESPONSE; MAP KINASE; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; MOLECULAR-CLONING; CELLULAR STRESSES; HAPTOGLOBIN GENE; REGULATED KINASE	The acute phase protein expression In HepG2 human hepatoma cells and promotes the growth of mouse B9 hybridoma. The signaling cascades leading to these biological functions are only partially known. We analysed the involvement of MAPK homologues in IL-6 transduction pathways and found that interleukin-6 triggered activation of p38 stress-activated protein kinase (p38) but not of jun kinase. p38 activity was required for biological functions including acute phase protein secretion from HepG2 hepatoma and proliferation of B9 hybridoma cells. Using a reporter gene construct containing a 190 bp promoter fragment of the acute phase protein haptoglobin we found that p38 is involved in transcriptional activation of the haptoglobin promoter by STAT3 but not by NF-IL6. Thus, we present evidence for a role of p38 in IL-6 induced functions and a possible cross-talk between this MAPK homologue and the STAT pathway.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zipori, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRETON J, 1995, EUR J BIOCHEM, V227, P573, DOI 10.1111/j.1432-1033.1995.tb20427.x; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAULDIE J, 1992, RES IMMUNOL, V143, P755, DOI 10.1016/0923-2494(92)80018-G; HELLE M, 1988, EUR J IMMUNOL, V18, P1535, DOI 10.1002/eji.1830181010; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KISHIMOTO T, 1992, PROG IMMUNOL, V8, P887; KUSHNER I, 1987, DIS MARKERS, V5, P1; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Ogata A, 1997, J IMMUNOL, V159, P2212; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PAJOVIC S, 1994, J BIOL CHEM, V269, P2215; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	58	71	71	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3886	3893		10.1038/sj.onc.1202738	http://dx.doi.org/10.1038/sj.onc.1202738			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445852				2022-12-17	WOS:000081171700010
J	Marsh, SK; Bansal, GS; Zammit, C; Barnard, R; Coope, R; Roberts-Clarke, D; Gomm, JJ; Coombes, RC; Johnston, CL				Marsh, SK; Bansal, GS; Zammit, C; Barnard, R; Coope, R; Roberts-Clarke, D; Gomm, JJ; Coombes, RC; Johnston, CL			Increased expression of fibroblast growth factor 8 in human breast cancer	ONCOGENE			English	Article						fibroblast growth factor 8; human breast cancer; fibroblast growth factor receptor 4	HIGH-AFFINITY RECEPTOR; FACTOR FGF RECEPTORS; HUMAN MAMMARY-GLAND; CARCINOMA-CELLS; MOLECULAR-CLONING; FACTOR FAMILY; FACTOR-VIII; SIGNAL-TRANSDUCTION; GENE; ANDROGEN	Fibroblast growth factor 8 (FGF8) is an important developmental protein which is oncogenic and able to cooperate with wnt-1 to produce mouse mammary carcinoma. The level of expression of FGF8 mRNA was measured in 68 breast cancers and 24 non-malignant breast tissues. Elevated levels of FGF8 mRNA were found in malignant compared to non-malignant breast tissues with significantly more malignant tissues expressing FGF8 (P = 0.019) at significantly higher levels (P = 0.031), In situ hybridization of breast cancer tissues and analysis of purified populations of normal epithelial cells and breast cancer cell lines showed that malignant epithelial cells expressed FGF8 mRNA at high levels compared to non-malignant epithelial and myoepithelial cells and fibroblasts. Although two of the receptors which FGF8 binds to (FGFR2-IIIc, FGFR3-IIIc) are not expressed in breast cancer cells, an autocrine activation loop is possible since expression of fibroblast growth factor receptor (FGFR) 4 and FGFR1 are retained in malignant epithelial cells. This is the first member of the FGF family to have increased expression in breast cancer and a potential autocrine role in its progression.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Oncol, London W6 8RP, England	Imperial College London	Johnston, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Oncol, Charing Cross Campus,St Dunstans Rd, London W6 8RP, England.			Coombes, Raoul Charles/0000-0002-4811-1100				ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coope RC, 1997, BRIT J CANCER, V75, P1621, DOI 10.1038/bjc.1997.277; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Gomm JJ, 1997, EXP CELL RES, V234, P165, DOI 10.1006/excr.1997.3593; GOMM JJ, 1991, CANCER RES, V51, P4685; GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOUHARA H, 1994, ONCOGENE, V9, P455; Leung HY, 1996, ONCOGENE, V12, P1833; LORENZI MV, 1995, ONCOGENE, V10, P2051; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MCLESKEY SW, 1994, CANCER RES, V54, P523; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Payson RA, 1996, ONCOGENE, V13, P47; PEKONEN F, 1993, MOL CELL ENDOCRINOL, V95, P43, DOI 10.1016/0303-7207(93)90027-H; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RON D, 1993, J BIOL CHEM, V268, P5388; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; SMITH J, 1994, EUR J CANCER, V30A, P496, DOI 10.1016/0959-8049(94)90426-X; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Yiangou C, 1997, BRIT J CANCER, V76, P1419, DOI 10.1038/bjc.1997.573	53	71	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1053	1060		10.1038/sj.onc.1202392	http://dx.doi.org/10.1038/sj.onc.1202392			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023681				2022-12-17	WOS:000078510600022
J	Saville, MK; Watson, RJ				Saville, MK; Watson, RJ			The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties	ONCOGENE			English	Article						B-Myb; cyclin A; Cdk2; phosphorylation; transcriptional regulation	GENE V-MYB; C-MYB; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; S-PHASE; HEMATOPOIETIC-CELLS; EXPRESSION; PRODUCT; ACTIVATION; PROLIFERATION	Expression of the B-Myb transcription factor is upregulated during late G(1) phase of the cell cycle by an E2F-dependent transcriptional mechanism. B-Myb is specifically phosphorylated during S phase, suggesting that a cyclin-dependent kinase (Cdk) regulates its activity. Consistent with this notion, the S phase-specific cyclin A/Cdk2 was found previously to enhance B-Myb transactivation activity in cotransfected cells. In this study we provide evidence that B-Myb is a direct physiological target for cyclin A/Cdk2. We demonstrate that B-Myb is an in vitro substrate for cyclin A/Cdk2, but not for cyclin D1/Cdk4 or cyclin E/Cdk2. By mutating candidate Cdk2 phosphorylation sites, we show that B-Myb is phosphorylated at Thr447, Thr490, Thr497 and Ser581 by cyclin A/Cdk2 in vitro and that these sites are also phosphorylated in cycling U-2 OS cells. Inhibition of endogenous Cdk2 by dominant negative Cdk2 attenuated phosphorylation of Thr447, Thr490 and Thr497, but had no effect upon Ser581 modification. B-Myb transactivation activity was significantly reduced in a mutant containing amino acid substitutions at all four identified cyclin A/Cdk2 sites and was constitutively low in Saos-2 cells where endogenous cyclin A/Cdk2 activity was unable to phosphorylate ectopically expressed B-Myb. These data indicate that phosphorylation by cyclin A/Cdk2 is directly involved in enhancing B-Myb transactivation activity and that levels of endogenous cyclin A/Cdk2 activity may contribute to cell line-specific B-Myb function.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London SW7 2AZ, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, St Marys Campus, London SW7 2AZ, England.							Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bennett JD, 1996, ONCOGENE, V13, P1073; Bies J, 1996, ONCOGENE, V12, P355; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brandt TL, 1997, J BIOL CHEM, V272, P6278, DOI 10.1074/jbc.272.10.6278; Chang ZF, 1998, J BIOL CHEM, V273, P12095, DOI 10.1074/jbc.273.20.12095; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOOS G, 1993, ONCOGENE, V8, P1775; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Horton LE, 1997, ONCOGENE, V14, P491, DOI 10.1038/sj.onc.1200851; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kamano H, 1995, ONCOGENE, V11, P2575; KATO J, 1983, GENE DEV, V7, P331; KITAGAWA M, 1995, ONCOGENE, V10, P229; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NOMURA N, 1998, NUCLEIC ACIDS RES, V16, P11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEEPER DS, 1995, ONCOGENE, V10, P39; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Saville MK, 1998, ADV CANCER RES, V72, P109; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TASHIRO S, 1995, ONCOGENE, V10, P1699; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	66	71	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	1998	17	21					2679	2689		10.1038/sj.onc.1202503	http://dx.doi.org/10.1038/sj.onc.1202503			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840932				2022-12-17	WOS:000077146700001
J	Zhou, J; Ng, AYN; Tymms, MJ; Jermiin, LS; Seth, AK; Thomas, RS; Kola, I				Zhou, J; Ng, AYN; Tymms, MJ; Jermiin, LS; Seth, AK; Thomas, RS; Kola, I			A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13-15, a region subject to LOH and rearrangement in human carcinoma cell lines	ONCOGENE			English	Article						transcription factor; epithelial cells; cancer; erbB2; transcription; LOH	MURINE LEUKEMIA-VIRUS; HUMAN PROSTATE-CANCER; HUMAN BREAST-CANCER; DNA-BINDING MOTIF; PROTEIN-KINASE-C; GM-CSF PROMOTER; T-CELLS; ONCOGENIC ACTIVITY; TRANSGENIC MICE; MESSENGER-RNAS	The ETS transcription factors are a large family implicated in the control of cellular proliferation and tumorigenesis. In addition, chromosomal translocations involving ETS family members are associated with a range of different human cancers. Given the extensive involvement of ETS factors in tumorigenesis, it becomes important to identify any additional ETS genes that may also play oncogenic roles. We identify a novel gene, ELF5, that appears to belong to the ELF (E74-like-factor) subfamily of the ETS transcription factor family, based upon similarity within the 'ETS domain'. ELF5 displays a similar, but more restricted, expression pattern to that of the newly isolated epithelium-specific ETS gene, ELF3. Unlike most other ETS family members, ELF5 is not expressed in hematopoietic compartments, but is restricted to organs such as lung, stomach, kidney, prostate, bladder and mammary gland. ELF5 is localized to human chromosome 11p13-15, a region that frequently undergoes loss of heterozygosity (LOH) in several types of carcinoma, including those of breast, kidney and prostate. We find that ELF5 expression is not detectable in a number of carcinoma cell lines, some of which display loss or rearrangement of an ELF5 allele. Similar to other ETS family members, ELF5 displays specific binding to DNA sequences containing a GGAA-core. In addition, ELF5 is able to transactivate through these ETS sequences, present upstream from a minimal promoter. Our data suggest that ELF5 may play roles in mammary, lung, prostate and/or kidney function, and possibly also in tumorigenesis.	Monash Univ, Inst Reprod & Dev, Mol Genet & Dev Grp, Melbourne, Vic 3004, Australia; Natl Vis Res Inst Australia, Melbourne, Vic, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Univ Toronto, Womens Coll Hosp, Dept Pathol, Toronto, ON, Canada	Monash University; Australian National University; John Curtin School of Medical Research; University of Toronto; University Toronto Affiliates; Womens College Hospital	Kola, I (corresponding author), Monash Univ, Inst Reprod & Dev, Mol Genet & Dev Grp, Melbourne, Vic 3004, Australia.		Thomas, Ross/C-6434-2008; Jermiin, Lars Sommer/AAQ-7033-2020; Jermiin, Lars Sommer/C-2458-2009; Kola, Ismail/C-5254-2013	Jermiin, Lars Sommer/0000-0002-9619-3809; Jermiin, Lars Sommer/0000-0002-9619-3809; 				AKASHI M, 1994, BLOOD, V83, P3182; Baffa R, 1996, CANCER RES, V56, P268; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Coleman WB, 1997, MOL CARCINOGEN, V19, P267, DOI 10.1002/(SICI)1098-2744(199708)19:4<267::AID-MC8>3.0.CO;2-9; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Dahiya R, 1997, INT J CANCER, V72, P283, DOI 10.1002/(SICI)1097-0215(19970717)72:2<283::AID-IJC14>3.0.CO;2-H; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Easteal S, 1997, J MOL EVOL, V44, pS121, DOI 10.1007/PL00000066; Feinberg AP, 1996, MED PEDIATR ONCOL, V27, P484; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FISHER RJ, 1991, ONCOGENE, V6, P2249; Gambarotta G, 1996, ONCOGENE, V13, P1911; Gao AC, 1997, CANCER RES, V57, P846; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GRAVES BL, 1998, IN PRESS ADV CANC RE; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HART AH, 1995, ONCOGENE, V10, P1423; Hasegawa M., 1996, MOLPHY VERSION 2 3 P; HILLIS DM, 1994, NATURE, V369, P363, DOI 10.1038/369363a0; Hirose M, 1996, MED PEDIATR ONCOL, V27, P174; HUNTER T, 1982, J BIOL CHEM, V257, P4843; Ichikawa T, 1996, PROSTATE, P31; IDA K, 1995, INT J CANCER, V63, P500, DOI 10.1002/ijc.2910630407; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kawana Y, 1997, PROSTATE, V32, P205; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lee JH, 1996, J BIOL CHEM, V271, P4561; Lichy JH, 1998, AM J PATHOL, V153, P271, DOI 10.1016/S0002-9440(10)65568-X; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MORI S, 1989, LAB INVEST, V61, P93; Moritz Craig, 1996, P1; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRESS MF, 1990, ONCOGENE, V5, P953; SAMBROOK J, 1997, MOL CLONING LAB MANU; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIPATHY D, 1994, HEMATOL ONCOL CLIN N, V8, P29, DOI 10.1016/S0889-8588(18)30186-2; Tymms M J, 1995, Methods Mol Biol, V37, P31; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; VANDENBUNDER B, 1994, FOLIA BIOL-PRAGUE, V40, P301; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1990, ONCOGENE, V5, P101; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WERNERT N, 1992, AM J PATHOL, V140, P119; Wilson AP, 1996, BRIT J CANCER, V74, P722, DOI 10.1038/bjc.1996.428; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZENKLUSEN JC, 1995, GENE CHROMOSOME CANC, V13, P47, DOI 10.1002/gcc.2870130108; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	99	71	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	1998	17	21					2719	2732		10.1038/sj.onc.1202198	http://dx.doi.org/10.1038/sj.onc.1202198			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840936				2022-12-17	WOS:000077146700005
J	Jerry, DJ; Kuperwasser, C; Downing, SR; Pinkas, J; He, C; Dickinson, E; Marconi, S; Naber, SP				Jerry, DJ; Kuperwasser, C; Downing, SR; Pinkas, J; He, C; Dickinson, E; Marconi, S; Naber, SP			Delayed involution of the mammary epithelium in BALB/c-p53(null) mice	ONCOGENE			English	Article						p53; mice; mammary involution; p21(WAF1) apoptosis	PROGRAMMED CELL-DEATH; TRANSGENIC MICE; BASEMENT-MEMBRANE; GLAND INVOLUTION; P53; APOPTOSIS; TISSUE; DIFFERENTIATION; SUPPRESSION; STROMELYSIN-1	In mammals, weaning of neonates and subsequent milk stasis initiates removal of the secretory epithelium of the mammary gland by apoptosis, The p53 tumor suppressor gene is induced rapidly following weaning of neonates, but its role in the process of involution has not been defined. Therefore, experiments were performed to identify the cell types in which the p53 gene is expressed during involution and determine the consequences of its absence in BALB/c-p53(null) mice. Both p53 mRNA and protein were detected in the mammary epithelium within 48 h following meaning and resulted in an eightfold increase in levels of p21(WAF1) mRNA, Induction of p21(WAF1) mRNA was absent in BALB/c-p53(null) mice, and therefore, was shown to be p53-dependent, The BALB/c-p53(null) mice exhibited delayed involution of the mammary epithelium, as measured by 60% greater epithelial area compared to BALB/c-p53(wt) mice through 5 days postweaning, The delay was transient with no differences being apparent at 7 days post-weaning. Expression of the stromal protease stromelysin-1 was unaffected by the absence of p53 suggesting that stromal responses were intact. These data demonstrate that p53 participates in the first stage of involution initiated by the epithelium itself, but does not affect the second phase during which stromal proteases are induced.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Baystate Med Ctr, Dept Pathol, Springfield, MA 01199 USA	University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center	Jerry, DJ (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.				NATIONAL CANCER INSTITUTE [R29CA066670] Funding Source: NIH RePORTER; NCI NIH HHS [CA66670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; ATWOOD CS, 1995, BIOCHEM BIOPH RES CO, V207, P860, DOI 10.1006/bbrc.1995.1265; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; COLOMBEL M, 1995, ONCOGENE, V10, P1269; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; HENSON DE, 1994, CANCER, V74, P424, DOI 10.1002/cncr.2820741330; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; MacCallum DE, 1996, ONCOGENE, V13, P2575; MUNFORD RE, 1963, J ENDOCRINOL, V28, P17, DOI 10.1677/joe.0.0280017; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Petersen SL, 1996, ENDOCRINOLOGY, V137, P234, DOI 10.1210/en.137.1.234; Pullan S, 1996, J CELL SCI, V109, P631; QUARRIE LH, 1995, CELL TISSUE RES, V281, P413, DOI 10.1007/BF00417859; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WITTY JP, 1995, CANCER RES, V55, P1401	32	71	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2305	2312		10.1038/sj.onc.1202157	http://dx.doi.org/10.1038/sj.onc.1202157			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811461				2022-12-17	WOS:000076723300004
J	Krosl, J; Baban, S; Krosl, G; Rozenfeld, S; Largman, C; Sauvageau, G				Krosl, J; Baban, S; Krosl, G; Rozenfeld, S; Largman, C; Sauvageau, G			Cellular proliferation and transformation induced by HOXB4 and HOXB3 proteins involves cooperation with PBX1	ONCOGENE			English	Article						oncogenes; proliferation; Hox; Pbx; cancer	HOMEODOMAIN-DNA INTERACTIONS; ACUTE MYELOID-LEUKEMIA; HOMEOBOX GENES; CRYSTAL-STRUCTURE; GROWTH-FACTOR; PRE-B; TRANSLOCATION; EXPRESSION; E2A-PBX1; BINDING	The products of PBX homeobox genes, which mere initially discovered in reciprocal translocations occurring in human leukemias, have been shown to cooperate in the in vitro DNA binding with HOX proteins. Despite the growing body of data implicating Hox genes in the development of various cancers, little is known about the role of HOX-PBX interactions in the regulation of proliferation and induction of transformation of mammalian cells. We build on the existing model of Hox-induced transformation of Rat-1 cells to show that both cellular transformation and proliferation induced by Hoxb4 and Hoxb3 are greatly modulated by the levels of available PBX1 present in these cells. Furthermore, we show that the transforming capacity of these two HOX proteins depends on their conserved tetrapeptide and homeodomain regions which mediate binding to PBX and DNA, respectively. Taken together, results of this study demonstrate that cooperation between HOX and PBX proteins modulates cellular proliferation and strongly suggest that cooperative DIVA binding by these two groups of proteins represent the basis for Hox-induced cellular transformation.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada; Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sauvageau, G (corresponding author), Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Sauvageau, Guy/0000-0002-4333-7266				BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Care A, 1996, MOL CELL BIOL, V16, P4842; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; JIANG W, 1993, ONCOGENE, V8, P3447; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NEUTEBOOM ST, 1995, P NATL ACAD SCI USA, V92, P9196; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; ROCCO GD, 1997, EMBO J, V16, P3644; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; SUN B, 1995, EMBO J, V14, P520, DOI 10.1002/j.1460-2075.1995.tb07028.x; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Zhao JJG, 1996, EMBO J, V15, P1313, DOI 10.1002/j.1460-2075.1996.tb00473.x	40	71	78	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3403	3412		10.1038/sj.onc.1201883	http://dx.doi.org/10.1038/sj.onc.1201883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692548				2022-12-17	WOS:000074544100007
J	Perletti, GP; Concari, P; Brusaferri, S; Marras, E; Piccinini, F; Tashjian, AH				Perletti, GP; Concari, P; Brusaferri, S; Marras, E; Piccinini, F; Tashjian, AH			Protein kinase C epsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway	ONCOGENE			English	Article						PKC epsilon; Raf-1; colon cancer; oncogene		We have shown previously that overexpression of the epsilon isoform of protein kinase C (PKC epsilon) in rat colonic epithelial cells causes malignant transformation, possibly by interacting with the ras signal transduction pathway (Oncogene 12: 847, 1996). We have now performed experiments to examine certain early steps in the ras signaling pathway. A marked increase of Raf-1 phosphorylation was detected in tumorigenic ras-transformed D/ras as well as in D/epsilon cells (overexpressing PKC epsilon), compared to the nontumorigenic D/WT parental Line. Moreover, in the PKC epsilon-transformed D/epsilon cell line, stable transfection with a dominant-negative raf-1 (DNraf) sequence caused complete regression of the neoplastic phenotype. These results suggested that PKC epsilon-induced transformation was associated with increased Raf-1 activation, and that DNraf could block the oncogenic effect of PKC epsilon, Furthermore, transfection of D/WT cells with dominant-negative ras induced arrest of cell growth, and subsequent transfection,vith PKC epsilon cDNA enhanced cell proliferation and induced neoplastic transformation. These results suggest that ras acts upstream of PKC epsilon, and that overexpression of PKC epsilon circumvents the block in cell proliferation caused by dominant-negative ras. We conclude that PKC epsilon exerts its oncogenic activity in rat colonic cells by affecting the ras signaling cascade at the level of Raf-1 activation.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Milan, Ist Farmacol, I-20129 Milan, Italy	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Milan	Tashjian, AH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.				NIEHS NIH HHS [ES 00002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLIND E, 1995, ENDOCRINOLOGY, V136, P4271, DOI 10.1210/en.136.10.4271; CACACE AM, 1993, ONCOGENE, V8, P2095; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CCACE AM, 1996, ONCOGENE, V13, P2517; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Perletti GP, 1996, INT J ONCOL, V9, P171; Perletti GP, 1996, ONCOGENE, V12, P847; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B	12	71	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3345	3348		10.1038/sj.onc.1201871	http://dx.doi.org/10.1038/sj.onc.1201871			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681835				2022-12-17	WOS:000074343600017
J	Lee, YI; Lee, S; Lee, Y; Bong, YS; Hyun, SW; Do Yoo, Y; Kim, SJ; Kim, YW; Poo, HR				Lee, YI; Lee, S; Lee, Y; Bong, YS; Hyun, SW; Do Yoo, Y; Kim, SJ; Kim, YW; Poo, HR			The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4	ONCOGENE			English	Article						hepatitis B virus; insulin-like growth factor-II; hepatocellular carcinoma; transactivation	BOX-BINDING-PROTEINS; LONG TERMINAL REPEAT; DNA-BINDING; SP1-MEDIATED TRANSCRIPTION; TRANS-ACTIVATION; MESSENGER-RNA; EXPRESSION; LIVER; CELLS; SEQUENCES	Human hepatitis B virus (HBV) is one of the causative agents of hepatocellular carcinoma (HCC). The virus encodes a 17 kDa protein, X, which is known to be a causative agent in the formation of HCC. An insulin-like growth factor-II (IGF-II) is expressed during the formation of HCC. Among the four promoters of the IGF-II gene, promoters 2, 3 and 4 become activated during the formation of HCC. The high frequency of detection of hepatitis B virus X (HBV-X) antigen in liver cells from patients with chronic hepatitis, cirrhosis, and liver cancer suggested that the expressions of HBV-X and IGF-II are associated. Studies were carried out to test the relationship between the HBV-X gene product and the activation of IGF-II promoter 4, We demonstrated that the HBV-X protein increases the endogenous IGF-II expression from promoter 3 and 4 of IGF-II gene. Analysis of the fourth promoter of IGF-II gene showed that the HBV-X gene product positively regulates transcription. Two copies of a motif are responsible for conferring HBV-X regulation on the fourth promoter of IGF-II. These motifs have been identified as Sp1 binding sites, Sp1 binding to IGF-II P4 promoter was identified by gel mobility shift assay using purified Sp1. By using a GAL4-Sp1 fusion protein it was demonstrated that HBV-X positively regulates the Sp1 mediated transcriptional activity of IGF-II in vivo. A protein-affinity chromatography experiment showed that HBV-X protein does not bind directly to Sp1, but HBV-X does augment the DNA binding activity of the phosphorylated form of Sp1 in HepG2 cells. Sp1 was phosphorylated by HBV-X and its DNA-binding activity was up-regulated upon HBV-X transfections. Various HBV-X mutant expression vectors were used for the demonstration of specific interactions between Sp1 and HBV-X. These results indicate that HBV-X functions as a positive regulator of transcription, and that Sp1 is a direct target for the transcriptional regulation of IGF-II. Increasing the DNA binding ability of the phosphorylated form of Sp1 by HBV-X might be an important mechanism for regulating the IGF-II gene expression and possibly promoting cell division during hepatic carcinogenesis. Our experimental results suggest that expression of HBV-X might induce the expression of IGF-II and the IGF-II might play a role in hepatitis B virus pathogenesis during the formation of HCC.	Korea Adv Inst Sci & Technol, Korea Res Inst Biosci & Biotechnol, Mol Cell Biol Res Div, Liver Cell Signal Transduct Lab, Taejon 305606, South Korea; NCI, Chemoprevent Lab, NIH, Bethesda, MD 20892 USA	Korea Advanced Institute of Science & Technology (KAIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lee, YI (corresponding author), Korea Adv Inst Sci & Technol, Korea Res Inst Biosci & Biotechnol, Mol Cell Biol Res Div, Liver Cell Signal Transduct Lab, Taejon 305606, South Korea.							BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; CARIANI E, 1988, CANCER RES, V48, P6844; CAROLYN ND, 1991, HEPATOLOGY, V13, P310; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN XR, 1992, ONCOGENE, V7, P1805; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DARVILLE CN, 1991, HEPATOLOGY, V13, P310, DOI 10.1002/hep.1840130217; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FLORINI JR, 1992, GROWTH REGULAT, V2, P23; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY A, 1987, DNA-J MOLEC CELL BIO, V6, P283, DOI 10.1089/dna.1987.6.283; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HYUN SW, 1993, FEBS LETT, V332, P153, DOI 10.1016/0014-5793(93)80503-M; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM YH, 1993, BIOCHEM BIOPH RES CO, V197, P894, DOI 10.1006/bbrc.1993.2563; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LAMAS E, 1989, FALK S OCT 15 17 BAS, V55, P45; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LO SJ, 1988, VIROLOGY, V167, P289, DOI 10.1016/0042-6822(88)90081-5; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NANCY CA, 1991, NUCLEIC ACIDS RES, V19, P2499; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SOARES MB, 1985, NUCLEIC ACIDS RES, V13, P1119, DOI 10.1093/nar/13.4.1119; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; TAKADA S, 1994, ONCOGENE, V9, P341; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; VEDA K, 1996, J VIROL, V70, P1375; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YANG D, 1993, CANCER RES, V53, P2020; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427	68	71	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2367	2380		10.1038/sj.onc.1201760	http://dx.doi.org/10.1038/sj.onc.1201760			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620554				2022-12-17	WOS:000073428000009
J	Filatov, L; Golubovskaya, V; Hurt, JC; Byrd, LL; Phillips, JM; Kaufmann, WK				Filatov, L; Golubovskaya, V; Hurt, JC; Byrd, LL; Phillips, JM; Kaufmann, WK			Chromosomal instability is correlated with telomere erosion and inactivation of G2 checkpoint function in human fibroblasts expressing human papillomavirus type 16 E6 oncoprotein	ONCOGENE			English	Article						chromosome; instability; telomere; cell cycle; checkpoint	CELL-CYCLE CHECKPOINT; ATAXIA-TELANGIECTASIA CELLS; WILD-TYPE P53; GENE AMPLIFICATION; EPITHELIAL-CELLS; END ASSOCIATIONS; IMMORTAL CELLS; MUTANT P53; IN-VIVO; CANCER	Cell cycle checkpoints and tumor suppressor gene functions appear to be required for the maintenance of a stable genome in proliferating cells. In this study chromosomal destabilization was monitored in relation to telomere structure, lifespan control and G2 checkpoint function. Replicative senescence was inactivated in secondary cultures of human skin fibroblasts by expressing the human papillomavirus type 16 (HPV-16) E6 oncoprotein to inactivate p53, Chromosome aberrations were enumerated during in vitro aging of isogenic control (F5neo) and HPV-16E6-expressing (F5E6) fibroblasts. We found that structural and numerical aberrations in chromosomes were significantly increased in F5E6 cells during aging in vitro and fluorescence in situ hybridization (FISH) analysis using chromosome-specific probes demonstrated the occurrence of rearrangements involving chromosome 4 and 6 in genetically unstable F5E6 cells. Flow cytometry and karyotypic analyses revealed increased polyploidy and aneuploidy in F5E6 cells only at passages >16, although these cells displayed defective mitotic spindle checkpoint function associated with inactivation of p53 at passages 5 and 16, G2 checkpoint function was confirmed to be gradually but progressively inactivated during in vitro aging of E6-expressing cells. Aging of F5neo fibroblasts was documented during in vitro passaging by induction of a senescence-associated marker, pH 6.0 lysosomal beta-galactosidase, F5E6 cells displayed extension of in vitro lifespan and did not induce beta-galactosidase at high passage, Erosion of telomeres during in vitro aging of telomerase-negative F5neo cells was demonstrated by Southern hybridization and by quantitative FISH analysis on an individual cell level. Telomeric signals diminished continuously as F5neo cells aged in vitro being reduced by 80% near the time of replicative senescence. Telomeric signals detected by FISH also decreased continuously during aging of telomerase-negative F5E6 cells, but telomeres appeared to be stabilized at passage 34 when telomerase was expressed. Chromosomal instability in E6-expressing cells was correlated (P < 0.05) with both loss of telomeric signals and inactivation of C2 checkpoint function. The results suggest that chromosomal stability depends upon a complex interaction among the systems of telomere length maintenance and cell cycle checkpoints.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Kaufmann, WK (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [P01CA042765] Funding Source: NIH RePORTER; NCI NIH HHS [CA42765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BOND JA, 1994, ONCOGENE, V9, P1885; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; COHEN MM, 1989, ADV HUM GENET, V18, P43; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EJIMA Y, 1986, MUTAT RES, V159, P117, DOI 10.1016/0027-5107(86)90120-X; Filatov LV, 1996, CANCER GENET CYTOGEN, V89, P136, DOI 10.1016/0165-4608(95)00363-0; FILATOV LV, 1987, MOL BIOL REP, V12, P117, DOI 10.1007/BF00368879; FILATOV LV, 1991, CANCER GENET CYTOGEN, V56, P11, DOI 10.1016/0165-4608(91)90357-Z; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GALLOWAY DA, 1994, COLD SPRING HARB SYM, V59, P297, DOI 10.1101/SQB.1994.059.01.034; Golubovskaya VM, 1997, ONCOGENE, V15, P1233, DOI 10.1038/sj.onc.1201278; GRANA X, 1995, ONCOGENE, V11, P211; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALY KC, 1995, ONCOL RES, V7, P121; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; Ishikawa F, 1997, BIOCHEM BIOPH RES CO, V230, P1, DOI 10.1006/bbrc.1996.5928; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KAUFMANN WK, 1995, CANCER RES, V55, P7; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; McClintock B, 1941, GENETICS, V26, P234; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PAULES RS, 1995, CANCER RES, V55, P1763; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schwartz JL, 1996, RADIAT RES, V146, P139, DOI 10.2307/3579585; SHAY JW, 1993, ONCOGENE, V8, P1407; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TAYLOR AMR, 1976, NATURE, V260, P441, DOI 10.1038/260441a0; THERKELSEN AJ, 1995, CYTOGENET CELL GENET, V68, P115, DOI 10.1159/000133903; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	62	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	1998	16	14					1825	1838		10.1038/sj.onc.1201711	http://dx.doi.org/10.1038/sj.onc.1201711			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583680				2022-12-17	WOS:000072994600006
J	Kobayashi, T; Ruan, SB; Clodi, K; Kliche, KO; Shiku, H; Andreeff, M; Zhang, W				Kobayashi, T; Ruan, SB; Clodi, K; Kliche, KO; Shiku, H; Andreeff, M; Zhang, W			Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents	ONCOGENE			English	Article						Bax; Bcl-2; apoptosis; K562; chemotherapeutic agents	ANNEXIN-V; HUMAN P53; IN-VIVO; DEATH; BCL-2; EXPRESSION; PHOSPHATIDYLSERINE; INHIBITION; CISPLATIN; BCL-X(L)	Bax and Bcl-2 are a pair of important genes that control programmed cell death, or apoptosis, with Bax being the apoptosis promoter and Bcl-2 the apoptosis protector. Although the detailed mechanism is unknown, the protein products of these two genes form protein dimers with each other and the relative ratio of the two proteins is believed to be a determinant of the balance between life and death. In our preliminary study, we found that K562 erythroleukemia cells have an extremely low level of endogenous Bcl-2 expression and a fairly high level of endogenous Bax expression. We constructed Bax and Bcl-2 expression vectors and transfected them into K562 cells. We found that transfection of Bax vector increased the expression of Bax protein; a shortened form of Bax also appeared. Cell death analysis using the Annexin V assay showed that the Bax vector caused significantly more apoptotic cells that the Bcl-2 or pCI-neo vector did. After selection with G418, Bax, Bcl-2 and pCI-neo stably transfected cells were established. These three cell Lines were examined for their response to the chemotherapeutic agents ara-C, doxorubicin, etoposide and SN-38. Bax-K562 cells showed significantly higher fractions of apoptotic cells than pCI-neo-K562 cells when treated with ara-C, doxorubicin or SN-38. No sensitization effect was seen when etoposide was used. In contrast, Bcl-2-K562 cells had fewer apoptotic cells than pCI-neo-K562 cells after treatment with all these agents. Therefore, Bax may sensitize K562 cells to apoptosis induced by a wide range of, but not all, chemotherapeutic agents.	Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Hematol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Mie Univ, Sch Med, Dept Internal Med 2, Tsu, Mie 514, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Mie University	Zhang, W (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA55164, CA57639, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, R01CA057639, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boersma AWM, 1996, CYTOMETRY, V24, P123, DOI 10.1002/(SICI)1097-0320(19960601)24:2<123::AID-CYTO4>3.0.CO;2-K; Ibrado AM, 1996, CANCER RES, V56, P4743; Kobayashi T, 1995, ONCOGENE, V11, P2311; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	23	71	79	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1587	1591		10.1038/sj.onc.1201681	http://dx.doi.org/10.1038/sj.onc.1201681			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569026				2022-12-17	WOS:000072743200009
J	Svedberg, H; Chylicki, K; Baldetorp, B; Rauscher, FJ; Gullberg, U				Svedberg, H; Chylicki, K; Baldetorp, B; Rauscher, FJ; Gullberg, U			Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program	ONCOGENE			English	Article						WT1; leukemia; differentiation; hematopoiesis; U937	ZINC FINGER PROTEIN; I RECEPTOR GENE; SUPPRESSOR GENE; RETINOIC ACID; MYELOID-LEUKEMIA; ADHESION MOLECULES; PROMOTER ACTIVITY; FLOW-CYTOMETRY; U-937 CELLS; PRODUCT	The Wilms tumor gene, WT1, encodes a zinc-finger DNA binding protein which is thought to function as a tissue specific transcription factor, regulating cell growth and differentiation, High expression of WT1 has been detected in a range of acute leukemias. To elucidate a role for WT1 in leukemogenesis, we transfected the monoblastic cell line U937, which lacks detectable levels of endogenous WT1, with two isoforms of WT1, We showed that, in contrast to U937 control cells, cells constitutively expressing either of the isoforms, WT1(-KTS) or WT1(+KTS), did not respond to differentiation induction by retinoic acid or vitamin D3, as judged by the capacity to reduce nitro blue tetrazolium and morphology. Although U937 cells expressing WT1 were hampered in their ability to differentiate on incubation with retinoic acid and vitamin D3, the induced G1/G0-accumulation was similar to differentiating control cells treated with inducers, Furthermore, distinct effects on the maturation process were indicated by downregulation of the myeloid cell surface makers CD13 and CD15, while the upregulation of CD14 and CD11c on WT1 transfected cells was similar to control cells upon incubation with retinoic acid and vitamin D3, Taken together our results demonstrate that a constitutive expression of WT1 in the leukemic cell line U937 leads to impairment of differentiation responses, indicating that a high expression of WT1 can contribute to the differentiation block of acute leukemia.	Lund Univ, Dept Hematol, S-22185 Lund, Sweden; Lund Univ, Dept Oncol, S-22185 Lund, Sweden; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Lund University; Lund University; The Wistar Institute	Gullberg, U (corresponding author), Lund Univ, Dept Hematol, S-22185 Lund, Sweden.		Baldetorp, Bo/HDM-9924-2022					Algar EM, 1996, ONCOGENE, V12, P1005; Baird PN, 1997, EXP HEMATOL, V25, P312; BALDETORP B, 1989, CYTOMETRY, V10, P695, DOI 10.1002/cyto.990100605; BALDETORP B, 1992, CYTOMETRY, V13, P577, DOI 10.1002/cyto.990130605; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARLOS TM, 1994, BLOOD, V84, P2068; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; HEWITT SM, 1995, CANCER RES, V55, P5386; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kudoh T, 1996, ONCOGENE, V13, P1431; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; LUO XN, 1995, ONCOGENE, V11, P743; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIWA H, 1992, LEUKEMIA, V6, P405; MORRIS JF, 1991, ONCOGENE, V6, P2339; OBERG F, 1993, J IMMUNOL, V150, P3487; Olsson I, 1996, EUR J HAEMATOL, V57, P1; OLSSON I, 1983, CANCER RES, V43, P5862; OLSSON IL, 1982, CANCER RES, V42, P3924; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SEKIYA M, 1994, BLOOD, V83, P1876; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STOCKS SC, 1990, BIOCHEM J, V268, P275, DOI 10.1042/bj2680275; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	55	71	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	1998	16	7					925	932		10.1038/sj.onc.1201613	http://dx.doi.org/10.1038/sj.onc.1201613			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484784				2022-12-17	WOS:000072053200012
J	Li, CD; Larsson, C; Futreal, A; Lancaster, J; Phelan, C; Aspenblad, U; Sundelin, B; Liu, Y; Ekman, P; Auer, G; Bergerheim, USR				Li, CD; Larsson, C; Futreal, A; Lancaster, J; Phelan, C; Aspenblad, U; Sundelin, B; Liu, Y; Ekman, P; Auer, G; Bergerheim, USR			Identification of two distinct deleted regions on chromosome 13 in prostate cancer	ONCOGENE			English	Article						prostate cancer; chromosome 13; BRCA2; Rb1; pRb; DBM	RETINOBLASTOMA SUSCEPTIBILITY GENE; COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC LOSS; IN-SITU; BREAST; BRCA2; HETEROZYGOSITY; CARCINOMA; MUTATIONS; PROTEIN	Aberrations of 13q occur frequently in prostate cancer and this chromosome contains two known tumor suppressor genes, BRCA2 and Rb1. This study analysed 13q LOH, DNA ploidy, BRCA2 mutation and pRb expression in prostate cancers, In total, 13q deletions were found in 18 of 36 tumors but did not correlate with histological grade, stage or DNA ploidy. Two smallest regions of overlapping deletions were defined: one flanked by D13S218 and D13S153; the other flanked by D13S31 and D13S137. BRCA2 was less frequently deleted ,whereas Rb1 did have a high frequency of deletion. None of the two genes was located in any of these two regions, Furthermore, BRCA2 mutation was not found in the five tumors where deletions had involved the BRCA2 locus, Neither did the Rb1 deletion correlate with absent pRb expression. In addition, tetraploidy was found in 14 out of 25 tumors analysed and correlated with aberrant pRb expression. Our results indicate that 13q deletion is an early non-random event, Tumor suppressor genes other than BRCA2 or Rb1 may be the target of 13q deletions. Aberrant pRb expression was not reflect the tyro-hit Rb1 inactivation but may be involved in the tetraploidization of prostate cancer cells.	Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Pathol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Oncol, S-17176 Stockholm, Sweden; Duke Univ, Med Ctr, Dept Surg, Div Gynecol Oncol, Durham, NC 27710 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Duke University	Li, CD (corresponding author), Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden.			Auer, Gert/0000-0003-3911-0285; Li, Chunde/0000-0003-4331-079X	NCI NIH HHS [P50-CA68438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; Cher ML, 1996, CANCER RES, V56, P3091; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; Cooney KA, 1996, CANCER RES, V56, P1142; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Herzog H, 1996, GENOME RES, V6, P858, DOI 10.1101/gr.6.9.858; HSIEH CL, 1990, SOMAT CELL MOLEC GEN, V16, P567, DOI 10.1007/BF01233097; JEWITT HJ, 1975, UROL CLIN N AM, V2, P105; Kubota Y, 1995, PROSTATE, V27, P314, DOI 10.1002/pros.2990270604; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEONARDO AD, 1997, CANCER RES, V57, P1013; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; Maestro R, 1996, CANCER RES, V56, P1146; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MOSTOFI FK, 1980, 10 WHO INT HIST CLAS; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P195, DOI 10.1046/j.1365-2265.1996.d01-1561.x; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; RADFORD DM, 1995, CANCER RES, V55, P3399; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; STEINBECK RG, 1994, ANAL QUANT CYTOL, V16, P196; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tricoli JV, 1996, GENE CHROMOSOME CANC, V15, P108, DOI 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7; VISAKORPI T, 1995, CANCER RES, V55, P342; Whitmore Jr WF, 1956, AM J MED, V21, P697; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; ZHANG X, 1994, CANCER RES, V54, P4177	34	71	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					481	487		10.1038/sj.onc.1201554	http://dx.doi.org/10.1038/sj.onc.1201554			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484837				2022-12-17	WOS:000071739400006
J	Schwartz, D; Almog, N; Peled, A; Goldfinger, N; Rotter, V				Schwartz, D; Almog, N; Peled, A; Goldfinger, N; Rotter, V			Role of wild type p53 in the G(2) phase: regulation of the gamma-irradiation-induced delay and DNA repair	ONCOGENE			English	Article						p53; G(2) checkpoint; DNA damage; micronucleated cells	NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE CHECKPOINTS; SUPPRESSOR PROTEIN P53; C-TERMINAL DOMAIN; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; TUMOR-SUPPRESSOR; FLOW-CYTOMETRY; NUCLEAR ACCUMULATION; INDUCED MICRONUCLEI	Upregulation of the p53 protein was shown to induce cell cycle arrest at the G(1)/S border and in some cases at the G(2)/M border. Furthermore, it was suggested that p53 is associated with the induction of the various DNA repair pathways. Previously, we demonstrated that cells coexpressing endogenous wild type p53 protein, together with dominant negative mutant p53, exhibit deregulation of apoptosis, G(1) arrest and delay in G(2) following gamma-irradiation. In the present study, we investigated the role of p53 protein in the DNA damage response at the G(2) phase. Using p53-null, wild type p53 and mutant p53-producer cell lines, we found that the two C-terminally spliced p53 forms could prevent gamma-irradiation induced mutagenesis prior to mitosis, at the G(2)/M checkpoint. We found that at the G(2) phase, p53 may facilitate repair of DNA breaks giving rise to micronuclei, and regulate the exit from the G(2) checkpoint. At the G(1) phase, only the regularly spliced form of p53 caused growth arrest. In contrast, both the regularly and the alternatively spliced p53 forms directed postmitotic micronucleated cells towards apoptosis. These results provide a functional explanation for the cell cycle-independent expression of p53 in normal cycling cells, as well as in cells where p53 is up-regulated, following DNA damage.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN IT, 1995, ONCOGENE, V11, P1931; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAWLEY RS, 1996, GENE DEV, V10, P2382; HEDDLE JA, 1977, MUTAT RES, V44, P63, DOI 10.1016/0027-5107(77)90115-4; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McDonald E, 1996, CANCER RES, V56, P2250; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NUSSE M, 1994, METHOD CELL BIOL, V42, P149; NUSSE M, 1992, INT J RADIAT BIOL, V62, P587, DOI 10.1080/09553009214552511; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAULES RS, 1995, CANCER RES, V55, P1763; Peled A, 1996, ONCOGENE, V13, P1677; POWELL SN, 1995, CANCER RES, V55, P1643; REMVIKOS Y, 1990, INT J CANCER, V45, P450, DOI 10.1002/ijc.2910450313; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHREIBER GA, 1992, INT J RADIAT BIOL, V62, P695, DOI 10.1080/09553009214552651; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STEWART N, 1995, ONCOGENE, V10, P109; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER C, 1994, CANCER RES, V54, P3651; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	75	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2597	2607		10.1038/sj.onc.1201436	http://dx.doi.org/10.1038/sj.onc.1201436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399647				2022-12-17	WOS:A1997YG73200009
J	Pells, S; Divjak, M; Romanowski, P; Impey, H; Hawkins, NJ; Clarke, AR; Hooper, ML; Williamson, DJ				Pells, S; Divjak, M; Romanowski, P; Impey, H; Hawkins, NJ; Clarke, AR; Hooper, ML; Williamson, DJ			Developmentally-regulated expression of murine K-ras isoforms	ONCOGENE			English	Article						ras; expression; splicing	STEM-CELL LINE; C-MYC; DIFFERENTIAL EXPRESSION; PROTO-ONCOGENE; N-RAS; MOUSE; GENE; TRANSFORMATION; PROTEINS; MEMBRANE	The products (p21) of the three mammalian H-, N- and K-ras genes play important roles in intracellular signal transduction, linking membrane receptor kinases to the nuclear pathway through raf and mitogen activated protein kinase. They are involved in the regulation of proliferation and differentiation, and activating mutations of these genes are commonly associated with human cancers. Two p21 proteins are encoded by the K-ras gene (p21(K-rasA) and p21(K-rasB)) due to alternative splicing of the fast exon. While the four p21(ras) proteins are highly homologous, their sequences diverge significantly at the C-termini, to which distinct biochemical and perhaps even functional differences may be ascribed. However, H-, N- and K-rasB appear to be ubiquitously expressed, with little evidence of tissue-specific or developmental regulation. In contrast, we now demonstrate that the expression of K-rasA is strikingly different, K-rasA is induced during differentiation of pluripotent embryonal stem cells in vitro. Its expression during early embryogenesis is limited temporally and spatially in a tissue-specific distribution which is largely maintained as an adult. This suggests a distinct biological role for p21(K-rasA).	UNIV EDINBURGH,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; ST VINCENTS HOSP,CTR IMMUNOL,DARLINGHURST,NSW 2010,AUSTRALIA; UNIV NEW S WALES,SCH PATHOL,KENSINGTON,NSW 2052,AUSTRALIA	University of Edinburgh; St Vincents Hospital Sydney; University of New South Wales Sydney			Clarke, Alan R/A-6256-2008; Hawkins, Nicholas J/A-8461-2008; clarke, alan r/P-2820-2014	Hawkins, Nicholas J/0000-0002-2204-3189; Clarke, Alan/0000-0002-4281-426X; Pells, Stephen/0000-0001-5866-5759				AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARBONE A, 1991, ONCOGENE, V6, P731; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; ELLIS RW, 1982, MOL CELL BIOL, V2, P1339, DOI 10.1128/MCB.2.11.1339; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P48, DOI 10.1007/BF00376370; Hogan B. L. M, 1983, CANCER SURV, V2, P115; JACKS T, 1995, COMMUNICATION; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LOCKETT TJ, 1987, EXP CELL RES, V173, P370, DOI 10.1016/0014-4827(87)90277-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MARTIN GR, 1975, TERATOMAS DIFFERENTI, P169; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1983, TERATOCARCINOMA STEM, P451; MULLER R, 1982, MOL CELL BIOL, V3, P1062; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; PAL SK, 1993, MOL REPROD DEV, V35, P8, DOI 10.1002/mrd.1080350103; SEJERSEN T, 1985, EXP CELL RES, V160, P19, DOI 10.1016/0014-4827(85)90232-0; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YAMAUCHI N, 1994, MOL CELL BIOL, V14, P6655, DOI 10.1128/MCB.14.10.6655; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	39	71	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1781	1786		10.1038/sj.onc.1201354	http://dx.doi.org/10.1038/sj.onc.1201354			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362444				2022-12-17	WOS:A1997XZ72500004
J	Cao, WS; BritosBray, M; Claxton, DF; Kelley, CA; Speck, NA; Liu, PP; Friedman, AD				Cao, WS; BritosBray, M; Claxton, DF; Kelley, CA; Speck, NA; Liu, PP; Friedman, AD			CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells	ONCOGENE			English	Article						CBF beta-SMMHC; inv(16); CBF; leukemia; myeloid; cell cycle	MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE MYELOMONOCYTIC LEUKEMIA; FACTOR-RECEPTOR PROMOTER; TRANSCRIPTION FACTOR; FUSION TRANSCRIPT; CHIMERIC PROTEIN; NUCLEAR FACTOR	CBF beta-SMMHC is expressed from the inv(16) chromosome in M4Eo AML. Mice lacking CBF subunits or expressing the CBF beta-SMMHC or AML1-ETO onco-proteins failed to develop definitive hematopoiesis. To investigate these effects on hematopoiesis, we expressed CBF beta-SMMHC from the metallothionein promoter, in both 32D c13 myeloid cells and Ba/F3 B-lymphoid cells. Addition of zinc increased CBF beta-SMMHC levels more than tenfold, with higher levels evident in Ba/F3 lines. Levels obtained in 32D c13 cells were similar to those of endogenous CBF beta. Indirect immunofluorescence revealed zinc-inducible speckled, nuclear staining in Ba/F3 cells and diffuse nuclear staining in 32D c13 cells. CBF beta-SMMHC reduced endogenous CBF DNA-binding fivefold in both cell types, increased cell generation time 1.9-fold, on average, in 32D c13 cells and 1.5-fold in Ba/ F3 cells and decreased tritiated thymidine incorporation into DNA correspondingly. CBFP beta-SMMHC increased the proportion of cells in G1 1.7-fold, on average, in 32D c13 and Ba/F3 cells, and decreased the proportion of cells in S phase by a similar degree. CBF beta-SMMHC induced a marked increase in hypophosphorylated Rb, but did not alter IL-3 Receptor alpha or beta subunit levels. Neither apoptosis nor 32D differentiation was induced by zinc in IL-3 in these lines. Induction of CBF beta-SMMHC WC in 32D c13 cells did not inhibit their differentiation to neutrophils or their expression of myeloperoxidase mRNA in GCSF, and did not produce an eosinophilic phenotype. Additional, proliferative genetic changes in M4eo AMLs might potentiate inhibition of differentiation by CBF beta-SMMHC by allowing its increased expression.	JOHNS HOPKINS UNIV, CTR ONCOL, DIV PEDIAT ONCOL, BALTIMORE, MD 21287 USA; UNIV TEXAS, DEPT HEMATOL, HOUSTON, TX 77030 USA; NHLBI, NIH, BETHESDA, MD 20892 USA; DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Dartmouth College; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Liu, Paul/A-7976-2012	Liu, Paul/0000-0002-6779-025X	NHLBI NIH HHS [R01 HL51388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARTHUR DC, 1983, BLOOD, V61, P994; BAE SC, 1993, ONCOGENE, V8, P809; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BritosBray M, 1996, LEUKEMIA, V10, P984; BRITOSBRAY M, 1997, IN PRESS MOL CELL BI; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Claxton D, 1996, LEUKEMIA, V10, P1479; CLAXTON DF, 1994, BLOOD, V83, P1750; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; Friedman AD, 1996, CANCER RES, V56, P3250; FRIEDMAN AD, 1991, BLOOD, V78, P2426; FRIEDMAN AD, 1994, BLOOD, V84, pA374; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Haferlach T, 1996, BLOOD, V87, P2459, DOI 10.1182/blood.V87.6.2459.bloodjournal8762459; Hiddemann W., 1995, Blood, V86, p267A; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1996, BLOOD, V88, P1148; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SACCHI N, 1994, GENE CHROMOSOME CANC, V11, P226, DOI 10.1002/gcc.2870110405; Sacchi N, 1996, ONCOGENE, V12, P437; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SCOTT LM, 1992, BLOOD, V80, P1725; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	67	71	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1315	1327		10.1038/sj.onc.1201305	http://dx.doi.org/10.1038/sj.onc.1201305			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315100				2022-12-17	WOS:A1997XV84500010
J	Zhan, QM; Alamo, I; Yu, K; Boise, LH; Cherney, B; Tosato, G; OConnor, PM; Fornace, AJ				Zhan, QM; Alamo, I; Yu, K; Boise, LH; Cherney, B; Tosato, G; OConnor, PM; Fornace, AJ			The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function	ONCOGENE			English	Article						BCL-X(L); p53; apoptosis; ionizing radiation	TUMOR-SUPPRESSOR P53; CELL-CYCLE; BCL-X; ATAXIA-TELANGIECTASIA; CANCER-CELLS; DNA-DAMAGE; BAX GENE; IN-VIVO; C-MYC; EXPRESSION	We have investigated the effect of DNA damage on the expression of BCL-X, a member of the BCL-2 family. BCL-X mRNA levels were found to increase upon exposure human cells to ionizing radiation (IR). The Bcl-X(L) protein, but not Bcl-X(S), was identified to be induced by IR. Like BAX, another member of the BCL-2 family and a p53-regulated gene, the induction of BCL-X(L) was dependent on normal p53 function and required that cells have an apoptosis-susceptible phenotype. The induction of BCL-X(L) was rapid, transient and dose-dependent. The mRNA level peaked at 4 h and returned to baseline by 24 h post-irradiation. In agreement with the increased transcript level, Bcl-X(L) protein level was also observed to increase in cells with wild-type p53 where IR triggered apoptosis. In addition, a survey of the BCL-X(L) mRNA basal levels in human cells with known apoptotic responses showed that low basal levels of BCL-X(L) mRNA in cells were highly correlated with a strong ability of cells to undergo IR-induced apoptosis. On the other hand, high levels of basal BCL-X(L) were correlated,vith the resistance of cells to IR-induced apoptosis regardless of p53 status. These results indicate that BCL-2 and BCL-X(L) behave differently in response to DNA damage treatment even though they both are able to protect cells from p53-mediated apoptosis; along with down-regulation of BCL-2, BCL-X(L) was up-regulated by IR in human cells with wild-type p53 and susceptibility to IR-induced apoptosis. We speculate that the physiological function of increased BCL-X(L) protein would be expected to probably limit the severity and length of BAX effect in order to maintain a proper threshold for apoptosis and to complete cell cycle arrest activated by p53.	UNIV CHICAGO,GWEN KNAPP CTR LUPUS & IMMUNOL,CHICAGO,IL 60637; US FDA,CTR BIOL,BETHESDA,MD 20892	University of Chicago; US Food & Drug Administration (FDA)	Zhan, QM (corresponding author), NCI,MOL PHARMACOL LAB,DIV BASIC SCI,ROOM 5C09,BLDG 37,BETHESDA,MD 20892, USA.		Boise, Lawrence/AAD-2314-2019; Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Boise, Lawrence/0000-0001-9436-8815; Tosato, Giovanna/0000-0003-1663-3227				BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN S, 1996, UNPUB; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORNACE AJ, 1980, BIOCHIM BIOPHYS ACTA, V607, P432, DOI 10.1016/0005-2787(80)90153-7; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1994, CANCER RES, V54, P2095; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SCOTT WL, 1993, CELL, V74, P957; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1995, ONCOGENE, V10, P1053; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937	35	71	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2287	2293						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950997				2022-12-17	WOS:A1996VV14500027
J	Harigai, M; Miyashita, T; Hanada, M; Reed, JC				Harigai, M; Miyashita, T; Hanada, M; Reed, JC			A cis-acting element in the BCL-2 gene controls expression through translational mechanisms	ONCOGENE			English	Article						Bcl-2; apoptosis; translation	HUMAN FOLLICULAR LYMPHOMA; MESSENGER-RNA; PROTOONCOGENE EXPRESSION; MAMMALIAN-CELLS; PROTO-ONCOGENE; DNA-SEQUENCE; REGION; NEUROBLASTOMA; INHIBITION; CARCINOMA	The bcl-2 gene becomes activated in many types of human cancers and contributes to neoplastic cell expansion, as well as to resistance to radiation and chemotherapy, by blocking programmed cell death or apoptosis. The expression of this proto-oncogene is regulated at both the transcriptional and post-transcriptional levels. DNA sequence comparisons of human, mouse, rat and chicken bcl-2 cDNAs revealed the presence of an open reading frame (OFR) located upstream of the normal coding region. Because upstream ORFs (uORFs) have been associated with translational repression, we analysed the functional significance of the 11 amino-acid uORF in the human BCL-2 gene (-119 to -84 bp). Deletion of this uORF from chloramphenicol acetyltransferase (CAT) reporter gene constructs that contained the bcl-2 promoter and entire 5'-untranslated region (5'-UTR), as well as introduction of an A --> T mutation at position -119 bp that destroyed the AUG-initiation codon, significantly increased CAT activity in HeLa, CEM, and other cell lines, without producing a corresponding elevation in CAT mRNA levels. Positioning this uORF, together with its accompanying Kozak sequences, between a heterologous promoter from SV40 and a CAT reporter gene resulted in marked inhibition of CAT protein production without a decrease in CAT mRNA, Mutation of the start codon (ATG --> TTG) of this uORF completely abolished its inhibitory activity, consistent with a translational mechanism, Taken together, these findings suggest that the uORF located within the 5'UTR of the bcl-2 gene is necessary and sufficient for translational regulation of bcl-2 gene expression.	LA JOLLA CANC RES FDN,ONCOGENE & TUMOR SUPPRESSOR GENE PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRONNER M, 1994, AM J PATHOL, V146, P20; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P292; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; HANADA M, 1993, CANCER RES, V53, P4978; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; KONDO E, 1992, BLOOD, V80, P2044; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAKOVER D, 1991, ONCOGENE, V6, P455; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIYASHITA T, 1994, CANCER RES, V54, P3131; PANTOPOULOS K, 1994, PROG NUCLEIC ACID RE, V48, P181, DOI 10.1016/S0079-6603(08)60856-9; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; PEABODY DS, 1986, MOL CELL BIOL, V6, P2704, DOI 10.1128/MCB.6.7.2704; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REED JC, 1989, ONCOGENE RES, V4, P271; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAKURAGI N, 1994, J SOC GYNECOL INVEST, V1, P164, DOI 10.1177/107155769400100212; SATO T, 1994, GENE, V140, P291, DOI 10.1016/0378-1119(94)90561-4; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SONNENBERG N, 1990, CURR TOP MICROBIOL I, V161, P23; TANAKA S, 1992, BLOOD, V79, P229; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	41	71	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1369	1374						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649841				2022-12-17	WOS:A1996UC06700024
J	Lehar, SM; Naeht, M; Jacks, T; Vater, CA; Chittenden, T; Guild, BC				Lehar, SM; Naeht, M; Jacks, T; Vater, CA; Chittenden, T; Guild, BC			Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells	ONCOGENE			English	Article						p53; gene induction; differential display; apoptosis	TUMOR-SUPPRESSOR; WILD-TYPE; APOPTOSIS; EXPRESSION; PROTEIN; THYMOCYTES; RECEPTOR; SEQUENCE	To search for candidate genes involved in p53-mediated apoptosis, the differential display technique was used to identify RNA species whose expression was altered in murine NIH3T3 cells treated with the cytotoxic drug etoposide. We report here the isolation and characterization of EI24, a novel gene whose 2.4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53 in murine embryonic fibroblasts which had been transformed with the oncogenes E1A and T24 H-ras; and overexpression of functional p53 in these cells was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. Isolation of a full-length EI24 cDNA revealed that its protein product bears homology to CELF37C12.2, a Caenorhabditis elegans protein of unknown function.	APOPTOSIS TECHNOL INC,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; Sambrook J, 1989, MOL CLONING LAB MANU; SHAKLEFORD GM, 1987, CELL, V50, P89; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WALKER PR, 1991, CANCER RES, V51, P1078; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1994, ONCOGENE, V9, P3743	36	71	74	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1181	1187						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649819				2022-12-17	WOS:A1996UC06700002
J	DelSal, G; Murphy, M; Ruaro, EM; Lazarevic, D; Levine, AJ; Schneider, C				DelSal, G; Murphy, M; Ruaro, EM; Lazarevic, D; Levine, AJ; Schneider, C			Cyclin D1 and p21/waf1 are both involved in p53 growth suppression	ONCOGENE			English	Article						cyclin; D1; p53; p21/waf1; cell cycle G1 arrest	WILD-TYPE P53; CELL-CYCLE; DEPENDENT KINASES; PROTEIN; APOPTOSIS; GENE; DNA; TRANSFORMATION; FIBROBLASTS; INHIBITION	Overexpression of the wild type p53 gene in normal and transformed cells induces G1 arrest of cellular proliferation. In cell lines carrying the valine 135 temperature-sensitive p53 mutant gene, restoration of wild type p53 protein conformation at the permissive temperature causes an increase in the levels of cyclin D1, as well as the cyclin/cdk inhibitor p21/waf1, Accumulation of cyclin D1 is the result both of (post)transcriptional and post-translational regulatory mechanisms. Ablation of cyclin D1 induction by antisense cDNA microinjection significantly delays the onset of growth arrest, indicating that increased cyclin D1 levels Likely contribute to wild type p53 G1 arrest. Whereas antisense ablation of either cyclin D1 or p21/waf1 can delay the onset of p53-induced growth arrest, ablation of neither is able to overcome a pre-existing p53-induced G1 block. In summary, the accumulated evidence indicate that induction of both cyclin D1 and p21/waf1 are involved in establishing the p53-mediated growth arrest in murine cell lines expressing temperature sensitive p53 protein.	LAB NAZL CONSORZIO INTERUNIV BIOTECHNOL, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY; DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC VL, I-34012 TRIESTE, ITALY; PRINCETON UNIV, LEWIS THOMAS LAB, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Princeton University			Lazarevic, Dejan/AAN-1861-2020	DEL SAL, GIANNINO/0000-0003-2185-6003; Murphy, Maureen/0000-0001-7644-7296; lazarevic, dejan/0000-0003-4527-290X				ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, ONCOGENE, V9, P2663; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	47	71	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					177	185						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552389				2022-12-17	WOS:A1996TQ01400022
J	APPEL, K; WAGNER, P; BOLDYREFF, B; ISSINGER, OG; MONTENARH, M				APPEL, K; WAGNER, P; BOLDYREFF, B; ISSINGER, OG; MONTENARH, M			MAPPING OF THE INTERACTION SITES OF THE GROWTH SUPPRESSOR PROTEIN P53 WITH THE REGULATORY BETA-SUBUNIT OF PROTEIN-KINASE CK2	ONCOGENE			English	Article						P53; GROWTH SUPPRESSOR PROTEIN; PROTEIN KINASE; PHOSPHORYLATION	WILD-TYPE P53; DNA-BINDING FUNCTION; CELL-CYCLE CONTROL; CASEIN KINASE-2; T-ANTIGEN; TRANSFORMED-CELLS; TUMOR-ANTIGEN; PHOSPHORYLATION; DOMAIN; OLIGOMERIZATION	p53 plays an essential role in cellular growth control. Some of its distinct biological functions are regulated by interaction with cellular proteins. We have previously (Wagner et al., 1994) shown that p53 binds to the regulatory subunit of protein kinase CK2. Using C-terminal protein fragments of p53 we now demonstrate that the region between amino acids 287 and 340 on the polypeptide chain of p53 is critical for binding of p53 to the beta-subunit of CK2. Neither phosphorylation at the p34(cdc2) site (aa315) nor at the CK2 site (aa392) is necessary for binding of p53 to the beta-subunit of CK2. Using deletion mutants of the beta-subunit of CK2 we also show that an internal region between amino acids 72 and 149 of the beta-subunit of CK2 is necessary for binding to p53. Thus, this study defines new functional regions on the polypeptide chains of p53 and of protein kinase CK2.	UNIV SAARLAND,D-66421 HOMBURG,GERMANY	Saarland University			Montenarh, Mathias/AAB-6689-2020					ADDISON C, 1990, ONCOGENE, V5, P423; APPEL K, 1994, INT J ONCOL, V5, P667; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOLDYREFF B, 1994, CELL MOL BIOL RES, V40, P391; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; CHEN J, 1993, MOL CELL BIOL, V13, P4104; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1994, ONCOGENE, V9, P3249; GOTZ C, 1995, INT J ONCOL, V6, P1129; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1994, GASTROENTEROLOGY, V106, P1708, DOI 10.1016/0016-5085(94)90431-6; KRAISS S, 1990, ONCOGENE, V5, P845; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LORENZ A, 1992, INT J ONCOL, V1, P571; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; OROURKE RW, 1990, ONCOGENE, V5, P1829; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REIHSAUS E, 1990, ONCOGENE, V5, P137; REIHSAUS E, 1992, EXP CELL RES, V199, P10, DOI 10.1016/0014-4827(92)90456-I; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WAGNER P, 1994, INT J ONCOL, V4, P987; WAGNER P, 1994, INT J ONCOL, V4, P491; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	67	71	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1971	1978						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478515				2022-12-17	WOS:A1995TF29700006
J	LI, CY; NAGASAWA, H; DAHLBERG, WK; LITTLE, JB				LI, CY; NAGASAWA, H; DAHLBERG, WK; LITTLE, JB			DIMINISHED CAPACITY FOR P53 IN MEDIATING A RADIATION-INDUCED G(1) ARREST IN ESTABLISHED HUMAN TUMOR-CELL LINES	ONCOGENE			English	Article						G(1)-ARREST; P53; RB; RADIATION; HUMAN PAPILLOMA VIRUS E6; HUMAN TUMOR CELLS	ATAXIA-TELANGIECTASIA; CHROMOSOMAL-ABERRATIONS; CYCLE PROGRESSION; X-IRRADIATION; CANCER; FIBROBLASTS; MUTATIONS; INDUCTION; ONCOGENE; PROTEIN	It has been reported that the p53 gene mediates an ionizing radiation-induced G(1) arrest in mammalian cells. To further characterize this important phenomenon, a panel of seven human diploid fibroblast cell strains and 14 human tumor cell lines from a variety of sources with both wild-type and mutant p53 status were assayed for their susceptibility to G(1) arrest after gamma-ray irradiation by a continuous labeling [H-3]thymidine incorporation technique. An irreversible G(1)-block involving 20-70% of the cell population was observed in diploid fibroblasts irradiated with 4 Gy. The block was abolished by transfection with the Human Papilloma Virus E6 gene and in an ataxia telangiectasia (AT) tell line, indicating a role for the AT and p53 genes respectively in this process. In contrast to wild-type normal fibroblast cell strains, the G(1)-block in all tumor cell lines was significantly reduced, irrespective of their p53 status. None of the nine human tumor cell lines with mutant p53 genes showed a significant G(1)-block following irradiation with 4 Gy. Among the five tumor cell lines expressing wild-type p53, two showed no apparent G(1)-block. The remaining three showed a G(1)-block involving only 8-15% of the cell population, a block much smaller in magnitude than that seen in diploid fibroblasts. Finally, a diploid fibroblast cell strain and a tumor cell line, both showing a normal p53 and p21/WAF1 expression pattern, were examined for pRb phosphorylation before and after irradiation. The diploid fibroblast cell strain showed a significant G(1)-arrest and a clear inhibition of pRb phosphorylation by irradiation whereas the tumor cells showed no G(1)-arrest and no inhibition of pRb phosphorylation. These results suggest that (1) multiple genetic factors may modulate the occurrence and magnitude of the G(1)-arrest induced by exposure to ionizing radiation, (2) the capacity for p53 to mediate a radiation-induced G(1) arrest is significantly reduced in tumor cells, (3) the disruption of G(1)-block modulating factor(s) other than p53 may be an important step in carcinogenesis.			LI, CY (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Li, Chuan-Yuan/H-4148-2013		NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES0002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTMAN KI, 1970, RAD BIOCHEM, V1, P189; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CASEY G, 1991, ONCOGENE, V6, P1991; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HE J, 1994, CANCER RES, V54, P5804; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISSACS WB, 1991, CANCER RES, V51, P4716; JIANG W, 1992, CANCER RES, V52, P2980; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1992, CELL, V71, P687; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEONARDO AD, 1994, GENE DEV, V8, P2540; LI CY, 1995, INT J ONCOL, V7, P223; LITTLE J B, 1970, Radiation Research, V44, P674, DOI 10.2307/3573149; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LITTLE JB, 1969, NATURE, V224, P804, DOI 10.1038/224804a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NAGASAWA H, 1995, CANCER RES, V55, P1842; NAGASAWA H, 1994, INT J RADIAT BIOL, V66, P373, DOI 10.1080/09553009414551311; NAGASAWA H, 1984, RADIAT RES, V97, P537, DOI 10.2307/3576145; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1994, NATURE, V366, P701	39	71	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1885	1892						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478618				2022-12-17	WOS:A1995TD09400025
J	NAKAGAWA, K; CONRAD, NK; WILLIAMS, JP; JOHNSON, BE; KELLEY, MJ				NAKAGAWA, K; CONRAD, NK; WILLIAMS, JP; JOHNSON, BE; KELLEY, MJ			MECHANISM OF INACTIVATION OF CDKN2 AND MTS2 IN NON-SMALL-CELL LUNG-CANCER AND ASSOCIATION WITH ADVANCED-STAGE	ONCOGENE			English	Article						P16(INK4); CDKN2; P15(IMK4B); POINT MUTATION; LUNG NEOPLASM	P53 GENE-MUTATIONS; LINES; IDENTIFICATION; FEATURES	The CDKN2 tumor suppressor gene encodes an inhibitor of type D cyclin dependent kinases. CDKN2 is homozygously deleted in approximately 25% of nonsmall cell lung cancer (NSCLC) cell lines and these deletions are associated with advanced stage cancer. Conflicting reports of the frequency of CDKN2 alterations in NSCLC tumors prompted us to examine the relationship of these alterations and those of the related gene, MTS2, with patient stage and site of cancer. One hundred twenty-five NSCLC samples (71 cell lines and 54 tumors) were examined by PCR-SSCP. Twenty of 71 (28%) tumor cell lines had homozygous deletions, and six (8%) had point mutations compared to 4 (7%) with point mutations among 54 tumor samples. All mutations mere observed in tumors or cell lines from patients with stage III or IV disease. Two patients with no mutations in their primary tumor had a CDKN2 point mutation detected in a metastatic tumor. Point mutations were G:C to T:A transversion on the coding strand in five of 10 and resulted in nonsense mutations in seven of 10. Undetectable CDKN2 mRNA, in the absence of detectable genetic alteration, was noted in a similar fraction of cell lines derived from patients with stage I or IZ disease [two of seven (29%)] and stage Hi or TV disease [15 of 49 (31%)]. Homozygous deletion of MTS2 was found in 17 of 20 cell lines with CDKN2 deletions; no point mutations of MTS2 were identified by SSCP in the 125 samples. Thus, CDKN2 is a frequent target of genetic alterations at 9p21 in NSCLC. Both deletions and point mutations of CDKN2 are closely associated with tumor dissemination.	NATL CANC INST, NAVAL MED ONCOL BRANCH, BETHESDA, MD 20889 USA; NATL NAVAL MED CTR, DEPT LAB, BETHESDA, MD 20889 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center			Kelley, Michael/AAC-8939-2019	Kelley, Michael/0000-0001-9523-6080				CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CARNEY DN, 1985, CANCER RES, V45, P2913; DAVIS LG, 1994, BASIC METHODS MOL BI, P306; GAZDAR AF, 1985, CANCER RES, V45, P2924; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Herman J. G., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P201; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JOHNSON BE, 1993, CHEST, V103, pS1, DOI 10.1378/chest.103.1_Supplement.1S; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAVANAUGH DY, 1995, P AN M AM SOC CLIN, V14, P546; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KELLEY MJ, 1992, P NATL ACAD SCI USA, V89, P9287, DOI 10.1073/pnas.89.19.9287; KELLEY MJ, 1994, LUNG CANCER, V11, P58; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; LIU Q, 1995, ONCOGENE, V10, P1061; MITSUDOMI T, 1993, CHEST, V104, P362, DOI 10.1378/chest.104.2.362; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOULTON T, 1995, AM J PATHOL, V146, P613; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHAW GL, 1993, CANCER RES, V53, P5181; SHIMIZU E, 1994, ONCOGENE, V9, P2441; SOZZI G, 1992, CANCER RES, V52, P6079; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STEVENSON H, 1990, ANN INTERN MED, V113, P764, DOI 10.7326/0003-4819-113-10-764; SUGIO K, 1994, CANCER RES, V54, P5811; WALKER DG, 1995, CANCER RES, V55, P20; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU L, 1994, CANCER RES, V54, P5262; ZHANG SY, 1994, CANCER RES, V54, P5050	43	71	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1843	1851						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478613				2022-12-17	WOS:A1995TD09400020
J	HABETS, GGM; VANDERKAMMEN, RA; STAM, JC; MICHIELS, F; COLLARD, JG				HABETS, GGM; VANDERKAMMEN, RA; STAM, JC; MICHIELS, F; COLLARD, JG			SEQUENCE OF THE HUMAN INVASION-INDUCING TIAM1 GENE, ITS CONSERVATION IN EVOLUTION AND ITS EXPRESSION IN TUMOR-CELL LINES OF DIFFERENT TISSUE ORIGIN	ONCOGENE			English	Article						TIAM1; HUMAN SEQUENCE; GENE EXPRESSION; INVASION METASTASIS; GDS-PROTEINS; RHO-LIKE GTPASES; SIGNAL TRANSDUCTION	VAV PROTOONCOGENE; ANTIGEN EXPRESSION; PROTEINS; ONCOGENE; LEUKEMIA; RAS; BCR	By means of proviral tagging in combination with in vitro selection for invasive T-lymphoma variants, we have previously identified the murine invasion- and metastasis-inducing Tiam1 gene. Tiam1 encodes a novel protein which shares a Dbl-homology (DH) domain with GDP dissociation stimulator-(GDS) proteins that activate Rho-like GTPases, We have cloned the human TIAM1 coding sequence and studied its evolutionary conservation and expression pattern, TIAM1 is highly conserved among vertebrates, The close similarity between human T1AM1 and the mouse homologue is indicated by 88% and 95% identity of nucleotides and predicted sequences, respectively, The murine gene is highly expressed in brain and testis and at low or moderate levels in almost all other normal tissues, Interestingly, Tiam1 transcripts were found in virtually all analysed tumor cell lines of human and rodent origin including B- and T-lymphomas, neuroblastomas, melanomas and carcinomas, The evolutionary conservation as well as the broad expression pattern of Tiam1 in most normal tissues, suggests a general function in cellular signaling processes presumably by activation of a Rho-like GTPase that regulates the cytoskeletal organization.	NETHERLANDS CANC INST, ANTONI VAN LEEUWENHOEKHUIS, DIV CELL BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								ADAMS JM, 1992, ONCOGENE, V7, P611; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BORST J, 1989, EUR J IMMUNOL, V19, P1559, DOI 10.1002/eji.1830190907; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CHAN AML, 1994, ONCOGENE, V9, P1057; COLLARD JG, 1987, CANCER RES, V47, P754; DEFRANCISCIS V, 1991, CANCER RES, V51, P4234; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, IN PRESS CYTOGENET C; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOOLENAAR CEC, 1992, INT J CANCER, V51, P238, DOI 10.1002/ijc.2910510212; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V80, P389; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1989, ONCOGENE, V4, P1076; Schrier P I, 1991, Semin Cancer Biol, V2, P73; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; VANNOESEL CJM, 1992, J EXP MED, V175, P1511, DOI 10.1084/jem.175.6.1511; VECCHIO G, 1989, ONCOGENE, V4, P879; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	35	71	89	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1371	1376						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731688				2022-12-17	WOS:A1995QR65100014
J	SUN, Y; HILDESHEIM, A; LANIER, AEP; CAO, Y; YAO, KT; RAABTRAUB, N; YANG, CS				SUN, Y; HILDESHEIM, A; LANIER, AEP; CAO, Y; YAO, KT; RAABTRAUB, N; YANG, CS			NO POINT MUTATION BUT DECREASED EXPRESSION OF THE P16/MTS1 TUMOR-SUPPRESSOR GENE IN NASOPHARYNGEAL CARCINOMAS	ONCOGENE			English	Note						NASOPHARYNGEAL CARCINOMA; TUMOR SUPPRESSOR GENE; GENE MUTATION AND EXPRESSION	P53; PROGRESSION; LINKAGE; REGION; PCR; DNA	Nasopharyngeal carcinoma (NPC) is a malignancy which occurs at high incidence in southern China and southeast Asia. The molecular mechanism of this disease, however, is not well understood. Recently, a homozygous deletion and/or loss of heterozygosity on chromosome 9p21-22 was found in several primary NPCs (Huang et al., Cancer Res, 54: 4003-4006, 1994), suggesting that a potential tumor suppressor gene(s) residing in this region may play a role in nasopharyngeal carcinogenesis. Since p16/MTS1, a potential tumor suppressor gene, whose mutations/deletions are frequently found in variety of tumor cells, was mapped to chromosome 9p21, we investigated the possible involvement of this gene in the development of NPC by mutational and Northern blot analysis. SSCP-direct sequencing revealed no point mutations of the p16/MTS-1 gene in any of 42 primary NPC biopsies from three geographical regions nor in two NPC cell lines. We did, however, observe a codon 140(ala-->thr) polymorphism in the gene, which has been previously reported as a point mutation. Furthermore, Northern analysis revealed a decreased expression of the p16/MTS1 gene in two out of two NPC cell lines as compared with immortalized/nontransformed cell lines. These results suggest that down regulation rather than a point mutation of the p16/MTS1 gene may play a role in the genesis of NPC.	NCI, FREDERICK CANC RES & DEV CTR, CELL BIOL SECT, VIRAL CARCINOGENESIS LAB, FREDERICK, MD USA; NCI, ENVIRONM EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; US PHS, INDIAN HLTH SERV, ALASKA AREA NAT HLTH SERV, ANCHORAGE, AK USA; HUNAN MED UNIV, INST HUMAN CANC, CHANGSHA, PEOPLES R CHINA; UNIV N CAROLINA, DEPT MICROBIOL, CHAPEL HILL, NC USA; NATL TAIWAN UNIV, COLL MED, INST MICROBIOL, TAIPEI 10764, TAIWAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Public Health Service; Central South University; University of North Carolina; University of North Carolina Chapel Hill; National Taiwan University								BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; HUANG DP, 1994, CANCER RES, V54, P4003; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LU SJ, 1990, NATURE, V346, P470, DOI 10.1038/346470a0; MORI T, 1994, CANCER RES, V54, P3396; NAWROZ H, 1994, CANCER RES, V54, P1152; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUN Y, 1993, ONCOGENE, V8, P791; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1993, BIOTECHNIQUES, V15, P372; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; SUN Y, 1992, BIOTECHNIQUES, V12, P639; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; VANDERRIET P, 1994, CANCER RES, V54, P1156; YA C, 1991, MOL CARCINOGEN, V4, P297, DOI 10.1002/mc.2940040408	23	71	85	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					785	788						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862458				2022-12-17	WOS:A1995QH61200021
J	GILLARDON, F; ESCHENFELDER, C; UHLMANN, E; HARTSCHUH, W; ZIMMERMANN, M				GILLARDON, F; ESCHENFELDER, C; UHLMANN, E; HARTSCHUH, W; ZIMMERMANN, M			DIFFERENTIAL REGULATION OF C-FOS, FOSB, C-JUN, JUNB, BCL-2 AND BAX EXPRESSION IN RAT SKIN FOLLOWING SINGLE OR CHRONIC ULTRAVIOLET-IRRADIATION AND IN-VIVO MODULATION BY ANTISENSE OLIGODEOXYNUCLEOTIDE SUPERFUSION	ONCOGENE			English	Article							PROGRAMMED CELL-DEATH; SUNBURN CELL; FOLLICULAR LYMPHOMA; GENE-EXPRESSION; PROTO-ONCOGENE; MESSENGER-RNA; VIRUS TYPE-1; DNA; APOPTOSIS; MOUSE	Single ultraviolet (u.v.) irradiation of mammalian cells in culture evokes the transcriptional activation of various proto-oncogenes, among them members of the fos/jun family which are known to play an important role in cell proliferation and differentiation. u.v. exposure of mammalian skin results in growth arrest and cell death followed by hyperproliferation of epidermal cells. To obtain information in vivo about a possible relationship between u.v.-induced proto-oncogene expression and cellular alterations, me have analysed the expression of c-fos, fosB, c-jun, junB, bcl-2 and bdx in rat epidermis after single and chronic u.v. irradiation. We present data demonstrating that the transcripts of these genes are constitutively expressed in the epidermis and that expression is differentially modulated by u.v. exposure, Single u.v. irradiation causes a rapid and sustained increase in c-jun, junB and c-fos mRNA and a decline in bcl-2 transcripts, whereas expression of bax remained unchanged. c-Fos and c-Jun immunoreactivity was localized throughout the epidermal cell layers 1.5 h after single irradiation, but restricted to basal cells at 48 h suggesting an involvement in both u.v.-induced apoptosis and hyperproliferation. 48 h after chronic exposure a significantly higher induction and a totally different pattern of epidermal proto-oncogene expression was detectable which may be associated with malignancy. Superfusion of rat skin with c-fos antisense oligodeoxynucleotides inhibited the increase in c-Fos immunolabeled epidermal cells 1.5 h after single u.v. irradiation demonstrating that antisense oligodeoxynucleotides are capable of penetrating mammalian skin and modulating the u.v. response in vivo. However, suppression of the early c-Fos activation did not significantly affect the formation of sunburn cells in the u.v.-exposed epidermis. Thus, c-Fos does not seem to play a major role in u.v.-induced apoptosis or other members of the fos/jun family may compensate for a loss in c-Fos.	HOECHST AG, GEN PHARMA RES G838, D-65926 FRANKFURT, GERMANY; UNIV HEIDELBERG, HAUT KLIN, D-69115 HEIDELBERG, GERMANY	Sanofi-Aventis; Ruprecht Karls University Heidelberg	GILLARDON, F (corresponding author), UNIV HEIDELBERG, INST PHYSIOL 2, INF 326, D-69120 HEIDELBERG, GERMANY.			Eschenfelder, Christoph/0000-0003-2766-2488				BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BHALLA K, 1992, BLOOD, V80, P2883; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BRUNET S, 1990, J PHOTOCH PHOTOBIO B, V6, P431, DOI 10.1016/1011-1344(90)85116-E; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DANNO K, 1981, PHOTOCHEM PHOTOBIOL, V34, P203; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dilworth D D, 1992, PCR Methods Appl, V1, P279; DONAWHO CK, 1991, CANCER METAST REV, V10, P177, DOI 10.1007/BF00049413; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; Ferre F, 1992, PCR Methods Appl, V2, P1; FISHER C, 1991, DEVELOPMENT, V111, P253; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GARMYN M, 1991, LAB INVEST, V65, P471; GILLARDON F, 1991, NEUROSCI LETT, V124, P144, DOI 10.1016/0304-3940(91)90080-D; GRASSILLI E, 1992, BIOCHEM BIOPH RES CO, V188, P1261, DOI 10.1016/0006-291X(92)91367-Y; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANADA K, 1991, J INVEST DERMATOL, V96, P838, DOI 10.1111/1523-1747.ep12474538; HERDEGEN T, 1991, J COMP NEUROL, V312, P1; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1989, CANCER RES, V49, P1687; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KULKA M, 1993, ANTIVIR RES, V20, P115, DOI 10.1016/0166-3542(93)90002-Z; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MAI S, 1989, J CELL SCI, V94, P609; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; MATTEUCCI MD, 1981, J AM CHEM SOC, V103, P3185, DOI 10.1021/ja00401a041; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; OLSEN WM, 1990, J INVEST DERMATOL, V94, P101, DOI 10.1111/1523-1747.ep12873961; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARRISH JA, 1979, DERMATOLOGY GENERAL, P957; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SAKAI M, 1989, CANCER RES, V49, P5633; Sambrook J., 1989, MOL CLONING LAB MANU; SHAH G, 1993, CANCER RES, V53, P38; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UHLMANN E, 1990, CHEM REV, V90, P544; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Weedon D, 1979, Am J Dermatopathol, V1, P133; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	59	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3219	3225						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936645				2022-12-17	WOS:A1994PM65800014
J	MARSTON, NJ; CROOK, T; VOUSDEN, KH				MARSTON, NJ; CROOK, T; VOUSDEN, KH			INTERACTION OF P53 WITH MDM2 IS INDEPENDENT OF E6 AND DOES NOT MEDIATE WILD-TYPE TRANSFORMATION SUPPRESSOR FUNCTION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CASEIN KINASE-II; MUTANT P53; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION FUNCTION; MONOCLONAL-ANTIBODIES; TUMOR SUPPRESSION; GENE-EXPRESSION; CELL-GROWTH	Using a new series of p53 mutants targeting the conserved regions we have analysed the relationship of various activities of the protein. Mdm-2 and human papillomavirus (HPV) E6, two proteins which interact with and abrogate p53 function, were shown to bind independently. Deletion of the conserved regions of the protein in which most of the naturally occurring mutations are found (boxes II-V) abrogated transcriptional activity and the ability to interact with E6, supporting the importance of this DNA binding domain to these activities. Nevertheless, these mutants retained the ability to interact with mdm2. One mutant, deleted of all the C-terminal sequences, showed loss of mdm2 binding, E6 binding and transcriptional activity. More subtle mutations within the C-terminus of the protein, including alterations of the cdc2 and CKII phosphorylation sites, had no effect on the transcriptional trans-activation, mdm-2 or E6 binding functions, indicating that phosphorylation of these sites is not essential for these activities. Deletion of conserved box I sequences abolished the interaction with mdm-2 without loss of transcriptional activation or transformation suppressor activity, suggesting that mdm-2 is not a downstream effector of p53 function.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								ADDISON C, 1990, ONCOGENE, V5, P423; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LEACH FS, 1993, CANCER RES, V53, P2231; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, IN PRESS J VIROL; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P81; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1993, MOL CELL BIOL, V12, P2789; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P275; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	90	71	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2707	2716						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058335				2022-12-17	WOS:A1994PC05400032
J	FENG, GS; SHEN, R; HENG, HHQ; TSUI, LC; KAZLAUSKAS, A; PAWSON, T				FENG, GS; SHEN, R; HENG, HHQ; TSUI, LC; KAZLAUSKAS, A; PAWSON, T			RECEPTOR-BINDING, TYROSINE PHOSPHORYLATION AND CHROMOSOME LOCALIZATION OF THE MOUSE SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SYP	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC-CELL PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; MOTH-EATEN MICE; SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; SEQUENCE SIMILARITY; SIGNAL TRANSDUCTION	The murine phosphotyrosine phosphatase, Syp, is a widely-expressed cytoplasmic enzyme that contains two SH2 domains. Syp is physically associated with activated receptors for epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), apparently through its SH2 domains. This phosphatase is rapidly phosphorylated in cells treated with PDGF or EGF, and is constitutively phosphorylated in v-src transformed cells. Here we report that either the N-terminal or C-terminal Syp SH2 domain alone bound to the activated beta PDGF receptor or EGF-receptor in vitro, and that the two SH2 domains linked together exhibited synergistic binding. Substitution of the Tyr1009 autophosphorylation site in the C-terminal tail of activated beta PDGFR with Phe abolished the in vitro binding of either SH2 domain to the activated receptor. A 9 amino acid phosphopeptide corresponding to the Tyr1009 autophosphorylation site of the beta PDGFR inhibited association of the Syp SH2 domains with the receptor. These results indicate that the Syp SH2 domains have an intrinsic specificity for the Tyr1009 autophosphorylation site of the beta PDGFR that dictates binding of the intact Syp phosphatase, and suggest that both SH2 domains have a related binding specificity. Phosphoamino acid analysis of Syp from PDGF-stimulated cells indicated that PDGF primarily induces Syp phosphorylation on tyrosine residues. The mouse Syp gene has been mapped to chromosome 5F region by the fluorescence in situ hybridization. These findings suggest specific functions for Syp in signal transduction downstream of receptor tyrosine kinases.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA; HOSP SICK CHILDREN, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Jewish Health			Pawson, Tony J/E-4578-2013; Tsui, Lap-chee/A-1081-2010					ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, IN PRESS METHODS MOL; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LAROSE L, 1993, ONCOGENE, V8, P2493; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J., 1989, MOL CLONING LAB MANU; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Shultz L D, 1991, Semin Immunol, V3, P397; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	71	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1545	1550						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183548				2022-12-17	WOS:A1994NL81500004
J	ROTTAPEL, R; TURCK, CW; CASTERAN, N; LIU, XG; BIRNBAUM, D; PAWSON, T; DUBREUIL, P				ROTTAPEL, R; TURCK, CW; CASTERAN, N; LIU, XG; BIRNBAUM, D; PAWSON, T; DUBREUIL, P			SUBSTRATE SPECIFICITIES AND IDENTIFICATION OF A PUTATIVE BINDING-SITE FOR PI3K IN THE CARBOXY TAIL OF THE MURINE FLT3 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; GTPASE-ACTIVATING PROTEIN; FACTOR-I RECEPTOR; VAV PROTOONCOGENE PRODUCT; GAP-ASSOCIATED PROTEINS; GRB2 ADAPTER PROTEIN; PDGF BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE	Flt3 is a receptor tyrosine kinase (RTK) structurally related to the CSF-1R encoded by the c-fms locus, Kit and the PDGFR which is restricted in its expression to hematopoietic precursor populations and several distinct cell types within the central nervous system. Although the ligand for Flt3 has recently been identified, the developmental function of Flt3 within these tissues has not yet been described. In order to examine the signalling properties of this receptor, we previously constructed a chimeric molecule containing the extracellular domain of CSF-1R fused to the transmembrane and cytoplasmic domain of mouse Flt3 (FF3). The ability of the FF3 to directly associate with or tyrosine phosphorylate specific cytoplasmic signalling molecules in vivo was examined. GAP, Vav, She, and to a lessor extent PLC gamma become tyrosine-phosphorylated but no in vivo association with the receptor was detectable. FF3 associates with PI3K activity and the SH2 domains of p85 and Grb-2. Phosphopeptide competition experiments suggest that the PI3K binding site is located outside of the kinase insert in the carboxy tail of the receptor.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV TORONTO, MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA; UNIV TORONTO, DEPT MOLEC GENET, TORONTO M5G 1X5, ON, CANADA; INSERM, U119, MOLEC ONCOL LAB, F-13009 MARSEILLE, FRANCE	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)	ROTTAPEL, R (corresponding author), INSERM, U119, MOLEC HEMATOL LAB, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE.		Pawson, Tony J/E-4578-2013; dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Rottapel, Robert/0000-0002-6024-5558; Liu, X. Johne/0000-0003-3381-5030				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAMEN JE, 1993, BLOOD, V81, P3204; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1991, ONCOGENE, V6, P895; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Jones Gwenith, 1992, Progress in Growth Factor Research, V4, P97, DOI 10.1016/0955-2235(92)90025-D; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LYMAN S, 1993, CELL, V75; LYMAN SD, 1993, ONCOGENE, V8, P815; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSNET O, 1991, ONCOGENE, V6, P1641; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEGATTO O, 1993, ONCOGENE, V8, P2105; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHERR CJ, 1990, BLOOD, V75, P1; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	85	71	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1755	1765						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183574				2022-12-17	WOS:A1994NL81500031
J	LIAUDET, E; GARCIA, M; ROCHEFORT, H				LIAUDET, E; GARCIA, M; ROCHEFORT, H			CATHEPSIN-D MATURATION AND ITS STIMULATORY EFFECT ON METASTASIS ARE PREVENTED BY ADDITION OF KDEL RETENTION SIGNAL	ONCOGENE			English	Article						CATHEPSIN-D OVEREXPRESSION; METASTASIS; PROTEOLYSIS; KDEL SIGNAL	BREAST-CANCER-CELLS; LUMINAL ER PROTEINS; FACTOR-II RECEPTOR; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; LYSOSOMAL PROENZYMES; AUTOCRINE GROWTH; GOLGI-COMPLEX; MCF7 CELLS; SECRETION	Cathepsin D is overexpressed in most primary breast cancers where its concentration is correlated with increased metastatic potential. To investigate the possible role and mechanism of this lysosomal protease in metastasis, we transfected low-metastatic rat tumor cells with wild-type human cathepsin D, or mutated forms obtained by insertion of a KDEL peptide signal responsible for ER retention, or a control KDAS peptide. The overexpressed pro-cathepsin D in wild-type and KDAS clones was normally sorted and maturated in lysosomes. In KDEL clones, pro-cathepsin D was mostly retained in the ER or partially secreted by high-producer clones but was not maturated. While overexpressed cathepsin D increased experimental metastasis in athymic mice, the pro-cathepsin/D-KDEL was totally ineffective. Moreover, the effect of cathepsin D on metastasis did not seem to be due to saturation of the mannose-6-phosphate receptor since the secretion of two other rat lysosomal enzymes was unaffected by cathepsin D overexpression. We conclude that pro-cathepsin D overexpression facilitates tumor metastasis only when maturated into an active enzyme.	INSERM,U148,UNITE HORMONES & CANC,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE; UNIV MONTPELLIER 1,F-34090 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier			Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRIOZZO P, 1988, CANCER RES, V48, P3688; BROUILLET JP, 1991, CLIN BIOCHEM, V24, P491, DOI 10.1016/S0009-9120(05)80008-6; BROUILLET JP, 1993, EUR J CANCER, V29A, P1248, DOI 10.1016/0959-8049(93)90066-O; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CAPONY F, 1990, BIOCHEM BIOPH RES CO, V171, P972, DOI 10.1016/0006-291X(90)90779-M; CAPONY F, 1989, CANCER RES, V49, P3904; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FREISS G, 1988, CANCER RES, V48, P3709; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; GOTTESMAN MM, 1990, SEMINARS CANCER BIOL; GRASSEL S, 1992, BIOCHEM BIOPH RES CO, V182, P276, DOI 10.1016/S0006-291X(05)80141-X; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maniatis T., 1982, MOL CLONING; MAREEL MM, 1991, MECHANISMS INVASION; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; MONTCOURRIER P, 1993, CR ACAD SCI III-VIE, V316, P421; MONTCOURRIER P, 1990, CANCER RES, V50, P6045; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; SPYRATOS F, 1989, LANCET, V2, P1115; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; THORPE SM, 1989, CANCER RES, V49, P6008; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WESTLEY B, 1980, CELL, V20, P352; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408	42	71	71	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1145	1154						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134116				2022-12-17	WOS:A1994NC04800017
J	MULLAUER, L; FUJITA, H; ISHIZAKI, A; KUZUMAKI, N				MULLAUER, L; FUJITA, H; ISHIZAKI, A; KUZUMAKI, N			TUMOR-SUPPRESSIVE FUNCTION OF MUTATED GELSOLIN IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPASE-C; HUMAN PLATELET; IDENTIFICATION; EXPRESSION; CARCINOMA; ONCOGENE; PROFILIN; SEQUENCE; PROTEINS	The flat revertant R1, isolated from human activated Ha-ras oncogene-transformed NIH3T3 fibroblasts (EJ-NIH3T3), expresses a variant form of the actin-regulatory protein gelsolin (p92-5.7). We have cloned cDNAs encoding p92-5.7 and identified as the cause of the expression of p92-5.7 a point mutation in codon 321, which results in an amino acid change from proline to histidine. In order to understand the role of p92-5.7 in reversion of ras-transformed cells, cDNAs encoding p92-5.7 or human authentic gelsolin as a control were transfected into EJ-NIH3T3 cells. All the transfectants that produced p92-5.7 and one of three transfectants that produced human authentic gelsolin either lost or reduced tumorigenicity in syngeneic mice. These results demonstrate that mutated gelsolin can suppress a ras tumor and suggest that authentic gelsolin, if expressed at increased levels, may have a similar suppressive potential. Our data propose an important role for gelsolin in celllar signal transduction pathways that involve the mammalian ras proto-oncogene.	HOKKAIDO UNIV,SCH MED,INST CANC,MOLEC GENET LAB,KITA 15 NISHI 7,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University			Müllauer, Leonhard/GSN-9884-2022	Müllauer, Leonhard/0000-0002-3399-078X				BANNO Y, 1992, J BIOL CHEM, V267, P6488; BANYARD MRC, 1990, EXP CELL RES, V187, P180, DOI 10.1016/0014-4827(90)90135-W; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KWIATKOWSKI DJ, 1988, AM J HUM GENET, V42, P565; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MULLAUER L, 1991, CANCER LETT, V59, P37, DOI 10.1016/0304-3835(91)90133-3; OIKAWA T, 1988, INT J CANCER, V42, P435, DOI 10.1002/ijc.2910420321; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WANG E, 1984, J CELL BIOL, V98, P761, DOI 10.1083/jcb.98.2.761; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1984, J BIOL CHEM, V259, P5271; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	32	71	72	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2531	2536						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395682				2022-12-17	WOS:A1993LT36800025
J	REDDY, ESP; RAO, VN				REDDY, ESP; RAO, VN			ERG, AN ETS-RELATED GENE, CODES FOR SEQUENCE-SPECIFIC TRANSCRIPTIONAL ACTIVATORS	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; LONG TERMINAL REPEAT; AVIAN LEUKEMIA-VIRUS; PROTO-ONCOGENE; DNA-BINDING; C-ETS; V-ETS; CHROMOSOME-21; PROTEINS; CELLS	E26 is a replication-defective avian acute leukemia virus which causes erythroblastosis and myeloblastosis in chickens. It carries two distinct oncogenes, v-myb and v-ets, both of which contribute to its transforming properties. Several genes related to the ets oncogene (c-ets-1, ets-2, erg, elk-1, elk-2, PU.1/Spi-1, E74 and Fli-1) have been described. Previously we have shown that the erg gene (ets-related gene) codes for at least two proteins (erg-1 and erg-2) because of alternative splicing and alternative usage of the initiation codon. We have expressed erg-1 and erg-2 proteins in Escherichia coli and have used these recombinant proteins to show that they bind to DNA in a sequence-specific manner. erg proteins exhibited different sequence specificity and affinity for the oligonucleotides recognized by c-ets-1, ets-2, some of PU.1/Spi-1 and elk-1, suggesting that the DNA-binding specificities of erg and other members may overlap but are not necessarily identical. The erg gene was found to transactivate a reporter gene that was linked to erg target sequences. These results suggest that erg-1 and erg-2 are sequence-specific transcriptional activators like the other members of the ets oncogene superfamily which represent a distinct class of transcriptional activators.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1991, IN PRESS ONCOGENE; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1986, GENE ANAL TECH, V3, P41; REDDY ESP, 1991, ERG ELK 1 ELK 2 GUID; REDDY ESP, 1990, CANCER RES, V50, P5013; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; [No title captured]	36	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2285	2289						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766675				2022-12-17	WOS:A1991GX73500016
J	BARTHOLOMEW, C; MORISHITA, K; ASKEW, D; BUCHBERG, A; JENKINS, NA; COPELAND, NG; IHLE, JN				BARTHOLOMEW, C; MORISHITA, K; ASKEW, D; BUCHBERG, A; JENKINS, NA; COPELAND, NG; IHLE, JN			RETROVIRAL INSERTIONS IN THE CB-1/FIM-3 COMMON SITE OF INTEGRATION ACTIVATE EXPRESSION OF THE EVI-1 GENE	ONCOGENE			English	Article									ST JUDE CHILDRENS RES HOSP,DEPT BIOCHEM,332 N LAUDERDALE,MEMPHIS,TN 38101; NCI,FREDERICK CANC RES FACIL,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21701	St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Askew, David/0000-0002-6477-2515; Buchberg, Arthur/0000-0002-0543-5631	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA21765, N01-CO-74101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUYPERS HT, 1984, CELL, V37, P141; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IHLE JN, 1982, J IMMUNOL, V129, P2431; IHLE JN, 1982, J IMMUNOL, V129, P1377; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; Maniatis T., 1982, MOL CLONING; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, ONCOGENE RES, V2, P219; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SOLA B, 1988, J VIROL, V62, P3973, DOI 10.1128/JVI.62.11.3973-3978.1988; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987	30	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					529	534						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2542863				2022-12-17	WOS:A1989U768800001
J	Mancini, R; Noto, A; Pisanu, ME; De Vitis, C; Maugeri-Sacca, M; Ciliberto, G				Mancini, Rita; Noto, Alessia; Pisanu, Maria Elena; De Vitis, Claudia; Maugeri-Sacca, Marcello; Ciliberto, Gennaro			Metabolic features of cancer stem cells: the emerging role of lipid metabolism	ONCOGENE			English	Review							CHOLESTERYL ESTER ACCUMULATION; BREAST-CANCER; OXIDATIVE-PHOSPHORYLATION; LACTIC-ACID; PROSPECTIVE WINDOW; INITIATING CELLS; AMINO-ACID; METFORMIN; IDENTIFICATION; LEUKEMIA	Cancer stem cells (CSCs) are an uncommon subset of tumor cells capable of self-renewal, differentiating, and recreating the parental tumor when transplanted into the murine background. Over the past two decades, efforts toward understanding CSC biology culminated into identifying a set of signaling pathways sustaining "stemness". Nevertheless, while metabolic rewiring is nowadays considered a hallmark of cancer, no consensus has been reached on the metabolic features underlying the plastic nature of CSCs, which are capable of residing in a dormant state, and able to rapidly proliferate when the need to repopulate the tumor mass arises. An emerging concept in the field of CSC metabolism is that these cells are extremely reliant on the activity of enzymes involved in lipid metabolism, such as stearoyl-CoA desaturase 1 (SCD1) and 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR). Indeed, SCD1 and HMG-CoAR have been described as key factors for the correct function of a number of concatenated pathways involved in CSC fate decision, such as Hippo and Wnt. In the present review, we describe metabolic futures of CSCs with a special focus on lipid metabolism, which until now represents an underappreciated force in maintaining CSCs and an attractive therapeutic target.	[Mancini, Rita; Noto, Alessia; Pisanu, Maria Elena; De Vitis, Claudia] Sapienza Univ Rome, Dept Clin & Mol Med, I-00161 Rome, Italy; [Maugeri-Sacca, Marcello] Regina Elena Inst Canc Res, Div Med Oncol 2, Via Elio Chianesi 53, I-00144 Rome, Italy; [Ciliberto, Gennaro] Regina Elena Inst Canc Res, Sci Direct, Via Elio Chianesi 53, I-00144 Rome, Italy	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Maugeri-Sacca, M (corresponding author), Regina Elena Inst Canc Res, Div Med Oncol 2, Via Elio Chianesi 53, I-00144 Rome, Italy.; Ciliberto, G (corresponding author), Regina Elena Inst Canc Res, Sci Direct, Via Elio Chianesi 53, I-00144 Rome, Italy.	marcello.maugerisacca@ifo.gov.it; gennaro.ciliberto@ifo.gov.it	Ciliberto, Gennaro/J-4131-2017; Pisanu, Maria Elena/AAC-9143-2019; De Vitis, Claudia/K-4726-2016; Maugeri-Saccà, Marcello/K-2350-2014	Ciliberto, Gennaro/0000-0003-2851-8605; De Vitis, Claudia/0000-0001-8899-2347; Maugeri-Saccà, Marcello/0000-0003-2287-9581; pisanu, maria elena/0000-0002-0029-3523	Italian Association for Cancer Research (AIRC) [IG17009, IG15216]; Fondo di Ricerca di Ateneo [C26A142LZ8]; POR FESR Lazio; Fondazione Veronesi fellowship	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondo di Ricerca di Ateneo; POR FESR Lazio; Fondazione Veronesi fellowship(Fondazione Umberto Veronesi)	We thank Tania Merlino for editorial assistance. This work was supported by Italian Association for Cancer Research (AIRC) grant IG17009 to RM, and grant IG15216 to GC, and by Fondo di Ricerca di Ateneo 2014 (C26A142LZ8) and POR FESR Lazio 2007/2013 to RM. MEP is supported by a Fondazione Veronesi fellowship.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Ben-David U, 2013, CELL STEM CELL, V12, P167, DOI 10.1016/j.stem.2012.11.015; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Bjarnadottir O, 2013, BREAST CANCER RES TR, V138, P499, DOI 10.1007/s10549-013-2473-6; Bonanni B, 2012, J CLIN ONCOL, V30, P2593, DOI 10.1200/JCO.2011.39.3769; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Cai J, 2015, GENE DEV, V29, P1493, DOI 10.1101/gad.264515.115; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Castro LFC, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-132; Cazzaniga M, 2013, BRIT J CANCER, V109, P2792, DOI 10.1038/bjc.2013.657; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chen CL, 2016, CELL METAB, V23, P206, DOI 10.1016/j.cmet.2015.12.004; Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; de Gonzalo-Calvo D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1469-5; DeCensi A, 2014, BREAST CANCER RES TR, V148, P81, DOI 10.1007/s10549-014-3141-1; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dowling RJO, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0540-0; EAGLE H, 1955, SCIENCE, V122, P501, DOI 10.1126/science.122.3168.501; El Helou R, 2017, CELL REP, V18, P2256, DOI 10.1016/j.celrep.2017.02.016; Emmink BL, 2013, J PROTEOMICS, V91, P84, DOI 10.1016/j.jprot.2013.06.027; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Ferber EC, 2012, CELL DEATH DIFFER, V19, P968, DOI 10.1038/cdd.2011.179; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002; Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011; Freitas DP, 2014, INT J CANCER, V134, P1270, DOI 10.1002/ijc.28478; Garwood ER, 2010, BREAST CANCER RES TR, V119, P137, DOI 10.1007/s10549-009-0507-x; Gazi E, 2007, J LIPID RES, V48, P1846, DOI 10.1194/jlr.M700131-JLR200; Giarnieri E, 2013, J CELL PHYSIOL, V228, P1720, DOI 10.1002/jcp.24300; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Goetze K, 2011, INT J ONCOL, V39, P453, DOI 10.3892/ijo.2011.1055; Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007; Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hadad S, 2011, BREAST CANCER RES TR, V128, P783, DOI 10.1007/s10549-011-1612-1; Hadad SM, 2015, BREAST CANCER RES TR, V150, P149, DOI 10.1007/s10549-015-3307-5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hjelmeland AB, 2011, CELL DEATH DIFFER, V18, P829, DOI 10.1038/cdd.2010.150; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; Kalinsky K, 2014, CANCER INVEST, V32, P150, DOI 10.3109/07357907.2014.889706; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lewis CA, 2015, ONCOGENE, V34, P5128, DOI 10.1038/onc.2014.439; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li JJ, 2017, CELL STEM CELL, V20, P303, DOI 10.1016/j.stem.2016.11.004; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liao JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084941; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Lobello N, 2016, ONCOTARGET, V7, P62019, DOI 10.18632/oncotarget.11495; Ma MKF, 2017, J HEPATOL, V67, P979, DOI 10.1016/j.jhep.2017.06.015; Mancini R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021320; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MARQUEZ J, 1989, ARCH BIOCHEM BIOPHYS, V268, P667, DOI 10.1016/0003-9861(89)90335-4; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Maugeri-Sacca M, 2016, CRIT REV ONCOL HEMAT, V106, P132, DOI 10.1016/j.critrevonc.2016.08.004; Mitra R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-540; Mollinedo Faustino, 2015, Adv Biol Regul, V57, P130, DOI 10.1016/j.jbior.2014.10.003; Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Niraula S, 2012, BREAST CANCER RES TR, V135, P821, DOI 10.1007/s10549-012-2223-1; Noto A, 2017, ONCOGENE, V36, P4573, DOI [10.1038/onc.2017.75, 10.1038/onc.2017.212]; Noto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.444; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; Palorini R, 2014, J CELL BIOCHEM, V115, P368, DOI 10.1002/jcb.24671; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Peck B, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0146-8; Peiris-Pages M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0712-6; Piccirillo SGM, 2009, ONCOGENE, V28, P1807, DOI 10.1038/onc.2009.27; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Pisanu ME, 2017, CANCER LETT, V406, P93, DOI 10.1016/j.canlet.2017.07.027; Prigione A, 2010, STEM CELLS, V28, P721, DOI 10.1002/stem.404; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; RIVERA S, 1988, BIOCHEM J, V249, P443, DOI 10.1042/bj2490443; Rocheteau P, 2012, CELL, V148, P112, DOI 10.1016/j.cell.2011.11.049; Rodriguez-Colman MJ, 2017, NATURE, V543, P424, DOI 10.1038/nature21673; Rothberg JM, 2013, NEOPLASIA, V15, P1111, DOI 10.1593/neo.13946; Samudio I, 2010, J CLIN INVEST, V120, P142, DOI 10.1172/JCI38942; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; SAUER LA, 1982, CANCER RES, V42, P4090; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shen YA, 2015, CELL CYCLE, V14, P86, DOI 10.4161/15384101.2014.974419; Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Sugihara E, 2013, INT J CANCER, V132, P1249, DOI 10.1002/ijc.27961; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tirinato L, 2015, STEM CELLS, V33, P35, DOI 10.1002/stem.1837; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Vargas T, 2015, ONCOTARGET, V6, P7348, DOI 10.18632/oncotarget.3130; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang XX, 2017, CANCER RES, V77, P4947, DOI 10.1158/0008-5472.CAN-17-0114; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015; Zhang JQ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0704-x; Zhou WY, 2012, EMBO J, V31, P2103, DOI 10.1038/emboj.2012.71; Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935; Zhuang LY, 2005, J CLIN INVEST, V115, P959	121	70	71	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2367	2378		10.1038/s41388-018-0141-3	http://dx.doi.org/10.1038/s41388-018-0141-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29445137				2022-12-17	WOS:000431386000002
J	Sun, Y; Wei, G; Luo, H; Wu, W; Skogerbo, G; Luo, J; Chen, R				Sun, Y.; Wei, G.; Luo, H.; Wu, W.; Skogerbo, G.; Luo, J.; Chen, R.			The long noncoding RNA SNHG1 promotes tumor growth through regulating transcription of both local and distal genes	ONCOGENE			English	Article							FAR UPSTREAM ELEMENT; C-MYC; CANCER; EXPRESSION; TFIIH	Increasing evidence indicates that long noncoding RNAs (lncRNAs) have important roles in various physiological processes and dysfunction of lncRNAs could be a prevalent cause in human diseases. Here we functionally characterized the nuclear-enriched lncRNA SNHG1, which is highly expressed in multiple types of cancer. We also provide evidence that SNHG1 promotes cancer cell growth by regulating gene expression both in cis and in trans. SNHG1 was involved in the AKT signaling pathway as it promotes the neighboring transcription of the protein-coding gene SLC3A2 in cis by binding the Mediator complex to facilitate the establishment of enhancer-promoter interaction. In trans, SNHG1 directly interacted with central domain of FUBP1 and antagonize the binding of FBP-interacting repressor to FUBP1, thereby coordinating the expression of the oncogene MYC. Collectively, our findings demonstrate that lncRNA SNHG1 can function both in cis and in trans with distinct mechanisms to regulate transcription, promoting tumorigenesis and cancer progression.	[Sun, Y.; Wei, G.; Luo, H.; Wu, W.; Skogerbo, G.; Luo, J.; Chen, R.] Chinese Acad Sci, Inst Biophys, Key Lab RNA Biol, 15 Datun Rd, Beijing 100101, Peoples R China; [Wei, G.] Univ Oxford, Dept Biochem, Oxford, England; [Wu, W.] Univ Chinese Acad Sci, Coll Life Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Oxford; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Chen, R (corresponding author), Chinese Acad Sci, Inst Biophys, Key Lab RNA Biol, 15 Datun Rd, Beijing 100101, Peoples R China.	rschen@ibp.ac.cn	Luo, Jianjun/L-1264-2015; Chen, Runsheng/S-9834-2017	Luo, Jianjun/0000-0002-5550-9889; Chen, Runsheng/0000-0001-6049-8347; Wei, Guifeng/0000-0002-5698-426X	National Natural Science Foundation of China [31520103905, 31401098]; National High Technology Research and Development Program ('863' Program of China) [2015AA020108]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program ('863' Program of China)(National High Technology Research and Development Program of China)	We thank Professor Zushen Fan, Dr Greta Pintacuda and Dr Tianyi Zhang for helpful suggestions and critical reading of this manuscript and Professors Yajun Guo and Mingzhou Guo of Chinese PLA General Hospital and Youyong Lu of Peking University Cancer Hospital and Institute for kindly providing clinical samples. We also thank Dr Junbing Wu, Dongpeng Wang, Shuheng Wu and Bao Zhang for helping with animal experiments. This work was supported by grants from the National Natural Science Foundation of China (31520103905, 31401098) and the National High Technology Research and Development Program ('863' Program of China) 2015AA020108. The raw sequencing data reported in this work have been deposited in GEO (GSE85842).	Allen BL, 2015, NAT REV MOL CELL BIO, V16, P155, DOI 10.1038/nrm3951; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Chu C, 2012, JOVE-J VIS EXP, DOI 10.3791/3912; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Chung HJ, 2006, MOL CELL BIOL, V26, P6584, DOI 10.1128/MCB.00754-06; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Herriges MJ, 2014, GENE DEV, V28, P1363, DOI 10.1101/gad.238782.114; Kim T, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju505; Lee JT, 2013, CELL, V152, P1308, DOI 10.1016/j.cell.2013.02.016; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; Liu JH, 2001, CELL, V104, P353, DOI 10.1016/S0092-8674(01)00223-9; Liu JH, 2006, EMBO J, V25, P2119, DOI 10.1038/sj.emboj.7601101; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Luo HX, 2015, BIOCHEMISTRY-US, V54, P2895, DOI 10.1021/acs.biochem.5b00259; Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024; McHugh CA, 2015, NATURE, V521, P232, DOI 10.1038/nature14443; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Miele Adriana, 2008, V464, P105; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Roberts TC, 2015, NAT PROTOC, V10, P1198, DOI 10.1038/nprot.2015.076; Takahashi K, 2016, NAT REV MOL CELL BIO, V17, P183, DOI 10.1038/nrm.2016.8; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; Vance KW, 2014, EMBO J, V33, P296, DOI 10.1002/embj.201386225; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Xiao TF, 2015, STEM CELL REP, V5, P856, DOI 10.1016/j.stemcr.2015.09.007; Yuan J, 2016, ONCOTARGET, V7, P8131, DOI 10.18632/oncotarget.6993; Zhang J, 2013, ONCOGENE, V32, P2907, DOI 10.1038/onc.2012.350; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	40	70	72	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6774	6783		10.1038/onc.2017.286	http://dx.doi.org/10.1038/onc.2017.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28825722				2022-12-17	WOS:000417282500003
J	Chen, Y; Zeng, C; Zhan, Y; Wang, H; Jiang, X; Li, W				Chen, Y.; Zeng, C.; Zhan, Y.; Wang, H.; Jiang, X.; Li, W.			Aberrant low expression of p85 alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b	ONCOGENE			English	Article							PHOSPHOINOSITIDE 3-KINASES; TUMOR-SUPPRESSOR; PI3K PATHWAY; TGF-BETA; ACQUISITION; GROWTH; TUMORIGENESIS; TRANSITIONS; ACTIVATION; MUTATIONS	P85 alpha, which acts as a tumour suppressor, is frequently found to be downregulated in various human cancers. However, the role of p85 alpha in the tumour microenvironment is unknown. Here, we report that aberrantly low expression of p85 alpha in breast cancer stroma is clinically relevant to breast cancer disease progression. Stromal fibroblasts can acquire the hallmarks of cancer-associated fibroblasts (CAFs) as a result of the loss of p85 alpha expression. Paracrine Wnt10b from p85 alpha-deficient fibroblasts can promote cancer progression via epithelial-to-mesenchymal transition (EMT) induced by the canonical Wnt pathway. Moreover, exosomes have a key role in paracrine Wnt10b transport from fibroblasts to breast cancer epithelial cells. Our results reveal that p85 alpha expression in stromal fibroblasts haves a crucial role in regulating breast cancer tumourigenesis and progression by modifying stromal-epithelial crosstalk and remodelling the tumour microenvironment. Therefore, p85 alpha can function as a tumour suppressor and represent a new candidate for diagnosis, prognosis and targeted therapy.	[Chen, Y.; Zeng, C.; Zhan, Y.; Wang, H.; Li, W.] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Hubei, Peoples R China; [Jiang, X.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Sinofrance Lab Drug Screening, Key Lab Mol Biophys,Minist Educ, Wuhan, Hubei, Peoples R China	Wuhan University; Huazhong University of Science & Technology	Li, W (corresponding author), Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Hubei, Peoples R China.	whli@whu.edu.cn			National Basic Research Program of China [2014CB910603]; National Natural Science Foundation of China [81472684, 81072151]; Program for New Century Excellent Talents in University of Ministry of Education of China [NCET-13-0436]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University of Ministry of Education of China(Program for New Century Excellent Talents in University (NCET))	We thank Professor Lewis C Cantley for the gift of the knockout cell lines. This study was supported by National Basic Research Program of China (2014CB910603), the National Natural Science Foundation of China (81472684, 81072151) and Program for New Century Excellent Talents in University of Ministry of Education of China (NCET-13-0436).	Albrengues J, 2014, CELL REP, V7, P1664, DOI 10.1016/j.celrep.2014.04.036; Bergamaschi A, 2008, J PATHOL, V214, P357, DOI 10.1002/path.2278; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Bogatkevich GS, 2001, J BIOL CHEM, V276, P45184, DOI 10.1074/jbc.M106441200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Chiu YH, 2014, MOL CELL, V54, P193, DOI 10.1016/j.molcel.2014.02.016; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Franch-Marro X, 2008, NAT CELL BIOL, V10, P170, DOI 10.1038/ncb1678; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Gong K, 2012, J BIOL CHEM, V287, P35576, DOI 10.1074/jbc.M112.370585; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu BA, 2013, CURR OPIN RHEUMATOL, V25, P71, DOI 10.1097/BOR.0b013e32835b1352; Hu HM, 2013, FASEB J, V27, P163, DOI 10.1096/fj.12-216622; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Klarenbeek S, 2013, MOL ONCOL, V7, P146, DOI 10.1016/j.molonc.2013.02.003; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Melchor L, 2013, HUM GENET, V132, P845, DOI 10.1007/s00439-013-1299-y; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Procopio MG, 2015, NAT CELL BIOL, V17, P1193, DOI 10.1038/ncb3228; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rajaram M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003789; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Shannon KM, 2012, CANCER J, V18, P310, DOI 10.1097/PPO.0b013e318260946f; Shimoda M, 2014, NAT CELL BIOL, V16, P889, DOI 10.1038/ncb3021; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Spaeth EL, 2013, CANCER RES, V73, P5347, DOI 10.1158/0008-5472.CAN-13-0087; Stoeck A, 2006, BIOCHEM J, V393, P609, DOI 10.1042/BJ20051013; Taniguchi CM, 2010, CANCER RES, V70, P5305, DOI 10.1158/0008-5472.CAN-09-3399; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Weinberg RA, 2008, NAT GENET, V40, P494, DOI 10.1038/ng0508-494; Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864; Yang PT, 2008, DEV CELL, V14, P140, DOI 10.1016/j.devcel.2007.12.004; Ye K, 2016, NAT MED, V22, P97, DOI 10.1038/nm.4002; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	56	70	75	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4692	4705		10.1038/onc.2017.100	http://dx.doi.org/10.1038/onc.2017.100			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394344	Green Published, hybrid			2022-12-17	WOS:000407702400003
J	Hazawa, M; Lin, DC; Handral, H; Xu, L; Chen, Y; Jiang, YY; Mayakonda, A; Ding, LW; Meng, X; Sharma, A; Samuel, S; Movahednia, MM; Wong, RW; Yang, H; Tong, C; Koeffler, HP				Hazawa, M.; Lin, D-C; Handral, H.; Xu, L.; Chen, Y.; Jiang, Y-Y; Mayakonda, A.; Ding, L-W; Meng, X.; Sharma, A.; Samuel, S.; Movahednia, M. M.; Wong, R. W.; Yang, H.; Tong, C.; Koeffler, H. P.			ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma	ONCOGENE			English	Article								ZNF750 controls epithelial homeostasis by regulating epidermal-differentiation genes, a role underscored by its pathogenic mutations in esophageal squamous cell cancers (SCCs). However, the precise role of ZNF750 in SCC cell biology remains unclear. In this study, we report that ZNF750 is exclusively deleted, mutated and underexpressed in human SCCs, and low ZNF750 expression is associated with poor survival. Restoration of wildtype, but not mutant ZNF750 protein uniquely inhibited the malignant phenotypes of SCC cells both in vitro and in vivo. Notably, ZNF750 promoted the expression of a long non-coding RNA (TINCR), which mediated both cancer-inhibition and differentiation-induction effects of ZNF750. In addition, ZNF750 potently suppressed cell migration by directly inhibiting the transactivation of LAMC2. Together, our findings characterize ZNF750 as a crucial SCC-specific suppressor and uncover its novel anticancer-associated functions.	[Hazawa, M.; Lin, D-C; Xu, L.; Chen, Y.; Jiang, Y-Y; Mayakonda, A.; Ding, L-W; Meng, X.; Sharma, A.; Samuel, S.; Yang, H.; Koeffler, H. P.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Hazawa, M.; Wong, R. W.] Kanazawa Univ, Inst Frontier Sci Initiat, Cell Bion Res Unit, Innovat Integrated Biores Core, Kanazawa, Ishikawa, Japan; [Lin, D-C; Koeffler, H. P.] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Los Angeles, CA 90024 USA; [Handral, H.; Movahednia, M. M.; Tong, C.] Natl Univ Singapore, Dept Oral & Maxillofacial Surg, Fac Dent, Singapore, Singapore; [Koeffler, H. P.] Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore, Singapore; [Koeffler, H. P.] Natl Univ Singapore, Singapore, Singapore	National University of Singapore; Kanazawa University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National University of Singapore; National University of Singapore; National University of Singapore	Hazawa, M (corresponding author), Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa 9201192, Japan.; Lin, DC (corresponding author), Los Angeles Sch Med, Los Angeles, CA 90048 USA.	masaharu.akj@gmail.com; dchlin11@gmail.com	Xu, Liang/I-9877-2014; Ding, Ling-Wen/H-6916-2019; Tong CAO, iHuman/B-1008-2008; HANDRAL, HARISH/AAM-6564-2020; Hazawa, M/AAA-2712-2021; Wong, Richard W./E-9155-2011; HAZAWA, Masaharu/A-6520-2016; SHARMA, ARJUN/U-5920-2019	Xu, Liang/0000-0002-2700-4840; Ding, Ling-Wen/0000-0003-0022-1551; Tong CAO, iHuman/0000-0002-7994-9627; HANDRAL, HARISH/0000-0002-3892-3316; Wong, Richard/0000-0002-2131-6595; Sharma, ARJUN/0000-0002-5705-5470	Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award; NMRC Individual Research Grant [NMRC/1311/2011]; NMRC Centre Grant; American Society of Hematology Fellow Scholar Award; Donna and Jesse Garber Awards for Cancer Research, National Center for Advancing Translational Sciences UCLA CTSI Grant [UL1TR000124]; RNA Biology Center at the Cancer Science Institute of Singapore, NUS, under the Singapore Ministry of Education's Tier 3 grants [MOE2014-T3-1-006]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER	Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); NMRC Individual Research Grant; NMRC Centre Grant(National Medical Research Council, Singapore); American Society of Hematology Fellow Scholar Award; Donna and Jesse Garber Awards for Cancer Research, National Center for Advancing Translational Sciences UCLA CTSI Grant; RNA Biology Center at the Cancer Science Institute of Singapore, NUS, under the Singapore Ministry of Education's Tier 3 grants(Ministry of Education, SingaporeNational University of Singapore); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded by the Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award to HPK, NMRC Individual Research Grant (NMRC/1311/2011) and the NMRC Centre Grant awarded to National University Cancer Institute of Singapore, the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiatives. D-C.L was supported by American Society of Hematology Fellow Scholar Award, Donna and Jesse Garber Awards for Cancer Research, National Center for Advancing Translational Sciences UCLA CTSI Grant UL1TR000124. This study was partially supported by a generous donation from the Melamed family. This research was also supported by the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants, grant number MOE2014-T3-1-006.	American Cancer Society, 2011, CANC FACTS FIG 2011; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boxer LD, 2014, GENE DEV, V28, P2013, DOI 10.1101/gad.246579.114; Brooks YS, 2014, J CLIN INVEST, V124, P2260, DOI 10.1172/JCI72718; Degen M, 2012, AM J PATHOL, V180, P2462, DOI 10.1016/j.ajpath.2012.02.028; Garg M, 2014, EXPERT OPIN THER TAR, V18, P979, DOI 10.1517/14728222.2014.934814; Garg M, 2014, J CLIN ENDOCR METAB, V99, pE62, DOI 10.1210/jc.2013-2994; Hamasaki H, 2011, BRIT J CANCER, V6, P824; Hlubek F, 2001, CANCER RES, V61, P8089; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Khammanivong A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069395; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Kypriotou M, 2012, EXP DERMATOL, V21, P643, DOI 10.1111/j.1600-0625.2012.01472.x; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Lopez-Pajares V, 2015, DEV CELL, V32, P693, DOI 10.1016/j.devcel.2015.01.028; Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054; Ono Y, 1999, CANCER, V85, P2315, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2315::AID-CNCR3>3.0.CO;2-Y; Rothenberg SM, 2012, J CLIN INVEST, V122, P1951, DOI 10.1172/JCI59889; Sen GL, 2012, DEV CELL, V22, P669, DOI 10.1016/j.devcel.2011.12.001; Tugizov S, 2005, J VIROL, V79, P1099, DOI 10.1128/JVI.79.2.1099-1112.2005; Xu TP, 2015, ONCOGENE, V34, P5648, DOI 10.1038/onc.2015.18; Yamamoto H, 2001, CLIN CANCER RES, V7, P896; Zhang L, 2015, AM J HUM GENET, V96, P597, DOI 10.1016/j.ajhg.2015.02.017; Zhong XL, 2012, CELL SIGNAL, V24, P393, DOI 10.1016/j.cellsig.2011.10.005	24	70	74	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2243	2254		10.1038/onc.2016.377	http://dx.doi.org/10.1038/onc.2016.377			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27819679	Green Published, hybrid			2022-12-17	WOS:000399782700005
J	Deng, X; Shao, G; Zhang, HT; Li, C; Zhang, D; Cheng, L; Elzey, BD; Pili, R; Ratliff, TL; Huang, J; Hu, CD				Deng, X.; Shao, G.; Zhang, H-T; Li, C.; Zhang, D.; Cheng, L.; Elzey, B. D.; Pili, R.; Ratliff, T. L.; Huang, J.; Hu, C-D			Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth	ONCOGENE			English	Article							SPLICE VARIANTS; GENE-EXPRESSION; IN-VITRO; PRMT5; TARGET; METHYLATION; TRANSCRIPTION; COMPLEX; RESISTANCE; INITIATION	Protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme that mainly represses transcription of target genes via symmetric dimethylation of arginine residues on histones H4R3, H3R8 and H2AR3. Accumulating evidence suggests that PRMT5 may function as an oncogene to drive cancer cell growth by epigenetic inactivation of several tumor suppressors. Here, we provide evidence that PRMT5 promotes prostate cancer cell growth by epigenetically activating transcription of the androgen receptor (AR) in prostate cancer cells. Knockdown of PRMT5 or inhibition of PRMT5 by a specific inhibitor reduces the expression of AR and suppresses the growth of multiple AR-positive, but not AR-negative, prostate cancer cells. Significantly, knockdown of PRMT5 in AR-positive LNCaP cells completely suppresses the growth of xenograft tumors in mice. Molecular analysis reveals that PRMT5 binds to the proximal promoter region of the AR gene and contributes mainly to the enriched symmetric dimethylation of H4R3 in the same region. Mechanistically, PRMT5 is recruited to the AR promoter by its interaction with Sp1, the major transcription factor responsible for AR transcription, and forms a complex with Brg1, an ATP-dependent chromatin remodeler, on the proximal promoter region of the AR gene. Furthermore, PRMT5 expression in prostate cancer tissues is significantly higher than that in benign prostatic hyperplasia tissues, and PRMT5 expression correlates positively with AR expression at both the protein and mRNA levels. Taken together, our results identify PRMT5 as a novel epigenetic activator of AR in prostate cancer. Given that inhibiting AR transcriptional activity or androgen synthesis remains the major mechanism of action for most existing anti-androgen agents, our findings also raise an interesting possibility that targeting PRMT5 may represent a novel approach for prostate cancer treatment by eliminating AR expression.	[Deng, X.; Shao, G.; Zhang, H-T; Hu, C-D] Purdue Univ, Dept Med Chem & Mol Pharmacol, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA; [Shao, G.] Jiangsu Univ, Sch Med, Dept Bas Med Sci, Zhenjiang, Peoples R China; [Zhang, H-T] Jinan Univ, First Affiliated Hosp, Inst Orthoped Dis, Dept Orthoped, Guangzhou, Peoples R China; [Li, C.] Ohio State Univ, Div Med Chem & Pharmacognosy, Columbus, OH USA; [Zhang, D.] Purdue Univ, Dept Stat, W Lafayette, IN USA; [Cheng, L.] Indiana Univ, Dept Pathol, Indianapolis, IN USA; [Cheng, L.] Indiana Univ, Lab Med, Indianapolis, IN USA; [Elzey, B. D.; Ratliff, T. L.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN USA; [Pili, R.] Indiana Univ, Simon Canc Ctr, Dept Med Oncol, Indianapolis, IN USA; [Ratliff, T. L.; Hu, C-D] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA; [Huang, J.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Jiangsu University; Jinan University; University System of Ohio; Ohio State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California Los Angeles	Hu, CD (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA.	hu1@purdue.edu		Cheng, Liang/0000-0001-6049-5293	U.S. Army Medical Research Acquisition Activity; Prostate Cancer Research Program [PC11190, PC120512, PC150697]; Purdue University Center for Cancer Research Small Grants; NCI CCSG; China Scholarship Council; NATIONAL CANCER INSTITUTE [P30CA023168, R01CA212403] Funding Source: NIH RePORTER	U.S. Army Medical Research Acquisition Activity; Prostate Cancer Research Program; Purdue University Center for Cancer Research Small Grants; NCI CCSG; China Scholarship Council(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was partially supported by grants from U.S. Army Medical Research Acquisition Activity, Prostate Cancer Research Program (PC11190, PC120512, and PC150697) to C-D Hu, and Purdue University Center for Cancer Research Small Grants. DNA sequencing and animal experiments were conducted in Genomic Core facility and the Biological Evaluation Shared Resource facility, respectively, supported by NCI CCSG CA23168 to Purdue University Center for Cancer Research. Genbao Shao and Huan-Tian Zhang were visiting scholars supported by the China Scholarship Council.	Agoulnik IU, 2008, ADV EXP MED BIOL, V617, P245, DOI 10.1007/978-0-387-69080-3_23; Alinari L, 2015, BLOOD, V125, P2530, DOI 10.1182/blood-2014-12-619783; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Cai CM, 2013, TRANSL ANDROL UROL, V2, P148, DOI 10.3978/j.issn.2223-4683.2013.09.02; Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI [10.1038/NCHEMBIO.1810, 10.1038/nchembio.1810]; Chandrasekar T, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0457-6; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Cho EC, 2012, EMBO J, V31, P1785, DOI 10.1038/emboj.2012.17; Dacwag CS, 2007, MOL CELL BIOL, V27, P384, DOI 10.1128/MCB.01528-06; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Deng XH, 2011, AM J CANCER RES, V1, P834; Dutt SS, 2009, FUTURE ONCOL, V5, P1403, DOI 10.2217/FON.09.117; FABER PW, 1993, J BIOL CHEM, V268, P9296; Gao L, 2010, EPIGENETICS-US, V5, P100, DOI 10.4161/epi.5.2.10778; Giacinti S, 2014, ANTICANCER RES, V34, P6265; Gu ZP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044033; Gu ZP, 2012, BIOCHEM J, V446, P235, DOI 10.1042/BJ20120768; Guo ZY, 2011, INT J BIOL SCI, V7, P815, DOI 10.7150/ijbs.7.815; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Hay CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139990; Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486; Hedges LV, 1985, STATISCAL METHODS ME; Hosohata K, 2003, MOL CELL BIOL, V23, P7019, DOI 10.1128/MCB.23.19.7019-7029.2003; Hsu CC, 2013, MOL CELL ENDOCRINOL, V372, P12, DOI 10.1016/j.mce.2013.03.004; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Karkhanis V, 2011, TRENDS BIOCHEM SCI, V36, P633, DOI 10.1016/j.tibs.2011.09.001; Ke N, 2004, BIOTECHNIQUES, V36, P826, DOI 10.2144/04365ST07; Krause CD, 2007, PHARMACOL THERAPEUT, V113, P50, DOI 10.1016/j.pharmthera.2006.06.007; LeBlanc SE, 2012, MOL ENDOCRINOL, V26, P583, DOI 10.1210/me.2011-1162; Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304; Mirochnik Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031052; Nakazawa M, 2014, HORM CANCER-US, V5, P265, DOI 10.1007/s12672-014-0190-1; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Powers MA, 2011, CANCER RES, V71, P5579, DOI 10.1158/0008-5472.CAN-11-0458; Ryan CJ, 2011, J CLIN ONCOL, V29, P3651, DOI 10.1200/JCO.2011.35.2005; Seth-Vollenweider T, 2014, J BIOL CHEM, V289, P33958, DOI 10.1074/jbc.M114.583302; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Stopa N, 2015, CELL MOL LIFE SCI, V72, P2041, DOI 10.1007/s00018-015-1847-9; Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308; Tee WW, 2010, GENE DEV, V24, P2772, DOI 10.1101/gad.606110; Teng Y, 2007, CANCER RES, V67, P10491, DOI 10.1158/0008-5472.CAN-06-4206; TILLEY WD, 1990, CANCER RES, V50, P5382; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Wang L, 2008, MOL CELL BIOL, V28, P6262, DOI 10.1128/MCB.00923-08; Wei TYW, 2012, CANCER SCI, V103, P1640, DOI 10.1111/j.1349-7006.2012.02367.x; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Yan FT, 2014, CANCER RES, V74, P1752, DOI 10.1158/0008-5472.CAN-13-0884; Zhang HT, 2014, BBA-GENE REGUL MECH, V1839, P1330, DOI 10.1016/j.bbagrm.2014.09.015	53	70	73	2	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1223	1231		10.1038/onc.2016.287	http://dx.doi.org/10.1038/onc.2016.287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27546619	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000395861300006
J	Lu, J; Song, G; Tang, Q; Yin, J; Zou, C; Zhao, Z; Xie, X; Xu, H; Huang, G; Wang, J; Lee, DF; Khokha, R; Yang, H; Shen, J				Lu, J.; Song, G.; Tang, Q.; Yin, J.; Zou, C.; Zhao, Z.; Xie, X.; Xu, H.; Huang, G.; Wang, J.; Lee, D-F; Khokha, R.; Yang, H.; Shen, J.			MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1	ONCOGENE			English	Article							SELF-RENEWAL; ALDEHYDE DEHYDROGENASE; CANCER; NOTCH; DIFFERENTIATION; MICRORNA-26A; TUMORIGENESIS; PATHWAY; PROLIFERATION; REGENERATION	MicroRNAs (miRNAs) are important epigenetic regulators of gene expression. Although several miRNAs have been implicated in osteosarcoma, their role in regulation of osteosarcoma cancer stem cells (CSCs) remains unknown. Here we demonstrated that miR-26a is downregulated in osteosarcoma CSCs when derived by either sarcosphere generation, chemodrug or aldehyde dehydrogenase (ALDH) activity selection. Lentiviral overexpression of miR-26a in ZOS and 143B osteosarcoma cells decreases the expression of stem cell markers and suppresses sarcosphere formation, as well as ALDH activity. Moreover, miR-26a overexpression inhibits the tumor cell growth both in vitro and in vivo. We further demonstrate that miR-26a directly target Jagged1, one of the Notch ligand, and that its tumor suppressive effects are mediated through inhibition of Jaggedl/Notch signaling. Importantly, reduced miR-26a expression, as determined by in situ hybridization in patient tumors (n=92), is associated with lung metastasis and poor overall survival of osteosarcoma patients. Together, these data suggest the essential role of miR-26a/Jaggedl/Notch pathway in regulating the stem cell-like traits of osteosarcoma cells and provide a potential target for osteosarcoma therapy.	[Lu, J.; Song, G.; Tang, Q.; Yin, J.; Zou, C.; Zhao, Z.; Xie, X.; Xu, H.; Huang, G.; Wang, J.; Shen, J.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Musculoskeletal Oncol, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China; [Lee, D-F] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Khokha, R.] Univ Hlth Network, Ontario Canc Inst, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Yang, H.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University; University of Texas System; University of Texas Health Science Center Houston; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Sun Yat Sen University	Shen, J (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Musculoskeletal Oncol, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.; Yang, H (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	yanghl@mail.sysu.edu.cn; shenjingnan@126.com		Khokha, Rama/0000-0002-6028-1524	National Natural Science Foundation of China [81272939, 81472506]; Natural Science Foundation of Guangdong Province [S2013020012460]; National Institutes of Health (NIH) Pathway to Independence Award [R00 CA181496]; CPRIT Award [RR160019]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Institutes of Health (NIH) Pathway to Independence Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT Award	This research was supported by National Natural Science Foundation of China (81272939 and 81472506 to JS) and Natural Science Foundation of Guangdong Province (S2013020012460 to JS). D-FL is the Cancer Prevention Research Institute of Texas (CPRIT) scholar in Cancer Research and supported by National Institutes of Health (NIH) Pathway to Independence Award R00 CA181496 and CPRIT Award RR160019. We thank Jingling Zhao (Sun Yat-Sen University) for expert technical assistance and Meghan Lambie (University of Toronto) for language editing.	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Basu-Roy U, 2013, CANCER LETT, V338, P158, DOI 10.1016/j.canlet.2012.05.028; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Dey BK, 2012, GENE DEV, V26, P2180, DOI 10.1101/gad.198085.112; Di Fiore R, 2014, INT J ONCOL, V45, P2013, DOI 10.3892/ijo.2014.2618; Donnem T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-6; Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fu XH, 2013, P NATL ACAD SCI USA, V110, P17892, DOI 10.1073/pnas.1317397110; Fujiwara T, 2014, STEM CELLS, V32, P959, DOI 10.1002/stem.1618; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c; Hopkins TG, 2016, NUCLEIC ACIDS RES, V44, P1227, DOI 10.1093/nar/gkv1515; Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505; Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052; Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234; Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287; Lu JC, 2015, J CLIN INVEST, V125, P1839, DOI 10.1172/JCI78437; Mitra A, 2015, ONCOTARGET, V6, P10697, DOI 10.18632/oncotarget.4037; Mu XD, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00143; Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Salvatori B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.151; Shcherbata HR, 2006, CELL CYCLE, V5, P172, DOI 10.4161/cc.5.2.2343; Siclari VA, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-78; Siegel HJ, 2008, EXPERT REV ANTICANC, V8, P1257, DOI 10.1586/14737140.8.8.1257; Song QC, 2014, ONCOL REP, V31, P1263, DOI 10.3892/or.2014.2989; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060; Tang QL, 2012, JNCI-J NATL CANCER I, V104, P749, DOI 10.1093/jnci/djs210; Tang QL, 2011, CANCER LETT, V311, P113, DOI 10.1016/j.canlet.2011.07.016; Tao JN, 2014, CANCER CELL, V26, P390, DOI 10.1016/j.ccr.2014.07.023; Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331; Wang X., 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072015; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zhang AD, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/187509; Zou CY, 2008, ACTA PHARMACOL SIN, V29, P325, DOI 10.1111/j.1745-7254.2008.00756.x	44	70	75	4	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					231	241		10.1038/onc.2016.194	http://dx.doi.org/10.1038/onc.2016.194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270422				2022-12-17	WOS:000393938100008
J	Phatak, P; Byrnes, KA; Mansour, D; Liu, L; Cao, S; Li, R; Rao, JN; Turner, DJ; Wang, JY; Donahue, JM				Phatak, P.; Byrnes, K. A.; Mansour, D.; Liu, L.; Cao, S.; Li, R.; Rao, J. N.; Turner, D. J.; Wang, J-Y; Donahue, J. M.			Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1	ONCOGENE			English	Article							MESSENGER-RNA; DOWN-REGULATION; EXPRESSION; MICRORNAS; APOPTOSIS	Based on its marked overexpression in multiple malignancies and its roles in promoting cell survival and proliferation, survivin is an attractive candidate for targeted therapy. Toward this end, a detailed understanding of the mechanisms regulating survivin expression in different cancer cells will be critical. We have previously shown that the RNA-binding protein (RBP) CUG-BP1 is overexpressed in esophageal cancer cells and post-transcriptionally regulates survivin in these cells. The objective of this study was to investigate the role of microRNAs (miRs) in regulating survivin expression in esophageal cancer cells. Using miR expression profiling analysis, we found that miR-214-3p is one of the most markedly downregulated miRs in two esophageal squamous cancer cell lines compared with esophageal epithelial cells. Interestingly, using miR target prediction programs, both survivin and CUG-BP1 mRNA were found to contain potential binding sites for miR-214-3p. Forced expression of miR-214-3p in esophageal cancer cells leads to a decrease in the mRNA and protein levels of both survivin and CUG-BP1. This effect is due to decreased mRNA stability of both targets. By contrast, silencing miR-214-3p in esophageal epithelial cells leads to an increase in both survivin and CUG-BP1 mRNA and protein. To determine whether the observed effect of miR-214-3p on survivin expression was direct, mediated through CUG-BP1, or both, binding studies utilizing biotin pull-down assays and heterologous luciferase reporter constructs were performed. These demonstrated that the mRNA of survivin and CUG-BP1 each contain two functional miR-214-3p-binding sites as confirmed by mutational analysis. Finally, forced expression of miR-214-3p enhances the sensitivity of esophageal cancer cells to cisplatin-induced apoptosis. This effect is abrogated with rescue expression of survivin or CUG-BP1. These findings suggest that miR-214-3p acts as a tumor suppressor and that its downregulation contributes to chemoresistance in esophageal cancer cells by targeting both survivin and CUG-BP1.	[Phatak, P.; Byrnes, K. A.; Mansour, D.; Liu, L.; Cao, S.; Li, R.; Rao, J. N.; Turner, D. J.; Wang, J-Y; Donahue, J. M.] Univ Maryland, Sch Med, Dept Surg, Cell Biol Grp, 29 South Greene St,Suite 504, Baltimore, MD 21201 USA; [Phatak, P.; Byrnes, K. A.; Mansour, D.; Liu, L.; Cao, S.; Li, R.; Rao, J. N.; Turner, D. J.; Wang, J-Y; Donahue, J. M.] Baltimore Vet Affairs Med Ctr, Baltimore, MD USA; [Wang, J-Y] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore	Donahue, JM (corresponding author), Univ Maryland, Sch Med, Dept Surg, Cell Biol Grp, 29 South Greene St,Suite 504, Baltimore, MD 21201 USA.	jdonahue@smail.umaryland.edu			Department of Veterans Affairs, USA; National Institutes of Health [DK-57819, DK-61972, DK-68491]; Department of Surgery, University of Maryland School of Medicine; NATIONAL CANCER INSTITUTE [T32CA154274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061972, R01DK057819, R01DK068491] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000332, I01BX000113, I01BX000713] Funding Source: NIH RePORTER	Department of Veterans Affairs, USA(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Surgery, University of Maryland School of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Department of Veterans Affairs, USA (Merit Review Grants to JNR, DJT and J-YW; VA Career Development Award to JMD); the National Institutes of Health (grant numbers DK-57819, DK-61972 and DK-68491 to J-YW) and departmental funds from the Department of Surgery, University of Maryland School of Medicine (to JMD). The authors also acknowledge Dr Karthika Natarajan, Dr Xi Yang and Ratnakar Potla for their technical assistance as well as Dr Anne W Hamburger for assistance in preparation of the manuscript.	Audic Y, 2004, BIOL CELL, V96, P479, DOI 10.1016/j.biolcel.2004.05.002; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Cao WG, 2013, TUMOR BIOL, V34, P963, DOI 10.1007/s13277-012-0632-8; Chang E, 2010, J THORAC CARDIOV SUR, V140, P225, DOI 10.1016/j.jtcvs.2009.11.038; Chang ET, 2012, BIOCHEM J, V446, P113, DOI 10.1042/BJ20120112; Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233; Choi YE, 2014, ELIFE, V3, DOI 10.7554/eLife.02445; Ciafre SA, 2013, RNA BIOL, V10, P935, DOI 10.4161/rna.24641; Cui YH, 2012, MOL BIOL CELL, V23, P151, DOI 10.1091/mbc.E11-05-0456; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Donahue JM, 2011, BIOCHEM J, V437, P89, DOI 10.1042/BJ20110028; Duan Q, 2012, PLOS ONE, V7, P1; Gareau C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020254; Huang SD, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-51; Jangpatarapongsa K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045971; Kato J, 2001, INT J CANCER, V95, P92; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Liu L, 2009, MOL BIOL CELL, V20, P4885, DOI 10.1091/mbc.E09-07-0550; Matsushima K, 2010, DIGESTION, V82, P138, DOI 10.1159/000310918; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; Orom UA, 2007, METHODS, V43, P162, DOI 10.1016/j.ymeth.2007.04.007; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Shen ZS, 2012, MED ONCOL, V29, P2473, DOI 10.1007/s12032-011-0156-x; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Talwar S, 2013, RNA BIOL, V10, P277, DOI 10.4161/rna.23315; Vallbohmer D, 2008, PHARMACOGENOMICS, V9, P681, DOI 10.2217/14622416.9.6.681; Wang F, 2013, FEBS LETT, V587, P488, DOI 10.1016/j.febslet.2013.01.016; Wang W, 2013, CELL BIOCHEM FUNCT, V31, P82, DOI 10.1002/cbf.2863; Xu D, 2013, MOL MED REP, V8, P379, DOI 10.3892/mmr.2013.1504; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Zhang ZX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0089140, 10.1371/journal.pone.0100416, 10.1371/journal.pone.0099511]	33	70	76	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2087	2097		10.1038/onc.2015.271	http://dx.doi.org/10.1038/onc.2015.271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26234674	Green Accepted			2022-12-17	WOS:000374505600008
J	Takahashi, H; Jin, C; Rajabi, H; Pitroda, S; Alam, M; Ahmad, R; Raina, D; Hasegawa, M; Suzuki, Y; Tagde, A; Bronson, RT; Weichselbaum, R; Kufe, D				Takahashi, H.; Jin, C.; Rajabi, H.; Pitroda, S.; Alam, M.; Ahmad, R.; Raina, D.; Hasegawa, M.; Suzuki, Y.; Tagde, A.; Bronson, R. T.; Weichselbaum, R.; Kufe, D.			MUC1-C activates the TAK1 inflammatory pathway in colon cancer	ONCOGENE			English	Article							BOWEL-DISEASE; MONOCLONAL-ANTIBODY; COLORECTAL-CANCER; MOUSE MODEL; ONCOPROTEIN; KINASE; EXPRESSION; MUCIN; INHIBITION; BREAST	The mucin 1 (MUC1) oncoprotein has been linked to the inflammatory response by promoting cytokine-mediated activation of the NF-kappa B pathway. The TGF-beta-activated kinase 1 (TAK1) is an essential effector of proinflammatory NF-kappa B signaling that also regulates cancer cell survival. The present studies demonstrate that the MUC1-C transmembrane subunit induces TAK1 expression in colon cancer cells. MUC1 also induces TAK1 in a MUC1(+/-)/IL-10(-/-) mouse model of colitis and colon tumorigenesis. We show that MUC1C promotes NF-kappa B-mediated activation of TAK1 transcription and, in a positive regulatory loop, MUC1-C contributes to TAK1-induced NF-kappa B signaling. In this way, MUC1-C binds directly to TAK1 and confers the association of TAK1 with TRAF6, which is necessary for TAK1-mediated activation of NF-kappa B. Targeting MUC1-C thus suppresses the TAK1 -> NF-kappa B pathway, downregulates BCL-XL and in turn sensitizes colon cancer cells to MEK inhibition. Analysis of colon cancer databases further indicates that MUC1, TAK1 and TRAF6 are upregulated in tumors associated with decreased survival and that MUC1-C-induced gene expression patterns predict poor outcomes in patients. These results support a model in which MUC1-C-induced TAK1 -> NF-kappa B signaling contributes to intestinal inflammation and colon cancer progression.	[Takahashi, H.; Rajabi, H.; Alam, M.; Ahmad, R.; Hasegawa, M.; Suzuki, Y.; Tagde, A.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA; [Jin, C.; Raina, D.] Genus Oncol, Boston, MA USA; [Pitroda, S.; Weichselbaum, R.] Univ Chicago, Dept Radiat & Cellular Oncol, Ludwig Ctr Metastasis Res, Chicago, IL 60637 USA; [Bronson, R. T.] Harvard Univ, Sch Med, Div Immunol, Dept Microbiol & Immunobiol, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Harvard University; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu	Tagde, Ashujit/M-9497-2014	Tagde, Ashujit/0000-0002-0770-097X; Ahmad, Rehan/0000-0003-2612-2818; Hasegawa, Masanori/0000-0002-4354-6105	Department of Defense; National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; CDMRP [CA110495]; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA097098] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CDMRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by Grant CDMRP CA110495 awarded by the Department of Defense and by the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Ajibade AA, 2013, TRENDS IMMUNOL, V34, P307, DOI 10.1016/j.it.2013.03.007; Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158; Baldus SE, 2002, HISTOPATHOLOGY, V40, P440, DOI 10.1046/j.1365-2559.2002.01389.x; Beatty PL, 2007, J IMMUNOL, V179, P735, DOI 10.4049/jimmunol.179.2.735; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Cai PCH, 2014, ONCOTARGET, V5, P7549, DOI 10.18632/oncotarget.2273; Campbell BJ, 2001, GLYCOCONJUGATE J, V18, P851, DOI 10.1023/A:1022240107040; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Duncan Timothy J, 2007, World J Surg Oncol, V5, P31, DOI 10.1186/1477-7819-5-31; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Furr AE, 2010, PEDIATR DEVEL PATHOL, V13, P24, DOI 10.2350/08-06-0479.1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hoebler C, 2006, DIGEST DIS SCI, V51, P381, DOI 10.1007/s10620-006-3142-y; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Lugli A, 2007, J CLIN PATHOL, V60, P534, DOI 10.1136/jcp.2006.039552; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123; NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4; Niv Y, 2008, WORLD J GASTROENTERO, V14, P2139, DOI 10.3748/wjg.14.2139; Omori E, 2012, P NATL ACAD SCI USA, V109, P3365, DOI 10.1073/pnas.1116188109; Omori E, 2010, CANCER RES, V70, P8417, DOI 10.1158/0008-5472.CAN-10-1227; Panchamoorthy G, 2011, HYBRIDOMA, V30, P531, DOI 10.1089/hyb.2011.0070; Petersson J, 2011, AM J PHYSIOL-GASTR L, V300, pG327, DOI 10.1152/ajpgi.00422.2010; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Ray DM, 2012, BRIT J CANCER, V107, P129, DOI 10.1038/bjc.2012.214; Relic B, 2004, J BIOL CHEM, V279, P22399, DOI 10.1074/jbc.M314118200; Rhodes JM, 1996, LANCET, V347, P40, DOI 10.1016/S0140-6736(96)91563-9; Rowse GJ, 1998, CANCER RES, V58, P315; Sakurai H, 2012, TRENDS PHARMACOL SCI, V33, P522, DOI 10.1016/j.tips.2012.06.007; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Starczynowski DT, 2011, J CLIN INVEST, V121, P4095, DOI 10.1172/JCI58818; Suzuki H, 2004, CLIN EXP METASTAS, V21, P321, DOI 10.1023/B:CLIN.0000046133.35133.cc; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Yamazaki K, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000387	50	70	74	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5187	5197		10.1038/onc.2014.442	http://dx.doi.org/10.1038/onc.2014.442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25659581	Green Accepted, Green Submitted			2022-12-17	WOS:000362233400008
J	Azoulay-Alfaguter, I; Elya, R; Avrahami, L; Katz, A; Eldar-Finkelman, H				Azoulay-Alfaguter, I.; Elya, R.; Avrahami, L.; Katz, A.; Eldar-Finkelman, H.			Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth	ONCOGENE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR TYROSINE KINASES; TUBEROUS-SCLEROSIS; THERAPEUTIC TARGET; SIGNALING PATHWAY; MAMMALIAN TARGET; TUMOR-SUPPRESSOR; AMINO-ACIDS; INHIBITORS; DISEASE	There is controversy over the role of glycogen synthase kinase-3 (GSK-3) in cancer progression. Recent work has implicated GSK-3 in the regulation of mammalian target of rapamycin (mTOR), a known player in malignant transformation. Autophagy, a selfdegradation pathway, is inhibited by mTOR and is tightly associated with cell survival and tumor growth. Here we show that GSK-3 suppresses autophagy via mTOR complex-1 (mTORC1) and lysosomal regulation. We show that overexpression of GSK-3 isoforms (GSK-3 alpha and GSK-3 alpha) activated mTORC1 and suppressed autophagy in MCF-7 human breast cancer cells as indicated by reduced beclin-1 levels and upregulation of sequestosome 1 (p62/SQSTM1). Further, overexpression of GSK-3 increased the number of autophagosomes and inhibited autophagic flux. This activity was directly related to reduced lysosomal acidification triggered by GSK-3 (in which GSK-3 beta has a stronger impact). We found that lysosomal acidification is reduced in MCF-7 cells that also exhibit increased levels of autophagosomes and p62/SQSTM1 and increased activity of mTORC1. Subsequently, treating cells with GSK-3 inhibitors restored lysosomal acidification, enhanced autophagic flux and inhibited mTORC1. Furthermore, GSK-3 inhibitors inhibited cell proliferation. We provide evidence that GSK3-mediated mTORC1 activity and GSK-3-mediated lysosomal acidification occur via distinct pathways, yet both mTORC1 and lysosomes control cell growth. Finally, we show that GSK-3-reduced lysosomal acidification inhibits endocytic clearance as demonstrated by reduced endocytic degradation of the epidermal growth factor receptor. Taken together, our study places GSK-3 as a key regulator coordinating cellular homeostasis. GSK-3 inhibitors may be useful in targeting mTORC1 and lysosomal acidification for cancer therapy.	[Azoulay-Alfaguter, I.; Elya, R.; Avrahami, L.; Katz, A.; Eldar-Finkelman, H.] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Eldar-Finkelman, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.	heldar@post.tau.ac.il		Eldar-Finkelman, Hagit/0000-0002-8460-9686	Israel Science Foundation [341/10]; Finghort Fund for Cancer Research at Tel Aviv University	Israel Science Foundation(Israel Science Foundation); Finghort Fund for Cancer Research at Tel Aviv University	This research was supported by the Israel Science Foundation grant No. 341/10 and the Finghort Fund for Cancer Research at Tel Aviv University. We thank Dr Dan Klionsky and Dr Zvulun Elazar for their constructive comments.	Aguilar-Morante D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013879; Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Avrahami L, 2013, J BIOL CHEM, V288, P1295, DOI 10.1074/jbc.M112.409250; Azoulay-Alfaguter I, 2011, J BIOL CHEM, V286, P13470, DOI 10.1074/jbc.M110.127969; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Birch NW, 2010, CANCER CELL, V17, P529, DOI 10.1016/j.ccr.2010.05.017; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Boya P, 2012, ANTIOXID REDOX SIGN, V17, P766, DOI 10.1089/ars.2011.4405; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158; Cornu M, 2013, CURR OPIN GENET DEV, V23, P53, DOI 10.1016/j.gde.2012.12.005; Davis NM, 2014, ONCOTARGET, V5, P4603, DOI 10.18632/oncotarget.2209; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Doherty L, 2006, NEUROLOGY, V67, P156, DOI 10.1212/01.wnl.0000223844.77636.29; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Eldar-Finkelman H, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00032; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Gulen MF, 2012, IMMUNITY, V37, P800, DOI 10.1016/j.immuni.2012.08.019; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Harris RA, 2002, PROTEOMICS, V2, P212, DOI 10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hernandez F, 2013, J ALZHEIMERS DIS, V33, pS141, DOI 10.3233/JAD-2012-129025; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang J, 2009, J CLIN INVEST, V119, P3519, DOI 10.1172/JCI40572; Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Karyo R, 2010, MOL CELL NEUROSCI, V45, P449, DOI 10.1016/j.mcn.2010.08.004; Kim HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060383; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lauring J, 2013, J NATL COMPR CANC NE, V11, P670, DOI 10.6004/jnccn.2013.0086; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032; Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; McCubrey James A., 2014, Advances in Biological Regulation, V54, P176, DOI 10.1016/j.jbior.2013.09.013; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Ougolkov Andrei V, 2006, Future Oncol, V2, P91, DOI 10.2217/14796694.2.1.91; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371; Patel S, 2008, CANCER CELL, V14, P351, DOI 10.1016/j.ccr.2008.10.013; Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123; Pluquet O, 2005, MOL CELL BIOL, V25, P9392, DOI 10.1128/MCB.25.21.9392-9405.2005; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Proud CG., 2013, BIOCHEM SOC T, V39, P431; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Rix LLR, 2014, ACS CHEM BIOL, V9, P353, DOI 10.1021/cb400660a; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schneider JL, 2014, CURR OPIN GENET DEV, V26, P16, DOI 10.1016/j.gde.2014.04.003; Shin S, 2014, ONCOGENE, V33, P1690, DOI 10.1038/onc.2013.113; Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Suzuki T, 2013, MOL CELL, V50, P407, DOI 10.1016/j.molcel.2013.03.022; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Voss MH, 2011, HEMATOL ONCOL CLIN N, V25, P835, DOI 10.1016/j.hoc.2011.04.008; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; Wazir U, 2014, CANCER GENOM PROTEOM, V11, P167; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhou JB, 2013, J CLIN INVEST, V123, P1821, DOI 10.1172/JCI64398; Zhu Q, 2011, PROSTATE, V71, P835, DOI 10.1002/pros.21300; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	89	70	72	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4613	4623		10.1038/onc.2014.390	http://dx.doi.org/10.1038/onc.2014.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25500539				2022-12-17	WOS:000360189300007
J	Satoyoshi, R; Kuriyama, S; Aiba, N; Yashiro, M; Tanaka, M				Satoyoshi, R.; Kuriyama, S.; Aiba, N.; Yashiro, M.; Tanaka, M.			Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts	ONCOGENE			English	Article						aspirin; CAF; rac1; scirrhous gastric cancer; SLRP	GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; DECORIN; PROTEOGLYCANS; EXPRESSION; PROTEIN; MYOFIBROBLASTS; METASTASIS; ROLES; CELLS	Scirrhous gastric cancer, which has the worst prognosis among the various types of gastric cancer, is highly invasive and associated with abundant stromal fibroblasts. Although cancer-associated fibroblasts (CAFs) have been proposed to generate a tumor-supportive extracellular matrix that promotes the expansion of this type of cancer, the molecular mechanisms by which CAFs assist cancer cells are not yet fully understood. Here, we show for the first time that Asporin, a small leucine-rich proteoglycan (SLRP), is predominantly expressed in CAFs, and has essential roles in promoting co-invasion of CAFs and cancer cells. CAFs of scirrhous gastric cancer possess high potential for invasion, and invasion by CAFs frequently proceeded invasion by cancer cells, both in vitro and in vivo. Expression of Asporin was induced in fibroblasts by exposure to gastric cancer cells. Asporin secreted from CAFs activates Rac1 via an interaction with CD44 and promotes invasion by CAFs themselves. Moreover, Asporin promoted invasion by neighboring cancer cells, via paracrine effects mediated by activation of the CD44-Rac1 pathway. These results suggest that Asporin is a unique SLRP that promotes progression of scirrhous gastric cancer and is required for coordinated invasion by CAFs and cancer cells. Therefore, Asporin may represent a new therapeutic target molecule for the development of drugs aimed at manipulating the cancer microenvironment.	[Satoyoshi, R.; Kuriyama, S.; Aiba, N.; Tanaka, M.] Akita Univ, Grad Sch Med, Dept Mol Med & Biochem, Akita 0108543, Japan; [Yashiro, M.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka 558, Japan	Akita University; Osaka Metropolitan University	Tanaka, M (corresponding author), Akita Univ, 1-1-1 Hondo, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp	Kuriyama, Sei/AAV-2368-2020	Kuriyama, Sei/0000-0002-5502-7177	JSPS KAKENHI [22300324, 25290042, 24700962]; MEXT KAKENHI [25111702]; National Cancer Center Research and Development Fund [23-A-9]; Grants-in-Aid for Scientific Research [24700962] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI (Grant Nos. 22300324 and 25290042; to MT, 24700962 to SK), MEXT KAKENHI 25111702 to SK and the National Cancer Center Research and Development Fund (Grant No. 23-A-9; to MT).	Chen SJ, 2013, FEBS J, V280, P2120, DOI 10.1111/febs.12136; Chong HC, 2012, J ONCOL, V2012, DOI 10.1155/2012/351089; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Duval E, 2011, MOL MED, V17, P816, DOI 10.2119/molmed.2011.00052; Edwards IJ, 2012, NAT REV UROL, V9, P196, DOI 10.1038/nrurol.2012.19; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gruber HE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2660; Hagiyama M, 2009, AM J PATHOL, V174, P2278, DOI 10.2353/ajpath.2009.080743; Horie M, 2012, BIOCHEM BIOPH RES CO, V423, P158, DOI 10.1016/j.bbrc.2012.05.104; Iozzo RV, 2011, J CELL MOL MED, V15, P1013, DOI 10.1111/j.1582-4934.2010.01236.x; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Klee EW, 2012, CLIN CHEM, V58, P599, DOI 10.1373/clinchem.2011.171637; Merline R, 2009, J CELL COMMUN SIGNAL, V3, P323, DOI 10.1007/s12079-009-0066-2; Nakajima M, 2007, J BIOL CHEM, V282, P32185, DOI 10.1074/jbc.M700522200; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Pena C, 2013, CANCER RES, V73, P1287, DOI 10.1158/0008-5472.CAN-12-1875; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Seidler DG, 2006, J BIOL CHEM, V281, P26408, DOI 10.1074/jbc.M602853200; Shimamura S, 2013, J BIOL CHEM, V288, P1171, DOI 10.1074/jbc.M112.386722; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Terawaki S, 2010, EMBO J, V29, P236, DOI 10.1038/emboj.2009.323; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Ungefroren H, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-18; Yashiro M, 2010, CANCER MICROENVIRON, V3, P127, DOI 10.1007/s12307-010-0036-5; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	31	70	71	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					650	660		10.1038/onc.2013.584	http://dx.doi.org/10.1038/onc.2013.584			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24441039				2022-12-17	WOS:000348853500012
J	Rojas-Rivera, D; Hetz, C				Rojas-Rivera, D.; Hetz, C.			TMBIM protein family: ancestral regulators of cell death	ONCOGENE			English	Review						TMBIM; BI-1; BCL-2; apoptosis; ER-stress; calcium	ENDOPLASMIC-RETICULUM STRESS; BREAST-CANCER CELLS; OUTER MITOCHONDRIAL-MEMBRANE; GLUTAMATE-BINDING SUBUNIT; BAX INHIBITOR MOTIF; CYTOCHROME-C; ER STRESS; TRANSMEMBRANE PROTEIN; SENSOR IRE1-ALPHA; DOWN-REGULATION	The control of apoptosis in mammals has been historically associated with the activity of the BCL-2 family of proteins at the mitochondria. In the past years, a novel group of cell death regulators have emerged, known as the Transmembrane BAX Inhibitor-1 Motif-containing (TMBIM) protein family. This group of proteins is composed of at least six highly conserved members expressed in mammals, with homologs in insects, fish, plants, viruses and yeast. Different studies indicate that all TMBIM family members have inhibitory activities in different setting of apoptosis. Here, we overview and integrate possible mechanisms underlying the impact of the TMBIM protein family in the regulation of cell death, which include activities at diverse subcellular compartments, including death receptor regulation, modulation of endoplasmic reticulum (ER) calcium homeostasis, ER stress signaling, autophagy, reactive oxygen species production, among other effects. The possible intersection between the BCL-2 and TMBIM family in the control of cell death is also discussed, in addition to their implication in the progression of cancer.	[Rojas-Rivera, D.; Hetz, C.] Univ Chile, Fac Med, Biomed Neurosci Inst, Santiago 70086, Chile; [Rojas-Rivera, D.; Hetz, C.] Univ Chile, Fac Med, Inst Biomed Sci, Ctr Mol Studies Cell, Santiago 70086, Chile; [Hetz, C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Hetz, C.] Neurounion Biomed Fdn, Santiago, Chile	Universidad de Chile; Universidad de Chile; Harvard University; Harvard T.H. Chan School of Public Health	Hetz, C (corresponding author), Univ Chile, Fac Med, Inst Biomed Sci, Program Cellular & Mol Biol, 1027 Independencia Ave, Santiago 70086, Chile.	chetz@med.uchile.cl	Hetz, Claudio/ABD-7514-2021; Rivera, Diego Rojas/ABF-5865-2020; Rojas Rivera, Diego/N-1870-2016; Rojas-Riviera, Diego/AAN-5222-2020	Rivera, Diego Rojas/0000-0002-8773-9830; Rojas Rivera, Diego/0000-0002-8773-9830; 	FONDEF [D11l1007, 3130365]; Ring Initiative [ACT1109]; Millennium Institute [P09-015-F]; Alzheimers Association, FONDECYT [1100176]; Muscular Dystrophy Association, ALS Therapy Alliance; FONDECYT [3130365, 1140549]; ECOS CONICYT C13S02 CONICYT Grant [USA2013-0003]	FONDEF; Ring Initiative; Millennium Institute(Takeda Pharmaceutical Company Ltd); Alzheimers Association, FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Muscular Dystrophy Association, ALS Therapy Alliance(Muscular Dystrophy Association); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); ECOS CONICYT C13S02 CONICYT Grant	This work was funded by FONDEF D11l1007, Ring Initiative ACT1109, Millennium Institute No. P09-015-F, the Alzheimers Association, FONDECYT No. 1100176, FONDECYT No. 1140549, ECOS CONICYT C13S02 CONICYT Grant USA2013-0003, the Muscular Dystrophy Association, ALS Therapy Alliance (CH) and FONDECYT No. 3130365 Post-doctoral grant (DRR).	Ahn T, 2010, CELL CALCIUM, V47, P387, DOI 10.1016/j.ceca.2010.02.003; ALCAMI A, 1995, J VIROL, V69, P4633; Ameisen JC, 1996, SCIENCE, V272, P1278, DOI 10.1126/science.272.5266.1278; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Aouacheria A, 2013, TRENDS CELL BIOL, V23, P103, DOI 10.1016/j.tcb.2012.10.010; Bailly-Maitre B, 2006, P NATL ACAD SCI USA, V103, P2809, DOI 10.1073/pnas.0506854103; Bailly-Maitre B, 2007, CANCER RES, V67, P1442, DOI 10.1158/0008-5472.CAN-06-0850; Bailly-Maitre B, 2010, J BIOL CHEM, V285, P6198, DOI 10.1074/jbc.M109.056648; Bucan V, 2011, ONCOL LETT, V2, P419, DOI 10.3892/ol.2011.285; Bucan V, 2010, APOPTOSIS, V15, P814, DOI 10.1007/s10495-010-0493-9; Bucan V, 2010, CELL MOL BIOL LETT, V15, P296, DOI 10.2478/s11658-010-0009-1; Buttner S, 2007, MOL CELL, V25, P233, DOI 10.1016/j.molcel.2006.12.021; Buttner S, 2011, EMBO J, V30, P2779, DOI 10.1038/emboj.2011.197; Bultynck G, 2012, J BIOL CHEM, V287, P2544, DOI 10.1074/jbc.M111.275354; Cakir B, 2012, YEAST, V29, P395, DOI 10.1002/yea.2918; Carmona-Gutierrez D, 2010, CELL DEATH DIFFER, V17, P763, DOI 10.1038/cdd.2009.219; Carrara G, 2012, J BIOL CHEM, V287, P15896, DOI 10.1074/jbc.M111.336149; Castillo K, 2011, EMBO J, V30, P4465, DOI 10.1038/emboj.2011.318; Cebulski J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020882; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Chen YB, 2011, J CELL BIOL, V195, P263, DOI 10.1083/jcb.201108059; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; de Mattia F, 2009, MOL BIOL CELL, V20, P3638, DOI 10.1091/mbc.E09-05-0385; de Mendoza TH, 2011, P NATL ACAD SCI USA, V108, P17189, DOI 10.1073/pnas.1114226108; Dejeans N, 2014, TRENDS MOL MED; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; Eisenberg T, 2007, APOPTOSIS, V12, P1011, DOI 10.1007/s10495-007-0758-0; Fernandez M, 2007, J NEUROCHEM, V103, P190, DOI 10.1111/j.1471-4159.2007.04767.x; Galindo KA, 2009, DEVELOPMENT, V136, P275, DOI 10.1242/dev.019042; Goswami DB, 2013, PROG NEURO-PSYCHOPH, V43, P126, DOI 10.1016/j.pnpbp.2012.12.010; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grzmil M, 2006, J PATHOL, V208, P340, DOI 10.1002/path.1902; Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6; Gubser C, 2007, PLOS PATHOG, V3, P246, DOI 10.1371/journal.ppat.0030017; Happo L, 2012, J CELL SCI, V125, P1081, DOI 10.1242/jcs.090514; Hemrajani C, 2010, P NATL ACAD SCI USA, V107, P3129, DOI 10.1073/pnas.0911609106; Henke N, 2011, CELL CALCIUM, V50, P251, DOI 10.1016/j.ceca.2011.05.005; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011; Hetz C, 2009, MOL CELL, V35, P551, DOI 10.1016/j.molcel.2009.08.021; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hsu CF, 2011, INT J BIOCHEM CELL B, V43, P666, DOI 10.1016/j.biocel.2011.01.010; Hu L, 2009, APOPTOSIS, V14, P1255, DOI 10.1007/s10495-009-0402-2; Huckelhoven R, 2004, APOPTOSIS, V9, P299, DOI 10.1023/B:APPT.0000025806.71000.1c; Hunsberger JG, 2011, BRAIN RES, V1403, P19, DOI 10.1016/j.brainres.2011.05.067; Ishikawa T, 2011, CELL DEATH DIFFER, V18, P1271, DOI 10.1038/cdd.2011.59; Jette CA, 2008, CELL DEATH DIFFER, V15, P1063, DOI 10.1038/cdd.2008.42; Kawai M, 1999, FEBS LETT, V464, P143, DOI 10.1016/S0014-5793(99)01695-6; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim HR, 2008, J BIOL CHEM, V283, P15946, DOI 10.1074/jbc.M800075200; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim JH, 2012, BBA-MOL CELL RES, V1823, P876, DOI 10.1016/j.bbamcr.2012.01.016; Kiviluoto S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.103; Kiviluoto S, 2013, CELL CALCIUM, V54, P186, DOI 10.1016/j.ceca.2013.06.002; Kiviluoto S, 2013, BBA-MOL CELL RES, V1833, P1612, DOI 10.1016/j.bbamcr.2013.01.026; Kotsafti A, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-35; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; KUMAR KN, 1991, NATURE, V354, P70, DOI 10.1038/354070a0; Lee GH, 2010, ONCOGENE, V29, P2130, DOI 10.1038/onc.2009.491; Lee GH, 2012, INT J BIOCHEM CELL B, V44, P600, DOI 10.1016/j.biocel.2011.12.017; Lee GH, 2011, INT J BIOCHEM CELL B, V43, P1305, DOI 10.1016/j.biocel.2011.05.004; Lee GH, 2011, J BIOL CHEM, V286, P24743, DOI 10.1074/jbc.M110.167734; Lee GH, 2011, INT J ONCOL, V39, P209, DOI 10.3892/ijo.2011.1024; Lee GH, 2010, MOL CELL BIOL, V30, P1800, DOI 10.1128/MCB.01357-09; Lee Geung-Joo, 2007, V2, P1; Lewis TB, 1996, GENOMICS, V32, P131, DOI 10.1006/geno.1996.0088; Li XY, 2011, HUM GENE THER, V22, P1201, DOI 10.1089/hum.2010.178; Li XY, 2010, CELL BIOL INT, V34, P1099, DOI 10.1042/CBI20090400; Li YS, 2001, ENDOCRINOLOGY, V142, P2937, DOI 10.1210/en.142.7.2937; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lisbona F, 2009, MOL CELL, V33, P679, DOI 10.1016/j.molcel.2009.02.017; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Markkula E, 2013, MICROB PATHOGENESIS, V54, P46, DOI 10.1016/j.micpath.2012.09.004; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; MOORE JB, 1992, EMBO J, V11, P1973, DOI 10.1002/j.1460-2075.1992.tb05251.x; Nielsen JA, 2011, MOL CELL BIOCHEM, V357, P73, DOI 10.1007/s11010-011-0877-3; Oka T, 2008, MOL BIOL CELL, V19, P2597, DOI 10.1091/mbc.E07-12-1205; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Reich A, 2011, J NEUROSCI, V31, P225, DOI 10.1523/JNEUROSCI.2188-10.2011; Reimers K, 2008, CURR MOL MED, V8, P148, DOI 10.2174/156652408783769562; Reimers K, 2007, INT J BIOL SCI, V3, P471; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Robinson KS, 2011, ONCOGENE, V30, P2391, DOI 10.1038/onc.2010.636; Robinson KS, 2010, MICROBIOL-SGM, V156, P1815, DOI 10.1099/mic.0.037259-0; Rodriguez DA, 2012, EMBO J, V31, P2322, DOI 10.1038/emboj.2012.84; Rojas-Rivera D, 2012, CELL DEATH DIFFER, V19, P1013, DOI 10.1038/cdd.2011.189; Rong JA, 2011, J BIOL CHEM, V286, P1453, DOI 10.1074/jbc.M110.175232; Sano R, 2012, GENE DEV, V26, P1041, DOI 10.1101/gad.184325.111; Saraiva N, 2013, J CELL BIOL, V202, P699, DOI 10.1083/jcb.201301016; Saraiva N, 2013, J BIOL CHEM, V288, P13057, DOI 10.1074/jbc.M112.414367; Schmidt SM, 2009, LEUKEMIA, V23, P1818, DOI 10.1038/leu.2009.138; Schmits R, 2002, INT J CANCER, V98, P73, DOI 10.1002/ijc.10170; Schweitzer B, 2002, MOL BRAIN RES, V107, P47, DOI 10.1016/S0169-328X(02)00445-X; Sevrioukov EA, 2007, GENESIS, V45, P184, DOI 10.1002/dvg.20279; Shukla S, 2011, APOPTOSIS, V16, P162, DOI 10.1007/s10495-010-0556-y; Somia NV, 1999, P NATL ACAD SCI USA, V96, P12667, DOI 10.1073/pnas.96.22.12667; Szuchet S, 2001, BIOCHEM BIOPH RES CO, V283, P900, DOI 10.1006/bbrc.2001.4859; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tanaka R, 2006, CANCER-AM CANCER SOC, V106, P648, DOI 10.1002/cncr.21639; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Villalva C, 2002, BRIT J HAEMATOL, V118, P791, DOI 10.1046/j.1365-2141.2002.03671.x; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Westphalen BC, 2005, CELL DEATH DIFFER, V12, P304, DOI 10.1038/sj.cdd.4401547; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Wu XF, 2013, CANCER RES, V73, P4028, DOI 10.1158/0008-5472.CAN-12-4033; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yamaji T, 2010, J BIOL CHEM, V285, P35505, DOI 10.1074/jbc.M110.154229; Yoshida T, 2006, BIOCHEM BIOPH RES CO, V341, P13, DOI 10.1016/j.bbrc.2005.12.141; Yoshisue H, 2002, ATHEROSCLEROSIS, V162, P323, DOI 10.1016/S0021-9150(01)00735-3; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yun CH, 2012, J PHARM SCI-US, V101, P1314, DOI 10.1002/jps.23007; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang MH, 2010, MOL CELL BIOCHEM, V333, P1, DOI 10.1007/s11010-009-0198-y; Zhao H, 2006, GENES GENET SYST, V81, P41, DOI 10.1266/ggs.81.41; Zhivotovsky B, 2009, CELL DEATH DIFFER, V16, P1419, DOI 10.1038/cdd.2009.118; Zhou JH, 2008, COMPUT BIOL CHEM, V32, P159, DOI 10.1016/j.compbiolchem.2008.01.002	131	70	73	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					269	280		10.1038/onc.2014.6	http://dx.doi.org/10.1038/onc.2014.6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24561528	Bronze			2022-12-17	WOS:000348145500001
J	Bengsch, F; Buck, A; Gunther, SC; Seiz, JR; Tacke, M; Pfeifer, D; von Elverfeldt, D; Sevenich, L; Hillebrand, LE; Kern, U; Sameni, M; Peters, C; Sloane, BF; Reinheckel, T				Bengsch, F.; Buck, A.; Guenther, S. C.; Seiz, J. R.; Tacke, M.; Pfeifer, D.; von Elverfeldt, D.; Sevenich, L.; Hillebrand, L. E.; Kern, U.; Sameni, M.; Peters, C.; Sloane, B. F.; Reinheckel, T.			Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression	ONCOGENE			English	Article						CTSB; breast cancer; macrophages; invasion	CYSTEINE CATHEPSINS; TUMOR-GROWTH; PLASMINOGEN-ACTIVATOR; PROMOTES PROGRESSION; PROTEASE ACTIVITY; MOUSE MODEL; EXPRESSION; METASTASIS; INVASION; MACROPHAGES	The cysteine protease cathepsin B (CTSB) is frequently overexpressed in human breast cancer and correlated with a poor prognosis. Genetic deficiency or pharmacological inhibition of CTSB attenuates tumor growth, invasion and metastasis in mouse models of human cancers. CTSB is expressed in both cancer cells and cells of the tumor stroma, in particular in tumor-associated macrophages (TAM). In order to evaluate the impact of tumor- or stromal cell-derived CTSB on Polyoma Middle T (PyMT)-induced breast cancer progression, we used in vivo and in vitro approaches to induce human CTSB overexpression in PyMT cancer cells or stromal cells alone or in combination. Orthotopic transplantation experiments revealed that CTSB overexpression in cancer cells rather than in the stroma affects PyMT tumor progression. In 3D cultures, primary PyMT tumor cells showed higher extracellular matrix proteolysis and enhanced collective cell invasion when CTSB was overexpressed and proteolytically active. Coculture of PyMT cells with bone marrow-derived macrophages induced a TAM-like macrophage phenotype in vitro, and the presence of such M2-polarized macrophages in 3D cultures enhanced sprouting of tumor spheroids. We employed a doxycycline (DOX)-inducible CTSB expression system to selectively overexpress human CTSB either in cancer cells or in macrophages in 3D cocultures. Tumor spheroid invasiveness was only enhanced when CTSB was overexpressed in cancer cells, whereas CTSB expression in macrophages alone did not further promote invasiveness of tumor spheroids. We conclude that CTSB overexpression in the PyMT mouse model promotes tumor progression not by a stromal effect, but by a direct, cancer cell-inherent mode of action: CTSB overexpression renders the PyMT cancers more invasive by increasing proteolytic extracellular matrix protein degradation fostering collective cell invasion into adjacent tissue.	[Bengsch, F.; Buck, A.; Guenther, S. C.; Seiz, J. R.; Tacke, M.; Sevenich, L.; Hillebrand, L. E.; Kern, U.; Peters, C.; Reinheckel, T.] Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; [Bengsch, F.; Kern, U.] Univ Freiburg, Spemann Grad Sch Biol & Med, D-79104 Freiburg, Germany; [Bengsch, F.; Hillebrand, L. E.; Kern, U.] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Pfeifer, D.] Univ Med Ctr, Genom Core Lab, Dept Hematol Oncol, Freiburg, Germany; [von Elverfeldt, D.] Univ Med Ctr, Dept Radiol, Freiburg, Germany; [Hillebrand, L. E.; Peters, C.; Reinheckel, T.] BIOSS Ctr Biol Signalling Studies, Freiburg, Germany; [Sameni, M.; Sloane, B. F.] Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA; [Sloane, B. F.] Wayne State Univ, Barbara Ann Carmanos Canc Inst, Detroit, MI USA	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Wayne State University; Wayne State University	Reinheckel, T (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.	thomas.reinheckel@uniklinik-freiburg.de	Buck, Achim/S-4843-2016; Sloane, Bonnie F/A-1050-2009; Buck, Achim/A-5092-2017; Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Buck, Achim/0000-0001-9135-9032; von Elverfeldt, Dominik/0000-0002-6219-3528	NIH [P30CA22453]; Excellence Initiative of the German Federal and State Governments [EXC 294, GSC-4]; Deutsche Forschungsgemeinschaft [SFB 850, B7]; NATIONAL CANCER INSTITUTE [P30CA022453, R01CA140314] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Excellence Initiative of the German Federal and State Governments; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The CTSB<SUP>+/0</SUP> mice were kindly provided by Dr L. Pennacchio, Genomics Division, Lawrence Berkeley Laboratory, Berkeley, USA. The immortalized macrophage cell line from FVB/n mice was kindly provided by Eike Latz, currently University of Bonn, Germany. We thank Nicole Klemm, Anja Faulhaber and Julia Wolanski for excellent technical assistance. Proteolysis imaging was mainly performed with kind help of the Microscopy, Imaging & Cytometry Resources Core at Wayne State University, Detroit, MI, USA, directed by Dr Kamiar Moin and supported in part by NIH Center grant P30CA22453 to the Karmanos Cancer Institute, Wayne State University. This work was supported by the Excellence Initiative of the German Federal and State Governments (EXC 294 and GSC-4, Spemann Graduate School), and the Deutsche Forschungsgemeinschaft SFB 850 project B7.	Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bell-McGuinn KM, 2007, CANCER RES, V67, P7378, DOI 10.1158/0008-5472.CAN-07-0602; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Brisson L, 2012, EUR J CELL BIOL, V91, P847, DOI 10.1016/j.ejcb.2012.04.004; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; Cavallo-Medved D, 2005, J CELL SCI, V118, P1493, DOI 10.1242/jcs.02278; Cesen MH, 2012, EXP CELL RES, V318, P1245, DOI 10.1016/j.yexcr.2012.03.005; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Gopinathan A, 2012, GUT, V61, P877, DOI 10.1136/gutjnl-2011-300850; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbeck N, 2001, CLIN CANCER RES, V7, P2757; Herroon MK, 2013, ONCOGENE, V32, P1580, DOI 10.1038/onc.2012.166; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jane DT, 2006, BIOL CHEM, V387, P223, DOI 10.1515/BC.2006.030; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; Malla RR, 2011, CANCER GENE THER, V18, P419, DOI 10.1038/cgt.2011.9; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Mikhaylov G, 2011, NAT NANOTECHNOL, V6, P594, DOI [10.1038/NNANO.2011.112, 10.1038/nnano.2011.112]; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nouh MA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-1; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Rawlings ND, 2008, NUCLEIC ACIDS RES, V36, pD320, DOI 10.1093/nar/gkm954; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sameni M, 2009, CLIN EXP METASTAS, V26, P299, DOI 10.1007/s10585-008-9218-7; Schurigt U, 2008, BIOL CHEM, V389, P1067, DOI 10.1515/BC.2008.115; Sevenich L, 2011, ONCOGENE, V30, P54, DOI 10.1038/onc.2010.387; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; SINHA AA, 1993, ANAT REC, V235, P233, DOI 10.1002/ar.1092350207; Tu C, 2008, CANCER RES, V68, P9147, DOI 10.1158/0008-5472.CAN-07-5127; Vasiljeva O, 2008, BIOCHIMIE, V90, P380, DOI 10.1016/j.biochi.2007.10.004; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Victor BC, 2007, BIOL CHEM, V388, P1131, DOI 10.1515/BC.2007.150; Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008-5472.CAN-11-2759; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823	55	70	71	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4474	4484		10.1038/onc.2013.395	http://dx.doi.org/10.1038/onc.2013.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24077280	Green Accepted			2022-12-17	WOS:000341158800003
J	Brouxhon, SM; Kyrkanides, S; Teng, X; Athar, M; Ghazizadeh, S; Simon, M; O'Banion, MK; Ma, L				Brouxhon, S. M.; Kyrkanides, S.; Teng, X.; Athar, M.; Ghazizadeh, S.; Simon, M.; O'Banion, M. K.; Ma, L.			Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling	ONCOGENE			English	Article						squamous cell carcinomas; UV-irradiation; soluble E-cadherin; HER/ErbB receptors; IGF-1R; oncogenecity	GROWTH-FACTOR RECEPTOR; CELL CARCINOMA PROGRESSION; BREAST-CANCER CELLS; TRANSGENIC MICE; FACTOR-I; ULTRAVIOLET-IRRADIATION; PROSTATE-CANCER; TUMOR PROMOTION; DOWN-REGULATION; GASTRIC-CANCER	E-cadherin, a cell-cell adhesion glycoprotein, is frequently downregulated with tumorigenic progression. The extracellular domain of E-cadherin is cleaved by proteases to generate a soluble ectodomain fragment, termed sEcad, which is elevated in the urine or serum of cancer patients. In this study, we explored the functional role of sEcad in the progression of skin squamous cell carcinomas (SCCs). We found that full-length E-cadherin expression was decreased and sEcad increased in human clinical tumor samples as well as in ultraviolet (UV)-induced SCCs in mice. Interestingly, sEcad associated with members of the human epidermal growth factor receptor (HER) and insulin-like growth factor-1 (IGF-1R) family of receptors in human and UV-induced mouse tumors. Moreover, in both E-cadherin-positive (E-cadherin(+)) and -negative (E-cadherin(-)) cells in vitro, sEcad activated downstream mitogen-activated protein (MAP) kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling and enhanced tumor growth, motility and invasion, the latter via activation of matrix metalloproteinase-2 (MMP-2) and MMP-9. To this end, HER, PI3K or MEK inhibitors suppressed sEcad's tumorigenic effects, including proliferation, migration and invasion. Taken together, our data suggest that sEcad contributes to skin carcinogenesis via association with the HER/IGF-1R-family of receptors and subsequent activation of the MAPK and PI3K/Akt/mTOR pathways, thereby implicating sEcad as a putative therapeutic target in cutaneous SCCs.	[Brouxhon, S. M.; Kyrkanides, S.; Teng, X.; Ghazizadeh, S.; Simon, M.; Ma, L.] SUNY Stony Brook, Hlth Sci Ctr, Dept Emergency Med, Stony Brook, NY 11794 USA; [Athar, M.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA; [O'Banion, M. K.] Univ Rochester, Sch Med & Dent, Dept Neurobiol, Rochester, NY USA; [O'Banion, M. K.] Univ Rochester, Sch Med & Dent, Dept Anat, Rochester, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Alabama System; University of Alabama Birmingham; University of Rochester; University of Rochester	Brouxhon, SM (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Sch Med, Westchester Hall,Room 154, Stony Brook, NY 11794 USA.	Sabine.Brouxhon@stonybrook.edu	Ma, Li/AAG-4109-2020	Ma, Li/0000-0001-8470-0378; O'Banion, M. Kerry/0000-0003-1246-3363	NIH [K08CA133910, R21ES015832, R01CA138998]; NATIONAL CANCER INSTITUTE [K08CA133910, R01CA138998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES015832] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Yuspa (NCI) and Dr Klein-Szanto (Fox Chase Cancer Center) for the PAM212 and CC4A cells, respectively. This work was supported by NIH grants K08CA133910 (NCI) and R21ES015832 (NIEHS) to SMB as well as NIH grant R01CA138998 (NCI) to MA.	Batistatou A, 2006, VIRCHOWS ARCH, V448, P763, DOI 10.1007/s00428-006-0183-8; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.0.CO;2-R; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; BONGIORNO PF, 1995, BRIT J CANCER, V71, P166, DOI 10.1038/bjc.1995.34; Brouxhon S, 2007, CANCER RES, V67, P7654, DOI 10.1158/0008-5472.CAN-06-4415; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chan ACO, 2003, J CLIN ONCOL, V21, P2288, DOI 10.1200/JCO.2003.08.078; Davies G, 2001, CLIN CANCER RES, V7, P3289; DiGiovanni J, 2000, CANCER RES, V60, P1561; Dlugosz AA, 1997, CANCER RES, V57, P3180; El-Abaseri TB, 2006, CARCINOGENESIS, V27, P225, DOI 10.1093/carcin/bgi220; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; Esch TR, 2000, J AUTOIMMUN, V15, P387, DOI 10.1006/jaut.2000.0451; Fong KP, 2011, BLOOD, V117, pE15, DOI 10.1182/blood-2010-05-283838; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; Galer CE, 2011, HEAD NECK-J SCI SPEC, V33, P189, DOI 10.1002/hed.21419; GAMALLO C, 1993, AM J PATHOL, V142, P987; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Inge LJ, 2011, EXP CELL RES, V317, P838, DOI 10.1016/j.yexcr.2010.12.025; KATAYAMA M, 1994, BRIT J CANCER, V69, P580, DOI 10.1038/bjc.1994.106; Kim AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P58, DOI 10.1562/0031-8655(2002)075<0058:SSAOCE>2.0.CO;2; Kuefer R, 2003, CLIN CANCER RES, V9, P6447; Kyrkanides S, 2007, J NEUROIMMUNOL, V188, P39, DOI 10.1016/j.jneuroim.2007.05.010; Madson JG, 2007, MOL CARCINOGEN, V46, P624, DOI 10.1002/mc.20335; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Maretzky T, 2008, J INVEST DERMATOL, V128, P1737, DOI 10.1038/sj.jid.5701242; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; MAYER B, 1993, CANCER RES, V53, P1690; MOLL R, 1993, AM J PATHOL, V143, P1731; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Najy AJ, 2008, J BIOL CHEM, V283, P18393, DOI 10.1074/jbc.M801329200; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Saha B, 2007, ANTICANCER RES, V27, P3903; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Uchida Y, 2011, J IMMUNOL, V186, P6945, DOI 10.4049/jimmunol.1003853; Van den Bossche J, 2012, BLOOD, V119, P1623, DOI 10.1182/blood-2011-10-384289; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Wan YS, 2001, INT J ONCOL, V18, P461; Wilding J, 1996, CANCER RES, V56, P5285; Wilker E, 2005, MOL CARCINOGEN, V44, P137, DOI 10.1002/mc.20132; Yang Jun, 2005, Zhonghua Zhong Liu Za Zhi, V27, P25	47	70	74	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					225	235		10.1038/onc.2012.563	http://dx.doi.org/10.1038/onc.2012.563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318419	Green Accepted			2022-12-17	WOS:000329440700010
J	Louie, E; Chen, XF; Coomes, A; Ji, K; Tsirka, S; Chen, E				Louie, E.; Chen, X. F.; Coomes, A.; Ji, K.; Tsirka, S.; Chen, El			Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis	ONCOGENE			English	Article						breast cancer; brain metastasis; neurotrophin-3; protein signature; HER2 positive; HER2 signaling	CENTRAL-NERVOUS-SYSTEM; OF-THE-LITERATURE; CARCINOMA-CELLS; E-CADHERIN; FACTOR RECEPTOR-2; EXPRESSION; MODEL; TRANSITION; LUNG; OVEREXPRESSION	Metastasis, which remains incompletely characterized at the molecular and biochemical levels, is a highly specific process. Despite the ability of disseminated cancer cells to intravasate into distant tissues, it has been long recognized that only a limited subset of target organs develop clinically overt metastases. Therefore, subsequent adaptation of disseminated cancer cells to foreign tissue microenvironment determines the metastatic latency and tissue tropism of these cells. As a result, studying interactions between the disseminated cancer cells and the adjacent stromal cells will provide a better understanding of what constitutes a favorable or unfavorable microenvironment for disseminated cancer cells in a tissue-specific manner. Previously, we reported a protein signature of brain metastasis showing increased ability of brain metastatic breast cancer cells to counteract oxidative stress. In this study, we showed that another protein from the brain metastatic protein signature, neurotrophin-3 (NT-3), has a dual function of regulating the metastatic growth of metastatic breast cancer cells and reducing the activation of immune response in the brain. More importantly, increased NT-3 secretion in metastatic breast cancer cells results in a reversion of mesenchymal-like (EMT) state to epithelial-like (MET) state and vice versa. Ectopic expression of NT-3 in EMT-like breast cancer cells reduces their migratory ability and increases the expression of HER2 (human epidermal growth factor receptor 2) and E-cadherin at the cell-cell junction. In addition, both endogenous and ectopic expression of NT-3 reduced the number of fully activated cytotoxic microglia. In summary, NT-3 appears to promote growth of metastatic breast cancer cells in the brain by facilitating the re-epithelialization of metastatic breast cancer cells and downmodulating the cytotoxic response of microglia. Most importantly, our results provide new insights into the latency and development of central nervous system macrometastases in patients with HER2-positive breast tumors and provide mechanistic rationale to target HER2 signaling for HER2-positive breast cancer brain metastasis.	[Louie, E.; Chen, X. F.; Coomes, A.; Ji, K.; Tsirka, S.; Chen, El] SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Louie, E (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, BST 8-125, Stony Brook, NY 11794 USA.	emily@pharm.stonybrook.edu	Tsirka, Stella/AAD-4018-2019		Susan Komen Foundation; Mary Anita Conroy Memorial Breast Cancer Fund from the Manhasset Women's Coalition Against Breast Cancer;  [R01NS42168]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI091175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042168] Funding Source: NIH RePORTER	Susan Komen Foundation(Susan G. Komen Breast Cancer Foundation); Mary Anita Conroy Memorial Breast Cancer Fund from the Manhasset Women's Coalition Against Breast Cancer; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants to EIC from the Susan Komen Foundation and the Mary Anita Conroy Memorial Breast Cancer Fund from the Manhasset Women's Coalition Against Breast Cancer. S Tsirka and K Ji were supported by R01NS42168.	Adriaenssens E, 2008, CANCER RES, V68, P346, DOI 10.1158/0008-5472.CAN-07-1183; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; Cameron D, 2008, BREAST CANCER RES TR, V112, P533, DOI 10.1007/s10549-007-9885-0; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chaffer CL, 2005, CLIN EXP METASTAS, V22, P115, DOI 10.1007/s10585-005-5141-3; Chang EL, 2003, ONCOLOGIST, V8, P398, DOI 10.1634/theoncologist.8-5-398; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Choi YH, 2009, ANN ONCOL, V20, P1337, DOI 10.1093/annonc/mdp003; Descamps S, 2001, CANCER RES, V61, P4337; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fitzgerald DP, 2008, CLIN EXP METASTAS, V25, P799, DOI 10.1007/s10585-008-9193-z; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; He BP, 2006, MOL MED, V12, P161, DOI 10.2119/2006-00033.He; Hondermarck H, 2008, AM J PATHOL, V172, P865, DOI 10.2353/ajpath.2008.080008; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Jung S, 2002, J CANCER RES CLIN, V128, P469, DOI 10.1007/s00432-002-0366-x; Kim JW, 2004, CANCER LETT, V213, P203, DOI 10.1016/j.canlet.2004.03.042; Kirsch David G, 2005, Clin Breast Cancer, V6, P115, DOI 10.3816/CBC.2005.n.013; Klos KJ, 2004, NEUROLOGIST, V10, P31, DOI 10.1097/01.nrl.0000106922.83090.71; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kwon HC, ONKOLOGIE, V33, P146; Lin NU, 2008, J CLIN ONCOL, V26, P1993, DOI 10.1200/JCO.2007.12.3588; Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773; Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3; MacDonald IC, 2002, BIOESSAYS, V24, P885, DOI 10.1002/bies.10156; Matsumura H, 2000, BIOCHEM BIOPH RES CO, V269, P513, DOI 10.1006/bbrc.2000.2332; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Menon MB, 2009, CELL MOTIL CYTOSKEL, V66, P1041, DOI 10.1002/cm.20418; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Montel V, 2005, AM J PATHOL, V166, P1565, DOI 10.1016/S0002-9440(10)62372-3; Nathoo N, 2005, J CLIN PATHOL, V58, P237, DOI 10.1136/jcp.2003.013623; Ohno Shinji, 2004, Breast Cancer, V11, P27, DOI 10.1007/BF02967997; Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j.1471-4159.2003.02213.x; Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Piccirilli M, 2007, TUMORI, V93, P150; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Puduvalli V K, 2001, Curr Oncol Rep, V3, P467, DOI 10.1007/s11912-001-0067-7; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Tomasevic Z, 2009, J BUON, V14, P225; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215; Tzeng SF, 2005, J NEUROSCI RES, V81, P666, DOI 10.1002/jnr.20586; Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890; Vincan E, 2005, DIFFERENTIATION, V73, P142, DOI 10.1111/j.1432-0436.2005.00015.x; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; Yarrow JC, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-21; Yates CC, 2007, BRIT J CANCER, V96, P1246, DOI 10.1038/sj.bjc.6603700; Yonemori K, 2010, CANCER-AM CANCER SOC, V116, P302, DOI 10.1002/cncr.24735	54	70	70	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4064	4077		10.1038/onc.2012.417	http://dx.doi.org/10.1038/onc.2012.417			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23001042	Green Accepted			2022-12-17	WOS:000323748500002
J	Guerra, E; Trerotola, M; Aloisi, AL; Tripaldi, R; Vacca, G; La Sorda, R; Lattanzio, R; Piantelli, M; Alberti, S				Guerra, E.; Trerotola, M.; Aloisi, A. L.; Tripaldi, R.; Vacca, G.; La Sorda, R.; Lattanzio, R.; Piantelli, M.; Alberti, S.			The Trop-2 signalling network in cancer growth	ONCOGENE			English	Article						Trop-2; human tumours; cell growth; cell signalling	CELL-ADHESION MOLECULES; HUMAN CARCINOMAS; BREAST-CANCER; MESSENGER-RNA; FREE SURVIVAL; PH DOMAINS; CYCLIN D1; EP-CAM; GENE; TRANSCRIPTION	Our findings show that upregulation of a wild-type Trop-2 has a key controlling role in human cancer growth, and that tumour development is quantitatively driven by Trop-2 expression levels. However, little is known about the regulation of expression of the TROP2 gene. Hence, we investigated the TROP2 transcription control network. TROP2 expression was shown to depend on a highly interconnected web of transcription factors: TP63/TP53L, ERG, GRHL1/Get-1 (grainyhead-like epithelial transactivator), HNF1A/TCF-1 (T-cell factor), SPI1/PU.1, WT (Wilms' tumour) 1, GLIS2, AIRE (autoimmune regulator), FOXM1 (forkhead box M1) and FOXP3, with HNF4A as the major network hub. TROP2 upregulation was shown to subsequently drive the expression and activation of CREB1 (cyclic AMP-responsive-element binding protein), Jun, NF-kappa B, Rb, STAT1 and STAT3 through induction of the cyclin D1 and ERK (extracellular signal regulated kinase)/MEK (MAPK/ERK kinase) pathways. Growth-stimulatory signalling through NF-kappa B, cyclin D1 and ERK was shown to require an intact Trop-2 cytoplasmic tail. Network hubs and interacting partners are co-expressed with Trop-2 in primary human tumours, supporting a role of this signalling network in cancer growth. Oncogene (2013) 32, 1594-1600; doi:10.1038/onc.2012.151; published online 7 May 2012	[Guerra, E.; Trerotola, M.; Aloisi, A. L.; Tripaldi, R.; Vacca, G.; La Sorda, R.; Lattanzio, R.; Piantelli, M.; Alberti, S.] Fdn Univ G DAnnunzio, Dept Oncol & Expt Med, Unit Canc Pathol, Chieti, Italy; [Guerra, E.; Trerotola, M.; Aloisi, A. L.; Tripaldi, R.; Vacca, G.; La Sorda, R.; Lattanzio, R.; Piantelli, M.; Alberti, S.] Fdn Univ G DAnnunzio, CeSI, Chieti, Italy; [Alberti, S.] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Alberti, S (corresponding author), Fdn Univ G DAnnunzio, CeSI, Dept Oncol & Expt Med, Unit Canc Pathol, Via Colle Ara, I-66100 Chieti, Italy.	s.alberti@unich.it	Lattanzio, Rossano/K-1927-2018; Alberti, Saverio/M-4511-2014; Trerotola, Marco/J-9015-2016	Lattanzio, Rossano/0000-0001-9803-4476; Alberti, Saverio/0000-0002-4647-6042; Trerotola, Marco/0000-0003-1855-7002; Piantelli, Mauro/0000-0003-0154-482X; Guerra, Emanuela/0000-0002-7091-8621	Fondazione of the Cassa di Risparmio della Provincia di Chieti; ABO Foundation [CH01D0081]; Fondazione compagnia di San Paolo; Italian Ministry of Health [RicOncol RF-EMR-2006-361866]; Italian Foundation for Cancer Research (FIRC, Italy); Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Fondazione of the Cassa di Risparmio della Provincia di Chieti; ABO Foundation; Fondazione compagnia di San Paolo(Compagnia di San Paolo); Italian Ministry of Health(Ministry of Health, Italy); Italian Foundation for Cancer Research (FIRC, Italy)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This study was supported by the Fondazione of the Cassa di Risparmio della Provincia di Chieti, ABO Foundation (Grant CH01D0081), Fondazione compagnia di San Paolo, and the Italian Ministry of Health (RicOncol RF-EMR-2006-361866). MT was a recipient of a scholarship from the Italian Foundation for Cancer Research (FIRC, Italy).	Alberti S, 1999, PROTEINS, V35, P360; Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; ALBERTI S, 1988, P NATL ACAD SCI USA, V85, P8391, DOI 10.1073/pnas.85.22.8391; ALBERTI S, 1990, NUCLEIC ACIDS RES, V18, P351, DOI 10.1093/nar/18.2.351; ALBERTI S, 1992, HYBRIDOMA, V11, P539, DOI 10.1089/hyb.1992.11.539; Ambrogi F, 2006, CLIN CANCER RES, V12, P781, DOI 10.1158/1078-0432.CCR-05-0763; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Aplin AE, 1998, PHARMACOL REV, V50, P197; Attanasio M, 2007, NAT GENET, V39, P1018, DOI 10.1038/ng2072; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bienvenu F, 2005, MOL BIOL CELL, V16, P1850, DOI 10.1091/mbc.e04-08-0654; Biganzoli E, 2011, JPN J CLIN ONCOL, V41, P172, DOI 10.1093/jjco/hyq227; Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Calabrese G, 2001, CYTOGENET CELL GENET, V92, P164, DOI 10.1159/000056891; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; Cheng C, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-225; Chong JM, 2001, J BIOL CHEM, V276, P5804, DOI 10.1074/jbc.M008839200; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Cubas R, 2009, BBA-REV CANCER, V1796, P309, DOI 10.1016/j.bbcan.2009.08.001; El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; Guerra E, 2008, CANCER RES, V68, P8113, DOI 10.1158/0008-5472.CAN-07-6135; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Horiuchi K, 2006, P NATL ACAD SCI USA, V103, P17278, DOI 10.1073/pnas.0608357103; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LINNENBACH AJ, 1993, MOL CELL BIOL, V13, P1507, DOI 10.1128/MCB.13.3.1507; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Loeb DM, 2002, INT J HEMATOL, V76, P117, DOI 10.1007/BF02982573; Mangino G, 2002, INT J CANCER, V101, P353, DOI 10.1002/ijc.10616; Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102; Merlo A, 2009, J CLIN ONCOL, V27, P1746, DOI 10.1200/JCO.2008.17.9036; NAQUET P, 1989, THYMUS, V13, P217; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Peiro G, 2007, AM J CLIN PATHOL, V127, P780, DOI 10.1309/FWHEQX6HB9190LVY; Querzoli P, 2006, CLIN CANCER RES, V12, P6696, DOI 10.1158/1078-0432.CCR-06-0569; Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Siu YT, 2007, FEBS J, V274, P3224, DOI 10.1111/j.1742-4658.2007.05884.x; Su AI, 2001, CANCER RES, V61, P7388; Terrinoni A, 2001, GENE CHROMOSOME CANC, V31, P209, DOI 10.1002/gcc.1137; Tinari N, 2006, CLIN CANCER RES, V12, P1501, DOI 10.1158/1078-0432.CCR-05-0978; Trerotola M, 2013, ONCOGENE, V32, P222, DOI 10.1038/onc.2012.36; Trerotola M, 2010, BBA-REV CANCER, V1805, P119, DOI 10.1016/j.bbcan.2009.12.002; Varughese J, 2011, CANCER-AM CANCER SOC, V117, P3163, DOI 10.1002/cncr.25891; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Yu ZQ, 2006, DEV BIOL, V299, P122, DOI 10.1016/j.ydbio.2006.07.015; Yuan L, 2009, CIRC RES, V104, P1049, DOI 10.1161/CIRCRESAHA.108.190751; Zanna P, 2007, CANCER-AM CANCER SOC, V110, P452, DOI 10.1002/cncr.22785; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	55	70	79	5	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1594	1600		10.1038/onc.2012.151	http://dx.doi.org/10.1038/onc.2012.151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22562244				2022-12-17	WOS:000316456000012
J	Yigit, MV; Ghosh, SK; Kumar, M; Petkova, V; Kavishwar, A; Moore, A; Medarova, Z				Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Petkova, V.; Kavishwar, A.; Moore, A.; Medarova, Z.			Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis	ONCOGENE			English	Article						imaging; miRNA; metastasis; miR-10b; nanoparticle; therapy	SUPERPARAMAGNETIC IRON-OXIDE; CANCER; MICRORNA; THERAPEUTICS; LNA	Metastases, and not the primary tumor from which they originate, are the main reason for mortality from carcinoma. Although the molecular mechanisms behind metastasis are poorly understood, it is clear that epigenetic dysregulation at the level of microRNA expression is a key characteristic of the metastatic process that can be exploited for therapy. Here, we describe an miRNA-targeted therapeutic approach for the prevention and arrest of lymph node metastasis. Therapy relies on the inhibition of the pro-metastatic microRNA-10b. It is delivered to primary and lymph node metastatic tumor cells using an imaging-capable nanodrug that is designed to specifically home to these tissues. Treatment of invasive human breast tumor cells (MDA-MB-231) with the nanodrug in vitro downregulates miR-10b and abolishes the invasion and migration of the tumor cells. After intravenous delivery to mice bearing orthotopic MDA-MB-231-luc-D3H2LN tumors, the nanodrug accumulates in the primary tumor and lymph nodes. When treatment is initiated before metastasis to lymph nodes, metastasis is prevented. Treatment after the formation of lymph node metastases arrests the metastatic process without a concomitant effect on primary tumor growth raising the possibility of a context-dependent variation in miR-10b breast oncogenesis. Oncogene (2013) 32, 1530-1538; doi:10.1038/onc.2012.173; published online 14 May 2012	[Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Kavishwar, A.; Moore, A.; Medarova, Z.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Mol Imaging Lab, Dept Radiol, Charlestown, MA USA; [Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Kavishwar, A.; Moore, A.; Medarova, Z.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Petkova, V.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Moore, A (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Mol Imaging Lab,MGH MIT HMS Athinoula, Bldg 75,13th St, Charlestown, MA 02129 USA.	amoore@helix.mgh.harvard.edu; zmedarova@partners.org		Kavishwar, Amol/0000-0001-8214-6625	National Cancer Institute [R00CA129070]; Breast Cancer Alliance; NATIONAL CANCER INSTITUTE [R00CA129070, R01CA163461] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR025504] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Alliance; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Pamela Pantazopoulos and Alana Ross for help with the in-vitro, in-vivo and ex-vivo studies and Marytheresa Ifediba for proofreading the manuscript. Confocal microscopy was performed at the Confocal Microscopy Core at MGH with technical assistance from Igor A Bagayev, MS Work at the Martinos Center for Biomedical Imaging was supported in part under Grant R00CA129070 from the National Cancer Institute and a Research Grant from the Breast Cancer Alliance.	Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Beer AJ, 2008, J NUCL MED, V49, P255, DOI 10.2967/jnumed.107.045526; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Gabriely G, 2011, AUTOPHAGY, V7, P1384, DOI 10.4161/auto.7.11.17371; Gabriely G, 2011, CANCER RES, V71, P3563, DOI 10.1158/0008-5472.CAN-10-3568; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Jepsen JS, 2004, OLIGONUCLEOTIDES, V14, P130, DOI 10.1089/1545457041526317; Kenny LM, 2008, J NUCL MED, V49, P879, DOI 10.2967/jnumed.107.049452; Kumar M, 2010, CANCER RES, V70, P7553, DOI 10.1158/0008-5472.CAN-10-2070; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Medarova Z, 2006, NAT PROTOC, V1, P429, DOI 10.1038/nprot.2006.63; Medarova Z, 2007, NAT MED, V13, P372, DOI 10.1038/nm1486; Medarova Z, 2009, CANCER RES, V69, P1182, DOI 10.1158/0008-5472.CAN-08-2001; Michel SCA, 2002, RADIOLOGY, V225, P527, DOI 10.1148/radiol.2252011605; Nathanson SD, 2009, ANN SURG ONCOL, V16, P3396, DOI 10.1245/s10434-009-0659-2; Petersen M, 2003, TRENDS BIOTECHNOL, V21, P74, DOI 10.1016/S0167-7799(02)00038-0; WEISSLEDER R, 1990, RADIOLOGY, V175, P494, DOI 10.1148/radiology.175.2.2326475; Xiang X, 2011, ONCOGENE, V30, P3440, DOI 10.1038/onc.2011.54; Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008-5472.CAN-06-4499	26	70	71	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1530	1538		10.1038/onc.2012.173	http://dx.doi.org/10.1038/onc.2012.173			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580603	Green Accepted			2022-12-17	WOS:000316456000006
J	Schonerr, C; Ruuth, K; Kamaraj, S; Wang, CL; Yang, HL; Combaret, V; Djos, A; Martinsson, T; Christensen, JG; Palmer, RH; Hallberg, B				Schonerr, C.; Ruuth, K.; Kamaraj, S.; Wang, C-L; Yang, H-L; Combaret, V.; Djos, A.; Martinsson, T.; Christensen, J. G.; Palmer, R. H.; Hallberg, B.			Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; anaplastic lymphoma kinase; ALK; MYCN; transcription factor	N-MYC; TYROSINE KINASE; ACTIVATING MUTATIONS; LUNG-CANCER; C-MET; EXPRESSION; INHIBITOR; PROTEIN; CRIZOTINIB; RECEPTOR	Neuroblastoma is a neural crest-derived embryonal tumour of the postganglionic sympathetic nervous system and a disease with several different chromosomal gains and losses, which include MYCN-amplified neuroblastoma on chromosome 2, deletions of parts of the chromosomes 1p and 11q, gain of parts of 17q and triploidy. Recently, activating mutations of the ALK (Anaplastic Lymphoma Kinase) RTK (Receptor Tyrosine Kinase) gene have been described in neuroblastoma. A meta-analysis of neuroblastoma cases revealed that ALK mutations (49 of 709 cases) in relation to genomic subtype were most frequently observed in MYCN amplified tumours (8.9%), correlating with a poor clinical outcome. MYCN proteins target proliferation and apoptotic pathways, and have an important role in the progression of neuroblastoma. Here, we show that both wild-type and gain-of-function mutants in ALK are able to stimulate transcription at the MYCN promoter and initiate mRNA transcription of the MYCN gene in both neuronal and neuroblastoma cell lines. Further, this stimulation of MYCN gene transcription and de novo MYCN protein expression is abrogated by specific ALK inhibitors, such as crizotinib (PF-2341066), NVP-TAE684, and by small interfering RNA to ALK resulting in a decrease in proliferation rate. Finally, co-transfection of ALK gain-of-function mutations together with MYCN leads to an increase in transformation potential. Taken together, our results indicate that ALK signalling regulates initiation of transcription of the MYCN gene providing a possible explanation for the poor clinical outcome observed when MYCN is amplified together with activated ALK. Oncogene (2012) 31, 5193 - 5200; doi:10.1038/onc.2012.12; published online 30 January 2012	[Schonerr, C.; Ruuth, K.; Kamaraj, S.; Palmer, R. H.; Hallberg, B.] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden; [Wang, C-L; Yang, H-L] Beijing Forestry Univ, Coll Life Sci & Biotechnol, Beijing, Peoples R China; [Combaret, V.] Ctr Leon Berard, FNCLCC, Lab Rech Translat, F-69373 Lyon, France; [Djos, A.; Martinsson, T.] Univ Gothenburg, Dept Clin Genet, Gothenburg, Sweden; [Christensen, J. G.] La Jolla Labs, Global Res & Dev, Dept Res Pharmacol, La Jolla, CA USA	Umea University; Beijing Forestry University; UNICANCER; Centre Leon Berard; University of Gothenburg	Palmer, RH (corresponding author), Umea Univ, Dept Mol Biol, Bldg 6L, S-90187 Umea, Sweden.	Ruth.Palmer@molbiol.umu.se; Bengt.Hallberg@molbiol.umu.se	Martinsson, Tommy/J-4140-2013; sattu, kamaraj/L-7247-2015	Martinsson, Tommy/0000-0002-9403-3123; sattu, kamaraj/0000-0002-3559-8423; Djos, Anna/0000-0002-5250-2163	Swedish Cancer Society [BH 08-0597]; Children's Cancer Foundation [BH 08/084, RHP 08/074]; Swedish Research Council [RHP 621-2003-3399]; Lions Cancer Society; Association for International Cancer Research [RHP 08-0177]; Umea	Swedish Cancer Society(Swedish Cancer Society); Children's Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Lions Cancer Society; Association for International Cancer Research; Umea	We thank Marc Vigny and Arturo Sala for support and the pGL2-N-myc-luc plasmid, respectively. Crizotinib was a generous gift from Pfizer and the neuroblastoma cell lines were from Valerie Combaret, Centre Leon Berard, France under MTA. This work has been supported by grants from the Swedish Cancer Society (BH 08-0597), the Children's Cancer Foundation (BH 08/084; RHP 08/074), the Swedish Research Council (RHP 621-2003-3399), Lions Cancer Society, Umea, Association for International Cancer Research (RHP 08-0177). SK is a Children's Cancer Foundation fellow (NBCNSPDHEL09/002). RHP is a Swedish Cancer Foundation Research Fellow.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Berthier A, 2011, HUM PATHOL, V42, P301, DOI 10.1016/j.humpath.2010.07.024; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brognard J, 2011, CURR OPIN GENET DEV, V21, P4, DOI 10.1016/j.gde.2010.10.012; Butrynski JE, 2010, NEW ENGL J MED, V363, P1727, DOI 10.1056/NEJMoa1007056; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365; COMBARET V, 1995, INT J CANCER, V61, P185, DOI 10.1002/ijc.2910610208; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Goodman LA, 1997, CLIN EXP METASTAS, V15, P130, DOI 10.1023/A:1018448710006; Gualdrini F, 2010, ONCOTARGET, V1, P278; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Hallberg Bengt, 2011, F1000 Med Rep, V3, P21, DOI 10.3410/M3-21; Hallberg B, 2010, NEW ENGL J MED, V363, P1760, DOI 10.1056/NEJMe1010404; Hatzi E, 2000, ADV EXP MED BIOL, V476, P239; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li YJ, 2011, NEOPLASIA, V13, P1, DOI 10.1593/neo.101120; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Martinsson T, 2011, CANCER RES, V71, P98, DOI 10.1158/0008-5472.CAN-10-2366; Michels E, 2007, GENE CHROMOSOME CANC, V46, P1098, DOI 10.1002/gcc.20496; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Schonherr C, 2010, ONCOGENE, V29, P2817, DOI 10.1038/onc.2010.27; Schonherr C, 2011, BIOCHEM J, V440, P405, DOI 10.1042/BJ20101796; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Tartari CJ, 2008, J BIOL CHEM, V283, P3743, DOI 10.1074/jbc.M706067200; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Yang HL, 2007, J EXP ZOOL PART B, V308B, P269, DOI 10.1002/jez.b.21146; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	49	70	70	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	50					5193	5200		10.1038/onc.2012.12	http://dx.doi.org/10.1038/onc.2012.12			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22286764				2022-12-17	WOS:000312449800008
J	Munro, S; Carr, SM; La Thangue, NB				Munro, S.; Carr, S. M.; La Thangue, N. B.			Diversity within the pRb pathway: is there a code of conduct?	ONCOGENE			English	Review						pRb; E2F-1; phosphorylation; acetylation; methylation	RETINOBLASTOMA TUMOR-SUPPRESSOR; CYCLIN-DEPENDENT KINASES; DNA-DAMAGE; CELL-CYCLE; LYSINE METHYLATION; KERATINOCYTE DIFFERENTIATION; E2F1-INDUCED APOPTOSIS; HISTONE METHYLATION; DOCKING SITE; PROTEIN PRB	The failure of cell proliferation to be properly regulated is a hallmark of tumourigenesis. The retinoblastoma protein (pRb) pathway represents a key component in the regulation of the cell cycle and tumour suppression. Recent findings have revealed new levels of complexity reflecting a repertoire of post-translational modifications that occur on pRb together with its key effector E2F-1. Here we provide an overview of the modifications and consider the possibility of a 'code' that endows pRb with the ability to function in diverse physiological settings. Oncogene (2012) 31, 4343-4352; doi: 10.1038/onc.2011.603; published online 16 January 2012	[Munro, S.; Carr, S. M.; La Thangue, N. B.] Univ Oxford, Canc Biol Lab, Dept Oncol, Div Med Sci, Oxford OX3 7DQ, England	University of Oxford	La Thangue, NB (corresponding author), Univ Oxford, Canc Biol Lab, Dept Oncol, Div Med Sci, Old Rd Campus Res Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.	nick.lathangue@clinpharm.ox.ac.uk			CRUK; MRC; LRF; EU; AICR; MRC [G1000807] Funding Source: UKRI; Medical Research Council [G1000807] Funding Source: researchfish	CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); LRF; EU(European Commission); AICR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from CRUK, MRC, LRF, EU and AICR.	Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bonasio R, 2010, SEMIN CELL DEV BIOL, V21, P221, DOI 10.1016/j.semcdb.2009.09.010; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Carr SM, 2011, EMBO J, V30, P317, DOI 10.1038/emboj.2010.311; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Delston RB, 2011, ONCOGENE, V30, P588, DOI 10.1038/onc.2010.442; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Fang YJ, 2011, CANCER LETT, V306, P10, DOI 10.1016/j.canlet.2011.02.019; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Gorges LL, 2008, AM J PHYSIOL-CELL PH, V295, pC1151, DOI 10.1152/ajpcell.00300.2008; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Hirschi A, 2010, NAT STRUCT MOL BIOL, V17, P1051, DOI 10.1038/nsmb.1868; Inoue Y, 2007, EMBO J, V26, P2083, DOI 10.1038/sj.emboj.7601652; Ivanova IA, 2009, ONCOGENE, V28, P52, DOI 10.1038/onc.2008.354; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Lents NH, 2006, CELL CYCLE, V5, P1699, DOI 10.4161/cc.5.15.3126; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Longworth MS, 2010, CHROMOSOMA, V119, P1, DOI 10.1007/s00412-009-0238-0; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Markham D, 2006, EMBO REP, V7, P192, DOI 10.1038/sj.embor.7400591; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Min JR, 2007, NAT STRUCT MOL BIOL, V14, P1229, DOI 10.1038/nsmb1340; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pickard A, 2010, J CELL SCI, V123, P3718, DOI 10.1242/jcs.068924; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612; Sahin F, 2010, INT J BIOL SCI, V6, P382; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2000, CANCER RES, V60, P3689; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yeste-Velasco M, 2009, NEUROCHEM INT, V54, P99, DOI 10.1016/j.neuint.2008.10.004; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814	94	70	73	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4343	4352		10.1038/onc.2011.603	http://dx.doi.org/10.1038/onc.2011.603			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249267				2022-12-17	WOS:000309591300001
J	Li, W; Melton, DW				Li, W.; Melton, D. W.			Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance	ONCOGENE			English	Article						chemotherapy; DNA damage; DUSP6 phosphatase; nucleotide excision repair; XPF	NUCLEOTIDE EXCISION-REPAIR; ACTIVATED PROTEIN-KINASES; OVARIAN-CANCER CELLS; SIGNALING PATHWAY; OXIDATIVE STRESS; RESISTANCE; INHIBITION; APOPTOSIS; PHOSPHATASES; GROWTH	The incidence of malignant melanoma is growing rapidly worldwide and there is still no effective therapy for metastatic disease. Melanoma is the second most common cancer among young adults in the UK, where incidence rates have more than quadrupled since the 1970s. Increased expression of a number of DNA repair genes has been reported in melanoma and this likely contributes to its extreme resistance to conventional DNA-damaging chemotherapeutics. One such chemotherapeutic that is effective against a range of other cancers, but not melanoma, is cisplatin. The DNA repair proteins ERCC1 and XPF are needed to remove cisplatin-induced DNA damage and we have investigated the response of these proteins to cisplatin in melanoma. The expression of both genes is induced by cisplatin. Use of a MEK inhibitor showed that ERCC1, but not XPF induction was regulated by the mitogen-activated protein kinase (MAPK) pathway, with reduction in expression of DUSP6, the phosphatase that inactivates the extracellular signal-regulated kinase (ERK), being particularly important. DUSP6 overexpression prevented cisplatin induction of both ERCC1 and XPF, resulting in increased sensitivity to cisplatin. A novel ERCC1 mRNA was found that initiated upstream of the normal transcription initiation site, and was strongly regulated by both cisplatin and the MAPK pathway and its role in cisplatin resistance merits further study. The cisplatin induction of ERCC1 and XPF provides important insights into the resistance of melanoma to DNA-damaging chemotherapeutics, which is one of the major obstacles to melanoma treatment. Oncogene (2012) 31, 2412-2422; doi: 10.1038/onc.2011.426; published online 26 September 2011	[Li, W.; Melton, D. W.] Univ Edinburgh, Inst Genet & Mol Med, Western Gen Hosp, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Inst Genet & Mol Med, Western Gen Hosp, MRC Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	David.Melton@ed.ac.uk		li, weiling/0000-0001-6681-9156	China Scholarship Council/University of Edinburgh; Charon Fund	China Scholarship Council/University of Edinburgh(China Scholarship Council); Charon Fund	The cisplatin colony-forming assay was carried out by Ann-Marie Ritchie. We are grateful to Professor Toru Furukawa (Tohoku University School of Medicine, Japan), who kindly provided the DUSP6 plasmid. WL was supported by a China Scholarship Council/University of Edinburgh Scholarship. This work was supported by the Charon Fund.	Agar N, 2005, MUTAT RES-FUND MOL M, V571, P121, DOI 10.1016/j.mrfmmm.2004.11.016; Andrieux LO, 2007, CANCER RES, V67, P2114, DOI 10.1158/0008-5472.CAN-06-3821; Bermudez O, 2010, AM J PHYSIOL-CELL PH, V299, pC189, DOI 10.1152/ajpcell.00347.2009; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Cancer Research UK, 2020, PANCR CANC STAT CANC, P1; Chan DW, 2008, CARCINOGENESIS, V29, P1742, DOI 10.1093/carcin/bgn167; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chapman PB, 1999, J CLIN ONCOL, V17, P2745, DOI 10.1200/JCO.1999.17.9.2745; Ciuffreda L, 2009, NEOPLASIA, V11, P720, DOI 10.1593/neo.09398; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Gozdz A, 2008, J NEUROCHEM, V106, P2056, DOI 10.1111/j.1471-4159.2008.05550.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Jansen B, 1997, CANCER RES, V57, P362; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kauffmann A, 2008, ONCOGENE, V27, P565, DOI 10.1038/sj.onc.1210700; Kirschner K, 2010, ANTICANCER RES, V30, P3223; Ko JC, 2010, BIOCHEM PHARMACOL, V79, P655, DOI 10.1016/j.bcp.2009.09.024; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Lee-Kwon W, 1998, BIOCHEM J, V331, P591, DOI 10.1042/bj3310591; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Mirmohammadsadegh A, 2007, J INVEST DERMATOL, V127, P2207, DOI 10.1038/sj.jid.5700870; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oliveria SA, 2006, ARCH DIS CHILD, V91, P131, DOI 10.1136/adc.2005.086918; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Rosell Rafael, 2003, Cancer Control, V10, P297; Selfridge J, 2010, DNA REPAIR, V9, P653, DOI 10.1016/j.dnarep.2010.02.018; Shahzad MMK, 2009, DRUG RESIST UPDATE, V12, P148, DOI 10.1016/j.drup.2009.09.001; Song L, 2011, TRANSGENIC RES, V20, P109, DOI 10.1007/s11248-010-9396-3; Stecca C, 1998, BIOCHEM PHARMACOL, V55, P941, DOI 10.1016/S0006-2952(97)00448-6; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; VANDUIN M, 1987, NUCLEIC ACIDS RES, V15, P9195, DOI 10.1093/nar/15.22.9195; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Welsh C, 2004, INT J CANCER, V110, P352, DOI 10.1002/ijc.20134; Winter AG, 2005, ONCOGENE, V24, P2110, DOI 10.1038/sj.onc.1208400; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yacoub A, 2003, RADIAT RES, V159, P439, DOI 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2	51	70	72	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	19					2412	2422		10.1038/onc.2011.426	http://dx.doi.org/10.1038/onc.2011.426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996734				2022-12-17	WOS:000303985300004
J	Wang, Y; Romigh, T; He, X; Tan, MH; Orloff, MS; Silverman, RH; Heston, WD; Eng, C				Wang, Y.; Romigh, T.; He, X.; Tan, M-H; Orloff, M. S.; Silverman, R. H.; Heston, W. D.; Eng, C.			Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers	ONCOGENE			English	Article						androgen receptor; PTEN; prostate cancer; breast cancer; Cowden syndrome	TUMOR-SUPPRESSOR; PHOSPHOINOSITOL-3-KINASE/AKT PATHWAY; TRANSCRIPTIONAL ACTIVITY; 3-KINASE/AKT PATHWAY; PROMOTER MUTATIONS; CELL-PROLIFERATION; COWDEN-DISEASE; GENE; AKT; COACTIVATOR	Prostate cancer and breast cancer are the most common malignancies in the western world. Androgen receptor (AR) and PTEN both have been well documented to have important roles in prostate carcinogenesis. In contrast, AR and PTEN in breast carcinogenesis have not been well studied. Furthermore, the crosstalk and connection between those two pathways remain unclear. Increased AR expression in prostate cancers, combined with decreased PTEN expression, portends a poor clinical outcome. Paradoxically, both high AR and high PTEN levels, detected by immunohistochemistry, in primary breast carcinomas have been associated with better disease-free survival. Here, we performed in silico analysis of publicly available microarray data sets from prostate or breast carcinomas. We found an inverse correlation between AR and PTEN transcript expression in prostate cancer tissues in contrast to the positive correlation in breast cancer. These data led us to hypothesize that AR may directly affect PTEN transcriptional regulation in prostate and breast cancer cells. Here, we show for the first time that AR inhibits PTEN transcription in prostate cancer cells, whereas AR upregulates PTEN transcription in breast cancer cells, which mechanistically explains both the immunohistochemical PTEN-AR expressional data noted in clinical trials and in our in silico analysis of the transcriptomes of breast and prostate cancers. In addition, we have fine-mapped the AR-binding motif within the PTEN promoter. Here we show that, in patients with Cowden syndrome, an inherited cancer syndrome caused by germline mutations scattered throughout PTEN, point variants affecting the 30 end of the AR-binding motif result in abrogation of androgen-mediated transcriptional regulation of PTEN expression. We may speculate that the differential AR effect on PTEN may begin to explain organ-specific and perhaps sex-specific neoplasia predisposition in Cowden syndrome, as well as why only a fraction of women with germline PTEN mutations develop breast cancer, depending on the androgen steroid milieu and levels. Oncogene (2011) 30, 4327-4338; doi: 10.1038/onc.2011.144; published online 2 May 2011	[Wang, Y.; Romigh, T.; He, X.; Tan, M-H; Orloff, M. S.; Eng, C.] Cleveland Clin, Genom Med Inst, Lerner Res Inst, Cleveland, OH 44195 USA; [Orloff, M. S.; Silverman, R. H.; Heston, W. D.; Eng, C.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA; [Silverman, R. H.; Heston, W. D.] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; [Silverman, R. H.; Heston, W. D.; Eng, C.] Case Western Reserve Univ, Sch Med, CASE Comprehens Canc Ctr, Cleveland, OH USA; [Eng, C.] Cleveland Clin, Stanley Shalom Zielony Inst Nursing Excellence, Cleveland, OH 44195 USA; [Eng, C.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University	Eng, C (corresponding author), Cleveland Clin, Genom Med Inst, Lerner Res Inst, 9500 Euclid Ave,Mailcode NE-50, Cleveland, OH 44195 USA.	engc@ccf.org	Tan, Min Han/D-9205-2014; he, xin/C-3122-2011; WANG, YU/E-4655-2013	Tan, Min Han/0000-0002-0644-3457; Eng, Charis/0000-0002-3693-5145	William Randolph Hearst Foundations; Susan G Komen for the Cure Breast Cancer Research Foundation; FM Kirby Foundation	William Randolph Hearst Foundations; Susan G Komen for the Cure Breast Cancer Research Foundation(Susan G. Komen Breast Cancer Foundation); FM Kirby Foundation	We are grateful to Dr George Stark for critical review of manuscript drafts and for helpful discussions. This work was supported, in part, by the William Randolph Hearst Foundations and Susan G Komen for the Cure Breast Cancer Research Foundation. CE is the Sondra J and Stephen R Hardis Chair of Cancer Genomic Medicine at the Cleveland Clinic, was a Doris Duke Distinguished Clinical Scientist and is an American Cancer Society Clinical Research Professor, generously funded, in part, by the FM Kirby Foundation.	Agoff SN, 2003, AM J CLIN PATHOL, V120, P725, DOI 10.1309/42F00D0DJD0J5EDT; Agrawal S, 2005, HUM MOL GENET, V14, P2459, DOI 10.1093/hmg/ddi246; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bedolla R, 2007, CLIN CANCER RES, V13, P3860, DOI 10.1158/1078-0432.CCR-07-0091; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; Ihaka S., 1996, J COMPUT GRAPH STAT, V5, P299; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Mikhailova M, 2008, ADV EXP MED BIOL, V617, P397, DOI 10.1007/978-0-387-69080-3_38; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nan B, 2003, J MOL ENDOCRINOL, V31, P169, DOI 10.1677/jme.0.0310169; Ogawa Y, 2008, INT J CLIN ONCOL, V13, P431, DOI 10.1007/s10147-008-0770-6; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Sircar K, 2009, J PATHOL, V218, P505, DOI 10.1002/path.2559; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Teresi RE, 2008, HUM MOL GENET, V17, P919, DOI 10.1093/hmg/ddm364; Teresi RE, 2007, AM J HUM GENET, V81, P756, DOI 10.1086/521051; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang Y, 2008, ONCOGENE, V27, P7106, DOI 10.1038/onc.2008.318; Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248; Wen Y, 2000, CANCER RES, V60, P6841; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109	36	70	71	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4327	4338		10.1038/onc.2011.144	http://dx.doi.org/10.1038/onc.2011.144			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21532617				2022-12-17	WOS:000296356400004
J	Burnier, JV; Wang, N; Michel, RP; Hassanain, M; Li, S; Lu, Y; Metrakos, P; Antecka, E; Burnier, MN; Ponton, A; Gallinger, S; Brodt, P				Burnier, J. V.; Wang, N.; Michel, R. P.; Hassanain, M.; Li, S.; Lu, Y.; Metrakos, P.; Antecka, E.; Burnier, M. N.; Ponton, A.; Gallinger, S.; Brodt, P.			Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis	ONCOGENE			English	Article						metastasis; liver; extracellular matrix; collagen IV; anoikis	FOCAL ADHESION KINASE; PANCREATIC ADENOCARCINOMA CELLS; MEMBRANE PROTEINS PLAY; VON-HIPPEL-LINDAU; BASEMENT-MEMBRANE; FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; COLORECTAL-CANCER; CARCINOMA-CELLS; TUMOR-METASTASIS	The liver is a major site of metastasis for human malignancies, yet the factors that regulate tumor cell survival and growth in this organ remain elusive. Previously, we reported that M-27(IGF-IR) murine lung carcinoma cells with ectopic insulin-like growth factor-1 (IGF-I) receptor overexpression acquired a site-specific, liver-metastasizing potential. Gene expression profiling and subsequent RNA and protein analyses revealed that this was associated with major changes to the expression of extracellular matrix (ECM) protein-encoding genes including type III, IV and XVIII collagen genes, and these changes were also observed in the respective tumors in vivo. Because type IV collagen was the most prominently altered ECM protein in this model, we further analyzed its functional relevance to liver metastasis. M-27 cells stably overexpressing type IV collagen alpha 1 and alpha 2 chains were generated and their growth and metastatic properties investigated. We found that these cells acquired a site-selective growth advantage in the liver and this was associated with cell rescue from anoikis in a collagen IV/alpha 2 integrin/FAK-dependent manner and increased responsiveness to IGF-I. Conversely, collagen IV or focal adhesion kinase (FAK) silencing by small-interfering RNA in highly metastatic tumor cells enhanced anoikis and decreased liver metastases formation. Moreover, analysis of human surgical specimens revealed uniformly high collagen IV expression in 65/65 hepatic metastases analyzed, regardless of tissue of origin, whereas it was variable and generally low in 50/50 primary colorectal carcinoma specimens examined. The results suggest that collagen IV-conveyed signals are essential cues for liver metastasis in diverse tumor types and identify mediators of collagen IV signaling as potential therapeutic targets in the management of hepatic metastases. Oncogene (2011) 30, 3766-3783; doi:10.1038/onc.2011.89; published online 11 April 2011	[Burnier, J. V.; Wang, N.; Hassanain, M.; Li, S.; Lu, Y.; Metrakos, P.; Burnier, M. N.; Brodt, P.] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; [Wang, N.; Hassanain, M.; Lu, Y.; Metrakos, P.; Brodt, P.] McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; [Michel, R. P.; Antecka, E.; Burnier, M. N.] McGill Univ, Dept Surg, Montreal, PQ H3A 1A1, Canada; [Michel, R. P.; Burnier, M. N.; Brodt, P.] McGill Univ, Dept Pathol, Montreal, PQ H3A 1A1, Canada; [Burnier, M. N.] McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; [Ponton, A.] McGill Univ, Dept Ophthalmol, Montreal, PQ H3A 1A1, Canada; [Gallinger, S.] Univ Hlth Network Toronto, Mt Sinai Hosp, Dept Surg, Toronto, ON, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University Health Network Toronto	Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Room H6-25,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	pnina.brodt@mcgill.ca	metrakos, peter/D-3726-2013; Hassanain, Mazen/C-7256-2011; Gallinger, Steven/E-4575-2013	Hassanain, Mazen/0000-0002-2441-5142; burnier, julia/0000-0002-2184-2157	Canadian Institute for Health Research [MOP-81201]; Research Institute of the McGill University Health Center; Stewart family award for Cancer Research	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Research Institute of the McGill University Health Center; Stewart family award for Cancer Research	We thank Dr Zelia Correa (Department of Ophthalmology, University of Cincinnati) for the kind gift of the uveal melanoma specimens, Dr Yoshihiko Yamada for collagen IV alpha 1 and alpha 2 plasmids, Dr Taina Pihlajaniemi for antibodies to collagen XVIII and Ms Boram Ham for her help with the submission. This work was supported by Grant MOP-81201 from the Canadian Institute for Health Research (to PB). JVB was supported by a doctoral fellowship from the Research Institute of the McGill University Health Center and PB is a recipient of the Stewart family award for Cancer Research.	All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; Andersson S, 2009, BIOCHEM BIOPH RES CO, V387, P36, DOI 10.1016/j.bbrc.2009.06.088; BARSKY SH, 1983, LANCET, V1, P296; Beattie J, 2010, J CELL PHYSIOL, V224, P605, DOI 10.1002/jcp.22183; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brooks SA, 2010, ACTA HISTOCHEM, V112, P3, DOI 10.1016/j.acthis.2008.11.022; Catusse C, 2000, J HISTOCHEM CYTOCHEM, V48, P663, DOI 10.1177/002215540004800510; Clark RAF, 2008, J INVEST DERMATOL, V128, P1354, DOI 10.1038/jid.2008.75; Clemmons DR, 2003, ENDOCRINOLOGY, V144, P1664, DOI 10.1210/en.2002-221102; Decker NK, 2008, AM J PATHOL, V173, P1002, DOI 10.2353/ajpath.2008.080158; Duxbury MS, 2004, SURGERY, V135, P555, DOI 10.1016/j.surg.2003.10.017; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Edderkaoui M, 2007, J BIOL CHEM, V282, P26646, DOI 10.1074/jbc.M702836200; Enns AE, 2004, J GASTROINTEST SURG, V8, P1049, DOI 10.1016/j.gassur.2004.08.016; ERIN N, 2009, INT J CANCER, V124, P14; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; FENYVESI A, 2003, ARCH ONCOL, V11, P15; Furukawa M, 2005, CLIN CANCER RES, V11, P3233, DOI 10.1158/1078-0432.CCR-04-1915; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Goel HL, 2005, CANCER RES, V65, P6692, DOI 10.1158/0008-5472.CAN-04-4315; Goel HL, 2004, J CELL BIOL, V166, P407, DOI 10.1083/jcb.200403003; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Gulubova MV, 2004, CLIN EXP METASTAS, V21, P485, DOI 10.1007/s10585-004-3171-x; Gydee H, 2004, PEDIATR RES, V55, P709, DOI 10.1203/01.PDR.0000111282.98401.93; Habeck M, 2001, DRUG DISCOV TODAY, V6, P1077, DOI 10.1016/S1359-6446(01)02023-2; HAVENITH MG, 1988, CANCER-AM CANCER SOC, V62, P2207, DOI 10.1002/1097-0142(19881115)62:10<2207::AID-CNCR2820621023>3.0.CO;2-L; Hiki Y, 2002, PATHOL INT, V52, P224, DOI 10.1046/j.1440-1827.2002.01341.x; Iglesias-de la Cruz MC, 2002, KIDNEY INT, V62, P901, DOI 10.1046/j.1523-1755.2002.00528.x; Ikeda K, 2006, AM J PATHOL, V168, P856, DOI 10.2353/ajpath.2006.050384; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jeschke MG, 2005, WOUND REPAIR REGEN, V13, P269, DOI 10.1111/j.1067-1927.2005.130309.x; Kahana O, 2002, ONCOGENE, V21, P3969, DOI 10.1038/sj.onc.1205472; Khoshnoodi J, 2008, MICROSC RES TECHNIQ, V71, P357, DOI 10.1002/jemt.20564; Krensel K, 1999, INT J CANCER, V80, P546, DOI 10.1002/(SICI)1097-0215(19990209)80:4<546::AID-IJC11>3.0.CO;2-9; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Liu GY, 2008, CELL BIOL INT, V32, P663, DOI 10.1016/j.cellbi.2008.01.292; Liu WG, 2008, CARCINOGENESIS, V29, P1096, DOI 10.1093/carcin/bgn026; LONG L, 1995, CANCER RES, V55, P1006; Macri L, 2007, ADV DRUG DELIVER REV, V59, P1366, DOI 10.1016/j.addr.2007.08.015; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; Meir T, 2007, INVEST OPHTH VIS SCI, V48, P4890, DOI 10.1167/iovs.07-0215; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Miyamoto S, 2008, ADV EXP MED BIOL, V622, P281, DOI 10.1007/978-0-387-68969-2_23; Nadal C, 2007, WORLD J GASTROENTERO, V13, P5832, DOI 10.3748/wjg.v13.i44.5832; Nakano S, 1999, LAB INVEST, V79, P281; Neubauer K, 2001, CAN J GASTROENTEROL, V15, P187, DOI 10.1155/2001/870205; Oshima T, 2008, ONCOL REP, V20, P359, DOI 10.3892/or_00000015; PAGET S, 1989, CANCER METAST REV, V8, P98; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; Rosenow Felix, 2008, Neoplasia, V10, P168, DOI 10.1593/neo.07898; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Samani AA, 2004, CANCER RES, V64, P3380, DOI 10.1158/0008-5472.CAN-03-3780; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Sawai H, 2008, J SURG RES, V144, P117, DOI 10.1016/j.jss.2007.03.023; SCHAPERS RFM, 1990, CANCER, V66, P2583, DOI 10.1002/1097-0142(19901215)66:12<2583::AID-CNCR2820661222>3.0.CO;2-S; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Steenhard BM, 2010, AM J PATHOL, V177, P84, DOI 10.2353/ajpath.2010.090767; Tanaka K, 1997, HISTOCHEM J, V29, P563, DOI 10.1023/A:1026428010104; Tang YC, 2003, CANCER RES, V63, P1166; Theret N, 2001, HEPATOLOGY, V34, P82, DOI 10.1053/jhep.2001.25758; Tian B, 2005, J CANCER RES CLIN, V131, P80, DOI 10.1007/s00432-004-0614-3; Ueda S, 2006, MODERN PATHOL, V19, P788, DOI 10.1038/modpathol.3800582; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; Vidal-Vanaclocha F, 2008, CANCER MICROENVIRON, V1, P113, DOI 10.1007/s12307-008-0011-6; Wang JY, 2006, J NEUROSCI RES, V83, P7, DOI 10.1002/jnr.20712; Wang N, 2006, CANCER RES, V66, P3062, DOI 10.1158/0008-5472.CAN-05-2638; Wang N, 2009, MOL THER, V17, P1241, DOI 10.1038/mt.2009.82; Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345; Xie YT, 1999, CANCER RES, V59, P3588; Yakar S, 2006, ENDOCRINOLOGY, V147, P5826, DOI 10.1210/en.2006-0311; Yang CQ, 2003, GASTROENTEROLOGY, V124, P147, DOI 10.1053/gast.2003.50012; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315; Zeisberg M, 2006, MOL CELL BIOCHEM, V283, P181, DOI 10.1007/s11010-006-2677-8; Zha JP, 2010, CLIN CANCER RES, V16, P2512, DOI 10.1158/1078-0432.CCR-09-2232; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	83	70	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	35					3766	3783		10.1038/onc.2011.89	http://dx.doi.org/10.1038/onc.2011.89			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21478904				2022-12-17	WOS:000294481400004
J	Wolf, MJ; Seleznik, GM; Zeller, N; Heikenwalder, M				Wolf, M. J.; Seleznik, G. M.; Zeller, N.; Heikenwalder, M.			The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development	ONCOGENE			English	Review						lymphotoxin beta receptor signaling; inflammation-induced carcinogenesis; NF-kappa B signaling; lymphotoxin alpha; lymphotoxin beta	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FACTOR TNF-ALPHA; LT-ALPHA; GENE-EXPRESSION; IKK-ALPHA; T-CELLS; SURFACE LYMPHOTOXIN; SJOGRENS-SYNDROME	The cytokines lymphotoxin (LT) alpha, beta and their receptor (LT beta R) belong to the tumor necrosis factor (TNF) superfamily, whose founder-TNF alpha-was initially discovered due to its tumor necrotizing activity. LT beta R signaling serves pleiotropic functions including the control of lymphoid organ development, support of efficient immune responses against pathogens due to maintenance of intact lymphoid structures, induction of tertiary lymphoid organs, liver regeneration or control of lipid homeostasis. Signaling through LTbR comprises the noncanonical/canonical nuclear factor-kappa B (NF-kappa B) pathways thus inducing chemokine, cytokine or adhesion molecule expression, cell proliferation and cell survival. Blocking LT beta R signaling or Fc gamma-receptor mediated immunoablation of LT-expressing cells was demonstrated to be beneficial in various infectious or noninfectious inflammatory or autoimmune disorders. Only recently, LT beta R signaling was shown to initiate inflammation-induced carcinogenesis, to influence primary tumorigenesis and to control reemergence of carcinoma in various cancer models through distinct mechanisms. Indeed, LT beta R signaling inhibition has already been used as efficient anti-inflammatory, anti-cancer therapy in some experimental models. Here, we review the pleiotropic functions attributed to LT, the effects of its deregulation and extensively discuss the recent literature on LT's link to carcinogenesis. Oncogene (2010) 29, 5006-5018; doi:10.1038/onc.2010.260; published online 5 July 2010	[Wolf, M. J.; Seleznik, G. M.; Zeller, N.; Heikenwalder, M.] Univ Zurich Hosp, Inst Neuropathol, Dept Pathol, CH-8091 Zurich, Switzerland; [Heikenwalder, M.] Tech Univ Munich, Inst Virol, Helmholtz Zentrum Munchen, Munich, Germany	University of Zurich; University Zurich Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Heikenwalder, M (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Dept Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	mathias.heikenwaelder@usz.ch	Heikenwalder, Mathias/AAA-2269-2020		Biogen Idec; Oncosuisse foundation [OCS 02113-08-2007]; Novartis Stiftung fur Biologisch-Medizinische Forschung [09C62]; Stiftung zur Schweizerischen Krebsbekampfung; Helmholtz-foundation; Research foundation at the Medical Faculty Zurich; Julius-Muller foundation; Kurt und Senta Hermann Stiftung; Roche Research Foundation	Biogen Idec(Biogen); Oncosuisse foundation; Novartis Stiftung fur Biologisch-Medizinische Forschung; Stiftung zur Schweizerischen Krebsbekampfung; Helmholtz-foundation(Helmholtz Association); Research foundation at the Medical Faculty Zurich; Julius-Muller foundation; Kurt und Senta Hermann Stiftung; Roche Research Foundation	Dr Mathias Heikenwalder is in the process of designing a clinical trial using LTBR-Ig (baminercept) in hepatitis C virus-infected patients, which would be partially funded by Biogen Idec. The planned trial is not yet approved. Dr Nicolas Zeller, Monika Wolf and Gitta Seleznik declare no conflict of interest.; We thank Dr Tracy O'Connor, Dr Barbara Stecher, Jay Tracy and Lukas Frick for critically reading this paper. MH was supported by grants of the Oncosuisse foundation (OCS 02113-08-2007), the Novartis Stiftung fur Biologisch-Medizinische Forschung (Nr. 09C62), the 'Stiftung zur Schweizerischen Krebsbekampfung', the Helmholtz-foundation, the research foundation at the Medical Faculty Zurich, the Julius-Muller foundation and the 'Kurt und Senta Hermann Stiftung'. MJW was supported by a grant of the Roche Research Foundation. MH is a fellow of the Professor Dr Max Cloetta foundation.	AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1984, J BIOL CHEM, V259, P686; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2334; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; An MM, 2006, BIOL PHARM BULL, V29, P2025, DOI 10.1248/bpb.29.2025; An MM, 2005, PHARMACOL RES, V52, P234, DOI 10.1016/j.phrs.2005.03.009; Anand S, 2006, J CLIN INVEST, V116, P1045, DOI 10.1172/JCI27083; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Armengol MP, 2003, J IMMUNOL, V170, P6320, DOI 10.4049/jimmunol.170.12.6320; Aust G, 2004, EUR J ENDOCRINOL, V150, P225, DOI 10.1530/eje.0.1500225; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Boehm T, 2003, J EXP MED, V198, P757, DOI 10.1084/jem.20030794; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Britanova LV, 2008, BIOCHEM BIOPH RES CO, V365, P583, DOI 10.1016/j.bbrc.2007.10.200; Browning JL, 2008, IMMUNOL REV, V223, P202, DOI 10.1111/j.1600-065X.2008.00633.x; Browning JL, 2005, IMMUNITY, V23, P539, DOI 10.1016/j.immuni.2005.10.002; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CAVENDER DE, 1989, AM J PATHOL, V134, P551; Chae YS, 2010, CANCER CHEMOTH PHARM, V65, P571, DOI 10.1007/s00280-009-1066-x; Chiang EY, 2009, NAT MED, V15, P766, DOI 10.1038/nm.1984; Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Columba-Cabezas S, 2006, J NEUROIMMUNOL, V179, P76, DOI 10.1016/j.jneuroim.2006.06.015; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cuff CA, 1998, J IMMUNOL, V161, P6853; Cuff CA, 1999, J IMMUNOL, V162, P5965; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Drayton DL, 2003, J EXP MED, V197, P1153, DOI 10.1084/jem.20021761; Ettinger R, 2001, J EXP MED, V193, P1333, DOI 10.1084/jem.193.11.1333; Fava RA, 2003, J IMMUNOL, V171, P115, DOI 10.4049/jimmunol.171.1.115; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Fu YX, 2000, J IMMUNOL, V164, P2508, DOI 10.4049/jimmunol.164.5.2508; Fu YX, 1997, J EXP MED, V185, P2111, DOI 10.1084/jem.185.12.2111; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gatumu MK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2617; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; Ghosh S, 2005, J IMMUNOL, V174, P2860, DOI 10.4049/jimmunol.174.5.2860; Gommerman JL, 2003, NAT REV IMMUNOL, V3, P642, DOI 10.1038/nri1151; Gommerman JL, 2003, J CLIN INVEST, V112, P755, DOI 10.1172/JCI200318648; Grabner R, 2009, J EXP MED, V206, P233, DOI 10.1084/jem.20080752; GRANGER GA, 1968, NATURE, V218, P1253, DOI 10.1038/2181253a0; GRANGER GA, 1969, NATURE, V221, P1155, DOI 10.1038/2211155a0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haybaeck J, 2009, CANCER CELL, V16, P295, DOI 10.1016/j.ccr.2009.08.021; He GB, 2010, CANCER CELL, V17, P286, DOI 10.1016/j.ccr.2009.12.048; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Hehlgans T, 2002, CANCER RES, V62, P4034; Heikenwalder M, 2005, SCIENCE, V307, P1107, DOI 10.1126/science.1106460; Heikenwalder M, 2008, AM J PATHOL, V172, P1555, DOI 10.2353/ajpath.2008.070572; HISERODT JC, 1977, CELL IMMUNOL, V34, P326, DOI 10.1016/0008-8749(77)90255-6; Hjelmervik TOR, 2005, ARTHRITIS RHEUM, V52, P1534, DOI 10.1002/art.21006; Ito D, 1999, J IMMUNOL, V163, P2809; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kobayashi M, 2004, P NATL ACAD SCI USA, V101, P17807, DOI 10.1073/pnas.0407503101; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; Kuprash DV, 2008, CANCER LETT, V268, P70, DOI 10.1016/j.canlet.2008.03.023; Lee Y, 2006, IMMUNITY, V25, P499, DOI 10.1016/j.immuni.2006.06.016; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lo JC, 2007, SCIENCE, V316, P285, DOI 10.1126/science.1137221; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Lukashev M, 2006, CANCER RES, V66, P9617, DOI 10.1158/0008-5472.CAN-06-0217; Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Markey KA, 2010, BLOOD, V115, P122, DOI 10.1182/blood-2009-01-199927; Martin AP, 2004, J IMMUNOL, V173, P4791, DOI 10.4049/jimmunol.173.8.4791; McCarthy DA, 2006, IMMUNOL RES, V35, P41, DOI 10.1385/IR:35:1:41; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; MULLER U, 1987, NATURE, V325, P265, DOI 10.1038/325265a0; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; NEDWIN GE, 1985, J CELL BIOCHEM, V29, P171, DOI 10.1002/jcb.240290302; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Norris PS, 2007, ADV EXP MED BIOL, V597, P160; Or YYY, 2010, J PATHOL, V220, P97, DOI 10.1002/path.2609; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PICARELLA DE, 1992, P NATL ACAD SCI USA, V89, P10036, DOI 10.1073/pnas.89.21.10036; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Plant SR, 2007, J NEUROSCI, V27, P7429, DOI 10.1523/JNEUROSCI.1307-07.2007; POBER JS, 1987, J IMMUNOL, V138, P3319; POBER JS, 1987, CIBA F SYMP, V131, P170; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; PRINEAS JW, 1979, SCIENCE, V203, P1123, DOI 10.1126/science.424741; Puglielli MT, 1999, NAT MED, V5, P1370; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497; Ruddell RG, 2009, HEPATOLOGY, V49, P227, DOI 10.1002/hep.22597; RUDDLE NH, 1967, SCIENCE, V157, P1060, DOI 10.1126/science.157.3792.1060; RUDDLE NH, 1968, J EXP MED, V128, P1267, DOI 10.1084/jem.128.6.1267; Schneider K, 2004, IMMUNOL REV, V202, P49, DOI 10.1111/j.0105-2896.2004.00206.x; Schreyer SA, 2002, J BIOL CHEM, V277, P12364, DOI 10.1074/jbc.M111727200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Shao H, 2003, EUR J IMMUNOL, V33, P1736, DOI 10.1002/eji.200323745; STEERE AC, 1988, ARTHRITIS RHEUM, V31, P487, DOI 10.1002/art.1780310405; Stopfer P, 2004, J IMMUNOL, V172, P7459, DOI 10.4049/jimmunol.172.12.7459; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; Tamada K, 2000, NAT MED, V6, P283; Tamada K, 2002, J CLIN INVEST, V109, P549, DOI 10.1172/JCI200213604; Tumanov AV, 2007, CURR MOL MED, V7, P567, DOI 10.2174/156652407781695701; Tumanov AV, 2009, GASTROENTEROLOGY, V136, P694, DOI 10.1053/j.gastro.2008.09.015; Villanueva A, 2009, CANCER CELL, V16, P272, DOI 10.1016/j.ccr.2009.09.012; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Ware CF, 2005, ANNU REV IMMUNOL, V23, P787, DOI 10.1146/annurev.immunol.23.021704.115719; WARE CF, 1979, J IMMUNOL, V122, P1763; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; WORM M, 1994, INT IMMUNOL, V6, P1883, DOI 10.1093/intimm/6.12.1883; Wu Q, 2004, J IMMUNOL, V172, P1630, DOI 10.4049/jimmunol.172.3.1630; Wu Q, 2001, J EXP MED, V193, P1327, DOI 10.1084/jem.193.11.1327; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; YOUNG CL, 1984, ARTHRITIS RHEUM, V27, P32, DOI 10.1002/art.1780270106; Young J, 2010, CYTOKINE, V51, P78, DOI 10.1016/j.cyto.2010.03.003; Zhou PH, 2009, P NATL ACAD SCI USA, V106, P17134, DOI 10.1073/pnas.0905707106	129	70	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5006	5018		10.1038/onc.2010.260	http://dx.doi.org/10.1038/onc.2010.260			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20603617				2022-12-17	WOS:000281620100002
